Positron	O
emission	O
tomography	O
in	O
a	O
case	O
of	O
intracranial	O
hemangiopericytoma	O
.	O

Due	O
to	O
the	O
low	O
prevalence	O
of	O
hemangiopericytomas	O
(	O
HPCs	O
)	O
,	O
data	O
on	O
the	O
biophysiological	O
characteristics	O
of	O
this	O
tumor	O
are	O
rare	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
demonstrated	O
a	O
sixfold	O
increased	O
uptake	O
of	O
[	O
11C	O
]	O
methionine	O
and	O
hyperperfusion	O
in	O
the	O
HPC	O
,	O
whereas	O
glucose	O
utilization	O
was	O
decreased	O
in	O
this	O
area	O
.	O
<EOS>	B-X
Due	B-X
to	B-X
the	B-X
low	B-X
prevalence	B-X
of	B-X
hemangiopericytomas	B-X
(	B-X
HPCs	B-X
)	B-X
,	B-X
data	B-X
on	B-X
the	B-X
biophysiological	B-X
characteristics	B-X
of	B-X
this	B-X
tumor	B-X
are	B-X
rare	B-X
.	B-X
Positron	B-X
emission	B-X
tomography	B-X
(	B-X
PET	B-X
)	B-X
demonstrated	B-X
a	B-X
sixfold	B-X
increased	B-X
uptake	B-X
of	B-X
[	B-X
11C	B-X
]	B-X
methionine	B-X
and	B-X
hyperperfusion	B-X
in	B-X
the	B-X
HPC	B-X
,	B-X
whereas	B-X
glucose	B-X
utilization	B-X
was	B-X
decreased	B-X
in	B-X
this	B-X
area	B-X
.	B-X
This	B-X
low	B-X
glucose	B-X
utilization	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
high	B-X
[	B-X
11C	B-X
]	B-X
methionine	B-X
uptake	B-X
and	B-X
the	B-X
malignancy	B-X
of	B-X
these	B-X
tumors	B-X
.	B-X
The	B-X
characteristics	B-X
of	B-X
HPCs	B-X
in	B-X
PET	B-X
described	B-X
herein	B-X
for	B-X
the	B-X
first	B-X
time	B-X
offer	B-X
additional	B-X
diagnostic	B-X
criteria	B-X
and	B-X
may	B-X
help	B-X
especially	B-X
to	B-X
differentiate	B-X
these	B-X
tumors	B-X
from	B-X
meningiomas	B-X
.	B-X

This	O
low	O
glucose	O
utilization	O
is	O
in	O
contrast	O
to	O
the	O
high	O
[	O
11C	O
]	O
methionine	O
uptake	O
and	O
the	O
malignancy	O
of	O
these	O
tumors	O
.	O

The	O
characteristics	O
of	O
HPCs	O
in	O
PET	O
described	O
herein	O
for	O
the	O
first	O
time	O
offer	O
additional	O
diagnostic	O
criteria	O
and	O
may	O
help	O
especially	O
to	O
differentiate	O
these	O
tumors	O
from	O
meningiomas	O
.	O
<EOS>	B-X
Due	B-X
to	B-X
the	B-X
low	B-X
prevalence	B-X
of	B-X
hemangiopericytomas	B-X
(	B-X
HPCs	B-X
)	B-X
,	B-X
data	B-X
on	B-X
the	B-X
biophysiological	B-X
characteristics	B-X
of	B-X
this	B-X
tumor	B-X
are	B-X
rare	B-X
.	B-X
Positron	B-X
emission	B-X
tomography	B-X
(	B-X
PET	B-X
)	B-X
demonstrated	B-X
a	B-X
sixfold	B-X
increased	B-X
uptake	B-X
of	B-X
[	B-X
11C	B-X
]	B-X
methionine	B-X
and	B-X
hyperperfusion	B-X
in	B-X
the	B-X
HPC	B-X
,	B-X
whereas	B-X
glucose	B-X
utilization	B-X
was	B-X
decreased	B-X
in	B-X
this	B-X
area	B-X
.	B-X
This	B-X
low	B-X
glucose	B-X
utilization	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
high	B-X
[	B-X
11C	B-X
]	B-X
methionine	B-X
uptake	B-X
and	B-X
the	B-X
malignancy	B-X
of	B-X
these	B-X
tumors	B-X
.	B-X
The	B-X
characteristics	B-X
of	B-X
HPCs	B-X
in	B-X
PET	B-X
described	B-X
herein	B-X
for	B-X
the	B-X
first	B-X
time	B-X
offer	B-X
additional	B-X
diagnostic	B-X
criteria	B-X
and	B-X
may	B-X
help	B-X
especially	B-X
to	B-X
differentiate	B-X
these	B-X
tumors	B-X
from	B-X
meningiomas	B-X
.	B-X

Thyrotropin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
:	O
a	O
role	O
for	O
thyroid	O
tumourigenesis	O
?	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
TSH-R	B-X
mutations	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
differentiated	B-X
thyroid	B-X
carcinomas	B-X
.	B-X
Activating	B-X
mutations	B-X
of	B-X
the	B-X
TSH-R	B-X
gene	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
group	B-X
of	B-X
differentiated	B-X
carcinomas	B-X
with	B-X
high	B-X
basal	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
hyperfunctioning	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TSH-R	B-X
gene	B-X
alterations	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
neoplasia	B-X
is	B-X
examined	B-X
.	B-X

Human	O
thyroid	O
tumours	O
represent	O
an	O
example	O
of	O
the	O
interplay	O
of	O
genetic	O
and	O
non	O
genetic	O
carcinogenesis	O
.	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
TSH-R	B-X
mutations	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
differentiated	B-X
thyroid	B-X
carcinomas	B-X
.	B-X
At	B-X
present	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
such	B-X
a	B-X
modification	B-X
is	B-X
low	B-X
,	B-X
unless	B-X
referred	B-X
to	B-X
selected	B-X
series	B-X
of	B-X
tumours	B-X
.	B-X
Activating	B-X
mutations	B-X
of	B-X
the	B-X
TSH-R	B-X
gene	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
group	B-X
of	B-X
differentiated	B-X
carcinomas	B-X
with	B-X
high	B-X
basal	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
hyperfunctioning	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TSH-R	B-X
gene	B-X
alterations	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
neoplasia	B-X
is	B-X
examined	B-X
.	B-X

Recently	O
,	O
genetic	O
abnormalities	O
in	O
the	O
elements	O
of	O
the	O
Thyrotropin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
TSH	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
)	O
dependent	O
cAMP	O
regulatory	O
cascade	O
have	O
been	O
found	O
to	O
be	O
involved	O
both	O
in	O
benign	O
and	O
malignant	O
thyroid	O
tumours	O
.	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
TSH-R	B-X
mutations	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
differentiated	B-X
thyroid	B-X
carcinomas	B-X
.	B-X
At	B-X
present	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
such	B-X
a	B-X
modification	B-X
is	B-X
low	B-X
,	B-X
unless	B-X
referred	B-X
to	B-X
selected	B-X
series	B-X
of	B-X
tumours	B-X
.	B-X
Activating	B-X
mutations	B-X
of	B-X
the	B-X
TSH-R	B-X
gene	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
group	B-X
of	B-X
differentiated	B-X
carcinomas	B-X
with	B-X
high	B-X
basal	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
hyperfunctioning	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TSH-R	B-X
gene	B-X
alterations	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
neoplasia	B-X
is	B-X
examined	B-X
.	B-X

The	O
presence	O
of	O
activating	O
mutations	O
has	O
been	O
demonstrated	O
in	O
the	O
TSH	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
gene	O
as	O
well	O
as	O
in	O
the	O
Gs	B-Gene_or_gene_product
alpha	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
gene	O
in	O
thyroid	O
toxic	O
adenoma	O
resulting	O
in	O
the	O
constitutive	O
activation	O
of	O
the	O
cAMP	O
pathway	O
and	O
it	O
has	O
been	O
hypothesised	O
that	O
these	O
genetic	O
alterations	O
may	O
play	O
a	O
causative	O
role	O
in	O
the	O
disease	O
.	O

However	O
,	O
recent	O
observations	O
suggest	O
more	O
caution	O
in	O
accepting	O
such	O
a	O
hypothesis	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
observations	B-X
suggest	B-X
more	B-X
caution	B-X
in	B-X
accepting	B-X
such	B-X
a	B-X
hypothesis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
Like	B-X
many	B-X
other	B-X
rare	B-X
genomic	B-X
changes	B-X
(	B-X
RGCs	B-X
)	B-X
,	B-X
microinversions	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
virtually	B-X
homoplasy-free	B-X
evolutionary	B-X
characters	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
may	B-X
be	B-X
very	B-X
useful	B-X
for	B-X
difficult	B-X
phylogenetic	B-X
problems	B-X
such	B-X
as	B-X
the	B-X
avian	B-X
tree	B-X
of	B-X
life	B-X
.	B-X
However	B-X
,	B-X
few	B-X
detailed	B-X
surveys	B-X
of	B-X
these	B-X
genomic	B-X
rearrangements	B-X
have	B-X
been	B-X
conducted	B-X
,	B-X
making	B-X
it	B-X
difficult	B-X
to	B-X
assess	B-X
this	B-X
hypothesis	B-X
or	B-X
understand	B-X
the	B-X
impact	B-X
of	B-X
microinversions	B-X
upon	B-X
genome	B-X
evolution	B-X
.	B-X

The	O
presence	O
of	O
activating	O
TSH	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
mutations	O
has	O
also	O
been	O
demonstrated	O
in	O
differentiated	O
thyroid	O
carcinomas	O
.	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
TSH-R	B-X
mutations	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
differentiated	B-X
thyroid	B-X
carcinomas	B-X
.	B-X
Activating	B-X
mutations	B-X
of	B-X
the	B-X
TSH-R	B-X
gene	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
group	B-X
of	B-X
differentiated	B-X
carcinomas	B-X
with	B-X
high	B-X
basal	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
hyperfunctioning	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TSH-R	B-X
gene	B-X
alterations	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
neoplasia	B-X
is	B-X
examined	B-X
.	B-X

At	O
present	O
,	O
the	O
percentage	O
of	O
such	O
a	O
modification	O
is	O
low	O
,	O
unless	O
referred	O
to	O
selected	O
series	O
of	O
tumours	O
.	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
At	B-X
present	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
such	B-X
a	B-X
modification	B-X
is	B-X
low	B-X
,	B-X
unless	B-X
referred	B-X
to	B-X
selected	B-X
series	B-X
of	B-X
tumours	B-X
.	B-X

Activating	O
mutations	O
of	O
the	O
TSH	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
gene	O
have	O
been	O
detected	O
in	O
a	O
group	O
of	O
differentiated	O
carcinomas	O
with	O
high	O
basal	O
adenylyl	B-Gene_or_gene_product
cyclase	I-Gene_or_gene_product
activity	O
,	O
and	O
in	O
a	O
few	O
cases	O
of	O
hyperfunctioning	O
thyroid	O
carcinoma	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
TSH	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	O
cAMP	O
pathway	O
alterations	O
in	O
thyroid	O
transformation	O
remains	O
to	O
be	O
elucidated	O
.	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
observations	B-X
suggest	B-X
more	B-X
caution	B-X
in	B-X
accepting	B-X
such	B-X
a	B-X
hypothesis	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
TSH-R	B-X
mutations	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
differentiated	B-X
thyroid	B-X
carcinomas	B-X
.	B-X
Activating	B-X
mutations	B-X
of	B-X
the	B-X
TSH-R	B-X
gene	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
group	B-X
of	B-X
differentiated	B-X
carcinomas	B-X
with	B-X
high	B-X
basal	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
hyperfunctioning	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TSH-R	B-X
gene	B-X
alterations	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
neoplasia	B-X
is	B-X
examined	B-X
.	B-X

In	O
this	O
review	O
,	O
the	O
role	O
of	O
TSH	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
gene	O
alterations	O
in	O
benign	O
and	O
malignant	O
thyroid	O
neoplasia	O
is	O
examined	O
.	O
<EOS>	B-X
Human	B-X
thyroid	B-X
tumours	B-X
represent	B-X
an	B-X
example	B-X
of	B-X
the	B-X
interplay	B-X
of	B-X
genetic	B-X
and	B-X
non	B-X
genetic	B-X
carcinogenesis	B-X
.	B-X
Recently	B-X
,	B-X
genetic	B-X
abnormalities	B-X
in	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
Thyrotropin	B-X
receptor	B-X
(	B-X
TSH-R	B-X
)	B-X
dependent	B-X
cAMP	B-X
regulatory	B-X
cascade	B-X
have	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
both	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
tumours	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
mutations	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
the	B-X
TSH-R	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
Gs	B-X
alpha	B-X
protein	B-X
gene	B-X
in	B-X
thyroid	B-X
toxic	B-X
adenoma	B-X
resulting	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
and	B-X
it	B-X
has	B-X
been	B-X
hypothesised	B-X
that	B-X
these	B-X
genetic	B-X
alterations	B-X
may	B-X
play	B-X
a	B-X
causative	B-X
role	B-X
in	B-X
the	B-X
disease	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
activating	B-X
TSH-R	B-X
mutations	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
in	B-X
differentiated	B-X
thyroid	B-X
carcinomas	B-X
.	B-X
Activating	B-X
mutations	B-X
of	B-X
the	B-X
TSH-R	B-X
gene	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
group	B-X
of	B-X
differentiated	B-X
carcinomas	B-X
with	B-X
high	B-X
basal	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
of	B-X
hyperfunctioning	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
TSH-R-related	B-X
cAMP	B-X
pathway	B-X
alterations	B-X
in	B-X
thyroid	B-X
transformation	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TSH-R	B-X
gene	B-X
alterations	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
thyroid	B-X
neoplasia	B-X
is	B-X
examined	B-X
.	B-X

Cooccurrence	O
of	O
reduced	O
expression	O
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
and	O
overexpression	O
of	O
p53	B-Gene_or_gene_product
is	O
a	O
predictor	O
of	O
lymph	O
node	O
metastasis	O
in	O
early	O
gastric	O
cancer	O
.	O
<EOS>	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cadherin-catenin	B-X
complex	B-X
and	B-X
p53	B-X
was	B-X
studied	B-X
in	B-X
early	B-X
gastric	B-X
cancer	B-X
.	B-X
Their	B-X
correlation	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
the	B-X
predictability	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
by	B-X
combining	B-X
these	B-X
factors	B-X
,	B-X
were	B-X
also	B-X
discussed	B-X
.	B-X

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Even	O
though	O
the	O
pathological	O
background	O
contributes	O
to	O
lymph	O
node	O
metastasis	O
,	O
the	O
biological	O
characteristics	O
of	O
tumors	O
have	O
also	O
gained	O
wide	O
attention	O
.	O
<EOS>	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
Their	B-X
correlation	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
the	B-X
predictability	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
by	B-X
combining	B-X
these	B-X
factors	B-X
,	B-X
were	B-X
also	B-X
discussed	B-X
.	B-X

In	O
this	O
study	O
,	O
the	O
expression	O
of	O
the	O
cadherin	B-Gene_or_gene_product
-	O
catenin	B-Gene_or_gene_product
complex	O
and	O
p53	B-Gene_or_gene_product
was	O
studied	O
in	O
early	O
gastric	O
cancer	O
.	O

Their	O
correlation	O
with	O
lymph	O
node	O
metastasis	O
and	O
the	O
predictability	O
of	O
lymph	O
node	O
metastases	O
,	O
by	O
combining	O
these	O
factors	O
,	O
were	O
also	O
discussed	O
.	O
<EOS>	B-X
The	B-X
blood	B-X
flow	B-X
in	B-X
lymph	B-X
nodes	B-X
reflects	B-X
important	B-X
pathological	B-X
features	B-X
.	B-X
In	B-X
the	B-X
work	B-X
described	B-X
here	B-X
,	B-X
a	B-X
parametric	B-X
imaging	B-X
method	B-X
for	B-X
describing	B-X
blood	B-X
perfusion	B-X
pattern	B-X
was	B-X
proposed	B-X
and	B-X
a	B-X
multimodal	B-X
network	B-X
(	B-X
LN-Net	B-X
)	B-X
to	B-X
predict	B-X
lymph	B-X
node	B-X
metastasis	B-X
was	B-X
designed	B-X
.	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
Their	B-X
correlation	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
the	B-X
predictability	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
by	B-X
combining	B-X
these	B-X
factors	B-X
,	B-X
were	B-X
also	B-X
discussed	B-X
.	B-X

METHODS	O
:	O
One	O
hundred	O
and	O
one	O
specimens	O
obtained	O
from	O
surgery	O
were	O
studied	O
by	O
immunohistochemistry	O
using	O
monoclonal	O
anti	O
-	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
,	O
anti	O
-	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
and	O
anti	O
-	O
p53	B-Gene_or_gene_product
antibodies	O
.	O

RESULTS	O
:	O
Expression	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
and	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
was	O
reduced	O
in	O
50	O
.	O
5	O
and	O
64	O
.	O
4	O
%	O
,	O
respectively	O
.	O
<EOS>	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cadherin-catenin	B-X
complex	B-X
and	B-X
p53	B-X
was	B-X
studied	B-X
in	B-X
early	B-X
gastric	B-X
cancer	B-X
.	B-X

p53	B-Gene_or_gene_product
protein	O
staining	O
was	O
positive	O
in	O
29	O
.	O
7	O
%	O
.	O
<EOS>	B-X
Forty-nine	B-X
follicular	B-X
adenomas	B-X
and	B-X
11	B-X
follicular	B-X
carcinomas	B-X
of	B-X
the	B-X
thyroid	B-X
were	B-X
investigated	B-X
by	B-X
immunohistochemistry	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
and	B-X
proliferating	B-X
cell	B-X
nuclear	B-X
antigen	B-X
(	B-X
PCNA	B-X
)	B-X
.	B-X
Twelve	B-X
adenomas	B-X
(	B-X
24	B-X
per	B-X
cent	B-X
)	B-X
and	B-X
six	B-X
carcinomas	B-X
(	B-X
55	B-X
per	B-X
cent	B-X
)	B-X
were	B-X
DNA	B-X
non-diploid	B-X
(	B-X
P	B-X
=	B-X
0.07	B-X
)	B-X
.	B-X
The	B-X
carcinomas	B-X
had	B-X
a	B-X
higher	B-X
proliferation	B-X
rate	B-X
than	B-X
the	B-X
adenomas	B-X
when	B-X
assessed	B-X
either	B-X
by	B-X
SPF	B-X
size	B-X
(	B-X
median	B-X
9.9	B-X
per	B-X
cent	B-X
vs.	B-X
2.9	B-X
per	B-X
cent	B-X
,	B-X
P	B-X
=	B-X
0.0003	B-X
)	B-X
or	B-X
by	B-X
PCNA	B-X
staining	B-X
intensity	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Some	B-X
scattered	B-X
nuclei	B-X
in	B-X
two	B-X
(	B-X
4	B-X
per	B-X
cent	B-X
)	B-X
adenomas	B-X
and	B-X
in	B-X
three	B-X
(	B-X
27	B-X
per	B-X
cent	B-X
)	B-X
carcinomas	B-X
stained	B-X
positively	B-X
for	B-X
p53	B-X
(	B-X
P	B-X
=	B-X
0.04	B-X
)	B-X
.	B-X
The	B-X
two	B-X
adenomas	B-X
with	B-X
positive	B-X
staining	B-X
for	B-X
p53	B-X
were	B-X
subserially	B-X
sectioned	B-X
,	B-X
but	B-X
no	B-X
signs	B-X
of	B-X
invasion	B-X
were	B-X
found	B-X
;	B-X
both	B-X
patients	B-X
are	B-X
alive	B-X
and	B-X
well	B-X
6	B-X
and	B-X
7	B-X
years	B-X
after	B-X
surgery	B-X
.	B-X
One	B-X
of	B-X
the	B-X
two	B-X
adenomas	B-X
showing	B-X
positive	B-X
p53	B-X
nuclear	B-X
staining	B-X
was	B-X
DNA	B-X
aneuploid	B-X
,	B-X
and	B-X
both	B-X
were	B-X
positive	B-X
in	B-X
PCNA	B-X
staining	B-X
,	B-X
but	B-X
their	B-X
SPFs	B-X
were	B-X
low	B-X
(	B-X
2.1	B-X
and	B-X
3.3	B-X
per	B-X
cent	B-X
)	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
p53	B-X
protein	B-X
expression	B-X
is	B-X
not	B-X
confined	B-X
to	B-X
follicular	B-X
carcinomas	B-X
;	B-X
scattered	B-X
p53-positive	B-X
cells	B-X
may	B-X
also	B-X
be	B-X
present	B-X
in	B-X
histologically	B-X
and	B-X
clinically	B-X
benign	B-X
follicular	B-X
adenomas	B-X
.	B-X
Because	B-X
both	B-X
follicular	B-X
adenomas	B-X
and	B-X
carcinomas	B-X
may	B-X
be	B-X
DNA	B-X
aneuploid	B-X
and	B-X
their	B-X
SPF	B-X
and	B-X
PCNA	B-X
staining	B-X
distributions	B-X
overlap	B-X
,	B-X
the	B-X
distinction	B-X
between	B-X
follicular	B-X
adenoma	B-X
and	B-X
carcinoma	B-X
should	B-X
still	B-X
be	B-X
based	B-X
on	B-X
histological	B-X
criteria	B-X
.	B-X

There	O
was	O
a	O
significant	O
correlation	O
between	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
and	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
expression	O
,	O
but	O
no	O
correlation	O
was	O
found	O
between	O
p53	B-Gene_or_gene_product
expression	O
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
or	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
Î±-Catulin	B-X
promotes	B-X
cancer	B-X
stemness	B-X
by	B-X
antagonizing	B-X
WWP1-mediated	B-X
KLF5	B-X
degradation	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X
Furthermore	B-X
,	B-X
JAr	B-X
spheroid	B-X
attachment	B-X
experiments	B-X
show	B-X
that	B-X
attachment	B-X
rates	B-X
were	B-X
significantly	B-X
decreased	B-X
after	B-X
treatment	B-X
of	B-X
IK	B-X
cells	B-X
with	B-X
inhibitors	B-X
for	B-X
miR-183-5p	B-X
and	B-X
miR-182-5p	B-X
and	B-X
increased	B-X
after	B-X
treatment	B-X
with	B-X
miR-183-5p-mimic	B-X
and	B-X
miR-96-5p-mimic	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
downstream	B-X
analysis	B-X
shows	B-X
that	B-X
catenin	B-X
alpha	B-X
2	B-X
(	B-X
CTNNA2	B-X
)	B-X
is	B-X
a	B-X
potential	B-X
target	B-X
gene	B-X
for	B-X
miR-183-5p	B-X
,	B-X
and	B-X
this	B-X
was	B-X
confirmed	B-X
in	B-X
luciferase	B-X
reporter	B-X
assays	B-X
.	B-X
An	B-X
in	B-X
vivo	B-X
mouse	B-X
pregnancy	B-X
model	B-X
shows	B-X
that	B-X
inhibition	B-X
of	B-X
miR-183-5p	B-X
significantly	B-X
decreases	B-X
embryo	B-X
implantation	B-X
rates	B-X
and	B-X
increases	B-X
CTNNA2	B-X
expression	B-X
.	B-X
Downregulation	B-X
of	B-X
CTNNA2	B-X
in	B-X
endometrial	B-X
cells	B-X
by	B-X
miR-183-5p	B-X
may	B-X
be	B-X
significant	B-X
in	B-X
mediating	B-X
estrogenic	B-X
effects	B-X
on	B-X
endometrial	B-X
receptivity	B-X
.	B-X

A	O
reduction	O
in	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
expression	O
and	O
p53	B-Gene_or_gene_product
overexpression	O
correlated	O
to	O
lymph	O
node	O
metastases	O
,	O
respectively	O
.	O
<EOS>	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cadherin-catenin	B-X
complex	B-X
and	B-X
p53	B-X
was	B-X
studied	B-X
in	B-X
early	B-X
gastric	B-X
cancer	B-X
.	B-X
Their	B-X
correlation	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
the	B-X
predictability	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
by	B-X
combining	B-X
these	B-X
factors	B-X
,	B-X
were	B-X
also	B-X
discussed	B-X
.	B-X

Multivariate	O
analysis	O
showed	O
that	O
cooccurrence	O
of	O
reduced	O
expression	O
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
and	O
overexpression	O
of	O
p53	B-Gene_or_gene_product
was	O
an	O
independent	O
factor	O
indicating	O
lymph	O
node	O
metastases	O
.	O
<EOS>	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cadherin-catenin	B-X
complex	B-X
and	B-X
p53	B-X
was	B-X
studied	B-X
in	B-X
early	B-X
gastric	B-X
cancer	B-X
.	B-X
Their	B-X
correlation	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
the	B-X
predictability	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
by	B-X
combining	B-X
these	B-X
factors	B-X
,	B-X
were	B-X
also	B-X
discussed	B-X
.	B-X

CONCLUSION	O
:	O
A	O
study	O
of	O
both	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
and	O
p53	B-Gene_or_gene_product
expression	O
may	O
be	O
helpful	O
to	O
predict	O
lymph	O
node	O
metastases	O
in	O
early	O
gastric	O
cancer	O
.	O
<EOS>	B-X
Even	B-X
though	B-X
the	B-X
pathological	B-X
background	B-X
contributes	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
the	B-X
biological	B-X
characteristics	B-X
of	B-X
tumors	B-X
have	B-X
also	B-X
gained	B-X
wide	B-X
attention	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cadherin-catenin	B-X
complex	B-X
and	B-X
p53	B-X
was	B-X
studied	B-X
in	B-X
early	B-X
gastric	B-X
cancer	B-X
.	B-X
Their	B-X
correlation	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
the	B-X
predictability	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
by	B-X
combining	B-X
these	B-X
factors	B-X
,	B-X
were	B-X
also	B-X
discussed	B-X
.	B-X

Proto	O
-	O
oncogene	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
promoter	O
is	O
down	O
regulated	O
by	O
the	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
WT1	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
WT1	B-X
)	B-X
gene	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
zinc-finger	B-X
transcription	B-X
factor	B-X
.	B-X
WT1	B-X
represses	B-X
transcription	B-X
of	B-X
several	B-X
growth	B-X
factors	B-X
and	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
The	B-X
N-myc	B-X
proto-oncogene	B-X
encodes	B-X
a	B-X
transcription	B-X
factor	B-X
which	B-X
regulates	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
N-myc	B-X
is	B-X
coexpressed	B-X
with	B-X
WT1	B-X
in	B-X
the	B-X
developing	B-X
kidney	B-X
and	B-X
is	B-X
overexpressed	B-X
in	B-X
many	B-X
Wilms	B-X
'	B-X
tumors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
proto-oncogene	B-X
N-myc	B-X
promoter	B-X
was	B-X
down-regulated	B-X
by	B-X
WT1	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
mutant	B-X
WT1	B-X
(	B-X
R394W	B-X
)	B-X
which	B-X
has	B-X
a	B-X
mutation	B-X
in	B-X
the	B-X
DNA	B-X
binding	B-X
domain	B-X
could	B-X
not	B-X
repress	B-X
the	B-X
N-myc	B-X
promoter	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
oligonucleotides	B-X
containing	B-X
the	B-X
WT1	B-X
motifs	B-X
could	B-X
bind	B-X
recombinant	B-X
WT1	B-X
proteins	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
N-myc	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
the	B-X
WT1	B-X
binding	B-X
sites	B-X
.	B-X
This	B-X
finding	B-X
may	B-X
help	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
of	B-X
WT1	B-X
and	B-X
N-myc	B-X
in	B-X
tumorigenesis	B-X
and	B-X
renal	B-X
development	B-X
.	B-X

The	O
Wilms	B-Gene_or_gene_product
'	I-Gene_or_gene_product
tumor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
WT1	B-Gene_or_gene_product
)	O
gene	O
is	O
a	O
tumor	O
suppressor	O
gene	O
that	O
encodes	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
.	O
<EOS>	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
Wt1	B-X
)	B-X
encodes	B-X
a	B-X
zinc	B-X
finger	B-X
nuclear	B-X
transcription	B-X
factor	B-X
which	B-X
is	B-X
mutated	B-X
in	B-X
15-20	B-X
%	B-X
of	B-X
Wilms	B-X
'	B-X
tumor	B-X
,	B-X
a	B-X
pediatric	B-X
kidney	B-X
tumor	B-X
.	B-X
Wt1	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
many	B-X
organs	B-X
.	B-X
In	B-X
gonads	B-X
,	B-X
Wt1	B-X
is	B-X
expressed	B-X
in	B-X
genital	B-X
ridge	B-X
somatic	B-X
cells	B-X
before	B-X
sex	B-X
determination	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
is	B-X
maintained	B-X
in	B-X
Sertoli	B-X
cells	B-X
and	B-X
granulosa	B-X
cells	B-X
after	B-X
sex	B-X
determination	B-X
.	B-X
It	B-X
has	B-X
been	B-X
demonstrated	B-X
that	B-X
Wt1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
survival	B-X
of	B-X
the	B-X
genital	B-X
ridge	B-X
cells	B-X
.	B-X
Homozygous	B-X
mutation	B-X
of	B-X
Wt1	B-X
causes	B-X
gonad	B-X
agenesis	B-X
.	B-X
Recent	B-X
studies	B-X
find	B-X
that	B-X
Wt1	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
lineage	B-X
specification	B-X
and	B-X
maintenance	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
summarize	B-X
the	B-X
recent	B-X
research	B-X
works	B-X
about	B-X
Wt1	B-X
in	B-X
gonadal	B-X
somatic	B-X
cell	B-X
differentiation	B-X
.	B-X

WT1	B-Gene_or_gene_product
represses	O
transcription	O
of	O
several	O
growth	O
factors	O
and	O
growth	O
factor	O
receptors	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
tumor	B-X
suppressor	B-X
gene	B-X
WT1	B-X
encodes	B-X
a	B-X
developmentally	B-X
regulated	B-X
transcription	B-X
factor	B-X
that	B-X
is	B-X
mutated	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
embryonal	B-X
tumors	B-X
.	B-X
To	B-X
test	B-X
its	B-X
functional	B-X
properties	B-X
,	B-X
we	B-X
developed	B-X
osteosarcoma	B-X
cell	B-X
lines	B-X
expressing	B-X
WT1	B-X
under	B-X
an	B-X
inducible	B-X
tetracycline-regulated	B-X
promoter	B-X
.	B-X
Induction	B-X
of	B-X
WT1	B-X
resulted	B-X
in	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
This	B-X
effect	B-X
,	B-X
which	B-X
was	B-X
differentially	B-X
mediated	B-X
by	B-X
the	B-X
alternative	B-X
splicing	B-X
variants	B-X
of	B-X
WT1	B-X
,	B-X
was	B-X
independent	B-X
of	B-X
p53	B-X
.	B-X
WT1-mediated	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
reduced	B-X
synthesis	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
,	B-X
but	B-X
not	B-X
of	B-X
other	B-X
postulated	B-X
WT1-target	B-X
genes	B-X
,	B-X
and	B-X
it	B-X
was	B-X
abrogated	B-X
by	B-X
constitutive	B-X
expression	B-X
of	B-X
EGFR	B-X
.	B-X
WT1	B-X
repressed	B-X
transcription	B-X
from	B-X
the	B-X
EGFR	B-X
promoter	B-X
,	B-X
binding	B-X
to	B-X
two	B-X
TC-rich	B-X
repeat	B-X
sequences	B-X
.	B-X
In	B-X
the	B-X
developing	B-X
kidney	B-X
,	B-X
EGFR	B-X
expression	B-X
in	B-X
renal	B-X
precursor	B-X
cells	B-X
declined	B-X
with	B-X
the	B-X
onset	B-X
of	B-X
WT1	B-X
expression	B-X
.	B-X
Repression	B-X
of	B-X
EGFR	B-X
and	B-X
induction	B-X
of	B-X
apoptosis	B-X
by	B-X
mechanism	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
critical	B-X
role	B-X
in	B-X
normal	B-X
kidney	B-X
development	B-X
and	B-X
to	B-X
the	B-X
immortalization	B-X
of	B-X
tumor	B-X
cells	B-X
with	B-X
inactivated	B-X
WT1	B-X
alleles	B-X
.	B-X

The	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
proto	O
-	O
oncogene	O
encodes	O
a	O
transcription	O
factor	O
which	O
regulates	O
cell	O
growth	O
and	O
differentiation	O
.	O

N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
is	O
coexpressed	O
with	O
WT1	B-Gene_or_gene_product
in	O
the	O
developing	O
kidney	O
and	O
is	O
overexpressed	O
in	O
many	O
Wilms	O
'	O
tumors	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
WT1	B-X
)	B-X
gene	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
zinc-finger	B-X
transcription	B-X
factor	B-X
.	B-X
WT1	B-X
represses	B-X
transcription	B-X
of	B-X
several	B-X
growth	B-X
factors	B-X
and	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
The	B-X
N-myc	B-X
proto-oncogene	B-X
encodes	B-X
a	B-X
transcription	B-X
factor	B-X
which	B-X
regulates	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
N-myc	B-X
is	B-X
coexpressed	B-X
with	B-X
WT1	B-X
in	B-X
the	B-X
developing	B-X
kidney	B-X
and	B-X
is	B-X
overexpressed	B-X
in	B-X
many	B-X
Wilms	B-X
'	B-X
tumors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
proto-oncogene	B-X
N-myc	B-X
promoter	B-X
was	B-X
down-regulated	B-X
by	B-X
WT1	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
mutant	B-X
WT1	B-X
(	B-X
R394W	B-X
)	B-X
which	B-X
has	B-X
a	B-X
mutation	B-X
in	B-X
the	B-X
DNA	B-X
binding	B-X
domain	B-X
could	B-X
not	B-X
repress	B-X
the	B-X
N-myc	B-X
promoter	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
oligonucleotides	B-X
containing	B-X
the	B-X
WT1	B-X
motifs	B-X
could	B-X
bind	B-X
recombinant	B-X
WT1	B-X
proteins	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
N-myc	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
the	B-X
WT1	B-X
binding	B-X
sites	B-X
.	B-X
This	B-X
finding	B-X
may	B-X
help	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
of	B-X
WT1	B-X
and	B-X
N-myc	B-X
in	B-X
tumorigenesis	B-X
and	B-X
renal	B-X
development	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
the	O
proto	O
-	O
oncogene	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
promoter	O
was	O
down	O
-	O
regulated	O
by	O
WT1	B-Gene_or_gene_product
in	O
transient	O
transfection	O
assays	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
WT1	B-X
)	B-X
gene	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
zinc-finger	B-X
transcription	B-X
factor	B-X
.	B-X
WT1	B-X
represses	B-X
transcription	B-X
of	B-X
several	B-X
growth	B-X
factors	B-X
and	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
The	B-X
N-myc	B-X
proto-oncogene	B-X
encodes	B-X
a	B-X
transcription	B-X
factor	B-X
which	B-X
regulates	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
N-myc	B-X
is	B-X
coexpressed	B-X
with	B-X
WT1	B-X
in	B-X
the	B-X
developing	B-X
kidney	B-X
and	B-X
is	B-X
overexpressed	B-X
in	B-X
many	B-X
Wilms	B-X
'	B-X
tumors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
proto-oncogene	B-X
N-myc	B-X
promoter	B-X
was	B-X
down-regulated	B-X
by	B-X
WT1	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
mutant	B-X
WT1	B-X
(	B-X
R394W	B-X
)	B-X
which	B-X
has	B-X
a	B-X
mutation	B-X
in	B-X
the	B-X
DNA	B-X
binding	B-X
domain	B-X
could	B-X
not	B-X
repress	B-X
the	B-X
N-myc	B-X
promoter	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
oligonucleotides	B-X
containing	B-X
the	B-X
WT1	B-X
motifs	B-X
could	B-X
bind	B-X
recombinant	B-X
WT1	B-X
proteins	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
N-myc	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
the	B-X
WT1	B-X
binding	B-X
sites	B-X
.	B-X
This	B-X
finding	B-X
may	B-X
help	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
of	B-X
WT1	B-X
and	B-X
N-myc	B-X
in	B-X
tumorigenesis	B-X
and	B-X
renal	B-X
development	B-X
.	B-X

However	O
,	O
mutant	O
WT1	B-Gene_or_gene_product
(	O
R394W	O
)	O
which	O
has	O
a	O
mutation	O
in	O
the	O
DNA	O
binding	O
domain	O
could	O
not	O
repress	O
the	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
oligonucleotides	O
containing	O
the	O
WT1	B-Gene_or_gene_product
motifs	O
could	O
bind	O
recombinant	O
WT1	B-Gene_or_gene_product
proteins	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
1	B-X
(	B-X
WT1	B-X
)	B-X
gene	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
zinc-finger	B-X
transcription	B-X
factor	B-X
.	B-X
WT1	B-X
represses	B-X
transcription	B-X
of	B-X
several	B-X
growth	B-X
factors	B-X
and	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
N-myc	B-X
is	B-X
coexpressed	B-X
with	B-X
WT1	B-X
in	B-X
the	B-X
developing	B-X
kidney	B-X
and	B-X
is	B-X
overexpressed	B-X
in	B-X
many	B-X
Wilms	B-X
'	B-X
tumors	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
proto-oncogene	B-X
N-myc	B-X
promoter	B-X
was	B-X
down-regulated	B-X
by	B-X
WT1	B-X
in	B-X
transient	B-X
transfection	B-X
assays	B-X
.	B-X
However	B-X
,	B-X
mutant	B-X
WT1	B-X
(	B-X
R394W	B-X
)	B-X
which	B-X
has	B-X
a	B-X
mutation	B-X
in	B-X
the	B-X
DNA	B-X
binding	B-X
domain	B-X
could	B-X
not	B-X
repress	B-X
the	B-X
N-myc	B-X
promoter	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
oligonucleotides	B-X
containing	B-X
the	B-X
WT1	B-X
motifs	B-X
could	B-X
bind	B-X
recombinant	B-X
WT1	B-X
proteins	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
repression	B-X
of	B-X
the	B-X
N-myc	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
the	B-X
WT1	B-X
binding	B-X
sites	B-X
.	B-X
This	B-X
finding	B-X
may	B-X
help	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
of	B-X
WT1	B-X
and	B-X
N-myc	B-X
in	B-X
tumorigenesis	B-X
and	B-X
renal	B-X
development	B-X
.	B-X

This	O
suggests	O
that	O
the	O
repression	O
of	O
the	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
promoter	O
is	O
mediated	O
through	O
the	O
WT1	B-Gene_or_gene_product
binding	O
sites	O
.	O

This	O
finding	O
may	O
help	O
to	O
elucidate	O
the	O
relationship	O
of	O
WT1	B-Gene_or_gene_product
and	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
in	O
tumorigenesis	O
and	O
renal	O
development	O
.	O

Tumour	O
-	O
specific	O
distribution	O
of	O
BRCA1	B-Gene_or_gene_product
promoter	O
region	O
methylation	O
supports	O
a	O
pathogenetic	O
role	O
in	O
breast	O
and	O
ovarian	O
cancer	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
BRCA1	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
remains	B-X
elusive	B-X
.	B-X
Direct	B-X
involvement	B-X
of	B-X
BRCA1	B-X
in	B-X
the	B-X
development	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
the	B-X
BRCA1	B-X
promoter	B-X
region	B-X
CpG	B-X
island	B-X
is	B-X
methylated	B-X
in	B-X
a	B-X
proportion	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
incidence	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
methylation	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
loss	B-X
of	B-X
BRCA1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
(	B-X
breast	B-X
and	B-X
ovarian	B-X
carcinomas	B-X
)	B-X
with	B-X
the	B-X
incidence	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
BRCA1	B-X
is	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
.	B-X
Promoter	B-X
region	B-X
hypermethylation	B-X
was	B-X
significantly	B-X
more	B-X
common	B-X
(	B-X
P	B-X
<	B-X
0.008	B-X
)	B-X
in	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
(	B-X
6/38	B-X
tumours	B-X
methylated	B-X
)	B-X
than	B-X
in	B-X
colon	B-X
cancer	B-X
(	B-X
0/35	B-X
tumours	B-X
methylated	B-X
)	B-X
or	B-X
in	B-X
leukaemias	B-X
(	B-X
0/19	B-X
samples	B-X
methylated	B-X
)	B-X
.	B-X
The	B-X
restriction	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
hypermethylation	B-X
to	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
pathogenetic	B-X
role	B-X
of	B-X
BRCA1	B-X
promoter	B-X
methylation	B-X
in	B-X
these	B-X
tumours	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
rarity	B-X
of	B-X
observed	B-X
BRCA1	B-X
mutations	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
due	B-X
to	B-X
the	B-X
greater	B-X
likelihood	B-X
of	B-X
BRCA1	B-X
inactivation	B-X
by	B-X
non-mutational	B-X
mechanisms	B-X
such	B-X
as	B-X
methylation	B-X
.	B-X

The	O
role	O
of	O
BRCA1	B-Gene_or_gene_product
in	O
sporadic	O
breast	O
and	O
ovarian	O
cancers	O
remains	O
elusive	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
BRCA1	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
remains	B-X
elusive	B-X
.	B-X
Direct	B-X
involvement	B-X
of	B-X
BRCA1	B-X
in	B-X
the	B-X
development	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
the	B-X
BRCA1	B-X
promoter	B-X
region	B-X
CpG	B-X
island	B-X
is	B-X
methylated	B-X
in	B-X
a	B-X
proportion	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
incidence	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
methylation	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
loss	B-X
of	B-X
BRCA1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
(	B-X
breast	B-X
and	B-X
ovarian	B-X
carcinomas	B-X
)	B-X
with	B-X
the	B-X
incidence	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
BRCA1	B-X
is	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
.	B-X
Promoter	B-X
region	B-X
hypermethylation	B-X
was	B-X
significantly	B-X
more	B-X
common	B-X
(	B-X
P	B-X
<	B-X
0.008	B-X
)	B-X
in	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
(	B-X
6/38	B-X
tumours	B-X
methylated	B-X
)	B-X
than	B-X
in	B-X
colon	B-X
cancer	B-X
(	B-X
0/35	B-X
tumours	B-X
methylated	B-X
)	B-X
or	B-X
in	B-X
leukaemias	B-X
(	B-X
0/19	B-X
samples	B-X
methylated	B-X
)	B-X
.	B-X
The	B-X
restriction	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
hypermethylation	B-X
to	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
pathogenetic	B-X
role	B-X
of	B-X
BRCA1	B-X
promoter	B-X
methylation	B-X
in	B-X
these	B-X
tumours	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
rarity	B-X
of	B-X
observed	B-X
BRCA1	B-X
mutations	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
due	B-X
to	B-X
the	B-X
greater	B-X
likelihood	B-X
of	B-X
BRCA1	B-X
inactivation	B-X
by	B-X
non-mutational	B-X
mechanisms	B-X
such	B-X
as	B-X
methylation	B-X
.	B-X

Direct	O
involvement	O
of	O
BRCA1	B-Gene_or_gene_product
in	O
the	O
development	O
of	O
breast	O
and	O
ovarian	O
cancer	O
is	O
suggested	O
by	O
the	O
finding	O
that	O
the	O
BRCA1	B-Gene_or_gene_product
promoter	O
region	O
CpG	O
island	O
is	O
methylated	O
in	O
a	O
proportion	O
of	O
breast	O
and	O
ovarian	O
cancers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
incidence	O
of	O
BRCA1	B-Gene_or_gene_product
promoter	O
region	O
methylation	O
in	O
tumours	O
in	O
which	O
loss	O
of	O
BRCA1	B-Gene_or_gene_product
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
(	O
breast	O
and	O
ovarian	O
carcinomas	O
)	O
with	O
the	O
incidence	O
in	O
tumours	O
in	O
which	O
BRCA1	B-Gene_or_gene_product
is	O
unlikely	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
BRCA1	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
remains	B-X
elusive	B-X
.	B-X
Direct	B-X
involvement	B-X
of	B-X
BRCA1	B-X
in	B-X
the	B-X
development	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
the	B-X
BRCA1	B-X
promoter	B-X
region	B-X
CpG	B-X
island	B-X
is	B-X
methylated	B-X
in	B-X
a	B-X
proportion	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
incidence	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
methylation	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
loss	B-X
of	B-X
BRCA1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
(	B-X
breast	B-X
and	B-X
ovarian	B-X
carcinomas	B-X
)	B-X
with	B-X
the	B-X
incidence	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
BRCA1	B-X
is	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
.	B-X
Promoter	B-X
region	B-X
hypermethylation	B-X
was	B-X
significantly	B-X
more	B-X
common	B-X
(	B-X
P	B-X
<	B-X
0.008	B-X
)	B-X
in	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
(	B-X
6/38	B-X
tumours	B-X
methylated	B-X
)	B-X
than	B-X
in	B-X
colon	B-X
cancer	B-X
(	B-X
0/35	B-X
tumours	B-X
methylated	B-X
)	B-X
or	B-X
in	B-X
leukaemias	B-X
(	B-X
0/19	B-X
samples	B-X
methylated	B-X
)	B-X
.	B-X
The	B-X
restriction	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
hypermethylation	B-X
to	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
pathogenetic	B-X
role	B-X
of	B-X
BRCA1	B-X
promoter	B-X
methylation	B-X
in	B-X
these	B-X
tumours	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
rarity	B-X
of	B-X
observed	B-X
BRCA1	B-X
mutations	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
due	B-X
to	B-X
the	B-X
greater	B-X
likelihood	B-X
of	B-X
BRCA1	B-X
inactivation	B-X
by	B-X
non-mutational	B-X
mechanisms	B-X
such	B-X
as	B-X
methylation	B-X
.	B-X

Promoter	O
region	O
hypermethylation	O
was	O
significantly	O
more	O
common	O
(	O
P	O
<	O
0	O
.	O
008	O
)	O
in	O
breast	O
and	O
ovarian	O
cancer	O
(	O
6	O
/	O
38	O
tumours	O
methylated	O
)	O
than	O
in	O
colon	O
cancer	O
(	O
0	O
/	O
35	O
tumours	O
methylated	O
)	O
or	O
in	O
leukaemias	O
(	O
0	O
/	O
19	O
samples	O
methylated	O
)	O
.	O

The	O
restriction	O
of	O
BRCA1	B-Gene_or_gene_product
promoter	O
region	O
hypermethylation	O
to	O
breast	O
and	O
ovarian	O
cancer	O
is	O
consistent	O
with	O
a	O
pathogenetic	O
role	O
of	O
BRCA1	B-Gene_or_gene_product
promoter	O
methylation	O
in	O
these	O
tumours	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
BRCA1	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
remains	B-X
elusive	B-X
.	B-X
Direct	B-X
involvement	B-X
of	B-X
BRCA1	B-X
in	B-X
the	B-X
development	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
the	B-X
BRCA1	B-X
promoter	B-X
region	B-X
CpG	B-X
island	B-X
is	B-X
methylated	B-X
in	B-X
a	B-X
proportion	B-X
of	B-X
breast	B-X
and	B-X
ovarian	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
incidence	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
methylation	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
loss	B-X
of	B-X
BRCA1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
(	B-X
breast	B-X
and	B-X
ovarian	B-X
carcinomas	B-X
)	B-X
with	B-X
the	B-X
incidence	B-X
in	B-X
tumours	B-X
in	B-X
which	B-X
BRCA1	B-X
is	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
pathogenesis	B-X
.	B-X
Promoter	B-X
region	B-X
hypermethylation	B-X
was	B-X
significantly	B-X
more	B-X
common	B-X
(	B-X
P	B-X
<	B-X
0.008	B-X
)	B-X
in	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
(	B-X
6/38	B-X
tumours	B-X
methylated	B-X
)	B-X
than	B-X
in	B-X
colon	B-X
cancer	B-X
(	B-X
0/35	B-X
tumours	B-X
methylated	B-X
)	B-X
or	B-X
in	B-X
leukaemias	B-X
(	B-X
0/19	B-X
samples	B-X
methylated	B-X
)	B-X
.	B-X
The	B-X
restriction	B-X
of	B-X
BRCA1	B-X
promoter	B-X
region	B-X
hypermethylation	B-X
to	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
pathogenetic	B-X
role	B-X
of	B-X
BRCA1	B-X
promoter	B-X
methylation	B-X
in	B-X
these	B-X
tumours	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
rarity	B-X
of	B-X
observed	B-X
BRCA1	B-X
mutations	B-X
in	B-X
sporadic	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
is	B-X
due	B-X
to	B-X
the	B-X
greater	B-X
likelihood	B-X
of	B-X
BRCA1	B-X
inactivation	B-X
by	B-X
non-mutational	B-X
mechanisms	B-X
such	B-X
as	B-X
methylation	B-X
.	B-X

We	O
suggest	O
that	O
the	O
rarity	O
of	O
observed	O
BRCA1	B-Gene_or_gene_product
mutations	O
in	O
sporadic	O
breast	O
and	O
ovarian	O
cancer	O
is	O
due	O
to	O
the	O
greater	O
likelihood	O
of	O
BRCA1	B-Gene_or_gene_product
inactivation	O
by	O
non	O
-	O
mutational	O
mechanisms	O
such	O
as	O
methylation	O
.	O

Regulation	O
of	O
the	O
resident	O
chromosomal	O
copy	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
by	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Myb	I-Gene_or_gene_product
is	O
involved	O
in	O
myeloid	O
leukemogenesis	O
.	O

c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myb	I-Gene_or_gene_product
is	O
a	O
frequent	O
target	O
of	O
retroviral	O
insertional	O
mutagenesis	O
in	O
murine	O
leukemia	O
virus	O
-	O
induced	O
myeloid	O
leukemia	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Induction	O
of	O
the	O
leukemogenic	O
phenotype	O
is	O
generally	O
associated	O
with	O
inappropriate	O
expression	O
of	O
this	O
transcriptional	O
regulator	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Despite	O
intensive	O
investigations	O
,	O
the	O
target	O
genes	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myb	I-Gene_or_gene_product
that	O
are	O
specifically	O
involved	O
in	O
development	O
of	O
these	O
myeloid	O
lineage	O
neoplasms	O
are	O
still	O
unknown	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

In	O
vitro	O
assays	O
have	O
indicated	O
that	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
may	O
be	O
a	O
target	O
gene	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Myb	I-Gene_or_gene_product
;	O
however	O
,	O
regulation	O
of	O
the	O
resident	O
chromosomal	O
gene	O
has	O
not	O
yet	O
been	O
demonstrated	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

To	O
address	O
this	O
question	O
further	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
in	O
a	O
myeloblastic	O
cell	O
line	O
,	O
M1	O
,	O
expressing	O
a	O
conditionally	O
active	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Myb	I-Gene_or_gene_product
-	I-Gene_or_gene_product
estrogen	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
fusion	O
protein	O
(	O
MybER	B-Gene_or_gene_product
)	O
.	O

Activation	O
of	O
MybER	B-Gene_or_gene_product
both	O
prevented	O
the	O
growth	O
arrest	O
induced	O
by	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
)	O
and	O
rapidly	O
restored	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
expression	O
in	O
nearly	O
terminal	O
differentiated	O
cells	O
that	O
had	O
been	O
exposed	O
to	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
for	O
3	O
days	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Restoration	O
occurred	O
in	O
the	O
presence	O
of	O
a	O
protein	O
synthesis	O
inhibitor	O
but	O
not	O
after	O
a	O
transcriptional	O
block	O
,	O
indicating	O
that	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
is	O
a	O
direct	O
,	O
transcriptionally	O
regulated	O
target	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Myb	I-Gene_or_gene_product
.	O
<EOS>	B-X
Maintenance	B-X
of	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
corneal	B-X
endothelial	B-X
monolayer	B-X
is	B-X
essential	B-X
for	B-X
corneal	B-X
clarity	B-X
.	B-X
Aging	B-X
,	B-X
trauma	B-X
,	B-X
inflammation	B-X
,	B-X
and	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
diabetes	B-X
,	B-X
can	B-X
compromise	B-X
monolayer	B-X
integrity	B-X
,	B-X
resulting	B-X
in	B-X
corneal	B-X
edema	B-X
and	B-X
loss	B-X
of	B-X
visual	B-X
acuity	B-X
.	B-X
In	B-X
adult	B-X
humans	B-X
,	B-X
repair	B-X
of	B-X
the	B-X
monolayer	B-X
occurs	B-X
mainly	B-X
by	B-X
two	B-X
forms	B-X
of	B-X
cell	B-X
movement	B-X
:	B-X
``	B-X
migration	B-X
,	B-X
''	B-X
in	B-X
which	B-X
individual	B-X
cells	B-X
move	B-X
from	B-X
the	B-X
wound	B-X
edge	B-X
to	B-X
repopulate	B-X
the	B-X
defect	B-X
,	B-X
and	B-X
``	B-X
spreading	B-X
,	B-X
''	B-X
in	B-X
which	B-X
cells	B-X
enlarge	B-X
and	B-X
flatten	B-X
,	B-X
causing	B-X
movement	B-X
of	B-X
the	B-X
monolayer	B-X
as	B-X
a	B-X
sheet	B-X
to	B-X
cover	B-X
the	B-X
defect	B-X
.	B-X
Previous	B-X
studies	B-X
from	B-X
this	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
these	B-X
two	B-X
forms	B-X
of	B-X
movement	B-X
can	B-X
be	B-X
pharmacologically	B-X
separated	B-X
.	B-X
In	B-X
the	B-X
current	B-X
studies	B-X
,	B-X
an	B-X
established	B-X
tissue	B-X
culture	B-X
model	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
prostaglandin	B-X
E2	B-X
(	B-X
PGE2	B-X
)	B-X
and	B-X
of	B-X
mediators	B-X
of	B-X
the	B-X
adenosine	B-X
3',5'-cyclic	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
pathway	B-X
on	B-X
individual	B-X
cell	B-X
migration	B-X
.	B-X
Indomethacin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
prostaglandin	B-X
synthesis	B-X
,	B-X
significantly	B-X
decreased	B-X
individual	B-X
cell	B-X
migration	B-X
below	B-X
levels	B-X
obtained	B-X
when	B-X
wounds	B-X
were	B-X
exposed	B-X
to	B-X
culture	B-X
medium	B-X
alone	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
indomethacin	B-X
,	B-X
forskolin	B-X
,	B-X
a	B-X
direct	B-X
adenylate	B-X
cyclase	B-X
activator	B-X
,	B-X
stimulated	B-X
individual	B-X
cell	B-X
migration	B-X
.	B-X
2',5'-Dideoxyadenosine	B-X
,	B-X
an	B-X
adenylate	B-X
cyclase	B-X
inhibitor	B-X
,	B-X
reversed	B-X
the	B-X
stimulatory	B-X
effects	B-X
of	B-X
both	B-X
forskolin	B-X
and	B-X
PGE2	B-X
.	B-X
Dibutyryl	B-X
cAMP	B-X
(	B-X
DBcAMP	B-X
)	B-X
also	B-X
stimulated	B-X
individual	B-X
cell	B-X
migration	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
indomethacin	B-X
,	B-X
whereas	B-X
,	B-X
H89	B-X
,	B-X
a	B-X
protein	B-X
kinase	B-X
A	B-X
inhibitor	B-X
,	B-X
reversed	B-X
both	B-X
the	B-X
DBcAMP	B-X
and	B-X
PGE2-induced	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
stimulation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
enhances	B-X
individual	B-X
cell	B-X
migration	B-X
and	B-X
that	B-X
PGE2	B-X
,	B-X
acting	B-X
via	B-X
this	B-X
pathway	B-X
,	B-X
may	B-X
be	B-X
an	B-X
endogenous	B-X
stimulator	B-X
of	B-X
this	B-X
response	B-X
during	B-X
corneal	B-X
endothelial	B-X
wound	B-X
repair	B-X
.	B-X

c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
is	O
a	O
major	O
target	O
that	O
transduces	O
Myb	B-Gene_or_gene_product
'	O
s	O
proliferative	O
signal	O
,	O
as	O
shown	O
by	O
the	O
ability	O
of	O
a	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Myc	I-Gene_or_gene_product
-	I-Gene_or_gene_product
estrogen	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
fusion	O
protein	O
alone	O
to	O
also	O
reverse	O
growth	O
arrest	O
in	O
this	O
system	O
.	O

To	O
investigate	O
the	O
possibility	O
that	O
this	O
regulatory	O
connection	O
contributes	O
to	O
Myb	B-Gene_or_gene_product
'	O
s	O
oncogenicity	O
,	O
we	O
expressed	O
a	O
dominant	O
negative	O
Myb	B-Gene_or_gene_product
in	O
the	O
myeloid	O
leukemic	O
cell	O
line	O
RI	O
-	O
4	O
-	O
11	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

In	O
this	O
cell	O
line	O
,	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myb	I-Gene_or_gene_product
is	O
activated	O
by	O
insertional	O
mutagenesis	O
and	O
cannot	O
be	O
effectively	O
down	O
regulated	O
by	O
cytokine	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Myb	B-Gene_or_gene_product
'	O
s	O
ability	O
to	O
regulate	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
'	I-Gene_or_gene_product
s	I-Gene_or_gene_product
expression	O
was	O
also	O
demonstrated	O
in	O
these	O
cells	O
,	O
showing	O
a	O
mechanism	O
through	O
which	O
the	O
proto	O
-	O
oncogene	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myb	I-Gene_or_gene_product
can	O
exert	O
its	O
oncogenic	O
potential	O
in	O
myeloid	O
lineage	O
hematopoietic	O
cells	O
.	O
<EOS>	B-X
c-myb	B-X
is	B-X
a	B-X
frequent	B-X
target	B-X
of	B-X
retroviral	B-X
insertional	B-X
mutagenesis	B-X
in	B-X
murine	B-X
leukemia	B-X
virus-induced	B-X
myeloid	B-X
leukemia	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
leukemogenic	B-X
phenotype	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
inappropriate	B-X
expression	B-X
of	B-X
this	B-X
transcriptional	B-X
regulator	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
the	B-X
target	B-X
genes	B-X
of	B-X
c-myb	B-X
that	B-X
are	B-X
specifically	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
these	B-X
myeloid	B-X
lineage	B-X
neoplasms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
have	B-X
indicated	B-X
that	B-X
c-myc	B-X
may	B-X
be	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
c-Myb	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
the	B-X
resident	B-X
chromosomal	B-X
gene	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
further	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
c-myc	B-X
in	B-X
a	B-X
myeloblastic	B-X
cell	B-X
line	B-X
,	B-X
M1	B-X
,	B-X
expressing	B-X
a	B-X
conditionally	B-X
active	B-X
c-Myb-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
(	B-X
MybER	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
MybER	B-X
both	B-X
prevented	B-X
the	B-X
growth	B-X
arrest	B-X
induced	B-X
by	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
rapidly	B-X
restored	B-X
c-myc	B-X
expression	B-X
in	B-X
nearly	B-X
terminal	B-X
differentiated	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
exposed	B-X
to	B-X
IL-6	B-X
for	B-X
3	B-X
days	B-X
.	B-X
Restoration	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
but	B-X
not	B-X
after	B-X
a	B-X
transcriptional	B-X
block	B-X
,	B-X
indicating	B-X
that	B-X
c-myc	B-X
is	B-X
a	B-X
direct	B-X
,	B-X
transcriptionally	B-X
regulated	B-X
target	B-X
of	B-X
c-Myb	B-X
.	B-X
c-myc	B-X
is	B-X
a	B-X
major	B-X
target	B-X
that	B-X
transduces	B-X
Myb	B-X
's	B-X
proliferative	B-X
signal	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
c-Myc-estrogen	B-X
receptor	B-X
fusion	B-X
protein	B-X
alone	B-X
to	B-X
also	B-X
reverse	B-X
growth	B-X
arrest	B-X
in	B-X
this	B-X
system	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
possibility	B-X
that	B-X
this	B-X
regulatory	B-X
connection	B-X
contributes	B-X
to	B-X
Myb	B-X
's	B-X
oncogenicity	B-X
,	B-X
we	B-X
expressed	B-X
a	B-X
dominant	B-X
negative	B-X
Myb	B-X
in	B-X
the	B-X
myeloid	B-X
leukemic	B-X
cell	B-X
line	B-X
RI-4-11	B-X
.	B-X
In	B-X
this	B-X
cell	B-X
line	B-X
,	B-X
c-myb	B-X
is	B-X
activated	B-X
by	B-X
insertional	B-X
mutagenesis	B-X
and	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
down	B-X
regulated	B-X
by	B-X
cytokine	B-X
.	B-X
Myb	B-X
's	B-X
ability	B-X
to	B-X
regulate	B-X
c-myc	B-X
's	B-X
expression	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
showing	B-X
a	B-X
mechanism	B-X
through	B-X
which	B-X
the	B-X
proto-oncogene	B-X
c-myb	B-X
can	B-X
exert	B-X
its	B-X
oncogenic	B-X
potential	B-X
in	B-X
myeloid	B-X
lineage	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Adenovirus	O
-	O
mediated	O
gene	O
transfer	O
of	O
endostatin	B-Gene_or_gene_product
in	O
vivo	O
results	O
in	O
high	O
level	O
of	O
transgene	O
expression	O
and	O
inhibition	O
of	O
tumor	O
growth	O
and	O
metastases	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
angiogenesis	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
strategy	B-X
in	B-X
cancer	B-X
therapy	B-X
in	B-X
mice	B-X
.	B-X
This	B-X
limitation	B-X
may	B-X
be	B-X
resolved	B-X
by	B-X
in	B-X
vivo	B-X
delivery	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
antiangiogenic	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
a	B-X
recombinant	B-X
adenovirus	B-X
that	B-X
expresses	B-X
murine	B-X
endostatin	B-X
that	B-X
is	B-X
biologically	B-X
active	B-X
both	B-X
in	B-X
vitro	B-X
,	B-X
as	B-X
determined	B-X
in	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
by	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
165	B-X
.	B-X
Persistent	B-X
high	B-X
serum	B-X
levels	B-X
of	B-X
endostatin	B-X
(	B-X
605-1740	B-X
ng/ml	B-X
;	B-X
mean	B-X
,	B-X
936	B-X
ng/ml	B-X
)	B-X
were	B-X
achieved	B-X
after	B-X
systemic	B-X
administration	B-X
of	B-X
the	B-X
vector	B-X
to	B-X
nude	B-X
mice	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
significant	B-X
reduction	B-X
of	B-X
the	B-X
growth	B-X
rates	B-X
and	B-X
the	B-X
volumes	B-X
of	B-X
JC	B-X
breast	B-X
carcinoma	B-X
and	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
and	B-X
P	B-X
<	B-X
0.05	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
endostatin	B-X
vector	B-X
treatment	B-X
completely	B-X
prevented	B-X
the	B-X
formation	B-X
of	B-X
pulmonary	B-X
micrometastases	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
=	B-X
0.0001	B-X
)	B-X
.	B-X
Immunohistochemical	B-X
staining	B-X
of	B-X
the	B-X
tumors	B-X
demonstrated	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
blood	B-X
vessels	B-X
in	B-X
the	B-X
treatment	B-X
group	B-X
versus	B-X
the	B-X
controls	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
present	B-X
study	B-X
clearly	B-X
demonstrates	B-X
the	B-X
potential	B-X
of	B-X
vector-mediated	B-X
antiangiogenic	B-X
gene	B-X
therapy	B-X
as	B-X
a	B-X
component	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X

Inhibition	O
of	O
angiogenesis	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
strategy	O
in	O
cancer	O
therapy	O
in	O
mice	O
.	O
<EOS>	B-X
Anti-angiogenesis	B-X
is	B-X
an	B-X
important	B-X
and	B-X
promising	B-X
strategy	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Anti-angiogenesis	B-X
can	B-X
be	B-X
one	B-X
of	B-X
the	B-X
pathways	B-X
through	B-X
which	B-X
beta-glucans	B-X
can	B-X
reduce	B-X
tumor	B-X
proliferation	B-X
,	B-X
prevent	B-X
tumor	B-X
metastasis	B-X
.	B-X
beta-Glucan	B-X
as	B-X
adjuvant	B-X
to	B-X
cancer	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
demonstrated	B-X
the	B-X
positive	B-X
role	B-X
in	B-X
the	B-X
restoration	B-X
of	B-X
hematopiesis	B-X
following	B-X
by	B-X
bone	B-X
marrow	B-X
injury	B-X
.	B-X
Immunotherapy	B-X
using	B-X
monoclonal	B-X
antibodies	B-X
is	B-X
a	B-X
novel	B-X
strategy	B-X
of	B-X
cancer	B-X
treatment	B-X
.	B-X

However	O
,	O
its	O
widespread	O
application	O
has	O
been	O
hampered	O
by	O
difficulties	O
in	O
the	O
large	O
-	O
scale	O
production	O
of	O
the	O
antiangiogenic	O
proteins	O
.	O
<EOS>	B-X
However	B-X
,	B-X
its	B-X
widespread	B-X
application	B-X
has	B-X
been	B-X
hampered	B-X
by	B-X
difficulties	B-X
in	B-X
the	B-X
large-scale	B-X
production	B-X
of	B-X
the	B-X
antiangiogenic	B-X
proteins	B-X
.	B-X
This	B-X
limitation	B-X
may	B-X
be	B-X
resolved	B-X
by	B-X
in	B-X
vivo	B-X
delivery	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
antiangiogenic	B-X
genes	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
present	B-X
study	B-X
clearly	B-X
demonstrates	B-X
the	B-X
potential	B-X
of	B-X
vector-mediated	B-X
antiangiogenic	B-X
gene	B-X
therapy	B-X
as	B-X
a	B-X
component	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X

This	O
limitation	O
may	O
be	O
resolved	O
by	O
in	O
vivo	O
delivery	O
and	O
expression	O
of	O
the	O
antiangiogenic	O
genes	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
the	B-X
observation	B-X
that	B-X
the	B-X
growth	B-X
of	B-X
solid	B-X
tumors	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
,	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
inhibiting	B-X
angiogenesis	B-X
have	B-X
been	B-X
proposed	B-X
.	B-X
These	B-X
limitations	B-X
may	B-X
be	B-X
resolved	B-X
using	B-X
a	B-X
gene	B-X
therapy	B-X
approach	B-X
whereby	B-X
the	B-X
genes	B-X
are	B-X
delivered	B-X
and	B-X
expressed	B-X
in	B-X
vivo	B-X
.	B-X
Here	B-X
we	B-X
compared	B-X
adenoviral	B-X
delivery	B-X
of	B-X
endostatin	B-X
,	B-X
proliferin-related	B-X
protein	B-X
(	B-X
PRP	B-X
)	B-X
,	B-X
and	B-X
interferon-inducible	B-X
protein	B-X
10	B-X
(	B-X
IP10	B-X
)	B-X
genes	B-X
.	B-X
Recombinant	B-X
adenoviruses	B-X
carrying	B-X
the	B-X
three	B-X
angiostatic	B-X
genes	B-X
express	B-X
biologically	B-X
active	B-X
gene	B-X
products	B-X
as	B-X
determined	B-X
in	B-X
vitro	B-X
in	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
migration	B-X
assays	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
by	B-X
inhibition	B-X
of	B-X
neoangiogenesis	B-X
in	B-X
rat	B-X
chambers	B-X
.	B-X
Eradication	B-X
of	B-X
established	B-X
tumors	B-X
in	B-X
vivo	B-X
,	B-X
in	B-X
the	B-X
murine	B-X
B16F10	B-X
melanoma	B-X
model	B-X
in	B-X
immunocompetent	B-X
mice	B-X
,	B-X
was	B-X
not	B-X
achieved	B-X
by	B-X
intratumoral	B-X
injection	B-X
of	B-X
the	B-X
different	B-X
vectors	B-X
.	B-X
These	B-X
data	B-X
support	B-X
the	B-X
use	B-X
of	B-X
in	B-X
vivo	B-X
gene	B-X
delivery	B-X
approaches	B-X
to	B-X
produce	B-X
high-circulating	B-X
and	B-X
local	B-X
levels	B-X
of	B-X
antiangiogenic	B-X
agents	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
local	B-X
and	B-X
metastatic	B-X
human	B-X
tumors	B-X
.	B-X

We	O
have	O
constructed	O
a	O
recombinant	O
adenovirus	O
that	O
expresses	O
murine	O
endostatin	B-Gene_or_gene_product
that	O
is	O
biologically	O
active	O
both	O
in	O
vitro	O
,	O
as	O
determined	O
in	O
endothelial	O
cell	O
proliferation	O
assays	O
,	O
and	O
in	O
vivo	O
,	O
by	O
suppression	O
of	O
angiogenesis	O
induced	O
by	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
165	I-Gene_or_gene_product
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
angiogenesis	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
strategy	B-X
in	B-X
cancer	B-X
therapy	B-X
in	B-X
mice	B-X
.	B-X
This	B-X
limitation	B-X
may	B-X
be	B-X
resolved	B-X
by	B-X
in	B-X
vivo	B-X
delivery	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
antiangiogenic	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
a	B-X
recombinant	B-X
adenovirus	B-X
that	B-X
expresses	B-X
murine	B-X
endostatin	B-X
that	B-X
is	B-X
biologically	B-X
active	B-X
both	B-X
in	B-X
vitro	B-X
,	B-X
as	B-X
determined	B-X
in	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
by	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
165	B-X
.	B-X
Persistent	B-X
high	B-X
serum	B-X
levels	B-X
of	B-X
endostatin	B-X
(	B-X
605-1740	B-X
ng/ml	B-X
;	B-X
mean	B-X
,	B-X
936	B-X
ng/ml	B-X
)	B-X
were	B-X
achieved	B-X
after	B-X
systemic	B-X
administration	B-X
of	B-X
the	B-X
vector	B-X
to	B-X
nude	B-X
mice	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
significant	B-X
reduction	B-X
of	B-X
the	B-X
growth	B-X
rates	B-X
and	B-X
the	B-X
volumes	B-X
of	B-X
JC	B-X
breast	B-X
carcinoma	B-X
and	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
and	B-X
P	B-X
<	B-X
0.05	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
endostatin	B-X
vector	B-X
treatment	B-X
completely	B-X
prevented	B-X
the	B-X
formation	B-X
of	B-X
pulmonary	B-X
micrometastases	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
=	B-X
0.0001	B-X
)	B-X
.	B-X

Persistent	O
high	O
serum	O
levels	O
of	O
endostatin	B-Gene_or_gene_product
(	O
605	O
-	O
1740	O
ng	O
/	O
ml	O
;	O
mean	O
,	O
936	O
ng	O
/	O
ml	O
)	O
were	O
achieved	O
after	O
systemic	O
administration	O
of	O
the	O
vector	O
to	O
nude	O
mice	O
,	O
which	O
resulted	O
in	O
significant	O
reduction	O
of	O
the	O
growth	O
rates	O
and	O
the	O
volumes	O
of	O
JC	O
breast	O
carcinoma	O
and	O
Lewis	O
lung	O
carcinoma	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
and	O
P	O
less	O
than	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
endostatin	B-Gene_or_gene_product
vector	O
treatment	O
completely	O
prevented	O
the	O
formation	O
of	O
pulmonary	O
micrometastases	O
in	O
Lewis	O
lung	O
carcinoma	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

Immunohistochemical	O
staining	O
of	O
the	O
tumors	O
demonstrated	O
a	O
decreased	O
number	O
of	O
blood	O
vessels	O
in	O
the	O
treatment	O
group	O
versus	O
the	O
controls	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
endostatin	B-X
vector	B-X
treatment	B-X
completely	B-X
prevented	B-X
the	B-X
formation	B-X
of	B-X
pulmonary	B-X
micrometastases	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
=	B-X
0.0001	B-X
)	B-X
.	B-X
Immunohistochemical	B-X
staining	B-X
of	B-X
the	B-X
tumors	B-X
demonstrated	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
blood	B-X
vessels	B-X
in	B-X
the	B-X
treatment	B-X
group	B-X
versus	B-X
the	B-X
controls	B-X
.	B-X

In	O
conclusion	O
,	O
the	O
present	O
study	O
clearly	O
demonstrates	O
the	O
potential	O
of	O
vector	O
-	O
mediated	O
antiangiogenic	O
gene	O
therapy	O
as	O
a	O
component	O
in	O
cancer	O
therapy	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
angiogenesis	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
strategy	B-X
in	B-X
cancer	B-X
therapy	B-X
in	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
its	B-X
widespread	B-X
application	B-X
has	B-X
been	B-X
hampered	B-X
by	B-X
difficulties	B-X
in	B-X
the	B-X
large-scale	B-X
production	B-X
of	B-X
the	B-X
antiangiogenic	B-X
proteins	B-X
.	B-X
This	B-X
limitation	B-X
may	B-X
be	B-X
resolved	B-X
by	B-X
in	B-X
vivo	B-X
delivery	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
antiangiogenic	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
a	B-X
recombinant	B-X
adenovirus	B-X
that	B-X
expresses	B-X
murine	B-X
endostatin	B-X
that	B-X
is	B-X
biologically	B-X
active	B-X
both	B-X
in	B-X
vitro	B-X
,	B-X
as	B-X
determined	B-X
in	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
by	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
165	B-X
.	B-X
Persistent	B-X
high	B-X
serum	B-X
levels	B-X
of	B-X
endostatin	B-X
(	B-X
605-1740	B-X
ng/ml	B-X
;	B-X
mean	B-X
,	B-X
936	B-X
ng/ml	B-X
)	B-X
were	B-X
achieved	B-X
after	B-X
systemic	B-X
administration	B-X
of	B-X
the	B-X
vector	B-X
to	B-X
nude	B-X
mice	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
significant	B-X
reduction	B-X
of	B-X
the	B-X
growth	B-X
rates	B-X
and	B-X
the	B-X
volumes	B-X
of	B-X
JC	B-X
breast	B-X
carcinoma	B-X
and	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
and	B-X
P	B-X
<	B-X
0.05	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
endostatin	B-X
vector	B-X
treatment	B-X
completely	B-X
prevented	B-X
the	B-X
formation	B-X
of	B-X
pulmonary	B-X
micrometastases	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
P	B-X
=	B-X
0.0001	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
present	B-X
study	B-X
clearly	B-X
demonstrates	B-X
the	B-X
potential	B-X
of	B-X
vector-mediated	B-X
antiangiogenic	B-X
gene	B-X
therapy	B-X
as	B-X
a	B-X
component	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X

High	O
frequency	O
of	O
hypermethylation	O
at	O
the	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
sigma	I-Gene_or_gene_product
locus	O
leads	O
to	O
gene	O
silencing	O
in	O
breast	O
cancer	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

Expression	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
final	I-Gene_or_gene_product
sigma	I-Gene_or_gene_product
(	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
)	O
is	O
induced	O
in	O
response	O
to	O
DNA	O
damage	O
,	O
and	O
causes	O
cells	O
to	O
arrest	O
in	O
G	O
(	O
2	O
)	O
.	O

By	O
SAGE	O
(	O
serial	O
analysis	O
of	O
gene	O
expression	O
)	O
analysis	O
,	O
we	O
identified	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
as	O
a	O
gene	O
whose	O
expression	O
is	O
7	O
-	O
fold	O
lower	O
in	O
breast	O
carcinoma	O
cells	O
than	O
in	O
normal	O
breast	O
epithelium	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
We	B-X
verified	B-X
this	B-X
finding	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

We	O
verified	O
this	O
finding	O
by	O
Northern	O
blot	O
analysis	O
.	O
<EOS>	B-X
This	B-X
article	B-X
gives	B-X
an	B-X
outline	B-X
of	B-X
molecular	B-X
biological	B-X
approaches	B-X
to	B-X
analysis	B-X
of	B-X
neurological	B-X
disorders	B-X
such	B-X
as	B-X
giant	B-X
cell	B-X
glioblastoma	B-X
(	B-X
GGBM	B-X
)	B-X
and	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
(	B-X
ALS	B-X
)	B-X
,	B-X
and	B-X
their	B-X
respective	B-X
animal	B-X
models	B-X
:	B-X
p53	B-X
knockout	B-X
mice	B-X
for	B-X
GGBM	B-X
and	B-X
mutant	B-X
superoxide	B-X
dismutase-1	B-X
transgenic	B-X
mice	B-X
for	B-X
ALS	B-X
.	B-X
Genomic	B-X
DNA	B-X
extracted	B-X
from	B-X
fresh-frozen	B-X
tissue	B-X
is	B-X
examined	B-X
by	B-X
Southern	B-X
blotting	B-X
for	B-X
screening	B-X
mutations	B-X
in	B-X
a	B-X
certain	B-X
gene	B-X
.	B-X
Polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
in	B-X
genomic	B-X
DNA	B-X
are	B-X
examined	B-X
by	B-X
single-stranded	B-X
conformation	B-X
polymorphism	B-X
,	B-X
sequencing	B-X
and	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
for	B-X
identifying	B-X
mutations	B-X
,	B-X
and	B-X
for	B-X
preparing	B-X
and	B-X
evaluating	B-X
DNA	B-X
probes	B-X
used	B-X
in	B-X
Southern	B-X
blotting	B-X
and	B-X
DNA	B-X
in	B-X
situ	B-X
hybridization	B-X
(	B-X
ISH	B-X
)	B-X
.	B-X
Total	B-X
RNA	B-X
from	B-X
tissue	B-X
is	B-X
examined	B-X
by	B-X
northern	B-X
blotting	B-X
for	B-X
quantifying	B-X
and	B-X
verifying	B-X
a	B-X
certain	B-X
mRNA	B-X
.	B-X
Reverse	B-X
transcription-PCR	B-X
products	B-X
of	B-X
a	B-X
certain	B-X
mRNA	B-X
in	B-X
total	B-X
RNA	B-X
are	B-X
examined	B-X
by	B-X
sequencing	B-X
and	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
for	B-X
preparing	B-X
and	B-X
evaluating	B-X
cDNA	B-X
probes	B-X
used	B-X
in	B-X
northern	B-X
blotting	B-X
and	B-X
mRNA	B-X
ISH	B-X
.	B-X
Tissue	B-X
total	B-X
protein	B-X
is	B-X
immunoblotted	B-X
for	B-X
quantifying	B-X
and	B-X
verifying	B-X
a	B-X
certain	B-X
protein	B-X
,	B-X
and	B-X
for	B-X
evaluating	B-X
the	B-X
specificity	B-X
of	B-X
antibodies	B-X
used	B-X
in	B-X
western	B-X
blotting	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
Immunoprecipitates	B-X
are	B-X
immunoblotted	B-X
for	B-X
evaluating	B-X
a	B-X
profile	B-X
of	B-X
protein	B-X
or	B-X
other	B-X
substances	B-X
.	B-X
By	B-X
these	B-X
procedures	B-X
,	B-X
chronological	B-X
analysis	B-X
of	B-X
animal	B-X
models	B-X
for	B-X
human	B-X
diseases	B-X
contribute	B-X
to	B-X
elucidating	B-X
pathogenic	B-X
mechanisms	B-X
and	B-X
exploiting	B-X
new	B-X
therapies	B-X
.	B-X

Remarkably	O
,	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
mRNA	O
was	O
undetectable	O
in	O
45	O
of	O
48	O
primary	O
breast	O
carcinomas	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

Genetic	O
alterations	O
at	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
such	O
as	O
loss	O
of	O
heterozygosity	O
were	O
rare	O
(	O
1	O
/	O
20	O
informative	O
cases	O
)	O
,	O
and	O
no	O
mutations	O
were	O
detected	O
(	O
0	O
/	O
34	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
hypermethylation	O
of	O
CpG	O
islands	O
in	O
the	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
gene	O
was	O
detected	O
in	O
91	O
%	O
(	O
75	O
/	O
82	O
)	O
of	O
breast	O
tumors	O
and	O
was	O
associated	O
with	O
lack	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

Hypermethylation	O
of	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
is	O
functionally	O
important	O
,	O
because	O
treatment	O
of	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
-	O
non	O
-	O
expressing	O
breast	O
cancer	O
cell	O
lines	O
with	O
the	O
drug	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
resulted	O
in	O
demethylation	O
of	O
the	O
gene	O
and	O
synthesis	O
of	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
mRNA	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

Breast	O
cancer	O
cells	O
lacking	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
expression	O
showed	O
increased	O
number	O
of	O
chromosomal	O
breaks	O
and	O
gaps	O
when	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

Therefore	O
,	O
it	O
is	O
possible	O
that	O
loss	O
of	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
expression	O
contributes	O
to	O
malignant	O
transformation	O
by	O
impairing	O
the	O
G	O
(	O
2	O
)	O
cell	O
cycle	O
checkpoint	O
function	O
,	O
thus	O
allowing	O
an	O
accumulation	O
of	O
genetic	O
defects	O
.	O

Hypermethylation	O
and	O
loss	O
of	O
final	B-Gene_or_gene_product
sigma	I-Gene_or_gene_product
expression	O
are	O
the	O
most	O
consistent	O
molecular	O
alterations	O
in	O
breast	O
cancer	O
identified	O
so	O
far	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
14-3-3	B-X
final	B-X
sigma	B-X
(	B-X
final	B-X
sigma	B-X
)	B-X
is	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
causes	B-X
cells	B-X
to	B-X
arrest	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
.	B-X
By	B-X
SAGE	B-X
(	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
)	B-X
analysis	B-X
,	B-X
we	B-X
identified	B-X
final	B-X
sigma	B-X
as	B-X
a	B-X
gene	B-X
whose	B-X
expression	B-X
is	B-X
7-fold	B-X
lower	B-X
in	B-X
breast	B-X
carcinoma	B-X
cells	B-X
than	B-X
in	B-X
normal	B-X
breast	B-X
epithelium	B-X
.	B-X
Remarkably	B-X
,	B-X
final	B-X
sigma	B-X
mRNA	B-X
was	B-X
undetectable	B-X
in	B-X
45	B-X
of	B-X
48	B-X
primary	B-X
breast	B-X
carcinomas	B-X
.	B-X
Genetic	B-X
alterations	B-X
at	B-X
final	B-X
sigma	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
rare	B-X
(	B-X
1/20	B-X
informative	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
0/34	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hypermethylation	B-X
of	B-X
CpG	B-X
islands	B-X
in	B-X
the	B-X
final	B-X
sigma	B-X
gene	B-X
was	B-X
detected	B-X
in	B-X
91	B-X
%	B-X
(	B-X
75/82	B-X
)	B-X
of	B-X
breast	B-X
tumors	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Hypermethylation	B-X
of	B-X
final	B-X
sigma	B-X
is	B-X
functionally	B-X
important	B-X
,	B-X
because	B-X
treatment	B-X
of	B-X
final	B-X
sigma-non-expressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
drug	B-X
5-aza-2'-deoxycytidine	B-X
resulted	B-X
in	B-X
demethylation	B-X
of	B-X
the	B-X
gene	B-X
and	B-X
synthesis	B-X
of	B-X
final	B-X
sigma	B-X
mRNA	B-X
.	B-X
Breast	B-X
cancer	B-X
cells	B-X
lacking	B-X
final	B-X
sigma	B-X
expression	B-X
showed	B-X
increased	B-X
number	B-X
of	B-X
chromosomal	B-X
breaks	B-X
and	B-X
gaps	B-X
when	B-X
exposed	B-X
to	B-X
gamma-irradiation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
contributes	B-X
to	B-X
malignant	B-X
transformation	B-X
by	B-X
impairing	B-X
the	B-X
G	B-X
(	B-X
2	B-X
)	B-X
cell	B-X
cycle	B-X
checkpoint	B-X
function	B-X
,	B-X
thus	B-X
allowing	B-X
an	B-X
accumulation	B-X
of	B-X
genetic	B-X
defects	B-X
.	B-X
Hypermethylation	B-X
and	B-X
loss	B-X
of	B-X
final	B-X
sigma	B-X
expression	B-X
are	B-X
the	B-X
most	B-X
consistent	B-X
molecular	B-X
alterations	B-X
in	B-X
breast	B-X
cancer	B-X
identified	B-X
so	B-X
far	B-X
.	B-X

Reduced	O
oncogenicity	O
of	O
p190	B-Gene_or_gene_product
Bcr	I-Gene_or_gene_product
/	I-Gene_or_gene_product
Abl	I-Gene_or_gene_product
F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
actin	I-Gene_or_gene_product
-	O
binding	O
domain	O
mutants	O
.	O
<EOS>	B-X
The	B-X
deregulated	B-X
Bcr/Abl	B-X
tyrosine	B-X
kinase	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
development	B-X
of	B-X
Philadelphia	B-X
(	B-X
Ph	B-X
)	B-X
-positive	B-X
leukemia	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
significance	B-X
of	B-X
the	B-X
C-terminal	B-X
Abl	B-X
actin-binding	B-X
domain	B-X
within	B-X
Bcr/Abl	B-X
p190	B-X
in	B-X
the	B-X
development	B-X
of	B-X
leukemia/lymphoma	B-X
in	B-X
vivo	B-X
,	B-X
mutant	B-X
p190	B-X
DNA	B-X
constructs	B-X
were	B-X
used	B-X
to	B-X
generate	B-X
transgenic	B-X
mice	B-X
.	B-X
Latency	B-X
was	B-X
markedly	B-X
increased	B-X
and	B-X
occurrence	B-X
decreased	B-X
in	B-X
the	B-X
p190	B-X
del	B-X
C	B-X
lines	B-X
as	B-X
compared	B-X
with	B-X
nonmutated	B-X
p190	B-X
BCR/ABL	B-X
transgenics	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
involved	B-X
hematologic	B-X
tissues	B-X
of	B-X
the	B-X
p190	B-X
del	B-X
C	B-X
transgenics	B-X
with	B-X
end-stage	B-X
disease	B-X
showed	B-X
high-level	B-X
expression	B-X
of	B-X
the	B-X
transgene	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
Cbl	B-X
and	B-X
Hef1/Cas	B-X
,	B-X
proteins	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
affected	B-X
by	B-X
Bcr/Abl	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
actin-binding	B-X
domain	B-X
of	B-X
Abl	B-X
enhances	B-X
leukemia	B-X
development	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
leukemogenesis	B-X
.	B-X

The	O
deregulated	O
Bcr	B-Gene_or_gene_product
/	I-Gene_or_gene_product
Abl	I-Gene_or_gene_product
tyrosine	O
kinase	O
is	O
responsible	O
for	O
the	O
development	O
of	O
Philadelphia	O
(	O
Ph	O
)	O
-	O
positive	O
leukemia	O
in	O
humans	O
.	O
<EOS>	B-X
Chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
results	B-X
from	B-X
the	B-X
neoplastic	B-X
transformation	B-X
of	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
has	B-X
been	B-X
classified	B-X
as	B-X
a	B-X
myeloproliferative	B-X
disorder	B-X
.	B-X
The	B-X
hallmark	B-X
of	B-X
CML	B-X
is	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
balanced	B-X
translocation	B-X
between	B-X
the	B-X
long	B-X
arms	B-X
of	B-X
chromosomes	B-X
9	B-X
and	B-X
22	B-X
,	B-X
t	B-X
(	B-X
9	B-X
;	B-X
22	B-X
)	B-X
(	B-X
q34	B-X
;	B-X
q11.2	B-X
)	B-X
,	B-X
which	B-X
is	B-X
known	B-X
as	B-X
the	B-X
Philadelphia	B-X
(	B-X
Ph	B-X
)	B-X
chromosome	B-X
.	B-X
This	B-X
translocation	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
bcr-abl	B-X
fusion	B-X
gene	B-X
,	B-X
which	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
is	B-X
translated	B-X
into	B-X
a	B-X
chimeric	B-X
Bcr-Abl	B-X
protein	B-X
with	B-X
deregulated	B-X
tyrosine	B-X
kinase	B-X
activity	B-X
.	B-X
Constitutive	B-X
Bcr-Abl	B-X
expression	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
the	B-X
transformed	B-X
phenotype	B-X
of	B-X
CML	B-X
cells	B-X
.	B-X
CML	B-X
is	B-X
unique	B-X
among	B-X
human	B-X
cancers	B-X
in	B-X
that	B-X
a	B-X
single	B-X
genetic	B-X
defect	B-X
,	B-X
the	B-X
Ph	B-X
chromosome	B-X
,	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
transformed	B-X
phenotype	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
authors	B-X
describe	B-X
the	B-X
molecular	B-X
biology	B-X
of	B-X
CML	B-X
and	B-X
the	B-X
development	B-X
of	B-X
imatinib	B-X
as	B-X
a	B-X
therapeutic	B-X
agent	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
CML	B-X
.	B-X

To	O
investigate	O
the	O
significance	O
of	O
the	O
C	O
-	O
terminal	O
Abl	B-Gene_or_gene_product
actin	B-Gene_or_gene_product
-	O
binding	O
domain	O
within	O
Bcr	B-Gene_or_gene_product
/	I-Gene_or_gene_product
Abl	I-Gene_or_gene_product
p190	I-Gene_or_gene_product
in	O
the	O
development	O
of	O
leukemia	O
/	O
lymphoma	O
in	O
vivo	O
,	O
mutant	O
p190	B-Gene_or_gene_product
DNA	O
constructs	O
were	O
used	O
to	O
generate	O
transgenic	O
mice	O
.	O

Eight	O
founder	O
and	O
progeny	O
mice	O
of	O
5	O
different	O
lines	O
were	O
monitored	O
for	O
leukemogenesis	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
significance	B-X
of	B-X
the	B-X
C-terminal	B-X
Abl	B-X
actin-binding	B-X
domain	B-X
within	B-X
Bcr/Abl	B-X
p190	B-X
in	B-X
the	B-X
development	B-X
of	B-X
leukemia/lymphoma	B-X
in	B-X
vivo	B-X
,	B-X
mutant	B-X
p190	B-X
DNA	B-X
constructs	B-X
were	B-X
used	B-X
to	B-X
generate	B-X
transgenic	B-X
mice	B-X
.	B-X
Eight	B-X
founder	B-X
and	B-X
progeny	B-X
mice	B-X
of	B-X
5	B-X
different	B-X
lines	B-X
were	B-X
monitored	B-X
for	B-X
leukemogenesis	B-X
.	B-X
Latency	B-X
was	B-X
markedly	B-X
increased	B-X
and	B-X
occurrence	B-X
decreased	B-X
in	B-X
the	B-X
p190	B-X
del	B-X
C	B-X
lines	B-X
as	B-X
compared	B-X
with	B-X
nonmutated	B-X
p190	B-X
BCR/ABL	B-X
transgenics	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
actin-binding	B-X
domain	B-X
of	B-X
Abl	B-X
enhances	B-X
leukemia	B-X
development	B-X
but	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
leukemogenesis	B-X
.	B-X

Latency	O
was	O
markedly	O
increased	O
and	O
occurrence	O
decreased	O
in	O
the	O
p190	B-Gene_or_gene_product
del	O
C	O
lines	O
as	O
compared	O
with	O
nonmutated	O
p190	B-Gene_or_gene_product
BCR	I-Gene_or_gene_product
/	I-Gene_or_gene_product
ABL	I-Gene_or_gene_product
transgenics	O
.	O

Western	O
blot	O
analysis	O
of	O
involved	O
hematologic	O
tissues	O
of	O
the	O
p190	B-Gene_or_gene_product
del	O
C	O
transgenics	O
with	O
end	O
-	O
stage	O
disease	O
showed	O
high	O
-	O
level	O
expression	O
of	O
the	O
transgene	O
and	O
tyrosine	O
phosphorylation	O
of	O
Cbl	B-Gene_or_gene_product
and	O
Hef1	B-Gene_or_gene_product
/	O
Cas	B-Gene_or_gene_product
,	O
proteins	O
previously	O
shown	O
to	O
be	O
affected	O
by	O
Bcr	B-Gene_or_gene_product
/	I-Gene_or_gene_product
Abl	I-Gene_or_gene_product
.	O

These	O
results	O
show	O
that	O
the	O
actin	B-Gene_or_gene_product
-	O
binding	O
domain	O
of	O
Abl	B-Gene_or_gene_product
enhances	O
leukemia	O
development	O
but	O
does	O
not	O
appear	O
to	O
be	O
an	O
absolute	O
requirement	O
for	O
leukemogenesis	O
.	O

Building	O
the	O
vertebrate	O
vasculature	O
:	O
research	O
is	O
going	O
swimmingly	O
.	O
<EOS>	B-X
The	B-X
vertebrate	B-X
vasculature	B-X
develops	B-X
in	B-X
remarkably	B-X
similar	B-X
fashion	B-X
in	B-X
all	B-X
vertebrates	B-X
.	B-X
A	B-X
cohort	B-X
of	B-X
unspecified	B-X
mesodermal	B-X
cells	B-X
differentiates	B-X
into	B-X
primitive	B-X
endothelial	B-X
cells	B-X
,	B-X
which	B-X
migrate	B-X
to	B-X
and	B-X
occupy	B-X
positions	B-X
within	B-X
the	B-X
stereotypical	B-X
blueprint	B-X
of	B-X
the	B-X
primitive	B-X
vasculature	B-X
.	B-X
Various	B-X
studies	B-X
using	B-X
the	B-X
mouse	B-X
,	B-X
quail/chick	B-X
,	B-X
and	B-X
frog	B-X
have	B-X
uncovered	B-X
a	B-X
number	B-X
of	B-X
signals	B-X
that	B-X
guide	B-X
these	B-X
complex	B-X
processes	B-X
but	B-X
many	B-X
gaps	B-X
still	B-X
exist	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
embryonic	B-X
vasculature	B-X
is	B-X
built	B-X
.	B-X

The	O
vertebrate	O
vasculature	O
develops	O
in	O
remarkably	O
similar	O
fashion	O
in	O
all	O
vertebrates	O
.	O
<EOS>	B-X
The	B-X
vertebrate	B-X
vasculature	B-X
develops	B-X
in	B-X
remarkably	B-X
similar	B-X
fashion	B-X
in	B-X
all	B-X
vertebrates	B-X
.	B-X
A	B-X
cohort	B-X
of	B-X
unspecified	B-X
mesodermal	B-X
cells	B-X
differentiates	B-X
into	B-X
primitive	B-X
endothelial	B-X
cells	B-X
,	B-X
which	B-X
migrate	B-X
to	B-X
and	B-X
occupy	B-X
positions	B-X
within	B-X
the	B-X
stereotypical	B-X
blueprint	B-X
of	B-X
the	B-X
primitive	B-X
vasculature	B-X
.	B-X
Various	B-X
studies	B-X
using	B-X
the	B-X
mouse	B-X
,	B-X
quail/chick	B-X
,	B-X
and	B-X
frog	B-X
have	B-X
uncovered	B-X
a	B-X
number	B-X
of	B-X
signals	B-X
that	B-X
guide	B-X
these	B-X
complex	B-X
processes	B-X
but	B-X
many	B-X
gaps	B-X
still	B-X
exist	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
embryonic	B-X
vasculature	B-X
is	B-X
built	B-X
.	B-X
Protein	B-X
expression	B-X
induced	B-X
by	B-X
PC	B-X
exhibited	B-X
a	B-X
similar	B-X
profile	B-X
.	B-X
Therefore	B-X
,	B-X
PC	B-X
that	B-X
results	B-X
in	B-X
brain	B-X
tolerance/neuroprotection	B-X
increases	B-X
neuronal	B-X
Hsp70	B-X
in	B-X
the	B-X
PC	B-X
cortex	B-X
and	B-X
activated	B-X
astrocytic	B-X
Hsp27	B-X
in	B-X
the	B-X
PC	B-X
cortex	B-X
in	B-X
a	B-X
temporal	B-X
fashion	B-X
associated	B-X
with	B-X
developing	B-X
IT	B-X
.	B-X

A	O
cohort	O
of	O
unspecified	O
mesodermal	O
cells	O
differentiates	O
into	O
primitive	O
endothelial	O
cells	O
,	O
which	O
migrate	O
to	O
and	O
occupy	O
positions	O
within	O
the	O
stereotypical	O
blueprint	O
of	O
the	O
primitive	O
vasculature	O
.	O
<EOS>	B-X
The	B-X
vertebrate	B-X
vasculature	B-X
develops	B-X
in	B-X
remarkably	B-X
similar	B-X
fashion	B-X
in	B-X
all	B-X
vertebrates	B-X
.	B-X
A	B-X
cohort	B-X
of	B-X
unspecified	B-X
mesodermal	B-X
cells	B-X
differentiates	B-X
into	B-X
primitive	B-X
endothelial	B-X
cells	B-X
,	B-X
which	B-X
migrate	B-X
to	B-X
and	B-X
occupy	B-X
positions	B-X
within	B-X
the	B-X
stereotypical	B-X
blueprint	B-X
of	B-X
the	B-X
primitive	B-X
vasculature	B-X
.	B-X
Once	B-X
in	B-X
position	B-X
,	B-X
these	B-X
cells	B-X
coalesce	B-X
and	B-X
form	B-X
cords	B-X
,	B-X
which	B-X
lumenize	B-X
and	B-X
become	B-X
ensheathed	B-X
by	B-X
supporting	B-X
pericytes	B-X
and	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
This	B-X
primitive	B-X
vascular	B-X
network	B-X
is	B-X
extensively	B-X
remodeled	B-X
in	B-X
some	B-X
places	B-X
,	B-X
and	B-X
expanded	B-X
by	B-X
sprouting	B-X
in	B-X
others	B-X
.	B-X
Various	B-X
studies	B-X
using	B-X
the	B-X
mouse	B-X
,	B-X
quail/chick	B-X
,	B-X
and	B-X
frog	B-X
have	B-X
uncovered	B-X
a	B-X
number	B-X
of	B-X
signals	B-X
that	B-X
guide	B-X
these	B-X
complex	B-X
processes	B-X
but	B-X
many	B-X
gaps	B-X
still	B-X
exist	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
embryonic	B-X
vasculature	B-X
is	B-X
built	B-X
.	B-X

Once	O
in	O
position	O
,	O
these	O
cells	O
coalesce	O
and	O
form	O
cords	O
,	O
which	O
lumenize	O
and	O
become	O
ensheathed	O
by	O
supporting	O
pericytes	O
and	O
smooth	O
muscle	O
cells	O
.	O
<EOS>	B-X
A	B-X
cohort	B-X
of	B-X
unspecified	B-X
mesodermal	B-X
cells	B-X
differentiates	B-X
into	B-X
primitive	B-X
endothelial	B-X
cells	B-X
,	B-X
which	B-X
migrate	B-X
to	B-X
and	B-X
occupy	B-X
positions	B-X
within	B-X
the	B-X
stereotypical	B-X
blueprint	B-X
of	B-X
the	B-X
primitive	B-X
vasculature	B-X
.	B-X
Once	B-X
in	B-X
position	B-X
,	B-X
these	B-X
cells	B-X
coalesce	B-X
and	B-X
form	B-X
cords	B-X
,	B-X
which	B-X
lumenize	B-X
and	B-X
become	B-X
ensheathed	B-X
by	B-X
supporting	B-X
pericytes	B-X
and	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Because	B-X
many	B-X
questions	B-X
will	B-X
require	B-X
in	B-X
vivo	B-X
studies	B-X
to	B-X
be	B-X
properly	B-X
addressed	B-X
,	B-X
the	B-X
zebrafish	B-X
,	B-X
with	B-X
its	B-X
unique	B-X
accessibility	B-X
to	B-X
analysis	B-X
by	B-X
combined	B-X
embryological	B-X
,	B-X
molecular	B-X
,	B-X
and	B-X
genetic	B-X
methods	B-X
,	B-X
should	B-X
prove	B-X
invaluable	B-X
in	B-X
identifying	B-X
new	B-X
molecules	B-X
involved	B-X
in	B-X
blood	B-X
vessel	B-X
development	B-X
and	B-X
integrating	B-X
pathways	B-X
that	B-X
influence	B-X
embryonic	B-X
blood	B-X
vessel	B-X
formation	B-X
.	B-X

This	O
primitive	O
vascular	O
network	O
is	O
extensively	O
remodeled	O
in	O
some	O
places	O
,	O
and	O
expanded	O
by	O
sprouting	O
in	O
others	O
.	O
<EOS>	B-X
A	B-X
cohort	B-X
of	B-X
unspecified	B-X
mesodermal	B-X
cells	B-X
differentiates	B-X
into	B-X
primitive	B-X
endothelial	B-X
cells	B-X
,	B-X
which	B-X
migrate	B-X
to	B-X
and	B-X
occupy	B-X
positions	B-X
within	B-X
the	B-X
stereotypical	B-X
blueprint	B-X
of	B-X
the	B-X
primitive	B-X
vasculature	B-X
.	B-X
This	B-X
primitive	B-X
vascular	B-X
network	B-X
is	B-X
extensively	B-X
remodeled	B-X
in	B-X
some	B-X
places	B-X
,	B-X
and	B-X
expanded	B-X
by	B-X
sprouting	B-X
in	B-X
others	B-X
.	B-X

Various	O
studies	O
using	O
the	O
mouse	O
,	O
quail	O
/	O
chick	O
,	O
and	O
frog	O
have	O
uncovered	O
a	O
number	O
of	O
signals	O
that	O
guide	O
these	O
complex	O
processes	O
but	O
many	O
gaps	O
still	O
exist	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
the	O
embryonic	O
vasculature	O
is	O
built	O
.	O
<EOS>	B-X
The	B-X
vertebrate	B-X
vasculature	B-X
develops	B-X
in	B-X
remarkably	B-X
similar	B-X
fashion	B-X
in	B-X
all	B-X
vertebrates	B-X
.	B-X
A	B-X
cohort	B-X
of	B-X
unspecified	B-X
mesodermal	B-X
cells	B-X
differentiates	B-X
into	B-X
primitive	B-X
endothelial	B-X
cells	B-X
,	B-X
which	B-X
migrate	B-X
to	B-X
and	B-X
occupy	B-X
positions	B-X
within	B-X
the	B-X
stereotypical	B-X
blueprint	B-X
of	B-X
the	B-X
primitive	B-X
vasculature	B-X
.	B-X
Various	B-X
studies	B-X
using	B-X
the	B-X
mouse	B-X
,	B-X
quail/chick	B-X
,	B-X
and	B-X
frog	B-X
have	B-X
uncovered	B-X
a	B-X
number	B-X
of	B-X
signals	B-X
that	B-X
guide	B-X
these	B-X
complex	B-X
processes	B-X
but	B-X
many	B-X
gaps	B-X
still	B-X
exist	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
embryonic	B-X
vasculature	B-X
is	B-X
built	B-X
.	B-X
Because	B-X
many	B-X
questions	B-X
will	B-X
require	B-X
in	B-X
vivo	B-X
studies	B-X
to	B-X
be	B-X
properly	B-X
addressed	B-X
,	B-X
the	B-X
zebrafish	B-X
,	B-X
with	B-X
its	B-X
unique	B-X
accessibility	B-X
to	B-X
analysis	B-X
by	B-X
combined	B-X
embryological	B-X
,	B-X
molecular	B-X
,	B-X
and	B-X
genetic	B-X
methods	B-X
,	B-X
should	B-X
prove	B-X
invaluable	B-X
in	B-X
identifying	B-X
new	B-X
molecules	B-X
involved	B-X
in	B-X
blood	B-X
vessel	B-X
development	B-X
and	B-X
integrating	B-X
pathways	B-X
that	B-X
influence	B-X
embryonic	B-X
blood	B-X
vessel	B-X
formation	B-X
.	B-X

Because	O
many	O
questions	O
will	O
require	O
in	O
vivo	O
studies	O
to	O
be	O
properly	O
addressed	O
,	O
the	O
zebrafish	O
,	O
with	O
its	O
unique	O
accessibility	O
to	O
analysis	O
by	O
combined	O
embryological	O
,	O
molecular	O
,	O
and	O
genetic	O
methods	O
,	O
should	O
prove	O
invaluable	O
in	O
identifying	O
new	O
molecules	O
involved	O
in	O
blood	O
vessel	O
development	O
and	O
integrating	O
pathways	O
that	O
influence	O
embryonic	O
blood	O
vessel	O
formation	O
.	O
<EOS>	B-X
Various	B-X
studies	B-X
using	B-X
the	B-X
mouse	B-X
,	B-X
quail/chick	B-X
,	B-X
and	B-X
frog	B-X
have	B-X
uncovered	B-X
a	B-X
number	B-X
of	B-X
signals	B-X
that	B-X
guide	B-X
these	B-X
complex	B-X
processes	B-X
but	B-X
many	B-X
gaps	B-X
still	B-X
exist	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
embryonic	B-X
vasculature	B-X
is	B-X
built	B-X
.	B-X
Because	B-X
many	B-X
questions	B-X
will	B-X
require	B-X
in	B-X
vivo	B-X
studies	B-X
to	B-X
be	B-X
properly	B-X
addressed	B-X
,	B-X
the	B-X
zebrafish	B-X
,	B-X
with	B-X
its	B-X
unique	B-X
accessibility	B-X
to	B-X
analysis	B-X
by	B-X
combined	B-X
embryological	B-X
,	B-X
molecular	B-X
,	B-X
and	B-X
genetic	B-X
methods	B-X
,	B-X
should	B-X
prove	B-X
invaluable	B-X
in	B-X
identifying	B-X
new	B-X
molecules	B-X
involved	B-X
in	B-X
blood	B-X
vessel	B-X
development	B-X
and	B-X
integrating	B-X
pathways	B-X
that	B-X
influence	B-X
embryonic	B-X
blood	B-X
vessel	B-X
formation	B-X
.	B-X

[	O
Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
and	O
new	O
drugs	O
.	O
Protective	O
effect	O
against	O
tumor	O
growth	O
and	O
infections	O
]	O
.	O
<EOS>	B-X
IL-18	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
interferon-gamma	B-X
inducing	B-X
factor	B-X
(	B-X
IGIF	B-X
)	B-X
,	B-X
is	B-X
related	B-X
to	B-X
the	B-X
IL-1	B-X
family	B-X
in	B-X
terms	B-X
of	B-X
its	B-X
structure	B-X
as	B-X
well	B-X
as	B-X
its	B-X
processing	B-X
,	B-X
receptor	B-X
,	B-X
signal	B-X
transduction	B-X
pathway	B-X
and	B-X
pro-inflammatory	B-X
properties	B-X
.	B-X
IL-18	B-X
is	B-X
also	B-X
functionally	B-X
related	B-X
to	B-X
IL-12	B-X
,	B-X
as	B-X
it	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
Th1	B-X
cytokines	B-X
and	B-X
participates	B-X
in	B-X
cell-mediated	B-X
immune	B-X
cytotoxicity	B-X
.	B-X
A	B-X
summary	B-X
is	B-X
made	B-X
of	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
IL-18	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
receptor	B-X
expression	B-X
and	B-X
immunoregulatory	B-X
functions	B-X
.	B-X
It	B-X
focuses	B-X
on	B-X
the	B-X
role	B-X
of	B-X
IL-18	B-X
modulation	B-X
in	B-X
tumours	B-X
,	B-X
infections	B-X
and	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
.	B-X

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
,	O
originally	O
identified	O
as	O
interferon	B-Gene_or_gene_product
-	I-Gene_or_gene_product
gamma	I-Gene_or_gene_product
inducing	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
IGIF	B-Gene_or_gene_product
)	O
,	O
is	O
related	O
to	O
the	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
family	O
in	O
terms	O
of	O
its	O
structure	O
as	O
well	O
as	O
its	O
processing	O
,	O
receptor	O
,	O
signal	O
transduction	O
pathway	O
and	O
pro	O
-	O
inflammatory	O
properties	O
.	O

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
is	O
also	O
functionally	O
related	O
to	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
12	I-Gene_or_gene_product
,	O
as	O
it	O
induces	O
the	O
production	O
of	O
Th1	B-Gene_or_gene_product
cytokines	O
and	O
participates	O
in	O
cell	O
-	O
mediated	O
immune	O
cytotoxicity	O
.	O
<EOS>	B-X
Interleukin-18	B-X
(	B-X
IL-18	B-X
)	B-X
is	B-X
a	B-X
proinflammatory	B-X
cytokine	B-X
that	B-X
belongs	B-X
to	B-X
the	B-X
IL-1	B-X
cytokine	B-X
family	B-X
,	B-X
due	B-X
to	B-X
its	B-X
structure	B-X
,	B-X
receptor	B-X
family	B-X
and	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
Similarly	B-X
to	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
is	B-X
synthesized	B-X
as	B-X
a	B-X
precursor	B-X
requiring	B-X
caspase-1	B-X
for	B-X
cleavage	B-X
into	B-X
an	B-X
active	B-X
IL-18	B-X
molecule	B-X
.	B-X
However	B-X
,	B-X
with	B-X
regard	B-X
to	B-X
its	B-X
capacity	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
Th1	B-X
cytokines	B-X
and	B-X
to	B-X
enhance	B-X
cell-mediated	B-X
cytotoxicity	B-X
,	B-X
IL-18	B-X
is	B-X
also	B-X
related	B-X
to	B-X
IL-12	B-X
.	B-X
Produced	B-X
mainly	B-X
by	B-X
antigen-presenting	B-X
cells	B-X
,	B-X
IL-18	B-X
is	B-X
a	B-X
pleiotropic	B-X
factor	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
both	B-X
innate	B-X
and	B-X
acquired	B-X
immune	B-X
responses	B-X
,	B-X
playing	B-X
a	B-X
key	B-X
role	B-X
in	B-X
autoimmune	B-X
,	B-X
inflammatory	B-X
,	B-X
and	B-X
infectious	B-X
diseases	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
IL-18	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
receptor	B-X
expression	B-X
,	B-X
and	B-X
immunoregulatory	B-X
functions	B-X
and	B-X
emphasizes	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
this	B-X
cytokine	B-X
in	B-X
bacterial	B-X
infections	B-X
.	B-X
It	B-X
focuses	B-X
on	B-X
the	B-X
participation	B-X
of	B-X
this	B-X
cytokine	B-X
in	B-X
the	B-X
defense	B-X
against	B-X
intracellular	B-X
bacteria	B-X
,	B-X
including	B-X
Listeria	B-X
,	B-X
Shigella	B-X
,	B-X
Salmonella	B-X
,	B-X
and	B-X
Mycobacterium	B-X
tuberculosis	B-X
.	B-X
Since	B-X
this	B-X
cytokine	B-X
may	B-X
be	B-X
particularly	B-X
useful	B-X
in	B-X
immunoprophylactic	B-X
and	B-X
immunotherapeutic	B-X
interventions	B-X
in	B-X
which	B-X
the	B-X
cellular	B-X
response	B-X
is	B-X
most	B-X
desirable	B-X
,	B-X
the	B-X
potential	B-X
therapeutic	B-X
aspects	B-X
of	B-X
IL-18	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X

A	O
summary	O
is	O
made	O
of	O
recent	O
advances	O
in	O
the	O
understanding	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
structure	O
,	O
processing	O
,	O
receptor	O
expression	O
and	O
immunoregulatory	O
functions	O
.	O
<EOS>	B-X
IL-18	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
interferon-gamma	B-X
inducing	B-X
factor	B-X
(	B-X
IGIF	B-X
)	B-X
,	B-X
is	B-X
related	B-X
to	B-X
the	B-X
IL-1	B-X
family	B-X
in	B-X
terms	B-X
of	B-X
its	B-X
structure	B-X
as	B-X
well	B-X
as	B-X
its	B-X
processing	B-X
,	B-X
receptor	B-X
,	B-X
signal	B-X
transduction	B-X
pathway	B-X
and	B-X
pro-inflammatory	B-X
properties	B-X
.	B-X
IL-18	B-X
is	B-X
also	B-X
functionally	B-X
related	B-X
to	B-X
IL-12	B-X
,	B-X
as	B-X
it	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
Th1	B-X
cytokines	B-X
and	B-X
participates	B-X
in	B-X
cell-mediated	B-X
immune	B-X
cytotoxicity	B-X
.	B-X
A	B-X
summary	B-X
is	B-X
made	B-X
of	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
IL-18	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
receptor	B-X
expression	B-X
and	B-X
immunoregulatory	B-X
functions	B-X
.	B-X
It	B-X
focuses	B-X
on	B-X
the	B-X
role	B-X
of	B-X
IL-18	B-X
modulation	B-X
in	B-X
tumours	B-X
,	B-X
infections	B-X
and	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
.	B-X

It	O
focuses	O
on	O
the	O
role	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
modulation	O
in	O
tumours	O
,	O
infections	O
and	O
autoimmune	O
and	O
inflammatory	O
diseases	O
.	O
<EOS>	B-X
IL-18	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
interferon-gamma	B-X
inducing	B-X
factor	B-X
(	B-X
IGIF	B-X
)	B-X
,	B-X
is	B-X
related	B-X
to	B-X
the	B-X
IL-1	B-X
family	B-X
in	B-X
terms	B-X
of	B-X
its	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
receptor	B-X
,	B-X
signal	B-X
transduction	B-X
pathway	B-X
and	B-X
pro-inflammatory	B-X
properties	B-X
.	B-X
IL-18	B-X
is	B-X
also	B-X
functionally	B-X
related	B-X
to	B-X
IL-12	B-X
,	B-X
as	B-X
it	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
Th1	B-X
cytokines	B-X
and	B-X
participates	B-X
in	B-X
cell-mediated	B-X
immune	B-X
cytotoxicity	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
IL-18	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
receptor	B-X
expression	B-X
and	B-X
immunoregulatory	B-X
functions	B-X
,	B-X
and	B-X
focuses	B-X
on	B-X
the	B-X
role	B-X
of	B-X
IL-18	B-X
modulation	B-X
in	B-X
tumours	B-X
,	B-X
infections	B-X
,	B-X
and	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
.	B-X
IL-18	B-X
,	B-X
originally	B-X
identified	B-X
as	B-X
interferon-gamma	B-X
inducing	B-X
factor	B-X
(	B-X
IGIF	B-X
)	B-X
,	B-X
is	B-X
related	B-X
to	B-X
the	B-X
IL-1	B-X
family	B-X
in	B-X
terms	B-X
of	B-X
its	B-X
structure	B-X
as	B-X
well	B-X
as	B-X
its	B-X
processing	B-X
,	B-X
receptor	B-X
,	B-X
signal	B-X
transduction	B-X
pathway	B-X
and	B-X
pro-inflammatory	B-X
properties	B-X
.	B-X
IL-18	B-X
is	B-X
also	B-X
functionally	B-X
related	B-X
to	B-X
IL-12	B-X
,	B-X
as	B-X
it	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
Th1	B-X
cytokines	B-X
and	B-X
participates	B-X
in	B-X
cell-mediated	B-X
immune	B-X
cytotoxicity	B-X
.	B-X
A	B-X
summary	B-X
is	B-X
made	B-X
of	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
IL-18	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
receptor	B-X
expression	B-X
and	B-X
immunoregulatory	B-X
functions	B-X
.	B-X
It	B-X
focuses	B-X
on	B-X
the	B-X
role	B-X
of	B-X
IL-18	B-X
modulation	B-X
in	B-X
tumours	B-X
,	B-X
infections	B-X
and	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
.	B-X

A	O
small	O
peptide	O
derived	O
from	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
.	O
<EOS>	B-X
Immunotherapy	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
effective	B-X
as	B-X
a	B-X
first-line	B-X
treatment	B-X
option	B-X
for	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
patients	B-X
.	B-X
Endostar	B-X
is	B-X
a	B-X
novel	B-X
recombinant	B-X
human	B-X
endostatin	B-X
that	B-X
exerts	B-X
its	B-X
anti-angiogenic	B-X
effects	B-X
via	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
-related	B-X
signalling	B-X
pathways	B-X
.	B-X
Anti-programmed	B-X
death	B-X
receptor	B-X
1	B-X
(	B-X
PD-1	B-X
)	B-X
antibody	B-X
is	B-X
an	B-X
immune	B-X
checkpoint	B-X
inhibitor	B-X
that	B-X
was	B-X
developed	B-X
to	B-X
stimulate	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
synergy	B-X
of	B-X
PD-1	B-X
blockade	B-X
and	B-X
endostar	B-X
was	B-X
assessed	B-X
in	B-X
a	B-X
lung	B-X
carcinoma	B-X
mouse	B-X
model	B-X
.	B-X

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
is	O
an	O
angiogenic	O
stimulator	O
which	O
functions	O
through	O
two	O
endothelial	O
specific	O
tyrosine	O
kinase	O
receptors	O
,	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
Flk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
a	B-X
process	B-X
of	B-X
development	B-X
and	B-X
of	B-X
growth	B-X
of	B-X
new	B-X
capillary	B-X
blood	B-X
vessels	B-X
from	B-X
pre-existing	B-X
vessels	B-X
.	B-X
The	B-X
transition	B-X
from	B-X
the	B-X
latent	B-X
phase	B-X
to	B-X
the	B-X
invasive	B-X
and	B-X
metastatic	B-X
phase	B-X
of	B-X
a	B-X
cancer	B-X
is	B-X
linked	B-X
to	B-X
what	B-X
is	B-X
called	B-X
the	B-X
angiogenic	B-X
switch	B-X
.	B-X
It	B-X
implies	B-X
complex	B-X
cellular	B-X
and	B-X
molecular	B-X
interactions	B-X
between	B-X
cancerous	B-X
cells	B-X
,	B-X
endothelial	B-X
cells	B-X
and	B-X
the	B-X
components	B-X
of	B-X
the	B-X
extra-cellular	B-X
matrix	B-X
and	B-X
namely	B-X
the	B-X
existence	B-X
of	B-X
specific	B-X
proteins	B-X
secreted	B-X
by	B-X
the	B-X
tumoral	B-X
cells	B-X
able	B-X
to	B-X
stimulate	B-X
the	B-X
proliferation	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
VEGF	B-X
,	B-X
Vascular	B-X
Endothelial	B-X
Growth	B-X
Factor	B-X
was	B-X
found	B-X
in	B-X
several	B-X
types	B-X
of	B-X
tumors	B-X
.	B-X
It	B-X
has	B-X
shown	B-X
a	B-X
tumoral	B-X
angiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
thus	B-X
is	B-X
a	B-X
privileged	B-X
target	B-X
for	B-X
the	B-X
control	B-X
of	B-X
angiogenesis	B-X
in	B-X
an	B-X
anti-tumoral	B-X
goal	B-X
.	B-X
The	B-X
role	B-X
of	B-X
VEGF	B-X
in	B-X
tumoral	B-X
angiogenesis	B-X
has	B-X
been	B-X
extensively	B-X
studied	B-X
.	B-X
During	B-X
the	B-X
last	B-X
few	B-X
years	B-X
,	B-X
several	B-X
members	B-X
of	B-X
the	B-X
VEGF	B-X
family	B-X
have	B-X
been	B-X
described	B-X
namely	B-X
the	B-X
VEGF-A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
and	B-X
placenta	B-X
growth	B-X
factor	B-X
(	B-X
PlGF	B-X
)	B-X
among	B-X
which	B-X
VEGF-A	B-X
(	B-X
121	B-X
aminoacids	B-X
)	B-X
plays	B-X
a	B-X
role	B-X
of	B-X
prime	B-X
importance	B-X
in	B-X
angiogenesis	B-X
.	B-X
VEGF	B-X
is	B-X
a	B-X
45	B-X
kDA	B-X
glycoprotein	B-X
,	B-X
homodimeric	B-X
,	B-X
basic	B-X
,	B-X
and	B-X
able	B-X
to	B-X
bind	B-X
heparin	B-X
.	B-X
The	B-X
three-dimensional	B-X
structure	B-X
of	B-X
VEGF	B-X
has	B-X
been	B-X
recently	B-X
determined	B-X
,	B-X
by	B-X
X-rays	B-X
diffraction	B-X
,	B-X
and	B-X
NMR	B-X
spectroscopy	B-X
.	B-X
The	B-X
different	B-X
forms	B-X
of	B-X
the	B-X
VEGF	B-X
bind	B-X
to	B-X
receptors	B-X
that	B-X
exhibit	B-X
a	B-X
tyrosine-kinase	B-X
activity	B-X
(	B-X
RTK	B-X
)	B-X
.	B-X
The	B-X
specific	B-X
action	B-X
of	B-X
the	B-X
VEGF	B-X
on	B-X
the	B-X
endothelial	B-X
cells	B-X
is	B-X
mainly	B-X
regulated	B-X
by	B-X
two	B-X
types	B-X
of	B-X
RTK	B-X
of	B-X
the	B-X
VEGF	B-X
family	B-X
,	B-X
VEGFR1	B-X
,	B-X
or	B-X
Flt-1	B-X
,	B-X
and	B-X
VEGFR2	B-X
,	B-X
or	B-X
KDR/Flk-1	B-X
.	B-X
Mutagenesis	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
only	B-X
a	B-X
small	B-X
number	B-X
of	B-X
VEGF	B-X
residues	B-X
are	B-X
important	B-X
and	B-X
essential	B-X
for	B-X
the	B-X
binding	B-X
with	B-X
RTK	B-X
.	B-X
Data	B-X
described	B-X
to	B-X
date	B-X
from	B-X
the	B-X
studies	B-X
of	B-X
VEGF/RTK	B-X
interactions	B-X
agree	B-X
to	B-X
the	B-X
hypothesis	B-X
that	B-X
KDR	B-X
receptor	B-X
is	B-X
the	B-X
main	B-X
human	B-X
receptor	B-X
responsible	B-X
for	B-X
the	B-X
VEGF	B-X
activity	B-X
in	B-X
both	B-X
physiological	B-X
and	B-X
pathological	B-X
vascular	B-X
development	B-X
,	B-X
and	B-X
VEGF-KDR	B-X
signalling	B-X
pathway	B-X
has	B-X
been	B-X
validated	B-X
as	B-X
a	B-X
priority	B-X
target	B-X
for	B-X
the	B-X
development	B-X
of	B-X
anti-	B-X
and	B-X
pro-	B-X
angiogenic	B-X
agents	B-X
.	B-X
Therefore	B-X
angiogenesis	B-X
mediated	B-X
by	B-X
VEGF	B-X
constitutes	B-X
a	B-X
new	B-X
target	B-X
for	B-X
anti-cancer	B-X
therapy	B-X
which	B-X
has	B-X
explored	B-X
through	B-X
different	B-X
ways	B-X
of	B-X
intervention	B-X
aiming	B-X
at	B-X
the	B-X
blocking	B-X
of	B-X
the	B-X
tumoral	B-X
angiogenesis	B-X
.	B-X
The	B-X
main	B-X
ones	B-X
are	B-X
:	B-X
-Struggle	B-X
against	B-X
the	B-X
stroma	B-X
degradation	B-X
and	B-X
invasion	B-X
by	B-X
the	B-X
neo-vessels	B-X
-Inhibition	B-X
of	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
-Inhibition	B-X
of	B-X
angiogenic	B-X
factors	B-X
production	B-X
and	B-X
of	B-X
their	B-X
receptors	B-X
.	B-X
-Inhibition	B-X
of	B-X
the	B-X
VEGF	B-X
signal	B-X
pathway	B-X
,	B-X
by	B-X
peptides	B-X
blocking	B-X
the	B-X
bond	B-X
between	B-X
VEGF	B-X
and	B-X
its	B-X
receptors	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
intracellular	B-X
transduction	B-X
of	B-X
VEGF	B-X
signal	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
bibliographic	B-X
study	B-X
allows	B-X
to	B-X
situate	B-X
works	B-X
of	B-X
medicinal	B-X
chemistry	B-X
in	B-X
the	B-X
context	B-X
of	B-X
present	B-X
knowledge	B-X
concerning	B-X
the	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
its	B-X
role	B-X
in	B-X
angiogenesis	B-X
.	B-X

In	O
this	O
work	O
,	O
we	O
show	O
that	O
an	O
11	O
-	O
amino	O
acid	O
peptide	O
derived	O
from	O
the	O
second	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
in	O
chick	O
chorioallantoic	O
membrane	O
and	O
inhibited	O
VEGF	B-Gene_or_gene_product
-	O
induced	O
vascular	O
permeability	O
in	O
Miles	O
'	O
assay	O
without	O
binding	O
to	O
VEGF	B-Gene_or_gene_product
directly	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
an	B-X
angiogenic	B-X
stimulator	B-X
which	B-X
functions	B-X
through	B-X
two	B-X
endothelial	B-X
specific	B-X
tyrosine	B-X
kinase	B-X
receptors	B-X
,	B-X
Flt-1	B-X
and	B-X
Flk-1	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
an	B-X
11-amino	B-X
acid	B-X
peptide	B-X
derived	B-X
from	B-X
the	B-X
second	B-X
immunoglobulin-like	B-X
domain	B-X
of	B-X
Flt-1	B-X
functions	B-X
as	B-X
an	B-X
angiogenic	B-X
inhibitor	B-X
in	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
and	B-X
inhibited	B-X
VEGF-induced	B-X
vascular	B-X
permeability	B-X
in	B-X
Miles	B-X
'	B-X
assay	B-X
without	B-X
binding	B-X
to	B-X
VEGF	B-X
directly	B-X
.	B-X
Circular	B-X
dichroism	B-X
and	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
analyses	B-X
indicate	B-X
that	B-X
this	B-X
peptide	B-X
forms	B-X
a	B-X
stable	B-X
extended	B-X
structure	B-X
in	B-X
solution	B-X
,	B-X
presumably	B-X
beta-sheet	B-X
structure	B-X
and	B-X
is	B-X
most	B-X
likely	B-X
existing	B-X
as	B-X
a	B-X
dimer	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
this	B-X
small	B-X
peptide	B-X
functions	B-X
as	B-X
an	B-X
angiogenic	B-X
inhibitor	B-X
by	B-X
inhibiting	B-X
VEGF	B-X
function	B-X
through	B-X
a	B-X
non-VEGF	B-X
binding	B-X
mechanism	B-X
.	B-X

Circular	O
dichroism	O
and	O
nuclear	O
magnetic	O
resonance	O
analyses	O
indicate	O
that	O
this	O
peptide	O
forms	O
a	O
stable	O
extended	O
structure	O
in	O
solution	O
,	O
presumably	O
beta	O
-	O
sheet	O
structure	O
and	O
is	O
most	O
likely	O
existing	O
as	O
a	O
dimer	O
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
an	B-X
11-amino	B-X
acid	B-X
peptide	B-X
derived	B-X
from	B-X
the	B-X
second	B-X
immunoglobulin-like	B-X
domain	B-X
of	B-X
Flt-1	B-X
functions	B-X
as	B-X
an	B-X
angiogenic	B-X
inhibitor	B-X
in	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
and	B-X
inhibited	B-X
VEGF-induced	B-X
vascular	B-X
permeability	B-X
in	B-X
Miles	B-X
'	B-X
assay	B-X
without	B-X
binding	B-X
to	B-X
VEGF	B-X
directly	B-X
.	B-X
Circular	B-X
dichroism	B-X
and	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
analyses	B-X
indicate	B-X
that	B-X
this	B-X
peptide	B-X
forms	B-X
a	B-X
stable	B-X
extended	B-X
structure	B-X
in	B-X
solution	B-X
,	B-X
presumably	B-X
beta-sheet	B-X
structure	B-X
and	B-X
is	B-X
most	B-X
likely	B-X
existing	B-X
as	B-X
a	B-X
dimer	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
this	B-X
small	B-X
peptide	B-X
functions	B-X
as	B-X
an	B-X
angiogenic	B-X
inhibitor	B-X
by	B-X
inhibiting	B-X
VEGF	B-X
function	B-X
through	B-X
a	B-X
non-VEGF	B-X
binding	B-X
mechanism	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
this	O
small	O
peptide	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
by	O
inhibiting	O
VEGF	B-Gene_or_gene_product
function	O
through	O
a	O
non	O
-	O
VEGF	B-Gene_or_gene_product
binding	O
mechanism	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
an	B-X
angiogenic	B-X
stimulator	B-X
which	B-X
functions	B-X
through	B-X
two	B-X
endothelial	B-X
specific	B-X
tyrosine	B-X
kinase	B-X
receptors	B-X
,	B-X
Flt-1	B-X
and	B-X
Flk-1	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
an	B-X
11-amino	B-X
acid	B-X
peptide	B-X
derived	B-X
from	B-X
the	B-X
second	B-X
immunoglobulin-like	B-X
domain	B-X
of	B-X
Flt-1	B-X
functions	B-X
as	B-X
an	B-X
angiogenic	B-X
inhibitor	B-X
in	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
and	B-X
inhibited	B-X
VEGF-induced	B-X
vascular	B-X
permeability	B-X
in	B-X
Miles	B-X
'	B-X
assay	B-X
without	B-X
binding	B-X
to	B-X
VEGF	B-X
directly	B-X
.	B-X
Circular	B-X
dichroism	B-X
and	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
analyses	B-X
indicate	B-X
that	B-X
this	B-X
peptide	B-X
forms	B-X
a	B-X
stable	B-X
extended	B-X
structure	B-X
in	B-X
solution	B-X
,	B-X
presumably	B-X
beta-sheet	B-X
structure	B-X
and	B-X
is	B-X
most	B-X
likely	B-X
existing	B-X
as	B-X
a	B-X
dimer	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
this	B-X
small	B-X
peptide	B-X
functions	B-X
as	B-X
an	B-X
angiogenic	B-X
inhibitor	B-X
by	B-X
inhibiting	B-X
VEGF	B-X
function	B-X
through	B-X
a	B-X
non-VEGF	B-X
binding	B-X
mechanism	B-X
.	B-X

Coexpression	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
and	O
p53	B-Gene_or_gene_product
protein	O
in	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
esophagus	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X
Experimental	B-X
study	B-X
proved	B-X
that	B-X
the	B-X
coexpression	B-X
of	B-X
p53	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
angiogenesis	B-X
of	B-X
tumor	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
mechanism	B-X
that	B-X
p53	B-X
participate	B-X
angiogenesis	B-X
and	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
p53	B-X
and	B-X
VEGF	B-X
and	B-X
clinical	B-X
pathologic	B-X
parameters	B-X
and	B-X
prognosis	B-X
of	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
ESCC	B-X
)	B-X
.	B-X

OBJECTIVE	O
:	O
p53	B-Gene_or_gene_product
plays	O
a	O
role	O
in	O
tumor	O
angiogenesis	O
,	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
plays	O
a	O
key	O
role	O
in	O
tumor	O
angiogenesis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
how	O
expression	O
of	O
p53	B-Gene_or_gene_product
protein	O
participates	O
in	O
angiogenesis	O
,	O
and	O
whether	O
the	O
coexpression	O
of	O
VEGF	B-Gene_or_gene_product
and	O
p53	B-Gene_or_gene_product
protein	O
has	O
a	O
significance	O
for	O
angiogenesis	O
and	O
the	O
clinicopathological	O
features	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
.	O

METHODS	O
:	O
Tissues	O
samples	O
were	O
taken	O
from	O
60	O
patients	O
with	O
esophageal	O
SCC	O
after	O
surgery	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

The	O
expression	O
of	O
VEGF	B-Gene_or_gene_product
and	O
p53	B-Gene_or_gene_product
protein	O
in	O
these	O
SCC	O
was	O
examined	O
immunohistochemically	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
expressions	B-X
of	B-X
p53	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
C	B-X
(	B-X
VEGF	B-X
C	B-X
)	B-X
and	B-X
p21	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
in	B-X
preoperative	B-X
endoscopic	B-X
biopsy	B-X
and	B-X
postoperative	B-X
resection	B-X
material	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
p53	B-X
,	B-X
VEGF	B-X
C	B-X
and	B-X
p21	B-X
proteins	B-X
in	B-X
these	B-X
sections	B-X
were	B-X
immunohistochemically	B-X
examined	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
each	B-X
antibody	B-X
was	B-X
characterized	B-X
as	B-X
a	B-X
negative	B-X
or	B-X
positive	B-X
reaction	B-X
according	B-X
to	B-X
the	B-X
pattern	B-X
and	B-X
intensity	B-X
of	B-X
semiquantitative	B-X
immunostaining	B-X
.	B-X
p53	B-X
expression	B-X
was	B-X
observed	B-X
in	B-X
65.5	B-X
%	B-X
(	B-X
19/29	B-X
)	B-X
of	B-X
lymph	B-X
node	B-X
positive	B-X
cases	B-X
,	B-X
whereas	B-X
p53	B-X
was	B-X
in	B-X
50	B-X
%	B-X
(	B-X
20/40	B-X
)	B-X
of	B-X
cases	B-X
.	B-X
VEGF	B-X
C	B-X
was	B-X
in	B-X
65	B-X
%	B-X
(	B-X
26/40	B-X
)	B-X
and	B-X
p21	B-X
was	B-X
in	B-X
15	B-X
%	B-X
(	B-X
6/40	B-X
)	B-X
of	B-X
cases	B-X
.	B-X
p53	B-X
has	B-X
the	B-X
specificity	B-X
of	B-X
90.9	B-X
%	B-X
and	B-X
sensitivity	B-X
rate	B-X
of	B-X
65.5	B-X
%	B-X
in	B-X
detecting	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
positive	B-X
predictive	B-X
value	B-X
was	B-X
95	B-X
%	B-X
.	B-X
Expression	B-X
of	B-X
p53	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
stage	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
P	B-X
=	B-X
0.02	B-X
and	B-X
P	B-X
=	B-X
0.03	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Prediction	B-X
of	B-X
lymph	B-X
node	B-X
metastasis	B-X
by	B-X
p53	B-X
was	B-X
correlated	B-X
independently	B-X
and	B-X
in	B-X
coexpression	B-X
with	B-X
VEGF	B-X
C	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
In	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
,	B-X
p53	B-X
and	B-X
VEGF	B-X
C	B-X
expressions	B-X
were	B-X
correlated	B-X
with	B-X
pathologically	B-X
positive	B-X
lymph	B-X
nodes	B-X
.	B-X
When	B-X
preoperative	B-X
staging	B-X
has	B-X
been	B-X
insufficient	B-X
in	B-X
esophageal	B-X
carcinoma	B-X
cases	B-X
,	B-X
immunohistochemical	B-X
analysis	B-X
of	B-X
p53	B-X
and	B-X
VEGF	B-X
C	B-X
staining	B-X
in	B-X
tissues	B-X
could	B-X
be	B-X
an	B-X
aid	B-X
to	B-X
clinicians	B-X
regarding	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X

Microvessel	O
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
counting	O
microvessels	O
in	O
tumor	O
sections	O
stained	O
for	O
Factor	B-Gene_or_gene_product
VIII	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
tumor	B-X
angiogenesis	B-X
as	B-X
measured	B-X
by	B-X
microvessel	B-X
density	B-X
(	B-X
MVD	B-X
)	B-X
as	B-X
an	B-X
independent	B-X
prognostic	B-X
factor	B-X
in	B-X
patients	B-X
with	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
treated	B-X
with	B-X
radiotherapy	B-X
alone	B-X
.	B-X
VEGF	B-X
expression	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
high	B-X
vascularity	B-X
in	B-X
IDC	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
prognostic	B-X
significance	B-X
of	B-X
microvessel	B-X
density	B-X
(	B-X
MVD	B-X
)	B-X
and	B-X
its	B-X
correlation	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
VEGF	B-X
in	B-X
infiltrating	B-X
lobular	B-X
carcinoma	B-X
(	B-X
ILC	B-X
)	B-X
.	B-X
We	B-X
analyzed	B-X
tumor	B-X
samples	B-X
from	B-X
51	B-X
patients	B-X
with	B-X
primary	B-X
classic	B-X
ILC	B-X
to	B-X
determine	B-X
the	B-X
relationship	B-X
between	B-X
tumoral	B-X
MVD	B-X
and	B-X
VEGF	B-X
expression	B-X
.	B-X
Five-micron	B-X
thick	B-X
sections	B-X
obtained	B-X
from	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
tissue	B-X
blocks	B-X
were	B-X
immunostained	B-X
with	B-X
antibodies	B-X
to	B-X
factor	B-X
VIII-related	B-X
antigen	B-X
(	B-X
Dako	B-X
,	B-X
Carpenteria	B-X
,	B-X
CA	B-X
)	B-X
and	B-X
VEGF	B-X
(	B-X
Calbiochem	B-X
,	B-X
Boston	B-X
,	B-X
MA	B-X
)	B-X
.	B-X
The	B-X
former	B-X
was	B-X
used	B-X
for	B-X
MVD	B-X
analysis	B-X
.	B-X
The	B-X
vessel	B-X
counts	B-X
from	B-X
the	B-X
three	B-X
most	B-X
vascular	B-X
fields	B-X
(	B-X
x200	B-X
magnification	B-X
)	B-X
were	B-X
recorded	B-X
and	B-X
the	B-X
highest	B-X
of	B-X
the	B-X
vessel	B-X
counts	B-X
of	B-X
the	B-X
three	B-X
fields	B-X
was	B-X
designated	B-X
as	B-X
the	B-X
MVD	B-X
.	B-X
The	B-X
Student	B-X
's	B-X
t-test	B-X
and	B-X
Wilcoxon	B-X
rank	B-X
sum	B-X
test	B-X
were	B-X
used	B-X
to	B-X
compare	B-X
mean	B-X
MVD	B-X
and	B-X
VEGF	B-X
scores	B-X
according	B-X
to	B-X
various	B-X
clinical	B-X
and	B-X
pathologic	B-X
features	B-X
.	B-X
There	B-X
was	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
MVD	B-X
of	B-X
each	B-X
observer	B-X
(	B-X
correlation	B-X
coefficient	B-X
0.775	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
of	B-X
MVD	B-X
or	B-X
VEGF	B-X
score	B-X
with	B-X
the	B-X
size	B-X
or	B-X
stage	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MVD	B-X
or	B-X
VEGF	B-X
score	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
axillary	B-X
lymph	B-X
node-positive	B-X
cases	B-X
and	B-X
node-negative	B-X
cases	B-X
,	B-X
between	B-X
patients	B-X
with	B-X
recurrence	B-X
and	B-X
those	B-X
without	B-X
,	B-X
and	B-X
between	B-X
patients	B-X
who	B-X
survived	B-X
and	B-X
those	B-X
who	B-X
died	B-X
of	B-X
disease	B-X
.	B-X
There	B-X
was	B-X
,	B-X
however	B-X
,	B-X
a	B-X
weak	B-X
negative	B-X
correlation	B-X
between	B-X
the	B-X
MVD	B-X
and	B-X
VEGF	B-X
expression	B-X
(	B-X
Spearman	B-X
correlation	B-X
coefficient	B-X
-0.08	B-X
)	B-X
.	B-X
Neither	B-X
MVD	B-X
or	B-X
VEGF	B-X
immunoscore	B-X
were	B-X
associated	B-X
with	B-X
tumor	B-X
recurrence	B-X
or	B-X
vital	B-X
status	B-X
in	B-X
patients	B-X
with	B-X
ILC	B-X
.	B-X
The	B-X
absence	B-X
of	B-X
a	B-X
statistically	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
MVD	B-X
and	B-X
VEGF	B-X
expression	B-X
suggests	B-X
that	B-X
other	B-X
factors	B-X
may	B-X
play	B-X
a	B-X
more	B-X
important	B-X
role	B-X
in	B-X
the	B-X
angiogenesis	B-X
of	B-X
ILC	B-X
.	B-X

Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
labeling	O
index	O
(	O
LI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
antigen	O
immunostaining	O
,	O
as	O
a	O
proliferative	O
marker	O
.	O

Apoptotic	O
index	O
(	O
AI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
the	O
terminal	B-Gene_or_gene_product
deoxynucleotidyl	I-Gene_or_gene_product
transferase	I-Gene_or_gene_product
-	O
mediated	O
deoxyuridine	O
triphosphate	O
biotin	O
nick	O
end	O
labeling	O
,	O
to	O
evaluate	O
apoptosis	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X

RESULTS	O
:	O
VEGF	B-Gene_or_gene_product
expression	O
was	O
observed	O
in	O
58	O
.	O
3	O
%	O
,	O
and	O
p53	B-Gene_or_gene_product
protein	O
expression	O
was	O
observed	O
in	O
61	O
.	O
7	O
%	O
of	O
the	O
60	O
patients	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

VEGF	B-Gene_or_gene_product
and	O
p53	B-Gene_or_gene_product
protein	O
were	O
significantly	O
coexpressed	O
in	O
26	O
(	O
43	O
.	O
4	O
%	O
)	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

Histological	O
venous	O
invasion	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
distant	O
metastasis	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
significantly	O
correlated	O
with	O
p53	B-Gene_or_gene_product
protein	O
expression	O
.	O

The	O
two	O
parameters	O
were	O
more	O
frequently	O
observed	O
in	O
the	O
SCC	O
with	O
VEGF	B-Gene_or_gene_product
/	O
p53	B-Gene_or_gene_product
coexpression	O
than	O
in	O
those	O
without	O
the	O
coexpression	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

The	O
MVD	O
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
LI	O
were	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
and	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
AI	O
was	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
in	O
the	O
SCC	O
with	O
p53	B-Gene_or_gene_product
protein	O
expression	O
than	O
in	O
the	O
SCC	O
without	O
it	O
.	O

The	O
MVD	O
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
LI	O
were	O
higher	O
,	O
and	O
the	O
AI	O
was	O
lower	O
in	O
the	O
SCC	O
with	O
VEGF	B-Gene_or_gene_product
/	O
p53	B-Gene_or_gene_product
coexpression	O
than	O
in	O
those	O
without	O
the	O
coexpression	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

The	O
5	O
-	O
yr	O
survival	O
rate	O
in	O
patients	O
with	O
the	O
coexpression	O
was	O
poorer	O
than	O
in	O
the	O
other	O
patients	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
mutant	O
p53	B-Gene_or_gene_product
expression	O
is	O
associated	O
with	O
angiogenesis	O
and	O
distant	O
metastasis	O
in	O
esophageal	O
SCC	O
,	O
and	O
that	O
the	O
coexpression	O
of	O
p53	B-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
may	O
play	O
an	O
important	O
role	O
in	O
angiogenesis	O
,	O
and	O
have	O
important	O
clinical	O
significance	O
.	O
<EOS>	B-X
p53	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
clarify	B-X
how	B-X
expression	B-X
of	B-X
p53	B-X
protein	B-X
participates	B-X
in	B-X
angiogenesis	B-X
,	B-X
and	B-X
whether	B-X
the	B-X
coexpression	B-X
of	B-X
VEGF	B-X
and	B-X
p53	B-X
protein	B-X
has	B-X
a	B-X
significance	B-X
for	B-X
angiogenesis	B-X
and	B-X
the	B-X
clinicopathological	B-X
features	B-X
in	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
.	B-X

[	O
mRNA	O
expression	O
of	O
metastasis	O
-	O
suppressor	O
gene	O
nm23	B-Gene_or_gene_product
in	O
carcinoma	O
of	O
buccal	O
mucosa	O
.	O
II	O
.	O
Quantitative	O
reverse	O
transcription	O
PCR	O
amplification	O
]	O
.	O
<EOS>	B-X
The	B-X
nm23	B-X
gene	B-X
is	B-X
a	B-X
conspicuous	B-X
metastasis-suppressor	B-X
gene	B-X
.	B-X
The	B-X
authors	B-X
detected	B-X
both	B-X
nm23-H1	B-X
and	B-X
nm23-H2	B-X
mRNA	B-X
levels	B-X
in	B-X
47	B-X
tissues	B-X
samples	B-X
of	B-X
patients	B-X
with	B-X
carcinoma	B-X
of	B-X
buccal	B-X
mucosa	B-X
(	B-X
CBM	B-X
)	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcription	B-X
PCR	B-X
amplification	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
expression	B-X
levels	B-X
of	B-X
both	B-X
nm23-H1	B-X
and	B-X
nm23-H2	B-X
mRNA	B-X
varied	B-X
in	B-X
normal	B-X
buccal	B-X
mucosa	B-X
,	B-X
leukoplakia	B-X
,	B-X
adjacent	B-X
nontumorous	B-X
mucosa	B-X
,	B-X
submandibular	B-X
gland	B-X
,	B-X
CBM	B-X
and	B-X
lymph	B-X
nodes	B-X
with	B-X
or	B-X
without	B-X
metastasis	B-X
.	B-X
The	B-X
nm23-H1	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
CBM	B-X
with	B-X
lymph	B-X
nodes	B-X
metastases	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
CBM	B-X
without	B-X
metastases	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
while	B-X
no	B-X
significance	B-X
of	B-X
nm23-H2	B-X
mRNA	B-X
expression	B-X
levels	B-X
was	B-X
found	B-X
between	B-X
CBM	B-X
with	B-X
and	B-X
CBM	B-X
without	B-X
metastasis	B-X
(	B-X
P	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
authors	B-X
concluded	B-X
that	B-X
,	B-X
as	B-X
also	B-X
in	B-X
the	B-X
study	B-X
of	B-X
Northern	B-X
blotting	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
nm23-H1	B-X
mRNA	B-X
significantly	B-X
correlated	B-X
inversely	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
in	B-X
CBM	B-X
,	B-X
while	B-X
the	B-X
expression	B-X
of	B-X
nm23-H2	B-X
mRNA	B-X
not	B-X
.	B-X
Q-RT-PCR	B-X
was	B-X
a	B-X
useful	B-X
method	B-X
to	B-X
detect	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
nm23	B-X
gene	B-X
in	B-X
buccal	B-X
carcinoma	B-X
.	B-X

The	O
nm23	B-Gene_or_gene_product
gene	O
is	O
a	O
conspicuous	O
metastasis	O
-	O
suppressor	O
gene	O
.	O
<EOS>	B-X
The	B-X
NM23	B-X
gene	B-X
is	B-X
a	B-X
conspicuous	B-X
metastasis-suppressor	B-X
gene	B-X
.	B-X
Eight	B-X
human	B-X
genes	B-X
of	B-X
the	B-X
NM23/nucleoside	B-X
diphosphate	B-X
kinase	B-X
family	B-X
have	B-X
been	B-X
discovered	B-X
.	B-X
The	B-X
nm23	B-X
gene	B-X
is	B-X
a	B-X
conspicuous	B-X
metastasis-suppressor	B-X
gene	B-X
.	B-X
The	B-X
authors	B-X
detected	B-X
both	B-X
nm23-H1	B-X
and	B-X
nm23-H2	B-X
mRNA	B-X
levels	B-X
in	B-X
47	B-X
tissues	B-X
samples	B-X
of	B-X
patients	B-X
with	B-X
carcinoma	B-X
of	B-X
buccal	B-X
mucosa	B-X
(	B-X
CBM	B-X
)	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcription	B-X
PCR	B-X
amplification	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
expression	B-X
levels	B-X
of	B-X
both	B-X
nm23-H1	B-X
and	B-X
nm23-H2	B-X
mRNA	B-X
varied	B-X
in	B-X
normal	B-X
buccal	B-X
mucosa	B-X
,	B-X
leukoplakia	B-X
,	B-X
adjacent	B-X
nontumorous	B-X
mucosa	B-X
,	B-X
submandibular	B-X
gland	B-X
,	B-X
CBM	B-X
and	B-X
lymph	B-X
nodes	B-X
with	B-X
or	B-X
without	B-X
metastasis	B-X
.	B-X
The	B-X
nm23-H1	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
CBM	B-X
with	B-X
lymph	B-X
nodes	B-X
metastases	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
CBM	B-X
without	B-X
metastases	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
while	B-X
no	B-X
significance	B-X
of	B-X
nm23-H2	B-X
mRNA	B-X
expression	B-X
levels	B-X
was	B-X
found	B-X
between	B-X
CBM	B-X
with	B-X
and	B-X
CBM	B-X
without	B-X
metastasis	B-X
(	B-X
P	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
authors	B-X
concluded	B-X
that	B-X
,	B-X
as	B-X
also	B-X
in	B-X
the	B-X
study	B-X
of	B-X
Northern	B-X
blotting	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
nm23-H1	B-X
mRNA	B-X
significantly	B-X
correlated	B-X
inversely	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
in	B-X
CBM	B-X
,	B-X
while	B-X
the	B-X
expression	B-X
of	B-X
nm23-H2	B-X
mRNA	B-X
not	B-X
.	B-X
Q-RT-PCR	B-X
was	B-X
a	B-X
useful	B-X
method	B-X
to	B-X
detect	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
nm23	B-X
gene	B-X
in	B-X
buccal	B-X
carcinoma	B-X
.	B-X

The	O
authors	O
detected	O
both	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H1	I-Gene_or_gene_product
and	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H2	I-Gene_or_gene_product
mRNA	O
levels	O
in	O
47	O
tissues	O
samples	O
of	O
patients	O
with	O
carcinoma	O
of	O
buccal	O
mucosa	O
(	O
CBM	O
)	O
by	O
quantitative	O
reverse	O
transcription	O
PCR	O
amplification	O
.	O

The	O
results	O
showed	O
that	O
expression	O
levels	O
of	O
both	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H1	I-Gene_or_gene_product
and	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H2	I-Gene_or_gene_product
mRNA	O
varied	O
in	O
normal	O
buccal	O
mucosa	O
,	O
leukoplakia	O
,	O
adjacent	O
nontumorous	O
mucosa	O
,	O
submandibular	O
gland	O
,	O
CBM	O
and	O
lymph	O
nodes	O
with	O
or	O
without	O
metastasis	O
.	O
<EOS>	B-X
Bone	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
site	B-X
for	B-X
metastasis	B-X
for	B-X
many	B-X
cancers	B-X
,	B-X
notably	B-X
for	B-X
tumours	B-X
originating	B-X
in	B-X
the	B-X
breast	B-X
and	B-X
the	B-X
prostate	B-X
.	B-X
Within	B-X
the	B-X
bone	B-X
,	B-X
these	B-X
disseminated	B-X
tumour	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
those	B-X
arising	B-X
in	B-X
the	B-X
context	B-X
of	B-X
multiple	B-X
myeloma	B-X
,	B-X
may	B-X
assume	B-X
a	B-X
state	B-X
of	B-X
dormancy	B-X
,	B-X
remaining	B-X
quiescent	B-X
for	B-X
years	B-X
before	B-X
resuming	B-X
proliferation	B-X
and	B-X
causing	B-X
overt	B-X
metastasis	B-X
,	B-X
which	B-X
causes	B-X
bone	B-X
destruction	B-X
via	B-X
activation	B-X
of	B-X
osteoclast-mediated	B-X
osteolysis	B-X
.	B-X
I	B-X
argue	B-X
here	B-X
that	B-X
the	B-X
understanding	B-X
of	B-X
early	B-X
metastasis	B-X
formation	B-X
,	B-X
particularly	B-X
of	B-X
the	B-X
currently	B-X
invisible	B-X
phase	B-X
of	B-X
metastatic	B-X
colonization	B-X
,	B-X
will	B-X
be	B-X
essential	B-X
for	B-X
the	B-X
next	B-X
stage	B-X
in	B-X
adjuvant	B-X
therapy	B-X
development	B-X
that	B-X
reliably	B-X
prevents	B-X
metachronous	B-X
metastasis	B-X
.	B-X
Initiation	B-X
of	B-X
metastasis	B-X
relies	B-X
on	B-X
the	B-X
tumor	B-X
cell	B-X
cross-talking	B-X
with	B-X
stromal	B-X
cells	B-X
and	B-X
taking	B-X
an	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
in	B-X
single	B-X
cells	B-X
,	B-X
and	B-X
a	B-X
hybrid	B-X
EMT	B-X
in	B-X
collective	B-X
migratory	B-X
cells	B-X
.	B-X
Stromal	B-X
cross-talking	B-X
along	B-X
with	B-X
an	B-X
abnormal	B-X
leaky	B-X
vasculature	B-X
facilitate	B-X
intravasation	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
here	B-X
the	B-X
cells	B-X
are	B-X
called	B-X
circulating	B-X
tumor	B-X
cells	B-X
(	B-X
CTCs	B-X
)	B-X
.	B-X

The	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H1	I-Gene_or_gene_product
mRNA	O
expression	O
levels	O
in	O
CBM	O
with	O
lymph	O
nodes	O
metastases	O
were	O
lower	O
than	O
those	O
in	O
CBM	O
without	O
metastases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
no	O
significance	O
of	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H2	I-Gene_or_gene_product
mRNA	O
expression	O
levels	O
was	O
found	O
between	O
CBM	O
with	O
and	O
CBM	O
without	O
metastasis	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
results	O
were	O
comparative	O
to	O
those	O
of	O
Northern	O
blotting	O
of	O
the	O
same	O
cases	O
.	O
<EOS>	B-X
Only	B-X
in	B-X
a	B-X
few	B-X
conditions	B-X
this	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
limited	B-X
mRNA	B-X
availability	B-X
since	B-X
,	B-X
in	B-X
most	B-X
cases	B-X
,	B-X
recombinant	B-X
mRNAs	B-X
accumulated	B-X
quite	B-X
well	B-X
when	B-X
compared	B-X
to	B-X
the	B-X
atpA	B-X
mRNA	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
point	B-X
to	B-X
translation	B-X
as	B-X
the	B-X
main	B-X
step	B-X
limiting	B-X
the	B-X
expression	B-X
of	B-X
heterologous	B-X
proteins	B-X
in	B-X
the	B-X
C.	B-X
reinhardtii	B-X
chloroplast	B-X
.	B-X
ERBB2	B-X
gene	B-X
copy	B-X
numbers	B-X
and	B-X
RNA	B-X
transcripts	B-X
were	B-X
measured	B-X
by	B-X
Southern	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X
in	B-X
all	B-X
samples	B-X
.	B-X
Complete	B-X
concordance	B-X
between	B-X
immunohistochemistry	B-X
and	B-X
molecular	B-X
biology	B-X
was	B-X
observed	B-X
in	B-X
43/58	B-X
cases	B-X
(	B-X
74	B-X
per	B-X
cent	B-X
)	B-X
.	B-X
The	B-X
most	B-X
consistent	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
NCLCB11	B-X
on	B-X
frozen	B-X
sections	B-X
and	B-X
with	B-X
Tab250	B-X
on	B-X
paraffin-embedded	B-X
sections	B-X
.	B-X
For	B-X
prospective	B-X
studies	B-X
,	B-X
the	B-X
use	B-X
of	B-X
alcoholic	B-X
formalin	B-X
in	B-X
association	B-X
with	B-X
a	B-X
highly	B-X
specific	B-X
antibody	B-X
(	B-X
Tab250	B-X
,	B-X
9G6	B-X
,	B-X
NCLCB11	B-X
,	B-X
or	B-X
OA-11-854	B-X
)	B-X
gave	B-X
the	B-X
best	B-X
results	B-X
.	B-X
Methacarn	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
reliable	B-X
fixative	B-X
,	B-X
but	B-X
was	B-X
studied	B-X
in	B-X
only	B-X
28	B-X
cases	B-X
.	B-X
Thus	B-X
,	B-X
with	B-X
Bouin	B-X
's	B-X
fixation	B-X
,	B-X
3B5	B-X
was	B-X
the	B-X
only	B-X
reliable	B-X
antibody	B-X
,	B-X
whereas	B-X
with	B-X
buffered	B-X
formalin	B-X
,	B-X
Tab250	B-X
gave	B-X
the	B-X
most	B-X
consistent	B-X
results	B-X
.	B-X

The	O
authors	O
concluded	O
that	O
,	O
as	O
also	O
in	O
the	O
study	O
of	O
Northern	O
blotting	O
,	O
the	O
expression	O
of	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H1	I-Gene_or_gene_product
mRNA	O
significantly	O
correlated	O
inversely	O
with	O
lymph	O
node	O
metastasis	O
in	O
CBM	O
,	O
while	O
the	O
expression	O
of	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
H2	I-Gene_or_gene_product
mRNA	O
not	O
.	O

Q	O
-	O
RT	O
-	O
PCR	O
was	O
a	O
useful	O
method	O
to	O
detect	O
the	O
mRNA	O
levels	O
of	O
nm23	B-Gene_or_gene_product
gene	O
in	O
buccal	O
carcinoma	O
.	O
<EOS>	B-X
The	B-X
nm23	B-X
gene	B-X
is	B-X
a	B-X
conspicuous	B-X
metastasis-suppressor	B-X
gene	B-X
.	B-X
The	B-X
authors	B-X
detected	B-X
both	B-X
nm23-H1	B-X
and	B-X
nm23-H2	B-X
mRNA	B-X
levels	B-X
in	B-X
47	B-X
tissues	B-X
samples	B-X
of	B-X
patients	B-X
with	B-X
carcinoma	B-X
of	B-X
buccal	B-X
mucosa	B-X
(	B-X
CBM	B-X
)	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcription	B-X
PCR	B-X
amplification	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
expression	B-X
levels	B-X
of	B-X
both	B-X
nm23-H1	B-X
and	B-X
nm23-H2	B-X
mRNA	B-X
varied	B-X
in	B-X
normal	B-X
buccal	B-X
mucosa	B-X
,	B-X
leukoplakia	B-X
,	B-X
adjacent	B-X
nontumorous	B-X
mucosa	B-X
,	B-X
submandibular	B-X
gland	B-X
,	B-X
CBM	B-X
and	B-X
lymph	B-X
nodes	B-X
with	B-X
or	B-X
without	B-X
metastasis	B-X
.	B-X
The	B-X
nm23-H1	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
CBM	B-X
with	B-X
lymph	B-X
nodes	B-X
metastases	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
in	B-X
CBM	B-X
without	B-X
metastases	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
while	B-X
no	B-X
significance	B-X
of	B-X
nm23-H2	B-X
mRNA	B-X
expression	B-X
levels	B-X
was	B-X
found	B-X
between	B-X
CBM	B-X
with	B-X
and	B-X
CBM	B-X
without	B-X
metastasis	B-X
(	B-X
P	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
authors	B-X
concluded	B-X
that	B-X
,	B-X
as	B-X
also	B-X
in	B-X
the	B-X
study	B-X
of	B-X
Northern	B-X
blotting	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
nm23-H1	B-X
mRNA	B-X
significantly	B-X
correlated	B-X
inversely	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
in	B-X
CBM	B-X
,	B-X
while	B-X
the	B-X
expression	B-X
of	B-X
nm23-H2	B-X
mRNA	B-X
not	B-X
.	B-X
Q-RT-PCR	B-X
was	B-X
a	B-X
useful	B-X
method	B-X
to	B-X
detect	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
nm23	B-X
gene	B-X
in	B-X
buccal	B-X
carcinoma	B-X
.	B-X

Neoplastic	O
transformation	O
and	O
tumorigenesis	O
associated	O
with	O
overexpression	O
of	O
phospholipase	B-Gene_or_gene_product
D	I-Gene_or_gene_product
isozymes	O
in	O
cultured	O
murine	O
fibroblasts	O
.	O
<EOS>	B-X
PLD	B-X
activity	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
significantly	B-X
elevated	B-X
in	B-X
many	B-X
tumours	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
possibility	B-X
that	B-X
PLD	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
tumorigenesis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
PLD	B-X
isozymes	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Phospholipase	B-Gene_or_gene_product
D	I-Gene_or_gene_product
(	O
PLD	B-Gene_or_gene_product
)	O
has	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

PLD	B-Gene_or_gene_product
activity	O
has	O
been	O
shown	O
to	O
be	O
significantly	O
elevated	O
in	O
many	O
tumours	O
and	O
transformed	O
cells	O
,	O
suggesting	O
the	O
possibility	O
that	O
PLD	B-Gene_or_gene_product
might	O
be	O
involved	O
in	O
tumorigenesis	O
.	O
<EOS>	B-X
Phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
.	B-X
PLD	B-X
activity	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
significantly	B-X
elevated	B-X
in	B-X
many	B-X
tumours	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
possibility	B-X
that	B-X
PLD	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
tumorigenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
established	B-X
stable	B-X
cell	B-X
lines	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
from	B-X
fibroblast	B-X
cells	B-X
.	B-X
These	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
control	B-X
cells	B-X
,	B-X
showed	B-X
altered	B-X
growth	B-X
properties	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
Both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
also	B-X
induced	B-X
an	B-X
up-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
matrix	B-X
metalloprotease-9	B-X
as	B-X
detected	B-X
by	B-X
zymograms	B-X
.	B-X
Furthermore	B-X
,	B-X
both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
transformants	B-X
,	B-X
but	B-X
not	B-X
vector-transfectants	B-X
,	B-X
induced	B-X
undifferentiated	B-X
sarcoma	B-X
when	B-X
transplanted	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Both	B-X
PLD1-	B-X
and	B-X
PLD2-mediated	B-X
cell	B-X
cycle	B-X
distributions	B-X
in	B-X
stable	B-X
cell	B-X
lines	B-X
revealed	B-X
an	B-X
increased	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
phase	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cyclin	B-X
D3	B-X
protein	B-X
,	B-X
known	B-X
as	B-X
an	B-X
activator	B-X
of	B-X
G	B-X
(	B-X
1	B-X
)	B-X
to	B-X
S	B-X
phase	B-X
transition	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
was	B-X
aberrantly	B-X
high	B-X
in	B-X
cells	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
PLD	B-X
isozymes	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
neoplastic	B-X
transformation	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
have	O
established	O
stable	O
cell	O
lines	O
overexpressing	O
PLD1	B-Gene_or_gene_product
and	O
PLD2	B-Gene_or_gene_product
from	O
fibroblast	O
cells	O
.	O
<EOS>	B-X
Phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
.	B-X
PLD	B-X
activity	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
significantly	B-X
elevated	B-X
in	B-X
many	B-X
tumours	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
possibility	B-X
that	B-X
PLD	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
tumorigenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
established	B-X
stable	B-X
cell	B-X
lines	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
from	B-X
fibroblast	B-X
cells	B-X
.	B-X
These	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
control	B-X
cells	B-X
,	B-X
showed	B-X
altered	B-X
growth	B-X
properties	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
Both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
also	B-X
induced	B-X
an	B-X
up-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
matrix	B-X
metalloprotease-9	B-X
as	B-X
detected	B-X
by	B-X
zymograms	B-X
.	B-X
Furthermore	B-X
,	B-X
both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
transformants	B-X
,	B-X
but	B-X
not	B-X
vector-transfectants	B-X
,	B-X
induced	B-X
undifferentiated	B-X
sarcoma	B-X
when	B-X
transplanted	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Both	B-X
PLD1-	B-X
and	B-X
PLD2-mediated	B-X
cell	B-X
cycle	B-X
distributions	B-X
in	B-X
stable	B-X
cell	B-X
lines	B-X
revealed	B-X
an	B-X
increased	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
phase	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cyclin	B-X
D3	B-X
protein	B-X
,	B-X
known	B-X
as	B-X
an	B-X
activator	B-X
of	B-X
G	B-X
(	B-X
1	B-X
)	B-X
to	B-X
S	B-X
phase	B-X
transition	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
was	B-X
aberrantly	B-X
high	B-X
in	B-X
cells	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X

These	O
cells	O
,	O
but	O
not	O
control	O
cells	O
,	O
showed	O
altered	O
growth	O
properties	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
.	O
<EOS>	B-X
It	B-X
consists	B-X
primarily	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
,	B-X
a	B-X
prominence	B-X
of	B-X
the	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
2	B-X
subtype	B-X
but	B-X
also	B-X
Th1	B-X
cells	B-X
,	B-X
with	B-X
Th17	B-X
cell-derived	B-X
cytokines	B-X
elevated	B-X
in	B-X
plasma	B-X
.	B-X
Chemokines	B-X
derived	B-X
from	B-X
mast	B-X
cells	B-X
and	B-X
activated	B-X
endothelial	B-X
cells	B-X
drive	B-X
the	B-X
process	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
that	B-X
CSU	B-X
responds	B-X
to	B-X
corticosteroid	B-X
,	B-X
yet	B-X
,	B-X
short-term	B-X
steroids	B-X
do	B-X
not	B-X
affect	B-X
autoimmunity	B-X
or	B-X
degranulation	B-X
of	B-X
mast	B-X
cells	B-X
,	B-X
and	B-X
act	B-X
on	B-X
margination	B-X
of	B-X
cells	B-X
along	B-X
the	B-X
endothelium	B-X
and	B-X
chemotaxis	B-X
to	B-X
enter	B-X
the	B-X
surrounding	B-X
dermis	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
address	B-X
each	B-X
cell	B-X
's	B-X
contribution	B-X
to	B-X
the	B-X
overall	B-X
inflammatory	B-X
response	B-X
,	B-X
as	B-X
it	B-X
is	B-X
currently	B-X
understood	B-X
,	B-X
with	B-X
a	B-X
view	B-X
toward	B-X
development	B-X
of	B-X
therapeutic	B-X
options	B-X
that	B-X
impede	B-X
the	B-X
function	B-X
of	B-X
critical	B-X
cells	B-X
and/or	B-X
their	B-X
secretory	B-X
products	B-X
.	B-X

Both	O
PLD1	B-Gene_or_gene_product
and	O
PLD2	B-Gene_or_gene_product
also	O
induced	O
an	O
up	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
matrix	B-Gene_or_gene_product
metalloprotease	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
as	O
detected	O
by	O
zymograms	O
.	O
<EOS>	B-X
PLD	B-X
activity	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
significantly	B-X
elevated	B-X
in	B-X
many	B-X
tumours	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
possibility	B-X
that	B-X
PLD	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
tumorigenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
established	B-X
stable	B-X
cell	B-X
lines	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
from	B-X
fibroblast	B-X
cells	B-X
.	B-X
Both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
also	B-X
induced	B-X
an	B-X
up-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
matrix	B-X
metalloprotease-9	B-X
as	B-X
detected	B-X
by	B-X
zymograms	B-X
.	B-X
Furthermore	B-X
,	B-X
both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
transformants	B-X
,	B-X
but	B-X
not	B-X
vector-transfectants	B-X
,	B-X
induced	B-X
undifferentiated	B-X
sarcoma	B-X
when	B-X
transplanted	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Both	B-X
PLD1-	B-X
and	B-X
PLD2-mediated	B-X
cell	B-X
cycle	B-X
distributions	B-X
in	B-X
stable	B-X
cell	B-X
lines	B-X
revealed	B-X
an	B-X
increased	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
phase	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cyclin	B-X
D3	B-X
protein	B-X
,	B-X
known	B-X
as	B-X
an	B-X
activator	B-X
of	B-X
G	B-X
(	B-X
1	B-X
)	B-X
to	B-X
S	B-X
phase	B-X
transition	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
was	B-X
aberrantly	B-X
high	B-X
in	B-X
cells	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
both	O
PLD1	B-Gene_or_gene_product
and	O
PLD2	B-Gene_or_gene_product
transformants	O
,	O
but	O
not	O
vector	O
-	O
transfectants	O
,	O
induced	O
undifferentiated	O
sarcoma	O
when	O
transplanted	O
into	O
nude	O
mice	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
active	B-X
metabolite	B-X
4-OH-tamoxifen	B-X
can	B-X
be	B-X
used	B-X
to	B-X
pharmacologically	B-X
discriminate	B-X
the	B-X
two	B-X
isoforms	B-X
of	B-X
PLD	B-X
,	B-X
through	B-X
a	B-X
stimulatory	B-X
effect	B-X
on	B-X
PLD1	B-X
and	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
PLD2	B-X
.	B-X
Using	B-X
recombinant	B-X
PLD1	B-X
,	B-X
we	B-X
show	B-X
stimulation	B-X
by	B-X
tamoxifen	B-X
requires	B-X
a	B-X
factor	B-X
present	B-X
in	B-X
Sf21	B-X
insect	B-X
cells	B-X
that	B-X
is	B-X
not	B-X
required	B-X
for	B-X
inhibition	B-X
of	B-X
PLD1	B-X
by	B-X
raloxifene	B-X
.	B-X
Furthermore	B-X
,	B-X
tamoxifen	B-X
stimulation	B-X
and	B-X
raloxifene	B-X
inhibition	B-X
of	B-X
PLD	B-X
activities	B-X
are	B-X
independent	B-X
of	B-X
the	B-X
amino-terminal	B-X
portion	B-X
of	B-X
PLD1	B-X
(	B-X
amino	B-X
acids	B-X
1-324	B-X
)	B-X
.	B-X

Both	O
PLD1	B-Gene_or_gene_product
-	O
and	O
PLD2	B-Gene_or_gene_product
-	O
mediated	O
cell	O
cycle	O
distributions	O
in	O
stable	O
cell	O
lines	O
revealed	O
an	O
increased	O
fraction	O
of	O
cells	O
in	O
the	O
S	O
phase	O
compared	O
with	O
control	O
cells	O
.	O

Interestingly	O
,	O
the	O
level	O
of	O
cyclin	B-Gene_or_gene_product
D3	I-Gene_or_gene_product
protein	O
,	O
known	O
as	O
an	O
activator	O
of	O
G	O
(	O
1	O
)	O
to	O
S	O
phase	O
transition	O
in	O
the	O
cell	O
cycle	O
,	O
was	O
aberrantly	O
high	O
in	O
cells	O
overexpressing	O
PLD1	B-Gene_or_gene_product
and	O
PLD2	B-Gene_or_gene_product
compared	O
with	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
overexpression	O
of	O
PLD	B-Gene_or_gene_product
isozymes	O
may	O
play	O
an	O
important	O
role	O
in	O
neoplastic	O
transformation	O
.	O
<EOS>	B-X
Phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
functions	B-X
.	B-X
PLD	B-X
activity	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
significantly	B-X
elevated	B-X
in	B-X
many	B-X
tumours	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
possibility	B-X
that	B-X
PLD	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
tumorigenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
established	B-X
stable	B-X
cell	B-X
lines	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
from	B-X
fibroblast	B-X
cells	B-X
.	B-X
Both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
also	B-X
induced	B-X
an	B-X
up-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
matrix	B-X
metalloprotease-9	B-X
as	B-X
detected	B-X
by	B-X
zymograms	B-X
.	B-X
Furthermore	B-X
,	B-X
both	B-X
PLD1	B-X
and	B-X
PLD2	B-X
transformants	B-X
,	B-X
but	B-X
not	B-X
vector-transfectants	B-X
,	B-X
induced	B-X
undifferentiated	B-X
sarcoma	B-X
when	B-X
transplanted	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Both	B-X
PLD1-	B-X
and	B-X
PLD2-mediated	B-X
cell	B-X
cycle	B-X
distributions	B-X
in	B-X
stable	B-X
cell	B-X
lines	B-X
revealed	B-X
an	B-X
increased	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
phase	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cyclin	B-X
D3	B-X
protein	B-X
,	B-X
known	B-X
as	B-X
an	B-X
activator	B-X
of	B-X
G	B-X
(	B-X
1	B-X
)	B-X
to	B-X
S	B-X
phase	B-X
transition	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
was	B-X
aberrantly	B-X
high	B-X
in	B-X
cells	B-X
overexpressing	B-X
PLD1	B-X
and	B-X
PLD2	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
PLD	B-X
isozymes	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Troponin	B-Gene_or_gene_product
I	I-Gene_or_gene_product
inhibits	O
capillary	O
endothelial	O
cell	O
proliferation	O
by	O
interaction	O
with	O
the	O
cell	O
'	O
s	O
bFGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
USA	B-X
2645-2650	B-X
)	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
,	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
to	B-X
inhibit	B-X
metastasis	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumors	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

Troponin	B-Gene_or_gene_product
I	I-Gene_or_gene_product
(	O
TnI	B-Gene_or_gene_product
)	O
is	O
a	O
novel	O
cartilage	O
-	O
derived	O
angiogenesis	O
inhibitor	O
,	O
first	O
demonstrated	O
by	O
Moses	O
et	O
al	O
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
USA	B-X
2645-2650	B-X
)	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
,	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
to	B-X
inhibit	B-X
metastasis	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumors	B-X
in	B-X
vivo	B-X
.	B-X
Despite	B-X
convincing	B-X
evidence	B-X
of	B-X
its	B-X
efficacy	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
TnI	B-X
as	B-X
an	B-X
anti-proliferative	B-X
and	B-X
anti-angiogenic	B-X
agent	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

(	O
1999	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
2645	O
-	O
2650	O
)	O
to	O
inhibit	O
endothelial	O
cell	O
proliferation	O
and	O
angiogenesis	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
to	O
inhibit	O
metastasis	O
of	O
a	O
wide	O
variety	O
of	O
tumors	O
in	O
vivo	O
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
(	B-X
1999	B-X
,	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
USA	B-X
2645-2650	B-X
)	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
,	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
to	B-X
inhibit	B-X
metastasis	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumors	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

Despite	O
convincing	O
evidence	O
of	O
its	O
efficacy	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
of	O
action	O
of	O
TnI	B-Gene_or_gene_product
as	O
an	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
angiogenic	O
agent	O
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
Despite	B-X
convincing	B-X
evidence	B-X
of	B-X
its	B-X
efficacy	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
TnI	B-X
as	B-X
an	B-X
anti-proliferative	B-X
and	B-X
anti-angiogenic	B-X
agent	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

In	O
the	O
current	O
article	O
we	O
demonstrate	O
that	O
TnI	B-Gene_or_gene_product
inhibits	O
both	O
bFGF	B-Gene_or_gene_product
-	O
stimulated	O
and	O
basal	O
levels	O
of	O
endothelial	O
cell	O
proliferation	O
,	O
and	O
we	O
hypothesize	O
that	O
this	O
inhibition	O
is	O
occurring	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
an	O
interaction	O
of	O
TnI	B-Gene_or_gene_product
with	O
the	O
cell	O
-	O
surface	O
bFGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
on	O
capillary	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
USA	B-X
2645-2650	B-X
)	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
,	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
to	B-X
inhibit	B-X
metastasis	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumors	B-X
in	B-X
vivo	B-X
.	B-X
Despite	B-X
convincing	B-X
evidence	B-X
of	B-X
its	B-X
efficacy	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
TnI	B-X
as	B-X
an	B-X
anti-proliferative	B-X
and	B-X
anti-angiogenic	B-X
agent	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

We	O
further	O
support	O
this	O
hypothesis	O
by	O
providing	O
the	O
first	O
evidence	O
that	O
TnI	B-Gene_or_gene_product
can	O
act	O
on	O
nonendothelial	O
as	O
well	O
as	O
endothelial	O
cells	O
and	O
by	O
demonstrating	O
that	O
this	O
inhibitory	O
action	O
is	O
specific	O
for	O
the	O
bFGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
on	O
the	O
target	O
cells	O
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
USA	B-X
2645-2650	B-X
)	B-X
to	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
,	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
to	B-X
inhibit	B-X
metastasis	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumors	B-X
in	B-X
vivo	B-X
.	B-X
Despite	B-X
convincing	B-X
evidence	B-X
of	B-X
its	B-X
efficacy	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
TnI	B-X
as	B-X
an	B-X
anti-proliferative	B-X
and	B-X
anti-angiogenic	B-X
agent	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

Preliminary	O
data	O
suggest	O
that	O
TnI	B-Gene_or_gene_product
may	O
be	O
competing	O
with	O
bFGF	B-Gene_or_gene_product
for	O
interaction	O
with	O
the	O
bFGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
on	O
responsive	O
cells	O
.	O
<EOS>	B-X
Troponin	B-X
I	B-X
(	B-X
TnI	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cartilage-derived	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
first	B-X
demonstrated	B-X
by	B-X
Moses	B-X
et	B-X
al	B-X
.	B-X
Despite	B-X
convincing	B-X
evidence	B-X
of	B-X
its	B-X
efficacy	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
TnI	B-X
as	B-X
an	B-X
anti-proliferative	B-X
and	B-X
anti-angiogenic	B-X
agent	B-X
.	B-X
In	B-X
the	B-X
current	B-X
article	B-X
we	B-X
demonstrate	B-X
that	B-X
TnI	B-X
inhibits	B-X
both	B-X
bFGF-stimulated	B-X
and	B-X
basal	B-X
levels	B-X
of	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
inhibition	B-X
is	B-X
occurring	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
via	B-X
an	B-X
interaction	B-X
of	B-X
TnI	B-X
with	B-X
the	B-X
cell-surface	B-X
bFGF	B-X
receptor	B-X
on	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
support	B-X
this	B-X
hypothesis	B-X
by	B-X
providing	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TnI	B-X
can	B-X
act	B-X
on	B-X
nonendothelial	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
and	B-X
by	B-X
demonstrating	B-X
that	B-X
this	B-X
inhibitory	B-X
action	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
the	B-X
target	B-X
cells	B-X
.	B-X
Preliminary	B-X
data	B-X
suggest	B-X
that	B-X
TnI	B-X
may	B-X
be	B-X
competing	B-X
with	B-X
bFGF	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
bFGF	B-X
receptor	B-X
on	B-X
responsive	B-X
cells	B-X
.	B-X

RhoA	B-Gene_or_gene_product
activation	O
promotes	O
transformation	O
and	O
loss	O
of	O
thyroid	O
cell	O
differentiation	O
interfering	O
with	O
thyroid	B-Gene_or_gene_product
transcription	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
activity	O
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

Highly	O
specialized	O
cells	O
,	O
the	O
thyrocytes	O
,	O
express	O
a	O
thyroid	O
-	O
specific	O
set	O
of	O
genes	O
for	O
thyroglobulin	B-Gene_or_gene_product
(	O
Tg	B-Gene_or_gene_product
)	O
,	O
thyroperoxidase	B-Gene_or_gene_product
,	O
and	O
the	O
transcription	O
factors	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
and	O
Pax	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

The	O
implication	O
of	O
the	O
small	O
GTPase	O
RhoA	B-Gene_or_gene_product
in	O
TSH	B-Gene_or_gene_product
-	O
mediated	O
proliferation	O
of	O
FRTL	O
-	O
5	O
rat	O
thyroid	O
cells	O
has	O
been	O
previously	O
demonstrated	O
.	O

To	O
further	O
analyze	O
RhoA	B-Gene_or_gene_product
function	O
in	O
thyroid	O
cell	O
proliferation	O
and	O
differentiation	O
patterns	O
,	O
we	O
combined	O
transient	O
and	O
stable	O
transfection	O
assays	O
to	O
express	O
different	O
mutant	O
RhoA	B-Gene_or_gene_product
forms	O
in	O
FRTL	O
-	O
5	O
cells	O
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

Constitutively	O
active	O
RhoA	B-Gene_or_gene_product
(	O
FRTL	O
-	O
5	O
-	O
RhoA	B-Gene_or_gene_product
QL	O
cells	O
)	O
exhibited	O
a	O
fibroblast	O
-	O
like	O
phenotype	O
with	O
organized	O
actin	B-Gene_or_gene_product
fibers	O
,	O
whereas	O
cells	O
expressing	O
the	O
RhoA	B-Gene_or_gene_product
negative	O
dominant	O
phenotype	O
(	O
FRTL	O
-	O
5	O
-	O
RhoA	O
N19	O
cells	O
)	O
present	O
a	O
rounded	O
morphology	O
and	O
lose	O
normal	O
cytoskeletal	O
architecture	O
.	O

In	O
addition	O
,	O
expression	O
of	O
the	O
constitutively	O
active	O
form	O
of	O
RhoA	B-Gene_or_gene_product
results	O
in	O
TSH	B-Gene_or_gene_product
-	O
independent	O
proliferation	O
and	O
anchorage	O
-	O
independent	O
growth	O
and	O
induces	O
tumors	O
when	O
inoculated	O
in	O
nude	O
mice	O
.	O

Interestingly	O
,	O
FRTL	O
-	O
5	O
-	O
RhoA	B-Gene_or_gene_product
QL	O
cells	O
express	O
less	O
Tg	B-Gene_or_gene_product
and	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
than	O
wild	O
-	O
type	O
FRTL	O
-	O
5	O
(	O
FRTL	O
-	O
5	O
-	O
vector	O
)	O
or	O
FRTL	O
-	O
5	O
-	O
RhoA	B-Gene_or_gene_product
N19	O
,	O
suggesting	O
a	O
loss	O
at	O
the	O
differentiation	O
stage	O
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

This	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
decrease	O
in	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
activity	O
,	O
since	O
transient	O
or	O
stable	O
expression	O
of	O
RhoA	B-Gene_or_gene_product
QL	O
results	O
in	O
a	O
reduction	O
in	O
the	O
activity	O
of	O
the	O
wild	O
-	O
type	O
Tg	B-Gene_or_gene_product
promoter	O
as	O
well	O
as	O
an	O
artificial	O
promoter	O
the	O
activation	O
of	O
which	O
depends	O
exclusively	O
on	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

The	O
similarity	O
between	O
RhoA	B-Gene_or_gene_product
effects	O
and	O
thyroid	O
transformation	O
by	O
Ras	B-Gene_or_gene_product
suggests	O
that	O
RhoA	B-Gene_or_gene_product
may	O
act	O
as	O
a	O
downstream	O
effector	O
of	O
Ras	B-Gene_or_gene_product
;	O
in	O
fact	O
,	O
the	O
dominant	O
negative	O
RhoA	B-Gene_or_gene_product
N19	O
abolished	O
the	O
down	O
-	O
regulatory	O
effect	O
of	O
Ras	B-Gene_or_gene_product
V12	O
over	O
the	O
Tg	B-Gene_or_gene_product
promoter	O
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

Taken	O
together	O
,	O
these	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
active	O
RhoA	B-Gene_or_gene_product
is	O
able	O
to	O
transform	O
FRTL	O
-	O
5	O
cells	O
and	O
that	O
this	O
effect	O
is	O
coupled	O
to	O
a	O
loss	O
of	O
thyroid	O
differentiation	O
due	O
to	O
impaired	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
activity	O
.	O
<EOS>	B-X
Highly	B-X
specialized	B-X
cells	B-X
,	B-X
the	B-X
thyrocytes	B-X
,	B-X
express	B-X
a	B-X
thyroid-specific	B-X
set	B-X
of	B-X
genes	B-X
for	B-X
thyroglobulin	B-X
(	B-X
Tg	B-X
)	B-X
,	B-X
thyroperoxidase	B-X
,	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
TTF-1	B-X
,	B-X
TTF-2	B-X
,	B-X
and	B-X
Pax-8	B-X
.	B-X
The	B-X
implication	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
RhoA	B-X
in	B-X
TSH-mediated	B-X
proliferation	B-X
of	B-X
FRTL-5	B-X
rat	B-X
thyroid	B-X
cells	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
To	B-X
further	B-X
analyze	B-X
RhoA	B-X
function	B-X
in	B-X
thyroid	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
patterns	B-X
,	B-X
we	B-X
combined	B-X
transient	B-X
and	B-X
stable	B-X
transfection	B-X
assays	B-X
to	B-X
express	B-X
different	B-X
mutant	B-X
RhoA	B-X
forms	B-X
in	B-X
FRTL-5	B-X
cells	B-X
.	B-X
Constitutively	B-X
active	B-X
RhoA	B-X
(	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
)	B-X
exhibited	B-X
a	B-X
fibroblast-like	B-X
phenotype	B-X
with	B-X
organized	B-X
actin	B-X
fibers	B-X
,	B-X
whereas	B-X
cells	B-X
expressing	B-X
the	B-X
RhoA	B-X
negative	B-X
dominant	B-X
phenotype	B-X
(	B-X
FRTL-5-RhoA	B-X
N19	B-X
cells	B-X
)	B-X
present	B-X
a	B-X
rounded	B-X
morphology	B-X
and	B-X
lose	B-X
normal	B-X
cytoskeletal	B-X
architecture	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
RhoA	B-X
results	B-X
in	B-X
TSH-independent	B-X
proliferation	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
and	B-X
induces	B-X
tumors	B-X
when	B-X
inoculated	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
FRTL-5-RhoA	B-X
QL	B-X
cells	B-X
express	B-X
less	B-X
Tg	B-X
and	B-X
TTF-1	B-X
than	B-X
wild-type	B-X
FRTL-5	B-X
(	B-X
FRTL-5-	B-X
vector	B-X
)	B-X
or	B-X
FRTL-5-RhoA	B-X
N19	B-X
,	B-X
suggesting	B-X
a	B-X
loss	B-X
at	B-X
the	B-X
differentiation	B-X
stage	B-X
.	B-X
This	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
TTF-1	B-X
activity	B-X
,	B-X
since	B-X
transient	B-X
or	B-X
stable	B-X
expression	B-X
of	B-X
RhoA	B-X
QL	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
wild-type	B-X
Tg	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
an	B-X
artificial	B-X
promoter	B-X
the	B-X
activation	B-X
of	B-X
which	B-X
depends	B-X
exclusively	B-X
on	B-X
TTF-1	B-X
.	B-X
The	B-X
similarity	B-X
between	B-X
RhoA	B-X
effects	B-X
and	B-X
thyroid	B-X
transformation	B-X
by	B-X
Ras	B-X
suggests	B-X
that	B-X
RhoA	B-X
may	B-X
act	B-X
as	B-X
a	B-X
downstream	B-X
effector	B-X
of	B-X
Ras	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
dominant	B-X
negative	B-X
RhoA	B-X
N19	B-X
abolished	B-X
the	B-X
down-	B-X
regulatory	B-X
effect	B-X
of	B-X
Ras	B-X
V12	B-X
over	B-X
the	B-X
Tg	B-X
promoter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
active	B-X
RhoA	B-X
is	B-X
able	B-X
to	B-X
transform	B-X
FRTL-5	B-X
cells	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
coupled	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
thyroid	B-X
differentiation	B-X
due	B-X
to	B-X
impaired	B-X
TTF-1	B-X
activity	B-X
.	B-X

Clinical	O
significance	O
of	O
plasma	O
endostatin	B-Gene_or_gene_product
in	O
acute	O
myeloid	O
leukemia	O
/	O
myelodysplastic	O
syndrome	O
.	O
<EOS>	B-X
While	B-X
endostatin	B-X
is	B-X
being	B-X
investigated	B-X
for	B-X
its	B-X
usefulness	B-X
in	B-X
treating	B-X
solid	B-X
tumors	B-X
,	B-X
its	B-X
significance	B-X
in	B-X
hematologic	B-X
malignancies	B-X
is	B-X
unknown	B-X
.	B-X

BACKGROUND	O
:	O
Endostatin	B-Gene_or_gene_product
,	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	B-Gene_or_gene_product
XVIII	I-Gene_or_gene_product
,	O
is	O
an	O
endogenous	O
angiogenesis	O
inhibitor	O
.	O

While	O
endostatin	B-Gene_or_gene_product
is	O
being	O
investigated	O
for	O
its	O
usefulness	O
in	O
treating	O
solid	O
tumors	O
,	O
its	O
significance	O
in	O
hematologic	O
malignancies	O
is	O
unknown	O
.	O
<EOS>	B-X
While	B-X
endostatin	B-X
is	B-X
being	B-X
investigated	B-X
for	B-X
its	B-X
usefulness	B-X
in	B-X
treating	B-X
solid	B-X
tumors	B-X
,	B-X
its	B-X
significance	B-X
in	B-X
hematologic	B-X
malignancies	B-X
is	B-X
unknown	B-X
.	B-X

METHODS	O
:	O
The	O
authors	O
evaluated	O
plasma	O
endostatin	B-Gene_or_gene_product
(	O
PE	B-Gene_or_gene_product
)	O
levels	O
using	O
an	O
enzyme	O
linked	O
immunoassay	O
in	O
71	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
43	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
,	O
and	O
correlated	O
PE	B-Gene_or_gene_product
with	O
various	O
clinical	O
parameters	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
median	O
PE	B-Gene_or_gene_product
level	O
between	O
AML	O
/	O
MDS	O
patients	O
and	O
the	O
normal	O
controls	O
.	O

Nevertheless	O
,	O
patients	O
who	O
achieved	O
complete	O
remission	O
(	O
CR	O
)	O
had	O
a	O
significantly	O
lower	O
median	O
PE	B-Gene_or_gene_product
level	O
compared	O
to	O
those	O
who	O
did	O
not	O
.	O

In	O
multivariate	O
analysis	O
,	O
PE	B-Gene_or_gene_product
was	O
found	O
to	O
be	O
a	O
significant	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
predictor	O
of	O
overall	O
survival	O
(	O
OS	O
)	O
with	O
adjustment	O
of	O
the	O
other	O
baseline	O
covariates	O
,	O
including	O
patient	O
age	O
,	O
history	O
of	O
antecedent	O
hematologic	O
disorders	O
,	O
and	O
the	O
use	O
of	O
protective	O
environments	O
.	O

The	O
prognostic	O
value	O
of	O
PE	B-Gene_or_gene_product
was	O
also	O
evaluated	O
by	O
dividing	O
MDS	O
/	O
AML	O
patients	O
into	O
high	O
and	O
low	O
PE	B-Gene_or_gene_product
groups	O
using	O
the	O
median	O
PE	B-Gene_or_gene_product
level	O
of	O
normal	O
controls	O
as	O
the	O
cut	O
-	O
off	O
.	O

The	O
authors	O
found	O
that	O
patients	O
in	O
the	O
high	O
PE	B-Gene_or_gene_product
group	O
survived	O
for	O
a	O
significantly	O
shorter	O
time	O
than	O
those	O
patients	O
in	O
the	O
low	O
PE	B-Gene_or_gene_product
group	O
.	O

CONCLUSIONS	O
:	O
PE	B-Gene_or_gene_product
is	O
a	O
useful	O
prognostic	O
predictor	O
of	O
CR	O
and	O
OS	O
for	O
AML	O
/	O
MDS	O
patients	O
.	O
<EOS>	B-X
While	B-X
endostatin	B-X
is	B-X
being	B-X
investigated	B-X
for	B-X
its	B-X
usefulness	B-X
in	B-X
treating	B-X
solid	B-X
tumors	B-X
,	B-X
its	B-X
significance	B-X
in	B-X
hematologic	B-X
malignancies	B-X
is	B-X
unknown	B-X
.	B-X

The	O
mechanism	O
underlying	O
the	O
association	O
between	O
high	O
PE	B-Gene_or_gene_product
and	O
poor	O
clinical	O
outcome	O
is	O
unclear	O
,	O
although	O
it	O
may	O
be	O
related	O
to	O
the	O
possible	O
PE	B-Gene_or_gene_product
reflection	O
of	O
tumor	O
burden	O
.	O

Modulation	O
of	O
angiogenesis	O
and	O
progelatinase	B-Gene_or_gene_product
a	I-Gene_or_gene_product
by	O
thrombin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
mimetics	O
and	O
antagonists	O
.	O
<EOS>	B-X
The	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
thrombin	B-X
receptor	B-X
.	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
As	B-X
antagonists	B-X
were	B-X
used	B-X
the	B-X
tripeptide	B-X
FPR	B-X
and	B-X
non-peptide	B-X
1,4-disubstituted	B-X
piperazine	B-X
derivatives	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
Thrombin	B-X
and	B-X
SFLLR	B-X
activated	B-X
progelatinase	B-X
A	B-X
(	B-X
MMP-2	B-X
)	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
human	B-X
umbilical	B-X
cord	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

The	O
angiogenic	O
action	O
of	O
thrombin	B-Gene_or_gene_product
has	O
been	O
shown	O
to	O
be	O
mediated	O
by	O
activation	O
of	O
the	O
thrombin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
.	O
<EOS>	B-X
Clinical	B-X
,	B-X
laboratory	B-X
,	B-X
histopathological	B-X
and	B-X
pharmacological	B-X
evidence	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
a	B-X
systemic	B-X
activation	B-X
of	B-X
blood	B-X
coagulation	B-X
is	B-X
often	B-X
present	B-X
in	B-X
cancer	B-X
patients	B-X
.	B-X
Additionally	B-X
,	B-X
thrombin	B-X
was	B-X
shown	B-X
to	B-X
promote	B-X
tumour	B-X
progression	B-X
and	B-X
metastasis	B-X
in	B-X
animals	B-X
,	B-X
and	B-X
epidemiological	B-X
studies	B-X
suggest	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
cancer	B-X
diagnosis	B-X
after	B-X
primary	B-X
thromboembolism	B-X
.	B-X
We	B-X
have	B-X
proposed	B-X
that	B-X
the	B-X
aforementioned	B-X
results	B-X
may	B-X
be	B-X
related	B-X
to	B-X
our	B-X
finding	B-X
that	B-X
thrombin	B-X
is	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
angiogenesis	B-X
.	B-X
This	B-X
is	B-X
a	B-X
thrombin	B-X
receptor-mediated	B-X
event	B-X
(	B-X
the	B-X
receptor	B-X
is	B-X
referred	B-X
to	B-X
as	B-X
protease-activate	B-X
receptor	B-X
)	B-X
and	B-X
is	B-X
independent	B-X
of	B-X
fibrin	B-X
formation	B-X
.	B-X
Many	B-X
cellular	B-X
effects	B-X
of	B-X
thrombin	B-X
on	B-X
endothelial	B-X
cells	B-X
can	B-X
contribute	B-X
to	B-X
the	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Exposure	B-X
of	B-X
endothelial	B-X
cells	B-X
to	B-X
thrombin	B-X
cause	B-X
a	B-X
time-	B-X
and	B-X
dose-dependent	B-X
decrease	B-X
in	B-X
the	B-X
attachment	B-X
of	B-X
these	B-X
cells	B-X
to	B-X
basement	B-X
membrane	B-X
components	B-X
,	B-X
with	B-X
a	B-X
concomitant	B-X
increase	B-X
in	B-X
matrix	B-X
metalloproteinase	B-X
2	B-X
activation	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
Thrombin	B-X
upregulates	B-X
the	B-X
expression	B-X
of	B-X
integrin	B-X
alphavbeta3	B-X
,	B-X
the	B-X
marker	B-X
of	B-X
the	B-X
angiogenic	B-X
phenotype	B-X
of	B-X
endothelial	B-X
cells	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
Thrombin	B-X
has	B-X
chemotactic	B-X
and	B-X
aptotactic	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
and	B-X
upregulates	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
receptors	B-X
(	B-X
KDR	B-X
and	B-X
Flt1	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
thrombin	B-X
synergizes	B-X
with	B-X
the	B-X
key	B-X
angiogenic	B-X
factor	B-X
VEGF	B-X
in	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
.	B-X
Furthermore	B-X
,	B-X
thrombin	B-X
enhances	B-X
the	B-X
secretion	B-X
of	B-X
VEGF	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
9	B-X
of	B-X
PC3	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
can	B-X
explain	B-X
the	B-X
angiogenic	B-X
and	B-X
tumour-promoting	B-X
effect	B-X
of	B-X
thrombin	B-X
and	B-X
provide	B-X
the	B-X
basis	B-X
for	B-X
development	B-X
of	B-X
thrombin	B-X
receptor	B-X
mimetics	B-X
or	B-X
antagonists	B-X
for	B-X
therapeutic	B-X
application	B-X
.	B-X

In	O
this	O
report	O
we	O
studied	O
the	O
effects	O
of	O
SFLLR	B-Gene_or_gene_product
,	O
an	O
agonist	O
of	O
the	O
activated	O
thrombin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
and	O
thrombin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
peptide	O
and	O
non	O
peptide	O
antagonists	O
on	O
angiogenesis	O
in	O
the	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
system	O
.	O
<EOS>	B-X
The	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
thrombin	B-X
receptor	B-X
.	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
As	B-X
antagonists	B-X
were	B-X
used	B-X
the	B-X
tripeptide	B-X
FPR	B-X
and	B-X
non-peptide	B-X
1,4-disubstituted	B-X
piperazine	B-X
derivatives	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
Thrombin	B-X
and	B-X
SFLLR	B-X
activated	B-X
progelatinase	B-X
A	B-X
(	B-X
MMP-2	B-X
)	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
human	B-X
umbilical	B-X
cord	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

As	O
antagonists	O
were	O
used	O
the	O
tripeptide	B-Gene_or_gene_product
FPR	I-Gene_or_gene_product
and	O
non	O
-	O
peptide	O
1	O
,	O
4	O
-	O
disubstituted	O
piperazine	O
derivatives	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
As	B-X
antagonists	B-X
were	B-X
used	B-X
the	B-X
tripeptide	B-X
FPR	B-X
and	B-X
non-peptide	B-X
1,4-disubstituted	B-X
piperazine	B-X
derivatives	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

The	O
pentapeptide	B-Gene_or_gene_product
SFLLR	I-Gene_or_gene_product
,	O
like	O
thrombin	B-Gene_or_gene_product
,	O
caused	O
a	O
marked	O
stimulation	O
of	O
angiogenesis	O
in	O
the	O
CAM	O
.	O
<EOS>	B-X
The	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
thrombin	B-X
receptor	B-X
.	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
Thrombin	B-X
and	B-X
SFLLR	B-X
activated	B-X
progelatinase	B-X
A	B-X
(	B-X
MMP-2	B-X
)	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
human	B-X
umbilical	B-X
cord	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

FPR	B-Gene_or_gene_product
and	O
the	O
piperazine	O
derivatives	O
caused	O
suppression	O
of	O
angiogenesis	O
and	O
in	O
combination	O
with	O
thrombin	B-Gene_or_gene_product
antagonized	O
its	O
angiogenic	O
effect	O
.	O
<EOS>	B-X
The	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
thrombin	B-X
receptor	B-X
.	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
As	B-X
antagonists	B-X
were	B-X
used	B-X
the	B-X
tripeptide	B-X
FPR	B-X
and	B-X
non-peptide	B-X
1,4-disubstituted	B-X
piperazine	B-X
derivatives	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

Thrombin	B-Gene_or_gene_product
and	O
SFLLR	B-Gene_or_gene_product
activated	O
progelatinase	B-Gene_or_gene_product
A	I-Gene_or_gene_product
(	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	O
in	O
the	O
culture	O
medium	O
of	O
human	O
umbilical	O
cord	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
Thrombin	B-X
and	B-X
SFLLR	B-X
activated	B-X
progelatinase	B-X
A	B-X
(	B-X
MMP-2	B-X
)	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
human	B-X
umbilical	B-X
cord	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
is	O
involved	O
in	O
the	O
early	O
steps	O
of	O
angiogenesis	O
leading	O
to	O
local	O
dissolution	O
of	O
basement	O
membrane	O
collagen	B-Gene_or_gene_product
and	O
migration	O
of	O
the	O
activated	O
endothelial	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
Thrombin	B-X
and	B-X
SFLLR	B-X
activated	B-X
progelatinase	B-X
A	B-X
(	B-X
MMP-2	B-X
)	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
human	B-X
umbilical	B-X
cord	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

FPR	B-Gene_or_gene_product
and	O
the	O
piperazine	O
derivatives	O
inhibited	O
the	O
activation	O
of	O
this	O
enzyme	O
.	O
<EOS>	B-X
The	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
thrombin	B-X
receptor	B-X
.	B-X
As	B-X
antagonists	B-X
were	B-X
used	B-X
the	B-X
tripeptide	B-X
FPR	B-X
and	B-X
non-peptide	B-X
1,4-disubstituted	B-X
piperazine	B-X
derivatives	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X

They	O
also	O
antagonised	O
the	O
effects	O
of	O
both	O
thrombin	B-Gene_or_gene_product
and	O
SFLLR	B-Gene_or_gene_product
on	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
activation	O
.	O
<EOS>	B-X
The	B-X
angiogenic	B-X
action	B-X
of	B-X
thrombin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
thrombin	B-X
receptor	B-X
.	B-X
In	B-X
this	B-X
report	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
SFLLR	B-X
,	B-X
an	B-X
agonist	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
and	B-X
thrombin	B-X
receptor	B-X
peptide	B-X
and	B-X
non	B-X
peptide	B-X
antagonists	B-X
on	B-X
angiogenesis	B-X
in	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
system	B-X
.	B-X
The	B-X
pentapeptide	B-X
SFLLR	B-X
,	B-X
like	B-X
thrombin	B-X
,	B-X
caused	B-X
a	B-X
marked	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
CAM	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
caused	B-X
suppression	B-X
of	B-X
angiogenesis	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
thrombin	B-X
antagonized	B-X
its	B-X
angiogenic	B-X
effect	B-X
.	B-X
Thrombin	B-X
and	B-X
SFLLR	B-X
activated	B-X
progelatinase	B-X
A	B-X
(	B-X
MMP-2	B-X
)	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
human	B-X
umbilical	B-X
cord	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
MMP-2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
angiogenesis	B-X
leading	B-X
to	B-X
local	B-X
dissolution	B-X
of	B-X
basement	B-X
membrane	B-X
collagen	B-X
and	B-X
migration	B-X
of	B-X
the	B-X
activated	B-X
endothelial	B-X
cells	B-X
.	B-X
FPR	B-X
and	B-X
the	B-X
piperazine	B-X
derivatives	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
They	B-X
also	B-X
antagonised	B-X
the	B-X
effects	B-X
of	B-X
both	B-X
thrombin	B-X
and	B-X
SFLLR	B-X
on	B-X
MMP-2	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
non-thrombogenic	B-X
agonists	B-X
or	B-X
antagonists	B-X
of	B-X
the	B-X
activated	B-X
thrombin	B-X
receptor	B-X
can	B-X
be	B-X
used	B-X
as	B-X
modulators	B-X
of	B-X
angiogenesis	B-X
.	B-X

These	O
results	O
suggest	O
that	O
non	O
-	O
thrombogenic	O
agonists	O
or	O
antagonists	O
of	O
the	O
activated	O
thrombin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
can	O
be	O
used	O
as	O
modulators	O
of	O
angiogenesis	O
.	O
<EOS>	B-X
In	B-X
turn	B-X
,	B-X
this	B-X
causes	B-X
hypoxia	B-X
leading	B-X
to	B-X
release	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
to	B-X
induce	B-X
the	B-X
angiogenesis	B-X
process	B-X
.	B-X
Its	B-X
targets	B-X
include	B-X
elastase	B-X
,	B-X
plasmin	B-X
,	B-X
thrombin	B-X
,	B-X
trypsin	B-X
,	B-X
chymotrypsin	B-X
,	B-X
proteinase	B-X
3	B-X
(	B-X
PR-3	B-X
)	B-X
and	B-X
plasminogen	B-X
activator	B-X
(	B-X
PAI	B-X
)	B-X
.	B-X
AAT	B-X
modulates	B-X
the	B-X
effect	B-X
of	B-X
protease-activated	B-X
receptors	B-X
(	B-X
PARs	B-X
)	B-X
during	B-X
inflammatory	B-X
responses	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
best	B-X
known	B-X
as	B-X
an	B-X
angiogenic	B-X
factor	B-X
essential	B-X
for	B-X
embryonic	B-X
vasculogenesis	B-X
and	B-X
postnatal	B-X
angiogenesis	B-X
.	B-X
Considerable	B-X
evidence	B-X
has	B-X
accumulated	B-X
that	B-X
VEGF	B-X
also	B-X
has	B-X
non-angiogenic	B-X
functions	B-X
.	B-X
Early	B-X
studies	B-X
demonstrated	B-X
that	B-X
VEGF	B-X
transcripts	B-X
are	B-X
ubiquitously	B-X
expressed	B-X
,	B-X
and	B-X
the	B-X
phosphorylation	B-X
of	B-X
VEGF	B-X
receptor	B-X
is	B-X
detectable	B-X
in	B-X
adult	B-X
organs	B-X
that	B-X
have	B-X
no	B-X
feature	B-X
of	B-X
angiogenesis	B-X
.	B-X
Recent	B-X
clinical	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
VEGF	B-X
signaling	B-X
results	B-X
in	B-X
diverse	B-X
angiogenesis-irrelevant	B-X
side	B-X
effects	B-X
involving	B-X
the	B-X
dysfunctions	B-X
of	B-X
many	B-X
organs	B-X
,	B-X
suggesting	B-X
non-angiogenic	B-X
roles	B-X
of	B-X
VEGF	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
organ	B-X
homeostasis	B-X
.	B-X
Furthermore	B-X
,	B-X
very	B-X
recent	B-X
studies	B-X
including	B-X
ours	B-X
have	B-X
revealed	B-X
VEGF	B-X
as	B-X
a	B-X
potent	B-X
agonist	B-X
for	B-X
endothelial	B-X
exocytosis	B-X
of	B-X
Weibel-Palade	B-X
bodies	B-X
in	B-X
which	B-X
thrombogenic	B-X
and	B-X
inflammatory	B-X
factors	B-X
are	B-X
stored	B-X
.	B-X
In	B-X
this	B-X
brief	B-X
review	B-X
,	B-X
we	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
VEGF	B-X
non-angiogenic	B-X
functions	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
tissue	B-X
repair	B-X
and	B-X
organ	B-X
regeneration	B-X
,	B-X
vascular	B-X
homeostasis	B-X
,	B-X
and	B-X
inflammation	B-X
,	B-X
and	B-X
propose	B-X
that	B-X
the	B-X
non-angiogenic	B-X
functions	B-X
are	B-X
primarily	B-X
mediated	B-X
through	B-X
the	B-X
substances	B-X
released	B-X
from	B-X
ECs	B-X
.	B-X

Abnormal	O
expression	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
and	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
may	O
be	O
a	O
molecular	O
marker	O
of	O
submucosal	O
invasion	O
and	O
lymph	O
node	O
metastasis	O
in	O
early	O
gastric	O
cancer	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X
Predicting	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
LNM	B-X
)	B-X
accurately	B-X
is	B-X
very	B-X
important	B-X
to	B-X
decide	B-X
treatment	B-X
strategies	B-X
preoperatively	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
explore	B-X
risk	B-X
factors	B-X
that	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
LNM	B-X
in	B-X
early	B-X
gastric	B-X
cancer	B-X
(	B-X
EGC	B-X
)	B-X
.	B-X
A	B-X
total	B-X
of	B-X
230	B-X
patients	B-X
with	B-X
EGC	B-X
who	B-X
underwent	B-X
curative	B-X
gastrectomy	B-X
with	B-X
lymph	B-X
adenectomy	B-X
at	B-X
Xinhua	B-X
Hospital	B-X
from	B-X
January	B-X
2006	B-X
to	B-X
July	B-X
2014	B-X
were	B-X
retrospectively	B-X
reviewed	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
relationship	B-X
between	B-X
clinicopathological	B-X
factors	B-X
,	B-X
biological	B-X
markers	B-X
(	B-X
p53	B-X
,	B-X
ki67	B-X
,	B-X
nm23	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
,	B-X
E-cadherin	B-X
(	B-X
E-cad	B-X
)	B-X
,	B-X
beta-catenin	B-X
(	B-X
b-catenin	B-X
)	B-X
,	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
,	B-X
and	B-X
topoisomerase	B-X
II	B-X
(	B-X
Topo	B-X
II	B-X
)	B-X
)	B-X
,	B-X
and	B-X
LNM	B-X
of	B-X
EGC	B-X
patients	B-X
by	B-X
chi-square	B-X
test	B-X
and	B-X
logistic	B-X
regression	B-X
analysis	B-X
.	B-X
Meta-analyses	B-X
were	B-X
further	B-X
conducted	B-X
to	B-X
review	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
proteins	B-X
(	B-X
P53	B-X
,	B-X
ki67	B-X
,	B-X
E-cad	B-X
,	B-X
and	B-X
b-catenin	B-X
)	B-X
on	B-X
LNM	B-X
in	B-X
ECG	B-X
patients	B-X
.	B-X
Incidences	B-X
of	B-X
LNM	B-X
was	B-X
distinct	B-X
in	B-X
different	B-X
tumor	B-X
size	B-X
(	B-X
p	B-X
=	B-X
0.044	B-X
)	B-X
,	B-X
depth	B-X
of	B-X
submucosal	B-X
invasion	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
and	B-X
P53	B-X
overexpression	B-X
(	B-X
p	B-X
=	B-X
0.004	B-X
)	B-X
.	B-X
Multivariate	B-X
analysis	B-X
further	B-X
indentified	B-X
that	B-X
large	B-X
tumor	B-X
size	B-X
(	B-X
â¥20	B-X
mm	B-X
,	B-X
odds	B-X
ratio	B-X
(	B-X
OR	B-X
)	B-X
=	B-X
2.168	B-X
,	B-X
p	B-X
=	B-X
0.041	B-X
)	B-X
,	B-X
submucosa	B-X
(	B-X
OR	B-X
=	B-X
4.000	B-X
,	B-X
p	B-X
=	B-X
0.0005	B-X
)	B-X
,	B-X
and	B-X
P53	B-X
overexpression	B-X
(	B-X
OR	B-X
=	B-X
3.010	B-X
,	B-X
p	B-X
=	B-X
0.022	B-X
)	B-X
were	B-X
independent	B-X
risk	B-X
factors	B-X
of	B-X
LNM	B-X
in	B-X
EGC	B-X
patients	B-X
.	B-X
The	B-X
meta-analysis	B-X
revealed	B-X
a	B-X
significantly	B-X
statistical	B-X
association	B-X
of	B-X
P53	B-X
,	B-X
ki67	B-X
,	B-X
and	B-X
b-catenin	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
LNM	B-X
in	B-X
EGC	B-X
patients	B-X
(	B-X
P53	B-X
,	B-X
OR	B-X
=	B-X
1.81	B-X
,	B-X
p	B-X
=	B-X
0.017	B-X
;	B-X
ki67	B-X
,	B-X
OR	B-X
=	B-X
2.53	B-X
,	B-X
p	B-X
=	B-X
0.0003	B-X
;	B-X
b-catenin	B-X
,	B-X
OR	B-X
=	B-X
0.53	B-X
,	B-X
p	B-X
=	B-X
0.01	B-X
)	B-X
.	B-X
Tumor	B-X
size	B-X
(	B-X
â¥20	B-X
mm	B-X
)	B-X
,	B-X
the	B-X
depth	B-X
of	B-X
invasion	B-X
(	B-X
submucosa	B-X
)	B-X
,	B-X
and	B-X
P53	B-X
overexpression	B-X
may	B-X
be	B-X
helpful	B-X
predictors	B-X
of	B-X
LNM	B-X
in	B-X
EGC	B-X
patients	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
results	B-X
of	B-X
meta-analysis	B-X
revealed	B-X
that	B-X
P53	B-X
,	B-X
ki67	B-X
overexpression	B-X
,	B-X
and	B-X
abnormal	B-X
expression	B-X
of	B-X
b-catenin	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
LNM	B-X
in	B-X
EGC	B-X
.	B-X

BACKGROUND	O
:	O
Impaired	O
expression	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
and	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
and	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
is	O
frequently	O
observed	O
in	O
several	O
human	O
cancers	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X
Although	B-X
virtually	B-X
all	B-X
cases	B-X
of	B-X
lobular	B-X
carcinoma	B-X
in	B-X
situ	B-X
lack	B-X
E-cadherin	B-X
expression	B-X
,	B-X
a	B-X
proportion	B-X
of	B-X
morphologically	B-X
typical	B-X
invasive	B-X
lobular	B-X
carcinomas	B-X
(	B-X
ILCs	B-X
)	B-X
retain	B-X
its	B-X
expression	B-X
.	B-X
The	B-X
frequency	B-X
and	B-X
significance	B-X
of	B-X
E-cadherin	B-X
expression	B-X
in	B-X
ILC	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
assessed	B-X
E-cadherin	B-X
protein	B-X
expression	B-X
in	B-X
a	B-X
well-characterized	B-X
series	B-X
of	B-X
histologically	B-X
defined	B-X
ILC	B-X
(	B-X
239	B-X
cases	B-X
)	B-X
with	B-X
a	B-X
long-term	B-X
clinical	B-X
follow-up	B-X
to	B-X
determine	B-X
the	B-X
frequency	B-X
,	B-X
clinical	B-X
and	B-X
biological	B-X
significance	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
E-cadherin-positive	B-X
ILCs	B-X
(	B-X
ILC+	B-X
)	B-X
were	B-X
subsequently	B-X
examined	B-X
to	B-X
assess	B-X
the	B-X
expression	B-X
of	B-X
component	B-X
members	B-X
of	B-X
the	B-X
E-cadherin	B-X
membrane	B-X
complex	B-X
(	B-X
E-cadherin	B-X
,	B-X
p120	B-X
,	B-X
Î±	B-X
,	B-X
Î²	B-X
,	B-X
and	B-X
Î³-catenins	B-X
)	B-X
to	B-X
determine	B-X
its	B-X
integrity	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
immunohistochemical	O
expression	O
of	O
these	O
adhesion	O
molecules	O
,	O
focusing	O
on	O
early	O
gastric	O
carcinomas	O
,	O
and	O
to	O
investigate	O
differences	O
between	O
differentiated	O
and	O
undifferentiated	O
gastric	O
cancer	O
at	O
the	O
early	O
phase	O
of	O
carcinogenesis	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X

METHODS	O
:	O
Immunohistochemical	O
staining	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
and	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
and	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
was	O
performed	O
using	O
specimens	O
from	O
143	O
patients	O
with	O
early	O
gastric	O
cancer	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X

RESULTS	O
:	O
Abnormal	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
and	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
staining	O
correlated	O
with	O
depth	O
of	O
tumour	O
invasion	O
in	O
differentiated	O
-	O
type	O
tumours	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X
E-cadherin/catenin	B-X
complexes	B-X
exert	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
adhesion	B-X
.	B-X
Î²-catenin	B-X
is	B-X
a	B-X
key	B-X
player	B-X
in	B-X
Wnt	B-X
signaling	B-X
pathway	B-X
in	B-X
gastric	B-X
cancer	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
expression	B-X
of	B-X
E-cadherin	B-X
,	B-X
Î²-catenin	B-X
and	B-X
p53	B-X
in	B-X
gastric	B-X
adenocarcinoma	B-X
,	B-X
and	B-X
their	B-X
correlations	B-X
with	B-X
clinicopathological	B-X
features	B-X
.	B-X

In	O
contrast	O
,	O
abnormal	O
staining	O
was	O
frequently	O
found	O
even	O
in	O
intramucosal	O
carcinoma	O
of	O
undifferentiated	O
-	O
type	O
tumours	O
,	O
suggesting	O
an	O
apparent	O
difference	O
in	O
the	O
onset	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
-	O
catenin	B-Gene_or_gene_product
complex	O
abnormality	O
between	O
the	O
two	O
cancer	O
types	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X

Absent	O
staining	O
of	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
was	O
associated	O
with	O
lymph	O
node	O
metastasis	O
.	O
<EOS>	B-X
beta-catenin	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
function	B-X
of	B-X
cell	B-X
adhesion	B-X
molecules	B-X
and	B-X
also	B-X
participates	B-X
in	B-X
growth	B-X
regulatory	B-X
signalling	B-X
pathways	B-X
that	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
malignant	B-X
transformation	B-X
.	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
To	B-X
study	B-X
the	B-X
association	B-X
of	B-X
the	B-X
expressions	B-X
of	B-X
E-cadherin	B-X
,	B-X
beta	B-X
;	B-X
-	B-X
and	B-X
gamma-catenins	B-X
in	B-X
gastric	B-X
carcinoma	B-X
tissues	B-X
with	B-X
the	B-X
invasion	B-X
and	B-X
metastasis	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
prognostic	B-X
and	B-X
diagnostic	B-X
significance	B-X
of	B-X
beta-catenin	B-X
nuclear	B-X
immunostaining	B-X
in	B-X
60	B-X
specimens	B-X
of	B-X
normal	B-X
colorectal	B-X
tissue	B-X
;	B-X
180	B-X
specimens	B-X
of	B-X
colorectal	B-X
polyps	B-X
,	B-X
adenomas	B-X
,	B-X
and	B-X
carcinomas	B-X
;	B-X
and	B-X
40	B-X
specimens	B-X
from	B-X
patients	B-X
with	B-X
the	B-X
simultaneous	B-X
occurrence	B-X
of	B-X
polyps	B-X
,	B-X
adenomas	B-X
,	B-X
and	B-X
carcinomas	B-X
.	B-X
Immunohistochemical	B-X
staining	B-X
showed	B-X
that	B-X
the	B-X
occurrence	B-X
of	B-X
nuclear	B-X
beta-catenin	B-X
correlated	B-X
with	B-X
the	B-X
sequential	B-X
stages	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
in	B-X
which	B-X
positive	B-X
staining	B-X
was	B-X
observed	B-X
in	B-X
0	B-X
%	B-X
of	B-X
normal	B-X
tissues	B-X
,	B-X
8	B-X
%	B-X
of	B-X
polyps	B-X
,	B-X
92	B-X
%	B-X
of	B-X
adenomas	B-X
,	B-X
and	B-X
100	B-X
%	B-X
of	B-X
carcinomas	B-X
.	B-X
High	B-X
immunohistochemical	B-X
scores	B-X
in	B-X
colorectal	B-X
carcinoma	B-X
were	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
survival	B-X
.	B-X
Adenomas	B-X
associated	B-X
with	B-X
synchronous	B-X
or	B-X
metachronous	B-X
carcinomas	B-X
showed	B-X
significantly	B-X
higher	B-X
levels	B-X
of	B-X
nuclear	B-X
beta-catenin	B-X
compared	B-X
with	B-X
adenomas	B-X
without	B-X
associated	B-X
carcinomas	B-X
.	B-X
Nuclear	B-X
translocation	B-X
of	B-X
beta-catenin	B-X
was	B-X
rare	B-X
or	B-X
absent	B-X
in	B-X
other	B-X
types	B-X
of	B-X
cytokeratin	B-X
20	B-X
positive	B-X
adenocarcinomas	B-X
examined	B-X
(	B-X
99	B-X
cases	B-X
)	B-X
.	B-X
However	B-X
,	B-X
100	B-X
%	B-X
of	B-X
primary	B-X
and	B-X
metastatic	B-X
colorectal	B-X
adenocarcinomas	B-X
were	B-X
positive	B-X
for	B-X
nuclear	B-X
staining	B-X
for	B-X
beta-catenin	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
staining	B-X
for	B-X
beta-catenin	B-X
may	B-X
serve	B-X
as	B-X
an	B-X
additional	B-X
parameter	B-X
to	B-X
help	B-X
distinguish	B-X
colorectal	B-X
adenocarcinomas	B-X
from	B-X
adenocarcinomas	B-X
of	B-X
other	B-X
tissue	B-X
sites	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
present	B-X
large-scale	B-X
study	B-X
has	B-X
clearly	B-X
addressed	B-X
the	B-X
clinical	B-X
significance	B-X
of	B-X
beta-catenin	B-X
nuclear	B-X
translocation	B-X
with	B-X
respect	B-X
to	B-X
tumor	B-X
progression	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
differential	B-X
diagnosis	B-X
.	B-X

Multivariate	O
analysis	O
revealed	O
abnormal	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
expression	O
as	O
an	O
independent	O
factor	O
that	O
correlated	O
with	O
submucosal	O
invasion	O
in	O
early	O
gastric	O
cancer	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X

CONCLUSION	O
:	O
Abnormal	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
expression	O
is	O
a	O
possible	O
marker	O
of	O
submucosal	O
invasion	O
in	O
differentiated	O
-	O
type	O
early	O
gastric	O
cancer	O
and	O
absent	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
staining	O
could	O
be	O
used	O
as	O
a	O
predictor	O
of	O
lymph	O
node	O
metastasis	O
in	O
both	O
types	O
.	O
<EOS>	B-X
Impaired	B-X
expression	B-X
of	B-X
E-cadherin	B-X
and	B-X
alpha-	B-X
and	B-X
beta-catenin	B-X
is	B-X
frequently	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
,	B-X
focusing	B-X
on	B-X
early	B-X
gastric	B-X
carcinomas	B-X
,	B-X
and	B-X
to	B-X
investigate	B-X
differences	B-X
between	B-X
differentiated	B-X
and	B-X
undifferentiated	B-X
gastric	B-X
cancer	B-X
at	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
carcinogenesis	B-X
.	B-X

Dominant	O
negative	O
interference	O
of	O
transcription	O
factor	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
causes	O
inhibition	O
of	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
expression	O
and	O
suppresses	O
malignant	O
cell	O
growth	O
.	O
<EOS>	B-X
ErbB-3	B-X
(	B-X
HER3	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
family	B-X
.	B-X
Increasing	B-X
evidence	B-X
suggests	B-X
that	B-X
elevated	B-X
expression	B-X
of	B-X
ErbB-3	B-X
is	B-X
important	B-X
for	B-X
malignancy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
elevated	B-X
levels	B-X
of	B-X
ErbB-3	B-X
expression	B-X
did	B-X
not	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
AP-2gamma	B-X
in	B-X
a	B-X
panel	B-X
of	B-X
human	B-X
mammary	B-X
epithelial	B-X
and	B-X
fibroblasts	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
there	B-X
was	B-X
no	B-X
association	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
AP-2alpha	B-X
or	B-X
AP-2beta	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ErbB-3	B-X
,	B-X
or	B-X
between	B-X
AP-2alpha	B-X
and	B-X
AP-2gamma	B-X
double	B-X
positivity	B-X
and	B-X
ErbB-3	B-X
expression	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
exogenous	B-X
expression	B-X
of	B-X
AP-2gamma	B-X
robustly	B-X
activated	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
AP-2	B-X
protein	B-X
,	B-X
AP-2delta	B-X
(	B-X
deleted	B-X
residues	B-X
31-117	B-X
)	B-X
,	B-X
not	B-X
only	B-X
repressed	B-X
the	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
but	B-X
also	B-X
suppressed	B-X
endogenous	B-X
ErbB-3	B-X
transcription	B-X
in	B-X
the	B-X
ErbB-3	B-X
overexpressing	B-X
cell	B-X
line	B-X
MRC-5VA	B-X
.	B-X
Overexpression	B-X
of	B-X
AP-2A	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
proliferation	B-X
rate	B-X
and	B-X
inhibitin	B-X
of	B-X
colony	B-X
formation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
strongly	B-X
support	B-X
a	B-X
role	B-X
for	B-X
the	B-X
AP-2	B-X
gene	B-X
family	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
AP-2gamma	B-X
,	B-X
in	B-X
the	B-X
control	B-X
of	B-X
ErbB-3	B-X
expression	B-X
.	B-X
Interference	B-X
with	B-X
the	B-X
function	B-X
of	B-X
transcription	B-X
factor	B-X
AP-2	B-X
might	B-X
provide	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
modulation	B-X
of	B-X
the	B-X
malignant	B-X
phenotype	B-X
.	B-X

ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
(	O
HER3	B-Gene_or_gene_product
)	O
is	O
a	O
member	O
of	O
the	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
family	O
.	O
<EOS>	B-X
HER3	B-X
is	B-X
a	B-X
pseudokinase	B-X
member	B-X
of	B-X
the	B-X
EGFR	B-X
family	B-X
having	B-X
a	B-X
role	B-X
in	B-X
both	B-X
tumor	B-X
progression	B-X
and	B-X
drug	B-X
resistance	B-X
.	B-X
Although	B-X
HER3	B-X
was	B-X
discovered	B-X
more	B-X
than	B-X
30	B-X
years	B-X
ago	B-X
,	B-X
no	B-X
therapeutic	B-X
interventions	B-X
have	B-X
reached	B-X
clinical	B-X
approval	B-X
to	B-X
date	B-X
.	B-X
Because	B-X
the	B-X
evidence	B-X
of	B-X
the	B-X
importance	B-X
of	B-X
HER3	B-X
is	B-X
accumulating	B-X
,	B-X
increased	B-X
amounts	B-X
of	B-X
preclinical	B-X
and	B-X
clinical	B-X
trials	B-X
with	B-X
HER3-targeting	B-X
agents	B-X
are	B-X
emerging	B-X
.	B-X
In	B-X
this	B-X
review	B-X
article	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
most	B-X
recent	B-X
HER3	B-X
biology	B-X
in	B-X
tumorigenic	B-X
events	B-X
and	B-X
drug	B-X
resistance	B-X
and	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
current	B-X
and	B-X
emerging	B-X
strategies	B-X
to	B-X
target	B-X
HER3	B-X
.	B-X

Increasing	O
evidence	O
suggests	O
that	O
elevated	O
expression	O
of	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
is	O
important	O
for	O
malignancy	O
.	O
<EOS>	B-X
Increases	B-X
in	B-X
the	B-X
ratio	B-X
of	B-X
LIP/LAP	B-X
are	B-X
associated	B-X
with	B-X
aggressive	B-X
,	B-X
metastatic	B-X
breast	B-X
cancer	B-X
;	B-X
however	B-X
,	B-X
little	B-X
is	B-X
known	B-X
regarding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
regulate	B-X
LIP	B-X
expression	B-X
or	B-X
the	B-X
biological	B-X
actions	B-X
of	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
LIP/LAP	B-X
ratio	B-X
.	B-X
IGF-1R	B-X
signaling	B-X
is	B-X
important	B-X
for	B-X
the	B-X
survival	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
and	B-X
crosstalk	B-X
between	B-X
IGF-1R	B-X
and	B-X
EGFR	B-X
signaling	B-X
pathways	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
more	B-X
aggressive	B-X
disease	B-X
.	B-X
We	B-X
therefore	B-X
evaluated	B-X
in	B-X
mammary	B-X
epithelial	B-X
cells	B-X
whether	B-X
IGF-1R	B-X
signaling	B-X
regulates	B-X
the	B-X
LIP/LAP	B-X
ratio	B-X
,	B-X
analyzed	B-X
the	B-X
potential	B-X
interplay	B-X
between	B-X
EGFR	B-X
and	B-X
IGF-1R	B-X
signaling	B-X
and	B-X
addressed	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
increased	B-X
LIP	B-X
expression	B-X
in	B-X
cellular	B-X
survival	B-X
and	B-X
suppression	B-X
of	B-X
anoikis	B-X
.	B-X
ErbB-3	B-X
(	B-X
HER3	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
family	B-X
.	B-X
Increasing	B-X
evidence	B-X
suggests	B-X
that	B-X
elevated	B-X
expression	B-X
of	B-X
ErbB-3	B-X
is	B-X
important	B-X
for	B-X
malignancy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
elevated	B-X
levels	B-X
of	B-X
ErbB-3	B-X
expression	B-X
did	B-X
not	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
AP-2gamma	B-X
in	B-X
a	B-X
panel	B-X
of	B-X
human	B-X
mammary	B-X
epithelial	B-X
and	B-X
fibroblasts	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
there	B-X
was	B-X
no	B-X
association	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
AP-2alpha	B-X
or	B-X
AP-2beta	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ErbB-3	B-X
,	B-X
or	B-X
between	B-X
AP-2alpha	B-X
and	B-X
AP-2gamma	B-X
double	B-X
positivity	B-X
and	B-X
ErbB-3	B-X
expression	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
exogenous	B-X
expression	B-X
of	B-X
AP-2gamma	B-X
robustly	B-X
activated	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
AP-2	B-X
protein	B-X
,	B-X
AP-2delta	B-X
(	B-X
deleted	B-X
residues	B-X
31-117	B-X
)	B-X
,	B-X
not	B-X
only	B-X
repressed	B-X
the	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
but	B-X
also	B-X
suppressed	B-X
endogenous	B-X
ErbB-3	B-X
transcription	B-X
in	B-X
the	B-X
ErbB-3	B-X
overexpressing	B-X
cell	B-X
line	B-X
MRC-5VA	B-X
.	B-X
Overexpression	B-X
of	B-X
AP-2A	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
proliferation	B-X
rate	B-X
and	B-X
inhibitin	B-X
of	B-X
colony	B-X
formation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
strongly	B-X
support	B-X
a	B-X
role	B-X
for	B-X
the	B-X
AP-2	B-X
gene	B-X
family	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
AP-2gamma	B-X
,	B-X
in	B-X
the	B-X
control	B-X
of	B-X
ErbB-3	B-X
expression	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
found	O
that	O
elevated	O
levels	O
of	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
expression	O
did	O
not	O
occur	O
in	O
the	O
absence	O
of	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2gamma	I-Gene_or_gene_product
in	O
a	O
panel	O
of	O
human	O
mammary	O
epithelial	O
and	O
fibroblasts	O
cell	O
lines	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
genomic	B-X
whole-exome	B-X
sequencing	B-X
(	B-X
WES	B-X
)	B-X
data	B-X
identified	B-X
the	B-X
key	B-X
ErbB	B-X
pathway	B-X
mutations	B-X
that	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
malignancy	B-X
of	B-X
gallbladder	B-X
cancer	B-X
(	B-X
GBC	B-X
)	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
individual	B-X
cellular	B-X
components	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
in	B-X
GBC	B-X
function	B-X
differentially	B-X
to	B-X
participate	B-X
in	B-X
ErbB	B-X
pathway	B-X
mutation-dependent	B-X
tumor	B-X
progression	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
,	B-X
a	B-X
growth-factor-receptor	B-X
tyrosine	B-X
kinase	B-X
,	B-X
and/or	B-X
its	B-X
cognate	B-X
ligands	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
common	B-X
component	B-X
of	B-X
multiple	B-X
cancer	B-X
types	B-X
and	B-X
appear	B-X
to	B-X
promote	B-X
solid	B-X
tumour	B-X
growth	B-X
.	B-X
This	B-X
article	B-X
examines	B-X
the	B-X
relationship	B-X
between	B-X
EGFR	B-X
expression	B-X
and	B-X
cancer	B-X
prognosis	B-X
based	B-X
on	B-X
literature	B-X
compiled	B-X
on	B-X
PubMed	B-X
between	B-X
1985	B-X
and	B-X
September	B-X
2000	B-X
.	B-X
More	B-X
than	B-X
200	B-X
studies	B-X
were	B-X
identified	B-X
that	B-X
analysed	B-X
relapse-free-interval	B-X
or	B-X
survival	B-X
data	B-X
directly	B-X
in	B-X
relation	B-X
to	B-X
EGFR	B-X
levels	B-X
in	B-X
over	B-X
20000	B-X
patients	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
showed	B-X
that	B-X
10	B-X
cancer	B-X
types	B-X
both	B-X
express	B-X
elevated	B-X
levels	B-X
of	B-X
EGFR	B-X
relative	B-X
to	B-X
normal	B-X
tissues	B-X
and	B-X
have	B-X
been	B-X
studied	B-X
in	B-X
sufficient	B-X
depth	B-X
to	B-X
allow	B-X
sound	B-X
judgements	B-X
to	B-X
be	B-X
made	B-X
concerning	B-X
the	B-X
association	B-X
between	B-X
EGFR	B-X
and	B-X
patient	B-X
outlook	B-X
.	B-X
The	B-X
EGFR	B-X
was	B-X
found	B-X
to	B-X
act	B-X
as	B-X
a	B-X
strong	B-X
prognostic	B-X
indicator	B-X
in	B-X
head	B-X
and	B-X
neck	B-X
,	B-X
ovarian	B-X
,	B-X
cervical	B-X
,	B-X
bladder	B-X
and	B-X
oesophageal	B-X
cancers	B-X
.	B-X
In	B-X
these	B-X
cancers	B-X
,	B-X
increased	B-X
EGFR	B-X
expression	B-X
was	B-X
associated	B-X
with	B-X
reduced	B-X
recurrence-free	B-X
or	B-X
overall	B-X
survival	B-X
rates	B-X
in	B-X
70	B-X
%	B-X
(	B-X
52/74	B-X
)	B-X
of	B-X
studies	B-X
.	B-X
In	B-X
gastric	B-X
,	B-X
breast	B-X
,	B-X
endometrial	B-X
and	B-X
colorectal	B-X
cancers	B-X
,	B-X
the	B-X
EGFR	B-X
provided	B-X
more	B-X
modest	B-X
prognostic	B-X
information	B-X
,	B-X
correlating	B-X
to	B-X
poor	B-X
survival	B-X
rates	B-X
in	B-X
52	B-X
%	B-X
(	B-X
13/25	B-X
)	B-X
of	B-X
studies	B-X
,	B-X
while	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
,	B-X
EGFR	B-X
expression	B-X
only	B-X
rarely	B-X
(	B-X
3/10	B-X
studies	B-X
)	B-X
related	B-X
to	B-X
patient	B-X
outlook	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
likely	B-X
that	B-X
the	B-X
true	B-X
prognostic	B-X
significance	B-X
of	B-X
the	B-X
EGFR	B-X
has	B-X
been	B-X
underestimated	B-X
as	B-X
the	B-X
published	B-X
studies	B-X
only	B-X
assessed	B-X
total	B-X
cellular	B-X
EGFR	B-X
levels	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
activated	B-X
form	B-X
of	B-X
the	B-X
receptor	B-X
,	B-X
and	B-X
were	B-X
not	B-X
standardised	B-X
with	B-X
regard	B-X
to	B-X
patient	B-X
populations	B-X
or	B-X
assay	B-X
methods	B-X
.	B-X

In	O
contrast	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
expression	O
of	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2alpha	I-Gene_or_gene_product
or	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2beta	I-Gene_or_gene_product
and	O
the	O
level	O
of	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
,	O
or	O
between	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2alpha	I-Gene_or_gene_product
and	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2gamma	I-Gene_or_gene_product
double	O
positivity	O
and	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
AÎ²	B-X
increases	B-X
apoE	B-X
protein	B-X
levels	B-X
in	B-X
astrocytes	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
cholesterol	B-X
trafficking	B-X
,	B-X
neuroinflammatory	B-X
responses	B-X
and	B-X
AÎ²	B-X
clearance	B-X
.	B-X
Based	B-X
on	B-X
different	B-X
lines	B-X
of	B-X
evidence	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
the	B-X
beta-adrenergic	B-X
receptor	B-X
(	B-X
Î²AR	B-X
)	B-X
,	B-X
cAMP	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
activator	B-X
protein-2	B-X
(	B-X
AP-2	B-X
)	B-X
are	B-X
contributors	B-X
to	B-X
the	B-X
AÎ²-induced	B-X
increase	B-X
in	B-X
apoE	B-X
abundance	B-X
.	B-X
This	B-X
hypothesis	B-X
was	B-X
tested	B-X
in	B-X
mouse	B-X
primary	B-X
astrocytes	B-X
and	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
an	B-X
apoE	B-X
promoter	B-X
fragment	B-X
with	B-X
binding	B-X
sites	B-X
for	B-X
AP-2	B-X
.	B-X
AÎ²	B-X
(	B-X
42	B-X
)	B-X
induced	B-X
a	B-X
time-dependent	B-X
increase	B-X
in	B-X
apoE	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
which	B-X
were	B-X
significantly	B-X
inhibited	B-X
by	B-X
Î²AR	B-X
antagonists	B-X
.	B-X
A	B-X
novel	B-X
finding	B-X
was	B-X
that	B-X
AÎ²	B-X
incubation	B-X
significantly	B-X
reduced	B-X
AP-2Î±	B-X
levels	B-X
and	B-X
significantly	B-X
increased	B-X
AP-2Î²	B-X
levels	B-X
in	B-X
the	B-X
nuclear	B-X
fraction	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
AÎ²-induced	B-X
translocation	B-X
of	B-X
AP-2	B-X
into	B-X
the	B-X
nucleus	B-X
was	B-X
demonstrated	B-X
in	B-X
cells	B-X
expressing	B-X
AP-2	B-X
and	B-X
incubated	B-X
with	B-X
AÎ²	B-X
(	B-X
42	B-X
)	B-X
.	B-X
AP-2	B-X
expressing	B-X
cells	B-X
had	B-X
enhanced	B-X
activation	B-X
of	B-X
the	B-X
apoE	B-X
promoter	B-X
region	B-X
containing	B-X
AP-2	B-X
binding	B-X
sites	B-X
in	B-X
contrast	B-X
to	B-X
AP-2	B-X
deficient	B-X
cells	B-X
.	B-X
The	B-X
transcriptional	B-X
upregulation	B-X
of	B-X
apoE	B-X
expression	B-X
by	B-X
AÎ²	B-X
(	B-X
42	B-X
)	B-X
may	B-X
be	B-X
a	B-X
neuroprotective	B-X
response	B-X
to	B-X
AÎ²-induced	B-X
cytotoxicity	B-X
,	B-X
consistent	B-X
with	B-X
apoE	B-X
's	B-X
role	B-X
in	B-X
cytoprotection	B-X
.	B-X

In	O
co	O
-	O
transfection	O
experiments	O
,	O
exogenous	O
expression	O
of	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2gamma	I-Gene_or_gene_product
robustly	O
activated	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
promoter	O
activity	O
.	O
<EOS>	B-X
ErbB-3	B-X
(	B-X
HER3	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
family	B-X
.	B-X
Increasing	B-X
evidence	B-X
suggests	B-X
that	B-X
elevated	B-X
expression	B-X
of	B-X
ErbB-3	B-X
is	B-X
important	B-X
for	B-X
malignancy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
elevated	B-X
levels	B-X
of	B-X
ErbB-3	B-X
expression	B-X
did	B-X
not	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
AP-2gamma	B-X
in	B-X
a	B-X
panel	B-X
of	B-X
human	B-X
mammary	B-X
epithelial	B-X
and	B-X
fibroblasts	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
there	B-X
was	B-X
no	B-X
association	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
AP-2alpha	B-X
or	B-X
AP-2beta	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ErbB-3	B-X
,	B-X
or	B-X
between	B-X
AP-2alpha	B-X
and	B-X
AP-2gamma	B-X
double	B-X
positivity	B-X
and	B-X
ErbB-3	B-X
expression	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
exogenous	B-X
expression	B-X
of	B-X
AP-2gamma	B-X
robustly	B-X
activated	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
AP-2	B-X
protein	B-X
,	B-X
AP-2delta	B-X
(	B-X
deleted	B-X
residues	B-X
31-117	B-X
)	B-X
,	B-X
not	B-X
only	B-X
repressed	B-X
the	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
but	B-X
also	B-X
suppressed	B-X
endogenous	B-X
ErbB-3	B-X
transcription	B-X
in	B-X
the	B-X
ErbB-3	B-X
overexpressing	B-X
cell	B-X
line	B-X
MRC-5VA	B-X
.	B-X
Overexpression	B-X
of	B-X
AP-2A	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
proliferation	B-X
rate	B-X
and	B-X
inhibitin	B-X
of	B-X
colony	B-X
formation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
strongly	B-X
support	B-X
a	B-X
role	B-X
for	B-X
the	B-X
AP-2	B-X
gene	B-X
family	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
AP-2gamma	B-X
,	B-X
in	B-X
the	B-X
control	B-X
of	B-X
ErbB-3	B-X
expression	B-X
.	B-X
Interference	B-X
with	B-X
the	B-X
function	B-X
of	B-X
transcription	B-X
factor	B-X
AP-2	B-X
might	B-X
provide	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
modulation	B-X
of	B-X
the	B-X
malignant	B-X
phenotype	B-X
.	B-X

Moreover	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
protein	O
,	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2delta	I-Gene_or_gene_product
(	O
deleted	O
residues	O
31	O
-	O
117	O
)	O
,	O
not	O
only	O
repressed	O
the	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
promoter	O
activity	O
but	O
also	O
suppressed	O
endogenous	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
transcription	O
in	O
the	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
overexpressing	O
cell	O
line	O
MRC	O
-	O
5VA	O
.	O

Overexpression	O
of	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2A	I-Gene_or_gene_product
resulted	O
in	O
a	O
decreased	O
proliferation	O
rate	O
and	O
inhibitin	O
of	O
colony	O
formation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
strongly	O
support	O
a	O
role	O
for	O
the	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
gene	O
family	O
,	O
in	O
particular	O
,	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2gamma	I-Gene_or_gene_product
,	O
in	O
the	O
control	O
of	O
ErbB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
ErbB-3	B-X
(	B-X
HER3	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
family	B-X
.	B-X
Increasing	B-X
evidence	B-X
suggests	B-X
that	B-X
elevated	B-X
expression	B-X
of	B-X
ErbB-3	B-X
is	B-X
important	B-X
for	B-X
malignancy	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
elevated	B-X
levels	B-X
of	B-X
ErbB-3	B-X
expression	B-X
did	B-X
not	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
AP-2gamma	B-X
in	B-X
a	B-X
panel	B-X
of	B-X
human	B-X
mammary	B-X
epithelial	B-X
and	B-X
fibroblasts	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
there	B-X
was	B-X
no	B-X
association	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
AP-2alpha	B-X
or	B-X
AP-2beta	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ErbB-3	B-X
,	B-X
or	B-X
between	B-X
AP-2alpha	B-X
and	B-X
AP-2gamma	B-X
double	B-X
positivity	B-X
and	B-X
ErbB-3	B-X
expression	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
exogenous	B-X
expression	B-X
of	B-X
AP-2gamma	B-X
robustly	B-X
activated	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
AP-2	B-X
protein	B-X
,	B-X
AP-2delta	B-X
(	B-X
deleted	B-X
residues	B-X
31-117	B-X
)	B-X
,	B-X
not	B-X
only	B-X
repressed	B-X
the	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
but	B-X
also	B-X
suppressed	B-X
endogenous	B-X
ErbB-3	B-X
transcription	B-X
in	B-X
the	B-X
ErbB-3	B-X
overexpressing	B-X
cell	B-X
line	B-X
MRC-5VA	B-X
.	B-X
Overexpression	B-X
of	B-X
AP-2A	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
proliferation	B-X
rate	B-X
and	B-X
inhibitin	B-X
of	B-X
colony	B-X
formation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
strongly	B-X
support	B-X
a	B-X
role	B-X
for	B-X
the	B-X
AP-2	B-X
gene	B-X
family	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
AP-2gamma	B-X
,	B-X
in	B-X
the	B-X
control	B-X
of	B-X
ErbB-3	B-X
expression	B-X
.	B-X
Interference	B-X
with	B-X
the	B-X
function	B-X
of	B-X
transcription	B-X
factor	B-X
AP-2	B-X
might	B-X
provide	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
modulation	B-X
of	B-X
the	B-X
malignant	B-X
phenotype	B-X
.	B-X

Interference	O
with	O
the	O
function	O
of	O
transcription	O
factor	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
might	O
provide	O
a	O
potential	O
strategy	O
for	O
modulation	O
of	O
the	O
malignant	O
phenotype	O
.	O
<EOS>	B-X
ErbB-3	B-X
(	B-X
HER3	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
family	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
elevated	B-X
levels	B-X
of	B-X
ErbB-3	B-X
expression	B-X
did	B-X
not	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
AP-2gamma	B-X
in	B-X
a	B-X
panel	B-X
of	B-X
human	B-X
mammary	B-X
epithelial	B-X
and	B-X
fibroblasts	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
there	B-X
was	B-X
no	B-X
association	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
AP-2alpha	B-X
or	B-X
AP-2beta	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ErbB-3	B-X
,	B-X
or	B-X
between	B-X
AP-2alpha	B-X
and	B-X
AP-2gamma	B-X
double	B-X
positivity	B-X
and	B-X
ErbB-3	B-X
expression	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
exogenous	B-X
expression	B-X
of	B-X
AP-2gamma	B-X
robustly	B-X
activated	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
AP-2	B-X
protein	B-X
,	B-X
AP-2delta	B-X
(	B-X
deleted	B-X
residues	B-X
31-117	B-X
)	B-X
,	B-X
not	B-X
only	B-X
repressed	B-X
the	B-X
ErbB-3	B-X
promoter	B-X
activity	B-X
but	B-X
also	B-X
suppressed	B-X
endogenous	B-X
ErbB-3	B-X
transcription	B-X
in	B-X
the	B-X
ErbB-3	B-X
overexpressing	B-X
cell	B-X
line	B-X
MRC-5VA	B-X
.	B-X
Overexpression	B-X
of	B-X
AP-2A	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
proliferation	B-X
rate	B-X
and	B-X
inhibitin	B-X
of	B-X
colony	B-X
formation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
strongly	B-X
support	B-X
a	B-X
role	B-X
for	B-X
the	B-X
AP-2	B-X
gene	B-X
family	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
AP-2gamma	B-X
,	B-X
in	B-X
the	B-X
control	B-X
of	B-X
ErbB-3	B-X
expression	B-X
.	B-X
Interference	B-X
with	B-X
the	B-X
function	B-X
of	B-X
transcription	B-X
factor	B-X
AP-2	B-X
might	B-X
provide	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
modulation	B-X
of	B-X
the	B-X
malignant	B-X
phenotype	B-X
.	B-X

VEGF165	B-Gene_or_gene_product
mediates	O
formation	O
of	O
complexes	O
containing	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
neuropilin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
that	O
enhance	O
VEGF165	B-Gene_or_gene_product
-	O
receptor	O
binding	O
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

Co	O
-	O
expression	O
of	O
NRP1	B-Gene_or_gene_product
and	O
(	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	O
KDR	B-Gene_or_gene_product
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
enhances	O
VEGF165	B-Gene_or_gene_product
binding	O
to	O
KDR	B-Gene_or_gene_product
and	O
EC	O
chemotaxis	O
in	O
response	O
to	O
VEGF165	B-Gene_or_gene_product
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

Overexpression	O
of	O
NRP1	B-Gene_or_gene_product
by	O
prostate	O
tumor	O
cells	O
in	O
vivo	O
results	O
in	O
increased	O
tumor	O
angiogenesis	O
and	O
growth	O
.	O
<EOS>	B-X
Neuropilin-1	B-X
(	B-X
NRP1	B-X
)	B-X
is	B-X
a	B-X
VEGF	B-X
(	B-X
165	B-X
)	B-X
and	B-X
semaphorin	B-X
receptor	B-X
expressed	B-X
by	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
and	B-X
tumor	B-X
cells	B-X
.	B-X
The	B-X
function	B-X
of	B-X
NRP1	B-X
in	B-X
tumor	B-X
cells	B-X
is	B-X
unknown	B-X
.	B-X
NRP1	B-X
was	B-X
overexpressed	B-X
in	B-X
Dunning	B-X
rat	B-X
prostate	B-X
carcinoma	B-X
AT2.1	B-X
cells	B-X
using	B-X
a	B-X
tetracycline-inducible	B-X
promoter	B-X
.	B-X
Concomitant	B-X
with	B-X
increased	B-X
NRP1	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
a	B-X
tetracycline	B-X
homologue	B-X
,	B-X
doxycycline	B-X
(	B-X
Dox	B-X
)	B-X
,	B-X
basal	B-X
cell	B-X
motility	B-X
,	B-X
and	B-X
VEGF	B-X
(	B-X
165	B-X
)	B-X
binding	B-X
were	B-X
increased	B-X
three-	B-X
to	B-X
fourfold	B-X
in	B-X
vitro	B-X
.	B-X
However	B-X
,	B-X
induction	B-X
of	B-X
NRP1	B-X
did	B-X
not	B-X
affect	B-X
tumor	B-X
cell	B-X
proliferation	B-X
.	B-X
When	B-X
rats	B-X
injected	B-X
with	B-X
AT2.1/NRP1	B-X
tumor	B-X
cells	B-X
were	B-X
fed	B-X
Dox	B-X
,	B-X
NRP1	B-X
synthesis	B-X
was	B-X
induced	B-X
in	B-X
vivo	B-X
and	B-X
AT2.1	B-X
cell	B-X
tumor	B-X
size	B-X
was	B-X
increased	B-X
2.5-	B-X
to	B-X
7-fold	B-X
in	B-X
a	B-X
3-4	B-X
wk	B-X
period	B-X
compared	B-X
to	B-X
controls	B-X
.	B-X
The	B-X
larger	B-X
tumors	B-X
with	B-X
induced	B-X
NRP1	B-X
expression	B-X
were	B-X
characterized	B-X
by	B-X
markedly	B-X
increased	B-X
microvessel	B-X
density	B-X
,	B-X
increased	B-X
proliferating	B-X
EC	B-X
,	B-X
dilated	B-X
blood	B-X
vessels	B-X
,	B-X
and	B-X
notably	B-X
less	B-X
tumor	B-X
cell	B-X
apoptosis	B-X
compared	B-X
to	B-X
noninduced	B-X
controls	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
NRP1	B-X
expression	B-X
results	B-X
in	B-X
enlarged	B-X
tumors	B-X
associated	B-X
with	B-X
substantially	B-X
enhanced	B-X
tumor	B-X
angiogenesis	B-X
.	B-X

We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
NRP1	B-Gene_or_gene_product
-	O
mediated	O
angiogenesis	O
by	O
analyzing	O
the	O
association	O
of	O
NRP1	B-Gene_or_gene_product
and	O
KDR	B-Gene_or_gene_product
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

An	O
intracellular	O
complex	O
containing	O
NRP1	B-Gene_or_gene_product
and	O
KDR	B-Gene_or_gene_product
was	O
immunoprecipitated	O
from	O
EC	O
by	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
NRP1	I-Gene_or_gene_product
antibodies	I-Gene_or_gene_product
only	O
in	O
the	O
presence	O
of	O
VEGF165	B-Gene_or_gene_product
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

In	O
contrast	O
,	O
VEGF121	B-Gene_or_gene_product
,	O
which	O
does	O
not	O
bind	O
to	O
NRP1	B-Gene_or_gene_product
,	O
did	O
not	O
support	O
complex	O
formation	O
.	O
<EOS>	B-X
In	B-X
fact	B-X
,	B-X
although	B-X
pan-VEGF	B-X
agents	B-X
rapidly	B-X
and	B-X
effectively	B-X
contrast	B-X
ocular	B-X
neovascularization	B-X
,	B-X
vascular	B-X
leakage	B-X
,	B-X
and	B-X
other	B-X
pathological	B-X
changes	B-X
,	B-X
in	B-X
the	B-X
long-term	B-X
the	B-X
inhibition	B-X
of	B-X
all	B-X
VEGF	B-X
isoforms	B-X
likely	B-X
may	B-X
result	B-X
in	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
physiologic	B-X
effects	B-X
exerted	B-X
by	B-X
VEGF121	B-X
and	B-X
the	B-X
anti-angiogenic	B-X
VEGF165b	B-X
.	B-X
This	B-X
complex	B-X
picture	B-X
and	B-X
the	B-X
recent	B-X
findings	B-X
on	B-X
current	B-X
anti-VEGF	B-X
drugs	B-X
should	B-X
be	B-X
therefore	B-X
taken	B-X
into	B-X
account	B-X
to	B-X
guide	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
agents	B-X
targeting	B-X
VEGF	B-X
and/or	B-X
other	B-X
key	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
neovascular	B-X
ocular	B-X
diseases	B-X
along	B-X
the	B-X
signaling	B-X
pathways	B-X
stimulated	B-X
by	B-X
the	B-X
various	B-X
isoforms	B-X
.	B-X

Complexes	O
containing	O
VEGF165	B-Gene_or_gene_product
,	O
NRP1	B-Gene_or_gene_product
,	O
and	O
KDR	B-Gene_or_gene_product
were	O
also	O
formed	O
in	O
an	O
intercellular	O
fashion	O
by	O
co	O
-	O
culture	O
of	O
EC	O
expressing	O
KDR	B-Gene_or_gene_product
only	O
,	O
with	O
cells	O
expressing	O
NRP1	B-Gene_or_gene_product
only	O
,	O
for	O
example	O
,	O
breast	O
carcinoma	O
cells	O
.	O

VEGF165	B-Gene_or_gene_product
also	O
mediated	O
the	O
binding	O
of	O
a	O
soluble	O
NRP1	B-Gene_or_gene_product
dimer	O
to	O
cells	O
expressing	O
KDR	B-Gene_or_gene_product
only	O
,	O
confirming	O
the	O
formation	O
of	O
such	O
complexes	O
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

Furthermore	O
,	O
the	O
formation	O
of	O
complexes	O
containing	O
KDR	B-Gene_or_gene_product
and	O
NRP1	B-Gene_or_gene_product
markedly	O
increased	O
125I	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF165	I-Gene_or_gene_product
binding	O
to	O
KDR	B-Gene_or_gene_product
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
formation	O
of	O
a	O
ternary	O
complex	O
of	O
VEGF165	B-Gene_or_gene_product
,	O
KDR	B-Gene_or_gene_product
,	O
and	O
NRP1	B-Gene_or_gene_product
potentiates	O
VEGF165	B-Gene_or_gene_product
binding	O
to	O
KDR	B-Gene_or_gene_product
.	O
<EOS>	B-X
Co-expression	B-X
of	B-X
NRP1	B-X
and	B-X
(	B-X
VEGFR-2	B-X
)	B-X
KDR	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
enhances	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
and	B-X
EC	B-X
chemotaxis	B-X
in	B-X
response	B-X
to	B-X
VEGF165	B-X
.	B-X
Overexpression	B-X
of	B-X
NRP1	B-X
by	B-X
prostate	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
results	B-X
in	B-X
increased	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
growth	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
NRP1-mediated	B-X
angiogenesis	B-X
by	B-X
analyzing	B-X
the	B-X
association	B-X
of	B-X
NRP1	B-X
and	B-X
KDR	B-X
.	B-X
An	B-X
intracellular	B-X
complex	B-X
containing	B-X
NRP1	B-X
and	B-X
KDR	B-X
was	B-X
immunoprecipitated	B-X
from	B-X
EC	B-X
by	B-X
anti-NRP1	B-X
antibodies	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VEGF165	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
VEGF121	B-X
,	B-X
which	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
NRP1	B-X
,	B-X
did	B-X
not	B-X
support	B-X
complex	B-X
formation	B-X
.	B-X
Complexes	B-X
containing	B-X
VEGF165	B-X
,	B-X
NRP1	B-X
,	B-X
and	B-X
KDR	B-X
were	B-X
also	B-X
formed	B-X
in	B-X
an	B-X
intercellular	B-X
fashion	B-X
by	B-X
co-culture	B-X
of	B-X
EC	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
with	B-X
cells	B-X
expressing	B-X
NRP1	B-X
only	B-X
,	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
VEGF165	B-X
also	B-X
mediated	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
soluble	B-X
NRP1	B-X
dimer	B-X
to	B-X
cells	B-X
expressing	B-X
KDR	B-X
only	B-X
,	B-X
confirming	B-X
the	B-X
formation	B-X
of	B-X
such	B-X
complexes	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
complexes	B-X
containing	B-X
KDR	B-X
and	B-X
NRP1	B-X
markedly	B-X
increased	B-X
125I-VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
ternary	B-X
complex	B-X
of	B-X
VEGF165	B-X
,	B-X
KDR	B-X
,	B-X
and	B-X
NRP1	B-X
potentiates	B-X
VEGF165	B-X
binding	B-X
to	B-X
KDR	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
formed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
EC	B-X
and	B-X
in	B-X
a	B-X
juxtacrine	B-X
manner	B-X
via	B-X
association	B-X
of	B-X
tumor	B-X
cell	B-X
NRP1	B-X
and	B-X
EC	B-X
KDR	B-X
.	B-X

These	O
complexes	O
are	O
formed	O
on	O
the	O
surface	O
of	O
EC	O
and	O
in	O
a	O
juxtacrine	O
manner	O
via	O
association	O
of	O
tumor	O
cell	O
NRP1	B-Gene_or_gene_product
and	O
EC	O
KDR	B-Gene_or_gene_product
.	O

[	O
Radiologic	O
-	O
pathologic	O
correlations	O
in	O
breast	O
diseases	O
]	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
explain	B-X
radiologic	B-X
patterns	B-X
of	B-X
benign	B-X
and	B-X
malignant	B-X
breast	B-X
lesions	B-X
(	B-X
masses	B-X
,	B-X
microcalcifications	B-X
)	B-X
based	B-X
on	B-X
histological	B-X
correlations	B-X
.	B-X
Mammographic	B-X
patterns	B-X
of	B-X
microcalcifications	B-X
depend	B-X
on	B-X
their	B-X
physiopathological	B-X
process	B-X
(	B-X
necrosis	B-X
,	B-X
secretion	B-X
)	B-X
,	B-X
and	B-X
the	B-X
shape	B-X
of	B-X
clusters	B-X
(	B-X
round	B-X
,	B-X
triangular	B-X
)	B-X
typifies	B-X
their	B-X
anatomical	B-X
site	B-X
of	B-X
origin	B-X
(	B-X
lobular	B-X
,	B-X
ductal	B-X
)	B-X
.	B-X
Less	B-X
frequent	B-X
lesions	B-X
(	B-X
invasive	B-X
lobular	B-X
,	B-X
mucinous	B-X
,	B-X
and	B-X
medullary	B-X
carcinomas	B-X
,	B-X
radial	B-X
scar	B-X
)	B-X
will	B-X
be	B-X
also	B-X
explained	B-X
based	B-X
on	B-X
radiopathological	B-X
correlations	B-X
.	B-X
Knowledge	B-X
of	B-X
radiopathological	B-X
correlations	B-X
in	B-X
breast	B-X
diseases	B-X
helps	B-X
the	B-X
radiologists	B-X
to	B-X
analyze	B-X
and	B-X
characterize	B-X
breast	B-X
lesions	B-X
.	B-X

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explain	O
radiologic	O
patterns	O
of	O
benign	O
and	O
malignant	O
breast	O
lesions	O
(	O
masses	O
,	O
microcalcifications	O
)	O
based	O
on	O
histological	O
correlations	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
explain	B-X
radiologic	B-X
patterns	B-X
of	B-X
benign	B-X
and	B-X
malignant	B-X
breast	B-X
lesions	B-X
(	B-X
masses	B-X
,	B-X
microcalcifications	B-X
)	B-X
based	B-X
on	B-X
histological	B-X
correlations	B-X
.	B-X
Mammographic	B-X
patterns	B-X
of	B-X
microcalcifications	B-X
depend	B-X
on	B-X
their	B-X
physiopathological	B-X
process	B-X
(	B-X
necrosis	B-X
,	B-X
secretion	B-X
)	B-X
,	B-X
and	B-X
the	B-X
shape	B-X
of	B-X
clusters	B-X
(	B-X
round	B-X
,	B-X
triangular	B-X
)	B-X
typifies	B-X
their	B-X
anatomical	B-X
site	B-X
of	B-X
origin	B-X
(	B-X
lobular	B-X
,	B-X
ductal	B-X
)	B-X
.	B-X
Less	B-X
frequent	B-X
lesions	B-X
(	B-X
invasive	B-X
lobular	B-X
,	B-X
mucinous	B-X
,	B-X
and	B-X
medullary	B-X
carcinomas	B-X
,	B-X
radial	B-X
scar	B-X
)	B-X
will	B-X
be	B-X
also	B-X
explained	B-X
based	B-X
on	B-X
radiopathological	B-X
correlations	B-X
.	B-X
Knowledge	B-X
of	B-X
radiopathological	B-X
correlations	B-X
in	B-X
breast	B-X
diseases	B-X
helps	B-X
the	B-X
radiologists	B-X
to	B-X
analyze	B-X
and	B-X
characterize	B-X
breast	B-X
lesions	B-X
.	B-X

The	O
stromal	O
fibrous	O
reaction	O
associated	O
to	O
infiltrating	O
carcinomas	O
is	O
responsible	O
of	O
focal	O
increased	O
density	O
,	O
and	O
architectural	O
distorsion	O
,	O
ultrasound	O
acoustic	O
shadowing	O
;	O
abnormal	O
neoangiogenesis	O
can	O
be	O
detected	O
by	O
Doppler	O
,	O
CT	O
or	O
MR	O
imaging	O
.	O
<EOS>	B-X
The	B-X
stromal	B-X
fibrous	B-X
reaction	B-X
associated	B-X
to	B-X
infiltrating	B-X
carcinomas	B-X
is	B-X
responsible	B-X
of	B-X
focal	B-X
increased	B-X
density	B-X
,	B-X
and	B-X
architectural	B-X
distorsion	B-X
,	B-X
ultrasound	B-X
acoustic	B-X
shadowing	B-X
;	B-X
abnormal	B-X
neoangiogenesis	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
Doppler	B-X
,	B-X
CT	B-X
or	B-X
MR	B-X
imaging	B-X
.	B-X
Invasive	B-X
carcinomas	B-X
without	B-X
spiculated	B-X
margins	B-X
are	B-X
poorly	B-X
differentiated	B-X
tumors	B-X
.	B-X
Less	B-X
frequent	B-X
lesions	B-X
(	B-X
invasive	B-X
lobular	B-X
,	B-X
mucinous	B-X
,	B-X
and	B-X
medullary	B-X
carcinomas	B-X
,	B-X
radial	B-X
scar	B-X
)	B-X
will	B-X
be	B-X
also	B-X
explained	B-X
based	B-X
on	B-X
radiopathological	B-X
correlations	B-X
.	B-X

Invasive	O
carcinomas	O
without	O
spiculated	O
margins	O
are	O
poorly	O
differentiated	O
tumors	O
.	O
<EOS>	B-X
The	B-X
stromal	B-X
fibrous	B-X
reaction	B-X
associated	B-X
to	B-X
infiltrating	B-X
carcinomas	B-X
is	B-X
responsible	B-X
of	B-X
focal	B-X
increased	B-X
density	B-X
,	B-X
and	B-X
architectural	B-X
distorsion	B-X
,	B-X
ultrasound	B-X
acoustic	B-X
shadowing	B-X
;	B-X
abnormal	B-X
neoangiogenesis	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
Doppler	B-X
,	B-X
CT	B-X
or	B-X
MR	B-X
imaging	B-X
.	B-X
Invasive	B-X
carcinomas	B-X
without	B-X
spiculated	B-X
margins	B-X
are	B-X
poorly	B-X
differentiated	B-X
tumors	B-X
.	B-X
Less	B-X
frequent	B-X
lesions	B-X
(	B-X
invasive	B-X
lobular	B-X
,	B-X
mucinous	B-X
,	B-X
and	B-X
medullary	B-X
carcinomas	B-X
,	B-X
radial	B-X
scar	B-X
)	B-X
will	B-X
be	B-X
also	B-X
explained	B-X
based	B-X
on	B-X
radiopathological	B-X
correlations	B-X
.	B-X
Mammography	B-X
discloses	B-X
a	B-X
3.2-cm	B-X
spiculated	B-X
lesion	B-X
corresponding	B-X
with	B-X
the	B-X
palpable	B-X
abnormality	B-X
,	B-X
and	B-X
ultrasonography	B-X
confirms	B-X
a	B-X
solid	B-X
mass	B-X
in	B-X
the	B-X
breast	B-X
and	B-X
an	B-X
enlarged	B-X
,	B-X
2.1-cm	B-X
lymph	B-X
node	B-X
with	B-X
a	B-X
thickened	B-X
cortex	B-X
in	B-X
the	B-X
ipsilateral	B-X
axilla	B-X
.	B-X
Ultrasound-guided	B-X
core	B-X
needle	B-X
biopsy	B-X
of	B-X
the	B-X
breast	B-X
mass	B-X
diagnoses	B-X
an	B-X
invasive	B-X
ductal	B-X
carcinoma	B-X
,	B-X
poorly	B-X
differentiated	B-X
(	B-X
grade	B-X
3	B-X
)	B-X
,	B-X
with	B-X
lymphovascular	B-X
invasion	B-X
.	B-X
The	B-X
margins	B-X
are	B-X
negative	B-X
,	B-X
as	B-X
are	B-X
all	B-X
11	B-X
axillary	B-X
lymph	B-X
nodes	B-X
.	B-X

Mammographic	O
patterns	O
of	O
microcalcifications	O
depend	O
on	O
their	O
physiopathological	O
process	O
(	O
necrosis	O
,	O
secretion	O
)	O
,	O
and	O
the	O
shape	O
of	O
clusters	O
(	O
round	O
,	O
triangular	O
)	O
typifies	O
their	O
anatomical	O
site	O
of	O
origin	O
(	O
lobular	O
,	O
ductal	O
)	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
explain	B-X
radiologic	B-X
patterns	B-X
of	B-X
benign	B-X
and	B-X
malignant	B-X
breast	B-X
lesions	B-X
(	B-X
masses	B-X
,	B-X
microcalcifications	B-X
)	B-X
based	B-X
on	B-X
histological	B-X
correlations	B-X
.	B-X
Mammographic	B-X
patterns	B-X
of	B-X
microcalcifications	B-X
depend	B-X
on	B-X
their	B-X
physiopathological	B-X
process	B-X
(	B-X
necrosis	B-X
,	B-X
secretion	B-X
)	B-X
,	B-X
and	B-X
the	B-X
shape	B-X
of	B-X
clusters	B-X
(	B-X
round	B-X
,	B-X
triangular	B-X
)	B-X
typifies	B-X
their	B-X
anatomical	B-X
site	B-X
of	B-X
origin	B-X
(	B-X
lobular	B-X
,	B-X
ductal	B-X
)	B-X
.	B-X
Less	B-X
frequent	B-X
lesions	B-X
(	B-X
invasive	B-X
lobular	B-X
,	B-X
mucinous	B-X
,	B-X
and	B-X
medullary	B-X
carcinomas	B-X
,	B-X
radial	B-X
scar	B-X
)	B-X
will	B-X
be	B-X
also	B-X
explained	B-X
based	B-X
on	B-X
radiopathological	B-X
correlations	B-X
.	B-X

Less	O
frequent	O
lesions	O
(	O
invasive	O
lobular	O
,	O
mucinous	O
,	O
and	O
medullary	O
carcinomas	O
,	O
radial	O
scar	O
)	O
will	O
be	O
also	O
explained	O
based	O
on	O
radiopathological	O
correlations	O
.	O

Knowledge	O
of	O
radiopathological	O
correlations	O
in	O
breast	O
diseases	O
helps	O
the	O
radiologists	O
to	O
analyze	O
and	O
characterize	O
breast	O
lesions	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
explain	B-X
radiologic	B-X
patterns	B-X
of	B-X
benign	B-X
and	B-X
malignant	B-X
breast	B-X
lesions	B-X
(	B-X
masses	B-X
,	B-X
microcalcifications	B-X
)	B-X
based	B-X
on	B-X
histological	B-X
correlations	B-X
.	B-X
Less	B-X
frequent	B-X
lesions	B-X
(	B-X
invasive	B-X
lobular	B-X
,	B-X
mucinous	B-X
,	B-X
and	B-X
medullary	B-X
carcinomas	B-X
,	B-X
radial	B-X
scar	B-X
)	B-X
will	B-X
be	B-X
also	B-X
explained	B-X
based	B-X
on	B-X
radiopathological	B-X
correlations	B-X
.	B-X
Knowledge	B-X
of	B-X
radiopathological	B-X
correlations	B-X
in	B-X
breast	B-X
diseases	B-X
helps	B-X
the	B-X
radiologists	B-X
to	B-X
analyze	B-X
and	B-X
characterize	B-X
breast	B-X
lesions	B-X
.	B-X

Pten	B-Gene_or_gene_product
signaling	O
in	O
gliomas	O
.	O
<EOS>	B-X
Since	B-X
then	B-X
,	B-X
important	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
Pten	B-X
protein	B-X
in	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
the	B-X
brain	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
human	B-X
gliomas	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
state	B-X
of	B-X
the	B-X
art	B-X
concerning	B-X
the	B-X
involvement	B-X
of	B-X
aberrant	B-X
Pten	B-X
function	B-X
in	B-X
the	B-X
development	B-X
of	B-X
different	B-X
biologic	B-X
features	B-X
of	B-X
malignant	B-X
gliomas	B-X
,	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
cell-cycle	B-X
control	B-X
and	B-X
uncontrolled	B-X
cell	B-X
proliferation	B-X
,	B-X
escape	B-X
from	B-X
apoptosis	B-X
,	B-X
brain	B-X
invasion	B-X
,	B-X
and	B-X
aberrant	B-X
neoangiogenesis	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
tumor-suppressive	B-X
properties	B-X
of	B-X
Pten	B-X
are	B-X
dependent	B-X
on	B-X
its	B-X
lipid	B-X
phosphatase	B-X
activity	B-X
,	B-X
which	B-X
inhibits	B-X
the	B-X
phosphatidylinositol-3'-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
signaling	B-X
pathway	B-X
through	B-X
dephosphorylation	B-X
of	B-X
phosphatidylinositol-	B-X
(	B-X
3,4,5	B-X
)	B-X
-triphosphate	B-X
.	B-X
The	B-X
additional	B-X
function	B-X
of	B-X
Pten	B-X
as	B-X
a	B-X
dual-specificity	B-X
protein	B-X
phosphatase	B-X
may	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
glioma	B-X
pathogenesis	B-X
.	B-X
Besides	B-X
the	B-X
wealth	B-X
of	B-X
data	B-X
elucidating	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
Pten	B-X
,	B-X
recent	B-X
studies	B-X
suggest	B-X
a	B-X
diagnostic	B-X
significance	B-X
of	B-X
PTEN	B-X
gene	B-X
alterations	B-X
as	B-X
a	B-X
molecular	B-X
marker	B-X
for	B-X
poor	B-X
prognosis	B-X
in	B-X
anaplastic	B-X
astrocytomas	B-X
and	B-X
anaplastic	B-X
oligodendrogliomas	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
possibility	B-X
of	B-X
selective	B-X
targeting	B-X
of	B-X
PTEN	B-X
mutant	B-X
tumor	B-X
cells	B-X
by	B-X
specific	B-X
pharmacologic	B-X
inhibitors	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Pten/PI3K/Akt	B-X
pathway	B-X
opens	B-X
up	B-X
new	B-X
perspectives	B-X
for	B-X
a	B-X
targeted	B-X
molecular	B-X
therapy	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X

In	O
1997	O
,	O
the	O
PTEN	B-Gene_or_gene_product
gene	O
(	O
phosphatase	B-Gene_or_gene_product
and	I-Gene_or_gene_product
tensin	I-Gene_or_gene_product
homolog	I-Gene_or_gene_product
deleted	I-Gene_or_gene_product
on	I-Gene_or_gene_product
chromosome	I-Gene_or_gene_product
10	I-Gene_or_gene_product
)	O
was	O
identified	O
as	O
a	O
tumor	O
suppressor	O
gene	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
10	O
.	O

Since	O
then	O
,	O
important	O
progress	O
has	O
been	O
made	O
with	O
respect	O
to	O
the	O
understanding	O
of	O
the	O
role	O
of	O
the	O
Pten	B-Gene_or_gene_product
protein	O
in	O
the	O
normal	O
development	O
of	O
the	O
brain	O
as	O
well	O
as	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
human	O
gliomas	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
state	O
of	O
the	O
art	O
concerning	O
the	O
involvement	O
of	O
aberrant	O
Pten	B-Gene_or_gene_product
function	O
in	O
the	O
development	O
of	O
different	O
biologic	O
features	O
of	O
malignant	O
gliomas	O
,	O
such	O
as	O
loss	O
of	O
cell	O
-	O
cycle	O
control	O
and	O
uncontrolled	O
cell	O
proliferation	O
,	O
escape	O
from	O
apoptosis	O
,	O
brain	O
invasion	O
,	O
and	O
aberrant	O
neoangiogenesis	O
.	O
<EOS>	B-X
Since	B-X
then	B-X
,	B-X
important	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
Pten	B-X
protein	B-X
in	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
the	B-X
brain	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
human	B-X
gliomas	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
state	B-X
of	B-X
the	B-X
art	B-X
concerning	B-X
the	B-X
involvement	B-X
of	B-X
aberrant	B-X
Pten	B-X
function	B-X
in	B-X
the	B-X
development	B-X
of	B-X
different	B-X
biologic	B-X
features	B-X
of	B-X
malignant	B-X
gliomas	B-X
,	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
cell-cycle	B-X
control	B-X
and	B-X
uncontrolled	B-X
cell	B-X
proliferation	B-X
,	B-X
escape	B-X
from	B-X
apoptosis	B-X
,	B-X
brain	B-X
invasion	B-X
,	B-X
and	B-X
aberrant	B-X
neoangiogenesis	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
tumor-suppressive	B-X
properties	B-X
of	B-X
Pten	B-X
are	B-X
dependent	B-X
on	B-X
its	B-X
lipid	B-X
phosphatase	B-X
activity	B-X
,	B-X
which	B-X
inhibits	B-X
the	B-X
phosphatidylinositol-3'-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
signaling	B-X
pathway	B-X
through	B-X
dephosphorylation	B-X
of	B-X
phosphatidylinositol-	B-X
(	B-X
3,4,5	B-X
)	B-X
-triphosphate	B-X
.	B-X
The	B-X
additional	B-X
function	B-X
of	B-X
Pten	B-X
as	B-X
a	B-X
dual-specificity	B-X
protein	B-X
phosphatase	B-X
may	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
glioma	B-X
pathogenesis	B-X
.	B-X
Besides	B-X
the	B-X
wealth	B-X
of	B-X
data	B-X
elucidating	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
Pten	B-X
,	B-X
recent	B-X
studies	B-X
suggest	B-X
a	B-X
diagnostic	B-X
significance	B-X
of	B-X
PTEN	B-X
gene	B-X
alterations	B-X
as	B-X
a	B-X
molecular	B-X
marker	B-X
for	B-X
poor	B-X
prognosis	B-X
in	B-X
anaplastic	B-X
astrocytomas	B-X
and	B-X
anaplastic	B-X
oligodendrogliomas	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
possibility	B-X
of	B-X
selective	B-X
targeting	B-X
of	B-X
PTEN	B-X
mutant	B-X
tumor	B-X
cells	B-X
by	B-X
specific	B-X
pharmacologic	B-X
inhibitors	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Pten/PI3K/Akt	B-X
pathway	B-X
opens	B-X
up	B-X
new	B-X
perspectives	B-X
for	B-X
a	B-X
targeted	B-X
molecular	B-X
therapy	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X

Most	O
of	O
the	O
tumor	O
-	O
suppressive	O
properties	O
of	O
Pten	B-Gene_or_gene_product
are	O
dependent	O
on	O
its	O
lipid	O
phosphatase	O
activity	O
,	O
which	O
inhibits	O
the	O
phosphatidylinositol	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
'	I-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
PI3K	B-Gene_or_gene_product
)	O
/	O
Akt	B-Gene_or_gene_product
signaling	O
pathway	O
through	O
dephosphorylation	O
of	O
phosphatidylinositol	O
-	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
-	O
triphosphate	O
.	O

The	O
additional	O
function	O
of	O
Pten	B-Gene_or_gene_product
as	O
a	O
dual	O
-	O
specificity	O
protein	O
phosphatase	O
may	O
also	O
play	O
a	O
role	O
in	O
glioma	O
pathogenesis	O
.	O
<EOS>	B-X
In	B-X
1997	B-X
,	B-X
the	B-X
PTEN	B-X
gene	B-X
(	B-X
phosphatase	B-X
and	B-X
tensin	B-X
homolog	B-X
deleted	B-X
on	B-X
chromosome	B-X
10	B-X
)	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
the	B-X
long	B-X
arm	B-X
of	B-X
chromosome	B-X
10	B-X
.	B-X
Since	B-X
then	B-X
,	B-X
important	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
Pten	B-X
protein	B-X
in	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
the	B-X
brain	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
human	B-X
gliomas	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
state	B-X
of	B-X
the	B-X
art	B-X
concerning	B-X
the	B-X
involvement	B-X
of	B-X
aberrant	B-X
Pten	B-X
function	B-X
in	B-X
the	B-X
development	B-X
of	B-X
different	B-X
biologic	B-X
features	B-X
of	B-X
malignant	B-X
gliomas	B-X
,	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
cell-cycle	B-X
control	B-X
and	B-X
uncontrolled	B-X
cell	B-X
proliferation	B-X
,	B-X
escape	B-X
from	B-X
apoptosis	B-X
,	B-X
brain	B-X
invasion	B-X
,	B-X
and	B-X
aberrant	B-X
neoangiogenesis	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
tumor-suppressive	B-X
properties	B-X
of	B-X
Pten	B-X
are	B-X
dependent	B-X
on	B-X
its	B-X
lipid	B-X
phosphatase	B-X
activity	B-X
,	B-X
which	B-X
inhibits	B-X
the	B-X
phosphatidylinositol-3'-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
signaling	B-X
pathway	B-X
through	B-X
dephosphorylation	B-X
of	B-X
phosphatidylinositol-	B-X
(	B-X
3,4,5	B-X
)	B-X
-triphosphate	B-X
.	B-X
The	B-X
additional	B-X
function	B-X
of	B-X
Pten	B-X
as	B-X
a	B-X
dual-specificity	B-X
protein	B-X
phosphatase	B-X
may	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
glioma	B-X
pathogenesis	B-X
.	B-X
Besides	B-X
the	B-X
wealth	B-X
of	B-X
data	B-X
elucidating	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
Pten	B-X
,	B-X
recent	B-X
studies	B-X
suggest	B-X
a	B-X
diagnostic	B-X
significance	B-X
of	B-X
PTEN	B-X
gene	B-X
alterations	B-X
as	B-X
a	B-X
molecular	B-X
marker	B-X
for	B-X
poor	B-X
prognosis	B-X
in	B-X
anaplastic	B-X
astrocytomas	B-X
and	B-X
anaplastic	B-X
oligodendrogliomas	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
possibility	B-X
of	B-X
selective	B-X
targeting	B-X
of	B-X
PTEN	B-X
mutant	B-X
tumor	B-X
cells	B-X
by	B-X
specific	B-X
pharmacologic	B-X
inhibitors	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Pten/PI3K/Akt	B-X
pathway	B-X
opens	B-X
up	B-X
new	B-X
perspectives	B-X
for	B-X
a	B-X
targeted	B-X
molecular	B-X
therapy	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X

Besides	O
the	O
wealth	O
of	O
data	O
elucidating	O
the	O
functional	O
roles	O
of	O
Pten	B-Gene_or_gene_product
,	O
recent	O
studies	O
suggest	O
a	O
diagnostic	O
significance	O
of	O
PTEN	B-Gene_or_gene_product
gene	O
alterations	O
as	O
a	O
molecular	O
marker	O
for	O
poor	O
prognosis	O
in	O
anaplastic	O
astrocytomas	O
and	O
anaplastic	O
oligodendrogliomas	O
.	O
<EOS>	B-X
In	B-X
1997	B-X
,	B-X
the	B-X
PTEN	B-X
gene	B-X
(	B-X
phosphatase	B-X
and	B-X
tensin	B-X
homolog	B-X
deleted	B-X
on	B-X
chromosome	B-X
10	B-X
)	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
the	B-X
long	B-X
arm	B-X
of	B-X
chromosome	B-X
10	B-X
.	B-X
Since	B-X
then	B-X
,	B-X
important	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
Pten	B-X
protein	B-X
in	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
the	B-X
brain	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
human	B-X
gliomas	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
state	B-X
of	B-X
the	B-X
art	B-X
concerning	B-X
the	B-X
involvement	B-X
of	B-X
aberrant	B-X
Pten	B-X
function	B-X
in	B-X
the	B-X
development	B-X
of	B-X
different	B-X
biologic	B-X
features	B-X
of	B-X
malignant	B-X
gliomas	B-X
,	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
cell-cycle	B-X
control	B-X
and	B-X
uncontrolled	B-X
cell	B-X
proliferation	B-X
,	B-X
escape	B-X
from	B-X
apoptosis	B-X
,	B-X
brain	B-X
invasion	B-X
,	B-X
and	B-X
aberrant	B-X
neoangiogenesis	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
tumor-suppressive	B-X
properties	B-X
of	B-X
Pten	B-X
are	B-X
dependent	B-X
on	B-X
its	B-X
lipid	B-X
phosphatase	B-X
activity	B-X
,	B-X
which	B-X
inhibits	B-X
the	B-X
phosphatidylinositol-3'-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
signaling	B-X
pathway	B-X
through	B-X
dephosphorylation	B-X
of	B-X
phosphatidylinositol-	B-X
(	B-X
3,4,5	B-X
)	B-X
-triphosphate	B-X
.	B-X
The	B-X
additional	B-X
function	B-X
of	B-X
Pten	B-X
as	B-X
a	B-X
dual-specificity	B-X
protein	B-X
phosphatase	B-X
may	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
glioma	B-X
pathogenesis	B-X
.	B-X
Besides	B-X
the	B-X
wealth	B-X
of	B-X
data	B-X
elucidating	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
Pten	B-X
,	B-X
recent	B-X
studies	B-X
suggest	B-X
a	B-X
diagnostic	B-X
significance	B-X
of	B-X
PTEN	B-X
gene	B-X
alterations	B-X
as	B-X
a	B-X
molecular	B-X
marker	B-X
for	B-X
poor	B-X
prognosis	B-X
in	B-X
anaplastic	B-X
astrocytomas	B-X
and	B-X
anaplastic	B-X
oligodendrogliomas	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
possibility	B-X
of	B-X
selective	B-X
targeting	B-X
of	B-X
PTEN	B-X
mutant	B-X
tumor	B-X
cells	B-X
by	B-X
specific	B-X
pharmacologic	B-X
inhibitors	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Pten/PI3K/Akt	B-X
pathway	B-X
opens	B-X
up	B-X
new	B-X
perspectives	B-X
for	B-X
a	B-X
targeted	B-X
molecular	B-X
therapy	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X

Furthermore	O
,	O
the	O
possibility	O
of	O
selective	O
targeting	O
of	O
PTEN	B-Gene_or_gene_product
mutant	O
tumor	O
cells	O
by	O
specific	O
pharmacologic	O
inhibitors	O
of	O
members	O
of	O
the	O
Pten	B-Gene_or_gene_product
/	O
PI3K	B-Gene_or_gene_product
/	O
Akt	B-Gene_or_gene_product
pathway	O
opens	O
up	O
new	O
perspectives	O
for	O
a	O
targeted	O
molecular	O
therapy	O
of	O
malignant	O
gliomas	O
.	O
<EOS>	B-X
In	B-X
1997	B-X
,	B-X
the	B-X
PTEN	B-X
gene	B-X
(	B-X
phosphatase	B-X
and	B-X
tensin	B-X
homolog	B-X
deleted	B-X
on	B-X
chromosome	B-X
10	B-X
)	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
the	B-X
long	B-X
arm	B-X
of	B-X
chromosome	B-X
10	B-X
.	B-X
Since	B-X
then	B-X
,	B-X
important	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
Pten	B-X
protein	B-X
in	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
the	B-X
brain	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
human	B-X
gliomas	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
state	B-X
of	B-X
the	B-X
art	B-X
concerning	B-X
the	B-X
involvement	B-X
of	B-X
aberrant	B-X
Pten	B-X
function	B-X
in	B-X
the	B-X
development	B-X
of	B-X
different	B-X
biologic	B-X
features	B-X
of	B-X
malignant	B-X
gliomas	B-X
,	B-X
such	B-X
as	B-X
loss	B-X
of	B-X
cell-cycle	B-X
control	B-X
and	B-X
uncontrolled	B-X
cell	B-X
proliferation	B-X
,	B-X
escape	B-X
from	B-X
apoptosis	B-X
,	B-X
brain	B-X
invasion	B-X
,	B-X
and	B-X
aberrant	B-X
neoangiogenesis	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
tumor-suppressive	B-X
properties	B-X
of	B-X
Pten	B-X
are	B-X
dependent	B-X
on	B-X
its	B-X
lipid	B-X
phosphatase	B-X
activity	B-X
,	B-X
which	B-X
inhibits	B-X
the	B-X
phosphatidylinositol-3'-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
signaling	B-X
pathway	B-X
through	B-X
dephosphorylation	B-X
of	B-X
phosphatidylinositol-	B-X
(	B-X
3,4,5	B-X
)	B-X
-triphosphate	B-X
.	B-X
The	B-X
additional	B-X
function	B-X
of	B-X
Pten	B-X
as	B-X
a	B-X
dual-specificity	B-X
protein	B-X
phosphatase	B-X
may	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
glioma	B-X
pathogenesis	B-X
.	B-X
Besides	B-X
the	B-X
wealth	B-X
of	B-X
data	B-X
elucidating	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
Pten	B-X
,	B-X
recent	B-X
studies	B-X
suggest	B-X
a	B-X
diagnostic	B-X
significance	B-X
of	B-X
PTEN	B-X
gene	B-X
alterations	B-X
as	B-X
a	B-X
molecular	B-X
marker	B-X
for	B-X
poor	B-X
prognosis	B-X
in	B-X
anaplastic	B-X
astrocytomas	B-X
and	B-X
anaplastic	B-X
oligodendrogliomas	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
possibility	B-X
of	B-X
selective	B-X
targeting	B-X
of	B-X
PTEN	B-X
mutant	B-X
tumor	B-X
cells	B-X
by	B-X
specific	B-X
pharmacologic	B-X
inhibitors	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Pten/PI3K/Akt	B-X
pathway	B-X
opens	B-X
up	B-X
new	B-X
perspectives	B-X
for	B-X
a	B-X
targeted	B-X
molecular	B-X
therapy	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X

[	O
A	O
case	O
report	O
of	O
advanced	O
gastric	O
cancer	O
responding	O
to	O
TS	O
-	O
1	O
,	O
a	O
novel	O
oral	O
fluorouracil	O
derivative	O
]	O
.	O

TS	O
-	O
1	O
is	O
a	O
new	O
,	O
oral	O
anticancer	O
agent	O
composed	O
of	O
two	O
modulators	O
,	O
gimeracil	O
(	O
CDHP	O
)	O
and	O
oteracil	O
potassium	O
(	O
Oxo	O
)	O
are	O
mixed	O
with	O
tegafur	O
in	O
a	O
ratio	O
of	O
1	O
:	O
0	O
.	O
4	O
:	O
1	O
.	O

We	O
report	O
one	O
case	O
of	O
advanced	O
gastric	O
cancer	O
with	O
lung	O
and	O
lymph	O
node	O
metastases	O
that	O
completely	O
responded	O
to	O
TS	O
-	O
1	O
.	O

A	O
71	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
breathlessness	O
.	O
<EOS>	B-X
A	B-X
71-year-old	B-X
woman	B-X
was	B-X
admitted	B-X
to	B-X
the	B-X
Emergency	B-X
Department	B-X
with	B-X
severe	B-X
dyspnea	B-X
followed	B-X
by	B-X
unconsciousness	B-X
.	B-X
A	B-X
71-year-old	B-X
woman	B-X
with	B-X
idiopathic	B-X
thrombocytopenic	B-X
purpura	B-X
(	B-X
ITP	B-X
)	B-X
,	B-X
who	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
steroid	B-X
and	B-X
cyclosporine	B-X
,	B-X
was	B-X
admitted	B-X
in	B-X
an	B-X
emergency	B-X
with	B-X
fever	B-X
and	B-X
dyspnea	B-X
.	B-X
A	B-X
71-year-old	B-X
woman	B-X
presented	B-X
to	B-X
our	B-X
hospital	B-X
with	B-X
fever	B-X
and	B-X
dyspnea	B-X
.	B-X
She	B-X
was	B-X
admitted	B-X
to	B-X
our	B-X
hospital	B-X
for	B-X
respiratory	B-X
failure	B-X
.	B-X
After	B-X
confirming	B-X
that	B-X
all	B-X
the	B-X
culture	B-X
results	B-X
and	B-X
inflammation	B-X
findings	B-X
had	B-X
turned	B-X
negative	B-X
,	B-X
the	B-X
patient	B-X
was	B-X
discharged	B-X
from	B-X
the	B-X
hospital	B-X
.	B-X

A	O
diagnosis	O
of	O
advanced	O
gastric	O
cancer	O
with	O
extensive	O
lymph	O
node	O
metastases	O
and	O
multiple	O
pulmonary	O
metastases	O
was	O
made	O
.	O
<EOS>	B-X
Multiple	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
long	B-X
non-coding	B-X
RNAs	B-X
(	B-X
lncRNAs	B-X
)	B-X
extensively	B-X
participate	B-X
in	B-X
human	B-X
cancer	B-X
malignant	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
gastric	B-X
cancer	B-X
(	B-X
GC	B-X
)	B-X
remains	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
that	B-X
LINC00707	B-X
was	B-X
excessively	B-X
expressed	B-X
in	B-X
GC	B-X
tissues	B-X
and	B-X
correlated	B-X
with	B-X
advanced	B-X
stage	B-X
,	B-X
larger	B-X
tumor	B-X
size	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poorer	B-X
prognosis	B-X
in	B-X
GC	B-X
patients	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
prove	B-X
that	B-X
LINC00707	B-X
may	B-X
act	B-X
as	B-X
an	B-X
oncogene	B-X
in	B-X
GC	B-X
by	B-X
regulating	B-X
mRNA	B-X
stability	B-X
and	B-X
serve	B-X
as	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
GC	B-X
diagnosis	B-X
and	B-X
prognosis	B-X
.	B-X

One	O
hundred	O
mg	O
/	O
body	O
/	O
day	O
of	O
TS	O
-	O
1	O
was	O
orally	O
administrated	O
for	O
4	O
weeks	O
.	O
<EOS>	B-X
TS-1	B-X
is	B-X
a	B-X
new	B-X
,	B-X
oral	B-X
anticancer	B-X
agent	B-X
composed	B-X
of	B-X
two	B-X
modulators	B-X
,	B-X
gimeracil	B-X
(	B-X
CDHP	B-X
)	B-X
and	B-X
oteracil	B-X
potassium	B-X
(	B-X
Oxo	B-X
)	B-X
are	B-X
mixed	B-X
with	B-X
tegafur	B-X
in	B-X
a	B-X
ratio	B-X
of	B-X
1:0.4:1	B-X
.	B-X
We	B-X
report	B-X
one	B-X
case	B-X
of	B-X
advanced	B-X
gastric	B-X
cancer	B-X
with	B-X
lung	B-X
and	B-X
lymph	B-X
node	B-X
metastases	B-X
that	B-X
completely	B-X
responded	B-X
to	B-X
TS-1	B-X
.	B-X
A	B-X
71-year-old	B-X
woman	B-X
was	B-X
admitted	B-X
to	B-X
our	B-X
hospital	B-X
because	B-X
of	B-X
breathlessness	B-X
.	B-X
One	B-X
hundred	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
was	B-X
orally	B-X
administrated	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
After	B-X
1	B-X
drug-free	B-X
week	B-X
,	B-X
the	B-X
second	B-X
course	B-X
was	B-X
administered	B-X
with	B-X
120	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
The	B-X
serum	B-X
level	B-X
of	B-X
CEA	B-X
was	B-X
reduced	B-X
from	B-X
172.7	B-X
ng/ml	B-X
to	B-X
8.1	B-X
ng/ml	B-X
after	B-X
TS-1	B-X
treatment	B-X
.	B-X

A	O
partial	O
response	O
(	O
PR	O
)	O
was	O
obtained	O
after	O
the	O
first	O
course	O
with	O
regression	O
of	O
multiple	O
pulmonary	O
metastases	O
.	O
<EOS>	B-X
We	B-X
report	B-X
one	B-X
case	B-X
of	B-X
advanced	B-X
gastric	B-X
cancer	B-X
with	B-X
lung	B-X
and	B-X
lymph	B-X
node	B-X
metastases	B-X
that	B-X
completely	B-X
responded	B-X
to	B-X
TS-1	B-X
.	B-X
A	B-X
diagnosis	B-X
of	B-X
advanced	B-X
gastric	B-X
cancer	B-X
with	B-X
extensive	B-X
lymph	B-X
node	B-X
metastases	B-X
and	B-X
multiple	B-X
pulmonary	B-X
metastases	B-X
was	B-X
made	B-X
.	B-X
A	B-X
partial	B-X
response	B-X
(	B-X
PR	B-X
)	B-X
was	B-X
obtained	B-X
after	B-X
the	B-X
first	B-X
course	B-X
with	B-X
regression	B-X
of	B-X
multiple	B-X
pulmonary	B-X
metastases	B-X
.	B-X
After	B-X
1	B-X
drug-free	B-X
week	B-X
,	B-X
the	B-X
second	B-X
course	B-X
was	B-X
administered	B-X
with	B-X
120	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
After	B-X
two	B-X
courses	B-X
,	B-X
the	B-X
primary	B-X
tumor	B-X
was	B-X
reduced	B-X
to	B-X
an	B-X
ulcer	B-X
scar	B-X
with	B-X
pathological	B-X
confirmation	B-X
of	B-X
a	B-X
complete	B-X
disappearance	B-X
of	B-X
the	B-X
cancer	B-X
tissue	B-X
.	B-X
Moreover	B-X
,	B-X
computed	B-X
tomography	B-X
(	B-X
CT	B-X
)	B-X
showed	B-X
a	B-X
complete	B-X
regression	B-X
of	B-X
the	B-X
extensive	B-X
lymph	B-X
node	B-X
and	B-X
diffuse	B-X
lung	B-X
metastases	B-X
,	B-X
for	B-X
a	B-X
complete	B-X
response	B-X
(	B-X
CR	B-X
)	B-X
.	B-X

After	O
1	O
drug	O
-	O
free	O
week	O
,	O
the	O
second	O
course	O
was	O
administered	O
with	O
120	O
mg	O
/	O
body	O
/	O
day	O
of	O
TS	O
-	O
1	O
for	O
4	O
weeks	O
.	O
<EOS>	B-X
TS-1	B-X
is	B-X
a	B-X
new	B-X
,	B-X
oral	B-X
anticancer	B-X
agent	B-X
composed	B-X
of	B-X
two	B-X
modulators	B-X
,	B-X
gimeracil	B-X
(	B-X
CDHP	B-X
)	B-X
and	B-X
oteracil	B-X
potassium	B-X
(	B-X
Oxo	B-X
)	B-X
are	B-X
mixed	B-X
with	B-X
tegafur	B-X
in	B-X
a	B-X
ratio	B-X
of	B-X
1:0.4:1	B-X
.	B-X
We	B-X
report	B-X
one	B-X
case	B-X
of	B-X
advanced	B-X
gastric	B-X
cancer	B-X
with	B-X
lung	B-X
and	B-X
lymph	B-X
node	B-X
metastases	B-X
that	B-X
completely	B-X
responded	B-X
to	B-X
TS-1	B-X
.	B-X
A	B-X
71-year-old	B-X
woman	B-X
was	B-X
admitted	B-X
to	B-X
our	B-X
hospital	B-X
because	B-X
of	B-X
breathlessness	B-X
.	B-X
One	B-X
hundred	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
was	B-X
orally	B-X
administrated	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
A	B-X
partial	B-X
response	B-X
(	B-X
PR	B-X
)	B-X
was	B-X
obtained	B-X
after	B-X
the	B-X
first	B-X
course	B-X
with	B-X
regression	B-X
of	B-X
multiple	B-X
pulmonary	B-X
metastases	B-X
.	B-X
After	B-X
1	B-X
drug-free	B-X
week	B-X
,	B-X
the	B-X
second	B-X
course	B-X
was	B-X
administered	B-X
with	B-X
120	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
After	B-X
two	B-X
courses	B-X
,	B-X
the	B-X
primary	B-X
tumor	B-X
was	B-X
reduced	B-X
to	B-X
an	B-X
ulcer	B-X
scar	B-X
with	B-X
pathological	B-X
confirmation	B-X
of	B-X
a	B-X
complete	B-X
disappearance	B-X
of	B-X
the	B-X
cancer	B-X
tissue	B-X
.	B-X
The	B-X
serum	B-X
level	B-X
of	B-X
CEA	B-X
was	B-X
reduced	B-X
from	B-X
172.7	B-X
ng/ml	B-X
to	B-X
8.1	B-X
ng/ml	B-X
after	B-X
TS-1	B-X
treatment	B-X
.	B-X

After	O
two	O
courses	O
,	O
the	O
primary	O
tumor	O
was	O
reduced	O
to	O
an	O
ulcer	O
scar	O
with	O
pathological	O
confirmation	O
of	O
a	O
complete	O
disappearance	O
of	O
the	O
cancer	O
tissue	O
.	O

Moreover	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
showed	O
a	O
complete	O
regression	O
of	O
the	O
extensive	O
lymph	O
node	O
and	O
diffuse	O
lung	O
metastases	O
,	O
for	O
a	O
complete	O
response	O
(	O
CR	O
)	O
.	O
<EOS>	B-X
We	B-X
report	B-X
one	B-X
case	B-X
of	B-X
advanced	B-X
gastric	B-X
cancer	B-X
with	B-X
lung	B-X
and	B-X
lymph	B-X
node	B-X
metastases	B-X
that	B-X
completely	B-X
responded	B-X
to	B-X
TS-1	B-X
.	B-X
A	B-X
diagnosis	B-X
of	B-X
advanced	B-X
gastric	B-X
cancer	B-X
with	B-X
extensive	B-X
lymph	B-X
node	B-X
metastases	B-X
and	B-X
multiple	B-X
pulmonary	B-X
metastases	B-X
was	B-X
made	B-X
.	B-X
A	B-X
partial	B-X
response	B-X
(	B-X
PR	B-X
)	B-X
was	B-X
obtained	B-X
after	B-X
the	B-X
first	B-X
course	B-X
with	B-X
regression	B-X
of	B-X
multiple	B-X
pulmonary	B-X
metastases	B-X
.	B-X
After	B-X
two	B-X
courses	B-X
,	B-X
the	B-X
primary	B-X
tumor	B-X
was	B-X
reduced	B-X
to	B-X
an	B-X
ulcer	B-X
scar	B-X
with	B-X
pathological	B-X
confirmation	B-X
of	B-X
a	B-X
complete	B-X
disappearance	B-X
of	B-X
the	B-X
cancer	B-X
tissue	B-X
.	B-X
Moreover	B-X
,	B-X
computed	B-X
tomography	B-X
(	B-X
CT	B-X
)	B-X
showed	B-X
a	B-X
complete	B-X
regression	B-X
of	B-X
the	B-X
extensive	B-X
lymph	B-X
node	B-X
and	B-X
diffuse	B-X
lung	B-X
metastases	B-X
,	B-X
for	B-X
a	B-X
complete	B-X
response	B-X
(	B-X
CR	B-X
)	B-X
.	B-X

The	O
serum	O
level	O
of	O
CEA	B-Gene_or_gene_product
was	O
reduced	O
from	O
172	O
.	O
7	O
ng	O
/	O
ml	O
to	O
8	O
.	O
1	O
ng	O
/	O
ml	O
after	O
TS	O
-	O
1	O
treatment	O
.	O

As	O
for	O
adverse	O
events	O
,	O
only	O
pigmentation	O
of	O
the	O
skin	O
and	O
Grade	O
2	O
oral	O
aphta	O
were	O
observed	O
.	O
<EOS>	B-X
TS-1	B-X
is	B-X
a	B-X
new	B-X
,	B-X
oral	B-X
anticancer	B-X
agent	B-X
composed	B-X
of	B-X
two	B-X
modulators	B-X
,	B-X
gimeracil	B-X
(	B-X
CDHP	B-X
)	B-X
and	B-X
oteracil	B-X
potassium	B-X
(	B-X
Oxo	B-X
)	B-X
are	B-X
mixed	B-X
with	B-X
tegafur	B-X
in	B-X
a	B-X
ratio	B-X
of	B-X
1:0.4:1	B-X
.	B-X
One	B-X
hundred	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
was	B-X
orally	B-X
administrated	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
After	B-X
1	B-X
drug-free	B-X
week	B-X
,	B-X
the	B-X
second	B-X
course	B-X
was	B-X
administered	B-X
with	B-X
120	B-X
mg/body/day	B-X
of	B-X
TS-1	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
The	B-X
serum	B-X
level	B-X
of	B-X
CEA	B-X
was	B-X
reduced	B-X
from	B-X
172.7	B-X
ng/ml	B-X
to	B-X
8.1	B-X
ng/ml	B-X
after	B-X
TS-1	B-X
treatment	B-X
.	B-X
As	B-X
for	B-X
adverse	B-X
events	B-X
,	B-X
only	B-X
pigmentation	B-X
of	B-X
the	B-X
skin	B-X
and	B-X
Grade	B-X
2	B-X
oral	B-X
aphta	B-X
were	B-X
observed	B-X
.	B-X

Systemic	O
regulation	O
of	O
distraction	O
osteogenesis	O
:	O
a	O
cascade	O
of	O
biochemical	O
factors	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
systemic	B-X
biochemical	B-X
regulation	B-X
of	B-X
fracture	B-X
healing	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
compared	B-X
with	B-X
rigid	B-X
osteotomy	B-X
in	B-X
a	B-X
prospective	B-X
in	B-X
vivo	B-X
study	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
further	B-X
clarify	B-X
the	B-X
influence	B-X
of	B-X
mechanical	B-X
strain	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
bone	B-X
formation	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
insulin-like	B-X
growth	B-X
factor	B-X
[	B-X
IGF	B-X
]	B-X
I	B-X
,	B-X
IGF	B-X
binding	B-X
protein	B-X
[	B-X
IGFBP	B-X
]	B-X
3	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
[	B-X
TGF	B-X
]	B-X
beta1	B-X
,	B-X
and	B-X
basic	B-X
FGF	B-X
[	B-X
bFGF	B-X
]	B-X
)	B-X
,	B-X
bone	B-X
matrix	B-X
degrading	B-X
enzymes	B-X
(	B-X
matrix-metalloproteinases	B-X
[	B-X
MMPs	B-X
]	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
)	B-X
,	B-X
human	B-X
growth	B-X
hormone	B-X
(	B-X
hGH	B-X
)	B-X
,	B-X
and	B-X
bone	B-X
formation	B-X
markers	B-X
(	B-X
ALP	B-X
,	B-X
bone-specific	B-X
ALP	B-X
[	B-X
BAP	B-X
]	B-X
,	B-X
and	B-X
osteocalcin	B-X
[	B-X
OC	B-X
]	B-X
)	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
serum	B-X
samples	B-X
from	B-X
10	B-X
patients	B-X
in	B-X
each	B-X
group	B-X
pre-	B-X
and	B-X
postoperatively	B-X
.	B-X
In	B-X
the	B-X
distraction	B-X
group	B-X
,	B-X
a	B-X
significant	B-X
postoperative	B-X
increase	B-X
in	B-X
MMP-1	B-X
,	B-X
bFGF	B-X
,	B-X
ALP	B-X
,	B-X
and	B-X
BAP	B-X
could	B-X
be	B-X
observed	B-X
during	B-X
the	B-X
lengthening	B-X
and	B-X
the	B-X
consolidation	B-X
period	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
levels	B-X
.	B-X
Osteotomy	B-X
fracture	B-X
healing	B-X
without	B-X
the	B-X
traction	B-X
stimulus	B-X
failed	B-X
to	B-X
induce	B-X
a	B-X
corresponding	B-X
increase	B-X
in	B-X
these	B-X
factors	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
comparison	B-X
of	B-X
both	B-X
groups	B-X
revealed	B-X
a	B-X
significantly	B-X
higher	B-X
increase	B-X
in	B-X
TGF-beta1	B-X
,	B-X
IGF-I	B-X
,	B-X
IGFBP-3	B-X
,	B-X
and	B-X
hGH	B-X
in	B-X
the	B-X
lengthening	B-X
group	B-X
during	B-X
the	B-X
distraction	B-X
period	B-X
,	B-X
indicating	B-X
key	B-X
regulatory	B-X
functions	B-X
in	B-X
mechanotransduction	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
changes	B-X
in	B-X
MMP-1	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
TGF-beta1	B-X
and	B-X
bFGF	B-X
)	B-X
,	B-X
and	B-X
hGH	B-X
,	B-X
respectively	B-X
,	B-X
correlated	B-X
significantly	B-X
during	B-X
the	B-X
lengthening	B-X
phase	B-X
,	B-X
indicating	B-X
common	B-X
regulatory	B-X
pathways	B-X
for	B-X
these	B-X
factors	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
.	B-X
Significant	B-X
correlation	B-X
between	B-X
the	B-X
osteoblastic	B-X
marker	B-X
BAP	B-X
,	B-X
TGF-beta1	B-X
,	B-X
and	B-X
bFGF	B-X
suggests	B-X
strain-activated	B-X
osteoblastic	B-X
cells	B-X
as	B-X
a	B-X
major	B-X
source	B-X
of	B-X
systemically	B-X
increased	B-X
bone	B-X
growth	B-X
factors	B-X
during	B-X
callus	B-X
distraction	B-X
.	B-X
The	B-X
systemic	B-X
increase	B-X
in	B-X
bFGF	B-X
and	B-X
MMP-1	B-X
might	B-X
reflect	B-X
an	B-X
increased	B-X
local	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
during	B-X
distraction	B-X
osteogenesis	B-X
.	B-X

This	O
study	O
investigates	O
the	O
systemic	O
biochemical	O
regulation	O
of	O
fracture	O
healing	O
in	O
distraction	O
osteogenesis	O
compared	O
with	O
rigid	O
osteotomy	O
in	O
a	O
prospective	O
in	O
vivo	O
study	O
in	O
humans	O
.	O

To	O
further	O
clarify	O
the	O
influence	O
of	O
mechanical	O
strain	O
on	O
the	O
regulation	O
of	O
bone	O
formation	O
,	O
bone	O
growth	O
factors	O
(	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
[	I-Gene_or_gene_product
IGF	I-Gene_or_gene_product
]	I-Gene_or_gene_product
I	I-Gene_or_gene_product
,	O
IGF	B-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
[	I-Gene_or_gene_product
IGFBP	I-Gene_or_gene_product
]	I-Gene_or_gene_product
3	I-Gene_or_gene_product
,	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
[	I-Gene_or_gene_product
TGF	I-Gene_or_gene_product
]	I-Gene_or_gene_product
beta1	I-Gene_or_gene_product
,	O
and	O
basic	B-Gene_or_gene_product
FGF	I-Gene_or_gene_product
[	O
bFGF	B-Gene_or_gene_product
]	O
)	O
,	O
bone	O
matrix	O
degrading	O
enzymes	O
(	O
matrix	B-Gene_or_gene_product
-	I-Gene_or_gene_product
metalloproteinases	I-Gene_or_gene_product
[	I-Gene_or_gene_product
MMPs	I-Gene_or_gene_product
]	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
2	B-Gene_or_gene_product
,	O
and	O
3	B-Gene_or_gene_product
)	O
,	O
human	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
hormone	I-Gene_or_gene_product
(	O
hGH	B-Gene_or_gene_product
)	O
,	O
and	O
bone	O
formation	O
markers	O
(	O
ALP	B-Gene_or_gene_product
,	O
bone	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
ALP	I-Gene_or_gene_product
[	O
BAP	B-Gene_or_gene_product
]	O
,	O
and	O
osteocalcin	B-Gene_or_gene_product
[	O
OC	B-Gene_or_gene_product
]	O
)	O
have	O
been	O
analyzed	O
in	O
serum	O
samples	O
from	O
10	O
patients	O
in	O
each	O
group	O
pre	O
-	O
and	O
postoperatively	O
.	O

In	O
the	O
distraction	O
group	O
,	O
a	O
significant	O
postoperative	O
increase	O
in	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
bFGF	B-Gene_or_gene_product
,	O
ALP	B-Gene_or_gene_product
,	O
and	O
BAP	B-Gene_or_gene_product
could	O
be	O
observed	O
during	O
the	O
lengthening	O
and	O
the	O
consolidation	O
period	O
when	O
compared	O
with	O
the	O
baseline	O
levels	O
.	O

Osteotomy	O
fracture	O
healing	O
without	O
the	O
traction	O
stimulus	O
failed	O
to	O
induce	O
a	O
corresponding	O
increase	O
in	O
these	O
factors	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
systemic	B-X
biochemical	B-X
regulation	B-X
of	B-X
fracture	B-X
healing	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
compared	B-X
with	B-X
rigid	B-X
osteotomy	B-X
in	B-X
a	B-X
prospective	B-X
in	B-X
vivo	B-X
study	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
further	B-X
clarify	B-X
the	B-X
influence	B-X
of	B-X
mechanical	B-X
strain	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
bone	B-X
formation	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
insulin-like	B-X
growth	B-X
factor	B-X
[	B-X
IGF	B-X
]	B-X
I	B-X
,	B-X
IGF	B-X
binding	B-X
protein	B-X
[	B-X
IGFBP	B-X
]	B-X
3	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
[	B-X
TGF	B-X
]	B-X
beta1	B-X
,	B-X
and	B-X
basic	B-X
FGF	B-X
[	B-X
bFGF	B-X
]	B-X
)	B-X
,	B-X
bone	B-X
matrix	B-X
degrading	B-X
enzymes	B-X
(	B-X
matrix-metalloproteinases	B-X
[	B-X
MMPs	B-X
]	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
)	B-X
,	B-X
human	B-X
growth	B-X
hormone	B-X
(	B-X
hGH	B-X
)	B-X
,	B-X
and	B-X
bone	B-X
formation	B-X
markers	B-X
(	B-X
ALP	B-X
,	B-X
bone-specific	B-X
ALP	B-X
[	B-X
BAP	B-X
]	B-X
,	B-X
and	B-X
osteocalcin	B-X
[	B-X
OC	B-X
]	B-X
)	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
serum	B-X
samples	B-X
from	B-X
10	B-X
patients	B-X
in	B-X
each	B-X
group	B-X
pre-	B-X
and	B-X
postoperatively	B-X
.	B-X
In	B-X
the	B-X
distraction	B-X
group	B-X
,	B-X
a	B-X
significant	B-X
postoperative	B-X
increase	B-X
in	B-X
MMP-1	B-X
,	B-X
bFGF	B-X
,	B-X
ALP	B-X
,	B-X
and	B-X
BAP	B-X
could	B-X
be	B-X
observed	B-X
during	B-X
the	B-X
lengthening	B-X
and	B-X
the	B-X
consolidation	B-X
period	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
levels	B-X
.	B-X
Osteotomy	B-X
fracture	B-X
healing	B-X
without	B-X
the	B-X
traction	B-X
stimulus	B-X
failed	B-X
to	B-X
induce	B-X
a	B-X
corresponding	B-X
increase	B-X
in	B-X
these	B-X
factors	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
comparison	B-X
of	B-X
both	B-X
groups	B-X
revealed	B-X
a	B-X
significantly	B-X
higher	B-X
increase	B-X
in	B-X
TGF-beta1	B-X
,	B-X
IGF-I	B-X
,	B-X
IGFBP-3	B-X
,	B-X
and	B-X
hGH	B-X
in	B-X
the	B-X
lengthening	B-X
group	B-X
during	B-X
the	B-X
distraction	B-X
period	B-X
,	B-X
indicating	B-X
key	B-X
regulatory	B-X
functions	B-X
in	B-X
mechanotransduction	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
changes	B-X
in	B-X
MMP-1	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
TGF-beta1	B-X
and	B-X
bFGF	B-X
)	B-X
,	B-X
and	B-X
hGH	B-X
,	B-X
respectively	B-X
,	B-X
correlated	B-X
significantly	B-X
during	B-X
the	B-X
lengthening	B-X
phase	B-X
,	B-X
indicating	B-X
common	B-X
regulatory	B-X
pathways	B-X
for	B-X
these	B-X
factors	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
.	B-X
Significant	B-X
correlation	B-X
between	B-X
the	B-X
osteoblastic	B-X
marker	B-X
BAP	B-X
,	B-X
TGF-beta1	B-X
,	B-X
and	B-X
bFGF	B-X
suggests	B-X
strain-activated	B-X
osteoblastic	B-X
cells	B-X
as	B-X
a	B-X
major	B-X
source	B-X
of	B-X
systemically	B-X
increased	B-X
bone	B-X
growth	B-X
factors	B-X
during	B-X
callus	B-X
distraction	B-X
.	B-X
The	B-X
systemic	B-X
increase	B-X
in	B-X
bFGF	B-X
and	B-X
MMP-1	B-X
might	B-X
reflect	B-X
an	B-X
increased	B-X
local	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
during	B-X
distraction	B-X
osteogenesis	B-X
.	B-X

In	O
addition	O
,	O
comparison	O
of	O
both	O
groups	O
revealed	O
a	O
significantly	O
higher	O
increase	O
in	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	I-Gene_or_gene_product
,	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
,	O
IGFBP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
,	O
and	O
hGH	B-Gene_or_gene_product
in	O
the	O
lengthening	O
group	O
during	O
the	O
distraction	O
period	O
,	O
indicating	O
key	O
regulatory	O
functions	O
in	O
mechanotransduction	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
systemic	B-X
biochemical	B-X
regulation	B-X
of	B-X
fracture	B-X
healing	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
compared	B-X
with	B-X
rigid	B-X
osteotomy	B-X
in	B-X
a	B-X
prospective	B-X
in	B-X
vivo	B-X
study	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
further	B-X
clarify	B-X
the	B-X
influence	B-X
of	B-X
mechanical	B-X
strain	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
bone	B-X
formation	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
insulin-like	B-X
growth	B-X
factor	B-X
[	B-X
IGF	B-X
]	B-X
I	B-X
,	B-X
IGF	B-X
binding	B-X
protein	B-X
[	B-X
IGFBP	B-X
]	B-X
3	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
[	B-X
TGF	B-X
]	B-X
beta1	B-X
,	B-X
and	B-X
basic	B-X
FGF	B-X
[	B-X
bFGF	B-X
]	B-X
)	B-X
,	B-X
bone	B-X
matrix	B-X
degrading	B-X
enzymes	B-X
(	B-X
matrix-metalloproteinases	B-X
[	B-X
MMPs	B-X
]	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
)	B-X
,	B-X
human	B-X
growth	B-X
hormone	B-X
(	B-X
hGH	B-X
)	B-X
,	B-X
and	B-X
bone	B-X
formation	B-X
markers	B-X
(	B-X
ALP	B-X
,	B-X
bone-specific	B-X
ALP	B-X
[	B-X
BAP	B-X
]	B-X
,	B-X
and	B-X
osteocalcin	B-X
[	B-X
OC	B-X
]	B-X
)	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
serum	B-X
samples	B-X
from	B-X
10	B-X
patients	B-X
in	B-X
each	B-X
group	B-X
pre-	B-X
and	B-X
postoperatively	B-X
.	B-X
In	B-X
the	B-X
distraction	B-X
group	B-X
,	B-X
a	B-X
significant	B-X
postoperative	B-X
increase	B-X
in	B-X
MMP-1	B-X
,	B-X
bFGF	B-X
,	B-X
ALP	B-X
,	B-X
and	B-X
BAP	B-X
could	B-X
be	B-X
observed	B-X
during	B-X
the	B-X
lengthening	B-X
and	B-X
the	B-X
consolidation	B-X
period	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
levels	B-X
.	B-X
Osteotomy	B-X
fracture	B-X
healing	B-X
without	B-X
the	B-X
traction	B-X
stimulus	B-X
failed	B-X
to	B-X
induce	B-X
a	B-X
corresponding	B-X
increase	B-X
in	B-X
these	B-X
factors	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
comparison	B-X
of	B-X
both	B-X
groups	B-X
revealed	B-X
a	B-X
significantly	B-X
higher	B-X
increase	B-X
in	B-X
TGF-beta1	B-X
,	B-X
IGF-I	B-X
,	B-X
IGFBP-3	B-X
,	B-X
and	B-X
hGH	B-X
in	B-X
the	B-X
lengthening	B-X
group	B-X
during	B-X
the	B-X
distraction	B-X
period	B-X
,	B-X
indicating	B-X
key	B-X
regulatory	B-X
functions	B-X
in	B-X
mechanotransduction	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
changes	B-X
in	B-X
MMP-1	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
TGF-beta1	B-X
and	B-X
bFGF	B-X
)	B-X
,	B-X
and	B-X
hGH	B-X
,	B-X
respectively	B-X
,	B-X
correlated	B-X
significantly	B-X
during	B-X
the	B-X
lengthening	B-X
phase	B-X
,	B-X
indicating	B-X
common	B-X
regulatory	B-X
pathways	B-X
for	B-X
these	B-X
factors	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
.	B-X
Significant	B-X
correlation	B-X
between	B-X
the	B-X
osteoblastic	B-X
marker	B-X
BAP	B-X
,	B-X
TGF-beta1	B-X
,	B-X
and	B-X
bFGF	B-X
suggests	B-X
strain-activated	B-X
osteoblastic	B-X
cells	B-X
as	B-X
a	B-X
major	B-X
source	B-X
of	B-X
systemically	B-X
increased	B-X
bone	B-X
growth	B-X
factors	B-X
during	B-X
callus	B-X
distraction	B-X
.	B-X
The	B-X
systemic	B-X
increase	B-X
in	B-X
bFGF	B-X
and	B-X
MMP-1	B-X
might	B-X
reflect	B-X
an	B-X
increased	B-X
local	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
during	B-X
distraction	B-X
osteogenesis	B-X
.	B-X

The	O
time	O
courses	O
of	O
changes	O
in	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
bone	O
growth	O
factors	O
(	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	I-Gene_or_gene_product
and	O
bFGF	B-Gene_or_gene_product
)	O
,	O
and	O
hGH	B-Gene_or_gene_product
,	O
respectively	O
,	O
correlated	O
significantly	O
during	O
the	O
lengthening	O
phase	O
,	O
indicating	O
common	O
regulatory	O
pathways	O
for	O
these	O
factors	O
in	O
distraction	O
osteogenesis	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
systemic	B-X
biochemical	B-X
regulation	B-X
of	B-X
fracture	B-X
healing	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
compared	B-X
with	B-X
rigid	B-X
osteotomy	B-X
in	B-X
a	B-X
prospective	B-X
in	B-X
vivo	B-X
study	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
further	B-X
clarify	B-X
the	B-X
influence	B-X
of	B-X
mechanical	B-X
strain	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
bone	B-X
formation	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
insulin-like	B-X
growth	B-X
factor	B-X
[	B-X
IGF	B-X
]	B-X
I	B-X
,	B-X
IGF	B-X
binding	B-X
protein	B-X
[	B-X
IGFBP	B-X
]	B-X
3	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
[	B-X
TGF	B-X
]	B-X
beta1	B-X
,	B-X
and	B-X
basic	B-X
FGF	B-X
[	B-X
bFGF	B-X
]	B-X
)	B-X
,	B-X
bone	B-X
matrix	B-X
degrading	B-X
enzymes	B-X
(	B-X
matrix-metalloproteinases	B-X
[	B-X
MMPs	B-X
]	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
)	B-X
,	B-X
human	B-X
growth	B-X
hormone	B-X
(	B-X
hGH	B-X
)	B-X
,	B-X
and	B-X
bone	B-X
formation	B-X
markers	B-X
(	B-X
ALP	B-X
,	B-X
bone-specific	B-X
ALP	B-X
[	B-X
BAP	B-X
]	B-X
,	B-X
and	B-X
osteocalcin	B-X
[	B-X
OC	B-X
]	B-X
)	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
serum	B-X
samples	B-X
from	B-X
10	B-X
patients	B-X
in	B-X
each	B-X
group	B-X
pre-	B-X
and	B-X
postoperatively	B-X
.	B-X
In	B-X
the	B-X
distraction	B-X
group	B-X
,	B-X
a	B-X
significant	B-X
postoperative	B-X
increase	B-X
in	B-X
MMP-1	B-X
,	B-X
bFGF	B-X
,	B-X
ALP	B-X
,	B-X
and	B-X
BAP	B-X
could	B-X
be	B-X
observed	B-X
during	B-X
the	B-X
lengthening	B-X
and	B-X
the	B-X
consolidation	B-X
period	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
levels	B-X
.	B-X
Osteotomy	B-X
fracture	B-X
healing	B-X
without	B-X
the	B-X
traction	B-X
stimulus	B-X
failed	B-X
to	B-X
induce	B-X
a	B-X
corresponding	B-X
increase	B-X
in	B-X
these	B-X
factors	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
comparison	B-X
of	B-X
both	B-X
groups	B-X
revealed	B-X
a	B-X
significantly	B-X
higher	B-X
increase	B-X
in	B-X
TGF-beta1	B-X
,	B-X
IGF-I	B-X
,	B-X
IGFBP-3	B-X
,	B-X
and	B-X
hGH	B-X
in	B-X
the	B-X
lengthening	B-X
group	B-X
during	B-X
the	B-X
distraction	B-X
period	B-X
,	B-X
indicating	B-X
key	B-X
regulatory	B-X
functions	B-X
in	B-X
mechanotransduction	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
changes	B-X
in	B-X
MMP-1	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
TGF-beta1	B-X
and	B-X
bFGF	B-X
)	B-X
,	B-X
and	B-X
hGH	B-X
,	B-X
respectively	B-X
,	B-X
correlated	B-X
significantly	B-X
during	B-X
the	B-X
lengthening	B-X
phase	B-X
,	B-X
indicating	B-X
common	B-X
regulatory	B-X
pathways	B-X
for	B-X
these	B-X
factors	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
.	B-X
Significant	B-X
correlation	B-X
between	B-X
the	B-X
osteoblastic	B-X
marker	B-X
BAP	B-X
,	B-X
TGF-beta1	B-X
,	B-X
and	B-X
bFGF	B-X
suggests	B-X
strain-activated	B-X
osteoblastic	B-X
cells	B-X
as	B-X
a	B-X
major	B-X
source	B-X
of	B-X
systemically	B-X
increased	B-X
bone	B-X
growth	B-X
factors	B-X
during	B-X
callus	B-X
distraction	B-X
.	B-X
The	B-X
systemic	B-X
increase	B-X
in	B-X
bFGF	B-X
and	B-X
MMP-1	B-X
might	B-X
reflect	B-X
an	B-X
increased	B-X
local	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
during	B-X
distraction	B-X
osteogenesis	B-X
.	B-X

Significant	O
correlation	O
between	O
the	O
osteoblastic	O
marker	O
BAP	B-Gene_or_gene_product
,	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	I-Gene_or_gene_product
,	O
and	O
bFGF	B-Gene_or_gene_product
suggests	O
strain	O
-	O
activated	O
osteoblastic	O
cells	O
as	O
a	O
major	O
source	O
of	O
systemically	O
increased	O
bone	O
growth	O
factors	O
during	O
callus	O
distraction	O
.	O

The	O
systemic	O
increase	O
in	O
bFGF	B-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
might	O
reflect	O
an	O
increased	O
local	O
stimulation	O
of	O
angiogenesis	O
during	O
distraction	O
osteogenesis	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
systemic	B-X
biochemical	B-X
regulation	B-X
of	B-X
fracture	B-X
healing	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
compared	B-X
with	B-X
rigid	B-X
osteotomy	B-X
in	B-X
a	B-X
prospective	B-X
in	B-X
vivo	B-X
study	B-X
in	B-X
humans	B-X
.	B-X
To	B-X
further	B-X
clarify	B-X
the	B-X
influence	B-X
of	B-X
mechanical	B-X
strain	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
bone	B-X
formation	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
insulin-like	B-X
growth	B-X
factor	B-X
[	B-X
IGF	B-X
]	B-X
I	B-X
,	B-X
IGF	B-X
binding	B-X
protein	B-X
[	B-X
IGFBP	B-X
]	B-X
3	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
[	B-X
TGF	B-X
]	B-X
beta1	B-X
,	B-X
and	B-X
basic	B-X
FGF	B-X
[	B-X
bFGF	B-X
]	B-X
)	B-X
,	B-X
bone	B-X
matrix	B-X
degrading	B-X
enzymes	B-X
(	B-X
matrix-metalloproteinases	B-X
[	B-X
MMPs	B-X
]	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
)	B-X
,	B-X
human	B-X
growth	B-X
hormone	B-X
(	B-X
hGH	B-X
)	B-X
,	B-X
and	B-X
bone	B-X
formation	B-X
markers	B-X
(	B-X
ALP	B-X
,	B-X
bone-specific	B-X
ALP	B-X
[	B-X
BAP	B-X
]	B-X
,	B-X
and	B-X
osteocalcin	B-X
[	B-X
OC	B-X
]	B-X
)	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
serum	B-X
samples	B-X
from	B-X
10	B-X
patients	B-X
in	B-X
each	B-X
group	B-X
pre-	B-X
and	B-X
postoperatively	B-X
.	B-X
In	B-X
the	B-X
distraction	B-X
group	B-X
,	B-X
a	B-X
significant	B-X
postoperative	B-X
increase	B-X
in	B-X
MMP-1	B-X
,	B-X
bFGF	B-X
,	B-X
ALP	B-X
,	B-X
and	B-X
BAP	B-X
could	B-X
be	B-X
observed	B-X
during	B-X
the	B-X
lengthening	B-X
and	B-X
the	B-X
consolidation	B-X
period	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
levels	B-X
.	B-X
Osteotomy	B-X
fracture	B-X
healing	B-X
without	B-X
the	B-X
traction	B-X
stimulus	B-X
failed	B-X
to	B-X
induce	B-X
a	B-X
corresponding	B-X
increase	B-X
in	B-X
these	B-X
factors	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
comparison	B-X
of	B-X
both	B-X
groups	B-X
revealed	B-X
a	B-X
significantly	B-X
higher	B-X
increase	B-X
in	B-X
TGF-beta1	B-X
,	B-X
IGF-I	B-X
,	B-X
IGFBP-3	B-X
,	B-X
and	B-X
hGH	B-X
in	B-X
the	B-X
lengthening	B-X
group	B-X
during	B-X
the	B-X
distraction	B-X
period	B-X
,	B-X
indicating	B-X
key	B-X
regulatory	B-X
functions	B-X
in	B-X
mechanotransduction	B-X
.	B-X
The	B-X
time	B-X
courses	B-X
of	B-X
changes	B-X
in	B-X
MMP-1	B-X
,	B-X
bone	B-X
growth	B-X
factors	B-X
(	B-X
TGF-beta1	B-X
and	B-X
bFGF	B-X
)	B-X
,	B-X
and	B-X
hGH	B-X
,	B-X
respectively	B-X
,	B-X
correlated	B-X
significantly	B-X
during	B-X
the	B-X
lengthening	B-X
phase	B-X
,	B-X
indicating	B-X
common	B-X
regulatory	B-X
pathways	B-X
for	B-X
these	B-X
factors	B-X
in	B-X
distraction	B-X
osteogenesis	B-X
.	B-X
Significant	B-X
correlation	B-X
between	B-X
the	B-X
osteoblastic	B-X
marker	B-X
BAP	B-X
,	B-X
TGF-beta1	B-X
,	B-X
and	B-X
bFGF	B-X
suggests	B-X
strain-activated	B-X
osteoblastic	B-X
cells	B-X
as	B-X
a	B-X
major	B-X
source	B-X
of	B-X
systemically	B-X
increased	B-X
bone	B-X
growth	B-X
factors	B-X
during	B-X
callus	B-X
distraction	B-X
.	B-X
The	B-X
systemic	B-X
increase	B-X
in	B-X
bFGF	B-X
and	B-X
MMP-1	B-X
might	B-X
reflect	B-X
an	B-X
increased	B-X
local	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
during	B-X
distraction	B-X
osteogenesis	B-X
.	B-X

Human	O
papillomavirus	O
oncoprotein	O
E6	B-Gene_or_gene_product
inactivates	O
the	O
transcriptional	O
coactivator	O
human	O
ADA3	B-Gene_or_gene_product
.	O
<EOS>	B-X
High-risk	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPVs	B-X
)	B-X
are	B-X
associated	B-X
with	B-X
carcinomas	B-X
of	B-X
the	B-X
cervix	B-X
and	B-X
other	B-X
genital	B-X
tumors	B-X
.	B-X
The	B-X
HPV	B-X
oncoprotein	B-X
E6	B-X
is	B-X
essential	B-X
for	B-X
oncogenic	B-X
transformation	B-X
.	B-X
We	B-X
identify	B-X
here	B-X
hADA3	B-X
,	B-X
human	B-X
homologue	B-X
of	B-X
the	B-X
yeast	B-X
transcriptional	B-X
coactivator	B-X
yADA3	B-X
,	B-X
as	B-X
a	B-X
novel	B-X
E6-interacting	B-X
protein	B-X
and	B-X
a	B-X
target	B-X
of	B-X
E6-induced	B-X
degradation	B-X
.	B-X
hADA3	B-X
binds	B-X
selectively	B-X
to	B-X
the	B-X
high-risk	B-X
HPV	B-X
E6	B-X
proteins	B-X
and	B-X
only	B-X
to	B-X
immortalization-competent	B-X
E6	B-X
mutants	B-X
.	B-X
hADA3	B-X
functions	B-X
as	B-X
a	B-X
coactivator	B-X
for	B-X
p53-mediated	B-X
transactivation	B-X
by	B-X
stabilizing	B-X
p53	B-X
protein	B-X
.	B-X
Notably	B-X
,	B-X
three	B-X
immortalizing	B-X
E6	B-X
mutants	B-X
that	B-X
do	B-X
not	B-X
induce	B-X
direct	B-X
p53	B-X
degradation	B-X
but	B-X
do	B-X
interact	B-X
with	B-X
hADA3	B-X
induced	B-X
the	B-X
abrogation	B-X
of	B-X
p53-mediated	B-X
transactivation	B-X
and	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
arrest	B-X
after	B-X
DNA	B-X
damage	B-X
,	B-X
comparable	B-X
to	B-X
wild-type	B-X
E6	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
novel	B-X
strategy	B-X
of	B-X
HPV	B-X
E6-induced	B-X
loss	B-X
of	B-X
p53	B-X
function	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
direct	B-X
p53	B-X
degradation	B-X
.	B-X
Given	B-X
the	B-X
likely	B-X
role	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
hADA3	B-X
in	B-X
multiple	B-X
coactivator	B-X
complexes	B-X
,	B-X
inactivation	B-X
of	B-X
its	B-X
function	B-X
may	B-X
allow	B-X
E6	B-X
to	B-X
perturb	B-X
numerous	B-X
cellular	B-X
pathways	B-X
during	B-X
HPV	B-X
oncogenesis	B-X
.	B-X

High	O
-	O
risk	O
human	O
papillomaviruses	O
(	O
HPVs	O
)	O
are	O
associated	O
with	O
carcinomas	O
of	O
the	O
cervix	O
and	O
other	O
genital	O
tumors	O
.	O
<EOS>	B-X
Human	B-X
papillomaviruses	B-X
(	B-X
HPVs	B-X
)	B-X
are	B-X
a	B-X
necessary	B-X
cause	B-X
of	B-X
carcinoma	B-X
of	B-X
the	B-X
cervix	B-X
and	B-X
other	B-X
mucosal	B-X
epithelia	B-X
.	B-X
Key	B-X
events	B-X
in	B-X
high-risk	B-X
HPV	B-X
(	B-X
HRHPV	B-X
)	B-X
-associated	B-X
neoplastic	B-X
progression	B-X
include	B-X
persistent	B-X
infection	B-X
,	B-X
deregulated	B-X
expression	B-X
of	B-X
virus	B-X
early	B-X
genes	B-X
in	B-X
basal	B-X
epithelial	B-X
cells	B-X
and	B-X
genomic	B-X
instability	B-X
causing	B-X
secondary	B-X
host	B-X
genomic	B-X
imbalances	B-X
.	B-X
Integration	B-X
of	B-X
virus	B-X
DNA	B-X
into	B-X
host	B-X
chromosomes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
cervical	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
(	B-X
SCCs	B-X
)	B-X
,	B-X
although	B-X
in	B-X
â¼15	B-X
%	B-X
of	B-X
cases	B-X
the	B-X
virus	B-X
remains	B-X
extrachromosomal	B-X
(	B-X
episomal	B-X
)	B-X
.	B-X
New	B-X
approaches	B-X
to	B-X
treating	B-X
HRHPV-associated	B-X
mucosal	B-X
neoplasia	B-X
include	B-X
knockout	B-X
of	B-X
integrated	B-X
HRHPV	B-X
DNA	B-X
,	B-X
depletion	B-X
of	B-X
virus	B-X
transcripts	B-X
and	B-X
inhibition	B-X
of	B-X
virus	B-X
early	B-X
gene	B-X
transcription	B-X
through	B-X
targeting	B-X
or	B-X
use	B-X
of	B-X
epigenetic	B-X
modifiers	B-X
.	B-X

The	O
HPV	O
oncoprotein	O
E6	B-Gene_or_gene_product
is	O
essential	O
for	O
oncogenic	O
transformation	O
.	O
<EOS>	B-X
Infection	B-X
of	B-X
high-risk	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPVs	B-X
)	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
carcinoma	B-X
.	B-X
HPV	B-X
infections	B-X
are	B-X
also	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
other	B-X
types	B-X
of	B-X
carcinomas	B-X
.	B-X
Chronic	B-X
or	B-X
persistent	B-X
infection	B-X
of	B-X
HPV	B-X
is	B-X
essential	B-X
but	B-X
HPV	B-X
alone	B-X
is	B-X
inadequate	B-X
,	B-X
additional	B-X
endogenous	B-X
or	B-X
exogenous	B-X
cues	B-X
are	B-X
needed	B-X
along	B-X
with	B-X
HPV	B-X
to	B-X
induce	B-X
cervical	B-X
carcinogenesis	B-X
.	B-X
The	B-X
strategies	B-X
that	B-X
high-risk	B-X
HPVs	B-X
have	B-X
developed	B-X
in	B-X
differentiating	B-X
epithelial	B-X
cells	B-X
to	B-X
reach	B-X
a	B-X
DNA-synthesis	B-X
competent	B-X
state	B-X
leading	B-X
to	B-X
tumorigenic	B-X
transformation	B-X
are	B-X
basically	B-X
due	B-X
to	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
diverse	B-X
cellular	B-X
regulatory	B-X
or	B-X
signaling	B-X
pathways	B-X
that	B-X
are	B-X
targeted	B-X
by	B-X
them	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
Wnt/Î²-catenin/Notch	B-X
and	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/protein	B-X
kinase	B-X
B	B-X
(	B-X
Akt	B-X
)	B-X
pathways	B-X
are	B-X
deregulated	B-X
in	B-X
various	B-X
cancers	B-X
,	B-X
and	B-X
have	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
HPV-induced	B-X
cancers	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
research	B-X
on	B-X
treatment	B-X
strategies	B-X
has	B-X
proposed	B-X
several	B-X
options	B-X
,	B-X
including	B-X
the	B-X
role	B-X
of	B-X
HPV	B-X
E5	B-X
,	B-X
E6	B-X
,	B-X
and	B-X
E7	B-X
oncogenes	B-X
,	B-X
which	B-X
are	B-X
retained	B-X
and	B-X
overexpressed	B-X
in	B-X
most	B-X
of	B-X
the	B-X
cervical	B-X
cancers	B-X
and	B-X
whose	B-X
respective	B-X
oncoproteins	B-X
are	B-X
critical	B-X
to	B-X
the	B-X
induction	B-X
and	B-X
maintenance	B-X
of	B-X
the	B-X
malignant	B-X
phenotype	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
during	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
,	B-X
a	B-X
cascade	B-X
of	B-X
abnormal	B-X
events	B-X
is	B-X
induced	B-X
,	B-X
including	B-X
disruption	B-X
of	B-X
cell	B-X
cycle	B-X
control	B-X
,	B-X
perturbation	B-X
of	B-X
antitumor	B-X
immune	B-X
response	B-X
,	B-X
alteration	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
deregulation	B-X
of	B-X
microRNA	B-X
and	B-X
cancer	B-X
stem	B-X
cell	B-X
and	B-X
stemness	B-X
related	B-X
markers	B-X
expression	B-X
could	B-X
serve	B-X
as	B-X
novel	B-X
molecular	B-X
targets	B-X
for	B-X
reliable	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
HPV-positive	B-X
cancers	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
article	B-X
,	B-X
we	B-X
discuss	B-X
molecular	B-X
signaling	B-X
pathways	B-X
activated	B-X
by	B-X
HPV	B-X
and	B-X
potential	B-X
targets	B-X
or	B-X
biomarkers	B-X
for	B-X
early	B-X
detection	B-X
or	B-X
prevention	B-X
and	B-X
the	B-X
treatment	B-X
of	B-X
HPV-associated	B-X
cancers	B-X
.	B-X

We	O
identify	O
here	O
hADA3	B-Gene_or_gene_product
,	O
human	O
homologue	O
of	O
the	O
yeast	O
transcriptional	O
coactivator	O
yADA3	B-Gene_or_gene_product
,	O
as	O
a	O
novel	O
E6	B-Gene_or_gene_product
-	O
interacting	O
protein	O
and	O
a	O
target	O
of	O
E6	B-Gene_or_gene_product
-	O
induced	O
degradation	O
.	O

hADA3	B-Gene_or_gene_product
binds	O
selectively	O
to	O
the	O
high	O
-	O
risk	O
HPV	O
E6	B-Gene_or_gene_product
proteins	O
and	O
only	O
to	O
immortalization	O
-	O
competent	O
E6	B-Gene_or_gene_product
mutants	O
.	O

hADA3	B-Gene_or_gene_product
functions	O
as	O
a	O
coactivator	O
for	O
p53	B-Gene_or_gene_product
-	O
mediated	O
transactivation	O
by	O
stabilizing	O
p53	B-Gene_or_gene_product
protein	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
tumor	B-X
suppressor	B-X
protein	B-X
functions	B-X
as	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
genotoxic	B-X
stress	B-X
response	B-X
by	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
effector	B-X
gene	B-X
products	B-X
that	B-X
control	B-X
the	B-X
fate	B-X
of	B-X
a	B-X
cell	B-X
following	B-X
DNA	B-X
damage	B-X
.	B-X
Unstressed	B-X
cells	B-X
maintain	B-X
p53	B-X
at	B-X
low	B-X
levels	B-X
through	B-X
regulated	B-X
degradation	B-X
,	B-X
and	B-X
p53	B-X
levels	B-X
and	B-X
activity	B-X
are	B-X
rapidly	B-X
elevated	B-X
upon	B-X
genotoxic	B-X
stress	B-X
.	B-X
Biochemical	B-X
mechanisms	B-X
that	B-X
control	B-X
the	B-X
levels	B-X
and	B-X
activity	B-X
of	B-X
p53	B-X
are	B-X
therefore	B-X
of	B-X
great	B-X
interest	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
recently	B-X
identified	B-X
hAda3	B-X
(	B-X
human	B-X
homologue	B-X
of	B-X
yeast	B-X
alteration/deficiency	B-X
in	B-X
activation	B-X
3	B-X
)	B-X
as	B-X
a	B-X
p53-interacting	B-X
protein	B-X
and	B-X
enhancer	B-X
of	B-X
p53	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
endogenous	B-X
levels	B-X
of	B-X
p53	B-X
and	B-X
Ada3	B-X
interact	B-X
with	B-X
each	B-X
other	B-X
,	B-X
and	B-X
by	B-X
using	B-X
inducible	B-X
overexpression	B-X
and	B-X
short	B-X
hairpin	B-X
RNA-mediated	B-X
knockdown	B-X
strategies	B-X
we	B-X
demonstrate	B-X
that	B-X
hAda3	B-X
stabilizes	B-X
p53	B-X
protein	B-X
by	B-X
promoting	B-X
its	B-X
acetylation	B-X
.	B-X
Use	B-X
of	B-X
a	B-X
p53	B-X
mutant	B-X
with	B-X
mutations	B-X
of	B-X
known	B-X
p300/CREB-binding	B-X
protein	B-X
acetylation	B-X
sites	B-X
demonstrated	B-X
that	B-X
hAda3-dependent	B-X
acetylation	B-X
is	B-X
required	B-X
for	B-X
increase	B-X
in	B-X
p53	B-X
stability	B-X
and	B-X
target	B-X
gene	B-X
induction	B-X
.	B-X
Importantly	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
endogenous	B-X
hAda3	B-X
is	B-X
essential	B-X
for	B-X
DNA	B-X
damage-induced	B-X
acetylation	B-X
and	B-X
stabilization	B-X
of	B-X
p53	B-X
as	B-X
well	B-X
as	B-X
p53	B-X
target	B-X
gene	B-X
induction	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
establish	B-X
hAda3	B-X
,	B-X
a	B-X
component	B-X
of	B-X
coactivator	B-X
complexes	B-X
that	B-X
include	B-X
histone	B-X
acetyltransferase	B-X
p300/CREB-binding	B-X
protein	B-X
,	B-X
as	B-X
a	B-X
critical	B-X
mediator	B-X
of	B-X
acetylation-dependent	B-X
stabilization	B-X
and	B-X
activation	B-X
of	B-X
p53	B-X
upon	B-X
genotoxic	B-X
stress	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X

Notably	O
,	O
three	O
immortalizing	O
E6	B-Gene_or_gene_product
mutants	O
that	O
do	O
not	O
induce	O
direct	O
p53	B-Gene_or_gene_product
degradation	O
but	O
do	O
interact	O
with	O
hADA3	B-Gene_or_gene_product
induced	O
the	O
abrogation	O
of	O
p53	B-Gene_or_gene_product
-	O
mediated	O
transactivation	O
and	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
arrest	O
after	O
DNA	O
damage	O
,	O
comparable	O
to	O
wild	O
-	O
type	O
E6	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
HPV	B-X
oncoprotein	B-X
E6	B-X
is	B-X
essential	B-X
for	B-X
oncogenic	B-X
transformation	B-X
.	B-X
We	B-X
identify	B-X
here	B-X
hADA3	B-X
,	B-X
human	B-X
homologue	B-X
of	B-X
the	B-X
yeast	B-X
transcriptional	B-X
coactivator	B-X
yADA3	B-X
,	B-X
as	B-X
a	B-X
novel	B-X
E6-interacting	B-X
protein	B-X
and	B-X
a	B-X
target	B-X
of	B-X
E6-induced	B-X
degradation	B-X
.	B-X
hADA3	B-X
binds	B-X
selectively	B-X
to	B-X
the	B-X
high-risk	B-X
HPV	B-X
E6	B-X
proteins	B-X
and	B-X
only	B-X
to	B-X
immortalization-competent	B-X
E6	B-X
mutants	B-X
.	B-X
hADA3	B-X
functions	B-X
as	B-X
a	B-X
coactivator	B-X
for	B-X
p53-mediated	B-X
transactivation	B-X
by	B-X
stabilizing	B-X
p53	B-X
protein	B-X
.	B-X
Notably	B-X
,	B-X
three	B-X
immortalizing	B-X
E6	B-X
mutants	B-X
that	B-X
do	B-X
not	B-X
induce	B-X
direct	B-X
p53	B-X
degradation	B-X
but	B-X
do	B-X
interact	B-X
with	B-X
hADA3	B-X
induced	B-X
the	B-X
abrogation	B-X
of	B-X
p53-mediated	B-X
transactivation	B-X
and	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
arrest	B-X
after	B-X
DNA	B-X
damage	B-X
,	B-X
comparable	B-X
to	B-X
wild-type	B-X
E6	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
novel	B-X
strategy	B-X
of	B-X
HPV	B-X
E6-induced	B-X
loss	B-X
of	B-X
p53	B-X
function	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
direct	B-X
p53	B-X
degradation	B-X
.	B-X
Given	B-X
the	B-X
likely	B-X
role	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
hADA3	B-X
in	B-X
multiple	B-X
coactivator	B-X
complexes	B-X
,	B-X
inactivation	B-X
of	B-X
its	B-X
function	B-X
may	B-X
allow	B-X
E6	B-X
to	B-X
perturb	B-X
numerous	B-X
cellular	B-X
pathways	B-X
during	B-X
HPV	B-X
oncogenesis	B-X
.	B-X

These	O
findings	O
reveal	O
a	O
novel	O
strategy	O
of	O
HPV	O
E6	B-Gene_or_gene_product
-	O
induced	O
loss	O
of	O
p53	B-Gene_or_gene_product
function	O
that	O
is	O
independent	O
of	O
direct	O
p53	B-Gene_or_gene_product
degradation	O
.	O
<EOS>	B-X
High-risk	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPVs	B-X
)	B-X
are	B-X
associated	B-X
with	B-X
carcinomas	B-X
of	B-X
the	B-X
cervix	B-X
and	B-X
other	B-X
genital	B-X
tumors	B-X
.	B-X
The	B-X
HPV	B-X
oncoprotein	B-X
E6	B-X
is	B-X
essential	B-X
for	B-X
oncogenic	B-X
transformation	B-X
.	B-X
We	B-X
identify	B-X
here	B-X
hADA3	B-X
,	B-X
human	B-X
homologue	B-X
of	B-X
the	B-X
yeast	B-X
transcriptional	B-X
coactivator	B-X
yADA3	B-X
,	B-X
as	B-X
a	B-X
novel	B-X
E6-interacting	B-X
protein	B-X
and	B-X
a	B-X
target	B-X
of	B-X
E6-induced	B-X
degradation	B-X
.	B-X
hADA3	B-X
binds	B-X
selectively	B-X
to	B-X
the	B-X
high-risk	B-X
HPV	B-X
E6	B-X
proteins	B-X
and	B-X
only	B-X
to	B-X
immortalization-competent	B-X
E6	B-X
mutants	B-X
.	B-X
hADA3	B-X
functions	B-X
as	B-X
a	B-X
coactivator	B-X
for	B-X
p53-mediated	B-X
transactivation	B-X
by	B-X
stabilizing	B-X
p53	B-X
protein	B-X
.	B-X
Notably	B-X
,	B-X
three	B-X
immortalizing	B-X
E6	B-X
mutants	B-X
that	B-X
do	B-X
not	B-X
induce	B-X
direct	B-X
p53	B-X
degradation	B-X
but	B-X
do	B-X
interact	B-X
with	B-X
hADA3	B-X
induced	B-X
the	B-X
abrogation	B-X
of	B-X
p53-mediated	B-X
transactivation	B-X
and	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
arrest	B-X
after	B-X
DNA	B-X
damage	B-X
,	B-X
comparable	B-X
to	B-X
wild-type	B-X
E6	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
novel	B-X
strategy	B-X
of	B-X
HPV	B-X
E6-induced	B-X
loss	B-X
of	B-X
p53	B-X
function	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
direct	B-X
p53	B-X
degradation	B-X
.	B-X
Given	B-X
the	B-X
likely	B-X
role	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
hADA3	B-X
in	B-X
multiple	B-X
coactivator	B-X
complexes	B-X
,	B-X
inactivation	B-X
of	B-X
its	B-X
function	B-X
may	B-X
allow	B-X
E6	B-X
to	B-X
perturb	B-X
numerous	B-X
cellular	B-X
pathways	B-X
during	B-X
HPV	B-X
oncogenesis	B-X
.	B-X

Given	O
the	O
likely	O
role	O
of	O
the	O
evolutionarily	O
conserved	O
hADA3	B-Gene_or_gene_product
in	O
multiple	O
coactivator	O
complexes	O
,	O
inactivation	O
of	O
its	O
function	O
may	O
allow	O
E6	B-Gene_or_gene_product
to	O
perturb	O
numerous	O
cellular	O
pathways	O
during	O
HPV	O
oncogenesis	O
.	O
<EOS>	B-X
High-risk	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPVs	B-X
)	B-X
are	B-X
associated	B-X
with	B-X
carcinomas	B-X
of	B-X
the	B-X
cervix	B-X
and	B-X
other	B-X
genital	B-X
tumors	B-X
.	B-X
The	B-X
HPV	B-X
oncoprotein	B-X
E6	B-X
is	B-X
essential	B-X
for	B-X
oncogenic	B-X
transformation	B-X
.	B-X
We	B-X
identify	B-X
here	B-X
hADA3	B-X
,	B-X
human	B-X
homologue	B-X
of	B-X
the	B-X
yeast	B-X
transcriptional	B-X
coactivator	B-X
yADA3	B-X
,	B-X
as	B-X
a	B-X
novel	B-X
E6-interacting	B-X
protein	B-X
and	B-X
a	B-X
target	B-X
of	B-X
E6-induced	B-X
degradation	B-X
.	B-X
hADA3	B-X
binds	B-X
selectively	B-X
to	B-X
the	B-X
high-risk	B-X
HPV	B-X
E6	B-X
proteins	B-X
and	B-X
only	B-X
to	B-X
immortalization-competent	B-X
E6	B-X
mutants	B-X
.	B-X
hADA3	B-X
functions	B-X
as	B-X
a	B-X
coactivator	B-X
for	B-X
p53-mediated	B-X
transactivation	B-X
by	B-X
stabilizing	B-X
p53	B-X
protein	B-X
.	B-X
Notably	B-X
,	B-X
three	B-X
immortalizing	B-X
E6	B-X
mutants	B-X
that	B-X
do	B-X
not	B-X
induce	B-X
direct	B-X
p53	B-X
degradation	B-X
but	B-X
do	B-X
interact	B-X
with	B-X
hADA3	B-X
induced	B-X
the	B-X
abrogation	B-X
of	B-X
p53-mediated	B-X
transactivation	B-X
and	B-X
G	B-X
(	B-X
1	B-X
)	B-X
cell	B-X
cycle	B-X
arrest	B-X
after	B-X
DNA	B-X
damage	B-X
,	B-X
comparable	B-X
to	B-X
wild-type	B-X
E6	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
novel	B-X
strategy	B-X
of	B-X
HPV	B-X
E6-induced	B-X
loss	B-X
of	B-X
p53	B-X
function	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
direct	B-X
p53	B-X
degradation	B-X
.	B-X
Given	B-X
the	B-X
likely	B-X
role	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
hADA3	B-X
in	B-X
multiple	B-X
coactivator	B-X
complexes	B-X
,	B-X
inactivation	B-X
of	B-X
its	B-X
function	B-X
may	B-X
allow	B-X
E6	B-X
to	B-X
perturb	B-X
numerous	B-X
cellular	B-X
pathways	B-X
during	B-X
HPV	B-X
oncogenesis	B-X
.	B-X

Immunohistochemical	O
staining	O
for	O
thyroid	B-Gene_or_gene_product
transcription	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
:	O
a	O
helpful	O
aid	O
in	O
discerning	O
primary	O
site	O
of	O
tumor	O
origin	O
in	O
patients	O
with	O
brain	O
metastases	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Metastatic	O
carcinoma	O
of	O
unknown	O
primary	O
origin	O
is	O
a	O
perplexing	O
but	O
common	O
problem	O
,	O
accounting	O
for	O
up	O
to	O
10	O
%	O
to	O
15	O
%	O
of	O
all	O
solid	O
tumors	O
at	O
presentation	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Many	O
of	O
these	O
metastases	O
presumably	O
arise	O
from	O
primary	O
lung	O
carcinomas	O
,	O
but	O
the	O
morphologic	O
features	O
and	O
immunohistochemical	O
profile	O
of	O
lung	O
cancer	O
is	O
often	O
too	O
nonspecific	O
to	O
permit	O
unequivocal	O
confirmation	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Thyroid	B-Gene_or_gene_product
transcription	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
is	O
expressed	O
in	O
lung	O
adenocarcinomas	O
and	O
thyroid	O
carcinomas	O
but	O
not	O
in	O
adenocarcinomas	O
arising	O
from	O
other	O
sites	O
.	O
<EOS>	B-X
Somatic	B-X
mutations	B-X
in	B-X
SMARCA4	B-X
(	B-X
SWI/SNF-related	B-X
,	B-X
matrix-associated	B-X
,	B-X
actin-dependent	B-X
regulator	B-X
of	B-X
chromatin	B-X
,	B-X
subfamily	B-X
A	B-X
,	B-X
member	B-X
4	B-X
)	B-X
gene	B-X
and/or	B-X
BRG1	B-X
(	B-X
Brahma-related	B-X
gene	B-X
1	B-X
)	B-X
loss	B-X
identifies	B-X
a	B-X
subset	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinomas	B-X
(	B-X
NSCLCs	B-X
)	B-X
lacking	B-X
alterations	B-X
in	B-X
EGFR	B-X
(	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
)	B-X
,	B-X
ALK	B-X
(	B-X
anaplastic	B-X
lymphoma	B-X
kinase	B-X
)	B-X
,	B-X
and	B-X
ROS1	B-X
(	B-X
ROS	B-X
proto-oncogene	B-X
1	B-X
)	B-X
genes	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor	B-X
1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
a	B-X
prognostic	B-X
biomarker	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
;	B-X
however	B-X
,	B-X
TTF-1-positive	B-X
patients	B-X
also	B-X
display	B-X
more	B-X
favorable	B-X
factors	B-X
like	B-X
actionable	B-X
target	B-X
mutations	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TTF-1-negative	B-X
cancer	B-X
is	B-X
a	B-X
poorly	B-X
described	B-X
entity	B-X
.	B-X
We	B-X
performed	B-X
a	B-X
retrospective	B-X
study	B-X
to	B-X
characterize	B-X
a	B-X
TTF-1-negative	B-X
phenotype	B-X
and	B-X
to	B-X
evaluate	B-X
outcome	B-X
depending	B-X
on	B-X
the	B-X
chemotherapy	B-X
regimen	B-X
applied	B-X
in	B-X
the	B-X
EGFR/ALK-negative	B-X
population	B-X
.	B-X

For	O
patients	O
with	O
adenocarcinomas	O
in	O
the	O
lung	O
,	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
staining	O
is	O
now	O
routinely	O
used	O
to	O
distinguish	O
a	O
primary	O
lung	O
cancer	O
from	O
a	O
lung	O
metastasis	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Along	O
these	O
same	O
lines	O
,	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
staining	O
might	O
prove	O
useful	O
in	O
localizing	O
the	O
tumor	O
origin	O
of	O
adenocarcinomas	O
encountered	O
outside	O
of	O
the	O
lung	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

The	O
archival	O
surgical	O
pathology	O
files	O
of	O
The	O
Johns	O
Hopkins	O
Hospital	O
were	O
searched	O
for	O
cases	O
of	O
brain	O
metastases	O
biopsied	O
between	O
1990	O
and	O
2000	O
.	O

Tissue	O
blocks	O
were	O
obtained	O
and	O
immunoperoxidase	O
staining	O
was	O
performed	O
using	O
the	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
antibody	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
usefulness	B-X
of	B-X
thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
and	B-X
CDX-2	B-X
in	B-X
determining	B-X
the	B-X
primary	B-X
tumor	B-X
site	B-X
of	B-X
metastatic	B-X
adenocarcinomas	B-X
(	B-X
ACs	B-X
)	B-X
in	B-X
serous	B-X
effusions	B-X
.	B-X
Immunocytochemical	B-X
staining	B-X
(	B-X
ICC	B-X
)	B-X
is	B-X
often	B-X
limited	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
cell	B-X
blocks	B-X
that	B-X
contain	B-X
diagnostic	B-X
cells	B-X
or	B-X
by	B-X
the	B-X
unavailability	B-X
of	B-X
smear	B-X
materials	B-X
.	B-X
However	B-X
the	B-X
reliability	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
has	B-X
not	B-X
been	B-X
systematically	B-X
evaluated	B-X
.	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

The	O
medical	O
records	O
were	O
reviewed	O
independent	O
of	O
the	O
staining	O
results	O
to	O
determine	O
site	O
of	O
tumor	O
origin	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Seventy	O
-	O
five	O
patients	O
underwent	O
biopsies	O
of	O
carcinomas	O
metastatic	O
to	O
the	O
brain	O
.	O

At	O
the	O
time	O
of	O
brain	O
biopsy	O
,	O
the	O
primary	O
site	O
of	O
tumor	O
origin	O
was	O
known	O
in	O
45	O
cases	O
and	O
unknown	O
in	O
30	O
cases	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Ultimately	O
,	O
the	O
primary	O
site	O
was	O
established	O
on	O
clinical	O
and	O
radiographic	O
grounds	O
in	O
71	O
cases	O
(	O
95	O
%	O
)	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

These	O
included	O
40	O
(	O
56	O
%	O
)	O
metastases	O
from	O
a	O
primary	O
lung	O
carcinoma	O
and	O
31	O
(	O
44	O
%	O
)	O
metastases	O
from	O
some	O
nonpulmonary	O
carcinoma	O
.	O

TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
staining	O
was	O
present	O
in	O
31	O
of	O
the	O
40	O
(	O
78	O
%	O
)	O
metastatic	O
lung	O
carcinomas	O
,	O
but	O
in	O
only	O
1	O
of	O
the	O
31	O
(	O
3	O
%	O
)	O
metastatic	O
nonpulmonary	O
carcinomas	O
(	O
a	O
small	O
-	O
cell	O
carcinoma	O
of	O
the	O
sinonasal	O
tract	O
)	O
.	O

When	O
the	O
metastatic	O
lung	O
carcinomas	O
were	O
subtyped	O
,	O
TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
staining	O
was	O
noted	O
in	O
11	O
of	O
11	O
(	O
100	O
%	O
)	O
adenocarcinomas	O
,	O
in	O
6	O
of	O
7	O
(	O
86	O
%	O
)	O
small	O
-	O
cell	O
carcinomas	O
,	O
in	O
15	O
of	O
19	O
(	O
79	O
%	O
)	O
large	O
-	O
cell	O
carcinomas	O
,	O
and	O
in	O
none	O
of	O
3	O
(	O
0	O
%	O
)	O
squamous	O
cell	O
carcinomas	O
.	O

TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
staining	O
is	O
very	O
reliable	O
in	O
discerning	O
whether	O
a	O
brain	O
metastasis	O
has	O
arisen	O
from	O
a	O
pulmonary	O
or	O
nonpulmonary	O
site	O
,	O
particularly	O
when	O
dealing	O
with	O
adenocarcinomas	O
and	O
large	O
-	O
cell	O
carcinomas	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

TTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
immunohistochemistry	O
could	O
focus	O
the	O
search	O
for	O
the	O
primary	O
tumor	O
for	O
patients	O
presenting	O
with	O
brain	O
metastasis	O
as	O
the	O
initial	O
manifestation	O
.	O
<EOS>	B-X
Metastatic	B-X
carcinoma	B-X
of	B-X
unknown	B-X
primary	B-X
origin	B-X
is	B-X
a	B-X
perplexing	B-X
but	B-X
common	B-X
problem	B-X
,	B-X
accounting	B-X
for	B-X
up	B-X
to	B-X
10	B-X
%	B-X
to	B-X
15	B-X
%	B-X
of	B-X
all	B-X
solid	B-X
tumors	B-X
at	B-X
presentation	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
metastases	B-X
presumably	B-X
arise	B-X
from	B-X
primary	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
the	B-X
morphologic	B-X
features	B-X
and	B-X
immunohistochemical	B-X
profile	B-X
of	B-X
lung	B-X
cancer	B-X
is	B-X
often	B-X
too	B-X
nonspecific	B-X
to	B-X
permit	B-X
unequivocal	B-X
confirmation	B-X
.	B-X
Thyroid	B-X
transcription	B-X
factor-1	B-X
(	B-X
TTF-1	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
and	B-X
thyroid	B-X
carcinomas	B-X
but	B-X
not	B-X
in	B-X
adenocarcinomas	B-X
arising	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
For	B-X
patients	B-X
with	B-X
adenocarcinomas	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
TTF-1	B-X
staining	B-X
is	B-X
now	B-X
routinely	B-X
used	B-X
to	B-X
distinguish	B-X
a	B-X
primary	B-X
lung	B-X
cancer	B-X
from	B-X
a	B-X
lung	B-X
metastasis	B-X
.	B-X
Along	B-X
these	B-X
same	B-X
lines	B-X
,	B-X
TTF-1	B-X
staining	B-X
might	B-X
prove	B-X
useful	B-X
in	B-X
localizing	B-X
the	B-X
tumor	B-X
origin	B-X
of	B-X
adenocarcinomas	B-X
encountered	B-X
outside	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
The	B-X
archival	B-X
surgical	B-X
pathology	B-X
files	B-X
of	B-X
The	B-X
Johns	B-X
Hopkins	B-X
Hospital	B-X
were	B-X
searched	B-X
for	B-X
cases	B-X
of	B-X
brain	B-X
metastases	B-X
biopsied	B-X
between	B-X
1990	B-X
and	B-X
2000	B-X
.	B-X
Tissue	B-X
blocks	B-X
were	B-X
obtained	B-X
and	B-X
immunoperoxidase	B-X
staining	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
TTF-1	B-X
antibody	B-X
.	B-X
The	B-X
medical	B-X
records	B-X
were	B-X
reviewed	B-X
independent	B-X
of	B-X
the	B-X
staining	B-X
results	B-X
to	B-X
determine	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
.	B-X
Seventy-five	B-X
patients	B-X
underwent	B-X
biopsies	B-X
of	B-X
carcinomas	B-X
metastatic	B-X
to	B-X
the	B-X
brain	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
brain	B-X
biopsy	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
of	B-X
tumor	B-X
origin	B-X
was	B-X
known	B-X
in	B-X
45	B-X
cases	B-X
and	B-X
unknown	B-X
in	B-X
30	B-X
cases	B-X
.	B-X
Ultimately	B-X
,	B-X
the	B-X
primary	B-X
site	B-X
was	B-X
established	B-X
on	B-X
clinical	B-X
and	B-X
radiographic	B-X
grounds	B-X
in	B-X
71	B-X
cases	B-X
(	B-X
95	B-X
%	B-X
)	B-X
.	B-X
These	B-X
included	B-X
40	B-X
(	B-X
56	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
a	B-X
primary	B-X
lung	B-X
carcinoma	B-X
and	B-X
31	B-X
(	B-X
44	B-X
%	B-X
)	B-X
metastases	B-X
from	B-X
some	B-X
nonpulmonary	B-X
carcinoma	B-X
.	B-X
TTF-1	B-X
staining	B-X
was	B-X
present	B-X
in	B-X
31	B-X
of	B-X
the	B-X
40	B-X
(	B-X
78	B-X
%	B-X
)	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
,	B-X
but	B-X
in	B-X
only	B-X
1	B-X
of	B-X
the	B-X
31	B-X
(	B-X
3	B-X
%	B-X
)	B-X
metastatic	B-X
nonpulmonary	B-X
carcinomas	B-X
(	B-X
a	B-X
small-cell	B-X
carcinoma	B-X
of	B-X
the	B-X
sinonasal	B-X
tract	B-X
)	B-X
.	B-X
When	B-X
the	B-X
metastatic	B-X
lung	B-X
carcinomas	B-X
were	B-X
subtyped	B-X
,	B-X
TTF-1	B-X
staining	B-X
was	B-X
noted	B-X
in	B-X
11	B-X
of	B-X
11	B-X
(	B-X
100	B-X
%	B-X
)	B-X
adenocarcinomas	B-X
,	B-X
in	B-X
6	B-X
of	B-X
7	B-X
(	B-X
86	B-X
%	B-X
)	B-X
small-cell	B-X
carcinomas	B-X
,	B-X
in	B-X
15	B-X
of	B-X
19	B-X
(	B-X
79	B-X
%	B-X
)	B-X
large-cell	B-X
carcinomas	B-X
,	B-X
and	B-X
in	B-X
none	B-X
of	B-X
3	B-X
(	B-X
0	B-X
%	B-X
)	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
staining	B-X
is	B-X
very	B-X
reliable	B-X
in	B-X
discerning	B-X
whether	B-X
a	B-X
brain	B-X
metastasis	B-X
has	B-X
arisen	B-X
from	B-X
a	B-X
pulmonary	B-X
or	B-X
nonpulmonary	B-X
site	B-X
,	B-X
particularly	B-X
when	B-X
dealing	B-X
with	B-X
adenocarcinomas	B-X
and	B-X
large-cell	B-X
carcinomas	B-X
.	B-X
TTF-1	B-X
immunohistochemistry	B-X
could	B-X
focus	B-X
the	B-X
search	B-X
for	B-X
the	B-X
primary	B-X
tumor	B-X
for	B-X
patients	B-X
presenting	B-X
with	B-X
brain	B-X
metastasis	B-X
as	B-X
the	B-X
initial	B-X
manifestation	B-X
.	B-X

Protein	O
expression	O
profile	O
of	O
primary	O
human	O
squamous	O
cell	O
lung	O
carcinomas	O
indicative	O
of	O
the	O
incidence	O
of	O
metastases	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
investigation	B-X
was	B-X
to	B-X
evaluate	B-X
firstly	B-X
whether	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
in	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
of	B-X
patients	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
secondly	B-X
,	B-X
whether	B-X
or	B-X
not	B-X
different	B-X
patterns	B-X
exist	B-X
in	B-X
tumours	B-X
with	B-X
positive	B-X
lymph	B-X
nodes	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
specimens	B-X
from	B-X
130	B-X
patients	B-X
with	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
were	B-X
analyzed	B-X
by	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
JUN	B-X
,	B-X
ERBB2	B-X
,	B-X
MYC	B-X
,	B-X
cyclin	B-X
D	B-X
,	B-X
PCNA	B-X
,	B-X
bFGF	B-X
,	B-X
VEGF	B-X
and	B-X
Hsp70	B-X
proteins	B-X
revealed	B-X
a	B-X
positive	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
between	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
within	B-X
carcinomas	B-X
with	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
various	B-X
metastasis	B-X
profiles	B-X
exist	B-X
.	B-X

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
firstly	O
whether	O
different	O
protein	O
expression	O
patterns	O
exist	O
in	O
primary	O
squamous	O
cell	O
lung	O
carcinomas	O
of	O
patients	O
with	O
and	O
without	O
lymph	O
node	O
involvement	O
and	O
secondly	O
,	O
whether	O
or	O
not	O
different	O
patterns	O
exist	O
in	O
tumours	O
with	O
positive	O
lymph	O
nodes	O
.	O
<EOS>	B-X
The	B-X
number	B-X
of	B-X
positive	B-X
lymph	B-X
node	B-X
stations	B-X
has	B-X
been	B-X
viewed	B-X
as	B-X
a	B-X
subclassification	B-X
in	B-X
the	B-X
N1	B-X
category	B-X
in	B-X
the	B-X
new	B-X
revision	B-X
of	B-X
tumour	B-X
node	B-X
metastasis	B-X
(	B-X
TNM	B-X
)	B-X
staging	B-X
.	B-X
However	B-X
,	B-X
the	B-X
survival	B-X
curve	B-X
of	B-X
these	B-X
patients	B-X
overlapped	B-X
with	B-X
that	B-X
of	B-X
some	B-X
patients	B-X
in	B-X
the	B-X
N2	B-X
categories	B-X
.	B-X
Our	B-X
study	B-X
focused	B-X
on	B-X
the	B-X
prognostic	B-X
significance	B-X
of	B-X
different	B-X
subclassifications	B-X
for	B-X
N1	B-X
patients	B-X
.	B-X
In	B-X
the	B-X
last	B-X
10	B-X
years	B-X
,	B-X
evidence	B-X
has	B-X
accumulated	B-X
that	B-X
overexpression	B-X
of	B-X
Met	B-X
protein	B-X
is	B-X
a	B-X
distinguishing	B-X
feature	B-X
of	B-X
almost	B-X
every	B-X
case	B-X
of	B-X
well-differentiated	B-X
papillary	B-X
carcinoma	B-X
.	B-X
Increased	B-X
expression	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
enhanced	B-X
transcription	B-X
of	B-X
the	B-X
MET	B-X
gene	B-X
and/or	B-X
to	B-X
post-transcriptional	B-X
mechanisms	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
possibility	B-X
exists	B-X
that	B-X
dysregulation	B-X
of	B-X
MET	B-X
is	B-X
the	B-X
final	B-X
result	B-X
of	B-X
different	B-X
molecular	B-X
pathways	B-X
capable	B-X
of	B-X
inducing	B-X
thyroid	B-X
cell	B-X
transformation	B-X
;	B-X
RET	B-X
rearrangements	B-X
might	B-X
account	B-X
for	B-X
some	B-X
of	B-X
the	B-X
cases	B-X
,	B-X
but	B-X
the	B-X
demonstration	B-X
that	B-X
the	B-X
majority	B-X
of	B-X
papillary	B-X
carcinomas	B-X
do	B-X
not	B-X
have	B-X
recognized	B-X
alterations	B-X
of	B-X
the	B-X
RET	B-X
gene	B-X
strongly	B-X
suggests	B-X
that	B-X
MET	B-X
gene	B-X
dysregulation	B-X
can	B-X
also	B-X
be	B-X
achieved	B-X
through	B-X
other	B-X
molecular	B-X
pathways	B-X
.	B-X
Dysregulation	B-X
of	B-X
MET	B-X
causes	B-X
marked	B-X
accumulation	B-X
of	B-X
Met	B-X
protein	B-X
in	B-X
tumour	B-X
cells	B-X
that	B-X
is	B-X
promptly	B-X
detected	B-X
by	B-X
immunohistochemistry	B-X
.	B-X
Thus	B-X
,	B-X
overexpression	B-X
of	B-X
Met	B-X
protein	B-X
might	B-X
represent	B-X
an	B-X
immunohistochemical	B-X
marker	B-X
of	B-X
papillary	B-X
carcinoma	B-X
,	B-X
potentially	B-X
helpful	B-X
in	B-X
problematic	B-X
cases	B-X
,	B-X
but	B-X
caution	B-X
is	B-X
required	B-X
;	B-X
moderate	B-X
expression	B-X
of	B-X
Met	B-X
protein	B-X
is	B-X
observed	B-X
in	B-X
non-neoplastic	B-X
thyroid	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
Graves	B-X
'	B-X
and	B-X
Hashimoto	B-X
's	B-X
thyroiditis	B-X
,	B-X
and	B-X
reagents	B-X
active	B-X
on	B-X
paraffin	B-X
sections	B-X
may	B-X
have	B-X
a	B-X
low	B-X
affinity	B-X
and/or	B-X
low	B-X
specificity	B-X
for	B-X
Met	B-X
protein	B-X
,	B-X
leading	B-X
to	B-X
artifactual	B-X
staining	B-X
.	B-X
Met	B-X
protein-positive	B-X
papillary	B-X
carcinoma	B-X
cells	B-X
may	B-X
produce	B-X
hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
and	B-X
may	B-X
activate	B-X
HGF	B-X
through	B-X
the	B-X
urokinase-type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
bound	B-X
to	B-X
urokinase-type	B-X
plasminogen	B-X
activator	B-X
receptor	B-X
(	B-X
uPA-R	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
papillary	B-X
carcinoma	B-X
cells	B-X
possess	B-X
the	B-X
molecular	B-X
machinery	B-X
necessary	B-X
for	B-X
a	B-X
productive	B-X
HGF/Met	B-X
interaction	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
HGF	B-X
enhances	B-X
the	B-X
motility	B-X
and	B-X
invasiveness	B-X
of	B-X
tumour	B-X
cells	B-X
and	B-X
induces	B-X
the	B-X
synthesis	B-X
and	B-X
release	B-X
of	B-X
chemokines	B-X
active	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
dendritic	B-X
cells	B-X
.	B-X
First	B-X
,	B-X
the	B-X
tumour	B-X
is	B-X
often	B-X
characterized	B-X
by	B-X
early	B-X
metastatic	B-X
spread	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
by	B-X
multifocal	B-X
involvement	B-X
of	B-X
the	B-X
gland	B-X
,	B-X
which	B-X
suggests	B-X
highly	B-X
invasive	B-X
behaviour	B-X
.	B-X
Second	B-X
,	B-X
a	B-X
prominent	B-X
peritumoural	B-X
inflammatory	B-X
reaction	B-X
is	B-X
often	B-X
observed	B-X
,	B-X
which	B-X
suggests	B-X
cross-talk	B-X
between	B-X
tumour	B-X
cells	B-X
and	B-X
the	B-X
immune	B-X
system	B-X
.	B-X

For	O
this	O
reason	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
specimens	O
from	O
130	O
patients	O
with	O
squamous	O
cell	O
lung	O
carcinomas	O
were	O
analyzed	O
by	O
immunohistochemistry	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
investigation	B-X
was	B-X
to	B-X
evaluate	B-X
firstly	B-X
whether	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
in	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
of	B-X
patients	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
secondly	B-X
,	B-X
whether	B-X
or	B-X
not	B-X
different	B-X
patterns	B-X
exist	B-X
in	B-X
tumours	B-X
with	B-X
positive	B-X
lymph	B-X
nodes	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
specimens	B-X
from	B-X
130	B-X
patients	B-X
with	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
were	B-X
analyzed	B-X
by	B-X
immunohistochemistry	B-X
.	B-X
In	B-X
a	B-X
second	B-X
step	B-X
,	B-X
these	B-X
parameters	B-X
were	B-X
further	B-X
analyzed	B-X
by	B-X
hierarchical	B-X
cluster	B-X
analyses	B-X
.	B-X
The	B-X
resulting	B-X
clusters	B-X
were	B-X
correlated	B-X
to	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
between	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
within	B-X
carcinomas	B-X
with	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X

In	O
a	O
first	O
step	O
,	O
proteins	O
were	O
selected	O
which	O
showed	O
a	O
relationship	O
to	O
lymph	O
node	O
involvement	O
.	O

The	O
expression	O
of	O
JUN	B-Gene_or_gene_product
,	O
ERBB2	B-Gene_or_gene_product
,	O
MYC	B-Gene_or_gene_product
,	O
cyclin	B-Gene_or_gene_product
D	I-Gene_or_gene_product
,	O
PCNA	B-Gene_or_gene_product
,	O
bFGF	B-Gene_or_gene_product
,	O
VEGF	B-Gene_or_gene_product
and	O
Hsp70	B-Gene_or_gene_product
proteins	O
revealed	O
a	O
positive	O
correlation	O
to	O
lymph	O
node	O
involvement	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
investigation	B-X
was	B-X
to	B-X
evaluate	B-X
firstly	B-X
whether	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
in	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
of	B-X
patients	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
secondly	B-X
,	B-X
whether	B-X
or	B-X
not	B-X
different	B-X
patterns	B-X
exist	B-X
in	B-X
tumours	B-X
with	B-X
positive	B-X
lymph	B-X
nodes	B-X
.	B-X
In	B-X
a	B-X
first	B-X
step	B-X
,	B-X
proteins	B-X
were	B-X
selected	B-X
which	B-X
showed	B-X
a	B-X
relationship	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
JUN	B-X
,	B-X
ERBB2	B-X
,	B-X
MYC	B-X
,	B-X
cyclin	B-X
D	B-X
,	B-X
PCNA	B-X
,	B-X
bFGF	B-X
,	B-X
VEGF	B-X
and	B-X
Hsp70	B-X
proteins	B-X
revealed	B-X
a	B-X
positive	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
caspase-3	B-X
,	B-X
Fas	B-X
ligand	B-X
,	B-X
Fas/CD95	B-X
,	B-X
and	B-X
PAI	B-X
showed	B-X
an	B-X
inverse	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
resulting	B-X
clusters	B-X
were	B-X
correlated	B-X
to	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
between	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
within	B-X
carcinomas	B-X
with	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X

In	O
contrast	O
,	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
,	O
Fas	B-Gene_or_gene_product
ligand	I-Gene_or_gene_product
,	O
Fas	B-Gene_or_gene_product
/	O
CD95	B-Gene_or_gene_product
,	O
and	O
PAI	B-Gene_or_gene_product
showed	O
an	O
inverse	O
correlation	O
to	O
lymph	O
node	O
involvement	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
investigation	B-X
was	B-X
to	B-X
evaluate	B-X
firstly	B-X
whether	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
in	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
of	B-X
patients	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
secondly	B-X
,	B-X
whether	B-X
or	B-X
not	B-X
different	B-X
patterns	B-X
exist	B-X
in	B-X
tumours	B-X
with	B-X
positive	B-X
lymph	B-X
nodes	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
specimens	B-X
from	B-X
130	B-X
patients	B-X
with	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
were	B-X
analyzed	B-X
by	B-X
immunohistochemistry	B-X
.	B-X
In	B-X
a	B-X
first	B-X
step	B-X
,	B-X
proteins	B-X
were	B-X
selected	B-X
which	B-X
showed	B-X
a	B-X
relationship	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
JUN	B-X
,	B-X
ERBB2	B-X
,	B-X
MYC	B-X
,	B-X
cyclin	B-X
D	B-X
,	B-X
PCNA	B-X
,	B-X
bFGF	B-X
,	B-X
VEGF	B-X
and	B-X
Hsp70	B-X
proteins	B-X
revealed	B-X
a	B-X
positive	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
caspase-3	B-X
,	B-X
Fas	B-X
ligand	B-X
,	B-X
Fas/CD95	B-X
,	B-X
and	B-X
PAI	B-X
showed	B-X
an	B-X
inverse	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
resulting	B-X
clusters	B-X
were	B-X
correlated	B-X
to	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
between	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
within	B-X
carcinomas	B-X
with	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X

In	O
a	O
second	O
step	O
,	O
these	O
parameters	O
were	O
further	O
analyzed	O
by	O
hierarchical	O
cluster	O
analyses	O
.	O

The	O
resulting	O
clusters	O
were	O
correlated	O
to	O
patients	O
with	O
or	O
without	O
lymph	O
node	O
involvement	O
.	O
<EOS>	B-X
The	B-X
SINODAR-ONE	B-X
trial	B-X
is	B-X
a	B-X
prospective	B-X
noninferiority	B-X
multicenter	B-X
randomized	B-X
study	B-X
aimed	B-X
at	B-X
assessing	B-X
the	B-X
role	B-X
of	B-X
axillary	B-X
lymph	B-X
node	B-X
dissection	B-X
(	B-X
ALND	B-X
)	B-X
in	B-X
patients	B-X
undergoing	B-X
either	B-X
breast-conserving	B-X
surgery	B-X
or	B-X
mastectomy	B-X
for	B-X
T1-2	B-X
breast	B-X
cancer	B-X
(	B-X
BC	B-X
)	B-X
and	B-X
presenting	B-X
one	B-X
or	B-X
two	B-X
macrometastatic	B-X
sentinel	B-X
lymph	B-X
nodes	B-X
(	B-X
SLNs	B-X
)	B-X
.	B-X
Metastatic	B-X
lymph	B-X
node	B-X
involvement	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
a	B-X
key	B-X
determinant	B-X
of	B-X
the	B-X
overall	B-X
stage	B-X
of	B-X
disease	B-X
and	B-X
prognosis	B-X
.	B-X
Historically	B-X
,	B-X
lymph	B-X
node	B-X
status	B-X
was	B-X
determined	B-X
by	B-X
surgery	B-X
first	B-X
,	B-X
with	B-X
adjuvant	B-X
treatments	B-X
determined	B-X
based	B-X
on	B-X
the	B-X
results	B-X
of	B-X
the	B-X
final	B-X
surgical	B-X
pathologic	B-X
analysis	B-X
.	B-X
As	B-X
surgery	B-X
may	B-X
be	B-X
postponed	B-X
,	B-X
imaging	B-X
and	B-X
image-guided	B-X
lymph	B-X
node	B-X
interventions	B-X
have	B-X
gained	B-X
importance	B-X
as	B-X
the	B-X
primary	B-X
means	B-X
of	B-X
lymph	B-X
node	B-X
assessment	B-X
.	B-X
By	B-X
differentiating	B-X
limited	B-X
versus	B-X
extensive	B-X
nodal	B-X
involvement	B-X
,	B-X
imaging	B-X
findings	B-X
help	B-X
determine	B-X
whether	B-X
initial	B-X
treatment	B-X
should	B-X
be	B-X
surgical	B-X
or	B-X
medical	B-X
.	B-X
The	B-X
role	B-X
of	B-X
imaging	B-X
in	B-X
the	B-X
multidisciplinary	B-X
team	B-X
approach	B-X
is	B-X
emphasized	B-X
based	B-X
on	B-X
past	B-X
clinical	B-X
trials	B-X
of	B-X
lymph	B-X
node	B-X
management	B-X
and	B-X
recent	B-X
evolving	B-X
knowledge	B-X
of	B-X
breast	B-X
cancer	B-X
staging	B-X
.	B-X

The	O
data	O
show	O
that	O
different	O
protein	O
expression	O
patterns	O
exist	O
between	O
primary	O
squamous	O
cell	O
lung	O
carcinomas	O
with	O
and	O
without	O
lymph	O
node	O
involvement	O
and	O
within	O
carcinomas	O
with	O
lymph	O
node	O
involvement	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
investigation	B-X
was	B-X
to	B-X
evaluate	B-X
firstly	B-X
whether	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
in	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
of	B-X
patients	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
secondly	B-X
,	B-X
whether	B-X
or	B-X
not	B-X
different	B-X
patterns	B-X
exist	B-X
in	B-X
tumours	B-X
with	B-X
positive	B-X
lymph	B-X
nodes	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
specimens	B-X
from	B-X
130	B-X
patients	B-X
with	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
were	B-X
analyzed	B-X
by	B-X
immunohistochemistry	B-X
.	B-X
In	B-X
a	B-X
first	B-X
step	B-X
,	B-X
proteins	B-X
were	B-X
selected	B-X
which	B-X
showed	B-X
a	B-X
relationship	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
JUN	B-X
,	B-X
ERBB2	B-X
,	B-X
MYC	B-X
,	B-X
cyclin	B-X
D	B-X
,	B-X
PCNA	B-X
,	B-X
bFGF	B-X
,	B-X
VEGF	B-X
and	B-X
Hsp70	B-X
proteins	B-X
revealed	B-X
a	B-X
positive	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
caspase-3	B-X
,	B-X
Fas	B-X
ligand	B-X
,	B-X
Fas/CD95	B-X
,	B-X
and	B-X
PAI	B-X
showed	B-X
an	B-X
inverse	B-X
correlation	B-X
to	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
resulting	B-X
clusters	B-X
were	B-X
correlated	B-X
to	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
different	B-X
protein	B-X
expression	B-X
patterns	B-X
exist	B-X
between	B-X
primary	B-X
squamous	B-X
cell	B-X
lung	B-X
carcinomas	B-X
with	B-X
and	B-X
without	B-X
lymph	B-X
node	B-X
involvement	B-X
and	B-X
within	B-X
carcinomas	B-X
with	B-X
lymph	B-X
node	B-X
involvement	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
various	B-X
metastasis	B-X
profiles	B-X
exist	B-X
.	B-X

The	O
data	O
suggest	O
that	O
various	O
metastasis	O
profiles	O
exist	O
.	O
<EOS>	B-X
Molecular	B-X
profiling	B-X
of	B-X
tumor	B-X
organoids	B-X
was	B-X
matched	B-X
to	B-X
drug-screening	B-X
results	B-X
,	B-X
suggesting	B-X
that	B-X
PDOs	B-X
could	B-X
complement	B-X
existing	B-X
approaches	B-X
in	B-X
defining	B-X
cancer	B-X
vulnerabilities	B-X
and	B-X
improving	B-X
treatment	B-X
responses	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
PDOs	B-X
can	B-X
recapitulate	B-X
patient	B-X
responses	B-X
in	B-X
the	B-X
clinic	B-X
and	B-X
could	B-X
be	B-X
implemented	B-X
in	B-X
personalized	B-X
medicine	B-X
programs	B-X
.	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
analysis	B-X
reveals	B-X
a	B-X
significantly	B-X
higher	B-X
number	B-X
of	B-X
expanded	B-X
TCR	B-X
clones	B-X
pre-treatment	B-X
in	B-X
responders	B-X
suggesting	B-X
pre-existing	B-X
immunity	B-X
.	B-X
Maintenance	B-X
of	B-X
highly	B-X
similar	B-X
clusters	B-X
of	B-X
TCRs	B-X
post-treatment	B-X
predict	B-X
response	B-X
,	B-X
suggesting	B-X
ongoing	B-X
antigen	B-X
engagement	B-X
and	B-X
survival	B-X
of	B-X
families	B-X
of	B-X
T	B-X
cells	B-X
likely	B-X
recognizing	B-X
the	B-X
same	B-X
antigens	B-X
.	B-X

Antiangiogenic	O
and	O
antitumor	O
effects	O
of	O
a	O
protein	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
Cbeta	I-Gene_or_gene_product
inhibitor	O
in	O
human	O
breast	O
cancer	O
and	O
ovarian	O
cancer	O
xenografts	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X

In	O
cell	O
culture	O
,	O
the	O
compound	O
317615	O
2HCl	O
,	O
a	O
potent	O
inhibitor	O
of	O
VEGF	B-Gene_or_gene_product
-	O
stimulated	O
HUVEC	O
proliferation	O
,	O
was	O
not	O
very	O
effective	O
against	O
MX	O
-	O
1	O
breast	O
cancer	O
cells	O
(	O
IC50	O
=	O
8	O
.	O
1	O
microM	O
)	O
or	O
SKOV	O
-	O
3	O
ovarian	O
carcinoma	O
cells	O
(	O
IC50	O
=	O
9	O
.	O
5	O
microM	O
)	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

Exposure	O
to	O
combinations	O
of	O
paclitaxel	O
or	O
carboplatin	O
and	O
317615	O
x	O
2HCl	O
with	O
MX	O
-	O
1	O
cells	O
in	O
culture	O
resulted	O
in	O
cell	O
survival	O
that	O
reflected	O
primarily	O
additivity	O
of	O
the	O
two	O
agents	O
.	O
<EOS>	B-X
Autologous	B-X
dendritic	B-X
cell	B-X
immunotherapy	B-X
(	B-X
DCVAC	B-X
)	B-X
can	B-X
present	B-X
tumor	B-X
antigens	B-X
to	B-X
elicit	B-X
a	B-X
durable	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
KATHERINE	B-X
trial	B-X
showed	B-X
that	B-X
adjuvant	B-X
trastuzumab	B-X
emtansine	B-X
(	B-X
T-DM1	B-X
)	B-X
can	B-X
reduce	B-X
recurrence	B-X
in	B-X
patients	B-X
with	B-X
residual	B-X
disease	B-X
compared	B-X
with	B-X
patients	B-X
treated	B-X
with	B-X
trastuzumab	B-X
;	B-X
however	B-X
,	B-X
T-DM1	B-X
and	B-X
other	B-X
ERBB2-targeted	B-X
agents	B-X
are	B-X
costly	B-X
,	B-X
and	B-X
understanding	B-X
the	B-X
costs	B-X
and	B-X
health	B-X
consequences	B-X
of	B-X
various	B-X
combinations	B-X
of	B-X
neoadjuvant	B-X
followed	B-X
by	B-X
adjuvant	B-X
treatments	B-X
in	B-X
the	B-X
United	B-X
States	B-X
is	B-X
needed	B-X
.	B-X
Chemoresistance	B-X
of	B-X
cancer	B-X
cells	B-X
is	B-X
a	B-X
major	B-X
problem	B-X
in	B-X
treating	B-X
cancer	B-X
.	B-X
Knowledge	B-X
of	B-X
how	B-X
cancer	B-X
cells	B-X
may	B-X
die	B-X
or	B-X
resist	B-X
cancer	B-X
drugs	B-X
is	B-X
critical	B-X
to	B-X
providing	B-X
certain	B-X
strategies	B-X
to	B-X
overcome	B-X
tumour	B-X
resistance	B-X
to	B-X
treatment	B-X
.	B-X
Paclitaxel	B-X
is	B-X
known	B-X
as	B-X
a	B-X
chemotherapy	B-X
drug	B-X
that	B-X
can	B-X
suppress	B-X
the	B-X
proliferation	B-X
of	B-X
cancer	B-X
cells	B-X
by	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
induction	B-X
of	B-X
mitotic	B-X
catastrophe	B-X
.	B-X
However	B-X
,	B-X
today	B-X
,	B-X
it	B-X
is	B-X
well	B-X
known	B-X
that	B-X
paclitaxel	B-X
can	B-X
induce	B-X
multiple	B-X
kinds	B-X
of	B-X
cell	B-X
death	B-X
in	B-X
cancers	B-X
.	B-X
Besides	B-X
the	B-X
induction	B-X
of	B-X
mitotic	B-X
catastrophe	B-X
that	B-X
occurs	B-X
during	B-X
mitosis	B-X
,	B-X
paclitaxel	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
several	B-X
pro-apoptosis	B-X
mediators	B-X
.	B-X
However	B-X
,	B-X
certain	B-X
cell-killing	B-X
mechanisms	B-X
such	B-X
as	B-X
senescence	B-X
and	B-X
autophagy	B-X
can	B-X
increase	B-X
resistance	B-X
to	B-X
paclitaxel	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
mechanisms	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
including	B-X
apoptosis	B-X
,	B-X
mitotic	B-X
catastrophe	B-X
,	B-X
senescence	B-X
,	B-X
autophagic	B-X
cell	B-X
death	B-X
,	B-X
pyroptosis	B-X
,	B-X
etc.	B-X
,	B-X
following	B-X
paclitaxel	B-X
treatment	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
mechanisms	B-X
of	B-X
resistance	B-X
to	B-X
cell	B-X
death	B-X
due	B-X
to	B-X
exposure	B-X
to	B-X
paclitaxel	B-X
and	B-X
the	B-X
use	B-X
of	B-X
combinations	B-X
to	B-X
overcome	B-X
drug	B-X
resistance	B-X
will	B-X
be	B-X
discussed	B-X
.	B-X

Exposure	O
of	O
SKOV	O
-	O
3	O
cells	O
to	O
paclitaxel	O
or	O
carboplatin	O
along	O
with	O
317615	O
2HCl	O
resulted	O
in	O
cell	O
survivals	O
that	O
reflected	O
additivity	O
of	O
317615	O
x	O
2HCl	O
with	O
paclitaxel	O
and	O
greater	O
-	O
than	O
-	O
additive	O
cytotoxicity	O
with	O
carboplatin	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

Administration	O
of	O
317615	O
x	O
2HCI	O
orally	O
twice	O
daily	O
to	O
nude	O
mice	O
bearing	O
subcutaneous	O
MX	O
-	O
1	O
tumors	O
or	O
SKOV	O
-	O
3	O
tumors	O
resulted	O
in	O
a	O
decreased	O
number	O
of	O
intratumoral	O
vessels	O
as	O
determined	O
by	O
CD31	B-Gene_or_gene_product
and	O
CD105	B-Gene_or_gene_product
staining	O
with	O
decreases	O
of	O
35	O
%	O
and	O
43	O
%	O
in	O
MX	O
-	O
1	O
tumors	O
and	O
60	O
%	O
and	O
75	O
%	O
in	O
SKOV	O
-	O
3	O
tumors	O
,	O
respectively	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

317615	O
x	O
2HCl	O
was	O
an	O
active	O
antitumor	O
agent	O
against	O
the	O
MX	O
-	O
1	O
xenograft	O
and	O
increased	O
the	O
tumor	O
growth	O
delay	O
produced	O
by	O
paclitaxel	O
by	O
1	O
.	O
7	O
-	O
fold	O
and	O
the	O
tumor	O
growth	O
delay	O
produced	O
by	O
carboplatin	O
by	O
3	O
.	O
8	O
-	O
fold	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

Administration	O
of	O
317615	O
x	O
2HCl	O
also	O
increased	O
the	O
tumor	O
growth	O
delay	O
produced	O
by	O
fractionated	O
radiation	O
therapy	O
in	O
the	O
MX	O
-	O
1	O
tumor	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

Treatment	O
with	O
317615	O
x	O
2HCl	O
alone	O
increased	O
the	O
lifespan	O
of	O
animals	O
bearing	O
intraperitoneal	O
SKOV	O
-	O
3	O
xenografts	O
by	O
1	O
.	O
9	O
fold	O
compared	O
with	O
untreated	O
control	O
animals	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

The	O
combination	O
of	O
paclitaxel	O
and	O
317615	O
x	O
2HCl	O
resulted	O
in	O
100	O
%	O
120	O
-	O
day	O
survival	O
of	O
SKOV	O
-	O
3	O
bearing	O
animals	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

Administration	O
of	O
317615	O
x	O
2HCl	O
along	O
with	O
carboplatin	O
to	O
animals	O
bearing	O
the	O
SKOV	O
-	O
3	O
tumor	O
produced	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
lifespan	O
compared	O
with	O
carboplatin	O
alone	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

317615	O
x	O
2HCl	O
is	O
a	O
promising	O
new	O
antiangiogenic	O
agent	O
that	O
is	O
in	O
early	O
phase	O
clinical	O
testing	O
.	O
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
the	B-X
compound	B-X
317615	B-X
2HCl	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
VEGF-stimulated	B-X
HUVEC	B-X
proliferation	B-X
,	B-X
was	B-X
not	B-X
very	B-X
effective	B-X
against	B-X
MX-1	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
IC50=	B-X
8.1	B-X
microM	B-X
)	B-X
or	B-X
SKOV-3	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
(	B-X
IC50	B-X
=	B-X
9.5	B-X
microM	B-X
)	B-X
.	B-X
Exposure	B-X
to	B-X
combinations	B-X
of	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
MX-1	B-X
cells	B-X
in	B-X
culture	B-X
resulted	B-X
in	B-X
cell	B-X
survival	B-X
that	B-X
reflected	B-X
primarily	B-X
additivity	B-X
of	B-X
the	B-X
two	B-X
agents	B-X
.	B-X
Exposure	B-X
of	B-X
SKOV-3	B-X
cells	B-X
to	B-X
paclitaxel	B-X
or	B-X
carboplatin	B-X
along	B-X
with	B-X
317615	B-X
2HCl	B-X
resulted	B-X
in	B-X
cell	B-X
survivals	B-X
that	B-X
reflected	B-X
additivity	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
with	B-X
paclitaxel	B-X
and	B-X
greater-than-additive	B-X
cytotoxicity	B-X
with	B-X
carboplatin	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCI	B-X
orally	B-X
twice	B-X
daily	B-X
to	B-X
nude	B-X
mice	B-X
bearing	B-X
subcutaneous	B-X
MX-1	B-X
tumors	B-X
or	B-X
SKOV-3	B-X
tumors	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
intratumoral	B-X
vessels	B-X
as	B-X
determined	B-X
by	B-X
CD31	B-X
and	B-X
CD105	B-X
staining	B-X
with	B-X
decreases	B-X
of	B-X
35	B-X
%	B-X
and	B-X
43	B-X
%	B-X
in	B-X
MX-1	B-X
tumors	B-X
and	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
in	B-X
SKOV-3	B-X
tumors	B-X
,	B-X
respectively	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
was	B-X
an	B-X
active	B-X
antitumor	B-X
agent	B-X
against	B-X
the	B-X
MX-1	B-X
xenograft	B-X
and	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
paclitaxel	B-X
by	B-X
1.7-fold	B-X
and	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
carboplatin	B-X
by	B-X
3.8-fold	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
also	B-X
increased	B-X
the	B-X
tumor	B-X
growth	B-X
delay	B-X
produced	B-X
by	B-X
fractionated	B-X
radiation	B-X
therapy	B-X
in	B-X
the	B-X
MX-1	B-X
tumor	B-X
.	B-X
Treatment	B-X
with	B-X
317615	B-X
x	B-X
2HCl	B-X
alone	B-X
increased	B-X
the	B-X
lifespan	B-X
of	B-X
animals	B-X
bearing	B-X
intraperitoneal	B-X
SKOV-3	B-X
xenografts	B-X
by	B-X
1.9	B-X
fold	B-X
compared	B-X
with	B-X
untreated	B-X
control	B-X
animals	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
paclitaxel	B-X
and	B-X
317615	B-X
x	B-X
2HCl	B-X
resulted	B-X
in	B-X
100	B-X
%	B-X
120-day	B-X
survival	B-X
of	B-X
SKOV-3	B-X
bearing	B-X
animals	B-X
.	B-X
Administration	B-X
of	B-X
317615	B-X
x	B-X
2HCl	B-X
along	B-X
with	B-X
carboplatin	B-X
to	B-X
animals	B-X
bearing	B-X
the	B-X
SKOV-3	B-X
tumor	B-X
produced	B-X
a	B-X
1.8-fold	B-X
increase	B-X
in	B-X
lifespan	B-X
compared	B-X
with	B-X
carboplatin	B-X
alone	B-X
.	B-X
317615	B-X
x	B-X
2HCl	B-X
is	B-X
a	B-X
promising	B-X
new	B-X
antiangiogenic	B-X
agent	B-X
that	B-X
is	B-X
in	B-X
early	B-X
phase	B-X
clinical	B-X
testing	B-X
.	B-X

Expression	O
of	O
CD154	B-Gene_or_gene_product
on	O
renal	O
cell	O
carcinomas	O
and	O
effect	O
on	O
cell	O
proliferation	O
,	O
motility	O
and	O
platelet	O
-	O
activating	O
factor	O
synthesis	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

CD40	B-Gene_or_gene_product
activation	O
by	O
CD154	B-Gene_or_gene_product
may	O
trigger	O
diverse	O
cellular	O
responses	O
,	O
ranging	O
from	O
proliferation	O
and	O
differentiation	O
to	O
growth	O
suppression	O
and	O
cell	O
death	O
,	O
in	O
normal	O
and	O
malignant	O
cells	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

However	O
,	O
the	O
pathophysiologic	O
role	O
of	O
CD154	B-Gene_or_gene_product
expressed	O
by	O
tumor	O
cells	O
remains	O
unclear	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

We	O
have	O
investigated	O
the	O
expression	O
of	O
the	O
CD40	B-Gene_or_gene_product
-	O
CD154	B-Gene_or_gene_product
system	O
in	O
24	O
primary	O
cultures	O
derived	O
from	O
renal	O
cell	O
carcinomas	O
,	O
its	O
correlation	O
with	O
tumor	O
stage	O
and	O
its	O
potential	O
functional	O
significance	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

We	O
found	O
coexpression	O
of	O
CD40	B-Gene_or_gene_product
and	O
CD154	B-Gene_or_gene_product
in	O
most	O
of	O
the	O
renal	O
carcinoma	O
cell	O
lines	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
a	B-X
possible	B-X
autocrine	B-X
role	B-X
of	B-X
CD40L	B-X
,	B-X
the	B-X
expression	B-X
and	B-X
functional	B-X
activity	B-X
of	B-X
CD40L	B-X
on	B-X
NHL	B-X
and	B-X
breast	B-X
carcinoma	B-X
cell	B-X
lines	B-X
were	B-X
investigated	B-X
.	B-X
Using	B-X
flow	B-X
cytometry	B-X
,	B-X
CD40	B-X
was	B-X
consistently	B-X
detectable	B-X
at	B-X
the	B-X
surface	B-X
of	B-X
all	B-X
5	B-X
NHL	B-X
cell	B-X
lines	B-X
tested	B-X
.	B-X
CD40L	B-X
expression	B-X
was	B-X
detectable	B-X
at	B-X
the	B-X
surface	B-X
of	B-X
DAUDI	B-X
(	B-X
54	B-X
%	B-X
,	B-X
MFI	B-X
47	B-X
)	B-X
and	B-X
BJAB	B-X
(	B-X
12	B-X
%	B-X
,	B-X
MFI	B-X
32	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
marginally	B-X
on	B-X
the	B-X
RAJI	B-X
cell	B-X
line	B-X
(	B-X
7	B-X
%	B-X
,	B-X
MFI	B-X
30	B-X
)	B-X
,	B-X
while	B-X
4	B-X
of	B-X
5	B-X
NHL	B-X
cell	B-X
lines	B-X
(	B-X
DAUDI	B-X
,	B-X
RAJI	B-X
,	B-X
BJAB	B-X
,	B-X
BL70	B-X
)	B-X
had	B-X
detectable	B-X
CD40L	B-X
mRNA	B-X
.	B-X
CD40	B-X
was	B-X
expressed	B-X
on	B-X
T47D	B-X
and	B-X
BT20	B-X
breast	B-X
carcinoma	B-X
cell	B-X
lines	B-X
while	B-X
CD40L	B-X
was	B-X
detectable	B-X
on	B-X
T47D	B-X
(	B-X
93	B-X
%	B-X
,	B-X
MFI	B-X
137	B-X
)	B-X
only	B-X
.	B-X
Both	B-X
BT20	B-X
and	B-X
T47D	B-X
had	B-X
detectable	B-X
CD40	B-X
mRNA	B-X
,	B-X
while	B-X
CD40L	B-X
mRNA	B-X
was	B-X
detectable	B-X
only	B-X
in	B-X
the	B-X
T47D	B-X
cell	B-X
line	B-X
.	B-X
CD40	B-X
,	B-X
but	B-X
not	B-X
CD40L	B-X
,	B-X
was	B-X
detectable	B-X
on	B-X
6	B-X
renal	B-X
,	B-X
1	B-X
prostatic	B-X
and	B-X
1	B-X
colon	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD40L	B-X
expressed	B-X
on	B-X
tumor	B-X
cells	B-X
was	B-X
functional	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
its	B-X
capacity	B-X
to	B-X
decrease	B-X
drug-induced	B-X
apoptosis	B-X
on	B-X
CD40	B-X
expressing	B-X
NHL	B-X
and	B-X
breast	B-X
carcinoma	B-X
cell	B-X
lines	B-X
,	B-X
while	B-X
irradiated	B-X
CD40L	B-X
negative	B-X
cell	B-X
line	B-X
(	B-X
BT20	B-X
)	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Blocking	B-X
CD40L	B-X
antibody	B-X
abrogated	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
irradiated	B-X
CD40L	B-X
positive	B-X
T47D	B-X
cell	B-X
line	B-X
against	B-X
drug-induced	B-X
apoptosis	B-X
on	B-X
BL70	B-X
cell	B-X
line	B-X
,	B-X
confirming	B-X
that	B-X
CD40L	B-X
is	B-X
functional	B-X
in	B-X
the	B-X
DAUDI	B-X
and	B-X
T47D	B-X
cell	B-X
lines	B-X
.	B-X
Importantly	B-X
,	B-X
blocking	B-X
CD40L	B-X
antibody	B-X
increased	B-X
drug-induced	B-X
apoptosis	B-X
in	B-X
CD40L	B-X
positive	B-X
cell	B-X
lines	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
CD40L	B-X
negative	B-X
cell	B-X
lines	B-X
.	B-X
CD40L	B-X
is	B-X
expressed	B-X
on	B-X
CD40	B-X
positive	B-X
B	B-X
NHL	B-X
and	B-X
breast	B-X
carcinoma	B-X
cell	B-X
lines	B-X
and	B-X
induces	B-X
an	B-X
autocrine	B-X
antiapoptotic	B-X
signal	B-X
when	B-X
cells	B-X
are	B-X
exposed	B-X
to	B-X
cytotoxic	B-X
agents	B-X
.	B-X

CD154	B-Gene_or_gene_product
,	O
but	O
not	O
CD40	B-Gene_or_gene_product
expression	O
,	O
significantly	O
correlated	O
with	O
tumor	O
stage	O
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
CD40	B-X
and	B-X
CD154	B-X
(	B-X
CD40	B-X
ligand	B-X
)	B-X
is	B-X
central	B-X
in	B-X
immunology	B-X
,	B-X
participating	B-X
in	B-X
CD4	B-X
Platelet	B-X
activation	B-X
also	B-X
contributes	B-X
to	B-X
the	B-X
extensive	B-X
release	B-X
of	B-X
anti-	B-X
or	B-X
pro-inflammatory	B-X
mediators	B-X
such	B-X
as	B-X
IL-1Î²	B-X
,	B-X
RANTES	B-X
(	B-X
Regulated	B-X
on	B-X
Activation	B-X
,	B-X
Normal	B-X
T	B-X
Expressed	B-X
and	B-X
Secreted	B-X
)	B-X
or	B-X
CD154	B-X
,	B-X
also	B-X
known	B-X
as	B-X
the	B-X
CD40-ligand	B-X
.	B-X
Blockade	B-X
of	B-X
the	B-X
CD40/CD154	B-X
pathway	B-X
remains	B-X
one	B-X
of	B-X
the	B-X
most	B-X
effective	B-X
means	B-X
of	B-X
promoting	B-X
graft	B-X
survival	B-X
following	B-X
transplantation	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
CD40/CD154	B-X
antagonism	B-X
on	B-X
dendritic	B-X
cell	B-X
(	B-X
DC	B-X
)	B-X
phenotype	B-X
and	B-X
functionality	B-X
following	B-X
transplantation	B-X
remain	B-X
incompletely	B-X
understood	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
effects	B-X
of	B-X
CD154/CD40	B-X
blockade	B-X
on	B-X
DC	B-X
activation	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
generated	B-X
hematopoietic	B-X
chimeras	B-X
in	B-X
mice	B-X
that	B-X
expressed	B-X
a	B-X
surrogate	B-X
minor	B-X
Ag	B-X
(	B-X
OVA	B-X
)	B-X
.	B-X
Adoptive	B-X
transfer	B-X
of	B-X
OVA-specific	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
led	B-X
to	B-X
chimerism	B-X
rejection	B-X
,	B-X
which	B-X
was	B-X
inhibited	B-X
by	B-X
treatment	B-X
with	B-X
CD154	B-X
blockade	B-X
.	B-X
Surprisingly	B-X
,	B-X
CD154	B-X
antagonism	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
and	B-X
costimulatory	B-X
molecules	B-X
on	B-X
CD11c	B-X
(	B-X
+	B-X
)	B-X
DCs	B-X
compared	B-X
with	B-X
untreated	B-X
controls	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
isolated	B-X
from	B-X
anti-CD154-treated	B-X
animals	B-X
exhibited	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
inflammatory	B-X
cytokine	B-X
secretion	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
major	B-X
effect	B-X
of	B-X
CD154	B-X
antagonism	B-X
in	B-X
vivo	B-X
is	B-X
an	B-X
impairment	B-X
in	B-X
the	B-X
provision	B-X
of	B-X
signal	B-X
three	B-X
during	B-X
donor-reactive	B-X
T	B-X
cell	B-X
programming	B-X
,	B-X
as	B-X
opposed	B-X
to	B-X
an	B-X
impact	B-X
on	B-X
the	B-X
provision	B-X
of	B-X
signal	B-X
two	B-X
.	B-X

Moreover	O
,	O
renal	O
carcinoma	O
cell	O
lines	O
also	O
released	O
the	O
soluble	O
form	O
of	O
CD154	B-Gene_or_gene_product
into	O
the	O
supernatant	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

CD40	B-Gene_or_gene_product
engagement	O
by	O
CD154	B-Gene_or_gene_product
did	O
not	O
affect	O
apoptosis	O
or	O
survival	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
member	B-X
expressed	B-X
on	B-X
both	B-X
immune	B-X
and	B-X
non-immune	B-X
cells	B-X
.	B-X
Interactions	B-X
between	B-X
B	B-X
cell-expressed	B-X
CD40	B-X
and	B-X
its	B-X
binding	B-X
partner	B-X
,	B-X
CD40L	B-X
,	B-X
predominantly	B-X
expressed	B-X
on	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
promoting	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
the	B-X
production	B-X
of	B-X
class-switched	B-X
antibodies	B-X
.	B-X
Non-hematopoietic	B-X
cells	B-X
expressing	B-X
CD40	B-X
can	B-X
also	B-X
engage	B-X
CD40L	B-X
and	B-X
trigger	B-X
a	B-X
pro-inflammatory	B-X
response	B-X
.	B-X
This	B-X
article	B-X
will	B-X
highlight	B-X
what	B-X
is	B-X
known	B-X
about	B-X
the	B-X
biology	B-X
of	B-X
the	B-X
CD40-CD40L	B-X
axis	B-X
in	B-X
humans	B-X
and	B-X
describe	B-X
the	B-X
potential	B-X
contribution	B-X
of	B-X
CD40	B-X
signaling	B-X
on	B-X
both	B-X
hematopoietic	B-X
and	B-X
non-hematopoietic	B-X
cells	B-X
to	B-X
autoimmune	B-X
disease	B-X
pathogenesis	B-X
.	B-X

On	O
the	O
contrary	O
,	O
CD154	B-Gene_or_gene_product
stimulated	O
cell	O
proliferation	O
,	O
motility	O
and	O
production	O
of	O
PAF	O
,	O
a	O
phospholipid	O
mediator	O
of	O
inflammation	O
with	O
angiogenic	O
properties	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
the	O
renal	O
carcinoma	O
cell	O
lines	O
expressed	O
PAF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

Blockade	O
of	O
PAF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
by	O
WEB	O
-	O
2170	O
,	O
a	O
PAF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
antagonist	O
,	O
abolished	O
the	O
CD154	B-Gene_or_gene_product
-	O
dependent	O
motility	O
,	O
indicating	O
a	O
role	O
for	O
PAF	O
synthesized	O
after	O
CD154	B-Gene_or_gene_product
stimulation	O
in	O
renal	O
carcinoma	O
cell	O
motility	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

In	O
conclusion	O
,	O
this	O
study	O
identifies	O
new	O
functional	O
properties	O
for	O
CD154	B-Gene_or_gene_product
,	O
which	O
are	O
potentially	O
relevant	O
for	O
the	O
growth	O
and	O
dissemination	O
of	O
renal	O
carcinoma	O
cells	O
.	O
<EOS>	B-X
CD40	B-X
activation	B-X
by	B-X
CD154	B-X
may	B-X
trigger	B-X
diverse	B-X
cellular	B-X
responses	B-X
,	B-X
ranging	B-X
from	B-X
proliferation	B-X
and	B-X
differentiation	B-X
to	B-X
growth	B-X
suppression	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathophysiologic	B-X
role	B-X
of	B-X
CD154	B-X
expressed	B-X
by	B-X
tumor	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
CD40-CD154	B-X
system	B-X
in	B-X
24	B-X
primary	B-X
cultures	B-X
derived	B-X
from	B-X
renal	B-X
cell	B-X
carcinomas	B-X
,	B-X
its	B-X
correlation	B-X
with	B-X
tumor	B-X
stage	B-X
and	B-X
its	B-X
potential	B-X
functional	B-X
significance	B-X
.	B-X
We	B-X
found	B-X
coexpression	B-X
of	B-X
CD40	B-X
and	B-X
CD154	B-X
in	B-X
most	B-X
of	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
.	B-X
CD154	B-X
,	B-X
but	B-X
not	B-X
CD40	B-X
expression	B-X
,	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
stage	B-X
.	B-X
Moreover	B-X
,	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
also	B-X
released	B-X
the	B-X
soluble	B-X
form	B-X
of	B-X
CD154	B-X
into	B-X
the	B-X
supernatant	B-X
.	B-X
CD40	B-X
engagement	B-X
by	B-X
CD154	B-X
did	B-X
not	B-X
affect	B-X
apoptosis	B-X
or	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CD154	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
,	B-X
motility	B-X
and	B-X
production	B-X
of	B-X
PAF	B-X
,	B-X
a	B-X
phospholipid	B-X
mediator	B-X
of	B-X
inflammation	B-X
with	B-X
angiogenic	B-X
properties	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
renal	B-X
carcinoma	B-X
cell	B-X
lines	B-X
expressed	B-X
PAF-R.	B-X
Blockade	B-X
of	B-X
PAF-R	B-X
by	B-X
WEB-2170	B-X
,	B-X
a	B-X
PAF-R	B-X
antagonist	B-X
,	B-X
abolished	B-X
the	B-X
CD154-dependent	B-X
motility	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
PAF	B-X
synthesized	B-X
after	B-X
CD154	B-X
stimulation	B-X
in	B-X
renal	B-X
carcinoma	B-X
cell	B-X
motility	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
study	B-X
identifies	B-X
new	B-X
functional	B-X
properties	B-X
for	B-X
CD154	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
relevant	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
dissemination	B-X
of	B-X
renal	B-X
carcinoma	B-X
cells	B-X
.	B-X

DNA	O
damage	O
induces	O
a	O
novel	O
p53	B-Gene_or_gene_product
-	O
survivin	B-Gene_or_gene_product
signaling	O
pathway	O
regulating	O
cell	O
cycle	O
and	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
leukemia	O
cells	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Survivin	B-Gene_or_gene_product
is	O
a	O
novel	O
member	O
of	O
the	O
inhibitor	B-Gene_or_gene_product
of	I-Gene_or_gene_product
apoptosis	I-Gene_or_gene_product
protein	O
(	O
IAP	B-Gene_or_gene_product
)	O
family	O
.	O
<EOS>	B-X
Survivin	B-X
(	B-X
BIRC5	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
that	B-X
inhibits	B-X
caspases	B-X
and	B-X
blocks	B-X
cell	B-X
death	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
cancer	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poorer	B-X
clinical	B-X
outcome	B-X
.	B-X
Functioning	B-X
simultaneously	B-X
during	B-X
cell	B-X
division	B-X
and	B-X
apoptosis	B-X
inhibition	B-X
,	B-X
survivin	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
cell	B-X
survival	B-X
.	B-X
Survivin	B-X
has	B-X
consistently	B-X
been	B-X
identified	B-X
by	B-X
molecular	B-X
profiling	B-X
analysis	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
higher	B-X
tumor	B-X
grade	B-X
,	B-X
more	B-X
advanced	B-X
disease	B-X
,	B-X
abbreviated	B-X
survival	B-X
,	B-X
accelerated	B-X
rates	B-X
of	B-X
recurrence	B-X
,	B-X
and	B-X
chemotherapy	B-X
and	B-X
radiation	B-X
resistance	B-X
.	B-X
Survivin	B-X
's	B-X
differential	B-X
expression	B-X
in	B-X
cancer	B-X
compared	B-X
to	B-X
normal	B-X
tissue	B-X
and	B-X
its	B-X
role	B-X
as	B-X
a	B-X
nodal	B-X
protein	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cellular	B-X
pathways	B-X
make	B-X
it	B-X
a	B-X
highly	B-X
flexible	B-X
therapeutic	B-X
target	B-X
,	B-X
suitable	B-X
for	B-X
small-molecule	B-X
inhibitiors	B-X
,	B-X
molecular	B-X
antagonists	B-X
,	B-X
and	B-X
vaccination-based	B-X
therapies	B-X
.	B-X
To	B-X
date	B-X
,	B-X
survivin	B-X
inhibitors	B-X
have	B-X
shown	B-X
modest	B-X
activity	B-X
as	B-X
single	B-X
agents	B-X
,	B-X
but	B-X
it	B-X
is	B-X
anticipated	B-X
that	B-X
when	B-X
given	B-X
in	B-X
combination	B-X
with	B-X
cytotoxic	B-X
chemotherapy	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
they	B-X
may	B-X
exhibit	B-X
enhanced	B-X
efficacy	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
complex	B-X
circuitry	B-X
of	B-X
survivin	B-X
in	B-X
human	B-X
cancers	B-X
and	B-X
highlights	B-X
clinical	B-X
trials	B-X
involving	B-X
novel	B-X
agents	B-X
that	B-X
target	B-X
this	B-X
important	B-X
protein	B-X
.	B-X

Here	O
we	O
report	O
that	O
the	O
chemotherapeutic	O
drug	O
doxorubicin	O
,	O
a	O
DNA	O
-	O
damaging	O
agent	O
,	O
activates	O
a	O
p53	B-Gene_or_gene_product
-	O
survivin	B-Gene_or_gene_product
signaling	O
pathway	O
inducing	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Treatment	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
p53	B-Gene_or_gene_product
ALL	O
cells	O
(	O
EU	O
-	O
3	O
cell	O
line	O
)	O
with	O
doxorubicin	O
caused	O
accumulation	O
of	O
p53	B-Gene_or_gene_product
,	O
resulting	O
in	O
dramatic	O
down	O
-	O
regulation	O
of	O
survivin	B-Gene_or_gene_product
,	O
depletion	O
of	O
cells	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
and	O
apoptosis	O
(	O
increased	O
sub	O
-	O
G	O
(	O
1	O
)	O
compartment	O
)	O
.	O

In	O
contrast	O
,	O
doxorubicin	O
treatment	O
of	O
mutant	O
(	O
mut	O
)	O
p53	B-Gene_or_gene_product
cells	O
(	O
EU	O
-	O
6	O
/	O
ALL	O
line	O
)	O
up	O
-	O
regulated	O
survivin	B-Gene_or_gene_product
and	O
induced	O
G	O
(	O
2	O
)	O
/	O
M	O
arrest	O
without	O
inducing	O
apoptosis	O
.	O

However	O
,	O
treating	O
EU	O
-	O
6	O
with	O
anti	O
-	O
survivin	B-Gene_or_gene_product
antisense	O
resensitized	O
these	O
cells	O
to	O
doxorubicin	O
,	O
resulting	O
in	O
apoptosis	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

With	O
a	O
p53	B-Gene_or_gene_product
-	O
null	O
cell	O
line	O
(	O
EU	O
-	O
4	O
)	O
,	O
although	O
doxorubicin	O
treatment	O
arrested	O
cells	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
survivin	B-Gene_or_gene_product
expression	O
was	O
unchanged	O
,	O
and	O
cells	O
underwent	O
only	O
limited	O
apoptosis	O
.	O

However	O
,	O
re	O
-	O
expression	O
of	O
wt	O
-	O
p53	B-Gene_or_gene_product
in	O
EU	O
-	O
4	O
cells	O
could	O
restore	O
the	O
doxorubicin	O
-	O
p53	B-Gene_or_gene_product
-	O
survivin	B-Gene_or_gene_product
pathway	O
,	O
resulting	O
in	O
significantly	O
decreased	O
survivin	B-Gene_or_gene_product
expression	O
and	O
increased	O
apoptosis	O
in	O
these	O
cells	O
after	O
doxorubicin	O
treatment	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Following	O
cotransfection	O
of	O
p53	B-Gene_or_gene_product
-	O
null	O
EU	O
-	O
4	O
cells	O
with	O
survivin	B-Gene_or_gene_product
promoter	O
-	O
luciferase	B-Gene_or_gene_product
constructs	O
and	O
either	O
wt	O
-	O
p53	B-Gene_or_gene_product
or	O
different	O
mut	O
-	O
p53	B-Gene_or_gene_product
expression	O
vectors	O
,	O
wt	O
-	O
p53	B-Gene_or_gene_product
inhibited	O
survivin	B-Gene_or_gene_product
promoter	O
activity	O
;	O
p53	B-Gene_or_gene_product
-	O
mediated	O
inhibition	O
could	O
be	O
abrogated	O
by	O
overexpression	O
of	O
murine	B-Gene_or_gene_product
double	I-Gene_or_gene_product
minute2	I-Gene_or_gene_product
(	O
MDM2	B-Gene_or_gene_product
)	O
protein	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Together	O
,	O
these	O
studies	O
define	O
a	O
novel	O
p53	B-Gene_or_gene_product
-	O
survivin	B-Gene_or_gene_product
signaling	O
pathway	O
activated	O
by	O
DNA	O
damage	O
that	O
results	O
in	O
down	O
-	O
regulation	O
of	O
survivin	B-Gene_or_gene_product
,	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
(	B-X
IAP	B-X
)	B-X
family	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Furthermore	O
,	O
our	O
data	O
indicate	O
that	O
loss	O
of	O
wt	O
-	O
p53	B-Gene_or_gene_product
function	O
in	O
tumor	O
cells	O
may	O
contribute	O
to	O
up	O
-	O
regulation	O
of	O
survivin	B-Gene_or_gene_product
and	O
resistance	O
to	O
DNA	O
-	O
damaging	O
agents	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
chemotherapeutic	B-X
drug	B-X
doxorubicin	B-X
,	B-X
a	B-X
DNA-damaging	B-X
agent	B-X
,	B-X
activates	B-X
a	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
inducing	B-X
cell	B-X
cycle	B-X
arrest	B-X
and	B-X
apoptosis	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
.	B-X
Treatment	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
p53	B-X
ALL	B-X
cells	B-X
(	B-X
EU-3	B-X
cell	B-X
line	B-X
)	B-X
with	B-X
doxorubicin	B-X
caused	B-X
accumulation	B-X
of	B-X
p53	B-X
,	B-X
resulting	B-X
in	B-X
dramatic	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
depletion	B-X
of	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
and	B-X
apoptosis	B-X
(	B-X
increased	B-X
sub-G	B-X
(	B-X
1	B-X
)	B-X
compartment	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
doxorubicin	B-X
treatment	B-X
of	B-X
mutant	B-X
(	B-X
mut	B-X
)	B-X
p53	B-X
cells	B-X
(	B-X
EU-6/ALL	B-X
line	B-X
)	B-X
up-regulated	B-X
survivin	B-X
and	B-X
induced	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
arrest	B-X
without	B-X
inducing	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
treating	B-X
EU-6	B-X
with	B-X
anti-survivin	B-X
antisense	B-X
resensitized	B-X
these	B-X
cells	B-X
to	B-X
doxorubicin	B-X
,	B-X
resulting	B-X
in	B-X
apoptosis	B-X
.	B-X
With	B-X
a	B-X
p53-null	B-X
cell	B-X
line	B-X
(	B-X
EU-4	B-X
)	B-X
,	B-X
although	B-X
doxorubicin	B-X
treatment	B-X
arrested	B-X
cells	B-X
in	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
,	B-X
survivin	B-X
expression	B-X
was	B-X
unchanged	B-X
,	B-X
and	B-X
cells	B-X
underwent	B-X
only	B-X
limited	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
re-expression	B-X
of	B-X
wt-p53	B-X
in	B-X
EU-4	B-X
cells	B-X
could	B-X
restore	B-X
the	B-X
doxorubicin-p53-survivin	B-X
pathway	B-X
,	B-X
resulting	B-X
in	B-X
significantly	B-X
decreased	B-X
survivin	B-X
expression	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
these	B-X
cells	B-X
after	B-X
doxorubicin	B-X
treatment	B-X
.	B-X
Following	B-X
cotransfection	B-X
of	B-X
p53-null	B-X
EU-4	B-X
cells	B-X
with	B-X
survivin	B-X
promoter-luciferase	B-X
constructs	B-X
and	B-X
either	B-X
wt-p53	B-X
or	B-X
different	B-X
mut-p53	B-X
expression	B-X
vectors	B-X
,	B-X
wt-p53	B-X
inhibited	B-X
survivin	B-X
promoter	B-X
activity	B-X
;	B-X
p53-mediated	B-X
inhibition	B-X
could	B-X
be	B-X
abrogated	B-X
by	B-X
overexpression	B-X
of	B-X
murine	B-X
double	B-X
minute2	B-X
(	B-X
MDM2	B-X
)	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
define	B-X
a	B-X
novel	B-X
p53-survivin	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
DNA	B-X
damage	B-X
that	B-X
results	B-X
in	B-X
down-regulation	B-X
of	B-X
survivin	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
loss	B-X
of	B-X
wt-p53	B-X
function	B-X
in	B-X
tumor	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
up-regulation	B-X
of	B-X
survivin	B-X
and	B-X
resistance	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Effects	O
of	O
4	O
-	O
alkylmorpholine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	O
ascites	O
and	O
L1210	O
leukaemia	O
cells	O
.	O
<EOS>	B-X
The	B-X
main	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
investigation	B-X
was	B-X
to	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
homologous	B-X
series	B-X
of	B-X
4-alkylmorpholine	B-X
N-oxides	B-X
on	B-X
ATP-producing	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
and	B-X
L1210	B-X
murine	B-X
leukaemia	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
aerobic	B-X
glucose	B-X
consumption	B-X
,	B-X
lactic	B-X
acid	B-X
formation	B-X
,	B-X
content	B-X
of	B-X
total	B-X
(	B-X
T-SH	B-X
)	B-X
and	B-X
non-protein	B-X
thiol	B-X
groups	B-X
(	B-X
NP-SH	B-X
)	B-X
,	B-X
endogenous	B-X
and	B-X
exogenous	B-X
respiration	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
in	B-X
tumour	B-X
cells	B-X
incubated	B-X
in	B-X
vitro	B-X
were	B-X
investigated	B-X
.	B-X
4-Dodecylmorpholine	B-X
N-oxide	B-X
(	B-X
DMNO	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
active	B-X
compounds	B-X
,	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
immediately	B-X
after	B-X
addition	B-X
to	B-X
the	B-X
suspension	B-X
of	B-X
Ehrlich	B-X
cells	B-X
in	B-X
an	B-X
ice	B-X
bath	B-X
.	B-X
After	B-X
2	B-X
h	B-X
incubation	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
drop	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
.	B-X
A	B-X
possible	B-X
explanation	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
might	B-X
be	B-X
interaction	B-X
of	B-X
the	B-X
amine	B-X
oxide	B-X
with	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X

The	O
main	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
study	O
the	O
effect	O
of	O
the	O
homologous	O
series	O
of	O
4	O
-	O
alkylmorpholine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	O
ascites	O
and	O
L1210	O
murine	O
leukaemia	O
cells	O
.	O

The	O
effects	O
on	O
aerobic	O
glucose	O
consumption	O
,	O
lactic	O
acid	O
formation	O
,	O
content	O
of	O
total	O
(	O
T	O
-	O
SH	O
)	O
and	O
non	O
-	O
protein	O
thiol	O
groups	O
(	O
NP	O
-	O
SH	O
)	O
,	O
endogenous	O
and	O
exogenous	O
respiration	O
and	O
the	O
level	O
of	O
ATP	O
in	O
tumour	O
cells	O
incubated	O
in	O
vitro	O
were	O
investigated	O
.	O
<EOS>	B-X
The	B-X
main	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
investigation	B-X
was	B-X
to	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
homologous	B-X
series	B-X
of	B-X
4-alkylmorpholine	B-X
N-oxides	B-X
on	B-X
ATP-producing	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
and	B-X
L1210	B-X
murine	B-X
leukaemia	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
aerobic	B-X
glucose	B-X
consumption	B-X
,	B-X
lactic	B-X
acid	B-X
formation	B-X
,	B-X
content	B-X
of	B-X
total	B-X
(	B-X
T-SH	B-X
)	B-X
and	B-X
non-protein	B-X
thiol	B-X
groups	B-X
(	B-X
NP-SH	B-X
)	B-X
,	B-X
endogenous	B-X
and	B-X
exogenous	B-X
respiration	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
in	B-X
tumour	B-X
cells	B-X
incubated	B-X
in	B-X
vitro	B-X
were	B-X
investigated	B-X
.	B-X
4-Dodecylmorpholine	B-X
N-oxide	B-X
(	B-X
DMNO	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
active	B-X
compounds	B-X
,	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
immediately	B-X
after	B-X
addition	B-X
to	B-X
the	B-X
suspension	B-X
of	B-X
Ehrlich	B-X
cells	B-X
in	B-X
an	B-X
ice	B-X
bath	B-X
.	B-X
After	B-X
2	B-X
h	B-X
incubation	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
drop	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
.	B-X
A	B-X
possible	B-X
explanation	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
might	B-X
be	B-X
interaction	B-X
of	B-X
the	B-X
amine	B-X
oxide	B-X
with	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X

4	O
-	O
Dodecylmorpholine	O
N	O
-	O
oxide	O
(	O
DMNO	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
compounds	O
,	O
decreased	O
the	O
level	O
of	O
ATP	O
immediately	O
after	O
addition	O
to	O
the	O
suspension	O
of	O
Ehrlich	O
cells	O
in	O
an	O
ice	O
bath	O
.	O

After	O
2	O
h	O
incubation	O
at	O
37	O
degrees	O
C	O
the	O
drop	O
in	O
the	O
ATP	O
level	O
was	O
much	O
lower	O
.	O
<EOS>	B-X
The	B-X
main	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
investigation	B-X
was	B-X
to	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
homologous	B-X
series	B-X
of	B-X
4-alkylmorpholine	B-X
N-oxides	B-X
on	B-X
ATP-producing	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
and	B-X
L1210	B-X
murine	B-X
leukaemia	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
aerobic	B-X
glucose	B-X
consumption	B-X
,	B-X
lactic	B-X
acid	B-X
formation	B-X
,	B-X
content	B-X
of	B-X
total	B-X
(	B-X
T-SH	B-X
)	B-X
and	B-X
non-protein	B-X
thiol	B-X
groups	B-X
(	B-X
NP-SH	B-X
)	B-X
,	B-X
endogenous	B-X
and	B-X
exogenous	B-X
respiration	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
in	B-X
tumour	B-X
cells	B-X
incubated	B-X
in	B-X
vitro	B-X
were	B-X
investigated	B-X
.	B-X
4-Dodecylmorpholine	B-X
N-oxide	B-X
(	B-X
DMNO	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
active	B-X
compounds	B-X
,	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
immediately	B-X
after	B-X
addition	B-X
to	B-X
the	B-X
suspension	B-X
of	B-X
Ehrlich	B-X
cells	B-X
in	B-X
an	B-X
ice	B-X
bath	B-X
.	B-X
After	B-X
2	B-X
h	B-X
incubation	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
drop	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
.	B-X
A	B-X
possible	B-X
explanation	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
might	B-X
be	B-X
interaction	B-X
of	B-X
the	B-X
amine	B-X
oxide	B-X
with	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X

A	O
possible	O
explanation	O
for	O
the	O
decrease	O
in	O
the	O
ATP	O
level	O
might	O
be	O
interaction	O
of	O
the	O
amine	O
oxide	O
with	O
the	O
cell	O
membrane	O
.	O
<EOS>	B-X
The	B-X
main	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
investigation	B-X
was	B-X
to	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
homologous	B-X
series	B-X
of	B-X
4-alkylmorpholine	B-X
N-oxides	B-X
on	B-X
ATP-producing	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
and	B-X
L1210	B-X
murine	B-X
leukaemia	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
aerobic	B-X
glucose	B-X
consumption	B-X
,	B-X
lactic	B-X
acid	B-X
formation	B-X
,	B-X
content	B-X
of	B-X
total	B-X
(	B-X
T-SH	B-X
)	B-X
and	B-X
non-protein	B-X
thiol	B-X
groups	B-X
(	B-X
NP-SH	B-X
)	B-X
,	B-X
endogenous	B-X
and	B-X
exogenous	B-X
respiration	B-X
and	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
in	B-X
tumour	B-X
cells	B-X
incubated	B-X
in	B-X
vitro	B-X
were	B-X
investigated	B-X
.	B-X
4-Dodecylmorpholine	B-X
N-oxide	B-X
(	B-X
DMNO	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
active	B-X
compounds	B-X
,	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
ATP	B-X
immediately	B-X
after	B-X
addition	B-X
to	B-X
the	B-X
suspension	B-X
of	B-X
Ehrlich	B-X
cells	B-X
in	B-X
an	B-X
ice	B-X
bath	B-X
.	B-X
After	B-X
2	B-X
h	B-X
incubation	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
drop	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
was	B-X
much	B-X
lower	B-X
.	B-X
A	B-X
possible	B-X
explanation	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
ATP	B-X
level	B-X
might	B-X
be	B-X
interaction	B-X
of	B-X
the	B-X
amine	B-X
oxide	B-X
with	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X

Fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
2	I-Gene_or_gene_product
promotes	O
microvessel	O
formation	O
from	O
mouse	O
embryonic	O
aorta	O
.	O
<EOS>	B-X
To	B-X
delineate	B-X
the	B-X
roles	B-X
that	B-X
oxygen	B-X
and	B-X
fibroblast	B-X
growth	B-X
factors	B-X
(	B-X
FGFs	B-X
)	B-X
play	B-X
in	B-X
the	B-X
process	B-X
of	B-X
angiogenesis	B-X
from	B-X
the	B-X
embryonic	B-X
aorta	B-X
,	B-X
we	B-X
cultured	B-X
mouse	B-X
embryonic	B-X
aorta	B-X
explants	B-X
(	B-X
thoracic	B-X
level	B-X
to	B-X
lateral	B-X
vessels	B-X
supplying	B-X
the	B-X
mesonephros	B-X
and	B-X
metanephros	B-X
)	B-X
in	B-X
a	B-X
three-dimensional	B-X
type	B-X
I	B-X
collagen	B-X
gel	B-X
matrix	B-X
.	B-X
During	B-X
8	B-X
days	B-X
of	B-X
culture	B-X
under	B-X
5	B-X
%	B-X
O	B-X
(	B-X
2	B-X
)	B-X
,	B-X
but	B-X
not	B-X
room	B-X
air	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
FGF2	B-X
to	B-X
explants	B-X
stimulated	B-X
the	B-X
formation	B-X
of	B-X
Gs-IB	B-X
(	B-X
4-	B-X
)	B-X
positive	B-X
,	B-X
CD31-positive	B-X
,	B-X
and	B-X
Flk-1-positive	B-X
microvessels	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
FGF2-stimulated	B-X
microvessel	B-X
formation	B-X
was	B-X
inhibited	B-X
by	B-X
sequestration	B-X
of	B-X
FGF2	B-X
via	B-X
addition	B-X
of	B-X
soluble	B-X
FGF	B-X
receptor	B-X
(	B-X
FGFR	B-X
)	B-X
chimera	B-X
protein	B-X
or	B-X
anti-FGF2	B-X
antibodies	B-X
.	B-X
FGFR1	B-X
and	B-X
FGFR2	B-X
were	B-X
present	B-X
on	B-X
explants	B-X
.	B-X
Levels	B-X
of	B-X
FGFR1	B-X
,	B-X
but	B-X
not	B-X
FGFR2	B-X
,	B-X
were	B-X
increased	B-X
in	B-X
embryonic	B-X
aorta	B-X
cultured	B-X
under	B-X
5	B-X
%	B-X
O	B-X
(	B-X
2	B-X
)	B-X
relative	B-X
to	B-X
room	B-X
air	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
low	B-X
oxygen	B-X
upregulates	B-X
FGFR1	B-X
expression	B-X
in	B-X
embryonic	B-X
aorta	B-X
in	B-X
vitro	B-X
and	B-X
renders	B-X
it	B-X
more	B-X
responsive	B-X
to	B-X
FGF2	B-X
.	B-X

To	O
delineate	O
the	O
roles	O
that	O
oxygen	O
and	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	I-Gene_or_gene_product
(	O
FGFs	B-Gene_or_gene_product
)	O
play	O
in	O
the	O
process	O
of	O
angiogenesis	O
from	O
the	O
embryonic	O
aorta	O
,	O
we	O
cultured	O
mouse	O
embryonic	O
aorta	O
explants	O
(	O
thoracic	O
level	O
to	O
lateral	O
vessels	O
supplying	O
the	O
mesonephros	O
and	O
metanephros	O
)	O
in	O
a	O
three	O
-	O
dimensional	O
type	B-Gene_or_gene_product
I	I-Gene_or_gene_product
collagen	I-Gene_or_gene_product
gel	O
matrix	O
.	O

During	O
8	O
days	O
of	O
culture	O
under	O
5	O
%	O
O	O
(	O
2	O
)	O
,	O
but	O
not	O
room	O
air	O
,	O
the	O
addition	O
of	O
FGF2	B-Gene_or_gene_product
to	O
explants	O
stimulated	O
the	O
formation	O
of	O
Gs	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IB	I-Gene_or_gene_product
(	I-Gene_or_gene_product
4	I-Gene_or_gene_product
-	I-Gene_or_gene_product
)	I-Gene_or_gene_product
positive	O
,	O
CD31	B-Gene_or_gene_product
-	O
positive	O
,	O
and	O
Flk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
positive	O
microvessels	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

FGF2	B-Gene_or_gene_product
-	O
stimulated	O
microvessel	O
formation	O
was	O
inhibited	O
by	O
sequestration	O
of	O
FGF2	B-Gene_or_gene_product
via	O
addition	O
of	O
soluble	O
FGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
FGFR	B-Gene_or_gene_product
)	O
chimera	O
protein	O
or	O
anti	O
-	O
FGF2	B-Gene_or_gene_product
antibodies	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
programming	B-X
of	B-X
tumour-associated	B-X
macrophages	B-X
(	B-X
TAMs	B-X
)	B-X
controls	B-X
tumour	B-X
growth	B-X
and	B-X
anti-tumour	B-X
immunity	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
FGF2	B-X
in	B-X
that	B-X
regulation	B-X
.	B-X
Tumours	B-X
in	B-X
mice	B-X
genetically	B-X
deficient	B-X
in	B-X
low-molecular	B-X
weight	B-X
FGF2	B-X
(	B-X
FGF2	B-X
Three	B-X
members	B-X
of	B-X
the	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
family	B-X
,	B-X
FGF-2	B-X
,	B-X
FGF-18	B-X
,	B-X
and	B-X
FGF-8	B-X
,	B-X
have	B-X
been	B-X
implicated	B-X
as	B-X
contributing	B-X
factors	B-X
in	B-X
cartilage	B-X
homeostasis	B-X
.	B-X
The	B-X
role	B-X
of	B-X
FGF-2	B-X
is	B-X
controversial	B-X
in	B-X
both	B-X
articular	B-X
and	B-X
intervertebral	B-X
disc	B-X
(	B-X
IVD	B-X
)	B-X
cartilage	B-X
as	B-X
it	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
species-	B-X
and	B-X
age-dependent	B-X
anabolic	B-X
or	B-X
catabolic	B-X
events	B-X
.	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
FGF-2	B-X
selectively	B-X
activates	B-X
FGF	B-X
receptor	B-X
1	B-X
(	B-X
FGFR1	B-X
)	B-X
to	B-X
exert	B-X
catabolic	B-X
effects	B-X
in	B-X
human	B-X
articular	B-X
chondrocytes	B-X
and	B-X
IVD	B-X
tissue	B-X
via	B-X
upregulation	B-X
of	B-X
matrix-degrading	B-X
enzyme	B-X
production	B-X
,	B-X
inhibition	B-X
of	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
accumulation	B-X
and	B-X
proteoglycan	B-X
synthesis	B-X
,	B-X
and	B-X
clustering	B-X
of	B-X
cells	B-X
characteristic	B-X
of	B-X
arthritic	B-X
states	B-X
.	B-X
FGF-18	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
most	B-X
likely	B-X
exerts	B-X
anabolic	B-X
effects	B-X
in	B-X
human	B-X
articular	B-X
chondrocytes	B-X
by	B-X
activating	B-X
the	B-X
FGFR3	B-X
pathway	B-X
,	B-X
inducing	B-X
ECM	B-X
formation	B-X
and	B-X
chondrogenic	B-X
cell	B-X
differentiation	B-X
,	B-X
and	B-X
inhibiting	B-X
cell	B-X
proliferation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
FGF-8	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
catabolic	B-X
mediator	B-X
in	B-X
rat	B-X
and	B-X
rabbit	B-X
articular	B-X
cartilage	B-X
,	B-X
but	B-X
its	B-X
precise	B-X
biological	B-X
impact	B-X
on	B-X
human	B-X
adult	B-X
articular	B-X
cartilage	B-X
or	B-X
IVD	B-X
tissue	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
available	B-X
evidence	B-X
reveals	B-X
the	B-X
promise	B-X
of	B-X
FGF-2/FGFR1	B-X
antagonists	B-X
,	B-X
FGF-18/FGFR3	B-X
agonists	B-X
,	B-X
and	B-X
FGF-8	B-X
antagonists	B-X
(	B-X
i.e.	B-X
,	B-X
anti-FGF-8	B-X
antibody	B-X
)	B-X
as	B-X
potential	B-X
therapies	B-X
to	B-X
prevent	B-X
cartilage	B-X
degeneration	B-X
and/or	B-X
promote	B-X
cartilage	B-X
regeneration	B-X
and	B-X
repair	B-X
in	B-X
the	B-X
future	B-X
.	B-X

FGFR1	B-Gene_or_gene_product
and	O
FGFR2	B-Gene_or_gene_product
were	O
present	O
on	O
explants	O
.	O
<EOS>	B-X
To	B-X
delineate	B-X
the	B-X
roles	B-X
that	B-X
oxygen	B-X
and	B-X
fibroblast	B-X
growth	B-X
factors	B-X
(	B-X
FGFs	B-X
)	B-X
play	B-X
in	B-X
the	B-X
process	B-X
of	B-X
angiogenesis	B-X
from	B-X
the	B-X
embryonic	B-X
aorta	B-X
,	B-X
we	B-X
cultured	B-X
mouse	B-X
embryonic	B-X
aorta	B-X
explants	B-X
(	B-X
thoracic	B-X
level	B-X
to	B-X
lateral	B-X
vessels	B-X
supplying	B-X
the	B-X
mesonephros	B-X
and	B-X
metanephros	B-X
)	B-X
in	B-X
a	B-X
three-dimensional	B-X
type	B-X
I	B-X
collagen	B-X
gel	B-X
matrix	B-X
.	B-X
During	B-X
8	B-X
days	B-X
of	B-X
culture	B-X
under	B-X
5	B-X
%	B-X
O	B-X
(	B-X
2	B-X
)	B-X
,	B-X
but	B-X
not	B-X
room	B-X
air	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
FGF2	B-X
to	B-X
explants	B-X
stimulated	B-X
the	B-X
formation	B-X
of	B-X
Gs-IB	B-X
(	B-X
4-	B-X
)	B-X
positive	B-X
,	B-X
CD31-positive	B-X
,	B-X
and	B-X
Flk-1-positive	B-X
microvessels	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
FGFR1	B-X
and	B-X
FGFR2	B-X
were	B-X
present	B-X
on	B-X
explants	B-X
.	B-X
Levels	B-X
of	B-X
FGFR1	B-X
,	B-X
but	B-X
not	B-X
FGFR2	B-X
,	B-X
were	B-X
increased	B-X
in	B-X
embryonic	B-X
aorta	B-X
cultured	B-X
under	B-X
5	B-X
%	B-X
O	B-X
(	B-X
2	B-X
)	B-X
relative	B-X
to	B-X
room	B-X
air	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
low	B-X
oxygen	B-X
upregulates	B-X
FGFR1	B-X
expression	B-X
in	B-X
embryonic	B-X
aorta	B-X
in	B-X
vitro	B-X
and	B-X
renders	B-X
it	B-X
more	B-X
responsive	B-X
to	B-X
FGF2	B-X
.	B-X

Levels	O
of	O
FGFR1	B-Gene_or_gene_product
,	O
but	O
not	O
FGFR2	B-Gene_or_gene_product
,	O
were	O
increased	O
in	O
embryonic	O
aorta	O
cultured	O
under	O
5	O
%	O
O	O
(	O
2	O
)	O
relative	O
to	O
room	O
air	O
.	O
<EOS>	B-X
Tumour-induced	B-X
osteomalacia	B-X
(	B-X
TIO	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
oncogenic	B-X
osteomalacia	B-X
,	B-X
is	B-X
a	B-X
rare	B-X
paraneoplastic	B-X
disorder	B-X
caused	B-X
by	B-X
tumours	B-X
that	B-X
secrete	B-X
fibroblast	B-X
growth	B-X
factor	B-X
23	B-X
(	B-X
FGF23	B-X
)	B-X
.	B-X
Owing	B-X
to	B-X
the	B-X
role	B-X
of	B-X
FGF23	B-X
in	B-X
renal	B-X
phosphate	B-X
handling	B-X
and	B-X
vitamin	B-X
D	B-X
synthesis	B-X
,	B-X
TIO	B-X
is	B-X
characterized	B-X
by	B-X
decreased	B-X
renal	B-X
tubular	B-X
reabsorption	B-X
of	B-X
phosphate	B-X
,	B-X
by	B-X
hypophosphataemia	B-X
and	B-X
by	B-X
low	B-X
levels	B-X
of	B-X
active	B-X
vitamin	B-X
D.	B-X
Chronic	B-X
hypophosphataemia	B-X
ultimately	B-X
results	B-X
in	B-X
osteomalacia	B-X
(	B-X
that	B-X
is	B-X
,	B-X
inadequate	B-X
bone	B-X
mineralization	B-X
)	B-X
.	B-X
One	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
emerging	B-X
treatments	B-X
for	B-X
unresectable	B-X
tumours	B-X
that	B-X
cause	B-X
TIO	B-X
is	B-X
the	B-X
anti-FGF23	B-X
monoclonal	B-X
antibody	B-X
KRN23	B-X
.	B-X
The	B-X
recent	B-X
identification	B-X
of	B-X
a	B-X
fusion	B-X
of	B-X
fibronectin	B-X
and	B-X
fibroblast	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
FGFR1	B-X
)	B-X
as	B-X
a	B-X
molecular	B-X
driver	B-X
in	B-X
some	B-X
tumours	B-X
not	B-X
only	B-X
sheds	B-X
light	B-X
on	B-X
the	B-X
pathophysiology	B-X
of	B-X
TIO	B-X
but	B-X
also	B-X
opens	B-X
the	B-X
door	B-X
to	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
transcription	B-X
,	B-X
translocation	B-X
,	B-X
post-translational	B-X
modification	B-X
and	B-X
secretion	B-X
of	B-X
FGF23	B-X
,	B-X
as	B-X
well	B-X
as	B-X
suggesting	B-X
approaches	B-X
to	B-X
targeted	B-X
therapy	B-X
.	B-X
Further	B-X
study	B-X
will	B-X
reveal	B-X
if	B-X
the	B-X
FGFR1	B-X
pathway	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
tumours	B-X
that	B-X
do	B-X
not	B-X
harbour	B-X
the	B-X
translocation	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
low	O
oxygen	O
upregulates	O
FGFR1	B-Gene_or_gene_product
expression	O
in	O
embryonic	O
aorta	O
in	O
vitro	O
and	O
renders	O
it	O
more	O
responsive	O
to	O
FGF2	B-Gene_or_gene_product
.	O
<EOS>	B-X
To	B-X
delineate	B-X
the	B-X
roles	B-X
that	B-X
oxygen	B-X
and	B-X
fibroblast	B-X
growth	B-X
factors	B-X
(	B-X
FGFs	B-X
)	B-X
play	B-X
in	B-X
the	B-X
process	B-X
of	B-X
angiogenesis	B-X
from	B-X
the	B-X
embryonic	B-X
aorta	B-X
,	B-X
we	B-X
cultured	B-X
mouse	B-X
embryonic	B-X
aorta	B-X
explants	B-X
(	B-X
thoracic	B-X
level	B-X
to	B-X
lateral	B-X
vessels	B-X
supplying	B-X
the	B-X
mesonephros	B-X
and	B-X
metanephros	B-X
)	B-X
in	B-X
a	B-X
three-dimensional	B-X
type	B-X
I	B-X
collagen	B-X
gel	B-X
matrix	B-X
.	B-X
During	B-X
8	B-X
days	B-X
of	B-X
culture	B-X
under	B-X
5	B-X
%	B-X
O	B-X
(	B-X
2	B-X
)	B-X
,	B-X
but	B-X
not	B-X
room	B-X
air	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
FGF2	B-X
to	B-X
explants	B-X
stimulated	B-X
the	B-X
formation	B-X
of	B-X
Gs-IB	B-X
(	B-X
4-	B-X
)	B-X
positive	B-X
,	B-X
CD31-positive	B-X
,	B-X
and	B-X
Flk-1-positive	B-X
microvessels	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
FGF2-stimulated	B-X
microvessel	B-X
formation	B-X
was	B-X
inhibited	B-X
by	B-X
sequestration	B-X
of	B-X
FGF2	B-X
via	B-X
addition	B-X
of	B-X
soluble	B-X
FGF	B-X
receptor	B-X
(	B-X
FGFR	B-X
)	B-X
chimera	B-X
protein	B-X
or	B-X
anti-FGF2	B-X
antibodies	B-X
.	B-X
FGFR1	B-X
and	B-X
FGFR2	B-X
were	B-X
present	B-X
on	B-X
explants	B-X
.	B-X
Levels	B-X
of	B-X
FGFR1	B-X
,	B-X
but	B-X
not	B-X
FGFR2	B-X
,	B-X
were	B-X
increased	B-X
in	B-X
embryonic	B-X
aorta	B-X
cultured	B-X
under	B-X
5	B-X
%	B-X
O	B-X
(	B-X
2	B-X
)	B-X
relative	B-X
to	B-X
room	B-X
air	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
low	B-X
oxygen	B-X
upregulates	B-X
FGFR1	B-X
expression	B-X
in	B-X
embryonic	B-X
aorta	B-X
in	B-X
vitro	B-X
and	B-X
renders	B-X
it	B-X
more	B-X
responsive	B-X
to	B-X
FGF2	B-X
.	B-X

Insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	O
mediated	O
vasculogenesis	O
/	O
angiogenesis	O
in	O
human	O
lung	O
development	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

The	O
structural	O
and	O
functional	O
development	O
of	O
the	O
pulmonary	O
system	O
is	O
dependent	O
upon	O
appropriate	O
early	O
vascularization	O
of	O
the	O
embryonic	O
lung	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

Our	O
previous	O
in	O
vitro	O
studies	O
in	O
a	O
rat	O
model	O
indicated	O
that	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
)	O
is	O
a	O
potent	O
angiogenic	O
agent	O
for	O
fetal	O
lung	O
endothelial	O
cells	O
.	O

To	O
assess	O
its	O
role	O
on	O
human	O
vascular	O
lung	O
development	O
,	O
we	O
first	O
examined	O
the	O
expression	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
/	O
II	B-Gene_or_gene_product
and	O
IGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
type	I-Gene_or_gene_product
I	I-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
)	O
in	O
human	O
embryonic	O
and	O
fetal	O
lung	O
tissues	O
at	O
4	O
-	O
12	O
wk	O
of	O
gestation	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

Immunohistochemical	O
and	O
in	O
situ	O
hybridization	O
studies	O
revealed	O
the	O
presence	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
/	O
II	B-Gene_or_gene_product
-	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
ligands	O
and	O
mRNA	O
transcripts	O
in	O
embryonic	O
lungs	O
as	O
early	O
as	O
4	O
wk	O
gestation	O
.	O

Immunotargeting	O
using	O
an	O
anti	O
-	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
neutralizing	O
antibody	O
on	O
human	O
fetal	O
lung	O
explants	O
demonstrated	O
a	O
significant	O
blockade	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
signaling	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

Inactivation	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
resulted	O
in	O
a	O
loss	O
of	O
endothelial	O
cells	O
,	O
accompanied	O
by	O
dramatic	O
changes	O
in	O
fetal	O
lung	O
explant	O
morphology	O
.	O

Terminal	O
transferase	O
dUTP	O
end	O
-	O
labeling	O
assay	O
and	O
TEM	O
studies	O
of	O
anti	O
-	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
-	O
treated	O
lungs	O
demonstrated	O
numerous	O
apoptotic	O
mesenchymal	O
cells	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

Rat	O
embryonic	O
lung	O
explant	O
studies	O
further	O
validated	O
the	O
importance	O
of	O
the	O
IGF	B-Gene_or_gene_product
-	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
system	O
for	O
lung	O
vascular	O
development	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

These	O
data	O
provide	O
the	O
first	O
demonstration	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
/	O
II	B-Gene_or_gene_product
expression	O
in	O
the	O
human	O
lung	O
in	O
early	O
gestation	O
and	O
indicate	O
that	O
the	O
IGF	B-Gene_or_gene_product
family	O
of	O
growth	O
factors	O
,	O
acting	O
through	O
the	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
,	O
is	O
required	O
as	O
a	O
survival	O
factor	O
during	O
normal	O
human	O
lung	O
vascularization	O
.	O
<EOS>	B-X
The	B-X
structural	B-X
and	B-X
functional	B-X
development	B-X
of	B-X
the	B-X
pulmonary	B-X
system	B-X
is	B-X
dependent	B-X
upon	B-X
appropriate	B-X
early	B-X
vascularization	B-X
of	B-X
the	B-X
embryonic	B-X
lung	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
indicated	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
(	B-X
IGF-I	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenic	B-X
agent	B-X
for	B-X
fetal	B-X
lung	B-X
endothelial	B-X
cells	B-X
.	B-X
To	B-X
assess	B-X
its	B-X
role	B-X
on	B-X
human	B-X
vascular	B-X
lung	B-X
development	B-X
,	B-X
we	B-X
first	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
IGF-I/II	B-X
and	B-X
IGF	B-X
receptor	B-X
type	B-X
I	B-X
(	B-X
IGF-IR	B-X
)	B-X
in	B-X
human	B-X
embryonic	B-X
and	B-X
fetal	B-X
lung	B-X
tissues	B-X
at	B-X
4-12	B-X
wk	B-X
of	B-X
gestation	B-X
.	B-X
Immunohistochemical	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
studies	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
IGF-I/II-IGF-IR	B-X
ligands	B-X
and	B-X
mRNA	B-X
transcripts	B-X
in	B-X
embryonic	B-X
lungs	B-X
as	B-X
early	B-X
as	B-X
4	B-X
wk	B-X
gestation	B-X
.	B-X
Immunotargeting	B-X
using	B-X
an	B-X
anti-IGF-IR	B-X
neutralizing	B-X
antibody	B-X
on	B-X
human	B-X
fetal	B-X
lung	B-X
explants	B-X
demonstrated	B-X
a	B-X
significant	B-X
blockade	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
Inactivation	B-X
of	B-X
IGF-IR	B-X
resulted	B-X
in	B-X
a	B-X
loss	B-X
of	B-X
endothelial	B-X
cells	B-X
,	B-X
accompanied	B-X
by	B-X
dramatic	B-X
changes	B-X
in	B-X
fetal	B-X
lung	B-X
explant	B-X
morphology	B-X
.	B-X
Terminal	B-X
transferase	B-X
dUTP	B-X
end-labeling	B-X
assay	B-X
and	B-X
TEM	B-X
studies	B-X
of	B-X
anti-IGF-IR-treated	B-X
lungs	B-X
demonstrated	B-X
numerous	B-X
apoptotic	B-X
mesenchymal	B-X
cells	B-X
.	B-X
Rat	B-X
embryonic	B-X
lung	B-X
explant	B-X
studies	B-X
further	B-X
validated	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
IGF-IGF-IR	B-X
system	B-X
for	B-X
lung	B-X
vascular	B-X
development	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
of	B-X
IGF-I/II	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
lung	B-X
in	B-X
early	B-X
gestation	B-X
and	B-X
indicate	B-X
that	B-X
the	B-X
IGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
acting	B-X
through	B-X
the	B-X
IGF-IR	B-X
,	B-X
is	B-X
required	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
during	B-X
normal	B-X
human	B-X
lung	B-X
vascularization	B-X
.	B-X

Enhanced	O
expression	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
by	O
periodontal	O
pathogens	O
in	O
gingival	O
fibroblasts	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
has	O
recently	O
attracted	O
attention	O
as	O
a	O
potent	O
inducer	O
of	O
vascular	O
permeability	O
and	O
angiogenesis	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
Aberrant	B-X
angiogenesis	B-X
is	B-X
often	B-X
associated	B-X
with	B-X
lesion	B-X
formation	B-X
in	B-X
chronic	B-X
periodontitis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

Aberrant	O
angiogenesis	O
is	O
often	O
associated	O
with	O
lesion	O
formation	O
in	O
chronic	O
periodontitis	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
Aberrant	B-X
angiogenesis	B-X
is	B-X
often	B-X
associated	B-X
with	B-X
lesion	B-X
formation	B-X
in	B-X
chronic	B-X
periodontitis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X
The	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
secreted	B-X
from	B-X
P.	B-X
gingivalis	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
periodontitis	B-X
.	B-X
Aberrant	B-X
angiogenesis	B-X
is	B-X
often	B-X
associated	B-X
with	B-X
lesion	B-X
formation	B-X
in	B-X
chronic	B-X
periodontitis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
P.	B-X
gingivalis	B-X
LPS	B-X
activates	B-X
angiogenic	B-X
cascade	B-X
,	B-X
migration	B-X
,	B-X
invasion	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
.	B-X
P.	B-X
gingivalis	B-X
LPS	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
or	B-X
its	B-X
receptor	B-X
,	B-X
Flk-1	B-X
,	B-X
implying	B-X
that	B-X
P.	B-X
gingivalis	B-X
LPS-induced	B-X
angiogenesis	B-X
may	B-X
result	B-X
from	B-X
its	B-X
direct	B-X
action	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
P.	B-X
gingivalis	B-X
LPS	B-X
evoked	B-X
activation	B-X
of	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
ERK1/2	B-X
in	B-X
HUVECs	B-X
,	B-X
which	B-X
is	B-X
closely	B-X
linked	B-X
to	B-X
angiogenesis	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
strongly	B-X
suggest	B-X
P.	B-X
gingivalis	B-X
LPS	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathological	B-X
angiogenesis	B-X
for	B-X
periodontal	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
periodontitis	B-X
.	B-X

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
properties	O
of	O
VEGF	B-Gene_or_gene_product
expression	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HGF	O
)	O
culture	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

HGF	O
were	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
vesicle	B-Gene_or_gene_product
(	O
Ve	B-Gene_or_gene_product
)	O
and	O
outer	B-Gene_or_gene_product
membrane	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
(	O
OMP	B-Gene_or_gene_product
)	O
from	O
Actinobacillus	O
actinomycetemcomitans	O
and	O
Porphyromonas	O
gingivalis	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

HGF	O
constitutively	O
produced	O
VEGF	B-Gene_or_gene_product
and	O
levels	O
were	O
significantly	O
enhanced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
by	O
stimulation	O
with	O
Ve	B-Gene_or_gene_product
and	O
OMP	B-Gene_or_gene_product
from	O
A	O
.	O
actinomycetemcomitans	O
and	O
P	O
.	O
gingivalis	O
at	O
concentrations	O
of	O
10	O
microg	O
/	O
ml	O
or	O
higher	O
.	O
<EOS>	B-X
Higher	B-X
weight	B-X
results	B-X
in	B-X
higher	B-X
energy	B-X
requirement	B-X
through	B-X
a	B-X
higher	B-X
resting	B-X
requirement	B-X
because	B-X
of	B-X
a	B-X
higher	B-X
maintenance	B-X
cost	B-X
of	B-X
a	B-X
larger	B-X
body	B-X
.	B-X
Smaller	B-X
and	B-X
leaner	B-X
subjects	B-X
generally	B-X
move	B-X
more	B-X
as	B-X
activity	B-X
energy	B-X
expenditure	B-X
in	B-X
larger	B-X
subjects	B-X
is	B-X
not	B-X
higher	B-X
in	B-X
proportion	B-X
to	B-X
the	B-X
cost	B-X
of	B-X
moving	B-X
with	B-X
a	B-X
higher	B-X
body	B-X
weight	B-X
.	B-X
Trained	B-X
subjects	B-X
have	B-X
a	B-X
higher	B-X
performance	B-X
at	B-X
the	B-X
same	B-X
expenditure	B-X
through	B-X
a	B-X
higher	B-X
exercise	B-X
economy	B-X
.	B-X
This	B-X
review	B-X
highlights	B-X
the	B-X
effects	B-X
of	B-X
microplastics	B-X
on	B-X
higher	B-X
plant	B-X
growth	B-X
and	B-X
performance	B-X
.	B-X
The	B-X
various	B-X
responses	B-X
of	B-X
higher	B-X
plants	B-X
to	B-X
microplastics	B-X
in	B-X
both	B-X
soils	B-X
and	B-X
waters	B-X
were	B-X
critically	B-X
reviewed	B-X
.	B-X
We	B-X
also	B-X
highlighted	B-X
the	B-X
influencing	B-X
mechanisms	B-X
of	B-X
microplastics	B-X
on	B-X
higher	B-X
plants	B-X
.	B-X
Conclusively	B-X
,	B-X
more	B-X
than	B-X
13	B-X
types	B-X
of	B-X
common	B-X
microplastics	B-X
and	B-X
more	B-X
than	B-X
30	B-X
species	B-X
of	B-X
higher	B-X
plants	B-X
have	B-X
been	B-X
selected	B-X
and	B-X
studied	B-X
by	B-X
the	B-X
published	B-X
literatures	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
microplastics	B-X
on	B-X
higher	B-X
plants	B-X
varied	B-X
among	B-X
microplastic	B-X
properties	B-X
,	B-X
plant	B-X
species	B-X
,	B-X
and	B-X
environmental	B-X
factors	B-X
.	B-X
Microplastics	B-X
had	B-X
no	B-X
or	B-X
positive	B-X
effects	B-X
on	B-X
higher	B-X
plants	B-X
under	B-X
certain	B-X
experimental	B-X
conditions	B-X
.	B-X
However	B-X
,	B-X
more	B-X
studies	B-X
showed	B-X
that	B-X
microplastics	B-X
can	B-X
inhibit	B-X
higher	B-X
plant	B-X
growth	B-X
and	B-X
performance	B-X
.	B-X
This	B-X
review	B-X
improves	B-X
the	B-X
understanding	B-X
of	B-X
effects	B-X
and	B-X
influencing	B-X
mechanisms	B-X
of	B-X
microplastics	B-X
on	B-X
higher	B-X
plants	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
VEGF	B-Gene_or_gene_product
levels	O
were	O
not	O
increased	O
by	O
LPS	O
stimulation	O
.	O
<EOS>	B-X
At	B-X
the	B-X
cellular	B-X
level	B-X
,	B-X
an	B-X
increased	B-X
concentration	B-X
of	B-X
extracellular	B-X
adenosine	B-X
as	B-X
well	B-X
as	B-X
the	B-X
depletion	B-X
of	B-X
tryptophan	B-X
and	B-X
uncontrolled	B-X
activation	B-X
of	B-X
the	B-X
PI3K/AKT	B-X
pathway	B-X
induces	B-X
an	B-X
immune-tolerant	B-X
TME	B-X
,	B-X
reducing	B-X
the	B-X
response	B-X
to	B-X
ICIs	B-X
.	B-X
Moreover	B-X
,	B-X
aberrant	B-X
angiogenesis	B-X
induces	B-X
a	B-X
hypoxic	B-X
environment	B-X
by	B-X
recruiting	B-X
VEGF	B-X
,	B-X
T	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
D-panthenol	B-X
reduced	B-X
TGF-Î²1	B-X
expressions	B-X
in	B-X
both	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
VEGF	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
peripheral	B-X
blood	B-X
vessel	B-X
activation	B-X
;	B-X
was	B-X
up-regulated	B-X
by	B-X
D-panthenol	B-X
treatment	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
both	B-X
VEGF	B-X
and	B-X
its	B-X
receptor	B-X
(	B-X
VEGFR	B-X
)	B-X
were	B-X
up-regulated	B-X
by	B-X
D-panthenol	B-X
.	B-X

VEGF	B-Gene_or_gene_product
mRNA	O
expression	O
was	O
also	O
observed	O
in	O
Ve	B-Gene_or_gene_product
-	O
and	O
OMP	B-Gene_or_gene_product
-	O
stimulated	O
HGF	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

A	O
vascular	O
permeability	O
enhancement	O
(	O
VPE	O
)	O
assay	O
was	O
performed	O
using	O
guinea	O
pigs	O
to	O
ascertain	O
whether	O
supernatant	O
from	O
cultures	O
of	O
Ve	B-Gene_or_gene_product
-	O
and	O
OMP	B-Gene_or_gene_product
-	O
stimulated	O
HGF	O
enhance	O
vascular	O
permeability	O
in	O
vivo	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

Supernatant	O
from	O
cultures	O
of	O
Ve	B-Gene_or_gene_product
-	O
and	O
OMP	B-Gene_or_gene_product
-	O
stimulated	O
HGF	O
strongly	O
induced	O
VPE	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

This	O
was	O
markedly	O
suppressed	O
upon	O
simultaneous	O
injection	O
of	O
anti	O
-	O
VEGF	B-Gene_or_gene_product
polyclonal	O
antibodies	O
with	O
the	O
supernatant	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

Heating	O
and	O
protease	O
treatment	O
of	O
the	O
stimulants	O
reduced	O
the	O
VEGF	B-Gene_or_gene_product
enhancing	O
levels	O
in	O
Ve	B-Gene_or_gene_product
and	O
OMP	B-Gene_or_gene_product
in	O
vitro	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

These	O
results	O
suggest	O
that	O
Ve	B-Gene_or_gene_product
and	O
OMP	B-Gene_or_gene_product
may	O
be	O
crucial	O
heat	O
-	O
labile	O
and	O
protease	O
-	O
sensitive	O
components	O
of	O
periodontal	O
pathogens	O
that	O
enhance	O
VEGF	B-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

In	O
addition	O
,	O
VEGF	B-Gene_or_gene_product
might	O
be	O
associated	O
with	O
the	O
etiology	O
of	O
periodontitis	O
in	O
its	O
early	O
stages	O
according	O
to	O
neovascularization	O
stimulated	O
by	O
periodontal	O
pathogens	O
causing	O
swelling	O
and	O
edema	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
recently	B-X
attracted	B-X
attention	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
vascular	B-X
permeability	B-X
and	B-X
angiogenesis	B-X
.	B-X
Aberrant	B-X
angiogenesis	B-X
is	B-X
often	B-X
associated	B-X
with	B-X
lesion	B-X
formation	B-X
in	B-X
chronic	B-X
periodontitis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
properties	B-X
of	B-X
VEGF	B-X
expression	B-X
in	B-X
human	B-X
gingival	B-X
fibroblasts	B-X
(	B-X
HGF	B-X
)	B-X
culture	B-X
.	B-X
HGF	B-X
were	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
vesicle	B-X
(	B-X
Ve	B-X
)	B-X
and	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
from	B-X
Actinobacillus	B-X
actinomycetemcomitans	B-X
and	B-X
Porphyromonas	B-X
gingivalis	B-X
.	B-X
HGF	B-X
constitutively	B-X
produced	B-X
VEGF	B-X
and	B-X
levels	B-X
were	B-X
significantly	B-X
enhanced	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
by	B-X
stimulation	B-X
with	B-X
Ve	B-X
and	B-X
OMP	B-X
from	B-X
A.	B-X
actinomycetemcomitans	B-X
and	B-X
P.	B-X
gingivalis	B-X
at	B-X
concentrations	B-X
of	B-X
10	B-X
microg/ml	B-X
or	B-X
higher	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
VEGF	B-X
levels	B-X
were	B-X
not	B-X
increased	B-X
by	B-X
LPS	B-X
stimulation	B-X
.	B-X
VEGF	B-X
mRNA	B-X
expression	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
.	B-X
A	B-X
vascular	B-X
permeability	B-X
enhancement	B-X
(	B-X
VPE	B-X
)	B-X
assay	B-X
was	B-X
performed	B-X
using	B-X
guinea	B-X
pigs	B-X
to	B-X
ascertain	B-X
whether	B-X
supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
enhance	B-X
vascular	B-X
permeability	B-X
in	B-X
vivo	B-X
.	B-X
Supernatant	B-X
from	B-X
cultures	B-X
of	B-X
Ve-	B-X
and	B-X
OMP-stimulated	B-X
HGF	B-X
strongly	B-X
induced	B-X
VPE	B-X
.	B-X
This	B-X
was	B-X
markedly	B-X
suppressed	B-X
upon	B-X
simultaneous	B-X
injection	B-X
of	B-X
anti-VEGF	B-X
polyclonal	B-X
antibodies	B-X
with	B-X
the	B-X
supernatant	B-X
.	B-X
Heating	B-X
and	B-X
protease	B-X
treatment	B-X
of	B-X
the	B-X
stimulants	B-X
reduced	B-X
the	B-X
VEGF	B-X
enhancing	B-X
levels	B-X
in	B-X
Ve	B-X
and	B-X
OMP	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Ve	B-X
and	B-X
OMP	B-X
may	B-X
be	B-X
crucial	B-X
heat-labile	B-X
and	B-X
protease-sensitive	B-X
components	B-X
of	B-X
periodontal	B-X
pathogens	B-X
that	B-X
enhance	B-X
VEGF	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VEGF	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
etiology	B-X
of	B-X
periodontitis	B-X
in	B-X
its	B-X
early	B-X
stages	B-X
according	B-X
to	B-X
neovascularization	B-X
stimulated	B-X
by	B-X
periodontal	B-X
pathogens	B-X
causing	B-X
swelling	B-X
and	B-X
edema	B-X
.	B-X

NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
/	O
Rel	B-Gene_or_gene_product
transcriptional	O
pathway	O
:	O
implications	O
in	O
pancreatic	O
cancer	O
.	O
<EOS>	B-X
Despite	B-X
considerable	B-X
efforts	B-X
in	B-X
understanding	B-X
the	B-X
cellular	B-X
mechanisms	B-X
contributing	B-X
to	B-X
pancreatic	B-X
cancer	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
this	B-X
malignant	B-X
disease	B-X
is	B-X
still	B-X
extremely	B-X
poor	B-X
.	B-X
Although	B-X
pancreatic	B-X
cancer	B-X
is	B-X
the	B-X
fifth	B-X
common	B-X
cause	B-X
of	B-X
cancer	B-X
death	B-X
in	B-X
Western	B-X
countries	B-X
,	B-X
current	B-X
options	B-X
in	B-X
treatment	B-X
enable	B-X
a	B-X
5-yr	B-X
survival	B-X
rate	B-X
for	B-X
all	B-X
stages	B-X
of	B-X
less	B-X
than	B-X
5	B-X
%	B-X
.	B-X
Based	B-X
on	B-X
its	B-X
role	B-X
in	B-X
malignant	B-X
transformation	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB/Rel	B-X
has	B-X
gained	B-X
the	B-X
attention	B-X
of	B-X
many	B-X
laboratories	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
basic	B-X
information	B-X
for	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
biology	B-X
of	B-X
NF-kappaB	B-X
and	B-X
aims	B-X
at	B-X
presenting	B-X
experimental	B-X
data	B-X
illustrating	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
pancreatic	B-X
cancer	B-X
.	B-X

Despite	O
considerable	O
efforts	O
in	O
understanding	O
the	O
cellular	O
mechanisms	O
contributing	O
to	O
pancreatic	O
cancer	O
,	O
the	O
prognosis	O
of	O
this	O
malignant	O
disease	O
is	O
still	O
extremely	O
poor	O
.	O
<EOS>	B-X
Despite	B-X
considerable	B-X
efforts	B-X
in	B-X
understanding	B-X
the	B-X
cellular	B-X
mechanisms	B-X
contributing	B-X
to	B-X
pancreatic	B-X
cancer	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
this	B-X
malignant	B-X
disease	B-X
is	B-X
still	B-X
extremely	B-X
poor	B-X
.	B-X
Although	B-X
pancreatic	B-X
cancer	B-X
is	B-X
the	B-X
fifth	B-X
common	B-X
cause	B-X
of	B-X
cancer	B-X
death	B-X
in	B-X
Western	B-X
countries	B-X
,	B-X
current	B-X
options	B-X
in	B-X
treatment	B-X
enable	B-X
a	B-X
5-yr	B-X
survival	B-X
rate	B-X
for	B-X
all	B-X
stages	B-X
of	B-X
less	B-X
than	B-X
5	B-X
%	B-X
.	B-X
Based	B-X
on	B-X
its	B-X
role	B-X
in	B-X
malignant	B-X
transformation	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB/Rel	B-X
has	B-X
gained	B-X
the	B-X
attention	B-X
of	B-X
many	B-X
laboratories	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
basic	B-X
information	B-X
for	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
biology	B-X
of	B-X
NF-kappaB	B-X
and	B-X
aims	B-X
at	B-X
presenting	B-X
experimental	B-X
data	B-X
illustrating	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
pancreatic	B-X
cancer	B-X
.	B-X

Although	O
pancreatic	O
cancer	O
is	O
the	O
fifth	O
common	O
cause	O
of	O
cancer	O
death	O
in	O
Western	O
countries	O
,	O
current	O
options	O
in	O
treatment	O
enable	O
a	O
5	O
-	O
yr	O
survival	O
rate	O
for	O
all	O
stages	O
of	O
less	O
than	O
5	O
%	O
.	O
<EOS>	B-X
Despite	B-X
considerable	B-X
efforts	B-X
in	B-X
understanding	B-X
the	B-X
cellular	B-X
mechanisms	B-X
contributing	B-X
to	B-X
pancreatic	B-X
cancer	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
this	B-X
malignant	B-X
disease	B-X
is	B-X
still	B-X
extremely	B-X
poor	B-X
.	B-X
Although	B-X
pancreatic	B-X
cancer	B-X
is	B-X
the	B-X
fifth	B-X
common	B-X
cause	B-X
of	B-X
cancer	B-X
death	B-X
in	B-X
Western	B-X
countries	B-X
,	B-X
current	B-X
options	B-X
in	B-X
treatment	B-X
enable	B-X
a	B-X
5-yr	B-X
survival	B-X
rate	B-X
for	B-X
all	B-X
stages	B-X
of	B-X
less	B-X
than	B-X
5	B-X
%	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
basic	B-X
information	B-X
for	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
biology	B-X
of	B-X
NF-kappaB	B-X
and	B-X
aims	B-X
at	B-X
presenting	B-X
experimental	B-X
data	B-X
illustrating	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
pancreatic	B-X
cancer	B-X
.	B-X

In	O
the	O
face	O
fo	O
the	O
fatal	O
outcome	O
,	O
new	O
approaches	O
to	O
the	O
therapy	O
have	O
been	O
established	O
.	O

Based	O
on	O
its	O
role	O
in	O
malignant	O
transformation	O
,	O
apoptosis	O
,	O
and	O
cell	O
proliferation	O
,	O
the	O
transcription	O
factor	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
/	O
Rel	B-Gene_or_gene_product
has	O
gained	O
the	O
attention	O
of	O
many	O
laboratories	O
.	O
<EOS>	B-X
Despite	B-X
considerable	B-X
efforts	B-X
in	B-X
understanding	B-X
the	B-X
cellular	B-X
mechanisms	B-X
contributing	B-X
to	B-X
pancreatic	B-X
cancer	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
this	B-X
malignant	B-X
disease	B-X
is	B-X
still	B-X
extremely	B-X
poor	B-X
.	B-X
Based	B-X
on	B-X
its	B-X
role	B-X
in	B-X
malignant	B-X
transformation	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB/Rel	B-X
has	B-X
gained	B-X
the	B-X
attention	B-X
of	B-X
many	B-X
laboratories	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
basic	B-X
information	B-X
for	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
biology	B-X
of	B-X
NF-kappaB	B-X
and	B-X
aims	B-X
at	B-X
presenting	B-X
experimental	B-X
data	B-X
illustrating	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
pancreatic	B-X
cancer	B-X
.	B-X

This	O
review	O
provides	O
basic	O
information	O
for	O
the	O
understanding	O
of	O
the	O
biology	O
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
and	O
aims	O
at	O
presenting	O
experimental	O
data	O
illustrating	O
the	O
involvement	O
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
/	O
Rel	B-Gene_or_gene_product
in	O
pancreatic	O
cancer	O
.	O
<EOS>	B-X
Despite	B-X
considerable	B-X
efforts	B-X
in	B-X
understanding	B-X
the	B-X
cellular	B-X
mechanisms	B-X
contributing	B-X
to	B-X
pancreatic	B-X
cancer	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
this	B-X
malignant	B-X
disease	B-X
is	B-X
still	B-X
extremely	B-X
poor	B-X
.	B-X
Although	B-X
pancreatic	B-X
cancer	B-X
is	B-X
the	B-X
fifth	B-X
common	B-X
cause	B-X
of	B-X
cancer	B-X
death	B-X
in	B-X
Western	B-X
countries	B-X
,	B-X
current	B-X
options	B-X
in	B-X
treatment	B-X
enable	B-X
a	B-X
5-yr	B-X
survival	B-X
rate	B-X
for	B-X
all	B-X
stages	B-X
of	B-X
less	B-X
than	B-X
5	B-X
%	B-X
.	B-X
Based	B-X
on	B-X
its	B-X
role	B-X
in	B-X
malignant	B-X
transformation	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB/Rel	B-X
has	B-X
gained	B-X
the	B-X
attention	B-X
of	B-X
many	B-X
laboratories	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
basic	B-X
information	B-X
for	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
biology	B-X
of	B-X
NF-kappaB	B-X
and	B-X
aims	B-X
at	B-X
presenting	B-X
experimental	B-X
data	B-X
illustrating	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
pancreatic	B-X
cancer	B-X
.	B-X

Combined	O
topical	O
fluconazole	O
and	O
corticosteroid	O
treatment	O
for	O
experimental	O
Candida	O
albicans	O
keratomycosis	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
most	B-X
efficient	B-X
time	B-X
point	B-X
and	B-X
concentration	B-X
of	B-X
topical	B-X
corticosteroids	B-X
in	B-X
Candida	B-X
albicans	B-X
keratitis	B-X
treated	B-X
with	B-X
fluconazole	B-X
.	B-X

PURPOSE	O
:	O
To	O
determine	O
the	O
most	O
efficient	O
time	O
point	O
and	O
concentration	O
of	O
topical	O
corticosteroids	O
in	O
Candida	O
albicans	O
keratitis	O
treated	O
with	O
fluconazole	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
most	B-X
efficient	B-X
time	B-X
point	B-X
and	B-X
concentration	B-X
of	B-X
topical	B-X
corticosteroids	B-X
in	B-X
Candida	B-X
albicans	B-X
keratitis	B-X
treated	B-X
with	B-X
fluconazole	B-X
.	B-X

METHODS	O
:	O
Corneas	O
of	O
105	O
rabbits	O
were	O
infected	O
with	O
viable	O
yeast	O
cells	O
of	O
C	O
.	O
albicans	O
(	O
2	O
.	O
5	O
x	O
10	O
(	O
5	O
)	O
)	O
.	O

After	O
a	O
48	O
-	O
hour	O
incubation	O
period	O
,	O
seven	O
groups	O
of	O
animals	O
were	O
treated	O
for	O
21	O
days	O
with	O
fluconazole	O
,	O
with	O
group	O
I	O
acting	O
as	O
a	O
control	O
,	O
and	O
groups	O
II	O
to	O
VII	O
receiving	O
adjunct	O
therapy	O
with	O
the	O
corticosteroid	O
prednisolone	O
(	O
5	O
or	O
10	O
times	O
daily	O
;	O
3	O
,	O
9	O
,	O
or	O
15	O
days	O
after	O
infection	O
)	O
.	O
<EOS>	B-X
Dividing	B-X
training	B-X
objectives	B-X
into	B-X
consecutive	B-X
phases	B-X
to	B-X
gain	B-X
morphological	B-X
adaptations	B-X
(	B-X
hypertrophy	B-X
phase	B-X
)	B-X
and	B-X
neural	B-X
adaptations	B-X
(	B-X
strength	B-X
and	B-X
power	B-X
phases	B-X
)	B-X
is	B-X
called	B-X
strength-power	B-X
periodization	B-X
(	B-X
SPP	B-X
)	B-X
.	B-X
Undulating	B-X
periodization	B-X
strategies	B-X
rotate	B-X
these	B-X
program	B-X
variables	B-X
in	B-X
a	B-X
bi-weekly	B-X
,	B-X
weekly	B-X
,	B-X
or	B-X
daily	B-X
fashion	B-X
.	B-X
The	B-X
following	B-X
review	B-X
addresses	B-X
the	B-X
effects	B-X
of	B-X
different	B-X
short-term	B-X
periodization	B-X
models	B-X
on	B-X
strength	B-X
and	B-X
speed-strength	B-X
both	B-X
with	B-X
subjects	B-X
of	B-X
different	B-X
performance	B-X
levels	B-X
and	B-X
with	B-X
competitive	B-X
athletes	B-X
from	B-X
different	B-X
sports	B-X
who	B-X
use	B-X
a	B-X
particular	B-X
periodization	B-X
model	B-X
during	B-X
off-season	B-X
,	B-X
pre-season	B-X
,	B-X
and	B-X
in-season	B-X
conditioning	B-X
.	B-X
In	B-X
most	B-X
periodization	B-X
studies	B-X
,	B-X
it	B-X
is	B-X
obvious	B-X
that	B-X
the	B-X
strength	B-X
endurance	B-X
sessions	B-X
are	B-X
characterized	B-X
by	B-X
repetition	B-X
zones	B-X
(	B-X
12-15	B-X
repetitions	B-X
)	B-X
that	B-X
induce	B-X
muscle	B-X
hypertrophy	B-X
in	B-X
persons	B-X
with	B-X
a	B-X
low	B-X
performance	B-X
level	B-X
.	B-X
Strictly	B-X
speaking	B-X
,	B-X
when	B-X
examining	B-X
subjects	B-X
with	B-X
a	B-X
low	B-X
training	B-X
level	B-X
,	B-X
many	B-X
periodization	B-X
studies	B-X
include	B-X
mainly	B-X
hypertrophy	B-X
sessions	B-X
interspersed	B-X
with	B-X
heavy	B-X
strength/power	B-X
sessions	B-X
.	B-X
Studies	B-X
have	B-X
demonstrated	B-X
equal	B-X
or	B-X
statistically	B-X
significant	B-X
higher	B-X
gains	B-X
in	B-X
maximal	B-X
strength	B-X
for	B-X
daily	B-X
undulating	B-X
periodization	B-X
compared	B-X
with	B-X
SPP	B-X
in	B-X
subjects	B-X
with	B-X
a	B-X
low	B-X
to	B-X
moderate	B-X
performance	B-X
level	B-X
.	B-X
The	B-X
relatively	B-X
short	B-X
intervention	B-X
period	B-X
and	B-X
the	B-X
lack	B-X
of	B-X
concomitant	B-X
sports	B-X
conditioning	B-X
call	B-X
into	B-X
question	B-X
the	B-X
practical	B-X
value	B-X
of	B-X
these	B-X
findings	B-X
for	B-X
competitive	B-X
athletes	B-X
.	B-X
Possibly	B-X
owing	B-X
to	B-X
differences	B-X
in	B-X
mesocycle	B-X
length	B-X
,	B-X
conditioning	B-X
programs	B-X
,	B-X
and	B-X
program	B-X
variables	B-X
,	B-X
competitive	B-X
athletes	B-X
either	B-X
maintained	B-X
or	B-X
improved	B-X
strength	B-X
and/or	B-X
speed-strength	B-X
performance	B-X
by	B-X
integrating	B-X
daily	B-X
undulating	B-X
periodization	B-X
and	B-X
SPP	B-X
during	B-X
off-season	B-X
,	B-X
pre-season	B-X
and	B-X
in-season	B-X
conditioning	B-X
.	B-X
In	B-X
high-performance	B-X
sports	B-X
,	B-X
high-repetition	B-X
strength	B-X
training	B-X
(	B-X
>	B-X
15	B-X
)	B-X
should	B-X
be	B-X
avoided	B-X
because	B-X
it	B-X
does	B-X
not	B-X
provide	B-X
an	B-X
adequate	B-X
training	B-X
stimulus	B-X
for	B-X
gains	B-X
in	B-X
muscle	B-X
cross-sectional	B-X
area	B-X
and	B-X
strength	B-X
performance	B-X
.	B-X
Indeed	B-X
,	B-X
meta-analyses	B-X
and	B-X
results	B-X
with	B-X
weightlifters	B-X
,	B-X
American	B-X
Football	B-X
players	B-X
,	B-X
and	B-X
throwers	B-X
confirm	B-X
the	B-X
necessity	B-X
of	B-X
the	B-X
habitual	B-X
use	B-X
of	B-X
â¥80	B-X
%	B-X
1	B-X
RM	B-X
:	B-X
(	B-X
1	B-X
)	B-X
to	B-X
improve	B-X
maximal	B-X
strength	B-X
during	B-X
the	B-X
off-season	B-X
and	B-X
in-season	B-X
in	B-X
American	B-X
Football	B-X
,	B-X
(	B-X
2	B-X
)	B-X
to	B-X
reach	B-X
peak	B-X
performance	B-X
in	B-X
maximal	B-X
strength	B-X
and	B-X
vertical	B-X
jump	B-X
power	B-X
during	B-X
tapering	B-X
in	B-X
track-and-field	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
to	B-X
produce	B-X
hypertrophy	B-X
and	B-X
strength	B-X
improvements	B-X
in	B-X
advanced	B-X
athletes	B-X
.	B-X
The	B-X
integration	B-X
and	B-X
extent	B-X
of	B-X
hypertrophy	B-X
strength	B-X
training	B-X
in	B-X
in-season	B-X
conditioning	B-X
depend	B-X
on	B-X
the	B-X
duration	B-X
of	B-X
the	B-X
contest	B-X
period	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
the	B-X
contests	B-X
,	B-X
and	B-X
the	B-X
proportion	B-X
of	B-X
the	B-X
conditioning	B-X
program	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
literature	B-X
,	B-X
72	B-X
h	B-X
between	B-X
hypertrophy	B-X
strength	B-X
training	B-X
and	B-X
strength-power	B-X
training	B-X
should	B-X
be	B-X
provided	B-X
to	B-X
allow	B-X
for	B-X
adequate	B-X
regeneration	B-X
times	B-X
and	B-X
therefore	B-X
maximal	B-X
stimulus	B-X
intensities	B-X
in	B-X
training	B-X
.	B-X
Comparative	B-X
studies	B-X
in	B-X
competitive	B-X
athletes	B-X
who	B-X
integrated	B-X
strength	B-X
training	B-X
during	B-X
pre-season	B-X
conditioning	B-X
confirm	B-X
a	B-X
tendency	B-X
for	B-X
gains	B-X
in	B-X
explosive	B-X
strength	B-X
and	B-X
statistically	B-X
significant	B-X
improvements	B-X
in	B-X
medicine	B-X
ball	B-X
throw	B-X
through	B-X
SPP	B-X
but	B-X
not	B-X
through	B-X
daily	B-X
undulating	B-X
periodization	B-X
.	B-X
It	B-X
is	B-X
possible	B-X
to	B-X
perform	B-X
a	B-X
single	B-X
strength-power	B-X
session	B-X
with	B-X
the	B-X
method	B-X
of	B-X
maximum	B-X
explosive	B-X
strength	B-X
actions	B-X
moving	B-X
high-weight	B-X
loads	B-X
(	B-X
90	B-X
%	B-X
1	B-X
repetition	B-X
maximum	B-X
[	B-X
RM	B-X
]	B-X
)	B-X
at	B-X
least	B-X
1-2	B-X
days	B-X
before	B-X
competition	B-X
because	B-X
of	B-X
the	B-X
shorter	B-X
regeneration	B-X
times	B-X
and	B-X
potentiation	B-X
effects	B-X
.	B-X
Compared	B-X
with	B-X
ballistic	B-X
strength	B-X
training	B-X
(	B-X
30	B-X
%	B-X
1	B-X
RM	B-X
)	B-X
,	B-X
this	B-X
method	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
provide	B-X
statistically	B-X
superior	B-X
gains	B-X
in	B-X
maximal	B-X
strength	B-X
,	B-X
peak	B-X
power	B-X
,	B-X
impulse	B-X
size	B-X
,	B-X
and	B-X
explosive	B-X
strength	B-X
during	B-X
tapering	B-X
in	B-X
track-and-field	B-X
throwers	B-X
.	B-X
The	B-X
speed-strength	B-X
performance	B-X
in	B-X
drop	B-X
jumps	B-X
of	B-X
strength-trained	B-X
subjects	B-X
showed	B-X
potentiation	B-X
effects	B-X
48-148	B-X
h	B-X
after	B-X
a	B-X
single	B-X
strength-power	B-X
training	B-X
session	B-X
.	B-X
Regarding	B-X
neuromuscular	B-X
performance	B-X
,	B-X
plyometric	B-X
exercises	B-X
can	B-X
even	B-X
be	B-X
performed	B-X
after	B-X
strength-power	B-X
training	B-X
on	B-X
the	B-X
same	B-X
day	B-X
if	B-X
a	B-X
minimum	B-X
rest	B-X
period	B-X
of	B-X
3	B-X
h	B-X
is	B-X
provided	B-X
.	B-X

The	O
degree	O
of	O
corneal	O
infiltration	O
,	O
ulceration	O
,	O
corneal	O
clouding	O
,	O
hypopyon	O
,	O
conjunctivitis	O
,	O
neovascularization	O
,	O
and	O
corneal	O
perforation	O
was	O
monitored	O
over	O
a	O
24	O
-	O
day	O
period	O
,	O
as	O
well	O
as	O
recultivation	O
and	O
resistance	O
to	O
fluconazole	O
of	O
the	O
C	O
.	O
albicans	O
pathogen	O
.	O

RESULTS	O
:	O
The	O
control	O
group	O
showed	O
the	O
highest	O
level	O
of	O
corneal	O
clouding	O
and	O
neovascularization	O
.	O
<EOS>	B-X
Immunologic	B-X
graft	B-X
rejection	B-X
is	B-X
one	B-X
of	B-X
the	B-X
main	B-X
causes	B-X
of	B-X
short	B-X
and	B-X
long-term	B-X
graft	B-X
failure	B-X
in	B-X
corneal	B-X
transplantation	B-X
.	B-X
Steroids	B-X
are	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
immunosuppressive	B-X
agents	B-X
for	B-X
postoperative	B-X
management	B-X
and	B-X
prevention	B-X
of	B-X
corneal	B-X
graft	B-X
rejection	B-X
.	B-X
However	B-X
,	B-X
steroids	B-X
delivered	B-X
in	B-X
eye	B-X
drops	B-X
are	B-X
rapidly	B-X
cleared	B-X
from	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
eye	B-X
,	B-X
so	B-X
the	B-X
required	B-X
frequency	B-X
of	B-X
dosing	B-X
for	B-X
corneal	B-X
graft	B-X
rejection	B-X
management	B-X
can	B-X
be	B-X
as	B-X
high	B-X
as	B-X
once	B-X
every	B-X
2h	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
a	B-X
biodegradable	B-X
nanoparticle	B-X
system	B-X
composed	B-X
of	B-X
Generally	B-X
Regarded	B-X
as	B-X
Safe	B-X
(	B-X
GRAS	B-X
)	B-X
materials	B-X
that	B-X
can	B-X
provide	B-X
sustained	B-X
release	B-X
of	B-X
corticosteroids	B-X
to	B-X
prevent	B-X
corneal	B-X
graft	B-X
rejection	B-X
following	B-X
subconjunctival	B-X
injection	B-X
provided	B-X
initially	B-X
during	B-X
transplant	B-X
surgery	B-X
.	B-X
DSP-loaded	B-X
nanoparticles	B-X
provided	B-X
sustained	B-X
ocular	B-X
drug	B-X
levels	B-X
for	B-X
at	B-X
least	B-X
7	B-X
days	B-X
after	B-X
subconjunctival	B-X
administration	B-X
in	B-X
rats	B-X
,	B-X
and	B-X
prevented	B-X
corneal	B-X
allograft	B-X
rejection	B-X
over	B-X
the	B-X
entire	B-X
9-week	B-X
study	B-X
when	B-X
administered	B-X
weekly	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
control	B-X
treatment	B-X
groups	B-X
that	B-X
received	B-X
weekly	B-X
injections	B-X
of	B-X
either	B-X
placebo	B-X
nanoparticles	B-X
,	B-X
saline	B-X
,	B-X
or	B-X
DSP	B-X
in	B-X
solution	B-X
demonstrated	B-X
corneal	B-X
graft	B-X
rejection	B-X
accompanied	B-X
by	B-X
severe	B-X
corneal	B-X
edema	B-X
,	B-X
neovascularization	B-X
and	B-X
opacity	B-X
that	B-X
occurred	B-X
in	B-X
â¤	B-X
4	B-X
weeks	B-X
.	B-X
Local	B-X
controlled	B-X
release	B-X
of	B-X
corticosteroids	B-X
may	B-X
reduce	B-X
the	B-X
rate	B-X
of	B-X
corneal	B-X
graft	B-X
rejection	B-X
,	B-X
perhaps	B-X
especially	B-X
in	B-X
the	B-X
days	B-X
immediately	B-X
following	B-X
surgery	B-X
when	B-X
risk	B-X
of	B-X
rejection	B-X
is	B-X
highest	B-X
and	B-X
when	B-X
typical	B-X
steroid	B-X
eye	B-X
drop	B-X
administration	B-X
requirements	B-X
are	B-X
particularly	B-X
onerous	B-X
.	B-X

In	O
comparison	O
,	O
by	O
day	O
24	O
,	O
the	O
majority	O
of	O
groups	O
also	O
treated	O
with	O
prednisolone	O
displayed	O
significantly	O
less	O
corneal	O
clouding	O
and	O
neovascularization	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
most	B-X
efficient	B-X
time	B-X
point	B-X
and	B-X
concentration	B-X
of	B-X
topical	B-X
corticosteroids	B-X
in	B-X
Candida	B-X
albicans	B-X
keratitis	B-X
treated	B-X
with	B-X
fluconazole	B-X
.	B-X

An	O
immediate	O
decrease	O
in	O
corneal	O
clouding	O
was	O
observed	O
in	O
groups	O
treated	O
with	O
additional	O
low	O
-	O
or	O
high	O
-	O
dose	O
prednisolone	O
from	O
day	O
9	O
after	O
inoculation	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
most	B-X
efficient	B-X
time	B-X
point	B-X
and	B-X
concentration	B-X
of	B-X
topical	B-X
corticosteroids	B-X
in	B-X
Candida	B-X
albicans	B-X
keratitis	B-X
treated	B-X
with	B-X
fluconazole	B-X
.	B-X

After	O
additional	O
prednisolone	O
treatment	O
from	O
day	O
9	O
or	O
15	O
after	O
inoculation	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
recultivation	O
rate	O
of	O
C	O
.	O
albicans	O
compared	O
with	O
the	O
control	O
.	O
<EOS>	B-X
Previous	B-X
trials	B-X
have	B-X
suggested	B-X
that	B-X
vasopressin	B-X
and	B-X
methylprednisolone	B-X
administered	B-X
during	B-X
in-hospital	B-X
cardiac	B-X
arrest	B-X
might	B-X
improve	B-X
outcomes	B-X
.	B-X
To	B-X
update	B-X
the	B-X
2008	B-X
consensus	B-X
statements	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
management	B-X
of	B-X
critical	B-X
illness-related	B-X
corticosteroid	B-X
insufficiency	B-X
(	B-X
CIRCI	B-X
)	B-X
in	B-X
adult	B-X
and	B-X
pediatric	B-X
patients	B-X
.	B-X
Because	B-X
previous	B-X
reports	B-X
suggested	B-X
that	B-X
corticosteroids	B-X
may	B-X
improve	B-X
survival	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
multicenter	B-X
,	B-X
randomized	B-X
controlled	B-X
trial	B-X
of	B-X
corticosteroids	B-X
in	B-X
patients	B-X
with	B-X
persistent	B-X
ARDS	B-X
.	B-X
Background/Aims	B-X
:	B-X
Controversy	B-X
exists	B-X
regarding	B-X
3-	B-X
or	B-X
4	B-X
drug	B-X
antituberculosis	B-X
therapy	B-X
(	B-X
conventional	B-X
ATT	B-X
)	B-X
in	B-X
uveitis	B-X
patients	B-X
having	B-X
latent	B-X
tuberculosis	B-X
(	B-X
LTB	B-X
)	B-X
,	B-X
especially	B-X
while	B-X
initiating	B-X
therapy	B-X
with	B-X
corticosteroids	B-X
and/or	B-X
other	B-X
immunosuppressants	B-X
.	B-X
Ophthalmological	B-X
evaluation	B-X
consisted	B-X
of	B-X
Best	B-X
corrected	B-X
visual	B-X
acuity	B-X
(	B-X
BCVA	B-X
)	B-X
,	B-X
slit	B-X
lamp	B-X
examination	B-X
,	B-X
fundoscopy	B-X
,	B-X
OCT	B-X
,	B-X
and	B-X
fluorescein-	B-X
and	B-X
indocyaningreen-	B-X
angiography	B-X
before	B-X
and	B-X
at	B-X
months	B-X
3	B-X
,	B-X
6	B-X
,	B-X
12	B-X
,	B-X
24	B-X
,	B-X
and	B-X
the	B-X
last	B-X
follow-up	B-X
after	B-X
treatment	B-X
.	B-X
Mean	B-X
follow	B-X
up	B-X
was	B-X
28	B-X
Â±	B-X
15	B-X
months	B-X
.	B-X
Therapy	B-X
was	B-X
started	B-X
with	B-X
systemic	B-X
corticosteroids	B-X
(	B-X
mean	B-X
prednisolone	B-X
equivalent	B-X
71.3	B-X
mg/d	B-X
)	B-X
and	B-X
already	B-X
after	B-X
3	B-X
months	B-X
it	B-X
could	B-X
be	B-X
tapered	B-X
to	B-X
a	B-X
mean	B-X
maintenance	B-X
dosage	B-X
of	B-X
8.63	B-X
mg/d	B-X
.	B-X
Additional	B-X
immunosuppressive	B-X
treatment	B-X
with	B-X
cs-	B-X
or	B-X
bDMARDs	B-X
was	B-X
initiated	B-X
in	B-X
14	B-X
patients	B-X
(	B-X
82	B-X
%	B-X
)	B-X
due	B-X
to	B-X
recurrences	B-X
of	B-X
uveitis	B-X
while	B-X
tapering	B-X
the	B-X
corticosteroids	B-X
<	B-X
10	B-X
mg	B-X
per/day	B-X
or	B-X
because	B-X
of	B-X
severe	B-X
inflammation	B-X
at	B-X
the	B-X
initial	B-X
visit	B-X
.	B-X
While	B-X
being	B-X
on	B-X
immunosuppression	B-X
,	B-X
best	B-X
corrected	B-X
visual	B-X
acuity	B-X
increased	B-X
from	B-X
0.56	B-X
logMAR	B-X
to	B-X
0.32	B-X
logMAR	B-X
during	B-X
follow-up	B-X
and	B-X
only	B-X
three	B-X
patients	B-X
had	B-X
one	B-X
uveitis	B-X
relapse	B-X
,	B-X
which	B-X
was	B-X
followed	B-X
by	B-X
switch	B-X
of	B-X
immunosuppressive	B-X
treatment	B-X
.	B-X
As	B-X
recommended	B-X
,	B-X
TB	B-X
prophylaxis	B-X
with	B-X
300	B-X
mg/d	B-X
isoniazid	B-X
was	B-X
administered	B-X
in	B-X
11	B-X
patients	B-X
for	B-X
at	B-X
least	B-X
9	B-X
months	B-X
while	B-X
being	B-X
on	B-X
TNF-alpha-blocking	B-X
agents	B-X
.	B-X
Conclusion	B-X
:	B-X
Mainly	B-X
conventional	B-X
ATT	B-X
is	B-X
strongly	B-X
recommendedâas	B-X
monotherapy	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
immunosuppressivesâfor	B-X
effective	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
uveitis	B-X
due	B-X
to	B-X
latent	B-X
TB	B-X
.	B-X
Although	B-X
in	B-X
our	B-X
patient	B-X
group	B-X
no	B-X
conventional	B-X
ATT	B-X
was	B-X
initiated	B-X
,	B-X
immunosuppression	B-X
alone	B-X
occurred	B-X
as	B-X
an	B-X
efficient	B-X
treatment	B-X
.	B-X

Early	O
administration	O
of	O
prednisolone	O
(	O
day	O
3	O
,	O
low	O
and	O
high	O
dose	O
)	O
resulted	O
in	O
the	O
recultivation	O
of	O
significantly	O
more	O
C	O
.	O
albicans	O
.	O

CONCLUSIONS	O
:	O
Fluconazole	O
plus	O
adjunct	O
high	O
-	O
dose	O
prednisolone	O
treatment	O
was	O
most	O
effective	O
when	O
administered	O
9	O
days	O
after	O
infection	O
.	O

The	O
delayed	O
application	O
of	O
corticosteroids	O
after	O
treatment	O
with	O
antimycotic	O
drugs	O
in	O
cases	O
of	O
fungal	O
keratitis	O
is	O
therefore	O
not	O
contraindicated	O
and	O
may	O
be	O
beneficial	O
in	O
patients	O
.	O

Solid	O
tumor	O
therapy	O
:	O
manipulation	O
of	O
the	O
vasculature	O
with	O
TNF	B-Gene_or_gene_product
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
to	B-X
solid	B-X
tumors	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
challenging	B-X
aspects	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
A	B-X
major	B-X
step	B-X
forwards	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
solid	B-X
tumors	B-X
is	B-X
the	B-X
recognition	B-X
of	B-X
the	B-X
tumor-associated	B-X
vasculature	B-X
as	B-X
an	B-X
important	B-X
target	B-X
for	B-X
therapy	B-X
.	B-X
Inhibition	B-X
of	B-X
tumor	B-X
vascular	B-X
development	B-X
has	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
Destruction	B-X
of	B-X
an	B-X
existing	B-X
vasculature	B-X
also	B-X
directly	B-X
inflicts	B-X
serious	B-X
damage	B-X
to	B-X
the	B-X
tumor	B-X
cell	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
can	B-X
be	B-X
manipulated	B-X
facilitating	B-X
enhanced	B-X
permissiveness	B-X
of	B-X
the	B-X
tumor	B-X
for	B-X
administered	B-X
chemotherapeutics	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
use	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
local	B-X
and	B-X
systemic	B-X
therapy	B-X
in	B-X
conjunction	B-X
with	B-X
chemotherapy	B-X
.	B-X
In	B-X
these	B-X
settings	B-X
TNF	B-X
demonstrates	B-X
potent	B-X
and	B-X
selective	B-X
activity	B-X
on	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
,	B-X
which	B-X
strongly	B-X
improves	B-X
tumor	B-X
response	B-X
.	B-X

Drug	O
delivery	O
to	O
solid	O
tumors	O
is	O
one	O
of	O
the	O
most	O
challenging	O
aspects	O
in	O
cancer	O
therapy	O
.	O
<EOS>	B-X
Pancreatic	B-X
cancer	B-X
(	B-X
PC	B-X
)	B-X
remains	B-X
the	B-X
seventh	B-X
leading	B-X
cause	B-X
of	B-X
cancer-related	B-X
deaths	B-X
worldwide	B-X
and	B-X
the	B-X
third	B-X
in	B-X
the	B-X
United	B-X
States	B-X
,	B-X
making	B-X
it	B-X
one	B-X
of	B-X
the	B-X
most	B-X
lethal	B-X
solid	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
the	B-X
number	B-X
of	B-X
new	B-X
studies	B-X
on	B-X
systemic	B-X
therapy	B-X
,	B-X
very	B-X
little	B-X
research	B-X
has	B-X
been	B-X
conducted	B-X
on	B-X
localised	B-X
interventions	B-X
for	B-X
PC	B-X
.	B-X
Most	B-X
importantly	B-X
,	B-X
to	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
the	B-X
aspect	B-X
of	B-X
localised	B-X
drug	B-X
delivery	B-X
systems	B-X
used	B-X
in	B-X
PC	B-X
was	B-X
unprecedentedly	B-X
discussed	B-X
in	B-X
this	B-X
work	B-X
.	B-X
This	B-X
review	B-X
is	B-X
meant	B-X
for	B-X
researchers	B-X
and	B-X
clinicians	B-X
considering	B-X
utilizing	B-X
local	B-X
therapy	B-X
for	B-X
the	B-X
effective	B-X
treatment	B-X
of	B-X
PC	B-X
,	B-X
providing	B-X
a	B-X
thorough	B-X
guide	B-X
on	B-X
recent	B-X
advancements	B-X
in	B-X
research	B-X
and	B-X
clinical	B-X
trials	B-X
toward	B-X
locoregional	B-X
interventions	B-X
,	B-X
together	B-X
with	B-X
the	B-X
authors	B-X
'	B-X
insight	B-X
into	B-X
their	B-X
potential	B-X
improvements	B-X
.	B-X

Whereas	O
agents	O
seem	O
promising	O
in	O
the	O
test	O
tube	O
,	O
clinical	O
trials	O
often	O
fail	O
due	O
to	O
unfavorable	O
pharmacokinetics	O
,	O
poor	O
delivery	O
,	O
low	O
local	O
concentrations	O
,	O
and	O
limited	O
accumulation	O
in	O
the	O
target	O
cell	O
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
to	B-X
solid	B-X
tumors	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
challenging	B-X
aspects	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Whereas	B-X
agents	B-X
seem	B-X
promising	B-X
in	B-X
the	B-X
test	B-X
tube	B-X
,	B-X
clinical	B-X
trials	B-X
often	B-X
fail	B-X
due	B-X
to	B-X
unfavorable	B-X
pharmacokinetics	B-X
,	B-X
poor	B-X
delivery	B-X
,	B-X
low	B-X
local	B-X
concentrations	B-X
,	B-X
and	B-X
limited	B-X
accumulation	B-X
in	B-X
the	B-X
target	B-X
cell	B-X
.	B-X
A	B-X
major	B-X
step	B-X
forwards	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
solid	B-X
tumors	B-X
is	B-X
the	B-X
recognition	B-X
of	B-X
the	B-X
tumor-associated	B-X
vasculature	B-X
as	B-X
an	B-X
important	B-X
target	B-X
for	B-X
therapy	B-X
.	B-X
Destruction	B-X
of	B-X
an	B-X
existing	B-X
vasculature	B-X
also	B-X
directly	B-X
inflicts	B-X
serious	B-X
damage	B-X
to	B-X
the	B-X
tumor	B-X
cell	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
use	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
local	B-X
and	B-X
systemic	B-X
therapy	B-X
in	B-X
conjunction	B-X
with	B-X
chemotherapy	B-X
.	B-X

A	O
major	O
step	O
forwards	O
in	O
the	O
treatment	O
of	O
solid	O
tumors	O
is	O
the	O
recognition	O
of	O
the	O
tumor	O
-	O
associated	O
vasculature	O
as	O
an	O
important	O
target	O
for	O
therapy	O
.	O

Inhibition	O
of	O
tumor	O
vascular	O
development	O
has	O
a	O
direct	O
effect	O
on	O
the	O
growth	O
and	O
progression	O
of	O
the	O
tumor	O
.	O

Destruction	O
of	O
an	O
existing	O
vasculature	O
also	O
directly	O
inflicts	O
serious	O
damage	O
to	O
the	O
tumor	O
cell	O
.	O

Moreover	O
,	O
the	O
tumor	O
vascular	O
bed	O
can	O
be	O
manipulated	O
facilitating	O
enhanced	O
permissiveness	O
of	O
the	O
tumor	O
for	O
administered	O
chemotherapeutics	O
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
to	B-X
solid	B-X
tumors	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
challenging	B-X
aspects	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
A	B-X
major	B-X
step	B-X
forwards	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
solid	B-X
tumors	B-X
is	B-X
the	B-X
recognition	B-X
of	B-X
the	B-X
tumor-associated	B-X
vasculature	B-X
as	B-X
an	B-X
important	B-X
target	B-X
for	B-X
therapy	B-X
.	B-X
Inhibition	B-X
of	B-X
tumor	B-X
vascular	B-X
development	B-X
has	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
Destruction	B-X
of	B-X
an	B-X
existing	B-X
vasculature	B-X
also	B-X
directly	B-X
inflicts	B-X
serious	B-X
damage	B-X
to	B-X
the	B-X
tumor	B-X
cell	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
can	B-X
be	B-X
manipulated	B-X
facilitating	B-X
enhanced	B-X
permissiveness	B-X
of	B-X
the	B-X
tumor	B-X
for	B-X
administered	B-X
chemotherapeutics	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
use	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
local	B-X
and	B-X
systemic	B-X
therapy	B-X
in	B-X
conjunction	B-X
with	B-X
chemotherapy	B-X
.	B-X
In	B-X
these	B-X
settings	B-X
TNF	B-X
demonstrates	B-X
potent	B-X
and	B-X
selective	B-X
activity	B-X
on	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
,	B-X
which	B-X
strongly	B-X
improves	B-X
tumor	B-X
response	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
use	O
of	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
(	O
TNF	B-Gene_or_gene_product
)	O
in	O
local	O
and	O
systemic	O
therapy	O
in	O
conjunction	O
with	O
chemotherapy	O
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
to	B-X
solid	B-X
tumors	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
challenging	B-X
aspects	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Whereas	B-X
agents	B-X
seem	B-X
promising	B-X
in	B-X
the	B-X
test	B-X
tube	B-X
,	B-X
clinical	B-X
trials	B-X
often	B-X
fail	B-X
due	B-X
to	B-X
unfavorable	B-X
pharmacokinetics	B-X
,	B-X
poor	B-X
delivery	B-X
,	B-X
low	B-X
local	B-X
concentrations	B-X
,	B-X
and	B-X
limited	B-X
accumulation	B-X
in	B-X
the	B-X
target	B-X
cell	B-X
.	B-X
A	B-X
major	B-X
step	B-X
forwards	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
solid	B-X
tumors	B-X
is	B-X
the	B-X
recognition	B-X
of	B-X
the	B-X
tumor-associated	B-X
vasculature	B-X
as	B-X
an	B-X
important	B-X
target	B-X
for	B-X
therapy	B-X
.	B-X
Inhibition	B-X
of	B-X
tumor	B-X
vascular	B-X
development	B-X
has	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
Destruction	B-X
of	B-X
an	B-X
existing	B-X
vasculature	B-X
also	B-X
directly	B-X
inflicts	B-X
serious	B-X
damage	B-X
to	B-X
the	B-X
tumor	B-X
cell	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
can	B-X
be	B-X
manipulated	B-X
facilitating	B-X
enhanced	B-X
permissiveness	B-X
of	B-X
the	B-X
tumor	B-X
for	B-X
administered	B-X
chemotherapeutics	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
use	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
local	B-X
and	B-X
systemic	B-X
therapy	B-X
in	B-X
conjunction	B-X
with	B-X
chemotherapy	B-X
.	B-X
In	B-X
these	B-X
settings	B-X
TNF	B-X
demonstrates	B-X
potent	B-X
and	B-X
selective	B-X
activity	B-X
on	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
,	B-X
which	B-X
strongly	B-X
improves	B-X
tumor	B-X
response	B-X
.	B-X

In	O
these	O
settings	O
TNF	B-Gene_or_gene_product
demonstrates	O
potent	O
and	O
selective	O
activity	O
on	O
the	O
tumor	O
vascular	O
bed	O
,	O
which	O
strongly	O
improves	O
tumor	O
response	O
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
to	B-X
solid	B-X
tumors	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
challenging	B-X
aspects	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
A	B-X
major	B-X
step	B-X
forwards	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
solid	B-X
tumors	B-X
is	B-X
the	B-X
recognition	B-X
of	B-X
the	B-X
tumor-associated	B-X
vasculature	B-X
as	B-X
an	B-X
important	B-X
target	B-X
for	B-X
therapy	B-X
.	B-X
Inhibition	B-X
of	B-X
tumor	B-X
vascular	B-X
development	B-X
has	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
Destruction	B-X
of	B-X
an	B-X
existing	B-X
vasculature	B-X
also	B-X
directly	B-X
inflicts	B-X
serious	B-X
damage	B-X
to	B-X
the	B-X
tumor	B-X
cell	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
can	B-X
be	B-X
manipulated	B-X
facilitating	B-X
enhanced	B-X
permissiveness	B-X
of	B-X
the	B-X
tumor	B-X
for	B-X
administered	B-X
chemotherapeutics	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
use	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
local	B-X
and	B-X
systemic	B-X
therapy	B-X
in	B-X
conjunction	B-X
with	B-X
chemotherapy	B-X
.	B-X
In	B-X
these	B-X
settings	B-X
TNF	B-X
demonstrates	B-X
potent	B-X
and	B-X
selective	B-X
activity	B-X
on	B-X
the	B-X
tumor	B-X
vascular	B-X
bed	B-X
,	B-X
which	B-X
strongly	B-X
improves	B-X
tumor	B-X
response	B-X
.	B-X

Comparison	O
of	O
tissue	O
integration	O
between	O
polyester	O
and	O
polypropylene	O
prostheses	O
in	O
the	O
preperitoneal	O
space	O
.	O
<EOS>	B-X
Tissue	B-X
integration	B-X
and	B-X
implant	B-X
characteristics	B-X
of	B-X
various	B-X
biomaterials	B-X
commonly	B-X
used	B-X
for	B-X
inguinal	B-X
hernia	B-X
repair	B-X
have	B-X
not	B-X
been	B-X
studied	B-X
extensively	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
behavior	B-X
and	B-X
tissue	B-X
response	B-X
between	B-X
two	B-X
new	B-X
polyester	B-X
prostheses	B-X
and	B-X
a	B-X
commonly	B-X
used	B-X
polypropylene	B-X
(	B-X
PP	B-X
)	B-X
mesh	B-X
.	B-X
The	B-X
polyester	B-X
prostheses	B-X
utilized	B-X
were	B-X
polyester	B-X
flat	B-X
(	B-X
PF	B-X
)	B-X
and	B-X
polyester	B-X
soft	B-X
three-dimensional	B-X
(	B-X
PS	B-X
)	B-X
;	B-X
the	B-X
PP	B-X
mesh	B-X
utilized	B-X
was	B-X
Marlex	B-X
.	B-X
Eight	B-X
randomly	B-X
assigned	B-X
4	B-X
x	B-X
4-cm2	B-X
pieces	B-X
of	B-X
two	B-X
different	B-X
meshes	B-X
were	B-X
fixed	B-X
in	B-X
the	B-X
preperitoneal	B-X
space	B-X
with	B-X
a	B-X
centrally	B-X
placed	B-X
single	B-X
suture	B-X
.	B-X
Histological	B-X
evaluation	B-X
included	B-X
amount	B-X
of	B-X
fibrous	B-X
and	B-X
fat	B-X
encapsulation	B-X
,	B-X
connective	B-X
tissue	B-X
,	B-X
foreign-body	B-X
reaction	B-X
,	B-X
neovascularization	B-X
,	B-X
hemorrhage	B-X
,	B-X
necrosis	B-X
,	B-X
and	B-X
exudate	B-X
.	B-X
PP	B-X
mesh	B-X
resulted	B-X
in	B-X
more	B-X
fibrous	B-X
encapsulation	B-X
and	B-X
stiffness	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
PP	B-X
also	B-X
resulted	B-X
in	B-X
less	B-X
connective	B-X
tissue	B-X
formation	B-X
and	B-X
foreign-body	B-X
reaction	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
fat	B-X
encapsulation	B-X
,	B-X
necrosis	B-X
,	B-X
hemorrhage	B-X
,	B-X
or	B-X
exudate	B-X
between	B-X
prostheses	B-X
.	B-X
Both	B-X
polyester	B-X
prostheses	B-X
(	B-X
PF	B-X
and	B-X
PS	B-X
)	B-X
have	B-X
better	B-X
tissue	B-X
integration	B-X
than	B-X
the	B-X
PP	B-X
mesh	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
higher	B-X
amount	B-X
of	B-X
connective	B-X
tissue	B-X
and	B-X
lower	B-X
extent	B-X
of	B-X
fibrous	B-X
encapsulation	B-X
.	B-X

Tissue	O
integration	O
and	O
implant	O
characteristics	O
of	O
various	O
biomaterials	O
commonly	O
used	O
for	O
inguinal	O
hernia	O
repair	O
have	O
not	O
been	O
studied	O
extensively	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
behavior	O
and	O
tissue	O
response	O
between	O
two	O
new	O
polyester	O
prostheses	O
and	O
a	O
commonly	O
used	O
polypropylene	O
(	O
PP	O
)	O
mesh	O
.	O

The	O
polyester	O
prostheses	O
utilized	O
were	O
polyester	O
flat	O
(	O
PF	O
)	O
and	O
polyester	O
soft	O
three	O
-	O
dimensional	O
(	O
PS	O
)	O
;	O
the	O
PP	O
mesh	O
utilized	O
was	O
Marlex	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
behavior	B-X
and	B-X
tissue	B-X
response	B-X
between	B-X
two	B-X
new	B-X
polyester	B-X
prostheses	B-X
and	B-X
a	B-X
commonly	B-X
used	B-X
polypropylene	B-X
(	B-X
PP	B-X
)	B-X
mesh	B-X
.	B-X
The	B-X
polyester	B-X
prostheses	B-X
utilized	B-X
were	B-X
polyester	B-X
flat	B-X
(	B-X
PF	B-X
)	B-X
and	B-X
polyester	B-X
soft	B-X
three-dimensional	B-X
(	B-X
PS	B-X
)	B-X
;	B-X
the	B-X
PP	B-X
mesh	B-X
utilized	B-X
was	B-X
Marlex	B-X
.	B-X
Eight	B-X
randomly	B-X
assigned	B-X
4	B-X
x	B-X
4-cm2	B-X
pieces	B-X
of	B-X
two	B-X
different	B-X
meshes	B-X
were	B-X
fixed	B-X
in	B-X
the	B-X
preperitoneal	B-X
space	B-X
with	B-X
a	B-X
centrally	B-X
placed	B-X
single	B-X
suture	B-X
.	B-X
PP	B-X
mesh	B-X
resulted	B-X
in	B-X
more	B-X
fibrous	B-X
encapsulation	B-X
and	B-X
stiffness	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
PP	B-X
also	B-X
resulted	B-X
in	B-X
less	B-X
connective	B-X
tissue	B-X
formation	B-X
and	B-X
foreign-body	B-X
reaction	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
fat	B-X
encapsulation	B-X
,	B-X
necrosis	B-X
,	B-X
hemorrhage	B-X
,	B-X
or	B-X
exudate	B-X
between	B-X
prostheses	B-X
.	B-X
Both	B-X
polyester	B-X
prostheses	B-X
(	B-X
PF	B-X
and	B-X
PS	B-X
)	B-X
have	B-X
better	B-X
tissue	B-X
integration	B-X
than	B-X
the	B-X
PP	B-X
mesh	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
higher	B-X
amount	B-X
of	B-X
connective	B-X
tissue	B-X
and	B-X
lower	B-X
extent	B-X
of	B-X
fibrous	B-X
encapsulation	B-X
.	B-X

Eight	O
randomly	O
assigned	O
4	O
x	O
4	O
-	O
cm2	O
pieces	O
of	O
two	O
different	O
meshes	O
were	O
fixed	O
in	O
the	O
preperitoneal	O
space	O
with	O
a	O
centrally	O
placed	O
single	O
suture	O
.	O
<EOS>	B-X
Tissue	B-X
integration	B-X
and	B-X
implant	B-X
characteristics	B-X
of	B-X
various	B-X
biomaterials	B-X
commonly	B-X
used	B-X
for	B-X
inguinal	B-X
hernia	B-X
repair	B-X
have	B-X
not	B-X
been	B-X
studied	B-X
extensively	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
behavior	B-X
and	B-X
tissue	B-X
response	B-X
between	B-X
two	B-X
new	B-X
polyester	B-X
prostheses	B-X
and	B-X
a	B-X
commonly	B-X
used	B-X
polypropylene	B-X
(	B-X
PP	B-X
)	B-X
mesh	B-X
.	B-X
The	B-X
polyester	B-X
prostheses	B-X
utilized	B-X
were	B-X
polyester	B-X
flat	B-X
(	B-X
PF	B-X
)	B-X
and	B-X
polyester	B-X
soft	B-X
three-dimensional	B-X
(	B-X
PS	B-X
)	B-X
;	B-X
the	B-X
PP	B-X
mesh	B-X
utilized	B-X
was	B-X
Marlex	B-X
.	B-X
Eight	B-X
randomly	B-X
assigned	B-X
4	B-X
x	B-X
4-cm2	B-X
pieces	B-X
of	B-X
two	B-X
different	B-X
meshes	B-X
were	B-X
fixed	B-X
in	B-X
the	B-X
preperitoneal	B-X
space	B-X
with	B-X
a	B-X
centrally	B-X
placed	B-X
single	B-X
suture	B-X
.	B-X
Histological	B-X
evaluation	B-X
included	B-X
amount	B-X
of	B-X
fibrous	B-X
and	B-X
fat	B-X
encapsulation	B-X
,	B-X
connective	B-X
tissue	B-X
,	B-X
foreign-body	B-X
reaction	B-X
,	B-X
neovascularization	B-X
,	B-X
hemorrhage	B-X
,	B-X
necrosis	B-X
,	B-X
and	B-X
exudate	B-X
.	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
fat	B-X
encapsulation	B-X
,	B-X
necrosis	B-X
,	B-X
hemorrhage	B-X
,	B-X
or	B-X
exudate	B-X
between	B-X
prostheses	B-X
.	B-X
Both	B-X
polyester	B-X
prostheses	B-X
(	B-X
PF	B-X
and	B-X
PS	B-X
)	B-X
have	B-X
better	B-X
tissue	B-X
integration	B-X
than	B-X
the	B-X
PP	B-X
mesh	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
higher	B-X
amount	B-X
of	B-X
connective	B-X
tissue	B-X
and	B-X
lower	B-X
extent	B-X
of	B-X
fibrous	B-X
encapsulation	B-X
.	B-X

Gross	O
evaluation	O
included	O
shrinkage	O
and	O
stiffness	O
.	O
<EOS>	B-X
Gross	B-X
evaluation	B-X
included	B-X
shrinkage	B-X
and	B-X
stiffness	B-X
.	B-X
Histological	B-X
evaluation	B-X
included	B-X
amount	B-X
of	B-X
fibrous	B-X
and	B-X
fat	B-X
encapsulation	B-X
,	B-X
connective	B-X
tissue	B-X
,	B-X
foreign-body	B-X
reaction	B-X
,	B-X
neovascularization	B-X
,	B-X
hemorrhage	B-X
,	B-X
necrosis	B-X
,	B-X
and	B-X
exudate	B-X
.	B-X
PP	B-X
mesh	B-X
resulted	B-X
in	B-X
more	B-X
fibrous	B-X
encapsulation	B-X
and	B-X
stiffness	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X

Histological	O
evaluation	O
included	O
amount	O
of	O
fibrous	O
and	O
fat	O
encapsulation	O
,	O
connective	O
tissue	O
,	O
foreign	O
-	O
body	O
reaction	O
,	O
neovascularization	O
,	O
hemorrhage	O
,	O
necrosis	O
,	O
and	O
exudate	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
behavior	B-X
and	B-X
tissue	B-X
response	B-X
between	B-X
two	B-X
new	B-X
polyester	B-X
prostheses	B-X
and	B-X
a	B-X
commonly	B-X
used	B-X
polypropylene	B-X
(	B-X
PP	B-X
)	B-X
mesh	B-X
.	B-X
Gross	B-X
evaluation	B-X
included	B-X
shrinkage	B-X
and	B-X
stiffness	B-X
.	B-X
Histological	B-X
evaluation	B-X
included	B-X
amount	B-X
of	B-X
fibrous	B-X
and	B-X
fat	B-X
encapsulation	B-X
,	B-X
connective	B-X
tissue	B-X
,	B-X
foreign-body	B-X
reaction	B-X
,	B-X
neovascularization	B-X
,	B-X
hemorrhage	B-X
,	B-X
necrosis	B-X
,	B-X
and	B-X
exudate	B-X
.	B-X
PP	B-X
mesh	B-X
resulted	B-X
in	B-X
more	B-X
fibrous	B-X
encapsulation	B-X
and	B-X
stiffness	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
PP	B-X
also	B-X
resulted	B-X
in	B-X
less	B-X
connective	B-X
tissue	B-X
formation	B-X
and	B-X
foreign-body	B-X
reaction	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
fat	B-X
encapsulation	B-X
,	B-X
necrosis	B-X
,	B-X
hemorrhage	B-X
,	B-X
or	B-X
exudate	B-X
between	B-X
prostheses	B-X
.	B-X
Both	B-X
polyester	B-X
prostheses	B-X
(	B-X
PF	B-X
and	B-X
PS	B-X
)	B-X
have	B-X
better	B-X
tissue	B-X
integration	B-X
than	B-X
the	B-X
PP	B-X
mesh	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
higher	B-X
amount	B-X
of	B-X
connective	B-X
tissue	B-X
and	B-X
lower	B-X
extent	B-X
of	B-X
fibrous	B-X
encapsulation	B-X
.	B-X

Evaluations	O
were	O
graded	O
on	O
a	O
zero	O
to	O
four	O
scale	O
.	O
<EOS>	B-X
A	B-X
systematic	B-X
search	B-X
was	B-X
conducted	B-X
in	B-X
four	B-X
electronic	B-X
databases	B-X
following	B-X
PRISMA	B-X
guidelines	B-X
.	B-X
The	B-X
meta-analysis	B-X
included	B-X
those	B-X
six	B-X
articles	B-X
which	B-X
reported	B-X
means	B-X
and	B-X
SD	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
and	B-X
used	B-X
a	B-X
visual	B-X
analog	B-X
scale	B-X
or	B-X
a	B-X
Numeric	B-X
Pain	B-X
Rating	B-X
Scale	B-X
.	B-X
Although	B-X
four	B-X
of	B-X
the	B-X
seven	B-X
articles	B-X
reported	B-X
significant	B-X
within-group	B-X
differences	B-X
,	B-X
zero	B-X
was	B-X
included	B-X
in	B-X
the	B-X
CI	B-X
of	B-X
the	B-X
overall	B-X
effect	B-X
size	B-X
.	B-X
Color	B-X
images	B-X
are	B-X
visualized	B-X
on	B-X
medical	B-X
monitors	B-X
that	B-X
are	B-X
adjusted	B-X
by	B-X
a	B-X
grayscale	B-X
standard	B-X
display	B-X
function	B-X
(	B-X
GSDF	B-X
)	B-X
or	B-X
Î³2.2	B-X
.	B-X
Although	B-X
the	B-X
GSDF	B-X
is	B-X
visually	B-X
displayed	B-X
as	B-X
a	B-X
linear	B-X
graded	B-X
grayscale	B-X
,	B-X
it	B-X
does	B-X
not	B-X
specify	B-X
how	B-X
color	B-X
medical	B-X
images	B-X
should	B-X
be	B-X
presented	B-X
.	B-X
The	B-X
present	B-X
study	B-X
aimed	B-X
to	B-X
identify	B-X
differences	B-X
in	B-X
color-scale	B-X
characteristics	B-X
on	B-X
nuclear	B-X
medicine	B-X
images	B-X
displayed	B-X
on	B-X
medical	B-X
monitors	B-X
adjusted	B-X
by	B-X
CSDF	B-X
,	B-X
GSDF	B-X
,	B-X
and	B-X
Î³2.2	B-X
.	B-X

The	O
area	O
and	O
the	O
area	O
ratio	O
were	O
measured	O
using	O
a	O
calibrated	O
micrometer	O
.	O
<EOS>	B-X
The	B-X
diameters	B-X
of	B-X
the	B-X
orifices	B-X
of	B-X
the	B-X
pulmonary	B-X
trunk	B-X
and	B-X
aorta	B-X
were	B-X
measured	B-X
from	B-X
cineangiocardiographic	B-X
films	B-X
in	B-X
35	B-X
children	B-X
(	B-X
mean	B-X
age	B-X
7	B-X
years	B-X
and	B-X
6	B-X
months	B-X
,	B-X
mean	B-X
height	B-X
124.3	B-X
cm	B-X
)	B-X
without	B-X
heart	B-X
disease	B-X
.	B-X
Calipers	B-X
and	B-X
a	B-X
micrometer	B-X
were	B-X
used	B-X
and	B-X
the	B-X
values	B-X
were	B-X
expressed	B-X
to	B-X
the	B-X
nearest	B-X
0.5	B-X
mm	B-X
.	B-X
The	B-X
measured	B-X
size	B-X
of	B-X
the	B-X
intracardiac	B-X
catheter	B-X
was	B-X
used	B-X
for	B-X
calibration	B-X
.	B-X
The	B-X
mean	B-X
ratio	B-X
of	B-X
the	B-X
squared	B-X
diameters	B-X
of	B-X
the	B-X
orifices	B-X
was	B-X
1.22:1	B-X
(	B-X
SD	B-X
0.17	B-X
)	B-X
.	B-X
Significant	B-X
linear	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
the	B-X
diameter	B-X
of	B-X
the	B-X
orifice	B-X
of	B-X
the	B-X
pulmonary	B-X
trunk	B-X
and	B-X
body	B-X
height	B-X
(	B-X
r	B-X
=	B-X
0.71	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
weight	B-X
(	B-X
r	B-X
=	B-X
0.67	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
and	B-X
surface	B-X
area	B-X
(	B-X
r	B-X
=	B-X
0.70	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
.	B-X
Similar	B-X
correlations	B-X
were	B-X
found	B-X
for	B-X
measurements	B-X
of	B-X
the	B-X
aortic	B-X
orifice	B-X
and	B-X
body	B-X
height	B-X
(	B-X
r	B-X
=	B-X
0.70	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
weight	B-X
(	B-X
r	B-X
=	B-X
0.71	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
and	B-X
surface	B-X
area	B-X
(	B-X
r	B-X
=	B-X
0.71	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
,	B-X
and	B-X
between	B-X
the	B-X
diameters	B-X
of	B-X
the	B-X
two	B-X
orifices	B-X
themselves	B-X
(	B-X
r	B-X
=	B-X
0.91	B-X
,	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
relationship	B-X
of	B-X
the	B-X
sizes	B-X
of	B-X
the	B-X
orifices	B-X
of	B-X
the	B-X
pulmonary	B-X
trunk	B-X
and	B-X
aorta	B-X
to	B-X
body	B-X
height	B-X
may	B-X
therefore	B-X
be	B-X
more	B-X
applicable	B-X
than	B-X
their	B-X
relation	B-X
to	B-X
body	B-X
weight	B-X
and	B-X
surface	B-X
area	B-X
.	B-X

PP	O
mesh	O
resulted	O
in	O
more	O
fibrous	O
encapsulation	O
and	O
stiffness	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
behavior	B-X
and	B-X
tissue	B-X
response	B-X
between	B-X
two	B-X
new	B-X
polyester	B-X
prostheses	B-X
and	B-X
a	B-X
commonly	B-X
used	B-X
polypropylene	B-X
(	B-X
PP	B-X
)	B-X
mesh	B-X
.	B-X
The	B-X
polyester	B-X
prostheses	B-X
utilized	B-X
were	B-X
polyester	B-X
flat	B-X
(	B-X
PF	B-X
)	B-X
and	B-X
polyester	B-X
soft	B-X
three-dimensional	B-X
(	B-X
PS	B-X
)	B-X
;	B-X
the	B-X
PP	B-X
mesh	B-X
utilized	B-X
was	B-X
Marlex	B-X
.	B-X
Eight	B-X
randomly	B-X
assigned	B-X
4	B-X
x	B-X
4-cm2	B-X
pieces	B-X
of	B-X
two	B-X
different	B-X
meshes	B-X
were	B-X
fixed	B-X
in	B-X
the	B-X
preperitoneal	B-X
space	B-X
with	B-X
a	B-X
centrally	B-X
placed	B-X
single	B-X
suture	B-X
.	B-X
Gross	B-X
evaluation	B-X
included	B-X
shrinkage	B-X
and	B-X
stiffness	B-X
.	B-X
Histological	B-X
evaluation	B-X
included	B-X
amount	B-X
of	B-X
fibrous	B-X
and	B-X
fat	B-X
encapsulation	B-X
,	B-X
connective	B-X
tissue	B-X
,	B-X
foreign-body	B-X
reaction	B-X
,	B-X
neovascularization	B-X
,	B-X
hemorrhage	B-X
,	B-X
necrosis	B-X
,	B-X
and	B-X
exudate	B-X
.	B-X
PP	B-X
mesh	B-X
resulted	B-X
in	B-X
more	B-X
fibrous	B-X
encapsulation	B-X
and	B-X
stiffness	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
PP	B-X
also	B-X
resulted	B-X
in	B-X
less	B-X
connective	B-X
tissue	B-X
formation	B-X
and	B-X
foreign-body	B-X
reaction	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
fat	B-X
encapsulation	B-X
,	B-X
necrosis	B-X
,	B-X
hemorrhage	B-X
,	B-X
or	B-X
exudate	B-X
between	B-X
prostheses	B-X
.	B-X
Both	B-X
polyester	B-X
prostheses	B-X
(	B-X
PF	B-X
and	B-X
PS	B-X
)	B-X
have	B-X
better	B-X
tissue	B-X
integration	B-X
than	B-X
the	B-X
PP	B-X
mesh	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
higher	B-X
amount	B-X
of	B-X
connective	B-X
tissue	B-X
and	B-X
lower	B-X
extent	B-X
of	B-X
fibrous	B-X
encapsulation	B-X
.	B-X

PP	O
also	O
resulted	O
in	O
less	O
connective	O
tissue	O
formation	O
and	O
foreign	O
-	O
body	O
reaction	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
compare	B-X
behavior	B-X
and	B-X
tissue	B-X
response	B-X
between	B-X
two	B-X
new	B-X
polyester	B-X
prostheses	B-X
and	B-X
a	B-X
commonly	B-X
used	B-X
polypropylene	B-X
(	B-X
PP	B-X
)	B-X
mesh	B-X
.	B-X
The	B-X
polyester	B-X
prostheses	B-X
utilized	B-X
were	B-X
polyester	B-X
flat	B-X
(	B-X
PF	B-X
)	B-X
and	B-X
polyester	B-X
soft	B-X
three-dimensional	B-X
(	B-X
PS	B-X
)	B-X
;	B-X
the	B-X
PP	B-X
mesh	B-X
utilized	B-X
was	B-X
Marlex	B-X
.	B-X
Histological	B-X
evaluation	B-X
included	B-X
amount	B-X
of	B-X
fibrous	B-X
and	B-X
fat	B-X
encapsulation	B-X
,	B-X
connective	B-X
tissue	B-X
,	B-X
foreign-body	B-X
reaction	B-X
,	B-X
neovascularization	B-X
,	B-X
hemorrhage	B-X
,	B-X
necrosis	B-X
,	B-X
and	B-X
exudate	B-X
.	B-X
PP	B-X
mesh	B-X
resulted	B-X
in	B-X
more	B-X
fibrous	B-X
encapsulation	B-X
and	B-X
stiffness	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
PP	B-X
also	B-X
resulted	B-X
in	B-X
less	B-X
connective	B-X
tissue	B-X
formation	B-X
and	B-X
foreign-body	B-X
reaction	B-X
than	B-X
PF	B-X
and	B-X
PS	B-X
prostheses	B-X
.	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
fat	B-X
encapsulation	B-X
,	B-X
necrosis	B-X
,	B-X
hemorrhage	B-X
,	B-X
or	B-X
exudate	B-X
between	B-X
prostheses	B-X
.	B-X
Both	B-X
polyester	B-X
prostheses	B-X
(	B-X
PF	B-X
and	B-X
PS	B-X
)	B-X
have	B-X
better	B-X
tissue	B-X
integration	B-X
than	B-X
the	B-X
PP	B-X
mesh	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
higher	B-X
amount	B-X
of	B-X
connective	B-X
tissue	B-X
and	B-X
lower	B-X
extent	B-X
of	B-X
fibrous	B-X
encapsulation	B-X
.	B-X

There	O
was	O
no	O
difference	O
in	O
fat	O
encapsulation	O
,	O
necrosis	O
,	O
hemorrhage	O
,	O
or	O
exudate	O
between	O
prostheses	O
.	O
<EOS>	B-X
Pancreatic	B-X
fluid	B-X
collections	B-X
(	B-X
PFC	B-X
)	B-X
,	B-X
including	B-X
pancreatic	B-X
pseudocysts	B-X
and	B-X
walled-off	B-X
pancreatic	B-X
necrosis	B-X
,	B-X
are	B-X
a	B-X
known	B-X
complication	B-X
of	B-X
severe	B-X
acute	B-X
pancreatitis	B-X
.	B-X
Endoprostheses	B-X
used	B-X
to	B-X
drain	B-X
pancreatic	B-X
fluid	B-X
collections	B-X
include	B-X
plastic	B-X
and	B-X
metal	B-X
stents	B-X
.	B-X
Lumen	B-X
apposing	B-X
metallic	B-X
stents	B-X
(	B-X
LAMSs	B-X
)	B-X
permit	B-X
more	B-X
effective	B-X
drainage	B-X
with	B-X
larger	B-X
diameter	B-X
;	B-X
because	B-X
of	B-X
their	B-X
higher	B-X
costs	B-X
than	B-X
plastic	B-X
stents	B-X
,	B-X
their	B-X
main	B-X
role	B-X
is	B-X
probably	B-X
in	B-X
the	B-X
context	B-X
of	B-X
walled-off	B-X
necrosis	B-X
,	B-X
but	B-X
the	B-X
place	B-X
and	B-X
the	B-X
use	B-X
of	B-X
LAMS	B-X
should	B-X
be	B-X
studied	B-X
to	B-X
avoid	B-X
and	B-X
reduce	B-X
the	B-X
risks	B-X
of	B-X
complications	B-X
.	B-X
Bacterial	B-X
arthritis	B-X
.	B-X

Both	O
polyester	O
prostheses	O
(	O
PF	O
and	O
PS	O
)	O
have	O
better	O
tissue	O
integration	O
than	O
the	O
PP	O
mesh	O
,	O
as	O
evidenced	O
by	O
the	O
higher	O
amount	O
of	O
connective	O
tissue	O
and	O
lower	O
extent	O
of	O
fibrous	O
encapsulation	O
.	O

Integration	O
of	O
interferon	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
/	O
beta	B-Gene_or_gene_product
signalling	O
to	O
p53	B-Gene_or_gene_product
responses	O
in	O
tumour	O
suppression	O
and	O
antiviral	O
defence	O
.	O
<EOS>	B-X
Swift	B-X
elimination	B-X
of	B-X
undesirable	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
immunity	B-X
.	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transcription	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
induced	B-X
by	B-X
IFN-alpha/beta	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
protein	B-X
level	B-X
.	B-X
IFN-alpha/beta	B-X
signalling	B-X
itself	B-X
does	B-X
not	B-X
activate	B-X
p53	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
contributes	B-X
to	B-X
boosting	B-X
p53	B-X
responses	B-X
to	B-X
stress	B-X
signals	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

Swift	O
elimination	O
of	O
undesirable	O
cells	O
is	O
an	O
important	O
feature	O
in	O
tumour	O
suppression	O
and	O
immunity	O
.	O
<EOS>	B-X
Swift	B-X
elimination	B-X
of	B-X
undesirable	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
immunity	B-X
.	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

The	O
tumour	O
suppressor	O
p53	B-Gene_or_gene_product
and	O
interferon	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
/	O
beta	B-Gene_or_gene_product
)	O
are	O
essential	O
for	O
the	O
induction	O
of	O
apoptosis	O
in	O
cancerous	O
cells	O
and	O
in	O
antiviral	O
immune	O
responses	O
,	O
respectively	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
interrelationship	O
.	O
<EOS>	B-X
Swift	B-X
elimination	B-X
of	B-X
undesirable	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
immunity	B-X
.	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transcription	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
induced	B-X
by	B-X
IFN-alpha/beta	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
protein	B-X
level	B-X
.	B-X
IFN-alpha/beta	B-X
signalling	B-X
itself	B-X
does	B-X
not	B-X
activate	B-X
p53	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
contributes	B-X
to	B-X
boosting	B-X
p53	B-X
responses	B-X
to	B-X
stress	B-X
signals	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

Here	O
we	O
show	O
that	O
transcription	O
of	O
the	O
p53	B-Gene_or_gene_product
gene	O
is	O
induced	O
by	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
/	O
beta	B-Gene_or_gene_product
,	O
accompanied	O
by	O
an	O
increase	O
in	O
p53	B-Gene_or_gene_product
protein	O
level	O
.	O
<EOS>	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transcription	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
induced	B-X
by	B-X
IFN-alpha/beta	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
protein	B-X
level	B-X
.	B-X
IFN-alpha/beta	B-X
signalling	B-X
itself	B-X
does	B-X
not	B-X
activate	B-X
p53	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
contributes	B-X
to	B-X
boosting	B-X
p53	B-X
responses	B-X
to	B-X
stress	B-X
signals	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
/	O
beta	B-Gene_or_gene_product
signalling	O
itself	O
does	O
not	O
activate	O
p53	B-Gene_or_gene_product
;	O
rather	O
,	O
it	O
contributes	O
to	O
boosting	O
p53	B-Gene_or_gene_product
responses	O
to	O
stress	O
signals	O
.	O
<EOS>	B-X
Recombinant	B-X
interferon-alpha	B-X
(	B-X
IFN-alpha	B-X
)	B-X
was	B-X
approved	B-X
by	B-X
regulatory	B-X
agencies	B-X
in	B-X
many	B-X
countries	B-X
in	B-X
1986	B-X
.	B-X
As	B-X
the	B-X
first	B-X
biotherapeutic	B-X
approved	B-X
,	B-X
IFN-alpha	B-X
paved	B-X
the	B-X
way	B-X
for	B-X
the	B-X
development	B-X
of	B-X
many	B-X
other	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
.	B-X
Nevertheless	B-X
,	B-X
understanding	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
multitude	B-X
of	B-X
human	B-X
IFNs	B-X
and	B-X
IFN-like	B-X
cytokines	B-X
has	B-X
just	B-X
touched	B-X
the	B-X
surface	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
history	B-X
of	B-X
the	B-X
purification	B-X
of	B-X
human	B-X
IFNs	B-X
and	B-X
the	B-X
key	B-X
aspects	B-X
of	B-X
our	B-X
current	B-X
state	B-X
of	B-X
knowledge	B-X
of	B-X
human	B-X
IFN	B-X
genes	B-X
,	B-X
proteins	B-X
,	B-X
and	B-X
receptors	B-X
.	B-X
All	B-X
the	B-X
known	B-X
IFNs	B-X
and	B-X
IFN-like	B-X
cytokines	B-X
are	B-X
described	B-X
[	B-X
IFN-alpha	B-X
,	B-X
IFN-beta	B-X
,	B-X
IFN-epsilon	B-X
,	B-X
IFN-kappa	B-X
,	B-X
IFN-omega	B-X
,	B-X
IFN-delta	B-X
,	B-X
IFN-tau	B-X
,	B-X
IFN-gamma	B-X
,	B-X
limitin	B-X
,	B-X
interleukin-28A	B-X
(	B-X
IL-28A	B-X
)	B-X
,	B-X
IL-28B	B-X
,	B-X
and	B-X
IL-29	B-X
]	B-X
as	B-X
well	B-X
as	B-X
their	B-X
receptors	B-X
and	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
The	B-X
overall	B-X
structure	B-X
of	B-X
the	B-X
IFNs	B-X
is	B-X
put	B-X
into	B-X
perspective	B-X
in	B-X
relation	B-X
to	B-X
their	B-X
receptors	B-X
and	B-X
functions	B-X
.	B-X

We	O
show	O
examples	O
in	O
which	O
p53	B-Gene_or_gene_product
gene	O
induction	O
by	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
/	O
beta	B-Gene_or_gene_product
contributes	O
to	O
tumour	O
suppression	O
.	O
<EOS>	B-X
Swift	B-X
elimination	B-X
of	B-X
undesirable	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
immunity	B-X
.	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transcription	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
induced	B-X
by	B-X
IFN-alpha/beta	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
protein	B-X
level	B-X
.	B-X
IFN-alpha/beta	B-X
signalling	B-X
itself	B-X
does	B-X
not	B-X
activate	B-X
p53	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
contributes	B-X
to	B-X
boosting	B-X
p53	B-X
responses	B-X
to	B-X
stress	B-X
signals	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

Furthermore	O
,	O
we	O
show	O
that	O
p53	B-Gene_or_gene_product
is	O
activated	O
in	O
virally	O
infected	O
cells	O
to	O
evoke	O
an	O
apoptotic	O
response	O
and	O
that	O
p53	B-Gene_or_gene_product
is	O
critical	O
for	O
antiviral	O
defence	O
of	O
the	O
host	O
.	O
<EOS>	B-X
Swift	B-X
elimination	B-X
of	B-X
undesirable	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
immunity	B-X
.	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transcription	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
induced	B-X
by	B-X
IFN-alpha/beta	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
protein	B-X
level	B-X
.	B-X
IFN-alpha/beta	B-X
signalling	B-X
itself	B-X
does	B-X
not	B-X
activate	B-X
p53	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
contributes	B-X
to	B-X
boosting	B-X
p53	B-X
responses	B-X
to	B-X
stress	B-X
signals	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

Our	O
study	O
reveals	O
a	O
hitherto	O
unrecognized	O
link	O
between	O
p53	B-Gene_or_gene_product
and	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
/	O
beta	B-Gene_or_gene_product
in	O
tumour	O
suppression	O
and	O
antiviral	O
immunity	O
,	O
which	O
may	O
have	O
therapeutic	O
implications	O
.	O
<EOS>	B-X
Swift	B-X
elimination	B-X
of	B-X
undesirable	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
immunity	B-X
.	B-X
The	B-X
tumour	B-X
suppressor	B-X
p53	B-X
and	B-X
interferon-alpha	B-X
and	B-X
-beta	B-X
(	B-X
IFN-alpha/beta	B-X
)	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
cancerous	B-X
cells	B-X
and	B-X
in	B-X
antiviral	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
interrelationship	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transcription	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
induced	B-X
by	B-X
IFN-alpha/beta	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
p53	B-X
protein	B-X
level	B-X
.	B-X
IFN-alpha/beta	B-X
signalling	B-X
itself	B-X
does	B-X
not	B-X
activate	B-X
p53	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
contributes	B-X
to	B-X
boosting	B-X
p53	B-X
responses	B-X
to	B-X
stress	B-X
signals	B-X
.	B-X
We	B-X
show	B-X
examples	B-X
in	B-X
which	B-X
p53	B-X
gene	B-X
induction	B-X
by	B-X
IFN-alpha/beta	B-X
contributes	B-X
to	B-X
tumour	B-X
suppression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
p53	B-X
is	B-X
activated	B-X
in	B-X
virally	B-X
infected	B-X
cells	B-X
to	B-X
evoke	B-X
an	B-X
apoptotic	B-X
response	B-X
and	B-X
that	B-X
p53	B-X
is	B-X
critical	B-X
for	B-X
antiviral	B-X
defence	B-X
of	B-X
the	B-X
host	B-X
.	B-X
Our	B-X
study	B-X
reveals	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
link	B-X
between	B-X
p53	B-X
and	B-X
IFN-alpha/beta	B-X
in	B-X
tumour	B-X
suppression	B-X
and	B-X
antiviral	B-X
immunity	B-X
,	B-X
which	B-X
may	B-X
have	B-X
therapeutic	B-X
implications	B-X
.	B-X

T140	O
analogs	O
as	O
CXCR4	B-Gene_or_gene_product
antagonists	O
identified	O
as	O
anti	O
-	O
metastatic	O
agents	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O
<EOS>	B-X
A	B-X
chemokine	B-X
receptor	B-X
,	B-X
CXCR4	B-X
,	B-X
and	B-X
its	B-X
endogenous	B-X
ligand	B-X
,	B-X
stromal	B-X
cell-derived	B-X
factor-1	B-X
(	B-X
SDF-1	B-X
)	B-X
,	B-X
have	B-X
been	B-X
recognized	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
metastasis	B-X
of	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
T140	B-X
analogs	B-X
are	B-X
peptidic	B-X
CXCR4	B-X
antagonists	B-X
composed	B-X
of	B-X
14	B-X
amino	B-X
acid	B-X
residues	B-X
that	B-X
were	B-X
previously	B-X
developed	B-X
as	B-X
anti-HIV	B-X
agents	B-X
having	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-entry	B-X
through	B-X
its	B-X
co-receptor	B-X
,	B-X
CXCR4	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
that	B-X
these	B-X
compounds	B-X
effectively	B-X
inhibited	B-X
SDF-1-induced	B-X
migration	B-X
of	B-X
human	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
MDA-MB-231	B-X
)	B-X
,	B-X
human	B-X
leukemia	B-X
T	B-X
cells	B-X
(	B-X
Sup-T1	B-X
)	B-X
and	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
at	B-X
concentrations	B-X
of	B-X
10-100	B-X
nM	B-X
in	B-X
vitro	B-X
.	B-X
Furthermore	B-X
,	B-X
slow	B-X
release	B-X
administration	B-X
by	B-X
subcutaneous	B-X
injection	B-X
using	B-X
an	B-X
Alzet	B-X
osmotic	B-X
pump	B-X
of	B-X
a	B-X
potent	B-X
and	B-X
bio-stable	B-X
T140	B-X
analog	B-X
,	B-X
4F-benzoyl-TN14003	B-X
,	B-X
gave	B-X
a	B-X
partial	B-X
,	B-X
but	B-X
statistically	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
/=0.05	B-X
(	B-X
t-test	B-X
)	B-X
)	B-X
reduction	B-X
in	B-X
pulmonary	B-X
metastasis	B-X
of	B-X
MDA-MB-231	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
even	B-X
though	B-X
no	B-X
attempt	B-X
was	B-X
made	B-X
to	B-X
inhibit	B-X
other	B-X
important	B-X
targets	B-X
such	B-X
as	B-X
CCR7	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
T140	B-X
analogs	B-X
have	B-X
potential	B-X
use	B-X
for	B-X
cancer	B-X
therapy	B-X
,	B-X
and	B-X
that	B-X
small	B-X
molecular	B-X
CXCR4	B-X
antagonists	B-X
could	B-X
potentially	B-X
replace	B-X
neutralizing	B-X
antibodies	B-X
as	B-X
anti-metastatic	B-X
agents	B-X
for	B-X
breast	B-X
cancer	B-X
.	B-X

A	O
chemokine	O
receptor	O
,	O
CXCR4	B-Gene_or_gene_product
,	O
and	O
its	O
endogenous	O
ligand	O
,	O
stromal	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
SDF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
,	O
have	O
been	O
recognized	O
to	O
be	O
involved	O
in	O
the	O
metastasis	O
of	O
several	O
types	O
of	O
cancers	O
.	O
<EOS>	B-X
A	B-X
chemokine	B-X
receptor	B-X
,	B-X
CXCR4	B-X
,	B-X
and	B-X
its	B-X
endogenous	B-X
ligand	B-X
,	B-X
stromal	B-X
cell-derived	B-X
factor-1	B-X
(	B-X
SDF-1	B-X
)	B-X
,	B-X
have	B-X
been	B-X
recognized	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
metastasis	B-X
of	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
T140	B-X
analogs	B-X
are	B-X
peptidic	B-X
CXCR4	B-X
antagonists	B-X
composed	B-X
of	B-X
14	B-X
amino	B-X
acid	B-X
residues	B-X
that	B-X
were	B-X
previously	B-X
developed	B-X
as	B-X
anti-HIV	B-X
agents	B-X
having	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-entry	B-X
through	B-X
its	B-X
co-receptor	B-X
,	B-X
CXCR4	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
that	B-X
these	B-X
compounds	B-X
effectively	B-X
inhibited	B-X
SDF-1-induced	B-X
migration	B-X
of	B-X
human	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
MDA-MB-231	B-X
)	B-X
,	B-X
human	B-X
leukemia	B-X
T	B-X
cells	B-X
(	B-X
Sup-T1	B-X
)	B-X
and	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
at	B-X
concentrations	B-X
of	B-X
10-100	B-X
nM	B-X
in	B-X
vitro	B-X
.	B-X
Furthermore	B-X
,	B-X
slow	B-X
release	B-X
administration	B-X
by	B-X
subcutaneous	B-X
injection	B-X
using	B-X
an	B-X
Alzet	B-X
osmotic	B-X
pump	B-X
of	B-X
a	B-X
potent	B-X
and	B-X
bio-stable	B-X
T140	B-X
analog	B-X
,	B-X
4F-benzoyl-TN14003	B-X
,	B-X
gave	B-X
a	B-X
partial	B-X
,	B-X
but	B-X
statistically	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
/=0.05	B-X
(	B-X
t-test	B-X
)	B-X
)	B-X
reduction	B-X
in	B-X
pulmonary	B-X
metastasis	B-X
of	B-X
MDA-MB-231	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
even	B-X
though	B-X
no	B-X
attempt	B-X
was	B-X
made	B-X
to	B-X
inhibit	B-X
other	B-X
important	B-X
targets	B-X
such	B-X
as	B-X
CCR7	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
T140	B-X
analogs	B-X
have	B-X
potential	B-X
use	B-X
for	B-X
cancer	B-X
therapy	B-X
,	B-X
and	B-X
that	B-X
small	B-X
molecular	B-X
CXCR4	B-X
antagonists	B-X
could	B-X
potentially	B-X
replace	B-X
neutralizing	B-X
antibodies	B-X
as	B-X
anti-metastatic	B-X
agents	B-X
for	B-X
breast	B-X
cancer	B-X
.	B-X

T140	O
analogs	O
are	O
peptidic	O
CXCR4	B-Gene_or_gene_product
antagonists	O
composed	O
of	O
14	O
amino	O
acid	O
residues	O
that	O
were	O
previously	O
developed	O
as	O
anti	O
-	O
HIV	O
agents	O
having	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
entry	O
through	O
its	O
co	O
-	O
receptor	O
,	O
CXCR4	B-Gene_or_gene_product
.	O
<EOS>	B-X
A	B-X
chemokine	B-X
receptor	B-X
,	B-X
CXCR4	B-X
,	B-X
and	B-X
its	B-X
endogenous	B-X
ligand	B-X
,	B-X
stromal	B-X
cell-derived	B-X
factor-1	B-X
(	B-X
SDF-1	B-X
)	B-X
,	B-X
have	B-X
been	B-X
recognized	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
metastasis	B-X
of	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
T140	B-X
analogs	B-X
are	B-X
peptidic	B-X
CXCR4	B-X
antagonists	B-X
composed	B-X
of	B-X
14	B-X
amino	B-X
acid	B-X
residues	B-X
that	B-X
were	B-X
previously	B-X
developed	B-X
as	B-X
anti-HIV	B-X
agents	B-X
having	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-entry	B-X
through	B-X
its	B-X
co-receptor	B-X
,	B-X
CXCR4	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
that	B-X
these	B-X
compounds	B-X
effectively	B-X
inhibited	B-X
SDF-1-induced	B-X
migration	B-X
of	B-X
human	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
MDA-MB-231	B-X
)	B-X
,	B-X
human	B-X
leukemia	B-X
T	B-X
cells	B-X
(	B-X
Sup-T1	B-X
)	B-X
and	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
at	B-X
concentrations	B-X
of	B-X
10-100	B-X
nM	B-X
in	B-X
vitro	B-X
.	B-X
Furthermore	B-X
,	B-X
slow	B-X
release	B-X
administration	B-X
by	B-X
subcutaneous	B-X
injection	B-X
using	B-X
an	B-X
Alzet	B-X
osmotic	B-X
pump	B-X
of	B-X
a	B-X
potent	B-X
and	B-X
bio-stable	B-X
T140	B-X
analog	B-X
,	B-X
4F-benzoyl-TN14003	B-X
,	B-X
gave	B-X
a	B-X
partial	B-X
,	B-X
but	B-X
statistically	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
/=0.05	B-X
(	B-X
t-test	B-X
)	B-X
)	B-X
reduction	B-X
in	B-X
pulmonary	B-X
metastasis	B-X
of	B-X
MDA-MB-231	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
even	B-X
though	B-X
no	B-X
attempt	B-X
was	B-X
made	B-X
to	B-X
inhibit	B-X
other	B-X
important	B-X
targets	B-X
such	B-X
as	B-X
CCR7	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
T140	B-X
analogs	B-X
have	B-X
potential	B-X
use	B-X
for	B-X
cancer	B-X
therapy	B-X
,	B-X
and	B-X
that	B-X
small	B-X
molecular	B-X
CXCR4	B-X
antagonists	B-X
could	B-X
potentially	B-X
replace	B-X
neutralizing	B-X
antibodies	B-X
as	B-X
anti-metastatic	B-X
agents	B-X
for	B-X
breast	B-X
cancer	B-X
.	B-X

Herein	O
,	O
we	O
report	O
that	O
these	O
compounds	O
effectively	O
inhibited	O
SDF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
induced	O
migration	O
of	O
human	O
breast	O
cancer	O
cells	O
(	O
MDA	O
-	O
MB	O
-	O
231	O
)	O
,	O
human	O
leukemia	O
T	O
cells	O
(	O
Sup	O
-	O
T1	O
)	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
at	O
concentrations	O
of	O
10	O
-	O
100	O
nM	O
in	O
vitro	O
.	O
<EOS>	B-X
A	B-X
chemokine	B-X
receptor	B-X
,	B-X
CXCR4	B-X
,	B-X
and	B-X
its	B-X
endogenous	B-X
ligand	B-X
,	B-X
stromal	B-X
cell-derived	B-X
factor-1	B-X
(	B-X
SDF-1	B-X
)	B-X
,	B-X
have	B-X
been	B-X
recognized	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
metastasis	B-X
of	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
T140	B-X
analogs	B-X
are	B-X
peptidic	B-X
CXCR4	B-X
antagonists	B-X
composed	B-X
of	B-X
14	B-X
amino	B-X
acid	B-X
residues	B-X
that	B-X
were	B-X
previously	B-X
developed	B-X
as	B-X
anti-HIV	B-X
agents	B-X
having	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-entry	B-X
through	B-X
its	B-X
co-receptor	B-X
,	B-X
CXCR4	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
that	B-X
these	B-X
compounds	B-X
effectively	B-X
inhibited	B-X
SDF-1-induced	B-X
migration	B-X
of	B-X
human	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
MDA-MB-231	B-X
)	B-X
,	B-X
human	B-X
leukemia	B-X
T	B-X
cells	B-X
(	B-X
Sup-T1	B-X
)	B-X
and	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
at	B-X
concentrations	B-X
of	B-X
10-100	B-X
nM	B-X
in	B-X
vitro	B-X
.	B-X
Furthermore	B-X
,	B-X
slow	B-X
release	B-X
administration	B-X
by	B-X
subcutaneous	B-X
injection	B-X
using	B-X
an	B-X
Alzet	B-X
osmotic	B-X
pump	B-X
of	B-X
a	B-X
potent	B-X
and	B-X
bio-stable	B-X
T140	B-X
analog	B-X
,	B-X
4F-benzoyl-TN14003	B-X
,	B-X
gave	B-X
a	B-X
partial	B-X
,	B-X
but	B-X
statistically	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
/=0.05	B-X
(	B-X
t-test	B-X
)	B-X
)	B-X
reduction	B-X
in	B-X
pulmonary	B-X
metastasis	B-X
of	B-X
MDA-MB-231	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
even	B-X
though	B-X
no	B-X
attempt	B-X
was	B-X
made	B-X
to	B-X
inhibit	B-X
other	B-X
important	B-X
targets	B-X
such	B-X
as	B-X
CCR7	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
T140	B-X
analogs	B-X
have	B-X
potential	B-X
use	B-X
for	B-X
cancer	B-X
therapy	B-X
,	B-X
and	B-X
that	B-X
small	B-X
molecular	B-X
CXCR4	B-X
antagonists	B-X
could	B-X
potentially	B-X
replace	B-X
neutralizing	B-X
antibodies	B-X
as	B-X
anti-metastatic	B-X
agents	B-X
for	B-X
breast	B-X
cancer	B-X
.	B-X

Furthermore	O
,	O
slow	O
release	O
administration	O
by	O
subcutaneous	O
injection	O
using	O
an	O
Alzet	O
osmotic	O
pump	O
of	O
a	O
potent	O
and	O
bio	O
-	O
stable	O
T140	O
analog	O
,	O
4F	O
-	O
benzoyl	O
-	O
TN14003	O
,	O
gave	O
a	O
partial	O
,	O
but	O
statistically	O
significant	O
(	O
P	O
<	O
/	O
=	O
0	O
.	O
05	O
(	O
t	O
-	O
test	O
)	O
)	O
reduction	O
in	O
pulmonary	O
metastasis	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
in	O
SCID	O
mice	O
,	O
even	O
though	O
no	O
attempt	O
was	O
made	O
to	O
inhibit	O
other	O
important	O
targets	O
such	O
as	O
CCR7	B-Gene_or_gene_product
.	O

These	O
results	O
suggest	O
that	O
T140	O
analogs	O
have	O
potential	O
use	O
for	O
cancer	O
therapy	O
,	O
and	O
that	O
small	O
molecular	O
CXCR4	B-Gene_or_gene_product
antagonists	O
could	O
potentially	O
replace	O
neutralizing	O
antibodies	O
as	O
anti	O
-	O
metastatic	O
agents	O
for	O
breast	O
cancer	O
.	O
<EOS>	B-X
A	B-X
chemokine	B-X
receptor	B-X
,	B-X
CXCR4	B-X
,	B-X
and	B-X
its	B-X
endogenous	B-X
ligand	B-X
,	B-X
stromal	B-X
cell-derived	B-X
factor-1	B-X
(	B-X
SDF-1	B-X
)	B-X
,	B-X
have	B-X
been	B-X
recognized	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
metastasis	B-X
of	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
T140	B-X
analogs	B-X
are	B-X
peptidic	B-X
CXCR4	B-X
antagonists	B-X
composed	B-X
of	B-X
14	B-X
amino	B-X
acid	B-X
residues	B-X
that	B-X
were	B-X
previously	B-X
developed	B-X
as	B-X
anti-HIV	B-X
agents	B-X
having	B-X
inhibitory	B-X
activity	B-X
against	B-X
HIV-entry	B-X
through	B-X
its	B-X
co-receptor	B-X
,	B-X
CXCR4	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
that	B-X
these	B-X
compounds	B-X
effectively	B-X
inhibited	B-X
SDF-1-induced	B-X
migration	B-X
of	B-X
human	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
MDA-MB-231	B-X
)	B-X
,	B-X
human	B-X
leukemia	B-X
T	B-X
cells	B-X
(	B-X
Sup-T1	B-X
)	B-X
and	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
at	B-X
concentrations	B-X
of	B-X
10-100	B-X
nM	B-X
in	B-X
vitro	B-X
.	B-X
Furthermore	B-X
,	B-X
slow	B-X
release	B-X
administration	B-X
by	B-X
subcutaneous	B-X
injection	B-X
using	B-X
an	B-X
Alzet	B-X
osmotic	B-X
pump	B-X
of	B-X
a	B-X
potent	B-X
and	B-X
bio-stable	B-X
T140	B-X
analog	B-X
,	B-X
4F-benzoyl-TN14003	B-X
,	B-X
gave	B-X
a	B-X
partial	B-X
,	B-X
but	B-X
statistically	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
/=0.05	B-X
(	B-X
t-test	B-X
)	B-X
)	B-X
reduction	B-X
in	B-X
pulmonary	B-X
metastasis	B-X
of	B-X
MDA-MB-231	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
even	B-X
though	B-X
no	B-X
attempt	B-X
was	B-X
made	B-X
to	B-X
inhibit	B-X
other	B-X
important	B-X
targets	B-X
such	B-X
as	B-X
CCR7	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
T140	B-X
analogs	B-X
have	B-X
potential	B-X
use	B-X
for	B-X
cancer	B-X
therapy	B-X
,	B-X
and	B-X
that	B-X
small	B-X
molecular	B-X
CXCR4	B-X
antagonists	B-X
could	B-X
potentially	B-X
replace	B-X
neutralizing	B-X
antibodies	B-X
as	B-X
anti-metastatic	B-X
agents	B-X
for	B-X
breast	B-X
cancer	B-X
.	B-X

CCL16	B-Gene_or_gene_product
activates	O
an	O
angiogenic	O
program	O
in	O
vascular	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
promotes	B-X
endothelial	B-X
differentiation	B-X
into	B-X
capillary-like	B-X
structures	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
and	B-X
is	B-X
angiogenic	B-X
in	B-X
the	B-X
chick	B-X
chorionallantoic	B-X
membrane	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

Besides	O
regulating	O
leukocyte	O
trafficking	O
in	O
normal	O
and	O
injured	O
tissues	O
,	O
several	O
chemokines	O
may	O
positively	O
or	O
negatively	O
regulate	O
angiogenesis	O
.	O
<EOS>	B-X
Numerous	B-X
studies	B-X
suggest	B-X
that	B-X
autophagy	B-X
participates	B-X
in	B-X
regulating	B-X
various	B-X
cellular	B-X
functions	B-X
and	B-X
is	B-X
closely	B-X
associated	B-X
with	B-X
the	B-X
onset	B-X
and	B-X
progression	B-X
of	B-X
various	B-X
diseases	B-X
.	B-X
Specifically	B-X
,	B-X
in	B-X
the	B-X
inflammatory	B-X
phase	B-X
,	B-X
autophagy	B-X
has	B-X
an	B-X
anti-infection	B-X
effect	B-X
and	B-X
it	B-X
negatively	B-X
regulates	B-X
the	B-X
inflammatory	B-X
response	B-X
,	B-X
which	B-X
prevents	B-X
excessive	B-X
inflammation	B-X
from	B-X
causing	B-X
tissue	B-X
damage	B-X
.	B-X
Autophagy	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
promotes	B-X
wound	B-X
angiogenesis	B-X
and	B-X
that	B-X
of	B-X
keratinocytes	B-X
promotes	B-X
their	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
migration	B-X
,	B-X
which	B-X
is	B-X
conducive	B-X
to	B-X
the	B-X
completion	B-X
of	B-X
wound	B-X
re-epithelialisation	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
refractory	B-X
diabetic	B-X
wound	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
autophagy	B-X
,	B-X
and	B-X
the	B-X
regulation	B-X
of	B-X
mesenchymal	B-X
stem	B-X
cell	B-X
autophagy	B-X
may	B-X
improve	B-X
its	B-X
application	B-X
to	B-X
wound	B-X
healing	B-X
.	B-X
Therefore	B-X
,	B-X
understanding	B-X
the	B-X
relationship	B-X
between	B-X
autophagy	B-X
and	B-X
skin	B-X
wound	B-X
healing	B-X
and	B-X
exploring	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
autophagy	B-X
regulation	B-X
may	B-X
provide	B-X
novel	B-X
strategies	B-X
for	B-X
the	B-X
clinical	B-X
treatment	B-X
of	B-X
wound	B-X
healing	B-X
.	B-X

Here	O
we	O
report	O
that	O
CCL16	B-Gene_or_gene_product
activates	O
an	O
angiogenic	O
program	O
in	O
vascular	O
endothelial	O
cells	O
by	O
activating	O
CCR1	B-Gene_or_gene_product
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
promotes	B-X
endothelial	B-X
differentiation	B-X
into	B-X
capillary-like	B-X
structures	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
and	B-X
is	B-X
angiogenic	B-X
in	B-X
the	B-X
chick	B-X
chorionallantoic	B-X
membrane	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

CCL16	B-Gene_or_gene_product
induces	O
dose	O
-	O
dependent	O
random	O
and	O
directional	O
migration	O
of	O
endothelial	O
cells	O
isolated	O
from	O
large	O
vessels	O
and	O
liver	O
capillaries	O
without	O
inducing	O
their	O
proliferation	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
promotes	B-X
endothelial	B-X
differentiation	B-X
into	B-X
capillary-like	B-X
structures	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
and	B-X
is	B-X
angiogenic	B-X
in	B-X
the	B-X
chick	B-X
chorionallantoic	B-X
membrane	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

It	O
also	O
promotes	O
endothelial	O
differentiation	O
into	O
capillary	O
-	O
like	O
structures	O
in	O
an	O
in	O
vitro	O
assay	O
and	O
is	O
angiogenic	O
in	O
the	O
chick	O
chorionallantoic	O
membrane	O
.	O

These	O
angiogenic	O
activities	O
are	O
neutralized	O
by	O
a	O
specific	O
antibody	O
against	O
CCL16	B-Gene_or_gene_product
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
promotes	B-X
endothelial	B-X
differentiation	B-X
into	B-X
capillary-like	B-X
structures	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
and	B-X
is	B-X
angiogenic	B-X
in	B-X
the	B-X
chick	B-X
chorionallantoic	B-X
membrane	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

The	O
direct	O
angiogenic	O
activity	O
of	O
CCL16	B-Gene_or_gene_product
is	O
further	O
amplified	O
by	O
its	O
ability	O
to	O
prime	O
endothelium	O
to	O
a	O
mitogen	O
signal	O
induced	O
by	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
A	I-Gene_or_gene_product
and	O
to	O
raise	O
their	O
basal	O
production	O
of	O
CXCL8	B-Gene_or_gene_product
and	O
CCL2	B-Gene_or_gene_product
,	O
2	O
other	O
angiogenic	O
chemokines	O
.	O
<EOS>	B-X
Besides	B-X
regulating	B-X
leukocyte	B-X
trafficking	B-X
in	B-X
normal	B-X
and	B-X
injured	B-X
tissues	B-X
,	B-X
several	B-X
chemokines	B-X
may	B-X
positively	B-X
or	B-X
negatively	B-X
regulate	B-X
angiogenesis	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
promotes	B-X
endothelial	B-X
differentiation	B-X
into	B-X
capillary-like	B-X
structures	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
and	B-X
is	B-X
angiogenic	B-X
in	B-X
the	B-X
chick	B-X
chorionallantoic	B-X
membrane	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

BX471	O
(	O
R	O
-	O
N	O
-	O
[	O
5	O
-	O
chloro	O
-	O
2	O
-	O
[	O
2	O
-	O
[	O
4	O
(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
]	O
-	O
2	O
-	O
methyl	O
-	O
1	O
-	O
piperazinyl	O
]	O
-	O
2	O
-	O
oxoethoxy	O
]	O
phenyl	O
]	O
urea	O
hydrochloric	O
acid	O
salt	O
)	O
,	O
a	O
CCR1	B-Gene_or_gene_product
antagonist	O
,	O
inhibits	O
angiogenic	O
properties	O
of	O
CCL16	B-Gene_or_gene_product
,	O
whereas	O
blocking	O
of	O
CCR8	B-Gene_or_gene_product
or	O
desensitizing	O
CCR2	B-Gene_or_gene_product
,	O
which	O
are	O
both	O
well	O
known	O
receptors	O
for	O
CCL16	B-Gene_or_gene_product
,	O
did	O
not	O
abolish	O
endothelial	O
activation	O
.	O

CCL16	B-Gene_or_gene_product
may	O
be	O
specifically	O
cross	O
-	O
linked	O
to	O
CCR1	B-Gene_or_gene_product
expressed	O
on	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Besides	B-X
regulating	B-X
leukocyte	B-X
trafficking	B-X
in	B-X
normal	B-X
and	B-X
injured	B-X
tissues	B-X
,	B-X
several	B-X
chemokines	B-X
may	B-X
positively	B-X
or	B-X
negatively	B-X
regulate	B-X
angiogenesis	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
promotes	B-X
endothelial	B-X
differentiation	B-X
into	B-X
capillary-like	B-X
structures	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
and	B-X
is	B-X
angiogenic	B-X
in	B-X
the	B-X
chick	B-X
chorionallantoic	B-X
membrane	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

The	O
largely	O
restricted	O
CCL16	B-Gene_or_gene_product
expression	O
in	O
the	O
liver	O
suggests	O
that	O
this	O
chemokine	O
may	O
play	O
a	O
role	O
in	O
hepatic	O
vascular	O
formation	O
during	O
development	O
and	O
in	O
angiogenesis	O
associated	O
to	O
hepatic	O
diseases	O
.	O
<EOS>	B-X
Besides	B-X
regulating	B-X
leukocyte	B-X
trafficking	B-X
in	B-X
normal	B-X
and	B-X
injured	B-X
tissues	B-X
,	B-X
several	B-X
chemokines	B-X
may	B-X
positively	B-X
or	B-X
negatively	B-X
regulate	B-X
angiogenesis	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
CCL16	B-X
activates	B-X
an	B-X
angiogenic	B-X
program	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
by	B-X
activating	B-X
CCR1	B-X
.	B-X
CCL16	B-X
induces	B-X
dose-dependent	B-X
random	B-X
and	B-X
directional	B-X
migration	B-X
of	B-X
endothelial	B-X
cells	B-X
isolated	B-X
from	B-X
large	B-X
vessels	B-X
and	B-X
liver	B-X
capillaries	B-X
without	B-X
inducing	B-X
their	B-X
proliferation	B-X
.	B-X
These	B-X
angiogenic	B-X
activities	B-X
are	B-X
neutralized	B-X
by	B-X
a	B-X
specific	B-X
antibody	B-X
against	B-X
CCL16	B-X
.	B-X
The	B-X
direct	B-X
angiogenic	B-X
activity	B-X
of	B-X
CCL16	B-X
is	B-X
further	B-X
amplified	B-X
by	B-X
its	B-X
ability	B-X
to	B-X
prime	B-X
endothelium	B-X
to	B-X
a	B-X
mitogen	B-X
signal	B-X
induced	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
A	B-X
and	B-X
to	B-X
raise	B-X
their	B-X
basal	B-X
production	B-X
of	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
,	B-X
2	B-X
other	B-X
angiogenic	B-X
chemokines	B-X
.	B-X
BX471	B-X
(	B-X
R-N-	B-X
[	B-X
5-chloro-2-	B-X
[	B-X
2-	B-X
[	B-X
4	B-X
(	B-X
4-fluorophenyl	B-X
)	B-X
methyl	B-X
]	B-X
-2-methyl-1-piperazinyl	B-X
]	B-X
-2-oxoethoxy	B-X
]	B-X
phenyl	B-X
]	B-X
urea	B-X
hydrochloric	B-X
acid	B-X
salt	B-X
)	B-X
,	B-X
a	B-X
CCR1	B-X
antagonist	B-X
,	B-X
inhibits	B-X
angiogenic	B-X
properties	B-X
of	B-X
CCL16	B-X
,	B-X
whereas	B-X
blocking	B-X
of	B-X
CCR8	B-X
or	B-X
desensitizing	B-X
CCR2	B-X
,	B-X
which	B-X
are	B-X
both	B-X
well	B-X
known	B-X
receptors	B-X
for	B-X
CCL16	B-X
,	B-X
did	B-X
not	B-X
abolish	B-X
endothelial	B-X
activation	B-X
.	B-X
CCL16	B-X
may	B-X
be	B-X
specifically	B-X
cross-linked	B-X
to	B-X
CCR1	B-X
expressed	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
The	B-X
largely	B-X
restricted	B-X
CCL16	B-X
expression	B-X
in	B-X
the	B-X
liver	B-X
suggests	B-X
that	B-X
this	B-X
chemokine	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
hepatic	B-X
vascular	B-X
formation	B-X
during	B-X
development	B-X
and	B-X
in	B-X
angiogenesis	B-X
associated	B-X
to	B-X
hepatic	B-X
diseases	B-X
.	B-X

Simvastatin	O
induces	O
apoptosis	O
of	O
B	O
-	O
CLL	O
cells	O
by	O
activation	O
of	O
mitochondrial	O
caspase	B-Gene_or_gene_product
9	I-Gene_or_gene_product
.	O
<EOS>	B-X
Chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
leukemia	B-X
in	B-X
the	B-X
western	B-X
world	B-X
.	B-X
Therefore	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
simvastatin	B-X
(	B-X
Sim	B-X
)	B-X
on	B-X
malignant	B-X
B	B-X
cells	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
CLL	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
the	B-X
drug	B-X
.	B-X

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
is	O
the	O
most	O
common	O
leukemia	O
in	O
the	O
western	O
world	O
.	O
<EOS>	B-X
Chronic	B-X
lymphocytic	B-X
leukaemia	B-X
(	B-X
CLL	B-X
)	B-X
accounts	B-X
for	B-X
25	B-X
%	B-X
of	B-X
all	B-X
leukaemias	B-X
and	B-X
is	B-X
the	B-X
most	B-X
common	B-X
lymphoid	B-X
malignancy	B-X
in	B-X
western	B-X
countries	B-X
.	B-X
Chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
types	B-X
of	B-X
leukemia	B-X
in	B-X
the	B-X
western	B-X
world	B-X
which	B-X
affects	B-X
mainly	B-X
the	B-X
elderly	B-X
population	B-X
.	B-X
The	B-X
current	B-X
scoring	B-X
system	B-X
for	B-X
prognostic	B-X
evaluation	B-X
of	B-X
patients	B-X
with	B-X
CLL	B-X
is	B-X
called	B-X
CLL-IPI	B-X
and	B-X
predicts	B-X
the	B-X
general	B-X
progress	B-X
of	B-X
the	B-X
disease	B-X
but	B-X
is	B-X
not	B-X
a	B-X
measure	B-X
or	B-X
a	B-X
decision	B-X
aid	B-X
for	B-X
the	B-X
necessity	B-X
of	B-X
treatment	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
heterogeneous	B-X
behavior	B-X
of	B-X
CLL	B-X
it	B-X
is	B-X
important	B-X
to	B-X
develop	B-X
tools	B-X
that	B-X
will	B-X
identify	B-X
if	B-X
and	B-X
when	B-X
patients	B-X
will	B-X
necessitate	B-X
treatment	B-X
for	B-X
CLL	B-X
.	B-X

Despite	O
several	O
advances	O
in	O
therapeutic	O
options	O
,	O
the	O
disease	O
remains	O
incurable	O
.	O
<EOS>	B-X
Patients	B-X
affected	B-X
with	B-X
prostate	B-X
cancer	B-X
present	B-X
with	B-X
either	B-X
a	B-X
localized	B-X
or	B-X
advanced	B-X
disease	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
provide	B-X
a	B-X
holistic	B-X
overview	B-X
of	B-X
prostate	B-X
cancer	B-X
,	B-X
including	B-X
the	B-X
diagnosis	B-X
of	B-X
the	B-X
disease	B-X
,	B-X
mutations	B-X
leading	B-X
to	B-X
the	B-X
onset	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
disease	B-X
,	B-X
and	B-X
treatment	B-X
options	B-X
.	B-X
Currently	B-X
,	B-X
available	B-X
treatment	B-X
options	B-X
are	B-X
more	B-X
effective	B-X
when	B-X
used	B-X
as	B-X
combination	B-X
therapy	B-X
;	B-X
however	B-X
,	B-X
despite	B-X
available	B-X
treatment	B-X
options	B-X
,	B-X
prostate	B-X
cancer	B-X
remains	B-X
to	B-X
be	B-X
incurable	B-X
.	B-X
There	B-X
has	B-X
been	B-X
ongoing	B-X
research	B-X
on	B-X
finding	B-X
and	B-X
identifying	B-X
other	B-X
treatment	B-X
approaches	B-X
such	B-X
as	B-X
the	B-X
use	B-X
of	B-X
traditional	B-X
medicine	B-X
,	B-X
the	B-X
application	B-X
of	B-X
nanotechnologies	B-X
,	B-X
and	B-X
gene	B-X
therapy	B-X
to	B-X
combat	B-X
prostate	B-X
cancer	B-X
,	B-X
drug	B-X
resistance	B-X
,	B-X
as	B-X
well	B-X
as	B-X
to	B-X
reduce	B-X
the	B-X
adverse	B-X
effects	B-X
that	B-X
come	B-X
with	B-X
current	B-X
treatment	B-X
options	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
genes	B-X
involved	B-X
in	B-X
prostate	B-X
cancer	B-X
,	B-X
available	B-X
treatment	B-X
options	B-X
,	B-X
and	B-X
current	B-X
research	B-X
on	B-X
alternative	B-X
treatment	B-X
options	B-X
.	B-X

Recently	O
,	O
it	O
was	O
repeatedly	O
demonstrated	O
that	O
statins	O
,	O
competitive	O
inhibitors	O
of	O
3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
hydroxy	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
methyl	I-Gene_or_gene_product
glutaryl	I-Gene_or_gene_product
coenzyme	I-Gene_or_gene_product
A	I-Gene_or_gene_product
(	I-Gene_or_gene_product
HMG	I-Gene_or_gene_product
-	I-Gene_or_gene_product
CoA	I-Gene_or_gene_product
)	I-Gene_or_gene_product
reductase	I-Gene_or_gene_product
,	O
have	O
antineoplastic	O
effects	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
repeatedly	B-X
demonstrated	B-X
that	B-X
statins	B-X
,	B-X
competitive	B-X
inhibitors	B-X
of	B-X
3-hydroxy-3-methyl	B-X
glutaryl	B-X
coenzyme	B-X
A	B-X
(	B-X
HMG-CoA	B-X
)	B-X
reductase	B-X
,	B-X
have	B-X
antineoplastic	B-X
effects	B-X
.	B-X
Therefore	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
simvastatin	B-X
(	B-X
Sim	B-X
)	B-X
on	B-X
malignant	B-X
B	B-X
cells	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
CLL	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
the	B-X
drug	B-X
.	B-X

Therefore	O
we	O
aimed	O
to	O
study	O
the	O
effects	O
of	O
simvastatin	O
(	O
Sim	O
)	O
on	O
malignant	O
B	O
cells	O
derived	O
from	O
patients	O
with	O
CLL	O
and	O
mechanisms	O
of	O
action	O
of	O
the	O
drug	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Purified	O
B	O
-	O
CLL	O
cells	O
from	O
15	O
patients	O
were	O
cultured	O
either	O
alone	O
or	O
with	O
Sim	O
at	O
concentrations	O
of	O
10	O
,	O
50	O
,	O
and	O
100	O
microM	O
.	O
<EOS>	B-X
Chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
leukemia	B-X
in	B-X
the	B-X
western	B-X
world	B-X
.	B-X
Therefore	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
simvastatin	B-X
(	B-X
Sim	B-X
)	B-X
on	B-X
malignant	B-X
B	B-X
cells	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
CLL	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
the	B-X
drug	B-X
.	B-X

Viability	O
,	O
measured	O
by	O
the	O
activity	O
of	O
mitochondrial	O
dehydrogenases	O
,	O
was	O
reduced	O
significantly	O
in	O
the	O
cells	O
treated	O
with	O
Sim	O
at	O
50	O
and	O
100	O
microM	O
for	O
24	O
hours	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

The	O
level	O
of	O
apoptosis	O
,	O
as	O
measured	O
by	O
annexin	B-Gene_or_gene_product
binding	O
to	O
exposed	O
phosphatidylserine	O
moieties	O
,	O
increased	O
significantly	O
in	O
the	O
treated	O
cells	O
at	O
concentrations	O
higher	O
than	O
50	O
microM	O
for	O
24	O
hours	O
(	O
p	O
<	O
0	O
.	O
003	O
)	O
.	O

The	O
level	O
of	O
necrosis	O
,	O
as	O
measured	O
by	O
propidium	O
iodide	O
internalization	O
,	O
increased	O
significantly	O
after	O
24	O
hours	O
exposure	O
to	O
Sim	O
at	O
50	O
microM	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
apoptotic	O
cascade	O
was	O
studied	O
by	O
immunoblot	O
analysis	O
of	O
caspases	B-Gene_or_gene_product
following	O
Sim	O
treatment	O
.	O
<EOS>	B-X
Therefore	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
simvastatin	B-X
(	B-X
Sim	B-X
)	B-X
on	B-X
malignant	B-X
B	B-X
cells	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
CLL	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
the	B-X
drug	B-X
.	B-X

These	O
showed	O
cleavage	O
of	O
caspases	B-Gene_or_gene_product
9	I-Gene_or_gene_product
,	O
8	B-Gene_or_gene_product
,	O
and	O
3	B-Gene_or_gene_product
.	O
<EOS>	B-X
Protease	B-X
biology	B-X
is	B-X
intimately	B-X
linked	B-X
to	B-X
the	B-X
functional	B-X
consequences	B-X
of	B-X
substrate	B-X
cleavage	B-X
events	B-X
.	B-X
Human	B-X
caspases	B-X
are	B-X
a	B-X
family	B-X
of	B-X
12	B-X
fate-determining	B-X
cysteine	B-X
proteases	B-X
that	B-X
are	B-X
best	B-X
known	B-X
for	B-X
driving	B-X
cell	B-X
death	B-X
,	B-X
either	B-X
apoptosis	B-X
or	B-X
pyroptosis	B-X
.	B-X
More	B-X
recently	B-X
,	B-X
caspases	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
other	B-X
cellular	B-X
remodeling	B-X
events	B-X
as	B-X
well	B-X
including	B-X
stem	B-X
cell	B-X
fate	B-X
determination	B-X
,	B-X
spermatogenesis	B-X
,	B-X
and	B-X
erythroid	B-X
differentiation	B-X
.	B-X
Recent	B-X
global	B-X
proteomics	B-X
methods	B-X
enable	B-X
characterization	B-X
of	B-X
the	B-X
substrates	B-X
that	B-X
caspases	B-X
cleave	B-X
in	B-X
live	B-X
cells	B-X
and	B-X
cell	B-X
extracts	B-X
.	B-X
The	B-X
number	B-X
of	B-X
substrate	B-X
targets	B-X
identified	B-X
for	B-X
individual	B-X
caspases	B-X
can	B-X
vary	B-X
widely	B-X
ranging	B-X
from	B-X
only	B-X
a	B-X
(	B-X
few	B-X
)	B-X
dozen	B-X
targets	B-X
for	B-X
caspases-4	B-X
,	B-X
-5	B-X
,	B-X
-9	B-X
,	B-X
and	B-X
-14	B-X
to	B-X
hundreds	B-X
of	B-X
targets	B-X
for	B-X
caspases-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
-6	B-X
,	B-X
-7	B-X
,	B-X
and	B-X
-8	B-X
.	B-X
Proteomic	B-X
studies	B-X
characterizing	B-X
the	B-X
rates	B-X
of	B-X
target	B-X
cleavage	B-X
show	B-X
that	B-X
each	B-X
caspase	B-X
has	B-X
a	B-X
preferred	B-X
substrate	B-X
cohort	B-X
that	B-X
sometimes	B-X
overlaps	B-X
between	B-X
caspases	B-X
,	B-X
but	B-X
whose	B-X
rates	B-X
of	B-X
cleavage	B-X
vary	B-X
over	B-X
500-fold	B-X
within	B-X
each	B-X
group	B-X
.	B-X
From	B-X
the	B-X
handful	B-X
of	B-X
individual	B-X
targets	B-X
that	B-X
have	B-X
been	B-X
studied	B-X
in	B-X
detail	B-X
,	B-X
there	B-X
are	B-X
only	B-X
a	B-X
few	B-X
so	B-X
far	B-X
that	B-X
whose	B-X
single	B-X
cleavage	B-X
event	B-X
is	B-X
capable	B-X
of	B-X
sparking	B-X
apoptosis	B-X
alone	B-X
,	B-X
such	B-X
as	B-X
cleavage	B-X
of	B-X
caspase-3/-7	B-X
and	B-X
BIM	B-X

Addition	O
of	O
the	O
caspase	B-Gene_or_gene_product
inhibitor	O
Z	O
-	O
VAD	O
.	O
fmk	O
inhibited	O
caspase	B-Gene_or_gene_product
8	I-Gene_or_gene_product
and	O
3	B-Gene_or_gene_product
significantly	O
but	O
did	O
not	O
affect	O
caspase	B-Gene_or_gene_product
9	I-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
pan-caspase	B-X
inhibitor	B-X
Q-VD-OPh	B-X
on	B-X
caspase	B-X
activity	B-X
,	B-X
DNA	B-X
fragmentation	B-X
,	B-X
PARP	B-X
cleavage	B-X
,	B-X
7A6	B-X
exposition	B-X
,	B-X
and	B-X
cellular	B-X
adhesivity	B-X
to	B-X
fibronectin	B-X
were	B-X
analyzed	B-X
in	B-X
detail	B-X
in	B-X
three	B-X
different	B-X
apoptotic	B-X
systems	B-X
involving	B-X
two	B-X
cell	B-X
lines	B-X
(	B-X
JURL-MK1	B-X
and	B-X
HL60	B-X
)	B-X
and	B-X
two	B-X
apoptosis	B-X
inducers	B-X
(	B-X
imatinib	B-X
mesylate	B-X
and	B-X
suberoylanilide	B-X
hydroxamic	B-X
acid	B-X
)	B-X
.	B-X
Q-VD-OPh	B-X
fully	B-X
inhibited	B-X
caspase-3	B-X
and	B-X
-7	B-X
activity	B-X
at	B-X
0.05	B-X
ÂµM	B-X
concentration	B-X
as	B-X
indicated	B-X
both	B-X
by	B-X
the	B-X
measurement	B-X
of	B-X
the	B-X
rate	B-X
of	B-X
Ac-DEVD-AFC	B-X
cleavage	B-X
and	B-X
anti-caspase	B-X
immunoblots	B-X
.	B-X
Caspase-8	B-X
was	B-X
also	B-X
inhibited	B-X
at	B-X
low	B-X
Q-VD-OPh	B-X
concentrations	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
significantly	B-X
higher	B-X
Q-VD-OPh	B-X
dose	B-X
(	B-X
10	B-X
ÂµM	B-X
)	B-X
was	B-X
required	B-X
to	B-X
fully	B-X
prevent	B-X
the	B-X
cleavage	B-X
of	B-X
PARP-1	B-X
.	B-X
DNA	B-X
fragmentation	B-X
and	B-X
disruption	B-X
of	B-X
the	B-X
cell	B-X
membrane	B-X
functionality	B-X
(	B-X
Trypan	B-X
blue	B-X
exclusion	B-X
test	B-X
)	B-X
were	B-X
both	B-X
prevented	B-X
at	B-X
2	B-X
ÂµM	B-X
Q-VD-OPh	B-X
while	B-X
10	B-X
ÂµM	B-X
inhibitor	B-X
was	B-X
needed	B-X
to	B-X
inhibit	B-X
the	B-X
drug-induced	B-X
loss	B-X
of	B-X
cellular	B-X
adhesivity	B-X
to	B-X
fibronectin	B-X
which	B-X
was	B-X
observed	B-X
in	B-X
JURL-MK1	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
Q-VD-OPh	B-X
efficiency	B-X
in	B-X
the	B-X
inhibition	B-X
of	B-X
caspase-3	B-X
activity	B-X
and	B-X
DNA	B-X
fragmentation	B-X
in	B-X
the	B-X
whole-cell	B-X
environment	B-X
is	B-X
about	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
higher	B-X
than	B-X
that	B-X
of	B-X
z-VAD-fmk	B-X
.	B-X

CONCLUSION	O
:	O
Exposure	O
of	O
clonal	O
B	O
lymphocytes	O
from	O
patients	O
with	O
CLL	O
to	O
simvastatin	O
decreases	O
viability	O
significantly	O
by	O
the	O
induction	O
of	O
apoptosis	O
.	O
<EOS>	B-X
Chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
leukemia	B-X
in	B-X
the	B-X
western	B-X
world	B-X
.	B-X
Therefore	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
simvastatin	B-X
(	B-X
Sim	B-X
)	B-X
on	B-X
malignant	B-X
B	B-X
cells	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
CLL	B-X
and	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
the	B-X
drug	B-X
.	B-X

The	O
apoptosis	O
induced	O
by	O
Sim	O
is	O
probably	O
initiated	O
by	O
the	O
mitochondrial	O
caspase	B-Gene_or_gene_product
9	I-Gene_or_gene_product
,	O
which	O
indirectly	O
leads	O
to	O
activation	O
of	O
caspase	B-Gene_or_gene_product
3	I-Gene_or_gene_product
and	O
8	B-Gene_or_gene_product
.	O

Autocrine	O
angiotensin	B-Gene_or_gene_product
system	O
regulation	O
of	O
bovine	O
aortic	O
endothelial	O
cell	O
migration	O
and	O
plasminogen	B-Gene_or_gene_product
activator	I-Gene_or_gene_product
involves	O
modulation	O
of	O
proto	O
-	O
oncogene	O
pp60c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
Rapid	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
inhibition	B-X
of	B-X
thrombosis	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
resolution	B-X
of	B-X
denudation	B-X
injuries	B-X
to	B-X
the	B-X
vessel	B-X
wall	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
endothelial	B-X
cell	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
,	B-X
with	B-X
either	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
inhibitor	B-X
lisinopril	B-X
or	B-X
the	B-X
angiotensin	B-X
II	B-X
receptor	B-X
antagonist	B-X
sar1	B-X
,	B-X
ile8-angiotensin	B-X
II	B-X
,	B-X
leads	B-X
to	B-X
increased	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
urokinase-like	B-X
plasminogen	B-X
activator	B-X
(	B-X
u-PA	B-X
)	B-X
activity	B-X
(	B-X
Bell	B-X
,	B-X
L.	B-X
,	B-X
and	B-X
J.	B-X
Inhibition	B-X
of	B-X
the	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
with	B-X
the	B-X
converting-enzyme	B-X
inhibitor	B-X
or	B-X
the	B-X
receptor	B-X
antagonist	B-X
also	B-X
leads	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
proto-oncogene	B-X
c-src	B-X
:	B-X
pp60c-src	B-X
mRNA	B-X
increased	B-X
7-11-fold	B-X
,	B-X
c-src	B-X
protein	B-X
3-fold	B-X
,	B-X
and	B-X
c-src	B-X
kinase	B-X
activity	B-X
2-3-fold	B-X
.	B-X
Endothelial	B-X
cell	B-X
expression	B-X
of	B-X
c-src	B-X
was	B-X
constitutively	B-X
elevated	B-X
after	B-X
stable	B-X
infection	B-X
with	B-X
a	B-X
retroviral	B-X
vector	B-X
containing	B-X
the	B-X
c-src	B-X
coding	B-X
sequence	B-X
.	B-X
Constitutively	B-X
increased	B-X
c-src	B-X
kinase	B-X
activity	B-X
reconstituted	B-X
the	B-X
increases	B-X
in	B-X
migration	B-X
and	B-X
u-PA	B-X
observed	B-X
with	B-X
angiotensin	B-X
system	B-X
interruption	B-X
.	B-X
Antisera	B-X
to	B-X
bovine	B-X
u-PA	B-X
blocked	B-X
the	B-X
increase	B-X
in	B-X
migration	B-X
associated	B-X
with	B-X
increased	B-X
c-src	B-X
expression	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
increases	B-X
in	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
plasminogen	B-X
activator	B-X
after	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
are	B-X
at	B-X
least	B-X
partially	B-X
pp60c-src	B-X
mediated	B-X
.	B-X
Elevated	B-X
c-src	B-X
expression	B-X
with	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
may	B-X
act	B-X
to	B-X
enhance	B-X
intimal	B-X
wound	B-X
closure	B-X
and	B-X
to	B-X
reduce	B-X
luminal	B-X
thrombogenicity	B-X
in	B-X
vivo	B-X
.	B-X

Rapid	O
endothelial	O
cell	O
migration	O
and	O
inhibition	O
of	O
thrombosis	O
are	O
critical	O
for	O
the	O
resolution	O
of	O
denudation	O
injuries	O
to	O
the	O
vessel	O
wall	O
.	O

Inhibition	O
of	O
the	O
endothelial	O
cell	O
autocrine	O
angiotensin	B-Gene_or_gene_product
system	O
,	O
with	O
either	O
the	O
angiotensin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
converting	I-Gene_or_gene_product
enzyme	I-Gene_or_gene_product
inhibitor	O
lisinopril	O
or	O
the	O
angiotensin	B-Gene_or_gene_product
II	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
antagonist	O
sar1	B-Gene_or_gene_product
,	O
ile8	O
-	O
angiotensin	O
II	O
,	O
leads	O
to	O
increased	O
endothelial	O
cell	O
migration	O
and	O
urokinase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
plasminogen	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
(	O
u	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PA	I-Gene_or_gene_product
)	O
activity	O
(	O
Bell	O
,	O
L	O
.	O
,	O
and	O
J	O
.	O
A	O
.	O
Madri	O
.	O
1990	O
.	O
Am	O
.	O
J	O
.	O
Pathol	O
.	O
137	O
:	O
7	O
-	O
12	O
)	O
.	O

Inhibition	O
of	O
the	O
autocrine	O
angiotensin	B-Gene_or_gene_product
system	O
with	O
the	O
converting	O
-	O
enzyme	O
inhibitor	O
or	O
the	O
receptor	O
antagonist	O
also	O
leads	O
to	O
increased	O
expression	O
of	O
the	O
proto	O
-	O
oncogene	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
:	O
pp60c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
mRNA	O
increased	O
7	O
-	O
11	O
-	O
fold	O
,	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
protein	O
3	O
-	O
fold	O
,	O
and	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
kinase	O
activity	O
2	O
-	O
3	O
-	O
fold	O
.	O
<EOS>	B-X
A	B-X
collective	B-X
century	B-X
of	B-X
discoveries	B-X
establishes	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
renin	B-X
angiotensin	B-X
aldosterone	B-X
system	B-X
in	B-X
maintaining	B-X
blood	B-X
pressure	B-X
,	B-X
fluid	B-X
volume	B-X
and	B-X
electrolyte	B-X
homeostasis	B-X
via	B-X
autocrine	B-X
,	B-X
paracrine	B-X
and	B-X
endocrine	B-X
signaling	B-X
.	B-X
While	B-X
research	B-X
continues	B-X
to	B-X
yield	B-X
new	B-X
functions	B-X
of	B-X
angiotensin	B-X
II	B-X
and	B-X
angiotensin-	B-X
(	B-X
1-7	B-X
)	B-X
,	B-X
the	B-X
gap	B-X
between	B-X
basic	B-X
research	B-X
and	B-X
clinical	B-X
application	B-X
of	B-X
these	B-X
new	B-X
findings	B-X
is	B-X
widening	B-X
.	B-X
As	B-X
data	B-X
accumulates	B-X
on	B-X
the	B-X
efficacy	B-X
of	B-X
angiotensin	B-X
converting	B-X
enzyme	B-X
inhibitors	B-X
and	B-X
angiotensin	B-X
II	B-X
receptor	B-X
blockers	B-X
as	B-X
drugs	B-X
of	B-X
fundamental	B-X
importance	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cardiovascular	B-X
and	B-X
renal	B-X
disorders	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
apparent	B-X
that	B-X
the	B-X
achieved	B-X
clinical	B-X
benefits	B-X
is	B-X
suboptimal	B-X
and	B-X
surprisingly	B-X
no	B-X
different	B-X
than	B-X
what	B-X
can	B-X
be	B-X
achieved	B-X
with	B-X
other	B-X
therapeutic	B-X
interventions	B-X
.	B-X
We	B-X
discuss	B-X
this	B-X
issue	B-X
and	B-X
summarize	B-X
new	B-X
pathways	B-X
and	B-X
mechanisms	B-X
effecting	B-X
the	B-X
synthesis	B-X
and	B-X
actions	B-X
of	B-X
angiotensin	B-X
II	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
renin-independent	B-X
non-canonical	B-X
pathways	B-X
for	B-X
angiotensin	B-X
II	B-X
production	B-X
are	B-X
largely	B-X
unaffected	B-X
by	B-X
agents	B-X
inhibiting	B-X
renin	B-X
angiotensin	B-X
system	B-X
activity	B-X
.	B-X
Hence	B-X
,	B-X
new	B-X
efforts	B-X
should	B-X
be	B-X
directed	B-X
to	B-X
develop	B-X
drugs	B-X
that	B-X
can	B-X
effectively	B-X
block	B-X
the	B-X
synthesis	B-X
and/or	B-X
action	B-X
of	B-X
intracellular	B-X
angiotensin	B-X
II	B-X
.	B-X
Improved	B-X
drug	B-X
penetration	B-X
into	B-X
cardiac	B-X
or	B-X
renal	B-X
sites	B-X
of	B-X
disease	B-X
,	B-X
inhibiting	B-X
chymase	B-X
the	B-X
primary	B-X
angiotensin	B-X
II	B-X
forming	B-X
enzyme	B-X
in	B-X
the	B-X
human	B-X
heart	B-X
,	B-X
and/or	B-X
inhibiting	B-X
angiotensinogen	B-X
synthesis	B-X
would	B-X
all	B-X
be	B-X
more	B-X
effective	B-X
strategies	B-X
to	B-X
inhibit	B-X
the	B-X
system	B-X
.	B-X
Additionally	B-X
,	B-X
given	B-X
the	B-X
role	B-X
of	B-X
angiotensin	B-X
II	B-X
in	B-X
the	B-X
maintenance	B-X
of	B-X
renal	B-X
homeostatic	B-X
mechanisms	B-X
,	B-X
any	B-X
new	B-X
inhibitor	B-X
should	B-X
possess	B-X
greater	B-X
selectivity	B-X
of	B-X
targeting	B-X
pathogenic	B-X
angiotensin	B-X
II	B-X
signaling	B-X
processes	B-X
and	B-X
thereby	B-X
limit	B-X
inappropriate	B-X
inhibition	B-X
.	B-X

Endothelial	O
cell	O
expression	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
was	O
constitutively	O
elevated	O
after	O
stable	O
infection	O
with	O
a	O
retroviral	O
vector	O
containing	O
the	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
coding	O
sequence	O
.	O

Constitutively	O
increased	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
kinase	O
activity	O
reconstituted	O
the	O
increases	O
in	O
migration	O
and	O
u	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PA	I-Gene_or_gene_product
observed	O
with	O
angiotensin	B-Gene_or_gene_product
system	O
interruption	O
.	O
<EOS>	B-X
Rapid	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
inhibition	B-X
of	B-X
thrombosis	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
resolution	B-X
of	B-X
denudation	B-X
injuries	B-X
to	B-X
the	B-X
vessel	B-X
wall	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
endothelial	B-X
cell	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
,	B-X
with	B-X
either	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
inhibitor	B-X
lisinopril	B-X
or	B-X
the	B-X
angiotensin	B-X
II	B-X
receptor	B-X
antagonist	B-X
sar1	B-X
,	B-X
ile8-angiotensin	B-X
II	B-X
,	B-X
leads	B-X
to	B-X
increased	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
urokinase-like	B-X
plasminogen	B-X
activator	B-X
(	B-X
u-PA	B-X
)	B-X
activity	B-X
(	B-X
Bell	B-X
,	B-X
L.	B-X
,	B-X
and	B-X
J.	B-X
Inhibition	B-X
of	B-X
the	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
with	B-X
the	B-X
converting-enzyme	B-X
inhibitor	B-X
or	B-X
the	B-X
receptor	B-X
antagonist	B-X
also	B-X
leads	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
proto-oncogene	B-X
c-src	B-X
:	B-X
pp60c-src	B-X
mRNA	B-X
increased	B-X
7-11-fold	B-X
,	B-X
c-src	B-X
protein	B-X
3-fold	B-X
,	B-X
and	B-X
c-src	B-X
kinase	B-X
activity	B-X
2-3-fold	B-X
.	B-X
Endothelial	B-X
cell	B-X
expression	B-X
of	B-X
c-src	B-X
was	B-X
constitutively	B-X
elevated	B-X
after	B-X
stable	B-X
infection	B-X
with	B-X
a	B-X
retroviral	B-X
vector	B-X
containing	B-X
the	B-X
c-src	B-X
coding	B-X
sequence	B-X
.	B-X
Constitutively	B-X
increased	B-X
c-src	B-X
kinase	B-X
activity	B-X
reconstituted	B-X
the	B-X
increases	B-X
in	B-X
migration	B-X
and	B-X
u-PA	B-X
observed	B-X
with	B-X
angiotensin	B-X
system	B-X
interruption	B-X
.	B-X
Antisera	B-X
to	B-X
bovine	B-X
u-PA	B-X
blocked	B-X
the	B-X
increase	B-X
in	B-X
migration	B-X
associated	B-X
with	B-X
increased	B-X
c-src	B-X
expression	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
increases	B-X
in	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
plasminogen	B-X
activator	B-X
after	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
are	B-X
at	B-X
least	B-X
partially	B-X
pp60c-src	B-X
mediated	B-X
.	B-X
Elevated	B-X
c-src	B-X
expression	B-X
with	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
may	B-X
act	B-X
to	B-X
enhance	B-X
intimal	B-X
wound	B-X
closure	B-X
and	B-X
to	B-X
reduce	B-X
luminal	B-X
thrombogenicity	B-X
in	B-X
vivo	B-X
.	B-X

Antisera	O
to	O
bovine	O
u	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PA	I-Gene_or_gene_product
blocked	O
the	O
increase	O
in	O
migration	O
associated	O
with	O
increased	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
Rapid	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
inhibition	B-X
of	B-X
thrombosis	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
resolution	B-X
of	B-X
denudation	B-X
injuries	B-X
to	B-X
the	B-X
vessel	B-X
wall	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
endothelial	B-X
cell	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
,	B-X
with	B-X
either	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
inhibitor	B-X
lisinopril	B-X
or	B-X
the	B-X
angiotensin	B-X
II	B-X
receptor	B-X
antagonist	B-X
sar1	B-X
,	B-X
ile8-angiotensin	B-X
II	B-X
,	B-X
leads	B-X
to	B-X
increased	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
urokinase-like	B-X
plasminogen	B-X
activator	B-X
(	B-X
u-PA	B-X
)	B-X
activity	B-X
(	B-X
Bell	B-X
,	B-X
L.	B-X
,	B-X
and	B-X
J.	B-X
Inhibition	B-X
of	B-X
the	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
with	B-X
the	B-X
converting-enzyme	B-X
inhibitor	B-X
or	B-X
the	B-X
receptor	B-X
antagonist	B-X
also	B-X
leads	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
proto-oncogene	B-X
c-src	B-X
:	B-X
pp60c-src	B-X
mRNA	B-X
increased	B-X
7-11-fold	B-X
,	B-X
c-src	B-X
protein	B-X
3-fold	B-X
,	B-X
and	B-X
c-src	B-X
kinase	B-X
activity	B-X
2-3-fold	B-X
.	B-X
Endothelial	B-X
cell	B-X
expression	B-X
of	B-X
c-src	B-X
was	B-X
constitutively	B-X
elevated	B-X
after	B-X
stable	B-X
infection	B-X
with	B-X
a	B-X
retroviral	B-X
vector	B-X
containing	B-X
the	B-X
c-src	B-X
coding	B-X
sequence	B-X
.	B-X
Constitutively	B-X
increased	B-X
c-src	B-X
kinase	B-X
activity	B-X
reconstituted	B-X
the	B-X
increases	B-X
in	B-X
migration	B-X
and	B-X
u-PA	B-X
observed	B-X
with	B-X
angiotensin	B-X
system	B-X
interruption	B-X
.	B-X
Antisera	B-X
to	B-X
bovine	B-X
u-PA	B-X
blocked	B-X
the	B-X
increase	B-X
in	B-X
migration	B-X
associated	B-X
with	B-X
increased	B-X
c-src	B-X
expression	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
increases	B-X
in	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
plasminogen	B-X
activator	B-X
after	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
are	B-X
at	B-X
least	B-X
partially	B-X
pp60c-src	B-X
mediated	B-X
.	B-X
Elevated	B-X
c-src	B-X
expression	B-X
with	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
may	B-X
act	B-X
to	B-X
enhance	B-X
intimal	B-X
wound	B-X
closure	B-X
and	B-X
to	B-X
reduce	B-X
luminal	B-X
thrombogenicity	B-X
in	B-X
vivo	B-X
.	B-X

These	O
data	O
suggest	O
that	O
increases	O
in	O
endothelial	O
cell	O
migration	O
and	O
plasminogen	B-Gene_or_gene_product
activator	I-Gene_or_gene_product
after	O
angiotensin	B-Gene_or_gene_product
system	O
inhibition	O
are	O
at	O
least	O
partially	O
pp60c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
mediated	O
.	O
<EOS>	B-X
Rapid	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
inhibition	B-X
of	B-X
thrombosis	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
resolution	B-X
of	B-X
denudation	B-X
injuries	B-X
to	B-X
the	B-X
vessel	B-X
wall	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
endothelial	B-X
cell	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
,	B-X
with	B-X
either	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
inhibitor	B-X
lisinopril	B-X
or	B-X
the	B-X
angiotensin	B-X
II	B-X
receptor	B-X
antagonist	B-X
sar1	B-X
,	B-X
ile8-angiotensin	B-X
II	B-X
,	B-X
leads	B-X
to	B-X
increased	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
urokinase-like	B-X
plasminogen	B-X
activator	B-X
(	B-X
u-PA	B-X
)	B-X
activity	B-X
(	B-X
Bell	B-X
,	B-X
L.	B-X
,	B-X
and	B-X
J.	B-X
Inhibition	B-X
of	B-X
the	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
with	B-X
the	B-X
converting-enzyme	B-X
inhibitor	B-X
or	B-X
the	B-X
receptor	B-X
antagonist	B-X
also	B-X
leads	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
proto-oncogene	B-X
c-src	B-X
:	B-X
pp60c-src	B-X
mRNA	B-X
increased	B-X
7-11-fold	B-X
,	B-X
c-src	B-X
protein	B-X
3-fold	B-X
,	B-X
and	B-X
c-src	B-X
kinase	B-X
activity	B-X
2-3-fold	B-X
.	B-X
Endothelial	B-X
cell	B-X
expression	B-X
of	B-X
c-src	B-X
was	B-X
constitutively	B-X
elevated	B-X
after	B-X
stable	B-X
infection	B-X
with	B-X
a	B-X
retroviral	B-X
vector	B-X
containing	B-X
the	B-X
c-src	B-X
coding	B-X
sequence	B-X
.	B-X
Constitutively	B-X
increased	B-X
c-src	B-X
kinase	B-X
activity	B-X
reconstituted	B-X
the	B-X
increases	B-X
in	B-X
migration	B-X
and	B-X
u-PA	B-X
observed	B-X
with	B-X
angiotensin	B-X
system	B-X
interruption	B-X
.	B-X
Antisera	B-X
to	B-X
bovine	B-X
u-PA	B-X
blocked	B-X
the	B-X
increase	B-X
in	B-X
migration	B-X
associated	B-X
with	B-X
increased	B-X
c-src	B-X
expression	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
increases	B-X
in	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
plasminogen	B-X
activator	B-X
after	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
are	B-X
at	B-X
least	B-X
partially	B-X
pp60c-src	B-X
mediated	B-X
.	B-X
Elevated	B-X
c-src	B-X
expression	B-X
with	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
may	B-X
act	B-X
to	B-X
enhance	B-X
intimal	B-X
wound	B-X
closure	B-X
and	B-X
to	B-X
reduce	B-X
luminal	B-X
thrombogenicity	B-X
in	B-X
vivo	B-X
.	B-X

Elevated	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
expression	O
with	O
angiotensin	B-Gene_or_gene_product
system	O
inhibition	O
may	O
act	O
to	O
enhance	O
intimal	O
wound	O
closure	O
and	O
to	O
reduce	O
luminal	O
thrombogenicity	O
in	O
vivo	O
.	O
<EOS>	B-X
Rapid	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
inhibition	B-X
of	B-X
thrombosis	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
resolution	B-X
of	B-X
denudation	B-X
injuries	B-X
to	B-X
the	B-X
vessel	B-X
wall	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
endothelial	B-X
cell	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
,	B-X
with	B-X
either	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
inhibitor	B-X
lisinopril	B-X
or	B-X
the	B-X
angiotensin	B-X
II	B-X
receptor	B-X
antagonist	B-X
sar1	B-X
,	B-X
ile8-angiotensin	B-X
II	B-X
,	B-X
leads	B-X
to	B-X
increased	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
urokinase-like	B-X
plasminogen	B-X
activator	B-X
(	B-X
u-PA	B-X
)	B-X
activity	B-X
(	B-X
Bell	B-X
,	B-X
L.	B-X
,	B-X
and	B-X
J.	B-X
Inhibition	B-X
of	B-X
the	B-X
autocrine	B-X
angiotensin	B-X
system	B-X
with	B-X
the	B-X
converting-enzyme	B-X
inhibitor	B-X
or	B-X
the	B-X
receptor	B-X
antagonist	B-X
also	B-X
leads	B-X
to	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
proto-oncogene	B-X
c-src	B-X
:	B-X
pp60c-src	B-X
mRNA	B-X
increased	B-X
7-11-fold	B-X
,	B-X
c-src	B-X
protein	B-X
3-fold	B-X
,	B-X
and	B-X
c-src	B-X
kinase	B-X
activity	B-X
2-3-fold	B-X
.	B-X
Endothelial	B-X
cell	B-X
expression	B-X
of	B-X
c-src	B-X
was	B-X
constitutively	B-X
elevated	B-X
after	B-X
stable	B-X
infection	B-X
with	B-X
a	B-X
retroviral	B-X
vector	B-X
containing	B-X
the	B-X
c-src	B-X
coding	B-X
sequence	B-X
.	B-X
Constitutively	B-X
increased	B-X
c-src	B-X
kinase	B-X
activity	B-X
reconstituted	B-X
the	B-X
increases	B-X
in	B-X
migration	B-X
and	B-X
u-PA	B-X
observed	B-X
with	B-X
angiotensin	B-X
system	B-X
interruption	B-X
.	B-X
Antisera	B-X
to	B-X
bovine	B-X
u-PA	B-X
blocked	B-X
the	B-X
increase	B-X
in	B-X
migration	B-X
associated	B-X
with	B-X
increased	B-X
c-src	B-X
expression	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
increases	B-X
in	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
plasminogen	B-X
activator	B-X
after	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
are	B-X
at	B-X
least	B-X
partially	B-X
pp60c-src	B-X
mediated	B-X
.	B-X
Elevated	B-X
c-src	B-X
expression	B-X
with	B-X
angiotensin	B-X
system	B-X
inhibition	B-X
may	B-X
act	B-X
to	B-X
enhance	B-X
intimal	B-X
wound	B-X
closure	B-X
and	B-X
to	B-X
reduce	B-X
luminal	B-X
thrombogenicity	B-X
in	B-X
vivo	B-X
.	B-X

Cell	O
type	O
-	O
specific	O
regulation	O
of	O
angiogenic	O
growth	O
factor	O
gene	O
expression	O
and	O
induction	O
of	O
angiogenesis	O
in	O
nonischemic	O
tissue	O
by	O
a	O
constitutively	O
active	O
form	O
of	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
Understanding	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
angiogenesis	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
ischemic	B-X
disorders	B-X
.	B-X
Hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
activates	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
hypoxic/ischemic	B-X
tissue	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Loss-of-function	B-X
effects	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
HIF-1alpha-null	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
cell	B-X
type	B-X
,	B-X
expression	B-X
of	B-X
ANGPT1	B-X
and	B-X
ANGPT2	B-X
was	B-X
either	B-X
activated	B-X
or	B-X
repressed	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
.	B-X
In	B-X
all	B-X
cases	B-X
,	B-X
there	B-X
was	B-X
complete	B-X
concordance	B-X
between	B-X
the	B-X
effects	B-X
of	B-X
hypoxia	B-X
and	B-X
AdCA5	B-X
.	B-X
Analysis	B-X
of	B-X
gene	B-X
expression	B-X
revealed	B-X
increased	B-X
expression	B-X
of	B-X
ANGPT1	B-X
,	B-X
ANGPT2	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
VEGF	B-X
mRNA	B-X
in	B-X
AdCA5-injected	B-X
eyes	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HIF-1	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
multiple	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
that	B-X
adenovirus-mediated	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
is	B-X
sufficient	B-X
to	B-X
induce	B-X
angiogenesis	B-X
in	B-X
nonischemic	B-X
tissue	B-X
of	B-X
an	B-X
adult	B-X
animal	B-X
.	B-X

Understanding	O
molecular	O
mechanisms	O
regulating	O
angiogenesis	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
ischemic	O
disorders	O
.	O
<EOS>	B-X
Formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
,	B-X
by	B-X
either	B-X
angiogenesis	B-X
or	B-X
vasculogenesis	B-X
,	B-X
is	B-X
critical	B-X
for	B-X
normal	B-X
wound	B-X
healing	B-X
.	B-X
A	B-X
profound	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
underpinnings	B-X
of	B-X
gastric	B-X
cancer	B-X
has	B-X
lagged	B-X
compared	B-X
to	B-X
several	B-X
other	B-X
tumors	B-X
with	B-X
similar	B-X
incidence	B-X
and	B-X
morbidity	B-X
rates	B-X
,	B-X
owing	B-X
to	B-X
our	B-X
limited	B-X
knowledge	B-X
of	B-X
the	B-X
role	B-X
of	B-X
carcinogens	B-X
in	B-X
this	B-X
malignancy	B-X
.	B-X
This	B-X
review	B-X
aims	B-X
to	B-X
explore	B-X
the	B-X
potential	B-X
comprehensive	B-X
molecular	B-X
and	B-X
biological	B-X
impacts	B-X
of	B-X
carcinogens	B-X
on	B-X
gastric	B-X
cancer	B-X
development	B-X
and	B-X
their	B-X
interactions	B-X
and	B-X
interferences	B-X
with	B-X
various	B-X
cellular	B-X
signaling	B-X
pathways	B-X
.	B-X
In	B-X
the	B-X
last	B-X
few	B-X
decades	B-X
it	B-X
has	B-X
become	B-X
clear	B-X
that	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
of	B-X
angiogenesis	B-X
,	B-X
a	B-X
process	B-X
leading	B-X
to	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
,	B-X
should	B-X
lead	B-X
to	B-X
improved	B-X
treatment	B-X
of	B-X
diseases	B-X
such	B-X
as	B-X
ischemic	B-X
disorders	B-X
and	B-X
cancer	B-X
where	B-X
neovascularization	B-X
is	B-X
impaired	B-X
or	B-X
activated	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
outline	B-X
some	B-X
of	B-X
our	B-X
recent	B-X
findings	B-X
concerning	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
a	B-X
key	B-X
player	B-X
in	B-X
angiogenesis	B-X
and	B-X
one	B-X
of	B-X
its	B-X
transcription	B-X
factors	B-X
,	B-X
the	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
a	B-X
master	B-X
gene	B-X
product	B-X
driving	B-X
adaptation	B-X
to	B-X
hypoxia	B-X
.	B-X
We	B-X
will	B-X
discuss	B-X
the	B-X
observation	B-X
that	B-X
growth	B-X
factors	B-X
and	B-X
oncogenic	B-X
transformation	B-X
via	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
p42/p44	B-X
MAPKs	B-X
not	B-X
only	B-X
activate	B-X
the	B-X
VEGF	B-X
promoter	B-X
through	B-X
the	B-X
Sp1/AP-2	B-X
transcriptional	B-X
factor	B-X
complex	B-X
but	B-X
also	B-X
phosphorylate	B-X
HIF-1alpha	B-X
leading	B-X
in	B-X
turn	B-X
to	B-X
enhance	B-X
HIF-1	B-X
dependent	B-X
transcriptional	B-X
activation	B-X
of	B-X
VEGF	B-X
.	B-X
The	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPK	B-X
)	B-X
also	B-X
contribute	B-X
to	B-X
angiogenesis	B-X
by	B-X
stabilizing	B-X
VEGF	B-X
mRNA	B-X
.	B-X
The	B-X
revelation	B-X
of	B-X
these	B-X
oxygen	B-X
sensors	B-X
has	B-X
provided	B-X
pharmacologists	B-X
with	B-X
new	B-X
molecular	B-X
targets	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapies	B-X
to	B-X
control	B-X
angiogenesis	B-X
either	B-X
positively	B-X
or	B-X
negatively	B-X
.	B-X

Hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
activates	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
gene	O
expression	O
in	O
hypoxic	O
/	O
ischemic	O
tissue	O
.	O
<EOS>	B-X
Understanding	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
angiogenesis	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
ischemic	B-X
disorders	B-X
.	B-X
Hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
activates	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
hypoxic/ischemic	B-X
tissue	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Loss-of-function	B-X
effects	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
HIF-1alpha-null	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
cell	B-X
type	B-X
,	B-X
expression	B-X
of	B-X
ANGPT1	B-X
and	B-X
ANGPT2	B-X
was	B-X
either	B-X
activated	B-X
or	B-X
repressed	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
.	B-X
Injection	B-X
of	B-X
AdCA5	B-X
into	B-X
mouse	B-X
eyes	B-X
induced	B-X
neovascularization	B-X
in	B-X
multiple	B-X
capillary	B-X
beds	B-X
,	B-X
including	B-X
those	B-X
not	B-X
responsive	B-X
to	B-X
VEGF	B-X
alone	B-X
.	B-X
Analysis	B-X
of	B-X
gene	B-X
expression	B-X
revealed	B-X
increased	B-X
expression	B-X
of	B-X
ANGPT1	B-X
,	B-X
ANGPT2	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
VEGF	B-X
mRNA	B-X
in	B-X
AdCA5-injected	B-X
eyes	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HIF-1	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
multiple	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
that	B-X
adenovirus-mediated	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
is	B-X
sufficient	B-X
to	B-X
induce	B-X
angiogenesis	B-X
in	B-X
nonischemic	B-X
tissue	B-X
of	B-X
an	B-X
adult	B-X
animal	B-X
.	B-X

In	O
this	O
study	O
we	O
demonstrate	O
that	O
exposure	O
of	O
primary	O
cultures	O
of	O
cardiac	O
and	O
vascular	O
cells	O
to	O
hypoxia	O
or	O
AdCA5	O
,	O
an	O
adenovirus	O
encoding	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
,	O
modulates	O
the	O
expression	O
of	O
genes	O
encoding	O
the	O
angiogenic	O
factors	O
angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
ANGPT1	B-Gene_or_gene_product
)	O
,	O
ANGPT2	B-Gene_or_gene_product
,	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
,	O
and	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
B	I-Gene_or_gene_product
.	O
<EOS>	B-X
Understanding	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
angiogenesis	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
ischemic	B-X
disorders	B-X
.	B-X
Hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
activates	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
hypoxic/ischemic	B-X
tissue	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Loss-of-function	B-X
effects	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
HIF-1alpha-null	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
cell	B-X
type	B-X
,	B-X
expression	B-X
of	B-X
ANGPT1	B-X
and	B-X
ANGPT2	B-X
was	B-X
either	B-X
activated	B-X
or	B-X
repressed	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
.	B-X
In	B-X
all	B-X
cases	B-X
,	B-X
there	B-X
was	B-X
complete	B-X
concordance	B-X
between	B-X
the	B-X
effects	B-X
of	B-X
hypoxia	B-X
and	B-X
AdCA5	B-X
.	B-X
Injection	B-X
of	B-X
AdCA5	B-X
into	B-X
mouse	B-X
eyes	B-X
induced	B-X
neovascularization	B-X
in	B-X
multiple	B-X
capillary	B-X
beds	B-X
,	B-X
including	B-X
those	B-X
not	B-X
responsive	B-X
to	B-X
VEGF	B-X
alone	B-X
.	B-X
Analysis	B-X
of	B-X
gene	B-X
expression	B-X
revealed	B-X
increased	B-X
expression	B-X
of	B-X
ANGPT1	B-X
,	B-X
ANGPT2	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
VEGF	B-X
mRNA	B-X
in	B-X
AdCA5-injected	B-X
eyes	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HIF-1	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
multiple	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
that	B-X
adenovirus-mediated	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
is	B-X
sufficient	B-X
to	B-X
induce	B-X
angiogenesis	B-X
in	B-X
nonischemic	B-X
tissue	B-X
of	B-X
an	B-X
adult	B-X
animal	B-X
.	B-X

Loss	O
-	O
of	O
-	O
function	O
effects	O
were	O
also	O
observed	O
in	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
-	O
null	O
embryonic	O
stem	O
cells	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
activates	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
hypoxic/ischemic	B-X
tissue	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Loss-of-function	B-X
effects	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
HIF-1alpha-null	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
In	B-X
all	B-X
cases	B-X
,	B-X
there	B-X
was	B-X
complete	B-X
concordance	B-X
between	B-X
the	B-X
effects	B-X
of	B-X
hypoxia	B-X
and	B-X
AdCA5	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HIF-1	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
multiple	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
that	B-X
adenovirus-mediated	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
is	B-X
sufficient	B-X
to	B-X
induce	B-X
angiogenesis	B-X
in	B-X
nonischemic	B-X
tissue	B-X
of	B-X
an	B-X
adult	B-X
animal	B-X
.	B-X

Depending	O
on	O
the	O
cell	O
type	O
,	O
expression	O
of	O
ANGPT1	B-Gene_or_gene_product
and	O
ANGPT2	B-Gene_or_gene_product
was	O
either	O
activated	O
or	O
repressed	O
in	O
response	O
to	O
hypoxia	O
or	O
AdCA5	O
.	O
<EOS>	B-X
Cancer	B-X
and	B-X
chronic	B-X
infections	B-X
induce	B-X
T	B-X
cell	B-X
exhaustion	B-X
,	B-X
a	B-X
hypofunctional	B-X
fate	B-X
carrying	B-X
distinct	B-X
epigenetic	B-X
,	B-X
transcriptomic	B-X
and	B-X
metabolic	B-X
characteristics	B-X
.	B-X
As	B-X
intratumoral	B-X
exhausted	B-X
T	B-X
cells	B-X
experience	B-X
severe	B-X
hypoxia	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
metabolic	B-X
stress	B-X
alters	B-X
their	B-X
responses	B-X
to	B-X
other	B-X
signals	B-X
,	B-X
specifically	B-X
,	B-X
persistent	B-X
antigenic	B-X
stimulation	B-X
.	B-X
However	B-X
,	B-X
relationship	B-X
between	B-X
hypoxia	B-X
and	B-X
FTL	B-X
expression	B-X
and	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
EMT	B-X
remains	B-X
unclear	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
or	B-X
not	B-X
extracellular	B-X
vesicles	B-X
(	B-X
EVs	B-X
)	B-X
derived	B-X
from	B-X
such	B-X
microglia	B-X
are	B-X
the	B-X
biological	B-X
mediators	B-X
of	B-X
these	B-X
observations	B-X
and	B-X
which	B-X
signaling	B-X
pathways	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
process	B-X
.	B-X
Exposing	B-X
bEnd.3	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
and	B-X
primary	B-X
cortical	B-X
neurons	B-X
to	B-X
OGD	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
EVs	B-X
from	B-X
OGD-preconditioned	B-X
microglia	B-X
on	B-X
angiogenesis	B-X
and	B-X
neuronal	B-X
apoptosis	B-X
by	B-X
the	B-X
tube	B-X
formation	B-X
assay	B-X
and	B-X
TUNEL	B-X
staining	B-X
was	B-X
assessed	B-X
.	B-X
Under	B-X
these	B-X
conditions	B-X
,	B-X
EV	B-X
treatment	B-X
stimulated	B-X
both	B-X
angiogenesis	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
ECs	B-X
and	B-X
repressed	B-X
neuronal	B-X
cell	B-X
injury	B-X
.	B-X
Furthermore	B-X
,	B-X
enriched	B-X
TGF-Î²1	B-X
in	B-X
EVs	B-X
secreted	B-X
from	B-X
OGD-preconditioned	B-X
microglia	B-X
stimulated	B-X
M2	B-X
polarization	B-X
of	B-X
residing	B-X
microglia	B-X
within	B-X
the	B-X
ischemic	B-X
cerebral	B-X
environment	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
a	B-X
regulation	B-X
of	B-X
an	B-X
early	B-X
inflammatory	B-X
response	B-X
in	B-X
postischemic	B-X
hemispheres	B-X
.	B-X

In	O
all	O
cases	O
,	O
there	O
was	O
complete	O
concordance	O
between	O
the	O
effects	O
of	O
hypoxia	O
and	O
AdCA5	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Loss-of-function	B-X
effects	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
HIF-1alpha-null	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
cell	B-X
type	B-X
,	B-X
expression	B-X
of	B-X
ANGPT1	B-X
and	B-X
ANGPT2	B-X
was	B-X
either	B-X
activated	B-X
or	B-X
repressed	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
.	B-X
In	B-X
all	B-X
cases	B-X
,	B-X
there	B-X
was	B-X
complete	B-X
concordance	B-X
between	B-X
the	B-X
effects	B-X
of	B-X
hypoxia	B-X
and	B-X
AdCA5	B-X
.	B-X
Injection	B-X
of	B-X
AdCA5	B-X
into	B-X
mouse	B-X
eyes	B-X
induced	B-X
neovascularization	B-X
in	B-X
multiple	B-X
capillary	B-X
beds	B-X
,	B-X
including	B-X
those	B-X
not	B-X
responsive	B-X
to	B-X
VEGF	B-X
alone	B-X
.	B-X
Analysis	B-X
of	B-X
gene	B-X
expression	B-X
revealed	B-X
increased	B-X
expression	B-X
of	B-X
ANGPT1	B-X
,	B-X
ANGPT2	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
VEGF	B-X
mRNA	B-X
in	B-X
AdCA5-injected	B-X
eyes	B-X
.	B-X

Injection	O
of	O
AdCA5	O
into	O
mouse	O
eyes	O
induced	O
neovascularization	O
in	O
multiple	O
capillary	O
beds	O
,	O
including	O
those	O
not	O
responsive	O
to	O
VEGF	B-Gene_or_gene_product
alone	O
.	O

Analysis	O
of	O
gene	O
expression	O
revealed	O
increased	O
expression	O
of	O
ANGPT1	B-Gene_or_gene_product
,	O
ANGPT2	B-Gene_or_gene_product
,	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
B	I-Gene_or_gene_product
,	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
,	O
and	O
VEGF	B-Gene_or_gene_product
mRNA	O
in	O
AdCA5	O
-	O
injected	O
eyes	O
.	O
<EOS>	B-X
Understanding	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
angiogenesis	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
ischemic	B-X
disorders	B-X
.	B-X
Hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
activates	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
hypoxic/ischemic	B-X
tissue	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
cell	B-X
type	B-X
,	B-X
expression	B-X
of	B-X
ANGPT1	B-X
and	B-X
ANGPT2	B-X
was	B-X
either	B-X
activated	B-X
or	B-X
repressed	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
.	B-X
In	B-X
all	B-X
cases	B-X
,	B-X
there	B-X
was	B-X
complete	B-X
concordance	B-X
between	B-X
the	B-X
effects	B-X
of	B-X
hypoxia	B-X
and	B-X
AdCA5	B-X
.	B-X
Injection	B-X
of	B-X
AdCA5	B-X
into	B-X
mouse	B-X
eyes	B-X
induced	B-X
neovascularization	B-X
in	B-X
multiple	B-X
capillary	B-X
beds	B-X
,	B-X
including	B-X
those	B-X
not	B-X
responsive	B-X
to	B-X
VEGF	B-X
alone	B-X
.	B-X
Analysis	B-X
of	B-X
gene	B-X
expression	B-X
revealed	B-X
increased	B-X
expression	B-X
of	B-X
ANGPT1	B-X
,	B-X
ANGPT2	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
VEGF	B-X
mRNA	B-X
in	B-X
AdCA5-injected	B-X
eyes	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HIF-1	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
multiple	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
that	B-X
adenovirus-mediated	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
is	B-X
sufficient	B-X
to	B-X
induce	B-X
angiogenesis	B-X
in	B-X
nonischemic	B-X
tissue	B-X
of	B-X
an	B-X
adult	B-X
animal	B-X
.	B-X

These	O
results	O
indicate	O
that	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
functions	O
as	O
a	O
master	O
regulator	O
of	O
angiogenesis	O
by	O
controlling	O
the	O
expression	O
of	O
multiple	O
angiogenic	O
growth	O
factors	O
and	O
that	O
adenovirus	O
-	O
mediated	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
is	O
sufficient	O
to	O
induce	O
angiogenesis	O
in	O
nonischemic	O
tissue	O
of	O
an	O
adult	O
animal	O
.	O
<EOS>	B-X
Understanding	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
angiogenesis	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
ischemic	B-X
disorders	B-X
.	B-X
Hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
activates	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
hypoxic/ischemic	B-X
tissue	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
cultures	B-X
of	B-X
cardiac	B-X
and	B-X
vascular	B-X
cells	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
,	B-X
an	B-X
adenovirus	B-X
encoding	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
,	B-X
modulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
angiogenic	B-X
factors	B-X
angiopoietin-1	B-X
(	B-X
ANGPT1	B-X
)	B-X
,	B-X
ANGPT2	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
.	B-X
Loss-of-function	B-X
effects	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
HIF-1alpha-null	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
cell	B-X
type	B-X
,	B-X
expression	B-X
of	B-X
ANGPT1	B-X
and	B-X
ANGPT2	B-X
was	B-X
either	B-X
activated	B-X
or	B-X
repressed	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
or	B-X
AdCA5	B-X
.	B-X
Injection	B-X
of	B-X
AdCA5	B-X
into	B-X
mouse	B-X
eyes	B-X
induced	B-X
neovascularization	B-X
in	B-X
multiple	B-X
capillary	B-X
beds	B-X
,	B-X
including	B-X
those	B-X
not	B-X
responsive	B-X
to	B-X
VEGF	B-X
alone	B-X
.	B-X
Analysis	B-X
of	B-X
gene	B-X
expression	B-X
revealed	B-X
increased	B-X
expression	B-X
of	B-X
ANGPT1	B-X
,	B-X
ANGPT2	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor-B	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
VEGF	B-X
mRNA	B-X
in	B-X
AdCA5-injected	B-X
eyes	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HIF-1	B-X
functions	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
multiple	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
that	B-X
adenovirus-mediated	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
HIF-1alpha	B-X
is	B-X
sufficient	B-X
to	B-X
induce	B-X
angiogenesis	B-X
in	B-X
nonischemic	B-X
tissue	B-X
of	B-X
an	B-X
adult	B-X
animal	B-X
.	B-X

Differential	O
regulation	O
of	O
in	O
vivo	O
angiogenesis	O
by	O
angiotensin	B-Gene_or_gene_product
II	I-Gene_or_gene_product
receptors	I-Gene_or_gene_product
.	O
<EOS>	B-X
Angiotensin	B-X
II	B-X
(	B-X
ANG	B-X
II	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
blood	B-X
pressure	B-X
and	B-X
body	B-X
fluid	B-X
homeostasis	B-X
,	B-X
exerts	B-X
mitogenic	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
therefore	B-X
hypothesized	B-X
that	B-X
ANG	B-X
II	B-X
could	B-X
be	B-X
a	B-X
mediator	B-X
between	B-X
homeostatic	B-X
changes	B-X
within	B-X
the	B-X
vascular	B-X
perfusion	B-X
bed	B-X
and	B-X
growth	B-X
factor-driven	B-X
angiogenesis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
applied	B-X
the	B-X
alginate	B-X
implant	B-X
angiogenesis	B-X
model	B-X
in	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
,	B-X
elevated	B-X
ANG	B-X
II	B-X
levels	B-X
by	B-X
transgenic	B-X
overexpression	B-X
of	B-X
angiotensinogen	B-X
(	B-X
AOGEN	B-X
)	B-X
,	B-X
or	B-X
in	B-X
AT2	B-X
receptor-deficient	B-X
mice	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
circulating	B-X
ANG	B-X
II	B-X
by	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
(	B-X
ACE	B-X
)	B-X
inhibitor	B-X
enalapril	B-X
or	B-X
the	B-X
AT1	B-X
receptor	B-X
antagonist	B-X
losartan	B-X
induced	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
implying	B-X
an	B-X
inhibitory	B-X
function	B-X
of	B-X
ANG	B-X
II	B-X
through	B-X
the	B-X
AT1	B-X
receptor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
strong	B-X
increase	B-X
of	B-X
angiogenesis	B-X
in	B-X
AOGEN-transgenic	B-X
mice	B-X
compared	B-X
with	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
suggests	B-X
additional	B-X
stimulatory	B-X
activity	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
ANG	B-X
II-induced	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
AT2	B-X
receptor	B-X
as	B-X
an	B-X
impaired	B-X
induction	B-X
of	B-X
angiogenesis	B-X
was	B-X
obtained	B-X
in	B-X
AT2	B-X
receptor	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
the	B-X
AT2	B-X
receptor	B-X
mediates	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
and	B-X
indicate	B-X
that	B-X
ANG	B-X
II	B-X
is	B-X
a	B-X
humoral	B-X
regulator	B-X
of	B-X
peripheral	B-X
angiogenesis	B-X
involving	B-X
two	B-X
receptor	B-X
subtypes	B-X
with	B-X
opposing	B-X
actions	B-X
.	B-X

Angiotensin	B-Gene_or_gene_product
II	I-Gene_or_gene_product
(	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
)	O
,	O
a	O
key	O
regulator	O
of	O
blood	O
pressure	O
and	O
body	O
fluid	O
homeostasis	O
,	O
exerts	O
mitogenic	O
effects	O
on	O
endothelial	O
cells	O
.	O

We	O
therefore	O
hypothesized	O
that	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
could	O
be	O
a	O
mediator	O
between	O
homeostatic	O
changes	O
within	O
the	O
vascular	O
perfusion	O
bed	O
and	O
growth	O
factor	O
-	O
driven	O
angiogenesis	O
.	O
<EOS>	B-X
Angiotensin	B-X
II	B-X
(	B-X
ANG	B-X
II	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
blood	B-X
pressure	B-X
and	B-X
body	B-X
fluid	B-X
homeostasis	B-X
,	B-X
exerts	B-X
mitogenic	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
therefore	B-X
hypothesized	B-X
that	B-X
ANG	B-X
II	B-X
could	B-X
be	B-X
a	B-X
mediator	B-X
between	B-X
homeostatic	B-X
changes	B-X
within	B-X
the	B-X
vascular	B-X
perfusion	B-X
bed	B-X
and	B-X
growth	B-X
factor-driven	B-X
angiogenesis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
applied	B-X
the	B-X
alginate	B-X
implant	B-X
angiogenesis	B-X
model	B-X
in	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
,	B-X
elevated	B-X
ANG	B-X
II	B-X
levels	B-X
by	B-X
transgenic	B-X
overexpression	B-X
of	B-X
angiotensinogen	B-X
(	B-X
AOGEN	B-X
)	B-X
,	B-X
or	B-X
in	B-X
AT2	B-X
receptor-deficient	B-X
mice	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
circulating	B-X
ANG	B-X
II	B-X
by	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
(	B-X
ACE	B-X
)	B-X
inhibitor	B-X
enalapril	B-X
or	B-X
the	B-X
AT1	B-X
receptor	B-X
antagonist	B-X
losartan	B-X
induced	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
implying	B-X
an	B-X
inhibitory	B-X
function	B-X
of	B-X
ANG	B-X
II	B-X
through	B-X
the	B-X
AT1	B-X
receptor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
strong	B-X
increase	B-X
of	B-X
angiogenesis	B-X
in	B-X
AOGEN-transgenic	B-X
mice	B-X
compared	B-X
with	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
suggests	B-X
additional	B-X
stimulatory	B-X
activity	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
ANG	B-X
II-induced	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
AT2	B-X
receptor	B-X
as	B-X
an	B-X
impaired	B-X
induction	B-X
of	B-X
angiogenesis	B-X
was	B-X
obtained	B-X
in	B-X
AT2	B-X
receptor	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
the	B-X
AT2	B-X
receptor	B-X
mediates	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
and	B-X
indicate	B-X
that	B-X
ANG	B-X
II	B-X
is	B-X
a	B-X
humoral	B-X
regulator	B-X
of	B-X
peripheral	B-X
angiogenesis	B-X
involving	B-X
two	B-X
receptor	B-X
subtypes	B-X
with	B-X
opposing	B-X
actions	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
applied	O
the	O
alginate	O
implant	O
angiogenesis	O
model	O
in	O
mice	O
with	O
normal	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
levels	O
,	O
elevated	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
levels	O
by	O
transgenic	O
overexpression	O
of	O
angiotensinogen	B-Gene_or_gene_product
(	O
AOGEN	B-Gene_or_gene_product
)	O
,	O
or	O
in	O
AT2	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	O
deficient	O
mice	O
.	O
<EOS>	B-X
At	B-X
present	B-X
,	B-X
there	B-X
are	B-X
no	B-X
effective	B-X
drugs	B-X
for	B-X
improving	B-X
the	B-X
clinical	B-X
outcome	B-X
of	B-X
ARDS	B-X
.	B-X
ACE	B-X
cleaves	B-X
angiotensin	B-X
I	B-X
to	B-X
generate	B-X
angiotensin	B-X
II	B-X
,	B-X
whereas	B-X
ACE2	B-X
inactivates	B-X
angiotensin	B-X
II	B-X
and	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
system	B-X
.	B-X
ACE2	B-X
has	B-X
also	B-X
recently	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
potential	B-X
SARS	B-X
virus	B-X
receptor	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
lungs	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
ACE2	B-X
and	B-X
the	B-X
angiotensin	B-X
II	B-X
type	B-X
2	B-X
receptor	B-X
(	B-X
AT2	B-X
)	B-X
protect	B-X
mice	B-X
from	B-X
severe	B-X
acute	B-X
lung	B-X
injury	B-X
induced	B-X
by	B-X
acid	B-X
aspiration	B-X
or	B-X
sepsis	B-X
.	B-X
However	B-X
,	B-X
other	B-X
components	B-X
of	B-X
the	B-X
renin-angiotensin	B-X
system	B-X
,	B-X
including	B-X
ACE	B-X
,	B-X
angiotensin	B-X
II	B-X
and	B-X
the	B-X
angiotensin	B-X
II	B-X
type	B-X
1a	B-X
receptor	B-X
(	B-X
AT1a	B-X
)	B-X
,	B-X
promote	B-X
disease	B-X
pathogenesis	B-X
,	B-X
induce	B-X
lung	B-X
oedemas	B-X
and	B-X
impair	B-X
lung	B-X
function	B-X
.	B-X
We	B-X
show	B-X
that	B-X
mice	B-X
deficient	B-X
for	B-X
Ace	B-X
show	B-X
markedly	B-X
improved	B-X
disease	B-X
,	B-X
and	B-X
also	B-X
that	B-X
recombinant	B-X
ACE2	B-X
can	B-X
protect	B-X
mice	B-X
from	B-X
severe	B-X
acute	B-X
lung	B-X
injury	B-X
.	B-X

We	O
demonstrate	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
circulating	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
by	O
the	O
angiotensin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
converting	I-Gene_or_gene_product
enzyme	I-Gene_or_gene_product
(	O
ACE	B-Gene_or_gene_product
)	O
inhibitor	O
enalapril	O
or	O
the	O
AT1	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
antagonist	O
losartan	O
induced	O
a	O
stimulation	O
of	O
in	O
vivo	O
angiogenesis	O
implying	O
an	O
inhibitory	O
function	O
of	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
through	O
the	O
AT1	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
.	O
<EOS>	B-X
Angiotensin	B-X
II	B-X
(	B-X
ANG	B-X
II	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
blood	B-X
pressure	B-X
and	B-X
body	B-X
fluid	B-X
homeostasis	B-X
,	B-X
exerts	B-X
mitogenic	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
therefore	B-X
hypothesized	B-X
that	B-X
ANG	B-X
II	B-X
could	B-X
be	B-X
a	B-X
mediator	B-X
between	B-X
homeostatic	B-X
changes	B-X
within	B-X
the	B-X
vascular	B-X
perfusion	B-X
bed	B-X
and	B-X
growth	B-X
factor-driven	B-X
angiogenesis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
applied	B-X
the	B-X
alginate	B-X
implant	B-X
angiogenesis	B-X
model	B-X
in	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
,	B-X
elevated	B-X
ANG	B-X
II	B-X
levels	B-X
by	B-X
transgenic	B-X
overexpression	B-X
of	B-X
angiotensinogen	B-X
(	B-X
AOGEN	B-X
)	B-X
,	B-X
or	B-X
in	B-X
AT2	B-X
receptor-deficient	B-X
mice	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
circulating	B-X
ANG	B-X
II	B-X
by	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
(	B-X
ACE	B-X
)	B-X
inhibitor	B-X
enalapril	B-X
or	B-X
the	B-X
AT1	B-X
receptor	B-X
antagonist	B-X
losartan	B-X
induced	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
implying	B-X
an	B-X
inhibitory	B-X
function	B-X
of	B-X
ANG	B-X
II	B-X
through	B-X
the	B-X
AT1	B-X
receptor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
strong	B-X
increase	B-X
of	B-X
angiogenesis	B-X
in	B-X
AOGEN-transgenic	B-X
mice	B-X
compared	B-X
with	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
suggests	B-X
additional	B-X
stimulatory	B-X
activity	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
ANG	B-X
II-induced	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
AT2	B-X
receptor	B-X
as	B-X
an	B-X
impaired	B-X
induction	B-X
of	B-X
angiogenesis	B-X
was	B-X
obtained	B-X
in	B-X
AT2	B-X
receptor	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
the	B-X
AT2	B-X
receptor	B-X
mediates	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
and	B-X
indicate	B-X
that	B-X
ANG	B-X
II	B-X
is	B-X
a	B-X
humoral	B-X
regulator	B-X
of	B-X
peripheral	B-X
angiogenesis	B-X
involving	B-X
two	B-X
receptor	B-X
subtypes	B-X
with	B-X
opposing	B-X
actions	B-X
.	B-X

However	O
,	O
the	O
strong	O
increase	O
of	O
angiogenesis	O
in	O
AOGEN	B-Gene_or_gene_product
-	O
transgenic	O
mice	O
compared	O
with	O
mice	O
with	O
normal	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
levels	O
suggests	O
additional	O
stimulatory	O
activity	O
.	O
<EOS>	B-X
Angiotensin	B-X
II	B-X
(	B-X
ANG	B-X
II	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
blood	B-X
pressure	B-X
and	B-X
body	B-X
fluid	B-X
homeostasis	B-X
,	B-X
exerts	B-X
mitogenic	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
therefore	B-X
hypothesized	B-X
that	B-X
ANG	B-X
II	B-X
could	B-X
be	B-X
a	B-X
mediator	B-X
between	B-X
homeostatic	B-X
changes	B-X
within	B-X
the	B-X
vascular	B-X
perfusion	B-X
bed	B-X
and	B-X
growth	B-X
factor-driven	B-X
angiogenesis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
applied	B-X
the	B-X
alginate	B-X
implant	B-X
angiogenesis	B-X
model	B-X
in	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
,	B-X
elevated	B-X
ANG	B-X
II	B-X
levels	B-X
by	B-X
transgenic	B-X
overexpression	B-X
of	B-X
angiotensinogen	B-X
(	B-X
AOGEN	B-X
)	B-X
,	B-X
or	B-X
in	B-X
AT2	B-X
receptor-deficient	B-X
mice	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
circulating	B-X
ANG	B-X
II	B-X
by	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
(	B-X
ACE	B-X
)	B-X
inhibitor	B-X
enalapril	B-X
or	B-X
the	B-X
AT1	B-X
receptor	B-X
antagonist	B-X
losartan	B-X
induced	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
implying	B-X
an	B-X
inhibitory	B-X
function	B-X
of	B-X
ANG	B-X
II	B-X
through	B-X
the	B-X
AT1	B-X
receptor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
strong	B-X
increase	B-X
of	B-X
angiogenesis	B-X
in	B-X
AOGEN-transgenic	B-X
mice	B-X
compared	B-X
with	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
suggests	B-X
additional	B-X
stimulatory	B-X
activity	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
ANG	B-X
II-induced	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
AT2	B-X
receptor	B-X
as	B-X
an	B-X
impaired	B-X
induction	B-X
of	B-X
angiogenesis	B-X
was	B-X
obtained	B-X
in	B-X
AT2	B-X
receptor	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
the	B-X
AT2	B-X
receptor	B-X
mediates	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
and	B-X
indicate	B-X
that	B-X
ANG	B-X
II	B-X
is	B-X
a	B-X
humoral	B-X
regulator	B-X
of	B-X
peripheral	B-X
angiogenesis	B-X
involving	B-X
two	B-X
receptor	B-X
subtypes	B-X
with	B-X
opposing	B-X
actions	B-X
.	B-X

We	O
showed	O
that	O
the	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
-	O
induced	O
stimulation	O
of	O
angiogenesis	O
is	O
linked	O
to	O
the	O
AT2	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
as	O
an	O
impaired	O
induction	O
of	O
angiogenesis	O
was	O
obtained	O
in	O
AT2	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
knockout	O
mice	O
.	O

These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
AT2	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
mediates	O
a	O
stimulation	O
of	O
in	O
vivo	O
angiogenesis	O
and	O
indicate	O
that	O
ANG	B-Gene_or_gene_product
II	I-Gene_or_gene_product
is	O
a	O
humoral	O
regulator	O
of	O
peripheral	O
angiogenesis	O
involving	O
two	O
receptor	O
subtypes	O
with	O
opposing	O
actions	O
.	O
<EOS>	B-X
Angiotensin	B-X
II	B-X
(	B-X
ANG	B-X
II	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
blood	B-X
pressure	B-X
and	B-X
body	B-X
fluid	B-X
homeostasis	B-X
,	B-X
exerts	B-X
mitogenic	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
.	B-X
We	B-X
therefore	B-X
hypothesized	B-X
that	B-X
ANG	B-X
II	B-X
could	B-X
be	B-X
a	B-X
mediator	B-X
between	B-X
homeostatic	B-X
changes	B-X
within	B-X
the	B-X
vascular	B-X
perfusion	B-X
bed	B-X
and	B-X
growth	B-X
factor-driven	B-X
angiogenesis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
applied	B-X
the	B-X
alginate	B-X
implant	B-X
angiogenesis	B-X
model	B-X
in	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
,	B-X
elevated	B-X
ANG	B-X
II	B-X
levels	B-X
by	B-X
transgenic	B-X
overexpression	B-X
of	B-X
angiotensinogen	B-X
(	B-X
AOGEN	B-X
)	B-X
,	B-X
or	B-X
in	B-X
AT2	B-X
receptor-deficient	B-X
mice	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
circulating	B-X
ANG	B-X
II	B-X
by	B-X
the	B-X
angiotensin-converting	B-X
enzyme	B-X
(	B-X
ACE	B-X
)	B-X
inhibitor	B-X
enalapril	B-X
or	B-X
the	B-X
AT1	B-X
receptor	B-X
antagonist	B-X
losartan	B-X
induced	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
implying	B-X
an	B-X
inhibitory	B-X
function	B-X
of	B-X
ANG	B-X
II	B-X
through	B-X
the	B-X
AT1	B-X
receptor	B-X
.	B-X
However	B-X
,	B-X
the	B-X
strong	B-X
increase	B-X
of	B-X
angiogenesis	B-X
in	B-X
AOGEN-transgenic	B-X
mice	B-X
compared	B-X
with	B-X
mice	B-X
with	B-X
normal	B-X
ANG	B-X
II	B-X
levels	B-X
suggests	B-X
additional	B-X
stimulatory	B-X
activity	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
the	B-X
ANG	B-X
II-induced	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
AT2	B-X
receptor	B-X
as	B-X
an	B-X
impaired	B-X
induction	B-X
of	B-X
angiogenesis	B-X
was	B-X
obtained	B-X
in	B-X
AT2	B-X
receptor	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
the	B-X
AT2	B-X
receptor	B-X
mediates	B-X
a	B-X
stimulation	B-X
of	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
and	B-X
indicate	B-X
that	B-X
ANG	B-X
II	B-X
is	B-X
a	B-X
humoral	B-X
regulator	B-X
of	B-X
peripheral	B-X
angiogenesis	B-X
involving	B-X
two	B-X
receptor	B-X
subtypes	B-X
with	B-X
opposing	B-X
actions	B-X
.	B-X

Insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
enhances	O
invasion	O
and	O
induces	O
resistance	O
to	O
apoptosis	O
of	O
colon	O
cancer	O
cells	O
through	O
the	O
Akt	B-Gene_or_gene_product
/	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
(	I-Gene_or_gene_product
L	I-Gene_or_gene_product
)	I-Gene_or_gene_product
pathway	O
.	O
<EOS>	B-X
Colon	B-X
cancer	B-X
overexpresses	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
(	B-X
IGF1	B-X
)	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
receptor	B-X
(	B-X
IGF1-R	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
or	B-X
adenomatous	B-X
mucosa	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
postulated	B-X
that	B-X
colorectal	B-X
cancer	B-X
cells	B-X
depend	B-X
on	B-X
the	B-X
IGF1/IGF1-R	B-X
pathway	B-X
for	B-X
their	B-X
growth	B-X
and	B-X
progression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
the	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
line	B-X
HCT116	B-X
,	B-X
we	B-X
find	B-X
that	B-X
established	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
exhibit	B-X
a	B-X
more	B-X
aggressive	B-X
transformed	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
their	B-X
higher	B-X
proliferation	B-X
rate	B-X
in	B-X
response	B-X
to	B-X
IGF1	B-X
,	B-X
higher	B-X
degree	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
resistance	B-X
to	B-X
serum	B-X
deprivation-induced	B-X
apoptosis	B-X
,	B-X
and	B-X
higher	B-X
migratory	B-X
capability	B-X
in	B-X
a	B-X
monolayer	B-X
``	B-X
wounding	B-X
assay	B-X
.	B-X
''	B-X
When	B-X
injected	B-X
into	B-X
nude	B-X
mice	B-X
,	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
were	B-X
highly	B-X
invasive	B-X
and	B-X
produced	B-X
distant	B-X
metastases	B-X
,	B-X
whereas	B-X
the	B-X
parental	B-X
cell	B-X
did	B-X
not	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
IGF1-R	B-X
in	B-X
these	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
IGF1-R-induced	B-X
activation	B-X
of	B-X
Akt	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
antiapoptotic	B-X
protein	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
Akt	B-X
pathway	B-X
mediates	B-X
IGF1-R-induced	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
IGF1-R/Akt/Bcl-x	B-X
(	B-X
L	B-X
)	B-X
pathway	B-X
may	B-X
contribute	B-X
to	B-X
a	B-X
more	B-X
aggressive	B-X
malignant	B-X
phenotype	B-X
,	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
colorectal	B-X
cancers	B-X
.	B-X

Colon	O
cancer	O
overexpresses	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
IGF1	B-Gene_or_gene_product
)	O
and	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
)	O
,	O
as	O
compared	O
with	O
normal	O
or	O
adenomatous	O
mucosa	O
,	O
and	O
it	O
has	O
been	O
postulated	O
that	O
colorectal	O
cancer	O
cells	O
depend	O
on	O
the	O
IGF1	B-Gene_or_gene_product
/	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
pathway	O
for	O
their	O
growth	O
and	O
progression	O
.	O
<EOS>	B-X
Insulin	B-X
receptor	B-X
substrate	B-X
4	B-X
(	B-X
IRS-4	B-X
)	B-X
is	B-X
an	B-X
adaptor	B-X
protein	B-X
for	B-X
which	B-X
new	B-X
evidence	B-X
suggests	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tumour	B-X
promotion	B-X
.	B-X
Colon	B-X
cancer	B-X
overexpresses	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
(	B-X
IGF1	B-X
)	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
receptor	B-X
(	B-X
IGF1-R	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
or	B-X
adenomatous	B-X
mucosa	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
postulated	B-X
that	B-X
colorectal	B-X
cancer	B-X
cells	B-X
depend	B-X
on	B-X
the	B-X
IGF1/IGF1-R	B-X
pathway	B-X
for	B-X
their	B-X
growth	B-X
and	B-X
progression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
the	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
line	B-X
HCT116	B-X
,	B-X
we	B-X
find	B-X
that	B-X
established	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
exhibit	B-X
a	B-X
more	B-X
aggressive	B-X
transformed	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
their	B-X
higher	B-X
proliferation	B-X
rate	B-X
in	B-X
response	B-X
to	B-X
IGF1	B-X
,	B-X
higher	B-X
degree	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
resistance	B-X
to	B-X
serum	B-X
deprivation-induced	B-X
apoptosis	B-X
,	B-X
and	B-X
higher	B-X
migratory	B-X
capability	B-X
in	B-X
a	B-X
monolayer	B-X
``	B-X
wounding	B-X
assay	B-X
.	B-X
''	B-X
When	B-X
injected	B-X
into	B-X
nude	B-X
mice	B-X
,	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
were	B-X
highly	B-X
invasive	B-X
and	B-X
produced	B-X
distant	B-X
metastases	B-X
,	B-X
whereas	B-X
the	B-X
parental	B-X
cell	B-X
did	B-X
not	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
IGF1-R	B-X
in	B-X
these	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
IGF1-R-induced	B-X
activation	B-X
of	B-X
Akt	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
antiapoptotic	B-X
protein	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
Akt	B-X
pathway	B-X
mediates	B-X
IGF1-R-induced	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
IGF1-R/Akt/Bcl-x	B-X
(	B-X
L	B-X
)	B-X
pathway	B-X
may	B-X
contribute	B-X
to	B-X
a	B-X
more	B-X
aggressive	B-X
malignant	B-X
phenotype	B-X
,	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
colorectal	B-X
cancers	B-X
.	B-X

In	O
this	O
study	O
,	O
using	O
the	O
human	O
colon	O
cancer	O
cell	O
line	O
HCT116	O
,	O
we	O
find	O
that	O
established	O
HCT116	O
/	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
transfectants	O
exhibit	O
a	O
more	O
aggressive	O
transformed	O
phenotype	O
than	O
the	O
parental	O
cell	O
line	O
,	O
as	O
demonstrated	O
by	O
their	O
higher	O
proliferation	O
rate	O
in	O
response	O
to	O
IGF1	B-Gene_or_gene_product
,	O
higher	O
degree	O
of	O
anchorage	O
-	O
independent	O
growth	O
,	O
resistance	O
to	O
serum	O
deprivation	O
-	O
induced	O
apoptosis	O
,	O
and	O
higher	O
migratory	O
capability	O
in	O
a	O
monolayer	O
"	O
wounding	O
assay	O
.	O
"	O
When	O
injected	O
into	O
nude	O
mice	O
,	O
HCT116	O
/	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
transfectants	O
were	O
highly	O
invasive	O
and	O
produced	O
distant	O
metastases	O
,	O
whereas	O
the	O
parental	O
cell	O
did	O
not	O
.	O

Moreover	O
,	O
the	O
overexpression	O
of	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
in	O
these	O
cells	O
was	O
associated	O
with	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
-	O
induced	O
activation	O
of	O
Akt	B-Gene_or_gene_product
and	O
up	O
-	O
regulation	O
of	O
the	O
antiapoptotic	O
protein	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
(	I-Gene_or_gene_product
L	I-Gene_or_gene_product
)	I-Gene_or_gene_product
.	O
<EOS>	B-X
Colon	B-X
cancer	B-X
overexpresses	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
(	B-X
IGF1	B-X
)	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
receptor	B-X
(	B-X
IGF1-R	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
or	B-X
adenomatous	B-X
mucosa	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
postulated	B-X
that	B-X
colorectal	B-X
cancer	B-X
cells	B-X
depend	B-X
on	B-X
the	B-X
IGF1/IGF1-R	B-X
pathway	B-X
for	B-X
their	B-X
growth	B-X
and	B-X
progression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
the	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
line	B-X
HCT116	B-X
,	B-X
we	B-X
find	B-X
that	B-X
established	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
exhibit	B-X
a	B-X
more	B-X
aggressive	B-X
transformed	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
their	B-X
higher	B-X
proliferation	B-X
rate	B-X
in	B-X
response	B-X
to	B-X
IGF1	B-X
,	B-X
higher	B-X
degree	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
resistance	B-X
to	B-X
serum	B-X
deprivation-induced	B-X
apoptosis	B-X
,	B-X
and	B-X
higher	B-X
migratory	B-X
capability	B-X
in	B-X
a	B-X
monolayer	B-X
``	B-X
wounding	B-X
assay	B-X
.	B-X
''	B-X
When	B-X
injected	B-X
into	B-X
nude	B-X
mice	B-X
,	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
were	B-X
highly	B-X
invasive	B-X
and	B-X
produced	B-X
distant	B-X
metastases	B-X
,	B-X
whereas	B-X
the	B-X
parental	B-X
cell	B-X
did	B-X
not	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
IGF1-R	B-X
in	B-X
these	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
IGF1-R-induced	B-X
activation	B-X
of	B-X
Akt	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
antiapoptotic	B-X
protein	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
Akt	B-X
pathway	B-X
mediates	B-X
IGF1-R-induced	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
IGF1-R/Akt/Bcl-x	B-X
(	B-X
L	B-X
)	B-X
pathway	B-X
may	B-X
contribute	B-X
to	B-X
a	B-X
more	B-X
aggressive	B-X
malignant	B-X
phenotype	B-X
,	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
colorectal	B-X
cancers	B-X
.	B-X

We	O
also	O
show	O
that	O
Akt	B-Gene_or_gene_product
pathway	O
mediates	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
-	O
induced	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
(	I-Gene_or_gene_product
L	I-Gene_or_gene_product
)	I-Gene_or_gene_product
expression	O
at	O
transcriptional	O
level	O
.	O
<EOS>	B-X
Colon	B-X
cancer	B-X
overexpresses	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
(	B-X
IGF1	B-X
)	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor	B-X
1	B-X
receptor	B-X
(	B-X
IGF1-R	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
normal	B-X
or	B-X
adenomatous	B-X
mucosa	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
postulated	B-X
that	B-X
colorectal	B-X
cancer	B-X
cells	B-X
depend	B-X
on	B-X
the	B-X
IGF1/IGF1-R	B-X
pathway	B-X
for	B-X
their	B-X
growth	B-X
and	B-X
progression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
the	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
line	B-X
HCT116	B-X
,	B-X
we	B-X
find	B-X
that	B-X
established	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
exhibit	B-X
a	B-X
more	B-X
aggressive	B-X
transformed	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
their	B-X
higher	B-X
proliferation	B-X
rate	B-X
in	B-X
response	B-X
to	B-X
IGF1	B-X
,	B-X
higher	B-X
degree	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
resistance	B-X
to	B-X
serum	B-X
deprivation-induced	B-X
apoptosis	B-X
,	B-X
and	B-X
higher	B-X
migratory	B-X
capability	B-X
in	B-X
a	B-X
monolayer	B-X
``	B-X
wounding	B-X
assay	B-X
.	B-X
''	B-X
When	B-X
injected	B-X
into	B-X
nude	B-X
mice	B-X
,	B-X
HCT116/IGF1-R	B-X
transfectants	B-X
were	B-X
highly	B-X
invasive	B-X
and	B-X
produced	B-X
distant	B-X
metastases	B-X
,	B-X
whereas	B-X
the	B-X
parental	B-X
cell	B-X
did	B-X
not	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
IGF1-R	B-X
in	B-X
these	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
IGF1-R-induced	B-X
activation	B-X
of	B-X
Akt	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
antiapoptotic	B-X
protein	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
Akt	B-X
pathway	B-X
mediates	B-X
IGF1-R-induced	B-X
Bcl-x	B-X
(	B-X
L	B-X
)	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
IGF1-R/Akt/Bcl-x	B-X
(	B-X
L	B-X
)	B-X
pathway	B-X
may	B-X
contribute	B-X
to	B-X
a	B-X
more	B-X
aggressive	B-X
malignant	B-X
phenotype	B-X
,	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
colorectal	B-X
cancers	B-X
.	B-X

Our	O
data	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IGF1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
/	O
Akt	B-Gene_or_gene_product
/	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
(	I-Gene_or_gene_product
L	I-Gene_or_gene_product
)	I-Gene_or_gene_product
pathway	O
may	O
contribute	O
to	O
a	O
more	O
aggressive	O
malignant	O
phenotype	O
,	O
in	O
a	O
subset	O
of	O
colorectal	O
cancers	O
.	O

Expression	O
of	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
in	O
colorectal	O
cancer	O
:	O
correlation	O
with	O
cancer	O
metastasis	O
.	O

Recently	O
,	O
overexpression	O
of	O
EphA2	B-Gene_or_gene_product
,	O
a	O
member	O
of	O
the	O
Eph	B-Gene_or_gene_product
family	O
of	O
receptor	O
tyrosine	O
kinases	O
,	O
has	O
been	O
reported	O
in	O
several	O
cancers	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
overexpression	B-X
of	B-X
EphA2	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Eph	B-X
family	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
several	B-X
cancers	B-X
.	B-X
Reduced	B-X
expression	B-X
of	B-X
E-cadherin	B-X
,	B-X
an	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
of	B-X
epithelial	B-X
cells	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
aggressive	B-X
clinicopathological	B-X
phenotypes	B-X
in	B-X
various	B-X
cancers	B-X
.	B-X
In	B-X
epithelial	B-X
cells	B-X
,	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
co-localize	B-X
to	B-X
sites	B-X
of	B-X
cell-cell	B-X
contact	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
E-cadherin	B-X
regulates	B-X
EphA2	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
clarify	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
proteins	B-X
and	B-X
clinicopathological	B-X
characteristics	B-X
,	B-X
with	B-X
reference	B-X
to	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
both	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
colorectal	B-X
cancer	B-X
.	B-X
We	B-X
performed	B-X
immunohistochemical	B-X
staining	B-X
of	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
with	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
monoclonal	B-X
antibodies	B-X
in	B-X
samples	B-X
from	B-X
194	B-X
primary	B-X
lesions	B-X
of	B-X
colorectal	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
level	B-X
of	B-X
EphA2	B-X
had	B-X
a	B-X
statistically	B-X
significant	B-X
relationship	B-X
with	B-X
liver	B-X
metastasis	B-X
,	B-X
lymphatic	B-X
vessel	B-X
invasion	B-X
and	B-X
clinical	B-X
stage	B-X
(	B-X
p=0.0477	B-X
,	B-X
0.0316	B-X
and	B-X
0.0467	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
positivity	B-X
rate	B-X
of	B-X
EphA2	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
primary	B-X
lesions	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
than	B-X
in	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p=0.0014	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
significant	B-X
relationship	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
was	B-X
observed	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
revealed	B-X
that	B-X
the	B-X
overexpression	B-X
of	B-X
EphA2	B-X
protein	B-X
in	B-X
colorectal	B-X
carcinoma	B-X
tissue	B-X
correlates	B-X
closely	B-X
with	B-X
cancer	B-X
progression	B-X
and	B-X
hematogenous	B-X
and	B-X
lymphogenous	B-X
metastasis	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tumor	B-X
metastasis	B-X
in	B-X
colorectal	B-X
cancer	B-X
.	B-X

Reduced	O
expression	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
,	O
an	O
intercellular	O
adhesion	O
molecule	O
of	O
epithelial	O
cells	O
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
aggressive	O
clinicopathological	O
phenotypes	O
in	O
various	O
cancers	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
overexpression	B-X
of	B-X
EphA2	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Eph	B-X
family	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
several	B-X
cancers	B-X
.	B-X
Reduced	B-X
expression	B-X
of	B-X
E-cadherin	B-X
,	B-X
an	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
of	B-X
epithelial	B-X
cells	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
aggressive	B-X
clinicopathological	B-X
phenotypes	B-X
in	B-X
various	B-X
cancers	B-X
.	B-X
In	B-X
epithelial	B-X
cells	B-X
,	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
co-localize	B-X
to	B-X
sites	B-X
of	B-X
cell-cell	B-X
contact	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
E-cadherin	B-X
regulates	B-X
EphA2	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
clarify	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
proteins	B-X
and	B-X
clinicopathological	B-X
characteristics	B-X
,	B-X
with	B-X
reference	B-X
to	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
both	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
colorectal	B-X
cancer	B-X
.	B-X
We	B-X
performed	B-X
immunohistochemical	B-X
staining	B-X
of	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
with	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
monoclonal	B-X
antibodies	B-X
in	B-X
samples	B-X
from	B-X
194	B-X
primary	B-X
lesions	B-X
of	B-X
colorectal	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
level	B-X
of	B-X
EphA2	B-X
had	B-X
a	B-X
statistically	B-X
significant	B-X
relationship	B-X
with	B-X
liver	B-X
metastasis	B-X
,	B-X
lymphatic	B-X
vessel	B-X
invasion	B-X
and	B-X
clinical	B-X
stage	B-X
(	B-X
p=0.0477	B-X
,	B-X
0.0316	B-X
and	B-X
0.0467	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
positivity	B-X
rate	B-X
of	B-X
EphA2	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
primary	B-X
lesions	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
than	B-X
in	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p=0.0014	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
E-cadherin	B-X
had	B-X
an	B-X
inverse	B-X
relationship	B-X
with	B-X
both	B-X
differentiation	B-X
level	B-X
of	B-X
the	B-X
tumor	B-X
and	B-X
lymphatic	B-X
vessel	B-X
invasion	B-X
(	B-X
p=0.0430	B-X
and	B-X
0.0320	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
significant	B-X
relationship	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
was	B-X
observed	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
revealed	B-X
that	B-X
the	B-X
overexpression	B-X
of	B-X
EphA2	B-X
protein	B-X
in	B-X
colorectal	B-X
carcinoma	B-X
tissue	B-X
correlates	B-X
closely	B-X
with	B-X
cancer	B-X
progression	B-X
and	B-X
hematogenous	B-X
and	B-X
lymphogenous	B-X
metastasis	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
EphA2	B-X
and	B-X
E-cadherin	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tumor	B-X
metastasis	B-X
in	B-X
colorectal	B-X
cancer	B-X
.	B-X

In	O
epithelial	O
cells	O
,	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
co	O
-	O
localize	O
to	O
sites	O
of	O
cell	O
-	O
cell	O
contact	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
regulates	O
EphA2	B-Gene_or_gene_product
.	O

This	O
study	O
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
the	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
proteins	O
and	O
clinicopathological	O
characteristics	O
,	O
with	O
reference	O
to	O
the	O
expression	O
levels	O
of	O
both	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
,	O
in	O
patients	O
with	O
colorectal	O
cancer	O
.	O

We	O
performed	O
immunohistochemical	O
staining	O
of	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
with	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
monoclonal	O
antibodies	O
in	O
samples	O
from	O
194	O
primary	O
lesions	O
of	O
colorectal	O
cancer	O
.	O

The	O
expression	O
level	O
of	O
EphA2	B-Gene_or_gene_product
had	O
a	O
statistically	O
significant	O
relationship	O
with	O
liver	O
metastasis	O
,	O
lymphatic	O
vessel	O
invasion	O
and	O
clinical	O
stage	O
(	O
p	O
=	O
0	O
.	O
0477	O
,	O
0	O
.	O
0316	O
and	O
0	O
.	O
0467	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
positivity	O
rate	O
of	O
EphA2	B-Gene_or_gene_product
was	O
significantly	O
higher	O
in	O
primary	O
lesions	O
with	O
lymph	O
node	O
metastasis	O
than	O
in	O
those	O
without	O
metastasis	O
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
.	O

However	O
,	O
the	O
expression	O
level	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
had	O
an	O
inverse	O
relationship	O
with	O
both	O
differentiation	O
level	O
of	O
the	O
tumor	O
and	O
lymphatic	O
vessel	O
invasion	O
(	O
p	O
=	O
0	O
.	O
0430	O
and	O
0	O
.	O
0320	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
a	O
significant	O
relationship	O
between	O
the	O
expression	O
of	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
was	O
observed	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
revealed	O
that	O
the	O
overexpression	O
of	O
EphA2	B-Gene_or_gene_product
protein	O
in	O
colorectal	O
carcinoma	O
tissue	O
correlates	O
closely	O
with	O
cancer	O
progression	O
and	O
hematogenous	O
and	O
lymphogenous	O
metastasis	O
,	O
suggesting	O
that	O
both	O
EphA2	B-Gene_or_gene_product
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
may	O
play	O
an	O
important	O
role	O
in	O
tumor	O
metastasis	O
in	O
colorectal	O
cancer	O
.	O

Nuclear	O
translocation	O
of	O
a	O
clusterin	B-Gene_or_gene_product
isoform	O
is	O
associated	O
with	O
induction	O
of	O
anoikis	O
in	O
SV40	O
-	O
immortalized	O
human	O
prostate	O
epithelial	O
cells	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Anoikis	B-X
was	B-X
preceded	B-X
by	B-X
induction	B-X
and	B-X
transloction	B-X
of	B-X
a	B-X
45-kDa	B-X
clusterin	B-X
isoform	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
targeting	B-X
of	B-X
a	B-X
specific	B-X
45-kDa	B-X
isoform	B-X
of	B-X
clusterin	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
early	B-X
and	B-X
specific	B-X
molecular	B-X
signal	B-X
triggering	B-X
anoikis-death	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Clusterin	B-Gene_or_gene_product
gene	O
expression	O
is	O
potently	O
induced	O
in	O
experimental	O
models	O
in	O
which	O
apoptosis	O
is	O
activated	O
,	O
such	O
as	O
rat	O
prostate	O
involution	O
following	O
castration	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Nevertheless	B-X
,	B-X
its	B-X
precise	B-X
physiological	B-X
role	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
established	B-X
,	B-X
and	B-X
both	B-X
anti-apoptotic	B-X
and	B-X
pro-apoptotic	B-X
functions	B-X
have	B-X
been	B-X
suggested	B-X
for	B-X
this	B-X
gene	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Nevertheless	O
,	O
its	O
precise	O
physiological	O
role	O
has	O
not	O
yet	O
been	O
established	O
,	O
and	O
both	O
anti	O
-	O
apoptotic	O
and	O
pro	O
-	O
apoptotic	O
functions	O
have	O
been	O
suggested	O
for	O
this	O
gene	O
.	O
<EOS>	B-X
Muscle	B-X
glycogen	B-X
depletion	B-X
during	B-X
an	B-X
initial	B-X
prolonged	B-X
exercise	B-X
bout	B-X
is	B-X
a	B-X
main	B-X
factor	B-X
in	B-X
the	B-X
onset	B-X
of	B-X
fatigue	B-X
and	B-X
so	B-X
the	B-X
replenishment	B-X
of	B-X
glycogen	B-X
stores	B-X
may	B-X
be	B-X
important	B-X
for	B-X
recovery	B-X
of	B-X
functional	B-X
capacity	B-X
.	B-X
Nevertheless	B-X
,	B-X
nutritional	B-X
considerations	B-X
for	B-X
optimal	B-X
short-term	B-X
(	B-X
3-6	B-X
h	B-X
)	B-X
recovery	B-X
remain	B-X
incompletely	B-X
elucidated	B-X
,	B-X
particularly	B-X
surrounding	B-X
the	B-X
precise	B-X
amount	B-X
of	B-X
specific	B-X
types	B-X
of	B-X
nutrients	B-X
required	B-X
.	B-X
Current	B-X
nutritional	B-X
guidelines	B-X
to	B-X
maximise	B-X
muscle	B-X
glycogen	B-X
availability	B-X
within	B-X
limited	B-X
recovery	B-X
are	B-X
provided	B-X
under	B-X
the	B-X
assumption	B-X
that	B-X
similar	B-X
fatigue	B-X
mechanisms	B-X
(	B-X
i.e.	B-X
,	B-X
muscle	B-X
glycogen	B-X
depletion	B-X
)	B-X
are	B-X
involved	B-X
during	B-X
a	B-X
repeated	B-X
exercise	B-X
bout	B-X
.	B-X
One	B-X
strategy	B-X
with	B-X
the	B-X
potential	B-X
to	B-X
accelerate	B-X
muscle	B-X
glycogen	B-X
resynthesis	B-X
and/or	B-X
functional	B-X
capacity	B-X
beyond	B-X
merely	B-X
ingesting	B-X
adequate	B-X
carbohydrate	B-X
is	B-X
the	B-X
co-ingestion	B-X
of	B-X
added	B-X
protein	B-X
.	B-X
While	B-X
numerous	B-X
studies	B-X
have	B-X
been	B-X
instigated	B-X
,	B-X
a	B-X
consensus	B-X
that	B-X
is	B-X
related	B-X
to	B-X
the	B-X
influence	B-X
of	B-X
carbohydrate-protein	B-X
ingestion	B-X
in	B-X
maximising	B-X
muscle	B-X
glycogen	B-X
during	B-X
short-term	B-X
recovery	B-X
and	B-X
repeated	B-X
exercise	B-X
capacity	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X

Clusterin	B-Gene_or_gene_product
expression	O
level	O
depends	O
on	O
cell	O
proliferation	O
state	O
,	O
and	O
we	O
recently	O
showed	O
that	O
its	O
over	O
-	O
expression	O
inhibited	O
cell	O
cycle	O
progression	O
of	O
SV40	O
-	O
immortalized	O
human	O
prostate	O
epithelial	O
cells	O
PNT2	O
and	O
PNT1a	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Here	O
we	O
studied	O
clusterin	B-Gene_or_gene_product
expression	O
in	O
PNT1a	O
cells	O
subjected	O
to	O
serum	O
-	O
starvation	O
with	O
the	O
aim	O
of	O
defining	O
clusterin	B-Gene_or_gene_product
early	O
molecular	O
changes	O
following	O
apoptosis	O
induction	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Anoikis	B-X
was	B-X
preceded	B-X
by	B-X
induction	B-X
and	B-X
transloction	B-X
of	B-X
a	B-X
45-kDa	B-X
clusterin	B-X
isoform	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
targeting	B-X
of	B-X
a	B-X
specific	B-X
45-kDa	B-X
isoform	B-X
of	B-X
clusterin	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
early	B-X
and	B-X
specific	B-X
molecular	B-X
signal	B-X
triggering	B-X
anoikis-death	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Under	O
serum	O
-	O
starvation	O
conditions	O
,	O
decreased	O
growth	O
rate	O
,	O
slow	O
rounding	O
-	O
up	O
of	O
cells	O
,	O
cell	O
detachment	O
,	O
and	O
formation	O
of	O
apoptotic	O
bodies	O
indicative	O
of	O
anoikis	O
(	O
detachment	O
-	O
induced	O
apoptosis	O
)	O
were	O
preceded	O
by	O
significant	O
downregulation	O
of	O
70	O
kDa	O
clusterin	B-Gene_or_gene_product
precursor	O
and	O
upregulation	O
of	O
45	O
-	O
40	O
kDa	O
isoforms	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Nevertheless	B-X
,	B-X
its	B-X
precise	B-X
physiological	B-X
role	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
established	B-X
,	B-X
and	B-X
both	B-X
anti-apoptotic	B-X
and	B-X
pro-apoptotic	B-X
functions	B-X
have	B-X
been	B-X
suggested	B-X
for	B-X
this	B-X
gene	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Anoikis	B-X
was	B-X
preceded	B-X
by	B-X
induction	B-X
and	B-X
transloction	B-X
of	B-X
a	B-X
45-kDa	B-X
clusterin	B-X
isoform	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
targeting	B-X
of	B-X
a	B-X
specific	B-X
45-kDa	B-X
isoform	B-X
of	B-X
clusterin	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
early	B-X
and	B-X
specific	B-X
molecular	B-X
signal	B-X
triggering	B-X
anoikis-death	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

On	O
the	O
8th	O
day	O
of	O
serum	O
-	O
free	O
culturing	O
,	O
only	O
the	O
higher	O
molecular	O
weight	O
protein	O
-	O
band	O
of	O
about	O
45	O
kDa	O
was	O
clearly	O
induced	O
and	O
accumulated	O
in	O
detached	O
cells	O
and	O
apoptotic	O
bodies	O
in	O
which	O
PARP	B-Gene_or_gene_product
was	O
activated	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Nevertheless	B-X
,	B-X
its	B-X
precise	B-X
physiological	B-X
role	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
established	B-X
,	B-X
and	B-X
both	B-X
anti-apoptotic	B-X
and	B-X
pro-apoptotic	B-X
functions	B-X
have	B-X
been	B-X
suggested	B-X
for	B-X
this	B-X
gene	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Anoikis	B-X
was	B-X
preceded	B-X
by	B-X
induction	B-X
and	B-X
transloction	B-X
of	B-X
a	B-X
45-kDa	B-X
clusterin	B-X
isoform	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
targeting	B-X
of	B-X
a	B-X
specific	B-X
45-kDa	B-X
isoform	B-X
of	B-X
clusterin	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
early	B-X
and	B-X
specific	B-X
molecular	B-X
signal	B-X
triggering	B-X
anoikis-death	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Anoikis	O
was	O
preceded	O
by	O
induction	O
and	O
transloction	O
of	O
a	O
45	O
-	O
kDa	O
clusterin	B-Gene_or_gene_product
isoform	O
to	O
the	O
nucleus	O
.	O

Thus	O
,	O
nuclear	O
targeting	O
of	O
a	O
specific	O
45	O
-	O
kDa	O
isoform	O
of	O
clusterin	B-Gene_or_gene_product
appeared	O
to	O
be	O
an	O
early	O
and	O
specific	O
molecular	O
signal	O
triggering	O
anoikis	O
-	O
death	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Anoikis	B-X
was	B-X
preceded	B-X
by	B-X
induction	B-X
and	B-X
transloction	B-X
of	B-X
a	B-X
45-kDa	B-X
clusterin	B-X
isoform	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
targeting	B-X
of	B-X
a	B-X
specific	B-X
45-kDa	B-X
isoform	B-X
of	B-X
clusterin	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
early	B-X
and	B-X
specific	B-X
molecular	B-X
signal	B-X
triggering	B-X
anoikis-death	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Considering	O
also	O
that	O
clusterin	B-Gene_or_gene_product
is	O
downregulated	O
during	O
prostate	O
cancer	O
onset	O
and	O
progression	O
,	O
and	O
that	O
its	O
upregulation	O
has	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	O
cycle	O
progression	O
of	O
immortalized	O
human	O
prostate	O
epithelial	O
cells	O
,	O
we	O
suggest	O
that	O
clusterin	B-Gene_or_gene_product
might	O
be	O
a	O
new	O
anti	O
-	O
oncogene	O
in	O
the	O
prostate	O
.	O
<EOS>	B-X
Clusterin	B-X
gene	B-X
expression	B-X
is	B-X
potently	B-X
induced	B-X
in	B-X
experimental	B-X
models	B-X
in	B-X
which	B-X
apoptosis	B-X
is	B-X
activated	B-X
,	B-X
such	B-X
as	B-X
rat	B-X
prostate	B-X
involution	B-X
following	B-X
castration	B-X
.	B-X
Nevertheless	B-X
,	B-X
its	B-X
precise	B-X
physiological	B-X
role	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
established	B-X
,	B-X
and	B-X
both	B-X
anti-apoptotic	B-X
and	B-X
pro-apoptotic	B-X
functions	B-X
have	B-X
been	B-X
suggested	B-X
for	B-X
this	B-X
gene	B-X
.	B-X
Clusterin	B-X
expression	B-X
level	B-X
depends	B-X
on	B-X
cell	B-X
proliferation	B-X
state	B-X
,	B-X
and	B-X
we	B-X
recently	B-X
showed	B-X
that	B-X
its	B-X
over-expression	B-X
inhibited	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
SV40-immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
PNT2	B-X
and	B-X
PNT1a	B-X
.	B-X
Here	B-X
we	B-X
studied	B-X
clusterin	B-X
expression	B-X
in	B-X
PNT1a	B-X
cells	B-X
subjected	B-X
to	B-X
serum-starvation	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
defining	B-X
clusterin	B-X
early	B-X
molecular	B-X
changes	B-X
following	B-X
apoptosis	B-X
induction	B-X
.	B-X
Under	B-X
serum-starvation	B-X
conditions	B-X
,	B-X
decreased	B-X
growth	B-X
rate	B-X
,	B-X
slow	B-X
rounding-up	B-X
of	B-X
cells	B-X
,	B-X
cell	B-X
detachment	B-X
,	B-X
and	B-X
formation	B-X
of	B-X
apoptotic	B-X
bodies	B-X
indicative	B-X
of	B-X
anoikis	B-X
(	B-X
detachment-induced	B-X
apoptosis	B-X
)	B-X
were	B-X
preceded	B-X
by	B-X
significant	B-X
downregulation	B-X
of	B-X
70	B-X
kDa	B-X
clusterin	B-X
precursor	B-X
and	B-X
upregulation	B-X
of	B-X
45-40	B-X
kDa	B-X
isoforms	B-X
.	B-X
On	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
serum-free	B-X
culturing	B-X
,	B-X
only	B-X
the	B-X
higher	B-X
molecular	B-X
weight	B-X
protein-band	B-X
of	B-X
about	B-X
45	B-X
kDa	B-X
was	B-X
clearly	B-X
induced	B-X
and	B-X
accumulated	B-X
in	B-X
detached	B-X
cells	B-X
and	B-X
apoptotic	B-X
bodies	B-X
in	B-X
which	B-X
PARP	B-X
was	B-X
activated	B-X
.	B-X
Anoikis	B-X
was	B-X
preceded	B-X
by	B-X
induction	B-X
and	B-X
transloction	B-X
of	B-X
a	B-X
45-kDa	B-X
clusterin	B-X
isoform	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Thus	B-X
,	B-X
nuclear	B-X
targeting	B-X
of	B-X
a	B-X
specific	B-X
45-kDa	B-X
isoform	B-X
of	B-X
clusterin	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
early	B-X
and	B-X
specific	B-X
molecular	B-X
signal	B-X
triggering	B-X
anoikis-death	B-X
.	B-X
Considering	B-X
also	B-X
that	B-X
clusterin	B-X
is	B-X
downregulated	B-X
during	B-X
prostate	B-X
cancer	B-X
onset	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
that	B-X
its	B-X
upregulation	B-X
has	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
immortalized	B-X
human	B-X
prostate	B-X
epithelial	B-X
cells	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
clusterin	B-X
might	B-X
be	B-X
a	B-X
new	B-X
anti-oncogene	B-X
in	B-X
the	B-X
prostate	B-X
.	B-X

Levels	O
of	O
expression	O
of	O
CYR61	B-Gene_or_gene_product
and	O
CTGF	B-Gene_or_gene_product
are	O
prognostic	O
for	O
tumor	O
progression	O
and	O
survival	O
of	O
individuals	O
with	O
gliomas	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
properties	B-X
of	B-X
CCN	B-X
proteins	B-X
include	B-X
stimulation	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
angiogenesis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
We	B-X
quantified	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
samples	B-X
from	B-X
sixty-six	B-X
primary	B-X
gliomas	B-X
and	B-X
five	B-X
normal	B-X
brain	B-X
samples	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
assay	B-X
.	B-X
Statistical	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
explore	B-X
the	B-X
links	B-X
between	B-X
expression	B-X
of	B-X
the	B-X
CCN	B-X
genes	B-X
and	B-X
clinical	B-X
and	B-X
pathological	B-X
parameters	B-X
.	B-X
Overexpression	B-X
of	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
occurred	B-X
in	B-X
48	B-X
%	B-X
(	B-X
32	B-X
of	B-X
66	B-X
)	B-X
,	B-X
58	B-X
%	B-X
(	B-X
38	B-X
of	B-X
66	B-X
)	B-X
,	B-X
36	B-X
%	B-X
(	B-X
24	B-X
of	B-X
66	B-X
)	B-X
,	B-X
and	B-X
15	B-X
%	B-X
(	B-X
10	B-X
of	B-X
66	B-X
)	B-X
of	B-X
primary	B-X
gliomas	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
significant	B-X
associations	B-X
were	B-X
found	B-X
between	B-X
CYR61	B-X
expression	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
pathology	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
age	B-X
at	B-X
diagnosis	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
significant	B-X
correlation	B-X
existed	B-X
between	B-X
CTGF	B-X
mRNA	B-X
levels	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CYR61	B-X
and	B-X
CTGF	B-X
,	B-X
no	B-X
significant	B-X
association	B-X
was	B-X
found	B-X
between	B-X
expression	B-X
of	B-X
either	B-X
WISP-1	B-X
or	B-X
NOV	B-X
versus	B-X
any	B-X
of	B-X
the	B-X
pathological	B-X
features	B-X
.	B-X
Furthermore	B-X
,	B-X
Cox	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
expression	B-X
had	B-X
a	B-X
significant	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

The	O
biological	O
properties	O
of	O
CCN	B-Gene_or_gene_product
proteins	O
include	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
,	O
as	O
well	O
as	O
angiogenesis	O
and	O
tumorigenesis	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
properties	B-X
of	B-X
CCN	B-X
proteins	B-X
include	B-X
stimulation	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
angiogenesis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
Statistical	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
explore	B-X
the	B-X
links	B-X
between	B-X
expression	B-X
of	B-X
the	B-X
CCN	B-X
genes	B-X
and	B-X
clinical	B-X
and	B-X
pathological	B-X
parameters	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

We	O
quantified	O
CYR61	B-Gene_or_gene_product
,	O
CTGF	B-Gene_or_gene_product
,	O
WISP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
and	O
NOV	B-Gene_or_gene_product
mRNA	O
expression	O
levels	O
in	O
samples	O
from	O
sixty	O
-	O
six	O
primary	O
gliomas	O
and	O
five	O
normal	O
brain	O
samples	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
assay	O
.	O
<EOS>	B-X
We	B-X
quantified	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
samples	B-X
from	B-X
sixty-six	B-X
primary	B-X
gliomas	B-X
and	B-X
five	B-X
normal	B-X
brain	B-X
samples	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
assay	B-X
.	B-X
Statistical	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
explore	B-X
the	B-X
links	B-X
between	B-X
expression	B-X
of	B-X
the	B-X
CCN	B-X
genes	B-X
and	B-X
clinical	B-X
and	B-X
pathological	B-X
parameters	B-X
.	B-X
Overexpression	B-X
of	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
occurred	B-X
in	B-X
48	B-X
%	B-X
(	B-X
32	B-X
of	B-X
66	B-X
)	B-X
,	B-X
58	B-X
%	B-X
(	B-X
38	B-X
of	B-X
66	B-X
)	B-X
,	B-X
36	B-X
%	B-X
(	B-X
24	B-X
of	B-X
66	B-X
)	B-X
,	B-X
and	B-X
15	B-X
%	B-X
(	B-X
10	B-X
of	B-X
66	B-X
)	B-X
of	B-X
primary	B-X
gliomas	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
significant	B-X
associations	B-X
were	B-X
found	B-X
between	B-X
CYR61	B-X
expression	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
pathology	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
age	B-X
at	B-X
diagnosis	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
significant	B-X
correlation	B-X
existed	B-X
between	B-X
CTGF	B-X
mRNA	B-X
levels	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CYR61	B-X
and	B-X
CTGF	B-X
,	B-X
no	B-X
significant	B-X
association	B-X
was	B-X
found	B-X
between	B-X
expression	B-X
of	B-X
either	B-X
WISP-1	B-X
or	B-X
NOV	B-X
versus	B-X
any	B-X
of	B-X
the	B-X
pathological	B-X
features	B-X
.	B-X
Furthermore	B-X
,	B-X
Cox	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
expression	B-X
had	B-X
a	B-X
significant	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

Statistical	O
analysis	O
was	O
performed	O
to	O
explore	O
the	O
links	O
between	O
expression	O
of	O
the	O
CCN	B-Gene_or_gene_product
genes	O
and	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Overexpression	O
of	O
CYR61	B-Gene_or_gene_product
,	O
CTGF	B-Gene_or_gene_product
,	O
WISP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
and	O
NOV	B-Gene_or_gene_product
occurred	O
in	O
48	O
%	O
(	O
32	O
of	O
66	O
)	O
,	O
58	O
%	O
(	O
38	O
of	O
66	O
)	O
,	O
36	O
%	O
(	O
24	O
of	O
66	O
)	O
,	O
and	O
15	O
%	O
(	O
10	O
of	O
66	O
)	O
of	O
primary	O
gliomas	O
,	O
respectively	O
.	O

Interestingly	O
,	O
significant	O
associations	O
were	O
found	O
between	O
CYR61	B-Gene_or_gene_product
expression	O
versus	O
tumor	O
grade	O
,	O
pathology	O
,	O
gender	O
,	O
and	O
age	O
at	O
diagnosis	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
properties	B-X
of	B-X
CCN	B-X
proteins	B-X
include	B-X
stimulation	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
angiogenesis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
We	B-X
quantified	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
samples	B-X
from	B-X
sixty-six	B-X
primary	B-X
gliomas	B-X
and	B-X
five	B-X
normal	B-X
brain	B-X
samples	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
assay	B-X
.	B-X
Statistical	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
explore	B-X
the	B-X
links	B-X
between	B-X
expression	B-X
of	B-X
the	B-X
CCN	B-X
genes	B-X
and	B-X
clinical	B-X
and	B-X
pathological	B-X
parameters	B-X
.	B-X
Overexpression	B-X
of	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
occurred	B-X
in	B-X
48	B-X
%	B-X
(	B-X
32	B-X
of	B-X
66	B-X
)	B-X
,	B-X
58	B-X
%	B-X
(	B-X
38	B-X
of	B-X
66	B-X
)	B-X
,	B-X
36	B-X
%	B-X
(	B-X
24	B-X
of	B-X
66	B-X
)	B-X
,	B-X
and	B-X
15	B-X
%	B-X
(	B-X
10	B-X
of	B-X
66	B-X
)	B-X
of	B-X
primary	B-X
gliomas	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
significant	B-X
associations	B-X
were	B-X
found	B-X
between	B-X
CYR61	B-X
expression	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
pathology	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
age	B-X
at	B-X
diagnosis	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
significant	B-X
correlation	B-X
existed	B-X
between	B-X
CTGF	B-X
mRNA	B-X
levels	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CYR61	B-X
and	B-X
CTGF	B-X
,	B-X
no	B-X
significant	B-X
association	B-X
was	B-X
found	B-X
between	B-X
expression	B-X
of	B-X
either	B-X
WISP-1	B-X
or	B-X
NOV	B-X
versus	B-X
any	B-X
of	B-X
the	B-X
pathological	B-X
features	B-X
.	B-X
Furthermore	B-X
,	B-X
Cox	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
expression	B-X
had	B-X
a	B-X
significant	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

Also	O
,	O
a	O
significant	O
correlation	O
existed	O
between	O
CTGF	B-Gene_or_gene_product
mRNA	O
levels	O
versus	O
tumor	O
grade	O
,	O
gender	O
,	O
and	O
pathology	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
properties	B-X
of	B-X
CCN	B-X
proteins	B-X
include	B-X
stimulation	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
angiogenesis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
We	B-X
quantified	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
samples	B-X
from	B-X
sixty-six	B-X
primary	B-X
gliomas	B-X
and	B-X
five	B-X
normal	B-X
brain	B-X
samples	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
occurred	B-X
in	B-X
48	B-X
%	B-X
(	B-X
32	B-X
of	B-X
66	B-X
)	B-X
,	B-X
58	B-X
%	B-X
(	B-X
38	B-X
of	B-X
66	B-X
)	B-X
,	B-X
36	B-X
%	B-X
(	B-X
24	B-X
of	B-X
66	B-X
)	B-X
,	B-X
and	B-X
15	B-X
%	B-X
(	B-X
10	B-X
of	B-X
66	B-X
)	B-X
of	B-X
primary	B-X
gliomas	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
significant	B-X
associations	B-X
were	B-X
found	B-X
between	B-X
CYR61	B-X
expression	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
pathology	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
age	B-X
at	B-X
diagnosis	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
significant	B-X
correlation	B-X
existed	B-X
between	B-X
CTGF	B-X
mRNA	B-X
levels	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CYR61	B-X
and	B-X
CTGF	B-X
,	B-X
no	B-X
significant	B-X
association	B-X
was	B-X
found	B-X
between	B-X
expression	B-X
of	B-X
either	B-X
WISP-1	B-X
or	B-X
NOV	B-X
versus	B-X
any	B-X
of	B-X
the	B-X
pathological	B-X
features	B-X
.	B-X
Furthermore	B-X
,	B-X
Cox	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
expression	B-X
had	B-X
a	B-X
significant	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

In	O
contrast	O
to	O
CYR61	B-Gene_or_gene_product
and	O
CTGF	B-Gene_or_gene_product
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
expression	O
of	O
either	O
WISP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
or	O
NOV	B-Gene_or_gene_product
versus	O
any	O
of	O
the	O
pathological	O
features	O
.	O
<EOS>	B-X
A	B-X
diverse	B-X
spectrum	B-X
of	B-X
benign	B-X
oral	B-X
mucosal	B-X
lesions	B-X
exists	B-X
,	B-X
presenting	B-X
as	B-X
either	B-X
isolated	B-X
oral	B-X
findings	B-X
or	B-X
in	B-X
association	B-X
with	B-X
dermatologic	B-X
conditions	B-X
.	B-X
Oral	B-X
lesions	B-X
can	B-X
closely	B-X
resemble	B-X
one	B-X
another	B-X
;	B-X
therefore	B-X
,	B-X
it	B-X
is	B-X
important	B-X
for	B-X
clinicians	B-X
to	B-X
be	B-X
able	B-X
to	B-X
recognize	B-X
their	B-X
distinctive	B-X
features	B-X
,	B-X
to	B-X
be	B-X
able	B-X
to	B-X
recognize	B-X
benign	B-X
versus	B-X
malignant	B-X
disease	B-X
,	B-X
and	B-X
to	B-X
recognize	B-X
when	B-X
obtaining	B-X
a	B-X
biopsy	B-X
specimen	B-X
is	B-X
warranted	B-X
.	B-X
Pathologic	B-X
diagnosis	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
identification	B-X
of	B-X
the	B-X
characteristic	B-X
morphologic	B-X
features	B-X
.	B-X
The	B-X
most	B-X
common	B-X
immunohistochemical	B-X
markers	B-X
for	B-X
adenosarcoma	B-X
are	B-X
CD10	B-X
and	B-X
WT1	B-X
,	B-X
but	B-X
these	B-X
are	B-X
not	B-X
specific	B-X
.	B-X
Patients	B-X
with	B-X
sarcomatous	B-X
overgrowth	B-X
have	B-X
significantly	B-X
increased	B-X
risk	B-X
of	B-X
recurrence	B-X
23	B-X
versus	B-X
77	B-X
%	B-X
and	B-X
decreased	B-X
5-year	B-X
overall	B-X
survival	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X

Furthermore	O
,	O
Cox	O
regression	O
analysis	O
showed	O
that	O
CYR61	B-Gene_or_gene_product
and	O
CTGF	B-Gene_or_gene_product
expression	O
had	O
a	O
significant	O
correlation	O
with	O
patient	O
survival	O
.	O
<EOS>	B-X
We	B-X
quantified	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
samples	B-X
from	B-X
sixty-six	B-X
primary	B-X
gliomas	B-X
and	B-X
five	B-X
normal	B-X
brain	B-X
samples	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
assay	B-X
.	B-X
Statistical	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
explore	B-X
the	B-X
links	B-X
between	B-X
expression	B-X
of	B-X
the	B-X
CCN	B-X
genes	B-X
and	B-X
clinical	B-X
and	B-X
pathological	B-X
parameters	B-X
.	B-X
Overexpression	B-X
of	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
occurred	B-X
in	B-X
48	B-X
%	B-X
(	B-X
32	B-X
of	B-X
66	B-X
)	B-X
,	B-X
58	B-X
%	B-X
(	B-X
38	B-X
of	B-X
66	B-X
)	B-X
,	B-X
36	B-X
%	B-X
(	B-X
24	B-X
of	B-X
66	B-X
)	B-X
,	B-X
and	B-X
15	B-X
%	B-X
(	B-X
10	B-X
of	B-X
66	B-X
)	B-X
of	B-X
primary	B-X
gliomas	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
significant	B-X
associations	B-X
were	B-X
found	B-X
between	B-X
CYR61	B-X
expression	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
pathology	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
age	B-X
at	B-X
diagnosis	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
significant	B-X
correlation	B-X
existed	B-X
between	B-X
CTGF	B-X
mRNA	B-X
levels	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CYR61	B-X
and	B-X
CTGF	B-X
,	B-X
no	B-X
significant	B-X
association	B-X
was	B-X
found	B-X
between	B-X
expression	B-X
of	B-X
either	B-X
WISP-1	B-X
or	B-X
NOV	B-X
versus	B-X
any	B-X
of	B-X
the	B-X
pathological	B-X
features	B-X
.	B-X
Furthermore	B-X
,	B-X
Cox	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
expression	B-X
had	B-X
a	B-X
significant	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

These	O
results	O
suggest	O
that	O
CYR61	B-Gene_or_gene_product
and	O
CTGF	B-Gene_or_gene_product
may	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
gliomas	O
;	O
their	O
levels	O
at	O
diagnosis	O
may	O
have	O
prognostic	O
significance	O
;	O
and	O
these	O
proteins	O
might	O
serve	O
as	O
valuable	O
targets	O
for	O
therapeutic	O
intervention	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
properties	B-X
of	B-X
CCN	B-X
proteins	B-X
include	B-X
stimulation	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
angiogenesis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
We	B-X
quantified	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
mRNA	B-X
expression	B-X
levels	B-X
in	B-X
samples	B-X
from	B-X
sixty-six	B-X
primary	B-X
gliomas	B-X
and	B-X
five	B-X
normal	B-X
brain	B-X
samples	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
CYR61	B-X
,	B-X
CTGF	B-X
,	B-X
WISP-1	B-X
,	B-X
and	B-X
NOV	B-X
occurred	B-X
in	B-X
48	B-X
%	B-X
(	B-X
32	B-X
of	B-X
66	B-X
)	B-X
,	B-X
58	B-X
%	B-X
(	B-X
38	B-X
of	B-X
66	B-X
)	B-X
,	B-X
36	B-X
%	B-X
(	B-X
24	B-X
of	B-X
66	B-X
)	B-X
,	B-X
and	B-X
15	B-X
%	B-X
(	B-X
10	B-X
of	B-X
66	B-X
)	B-X
of	B-X
primary	B-X
gliomas	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
significant	B-X
associations	B-X
were	B-X
found	B-X
between	B-X
CYR61	B-X
expression	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
pathology	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
age	B-X
at	B-X
diagnosis	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
significant	B-X
correlation	B-X
existed	B-X
between	B-X
CTGF	B-X
mRNA	B-X
levels	B-X
versus	B-X
tumor	B-X
grade	B-X
,	B-X
gender	B-X
,	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CYR61	B-X
and	B-X
CTGF	B-X
,	B-X
no	B-X
significant	B-X
association	B-X
was	B-X
found	B-X
between	B-X
expression	B-X
of	B-X
either	B-X
WISP-1	B-X
or	B-X
NOV	B-X
versus	B-X
any	B-X
of	B-X
the	B-X
pathological	B-X
features	B-X
.	B-X
Furthermore	B-X
,	B-X
Cox	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
expression	B-X
had	B-X
a	B-X
significant	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CYR61	B-X
and	B-X
CTGF	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
gliomas	B-X
;	B-X
their	B-X
levels	B-X
at	B-X
diagnosis	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X
;	B-X
and	B-X
these	B-X
proteins	B-X
might	B-X
serve	B-X
as	B-X
valuable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

Targeting	O
wide	O
-	O
range	O
oncogenic	O
transformation	O
via	O
PU24FCl	O
,	O
a	O
specific	O
inhibitor	O
of	O
tumor	O
Hsp90	B-Gene_or_gene_product
.	O
<EOS>	B-X
Agents	B-X
that	B-X
inhibit	B-X
Hsp90	B-X
function	B-X
hold	B-X
significant	B-X
promise	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
PU24FCl	B-X
,	B-X
a	B-X
representative	B-X
of	B-X
the	B-X
first	B-X
class	B-X
of	B-X
designed	B-X
Hsp90	B-X
inhibitors	B-X
.	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X
Concentrations	B-X
achieved	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
lead	B-X
to	B-X
single-agent	B-X
anti-tumor	B-X
activity	B-X
at	B-X
non-toxic	B-X
doses	B-X
.	B-X

Agents	O
that	O
inhibit	O
Hsp90	B-Gene_or_gene_product
function	O
hold	O
significant	O
promise	O
in	O
cancer	O
therapy	O
.	O
<EOS>	B-X
Agents	B-X
that	B-X
inhibit	B-X
Hsp90	B-X
function	B-X
hold	B-X
significant	B-X
promise	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
PU24FCl	B-X
,	B-X
a	B-X
representative	B-X
of	B-X
the	B-X
first	B-X
class	B-X
of	B-X
designed	B-X
Hsp90	B-X
inhibitors	B-X
.	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X

Here	O
we	O
present	O
PU24FCl	O
,	O
a	O
representative	O
of	O
the	O
first	O
class	O
of	O
designed	O
Hsp90	B-Gene_or_gene_product
inhibitors	O
.	O
<EOS>	B-X
Agents	B-X
that	B-X
inhibit	B-X
Hsp90	B-X
function	B-X
hold	B-X
significant	B-X
promise	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
PU24FCl	B-X
,	B-X
a	B-X
representative	B-X
of	B-X
the	B-X
first	B-X
class	B-X
of	B-X
designed	B-X
Hsp90	B-X
inhibitors	B-X
.	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X

By	O
specifically	O
and	O
potently	O
inhibiting	O
tumor	O
Hsp90	B-Gene_or_gene_product
,	O
PU24FCl	O
exhibits	O
wide	O
-	O
ranging	O
anti	O
-	O
cancer	O
activities	O
that	O
occur	O
at	O
similar	O
doses	O
in	O
all	O
tested	O
tumor	O
types	O
.	O
<EOS>	B-X
Agents	B-X
that	B-X
inhibit	B-X
Hsp90	B-X
function	B-X
hold	B-X
significant	B-X
promise	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
PU24FCl	B-X
,	B-X
a	B-X
representative	B-X
of	B-X
the	B-X
first	B-X
class	B-X
of	B-X
designed	B-X
Hsp90	B-X
inhibitors	B-X
.	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X
Concentrations	B-X
achieved	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
lead	B-X
to	B-X
single-agent	B-X
anti-tumor	B-X
activity	B-X
at	B-X
non-toxic	B-X
doses	B-X
.	B-X

Normal	O
cells	O
are	O
10	O
-	O
to	O
50	O
-	O
fold	O
more	O
resistant	O
to	O
these	O
effects	O
.	O
<EOS>	B-X
Unfortunately	B-X
,	B-X
60	B-X
%	B-X
of	B-X
newly	B-X
diagnosed	B-X
GBM	B-X
patients	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
the	B-X
DNA	B-X
repair	B-X
enzyme	B-X
O6-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
and	B-X
are	B-X
TMZ-resistant	B-X
,	B-X
and	B-X
all	B-X
patients	B-X
eventually	B-X
become	B-X
refractory	B-X
to	B-X
treatment	B-X
.	B-X
The	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
is	B-X
an	B-X
obstacle	B-X
to	B-X
the	B-X
delivery	B-X
of	B-X
chemotherapeutic	B-X
agents	B-X
to	B-X
GBM	B-X
,	B-X
and	B-X
BBB-permeable	B-X
agents	B-X
that	B-X
are	B-X
efficacious	B-X
in	B-X
TMZ-resistant	B-X
and	B-X
refractory	B-X
patients	B-X
are	B-X
needed	B-X
.	B-X
Methods	B-X
We	B-X
report	B-X
a	B-X
novel	B-X
chemical	B-X
entity	B-X
(	B-X
QBS10072S	B-X
)	B-X
that	B-X
combines	B-X
a	B-X
potent	B-X
cytotoxic	B-X
chemotherapeutic	B-X
domain	B-X
(	B-X
tertiary	B-X
N-bis	B-X
(	B-X
2-chloroethyl	B-X
)	B-X
amine	B-X
)	B-X
with	B-X
the	B-X
structural	B-X
features	B-X
of	B-X
a	B-X
selective	B-X
LAT1	B-X
substrate	B-X
and	B-X
tested	B-X
it	B-X
against	B-X
GBM	B-X
models	B-X
To	B-X
explore	B-X
the	B-X
consequences	B-X
of	B-X
whole	B-X
body	B-X
proton	B-X
irradiation	B-X
,	B-X
mice	B-X
were	B-X
subjected	B-X
to	B-X
0.1	B-X
and	B-X
1	B-X
Gy	B-X
and	B-X
analyzed	B-X
for	B-X
morphometric	B-X
changes	B-X
in	B-X
hippocampal	B-X
neurons	B-X
10	B-X
and	B-X
30	B-X
days	B-X
following	B-X
exposure	B-X
.	B-X
At	B-X
equivalent	B-X
doses	B-X
and	B-X
times	B-X
,	B-X
significant	B-X
reductions	B-X
in	B-X
the	B-X
number	B-X
(	B-X
~30	B-X
%	B-X
)	B-X
and	B-X
density	B-X
(	B-X
50-75	B-X
%	B-X
)	B-X
of	B-X
dendritic	B-X
spines	B-X
along	B-X
hippocampal	B-X
neurons	B-X
of	B-X
the	B-X
dentate	B-X
gyrus	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
Immature	B-X
spines	B-X
(	B-X
filopodia	B-X
,	B-X
long	B-X
)	B-X
exhibited	B-X
the	B-X
greatest	B-X
sensitivity	B-X
(	B-X
1.5-	B-X
to	B-X
3-fold	B-X
)	B-X
to	B-X
irradiation	B-X
,	B-X
while	B-X
more	B-X
mature	B-X
spines	B-X
(	B-X
mushroom	B-X
)	B-X
were	B-X
more	B-X
resistant	B-X
to	B-X
changes	B-X
over	B-X
a	B-X
1-month	B-X
post-irradiation	B-X
timeframe	B-X
.	B-X

Its	O
Hsp90	B-Gene_or_gene_product
inhibition	O
results	O
in	O
multiple	O
anti	O
-	O
tumor	O
-	O
specific	O
effects	O
,	O
such	O
as	O
degradation	O
of	O
Hsp90	B-Gene_or_gene_product
-	O
client	O
proteins	O
involved	O
in	O
cell	O
growth	O
,	O
survival	O
,	O
and	O
specific	O
transformation	O
,	O
inhibition	O
of	O
cancer	O
cell	O
growth	O
,	O
delay	O
of	O
cell	O
cycle	O
progression	O
,	O
induction	O
of	O
morphological	O
and	O
functional	O
changes	O
,	O
and	O
apoptosis	O
.	O
<EOS>	B-X
Agents	B-X
that	B-X
inhibit	B-X
Hsp90	B-X
function	B-X
hold	B-X
significant	B-X
promise	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
PU24FCl	B-X
,	B-X
a	B-X
representative	B-X
of	B-X
the	B-X
first	B-X
class	B-X
of	B-X
designed	B-X
Hsp90	B-X
inhibitors	B-X
.	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Normal	B-X
cells	B-X
are	B-X
10-	B-X
to	B-X
50-fold	B-X
more	B-X
resistant	B-X
to	B-X
these	B-X
effects	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X
Concentrations	B-X
achieved	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
lead	B-X
to	B-X
single-agent	B-X
anti-tumor	B-X
activity	B-X
at	B-X
non-toxic	B-X
doses	B-X
.	B-X

In	O
concordance	O
with	O
its	O
higher	O
affinity	O
for	O
tumor	O
Hsp90	B-Gene_or_gene_product
,	O
in	O
vivo	O
PU24FCl	O
accumulates	O
in	O
tumors	O
while	O
being	O
rapidly	O
cleared	O
from	O
normal	O
tissue	O
.	O
<EOS>	B-X
Agents	B-X
that	B-X
inhibit	B-X
Hsp90	B-X
function	B-X
hold	B-X
significant	B-X
promise	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
PU24FCl	B-X
,	B-X
a	B-X
representative	B-X
of	B-X
the	B-X
first	B-X
class	B-X
of	B-X
designed	B-X
Hsp90	B-X
inhibitors	B-X
.	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X
Concentrations	B-X
achieved	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
lead	B-X
to	B-X
single-agent	B-X
anti-tumor	B-X
activity	B-X
at	B-X
non-toxic	B-X
doses	B-X
.	B-X

Concentrations	O
achieved	O
in	O
vivo	O
in	O
tumors	O
lead	O
to	O
single	O
-	O
agent	O
anti	O
-	O
tumor	O
activity	O
at	O
non	O
-	O
toxic	O
doses	O
.	O
<EOS>	B-X
By	B-X
specifically	B-X
and	B-X
potently	B-X
inhibiting	B-X
tumor	B-X
Hsp90	B-X
,	B-X
PU24FCl	B-X
exhibits	B-X
wide-ranging	B-X
anti-cancer	B-X
activities	B-X
that	B-X
occur	B-X
at	B-X
similar	B-X
doses	B-X
in	B-X
all	B-X
tested	B-X
tumor	B-X
types	B-X
.	B-X
Its	B-X
Hsp90	B-X
inhibition	B-X
results	B-X
in	B-X
multiple	B-X
anti-tumor-specific	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
degradation	B-X
of	B-X
Hsp90-client	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
growth	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
specific	B-X
transformation	B-X
,	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
growth	B-X
,	B-X
delay	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
induction	B-X
of	B-X
morphological	B-X
and	B-X
functional	B-X
changes	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
In	B-X
concordance	B-X
with	B-X
its	B-X
higher	B-X
affinity	B-X
for	B-X
tumor	B-X
Hsp90	B-X
,	B-X
in	B-X
vivo	B-X
PU24FCl	B-X
accumulates	B-X
in	B-X
tumors	B-X
while	B-X
being	B-X
rapidly	B-X
cleared	B-X
from	B-X
normal	B-X
tissue	B-X
.	B-X
Concentrations	B-X
achieved	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
lead	B-X
to	B-X
single-agent	B-X
anti-tumor	B-X
activity	B-X
at	B-X
non-toxic	B-X
doses	B-X
.	B-X

Differential	O
proteomic	O
analysis	O
of	O
human	O
hepatocellular	O
carcinoma	O
cell	O
line	O
metastasis	O
-	O
associated	O
proteins	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X
Malignant	B-X
tumors	B-X
are	B-X
relatively	B-X
resistant	B-X
to	B-X
treatment	B-X
due	B-X
to	B-X
their	B-X
heterogeneous	B-X
nature	B-X
,	B-X
drug	B-X
resistance	B-X
,	B-X
and	B-X
tendency	B-X
for	B-X
metastasis	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
a	B-X
subpopulation	B-X
of	B-X
cancer	B-X
cells	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
malignant	B-X
outcomes	B-X
.	B-X
These	B-X
cells	B-X
are	B-X
considered	B-X
as	B-X
cancer	B-X
stem	B-X
cells	B-X
(	B-X
CSC	B-X
)	B-X
.	B-X
Although	B-X
a	B-X
number	B-X
of	B-X
molecules	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
different	B-X
cancer	B-X
cells	B-X
as	B-X
markers	B-X
for	B-X
cancer	B-X
stem	B-X
cells	B-X
,	B-X
no	B-X
promising	B-X
markers	B-X
are	B-X
currently	B-X
available	B-X
for	B-X
hepatocellular	B-X
carcinoma	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
two	B-X
clones	B-X
of	B-X
Hep3B	B-X
cell	B-X
lines	B-X
were	B-X
functionally	B-X
characterized	B-X
as	B-X
control	B-X
or	B-X
CSC-like	B-X
cells	B-X
,	B-X
based	B-X
on	B-X
properties	B-X
including	B-X
spheroid	B-X
formation	B-X
,	B-X
drug	B-X
resistance	B-X
,	B-X
and	B-X
tumor	B-X
initiation	B-X
.	B-X
Furthermore	B-X
,	B-X
their	B-X
protein	B-X
expression	B-X
profiles	B-X
were	B-X
investigated	B-X
by	B-X
isobaric	B-X
tags	B-X
for	B-X
relative	B-X
and	B-X
absolute	B-X
quantitation	B-X
(	B-X
iTRAQ	B-X
)	B-X
,	B-X
and	B-X
a	B-X
total	B-X
of	B-X
1,127	B-X
proteins	B-X
were	B-X
identified	B-X
and	B-X
quantified	B-X
from	B-X
the	B-X
combined	B-X
fractions	B-X
;	B-X
50	B-X
proteins	B-X
exhibited	B-X
at	B-X
least	B-X
2-fold	B-X
differences	B-X
between	B-X
these	B-X
two	B-X
clones	B-X
.	B-X
These	B-X
50	B-X
proteins	B-X
were	B-X
analyzed	B-X
by	B-X
GeneGo	B-X
and	B-X
were	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
liver	B-X
neoplasms	B-X
,	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
,	B-X
and	B-X
liver	B-X
diseases	B-X
.	B-X
Among	B-X
these	B-X
proteins	B-X
,	B-X
the	B-X
expressions	B-X
of	B-X
S100P	B-X
,	B-X
S100A14	B-X
,	B-X
and	B-X
vimentin	B-X
were	B-X
verified	B-X
in	B-X
several	B-X
HCC	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
their	B-X
expressions	B-X
were	B-X
correlated	B-X
with	B-X
tumorigenicity	B-X
in	B-X
HCC	B-X
cell	B-X
lines	B-X
.	B-X

PURPOSE	O
:	O
The	O
comparative	O
study	O
of	O
differentially	O
expression	O
of	O
protein	O
profiles	O
of	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
with	O
various	O
metastasic	O
potential	O
and	O
screening	O
key	O
molecules	O
related	O
to	O
hepatocellular	O
carcinoma	O
metastasis	O
and	O
recurrence	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

METHODS	O
:	O
Using	O
two	O
-	O
dimensional	O
electrophoresis	O
and	O
liquid	O
chromatography	O
-	O
electrospray	O
ionization	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
,	O
we	O
analyzed	O
differentially	O
displayed	O
proteomics	O
of	O
human	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
Hep3B	O
,	O
MHCC97L	O
,	O
MHCC97H	O
with	O
different	O
metastasic	O
potential	O
.	O

RESULTS	O
:	O
Approximate	O
1	O
,	O
000	O
protein	O
spots	O
were	O
detected	O
on	O
silver	O
-	O
stained	O
gel	O
by	O
ImageMaster	O
(	O
977	O
+	O
/	O
-	O
113	O
spots	O
in	O
Hep3B	O
,	O
1092	O
+	O
/	O
-	O
40	O
in	O
MHCC97L	O
,	O
and	O
889	O
+	O
/	O
-	O
14	O
in	O
MHCC97H	O
)	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

Fifty	O
distinct	O
different	O
protein	O
spots	O
were	O
analyzed	O
with	O
online	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
.	O

Only	O
26	O
protein	O
spots	O
had	O
a	O
positive	O
result	O
,	O
including	O
annexin1	B-Gene_or_gene_product
,	O
S100A4	B-Gene_or_gene_product
,	O
and	O
so	O
on	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

In	O
comparison	O
with	O
nonmetastasis	O
Hep3B	O
cell	O
lines	O
,	O
there	O
were	O
16	O
proteins	O
overexpressed	O
in	O
MHCC97H	O
and	O
MHCC97L	O
,	O
10	O
proteins	O
underexpressed	O
in	O
MHCC97H	O
and	O
MHCC97L	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

Applying	O
cell	O
immunohistochemistry	O
and	O
RT	O
-	O
PCR	O
,	O
we	O
further	O
validated	O
two	O
interesting	O
and	O
different	O
proteins	O
,	O
annexin1	B-Gene_or_gene_product
and	O
S100A4	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

CONCLUSION	O
:	O
The	O
protein	O
profile	O
of	O
metastatic	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
displayed	O
obvious	O
differences	O
compared	O
with	O
non	O
-	O
metastatic	O
liver	O
cancer	O
cell	O
lines	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

The	O
results	O
imply	O
that	O
various	O
different	O
proteins	O
may	O
lead	O
to	O
HCC	O
metastasis	O
together	O
.	O
<EOS>	B-X
The	B-X
comparative	B-X
study	B-X
of	B-X
differentially	B-X
expression	B-X
of	B-X
protein	B-X
profiles	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
with	B-X
various	B-X
metastasic	B-X
potential	B-X
and	B-X
screening	B-X
key	B-X
molecules	B-X
related	B-X
to	B-X
hepatocellular	B-X
carcinoma	B-X
metastasis	B-X
and	B-X
recurrence	B-X
.	B-X

Clinical	O
implication	O
of	O
expression	O
of	O
cyclooxygenase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
peroxisome	B-Gene_or_gene_product
proliferator	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
-	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
gamma	I-Gene_or_gene_product
in	O
epithelial	O
ovarian	O
tumours	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumorigenesis	B-X
and	B-X
development	B-X
and	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
COX-2	B-X
expression	B-X
in	B-X
some	B-X
tissues	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
(	B-X
1	B-X
)	B-X
whether	B-X
expression	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
is	B-X
associated	B-X
with	B-X
ovarian	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
and	B-X
(	B-X
2	B-X
)	B-X
whether	B-X
COX-2	B-X
expression	B-X
is	B-X
controlled	B-X
through	B-X
ligand-mediated	B-X
activation	B-X
of	B-X
PPARgamma	B-X
in	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
was	B-X
immunohistochemically	B-X
examined	B-X
in	B-X
71	B-X
epithelial	B-X
ovarian	B-X
carcinomas	B-X
,	B-X
18	B-X
borderline	B-X
tumours	B-X
and	B-X
23	B-X
benign	B-X
tumours	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
proteins	B-X
were	B-X
determined	B-X
by	B-X
enzyme	B-X
immunoassay	B-X
in	B-X
four	B-X
benign	B-X
tumours	B-X
,	B-X
three	B-X
borderline	B-X
tumours	B-X
and	B-X
12	B-X
carcinomas	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
detection	B-X
was	B-X
significantly	B-X
increased	B-X
and	B-X
decreased	B-X
as	B-X
lesions	B-X
progressed	B-X
to	B-X
carcinoma	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
COX-2	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
three	B-X
borderline	B-X
tumours	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
them	B-X
.	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
eight	B-X
of	B-X
the	B-X
12	B-X
carcinomas	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
only	B-X
two	B-X
cases	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PPARgamma	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
carcinomas	B-X
in	B-X
which	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
was	B-X
in	B-X
a	B-X
reciprocal	B-X
relationship	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
cultured	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
,	B-X
Western	B-X
blot	B-X
revealed	B-X
that	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
expression	B-X
was	B-X
regulated	B-X
conversely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
stimulation	B-X
by	B-X
15-deoxy-Delta	B-X
(	B-X
12	B-X
,	B-X
14	B-X
)	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15-PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPARgamma	B-X
activator	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
15d-PGJ	B-X
(	B-X
2	B-X
)	B-X
suppressed	B-X
tumour	B-X
necrosis	B-X
factor-alpha-induced-COX-2	B-X
expression	B-X
,	B-X
confirming	B-X
the	B-X
reciprocal	B-X
correlation	B-X
between	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
PPARgamma	B-X
activation	B-X
might	B-X
suppress	B-X
COX-2	B-X
expression	B-X
via	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
pathway	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
that	B-X
low	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
COX-2	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
.	B-X

Expression	O
of	O
cyclooxygenase	B-Gene_or_gene_product
(	I-Gene_or_gene_product
COX	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
plays	O
a	O
key	O
role	O
in	O
tumorigenesis	O
and	O
development	O
and	O
peroxisome	B-Gene_or_gene_product
proliferator	I-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
gamma	I-Gene_or_gene_product
(	O
PPARgamma	B-Gene_or_gene_product
)	O
has	O
been	O
implicated	O
in	O
the	O
control	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
in	O
some	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
(	O
1	O
)	O
whether	O
expression	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
PPARgamma	B-Gene_or_gene_product
is	O
associated	O
with	O
ovarian	O
carcinogenesis	O
and	O
progression	O
of	O
ovarian	O
tumours	O
and	O
(	O
2	O
)	O
whether	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
is	O
controlled	O
through	O
ligand	O
-	O
mediated	O
activation	O
of	O
PPARgamma	B-Gene_or_gene_product
in	O
ovarian	O
carcinoma	O
cells	O
.	O

For	O
this	O
purpose	O
,	O
the	O
presence	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
PPARgamma	B-Gene_or_gene_product
was	O
immunohistochemically	O
examined	O
in	O
71	O
epithelial	O
ovarian	O
carcinomas	O
,	O
18	O
borderline	O
tumours	O
and	O
23	O
benign	O
tumours	O
and	O
the	O
levels	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
PPARgamma	B-Gene_or_gene_product
proteins	O
were	O
determined	O
by	O
enzyme	O
immunoassay	O
in	O
four	O
benign	O
tumours	O
,	O
three	O
borderline	O
tumours	O
and	O
12	O
carcinomas	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumorigenesis	B-X
and	B-X
development	B-X
and	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
COX-2	B-X
expression	B-X
in	B-X
some	B-X
tissues	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
(	B-X
1	B-X
)	B-X
whether	B-X
expression	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
is	B-X
associated	B-X
with	B-X
ovarian	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
and	B-X
(	B-X
2	B-X
)	B-X
whether	B-X
COX-2	B-X
expression	B-X
is	B-X
controlled	B-X
through	B-X
ligand-mediated	B-X
activation	B-X
of	B-X
PPARgamma	B-X
in	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
was	B-X
immunohistochemically	B-X
examined	B-X
in	B-X
71	B-X
epithelial	B-X
ovarian	B-X
carcinomas	B-X
,	B-X
18	B-X
borderline	B-X
tumours	B-X
and	B-X
23	B-X
benign	B-X
tumours	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
proteins	B-X
were	B-X
determined	B-X
by	B-X
enzyme	B-X
immunoassay	B-X
in	B-X
four	B-X
benign	B-X
tumours	B-X
,	B-X
three	B-X
borderline	B-X
tumours	B-X
and	B-X
12	B-X
carcinomas	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
detection	B-X
was	B-X
significantly	B-X
increased	B-X
and	B-X
decreased	B-X
as	B-X
lesions	B-X
progressed	B-X
to	B-X
carcinoma	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
COX-2	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
three	B-X
borderline	B-X
tumours	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
them	B-X
.	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
eight	B-X
of	B-X
the	B-X
12	B-X
carcinomas	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
only	B-X
two	B-X
cases	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PPARgamma	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
carcinomas	B-X
in	B-X
which	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
was	B-X
in	B-X
a	B-X
reciprocal	B-X
relationship	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
cultured	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
,	B-X
Western	B-X
blot	B-X
revealed	B-X
that	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
expression	B-X
was	B-X
regulated	B-X
conversely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
stimulation	B-X
by	B-X
15-deoxy-Delta	B-X
(	B-X
12	B-X
,	B-X
14	B-X
)	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15-PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPARgamma	B-X
activator	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
15d-PGJ	B-X
(	B-X
2	B-X
)	B-X
suppressed	B-X
tumour	B-X
necrosis	B-X
factor-alpha-induced-COX-2	B-X
expression	B-X
,	B-X
confirming	B-X
the	B-X
reciprocal	B-X
correlation	B-X
between	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
PPARgamma	B-X
activation	B-X
might	B-X
suppress	B-X
COX-2	B-X
expression	B-X
via	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
pathway	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
that	B-X
low	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
COX-2	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
.	B-X

The	O
frequency	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
PPARgamma	B-Gene_or_gene_product
detection	O
was	O
significantly	O
increased	O
and	O
decreased	O
as	O
lesions	O
progressed	O
to	O
carcinoma	O
,	O
respectively	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumorigenesis	B-X
and	B-X
development	B-X
and	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
COX-2	B-X
expression	B-X
in	B-X
some	B-X
tissues	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
(	B-X
1	B-X
)	B-X
whether	B-X
expression	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
is	B-X
associated	B-X
with	B-X
ovarian	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
and	B-X
(	B-X
2	B-X
)	B-X
whether	B-X
COX-2	B-X
expression	B-X
is	B-X
controlled	B-X
through	B-X
ligand-mediated	B-X
activation	B-X
of	B-X
PPARgamma	B-X
in	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
was	B-X
immunohistochemically	B-X
examined	B-X
in	B-X
71	B-X
epithelial	B-X
ovarian	B-X
carcinomas	B-X
,	B-X
18	B-X
borderline	B-X
tumours	B-X
and	B-X
23	B-X
benign	B-X
tumours	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
proteins	B-X
were	B-X
determined	B-X
by	B-X
enzyme	B-X
immunoassay	B-X
in	B-X
four	B-X
benign	B-X
tumours	B-X
,	B-X
three	B-X
borderline	B-X
tumours	B-X
and	B-X
12	B-X
carcinomas	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
detection	B-X
was	B-X
significantly	B-X
increased	B-X
and	B-X
decreased	B-X
as	B-X
lesions	B-X
progressed	B-X
to	B-X
carcinoma	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
COX-2	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
three	B-X
borderline	B-X
tumours	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
them	B-X
.	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
eight	B-X
of	B-X
the	B-X
12	B-X
carcinomas	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
only	B-X
two	B-X
cases	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PPARgamma	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
carcinomas	B-X
in	B-X
which	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
was	B-X
in	B-X
a	B-X
reciprocal	B-X
relationship	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
cultured	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
,	B-X
Western	B-X
blot	B-X
revealed	B-X
that	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
expression	B-X
was	B-X
regulated	B-X
conversely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
stimulation	B-X
by	B-X
15-deoxy-Delta	B-X
(	B-X
12	B-X
,	B-X
14	B-X
)	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15-PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPARgamma	B-X
activator	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
15d-PGJ	B-X
(	B-X
2	B-X
)	B-X
suppressed	B-X
tumour	B-X
necrosis	B-X
factor-alpha-induced-COX-2	B-X
expression	B-X
,	B-X
confirming	B-X
the	B-X
reciprocal	B-X
correlation	B-X
between	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
PPARgamma	B-X
activation	B-X
might	B-X
suppress	B-X
COX-2	B-X
expression	B-X
via	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
pathway	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
that	B-X
low	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
COX-2	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
.	B-X

The	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
protein	O
was	O
not	O
detected	O
in	O
the	O
three	O
borderline	O
tumours	O
,	O
whereas	O
PPARgamma	B-Gene_or_gene_product
protein	O
was	O
detected	O
in	O
all	O
of	O
them	O
.	O
<EOS>	B-X
Cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
,	B-X
first	B-X
purified	B-X
in	B-X
1976	B-X
and	B-X
cloned	B-X
in	B-X
1988	B-X
,	B-X
is	B-X
the	B-X
key	B-X
enzyme	B-X
in	B-X
the	B-X
synthesis	B-X
of	B-X
prostaglandins	B-X
(	B-X
PGs	B-X
)	B-X
from	B-X
arachidonic	B-X
acid	B-X
.	B-X
In	B-X
1991	B-X
,	B-X
several	B-X
laboratories	B-X
identified	B-X
a	B-X
product	B-X
from	B-X
a	B-X
second	B-X
gene	B-X
with	B-X
COX	B-X
activity	B-X
and	B-X
called	B-X
it	B-X
COX-2	B-X
.	B-X
However	B-X
,	B-X
COX-2	B-X
was	B-X
inducible	B-X
,	B-X
and	B-X
the	B-X
inducing	B-X
stimuli	B-X
included	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
,	B-X
implying	B-X
a	B-X
role	B-X
for	B-X
COX-2	B-X
in	B-X
both	B-X
inflammation	B-X
and	B-X
control	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X
The	B-X
two	B-X
isoforms	B-X
of	B-X
COX	B-X
are	B-X
almost	B-X
identical	B-X
in	B-X
structure	B-X
but	B-X
have	B-X
important	B-X
differences	B-X
in	B-X
substrate	B-X
and	B-X
inhibitor	B-X
selectivity	B-X
and	B-X
in	B-X
their	B-X
intracellular	B-X
locations	B-X
.	B-X
Protective	B-X
PGs	B-X
,	B-X
which	B-X
preserve	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
stomach	B-X
lining	B-X
and	B-X
maintain	B-X
normal	B-X
renal	B-X
function	B-X
in	B-X
a	B-X
compromised	B-X
kidney	B-X
,	B-X
are	B-X
synthesized	B-X
by	B-X
COX-1	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
COX-2	B-X
in	B-X
inflammatory	B-X
lesions	B-X
,	B-X
it	B-X
is	B-X
present	B-X
constitutively	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
spinal	B-X
cord	B-X
,	B-X
where	B-X
it	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
nerve	B-X
transmission	B-X
,	B-X
particularly	B-X
that	B-X
for	B-X
pain	B-X
and	B-X
fever	B-X
.	B-X
PGs	B-X
made	B-X
by	B-X
COX-2	B-X
are	B-X
also	B-X
important	B-X
in	B-X
ovulation	B-X
and	B-X
in	B-X
the	B-X
birth	B-X
process	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
COX-2	B-X
has	B-X
made	B-X
possible	B-X
the	B-X
design	B-X
of	B-X
drugs	B-X
that	B-X
reduce	B-X
inflammation	B-X
without	B-X
removing	B-X
the	B-X
protective	B-X
PGs	B-X
in	B-X
the	B-X
stomach	B-X
and	B-X
kidney	B-X
made	B-X
by	B-X
COX-1	B-X
.	B-X
These	B-X
highly	B-X
selective	B-X
COX-2	B-X
inhibitors	B-X
may	B-X
not	B-X
only	B-X
be	B-X
anti-inflammatory	B-X
but	B-X
may	B-X
also	B-X
be	B-X
active	B-X
in	B-X
colon	B-X
cancer	B-X
and	B-X
Alzheimer	B-X
's	B-X
disease	B-X
.	B-X

COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
protein	O
was	O
detected	O
in	O
eight	O
of	O
the	O
12	O
carcinomas	O
,	O
whereas	O
PPARgamma	B-Gene_or_gene_product
protein	O
was	O
detected	O
in	O
only	O
two	O
cases	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumorigenesis	B-X
and	B-X
development	B-X
and	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
COX-2	B-X
expression	B-X
in	B-X
some	B-X
tissues	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
(	B-X
1	B-X
)	B-X
whether	B-X
expression	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
is	B-X
associated	B-X
with	B-X
ovarian	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
and	B-X
(	B-X
2	B-X
)	B-X
whether	B-X
COX-2	B-X
expression	B-X
is	B-X
controlled	B-X
through	B-X
ligand-mediated	B-X
activation	B-X
of	B-X
PPARgamma	B-X
in	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
was	B-X
immunohistochemically	B-X
examined	B-X
in	B-X
71	B-X
epithelial	B-X
ovarian	B-X
carcinomas	B-X
,	B-X
18	B-X
borderline	B-X
tumours	B-X
and	B-X
23	B-X
benign	B-X
tumours	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
proteins	B-X
were	B-X
determined	B-X
by	B-X
enzyme	B-X
immunoassay	B-X
in	B-X
four	B-X
benign	B-X
tumours	B-X
,	B-X
three	B-X
borderline	B-X
tumours	B-X
and	B-X
12	B-X
carcinomas	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
detection	B-X
was	B-X
significantly	B-X
increased	B-X
and	B-X
decreased	B-X
as	B-X
lesions	B-X
progressed	B-X
to	B-X
carcinoma	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
COX-2	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
three	B-X
borderline	B-X
tumours	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
them	B-X
.	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
eight	B-X
of	B-X
the	B-X
12	B-X
carcinomas	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
only	B-X
two	B-X
cases	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PPARgamma	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
carcinomas	B-X
in	B-X
which	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
was	B-X
in	B-X
a	B-X
reciprocal	B-X
relationship	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
cultured	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
,	B-X
Western	B-X
blot	B-X
revealed	B-X
that	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
expression	B-X
was	B-X
regulated	B-X
conversely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
stimulation	B-X
by	B-X
15-deoxy-Delta	B-X
(	B-X
12	B-X
,	B-X
14	B-X
)	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15-PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPARgamma	B-X
activator	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
15d-PGJ	B-X
(	B-X
2	B-X
)	B-X
suppressed	B-X
tumour	B-X
necrosis	B-X
factor-alpha-induced-COX-2	B-X
expression	B-X
,	B-X
confirming	B-X
the	B-X
reciprocal	B-X
correlation	B-X
between	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
PPARgamma	B-X
activation	B-X
might	B-X
suppress	B-X
COX-2	B-X
expression	B-X
via	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
pathway	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
that	B-X
low	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
COX-2	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
.	B-X

In	O
addition	O
,	O
PPARgamma	B-Gene_or_gene_product
protein	O
was	O
not	O
detected	O
in	O
all	O
of	O
the	O
eight	O
carcinomas	O
in	O
which	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
protein	O
was	O
detected	O
,	O
suggesting	O
that	O
expression	O
of	O
PPARgamma	B-Gene_or_gene_product
and	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
was	O
in	O
a	O
reciprocal	O
relationship	O
.	O
<EOS>	B-X
Rosiglitazone	B-X
(	B-X
RGZ	B-X
)	B-X
and	B-X
other	B-X
thiazolidinedione	B-X
(	B-X
TZD	B-X
)	B-X
synthetic	B-X
ligands	B-X
of	B-X
PPARÎ³	B-X
are	B-X
insulin	B-X
sensitizers	B-X
that	B-X
have	B-X
been	B-X
used	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
type	B-X
2	B-X
diabetes	B-X
.	B-X
However	B-X
,	B-X
undesirable	B-X
side	B-X
effects	B-X
including	B-X
weight	B-X
gain	B-X
,	B-X
fluid	B-X
retention	B-X
,	B-X
bone	B-X
loss	B-X
,	B-X
congestive	B-X
heart	B-X
failure	B-X
,	B-X
and	B-X
a	B-X
possible	B-X
increased	B-X
risk	B-X
of	B-X
myocardial	B-X
infarction	B-X
and	B-X
bladder	B-X
cancer	B-X
,	B-X
have	B-X
limited	B-X
the	B-X
use	B-X
of	B-X
TZDs	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
PPARÎ³	B-X
itself	B-X
,	B-X
many	B-X
PPARÎ³	B-X
ligands	B-X
including	B-X
TZDs	B-X
bind	B-X
to	B-X
and	B-X
activate	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
40	B-X
(	B-X
GPR40	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
free	B-X
fatty	B-X
acid	B-X
receptor	B-X
1	B-X
.	B-X
RGZ/GPR40/p38	B-X
MAPK	B-X
signaling	B-X
induces	B-X
and	B-X
activates	B-X
PPARÎ³	B-X
co-activator-1Î±	B-X
,	B-X
and	B-X
recruits	B-X
E1A	B-X
binding	B-X
protein	B-X
p300	B-X
to	B-X
the	B-X
promoters	B-X
of	B-X
target	B-X
genes	B-X
,	B-X
markedly	B-X
enhancing	B-X
PPARÎ³-dependent	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
GPR40	B-X
can	B-X
also	B-X
activate	B-X
ERK1/2	B-X
,	B-X
a	B-X
proinflammatory	B-X
kinase	B-X
that	B-X
directly	B-X
phosphorylates	B-X
and	B-X
inactivates	B-X
PPARÎ³	B-X
.	B-X
Alternatively	B-X
,	B-X
biased	B-X
GPR40	B-X
agonists	B-X
might	B-X
be	B-X
sought	B-X
that	B-X
activate	B-X
both	B-X
p38	B-X
MAPK	B-X
and	B-X
PPARÎ³	B-X
,	B-X
but	B-X
not	B-X
ERK1/2	B-X
,	B-X
avoiding	B-X
its	B-X
harmful	B-X
effects	B-X
on	B-X
PPARÎ³	B-X
signaling	B-X
,	B-X
insulin	B-X
resistance	B-X
and	B-X
inflammation	B-X
.	B-X
Such	B-X
next	B-X
generation	B-X
drugs	B-X
might	B-X
be	B-X
useful	B-X
in	B-X
treating	B-X
not	B-X
only	B-X
type	B-X
2	B-X
diabetes	B-X
,	B-X
but	B-X
also	B-X
diverse	B-X
chronic	B-X
and	B-X
acute	B-X
forms	B-X
of	B-X
vascular	B-X
inflammation	B-X
such	B-X
as	B-X
atherosclerosis	B-X
and	B-X
septic	B-X
shock	B-X
.	B-X

Furthermore	O
,	O
in	O
cultured	O
ovarian	O
carcinoma	O
cells	O
,	O
Western	O
blot	O
revealed	O
that	O
PPARgamma	B-Gene_or_gene_product
and	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
was	O
regulated	O
conversely	O
as	O
a	O
result	O
of	O
stimulation	O
by	O
15	O
-	O
deoxy	O
-	O
Delta	O
(	O
12	O
,	O
14	O
)	O
PGJ	O
(	O
2	O
)	O
(	O
15	O
-	O
PGJ	O
(	O
2	O
)	O
)	O
,	O
a	O
PPARgamma	B-Gene_or_gene_product
activator	O
.	O

In	O
addition	O
,	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
suppressed	O
tumour	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
-	O
induced	O
-	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
,	O
confirming	O
the	O
reciprocal	O
correlation	O
between	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
PPARgamma	B-Gene_or_gene_product
.	O
<EOS>	B-X
Expression	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumorigenesis	B-X
and	B-X
development	B-X
and	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
COX-2	B-X
expression	B-X
in	B-X
some	B-X
tissues	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
(	B-X
1	B-X
)	B-X
whether	B-X
expression	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
is	B-X
associated	B-X
with	B-X
ovarian	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
and	B-X
(	B-X
2	B-X
)	B-X
whether	B-X
COX-2	B-X
expression	B-X
is	B-X
controlled	B-X
through	B-X
ligand-mediated	B-X
activation	B-X
of	B-X
PPARgamma	B-X
in	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
was	B-X
immunohistochemically	B-X
examined	B-X
in	B-X
71	B-X
epithelial	B-X
ovarian	B-X
carcinomas	B-X
,	B-X
18	B-X
borderline	B-X
tumours	B-X
and	B-X
23	B-X
benign	B-X
tumours	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
proteins	B-X
were	B-X
determined	B-X
by	B-X
enzyme	B-X
immunoassay	B-X
in	B-X
four	B-X
benign	B-X
tumours	B-X
,	B-X
three	B-X
borderline	B-X
tumours	B-X
and	B-X
12	B-X
carcinomas	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
detection	B-X
was	B-X
significantly	B-X
increased	B-X
and	B-X
decreased	B-X
as	B-X
lesions	B-X
progressed	B-X
to	B-X
carcinoma	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
COX-2	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
three	B-X
borderline	B-X
tumours	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
them	B-X
.	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
eight	B-X
of	B-X
the	B-X
12	B-X
carcinomas	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
only	B-X
two	B-X
cases	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PPARgamma	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
carcinomas	B-X
in	B-X
which	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
was	B-X
in	B-X
a	B-X
reciprocal	B-X
relationship	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
cultured	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
,	B-X
Western	B-X
blot	B-X
revealed	B-X
that	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
expression	B-X
was	B-X
regulated	B-X
conversely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
stimulation	B-X
by	B-X
15-deoxy-Delta	B-X
(	B-X
12	B-X
,	B-X
14	B-X
)	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15-PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPARgamma	B-X
activator	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
15d-PGJ	B-X
(	B-X
2	B-X
)	B-X
suppressed	B-X
tumour	B-X
necrosis	B-X
factor-alpha-induced-COX-2	B-X
expression	B-X
,	B-X
confirming	B-X
the	B-X
reciprocal	B-X
correlation	B-X
between	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
PPARgamma	B-X
activation	B-X
might	B-X
suppress	B-X
COX-2	B-X
expression	B-X
via	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
pathway	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
that	B-X
low	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
COX-2	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
.	B-X

From	O
these	O
results	O
,	O
it	O
was	O
suggested	O
that	O
PPARgamma	B-Gene_or_gene_product
activation	O
might	O
suppress	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
via	O
the	O
nuclear	B-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
pathway	O
in	O
the	O
ovarian	O
carcinoma	O
cells	O
and	O
that	O
low	O
expression	O
of	O
PPARgamma	B-Gene_or_gene_product
and	O
high	O
expression	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
might	O
be	O
involved	O
in	O
carcinogenesis	O
and	O
progression	O
of	O
ovarian	O
tumours	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumorigenesis	B-X
and	B-X
development	B-X
and	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
COX-2	B-X
expression	B-X
in	B-X
some	B-X
tissues	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
(	B-X
1	B-X
)	B-X
whether	B-X
expression	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
is	B-X
associated	B-X
with	B-X
ovarian	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
and	B-X
(	B-X
2	B-X
)	B-X
whether	B-X
COX-2	B-X
expression	B-X
is	B-X
controlled	B-X
through	B-X
ligand-mediated	B-X
activation	B-X
of	B-X
PPARgamma	B-X
in	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
was	B-X
immunohistochemically	B-X
examined	B-X
in	B-X
71	B-X
epithelial	B-X
ovarian	B-X
carcinomas	B-X
,	B-X
18	B-X
borderline	B-X
tumours	B-X
and	B-X
23	B-X
benign	B-X
tumours	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
proteins	B-X
were	B-X
determined	B-X
by	B-X
enzyme	B-X
immunoassay	B-X
in	B-X
four	B-X
benign	B-X
tumours	B-X
,	B-X
three	B-X
borderline	B-X
tumours	B-X
and	B-X
12	B-X
carcinomas	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
detection	B-X
was	B-X
significantly	B-X
increased	B-X
and	B-X
decreased	B-X
as	B-X
lesions	B-X
progressed	B-X
to	B-X
carcinoma	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
COX-2	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
three	B-X
borderline	B-X
tumours	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
them	B-X
.	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
eight	B-X
of	B-X
the	B-X
12	B-X
carcinomas	B-X
,	B-X
whereas	B-X
PPARgamma	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
only	B-X
two	B-X
cases	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PPARgamma	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
eight	B-X
carcinomas	B-X
in	B-X
which	B-X
COX-2	B-X
protein	B-X
was	B-X
detected	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
was	B-X
in	B-X
a	B-X
reciprocal	B-X
relationship	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
cultured	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
,	B-X
Western	B-X
blot	B-X
revealed	B-X
that	B-X
PPARgamma	B-X
and	B-X
COX-2	B-X
expression	B-X
was	B-X
regulated	B-X
conversely	B-X
as	B-X
a	B-X
result	B-X
of	B-X
stimulation	B-X
by	B-X
15-deoxy-Delta	B-X
(	B-X
12	B-X
,	B-X
14	B-X
)	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15-PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPARgamma	B-X
activator	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
15d-PGJ	B-X
(	B-X
2	B-X
)	B-X
suppressed	B-X
tumour	B-X
necrosis	B-X
factor-alpha-induced-COX-2	B-X
expression	B-X
,	B-X
confirming	B-X
the	B-X
reciprocal	B-X
correlation	B-X
between	B-X
COX-2	B-X
and	B-X
PPARgamma	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
PPARgamma	B-X
activation	B-X
might	B-X
suppress	B-X
COX-2	B-X
expression	B-X
via	B-X
the	B-X
nuclear	B-X
factor-kappaB	B-X
pathway	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
that	B-X
low	B-X
expression	B-X
of	B-X
PPARgamma	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
COX-2	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
and	B-X
progression	B-X
of	B-X
ovarian	B-X
tumours	B-X
.	B-X

Role	O
of	O
osteopontin	B-Gene_or_gene_product
in	O
adhesion	O
,	O
migration	O
,	O
cell	O
survival	O
and	O
bone	O
remodeling	O
.	O
<EOS>	B-X
Osteopontin	B-X
(	B-X
OPN	B-X
)	B-X
is	B-X
a	B-X
secreted	B-X
adhesive	B-X
glycophosphoprotein	B-X
expressed	B-X
by	B-X
several	B-X
cell	B-X
types	B-X
.	B-X
It	B-X
is	B-X
normally	B-X
produced	B-X
in	B-X
bone	B-X
,	B-X
teeth	B-X
,	B-X
kidney	B-X
and	B-X
epithelial	B-X
lining	B-X
tissues	B-X
and	B-X
is	B-X
found	B-X
in	B-X
plasma	B-X
and	B-X
breast	B-X
milk	B-X
.	B-X
In	B-X
this	B-X
review	B-X
focus	B-X
will	B-X
be	B-X
on	B-X
OPN	B-X
in	B-X
bone	B-X
and	B-X
its	B-X
role	B-X
in	B-X
adhesion	B-X
,	B-X
migration	B-X
and	B-X
cell	B-X
survival	B-X
.	B-X
Collagen	B-X
membranes	B-X
have	B-X
been	B-X
widely	B-X
applied	B-X
for	B-X
guided	B-X
bone	B-X
regeneration	B-X
(	B-X
GBR	B-X
)	B-X
,	B-X
a	B-X
technique	B-X
often	B-X
utilized	B-X
in	B-X
dental	B-X
implant	B-X
surgery	B-X
for	B-X
bone	B-X
argumentation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
scanning	B-X
electron	B-X
microscopy	B-X
images	B-X
showed	B-X
that	B-X
EGCG-modified	B-X
collagen	B-X
membranes	B-X
prevented	B-X
the	B-X
migration	B-X
of	B-X
keratinocytes	B-X
and	B-X
maintained	B-X
space	B-X
for	B-X
osteoblasts	B-X
.	B-X
CCK-8	B-X
and	B-X
live/dead	B-X
cell	B-X
assays	B-X
showed	B-X
that	B-X
EGCG-modified	B-X
collagen	B-X
membranes	B-X
unaffected	B-X
the	B-X
cell	B-X
viability	B-X
of	B-X
osteoblasts	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
immunofluorescent	B-X
staining	B-X
and	B-X
quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
showed	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
M2	B-X
macrophages	B-X
,	B-X
an	B-X
upregulated	B-X
expression	B-X
of	B-X
growth	B-X
factors	B-X
including	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
,	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
2	B-X
,	B-X
and	B-X
an	B-X
upregulation	B-X
of	B-X
osteogenic	B-X
differentiation-related	B-X
factors	B-X
including	B-X
Runt-related	B-X
transcription	B-X
factor	B-X
2	B-X
and	B-X
osteopontin	B-X
after	B-X
implantation	B-X
of	B-X
EGCG-modified	B-X
collagen	B-X
membranes	B-X
.	B-X
Hematoxylin-eosin	B-X
staining	B-X
and	B-X
Micro-CT	B-X
further	B-X
demonstrated	B-X
that	B-X
the	B-X
application	B-X
of	B-X
EGCG-modified	B-X
collagen	B-X
membranes	B-X
promoted	B-X
new	B-X
bone	B-X
formation	B-X
in	B-X
vivo	B-X
.	B-X
From	B-X
these	B-X
findings	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
EGCG-modified	B-X
collagen	B-X
membranes	B-X
have	B-X
promising	B-X
potentials	B-X
in	B-X
GBR	B-X
surgery	B-X
which	B-X
served	B-X
as	B-X
suitable	B-X
barrier	B-X
membranes	B-X
and	B-X
promoted	B-X
bone	B-X
regeneration	B-X
in	B-X
vivo	B-X
by	B-X
recruiting	B-X
M2	B-X
macrophages	B-X
,	B-X
promoting	B-X
secretion	B-X
of	B-X
growth	B-X
factors	B-X
and	B-X
osteogenic	B-X
differentiation	B-X
.	B-X

Osteopontin	B-Gene_or_gene_product
(	O
OPN	B-Gene_or_gene_product
)	O
is	O
a	O
secreted	O
adhesive	O
glycophosphoprotein	O
expressed	O
by	O
several	O
cell	O
types	O
.	O
<EOS>	B-X
Osteopontin	B-X
(	B-X
OPN	B-X
)	B-X
is	B-X
a	B-X
glycophosphoprotein	B-X
cytokine	B-X
that	B-X
has	B-X
multiple	B-X
functions	B-X
.	B-X
OPN	B-X
is	B-X
expressed	B-X
and	B-X
secreted	B-X
by	B-X
various	B-X
cells	B-X
,	B-X
and	B-X
has	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
adhesion	B-X
,	B-X
chemotaxis	B-X
,	B-X
prevention	B-X
of	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
migration	B-X
and	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X
Extensive	B-X
research	B-X
has	B-X
demonstrated	B-X
the	B-X
pivotal	B-X
participation	B-X
of	B-X
OPN	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
signaling	B-X
which	B-X
controls	B-X
neoplastic	B-X
and	B-X
malignant	B-X
transformation	B-X
.	B-X
The	B-X
elevated	B-X
expression	B-X
of	B-X
OPN	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cancers	B-X
.	B-X
OPN	B-X
has	B-X
been	B-X
linked	B-X
with	B-X
tumor	B-X
metastasis	B-X
and	B-X
signifies	B-X
a	B-X
poor	B-X
prognosis	B-X
for	B-X
the	B-X
patient	B-X
.	B-X
This	B-X
review	B-X
details	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
OPN	B-X
facilitates	B-X
these	B-X
pathological	B-X
events	B-X
.	B-X
It	B-X
will	B-X
also	B-X
show	B-X
that	B-X
gaining	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
OPN	B-X
's	B-X
action	B-X
at	B-X
a	B-X
cellular	B-X
level	B-X
has	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
a	B-X
number	B-X
of	B-X
therapeutic	B-X
strategies	B-X
against	B-X
the	B-X
cytokine	B-X
.	B-X
These	B-X
include	B-X
inhibiting	B-X
its	B-X
expression	B-X
,	B-X
antagonizing	B-X
cell	B-X
surface	B-X
receptor	B-X
activation	B-X
and	B-X
blocking	B-X
downstream	B-X
cell	B-X
signaling	B-X
pathways	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
potential	B-X
of	B-X
these	B-X
therapies	B-X
,	B-X
serum	B-X
levels	B-X
of	B-X
OPN	B-X
could	B-X
be	B-X
used	B-X
as	B-X
a	B-X
diagnostic	B-X
and	B-X
prognostic	B-X
marker	B-X
.	B-X

It	O
is	O
normally	O
produced	O
in	O
bone	O
,	O
teeth	O
,	O
kidney	O
and	O
epithelial	O
lining	O
tissues	O
and	O
is	O
found	O
in	O
plasma	O
and	O
breast	O
milk	O
.	O
<EOS>	B-X
It	B-X
is	B-X
normally	B-X
produced	B-X
in	B-X
bone	B-X
,	B-X
teeth	B-X
,	B-X
kidney	B-X
and	B-X
epithelial	B-X
lining	B-X
tissues	B-X
and	B-X
is	B-X
found	B-X
in	B-X
plasma	B-X
and	B-X
breast	B-X
milk	B-X
.	B-X
In	B-X
this	B-X
review	B-X
focus	B-X
will	B-X
be	B-X
on	B-X
OPN	B-X
in	B-X
bone	B-X
and	B-X
its	B-X
role	B-X
in	B-X
adhesion	B-X
,	B-X
migration	B-X
and	B-X
cell	B-X
survival	B-X
.	B-X

It	O
is	O
involved	O
in	O
a	O
number	O
of	O
physiologic	O
and	O
pathologic	O
events	O
including	O
angiogenesis	O
,	O
apoptosis	O
,	O
inflammation	O
,	O
wound	O
healing	O
and	O
tumor	O
metastasis	O
.	O

In	O
this	O
review	O
focus	O
will	O
be	O
on	O
OPN	B-Gene_or_gene_product
in	O
bone	O
and	O
its	O
role	O
in	O
adhesion	O
,	O
migration	O
and	O
cell	O
survival	O
.	O

These	O
aspects	O
of	O
OPN	B-Gene_or_gene_product
biology	O
are	O
important	O
in	O
tumorigenesis	O
.	O
<EOS>	B-X
Since	B-X
its	B-X
first	B-X
identification	B-X
as	B-X
a	B-X
transformation-associated	B-X
protein	B-X
,	B-X
osteopontin	B-X
(	B-X
OPN	B-X
)	B-X
has	B-X
been	B-X
recognised	B-X
as	B-X
important	B-X
in	B-X
the	B-X
processes	B-X
of	B-X
tumorigenicity	B-X
and	B-X
metastasis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
evidence	B-X
that	B-X
OPN	B-X
might	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
prognostic	B-X
marker	B-X
in	B-X
human	B-X
cancer	B-X
.	B-X
In	B-X
animal	B-X
systems	B-X
,	B-X
evidence	B-X
from	B-X
cell	B-X
injection	B-X
experiments	B-X
and	B-X
genetically	B-X
manipulated	B-X
mice	B-X
suggest	B-X
an	B-X
important	B-X
but	B-X
complex	B-X
role	B-X
for	B-X
the	B-X
protein	B-X
in	B-X
tumour	B-X
progression	B-X
.	B-X
Moreover	B-X
,	B-X
studies	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
associate	B-X
high	B-X
levels	B-X
of	B-X
OPN	B-X
expression	B-X
in	B-X
tumours	B-X
or	B-X
in	B-X
blood	B-X
with	B-X
more	B-X
advanced	B-X
cancers	B-X
.	B-X
The	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
OPN	B-X
in	B-X
promoting	B-X
cancer	B-X
is	B-X
still	B-X
unclear	B-X
,	B-X
and	B-X
we	B-X
consider	B-X
aspects	B-X
of	B-X
OPN	B-X
biology	B-X
that	B-X
can	B-X
complicate	B-X
interpretation	B-X
of	B-X
human	B-X
studies	B-X
.	B-X
Nevertheless	B-X
,	B-X
growing	B-X
evidence	B-X
supports	B-X
a	B-X
role	B-X
for	B-X
OPN	B-X
as	B-X
a	B-X
potential	B-X
prognostic	B-X
factor	B-X
for	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X

Oxidation	O
in	O
rheumatoid	O
arthritis	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
considered	B-X
a	B-X
chronic	B-X
systemic	B-X
,	B-X
multi-factorial	B-X
,	B-X
inflammatory	B-X
,	B-X
and	B-X
progressive	B-X
autoimmune	B-X
disease	B-X
affecting	B-X
many	B-X
people	B-X
worldwide	B-X
.	B-X
Oxygen	B-X
metabolism	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
An	B-X
understanding	B-X
of	B-X
the	B-X
complex	B-X
interactions	B-X
involved	B-X
in	B-X
these	B-X
pathways	B-X
might	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
for	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Rheumatoid	B-X
arthritis	B-X
is	B-X
a	B-X
chronic	B-X
,	B-X
inflammatory	B-X
joint	B-X
disease	B-X
leading	B-X
to	B-X
inflammation	B-X
of	B-X
synovial	B-X
membrane	B-X
that	B-X
lines	B-X
the	B-X
joints	B-X
.	B-X
Any	B-X
alteration	B-X
in	B-X
this	B-X
system	B-X
leads	B-X
to	B-X
dysregulated	B-X
cellular	B-X
homeostasis	B-X
;	B-X
progressively	B-X
leading	B-X
to	B-X
numerous	B-X
diseases	B-X
including	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Factors	B-X
including	B-X
TAK1	B-X
,	B-X
TRAF6	B-X
undergo	B-X
are	B-X
required	B-X
for	B-X
the	B-X
progression	B-X
of	B-X
disease	B-X
and	B-X
thus	B-X
contributes	B-X
towards	B-X
pathology	B-X
of	B-X
inflammatory	B-X
disorders	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
This	B-X
review	B-X
will	B-X
include	B-X
all	B-X
linked	B-X
aspects	B-X
which	B-X
contribute	B-X
its	B-X
major	B-X
role	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X

Oxygen	O
metabolism	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O
<EOS>	B-X
Profound	B-X
and	B-X
debilitating	B-X
fatigue	B-X
is	B-X
the	B-X
most	B-X
common	B-X
complaint	B-X
reported	B-X
among	B-X
individuals	B-X
with	B-X
autoimmune	B-X
disease	B-X
,	B-X
such	B-X
as	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
,	B-X
multiple	B-X
sclerosis	B-X
,	B-X
type	B-X
1	B-X
diabetes	B-X
,	B-X
celiac	B-X
disease	B-X
,	B-X
chronic	B-X
fatigue	B-X
syndrome	B-X
,	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Nevertheless	B-X
,	B-X
physiological	B-X
processes	B-X
known	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
fatigue	B-X
include	B-X
oxygen/nutrient	B-X
supply	B-X
,	B-X
metabolism	B-X
,	B-X
mood	B-X
,	B-X
motivation	B-X
,	B-X
and	B-X
sleepiness-all	B-X
which	B-X
are	B-X
affected	B-X
by	B-X
inflammation	B-X
.	B-X
Additionally	B-X
,	B-X
an	B-X
important	B-X
contributing	B-X
element	B-X
to	B-X
fatigue	B-X
is	B-X
the	B-X
central	B-X
nervous	B-X
system-a	B-X
region	B-X
impacted	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
in	B-X
numerous	B-X
autoimmune	B-X
and	B-X
related	B-X
disorders	B-X
.	B-X
At	B-X
moderate	B-X
concentrations	B-X
,	B-X
however	B-X
,	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
,	B-X
superoxide	B-X
anion	B-X
,	B-X
and	B-X
related	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
as	B-X
regulatory	B-X
mediators	B-X
in	B-X
signaling	B-X
processes	B-X
.	B-X
In	B-X
mitochondria	B-X
,	B-X
ROS	B-X
are	B-X
generated	B-X
as	B-X
undesirable	B-X
side	B-X
products	B-X
of	B-X
the	B-X
oxidative	B-X
energy	B-X
metabolism	B-X
.	B-X
An	B-X
excessive	B-X
and/or	B-X
sustained	B-X
increase	B-X
in	B-X
ROS	B-X
production	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
cancer	B-X
,	B-X
diabetes	B-X
mellitus	B-X
,	B-X
atherosclerosis	B-X
,	B-X
neurodegenerative	B-X
diseases	B-X
,	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
ischemia/reperfusion	B-X
injury	B-X
,	B-X
obstructive	B-X
sleep	B-X
apnea	B-X
,	B-X
and	B-X
other	B-X
diseases	B-X
.	B-X

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
produced	O
in	O
the	O
course	O
of	O
cellular	O
oxidative	O
phosphorylation	O
,	O
and	O
by	O
activated	O
phagocytic	O
cells	O
during	O
oxidative	O
bursts	O
,	O
exceed	O
the	O
physiological	O
buffering	O
capacity	O
and	O
result	O
in	O
oxidative	O
stress	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
course	B-X
of	B-X
cellular	B-X
oxidative	B-X
phosphorylation	B-X
,	B-X
and	B-X
by	B-X
activated	B-X
phagocytic	B-X
cells	B-X
during	B-X
oxidative	B-X
bursts	B-X
,	B-X
exceed	B-X
the	B-X
physiological	B-X
buffering	B-X
capacity	B-X
and	B-X
result	B-X
in	B-X
oxidative	B-X
stress	B-X
.	B-X
The	B-X
excessive	B-X
production	B-X
of	B-X
ROS	B-X
can	B-X
damage	B-X
protein	B-X
,	B-X
lipids	B-X
,	B-X
nucleic	B-X
acids	B-X
,	B-X
and	B-X
matrix	B-X
components	B-X
.	B-X
They	B-X
also	B-X
serve	B-X
as	B-X
important	B-X
intracellular	B-X
signaling	B-X
molecules	B-X
that	B-X
amplify	B-X
the	B-X
synovial	B-X
inflammatory-proliferative	B-X
response	B-X
.	B-X
Repetitive	B-X
cycles	B-X
of	B-X
hypoxia	B-X
and	B-X
reoxygenation	B-X
associated	B-X
with	B-X
changes	B-X
in	B-X
synovial	B-X
perfusion	B-X
are	B-X
postulated	B-X
to	B-X
activate	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
and	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
two	B-X
key	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
regulated	B-X
by	B-X
changes	B-X
in	B-X
cellular	B-X
oxygenation	B-X
and	B-X
cytokine	B-X
stimulation	B-X
,	B-X
and	B-X
that	B-X
in	B-X
turn	B-X
orchestrate	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
spectrum	B-X
of	B-X
genes	B-X
critical	B-X
to	B-X
the	B-X
persistence	B-X
of	B-X
synovitis	B-X
.	B-X

The	O
excessive	O
production	O
of	O
ROS	O
can	O
damage	O
protein	O
,	O
lipids	O
,	O
nucleic	O
acids	O
,	O
and	O
matrix	O
components	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
produced	B-X
in	B-X
the	B-X
course	B-X
of	B-X
cellular	B-X
oxidative	B-X
phosphorylation	B-X
,	B-X
and	B-X
by	B-X
activated	B-X
phagocytic	B-X
cells	B-X
during	B-X
oxidative	B-X
bursts	B-X
,	B-X
exceed	B-X
the	B-X
physiological	B-X
buffering	B-X
capacity	B-X
and	B-X
result	B-X
in	B-X
oxidative	B-X
stress	B-X
.	B-X
The	B-X
excessive	B-X
production	B-X
of	B-X
ROS	B-X
can	B-X
damage	B-X
protein	B-X
,	B-X
lipids	B-X
,	B-X
nucleic	B-X
acids	B-X
,	B-X
and	B-X
matrix	B-X
components	B-X
.	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
produced	B-X
by	B-X
abnormal	B-X
chondrocyte	B-X
metabolism	B-X
exceeds	B-X
the	B-X
physiological	B-X
buffering	B-X
capacity	B-X
and	B-X
results	B-X
in	B-X
oxidative	B-X
stress	B-X
.	B-X
The	B-X
excessive	B-X
production	B-X
of	B-X
ROS	B-X
can	B-X
damage	B-X
proteins	B-X
,	B-X
lipids	B-X
,	B-X
nucleic	B-X
acids	B-X
,	B-X
and	B-X
matrix	B-X
components	B-X
.	B-X

They	O
also	O
serve	O
as	O
important	O
intracellular	O
signaling	O
molecules	O
that	O
amplify	O
the	O
synovial	O
inflammatory	O
-	O
proliferative	O
response	O
.	O
<EOS>	B-X
Oxygen	B-X
metabolism	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
They	B-X
also	B-X
serve	B-X
as	B-X
important	B-X
intracellular	B-X
signaling	B-X
molecules	B-X
that	B-X
amplify	B-X
the	B-X
synovial	B-X
inflammatory-proliferative	B-X
response	B-X
.	B-X
Repetitive	B-X
cycles	B-X
of	B-X
hypoxia	B-X
and	B-X
reoxygenation	B-X
associated	B-X
with	B-X
changes	B-X
in	B-X
synovial	B-X
perfusion	B-X
are	B-X
postulated	B-X
to	B-X
activate	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
and	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
two	B-X
key	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
regulated	B-X
by	B-X
changes	B-X
in	B-X
cellular	B-X
oxygenation	B-X
and	B-X
cytokine	B-X
stimulation	B-X
,	B-X
and	B-X
that	B-X
in	B-X
turn	B-X
orchestrate	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
spectrum	B-X
of	B-X
genes	B-X
critical	B-X
to	B-X
the	B-X
persistence	B-X
of	B-X
synovitis	B-X
.	B-X
Oxygen	B-X
metabolism	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Abundant	B-X
amounts	B-X
of	B-X
ROS	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
synovial	B-X
fluid	B-X
of	B-X
RA	B-X
patients	B-X
.	B-X
The	B-X
accumulation	B-X
of	B-X
ROS	B-X
in	B-X
cells	B-X
also	B-X
serves	B-X
as	B-X
an	B-X
important	B-X
intracellular	B-X
signaling	B-X
of	B-X
molecules	B-X
that	B-X
amplify	B-X
the	B-X
synovial	B-X
inflammatory-proliferative	B-X
response	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
IMA	B-X
levels	B-X
and	B-X
other	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammatory	B-X
biomarkers	B-X
in	B-X
RA	B-X
subjects	B-X
.	B-X

Repetitive	O
cycles	O
of	O
hypoxia	O
and	O
reoxygenation	O
associated	O
with	O
changes	O
in	O
synovial	O
perfusion	O
are	O
postulated	O
to	O
activate	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
and	O
nuclear	B-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
,	O
two	O
key	O
transcription	O
factors	O
that	O
are	O
regulated	O
by	O
changes	O
in	O
cellular	O
oxygenation	O
and	O
cytokine	O
stimulation	O
,	O
and	O
that	O
in	O
turn	O
orchestrate	O
the	O
expression	O
of	O
a	O
spectrum	O
of	O
genes	O
critical	O
to	O
the	O
persistence	O
of	O
synovitis	O
.	O

An	O
understanding	O
of	O
the	O
complex	O
interactions	O
involved	O
in	O
these	O
pathways	O
might	O
allow	O
the	O
development	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
rheumatoid	O
arthritis	O
.	O
<EOS>	B-X
Oxygen	B-X
metabolism	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
An	B-X
understanding	B-X
of	B-X
the	B-X
complex	B-X
interactions	B-X
involved	B-X
in	B-X
these	B-X
pathways	B-X
might	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
for	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X

Glucocorticoid	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	O
induced	O
MAPK	B-Gene_or_gene_product
phosphatase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
MPK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
expression	O
inhibits	O
paclitaxel	O
-	O
associated	O
MAPK	B-Gene_or_gene_product
activation	O
and	O
contributes	O
to	O
breast	O
cancer	O
cell	O
survival	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

Glucocorticoid	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
GR	B-Gene_or_gene_product
)	O
activation	O
has	O
recently	O
been	O
shown	O
to	O
inhibit	O
apoptosis	O
in	O
breast	O
epithelial	O
cells	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

We	O
have	O
previously	O
described	O
a	O
group	O
of	O
genes	O
that	O
is	O
rapidly	O
up	O
-	O
regulated	O
in	O
these	O
cells	O
following	O
dexamethasone	O
(	O
Dex	O
)	O
treatment	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X

In	O
an	O
effort	O
to	O
dissect	O
the	O
mechanisms	O
of	O
GR	B-Gene_or_gene_product
-	O
mediated	O
breast	O
epithelial	O
cell	O
survival	O
,	O
we	O
now	O
examine	O
the	O
molecular	O
events	O
downstream	O
of	O
GR	B-Gene_or_gene_product
activation	O
.	O

Here	O
we	O
show	O
that	O
GR	B-Gene_or_gene_product
activation	O
leads	O
to	O
both	O
the	O
rapid	O
induction	O
of	O
MAPK	B-Gene_or_gene_product
phosphatase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
MKP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
mRNA	O
and	O
its	O
sustained	O
expression	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

Induction	O
of	O
the	O
MKP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
protein	O
in	O
the	O
MCF10A	O
-	O
Myc	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
epithelial	O
cell	O
lines	O
was	O
also	O
seen	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

Paclitaxel	O
treatment	O
resulted	O
in	O
MAPK	B-Gene_or_gene_product
activation	O
and	O
apoptosis	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
,	O
and	O
both	O
processes	O
were	O
inhibited	O
by	O
Dex	O
pretreatment	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

Furthermore	O
,	O
induction	O
of	O
MKP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
correlated	O
with	O
the	O
inhibition	O
of	O
extracellular	B-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
ERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	O
and	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Jun	I-Gene_or_gene_product
N	I-Gene_or_gene_product
-	I-Gene_or_gene_product
terminal	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
JNK	B-Gene_or_gene_product
)	O
activity	O
,	O
whereas	O
p38	B-Gene_or_gene_product
activity	O
was	O
minimally	O
affected	O
.	O

Blocking	O
Dex	O
-	O
induced	O
MKP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
induction	O
using	O
small	O
interfering	O
RNA	O
increased	O
ERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
JNK	B-Gene_or_gene_product
phosphorylation	O
and	O
decreased	O
cell	O
survival	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

ERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
JNK	B-Gene_or_gene_product
inactivation	O
was	O
associated	O
with	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
ELK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
dephosphorylation	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

To	O
explore	O
the	O
gene	O
expression	O
changes	O
that	O
occur	O
downstream	O
of	O
ELK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
dephosphorylation	O
,	O
we	O
used	O
a	O
combination	O
of	O
temporal	O
gene	O
expression	O
data	O
and	O
promoter	O
element	O
analyses	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

This	O
approach	O
revealed	O
a	O
previously	O
unrecognized	O
transcriptional	O
target	O
of	O
ELK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
the	O
human	O
tissue	B-Gene_or_gene_product
plasminogen	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
(	O
tPA	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

We	O
verified	O
the	O
predicted	O
ELK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
-	O
>	O
tPA	B-Gene_or_gene_product
transcriptional	O
regulatory	O
relationship	O
using	O
a	O
luciferase	B-Gene_or_gene_product
reporter	O
assay	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

We	O
conclude	O
that	O
GR	B-Gene_or_gene_product
-	O
mediated	O
MAPK	B-Gene_or_gene_product
inactivation	O
contributes	O
to	O
cell	O
survival	O
and	O
that	O
the	O
potential	O
transcriptional	O
targets	O
of	O
this	O
inhibition	O
can	O
be	O
identified	O
from	O
large	O
scale	O
gene	O
array	O
analysis	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
activation	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
in	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
a	B-X
group	B-X
of	B-X
genes	B-X
that	B-X
is	B-X
rapidly	B-X
up-regulated	B-X
in	B-X
these	B-X
cells	B-X
following	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
dissect	B-X
the	B-X
mechanisms	B-X
of	B-X
GR-mediated	B-X
breast	B-X
epithelial	B-X
cell	B-X
survival	B-X
,	B-X
we	B-X
now	B-X
examine	B-X
the	B-X
molecular	B-X
events	B-X
downstream	B-X
of	B-X
GR	B-X
activation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
GR	B-X
activation	B-X
leads	B-X
to	B-X
both	B-X
the	B-X
rapid	B-X
induction	B-X
of	B-X
MAPK	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
mRNA	B-X
and	B-X
its	B-X
sustained	B-X
expression	B-X
.	B-X
Induction	B-X
of	B-X
the	B-X
MKP-1	B-X
protein	B-X
in	B-X
the	B-X
MCF10A-Myc	B-X
and	B-X
MDA-MB-231	B-X
breast	B-X
epithelial	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
seen	B-X
.	B-X
Paclitaxel	B-X
treatment	B-X
resulted	B-X
in	B-X
MAPK	B-X
activation	B-X
and	B-X
apoptosis	B-X
of	B-X
MDA-MB-231	B-X
breast	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
inhibited	B-X
by	B-X
Dex	B-X
pretreatment	B-X
.	B-X
Furthermore	B-X
,	B-X
induction	B-X
of	B-X
MKP-1	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
activity	B-X
,	B-X
whereas	B-X
p38	B-X
activity	B-X
was	B-X
minimally	B-X
affected	B-X
.	B-X
Blocking	B-X
Dex-induced	B-X
MKP-1	B-X
induction	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
increased	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
phosphorylation	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
.	B-X
ERK1/2	B-X
and	B-X
JNK	B-X
inactivation	B-X
was	B-X
associated	B-X
with	B-X
Ets-like	B-X
transcription	B-X
factor-1	B-X
(	B-X
ELK-1	B-X
)	B-X
dephosphorylation	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
gene	B-X
expression	B-X
changes	B-X
that	B-X
occur	B-X
downstream	B-X
of	B-X
ELK-1	B-X
dephosphorylation	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
temporal	B-X
gene	B-X
expression	B-X
data	B-X
and	B-X
promoter	B-X
element	B-X
analyses	B-X
.	B-X
This	B-X
approach	B-X
revealed	B-X
a	B-X
previously	B-X
unrecognized	B-X
transcriptional	B-X
target	B-X
of	B-X
ELK-1	B-X
,	B-X
the	B-X
human	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
.	B-X
We	B-X
verified	B-X
the	B-X
predicted	B-X
ELK-1	B-X
--	B-X
>	B-X
tPA	B-X
transcriptional	B-X
regulatory	B-X
relationship	B-X
using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
GR-mediated	B-X
MAPK	B-X
inactivation	B-X
contributes	B-X
to	B-X
cell	B-X
survival	B-X
and	B-X
that	B-X
the	B-X
potential	B-X
transcriptional	B-X
targets	B-X
of	B-X
this	B-X
inhibition	B-X
can	B-X
be	B-X
identified	B-X
from	B-X
large	B-X
scale	B-X
gene	B-X
array	B-X
analysis	B-X
.	B-X

Investigating	O
the	O
causes	O
of	O
low	O
birth	O
weight	O
in	O
contrasting	O
ovine	O
paradigms	O
.	O
<EOS>	B-X
Two	B-X
natural	B-X
models	B-X
of	B-X
ovine	B-X
IUGR	B-X
are	B-X
those	B-X
of	B-X
hyperthermic	B-X
exposure	B-X
during	B-X
pregnancy	B-X
,	B-X
and	B-X
adolescent	B-X
overfeeding	B-X
,	B-X
also	B-X
during	B-X
pregnancy	B-X
.	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
Additionally	B-X
,	B-X
impaired	B-X
placental	B-X
angiogenesis	B-X
and	B-X
uteroplacental	B-X
blood	B-X
flow	B-X
appears	B-X
to	B-X
be	B-X
an	B-X
early	B-X
defect	B-X
in	B-X
both	B-X
the	B-X
hyperthermic	B-X
and	B-X
adolescent	B-X
paradigms	B-X
.	B-X
However	B-X
,	B-X
fetal	B-X
utilization	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
,	B-X
on	B-X
a	B-X
weight	B-X
basis	B-X
,	B-X
remain	B-X
constant	B-X
compared	B-X
with	B-X
control	B-X
pregnancies	B-X
.	B-X

Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
still	O
accounts	O
for	O
a	O
large	O
incidence	O
of	O
infant	O
mortality	O
and	O
morbidity	O
worldwide	O
.	O
<EOS>	B-X
Intrauterine	B-X
growth	B-X
restriction	B-X
(	B-X
IUGR	B-X
)	B-X
still	B-X
accounts	B-X
for	B-X
a	B-X
large	B-X
incidence	B-X
of	B-X
infant	B-X
mortality	B-X
and	B-X
morbidity	B-X
worldwide	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
circulatory	B-X
and	B-X
transport	B-X
properties	B-X
of	B-X
the	B-X
sheep	B-X
placenta	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
human	B-X
placenta	B-X
and	B-X
as	B-X
such	B-X
,	B-X
the	B-X
pregnant	B-X
sheep	B-X
offers	B-X
an	B-X
excellent	B-X
model	B-X
in	B-X
which	B-X
to	B-X
study	B-X
the	B-X
development	B-X
of	B-X
IUGR	B-X
.	B-X
Two	B-X
natural	B-X
models	B-X
of	B-X
ovine	B-X
IUGR	B-X
are	B-X
those	B-X
of	B-X
hyperthermic	B-X
exposure	B-X
during	B-X
pregnancy	B-X
,	B-X
and	B-X
adolescent	B-X
overfeeding	B-X
,	B-X
also	B-X
during	B-X
pregnancy	B-X
.	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
IUGR	B-X
fetuses	B-X
are	B-X
both	B-X
hypoxic	B-X
and	B-X
hypoglycaemic	B-X
,	B-X
and	B-X
have	B-X
reduced	B-X
insulin	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor-1	B-X
(	B-X
IGF-1	B-X
)	B-X
,	B-X
and	B-X
elevated	B-X
concentrations	B-X
of	B-X
lactate	B-X
.	B-X

Many	O
of	O
the	O
circulatory	O
and	O
transport	O
properties	O
of	O
the	O
sheep	O
placenta	O
are	O
similar	O
to	O
those	O
of	O
the	O
human	O
placenta	O
and	O
as	O
such	O
,	O
the	O
pregnant	O
sheep	O
offers	O
an	O
excellent	O
model	O
in	O
which	O
to	O
study	O
the	O
development	O
of	O
IUGR	O
.	O

Two	O
natural	O
models	O
of	O
ovine	O
IUGR	O
are	O
those	O
of	O
hyperthermic	O
exposure	O
during	O
pregnancy	O
,	O
and	O
adolescent	O
overfeeding	O
,	O
also	O
during	O
pregnancy	O
.	O
<EOS>	B-X
Intrauterine	B-X
growth	B-X
restriction	B-X
(	B-X
IUGR	B-X
)	B-X
still	B-X
accounts	B-X
for	B-X
a	B-X
large	B-X
incidence	B-X
of	B-X
infant	B-X
mortality	B-X
and	B-X
morbidity	B-X
worldwide	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
circulatory	B-X
and	B-X
transport	B-X
properties	B-X
of	B-X
the	B-X
sheep	B-X
placenta	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
human	B-X
placenta	B-X
and	B-X
as	B-X
such	B-X
,	B-X
the	B-X
pregnant	B-X
sheep	B-X
offers	B-X
an	B-X
excellent	B-X
model	B-X
in	B-X
which	B-X
to	B-X
study	B-X
the	B-X
development	B-X
of	B-X
IUGR	B-X
.	B-X
Two	B-X
natural	B-X
models	B-X
of	B-X
ovine	B-X
IUGR	B-X
are	B-X
those	B-X
of	B-X
hyperthermic	B-X
exposure	B-X
during	B-X
pregnancy	B-X
,	B-X
and	B-X
adolescent	B-X
overfeeding	B-X
,	B-X
also	B-X
during	B-X
pregnancy	B-X
.	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
Additionally	B-X
,	B-X
impaired	B-X
placental	B-X
angiogenesis	B-X
and	B-X
uteroplacental	B-X
blood	B-X
flow	B-X
appears	B-X
to	B-X
be	B-X
an	B-X
early	B-X
defect	B-X
in	B-X
both	B-X
the	B-X
hyperthermic	B-X
and	B-X
adolescent	B-X
paradigms	B-X
.	B-X
IUGR	B-X
fetuses	B-X
are	B-X
both	B-X
hypoxic	B-X
and	B-X
hypoglycaemic	B-X
,	B-X
and	B-X
have	B-X
reduced	B-X
insulin	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor-1	B-X
(	B-X
IGF-1	B-X
)	B-X
,	B-X
and	B-X
elevated	B-X
concentrations	B-X
of	B-X
lactate	B-X
.	B-X

Both	O
models	O
yield	O
significantly	O
reduced	O
placental	O
weights	O
and	O
an	O
asymmetrically	O
growth	O
-	O
restricted	O
fetus	O
,	O
and	O
display	O
altered	O
maternal	O
hormone	O
concentrations	O
,	O
indicative	O
of	O
an	O
impaired	O
trophoblast	O
capacity	O
.	O

Additionally	O
,	O
impaired	O
placental	O
angiogenesis	O
and	O
uteroplacental	O
blood	O
flow	O
appears	O
to	O
be	O
an	O
early	O
defect	O
in	O
both	O
the	O
hyperthermic	O
and	O
adolescent	O
paradigms	O
.	O
<EOS>	B-X
Two	B-X
natural	B-X
models	B-X
of	B-X
ovine	B-X
IUGR	B-X
are	B-X
those	B-X
of	B-X
hyperthermic	B-X
exposure	B-X
during	B-X
pregnancy	B-X
,	B-X
and	B-X
adolescent	B-X
overfeeding	B-X
,	B-X
also	B-X
during	B-X
pregnancy	B-X
.	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
Additionally	B-X
,	B-X
impaired	B-X
placental	B-X
angiogenesis	B-X
and	B-X
uteroplacental	B-X
blood	B-X
flow	B-X
appears	B-X
to	B-X
be	B-X
an	B-X
early	B-X
defect	B-X
in	B-X
both	B-X
the	B-X
hyperthermic	B-X
and	B-X
adolescent	B-X
paradigms	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
these	B-X
alterations	B-X
in	B-X
placental	B-X
functional	B-X
development	B-X
appear	B-X
to	B-X
be	B-X
irreversible	B-X
.	B-X

The	O
effects	O
of	O
these	O
alterations	O
in	O
placental	O
functional	O
development	O
appear	O
to	O
be	O
irreversible	O
.	O
<EOS>	B-X
Many	B-X
of	B-X
the	B-X
circulatory	B-X
and	B-X
transport	B-X
properties	B-X
of	B-X
the	B-X
sheep	B-X
placenta	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
human	B-X
placenta	B-X
and	B-X
as	B-X
such	B-X
,	B-X
the	B-X
pregnant	B-X
sheep	B-X
offers	B-X
an	B-X
excellent	B-X
model	B-X
in	B-X
which	B-X
to	B-X
study	B-X
the	B-X
development	B-X
of	B-X
IUGR	B-X
.	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
Additionally	B-X
,	B-X
impaired	B-X
placental	B-X
angiogenesis	B-X
and	B-X
uteroplacental	B-X
blood	B-X
flow	B-X
appears	B-X
to	B-X
be	B-X
an	B-X
early	B-X
defect	B-X
in	B-X
both	B-X
the	B-X
hyperthermic	B-X
and	B-X
adolescent	B-X
paradigms	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
these	B-X
alterations	B-X
in	B-X
placental	B-X
functional	B-X
development	B-X
appear	B-X
to	B-X
be	B-X
irreversible	B-X
.	B-X
Maintained	B-X
utilization	B-X
of	B-X
these	B-X
substrates	B-X
,	B-X
in	B-X
a	B-X
substrate-deficient	B-X
environment	B-X
,	B-X
suggests	B-X
increased	B-X
sensitivities	B-X
to	B-X
metabolic	B-X
signals	B-X
,	B-X
which	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
metabolic	B-X
diseases	B-X
in	B-X
later	B-X
adult	B-X
life	B-X
.	B-X

IUGR	O
fetuses	O
are	O
both	O
hypoxic	O
and	O
hypoglycaemic	O
,	O
and	O
have	O
reduced	O
insulin	B-Gene_or_gene_product
and	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
,	O
and	O
elevated	O
concentrations	O
of	O
lactate	O
.	O
<EOS>	B-X
Intrauterine	B-X
growth	B-X
restriction	B-X
(	B-X
IUGR	B-X
)	B-X
still	B-X
accounts	B-X
for	B-X
a	B-X
large	B-X
incidence	B-X
of	B-X
infant	B-X
mortality	B-X
and	B-X
morbidity	B-X
worldwide	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
circulatory	B-X
and	B-X
transport	B-X
properties	B-X
of	B-X
the	B-X
sheep	B-X
placenta	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
human	B-X
placenta	B-X
and	B-X
as	B-X
such	B-X
,	B-X
the	B-X
pregnant	B-X
sheep	B-X
offers	B-X
an	B-X
excellent	B-X
model	B-X
in	B-X
which	B-X
to	B-X
study	B-X
the	B-X
development	B-X
of	B-X
IUGR	B-X
.	B-X
Two	B-X
natural	B-X
models	B-X
of	B-X
ovine	B-X
IUGR	B-X
are	B-X
those	B-X
of	B-X
hyperthermic	B-X
exposure	B-X
during	B-X
pregnancy	B-X
,	B-X
and	B-X
adolescent	B-X
overfeeding	B-X
,	B-X
also	B-X
during	B-X
pregnancy	B-X
.	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
IUGR	B-X
fetuses	B-X
are	B-X
both	B-X
hypoxic	B-X
and	B-X
hypoglycaemic	B-X
,	B-X
and	B-X
have	B-X
reduced	B-X
insulin	B-X
and	B-X
insulin-like	B-X
growth	B-X
factor-1	B-X
(	B-X
IGF-1	B-X
)	B-X
,	B-X
and	B-X
elevated	B-X
concentrations	B-X
of	B-X
lactate	B-X
.	B-X

However	O
,	O
fetal	O
utilization	O
of	O
oxygen	O
and	O
glucose	O
,	O
on	O
a	O
weight	O
basis	O
,	O
remain	O
constant	O
compared	O
with	O
control	O
pregnancies	O
.	O
<EOS>	B-X
Both	B-X
models	B-X
yield	B-X
significantly	B-X
reduced	B-X
placental	B-X
weights	B-X
and	B-X
an	B-X
asymmetrically	B-X
growth-restricted	B-X
fetus	B-X
,	B-X
and	B-X
display	B-X
altered	B-X
maternal	B-X
hormone	B-X
concentrations	B-X
,	B-X
indicative	B-X
of	B-X
an	B-X
impaired	B-X
trophoblast	B-X
capacity	B-X
.	B-X
However	B-X
,	B-X
fetal	B-X
utilization	B-X
of	B-X
oxygen	B-X
and	B-X
glucose	B-X
,	B-X
on	B-X
a	B-X
weight	B-X
basis	B-X
,	B-X
remain	B-X
constant	B-X
compared	B-X
with	B-X
control	B-X
pregnancies	B-X
.	B-X
Maintained	B-X
utilization	B-X
of	B-X
these	B-X
substrates	B-X
,	B-X
in	B-X
a	B-X
substrate-deficient	B-X
environment	B-X
,	B-X
suggests	B-X
increased	B-X
sensitivities	B-X
to	B-X
metabolic	B-X
signals	B-X
,	B-X
which	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
metabolic	B-X
diseases	B-X
in	B-X
later	B-X
adult	B-X
life	B-X
.	B-X

Maintained	O
utilization	O
of	O
these	O
substrates	O
,	O
in	O
a	O
substrate	O
-	O
deficient	O
environment	O
,	O
suggests	O
increased	O
sensitivities	O
to	O
metabolic	O
signals	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
metabolic	O
diseases	O
in	O
later	O
adult	O
life	O
.	O

p53	B-Gene_or_gene_product
mutation	O
heterogeneity	O
in	O
cancer	O
.	O
<EOS>	B-X
Although	B-X
p53	B-X
inactivation	B-X
promotes	B-X
genomic	B-X
instability	B-X
Triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
accounts	B-X
for	B-X
15	B-X
%	B-X
to	B-X
20	B-X
%	B-X
of	B-X
breast	B-X
cancer	B-X
cases	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
2	B-X
receptors	B-X
.	B-X
Though	B-X
TNBC	B-X
is	B-X
a	B-X
highly	B-X
heterogenic	B-X
and	B-X
aggressive	B-X
disease	B-X
,	B-X
TNBC	B-X
patients	B-X
have	B-X
better	B-X
response	B-X
to	B-X
neoadjuvant	B-X
therapy	B-X
compared	B-X
to	B-X
other	B-X
breast	B-X
cancer	B-X
subtypes	B-X
.	B-X
In	B-X
spite	B-X
of	B-X
intensive	B-X
research	B-X
into	B-X
finding	B-X
new	B-X
molecular	B-X
biomarkers	B-X
and	B-X
designing	B-X
personalized	B-X
therapeutic	B-X
approaches	B-X
,	B-X
BRCA	B-X
mutational	B-X
status	B-X
is	B-X
the	B-X
only	B-X
clinically	B-X
validated	B-X
biomarker	B-X
for	B-X
personalized	B-X
therapy	B-X
in	B-X
TNBC	B-X
.	B-X

The	O
p53	B-Gene_or_gene_product
gene	O
is	O
inactivated	O
in	O
about	O
50	O
%	O
of	O
human	O
cancers	O
and	O
the	O
p53	B-Gene_or_gene_product
protein	O
is	O
an	O
essential	O
component	O
of	O
the	O
cell	O
response	O
induced	O
by	O
genotoxic	O
stresses	O
such	O
as	O
those	O
generated	O
by	O
radiotherapy	O
or	O
chemotherapy	O
.	O
<EOS>	B-X
These	B-X
include	B-X
general	B-X
side	B-X
effects	B-X
such	B-X
as	B-X
anemia	B-X
,	B-X
neutropenia	B-X
,	B-X
nausea	B-X
,	B-X
vomiting	B-X
,	B-X
diarrhea	B-X
,	B-X
mucositis	B-X
or	B-X
paravasation	B-X
as	B-X
well	B-X
as	B-X
special	B-X
toxicities	B-X
like	B-X
ototoxicity	B-X
,	B-X
nephrotoxicity	B-X
,	B-X
pulmonary	B-X
toxicity	B-X
,	B-X
neurotoxicity	B-X
or	B-X
Raynaud	B-X
's	B-X
syndrome	B-X
.	B-X
Accordingly	B-X
,	B-X
adequate	B-X
management	B-X
of	B-X
the	B-X
possible	B-X
side	B-X
effects	B-X
and	B-X
long-term	B-X
consequences	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
use	B-X
of	B-X
chemotherapy	B-X
is	B-X
essential	B-X
.	B-X
The	B-X
success	B-X
of	B-X
this	B-X
approach	B-X
has	B-X
so	B-X
far	B-X
led	B-X
to	B-X
the	B-X
approval	B-X
of	B-X
four	B-X
different	B-X
PARP	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
and	B-X
a	B-X
total	B-X
of	B-X
seven	B-X
different	B-X
compounds	B-X
are	B-X
currently	B-X
under	B-X
clinical	B-X
investigation	B-X
for	B-X
various	B-X
indications	B-X
.	B-X
Clinical	B-X
trials	B-X
have	B-X
demonstrated	B-X
promising	B-X
response	B-X
rates	B-X
among	B-X
patients	B-X
receiving	B-X
PARP	B-X
inhibitors	B-X
,	B-X
although	B-X
the	B-X
majority	B-X
will	B-X
inevitably	B-X
develop	B-X
resistance	B-X
.	B-X

It	O
is	O
therefore	O
highly	O
likely	O
that	O
these	O
alterations	O
are	O
an	O
important	O
component	O
in	O
tumor	O
resistance	O
to	O
therapy	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
inactivated	B-X
in	B-X
about	B-X
50	B-X
%	B-X
of	B-X
human	B-X
cancers	B-X
and	B-X
the	B-X
p53	B-X
protein	B-X
is	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
the	B-X
cell	B-X
response	B-X
induced	B-X
by	B-X
genotoxic	B-X
stresses	B-X
such	B-X
as	B-X
those	B-X
generated	B-X
by	B-X
radiotherapy	B-X
or	B-X
chemotherapy	B-X
.	B-X
It	B-X
is	B-X
therefore	B-X
highly	B-X
likely	B-X
that	B-X
these	B-X
alterations	B-X
are	B-X
an	B-X
important	B-X
component	B-X
in	B-X
tumor	B-X
resistance	B-X
to	B-X
therapy	B-X
.	B-X
The	B-X
particular	B-X
characteristics	B-X
of	B-X
these	B-X
alterations	B-X
,	B-X
80	B-X
%	B-X
of	B-X
which	B-X
are	B-X
missense	B-X
mutations	B-X
leading	B-X
to	B-X
functionally	B-X
heterogeneous	B-X
proteins	B-X
,	B-X
make	B-X
p53	B-X
a	B-X
unique	B-X
gene	B-X
in	B-X
the	B-X
class	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
.	B-X
A	B-X
considerable	B-X
number	B-X
of	B-X
mutant	B-X
p53	B-X
proteins	B-X
probably	B-X
have	B-X
an	B-X
oncogenic	B-X
activity	B-X
per	B-X
se	B-X
and	B-X
therefore	B-X
actively	B-X
participate	B-X
in	B-X
cell	B-X
transformation	B-X
.	B-X

The	O
particular	O
characteristics	O
of	O
these	O
alterations	O
,	O
80	O
%	O
of	O
which	O
are	O
missense	O
mutations	O
leading	O
to	O
functionally	O
heterogeneous	O
proteins	O
,	O
make	O
p53	B-Gene_or_gene_product
a	O
unique	O
gene	O
in	O
the	O
class	O
of	O
tumor	O
suppressor	O
genes	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
inactivated	B-X
in	B-X
about	B-X
50	B-X
%	B-X
of	B-X
human	B-X
cancers	B-X
and	B-X
the	B-X
p53	B-X
protein	B-X
is	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
the	B-X
cell	B-X
response	B-X
induced	B-X
by	B-X
genotoxic	B-X
stresses	B-X
such	B-X
as	B-X
those	B-X
generated	B-X
by	B-X
radiotherapy	B-X
or	B-X
chemotherapy	B-X
.	B-X
It	B-X
is	B-X
therefore	B-X
highly	B-X
likely	B-X
that	B-X
these	B-X
alterations	B-X
are	B-X
an	B-X
important	B-X
component	B-X
in	B-X
tumor	B-X
resistance	B-X
to	B-X
therapy	B-X
.	B-X
The	B-X
particular	B-X
characteristics	B-X
of	B-X
these	B-X
alterations	B-X
,	B-X
80	B-X
%	B-X
of	B-X
which	B-X
are	B-X
missense	B-X
mutations	B-X
leading	B-X
to	B-X
functionally	B-X
heterogeneous	B-X
proteins	B-X
,	B-X
make	B-X
p53	B-X
a	B-X
unique	B-X
gene	B-X
in	B-X
the	B-X
class	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
.	B-X
A	B-X
considerable	B-X
number	B-X
of	B-X
mutant	B-X
p53	B-X
proteins	B-X
probably	B-X
have	B-X
an	B-X
oncogenic	B-X
activity	B-X
per	B-X
se	B-X
and	B-X
therefore	B-X
actively	B-X
participate	B-X
in	B-X
cell	B-X
transformation	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
the	B-X
apoptotic	B-X
and	B-X
antiproliferative	B-X
functions	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
dissociated	B-X
in	B-X
certain	B-X
mutants	B-X
also	B-X
suggests	B-X
another	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
relationships	B-X
between	B-X
p53	B-X
inactivation	B-X
and	B-X
neoplasia	B-X
.	B-X

A	O
considerable	O
number	O
of	O
mutant	O
p53	B-Gene_or_gene_product
proteins	O
probably	O
have	O
an	O
oncogenic	O
activity	O
per	O
se	O
and	O
therefore	O
actively	O
participate	O
in	O
cell	O
transformation	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
inactivated	B-X
in	B-X
about	B-X
50	B-X
%	B-X
of	B-X
human	B-X
cancers	B-X
and	B-X
the	B-X
p53	B-X
protein	B-X
is	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
the	B-X
cell	B-X
response	B-X
induced	B-X
by	B-X
genotoxic	B-X
stresses	B-X
such	B-X
as	B-X
those	B-X
generated	B-X
by	B-X
radiotherapy	B-X
or	B-X
chemotherapy	B-X
.	B-X
It	B-X
is	B-X
therefore	B-X
highly	B-X
likely	B-X
that	B-X
these	B-X
alterations	B-X
are	B-X
an	B-X
important	B-X
component	B-X
in	B-X
tumor	B-X
resistance	B-X
to	B-X
therapy	B-X
.	B-X
The	B-X
particular	B-X
characteristics	B-X
of	B-X
these	B-X
alterations	B-X
,	B-X
80	B-X
%	B-X
of	B-X
which	B-X
are	B-X
missense	B-X
mutations	B-X
leading	B-X
to	B-X
functionally	B-X
heterogeneous	B-X
proteins	B-X
,	B-X
make	B-X
p53	B-X
a	B-X
unique	B-X
gene	B-X
in	B-X
the	B-X
class	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
.	B-X
A	B-X
considerable	B-X
number	B-X
of	B-X
mutant	B-X
p53	B-X
proteins	B-X
probably	B-X
have	B-X
an	B-X
oncogenic	B-X
activity	B-X
per	B-X
se	B-X
and	B-X
therefore	B-X
actively	B-X
participate	B-X
in	B-X
cell	B-X
transformation	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
the	B-X
apoptotic	B-X
and	B-X
antiproliferative	B-X
functions	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
dissociated	B-X
in	B-X
certain	B-X
mutants	B-X
also	B-X
suggests	B-X
another	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
relationships	B-X
between	B-X
p53	B-X
inactivation	B-X
and	B-X
neoplasia	B-X
.	B-X

The	O
fact	O
that	O
the	O
apoptotic	O
and	O
antiproliferative	O
functions	O
of	O
p53	B-Gene_or_gene_product
can	O
be	O
dissociated	O
in	O
certain	O
mutants	O
also	O
suggests	O
another	O
level	O
of	O
complexity	O
in	O
the	O
relationships	O
between	O
p53	B-Gene_or_gene_product
inactivation	O
and	O
neoplasia	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
inactivated	B-X
in	B-X
about	B-X
50	B-X
%	B-X
of	B-X
human	B-X
cancers	B-X
and	B-X
the	B-X
p53	B-X
protein	B-X
is	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
the	B-X
cell	B-X
response	B-X
induced	B-X
by	B-X
genotoxic	B-X
stresses	B-X
such	B-X
as	B-X
those	B-X
generated	B-X
by	B-X
radiotherapy	B-X
or	B-X
chemotherapy	B-X
.	B-X
The	B-X
particular	B-X
characteristics	B-X
of	B-X
these	B-X
alterations	B-X
,	B-X
80	B-X
%	B-X
of	B-X
which	B-X
are	B-X
missense	B-X
mutations	B-X
leading	B-X
to	B-X
functionally	B-X
heterogeneous	B-X
proteins	B-X
,	B-X
make	B-X
p53	B-X
a	B-X
unique	B-X
gene	B-X
in	B-X
the	B-X
class	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
.	B-X
A	B-X
considerable	B-X
number	B-X
of	B-X
mutant	B-X
p53	B-X
proteins	B-X
probably	B-X
have	B-X
an	B-X
oncogenic	B-X
activity	B-X
per	B-X
se	B-X
and	B-X
therefore	B-X
actively	B-X
participate	B-X
in	B-X
cell	B-X
transformation	B-X
.	B-X
The	B-X
fact	B-X
that	B-X
the	B-X
apoptotic	B-X
and	B-X
antiproliferative	B-X
functions	B-X
of	B-X
p53	B-X
can	B-X
be	B-X
dissociated	B-X
in	B-X
certain	B-X
mutants	B-X
also	B-X
suggests	B-X
another	B-X
level	B-X
of	B-X
complexity	B-X
in	B-X
the	B-X
relationships	B-X
between	B-X
p53	B-X
inactivation	B-X
and	B-X
neoplasia	B-X
.	B-X

Randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
on	O
the	O
effect	O
of	O
zoledronic	O
acid	O
on	O
the	O
prevention	O
of	O
bone	O
metastases	O
in	O
patients	O
with	O
recurrent	O
solid	O
tumors	O
that	O
did	O
not	O
present	O
with	O
bone	O
metastases	O
at	O
baseline	O
.	O

OBJECTIVES	O
:	O
Bisphosphonates	O
have	O
been	O
used	O
successfully	O
in	O
the	O
treatment	O
of	O
hypercalcemia	O
and	O
to	O
reduce	O
skeletal	O
-	O
related	O
complications	O
of	O
bone	O
metastases	O
.	O
<EOS>	B-X
Bisphosphonates	B-X
have	B-X
been	B-X
used	B-X
successfully	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hypercalcemia	B-X
and	B-X
to	B-X
reduce	B-X
skeletal-related	B-X
complications	B-X
of	B-X
bone	B-X
metastases	B-X
.	B-X
This	B-X
is	B-X
a	B-X
randomized	B-X
,	B-X
open	B-X
label	B-X
,	B-X
prospective	B-X
study	B-X
that	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
preventive	B-X
zoledronic	B-X
acid	B-X
treatment	B-X
on	B-X
the	B-X
development	B-X
of	B-X
bone	B-X
metastases	B-X
in	B-X
patients	B-X
with	B-X
recurrent	B-X
solid	B-X
tumors	B-X
,	B-X
without	B-X
bone	B-X
metastases	B-X
at	B-X
the	B-X
time	B-X
of	B-X
randomization	B-X
.	B-X

Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
they	O
may	O
also	O
have	O
direct	O
antitumor	O
effects	O
via	O
induction	O
of	O
apoptosis	O
,	O
inhibition	O
of	O
the	O
invasive	O
potential	O
of	O
tumor	O
cell	O
lines	O
in	O
vitro	O
,	O
inhibition	O
of	O
angiogenesis	O
,	O
and	O
reduction	O
in	O
tumor	O
growth	O
indirectly	O
via	O
effects	O
on	O
accessory	O
cells	O
.	O
<EOS>	B-X
Recent	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
evidence	B-X
suggest	B-X
that	B-X
they	B-X
may	B-X
also	B-X
have	B-X
direct	B-X
antitumor	B-X
effects	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
invasive	B-X
potential	B-X
of	B-X
tumor	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
,	B-X
inhibition	B-X
of	B-X
angiogenesis	B-X
,	B-X
and	B-X
reduction	B-X
in	B-X
tumor	B-X
growth	B-X
indirectly	B-X
via	B-X
effects	B-X
on	B-X
accessory	B-X
cells	B-X
.	B-X
This	B-X
is	B-X
a	B-X
randomized	B-X
,	B-X
open	B-X
label	B-X
,	B-X
prospective	B-X
study	B-X
that	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
preventive	B-X
zoledronic	B-X
acid	B-X
treatment	B-X
on	B-X
the	B-X
development	B-X
of	B-X
bone	B-X
metastases	B-X
in	B-X
patients	B-X
with	B-X
recurrent	B-X
solid	B-X
tumors	B-X
,	B-X
without	B-X
bone	B-X
metastases	B-X
at	B-X
the	B-X
time	B-X
of	B-X
randomization	B-X
.	B-X

This	O
is	O
a	O
randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
that	O
examined	O
the	O
effect	O
of	O
preventive	O
zoledronic	O
acid	O
treatment	O
on	O
the	O
development	O
of	O
bone	O
metastases	O
in	O
patients	O
with	O
recurrent	O
solid	O
tumors	O
,	O
without	O
bone	O
metastases	O
at	O
the	O
time	O
of	O
randomization	O
.	O
<EOS>	B-X
Bisphosphonates	B-X
have	B-X
been	B-X
used	B-X
successfully	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hypercalcemia	B-X
and	B-X
to	B-X
reduce	B-X
skeletal-related	B-X
complications	B-X
of	B-X
bone	B-X
metastases	B-X
.	B-X
Recent	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
evidence	B-X
suggest	B-X
that	B-X
they	B-X
may	B-X
also	B-X
have	B-X
direct	B-X
antitumor	B-X
effects	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
invasive	B-X
potential	B-X
of	B-X
tumor	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
,	B-X
inhibition	B-X
of	B-X
angiogenesis	B-X
,	B-X
and	B-X
reduction	B-X
in	B-X
tumor	B-X
growth	B-X
indirectly	B-X
via	B-X
effects	B-X
on	B-X
accessory	B-X
cells	B-X
.	B-X
This	B-X
is	B-X
a	B-X
randomized	B-X
,	B-X
open	B-X
label	B-X
,	B-X
prospective	B-X
study	B-X
that	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
preventive	B-X
zoledronic	B-X
acid	B-X
treatment	B-X
on	B-X
the	B-X
development	B-X
of	B-X
bone	B-X
metastases	B-X
in	B-X
patients	B-X
with	B-X
recurrent	B-X
solid	B-X
tumors	B-X
,	B-X
without	B-X
bone	B-X
metastases	B-X
at	B-X
the	B-X
time	B-X
of	B-X
randomization	B-X
.	B-X

METHODS	O
:	O
Forty	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
advanced	O
cancer	O
,	O
without	O
bone	O
metastases	O
,	O
were	O
randomized	O
into	O
the	O
trial	O
to	O
either	O
receive	O
zoledronic	O
acid	O
or	O
no	O
treatment	O
.	O
<EOS>	B-X
Tranexamic	B-X
acid	B-X
(	B-X
TA	B-X
)	B-X
is	B-X
an	B-X
antifibrinolytic	B-X
drug	B-X
currently	B-X
used	B-X
systemically	B-X
to	B-X
control	B-X
bleeding	B-X
.	B-X
To	B-X
date	B-X
,	B-X
there	B-X
have	B-X
been	B-X
no	B-X
prospective	B-X
studies	B-X
of	B-X
the	B-X
effectiveness	B-X
of	B-X
inhaled	B-X
TA	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
hemoptysis	B-X
.	B-X
This	B-X
randomized	B-X
study	B-X
compared	B-X
denosumab	B-X
,	B-X
a	B-X
fully	B-X
human	B-X
monoclonal	B-X
antibody	B-X
against	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
Îº	B-X
B	B-X
(	B-X
RANK	B-X
)	B-X
ligand	B-X
,	B-X
with	B-X
zoledronic	B-X
acid	B-X
in	B-X
delaying	B-X
or	B-X
preventing	B-X
skeletal-related	B-X
events	B-X
(	B-X
SREs	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
with	B-X
bone	B-X
metastases	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
denosumab	B-X
,	B-X
a	B-X
fully	B-X
human	B-X
monoclonal	B-X
anti-receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
ligand	B-X
antibody	B-X
,	B-X
with	B-X
zoledronic	B-X
acid	B-X
(	B-X
ZA	B-X
)	B-X
for	B-X
delaying	B-X
or	B-X
preventing	B-X
skeletal-related	B-X
events	B-X
(	B-X
SRE	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
advanced	B-X
cancer	B-X
and	B-X
bone	B-X
metastases	B-X
(	B-X
excluding	B-X
breast	B-X
and	B-X
prostate	B-X
)	B-X
or	B-X
myeloma	B-X
.	B-X

Patients	O
were	O
followed	O
up	O
until	O
bone	O
metastases	O
were	O
established	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
Ewing	B-X
sarcoma	B-X
or	B-X
osteosarcoma	B-X
have	B-X
a	B-X
median	B-X
overall	B-X
survival	B-X
of	B-X
less	B-X
than	B-X
12	B-X
months	B-X
after	B-X
diagnosis	B-X
,	B-X
and	B-X
a	B-X
standard	B-X
treatment	B-X
strategy	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
established	B-X
.	B-X
Introduction	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
identify	B-X
patients	B-X
with	B-X
malignant	B-X
hand	B-X
lesions	B-X
,	B-X
establish	B-X
the	B-X
proportions	B-X
of	B-X
those	B-X
that	B-X
were	B-X
metastases	B-X
and	B-X
review	B-X
their	B-X
clinical	B-X
course	B-X
.	B-X
Methods	B-X
A	B-X
retrospective	B-X
search	B-X
of	B-X
a	B-X
prospective	B-X
tumour	B-X
database	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
identify	B-X
all	B-X
patients	B-X
treated	B-X
at	B-X
our	B-X
unit	B-X
with	B-X
hand	B-X
metastases	B-X
.	B-X
Of	B-X
the	B-X
remaining	B-X
seven	B-X
patients	B-X
,	B-X
three	B-X
had	B-X
other	B-X
known	B-X
metastases	B-X
.	B-X
The	B-X
median	B-X
time	B-X
to	B-X
death	B-X
following	B-X
identification	B-X
of	B-X
acrometastases	B-X
was	B-X
18	B-X
months	B-X
.	B-X

RESULTS	O
:	O
The	O
percentage	O
of	O
patients	O
being	O
bone	O
metastases	O
free	O
at	O
12	O
mo	O
was	O
60	O
%	O
in	O
the	O
zoledronic	O
acid	O
and	O
10	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
,	O
while	O
the	O
percentages	O
at	O
18	O
mo	O
were	O
20	O
%	O
and	O
5	O
%	O
respectively	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
have	O
shown	O
that	O
bisphosphonates	O
as	O
adjuvant	O
treatment	O
might	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
bone	O
metastases	O
;	O
however	O
,	O
there	O
is	O
need	O
for	O
blinded	O
randomized	O
data	O
before	O
such	O
an	O
approach	O
would	O
be	O
confirmed	O
.	O
<EOS>	B-X
Bisphosphonates	B-X
have	B-X
been	B-X
used	B-X
successfully	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hypercalcemia	B-X
and	B-X
to	B-X
reduce	B-X
skeletal-related	B-X
complications	B-X
of	B-X
bone	B-X
metastases	B-X
.	B-X
This	B-X
is	B-X
a	B-X
randomized	B-X
,	B-X
open	B-X
label	B-X
,	B-X
prospective	B-X
study	B-X
that	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
preventive	B-X
zoledronic	B-X
acid	B-X
treatment	B-X
on	B-X
the	B-X
development	B-X
of	B-X
bone	B-X
metastases	B-X
in	B-X
patients	B-X
with	B-X
recurrent	B-X
solid	B-X
tumors	B-X
,	B-X
without	B-X
bone	B-X
metastases	B-X
at	B-X
the	B-X
time	B-X
of	B-X
randomization	B-X
.	B-X
Osteolytic	B-X
metastases	B-X
often	B-X
give	B-X
rise	B-X
to	B-X
hypercalcemia	B-X
,	B-X
fracture	B-X
,	B-X
and	B-X
bone	B-X
pain	B-X
,	B-X
and	B-X
occur	B-X
commonly	B-X
in	B-X
patients	B-X
with	B-X
recurrent	B-X
breast	B-X
cancer	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
bisphosphonate	B-X
,	B-X
clodronate	B-X
,	B-X
which	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
treatment	B-X
for	B-X
hypercalcemia	B-X
and	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tumor-induced	B-X
osteolysis	B-X
,	B-X
for	B-X
its	B-X
effect	B-X
on	B-X
reducing	B-X
the	B-X
osseous	B-X
complications	B-X
of	B-X
metastatic	B-X
breast	B-X
cancer	B-X
.	B-X

In	O
the	O
meantime	O
preventive	O
use	O
of	O
bisphosphonates	O
in	O
patients	O
without	O
any	O
bone	O
metastases	O
should	O
not	O
be	O
used	O
outside	O
the	O
scope	O
of	O
a	O
clinical	O
trial	O
.	O
<EOS>	B-X
Clodronate	B-X
(	B-X
clodronate	B-X
disodium	B-X
,	B-X
Bonefos	B-X
)	B-X
is	B-X
a	B-X
non-nitrogen-containing	B-X
bisphosphonate	B-X
that	B-X
inhibits	B-X
osteoclast	B-X
activity	B-X
,	B-X
and	B-X
thereby	B-X
inhibits	B-X
bone	B-X
resorption	B-X
.	B-X
Clodronate	B-X
has	B-X
been	B-X
extensively	B-X
used	B-X
in	B-X
patients	B-X
with	B-X
advanced	B-X
breast	B-X
cancer	B-X
,	B-X
and	B-X
is	B-X
generally	B-X
well	B-X
tolerated	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
primary	B-X
breast	B-X
cancer	B-X
,	B-X
clodronate	B-X
is	B-X
currently	B-X
the	B-X
only	B-X
bisphosphonate	B-X
shown	B-X
to	B-X
improve	B-X
survival	B-X
rates	B-X
and	B-X
to	B-X
reduce	B-X
the	B-X
incidence	B-X
of	B-X
bone	B-X
metastases	B-X
in	B-X
randomised	B-X
controlled	B-X
trials	B-X
.	B-X
Further	B-X
trials	B-X
in	B-X
patients	B-X
with	B-X
early	B-X
breast	B-X
cancer	B-X
are	B-X
warranted	B-X
to	B-X
confirm	B-X
results	B-X
to	B-X
date	B-X
and	B-X
to	B-X
determine	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
treatment	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
drug	B-X
compared	B-X
with	B-X
other	B-X
bisphosphonates	B-X
.	B-X
In	B-X
the	B-X
meantime	B-X
,	B-X
clodronate	B-X
is	B-X
a	B-X
well	B-X
established	B-X
bisphosphonate	B-X
which	B-X
has	B-X
shown	B-X
beneficial	B-X
effects	B-X
in	B-X
the	B-X
prevention	B-X
of	B-X
bone	B-X
metastases	B-X
and	B-X
on	B-X
survival	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
breast	B-X
cancer	B-X
.	B-X

Impaired	O
coronary	O
collateral	O
vessel	O
development	O
in	O
patients	O
with	O
proliferative	O
diabetic	O
retinopathy	O
.	O
<EOS>	B-X
Diabetic	B-X
patients	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
impaired	B-X
coronary	B-X
collateral	B-X
vessel	B-X
growth	B-X
,	B-X
although	B-X
they	B-X
have	B-X
excessive	B-X
neovascularization	B-X
in	B-X
the	B-X
retina	B-X
.	B-X

BACKGROUND	O
:	O
Diabetic	O
patients	O
have	O
been	O
reported	O
to	O
have	O
impaired	O
coronary	O
collateral	O
vessel	O
growth	O
,	O
although	O
they	O
have	O
excessive	O
neovascularization	O
in	O
the	O
retina	O
.	O
<EOS>	B-X
Diabetic	B-X
patients	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
impaired	B-X
coronary	B-X
collateral	B-X
vessel	B-X
growth	B-X
,	B-X
although	B-X
they	B-X
have	B-X
excessive	B-X
neovascularization	B-X
in	B-X
the	B-X
retina	B-X
.	B-X

HYPOTHESIS	O
:	O
This	O
study	O
was	O
designed	O
to	O
compare	O
coronary	O
collateral	O
circulation	O
(	O
CCC	O
)	O
in	O
patients	O
with	O
proliferative	O
diabetic	O
retinopathy	O
(	O
PDR	O
)	O
with	O
that	O
in	O
patients	O
without	O
DR	O
.	O
<EOS>	B-X
Diabetic	B-X
patients	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
impaired	B-X
coronary	B-X
collateral	B-X
vessel	B-X
growth	B-X
,	B-X
although	B-X
they	B-X
have	B-X
excessive	B-X
neovascularization	B-X
in	B-X
the	B-X
retina	B-X
.	B-X

METHODS	O
:	O
Ninety	O
diabetic	O
patients	O
with	O
chronic	O
total	O
occlusion	O
in	O
at	O
least	O
one	O
major	O
epicardial	O
coronary	O
artery	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Groups	O
1	O
and	O
2	O
consisted	O
of	O
48	O
patients	O
without	O
DR	O
and	O
42	O
patients	O
with	O
PDR	O
,	O
respectively	O
.	O
<EOS>	B-X
Diabetic	B-X
patients	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
impaired	B-X
coronary	B-X
collateral	B-X
vessel	B-X
growth	B-X
,	B-X
although	B-X
they	B-X
have	B-X
excessive	B-X
neovascularization	B-X
in	B-X
the	B-X
retina	B-X
.	B-X

Coronary	O
collateral	O
circulation	O
(	O
CCC	O
)	O
was	O
analyzed	O
according	O
to	O
the	O
Rentrop	O
system	O
.	O

Each	O
group	O
was	O
also	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
poor	O
and	O
good	O
CCC	O
.	O

Serum	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
levels	O
were	O
measured	O
using	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
.	O
<EOS>	B-X
Being	B-X
a	B-X
vascular	B-X
tumor	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
plays	B-X
a	B-X
vital	B-X
role	B-X
in	B-X
HCC	B-X
pathogenesis	B-X
,	B-X
growth	B-X
,	B-X
and	B-X
spread	B-X
.	B-X
Among	B-X
angiogenic	B-X
cytokines	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
levels	B-X
in	B-X
AD	B-X
patients	B-X
have	B-X
been	B-X
evaluated	B-X
,	B-X
but	B-X
the	B-X
results	B-X
are	B-X
controversial	B-X
among	B-X
studies	B-X
.	B-X
We	B-X
investigated	B-X
serum	B-X
levels	B-X
of	B-X
VEGF	B-X
in	B-X
AD	B-X
patients	B-X
with	B-X
depression	B-X
,	B-X
AD	B-X
patients	B-X
without	B-X
depression	B-X
,	B-X
and	B-X
the	B-X
controls	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
between	B-X
VEGF	B-X
,	B-X
depression	B-X
,	B-X
and	B-X
cognitive	B-X
impairment	B-X
in	B-X
AD	B-X
.	B-X

RESULTS	O
:	O
The	O
mean	O
Rentrop	O
collateral	O
score	O
was	O
higher	O
in	O
Group	O
1	O
than	O
in	O
Group	O
2	O
(	O
2	O
.	O
39	O
+	O
/	O
-	O
1	O
.	O
07	O
vs	O
.	O
1	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
76	O
,	O
respectively	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

When	O
the	O
two	O
groups	O
were	O
compared	O
with	O
respect	O
to	O
poor	O
and	O
good	O
CCC	O
,	O
poor	O
CCC	O
was	O
higher	O
in	O
patients	O
with	O
PDR	O
(	O
64	O
vs	O
.	O
36	O
%	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Serum	O
VEGF	B-Gene_or_gene_product
levels	O
were	O
higher	O
in	O
patients	O
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
(	O
219	O
+	O
/	O
-	O
99	O
vs	O
.	O
139	O
+	O
/	O
-	O
98	O
pg	O
/	O
ml	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
however	O
,	O
patients	O
with	O
poor	O
and	O
good	O
CCC	O
had	O
similar	O
VEGF	B-Gene_or_gene_product
levels	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
shown	O
that	O
patients	O
with	O
PDR	O
have	O
a	O
lower	O
coronary	O
collateral	O
score	O
than	O
patients	O
without	O
DR	O
.	O
<EOS>	B-X
Diabetic	B-X
patients	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
impaired	B-X
coronary	B-X
collateral	B-X
vessel	B-X
growth	B-X
,	B-X
although	B-X
they	B-X
have	B-X
excessive	B-X
neovascularization	B-X
in	B-X
the	B-X
retina	B-X
.	B-X

Also	O
,	O
serum	O
VEGF	B-Gene_or_gene_product
was	O
significantly	O
higher	O
in	O
patients	O
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
.	O
<EOS>	B-X
It	B-X
's	B-X
necessary	B-X
to	B-X
analyze	B-X
the	B-X
role	B-X
of	B-X
VEGF	B-X
,	B-X
apelin	B-X
,	B-X
and	B-X
HO-1	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
(	B-X
T2DM	B-X
)	B-X
,	B-X
and	B-X
to	B-X
evaluate	B-X
its	B-X
relevance	B-X
to	B-X
diabetic	B-X
retinopathy	B-X
(	B-X
DR	B-X
)	B-X
.	B-X
To	B-X
detect	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-26	B-X
in	B-X
diabetic	B-X
retinopathy	B-X
(	B-X
DR	B-X
)	B-X
patients	B-X
.	B-X
Hyperglycemia	B-X
induced	B-X
inflammation	B-X
and	B-X
angiogenic	B-X
factors	B-X
are	B-X
implicated	B-X
as	B-X
a	B-X
contributor	B-X
to	B-X
the	B-X
onset	B-X
and	B-X
progression	B-X
of	B-X
diabetic	B-X
retinopathy	B-X
(	B-X
DR	B-X
)	B-X
in	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
patients	B-X
(	B-X
T2DM	B-X
)	B-X
.	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
C-reactive	B-X
protein	B-X
(	B-X
CRP	B-X
)	B-X
are	B-X
inflammatory	B-X
cytokines	B-X
which	B-X
induce	B-X
retinal	B-X
VEGF	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
proliferative	B-X
diabetic	B-X
retinopathy	B-X
(	B-X
PDR	B-X
)	B-X
.	B-X
Therefore	B-X
the	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
relationship	B-X
between	B-X
diabetic	B-X
retinopathy	B-X
and	B-X
systemic	B-X
inflammation	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
.	B-X

These	O
findings	O
have	O
suggested	O
that	O
diabetes	O
mellitus	O
may	O
have	O
a	O
different	O
action	O
on	O
retinal	O
and	O
coronary	O
circulation	O
.	O
<EOS>	B-X
Diabetic	B-X
patients	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
impaired	B-X
coronary	B-X
collateral	B-X
vessel	B-X
growth	B-X
,	B-X
although	B-X
they	B-X
have	B-X
excessive	B-X
neovascularization	B-X
in	B-X
the	B-X
retina	B-X
.	B-X

VEGFR1	B-Gene_or_gene_product
-	O
positive	O
haematopoietic	O
bone	O
marrow	O
progenitors	O
initiate	O
the	O
pre	O
-	O
metastatic	O
niche	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

The	O
cellular	O
and	O
molecular	O
mechanisms	O
by	O
which	O
a	O
tumour	O
cell	O
undergoes	O
metastasis	O
to	O
a	O
predetermined	O
location	O
are	O
largely	O
unknown	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

Here	O
we	O
demonstrate	O
that	O
bone	O
marrow	O
-	O
derived	O
haematopoietic	O
progenitor	O
cells	O
that	O
express	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
VEGFR1	B-Gene_or_gene_product
;	O
also	O
known	O
as	O
Flt1	B-Gene_or_gene_product
)	O
home	O
to	O
tumour	O
-	O
specific	O
pre	O
-	O
metastatic	O
sites	O
and	O
form	O
cellular	O
clusters	O
before	O
the	O
arrival	O
of	O
tumour	O
cells	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

Preventing	O
VEGFR1	B-Gene_or_gene_product
function	O
using	O
antibodies	O
or	O
by	O
the	O
removal	O
of	O
VEGFR1	B-Gene_or_gene_product
(	O
+	O
)	O
cells	O
from	O
the	O
bone	O
marrow	O
of	O
wild	O
-	O
type	O
mice	O
abrogates	O
the	O
formation	O
of	O
these	O
pre	O
-	O
metastatic	O
clusters	O
and	O
prevents	O
tumour	O
metastasis	O
,	O
whereas	O
reconstitution	O
with	O
selected	O
Id3	B-Gene_or_gene_product
(	O
inhibitor	B-Gene_or_gene_product
of	I-Gene_or_gene_product
differentiation	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	O
-	O
competent	O
VEGFR1	B-Gene_or_gene_product
+	O
cells	O
establishes	O
cluster	O
formation	O
and	O
tumour	O
metastasis	O
in	O
Id3	B-Gene_or_gene_product
knockout	O
mice	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

We	O
also	O
show	O
that	O
VEGFR1	B-Gene_or_gene_product
+	O
cells	O
express	O
VLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	I-Gene_or_gene_product
(	O
also	O
known	O
as	O
integrin	B-Gene_or_gene_product
alpha4beta1	I-Gene_or_gene_product
)	O
,	O
and	O
that	O
tumour	O
-	O
specific	O
growth	O
factors	O
upregulate	O
fibronectin	B-Gene_or_gene_product
-	O
-	O
a	O
VLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	I-Gene_or_gene_product
ligand	O
-	O
-	O
in	O
resident	O
fibroblasts	O
,	O
providing	O
a	O
permissive	O
niche	O
for	O
incoming	O
tumour	O
cells	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

Conditioned	O
media	O
obtained	O
from	O
distinct	O
tumour	O
types	O
with	O
unique	O
patterns	O
of	O
metastatic	O
spread	O
redirected	O
fibronectin	B-Gene_or_gene_product
expression	O
and	O
cluster	O
formation	O
,	O
thereby	O
transforming	O
the	O
metastatic	O
profile	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

These	O
findings	O
demonstrate	O
a	O
requirement	O
for	O
VEGFR1	B-Gene_or_gene_product
+	O
haematopoietic	O
progenitors	O
in	O
the	O
regulation	O
of	O
metastasis	O
,	O
and	O
suggest	O
that	O
expression	O
patterns	O
of	O
fibronectin	B-Gene_or_gene_product
and	O
VEGFR1	B-Gene_or_gene_product
+	O
VLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	I-Gene_or_gene_product
+	O
clusters	O
dictate	O
organ	O
-	O
specific	O
tumour	O
spread	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
a	B-X
tumour	B-X
cell	B-X
undergoes	B-X
metastasis	B-X
to	B-X
a	B-X
predetermined	B-X
location	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
bone	B-X
marrow-derived	B-X
haematopoietic	B-X
progenitor	B-X
cells	B-X
that	B-X
express	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
VEGFR1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
Flt1	B-X
)	B-X
home	B-X
to	B-X
tumour-specific	B-X
pre-metastatic	B-X
sites	B-X
and	B-X
form	B-X
cellular	B-X
clusters	B-X
before	B-X
the	B-X
arrival	B-X
of	B-X
tumour	B-X
cells	B-X
.	B-X
Preventing	B-X
VEGFR1	B-X
function	B-X
using	B-X
antibodies	B-X
or	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
VEGFR1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
wild-type	B-X
mice	B-X
abrogates	B-X
the	B-X
formation	B-X
of	B-X
these	B-X
pre-metastatic	B-X
clusters	B-X
and	B-X
prevents	B-X
tumour	B-X
metastasis	B-X
,	B-X
whereas	B-X
reconstitution	B-X
with	B-X
selected	B-X
Id3	B-X
(	B-X
inhibitor	B-X
of	B-X
differentiation	B-X
3	B-X
)	B-X
-competent	B-X
VEGFR1+	B-X
cells	B-X
establishes	B-X
cluster	B-X
formation	B-X
and	B-X
tumour	B-X
metastasis	B-X
in	B-X
Id3	B-X
knockout	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
VEGFR1+	B-X
cells	B-X
express	B-X
VLA-4	B-X
(	B-X
also	B-X
known	B-X
as	B-X
integrin	B-X
alpha4beta1	B-X
)	B-X
,	B-X
and	B-X
that	B-X
tumour-specific	B-X
growth	B-X
factors	B-X
upregulate	B-X
fibronectin	B-X
--	B-X
a	B-X
VLA-4	B-X
ligand	B-X
--	B-X
in	B-X
resident	B-X
fibroblasts	B-X
,	B-X
providing	B-X
a	B-X
permissive	B-X
niche	B-X
for	B-X
incoming	B-X
tumour	B-X
cells	B-X
.	B-X
Conditioned	B-X
media	B-X
obtained	B-X
from	B-X
distinct	B-X
tumour	B-X
types	B-X
with	B-X
unique	B-X
patterns	B-X
of	B-X
metastatic	B-X
spread	B-X
redirected	B-X
fibronectin	B-X
expression	B-X
and	B-X
cluster	B-X
formation	B-X
,	B-X
thereby	B-X
transforming	B-X
the	B-X
metastatic	B-X
profile	B-X
.	B-X
These	B-X
findings	B-X
demonstrate	B-X
a	B-X
requirement	B-X
for	B-X
VEGFR1+	B-X
haematopoietic	B-X
progenitors	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
metastasis	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
expression	B-X
patterns	B-X
of	B-X
fibronectin	B-X
and	B-X
VEGFR1+VLA-4+	B-X
clusters	B-X
dictate	B-X
organ-specific	B-X
tumour	B-X
spread	B-X
.	B-X

The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
G	B-Gene_or_gene_product
protein	I-Gene_or_gene_product
-	I-Gene_or_gene_product
coupled	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
encodes	O
a	O
G	B-Gene_or_gene_product
protein	I-Gene_or_gene_product
-	I-Gene_or_gene_product
coupled	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
vGPCR	B-Gene_or_gene_product
)	O
that	O
has	O
been	O
implicated	O
in	O
the	O
initiation	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
,	O
identifying	O
vGPCR	B-Gene_or_gene_product
as	O
an	O
attractive	O
target	O
for	O
preventing	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

However	O
,	O
as	O
only	O
a	O
fraction	O
of	O
cells	O
in	O
advanced	O
Kaposi	O
'	O
s	O
sarcoma	O
lesions	O
express	O
vGPCR	B-Gene_or_gene_product
,	O
it	O
is	O
unclear	O
whether	O
this	O
unique	O
viral	O
oncogene	O
contributes	O
to	O
Kaposi	O
'	O
s	O
sarcoma	O
progression	O
.	O

We	O
therefore	O
set	O
out	O
to	O
determine	O
whether	O
the	O
few	O
cells	O
that	O
express	O
vGPCR	B-Gene_or_gene_product
in	O
established	O
tumors	O
represent	O
an	O
appropriate	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
preexisting	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

To	O
this	O
end	O
,	O
we	O
generated	O
endothelial	O
cell	O
lines	O
stably	O
expressing	O
vGPCR	B-Gene_or_gene_product
or	O
key	O
KSHV	O
latently	O
expressed	O
proteins	O
(	O
vCyclin	B-Gene_or_gene_product
,	O
vFlip	B-Gene_or_gene_product
,	O
and	O
LANA1	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

The	O
endothelial	O
cell	O
line	O
expressing	O
vGPCR	B-Gene_or_gene_product
was	O
rendered	O
sensitive	O
to	O
treatment	O
with	O
the	O
nucleoside	O
analogue	O
ganciclovir	O
by	O
using	O
a	O
bicistronic	O
construct	O
coexpressing	O
the	O
herpes	O
simplex	O
virus	O
1	O
thymidine	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

S	O
.	O
c	O
.	O
injection	O
into	O
nude	O
mice	O
with	O
mixed	O
-	O
cell	O
populations	O
formed	O
tumors	O
that	O
approximate	O
the	O
ratio	O
of	O
vGPCR	B-Gene_or_gene_product
-	O
expressing	O
and	O
KSHV	O
latent	O
gene	O
-	O
expressing	O
cells	O
.	O

These	O
mice	O
were	O
then	O
treated	O
with	O
ganciclovir	O
to	O
specifically	O
target	O
only	O
the	O
vGPCR	B-Gene_or_gene_product
-	O
expressing	O
cells	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

Surprisingly	O
,	O
despite	O
the	O
expression	O
of	O
KSHV	O
latent	O
genes	O
in	O
the	O
vast	O
majority	O
of	O
tumor	O
cells	O
,	O
specifically	O
targeting	O
only	O
the	O
few	O
vGPCR	B-Gene_or_gene_product
-	O
expressing	O
cells	O
in	O
established	O
tumors	O
resulted	O
in	O
tumor	O
regression	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
apoptosis	O
of	O
latent	O
gene	O
-	O
expressing	O
cells	O
after	O
the	O
pharmacologic	O
deletion	O
of	O
the	O
vGPCR	B-Gene_or_gene_product
-	O
expressing	O
cells	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

These	O
findings	O
indicate	O
that	O
vGPCR	B-Gene_or_gene_product
may	O
play	O
a	O
key	O
role	O
in	O
Kaposi	O
'	O
s	O
sarcoma	O
progression	O
and	O
provide	O
experimental	O
justification	O
for	O
developing	O
molecular	O
-	O
based	O
therapies	O
specifically	O
targeting	O
vGPCR	B-Gene_or_gene_product
and	O
its	O
effectors	O
for	O
the	O
treatment	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
patients	O
.	O
<EOS>	B-X
The	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
(	B-X
KSHV	B-X
)	B-X
encodes	B-X
a	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
(	B-X
vGPCR	B-X
)	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
,	B-X
identifying	B-X
vGPCR	B-X
as	B-X
an	B-X
attractive	B-X
target	B-X
for	B-X
preventing	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
However	B-X
,	B-X
as	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
in	B-X
advanced	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
lesions	B-X
express	B-X
vGPCR	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
this	B-X
unique	B-X
viral	B-X
oncogene	B-X
contributes	B-X
to	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
few	B-X
cells	B-X
that	B-X
express	B-X
vGPCR	B-X
in	B-X
established	B-X
tumors	B-X
represent	B-X
an	B-X
appropriate	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
preexisting	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
.	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
endothelial	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
vGPCR	B-X
or	B-X
key	B-X
KSHV	B-X
latently	B-X
expressed	B-X
proteins	B-X
(	B-X
vCyclin	B-X
,	B-X
vFlip	B-X
,	B-X
and	B-X
LANA1	B-X
)	B-X
.	B-X
The	B-X
endothelial	B-X
cell	B-X
line	B-X
expressing	B-X
vGPCR	B-X
was	B-X
rendered	B-X
sensitive	B-X
to	B-X
treatment	B-X
with	B-X
the	B-X
nucleoside	B-X
analogue	B-X
ganciclovir	B-X
by	B-X
using	B-X
a	B-X
bicistronic	B-X
construct	B-X
coexpressing	B-X
the	B-X
herpes	B-X
simplex	B-X
virus	B-X
1	B-X
thymidine	B-X
kinase	B-X
.	B-X
S.c.	B-X
injection	B-X
into	B-X
nude	B-X
mice	B-X
with	B-X
mixed-cell	B-X
populations	B-X
formed	B-X
tumors	B-X
that	B-X
approximate	B-X
the	B-X
ratio	B-X
of	B-X
vGPCR-expressing	B-X
and	B-X
KSHV	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
.	B-X
These	B-X
mice	B-X
were	B-X
then	B-X
treated	B-X
with	B-X
ganciclovir	B-X
to	B-X
specifically	B-X
target	B-X
only	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
the	B-X
expression	B-X
of	B-X
KSHV	B-X
latent	B-X
genes	B-X
in	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
specifically	B-X
targeting	B-X
only	B-X
the	B-X
few	B-X
vGPCR-expressing	B-X
cells	B-X
in	B-X
established	B-X
tumors	B-X
resulted	B-X
in	B-X
tumor	B-X
regression	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
observed	B-X
an	B-X
increase	B-X
in	B-X
apoptosis	B-X
of	B-X
latent	B-X
gene-expressing	B-X
cells	B-X
after	B-X
the	B-X
pharmacologic	B-X
deletion	B-X
of	B-X
the	B-X
vGPCR-expressing	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
vGPCR	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
progression	B-X
and	B-X
provide	B-X
experimental	B-X
justification	B-X
for	B-X
developing	B-X
molecular-based	B-X
therapies	B-X
specifically	B-X
targeting	B-X
vGPCR	B-X
and	B-X
its	B-X
effectors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
Kaposi	B-X
's	B-X
sarcoma	B-X
patients	B-X
.	B-X

Mechanisms	O
of	O
pericyte	O
recruitment	O
in	O
tumour	O
angiogenesis	O
:	O
a	O
new	O
role	O
for	O
metalloproteinases	B-Gene_or_gene_product
.	O
<EOS>	B-X
Pericytes	B-X
occur	B-X
in	B-X
tumour	B-X
blood	B-X
vessels	B-X
and	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
a	B-X
functional	B-X
vascular	B-X
network	B-X
.	B-X
Targeting	B-X
tumour	B-X
pericytes	B-X
is	B-X
a	B-X
promising	B-X
anti-angiogenic	B-X
therapy	B-X
but	B-X
requires	B-X
identifying	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
recruitment	B-X
in	B-X
tumour	B-X
and	B-X
addressing	B-X
whether	B-X
these	B-X
mechanisms	B-X
can	B-X
be	B-X
selectively	B-X
harnessed	B-X
.	B-X
Among	B-X
the	B-X
pathways	B-X
involved	B-X
in	B-X
pericyte	B-X
recruitment	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
B	B-X
and	B-X
sphingosine	B-X
1-phosphate	B-X
is	B-X
confirmed	B-X
in	B-X
tumour	B-X
angiogenesis	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
angiopoietin	B-X
1	B-X
depends	B-X
on	B-X
the	B-X
tumour	B-X
model	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta1	B-X
enhances	B-X
tumour	B-X
vascularization	B-X
and	B-X
microvessel	B-X
maturation	B-X
.	B-X
Recent	B-X
reports	B-X
suggest	B-X
a	B-X
participation	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
tumour	B-X
pericyte	B-X
recruitment	B-X
that	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
certain	B-X
MMPs	B-X
in	B-X
the	B-X
development	B-X
of	B-X
microvasculature	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
in	B-X
in	B-X
vitro	B-X
models	B-X
of	B-X
vascular	B-X
remodelling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
for	B-X
MMPs	B-X
to	B-X
contribute	B-X
to	B-X
pericyte	B-X
recruitment	B-X
at	B-X
six	B-X
levels	B-X
:	B-X
(	B-X
1	B-X
)	B-X
direct	B-X
promotion	B-X
of	B-X
pericyte	B-X
invasion	B-X
by	B-X
extracellular	B-X
matrix	B-X
degradation	B-X
;	B-X
(	B-X
2	B-X
)	B-X
stimulation	B-X
of	B-X
pericyte	B-X
proliferation	B-X
and	B-X
protection	B-X
against	B-X
apoptosis	B-X
by	B-X
modification	B-X
of	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
3	B-X
)	B-X
activation	B-X
of	B-X
pericytes	B-X
through	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factor	B-X
bound	B-X
to	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
4	B-X
)	B-X
transactivation	B-X
of	B-X
angiogenic	B-X
cell	B-X
surface	B-X
receptor	B-X
;	B-X
(	B-X
5	B-X
)	B-X
propagation	B-X
of	B-X
angiogenic	B-X
signalling	B-X
as	B-X
cofactor	B-X
;	B-X
and	B-X
(	B-X
6	B-X
)	B-X
recruitment	B-X
of	B-X
bone	B-X
marrow-derived	B-X
stem	B-X
cells	B-X
.	B-X

Pericytes	O
occur	O
in	O
tumour	O
blood	O
vessels	O
and	O
are	O
critical	O
for	O
the	O
development	O
of	O
a	O
functional	O
vascular	O
network	O
.	O
<EOS>	B-X
Microvascular	B-X
networks	B-X
are	B-X
vital	B-X
components	B-X
of	B-X
the	B-X
cardiovascular	B-X
system	B-X
,	B-X
performing	B-X
many	B-X
key	B-X
roles	B-X
in	B-X
maintaining	B-X
the	B-X
health	B-X
and	B-X
homeostasis	B-X
of	B-X
the	B-X
tissues	B-X
and	B-X
organs	B-X
in	B-X
which	B-X
they	B-X
develop	B-X
.	B-X
As	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
,	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
components	B-X
within	B-X
the	B-X
microcirculation	B-X
orchestrate	B-X
critical	B-X
processes	B-X
to	B-X
establish	B-X
functional	B-X
capillary	B-X
beds	B-X
,	B-X
including	B-X
organization	B-X
of	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
polarity	B-X
,	B-X
guiding	B-X
investment	B-X
of	B-X
vascular	B-X
pericytes	B-X
(	B-X
PCs	B-X
)	B-X
,	B-X
and	B-X
building	B-X
the	B-X
specialized	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
that	B-X
comprises	B-X
the	B-X
vascular	B-X
basement	B-X
membrane	B-X
(	B-X
vBM	B-X
)	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
further	B-X
discuss	B-X
the	B-X
unique	B-X
features	B-X
of	B-X
the	B-X
microvasculature	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
cells	B-X
contributing	B-X
to	B-X
the	B-X
neurovascular	B-X
unit	B-X
(	B-X
NVU	B-X
)	B-X
that	B-X
form	B-X
and	B-X
maintain	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
.	B-X
With	B-X
a	B-X
focus	B-X
on	B-X
vascular	B-X
PCs	B-X
,	B-X
we	B-X
offer	B-X
basic	B-X
and	B-X
clinical	B-X
perspectives	B-X
on	B-X
neurovascular-related	B-X
pathologies	B-X
that	B-X
involve	B-X
defects	B-X
within	B-X
the	B-X
cerebral	B-X
microvasculature	B-X
.	B-X
Specifically	B-X
,	B-X
we	B-X
present	B-X
microvascular	B-X
anomalies	B-X
associated	B-X
with	B-X
glioblastoma	B-X
multiforme	B-X
(	B-X
GBM	B-X
)	B-X
including	B-X
defects	B-X
in	B-X
vascular-immune	B-X
cell	B-X
interactions	B-X
and	B-X
associated	B-X
clinical	B-X
therapies	B-X
targeting	B-X
microvessels	B-X
(	B-X
ie	B-X
,	B-X
vascular-disrupting/anti-angiogenic	B-X
agents	B-X
and	B-X
focused	B-X
ultrasound	B-X
)	B-X
.	B-X
Our	B-X
goal	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
changes	B-X
that	B-X
occur	B-X
in	B-X
the	B-X
microvasculature	B-X
and	B-X
NVU	B-X
,	B-X
and	B-X
to	B-X
provide	B-X
a	B-X
commentary	B-X
on	B-X
factors	B-X
driving	B-X
disease	B-X
progression	B-X
in	B-X
GBM	B-X
and	B-X
stroke	B-X
.	B-X

Targeting	O
tumour	O
pericytes	O
is	O
a	O
promising	O
anti	O
-	O
angiogenic	O
therapy	O
but	O
requires	O
identifying	O
the	O
mechanisms	O
of	O
their	O
recruitment	O
in	O
tumour	O
and	O
addressing	O
whether	O
these	O
mechanisms	O
can	O
be	O
selectively	O
harnessed	O
.	O
<EOS>	B-X
Pericytes	B-X
occur	B-X
in	B-X
tumour	B-X
blood	B-X
vessels	B-X
and	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
a	B-X
functional	B-X
vascular	B-X
network	B-X
.	B-X
Targeting	B-X
tumour	B-X
pericytes	B-X
is	B-X
a	B-X
promising	B-X
anti-angiogenic	B-X
therapy	B-X
but	B-X
requires	B-X
identifying	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
recruitment	B-X
in	B-X
tumour	B-X
and	B-X
addressing	B-X
whether	B-X
these	B-X
mechanisms	B-X
can	B-X
be	B-X
selectively	B-X
harnessed	B-X
.	B-X
Among	B-X
the	B-X
pathways	B-X
involved	B-X
in	B-X
pericyte	B-X
recruitment	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
B	B-X
and	B-X
sphingosine	B-X
1-phosphate	B-X
is	B-X
confirmed	B-X
in	B-X
tumour	B-X
angiogenesis	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
angiopoietin	B-X
1	B-X
depends	B-X
on	B-X
the	B-X
tumour	B-X
model	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta1	B-X
enhances	B-X
tumour	B-X
vascularization	B-X
and	B-X
microvessel	B-X
maturation	B-X
.	B-X
Recent	B-X
reports	B-X
suggest	B-X
a	B-X
participation	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
tumour	B-X
pericyte	B-X
recruitment	B-X
that	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
certain	B-X
MMPs	B-X
in	B-X
the	B-X
development	B-X
of	B-X
microvasculature	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
in	B-X
in	B-X
vitro	B-X
models	B-X
of	B-X
vascular	B-X
remodelling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
for	B-X
MMPs	B-X
to	B-X
contribute	B-X
to	B-X
pericyte	B-X
recruitment	B-X
at	B-X
six	B-X
levels	B-X
:	B-X
(	B-X
1	B-X
)	B-X
direct	B-X
promotion	B-X
of	B-X
pericyte	B-X
invasion	B-X
by	B-X
extracellular	B-X
matrix	B-X
degradation	B-X
;	B-X
(	B-X
2	B-X
)	B-X
stimulation	B-X
of	B-X
pericyte	B-X
proliferation	B-X
and	B-X
protection	B-X
against	B-X
apoptosis	B-X
by	B-X
modification	B-X
of	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
3	B-X
)	B-X
activation	B-X
of	B-X
pericytes	B-X
through	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factor	B-X
bound	B-X
to	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
4	B-X
)	B-X
transactivation	B-X
of	B-X
angiogenic	B-X
cell	B-X
surface	B-X
receptor	B-X
;	B-X
(	B-X
5	B-X
)	B-X
propagation	B-X
of	B-X
angiogenic	B-X
signalling	B-X
as	B-X
cofactor	B-X
;	B-X
and	B-X
(	B-X
6	B-X
)	B-X
recruitment	B-X
of	B-X
bone	B-X
marrow-derived	B-X
stem	B-X
cells	B-X
.	B-X

Among	O
the	O
pathways	O
involved	O
in	O
pericyte	O
recruitment	O
during	O
embryonic	O
development	O
,	O
the	O
contribution	O
of	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
B	I-Gene_or_gene_product
and	O
sphingosine	B-Gene_or_gene_product
1	I-Gene_or_gene_product
-	I-Gene_or_gene_product
phosphate	I-Gene_or_gene_product
is	O
confirmed	O
in	O
tumour	O
angiogenesis	O
.	O
<EOS>	B-X
Pericytes	B-X
occur	B-X
in	B-X
tumour	B-X
blood	B-X
vessels	B-X
and	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
a	B-X
functional	B-X
vascular	B-X
network	B-X
.	B-X
Targeting	B-X
tumour	B-X
pericytes	B-X
is	B-X
a	B-X
promising	B-X
anti-angiogenic	B-X
therapy	B-X
but	B-X
requires	B-X
identifying	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
recruitment	B-X
in	B-X
tumour	B-X
and	B-X
addressing	B-X
whether	B-X
these	B-X
mechanisms	B-X
can	B-X
be	B-X
selectively	B-X
harnessed	B-X
.	B-X
Among	B-X
the	B-X
pathways	B-X
involved	B-X
in	B-X
pericyte	B-X
recruitment	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
B	B-X
and	B-X
sphingosine	B-X
1-phosphate	B-X
is	B-X
confirmed	B-X
in	B-X
tumour	B-X
angiogenesis	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
angiopoietin	B-X
1	B-X
depends	B-X
on	B-X
the	B-X
tumour	B-X
model	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta1	B-X
enhances	B-X
tumour	B-X
vascularization	B-X
and	B-X
microvessel	B-X
maturation	B-X
.	B-X
Recent	B-X
reports	B-X
suggest	B-X
a	B-X
participation	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
tumour	B-X
pericyte	B-X
recruitment	B-X
that	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
certain	B-X
MMPs	B-X
in	B-X
the	B-X
development	B-X
of	B-X
microvasculature	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
in	B-X
in	B-X
vitro	B-X
models	B-X
of	B-X
vascular	B-X
remodelling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
for	B-X
MMPs	B-X
to	B-X
contribute	B-X
to	B-X
pericyte	B-X
recruitment	B-X
at	B-X
six	B-X
levels	B-X
:	B-X
(	B-X
1	B-X
)	B-X
direct	B-X
promotion	B-X
of	B-X
pericyte	B-X
invasion	B-X
by	B-X
extracellular	B-X
matrix	B-X
degradation	B-X
;	B-X
(	B-X
2	B-X
)	B-X
stimulation	B-X
of	B-X
pericyte	B-X
proliferation	B-X
and	B-X
protection	B-X
against	B-X
apoptosis	B-X
by	B-X
modification	B-X
of	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
3	B-X
)	B-X
activation	B-X
of	B-X
pericytes	B-X
through	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factor	B-X
bound	B-X
to	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
4	B-X
)	B-X
transactivation	B-X
of	B-X
angiogenic	B-X
cell	B-X
surface	B-X
receptor	B-X
;	B-X
(	B-X
5	B-X
)	B-X
propagation	B-X
of	B-X
angiogenic	B-X
signalling	B-X
as	B-X
cofactor	B-X
;	B-X
and	B-X
(	B-X
6	B-X
)	B-X
recruitment	B-X
of	B-X
bone	B-X
marrow-derived	B-X
stem	B-X
cells	B-X
.	B-X

The	O
effect	O
of	O
angiopoietin	B-Gene_or_gene_product
1	I-Gene_or_gene_product
depends	O
on	O
the	O
tumour	O
model	O
.	O
<EOS>	B-X
We	B-X
have	B-X
observed	B-X
that	B-X
overexpression	B-X
of	B-X
angiopoietin-1	B-X
(	B-X
Ang1	B-X
)	B-X
in	B-X
both	B-X
subcutaneous	B-X
and	B-X
intracranial	B-X
xenograft	B-X
models	B-X
of	B-X
malignant	B-X
astrocytomas	B-X
reproduces	B-X
many	B-X
of	B-X
the	B-X
vascular	B-X
features	B-X
of	B-X
these	B-X
tumors	B-X
,	B-X
including	B-X
glomeruloid	B-X
bodies	B-X
.	B-X
To	B-X
confirm	B-X
that	B-X
the	B-X
formation	B-X
of	B-X
glomeruloid	B-X
bodies	B-X
was	B-X
directly	B-X
dependent	B-X
on	B-X
Ang1	B-X
,	B-X
we	B-X
performed	B-X
experiments	B-X
where	B-X
levels	B-X
of	B-X
Ang1	B-X
expression	B-X
were	B-X
regulated	B-X
under	B-X
tetracycline	B-X
control	B-X
,	B-X
and	B-X
we	B-X
found	B-X
a	B-X
direct	B-X
correlation	B-X
between	B-X
levels	B-X
of	B-X
Ang1	B-X
expression	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
glomeruloid	B-X
bodies	B-X
in	B-X
xenografts	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
inhibited	B-X
the	B-X
action	B-X
of	B-X
Ang1	B-X
by	B-X
blocking	B-X
its	B-X
cognate	B-X
receptor	B-X
Tie2	B-X
,	B-X
and	B-X
we	B-X
found	B-X
that	B-X
the	B-X
formation	B-X
of	B-X
glomeruloid	B-X
bodies	B-X
was	B-X
inhibited	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
support	B-X
our	B-X
hypothesis	B-X
that	B-X
Ang1	B-X
is	B-X
a	B-X
key	B-X
molecular	B-X
regulator	B-X
of	B-X
pathological	B-X
vascularization	B-X
characteristic	B-X
of	B-X
malignant	B-X
astrocytomas	B-X
.	B-X

Transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	I-Gene_or_gene_product
enhances	O
tumour	O
vascularization	O
and	O
microvessel	O
maturation	O
.	O
<EOS>	B-X
Pericytes	B-X
occur	B-X
in	B-X
tumour	B-X
blood	B-X
vessels	B-X
and	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
a	B-X
functional	B-X
vascular	B-X
network	B-X
.	B-X
Targeting	B-X
tumour	B-X
pericytes	B-X
is	B-X
a	B-X
promising	B-X
anti-angiogenic	B-X
therapy	B-X
but	B-X
requires	B-X
identifying	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
recruitment	B-X
in	B-X
tumour	B-X
and	B-X
addressing	B-X
whether	B-X
these	B-X
mechanisms	B-X
can	B-X
be	B-X
selectively	B-X
harnessed	B-X
.	B-X
Among	B-X
the	B-X
pathways	B-X
involved	B-X
in	B-X
pericyte	B-X
recruitment	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
B	B-X
and	B-X
sphingosine	B-X
1-phosphate	B-X
is	B-X
confirmed	B-X
in	B-X
tumour	B-X
angiogenesis	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
angiopoietin	B-X
1	B-X
depends	B-X
on	B-X
the	B-X
tumour	B-X
model	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta1	B-X
enhances	B-X
tumour	B-X
vascularization	B-X
and	B-X
microvessel	B-X
maturation	B-X
.	B-X
Recent	B-X
reports	B-X
suggest	B-X
a	B-X
participation	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
tumour	B-X
pericyte	B-X
recruitment	B-X
that	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
certain	B-X
MMPs	B-X
in	B-X
the	B-X
development	B-X
of	B-X
microvasculature	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
in	B-X
in	B-X
vitro	B-X
models	B-X
of	B-X
vascular	B-X
remodelling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
for	B-X
MMPs	B-X
to	B-X
contribute	B-X
to	B-X
pericyte	B-X
recruitment	B-X
at	B-X
six	B-X
levels	B-X
:	B-X
(	B-X
1	B-X
)	B-X
direct	B-X
promotion	B-X
of	B-X
pericyte	B-X
invasion	B-X
by	B-X
extracellular	B-X
matrix	B-X
degradation	B-X
;	B-X
(	B-X
2	B-X
)	B-X
stimulation	B-X
of	B-X
pericyte	B-X
proliferation	B-X
and	B-X
protection	B-X
against	B-X
apoptosis	B-X
by	B-X
modification	B-X
of	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
3	B-X
)	B-X
activation	B-X
of	B-X
pericytes	B-X
through	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factor	B-X
bound	B-X
to	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
4	B-X
)	B-X
transactivation	B-X
of	B-X
angiogenic	B-X
cell	B-X
surface	B-X
receptor	B-X
;	B-X
(	B-X
5	B-X
)	B-X
propagation	B-X
of	B-X
angiogenic	B-X
signalling	B-X
as	B-X
cofactor	B-X
;	B-X
and	B-X
(	B-X
6	B-X
)	B-X
recruitment	B-X
of	B-X
bone	B-X
marrow-derived	B-X
stem	B-X
cells	B-X
.	B-X

Recent	O
reports	O
suggest	O
a	O
participation	O
of	O
matrix	B-Gene_or_gene_product
metalloproteinases	I-Gene_or_gene_product
(	O
MMP	B-Gene_or_gene_product
)	O
in	O
tumour	O
pericyte	O
recruitment	O
that	O
is	O
consistent	O
with	O
the	O
effect	O
of	O
certain	O
MMPs	B-Gene_or_gene_product
in	O
the	O
development	O
of	O
microvasculature	O
in	O
embryonic	O
development	O
and	O
in	O
in	O
vitro	O
models	O
of	O
vascular	O
remodelling	O
.	O
<EOS>	B-X
Pericytes	B-X
occur	B-X
in	B-X
tumour	B-X
blood	B-X
vessels	B-X
and	B-X
are	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
a	B-X
functional	B-X
vascular	B-X
network	B-X
.	B-X
Targeting	B-X
tumour	B-X
pericytes	B-X
is	B-X
a	B-X
promising	B-X
anti-angiogenic	B-X
therapy	B-X
but	B-X
requires	B-X
identifying	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
recruitment	B-X
in	B-X
tumour	B-X
and	B-X
addressing	B-X
whether	B-X
these	B-X
mechanisms	B-X
can	B-X
be	B-X
selectively	B-X
harnessed	B-X
.	B-X
Among	B-X
the	B-X
pathways	B-X
involved	B-X
in	B-X
pericyte	B-X
recruitment	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
B	B-X
and	B-X
sphingosine	B-X
1-phosphate	B-X
is	B-X
confirmed	B-X
in	B-X
tumour	B-X
angiogenesis	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
angiopoietin	B-X
1	B-X
depends	B-X
on	B-X
the	B-X
tumour	B-X
model	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta1	B-X
enhances	B-X
tumour	B-X
vascularization	B-X
and	B-X
microvessel	B-X
maturation	B-X
.	B-X
Recent	B-X
reports	B-X
suggest	B-X
a	B-X
participation	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
tumour	B-X
pericyte	B-X
recruitment	B-X
that	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
certain	B-X
MMPs	B-X
in	B-X
the	B-X
development	B-X
of	B-X
microvasculature	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
in	B-X
in	B-X
vitro	B-X
models	B-X
of	B-X
vascular	B-X
remodelling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
for	B-X
MMPs	B-X
to	B-X
contribute	B-X
to	B-X
pericyte	B-X
recruitment	B-X
at	B-X
six	B-X
levels	B-X
:	B-X
(	B-X
1	B-X
)	B-X
direct	B-X
promotion	B-X
of	B-X
pericyte	B-X
invasion	B-X
by	B-X
extracellular	B-X
matrix	B-X
degradation	B-X
;	B-X
(	B-X
2	B-X
)	B-X
stimulation	B-X
of	B-X
pericyte	B-X
proliferation	B-X
and	B-X
protection	B-X
against	B-X
apoptosis	B-X
by	B-X
modification	B-X
of	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
3	B-X
)	B-X
activation	B-X
of	B-X
pericytes	B-X
through	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factor	B-X
bound	B-X
to	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
4	B-X
)	B-X
transactivation	B-X
of	B-X
angiogenic	B-X
cell	B-X
surface	B-X
receptor	B-X
;	B-X
(	B-X
5	B-X
)	B-X
propagation	B-X
of	B-X
angiogenic	B-X
signalling	B-X
as	B-X
cofactor	B-X
;	B-X
and	B-X
(	B-X
6	B-X
)	B-X
recruitment	B-X
of	B-X
bone	B-X
marrow-derived	B-X
stem	B-X
cells	B-X
.	B-X

Here	O
,	O
we	O
discuss	O
the	O
possibility	O
for	O
MMPs	B-Gene_or_gene_product
to	O
contribute	O
to	O
pericyte	O
recruitment	O
at	O
six	O
levels	O
:	O
(	O
1	O
)	O
direct	O
promotion	O
of	O
pericyte	O
invasion	O
by	O
extracellular	O
matrix	O
degradation	O
;	O
(	O
2	O
)	O
stimulation	O
of	O
pericyte	O
proliferation	O
and	O
protection	O
against	O
apoptosis	O
by	O
modification	O
of	O
the	O
ECM	O
;	O
(	O
3	O
)	O
activation	O
of	O
pericytes	O
through	O
the	O
release	O
of	O
growth	O
factor	O
bound	O
to	O
the	O
ECM	O
;	O
(	O
4	O
)	O
transactivation	O
of	O
angiogenic	O
cell	O
surface	O
receptor	O
;	O
(	O
5	O
)	O
propagation	O
of	O
angiogenic	O
signalling	O
as	O
cofactor	O
;	O
and	O
(	O
6	O
)	O
recruitment	O
of	O
bone	O
marrow	O
-	O
derived	O
stem	O
cells	O
.	O
<EOS>	B-X
Targeting	B-X
tumour	B-X
pericytes	B-X
is	B-X
a	B-X
promising	B-X
anti-angiogenic	B-X
therapy	B-X
but	B-X
requires	B-X
identifying	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
recruitment	B-X
in	B-X
tumour	B-X
and	B-X
addressing	B-X
whether	B-X
these	B-X
mechanisms	B-X
can	B-X
be	B-X
selectively	B-X
harnessed	B-X
.	B-X
Among	B-X
the	B-X
pathways	B-X
involved	B-X
in	B-X
pericyte	B-X
recruitment	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
B	B-X
and	B-X
sphingosine	B-X
1-phosphate	B-X
is	B-X
confirmed	B-X
in	B-X
tumour	B-X
angiogenesis	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
angiopoietin	B-X
1	B-X
depends	B-X
on	B-X
the	B-X
tumour	B-X
model	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta1	B-X
enhances	B-X
tumour	B-X
vascularization	B-X
and	B-X
microvessel	B-X
maturation	B-X
.	B-X
Recent	B-X
reports	B-X
suggest	B-X
a	B-X
participation	B-X
of	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP	B-X
)	B-X
in	B-X
tumour	B-X
pericyte	B-X
recruitment	B-X
that	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
certain	B-X
MMPs	B-X
in	B-X
the	B-X
development	B-X
of	B-X
microvasculature	B-X
in	B-X
embryonic	B-X
development	B-X
and	B-X
in	B-X
in	B-X
vitro	B-X
models	B-X
of	B-X
vascular	B-X
remodelling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
for	B-X
MMPs	B-X
to	B-X
contribute	B-X
to	B-X
pericyte	B-X
recruitment	B-X
at	B-X
six	B-X
levels	B-X
:	B-X
(	B-X
1	B-X
)	B-X
direct	B-X
promotion	B-X
of	B-X
pericyte	B-X
invasion	B-X
by	B-X
extracellular	B-X
matrix	B-X
degradation	B-X
;	B-X
(	B-X
2	B-X
)	B-X
stimulation	B-X
of	B-X
pericyte	B-X
proliferation	B-X
and	B-X
protection	B-X
against	B-X
apoptosis	B-X
by	B-X
modification	B-X
of	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
3	B-X
)	B-X
activation	B-X
of	B-X
pericytes	B-X
through	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factor	B-X
bound	B-X
to	B-X
the	B-X
ECM	B-X
;	B-X
(	B-X
4	B-X
)	B-X
transactivation	B-X
of	B-X
angiogenic	B-X
cell	B-X
surface	B-X
receptor	B-X
;	B-X
(	B-X
5	B-X
)	B-X
propagation	B-X
of	B-X
angiogenic	B-X
signalling	B-X
as	B-X
cofactor	B-X
;	B-X
and	B-X
(	B-X
6	B-X
)	B-X
recruitment	B-X
of	B-X
bone	B-X
marrow-derived	B-X
stem	B-X
cells	B-X
.	B-X

Sensitization	O
to	O
gimatecan	O
-	O
induced	O
apoptosis	O
by	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
apoptosis	I-Gene_or_gene_product
inducing	I-Gene_or_gene_product
ligand	I-Gene_or_gene_product
in	O
prostate	O
carcinoma	O
cells	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X

Since	O
the	O
intrinsic	O
resistance	O
of	O
prostate	O
carcinoma	O
likely	O
reflects	O
a	O
low	O
susceptibility	O
to	O
drug	O
-	O
induced	O
apoptosis	O
,	O
in	O
this	O
study	O
we	O
explored	O
the	O
possibility	O
of	O
sensitizing	O
prostate	O
carcinoma	O
cells	O
to	O
apoptosis	O
by	O
combination	O
of	O
TRAIL	B-Gene_or_gene_product
with	O
camptothecins	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signals	B-X
could	B-X
enhance	B-X
apoptotic	B-X
response	B-X
and	B-X
suggest	B-X
the	B-X
therapeutic	B-X
interest	B-X
of	B-X
the	B-X
TRAIL/camptothecin	B-X
combination	B-X
.	B-X

Indeed	O
,	O
these	O
agents	O
are	O
known	O
to	O
activate	O
different	O
pathways	O
of	O
apoptosis	O
.	O
<EOS>	B-X
Natural	B-X
retinoids	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
physiology	B-X
of	B-X
vision	B-X
and	B-X
as	B-X
morphogenic	B-X
agents	B-X
during	B-X
embryonic	B-X
development	B-X
;	B-X
they	B-X
are	B-X
also	B-X
known	B-X
to	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
normal	B-X
and	B-X
malignant	B-X
cell	B-X
types	B-X
,	B-X
and	B-X
,	B-X
indeed	B-X
,	B-X
they	B-X
can	B-X
in	B-X
various	B-X
ways	B-X
inhibit	B-X
cell	B-X
proliferation	B-X
,	B-X
induce	B-X
differentiation	B-X
and	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
The	B-X
development	B-X
of	B-X
new	B-X
active	B-X
retinoids	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
distinct	B-X
families	B-X
of	B-X
retinoid	B-X
receptors	B-X
has	B-X
led	B-X
to	B-X
an	B-X
increased	B-X
understanding	B-X
of	B-X
the	B-X
cellular	B-X
effects	B-X
of	B-X
activation	B-X
of	B-X
these	B-X
receptors	B-X
and	B-X
of	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
retinoid-induced	B-X
apoptosis	B-X
.	B-X
In	B-X
this	B-X
review	B-X
a	B-X
brief	B-X
summary	B-X
of	B-X
cellular	B-X
pathways	B-X
relevant	B-X
to	B-X
programmed	B-X
cell	B-X
death	B-X
is	B-X
given	B-X
together	B-X
with	B-X
therapeutic	B-X
potentialities	B-X
of	B-X
retinoids	B-X
having	B-X
apoptotic	B-X
activity	B-X
.	B-X
Structure-activity	B-X
relationship	B-X
studies	B-X
concerning	B-X
the	B-X
importance	B-X
of	B-X
different	B-X
stereochemistry	B-X
at	B-X
the	B-X
C9	B-X
double	B-X
bond	B-X
of	B-X
retinoids	B-X
in	B-X
conferring	B-X
apoptotic	B-X
activity	B-X
will	B-X
be	B-X
described	B-X
.	B-X

Topotecan	O
-	O
and	O
gimatecan	O
induced	O
moderate	O
up	O
-	O
regulation	O
of	O
TRAIL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R1	I-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
R2	I-Gene_or_gene_product
which	O
resulted	O
in	O
a	O
different	O
cell	O
response	O
to	O
the	O
combination	O
in	O
androgen	O
-	O
independent	O
cells	O
(	O
DU	O
-	O
145	O
and	O
PC	O
-	O
3	O
)	O
.	O

In	O
DU	O
-	O
145	O
cells	O
apoptosis	O
was	O
increased	O
by	O
lower	O
TRAIL	B-Gene_or_gene_product
concentrations	O
and	O
was	O
earlier	O
than	O
in	O
PC	O
-	O
3	O
cells	O
,	O
as	O
shown	O
using	O
Annexin	B-Gene_or_gene_product
V	I-Gene_or_gene_product
-	O
binding	O
assay	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signals	B-X
could	B-X
enhance	B-X
apoptotic	B-X
response	B-X
and	B-X
suggest	B-X
the	B-X
therapeutic	B-X
interest	B-X
of	B-X
the	B-X
TRAIL/camptothecin	B-X
combination	B-X
.	B-X

The	O
relative	O
resistance	O
of	O
PC	O
-	O
3	O
cells	O
to	O
drug	O
-	O
induced	O
apoptosis	O
was	O
associated	O
with	O
constitutive	O
Akt	B-Gene_or_gene_product
activation	O
,	O
higher	O
levels	O
of	O
cFLIP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
L	I-Gene_or_gene_product
and	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
and	O
lower	O
levels	O
of	O
Bax	B-Gene_or_gene_product
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signals	B-X
could	B-X
enhance	B-X
apoptotic	B-X
response	B-X
and	B-X
suggest	B-X
the	B-X
therapeutic	B-X
interest	B-X
of	B-X
the	B-X
TRAIL/camptothecin	B-X
combination	B-X
.	B-X

The	O
different	O
expression	O
/	O
activation	O
of	O
apoptosis	O
-	O
related	O
factors	O
appears	O
to	O
influence	O
the	O
sensitization	O
of	O
prostate	O
carcinoma	O
cells	O
by	O
TRAIL	B-Gene_or_gene_product
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signals	B-X
could	B-X
enhance	B-X
apoptotic	B-X
response	B-X
and	B-X
suggest	B-X
the	B-X
therapeutic	B-X
interest	B-X
of	B-X
the	B-X
TRAIL/camptothecin	B-X
combination	B-X
.	B-X

Potentiation	O
of	O
camptothecin	O
-	O
induced	O
apoptosis	O
by	O
TRAIL	B-Gene_or_gene_product
appears	O
dependent	O
on	O
cooperation	O
between	O
extrinsic	O
and	O
intrinsic	O
pathways	O
,	O
as	O
documented	O
by	O
loss	O
of	O
the	O
sensitization	O
to	O
apoptosis	O
following	O
reduction	O
of	O
caspase	B-Gene_or_gene_product
8	I-Gene_or_gene_product
after	O
small	O
interfering	O
RNA	O
transfection	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signals	B-X
could	B-X
enhance	B-X
apoptotic	B-X
response	B-X
and	B-X
suggest	B-X
the	B-X
therapeutic	B-X
interest	B-X
of	B-X
the	B-X
TRAIL/camptothecin	B-X
combination	B-X
.	B-X

The	O
efficacy	O
of	O
the	O
approach	O
may	O
be	O
critically	O
dependent	O
on	O
the	O
intrinsic	O
susceptibility	O
to	O
apoptosis	O
of	O
different	O
tumors	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Indeed	B-X
,	B-X
these	B-X
agents	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
different	B-X
pathways	B-X
of	B-X
apoptosis	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
the	B-X
approach	B-X
may	B-X
be	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
intrinsic	B-X
susceptibility	B-X
to	B-X
apoptosis	B-X
of	B-X
different	B-X
tumors	B-X
.	B-X

These	O
observations	O
support	O
that	O
the	O
activation	O
of	O
multiple	O
signals	O
could	O
enhance	O
apoptotic	O
response	O
and	O
suggest	O
the	O
therapeutic	O
interest	O
of	O
the	O
TRAIL	B-Gene_or_gene_product
/	O
camptothecin	O
combination	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
intrinsic	B-X
resistance	B-X
of	B-X
prostate	B-X
carcinoma	B-X
likely	B-X
reflects	B-X
a	B-X
low	B-X
susceptibility	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
sensitizing	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
to	B-X
apoptosis	B-X
by	B-X
combination	B-X
of	B-X
TRAIL	B-X
with	B-X
camptothecins	B-X
.	B-X
Topotecan-	B-X
and	B-X
gimatecan	B-X
induced	B-X
moderate	B-X
up-regulation	B-X
of	B-X
TRAIL-R1	B-X
and	B-X
-R2	B-X
which	B-X
resulted	B-X
in	B-X
a	B-X
different	B-X
cell	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
in	B-X
androgen-independent	B-X
cells	B-X
(	B-X
DU-145	B-X
and	B-X
PC-3	B-X
)	B-X
.	B-X
In	B-X
DU-145	B-X
cells	B-X
apoptosis	B-X
was	B-X
increased	B-X
by	B-X
lower	B-X
TRAIL	B-X
concentrations	B-X
and	B-X
was	B-X
earlier	B-X
than	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
as	B-X
shown	B-X
using	B-X
Annexin	B-X
V-binding	B-X
assay	B-X
.	B-X
The	B-X
relative	B-X
resistance	B-X
of	B-X
PC-3	B-X
cells	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
was	B-X
associated	B-X
with	B-X
constitutive	B-X
Akt	B-X
activation	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
cFLIP-L	B-X
and	B-X
Bcl-2	B-X
,	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
Bax	B-X
.	B-X
The	B-X
different	B-X
expression/activation	B-X
of	B-X
apoptosis-related	B-X
factors	B-X
appears	B-X
to	B-X
influence	B-X
the	B-X
sensitization	B-X
of	B-X
prostate	B-X
carcinoma	B-X
cells	B-X
by	B-X
TRAIL	B-X
.	B-X
Potentiation	B-X
of	B-X
camptothecin-induced	B-X
apoptosis	B-X
by	B-X
TRAIL	B-X
appears	B-X
dependent	B-X
on	B-X
cooperation	B-X
between	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
pathways	B-X
,	B-X
as	B-X
documented	B-X
by	B-X
loss	B-X
of	B-X
the	B-X
sensitization	B-X
to	B-X
apoptosis	B-X
following	B-X
reduction	B-X
of	B-X
caspase	B-X
8	B-X
after	B-X
small	B-X
interfering	B-X
RNA	B-X
transfection	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signals	B-X
could	B-X
enhance	B-X
apoptotic	B-X
response	B-X
and	B-X
suggest	B-X
the	B-X
therapeutic	B-X
interest	B-X
of	B-X
the	B-X
TRAIL/camptothecin	B-X
combination	B-X
.	B-X

c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
expression	O
is	O
regulated	O
by	O
Mitf	B-Gene_or_gene_product
in	O
the	O
melanocyte	O
lineage	O
.	O
<EOS>	B-X
Hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
/c-Met	B-X
signaling	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
key	B-X
pathway	B-X
in	B-X
both	B-X
melanocyte	B-X
development	B-X
and	B-X
melanoma	B-X
metastasis	B-X
.	B-X
Here	B-X
,	B-X
HGF	B-X
stimulation	B-X
of	B-X
melanocytes	B-X
was	B-X
seen	B-X
to	B-X
up-regulate	B-X
c-Met	B-X
expression	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
decipher	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
HGF	B-X
up-regulates	B-X
its	B-X
receptor	B-X
,	B-X
we	B-X
found	B-X
that	B-X
c-Met	B-X
is	B-X
a	B-X
direct	B-X
transcriptional	B-X
target	B-X
of	B-X
Mitf	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
with	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
of	B-X
the	B-X
human	B-X
c-Met	B-X
promoter	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
adenovirally	B-X
expressed	B-X
Mitf	B-X
to	B-X
modulate	B-X
endogenous	B-X
c-Met	B-X
protein	B-X
levels	B-X
in	B-X
melanocytes	B-X
.	B-X
Disruption	B-X
of	B-X
Mitf	B-X
blocked	B-X
HGF-dependent	B-X
increases	B-X
in	B-X
endogenous	B-X
c-Met	B-X
message	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
indicating	B-X
that	B-X
HGF	B-X
regulates	B-X
its	B-X
own	B-X
receptor	B-X
levels	B-X
via	B-X
Mitf	B-X
.	B-X
Finally	B-X
,	B-X
dominant-negative	B-X
inhibition	B-X
of	B-X
Mitf	B-X
resulted	B-X
in	B-X
profound	B-X
resistance	B-X
of	B-X
melanocytes	B-X
and	B-X
melanoma	B-X
cells	B-X
to	B-X
HGF-dependent	B-X
matrix	B-X
invasion	B-X
,	B-X
suggesting	B-X
a	B-X
physiologic	B-X
role	B-X
for	B-X
this	B-X
pathway	B-X
in	B-X
melanocytic	B-X
development	B-X
and	B-X
melanoma	B-X
.	B-X

Hepatocyte	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
HGF	B-Gene_or_gene_product
)	O
/	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
signaling	O
is	O
thought	O
to	O
be	O
a	O
key	O
pathway	O
in	O
both	O
melanocyte	O
development	O
and	O
melanoma	O
metastasis	O
.	O
<EOS>	B-X
Hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
/c-Met	B-X
signaling	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
key	B-X
pathway	B-X
in	B-X
both	B-X
melanocyte	B-X
development	B-X
and	B-X
melanoma	B-X
metastasis	B-X
.	B-X
Here	B-X
,	B-X
HGF	B-X
stimulation	B-X
of	B-X
melanocytes	B-X
was	B-X
seen	B-X
to	B-X
up-regulate	B-X
c-Met	B-X
expression	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
decipher	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
HGF	B-X
up-regulates	B-X
its	B-X
receptor	B-X
,	B-X
we	B-X
found	B-X
that	B-X
c-Met	B-X
is	B-X
a	B-X
direct	B-X
transcriptional	B-X
target	B-X
of	B-X
Mitf	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
with	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
of	B-X
the	B-X
human	B-X
c-Met	B-X
promoter	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
adenovirally	B-X
expressed	B-X
Mitf	B-X
to	B-X
modulate	B-X
endogenous	B-X
c-Met	B-X
protein	B-X
levels	B-X
in	B-X
melanocytes	B-X
.	B-X
Disruption	B-X
of	B-X
Mitf	B-X
blocked	B-X
HGF-dependent	B-X
increases	B-X
in	B-X
endogenous	B-X
c-Met	B-X
message	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
indicating	B-X
that	B-X
HGF	B-X
regulates	B-X
its	B-X
own	B-X
receptor	B-X
levels	B-X
via	B-X
Mitf	B-X
.	B-X
Finally	B-X
,	B-X
dominant-negative	B-X
inhibition	B-X
of	B-X
Mitf	B-X
resulted	B-X
in	B-X
profound	B-X
resistance	B-X
of	B-X
melanocytes	B-X
and	B-X
melanoma	B-X
cells	B-X
to	B-X
HGF-dependent	B-X
matrix	B-X
invasion	B-X
,	B-X
suggesting	B-X
a	B-X
physiologic	B-X
role	B-X
for	B-X
this	B-X
pathway	B-X
in	B-X
melanocytic	B-X
development	B-X
and	B-X
melanoma	B-X
.	B-X

Here	O
,	O
HGF	B-Gene_or_gene_product
stimulation	O
of	O
melanocytes	O
was	O
seen	O
to	O
up	O
-	O
regulate	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
The	B-X
MET	B-X
proto-oncogene	B-X
encodes	B-X
for	B-X
the	B-X
hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
receptor	B-X
,	B-X
a	B-X
plasma	B-X
membrane	B-X
tyrosine	B-X
kinase	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
melanocyte	B-X
growth	B-X
and	B-X
melanoma	B-X
development	B-X
.	B-X
In	B-X
mouse	B-X
melanoma	B-X
cells	B-X
,	B-X
Met	B-X
expression	B-X
is	B-X
increased	B-X
by	B-X
alphaMSH	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cAMP	B-X
pathway	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
cAMP	B-X
regulates	B-X
MET	B-X
and	B-X
the	B-X
biological	B-X
consequences	B-X
of	B-X
this	B-X
increase	B-X
were	B-X
not	B-X
known	B-X
.	B-X
In	B-X
the	B-X
present	B-X
report	B-X
,	B-X
we	B-X
show	B-X
that	B-X
alphaMSH	B-X
regulates	B-X
MET	B-X
expression	B-X
in	B-X
both	B-X
human	B-X
melanocytes	B-X
and	B-X
mouse	B-X
melanoma	B-X
cells	B-X
through	B-X
a	B-X
transcriptional	B-X
mechanism	B-X
that	B-X
requires	B-X
MITF	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
adenovirus	B-X
driven	B-X
expression	B-X
of	B-X
MITF	B-X
is	B-X
sufficient	B-X
to	B-X
increase	B-X
MET	B-X
in	B-X
melanoma	B-X
cells	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
the	B-X
MET	B-X
promoter	B-X
allows	B-X
us	B-X
to	B-X
identify	B-X
an	B-X
E-box	B-X
motif	B-X
conserved	B-X
in	B-X
both	B-X
human	B-X
and	B-X
mouse	B-X
promoter	B-X
that	B-X
mediates	B-X
the	B-X
effect	B-X
of	B-X
MITF	B-X
.	B-X
Interestingly	B-X
,	B-X
up-regulation	B-X
of	B-X
MET	B-X
expression	B-X
by	B-X
cAMP	B-X
leads	B-X
to	B-X
an	B-X
exacerbated	B-X
HGF	B-X
signaling	B-X
and	B-X
allows	B-X
HGF	B-X
to	B-X
protect	B-X
melanocytes	B-X
and	B-X
melanoma	B-X
cells	B-X
from	B-X
apoptosis	B-X
.	B-X
Thus	B-X
,	B-X
physiological	B-X
stimuli	B-X
or	B-X
pathological	B-X
events	B-X
that	B-X
would	B-X
induce	B-X
MITF	B-X
expression	B-X
may	B-X
lead	B-X
to	B-X
increased	B-X
MET	B-X
expression	B-X
thereby	B-X
favoring	B-X
melanoma	B-X
survival	B-X
.	B-X

In	O
an	O
effort	O
to	O
decipher	O
the	O
mechanism	O
by	O
which	O
HGF	B-Gene_or_gene_product
up	O
-	O
regulates	O
its	O
receptor	O
,	O
we	O
found	O
that	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
is	O
a	O
direct	O
transcriptional	O
target	O
of	O
Mitf	B-Gene_or_gene_product
.	O

This	O
was	O
confirmed	O
with	O
chromatin	O
immunoprecipitation	O
experiments	O
of	O
the	O
human	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
promoter	O
,	O
as	O
well	O
as	O
by	O
the	O
ability	O
of	O
adenovirally	O
expressed	O
Mitf	B-Gene_or_gene_product
to	O
modulate	O
endogenous	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
protein	O
levels	O
in	O
melanocytes	O
.	O

Disruption	O
of	O
Mitf	B-Gene_or_gene_product
blocked	O
HGF	B-Gene_or_gene_product
-	O
dependent	O
increases	O
in	O
endogenous	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Met	I-Gene_or_gene_product
message	O
and	O
protein	O
levels	O
,	O
indicating	O
that	O
HGF	B-Gene_or_gene_product
regulates	O
its	O
own	O
receptor	O
levels	O
via	O
Mitf	B-Gene_or_gene_product
.	O
<EOS>	B-X
Hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
/c-Met	B-X
signaling	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
key	B-X
pathway	B-X
in	B-X
both	B-X
melanocyte	B-X
development	B-X
and	B-X
melanoma	B-X
metastasis	B-X
.	B-X
Here	B-X
,	B-X
HGF	B-X
stimulation	B-X
of	B-X
melanocytes	B-X
was	B-X
seen	B-X
to	B-X
up-regulate	B-X
c-Met	B-X
expression	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
decipher	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
HGF	B-X
up-regulates	B-X
its	B-X
receptor	B-X
,	B-X
we	B-X
found	B-X
that	B-X
c-Met	B-X
is	B-X
a	B-X
direct	B-X
transcriptional	B-X
target	B-X
of	B-X
Mitf	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
with	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
of	B-X
the	B-X
human	B-X
c-Met	B-X
promoter	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
adenovirally	B-X
expressed	B-X
Mitf	B-X
to	B-X
modulate	B-X
endogenous	B-X
c-Met	B-X
protein	B-X
levels	B-X
in	B-X
melanocytes	B-X
.	B-X
Disruption	B-X
of	B-X
Mitf	B-X
blocked	B-X
HGF-dependent	B-X
increases	B-X
in	B-X
endogenous	B-X
c-Met	B-X
message	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
indicating	B-X
that	B-X
HGF	B-X
regulates	B-X
its	B-X
own	B-X
receptor	B-X
levels	B-X
via	B-X
Mitf	B-X
.	B-X
Finally	B-X
,	B-X
dominant-negative	B-X
inhibition	B-X
of	B-X
Mitf	B-X
resulted	B-X
in	B-X
profound	B-X
resistance	B-X
of	B-X
melanocytes	B-X
and	B-X
melanoma	B-X
cells	B-X
to	B-X
HGF-dependent	B-X
matrix	B-X
invasion	B-X
,	B-X
suggesting	B-X
a	B-X
physiologic	B-X
role	B-X
for	B-X
this	B-X
pathway	B-X
in	B-X
melanocytic	B-X
development	B-X
and	B-X
melanoma	B-X
.	B-X

Finally	O
,	O
dominant	O
-	O
negative	O
inhibition	O
of	O
Mitf	B-Gene_or_gene_product
resulted	O
in	O
profound	O
resistance	O
of	O
melanocytes	O
and	O
melanoma	O
cells	O
to	O
HGF	B-Gene_or_gene_product
-	O
dependent	O
matrix	O
invasion	O
,	O
suggesting	O
a	O
physiologic	O
role	O
for	O
this	O
pathway	O
in	O
melanocytic	O
development	O
and	O
melanoma	O
.	O
<EOS>	B-X
Hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
/c-Met	B-X
signaling	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
key	B-X
pathway	B-X
in	B-X
both	B-X
melanocyte	B-X
development	B-X
and	B-X
melanoma	B-X
metastasis	B-X
.	B-X
Here	B-X
,	B-X
HGF	B-X
stimulation	B-X
of	B-X
melanocytes	B-X
was	B-X
seen	B-X
to	B-X
up-regulate	B-X
c-Met	B-X
expression	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
decipher	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
HGF	B-X
up-regulates	B-X
its	B-X
receptor	B-X
,	B-X
we	B-X
found	B-X
that	B-X
c-Met	B-X
is	B-X
a	B-X
direct	B-X
transcriptional	B-X
target	B-X
of	B-X
Mitf	B-X
.	B-X
This	B-X
was	B-X
confirmed	B-X
with	B-X
chromatin	B-X
immunoprecipitation	B-X
experiments	B-X
of	B-X
the	B-X
human	B-X
c-Met	B-X
promoter	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
adenovirally	B-X
expressed	B-X
Mitf	B-X
to	B-X
modulate	B-X
endogenous	B-X
c-Met	B-X
protein	B-X
levels	B-X
in	B-X
melanocytes	B-X
.	B-X
Disruption	B-X
of	B-X
Mitf	B-X
blocked	B-X
HGF-dependent	B-X
increases	B-X
in	B-X
endogenous	B-X
c-Met	B-X
message	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
indicating	B-X
that	B-X
HGF	B-X
regulates	B-X
its	B-X
own	B-X
receptor	B-X
levels	B-X
via	B-X
Mitf	B-X
.	B-X
Finally	B-X
,	B-X
dominant-negative	B-X
inhibition	B-X
of	B-X
Mitf	B-X
resulted	B-X
in	B-X
profound	B-X
resistance	B-X
of	B-X
melanocytes	B-X
and	B-X
melanoma	B-X
cells	B-X
to	B-X
HGF-dependent	B-X
matrix	B-X
invasion	B-X
,	B-X
suggesting	B-X
a	B-X
physiologic	B-X
role	B-X
for	B-X
this	B-X
pathway	B-X
in	B-X
melanocytic	B-X
development	B-X
and	B-X
melanoma	B-X
.	B-X

Targeting	O
PIM	O
kinases	O
impairs	O
survival	O
of	O
hematopoietic	O
cells	O
transformed	O
by	O
kinase	O
inhibitor	O
-	O
sensitive	O
and	O
kinase	O
inhibitor	O
-	O
resistant	O
forms	O
of	O
Fms	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
3	I-Gene_or_gene_product
and	O
BCR	B-Gene_or_gene_product
/	O
ABL	B-Gene_or_gene_product
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Previous	O
studies	O
have	O
shown	O
that	O
activation	O
of	O
the	O
signal	B-Gene_or_gene_product
transducer	I-Gene_or_gene_product
and	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
of	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
5	I-Gene_or_gene_product
(	O
STAT5	B-Gene_or_gene_product
)	O
plays	O
an	O
essential	O
role	O
in	O
leukemogenesis	O
mediated	O
through	O
constitutive	O
activated	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Because	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
is	O
a	O
STAT5	B-Gene_or_gene_product
target	O
gene	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
family	O
of	O
PIM	O
serine	O
/	O
threonine	O
kinases	O
(	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
to	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	O
in	O
PTK	B-Gene_or_gene_product
-	O
mediated	O
transformation	O
of	O
hematopoietic	O
cells	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Ba	O
/	O
F3	O
cells	O
transformed	O
to	O
growth	O
factor	O
independence	O
by	O
various	O
oncogenic	O
PTKs	O
(	O
TEL	B-Gene_or_gene_product
/	O
JAK2	B-Gene_or_gene_product
,	O
TEL	B-Gene_or_gene_product
/	O
TRKC	B-Gene_or_gene_product
,	O
TEL	B-Gene_or_gene_product
/	O
ABL	B-Gene_or_gene_product
,	O
BCR	B-Gene_or_gene_product
/	O
ABL	B-Gene_or_gene_product
,	O
FLT3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ITD	I-Gene_or_gene_product
,	O
and	O
H4	B-Gene_or_gene_product
/	O
PDGFbetaR	B-Gene_or_gene_product
)	O
show	O
abundant	O
expression	O
of	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Suppression	O
of	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
activity	O
had	O
a	O
negligible	O
effect	O
on	O
transformation	O
.	O
<EOS>	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

In	O
contrast	O
,	O
expression	O
of	O
kinase	O
-	O
dead	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
mutant	O
(	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2KD	I-Gene_or_gene_product
)	O
led	O
to	O
a	O
rapid	O
decline	O
of	O
survival	O
in	O
Ba	O
/	O
F3	O
cells	O
transformed	O
by	O
FLT3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ITD	I-Gene_or_gene_product
but	O
not	O
by	O
other	O
oncogenic	O
PTKs	B-Gene_or_gene_product
tested	O
.	O

Coexpression	O
of	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1KD	I-Gene_or_gene_product
and	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2KD	I-Gene_or_gene_product
abrogated	O
growth	O
factor	O
-	O
independent	O
growth	O
of	O
Ba	O
/	O
F3	O
transformed	O
by	O
several	O
PTKs	O
,	O
including	O
BCR	B-Gene_or_gene_product
/	O
ABL	B-Gene_or_gene_product
.	O
<EOS>	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Targeted	O
down	O
-	O
regulation	O
of	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
selectively	O
abrogated	O
survival	O
of	O
Ba	O
/	O
F3	O
cells	O
transformed	O
by	O
various	O
Fms	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
3	I-Gene_or_gene_product
(	O
FLT3	B-Gene_or_gene_product
)	O
-	O
activating	O
mutants	O
[	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
and	O
kinase	O
domain	O
]	O
and	O
attenuated	O
growth	O
of	O
human	O
cell	O
lines	O
containing	O
FLT3	B-Gene_or_gene_product
mutations	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Interestingly	O
,	O
cells	O
transformed	O
by	O
FLT3	B-Gene_or_gene_product
and	O
BCR	B-Gene_or_gene_product
/	O
ABL	B-Gene_or_gene_product
mutations	O
that	O
confer	O
resistance	O
to	O
small	B-Gene_or_gene_product
-	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
inhibitors	O
were	O
still	O
sensitive	O
to	O
knockdown	O
of	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
or	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
by	O
RNAi	O
.	O
<EOS>	B-X
The	B-X
Special	B-X
AT-rich	B-X
Sequence	B-X
Binding	B-X
Protein	B-X
1	B-X
(	B-X
SATB1	B-X
)	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
genes	B-X
by	B-X
acting	B-X
as	B-X
a	B-X
global	B-X
chromatin	B-X
organizer	B-X
.	B-X
While	B-X
in	B-X
many	B-X
tumor	B-X
entities	B-X
SATB1	B-X
overexpression	B-X
has	B-X
been	B-X
observed	B-X
and	B-X
connected	B-X
to	B-X
pro-tumorigenic	B-X
processes	B-X
,	B-X
somewhat	B-X
contradictory	B-X
evidence	B-X
exists	B-X
in	B-X
brain	B-X
tumors	B-X
with	B-X
regard	B-X
to	B-X
SATB1	B-X
overexpression	B-X
in	B-X
glioblastoma	B-X
and	B-X
its	B-X
association	B-X
with	B-X
poorer	B-X
prognosis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
On	B-X
the	B-X
functional	B-X
side	B-X
,	B-X
initial	B-X
data	B-X
indicate	B-X
that	B-X
SATB1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
several	B-X
tumor	B-X
cell-relevant	B-X
processes	B-X
.	B-X
To	B-X
find	B-X
the	B-X
exact	B-X
downstream	B-X
effector	B-X
of	B-X
Pim-2	B-X
pathway	B-X
in	B-X
prostate	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
to	B-X
determine	B-X
the	B-X
means	B-X
by	B-X
which	B-X
it	B-X
affects	B-X
prostate	B-X
cancer	B-X
.	B-X
XIAP	B-X
,	B-X
Pim-2	B-X
and	B-X
p-eIF4B	B-X
expressions	B-X
were	B-X
detected	B-X
in	B-X
PCA	B-X
and	B-X
BPH	B-X
tissues	B-X
.	B-X
Then	B-X
the	B-X
Pim-2	B-X
and	B-X
XIAP	B-X
expressions	B-X
were	B-X
manipulated	B-X
using	B-X
transfection	B-X
or	B-X
RNAi	B-X
in	B-X
prostatic	B-X
cells	B-X
.	B-X
Finally	B-X
,	B-X
Pim-2/eIF4B/XIAP	B-X
levels	B-X
were	B-X
examined	B-X
in	B-X
PCA	B-X
tissues	B-X
with	B-X
different	B-X
clinicopathologic	B-X
features	B-X
.	B-X
When	B-X
Pim-2	B-X
was	B-X
transfected	B-X
into	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
RWPE-1	B-X
,	B-X
Pim-2	B-X
,	B-X
p-eIF4B	B-X
and	B-X
XIAP	B-X
were	B-X
all	B-X
significantly	B-X
increased	B-X
and	B-X
the	B-X
apoptosis	B-X
rate	B-X
was	B-X
significantly	B-X
decreased	B-X
.	B-X
When	B-X
XIAP	B-X
was	B-X
transfected	B-X
into	B-X
RWPE-1	B-X
cells	B-X
,	B-X
XIAP	B-X
was	B-X
significantly	B-X
increased	B-X
with	B-X
no	B-X
impact	B-X
on	B-X
Pim-2	B-X
,	B-X
p-eIF4B	B-X
and	B-X
the	B-X
apoptosis	B-X
rate	B-X
.	B-X
When	B-X
Pim-2	B-X
SiRNA	B-X
was	B-X
transfected	B-X
into	B-X
prostate	B-X
cancer	B-X
cells	B-X
PC-3	B-X
,	B-X
Pim-2	B-X
,	B-X
p-eIF4B	B-X
and	B-X
XIAP	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
the	B-X
apoptosis	B-X
rate	B-X
was	B-X
significantly	B-X
increased	B-X
.	B-X
When	B-X
XIAP	B-X
SiRNA	B-X
was	B-X
transfected	B-X
into	B-X
PC-3	B-X
cells	B-X
,	B-X
XIAP	B-X
was	B-X
significantly	B-X
decreased	B-X
with	B-X
no	B-X
impact	B-X
on	B-X
Pim-2	B-X
,	B-X
p-eIF4B	B-X
and	B-X
apoptosis	B-X
rate	B-X
.	B-X
Pim-2	B-X
,	B-X
p-eIF4B	B-X
and	B-X
XIAP	B-X
were	B-X
all	B-X
significantly	B-X
higher	B-X
in	B-X
PCA	B-X
tissues	B-X
with	B-X
GS	B-X
â¥8	B-X
than	B-X
those	B-X
with	B-X
GS	B-X
â¤7	B-X
.	B-X
XIAP	B-X
is	B-X
the	B-X
downstream	B-X
factor	B-X
of	B-X
Pim-2	B-X
pathway	B-X
in	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Pim-2	B-X
and	B-X
XIAP	B-X
cooperate	B-X
in	B-X
inhibiting	B-X
the	B-X
apoptosis	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
Pim-2	B-X
pathway	B-X
may	B-X
predict	B-X
higher	B-X
GS	B-X
in	B-X
prostate	B-X
cancer	B-X
.	B-X

Our	O
observations	O
indicate	O
that	O
combined	O
inactivation	O
of	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
PIM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
interferes	O
with	O
oncogenic	O
PTKs	O
and	O
suggest	O
that	O
PIMs	O
are	O
alternative	O
therapeutic	O
targets	O
in	O
PTK	O
-	O
mediated	O
leukemia	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Targeting	O
the	O
PIM	O
kinase	O
family	O
could	O
provide	O
a	O
new	O
avenue	O
to	O
overcome	O
resistance	O
against	O
small	O
-	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
STAT5	B-X
)	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
leukemogenesis	B-X
mediated	B-X
through	B-X
constitutive	B-X
activated	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
PTK	B-X
)	B-X
.	B-X
Because	B-X
PIM-1	B-X
is	B-X
a	B-X
STAT5	B-X
target	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
the	B-X
family	B-X
of	B-X
PIM	B-X
serine/threonine	B-X
kinases	B-X
(	B-X
PIM-1	B-X
to	B-X
PIM-3	B-X
)	B-X
in	B-X
PTK-mediated	B-X
transformation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
to	B-X
growth	B-X
factor	B-X
independence	B-X
by	B-X
various	B-X
oncogenic	B-X
PTKs	B-X
(	B-X
TEL/JAK2	B-X
,	B-X
TEL/TRKC	B-X
,	B-X
TEL/ABL	B-X
,	B-X
BCR/ABL	B-X
,	B-X
FLT3-ITD	B-X
,	B-X
and	B-X
H4/PDGFbetaR	B-X
)	B-X
show	B-X
abundant	B-X
expression	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
.	B-X
Suppression	B-X
of	B-X
PIM-1	B-X
activity	B-X
had	B-X
a	B-X
negligible	B-X
effect	B-X
on	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
kinase-dead	B-X
PIM-2	B-X
mutant	B-X
(	B-X
PIM-2KD	B-X
)	B-X
led	B-X
to	B-X
a	B-X
rapid	B-X
decline	B-X
of	B-X
survival	B-X
in	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3-ITD	B-X
but	B-X
not	B-X
by	B-X
other	B-X
oncogenic	B-X
PTKs	B-X
tested	B-X
.	B-X
Coexpression	B-X
of	B-X
PIM-1KD	B-X
and	B-X
PIM-2KD	B-X
abrogated	B-X
growth	B-X
factor-independent	B-X
growth	B-X
of	B-X
Ba/F3	B-X
transformed	B-X
by	B-X
several	B-X
PTKs	B-X
,	B-X
including	B-X
BCR/ABL	B-X
.	B-X
Targeted	B-X
down-regulation	B-X
of	B-X
PIM-2	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
selectively	B-X
abrogated	B-X
survival	B-X
of	B-X
Ba/F3	B-X
cells	B-X
transformed	B-X
by	B-X
various	B-X
Fms-like	B-X
tyrosine	B-X
kinase	B-X
3	B-X
(	B-X
FLT3	B-X
)	B-X
-activating	B-X
mutants	B-X
[	B-X
internal	B-X
tandem	B-X
duplication	B-X
(	B-X
ITD	B-X
)	B-X
and	B-X
kinase	B-X
domain	B-X
]	B-X
and	B-X
attenuated	B-X
growth	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
containing	B-X
FLT3	B-X
mutations	B-X
.	B-X
Interestingly	B-X
,	B-X
cells	B-X
transformed	B-X
by	B-X
FLT3	B-X
and	B-X
BCR/ABL	B-X
mutations	B-X
that	B-X
confer	B-X
resistance	B-X
to	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
were	B-X
still	B-X
sensitive	B-X
to	B-X
knockdown	B-X
of	B-X
PIM-2	B-X
,	B-X
or	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
by	B-X
RNAi	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
combined	B-X
inactivation	B-X
of	B-X
PIM-1	B-X
and	B-X
PIM-2	B-X
interferes	B-X
with	B-X
oncogenic	B-X
PTKs	B-X
and	B-X
suggest	B-X
that	B-X
PIMs	B-X
are	B-X
alternative	B-X
therapeutic	B-X
targets	B-X
in	B-X
PTK-mediated	B-X
leukemia	B-X
.	B-X
Targeting	B-X
the	B-X
PIM	B-X
kinase	B-X
family	B-X
could	B-X
provide	B-X
a	B-X
new	B-X
avenue	B-X
to	B-X
overcome	B-X
resistance	B-X
against	B-X
small-molecule	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X

Ectopic	O
localization	O
of	O
mitochondrial	O
ATP	B-Gene_or_gene_product
synthase	I-Gene_or_gene_product
:	O
a	O
target	O
for	O
anti	O
-	O
angiogenesis	O
intervention	O
?	O
<EOS>	B-X
A	B-X
receptor	B-X
for	B-X
angiostatin	B-X
was	B-X
identified	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
as	B-X
F	B-X
(	B-X
1	B-X
)	B-X
-F	B-X
(	B-X
0	B-X
)	B-X
ATP	B-X
synthase	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
1999	B-X
)	B-X
.	B-X
This	B-X
ectopic	B-X
ATP	B-X
synthase	B-X
catalyzes	B-X
ATP	B-X
synthesis	B-X
and	B-X
is	B-X
inhibited	B-X
by	B-X
angiostatin	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
.	B-X
Endothelial	B-X
cells	B-X
grown	B-X
at	B-X
normal	B-X
pH	B-X
suffer	B-X
no	B-X
ill	B-X
effects	B-X
from	B-X
this	B-X
angiostatin-mediated	B-X
inhibition	B-X
of	B-X
ATP	B-X
synthase	B-X
,	B-X
whereas	B-X
endothelial	B-X
cells	B-X
grown	B-X
at	B-X
low	B-X
,	B-X
tumor-like	B-X
extracellular	B-X
pH	B-X
can	B-X
not	B-X
maintain	B-X
a	B-X
normal	B-X
intracellular	B-X
pH	B-X
and	B-X
die	B-X
.	B-X
Angiostatin	B-X
inhibits	B-X
both	B-X
ATP	B-X
synthesis	B-X
and	B-X
ATP	B-X
hydrolysis	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
2001	B-X
)	B-X
and	B-X
interferes	B-X
with	B-X
intracellular	B-X
pH	B-X
regulation	B-X
(	B-X
Wahl	B-X
and	B-X
Grant	B-X
,	B-X
2002	B-X
;	B-X
Wahl	B-X
et	B-X
al.	B-X
,	B-X
2002	B-X
)	B-X
.	B-X
An	B-X
angiostatin-mimetic	B-X
activity	B-X
has	B-X
recently	B-X
been	B-X
observed	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
against	B-X
the	B-X
beta	B-X
catalytic	B-X
subunit	B-X
of	B-X
ATP	B-X
synthase	B-X
.	B-X

A	O
receptor	O
for	O
angiostatin	B-Gene_or_gene_product
was	O
identified	O
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
as	O
F	B-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
F	I-Gene_or_gene_product
(	I-Gene_or_gene_product
0	I-Gene_or_gene_product
)	I-Gene_or_gene_product
ATP	I-Gene_or_gene_product
synthase	I-Gene_or_gene_product
(	O
Moser	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Proc	O
.	O
<EOS>	B-X
Proc	B-X
IMechE	B-X
,	B-X
Part	B-X
H	B-X
:	B-X
Journal	B-X
of	B-X
Engineering	B-X
in	B-X
Medicine	B-X
;	B-X
230	B-X
(	B-X
5	B-X
)	B-X
:	B-X
373-388	B-X
.	B-X
Identification	B-X
of	B-X
Alpha	B-X
Thalassemia	B-X
,	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

96	O
,	O
2811	O
-	O
2816	O
.	O

This	O
ectopic	O
ATP	B-Gene_or_gene_product
synthase	I-Gene_or_gene_product
catalyzes	O
ATP	O
synthesis	O
and	O
is	O
inhibited	O
by	O
angiostatin	B-Gene_or_gene_product
over	O
a	O
wide	O
pH	O
range	O
.	O

Endothelial	O
cells	O
grown	O
at	O
normal	O
pH	O
suffer	O
no	O
ill	O
effects	O
from	O
this	O
angiostatin	B-Gene_or_gene_product
-	O
mediated	O
inhibition	O
of	O
ATP	B-Gene_or_gene_product
synthase	I-Gene_or_gene_product
,	O
whereas	O
endothelial	O
cells	O
grown	O
at	O
low	O
,	O
tumor	O
-	O
like	O
extracellular	O
pH	O
cannot	O
maintain	O
a	O
normal	O
intracellular	O
pH	O
and	O
die	O
.	O
<EOS>	B-X
A	B-X
receptor	B-X
for	B-X
angiostatin	B-X
was	B-X
identified	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
as	B-X
F	B-X
(	B-X
1	B-X
)	B-X
-F	B-X
(	B-X
0	B-X
)	B-X
ATP	B-X
synthase	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
1999	B-X
)	B-X
.	B-X
This	B-X
ectopic	B-X
ATP	B-X
synthase	B-X
catalyzes	B-X
ATP	B-X
synthesis	B-X
and	B-X
is	B-X
inhibited	B-X
by	B-X
angiostatin	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
.	B-X
Endothelial	B-X
cells	B-X
grown	B-X
at	B-X
normal	B-X
pH	B-X
suffer	B-X
no	B-X
ill	B-X
effects	B-X
from	B-X
this	B-X
angiostatin-mediated	B-X
inhibition	B-X
of	B-X
ATP	B-X
synthase	B-X
,	B-X
whereas	B-X
endothelial	B-X
cells	B-X
grown	B-X
at	B-X
low	B-X
,	B-X
tumor-like	B-X
extracellular	B-X
pH	B-X
can	B-X
not	B-X
maintain	B-X
a	B-X
normal	B-X
intracellular	B-X
pH	B-X
and	B-X
die	B-X
.	B-X
Angiostatin	B-X
inhibits	B-X
both	B-X
ATP	B-X
synthesis	B-X
and	B-X
ATP	B-X
hydrolysis	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
2001	B-X
)	B-X
and	B-X
interferes	B-X
with	B-X
intracellular	B-X
pH	B-X
regulation	B-X
(	B-X
Wahl	B-X
and	B-X
Grant	B-X
,	B-X
2002	B-X
;	B-X
Wahl	B-X
et	B-X
al.	B-X
,	B-X
2002	B-X
)	B-X
.	B-X
Although	B-X
angiostatin	B-X
administered	B-X
intravenously	B-X
is	B-X
cleared	B-X
from	B-X
the	B-X
circulation	B-X
in	B-X
a	B-X
matter	B-X
of	B-X
minutes	B-X
,	B-X
angiostatin-mimetics	B-X
that	B-X
are	B-X
more	B-X
stable	B-X
have	B-X
potential	B-X
for	B-X
clinical	B-X
application	B-X
.	B-X
An	B-X
angiostatin-mimetic	B-X
activity	B-X
has	B-X
recently	B-X
been	B-X
observed	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
against	B-X
the	B-X
beta	B-X
catalytic	B-X
subunit	B-X
of	B-X
ATP	B-X
synthase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
explore	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
angiostatin	B-X
and	B-X
its	B-X
mimetics	B-X
,	B-X
further	B-X
work	B-X
needs	B-X
to	B-X
be	B-X
done	B-X
to	B-X
evaluate	B-X
clinical	B-X
applicability	B-X
,	B-X
specificity	B-X
,	B-X
and	B-X
contraindications	B-X
for	B-X
this	B-X
class	B-X
of	B-X
therapeutics	B-X
.	B-X

Angiostatin	B-Gene_or_gene_product
inhibits	O
both	O
ATP	O
synthesis	O
and	O
ATP	O
hydrolysis	O
(	O
Moser	O
et	O
al	O
.	O
,	O
2001	O
)	O
and	O
interferes	O
with	O
intracellular	O
pH	O
regulation	O
(	O
Wahl	O
and	O
Grant	O
,	O
2002	O
;	O
Wahl	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Although	O
angiostatin	B-Gene_or_gene_product
administered	O
intravenously	O
is	O
cleared	O
from	O
the	O
circulation	O
in	O
a	O
matter	O
of	O
minutes	O
,	O
angiostatin	O
-	O
mimetics	O
that	O
are	O
more	O
stable	O
have	O
potential	O
for	O
clinical	O
application	O
.	O

An	O
angiostatin	O
-	O
mimetic	O
activity	O
has	O
recently	O
been	O
observed	O
using	O
a	O
polyclonal	O
antibody	O
against	O
the	O
beta	O
catalytic	O
subunit	O
of	O
ATP	B-Gene_or_gene_product
synthase	I-Gene_or_gene_product
.	O
<EOS>	B-X
A	B-X
receptor	B-X
for	B-X
angiostatin	B-X
was	B-X
identified	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
as	B-X
F	B-X
(	B-X
1	B-X
)	B-X
-F	B-X
(	B-X
0	B-X
)	B-X
ATP	B-X
synthase	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
1999	B-X
)	B-X
.	B-X
This	B-X
ectopic	B-X
ATP	B-X
synthase	B-X
catalyzes	B-X
ATP	B-X
synthesis	B-X
and	B-X
is	B-X
inhibited	B-X
by	B-X
angiostatin	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
.	B-X
Endothelial	B-X
cells	B-X
grown	B-X
at	B-X
normal	B-X
pH	B-X
suffer	B-X
no	B-X
ill	B-X
effects	B-X
from	B-X
this	B-X
angiostatin-mediated	B-X
inhibition	B-X
of	B-X
ATP	B-X
synthase	B-X
,	B-X
whereas	B-X
endothelial	B-X
cells	B-X
grown	B-X
at	B-X
low	B-X
,	B-X
tumor-like	B-X
extracellular	B-X
pH	B-X
can	B-X
not	B-X
maintain	B-X
a	B-X
normal	B-X
intracellular	B-X
pH	B-X
and	B-X
die	B-X
.	B-X
Angiostatin	B-X
inhibits	B-X
both	B-X
ATP	B-X
synthesis	B-X
and	B-X
ATP	B-X
hydrolysis	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
2001	B-X
)	B-X
and	B-X
interferes	B-X
with	B-X
intracellular	B-X
pH	B-X
regulation	B-X
(	B-X
Wahl	B-X
and	B-X
Grant	B-X
,	B-X
2002	B-X
;	B-X
Wahl	B-X
et	B-X
al.	B-X
,	B-X
2002	B-X
)	B-X
.	B-X
Although	B-X
angiostatin	B-X
administered	B-X
intravenously	B-X
is	B-X
cleared	B-X
from	B-X
the	B-X
circulation	B-X
in	B-X
a	B-X
matter	B-X
of	B-X
minutes	B-X
,	B-X
angiostatin-mimetics	B-X
that	B-X
are	B-X
more	B-X
stable	B-X
have	B-X
potential	B-X
for	B-X
clinical	B-X
application	B-X
.	B-X
An	B-X
angiostatin-mimetic	B-X
activity	B-X
has	B-X
recently	B-X
been	B-X
observed	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
against	B-X
the	B-X
beta	B-X
catalytic	B-X
subunit	B-X
of	B-X
ATP	B-X
synthase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
explore	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
angiostatin	B-X
and	B-X
its	B-X
mimetics	B-X
,	B-X
further	B-X
work	B-X
needs	B-X
to	B-X
be	B-X
done	B-X
to	B-X
evaluate	B-X
clinical	B-X
applicability	B-X
,	B-X
specificity	B-X
,	B-X
and	B-X
contraindications	B-X
for	B-X
this	B-X
class	B-X
of	B-X
therapeutics	B-X
.	B-X

In	O
order	O
to	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
angiostatin	B-Gene_or_gene_product
and	O
its	O
mimetics	O
,	O
further	O
work	O
needs	O
to	O
be	O
done	O
to	O
evaluate	O
clinical	O
applicability	O
,	O
specificity	O
,	O
and	O
contraindications	O
for	O
this	O
class	O
of	O
therapeutics	O
.	O
<EOS>	B-X
A	B-X
receptor	B-X
for	B-X
angiostatin	B-X
was	B-X
identified	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
as	B-X
F	B-X
(	B-X
1	B-X
)	B-X
-F	B-X
(	B-X
0	B-X
)	B-X
ATP	B-X
synthase	B-X
(	B-X
Moser	B-X
et	B-X
al.	B-X
,	B-X
1999	B-X
)	B-X
.	B-X
This	B-X
ectopic	B-X
ATP	B-X
synthase	B-X
catalyzes	B-X
ATP	B-X
synthesis	B-X
and	B-X
is	B-X
inhibited	B-X
by	B-X
angiostatin	B-X
over	B-X
a	B-X
wide	B-X
pH	B-X
range	B-X
.	B-X
Endothelial	B-X
cells	B-X
grown	B-X
at	B-X
normal	B-X
pH	B-X
suffer	B-X
no	B-X
ill	B-X
effects	B-X
from	B-X
this	B-X
angiostatin-mediated	B-X
inhibition	B-X
of	B-X
ATP	B-X
synthase	B-X
,	B-X
whereas	B-X
endothelial	B-X
cells	B-X
grown	B-X
at	B-X
low	B-X
,	B-X
tumor-like	B-X
extracellular	B-X
pH	B-X
can	B-X
not	B-X
maintain	B-X
a	B-X
normal	B-X
intracellular	B-X
pH	B-X
and	B-X
die	B-X
.	B-X
Although	B-X
angiostatin	B-X
administered	B-X
intravenously	B-X
is	B-X
cleared	B-X
from	B-X
the	B-X
circulation	B-X
in	B-X
a	B-X
matter	B-X
of	B-X
minutes	B-X
,	B-X
angiostatin-mimetics	B-X
that	B-X
are	B-X
more	B-X
stable	B-X
have	B-X
potential	B-X
for	B-X
clinical	B-X
application	B-X
.	B-X
An	B-X
angiostatin-mimetic	B-X
activity	B-X
has	B-X
recently	B-X
been	B-X
observed	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
against	B-X
the	B-X
beta	B-X
catalytic	B-X
subunit	B-X
of	B-X
ATP	B-X
synthase	B-X
.	B-X
In	B-X
order	B-X
to	B-X
explore	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
angiostatin	B-X
and	B-X
its	B-X
mimetics	B-X
,	B-X
further	B-X
work	B-X
needs	B-X
to	B-X
be	B-X
done	B-X
to	B-X
evaluate	B-X
clinical	B-X
applicability	B-X
,	B-X
specificity	B-X
,	B-X
and	B-X
contraindications	B-X
for	B-X
this	B-X
class	B-X
of	B-X
therapeutics	B-X
.	B-X

Hepatitis	O
B	O
virus	O
integration	O
event	O
in	O
human	O
chromosome	O
17p	O
near	O
the	O
p53	B-Gene_or_gene_product
gene	O
identifies	O
the	O
region	O
of	O
the	O
chromosome	O
commonly	O
deleted	O
in	O
virus	O
-	O
positive	O
hepatocellular	O
carcinomas	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
HBV	B-X
insert	B-X
from	B-X
a	B-X
Chinese	B-X
HCC	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
Restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
one	B-X
copy	B-X
of	B-X
portions	B-X
of	B-X
chromosome	B-X
17	B-X
occurred	B-X
in	B-X
10	B-X
(	B-X
53	B-X
%	B-X
)	B-X
of	B-X
the	B-X
19	B-X
patients	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
one	B-X
allele	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
(	B-X
located	B-X
on	B-X
chromosome	B-X
17p13	B-X
)	B-X
occurred	B-X
in	B-X
at	B-X
least	B-X
6	B-X
(	B-X
60	B-X
%	B-X
)	B-X
of	B-X
the	B-X
10	B-X
patients	B-X
who	B-X
were	B-X
heterozygous	B-X
at	B-X
the	B-X
p53	B-X
locus	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

The	O
development	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
presumably	O
occurs	O
in	O
multiple	O
steps	O
and	O
is	O
influenced	O
by	O
numerous	O
factors	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
HBV	B-X
insert	B-X
from	B-X
a	B-X
Chinese	B-X
HCC	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
is	O
strongly	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
in	O
people	O
chronically	O
infected	O
with	O
the	O
virus	O
,	O
but	O
the	O
mechanism	O
of	O
viral	O
involvement	O
remains	O
unclear	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
HBV	B-X
insert	B-X
from	B-X
a	B-X
Chinese	B-X
HCC	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

One	O
possibility	O
is	O
that	O
the	O
gross	O
chromosomal	O
alterations	O
frequently	O
observed	O
in	O
HCC	O
DNA	O
at	O
the	O
site	O
of	O
HBV	O
integration	O
may	O
alter	O
the	O
expression	O
of	O
important	O
nearby	O
cellular	O
genes	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
HBV	B-X
insert	B-X
from	B-X
a	B-X
Chinese	B-X
HCC	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

We	O
previously	O
reported	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
HBV	O
insert	O
from	O
a	O
Chinese	O
HCC	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
HBV	B-X
insert	B-X
from	B-X
a	B-X
Chinese	B-X
HCC	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

The	O
viral	O
insert	O
mapped	O
to	O
chromosome	O
17p11	O
.	O
2	O
-	O
12	O
,	O
and	O
cellular	O
sequences	O
were	O
duplicated	O
at	O
the	O
site	O
of	O
viral	O
integration	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
HBV	B-X
insert	B-X
from	B-X
a	B-X
Chinese	B-X
HCC	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
Restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
one	B-X
copy	B-X
of	B-X
portions	B-X
of	B-X
chromosome	B-X
17	B-X
occurred	B-X
in	B-X
10	B-X
(	B-X
53	B-X
%	B-X
)	B-X
of	B-X
the	B-X
19	B-X
patients	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
one	B-X
allele	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
(	B-X
located	B-X
on	B-X
chromosome	B-X
17p13	B-X
)	B-X
occurred	B-X
in	B-X
at	B-X
least	B-X
6	B-X
(	B-X
60	B-X
%	B-X
)	B-X
of	B-X
the	B-X
10	B-X
patients	B-X
who	B-X
were	B-X
heterozygous	B-X
at	B-X
the	B-X
p53	B-X
locus	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

In	O
the	O
present	O
study	O
a	O
DNA	O
probe	O
derived	O
from	O
cellular	O
DNA	O
sequences	O
adjacent	O
to	O
the	O
previously	O
characterized	O
HBV	O
insert	O
was	O
used	O
to	O
analyze	O
a	O
set	O
of	O
19	O
matched	O
normal	O
liver	O
and	O
HBV	O
-	O
positive	O
hepatoma	O
samples	O
obtained	O
from	O
the	O
same	O
region	O
of	O
China	O
,	O
near	O
Shanghai	O
.	O

Tumor	O
-	O
specific	O
DNA	O
changes	O
were	O
detected	O
in	O
two	O
additional	O
HCCs	O
,	O
suggesting	O
that	O
the	O
small	O
region	O
of	O
chromosome	O
17p	O
defined	O
by	O
the	O
flanking	O
cell	O
DNA	O
probe	O
is	O
commonly	O
altered	O
in	O
hepatomas	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
Restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
one	B-X
copy	B-X
of	B-X
portions	B-X
of	B-X
chromosome	B-X
17	B-X
occurred	B-X
in	B-X
10	B-X
(	B-X
53	B-X
%	B-X
)	B-X
of	B-X
the	B-X
19	B-X
patients	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
one	B-X
allele	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
(	B-X
located	B-X
on	B-X
chromosome	B-X
17p13	B-X
)	B-X
occurred	B-X
in	B-X
at	B-X
least	B-X
6	B-X
(	B-X
60	B-X
%	B-X
)	B-X
of	B-X
the	B-X
10	B-X
patients	B-X
who	B-X
were	B-X
heterozygous	B-X
at	B-X
the	B-X
p53	B-X
locus	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

Restriction	O
fragment	O
length	O
polymorphism	O
studies	O
demonstrated	O
that	O
the	O
loss	O
of	O
one	O
copy	O
of	O
portions	O
of	O
chromosome	O
17	O
occurred	O
in	O
10	O
(	O
53	O
%	O
)	O
of	O
the	O
19	O
patients	O
.	O

The	O
loss	O
of	O
one	O
allele	O
of	O
the	O
p53	B-Gene_or_gene_product
gene	O
(	O
located	O
on	O
chromosome	O
17p13	O
)	O
occurred	O
in	O
at	O
least	O
6	O
(	O
60	O
%	O
)	O
of	O
the	O
10	O
patients	O
who	O
were	O
heterozygous	O
at	O
the	O
p53	B-Gene_or_gene_product
locus	O
.	O

As	O
the	O
p53	B-Gene_or_gene_product
gene	O
is	O
known	O
to	O
possess	O
tumor	O
suppressor	O
activity	O
,	O
the	O
functional	O
loss	O
of	O
this	O
gene	O
may	O
be	O
a	O
significant	O
step	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
HCCs	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
Restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
one	B-X
copy	B-X
of	B-X
portions	B-X
of	B-X
chromosome	B-X
17	B-X
occurred	B-X
in	B-X
10	B-X
(	B-X
53	B-X
%	B-X
)	B-X
of	B-X
the	B-X
19	B-X
patients	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
one	B-X
allele	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
(	B-X
located	B-X
on	B-X
chromosome	B-X
17p13	B-X
)	B-X
occurred	B-X
in	B-X
at	B-X
least	B-X
6	B-X
(	B-X
60	B-X
%	B-X
)	B-X
of	B-X
the	B-X
10	B-X
patients	B-X
who	B-X
were	B-X
heterozygous	B-X
at	B-X
the	B-X
p53	B-X
locus	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

High	O
levels	O
of	O
allele	O
loss	O
also	O
were	O
detected	O
for	O
chromosomes	O
8q	O
(	O
4	O
of	O
9	O
;	O
44	O
%	O
)	O
and	O
16p	O
(	O
5	O
of	O
6	O
;	O
83	O
%	O
)	O
and	O
may	O
indicate	O
the	O
presence	O
of	O
additional	O
cellular	O
genes	O
whose	O
functional	O
loss	O
is	O
important	O
in	O
the	O
development	O
of	O
HCCs	O
.	O
<EOS>	B-X
ploidy	B-X
level	B-X
and	B-X
microdeletions	B-X
(	B-X
MDs	B-X
)	B-X
)	B-X
be	B-X
detected	B-X
using	B-X
a	B-X
preimplantation	B-X
genetic	B-X
testing	B-X
(	B-X
PGT	B-X
)	B-X
platform	B-X
?	B-X
The	B-X
development	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
presumably	B-X
occurs	B-X
in	B-X
multiple	B-X
steps	B-X
and	B-X
is	B-X
influenced	B-X
by	B-X
numerous	B-X
factors	B-X
.	B-X
Hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
is	B-X
strongly	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
HCC	B-X
in	B-X
people	B-X
chronically	B-X
infected	B-X
with	B-X
the	B-X
virus	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
of	B-X
viral	B-X
involvement	B-X
remains	B-X
unclear	B-X
.	B-X
One	B-X
possibility	B-X
is	B-X
that	B-X
the	B-X
gross	B-X
chromosomal	B-X
alterations	B-X
frequently	B-X
observed	B-X
in	B-X
HCC	B-X
DNA	B-X
at	B-X
the	B-X
site	B-X
of	B-X
HBV	B-X
integration	B-X
may	B-X
alter	B-X
the	B-X
expression	B-X
of	B-X
important	B-X
nearby	B-X
cellular	B-X
genes	B-X
.	B-X
The	B-X
viral	B-X
insert	B-X
mapped	B-X
to	B-X
chromosome	B-X
17p11.2-12	B-X
,	B-X
and	B-X
cellular	B-X
sequences	B-X
were	B-X
duplicated	B-X
at	B-X
the	B-X
site	B-X
of	B-X
viral	B-X
integration	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
a	B-X
DNA	B-X
probe	B-X
derived	B-X
from	B-X
cellular	B-X
DNA	B-X
sequences	B-X
adjacent	B-X
to	B-X
the	B-X
previously	B-X
characterized	B-X
HBV	B-X
insert	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
a	B-X
set	B-X
of	B-X
19	B-X
matched	B-X
normal	B-X
liver	B-X
and	B-X
HBV-positive	B-X
hepatoma	B-X
samples	B-X
obtained	B-X
from	B-X
the	B-X
same	B-X
region	B-X
of	B-X
China	B-X
,	B-X
near	B-X
Shanghai	B-X
.	B-X
Tumor-specific	B-X
DNA	B-X
changes	B-X
were	B-X
detected	B-X
in	B-X
two	B-X
additional	B-X
HCCs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
small	B-X
region	B-X
of	B-X
chromosome	B-X
17p	B-X
defined	B-X
by	B-X
the	B-X
flanking	B-X
cell	B-X
DNA	B-X
probe	B-X
is	B-X
commonly	B-X
altered	B-X
in	B-X
hepatomas	B-X
.	B-X
Restriction	B-X
fragment	B-X
length	B-X
polymorphism	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
one	B-X
copy	B-X
of	B-X
portions	B-X
of	B-X
chromosome	B-X
17	B-X
occurred	B-X
in	B-X
10	B-X
(	B-X
53	B-X
%	B-X
)	B-X
of	B-X
the	B-X
19	B-X
patients	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
one	B-X
allele	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
(	B-X
located	B-X
on	B-X
chromosome	B-X
17p13	B-X
)	B-X
occurred	B-X
in	B-X
at	B-X
least	B-X
6	B-X
(	B-X
60	B-X
%	B-X
)	B-X
of	B-X
the	B-X
10	B-X
patients	B-X
who	B-X
were	B-X
heterozygous	B-X
at	B-X
the	B-X
p53	B-X
locus	B-X
.	B-X
As	B-X
the	B-X
p53	B-X
gene	B-X
is	B-X
known	B-X
to	B-X
possess	B-X
tumor	B-X
suppressor	B-X
activity	B-X
,	B-X
the	B-X
functional	B-X
loss	B-X
of	B-X
this	B-X
gene	B-X
may	B-X
be	B-X
a	B-X
significant	B-X
step	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
HCCs	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
allele	B-X
loss	B-X
also	B-X
were	B-X
detected	B-X
for	B-X
chromosomes	B-X
8q	B-X
(	B-X
4	B-X
of	B-X
9	B-X
;	B-X
44	B-X
%	B-X
)	B-X
and	B-X
16p	B-X
(	B-X
5	B-X
of	B-X
6	B-X
;	B-X
83	B-X
%	B-X
)	B-X
and	B-X
may	B-X
indicate	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
cellular	B-X
genes	B-X
whose	B-X
functional	B-X
loss	B-X
is	B-X
important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HCCs	B-X
.	B-X

Prostate	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
membrane	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
regulates	O
angiogenesis	O
by	O
modulating	O
integrin	B-Gene_or_gene_product
signal	O
transduction	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

The	O
transmembrane	O
peptidase	O
prostate	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
membrane	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
(	O
PSMA	B-Gene_or_gene_product
)	O
is	O
universally	O
upregulated	O
in	O
the	O
vasculature	O
of	O
solid	O
tumors	O
,	O
but	O
its	O
functional	O
role	O
in	O
tumor	O
angiogenesis	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
we	O
show	O
that	O
angiogenesis	O
is	O
severely	O
impaired	O
in	O
PSMA	B-Gene_or_gene_product
-	O
null	O
animals	O
and	O
that	O
this	O
angiogenic	O
defect	O
occurs	O
at	O
the	O
level	O
of	O
endothelial	O
cell	O
invasion	O
through	O
the	O
extracellular	O
matrix	O
barrier	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
neutralization	B-X
of	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
or	B-X
the	B-X
inactivation	B-X
of	B-X
PAK	B-X
increases	B-X
PSMA	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
negatively	B-X
regulate	B-X
PSMA	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PAK	B-X
activation	B-X
enhances	B-X
the	B-X
PSMA/filamin	B-X
A	B-X
interaction	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
boosts	B-X
PSMA	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

Because	O
proteolytic	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
is	O
a	O
critical	O
component	O
of	O
endothelial	O
invasion	O
in	O
angiogenesis	O
,	O
it	O
is	O
logical	O
to	O
assume	O
that	O
PSMA	B-Gene_or_gene_product
participates	O
in	O
matrix	O
degradation	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
neutralization	B-X
of	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
or	B-X
the	B-X
inactivation	B-X
of	B-X
PAK	B-X
increases	B-X
PSMA	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
negatively	B-X
regulate	B-X
PSMA	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PAK	B-X
activation	B-X
enhances	B-X
the	B-X
PSMA/filamin	B-X
A	B-X
interaction	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
boosts	B-X
PSMA	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

However	O
,	O
we	O
demonstrate	O
a	O
novel	O
and	O
more	O
complex	O
role	O
for	O
PSMA	B-Gene_or_gene_product
in	O
angiogenesis	O
,	O
where	O
it	O
is	O
a	O
principal	O
component	O
of	O
a	O
regulatory	O
loop	O
that	O
is	O
tightly	O
modulating	O
laminin	B-Gene_or_gene_product
-	O
specific	O
integrin	B-Gene_or_gene_product
signaling	O
and	O
GTPase	O
-	O
dependent	O
,	O
p21	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
PAK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
activity	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
neutralization	B-X
of	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
or	B-X
the	B-X
inactivation	B-X
of	B-X
PAK	B-X
increases	B-X
PSMA	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
negatively	B-X
regulate	B-X
PSMA	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PAK	B-X
activation	B-X
enhances	B-X
the	B-X
PSMA/filamin	B-X
A	B-X
interaction	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
boosts	B-X
PSMA	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

We	O
show	O
that	O
PSMA	B-Gene_or_gene_product
inhibition	O
,	O
knockdown	O
,	O
or	O
deficiency	O
decreases	O
endothelial	O
cell	O
invasion	O
in	O
vitro	O
via	O
integrin	B-Gene_or_gene_product
and	O
PAK	B-Gene_or_gene_product
,	O
thus	O
abrogating	O
angiogenesis	O
.	O
<EOS>	B-X
The	B-X
curative	B-X
potential	B-X
of	B-X
radiotherapy	B-X
is	B-X
mediated	B-X
by	B-X
irradiation-induced	B-X
oxidative	B-X
stress	B-X
and	B-X
DNA	B-X
damage	B-X
in	B-X
tumor	B-X
cells	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
strikingly	B-X
upregulated	B-X
during	B-X
oncogenesis	B-X
and	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
progression	B-X
,	B-X
but	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
antigen	B-X
in	B-X
PCa	B-X
remain	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
constructed	B-X
PSMA-knockdown	B-X
LNCaP	B-X
and	B-X
22rv1	B-X
cell	B-X
lines	B-X
and	B-X
performed	B-X
metabonomic	B-X
and	B-X
transcriptomic	B-X
analyses	B-X
to	B-X
determine	B-X
the	B-X
effects	B-X
of	B-X
PSMA	B-X
on	B-X
PCa	B-X
metabolism	B-X
and	B-X
transcription	B-X
.	B-X
The	B-X
proliferation	B-X
of	B-X
each	B-X
cell	B-X
line	B-X
was	B-X
evaluated	B-X
through	B-X
CCK-8	B-X
,	B-X
EdU	B-X
and	B-X
colony	B-X
formation	B-X
assays	B-X
.	B-X
The	B-X
migration	B-X
and	B-X
invasion	B-X
abilities	B-X
of	B-X
each	B-X
cell	B-X
line	B-X
were	B-X
detected	B-X
using	B-X
wound	B-X
healing	B-X
and	B-X
transwell	B-X
assays	B-X
,	B-X
respectively	B-X
.	B-X
PSMA	B-X
knockdown	B-X
led	B-X
to	B-X
metabolic	B-X
disorder	B-X
and	B-X
abnormal	B-X
transcription	B-X
in	B-X
PCa	B-X
and	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
the	B-X
proliferation	B-X
and	B-X
metastasis	B-X
of	B-X
PCa	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
depletion	B-X
of	B-X
PSMA	B-X
also	B-X
promoted	B-X
the	B-X
biosynthesis	B-X
of	B-X
arginine	B-X
and	B-X
proline	B-X
,	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
AR	B-X
and	B-X
PSA	B-X
,	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
c-Fos	B-X
and	B-X
FosB	B-X
.	B-X
PSMA	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
metabolism	B-X
,	B-X
proliferation	B-X
and	B-X
metastasis	B-X
of	B-X
human	B-X
PCa	B-X
and	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
target	B-X
.	B-X

Interestingly	O
,	O
the	O
neutralization	O
of	O
beta	B-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
or	O
the	O
inactivation	O
of	O
PAK	B-Gene_or_gene_product
increases	O
PSMA	B-Gene_or_gene_product
activity	O
,	O
suggesting	O
that	O
they	O
negatively	O
regulate	O
PSMA	B-Gene_or_gene_product
.	O
<EOS>	B-X
In	B-X
dry	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
,	B-X
LCN2	B-X
(	B-X
lipocalin	B-X
2	B-X
)	B-X
is	B-X
upregulated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
in	B-X
retinal	B-X
pigmented	B-X
epithelial	B-X
(	B-X
RPE	B-X
)	B-X
cells	B-X
,	B-X
LCN2	B-X
regulates	B-X
macroautophagy/autophagy	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
maintaining	B-X
iron	B-X
homeostasis	B-X
.	B-X
LCN2	B-X
binds	B-X
to	B-X
ATG4B	B-X
to	B-X
form	B-X
an	B-X
LCN2-ATG4B-LC3-II	B-X
complex	B-X
,	B-X
thereby	B-X
regulating	B-X
ATG4B	B-X
activity	B-X
and	B-X
LC3-II	B-X
lipidation	B-X
.	B-X
Severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
transmissible	B-X
coronavirus	B-X
responsible	B-X
for	B-X
the	B-X
global	B-X
COVID-19	B-X
pandemic	B-X
.	B-X
SARS-CoV-2	B-X
spike	B-X
is	B-X
more	B-X
efficient	B-X
in	B-X
facilitating	B-X
cell-to-cell	B-X
transmission	B-X
than	B-X
is	B-X
SARS-CoV	B-X
spike	B-X
,	B-X
which	B-X
reflects	B-X
,	B-X
in	B-X
part	B-X
,	B-X
their	B-X
differential	B-X
cell-cell	B-X
fusion	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
treatment	B-X
of	B-X
cocultured	B-X
cells	B-X
with	B-X
endosomal	B-X
entry	B-X
inhibitors	B-X
impairs	B-X
cell-to-cell	B-X
transmission	B-X
,	B-X
implicating	B-X
endosomal	B-X
membrane	B-X
fusion	B-X
as	B-X
an	B-X
underlying	B-X
mechanism	B-X
.	B-X
Compared	B-X
with	B-X
cell-free	B-X
infection	B-X
,	B-X
cell-to-cell	B-X
transmission	B-X
of	B-X
SARS-CoV-2	B-X
is	B-X
refractory	B-X
to	B-X
inhibition	B-X
by	B-X
neutralizing	B-X
antibody	B-X
or	B-X
convalescent	B-X
sera	B-X
of	B-X
COVID-19	B-X
patients	B-X
.	B-X
Notably	B-X
,	B-X
despite	B-X
differences	B-X
in	B-X
cell-free	B-X
infectivity	B-X
,	B-X
the	B-X
authentic	B-X
variants	B-X
of	B-X
concern	B-X
(	B-X
VOCs	B-X
)	B-X
B.1.1.7	B-X
(	B-X
alpha	B-X
)	B-X
and	B-X
B.1.351	B-X
(	B-X
beta	B-X
)	B-X
have	B-X
similar	B-X
cell-to-cell	B-X
transmission	B-X
capability	B-X
.	B-X
Moreover	B-X
,	B-X
B.1.351	B-X
is	B-X
more	B-X
resistant	B-X
to	B-X
neutralization	B-X
by	B-X
vaccinee	B-X
sera	B-X
in	B-X
cell-free	B-X
infection	B-X
,	B-X
whereas	B-X
B.1.1.7	B-X
is	B-X
more	B-X
resistant	B-X
to	B-X
inhibition	B-X
by	B-X
vaccinee	B-X
sera	B-X
in	B-X
cell-to-cell	B-X
transmission	B-X
.	B-X

This	O
negative	O
regulation	O
is	O
mediated	O
by	O
the	O
cytoskeleton	O
as	O
the	O
disruption	O
of	O
interactions	O
between	O
the	O
PSMA	B-Gene_or_gene_product
cytoplasmic	O
tail	O
and	O
the	O
anchor	O
protein	O
filamin	B-Gene_or_gene_product
A	I-Gene_or_gene_product
decreases	O
PSMA	B-Gene_or_gene_product
activity	O
,	O
integrin	B-Gene_or_gene_product
function	O
,	O
and	O
PAK	B-Gene_or_gene_product
activation	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
neutralization	B-X
of	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
or	B-X
the	B-X
inactivation	B-X
of	B-X
PAK	B-X
increases	B-X
PSMA	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
negatively	B-X
regulate	B-X
PSMA	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PAK	B-X
activation	B-X
enhances	B-X
the	B-X
PSMA/filamin	B-X
A	B-X
interaction	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
boosts	B-X
PSMA	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

Finally	O
,	O
the	O
inhibition	O
of	O
PAK	B-Gene_or_gene_product
activation	O
enhances	O
the	O
PSMA	B-Gene_or_gene_product
/	O
filamin	B-Gene_or_gene_product
A	I-Gene_or_gene_product
interaction	O
and	O
,	O
thus	O
,	O
boosts	O
PSMA	B-Gene_or_gene_product
activity	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
neutralization	B-X
of	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
or	B-X
the	B-X
inactivation	B-X
of	B-X
PAK	B-X
increases	B-X
PSMA	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
negatively	B-X
regulate	B-X
PSMA	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PAK	B-X
activation	B-X
enhances	B-X
the	B-X
PSMA/filamin	B-X
A	B-X
interaction	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
boosts	B-X
PSMA	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

These	O
data	O
imply	O
that	O
PSMA	B-Gene_or_gene_product
participates	O
in	O
an	O
autoregulatory	O
loop	O
,	O
wherein	O
active	O
PSMA	B-Gene_or_gene_product
facilitates	O
integrin	B-Gene_or_gene_product
signaling	O
and	O
PAK	B-Gene_or_gene_product
activation	O
,	O
leading	O
to	O
both	O
productive	O
invasion	O
and	O
downregulation	O
of	O
integrin	B-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
signaling	O
via	O
reduced	O
PSMA	B-Gene_or_gene_product
activity	O
.	O

Therefore	O
,	O
we	O
have	O
identified	O
a	O
novel	O
role	O
for	O
PSMA	B-Gene_or_gene_product
as	O
a	O
true	O
molecular	O
interface	O
,	O
integrating	O
both	O
extracellular	O
and	O
intracellular	O
signals	O
during	O
angiogenesis	O
.	O
<EOS>	B-X
The	B-X
transmembrane	B-X
peptidase	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
PSMA	B-X
)	B-X
is	B-X
universally	B-X
upregulated	B-X
in	B-X
the	B-X
vasculature	B-X
of	B-X
solid	B-X
tumors	B-X
,	B-X
but	B-X
its	B-X
functional	B-X
role	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
angiogenesis	B-X
is	B-X
severely	B-X
impaired	B-X
in	B-X
PSMA-null	B-X
animals	B-X
and	B-X
that	B-X
this	B-X
angiogenic	B-X
defect	B-X
occurs	B-X
at	B-X
the	B-X
level	B-X
of	B-X
endothelial	B-X
cell	B-X
invasion	B-X
through	B-X
the	B-X
extracellular	B-X
matrix	B-X
barrier	B-X
.	B-X
Because	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
endothelial	B-X
invasion	B-X
in	B-X
angiogenesis	B-X
,	B-X
it	B-X
is	B-X
logical	B-X
to	B-X
assume	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
matrix	B-X
degradation	B-X
.	B-X
However	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
novel	B-X
and	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
PSMA	B-X
in	B-X
angiogenesis	B-X
,	B-X
where	B-X
it	B-X
is	B-X
a	B-X
principal	B-X
component	B-X
of	B-X
a	B-X
regulatory	B-X
loop	B-X
that	B-X
is	B-X
tightly	B-X
modulating	B-X
laminin-specific	B-X
integrin	B-X
signaling	B-X
and	B-X
GTPase-dependent	B-X
,	B-X
p21-activated	B-X
kinase	B-X
1	B-X
(	B-X
PAK-1	B-X
)	B-X
activity	B-X
.	B-X
We	B-X
show	B-X
that	B-X
PSMA	B-X
inhibition	B-X
,	B-X
knockdown	B-X
,	B-X
or	B-X
deficiency	B-X
decreases	B-X
endothelial	B-X
cell	B-X
invasion	B-X
in	B-X
vitro	B-X
via	B-X
integrin	B-X
and	B-X
PAK	B-X
,	B-X
thus	B-X
abrogating	B-X
angiogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
neutralization	B-X
of	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
or	B-X
the	B-X
inactivation	B-X
of	B-X
PAK	B-X
increases	B-X
PSMA	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
negatively	B-X
regulate	B-X
PSMA	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
cytoskeleton	B-X
as	B-X
the	B-X
disruption	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
PSMA	B-X
cytoplasmic	B-X
tail	B-X
and	B-X
the	B-X
anchor	B-X
protein	B-X
filamin	B-X
A	B-X
decreases	B-X
PSMA	B-X
activity	B-X
,	B-X
integrin	B-X
function	B-X
,	B-X
and	B-X
PAK	B-X
activation	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PAK	B-X
activation	B-X
enhances	B-X
the	B-X
PSMA/filamin	B-X
A	B-X
interaction	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
boosts	B-X
PSMA	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
imply	B-X
that	B-X
PSMA	B-X
participates	B-X
in	B-X
an	B-X
autoregulatory	B-X
loop	B-X
,	B-X
wherein	B-X
active	B-X
PSMA	B-X
facilitates	B-X
integrin	B-X
signaling	B-X
and	B-X
PAK	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
both	B-X
productive	B-X
invasion	B-X
and	B-X
downregulation	B-X
of	B-X
integrin	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
signaling	B-X
via	B-X
reduced	B-X
PSMA	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
PSMA	B-X
as	B-X
a	B-X
true	B-X
molecular	B-X
interface	B-X
,	B-X
integrating	B-X
both	B-X
extracellular	B-X
and	B-X
intracellular	B-X
signals	B-X
during	B-X
angiogenesis	B-X
.	B-X

Heparin	O
immobilized	O
porous	O
PLGA	O
microspheres	O
for	O
angiogenic	O
growth	O
factor	O
delivery	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

PURPOSE	O
:	O
Heparin	O
immobilized	O
porous	O
poly	O
(	O
D	O
,	O
L	O
-	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
(	O
PLGA	O
)	O
microspheres	O
were	O
prepared	O
for	O
sustained	O
release	O
of	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
bFGF	B-Gene_or_gene_product
)	O
to	O
induce	O
angiogenesis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Porous	O
PLGA	O
microspheres	O
having	O
primary	O
amine	O
groups	O
on	O
the	O
surface	O
were	O
prepared	O
using	O
an	O
oil	O
-	O
in	O
-	O
water	O
(	O
O	O
/	O
W	O
)	O
single	O
emulsion	O
method	O
using	O
Pluronic	O
F	O
-	O
127	O
as	O
an	O
extractable	O
porogen	O
.	O

Heparin	O
was	O
surface	O
immobilized	O
via	O
covalent	O
conjugation	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X
A	B-X
covalently	B-X
bonded	B-X
conjugate	B-X
of	B-X
commercial	B-X
grade	B-X
heparin	B-X
and	B-X
prostaglandin	B-X
E1	B-X
(	B-X
PGE1	B-X
)	B-X
was	B-X
synthesized	B-X
to	B-X
prevent	B-X
both	B-X
fibrin	B-X
formation	B-X
and	B-X
platelet	B-X
aggregation	B-X
during	B-X
thrombus	B-X
formation	B-X
.	B-X
The	B-X
PGE1-heparin	B-X
conjugate	B-X
was	B-X
immobilized	B-X
on	B-X
an	B-X
imidazole	B-X
carbamate	B-X
derivatized	B-X
sepharose	B-X
bead	B-X
surface	B-X
through	B-X
hydrophilic	B-X
spacer	B-X
groups	B-X
(	B-X
diamino-terminated	B-X
polyethylene	B-X
oxides	B-X
)	B-X
.	B-X
One	B-X
end	B-X
of	B-X
the	B-X
spacer	B-X
group	B-X
was	B-X
coupled	B-X
to	B-X
the	B-X
derivatized	B-X
surface	B-X
through	B-X
a	B-X
urethane	B-X
bond	B-X
between	B-X
the	B-X
amine	B-X
group	B-X
of	B-X
the	B-X
spacer	B-X
and	B-X
the	B-X
derivatized	B-X
surface	B-X
.	B-X
The	B-X
free	B-X
amine	B-X
group	B-X
of	B-X
the	B-X
immobilized	B-X
spacers	B-X
was	B-X
coupled	B-X
to	B-X
a	B-X
carboxylic	B-X
group	B-X
of	B-X
the	B-X
PGE1-heparin	B-X
conjugate	B-X
through	B-X
an	B-X
amide	B-X
bond	B-X
.	B-X
Bioactivity	B-X
of	B-X
the	B-X
immobilized	B-X
conjugate	B-X
(	B-X
heparin	B-X
activity	B-X
)	B-X
was	B-X
measured	B-X
in	B-X
terms	B-X
of	B-X
increased	B-X
clotting	B-X
times	B-X
(	B-X
thrombin	B-X
time	B-X
assay	B-X
)	B-X
and	B-X
for	B-X
the	B-X
inactivation	B-X
of	B-X
Factor	B-X
Xa	B-X
.	B-X
Bioactivity	B-X
of	B-X
the	B-X
immobilized	B-X
compound	B-X
(	B-X
PGE1	B-X
activity	B-X
)	B-X
was	B-X
analyzed	B-X
by	B-X
platelet	B-X
adhesion	B-X
and	B-X
platelet	B-X
release	B-X
reactions	B-X
using	B-X
C14-5-hydroxytryptamine	B-X
(	B-X
5-HT	B-X
)	B-X
.	B-X
The	B-X
conjugate	B-X
immobilized	B-X
via	B-X
the	B-X
C2	B-X
spacer	B-X
showed	B-X
the	B-X
highest	B-X
incidence	B-X
of	B-X
platelet	B-X
adhesion	B-X
,	B-X
5-HT	B-X
released	B-X
and	B-X
the	B-X
lowest	B-X
activity	B-X
for	B-X
coagulation	B-X
factors	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
1000	B-X
and	B-X
4000	B-X
immobilized	B-X
systems	B-X
showed	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
platelet	B-X
activation	B-X
,	B-X
while	B-X
having	B-X
the	B-X
greatest	B-X
effect	B-X
on	B-X
coagulation	B-X
factors	B-X
.	B-X
The	B-X
results	B-X
of	B-X
these	B-X
experiments	B-X
imply	B-X
that	B-X
the	B-X
immobilized	B-X
conjugate	B-X
is	B-X
active	B-X
in	B-X
preventing	B-X
both	B-X
pathways	B-X
of	B-X
thrombus	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
efficacy	B-X
is	B-X
improved	B-X
through	B-X
the	B-X
use	B-X
of	B-X
long-chain	B-X
hydrophilic	B-X
spacer	B-X
groups	B-X
.	B-X

bFGF	B-Gene_or_gene_product
was	O
loaded	O
into	O
the	O
heparin	O
functionalized	O
(	O
PLGA	O
-	O
heparin	O
)	O
microspheres	O
by	O
a	O
simple	O
dipping	O
method	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

The	O
bFGF	B-Gene_or_gene_product
loaded	O
PLGA	O
-	O
heparin	O
microspheres	O
were	O
tested	O
for	O
in	O
vitro	O
release	O
and	O
in	O
vivo	O
angiogenic	O
activity	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

RESULTS	O
:	O
PLGA	O
microspheres	O
with	O
an	O
open	O
-	O
porous	O
structure	O
were	O
formed	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

The	O
amount	O
of	O
conjugated	O
amine	O
group	O
onto	O
the	O
microspheres	O
was	O
1	O
.	O
93	O
+	O
/	O
-	O
0	O
.	O
01	O
nmol	O
/	O
mg	O
-	O
microspheres	O
,	O
while	O
the	O
amount	O
of	O
heparin	O
was	O
95	O
.	O
8	O
pmol	O
/	O
mg	O
-	O
microspheres	O
.	O

PLGA	O
-	O
heparin	O
microspheres	O
released	O
out	O
bFGF	B-Gene_or_gene_product
in	O
a	O
more	O
sustained	O
manner	O
with	O
a	O
smaller	O
extent	O
of	O
initial	O
burst	O
than	O
PLGA	O
microspheres	O
,	O
indicating	O
that	O
surface	O
immobilized	O
heparin	O
controlled	O
the	O
release	O
rate	O
of	O
bFGF	B-Gene_or_gene_product
.	O

Subcutaneous	O
implantation	O
of	O
bFGF	B-Gene_or_gene_product
loaded	O
PLGA	O
-	O
heparin	O
microspheres	O
in	O
mice	O
significantly	O
induced	O
the	O
formation	O
of	O
new	O
vascular	O
microvessels	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

CONCLUSIONS	O
:	O
PLGA	O
microspheres	O
with	O
an	O
open	O
porous	O
structure	O
allowed	O
significant	O
amount	O
of	O
heparin	O
immobilization	O
and	O
bFGF	B-Gene_or_gene_product
loading	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

bFGF	B-Gene_or_gene_product
loaded	O
PLGA	O
-	O
HP	O
microspheres	O
showed	O
sustained	O
release	O
profiles	O
of	O
bFGF	B-Gene_or_gene_product
in	O
vitro	O
,	O
demonstrating	O
reversible	O
and	O
specific	O
binding	O
of	O
bFGF	B-Gene_or_gene_product
to	O
immobilized	O
heparin	O
.	O
<EOS>	B-X
Heparin	B-X
immobilized	B-X
porous	B-X
poly	B-X
(	B-X
D	B-X
,	B-X
L-lactic-co-glycolic	B-X
acid	B-X
)	B-X
(	B-X
PLGA	B-X
)	B-X
microspheres	B-X
were	B-X
prepared	B-X
for	B-X
sustained	B-X
release	B-X
of	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X

They	O
also	O
induced	O
local	O
angiogenesis	O
in	O
vivo	O
in	O
an	O
animal	O
model	O
.	O

The	O
role	O
of	O
syndecans	B-Gene_or_gene_product
in	O
disease	O
and	O
wound	O
healing	O
.	O
<EOS>	B-X
Until	B-X
recently	B-X
,	B-X
their	B-X
role	B-X
in	B-X
pathogenesis	B-X
was	B-X
largely	B-X
unexplored	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
reported	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
infectious	B-X
diseases	B-X
,	B-X
obesity	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
syndecans	B-X
bind	B-X
to	B-X
obesity-related	B-X
factors	B-X
and	B-X
regulate	B-X
their	B-X
signaling	B-X
,	B-X
in	B-X
turn	B-X
modulating	B-X
food	B-X
consumption	B-X
and	B-X
weight	B-X
balance	B-X
.	B-X
In	B-X
vivo	B-X
animal	B-X
models	B-X
of	B-X
tissue	B-X
injury	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
also	B-X
implicate	B-X
syndecans	B-X
in	B-X
processes	B-X
necessary	B-X
for	B-X
wound	B-X
healing	B-X
,	B-X
including	B-X
fibroblast	B-X
and	B-X
endothelial	B-X
proliferation	B-X
,	B-X
cell	B-X
motility	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
organization	B-X
.	B-X
These	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
disease	B-X
and	B-X
tissue	B-X
repair	B-X
coupled	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
syndecan-specific	B-X
molecular	B-X
tools	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

Syndecans	B-Gene_or_gene_product
are	O
a	O
family	O
of	O
transmembrane	O
heparan	O
sulfate	O
proteoglycans	O
widely	O
expressed	O
in	O
both	O
developing	O
and	O
adult	O
tissues	O
.	O
<EOS>	B-X
Syndecans	B-X
are	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
heparan	B-X
sulfate	B-X
proteoglycans	B-X
widely	B-X
expressed	B-X
in	B-X
both	B-X
developing	B-X
and	B-X
adult	B-X
tissues	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X

Until	O
recently	O
,	O
their	O
role	O
in	O
pathogenesis	O
was	O
largely	O
unexplored	O
.	O
<EOS>	B-X
Genome-Wide	B-X
Analysis	B-X
of	B-X
Experimentally	B-X
Evolved	B-X
Candida	B-X
auris	B-X
Reveals	B-X
Multiple	B-X
Novel	B-X
Mechanisms	B-X
of	B-X
Multidrug	B-X
Resistance	B-X
.	B-X
Much	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
in	B-X
characterizing	B-X
biological	B-X
roles	B-X
of	B-X
DUBs	B-X
over	B-X
the	B-X
decades	B-X
,	B-X
yet	B-X
the	B-X
specific	B-X
functions	B-X
of	B-X
many	B-X
subclass	B-X
members	B-X
remain	B-X
largely	B-X
unexplored	B-X
.	B-X
It	B-X
was	B-X
not	B-X
until	B-X
recent	B-X
years	B-X
that	B-X
the	B-X
role	B-X
of	B-X
ubiquitin-specific-processing	B-X
protease	B-X
35	B-X
(	B-X
USP35	B-X
)	B-X
in	B-X
cancers	B-X
began	B-X
to	B-X
be	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
delineating	B-X
the	B-X
roles	B-X
and	B-X
underlying	B-X
mechanisms	B-X
of	B-X
USP35	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
USP35	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
resisting	B-X
ER	B-X
stress-induced	B-X
cell	B-X
death	B-X
through	B-X
deubiquitinating	B-X
RRBP1	B-X
,	B-X
hence	B-X
providing	B-X
a	B-X
rationale	B-X
to	B-X
target	B-X
the	B-X
USP35-RRBP1	B-X
axis	B-X
as	B-X
an	B-X
alternative	B-X
therapeutic	B-X
option	B-X
for	B-X
NSCLC	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
reported	O
involvement	O
of	O
syndecans	B-Gene_or_gene_product
in	O
human	O
cancers	O
,	O
infectious	O
diseases	O
,	O
obesity	O
,	O
wound	O
healing	O
and	O
angiogenesis	O
.	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
reported	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
infectious	B-X
diseases	B-X
,	B-X
obesity	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
some	B-X
cancers	B-X
,	B-X
syndecan	B-X
expression	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
tumor	B-X
cell	B-X
function	B-X
(	B-X
e.g	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
syndecans	B-X
bind	B-X
to	B-X
obesity-related	B-X
factors	B-X
and	B-X
regulate	B-X
their	B-X
signaling	B-X
,	B-X
in	B-X
turn	B-X
modulating	B-X
food	B-X
consumption	B-X
and	B-X
weight	B-X
balance	B-X
.	B-X
In	B-X
vivo	B-X
animal	B-X
models	B-X
of	B-X
tissue	B-X
injury	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
also	B-X
implicate	B-X
syndecans	B-X
in	B-X
processes	B-X
necessary	B-X
for	B-X
wound	B-X
healing	B-X
,	B-X
including	B-X
fibroblast	B-X
and	B-X
endothelial	B-X
proliferation	B-X
,	B-X
cell	B-X
motility	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
organization	B-X
.	B-X
These	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
disease	B-X
and	B-X
tissue	B-X
repair	B-X
coupled	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
syndecan-specific	B-X
molecular	B-X
tools	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

In	O
some	O
cancers	O
,	O
syndecan	B-Gene_or_gene_product
expression	O
has	O
been	O
shown	O
to	O
regulate	O
tumor	O
cell	O
function	O
(	O
e	O
.	O
g	O
.	O
proliferation	O
,	O
adhesion	O
,	O
and	O
motility	O
)	O
and	O
serve	O
as	O
a	O
prognostic	O
marker	O
for	O
tumor	O
progression	O
and	O
patient	O
survival	O
.	O

The	O
ectodomains	O
and	O
heparan	O
sulfate	O
glycosaminoglycan	O
chains	O
of	O
syndecans	B-Gene_or_gene_product
can	O
also	O
act	O
as	O
receptors	O
/	O
co	O
-	O
receptors	O
for	O
some	O
bacterial	O
and	O
viral	O
pathogens	O
,	O
mediating	O
infection	O
.	O
<EOS>	B-X
Syndecans	B-X
are	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
heparan	B-X
sulfate	B-X
proteoglycans	B-X
widely	B-X
expressed	B-X
in	B-X
both	B-X
developing	B-X
and	B-X
adult	B-X
tissues	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
reported	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
infectious	B-X
diseases	B-X
,	B-X
obesity	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
syndecans	B-X
bind	B-X
to	B-X
obesity-related	B-X
factors	B-X
and	B-X
regulate	B-X
their	B-X
signaling	B-X
,	B-X
in	B-X
turn	B-X
modulating	B-X
food	B-X
consumption	B-X
and	B-X
weight	B-X
balance	B-X
.	B-X
In	B-X
vivo	B-X
animal	B-X
models	B-X
of	B-X
tissue	B-X
injury	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
also	B-X
implicate	B-X
syndecans	B-X
in	B-X
processes	B-X
necessary	B-X
for	B-X
wound	B-X
healing	B-X
,	B-X
including	B-X
fibroblast	B-X
and	B-X
endothelial	B-X
proliferation	B-X
,	B-X
cell	B-X
motility	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
organization	B-X
.	B-X
These	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
disease	B-X
and	B-X
tissue	B-X
repair	B-X
coupled	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
syndecan-specific	B-X
molecular	B-X
tools	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

In	O
addition	O
,	O
syndecans	B-Gene_or_gene_product
bind	O
to	O
obesity	O
-	O
related	O
factors	O
and	O
regulate	O
their	O
signaling	O
,	O
in	O
turn	O
modulating	O
food	O
consumption	O
and	O
weight	O
balance	O
.	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
reported	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
infectious	B-X
diseases	B-X
,	B-X
obesity	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
some	B-X
cancers	B-X
,	B-X
syndecan	B-X
expression	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
tumor	B-X
cell	B-X
function	B-X
(	B-X
e.g	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
syndecans	B-X
bind	B-X
to	B-X
obesity-related	B-X
factors	B-X
and	B-X
regulate	B-X
their	B-X
signaling	B-X
,	B-X
in	B-X
turn	B-X
modulating	B-X
food	B-X
consumption	B-X
and	B-X
weight	B-X
balance	B-X
.	B-X
In	B-X
vivo	B-X
animal	B-X
models	B-X
of	B-X
tissue	B-X
injury	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
also	B-X
implicate	B-X
syndecans	B-X
in	B-X
processes	B-X
necessary	B-X
for	B-X
wound	B-X
healing	B-X
,	B-X
including	B-X
fibroblast	B-X
and	B-X
endothelial	B-X
proliferation	B-X
,	B-X
cell	B-X
motility	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
organization	B-X
.	B-X
These	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
disease	B-X
and	B-X
tissue	B-X
repair	B-X
coupled	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
syndecan-specific	B-X
molecular	B-X
tools	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

In	O
vivo	O
animal	O
models	O
of	O
tissue	O
injury	O
and	O
in	O
vitro	O
data	O
also	O
implicate	O
syndecans	B-Gene_or_gene_product
in	O
processes	O
necessary	O
for	O
wound	O
healing	O
,	O
including	O
fibroblast	O
and	O
endothelial	O
proliferation	O
,	O
cell	O
motility	O
,	O
angiogenesis	O
,	O
and	O
extracellular	O
matrix	O
organization	O
.	O
<EOS>	B-X
Syndecans	B-X
are	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
heparan	B-X
sulfate	B-X
proteoglycans	B-X
widely	B-X
expressed	B-X
in	B-X
both	B-X
developing	B-X
and	B-X
adult	B-X
tissues	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
reported	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
infectious	B-X
diseases	B-X
,	B-X
obesity	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
some	B-X
cancers	B-X
,	B-X
syndecan	B-X
expression	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
tumor	B-X
cell	B-X
function	B-X
(	B-X
e.g	B-X
.	B-X
proliferation	B-X
,	B-X
adhesion	B-X
,	B-X
and	B-X
motility	B-X
)	B-X
and	B-X
serve	B-X
as	B-X
a	B-X
prognostic	B-X
marker	B-X
for	B-X
tumor	B-X
progression	B-X
and	B-X
patient	B-X
survival	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
syndecans	B-X
bind	B-X
to	B-X
obesity-related	B-X
factors	B-X
and	B-X
regulate	B-X
their	B-X
signaling	B-X
,	B-X
in	B-X
turn	B-X
modulating	B-X
food	B-X
consumption	B-X
and	B-X
weight	B-X
balance	B-X
.	B-X
In	B-X
vivo	B-X
animal	B-X
models	B-X
of	B-X
tissue	B-X
injury	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
also	B-X
implicate	B-X
syndecans	B-X
in	B-X
processes	B-X
necessary	B-X
for	B-X
wound	B-X
healing	B-X
,	B-X
including	B-X
fibroblast	B-X
and	B-X
endothelial	B-X
proliferation	B-X
,	B-X
cell	B-X
motility	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
organization	B-X
.	B-X
These	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
disease	B-X
and	B-X
tissue	B-X
repair	B-X
coupled	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
syndecan-specific	B-X
molecular	B-X
tools	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

These	O
new	O
insights	O
into	O
the	O
involvement	O
of	O
syndecans	B-Gene_or_gene_product
in	O
disease	O
and	O
tissue	O
repair	O
coupled	O
with	O
the	O
emergence	O
of	O
syndecan	B-Gene_or_gene_product
-	O
specific	O
molecular	O
tools	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
a	O
variety	O
of	O
human	O
diseases	O
.	O
<EOS>	B-X
Syndecans	B-X
are	B-X
a	B-X
family	B-X
of	B-X
transmembrane	B-X
heparan	B-X
sulfate	B-X
proteoglycans	B-X
widely	B-X
expressed	B-X
in	B-X
both	B-X
developing	B-X
and	B-X
adult	B-X
tissues	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
reported	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
human	B-X
cancers	B-X
,	B-X
infectious	B-X
diseases	B-X
,	B-X
obesity	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
some	B-X
cancers	B-X
,	B-X
syndecan	B-X
expression	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
tumor	B-X
cell	B-X
function	B-X
(	B-X
e.g	B-X
.	B-X
The	B-X
ectodomains	B-X
and	B-X
heparan	B-X
sulfate	B-X
glycosaminoglycan	B-X
chains	B-X
of	B-X
syndecans	B-X
can	B-X
also	B-X
act	B-X
as	B-X
receptors/co-receptors	B-X
for	B-X
some	B-X
bacterial	B-X
and	B-X
viral	B-X
pathogens	B-X
,	B-X
mediating	B-X
infection	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
syndecans	B-X
bind	B-X
to	B-X
obesity-related	B-X
factors	B-X
and	B-X
regulate	B-X
their	B-X
signaling	B-X
,	B-X
in	B-X
turn	B-X
modulating	B-X
food	B-X
consumption	B-X
and	B-X
weight	B-X
balance	B-X
.	B-X
In	B-X
vivo	B-X
animal	B-X
models	B-X
of	B-X
tissue	B-X
injury	B-X
and	B-X
in	B-X
vitro	B-X
data	B-X
also	B-X
implicate	B-X
syndecans	B-X
in	B-X
processes	B-X
necessary	B-X
for	B-X
wound	B-X
healing	B-X
,	B-X
including	B-X
fibroblast	B-X
and	B-X
endothelial	B-X
proliferation	B-X
,	B-X
cell	B-X
motility	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
organization	B-X
.	B-X
These	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
involvement	B-X
of	B-X
syndecans	B-X
in	B-X
disease	B-X
and	B-X
tissue	B-X
repair	B-X
coupled	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
syndecan-specific	B-X
molecular	B-X
tools	B-X
may	B-X
lead	B-X
to	B-X
novel	B-X
therapies	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
is	O
over	O
-	O
expressed	O
in	O
gastric	O
carcinogenesis	O
and	O
is	O
associated	O
with	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

The	O
CCAAT	B-Gene_or_gene_product
/	I-Gene_or_gene_product
enhancer	I-Gene_or_gene_product
-	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
)	O
transcription	O
factor	O
has	O
been	O
associated	O
with	O
several	O
cancer	O
models	O
.	O
<EOS>	B-X
Myeloid-derived	B-X
suppressor	B-X
cells	B-X
(	B-X
MDSCs	B-X
)	B-X
inhibit	B-X
anti-tumor	B-X
immunity	B-X
.	B-X
Aerobic	B-X
glycolysis	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
the	B-X
link	B-X
between	B-X
MDSCs	B-X
and	B-X
glycolysis	B-X
is	B-X
unknown	B-X
in	B-X
patients	B-X
with	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
detect	B-X
abundant	B-X
glycolytic	B-X
activities	B-X
in	B-X
human	B-X
TNBC	B-X
.	B-X
In	B-X
two	B-X
TNBC	B-X
mouse	B-X
models	B-X
,	B-X
4T1	B-X
and	B-X
Py8119	B-X
,	B-X
glycolysis	B-X
restriction	B-X
inhibits	B-X
tumor	B-X
granulocyte	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
G-CSF	B-X
)	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
expression	B-X
and	B-X
reduces	B-X
MDSCs	B-X
.	B-X
Mechanistically	B-X
,	B-X
glycolysis	B-X
restriction	B-X
represses	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
specific	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
CEBPB	B-X
)	B-X
isoform	B-X
,	B-X
liver-enriched	B-X
activator	B-X
protein	B-X
(	B-X
LAP	B-X
)	B-X
,	B-X
via	B-X
the	B-X
AMP-activated	B-X
protein	B-X
kinase	B-X
(	B-X
AMPK	B-X
)	B-X
-ULK1	B-X
and	B-X
autophagy	B-X
pathways	B-X
,	B-X
whereas	B-X
LAP	B-X
controls	B-X
G-CSF	B-X
and	B-X
GM-CSF	B-X
expression	B-X
to	B-X
support	B-X
MDSC	B-X
development	B-X
.	B-X
Glycolytic	B-X
signatures	B-X
that	B-X
include	B-X
lactate	B-X
dehydrogenase	B-X
A	B-X
correlate	B-X
with	B-X
high	B-X
MDSCs	B-X
and	B-X
low	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
are	B-X
associated	B-X
with	B-X
poor	B-X
human	B-X
TNBC	B-X
outcome	B-X
.	B-X
Collectively	B-X
,	B-X
tumor	B-X
glycolysis	B-X
orchestrates	B-X
a	B-X
molecular	B-X
network	B-X
of	B-X
the	B-X
AMPK-ULK1	B-X
,	B-X
autophagy	B-X
,	B-X
and	B-X
CEBPB	B-X
pathways	B-X
to	B-X
affect	B-X
MDSCs	B-X
and	B-X
maintain	B-X
tumor	B-X
immunosuppression	B-X
.	B-X

In	O
this	O
study	O
,	O
the	O
expression	O
of	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
was	O
analysed	O
in	O
a	O
series	O
of	O
90	O
gastric	O
carcinomas	O
(	O
GCs	O
)	O
.	O

We	O
also	O
assessed	O
the	O
effect	O
of	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
on	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

In	O
normal	O
gastric	O
mucosa	O
,	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
expression	O
was	O
restricted	O
to	O
cells	O
in	O
the	O
proliferative	O
zone	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

In	O
intestinal	O
metaplasia	O
,	O
dysplasia	O
,	O
and	O
GC	O
of	O
the	O
intestinal	O
and	O
atypical	O
subtypes	O
,	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
was	O
over	O
-	O
expressed	O
(	O
p	O
<	O
0	O
.	O
0001	O
,	O
for	O
the	O
association	O
with	O
histological	O
type	O
)	O
.	O

C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
and	O
Ki67	B-Gene_or_gene_product
,	O
a	O
marker	O
of	O
cell	O
proliferation	O
,	O
were	O
also	O
co	O
-	O
expressed	O
in	O
primary	O
GC	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

We	O
also	O
observed	O
an	O
overlap	O
between	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
and	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
in	O
GC	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

Using	O
GC	O
cell	O
lines	O
we	O
show	O
that	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
can	O
regulate	O
the	O
expression	O
of	O
endogenous	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
transactivate	O
the	O
promoter	O
of	O
the	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
gene	O
,	O
depending	O
on	O
its	O
methylation	O
status	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

These	O
results	O
suggest	O
that	O
C	B-Gene_or_gene_product
/	I-Gene_or_gene_product
EBPbeta	I-Gene_or_gene_product
may	O
be	O
a	O
marker	O
of	O
neoplastic	O
transformation	O
and	O
also	O
play	O
an	O
active	O
role	O
in	O
gastric	O
tumourigenesis	O
by	O
regulating	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
The	B-X
CCAAT/enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
transcription	B-X
factor	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
cancer	B-X
models	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
C/EBPbeta	B-X
was	B-X
analysed	B-X
in	B-X
a	B-X
series	B-X
of	B-X
90	B-X
gastric	B-X
carcinomas	B-X
(	B-X
GCs	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
C/EBPbeta	B-X
on	B-X
COX-2	B-X
expression	B-X
.	B-X
In	B-X
normal	B-X
gastric	B-X
mucosa	B-X
,	B-X
C/EBPbeta	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
cells	B-X
in	B-X
the	B-X
proliferative	B-X
zone	B-X
.	B-X
In	B-X
intestinal	B-X
metaplasia	B-X
,	B-X
dysplasia	B-X
,	B-X
and	B-X
GC	B-X
of	B-X
the	B-X
intestinal	B-X
and	B-X
atypical	B-X
subtypes	B-X
,	B-X
C/EBPbeta	B-X
was	B-X
over-expressed	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
for	B-X
the	B-X
association	B-X
with	B-X
histological	B-X
type	B-X
)	B-X
.	B-X
C/EBPbeta	B-X
and	B-X
Ki67	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
were	B-X
also	B-X
co-expressed	B-X
in	B-X
primary	B-X
GC	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
an	B-X
overlap	B-X
between	B-X
C/EBPbeta	B-X
and	B-X
COX-2	B-X
expression	B-X
in	B-X
GC	B-X
.	B-X
Using	B-X
GC	B-X
cell	B-X
lines	B-X
we	B-X
show	B-X
that	B-X
C/EBPbeta	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
COX-2	B-X
and	B-X
transactivate	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
COX-2	B-X
gene	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
methylation	B-X
status	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
C/EBPbeta	B-X
may	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
neoplastic	B-X
transformation	B-X
and	B-X
also	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
gastric	B-X
tumourigenesis	B-X
by	B-X
regulating	B-X
COX-2	B-X
expression	B-X
.	B-X

Lysophosphatidic	O
acid	O
downregulates	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
metalloproteinases	I-Gene_or_gene_product
,	O
which	O
are	O
negatively	O
involved	O
in	O
lysophosphatidic	O
acid	O
-	O
induced	O
cell	O
invasion	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X

Ovarian	O
cancer	O
is	O
a	O
highly	O
metastatic	O
disease	O
.	O
<EOS>	B-X
Genomic	B-X
and	B-X
proteomic	B-X
approaches	B-X
have	B-X
provided	B-X
snapshots	B-X
of	B-X
the	B-X
proteogenomics	B-X
of	B-X
ovarian	B-X
cancer	B-X
Ovarian	B-X
cancer	B-X
cell-secreted	B-X
exosomal	B-X
miR-205	B-X
promotes	B-X
metastasis	B-X
by	B-X
inducing	B-X
angiogenesis	B-X
.	B-X
The	B-X
development	B-X
of	B-X
lethal	B-X
cancer	B-X
metastasis	B-X
depends	B-X
on	B-X
the	B-X
dynamic	B-X
interactions	B-X
between	B-X
cancer	B-X
cells	B-X
and	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
both	B-X
of	B-X
which	B-X
are	B-X
embedded	B-X
in	B-X
the	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
.	B-X
The	B-X
acquisition	B-X
of	B-X
resistance	B-X
to	B-X
detachment-induced	B-X
apoptosis	B-X
,	B-X
also	B-X
known	B-X
as	B-X
anoikis	B-X
,	B-X
is	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
cascade	B-X
.	B-X

Lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
levels	O
are	O
elevated	O
in	O
ascites	O
from	O
ovarian	O
cancer	O
patients	O
,	O
but	O
its	O
potential	O
role	O
in	O
ovarian	O
cancer	O
metastasis	O
has	O
just	O
begun	O
to	O
be	O
revealed	O
.	O
<EOS>	B-X
Ovarian	B-X
cancer	B-X
is	B-X
a	B-X
highly	B-X
metastatic	B-X
disease	B-X
.	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X
Our	B-X
in	B-X
vivo	B-X
metastasis	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
efficacy	B-X
of	B-X
therapeutic	B-X
regimes	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

In	O
this	O
work	O
,	O
we	O
show	O
that	O
LPA	O
stimulates	O
invasion	O
of	O
primary	O
ovarian	O
cancer	O
cells	O
,	O
but	O
not	O
ovarian	O
epithelial	O
or	O
borderline	O
ovarian	O
tumor	O
cells	O
,	O
although	O
these	O
benign	O
cells	O
indeed	O
respond	O
to	O
LPA	O
in	O
cell	O
migration	O
.	O
<EOS>	B-X
Ovarian	B-X
cancer	B-X
is	B-X
a	B-X
highly	B-X
metastatic	B-X
disease	B-X
.	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X
Our	B-X
in	B-X
vivo	B-X
metastasis	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
efficacy	B-X
of	B-X
therapeutic	B-X
regimes	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

We	O
have	O
found	O
that	O
LPA	O
downregulates	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
metalloproteinases	I-Gene_or_gene_product
(	O
TIMPs	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X

TIMP2	B-Gene_or_gene_product
and	O
TIMP3	B-Gene_or_gene_product
play	O
functional	O
role	O
in	O
LPA	O
-	O
induced	O
invasion	O
as	O
negative	O
regulators	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
TIMP3	B-X
may	B-X
affect	B-X
two	B-X
independent	B-X
downstream	B-X
targets	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
p38	B-X
MAPK	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X

G	B-Gene_or_gene_product
(	I-Gene_or_gene_product
i	I-Gene_or_gene_product
)	I-Gene_or_gene_product
protein	O
,	O
phosphatidylinositol	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
PI3K	B-Gene_or_gene_product
)	O
,	O
p38	B-Gene_or_gene_product
mitogen	I-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
MAPK	B-Gene_or_gene_product
)	O
,	O
cytosolic	O
phospholipase	B-Gene_or_gene_product
A	I-Gene_or_gene_product
(	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	I-Gene_or_gene_product
and	O
urokinase	B-Gene_or_gene_product
type	I-Gene_or_gene_product
plasminogen	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
(	O
uPA	B-Gene_or_gene_product
)	O
are	O
required	O
for	O
LPA	O
-	O
induced	O
cells	O
invasion	O
.	O

TIMP3	B-Gene_or_gene_product
may	O
affect	O
two	O
independent	O
downstream	O
targets	O
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
and	O
p38	B-Gene_or_gene_product
MAPK	I-Gene_or_gene_product
.	O
<EOS>	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
TIMP3	B-X
may	B-X
affect	B-X
two	B-X
independent	B-X
downstream	B-X
targets	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
p38	B-X
MAPK	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X

In	O
vivo	O
,	O
LPA	O
stimulates	O
tumor	O
metastasis	O
in	O
an	O
orthotopic	O
ovarian	O
tumor	O
model	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
a	O
PI3K	B-Gene_or_gene_product
inhibitor	O
,	O
LY294002	O
.	O

In	O
summary	O
,	O
LPA	O
is	O
likely	O
a	O
key	O
component	O
for	O
promoting	O
ovarian	O
metastasis	O
in	O
vivo	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X
Our	B-X
in	B-X
vivo	B-X
metastasis	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
efficacy	B-X
of	B-X
therapeutic	B-X
regimes	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

LPA	O
downregulates	O
TIMP3	B-Gene_or_gene_product
,	O
which	O
may	O
have	O
targets	O
other	O
than	O
metalloproteinases	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
LPA	B-X
downregulates	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
.	B-X
TIMP2	B-X
and	B-X
TIMP3	B-X
play	B-X
functional	B-X
role	B-X
in	B-X
LPA-induced	B-X
invasion	B-X
as	B-X
negative	B-X
regulators	B-X
.	B-X
G	B-X
(	B-X
i	B-X
)	B-X
protein	B-X
,	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X
(	B-X
2	B-X
)	B-X
and	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
are	B-X
required	B-X
for	B-X
LPA-induced	B-X
cells	B-X
invasion	B-X
.	B-X
TIMP3	B-X
may	B-X
affect	B-X
two	B-X
independent	B-X
downstream	B-X
targets	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
p38	B-X
MAPK	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
LPA	B-X
downregulates	B-X
TIMP3	B-X
,	B-X
which	B-X
may	B-X
have	B-X
targets	B-X
other	B-X
than	B-X
metalloproteinases	B-X
.	B-X

Our	O
in	O
vivo	O
metastasis	O
mouse	O
model	O
is	O
useful	O
for	O
studying	O
the	O
efficacy	O
of	O
therapeutic	O
regimes	O
of	O
ovarian	O
cancer	O
.	O
<EOS>	B-X
Ovarian	B-X
cancer	B-X
is	B-X
a	B-X
highly	B-X
metastatic	B-X
disease	B-X
.	B-X
Lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
ascites	B-X
from	B-X
ovarian	B-X
cancer	B-X
patients	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
ovarian	B-X
cancer	B-X
metastasis	B-X
has	B-X
just	B-X
begun	B-X
to	B-X
be	B-X
revealed	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
show	B-X
that	B-X
LPA	B-X
stimulates	B-X
invasion	B-X
of	B-X
primary	B-X
ovarian	B-X
cancer	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
ovarian	B-X
epithelial	B-X
or	B-X
borderline	B-X
ovarian	B-X
tumor	B-X
cells	B-X
,	B-X
although	B-X
these	B-X
benign	B-X
cells	B-X
indeed	B-X
respond	B-X
to	B-X
LPA	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
LPA	B-X
stimulates	B-X
tumor	B-X
metastasis	B-X
in	B-X
an	B-X
orthotopic	B-X
ovarian	B-X
tumor	B-X
model	B-X
,	B-X
which	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
LPA	B-X
is	B-X
likely	B-X
a	B-X
key	B-X
component	B-X
for	B-X
promoting	B-X
ovarian	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
Our	B-X
in	B-X
vivo	B-X
metastasis	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
efficacy	B-X
of	B-X
therapeutic	B-X
regimes	B-X
of	B-X
ovarian	B-X
cancer	B-X
.	B-X

Role	O
of	O
the	O
fibrinolytic	O
and	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
systems	O
in	O
development	O
of	O
adipose	O
tissue	O
.	O
<EOS>	B-X
Development	B-X
of	B-X
obesity	B-X
is	B-X
associated	B-X
with	B-X
extensive	B-X
modifications	B-X
in	B-X
adipose	B-X
tissue	B-X
involving	B-X
adipogenesis	B-X
,	B-X
angiogenesis	B-X
and	B-X
extracellular	B-X
matrix	B-X
proteolysis	B-X
.	B-X
The	B-X
fibrinolytic	B-X
(	B-X
plasminogen/plasmin	B-X
)	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
(	B-X
MMP	B-X
)	B-X
systems	B-X
cooperate	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
A	B-X
nutritionally	B-X
induced	B-X
obesity	B-X
model	B-X
in	B-X
transgenic	B-X
mice	B-X
has	B-X
been	B-X
used	B-X
extensively	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
fibrinolytic	B-X
and	B-X
MMP	B-X
systems	B-X
in	B-X
the	B-X
development	B-X
of	B-X
obesity	B-X
.	B-X
These	B-X
studies	B-X
support	B-X
a	B-X
role	B-X
of	B-X
both	B-X
systems	B-X
in	B-X
adipogenesis	B-X
and	B-X
obesity	B-X
;	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
members	B-X
of	B-X
these	B-X
families	B-X
,	B-X
however	B-X
,	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X

Obesity	O
is	O
a	O
common	O
disorder	O
and	O
related	O
diseases	O
such	O
as	O
diabetes	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
cardiovascular	O
disease	O
and	O
cancer	O
are	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
in	O
Western	O
-	O
type	O
societies	O
.	O

Development	O
of	O
obesity	O
is	O
associated	O
with	O
extensive	O
modifications	O
in	O
adipose	O
tissue	O
involving	O
adipogenesis	O
,	O
angiogenesis	O
and	O
extracellular	O
matrix	O
proteolysis	O
.	O
<EOS>	B-X
Development	B-X
of	B-X
obesity	B-X
is	B-X
associated	B-X
with	B-X
extensive	B-X
modifications	B-X
in	B-X
adipose	B-X
tissue	B-X
involving	B-X
adipogenesis	B-X
,	B-X
angiogenesis	B-X
and	B-X
extracellular	B-X
matrix	B-X
proteolysis	B-X
.	B-X
The	B-X
fibrinolytic	B-X
(	B-X
plasminogen/plasmin	B-X
)	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
(	B-X
MMP	B-X
)	B-X
systems	B-X
cooperate	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
A	B-X
nutritionally	B-X
induced	B-X
obesity	B-X
model	B-X
in	B-X
transgenic	B-X
mice	B-X
has	B-X
been	B-X
used	B-X
extensively	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
fibrinolytic	B-X
and	B-X
MMP	B-X
systems	B-X
in	B-X
the	B-X
development	B-X
of	B-X
obesity	B-X
.	B-X
These	B-X
studies	B-X
support	B-X
a	B-X
role	B-X
of	B-X
both	B-X
systems	B-X
in	B-X
adipogenesis	B-X
and	B-X
obesity	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
modulation	B-X
of	B-X
proteolytic	B-X
activity	B-X
may	B-X
affect	B-X
development	B-X
of	B-X
adipose	B-X
tissue	B-X
.	B-X

The	O
fibrinolytic	O
(	O
plasminogen	B-Gene_or_gene_product
/	O
plasmin	B-Gene_or_gene_product
)	O
and	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
(	O
MMP	B-Gene_or_gene_product
)	O
systems	O
cooperate	O
in	O
these	O
processes	O
.	O
<EOS>	B-X
Development	B-X
of	B-X
obesity	B-X
is	B-X
associated	B-X
with	B-X
extensive	B-X
modifications	B-X
in	B-X
adipose	B-X
tissue	B-X
involving	B-X
adipogenesis	B-X
,	B-X
angiogenesis	B-X
and	B-X
extracellular	B-X
matrix	B-X
proteolysis	B-X
.	B-X
The	B-X
fibrinolytic	B-X
(	B-X
plasminogen/plasmin	B-X
)	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
(	B-X
MMP	B-X
)	B-X
systems	B-X
cooperate	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
A	B-X
nutritionally	B-X
induced	B-X
obesity	B-X
model	B-X
in	B-X
transgenic	B-X
mice	B-X
has	B-X
been	B-X
used	B-X
extensively	B-X
to	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
fibrinolytic	B-X
and	B-X
MMP	B-X
systems	B-X
in	B-X
the	B-X
development	B-X
of	B-X
obesity	B-X
.	B-X
These	B-X
studies	B-X
support	B-X
a	B-X
role	B-X
of	B-X
both	B-X
systems	B-X
in	B-X
adipogenesis	B-X
and	B-X
obesity	B-X
;	B-X
the	B-X
role	B-X
of	B-X
specific	B-X
members	B-X
of	B-X
these	B-X
families	B-X
,	B-X
however	B-X
,	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X

A	O
nutritionally	O
induced	O
obesity	O
model	O
in	O
transgenic	O
mice	O
has	O
been	O
used	O
extensively	O
to	O
study	O
the	O
role	O
of	O
the	O
fibrinolytic	O
and	O
MMP	B-Gene_or_gene_product
systems	O
in	O
the	O
development	O
of	O
obesity	O
.	O

These	O
studies	O
support	O
a	O
role	O
of	O
both	O
systems	O
in	O
adipogenesis	O
and	O
obesity	O
;	O
the	O
role	O
of	O
specific	O
members	O
of	O
these	O
families	O
,	O
however	O
,	O
remains	O
to	O
be	O
determined	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
genetic	B-X
basis	B-X
of	B-X
obesity	B-X
better	B-X
,	B-X
here	B-X
we	B-X
conduct	B-X
a	B-X
genome-wide	B-X
association	B-X
study	B-X
and	B-X
Metabochip	B-X
meta-analysis	B-X
of	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
,	B-X
a	B-X
measure	B-X
commonly	B-X
used	B-X
to	B-X
define	B-X
obesity	B-X
and	B-X
assess	B-X
adiposity	B-X
,	B-X
in	B-X
up	B-X
to	B-X
339,224	B-X
individuals	B-X
.	B-X
Pathway	B-X
analyses	B-X
provide	B-X
strong	B-X
support	B-X
for	B-X
a	B-X
role	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
in	B-X
obesity	B-X
susceptibility	B-X
and	B-X
implicate	B-X
new	B-X
genes	B-X
and	B-X
pathways	B-X
,	B-X
including	B-X
those	B-X
related	B-X
to	B-X
synaptic	B-X
function	B-X
,	B-X
glutamate	B-X
signalling	B-X
,	B-X
insulin	B-X
secretion/action	B-X
,	B-X
energy	B-X
metabolism	B-X
,	B-X
lipid	B-X
biology	B-X
and	B-X
adipogenesis	B-X
.	B-X
Some	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
obesity	B-X
not	B-X
always	B-X
entails	B-X
metabolic	B-X
abnormalities	B-X
and	B-X
increased	B-X
risk	B-X
of	B-X
cardiometabolic	B-X
complications	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
lack	B-X
of	B-X
universally	B-X
accepted	B-X
criteria	B-X
to	B-X
identify	B-X
metabolically	B-X
healthy	B-X
obesity	B-X
(	B-X
MHO	B-X
)	B-X
,	B-X
its	B-X
prevalence	B-X
varies	B-X
widely	B-X
among	B-X
studies	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
prognostic	B-X
value	B-X
of	B-X
MHO	B-X
is	B-X
hotly	B-X
debated	B-X
,	B-X
mainly	B-X
because	B-X
it	B-X
likely	B-X
shifts	B-X
gradually	B-X
towards	B-X
metabolically	B-X
unhealthy	B-X
obesity	B-X
(	B-X
MUO	B-X
)	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
outline	B-X
the	B-X
differential	B-X
factors	B-X
contributing	B-X
to	B-X
the	B-X
metabolic	B-X
heterogeneity	B-X
of	B-X
obesity	B-X
by	B-X
discussing	B-X
the	B-X
behavioral	B-X
,	B-X
genetic	B-X
,	B-X
phenotypical	B-X
,	B-X
and	B-X
biological	B-X
aspects	B-X
associated	B-X
with	B-X
each	B-X
of	B-X
the	B-X
two	B-X
metabolic	B-X
phenotypes	B-X
(	B-X
MHO	B-X
and	B-X
MUO	B-X
)	B-X
of	B-X
obesity	B-X
and	B-X
their	B-X
clinical	B-X
implications	B-X
.	B-X
Particular	B-X
emphasis	B-X
will	B-X
be	B-X
laid	B-X
on	B-X
the	B-X
role	B-X
of	B-X
adipose	B-X
tissue	B-X
biology	B-X
and	B-X
function	B-X
,	B-X
including	B-X
genetic	B-X
determinants	B-X
of	B-X
body	B-X
fat	B-X
distribution	B-X
,	B-X
depot-specific	B-X
fat	B-X
metabolism	B-X
,	B-X
adipose	B-X
tissue	B-X
plasticity	B-X
and	B-X
,	B-X
particularly	B-X
,	B-X
adipogenesis	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
emerging	B-X
role	B-X
of	B-X
gut	B-X
microbiota	B-X
in	B-X
obesity	B-X
and	B-X
adipose	B-X
tissue	B-X
dysfunction	B-X
as	B-X
well	B-X
as	B-X
the	B-X
search	B-X
for	B-X
novel	B-X
biomarkers	B-X
for	B-X
the	B-X
obesity-related	B-X
metabolic	B-X
traits	B-X
and	B-X
associated	B-X
diseases	B-X
will	B-X
be	B-X
briefly	B-X
presented	B-X
.	B-X
A	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
main	B-X
determinants	B-X
of	B-X
a	B-X
healthy	B-X
metabolic	B-X
status	B-X
in	B-X
obesity	B-X
would	B-X
allow	B-X
promotion	B-X
of	B-X
this	B-X
favorable	B-X
condition	B-X
by	B-X
targeting	B-X
the	B-X
relevant	B-X
pathways	B-X
.	B-X

Extracellular	O
matrix	O
as	O
a	O
bioactive	O
material	O
for	O
soft	O
tissue	O
reconstruction	O
.	O
<EOS>	B-X
The	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
directs	B-X
all	B-X
phases	B-X
of	B-X
healing	B-X
following	B-X
trauma	B-X
or	B-X
disease	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
natural	B-X
source	B-X
of	B-X
prosthetic	B-X
mesh	B-X
material	B-X
that	B-X
can	B-X
be	B-X
used	B-X
strategically	B-X
to	B-X
induce	B-X
the	B-X
repair	B-X
and	B-X
restoration	B-X
of	B-X
soft	B-X
tissues	B-X
following	B-X
surgery	B-X
.	B-X
Biomaterials	B-X
such	B-X
as	B-X
Surgisis	B-X
(	B-X
Cook	B-X
Biotech	B-X
Incorporated	B-X
,	B-X
West	B-X
Lafayette	B-X
,	B-X
IN	B-X
,	B-X
USA	B-X
)	B-X
,	B-X
which	B-X
are	B-X
derived	B-X
from	B-X
natural	B-X
ECM	B-X
,	B-X
provide	B-X
the	B-X
extracellular	B-X
components	B-X
necessary	B-X
to	B-X
direct	B-X
the	B-X
healing	B-X
response	B-X
,	B-X
allow	B-X
for	B-X
the	B-X
proliferation	B-X
of	B-X
new	B-X
,	B-X
healthy	B-X
tissue	B-X
and	B-X
restore	B-X
tissue	B-X
integrity	B-X
to	B-X
the	B-X
damaged	B-X
site	B-X
.	B-X
The	B-X
3-D	B-X
organization	B-X
of	B-X
these	B-X
extracellular	B-X
components	B-X
distinguishes	B-X
the	B-X
Surgisis	B-X
mesh	B-X
from	B-X
synthetic	B-X
materials	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
constructive	B-X
tissue	B-X
remodelling	B-X
instead	B-X
of	B-X
scar	B-X
tissue	B-X
.	B-X
Common	B-X
features	B-X
of	B-X
this	B-X
ECM-assisted	B-X
tissue	B-X
remodelling	B-X
include	B-X
angiogenesis	B-X
,	B-X
recruitment	B-X
of	B-X
circulating	B-X
progenitor	B-X
cells	B-X
and	B-X
constructive	B-X
remodelling	B-X
of	B-X
damaged	B-X
tissue	B-X
structures	B-X
.	B-X
The	B-X
tissue	B-X
response	B-X
to	B-X
this	B-X
biologic	B-X
mesh	B-X
is	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
recent	B-X
reports	B-X
on	B-X
clinical	B-X
hernia	B-X
repair	B-X
.	B-X

The	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
directs	O
all	O
phases	O
of	O
healing	O
following	O
trauma	O
or	O
disease	O
and	O
is	O
therefore	O
a	O
natural	O
source	O
of	O
prosthetic	O
mesh	O
material	O
that	O
can	O
be	O
used	O
strategically	O
to	O
induce	O
the	O
repair	O
and	O
restoration	O
of	O
soft	O
tissues	O
following	O
surgery	O
.	O
<EOS>	B-X
The	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
directs	B-X
all	B-X
phases	B-X
of	B-X
healing	B-X
following	B-X
trauma	B-X
or	B-X
disease	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
natural	B-X
source	B-X
of	B-X
prosthetic	B-X
mesh	B-X
material	B-X
that	B-X
can	B-X
be	B-X
used	B-X
strategically	B-X
to	B-X
induce	B-X
the	B-X
repair	B-X
and	B-X
restoration	B-X
of	B-X
soft	B-X
tissues	B-X
following	B-X
surgery	B-X
.	B-X
Biomaterials	B-X
such	B-X
as	B-X
Surgisis	B-X
(	B-X
Cook	B-X
Biotech	B-X
Incorporated	B-X
,	B-X
West	B-X
Lafayette	B-X
,	B-X
IN	B-X
,	B-X
USA	B-X
)	B-X
,	B-X
which	B-X
are	B-X
derived	B-X
from	B-X
natural	B-X
ECM	B-X
,	B-X
provide	B-X
the	B-X
extracellular	B-X
components	B-X
necessary	B-X
to	B-X
direct	B-X
the	B-X
healing	B-X
response	B-X
,	B-X
allow	B-X
for	B-X
the	B-X
proliferation	B-X
of	B-X
new	B-X
,	B-X
healthy	B-X
tissue	B-X
and	B-X
restore	B-X
tissue	B-X
integrity	B-X
to	B-X
the	B-X
damaged	B-X
site	B-X
.	B-X
The	B-X
3-D	B-X
organization	B-X
of	B-X
these	B-X
extracellular	B-X
components	B-X
distinguishes	B-X
the	B-X
Surgisis	B-X
mesh	B-X
from	B-X
synthetic	B-X
materials	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
constructive	B-X
tissue	B-X
remodelling	B-X
instead	B-X
of	B-X
scar	B-X
tissue	B-X
.	B-X
Common	B-X
features	B-X
of	B-X
this	B-X
ECM-assisted	B-X
tissue	B-X
remodelling	B-X
include	B-X
angiogenesis	B-X
,	B-X
recruitment	B-X
of	B-X
circulating	B-X
progenitor	B-X
cells	B-X
and	B-X
constructive	B-X
remodelling	B-X
of	B-X
damaged	B-X
tissue	B-X
structures	B-X
.	B-X
The	B-X
tissue	B-X
response	B-X
to	B-X
this	B-X
biologic	B-X
mesh	B-X
is	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
recent	B-X
reports	B-X
on	B-X
clinical	B-X
hernia	B-X
repair	B-X
.	B-X

Biomaterials	O
such	O
as	O
Surgisis	O
(	O
Cook	O
Biotech	O
Incorporated	O
,	O
West	O
Lafayette	O
,	O
IN	O
,	O
USA	O
)	O
,	O
which	O
are	O
derived	O
from	O
natural	O
ECM	O
,	O
provide	O
the	O
extracellular	O
components	O
necessary	O
to	O
direct	O
the	O
healing	O
response	O
,	O
allow	O
for	O
the	O
proliferation	O
of	O
new	O
,	O
healthy	O
tissue	O
and	O
restore	O
tissue	O
integrity	O
to	O
the	O
damaged	O
site	O
.	O

The	O
3	O
-	O
D	O
organization	O
of	O
these	O
extracellular	O
components	O
distinguishes	O
the	O
Surgisis	O
mesh	O
from	O
synthetic	O
materials	O
and	O
is	O
associated	O
with	O
constructive	O
tissue	O
remodelling	O
instead	O
of	O
scar	O
tissue	O
.	O
<EOS>	B-X
The	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
directs	B-X
all	B-X
phases	B-X
of	B-X
healing	B-X
following	B-X
trauma	B-X
or	B-X
disease	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
natural	B-X
source	B-X
of	B-X
prosthetic	B-X
mesh	B-X
material	B-X
that	B-X
can	B-X
be	B-X
used	B-X
strategically	B-X
to	B-X
induce	B-X
the	B-X
repair	B-X
and	B-X
restoration	B-X
of	B-X
soft	B-X
tissues	B-X
following	B-X
surgery	B-X
.	B-X
Biomaterials	B-X
such	B-X
as	B-X
Surgisis	B-X
(	B-X
Cook	B-X
Biotech	B-X
Incorporated	B-X
,	B-X
West	B-X
Lafayette	B-X
,	B-X
IN	B-X
,	B-X
USA	B-X
)	B-X
,	B-X
which	B-X
are	B-X
derived	B-X
from	B-X
natural	B-X
ECM	B-X
,	B-X
provide	B-X
the	B-X
extracellular	B-X
components	B-X
necessary	B-X
to	B-X
direct	B-X
the	B-X
healing	B-X
response	B-X
,	B-X
allow	B-X
for	B-X
the	B-X
proliferation	B-X
of	B-X
new	B-X
,	B-X
healthy	B-X
tissue	B-X
and	B-X
restore	B-X
tissue	B-X
integrity	B-X
to	B-X
the	B-X
damaged	B-X
site	B-X
.	B-X
The	B-X
3-D	B-X
organization	B-X
of	B-X
these	B-X
extracellular	B-X
components	B-X
distinguishes	B-X
the	B-X
Surgisis	B-X
mesh	B-X
from	B-X
synthetic	B-X
materials	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
constructive	B-X
tissue	B-X
remodelling	B-X
instead	B-X
of	B-X
scar	B-X
tissue	B-X
.	B-X
Common	B-X
features	B-X
of	B-X
this	B-X
ECM-assisted	B-X
tissue	B-X
remodelling	B-X
include	B-X
angiogenesis	B-X
,	B-X
recruitment	B-X
of	B-X
circulating	B-X
progenitor	B-X
cells	B-X
and	B-X
constructive	B-X
remodelling	B-X
of	B-X
damaged	B-X
tissue	B-X
structures	B-X
.	B-X
The	B-X
tissue	B-X
response	B-X
to	B-X
this	B-X
biologic	B-X
mesh	B-X
is	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
recent	B-X
reports	B-X
on	B-X
clinical	B-X
hernia	B-X
repair	B-X
.	B-X

Common	O
features	O
of	O
this	O
ECM	O
-	O
assisted	O
tissue	O
remodelling	O
include	O
angiogenesis	O
,	O
recruitment	O
of	O
circulating	O
progenitor	O
cells	O
and	O
constructive	O
remodelling	O
of	O
damaged	O
tissue	O
structures	O
.	O
<EOS>	B-X
The	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
directs	B-X
all	B-X
phases	B-X
of	B-X
healing	B-X
following	B-X
trauma	B-X
or	B-X
disease	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
natural	B-X
source	B-X
of	B-X
prosthetic	B-X
mesh	B-X
material	B-X
that	B-X
can	B-X
be	B-X
used	B-X
strategically	B-X
to	B-X
induce	B-X
the	B-X
repair	B-X
and	B-X
restoration	B-X
of	B-X
soft	B-X
tissues	B-X
following	B-X
surgery	B-X
.	B-X
Biomaterials	B-X
such	B-X
as	B-X
Surgisis	B-X
(	B-X
Cook	B-X
Biotech	B-X
Incorporated	B-X
,	B-X
West	B-X
Lafayette	B-X
,	B-X
IN	B-X
,	B-X
USA	B-X
)	B-X
,	B-X
which	B-X
are	B-X
derived	B-X
from	B-X
natural	B-X
ECM	B-X
,	B-X
provide	B-X
the	B-X
extracellular	B-X
components	B-X
necessary	B-X
to	B-X
direct	B-X
the	B-X
healing	B-X
response	B-X
,	B-X
allow	B-X
for	B-X
the	B-X
proliferation	B-X
of	B-X
new	B-X
,	B-X
healthy	B-X
tissue	B-X
and	B-X
restore	B-X
tissue	B-X
integrity	B-X
to	B-X
the	B-X
damaged	B-X
site	B-X
.	B-X
The	B-X
3-D	B-X
organization	B-X
of	B-X
these	B-X
extracellular	B-X
components	B-X
distinguishes	B-X
the	B-X
Surgisis	B-X
mesh	B-X
from	B-X
synthetic	B-X
materials	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
constructive	B-X
tissue	B-X
remodelling	B-X
instead	B-X
of	B-X
scar	B-X
tissue	B-X
.	B-X
Common	B-X
features	B-X
of	B-X
this	B-X
ECM-assisted	B-X
tissue	B-X
remodelling	B-X
include	B-X
angiogenesis	B-X
,	B-X
recruitment	B-X
of	B-X
circulating	B-X
progenitor	B-X
cells	B-X
and	B-X
constructive	B-X
remodelling	B-X
of	B-X
damaged	B-X
tissue	B-X
structures	B-X
.	B-X
The	B-X
tissue	B-X
response	B-X
to	B-X
this	B-X
biologic	B-X
mesh	B-X
is	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
recent	B-X
reports	B-X
on	B-X
clinical	B-X
hernia	B-X
repair	B-X
.	B-X

The	O
tissue	O
response	O
to	O
this	O
biologic	O
mesh	O
is	O
discussed	O
in	O
the	O
context	O
of	O
recent	O
reports	O
on	O
clinical	O
hernia	O
repair	O
.	O
<EOS>	B-X
When	B-X
used	B-X
strategically	B-X
to	B-X
induce	B-X
the	B-X
repair	B-X
and	B-X
restoration	B-X
of	B-X
soft	B-X
tissues	B-X
following	B-X
surgery	B-X
,	B-X
exogenous	B-X
extracellular	B-X
matrix	B-X
scaffolds	B-X
interact	B-X
with	B-X
surrounding	B-X
tissues	B-X
and	B-X
cells	B-X
to	B-X
form	B-X
a	B-X
permanent	B-X
repair	B-X
without	B-X
leaving	B-X
behind	B-X
a	B-X
permanent	B-X
material	B-X
that	B-X
can	B-X
result	B-X
in	B-X
chronic	B-X
inflammation	B-X
or	B-X
infection	B-X
.	B-X
Biomaterials	B-X
derived	B-X
from	B-X
natural	B-X
extracellular	B-X
matrix	B-X
,	B-X
such	B-X
as	B-X
Surgisis	B-X
(	B-X
Cook	B-X
Medical	B-X
Incorporated	B-X
,	B-X
Bloomington	B-X
,	B-X
IN	B-X
,	B-X
USA	B-X
)	B-X
,	B-X
provide	B-X
the	B-X
extracellular	B-X
components	B-X
necessary	B-X
to	B-X
direct	B-X
the	B-X
healing	B-X
response	B-X
,	B-X
allow	B-X
for	B-X
the	B-X
reconstruction	B-X
of	B-X
new	B-X
,	B-X
healthy	B-X
tissue	B-X
and	B-X
restore	B-X
mechanical	B-X
and	B-X
functional	B-X
integrity	B-X
to	B-X
the	B-X
damaged	B-X
site	B-X
.	B-X
The	B-X
3-dimensional	B-X
organization	B-X
of	B-X
these	B-X
extracellular	B-X
components	B-X
distinguishes	B-X
the	B-X
Surgisis	B-X
mesh	B-X
from	B-X
synthetic	B-X
materials	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
better	B-X
long-term	B-X
repairs	B-X
.	B-X
The	B-X
tissue	B-X
response	B-X
to	B-X
this	B-X
biologic	B-X
mesh	B-X
is	B-X
discussed	B-X
in	B-X
the	B-X
context	B-X
of	B-X
recent	B-X
reports	B-X
on	B-X
successful	B-X
clinical	B-X
applications	B-X
.	B-X

[	O
Study	O
on	O
the	O
expression	O
of	O
angiogenesis	O
and	O
spontaneous	O
apoptosis	O
and	O
their	O
relevance	O
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
relationship	O
among	O
angiogenesis	O
,	O
spontaneous	O
apoptosis	O
and	O
clinicopathological	O
parameters	O
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
(	O
LSCC	O
)	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
among	B-X
angiogenesis	B-X
,	B-X
spontaneous	B-X
apoptosis	B-X
and	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
laryngeal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
LSCC	B-X
)	B-X
.	B-X

METHOD	O
:	O
The	O
intratumor	O
microvessel	O
density	O
(	O
IMVD	O
)	O
,	O
apoptotic	O
index	O
(	O
AI	O
)	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
expression	O
were	O
detected	O
by	O
immunohistochemistry	O
SABC	O
and	O
terminal	O
uridine	O
deoxynucleotidyl	O
transferase	O
mediated	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
methods	O
in34	O
LSCC	O
patients	O
.	O

RESULT	O
:	O
The	O
average	O
IMVD	O
was	O
(	O
21	O
.	O
50	O
+	O
/	O
-	O
8	O
.	O
87	O
)	O
,	O
and	O
median	O
of	O
AI	O
was	O
1	O
.	O
15	O
%	O
.	O

The	O
average	O
IMVD	O
in	O
positive	O
and	O
negative	O
cervical	O
lymphatic	O
metastasis	O
was	O
(	O
26	O
.	O
33	O
+	O
/	O
-	O
9	O
.	O
70	O
)	O
and	O
(	O
17	O
.	O
68	O
+	O
/	O
-	O
6	O
.	O
06	O
)	O
respectively	O
,	O
and	O
the	O
IMVD	O
with	O
positive	O
lymphatic	O
metastasis	O
tumors	O
was	O
statistical	O
significantly	O
higher	O
than	O
those	O
with	O
negative	O
cervical	O
lymphatic	O
metastasis	O
tumors	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
average	O
IMVD	O
had	O
statistical	O
difference	O
in	O
histological	O
grading	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
and	O
analysis	O
by	O
one	O
to	O
one	O
,	O
the	O
average	O
IMVD	O
had	O
statistical	O
difference	O
between	O
high	O
and	O
median	O
grading	O
.	O

Expression	O
of	O
VEGF	B-Gene_or_gene_product
had	O
a	O
significantly	O
positive	O
correlation	O
with	O
IMVD	O
(	O
r	O
=	O
0	O
.	O
51	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Statistical	O
analysis	O
revealed	O
a	O
significantly	O
inverse	O
correlation	O
between	O
AI	O
and	O
IMVD	O
(	O
r	O
=	O
-	O
0	O
.	O
53	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
failed	O
to	O
find	O
the	O
statistical	O
difference	O
between	O
IMVD	O
and	O
tumor	O
T	O
-	O
stage	O
in	O
LSCC	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
among	B-X
angiogenesis	B-X
,	B-X
spontaneous	B-X
apoptosis	B-X
and	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
laryngeal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
LSCC	B-X
)	B-X
.	B-X

CONCLUSION	O
:	O
IMVD	O
may	O
be	O
an	O
important	O
indicator	O
to	O
predict	O
cervical	O
lymphatic	O
metastasis	O
in	O
LSCC	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
among	B-X
angiogenesis	B-X
,	B-X
spontaneous	B-X
apoptosis	B-X
and	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
laryngeal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
LSCC	B-X
)	B-X
.	B-X

VEGF	B-Gene_or_gene_product
might	O
be	O
an	O
important	O
angiogenic	O
factor	O
,	O
and	O
could	O
promote	O
tumor	O
angiogenesis	O
in	O
LSCC	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
among	B-X
angiogenesis	B-X
,	B-X
spontaneous	B-X
apoptosis	B-X
and	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
laryngeal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
LSCC	B-X
)	B-X
.	B-X

Tumor	O
angiogenesis	O
might	O
contribute	O
to	O
tumor	O
malignant	O
progression	O
by	O
inhibiting	O
spontaneous	O
apoptosis	O
in	O
LSCC	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
among	B-X
angiogenesis	B-X
,	B-X
spontaneous	B-X
apoptosis	B-X
and	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
laryngeal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
LSCC	B-X
)	B-X
.	B-X

The	O
cancer	O
cell	O
'	O
s	O
"	O
power	O
plants	O
"	O
as	O
promising	O
therapeutic	O
targets	O
:	O
an	O
overview	O
.	O
<EOS>	B-X
This	B-X
introductory	B-X
article	B-X
to	B-X
the	B-X
review	B-X
series	B-X
entitled	B-X
``	B-X
The	B-X
Cancer	B-X
Cell	B-X
's	B-X
Power	B-X
Plants	B-X
as	B-X
Promising	B-X
Therapeutic	B-X
Targets	B-X
''	B-X
is	B-X
written	B-X
while	B-X
more	B-X
than	B-X
20	B-X
million	B-X
people	B-X
suffer	B-X
from	B-X
cancer	B-X
.	B-X
It	B-X
summarizes	B-X
strategies	B-X
to	B-X
destroy	B-X
or	B-X
prevent	B-X
cancers	B-X
by	B-X
targeting	B-X
their	B-X
energy	B-X
production	B-X
factories	B-X
,	B-X
i.e.	B-X
,	B-X
``	B-X
power	B-X
plants	B-X
.	B-X
''	B-X
All	B-X
nucleated	B-X
animal/human	B-X
cells	B-X
have	B-X
two	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
,	B-X
i.e.	B-X
,	B-X
systems	B-X
that	B-X
make	B-X
the	B-X
``	B-X
high	B-X
energy	B-X
''	B-X
compound	B-X
ATP	B-X
from	B-X
ADP	B-X
and	B-X
P	B-X
(	B-X
i	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
most	B-X
normal	B-X
cells	B-X
where	B-X
the	B-X
mitochondria	B-X
are	B-X
the	B-X
major	B-X
ATP	B-X
producers	B-X
(	B-X
>	B-X
90	B-X
%	B-X
)	B-X
in	B-X
fueling	B-X
growth	B-X
,	B-X
human	B-X
cancers	B-X
detected	B-X
via	B-X
Positron	B-X
Emission	B-X
Tomography	B-X
(	B-X
PET	B-X
)	B-X
rely	B-X
on	B-X
both	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
.	B-X
In	B-X
such	B-X
cancers	B-X
,	B-X
glycolysis	B-X
may	B-X
contribute	B-X
nearly	B-X
half	B-X
the	B-X
ATP	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
(	B-X
``	B-X
Warburg	B-X
effect	B-X
''	B-X
)	B-X
.	B-X
Based	B-X
solely	B-X
on	B-X
cell	B-X
energetics	B-X
,	B-X
this	B-X
presents	B-X
a	B-X
challenge	B-X
to	B-X
identify	B-X
curative	B-X
agents	B-X
that	B-X
destroy	B-X
only	B-X
cancer	B-X
cells	B-X
as	B-X
they	B-X
must	B-X
destroy	B-X
both	B-X
of	B-X
their	B-X
power	B-X
plants	B-X
causing	B-X
``	B-X
necrotic	B-X
cell	B-X
death	B-X
''	B-X
and	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
.	B-X
One	B-X
such	B-X
agent	B-X
,	B-X
3-bromopyruvate	B-X
(	B-X
3-BrPA	B-X
)	B-X
,	B-X
a	B-X
lactic	B-X
acid	B-X
analog	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
both	B-X
glycolytic	B-X
and	B-X
mitochondrial	B-X
ATP	B-X
production	B-X
in	B-X
rapidly	B-X
growing	B-X
cancers	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Cancer	B-X
Letts.	B-X
,	B-X
173	B-X
,	B-X
83-91	B-X
,	B-X
2001	B-X
)	B-X
,	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
,	B-X
and	B-X
eradicate	B-X
advanced	B-X
cancers	B-X
(	B-X
19	B-X
of	B-X
19	B-X
)	B-X
in	B-X
a	B-X
rodent	B-X
model	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Biochem	B-X
.	B-X
A	B-X
second	B-X
approach	B-X
is	B-X
to	B-X
induce	B-X
only	B-X
cancer	B-X
cells	B-X
to	B-X
undergo	B-X
``	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
''	B-X
Here	B-X
,	B-X
mitochondria	B-X
release	B-X
cell	B-X
death	B-X
inducing	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
cytochrome	B-X
c	B-X
)	B-X
.	B-X
In	B-X
a	B-X
third	B-X
approach	B-X
,	B-X
cancer	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
die	B-X
by	B-X
both	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
events	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
much	B-X
effort	B-X
is	B-X
being	B-X
focused	B-X
on	B-X
identifying	B-X
agents	B-X
that	B-X
induce	B-X
``	B-X
necrotic	B-X
,	B-X
''	B-X
``	B-X
apoptotic	B-X
''	B-X
or	B-X
apoptotic	B-X
plus	B-X
necrotic	B-X
cell	B-X
death	B-X
only	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
Regardless	B-X
how	B-X
death	B-X
is	B-X
inflicted	B-X
,	B-X
every	B-X
cancer	B-X
cell	B-X
must	B-X
die	B-X
,	B-X
be	B-X
it	B-X
fast	B-X
or	B-X
slow	B-X
.	B-X

This	O
introductory	O
article	O
to	O
the	O
review	O
series	O
entitled	O
"	O
The	O
Cancer	O
Cell	O
'	O
s	O
Power	O
Plants	O
as	O
Promising	O
Therapeutic	O
Targets	O
"	O
is	O
written	O
while	O
more	O
than	O
20	O
million	O
people	O
suffer	O
from	O
cancer	O
.	O

It	O
summarizes	O
strategies	O
to	O
destroy	O
or	O
prevent	O
cancers	O
by	O
targeting	O
their	O
energy	O
production	O
factories	O
,	O
i	O
.	O
e	O
.	O
,	O
"	O
power	O
plants	O
.	O
"	O
All	O
nucleated	O
animal	O
/	O
human	O
cells	O
have	O
two	O
types	O
of	O
power	O
plants	O
,	O
i	O
.	O
e	O
.	O
,	O
systems	O
that	O
make	O
the	O
"	O
high	O
energy	O
"	O
compound	O
ATP	O
from	O
ADP	O
and	O
P	O
(	O
i	O
)	O
.	O

One	O
type	O
is	O
"	O
glycolysis	O
,	O
"	O
the	O
other	O
the	O
"	O
mitochondria	O
.	O
"	O
In	O
contrast	O
to	O
most	O
normal	O
cells	O
where	O
the	O
mitochondria	O
are	O
the	O
major	O
ATP	O
producers	O
(	O
>	O
90	O
%	O
)	O
in	O
fueling	O
growth	O
,	O
human	O
cancers	O
detected	O
via	O
Positron	O
Emission	O
Tomography	O
(	O
PET	O
)	O
rely	O
on	O
both	O
types	O
of	O
power	O
plants	O
.	O

In	O
such	O
cancers	O
,	O
glycolysis	O
may	O
contribute	O
nearly	O
half	O
the	O
ATP	O
even	O
in	O
the	O
presence	O
of	O
oxygen	O
(	O
"	O
Warburg	O
effect	O
"	O
)	O
.	O
<EOS>	B-X
It	B-X
summarizes	B-X
strategies	B-X
to	B-X
destroy	B-X
or	B-X
prevent	B-X
cancers	B-X
by	B-X
targeting	B-X
their	B-X
energy	B-X
production	B-X
factories	B-X
,	B-X
i.e.	B-X
,	B-X
``	B-X
power	B-X
plants	B-X
.	B-X
''	B-X
All	B-X
nucleated	B-X
animal/human	B-X
cells	B-X
have	B-X
two	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
,	B-X
i.e.	B-X
,	B-X
systems	B-X
that	B-X
make	B-X
the	B-X
``	B-X
high	B-X
energy	B-X
''	B-X
compound	B-X
ATP	B-X
from	B-X
ADP	B-X
and	B-X
P	B-X
(	B-X
i	B-X
)	B-X
.	B-X
One	B-X
type	B-X
is	B-X
``	B-X
glycolysis	B-X
,	B-X
''	B-X
the	B-X
other	B-X
the	B-X
``	B-X
mitochondria	B-X
.	B-X
''	B-X
In	B-X
contrast	B-X
to	B-X
most	B-X
normal	B-X
cells	B-X
where	B-X
the	B-X
mitochondria	B-X
are	B-X
the	B-X
major	B-X
ATP	B-X
producers	B-X
(	B-X
>	B-X
90	B-X
%	B-X
)	B-X
in	B-X
fueling	B-X
growth	B-X
,	B-X
human	B-X
cancers	B-X
detected	B-X
via	B-X
Positron	B-X
Emission	B-X
Tomography	B-X
(	B-X
PET	B-X
)	B-X
rely	B-X
on	B-X
both	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
.	B-X
In	B-X
such	B-X
cancers	B-X
,	B-X
glycolysis	B-X
may	B-X
contribute	B-X
nearly	B-X
half	B-X
the	B-X
ATP	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
(	B-X
``	B-X
Warburg	B-X
effect	B-X
''	B-X
)	B-X
.	B-X
One	B-X
such	B-X
agent	B-X
,	B-X
3-bromopyruvate	B-X
(	B-X
3-BrPA	B-X
)	B-X
,	B-X
a	B-X
lactic	B-X
acid	B-X
analog	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
both	B-X
glycolytic	B-X
and	B-X
mitochondrial	B-X
ATP	B-X
production	B-X
in	B-X
rapidly	B-X
growing	B-X
cancers	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Cancer	B-X
Letts.	B-X
,	B-X
173	B-X
,	B-X
83-91	B-X
,	B-X
2001	B-X
)	B-X
,	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
,	B-X
and	B-X
eradicate	B-X
advanced	B-X
cancers	B-X
(	B-X
19	B-X
of	B-X
19	B-X
)	B-X
in	B-X
a	B-X
rodent	B-X
model	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Biochem	B-X
.	B-X
In	B-X
a	B-X
third	B-X
approach	B-X
,	B-X
cancer	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
die	B-X
by	B-X
both	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
events	B-X
.	B-X

Based	O
solely	O
on	O
cell	O
energetics	O
,	O
this	O
presents	O
a	O
challenge	O
to	O
identify	O
curative	O
agents	O
that	O
destroy	O
only	O
cancer	O
cells	O
as	O
they	O
must	O
destroy	O
both	O
of	O
their	O
power	O
plants	O
causing	O
"	O
necrotic	O
cell	O
death	O
"	O
and	O
leave	O
normal	O
cells	O
alone	O
.	O
<EOS>	B-X
This	B-X
introductory	B-X
article	B-X
to	B-X
the	B-X
review	B-X
series	B-X
entitled	B-X
``	B-X
The	B-X
Cancer	B-X
Cell	B-X
's	B-X
Power	B-X
Plants	B-X
as	B-X
Promising	B-X
Therapeutic	B-X
Targets	B-X
''	B-X
is	B-X
written	B-X
while	B-X
more	B-X
than	B-X
20	B-X
million	B-X
people	B-X
suffer	B-X
from	B-X
cancer	B-X
.	B-X
It	B-X
summarizes	B-X
strategies	B-X
to	B-X
destroy	B-X
or	B-X
prevent	B-X
cancers	B-X
by	B-X
targeting	B-X
their	B-X
energy	B-X
production	B-X
factories	B-X
,	B-X
i.e.	B-X
,	B-X
``	B-X
power	B-X
plants	B-X
.	B-X
''	B-X
All	B-X
nucleated	B-X
animal/human	B-X
cells	B-X
have	B-X
two	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
,	B-X
i.e.	B-X
,	B-X
systems	B-X
that	B-X
make	B-X
the	B-X
``	B-X
high	B-X
energy	B-X
''	B-X
compound	B-X
ATP	B-X
from	B-X
ADP	B-X
and	B-X
P	B-X
(	B-X
i	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
most	B-X
normal	B-X
cells	B-X
where	B-X
the	B-X
mitochondria	B-X
are	B-X
the	B-X
major	B-X
ATP	B-X
producers	B-X
(	B-X
>	B-X
90	B-X
%	B-X
)	B-X
in	B-X
fueling	B-X
growth	B-X
,	B-X
human	B-X
cancers	B-X
detected	B-X
via	B-X
Positron	B-X
Emission	B-X
Tomography	B-X
(	B-X
PET	B-X
)	B-X
rely	B-X
on	B-X
both	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
.	B-X
In	B-X
such	B-X
cancers	B-X
,	B-X
glycolysis	B-X
may	B-X
contribute	B-X
nearly	B-X
half	B-X
the	B-X
ATP	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
(	B-X
``	B-X
Warburg	B-X
effect	B-X
''	B-X
)	B-X
.	B-X
Based	B-X
solely	B-X
on	B-X
cell	B-X
energetics	B-X
,	B-X
this	B-X
presents	B-X
a	B-X
challenge	B-X
to	B-X
identify	B-X
curative	B-X
agents	B-X
that	B-X
destroy	B-X
only	B-X
cancer	B-X
cells	B-X
as	B-X
they	B-X
must	B-X
destroy	B-X
both	B-X
of	B-X
their	B-X
power	B-X
plants	B-X
causing	B-X
``	B-X
necrotic	B-X
cell	B-X
death	B-X
''	B-X
and	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
.	B-X
One	B-X
such	B-X
agent	B-X
,	B-X
3-bromopyruvate	B-X
(	B-X
3-BrPA	B-X
)	B-X
,	B-X
a	B-X
lactic	B-X
acid	B-X
analog	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
both	B-X
glycolytic	B-X
and	B-X
mitochondrial	B-X
ATP	B-X
production	B-X
in	B-X
rapidly	B-X
growing	B-X
cancers	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Cancer	B-X
Letts.	B-X
,	B-X
173	B-X
,	B-X
83-91	B-X
,	B-X
2001	B-X
)	B-X
,	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
,	B-X
and	B-X
eradicate	B-X
advanced	B-X
cancers	B-X
(	B-X
19	B-X
of	B-X
19	B-X
)	B-X
in	B-X
a	B-X
rodent	B-X
model	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Biochem	B-X
.	B-X
A	B-X
second	B-X
approach	B-X
is	B-X
to	B-X
induce	B-X
only	B-X
cancer	B-X
cells	B-X
to	B-X
undergo	B-X
``	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
''	B-X
Here	B-X
,	B-X
mitochondria	B-X
release	B-X
cell	B-X
death	B-X
inducing	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
cytochrome	B-X
c	B-X
)	B-X
.	B-X
In	B-X
a	B-X
third	B-X
approach	B-X
,	B-X
cancer	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
die	B-X
by	B-X
both	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
events	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
much	B-X
effort	B-X
is	B-X
being	B-X
focused	B-X
on	B-X
identifying	B-X
agents	B-X
that	B-X
induce	B-X
``	B-X
necrotic	B-X
,	B-X
''	B-X
``	B-X
apoptotic	B-X
''	B-X
or	B-X
apoptotic	B-X
plus	B-X
necrotic	B-X
cell	B-X
death	B-X
only	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
Regardless	B-X
how	B-X
death	B-X
is	B-X
inflicted	B-X
,	B-X
every	B-X
cancer	B-X
cell	B-X
must	B-X
die	B-X
,	B-X
be	B-X
it	B-X
fast	B-X
or	B-X
slow	B-X
.	B-X

One	O
such	O
agent	O
,	O
3	O
-	O
bromopyruvate	O
(	O
3	O
-	O
BrPA	O
)	O
,	O
a	O
lactic	O
acid	O
analog	O
,	O
has	O
been	O
shown	O
to	O
inhibit	O
both	O
glycolytic	O
and	O
mitochondrial	O
ATP	O
production	O
in	O
rapidly	O
growing	O
cancers	O
(	O
Ko	O
et	O
al	O
.	O
,	O
Cancer	O
Letts	O
.	O
,	O
173	O
,	O
83	O
-	O
91	O
,	O
2001	O
)	O
,	O
leave	O
normal	O
cells	O
alone	O
,	O
and	O
eradicate	O
advanced	O
cancers	O
(	O
19	O
of	O
19	O
)	O
in	O
a	O
rodent	O
model	O
(	O
Ko	O
et	O
al	O
.	O
,	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
,	O
324	O
,	O
269	O
-	O
275	O
,	O
2004	O
)	O
.	O

A	O
second	O
approach	O
is	O
to	O
induce	O
only	O
cancer	O
cells	O
to	O
undergo	O
"	O
apoptotic	O
cell	O
death	O
.	O
"	O
Here	O
,	O
mitochondria	O
release	O
cell	O
death	O
inducing	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
cytochrome	B-Gene_or_gene_product
c	I-Gene_or_gene_product
)	O
.	O

In	O
a	O
third	O
approach	O
,	O
cancer	O
cells	O
are	O
induced	O
to	O
die	O
by	O
both	O
apoptotic	O
and	O
necrotic	O
events	O
.	O

In	O
summary	O
,	O
much	O
effort	O
is	O
being	O
focused	O
on	O
identifying	O
agents	O
that	O
induce	O
"	O
necrotic	O
,	O
"	O
"	O
apoptotic	O
"	O
or	O
apoptotic	O
plus	O
necrotic	O
cell	O
death	O
only	O
in	O
cancer	O
cells	O
.	O
<EOS>	B-X
This	B-X
introductory	B-X
article	B-X
to	B-X
the	B-X
review	B-X
series	B-X
entitled	B-X
``	B-X
The	B-X
Cancer	B-X
Cell	B-X
's	B-X
Power	B-X
Plants	B-X
as	B-X
Promising	B-X
Therapeutic	B-X
Targets	B-X
''	B-X
is	B-X
written	B-X
while	B-X
more	B-X
than	B-X
20	B-X
million	B-X
people	B-X
suffer	B-X
from	B-X
cancer	B-X
.	B-X
It	B-X
summarizes	B-X
strategies	B-X
to	B-X
destroy	B-X
or	B-X
prevent	B-X
cancers	B-X
by	B-X
targeting	B-X
their	B-X
energy	B-X
production	B-X
factories	B-X
,	B-X
i.e.	B-X
,	B-X
``	B-X
power	B-X
plants	B-X
.	B-X
''	B-X
All	B-X
nucleated	B-X
animal/human	B-X
cells	B-X
have	B-X
two	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
,	B-X
i.e.	B-X
,	B-X
systems	B-X
that	B-X
make	B-X
the	B-X
``	B-X
high	B-X
energy	B-X
''	B-X
compound	B-X
ATP	B-X
from	B-X
ADP	B-X
and	B-X
P	B-X
(	B-X
i	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
most	B-X
normal	B-X
cells	B-X
where	B-X
the	B-X
mitochondria	B-X
are	B-X
the	B-X
major	B-X
ATP	B-X
producers	B-X
(	B-X
>	B-X
90	B-X
%	B-X
)	B-X
in	B-X
fueling	B-X
growth	B-X
,	B-X
human	B-X
cancers	B-X
detected	B-X
via	B-X
Positron	B-X
Emission	B-X
Tomography	B-X
(	B-X
PET	B-X
)	B-X
rely	B-X
on	B-X
both	B-X
types	B-X
of	B-X
power	B-X
plants	B-X
.	B-X
In	B-X
such	B-X
cancers	B-X
,	B-X
glycolysis	B-X
may	B-X
contribute	B-X
nearly	B-X
half	B-X
the	B-X
ATP	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
(	B-X
``	B-X
Warburg	B-X
effect	B-X
''	B-X
)	B-X
.	B-X
Based	B-X
solely	B-X
on	B-X
cell	B-X
energetics	B-X
,	B-X
this	B-X
presents	B-X
a	B-X
challenge	B-X
to	B-X
identify	B-X
curative	B-X
agents	B-X
that	B-X
destroy	B-X
only	B-X
cancer	B-X
cells	B-X
as	B-X
they	B-X
must	B-X
destroy	B-X
both	B-X
of	B-X
their	B-X
power	B-X
plants	B-X
causing	B-X
``	B-X
necrotic	B-X
cell	B-X
death	B-X
''	B-X
and	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
.	B-X
One	B-X
such	B-X
agent	B-X
,	B-X
3-bromopyruvate	B-X
(	B-X
3-BrPA	B-X
)	B-X
,	B-X
a	B-X
lactic	B-X
acid	B-X
analog	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
both	B-X
glycolytic	B-X
and	B-X
mitochondrial	B-X
ATP	B-X
production	B-X
in	B-X
rapidly	B-X
growing	B-X
cancers	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Cancer	B-X
Letts.	B-X
,	B-X
173	B-X
,	B-X
83-91	B-X
,	B-X
2001	B-X
)	B-X
,	B-X
leave	B-X
normal	B-X
cells	B-X
alone	B-X
,	B-X
and	B-X
eradicate	B-X
advanced	B-X
cancers	B-X
(	B-X
19	B-X
of	B-X
19	B-X
)	B-X
in	B-X
a	B-X
rodent	B-X
model	B-X
(	B-X
Ko	B-X
et	B-X
al.	B-X
,	B-X
Biochem	B-X
.	B-X
A	B-X
second	B-X
approach	B-X
is	B-X
to	B-X
induce	B-X
only	B-X
cancer	B-X
cells	B-X
to	B-X
undergo	B-X
``	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
''	B-X
Here	B-X
,	B-X
mitochondria	B-X
release	B-X
cell	B-X
death	B-X
inducing	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
cytochrome	B-X
c	B-X
)	B-X
.	B-X
In	B-X
a	B-X
third	B-X
approach	B-X
,	B-X
cancer	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
die	B-X
by	B-X
both	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
events	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
much	B-X
effort	B-X
is	B-X
being	B-X
focused	B-X
on	B-X
identifying	B-X
agents	B-X
that	B-X
induce	B-X
``	B-X
necrotic	B-X
,	B-X
''	B-X
``	B-X
apoptotic	B-X
''	B-X
or	B-X
apoptotic	B-X
plus	B-X
necrotic	B-X
cell	B-X
death	B-X
only	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
Regardless	B-X
how	B-X
death	B-X
is	B-X
inflicted	B-X
,	B-X
every	B-X
cancer	B-X
cell	B-X
must	B-X
die	B-X
,	B-X
be	B-X
it	B-X
fast	B-X
or	B-X
slow	B-X
.	B-X

Regardless	O
how	O
death	O
is	O
inflicted	O
,	O
every	O
cancer	O
cell	O
must	O
die	O
,	O
be	O
it	O
fast	O
or	O
slow	O
.	O
<EOS>	B-X
Everything	B-X
has	B-X
slowed	B-X
down	B-X
,	B-X
from	B-X
preparing	B-X
for	B-X
classes	B-X
,	B-X
to	B-X
doing	B-X
research	B-X
,	B-X
to	B-X
completing	B-X
the	B-X
simplest	B-X
tasks	B-X
of	B-X
everyday	B-X
life	B-X
.	B-X
Scholars	B-X
in	B-X
other	B-X
disciplines	B-X
have	B-X
been	B-X
doing	B-X
so	B-X
for	B-X
several	B-X
years	B-X
,	B-X
and	B-X
some	B-X
have	B-X
even	B-X
issued	B-X
manifestos	B-X
like	B-X
the	B-X
one	B-X
advocating	B-X
for	B-X
``	B-X
slow	B-X
science	B-X
.	B-X
''	B-X
``	B-X
Is	B-X
going	B-X
slow	B-X
good	B-X
for	B-X
historians	B-X
as	B-X
well	B-X
?	B-X
''	B-X
Sleep	B-X
slow	B-X
waves	B-X
are	B-X
studied	B-X
for	B-X
their	B-X
role	B-X
in	B-X
brain	B-X
plasticity	B-X
,	B-X
homeostatic	B-X
regulation	B-X
,	B-X
and	B-X
their	B-X
changes	B-X
during	B-X
aging	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
address	B-X
the	B-X
possibility	B-X
that	B-X
two	B-X
types	B-X
of	B-X
slow	B-X
waves	B-X
co-exist	B-X
in	B-X
humans	B-X
.	B-X

Pathological	O
animal	O
models	O
in	O
the	O
experimental	O
evaluation	O
of	O
tumour	O
microvasculature	O
with	O
magnetic	O
resonance	O
imaging	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X
The	B-X
peripheral	B-X
washout	B-X
sign	B-X
was	B-X
first	B-X
described	B-X
in	B-X
delayed	B-X
dynamic	B-X
contrast-enhanced	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
DCE-MRI	B-X
)	B-X
using	B-X
a	B-X
small	B-X
molecular	B-X
contrast	B-X
medium	B-X
in	B-X
solid	B-X
lesions	B-X
of	B-X
the	B-X
human	B-X
breast	B-X
and	B-X
liver	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
translate	B-X
the	B-X
peripheral	B-X
washout	B-X
sign	B-X
as	B-X
seen	B-X
in	B-X
solid	B-X
tumours	B-X
in	B-X
delayed	B-X
DCE-MRI	B-X
in	B-X
human	B-X
onto	B-X
an	B-X
animal	B-X
model	B-X
for	B-X
further	B-X
assessment	B-X
of	B-X
DCE-MRI	B-X
characteristics	B-X
and	B-X
histological	B-X
analysis	B-X
.	B-X
Small	B-X
molecular	B-X
contrast	B-X
medium	B-X
DCE-MRI	B-X
was	B-X
performed	B-X
over	B-X
42	B-X
min	B-X
in	B-X
experimental	B-X
colon	B-X
carcinoma	B-X
grown	B-X
subcutaneously	B-X
in	B-X
rats	B-X
.	B-X
Qualitative	B-X
and	B-X
quantitative	B-X
analyses	B-X
for	B-X
evaluation	B-X
of	B-X
presence	B-X
and	B-X
characteristics	B-X
of	B-X
the	B-X
peripheral	B-X
washout	B-X
sign	B-X
were	B-X
accomplished	B-X
,	B-X
defining	B-X
four	B-X
centripetally	B-X
distributed	B-X
tumour	B-X
zones	B-X
(	B-X
central	B-X
,	B-X
intermediate	B-X
,	B-X
peripheral	B-X
and	B-X
marginal	B-X
)	B-X
.	B-X
Histomorphological	B-X
analysis	B-X
was	B-X
performed	B-X
for	B-X
tissue	B-X
classification	B-X
and	B-X
evaluation	B-X
of	B-X
microvasculature	B-X
.	B-X
Quantitative	B-X
analysis	B-X
revealed	B-X
different	B-X
enhancement	B-X
profiles	B-X
of	B-X
the	B-X
four	B-X
tumour	B-X
zones	B-X
.	B-X
Histology	B-X
indicated	B-X
centripetally	B-X
asymmetric	B-X
vascularization	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
VEGF/VEGF	B-X
receptor	B-X
2	B-X
expression	B-X
within	B-X
the	B-X
tumour	B-X
tissue	B-X
.	B-X
Thus	B-X
,	B-X
peripheral	B-X
washout	B-X
sign	B-X
can	B-X
be	B-X
translated	B-X
to	B-X
an	B-X
animal	B-X
model	B-X
.	B-X

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
applications	O
of	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
and	O
in	O
particular	O
,	O
dynamic	O
contrast	O
-	O
enhanced	O
MRI	O
(	O
DCE	O
-	O
MRI	O
)	O
,	O
in	O
the	O
assessment	O
of	O
tumour	O
microvasculature	O
by	O
means	O
of	O
animal	O
tumour	O
models	O
evaluated	O
before	O
and	O
after	O
antiangiogenic	O
treatment	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
MRI	O
exams	O
were	O
performed	O
with	O
intravascular	O
contrast	O
media	O
in	O
21	O
rats	O
:	O
tumours	O
were	O
induced	O
by	O
subcutaneous	O
injection	O
of	O
colon	O
carcinoma	O
cells	O
in	O
7	O
rats	O
and	O
mammary	O
adenocarcinoma	O
cells	O
in	O
14	O
rats	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X

Perfusion	O
and	O
permeability	O
parameters	O
of	O
the	O
implanted	O
tumours	O
were	O
evaluated	O
by	O
using	O
two	O
contrast	O
media	O
(	O
B22956	O
/	O
1	O
and	O
Gd	O
-	O
DTPA37	O
-	O
albumin	O
)	O
to	O
establish	O
response	O
to	O
treatment	O
with	O
two	O
different	O
antiangiogenic	O
drugs	O
(	O
tamoxifen	O
and	O
SU6668	O
)	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X

These	O
parameters	O
were	O
correlated	O
with	O
histology	O
to	O
obtain	O
a	O
radiological	O
-	O
histological	O
map	O
of	O
tumour	O
microvasculature	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X

RESULTS	O
:	O
DCE	O
-	O
MRI	O
revealed	O
greater	O
enhancement	O
in	O
the	O
peripheral	O
area	O
than	O
in	O
the	O
central	O
area	O
in	O
all	O
the	O
examined	O
animal	O
models	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X

In	O
the	O
mammary	O
carcinoma	O
experiment	O
,	O
vascular	O
permeability	O
measured	O
by	O
means	O
of	O
B22956	O
/	O
1	O
in	O
the	O
animals	O
treated	O
with	O
the	O
antiangiogenic	O
drug	O
(	O
0	O
.	O
0043317	O
+	O
/	O
-	O
0	O
.	O
0040418	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
was	O
significantly	O
less	O
than	O
in	O
untreated	O
animals	O
(	O
0	O
.	O
0090460	O
+	O
/	O
-	O
0	O
.	O
0043680	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
with	O
Gd	O
-	O
DTPA	O
-	O
albumin	O
(	O
13	O
.	O
14	O
+	O
/	O
-	O
13	O
.	O
94	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
treated	O
animals	O
and	O
18	O
.	O
07	O
+	O
/	O
-	O
11	O
.	O
92	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
untreated	O
animals	O
)	O
.	O

In	O
the	O
colon	O
carcinoma	O
experiment	O
,	O
mean	O
permeability	O
and	O
perfusion	O
decreased	O
by	O
51	O
%	O
(	O
from	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
ml	O
/	O
100	O
ml	O
)	O
and	O
59	O
%	O
(	O
from	O
0	O
.	O
00165	O
+	O
/	O
-	O
5	O
.	O
1	O
to	O
0	O
.	O
0067	O
+	O
/	O
-	O
4	O
.	O
8	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
of	O
tissue	O
)	O
,	O
respectively	O
,	O
in	O
all	O
animals	O
after	O
antiangiogenic	O
drug	O
administration	O
.	O

CONCLUSIONS	O
:	O
DCE	O
-	O
MRI	O
permits	O
a	O
noninvasive	O
evaluation	O
of	O
tumour	O
microcirculation	O
and	O
in	O
particular	O
of	O
its	O
dynamic	O
characteristics	O
and	O
vascularity	O
before	O
and	O
after	O
antiangiogenic	O
treatment	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
applications	B-X
of	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
(	B-X
DCE-MRI	B-X
)	B-X
,	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
tumour	B-X
microvasculature	B-X
by	B-X
means	B-X
of	B-X
animal	B-X
tumour	B-X
models	B-X
evaluated	B-X
before	B-X
and	B-X
after	B-X
antiangiogenic	B-X
treatment	B-X
.	B-X

Angiogenesis	O
in	O
the	O
caprine	O
caruncles	O
in	O
non	O
-	O
pregnant	O
and	O
pregnant	O
normal	O
and	O
swainsonine	O
-	O
treated	O
does	O
.	O
<EOS>	B-X
Microvascular	B-X
corrosion	B-X
casts	B-X
of	B-X
caruncles	B-X
from	B-X
non-pregnant	B-X
and	B-X
pregnant	B-X
doe	B-X
goats	B-X
at	B-X
4	B-X
,	B-X
7	B-X
,	B-X
10	B-X
,	B-X
13	B-X
,	B-X
16	B-X
,	B-X
and	B-X
18	B-X
weeks	B-X
were	B-X
examined	B-X
with	B-X
scanning	B-X
electron	B-X
microscopy	B-X
.	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
Placental	B-X
angiogenesis	B-X
,	B-X
which	B-X
is	B-X
physiologically	B-X
normal	B-X
,	B-X
may	B-X
serve	B-X
as	B-X
a	B-X
general	B-X
model	B-X
of	B-X
this	B-X
process	B-X
in	B-X
other	B-X
circumstances	B-X
,	B-X
such	B-X
as	B-X
tumor	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X

Microvascular	O
corrosion	O
casts	O
of	O
caruncles	O
from	O
non	O
-	O
pregnant	O
and	O
pregnant	O
doe	O
goats	O
at	O
4	O
,	O
7	O
,	O
10	O
,	O
13	O
,	O
16	O
,	O
and	O
18	O
weeks	O
were	O
examined	O
with	O
scanning	O
electron	O
microscopy	O
.	O
<EOS>	B-X
Microvascular	B-X
corrosion	B-X
casts	B-X
of	B-X
caruncles	B-X
from	B-X
non-pregnant	B-X
and	B-X
pregnant	B-X
doe	B-X
goats	B-X
at	B-X
4	B-X
,	B-X
7	B-X
,	B-X
10	B-X
,	B-X
13	B-X
,	B-X
16	B-X
,	B-X
and	B-X
18	B-X
weeks	B-X
were	B-X
examined	B-X
with	B-X
scanning	B-X
electron	B-X
microscopy	B-X
.	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
Capillary	B-X
diameters	B-X
increased	B-X
significantly	B-X
during	B-X
pregnancy	B-X
,	B-X
especially	B-X
after	B-X
4	B-X
weeks	B-X
,	B-X
when	B-X
large	B-X
flattened	B-X
sinusoids	B-X
formed	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X
Swainsonine	B-X
caused	B-X
a	B-X
great	B-X
distortion	B-X
to	B-X
the	B-X
vasculature	B-X
at	B-X
18	B-X
weeks	B-X
.	B-X

The	O
internal	O
convex	O
surface	O
of	O
the	O
caruncles	O
of	O
non	O
-	O
pregnant	O
does	O
was	O
covered	O
with	O
capillary	O
meshes	O
of	O
regular	O
diameter	O
and	O
form	O
,	O
without	O
crypts	O
.	O
<EOS>	B-X
Microvascular	B-X
corrosion	B-X
casts	B-X
of	B-X
caruncles	B-X
from	B-X
non-pregnant	B-X
and	B-X
pregnant	B-X
doe	B-X
goats	B-X
at	B-X
4	B-X
,	B-X
7	B-X
,	B-X
10	B-X
,	B-X
13	B-X
,	B-X
16	B-X
,	B-X
and	B-X
18	B-X
weeks	B-X
were	B-X
examined	B-X
with	B-X
scanning	B-X
electron	B-X
microscopy	B-X
.	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
At	B-X
later	B-X
stages	B-X
,	B-X
branches	B-X
of	B-X
radial	B-X
arteries	B-X
penetrated	B-X
the	B-X
periphery	B-X
forming	B-X
an	B-X
extensive	B-X
mesh	B-X
of	B-X
capillaries	B-X
on	B-X
the	B-X
concave	B-X
surface	B-X
.	B-X
Capillary	B-X
diameters	B-X
increased	B-X
significantly	B-X
during	B-X
pregnancy	B-X
,	B-X
especially	B-X
after	B-X
4	B-X
weeks	B-X
,	B-X
when	B-X
large	B-X
flattened	B-X
sinusoids	B-X
formed	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X

As	O
pregnancy	O
advanced	O
the	O
complexity	O
of	O
the	O
vasculature	O
increased	O
:	O
at	O
4	O
weeks	O
the	O
surface	O
showed	O
a	O
pattern	O
of	O
ridges	O
separated	O
by	O
troughs	O
.	O
<EOS>	B-X
Microvascular	B-X
corrosion	B-X
casts	B-X
of	B-X
caruncles	B-X
from	B-X
non-pregnant	B-X
and	B-X
pregnant	B-X
doe	B-X
goats	B-X
at	B-X
4	B-X
,	B-X
7	B-X
,	B-X
10	B-X
,	B-X
13	B-X
,	B-X
16	B-X
,	B-X
and	B-X
18	B-X
weeks	B-X
were	B-X
examined	B-X
with	B-X
scanning	B-X
electron	B-X
microscopy	B-X
.	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
At	B-X
later	B-X
stages	B-X
,	B-X
branches	B-X
of	B-X
radial	B-X
arteries	B-X
penetrated	B-X
the	B-X
periphery	B-X
forming	B-X
an	B-X
extensive	B-X
mesh	B-X
of	B-X
capillaries	B-X
on	B-X
the	B-X
concave	B-X
surface	B-X
.	B-X
Capillary	B-X
diameters	B-X
increased	B-X
significantly	B-X
during	B-X
pregnancy	B-X
,	B-X
especially	B-X
after	B-X
4	B-X
weeks	B-X
,	B-X
when	B-X
large	B-X
flattened	B-X
sinusoids	B-X
formed	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X
Swainsonine	B-X
caused	B-X
a	B-X
great	B-X
distortion	B-X
to	B-X
the	B-X
vasculature	B-X
at	B-X
18	B-X
weeks	B-X
.	B-X

At	O
later	O
stages	O
,	O
branches	O
of	O
radial	O
arteries	O
penetrated	O
the	O
periphery	O
forming	O
an	O
extensive	O
mesh	O
of	O
capillaries	O
on	O
the	O
concave	O
surface	O
.	O
<EOS>	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
At	B-X
later	B-X
stages	B-X
,	B-X
branches	B-X
of	B-X
radial	B-X
arteries	B-X
penetrated	B-X
the	B-X
periphery	B-X
forming	B-X
an	B-X
extensive	B-X
mesh	B-X
of	B-X
capillaries	B-X
on	B-X
the	B-X
concave	B-X
surface	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X

Capillary	O
diameters	O
increased	O
significantly	O
during	O
pregnancy	O
,	O
especially	O
after	O
4	O
weeks	O
,	O
when	O
large	O
flattened	O
sinusoids	O
formed	O
.	O
<EOS>	B-X
Microvascular	B-X
corrosion	B-X
casts	B-X
of	B-X
caruncles	B-X
from	B-X
non-pregnant	B-X
and	B-X
pregnant	B-X
doe	B-X
goats	B-X
at	B-X
4	B-X
,	B-X
7	B-X
,	B-X
10	B-X
,	B-X
13	B-X
,	B-X
16	B-X
,	B-X
and	B-X
18	B-X
weeks	B-X
were	B-X
examined	B-X
with	B-X
scanning	B-X
electron	B-X
microscopy	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
Capillary	B-X
diameters	B-X
increased	B-X
significantly	B-X
during	B-X
pregnancy	B-X
,	B-X
especially	B-X
after	B-X
4	B-X
weeks	B-X
,	B-X
when	B-X
large	B-X
flattened	B-X
sinusoids	B-X
formed	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X
Swainsonine	B-X
caused	B-X
a	B-X
great	B-X
distortion	B-X
to	B-X
the	B-X
vasculature	B-X
at	B-X
18	B-X
weeks	B-X
.	B-X

These	O
sinusoids	O
had	O
a	O
great	O
deal	O
of	O
surface	O
area	O
for	O
potential	O
contact	O
with	O
the	O
fetal	O
component	O
.	O
<EOS>	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
At	B-X
later	B-X
stages	B-X
,	B-X
branches	B-X
of	B-X
radial	B-X
arteries	B-X
penetrated	B-X
the	B-X
periphery	B-X
forming	B-X
an	B-X
extensive	B-X
mesh	B-X
of	B-X
capillaries	B-X
on	B-X
the	B-X
concave	B-X
surface	B-X
.	B-X
Capillary	B-X
diameters	B-X
increased	B-X
significantly	B-X
during	B-X
pregnancy	B-X
,	B-X
especially	B-X
after	B-X
4	B-X
weeks	B-X
,	B-X
when	B-X
large	B-X
flattened	B-X
sinusoids	B-X
formed	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X
Swainsonine	B-X
caused	B-X
a	B-X
great	B-X
distortion	B-X
to	B-X
the	B-X
vasculature	B-X
at	B-X
18	B-X
weeks	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
this	B-X
compound	B-X
on	B-X
the	B-X
vascular	B-X
development	B-X
lend	B-X
credibility	B-X
to	B-X
its	B-X
potential	B-X
as	B-X
an	B-X
anticancer	B-X
agent	B-X
.	B-X

The	O
caprine	O
placenta	O
is	O
usually	O
considered	O
to	O
have	O
increased	O
interhemal	O
distance	O
compared	O
with	O
endotheliochorial	O
and	O
hemochorial	O
types	O
:	O
our	O
results	O
suggest	O
that	O
the	O
very	O
extensive	O
development	O
of	O
sinusoids	O
and	O
crypts	O
may	O
compensate	O
for	O
any	O
negative	O
consequences	O
of	O
the	O
placental	O
architecture	O
.	O
<EOS>	B-X
The	B-X
internal	B-X
convex	B-X
surface	B-X
of	B-X
the	B-X
caruncles	B-X
of	B-X
non-pregnant	B-X
does	B-X
was	B-X
covered	B-X
with	B-X
capillary	B-X
meshes	B-X
of	B-X
regular	B-X
diameter	B-X
and	B-X
form	B-X
,	B-X
without	B-X
crypts	B-X
.	B-X
As	B-X
pregnancy	B-X
advanced	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
vasculature	B-X
increased	B-X
:	B-X
at	B-X
4	B-X
weeks	B-X
the	B-X
surface	B-X
showed	B-X
a	B-X
pattern	B-X
of	B-X
ridges	B-X
separated	B-X
by	B-X
troughs	B-X
.	B-X
At	B-X
later	B-X
stages	B-X
,	B-X
branches	B-X
of	B-X
radial	B-X
arteries	B-X
penetrated	B-X
the	B-X
periphery	B-X
forming	B-X
an	B-X
extensive	B-X
mesh	B-X
of	B-X
capillaries	B-X
on	B-X
the	B-X
concave	B-X
surface	B-X
.	B-X
Capillary	B-X
diameters	B-X
increased	B-X
significantly	B-X
during	B-X
pregnancy	B-X
,	B-X
especially	B-X
after	B-X
4	B-X
weeks	B-X
,	B-X
when	B-X
large	B-X
flattened	B-X
sinusoids	B-X
formed	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
Placental	B-X
angiogenesis	B-X
,	B-X
which	B-X
is	B-X
physiologically	B-X
normal	B-X
,	B-X
may	B-X
serve	B-X
as	B-X
a	B-X
general	B-X
model	B-X
of	B-X
this	B-X
process	B-X
in	B-X
other	B-X
circumstances	B-X
,	B-X
such	B-X
as	B-X
tumor	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
this	B-X
compound	B-X
on	B-X
the	B-X
vascular	B-X
development	B-X
lend	B-X
credibility	B-X
to	B-X
its	B-X
potential	B-X
as	B-X
an	B-X
anticancer	B-X
agent	B-X
.	B-X

Placental	O
angiogenesis	O
,	O
which	O
is	O
physiologically	O
normal	O
,	O
may	O
serve	O
as	O
a	O
general	O
model	O
of	O
this	O
process	O
in	O
other	O
circumstances	O
,	O
such	O
as	O
tumor	O
.	O
<EOS>	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
Placental	B-X
angiogenesis	B-X
,	B-X
which	B-X
is	B-X
physiologically	B-X
normal	B-X
,	B-X
may	B-X
serve	B-X
as	B-X
a	B-X
general	B-X
model	B-X
of	B-X
this	B-X
process	B-X
in	B-X
other	B-X
circumstances	B-X
,	B-X
such	B-X
as	B-X
tumor	B-X
.	B-X

The	O
effect	O
of	O
swainsonine	O
(	O
active	O
compound	O
of	O
locoweed	O
and	O
a	O
potential	O
anticancer	O
drug	O
)	O
on	O
vascular	O
development	O
showed	O
no	O
differences	O
in	O
sinusoidal	O
diameters	O
at	O
7	O
weeks	O
,	O
but	O
a	O
decrease	O
in	O
capillary	O
density	O
was	O
noted	O
.	O

Swainsonine	O
caused	O
a	O
great	O
distortion	O
to	O
the	O
vasculature	O
at	O
18	O
weeks	O
.	O

The	O
effects	O
of	O
this	O
compound	O
on	O
the	O
vascular	O
development	O
lend	O
credibility	O
to	O
its	O
potential	O
as	O
an	O
anticancer	O
agent	O
.	O
<EOS>	B-X
Microvascular	B-X
corrosion	B-X
casts	B-X
of	B-X
caruncles	B-X
from	B-X
non-pregnant	B-X
and	B-X
pregnant	B-X
doe	B-X
goats	B-X
at	B-X
4	B-X
,	B-X
7	B-X
,	B-X
10	B-X
,	B-X
13	B-X
,	B-X
16	B-X
,	B-X
and	B-X
18	B-X
weeks	B-X
were	B-X
examined	B-X
with	B-X
scanning	B-X
electron	B-X
microscopy	B-X
.	B-X
These	B-X
sinusoids	B-X
had	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
surface	B-X
area	B-X
for	B-X
potential	B-X
contact	B-X
with	B-X
the	B-X
fetal	B-X
component	B-X
.	B-X
The	B-X
caprine	B-X
placenta	B-X
is	B-X
usually	B-X
considered	B-X
to	B-X
have	B-X
increased	B-X
interhemal	B-X
distance	B-X
compared	B-X
with	B-X
endotheliochorial	B-X
and	B-X
hemochorial	B-X
types	B-X
:	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
very	B-X
extensive	B-X
development	B-X
of	B-X
sinusoids	B-X
and	B-X
crypts	B-X
may	B-X
compensate	B-X
for	B-X
any	B-X
negative	B-X
consequences	B-X
of	B-X
the	B-X
placental	B-X
architecture	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
swainsonine	B-X
(	B-X
active	B-X
compound	B-X
of	B-X
locoweed	B-X
and	B-X
a	B-X
potential	B-X
anticancer	B-X
drug	B-X
)	B-X
on	B-X
vascular	B-X
development	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
sinusoidal	B-X
diameters	B-X
at	B-X
7	B-X
weeks	B-X
,	B-X
but	B-X
a	B-X
decrease	B-X
in	B-X
capillary	B-X
density	B-X
was	B-X
noted	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
this	B-X
compound	B-X
on	B-X
the	B-X
vascular	B-X
development	B-X
lend	B-X
credibility	B-X
to	B-X
its	B-X
potential	B-X
as	B-X
an	B-X
anticancer	B-X
agent	B-X
.	B-X

High	O
-	O
grade	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
has	O
a	O
higher	O
angiogenic	O
activity	O
than	O
low	O
-	O
grade	O
renal	O
cell	O
carcinoma	O
based	O
on	O
histomorphological	O
quantification	O
and	O
qRT	O
-	O
PCR	O
mRNA	O
expression	O
profile	O
.	O

Clear	O
cell	O
renal	O
cell	O
carcinoma	O
(	O
CC	O
-	O
RCC	O
)	O
is	O
a	O
highly	O
vascularised	O
tumour	O
and	O
is	O
therefore	O
an	O
attractive	O
disease	O
to	O
study	O
angiogenesis	O
and	O
to	O
test	O
novel	O
angiogenesis	O
inhibitors	O
in	O
early	O
clinical	O
development	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
angiogenesis	B-X
parameters	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
(	B-X
n=87	B-X
)	B-X
vs	B-X
high	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
(	B-X
n=63	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X
angiogenesis	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
were	B-X
determined	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
heterogeneity	B-X
in	B-X
angiogenic	B-X
activity	B-X
and	B-X
vessel	B-X
maturation	B-X
of	B-X
CC-RCC	B-X
,	B-X
to	B-X
a	B-X
large	B-X
extent	B-X
linked	B-X
to	B-X
nuclear	B-X
grade	B-X
,	B-X
and	B-X
,	B-X
with	B-X
probable	B-X
therapeutic	B-X
implications	B-X
.	B-X

Endothelial	O
cell	O
proliferation	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
of	O
angiogenesis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
angiogenesis	O
parameters	O
in	O
low	O
nuclear	O
grade	O
(	O
n	O
=	O
87	O
)	O
vs	O
high	O
nuclear	O
grade	O
CC	O
-	O
RCC	O
(	O
n	O
=	O
63	O
)	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
angiogenesis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
angiogenesis	B-X
parameters	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
(	B-X
n=87	B-X
)	B-X
vs	B-X
high	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
(	B-X
n=63	B-X
)	B-X
.	B-X
A	B-X
panel	B-X
of	B-X
antibodies	B-X
was	B-X
used	B-X
for	B-X
immunohistochemistry	B-X
:	B-X
CD34/Ki-67	B-X
,	B-X
carbonic	B-X
anhydrase	B-X
IX	B-X
,	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X
angiogenesis	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
were	B-X
determined	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Microvessel	B-X
density	B-X
and	B-X
ECP	B-X
%	B-X
were	B-X
inversely	B-X
correlated	B-X
(	B-X
Rho=-0.26	B-X
,	B-X
P=0.001	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
heterogeneity	B-X
in	B-X
angiogenic	B-X
activity	B-X
and	B-X
vessel	B-X
maturation	B-X
of	B-X
CC-RCC	B-X
,	B-X
to	B-X
a	B-X
large	B-X
extent	B-X
linked	B-X
to	B-X
nuclear	B-X
grade	B-X
,	B-X
and	B-X
,	B-X
with	B-X
probable	B-X
therapeutic	B-X
implications	B-X
.	B-X

A	O
panel	O
of	O
antibodies	O
was	O
used	O
for	O
immunohistochemistry	O
:	O
CD34	B-Gene_or_gene_product
/	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
,	O
carbonic	B-Gene_or_gene_product
anhydrase	I-Gene_or_gene_product
IX	I-Gene_or_gene_product
,	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
)	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
A	B-X
panel	B-X
of	B-X
antibodies	B-X
was	B-X
used	B-X
for	B-X
immunohistochemistry	B-X
:	B-X
CD34/Ki-67	B-X
,	B-X
carbonic	B-X
anhydrase	B-X
IX	B-X
,	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X

Vessel	O
density	O
(	O
MVD	O
-	O
microvessel	O
density	O
)	O
,	O
endothelial	O
cell	O
proliferation	O
fraction	O
(	O
ECP	O
%	O
)	O
and	O
tumour	O
cell	O
proliferation	O
fraction	O
(	O
TCP	O
%	O
)	O
were	O
assessed	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
angiogenesis	B-X
.	B-X
A	B-X
panel	B-X
of	B-X
antibodies	B-X
was	B-X
used	B-X
for	B-X
immunohistochemistry	B-X
:	B-X
CD34/Ki-67	B-X
,	B-X
carbonic	B-X
anhydrase	B-X
IX	B-X
,	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Microvessel	B-X
density	B-X
and	B-X
ECP	B-X
%	B-X
were	B-X
inversely	B-X
correlated	B-X
(	B-X
Rho=-0.26	B-X
,	B-X
P=0.001	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X

mRNA	O
expression	O
levels	O
of	O
angiogenesis	O
stimulators	O
and	O
inhibitors	O
were	O
determined	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O
<EOS>	B-X
Premenstrually	B-X
progesterone	B-X
levels	B-X
decline	B-X
,	B-X
stimulating	B-X
prostaglandin	B-X
(	B-X
PG	B-X
)	B-X
synthesis	B-X
,	B-X
vasoconstriction	B-X
,	B-X
and	B-X
hypoxia	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
1	B-X
)	B-X
AM	B-X
expression	B-X
throughout	B-X
the	B-X
menstrual	B-X
(	B-X
M	B-X
)	B-X
cycle	B-X
and	B-X
2	B-X
)	B-X
its	B-X
regulation	B-X
by	B-X
PG	B-X
and	B-X
hypoxia	B-X
.	B-X
AM	B-X
mRNA	B-X
expression	B-X
was	B-X
examined	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
and	B-X
was	B-X
found	B-X
to	B-X
be	B-X
selectively	B-X
elevated	B-X
in	B-X
endometrium	B-X
from	B-X
the	B-X
menstrual	B-X
(	B-X
M	B-X
)	B-X
phase	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Culture	B-X
of	B-X
secretory	B-X
,	B-X
but	B-X
not	B-X
P	B-X
,	B-X
explants	B-X
with	B-X
100	B-X
nm	B-X
PGF	B-X
(	B-X
2Î±	B-X
)	B-X
or	B-X
hypoxia	B-X
(	B-X
0.5	B-X
%	B-X
O2	B-X
)	B-X
increased	B-X
AM	B-X
mRNA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
P	B-X
explants	B-X
were	B-X
induced	B-X
to	B-X
increase	B-X
AM	B-X
expression	B-X
using	B-X
in	B-X
vitro	B-X
progesterone	B-X
withdrawal	B-X
but	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
hypoxia	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Short	B-X
hairpin	B-X
sequences	B-X
against	B-X
hypoxia-inducible	B-X
factor-1Î±	B-X
(	B-X
HIF-1Î±	B-X
)	B-X
inhibited	B-X
AM	B-X
hypoxic	B-X
up-regulation	B-X
but	B-X
did	B-X
not	B-X
alter	B-X
PGF	B-X
(	B-X
2Î±	B-X
)	B-X
-induced	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
AM	B-X
is	B-X
elevated	B-X
at	B-X
the	B-X
time	B-X
of	B-X
endometrial	B-X
repair	B-X
and	B-X
induces	B-X
both	B-X
angiogenesis	B-X
and	B-X
lymphangiogenesis	B-X
by	B-X
stimulating	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
tube	B-X
formation	B-X
.	B-X
In	B-X
the	B-X
human	B-X
endometrium	B-X
,	B-X
AM	B-X
expression	B-X
is	B-X
up-regulated	B-X
by	B-X
two	B-X
mechanisms	B-X
:	B-X
a	B-X
HIF-1Î±-mediated	B-X
hypoxic	B-X
induction	B-X
and	B-X
a	B-X
HIF-1Î±-independent	B-X
PGF	B-X
(	B-X
2Î±	B-X
)	B-X
pathway	B-X
.	B-X

High	O
-	O
grade	O
CC	O
-	O
RCC	O
showed	O
a	O
higher	O
ECP	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
)	O
,	O
a	O
higher	O
TCP	O
%	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
a	O
higher	O
VEGF	B-Gene_or_gene_product
protein	O
expression	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
a	O
lower	O
MVD	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
a	O
lower	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
protein	O
expression	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
than	O
low	O
-	O
grade	O
CC	O
-	O
RCC	O
.	O

Growth	O
factor	O
mRNA	O
expression	O
analyses	O
revealed	O
a	O
higher	O
expression	O
of	O
angiopoietin	B-Gene_or_gene_product
2	I-Gene_or_gene_product
in	O
low	O
-	O
grade	O
CC	O
-	O
RCC	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
angiogenesis	B-X
parameters	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
(	B-X
n=87	B-X
)	B-X
vs	B-X
high	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
(	B-X
n=63	B-X
)	B-X
.	B-X
A	B-X
panel	B-X
of	B-X
antibodies	B-X
was	B-X
used	B-X
for	B-X
immunohistochemistry	B-X
:	B-X
CD34/Ki-67	B-X
,	B-X
carbonic	B-X
anhydrase	B-X
IX	B-X
,	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X
angiogenesis	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
were	B-X
determined	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Microvessel	B-X
density	B-X
and	B-X
ECP	B-X
%	B-X
were	B-X
inversely	B-X
correlated	B-X
(	B-X
Rho=-0.26	B-X
,	B-X
P=0.001	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
heterogeneity	B-X
in	B-X
angiogenic	B-X
activity	B-X
and	B-X
vessel	B-X
maturation	B-X
of	B-X
CC-RCC	B-X
,	B-X
to	B-X
a	B-X
large	B-X
extent	B-X
linked	B-X
to	B-X
nuclear	B-X
grade	B-X
,	B-X
and	B-X
,	B-X
with	B-X
probable	B-X
therapeutic	B-X
implications	B-X
.	B-X

Microvessel	O
density	O
and	O
ECP	O
%	O
were	O
inversely	O
correlated	O
(	O
Rho	O
=	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Because	O
of	O
the	O
imperfect	O
association	O
of	O
nuclear	O
grade	O
and	O
ECP	O
%	O
or	O
MVD	O
,	O
CC	O
-	O
RCC	O
was	O
also	O
grouped	O
based	O
on	O
low	O
/	O
high	O
MVD	O
and	O
ECP	O
%	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
angiogenesis	B-X
parameters	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
(	B-X
n=87	B-X
)	B-X
vs	B-X
high	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
(	B-X
n=63	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Microvessel	B-X
density	B-X
and	B-X
ECP	B-X
%	B-X
were	B-X
inversely	B-X
correlated	B-X
(	B-X
Rho=-0.26	B-X
,	B-X
P=0.001	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
heterogeneity	B-X
in	B-X
angiogenic	B-X
activity	B-X
and	B-X
vessel	B-X
maturation	B-X
of	B-X
CC-RCC	B-X
,	B-X
to	B-X
a	B-X
large	B-X
extent	B-X
linked	B-X
to	B-X
nuclear	B-X
grade	B-X
,	B-X
and	B-X
,	B-X
with	B-X
probable	B-X
therapeutic	B-X
implications	B-X
.	B-X

This	O
analysis	O
revealed	O
a	O
higher	O
expression	O
of	O
vessel	O
maturation	O
and	O
stabilisation	O
factors	O
(	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
,	O
PDGFB1	B-Gene_or_gene_product
,	O
angiopoietin	B-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
in	O
CC	O
-	O
RCC	O
with	O
high	O
MVD	O
,	O
a	O
group	O
of	O
CC	O
-	O
RCC	O
highly	O
enriched	O
in	O
low	O
nuclear	O
grade	O
CC	O
-	O
RCC	O
,	O
with	O
low	O
ECP	O
%	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
angiogenesis	B-X
parameters	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
(	B-X
n=87	B-X
)	B-X
vs	B-X
high	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
(	B-X
n=63	B-X
)	B-X
.	B-X
A	B-X
panel	B-X
of	B-X
antibodies	B-X
was	B-X
used	B-X
for	B-X
immunohistochemistry	B-X
:	B-X
CD34/Ki-67	B-X
,	B-X
carbonic	B-X
anhydrase	B-X
IX	B-X
,	B-X
hypoxia-inducible	B-X
factor-1alpha	B-X
(	B-X
HIF-1alpha	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X
angiogenesis	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
were	B-X
determined	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Microvessel	B-X
density	B-X
and	B-X
ECP	B-X
%	B-X
were	B-X
inversely	B-X
correlated	B-X
(	B-X
Rho=-0.26	B-X
,	B-X
P=0.001	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
heterogeneity	B-X
in	B-X
angiogenic	B-X
activity	B-X
and	B-X
vessel	B-X
maturation	B-X
of	B-X
CC-RCC	B-X
,	B-X
to	B-X
a	B-X
large	B-X
extent	B-X
linked	B-X
to	B-X
nuclear	B-X
grade	B-X
,	B-X
and	B-X
,	B-X
with	B-X
probable	B-X
therapeutic	B-X
implications	B-X
.	B-X

Our	O
results	O
suggest	O
heterogeneity	O
in	O
angiogenic	O
activity	O
and	O
vessel	O
maturation	O
of	O
CC	O
-	O
RCC	O
,	O
to	O
a	O
large	O
extent	O
linked	O
to	O
nuclear	O
grade	O
,	O
and	O
,	O
with	O
probable	O
therapeutic	O
implications	O
.	O
<EOS>	B-X
Clear	B-X
cell	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
CC-RCC	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
vascularised	B-X
tumour	B-X
and	B-X
is	B-X
therefore	B-X
an	B-X
attractive	B-X
disease	B-X
to	B-X
study	B-X
angiogenesis	B-X
and	B-X
to	B-X
test	B-X
novel	B-X
angiogenesis	B-X
inhibitors	B-X
in	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
angiogenesis	B-X
parameters	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
(	B-X
n=87	B-X
)	B-X
vs	B-X
high	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
(	B-X
n=63	B-X
)	B-X
.	B-X
Vessel	B-X
density	B-X
(	B-X
MVD	B-X
-	B-X
microvessel	B-X
density	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
ECP	B-X
%	B-X
)	B-X
and	B-X
tumour	B-X
cell	B-X
proliferation	B-X
fraction	B-X
(	B-X
TCP	B-X
%	B-X
)	B-X
were	B-X
assessed	B-X
.	B-X
High-grade	B-X
CC-RCC	B-X
showed	B-X
a	B-X
higher	B-X
ECP	B-X
%	B-X
(	B-X
P=0.049	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
TCP	B-X
%	B-X
(	B-X
P=0.009	B-X
)	B-X
,	B-X
a	B-X
higher	B-X
VEGF	B-X
protein	B-X
expression	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
a	B-X
lower	B-X
MVD	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
a	B-X
lower	B-X
HIF-1alpha	B-X
protein	B-X
expression	B-X
(	B-X
P=0.002	B-X
)	B-X
than	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Growth	B-X
factor	B-X
mRNA	B-X
expression	B-X
analyses	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
angiopoietin	B-X
2	B-X
in	B-X
low-grade	B-X
CC-RCC	B-X
.	B-X
Microvessel	B-X
density	B-X
and	B-X
ECP	B-X
%	B-X
were	B-X
inversely	B-X
correlated	B-X
(	B-X
Rho=-0.26	B-X
,	B-X
P=0.001	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
imperfect	B-X
association	B-X
of	B-X
nuclear	B-X
grade	B-X
and	B-X
ECP	B-X
%	B-X
or	B-X
MVD	B-X
,	B-X
CC-RCC	B-X
was	B-X
also	B-X
grouped	B-X
based	B-X
on	B-X
low/high	B-X
MVD	B-X
and	B-X
ECP	B-X
%	B-X
.	B-X
This	B-X
analysis	B-X
revealed	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
vessel	B-X
maturation	B-X
and	B-X
stabilisation	B-X
factors	B-X
(	B-X
placental	B-X
growth	B-X
factor	B-X
,	B-X
PDGFB1	B-X
,	B-X
angiopoietin	B-X
1	B-X
)	B-X
in	B-X
CC-RCC	B-X
with	B-X
high	B-X
MVD	B-X
,	B-X
a	B-X
group	B-X
of	B-X
CC-RCC	B-X
highly	B-X
enriched	B-X
in	B-X
low	B-X
nuclear	B-X
grade	B-X
CC-RCC	B-X
,	B-X
with	B-X
low	B-X
ECP	B-X
%	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
heterogeneity	B-X
in	B-X
angiogenic	B-X
activity	B-X
and	B-X
vessel	B-X
maturation	B-X
of	B-X
CC-RCC	B-X
,	B-X
to	B-X
a	B-X
large	B-X
extent	B-X
linked	B-X
to	B-X
nuclear	B-X
grade	B-X
,	B-X
and	B-X
,	B-X
with	B-X
probable	B-X
therapeutic	B-X
implications	B-X
.	B-X

Deletion	O
of	O
Tip30	B-Gene_or_gene_product
leads	O
to	O
rapid	O
immortalization	O
of	O
murine	O
mammary	O
epithelial	O
cells	O
and	O
ductal	O
hyperplasia	O
in	O
the	O
mammary	O
gland	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Transformation	O
of	O
mammary	O
epithelial	O
cells	O
(	O
MECs	O
)	O
from	O
the	O
normal	O
to	O
the	O
neoplastic	O
stage	O
requires	O
the	O
dysregulation	O
of	O
tumor	O
suppressor	O
genes	O
and	O
proto	O
-	O
oncogenes	O
.	O

Tip30	B-Gene_or_gene_product
is	O
a	O
tumor	O
suppressor	O
that	O
can	O
inhibit	O
estrogen	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	O
mediated	O
transcription	O
in	O
MECs	O
,	O
but	O
its	O
role	O
in	O
MEC	O
proliferation	O
remains	O
unknown	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
deleting	O
the	O
Tip30	B-Gene_or_gene_product
gene	O
leads	O
to	O
ductal	O
hyperplasia	O
in	O
mouse	O
mammary	O
glands	O
early	O
in	O
life	O
and	O
extensive	O
mammary	O
hyperplasia	O
with	O
age	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Tip30	B-Gene_or_gene_product
(	O
-	O
/	O
-	O
)	O
mammary	O
glands	O
transplanted	O
into	O
wild	O
-	O
type	O
mammary	O
fat	O
pads	O
also	O
display	O
mammary	O
trees	O
with	O
extensive	O
ductal	O
hyperplasia	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Strikingly	O
,	O
Tip30	B-Gene_or_gene_product
deletion	O
promotes	O
proliferation	O
of	O
primary	O
MECs	O
and	O
results	O
in	O
rapid	O
immortalization	O
of	O
MECs	O
in	O
vitro	O
relative	O
to	O
wild	O
-	O
type	O
cells	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Gene	O
array	O
analysis	O
identified	O
significant	O
increases	O
in	O
the	O
expression	O
of	O
mammary	O
epithelial	O
growth	O
factors	O
Wisp2	B-Gene_or_gene_product
and	O
Igf	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
in	O
Tip30	B-Gene_or_gene_product
(	O
-	O
/	O
-	O
)	O
cells	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

Knockdown	O
of	O
either	O
Wisp2	B-Gene_or_gene_product
or	O
Igf	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
using	O
short	O
interfering	O
RNA	O
dramatically	O
inhibited	O
proliferation	O
of	O
Tip30	B-Gene_or_gene_product
(	O
-	O
/	O
-	O
)	O
cells	O
.	O
<EOS>	B-X
Vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
formed	B-X
by	B-X
aggressive	B-X
tumor	B-X
cells	B-X
to	B-X
create	B-X
vascular	B-X
networks	B-X
connected	B-X
with	B-X
the	B-X
endothelial	B-X
cells	B-X
,	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
breast	B-X
cancer	B-X
progression	B-X
.	B-X
Mechanistically	B-X
,	B-X
WISP2	B-X
increased	B-X
retention	B-X
of	B-X
oncogenic	B-X
activators	B-X
YAP/TAZ	B-X
in	B-X
cytoplasm	B-X
,	B-X
leading	B-X
to	B-X
decreased	B-X
expression	B-X
of	B-X
the	B-X
angiogenic	B-X
factor	B-X
CYR61	B-X
.	B-X
Studies	B-X
using	B-X
an	B-X
in	B-X
vivo	B-X
mouse	B-X
model	B-X
and	B-X
human	B-X
breast	B-X
tumors	B-X
confirmed	B-X
the	B-X
in	B-X
vitro	B-X
cell	B-X
lines	B-X
data	B-X
.	B-X
The	B-X
WNT1-inducible-signaling	B-X
pathway	B-X
protein	B-X
2	B-X
(	B-X
Wisp2	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-ÎºB	B-X
are	B-X
involved	B-X
in	B-X
fibrosis	B-X
in	B-X
many	B-X
diseases	B-X
.	B-X

Together	O
,	O
these	O
results	O
suggest	O
that	O
Tip30	B-Gene_or_gene_product
is	O
an	O
intrinsic	O
and	O
negative	O
regulator	O
of	O
MEC	O
proliferation	O
partly	O
through	O
the	O
inhibition	O
of	O
Wisp2	B-Gene_or_gene_product
and	O
Igf	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
expression	O
,	O
and	O
its	O
absence	O
in	O
the	O
mammary	O
gland	O
may	O
predispose	O
MECs	O
to	O
neoplastic	O
transformation	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
MECs	B-X
)	B-X
from	B-X
the	B-X
normal	B-X
to	B-X
the	B-X
neoplastic	B-X
stage	B-X
requires	B-X
the	B-X
dysregulation	B-X
of	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
proto-oncogenes	B-X
.	B-X
Tip30	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
can	B-X
inhibit	B-X
estrogen	B-X
receptor-mediated	B-X
transcription	B-X
in	B-X
MECs	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
MEC	B-X
proliferation	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deleting	B-X
the	B-X
Tip30	B-X
gene	B-X
leads	B-X
to	B-X
ductal	B-X
hyperplasia	B-X
in	B-X
mouse	B-X
mammary	B-X
glands	B-X
early	B-X
in	B-X
life	B-X
and	B-X
extensive	B-X
mammary	B-X
hyperplasia	B-X
with	B-X
age	B-X
.	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
mammary	B-X
glands	B-X
transplanted	B-X
into	B-X
wild-type	B-X
mammary	B-X
fat	B-X
pads	B-X
also	B-X
display	B-X
mammary	B-X
trees	B-X
with	B-X
extensive	B-X
ductal	B-X
hyperplasia	B-X
.	B-X
Strikingly	B-X
,	B-X
Tip30	B-X
deletion	B-X
promotes	B-X
proliferation	B-X
of	B-X
primary	B-X
MECs	B-X
and	B-X
results	B-X
in	B-X
rapid	B-X
immortalization	B-X
of	B-X
MECs	B-X
in	B-X
vitro	B-X
relative	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
Gene	B-X
array	B-X
analysis	B-X
identified	B-X
significant	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
mammary	B-X
epithelial	B-X
growth	B-X
factors	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
in	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Knockdown	B-X
of	B-X
either	B-X
Wisp2	B-X
or	B-X
Igf-1	B-X
using	B-X
short	B-X
interfering	B-X
RNA	B-X
dramatically	B-X
inhibited	B-X
proliferation	B-X
of	B-X
Tip30	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
Tip30	B-X
is	B-X
an	B-X
intrinsic	B-X
and	B-X
negative	B-X
regulator	B-X
of	B-X
MEC	B-X
proliferation	B-X
partly	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
Wisp2	B-X
and	B-X
Igf-1	B-X
expression	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
may	B-X
predispose	B-X
MECs	B-X
to	B-X
neoplastic	B-X
transformation	B-X
.	B-X

A	O
pivotal	O
role	O
for	O
p53	B-Gene_or_gene_product
:	O
balancing	O
aerobic	O
respiration	O
and	O
glycolysis	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
recent	B-X
evidence	B-X
of	B-X
a	B-X
simple	B-X
genetic	B-X
mechanism	B-X
by	B-X
which	B-X
tumor	B-X
suppressor	B-X
p53	B-X
regulates	B-X
mitochondrial	B-X
respiration	B-X
with	B-X
secondary	B-X
changes	B-X
in	B-X
glycolysis	B-X
that	B-X
are	B-X
reminiscent	B-X
of	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
The	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
regulation	B-X
of	B-X
the	B-X
two	B-X
major	B-X
pathways	B-X
of	B-X
energy	B-X
generation	B-X
by	B-X
p53	B-X
remains	B-X
to	B-X
be	B-X
seen	B-X
.	B-X

The	O
genetic	O
basis	O
of	O
increased	O
glycolytic	O
activity	O
observed	O
in	O
cancer	O
cells	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
complex	O
interactions	O
of	O
multiple	O
regulatory	O
pathways	O
.	O
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
increased	B-X
glycolytic	B-X
activity	B-X
observed	B-X
in	B-X
cancer	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
complex	B-X
interactions	B-X
of	B-X
multiple	B-X
regulatory	B-X
pathways	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
recent	B-X
evidence	B-X
of	B-X
a	B-X
simple	B-X
genetic	B-X
mechanism	B-X
by	B-X
which	B-X
tumor	B-X
suppressor	B-X
p53	B-X
regulates	B-X
mitochondrial	B-X
respiration	B-X
with	B-X
secondary	B-X
changes	B-X
in	B-X
glycolysis	B-X
that	B-X
are	B-X
reminiscent	B-X
of	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
The	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
regulation	B-X
of	B-X
the	B-X
two	B-X
major	B-X
pathways	B-X
of	B-X
energy	B-X
generation	B-X
by	B-X
p53	B-X
remains	B-X
to	B-X
be	B-X
seen	B-X
.	B-X

Here	O
we	O
review	O
the	O
recent	O
evidence	O
of	O
a	O
simple	O
genetic	O
mechanism	O
by	O
which	O
tumor	O
suppressor	O
p53	B-Gene_or_gene_product
regulates	O
mitochondrial	O
respiration	O
with	O
secondary	O
changes	O
in	O
glycolysis	O
that	O
are	O
reminiscent	O
of	O
the	O
Warburg	O
effect	O
.	O
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
increased	B-X
glycolytic	B-X
activity	B-X
observed	B-X
in	B-X
cancer	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
complex	B-X
interactions	B-X
of	B-X
multiple	B-X
regulatory	B-X
pathways	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
recent	B-X
evidence	B-X
of	B-X
a	B-X
simple	B-X
genetic	B-X
mechanism	B-X
by	B-X
which	B-X
tumor	B-X
suppressor	B-X
p53	B-X
regulates	B-X
mitochondrial	B-X
respiration	B-X
with	B-X
secondary	B-X
changes	B-X
in	B-X
glycolysis	B-X
that	B-X
are	B-X
reminiscent	B-X
of	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
The	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
regulation	B-X
of	B-X
the	B-X
two	B-X
major	B-X
pathways	B-X
of	B-X
energy	B-X
generation	B-X
by	B-X
p53	B-X
remains	B-X
to	B-X
be	B-X
seen	B-X
.	B-X

The	O
biological	O
significance	O
of	O
this	O
regulation	O
of	O
the	O
two	O
major	O
pathways	O
of	O
energy	O
generation	O
by	O
p53	B-Gene_or_gene_product
remains	O
to	O
be	O
seen	O
.	O
<EOS>	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
increased	B-X
glycolytic	B-X
activity	B-X
observed	B-X
in	B-X
cancer	B-X
cells	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
complex	B-X
interactions	B-X
of	B-X
multiple	B-X
regulatory	B-X
pathways	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
recent	B-X
evidence	B-X
of	B-X
a	B-X
simple	B-X
genetic	B-X
mechanism	B-X
by	B-X
which	B-X
tumor	B-X
suppressor	B-X
p53	B-X
regulates	B-X
mitochondrial	B-X
respiration	B-X
with	B-X
secondary	B-X
changes	B-X
in	B-X
glycolysis	B-X
that	B-X
are	B-X
reminiscent	B-X
of	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
The	B-X
biological	B-X
significance	B-X
of	B-X
this	B-X
regulation	B-X
of	B-X
the	B-X
two	B-X
major	B-X
pathways	B-X
of	B-X
energy	B-X
generation	B-X
by	B-X
p53	B-X
remains	B-X
to	B-X
be	B-X
seen	B-X
.	B-X

The	O
contribution	O
of	O
Harold	O
F	O
.	O
Dvorak	O
to	O
the	O
study	O
of	O
tumor	O
angiogenesis	O
and	O
stroma	O
generation	O
mechanisms	O
.	O

In	O
1983	O
,	O
Harold	O
Dvorak	O
and	O
his	O
colleagues	O
were	O
the	O
first	O
to	O
show	O
that	O
tumor	O
cells	O
secreted	O
vascular	B-Gene_or_gene_product
permeability	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VPF	B-Gene_or_gene_product
)	O
and	O
that	O
a	O
blocking	O
antibody	O
to	O
VPF	B-Gene_or_gene_product
could	O
prevent	O
the	O
edema	O
and	O
fluid	O
accumulation	O
that	O
is	O
characteristic	O
of	O
human	O
cancers	O
.	O

In	O
1986	O
,	O
Dvorak	O
went	O
on	O
to	O
demonstrate	O
that	O
VPF	B-Gene_or_gene_product
was	O
secreted	O
by	O
a	O
variety	O
of	O
human	O
tumor	O
cell	O
lines	O
and	O
proposed	O
that	O
VPF	B-Gene_or_gene_product
was	O
in	O
part	O
responsible	O
for	O
the	O
abnormal	O
vasculature	O
seen	O
in	O
human	O
tumors	O
.	O
<EOS>	B-X
In	B-X
1983	B-X
,	B-X
Harold	B-X
Dvorak	B-X
and	B-X
his	B-X
colleagues	B-X
were	B-X
the	B-X
first	B-X
to	B-X
show	B-X
that	B-X
tumor	B-X
cells	B-X
secreted	B-X
vascular	B-X
permeability	B-X
factor	B-X
(	B-X
VPF	B-X
)	B-X
and	B-X
that	B-X
a	B-X
blocking	B-X
antibody	B-X
to	B-X
VPF	B-X
could	B-X
prevent	B-X
the	B-X
edema	B-X
and	B-X
fluid	B-X
accumulation	B-X
that	B-X
is	B-X
characteristic	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
went	B-X
on	B-X
to	B-X
demonstrate	B-X
that	B-X
VPF	B-X
was	B-X
secreted	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
and	B-X
proposed	B-X
that	B-X
VPF	B-X
was	B-X
in	B-X
part	B-X
responsible	B-X
for	B-X
the	B-X
abnormal	B-X
vasculature	B-X
seen	B-X
in	B-X
human	B-X
tumors	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
he	B-X
and	B-X
other	B-X
investigators	B-X
demonstrated	B-X
that	B-X
VPF	B-X
was	B-X
capable	B-X
of	B-X
stimulating	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X
These	B-X
fundamental	B-X
discoveries	B-X
led	B-X
to	B-X
additional	B-X
research	B-X
conducted	B-X
by	B-X
Napoleone	B-X
Ferrara	B-X
and	B-X
his	B-X
laboratory	B-X
,	B-X
confirming	B-X
the	B-X
cloning	B-X
of	B-X
VPF	B-X
and	B-X
renaming	B-X
the	B-X
protein	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
proposed	B-X
that	B-X
by	B-X
secreting	B-X
VPF	B-X
,	B-X
tumors	B-X
induce	B-X
angiogenesis	B-X
by	B-X
turning	B-X
on	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
He	B-X
noted	B-X
that	B-X
wounds	B-X
,	B-X
like	B-X
tumors	B-X
,	B-X
secrete	B-X
VPF	B-X
,	B-X
causing	B-X
blood	B-X
vessels	B-X
to	B-X
leak	B-X
plasma	B-X
fibrinogen	B-X
,	B-X
which	B-X
stimulates	B-X
blood	B-X
vessel	B-X
growth	B-X
and	B-X
provides	B-X
a	B-X
matrix	B-X
on	B-X
which	B-X
they	B-X
can	B-X
spread	B-X
.	B-X
Unlike	B-X
wounds	B-X
,	B-X
however	B-X
,	B-X
that	B-X
turn	B-X
off	B-X
VPF	B-X
production	B-X
after	B-X
healing	B-X
,	B-X
tumors	B-X
did	B-X
not	B-X
turn	B-X
off	B-X
their	B-X
VPF	B-X
production	B-X
and	B-X
instead	B-X
continued	B-X
to	B-X
make	B-X
large	B-X
amounts	B-X
of	B-X
VPF	B-X
,	B-X
allowing	B-X
malignant	B-X
cells	B-X
to	B-X
continue	B-X
to	B-X
induce	B-X
new	B-X
blood	B-X
vessels	B-X
and	B-X
so	B-X
to	B-X
grow	B-X
and	B-X
spread	B-X
.	B-X
Thus	B-X
,	B-X
tumors	B-X
behave	B-X
like	B-X
wounds	B-X
that	B-X
fail	B-X
to	B-X
heal	B-X
.	B-X
This	B-X
work	B-X
is	B-X
again	B-X
extremely	B-X
significant	B-X
for	B-X
patients	B-X
worldwide	B-X
,	B-X
as	B-X
Dvorak	B-X
's	B-X
scientific	B-X
research	B-X
is	B-X
leading	B-X
his	B-X
colleagues	B-X
all	B-X
over	B-X
the	B-X
world	B-X
to	B-X
examine	B-X
how	B-X
to	B-X
treat	B-X
a	B-X
tumor	B-X
through	B-X
its	B-X
blood	B-X
supply	B-X
.	B-X

As	O
a	O
result	O
,	O
he	O
and	O
other	O
investigators	O
demonstrated	O
that	O
VPF	B-Gene_or_gene_product
was	O
capable	O
of	O
stimulating	O
endothelial	O
cell	O
growth	O
and	O
angiogenesis	O
.	O

These	O
fundamental	O
discoveries	O
led	O
to	O
additional	O
research	O
conducted	O
by	O
Napoleone	O
Ferrara	O
and	O
his	O
laboratory	O
,	O
confirming	O
the	O
cloning	O
of	O
VPF	B-Gene_or_gene_product
and	O
renaming	O
the	O
protein	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
.	O

In	O
1986	O
,	O
Dvorak	O
proposed	O
that	O
by	O
secreting	O
VPF	B-Gene_or_gene_product
,	O
tumors	O
induce	O
angiogenesis	O
by	O
turning	O
on	O
the	O
wound	O
healing	O
response	O
.	O
<EOS>	B-X
In	B-X
1983	B-X
,	B-X
Harold	B-X
Dvorak	B-X
and	B-X
his	B-X
colleagues	B-X
were	B-X
the	B-X
first	B-X
to	B-X
show	B-X
that	B-X
tumor	B-X
cells	B-X
secreted	B-X
vascular	B-X
permeability	B-X
factor	B-X
(	B-X
VPF	B-X
)	B-X
and	B-X
that	B-X
a	B-X
blocking	B-X
antibody	B-X
to	B-X
VPF	B-X
could	B-X
prevent	B-X
the	B-X
edema	B-X
and	B-X
fluid	B-X
accumulation	B-X
that	B-X
is	B-X
characteristic	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
went	B-X
on	B-X
to	B-X
demonstrate	B-X
that	B-X
VPF	B-X
was	B-X
secreted	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
and	B-X
proposed	B-X
that	B-X
VPF	B-X
was	B-X
in	B-X
part	B-X
responsible	B-X
for	B-X
the	B-X
abnormal	B-X
vasculature	B-X
seen	B-X
in	B-X
human	B-X
tumors	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
he	B-X
and	B-X
other	B-X
investigators	B-X
demonstrated	B-X
that	B-X
VPF	B-X
was	B-X
capable	B-X
of	B-X
stimulating	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X
These	B-X
fundamental	B-X
discoveries	B-X
led	B-X
to	B-X
additional	B-X
research	B-X
conducted	B-X
by	B-X
Napoleone	B-X
Ferrara	B-X
and	B-X
his	B-X
laboratory	B-X
,	B-X
confirming	B-X
the	B-X
cloning	B-X
of	B-X
VPF	B-X
and	B-X
renaming	B-X
the	B-X
protein	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
proposed	B-X
that	B-X
by	B-X
secreting	B-X
VPF	B-X
,	B-X
tumors	B-X
induce	B-X
angiogenesis	B-X
by	B-X
turning	B-X
on	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
He	B-X
noted	B-X
that	B-X
wounds	B-X
,	B-X
like	B-X
tumors	B-X
,	B-X
secrete	B-X
VPF	B-X
,	B-X
causing	B-X
blood	B-X
vessels	B-X
to	B-X
leak	B-X
plasma	B-X
fibrinogen	B-X
,	B-X
which	B-X
stimulates	B-X
blood	B-X
vessel	B-X
growth	B-X
and	B-X
provides	B-X
a	B-X
matrix	B-X
on	B-X
which	B-X
they	B-X
can	B-X
spread	B-X
.	B-X
Unlike	B-X
wounds	B-X
,	B-X
however	B-X
,	B-X
that	B-X
turn	B-X
off	B-X
VPF	B-X
production	B-X
after	B-X
healing	B-X
,	B-X
tumors	B-X
did	B-X
not	B-X
turn	B-X
off	B-X
their	B-X
VPF	B-X
production	B-X
and	B-X
instead	B-X
continued	B-X
to	B-X
make	B-X
large	B-X
amounts	B-X
of	B-X
VPF	B-X
,	B-X
allowing	B-X
malignant	B-X
cells	B-X
to	B-X
continue	B-X
to	B-X
induce	B-X
new	B-X
blood	B-X
vessels	B-X
and	B-X
so	B-X
to	B-X
grow	B-X
and	B-X
spread	B-X
.	B-X
Thus	B-X
,	B-X
tumors	B-X
behave	B-X
like	B-X
wounds	B-X
that	B-X
fail	B-X
to	B-X
heal	B-X
.	B-X
This	B-X
work	B-X
is	B-X
again	B-X
extremely	B-X
significant	B-X
for	B-X
patients	B-X
worldwide	B-X
,	B-X
as	B-X
Dvorak	B-X
's	B-X
scientific	B-X
research	B-X
is	B-X
leading	B-X
his	B-X
colleagues	B-X
all	B-X
over	B-X
the	B-X
world	B-X
to	B-X
examine	B-X
how	B-X
to	B-X
treat	B-X
a	B-X
tumor	B-X
through	B-X
its	B-X
blood	B-X
supply	B-X
.	B-X

He	O
noted	O
that	O
wounds	O
,	O
like	O
tumors	O
,	O
secrete	O
VPF	B-Gene_or_gene_product
,	O
causing	O
blood	O
vessels	O
to	O
leak	O
plasma	O
fibrinogen	B-Gene_or_gene_product
,	O
which	O
stimulates	O
blood	O
vessel	O
growth	O
and	O
provides	O
a	O
matrix	O
on	O
which	O
they	O
can	O
spread	O
.	O
<EOS>	B-X
In	B-X
1983	B-X
,	B-X
Harold	B-X
Dvorak	B-X
and	B-X
his	B-X
colleagues	B-X
were	B-X
the	B-X
first	B-X
to	B-X
show	B-X
that	B-X
tumor	B-X
cells	B-X
secreted	B-X
vascular	B-X
permeability	B-X
factor	B-X
(	B-X
VPF	B-X
)	B-X
and	B-X
that	B-X
a	B-X
blocking	B-X
antibody	B-X
to	B-X
VPF	B-X
could	B-X
prevent	B-X
the	B-X
edema	B-X
and	B-X
fluid	B-X
accumulation	B-X
that	B-X
is	B-X
characteristic	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
went	B-X
on	B-X
to	B-X
demonstrate	B-X
that	B-X
VPF	B-X
was	B-X
secreted	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
and	B-X
proposed	B-X
that	B-X
VPF	B-X
was	B-X
in	B-X
part	B-X
responsible	B-X
for	B-X
the	B-X
abnormal	B-X
vasculature	B-X
seen	B-X
in	B-X
human	B-X
tumors	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
he	B-X
and	B-X
other	B-X
investigators	B-X
demonstrated	B-X
that	B-X
VPF	B-X
was	B-X
capable	B-X
of	B-X
stimulating	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X
These	B-X
fundamental	B-X
discoveries	B-X
led	B-X
to	B-X
additional	B-X
research	B-X
conducted	B-X
by	B-X
Napoleone	B-X
Ferrara	B-X
and	B-X
his	B-X
laboratory	B-X
,	B-X
confirming	B-X
the	B-X
cloning	B-X
of	B-X
VPF	B-X
and	B-X
renaming	B-X
the	B-X
protein	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
proposed	B-X
that	B-X
by	B-X
secreting	B-X
VPF	B-X
,	B-X
tumors	B-X
induce	B-X
angiogenesis	B-X
by	B-X
turning	B-X
on	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
He	B-X
noted	B-X
that	B-X
wounds	B-X
,	B-X
like	B-X
tumors	B-X
,	B-X
secrete	B-X
VPF	B-X
,	B-X
causing	B-X
blood	B-X
vessels	B-X
to	B-X
leak	B-X
plasma	B-X
fibrinogen	B-X
,	B-X
which	B-X
stimulates	B-X
blood	B-X
vessel	B-X
growth	B-X
and	B-X
provides	B-X
a	B-X
matrix	B-X
on	B-X
which	B-X
they	B-X
can	B-X
spread	B-X
.	B-X
Unlike	B-X
wounds	B-X
,	B-X
however	B-X
,	B-X
that	B-X
turn	B-X
off	B-X
VPF	B-X
production	B-X
after	B-X
healing	B-X
,	B-X
tumors	B-X
did	B-X
not	B-X
turn	B-X
off	B-X
their	B-X
VPF	B-X
production	B-X
and	B-X
instead	B-X
continued	B-X
to	B-X
make	B-X
large	B-X
amounts	B-X
of	B-X
VPF	B-X
,	B-X
allowing	B-X
malignant	B-X
cells	B-X
to	B-X
continue	B-X
to	B-X
induce	B-X
new	B-X
blood	B-X
vessels	B-X
and	B-X
so	B-X
to	B-X
grow	B-X
and	B-X
spread	B-X
.	B-X
Thus	B-X
,	B-X
tumors	B-X
behave	B-X
like	B-X
wounds	B-X
that	B-X
fail	B-X
to	B-X
heal	B-X
.	B-X
This	B-X
work	B-X
is	B-X
again	B-X
extremely	B-X
significant	B-X
for	B-X
patients	B-X
worldwide	B-X
,	B-X
as	B-X
Dvorak	B-X
's	B-X
scientific	B-X
research	B-X
is	B-X
leading	B-X
his	B-X
colleagues	B-X
all	B-X
over	B-X
the	B-X
world	B-X
to	B-X
examine	B-X
how	B-X
to	B-X
treat	B-X
a	B-X
tumor	B-X
through	B-X
its	B-X
blood	B-X
supply	B-X
.	B-X

Unlike	O
wounds	O
,	O
however	O
,	O
that	O
turn	O
off	O
VPF	B-Gene_or_gene_product
production	O
after	O
healing	O
,	O
tumors	O
did	O
not	O
turn	O
off	O
their	O
VPF	B-Gene_or_gene_product
production	O
and	O
instead	O
continued	O
to	O
make	O
large	O
amounts	O
of	O
VPF	B-Gene_or_gene_product
,	O
allowing	O
malignant	O
cells	O
to	O
continue	O
to	O
induce	O
new	O
blood	O
vessels	O
and	O
so	O
to	O
grow	O
and	O
spread	O
.	O
<EOS>	B-X
In	B-X
1983	B-X
,	B-X
Harold	B-X
Dvorak	B-X
and	B-X
his	B-X
colleagues	B-X
were	B-X
the	B-X
first	B-X
to	B-X
show	B-X
that	B-X
tumor	B-X
cells	B-X
secreted	B-X
vascular	B-X
permeability	B-X
factor	B-X
(	B-X
VPF	B-X
)	B-X
and	B-X
that	B-X
a	B-X
blocking	B-X
antibody	B-X
to	B-X
VPF	B-X
could	B-X
prevent	B-X
the	B-X
edema	B-X
and	B-X
fluid	B-X
accumulation	B-X
that	B-X
is	B-X
characteristic	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
went	B-X
on	B-X
to	B-X
demonstrate	B-X
that	B-X
VPF	B-X
was	B-X
secreted	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
and	B-X
proposed	B-X
that	B-X
VPF	B-X
was	B-X
in	B-X
part	B-X
responsible	B-X
for	B-X
the	B-X
abnormal	B-X
vasculature	B-X
seen	B-X
in	B-X
human	B-X
tumors	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
he	B-X
and	B-X
other	B-X
investigators	B-X
demonstrated	B-X
that	B-X
VPF	B-X
was	B-X
capable	B-X
of	B-X
stimulating	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X
These	B-X
fundamental	B-X
discoveries	B-X
led	B-X
to	B-X
additional	B-X
research	B-X
conducted	B-X
by	B-X
Napoleone	B-X
Ferrara	B-X
and	B-X
his	B-X
laboratory	B-X
,	B-X
confirming	B-X
the	B-X
cloning	B-X
of	B-X
VPF	B-X
and	B-X
renaming	B-X
the	B-X
protein	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
proposed	B-X
that	B-X
by	B-X
secreting	B-X
VPF	B-X
,	B-X
tumors	B-X
induce	B-X
angiogenesis	B-X
by	B-X
turning	B-X
on	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
He	B-X
noted	B-X
that	B-X
wounds	B-X
,	B-X
like	B-X
tumors	B-X
,	B-X
secrete	B-X
VPF	B-X
,	B-X
causing	B-X
blood	B-X
vessels	B-X
to	B-X
leak	B-X
plasma	B-X
fibrinogen	B-X
,	B-X
which	B-X
stimulates	B-X
blood	B-X
vessel	B-X
growth	B-X
and	B-X
provides	B-X
a	B-X
matrix	B-X
on	B-X
which	B-X
they	B-X
can	B-X
spread	B-X
.	B-X
Unlike	B-X
wounds	B-X
,	B-X
however	B-X
,	B-X
that	B-X
turn	B-X
off	B-X
VPF	B-X
production	B-X
after	B-X
healing	B-X
,	B-X
tumors	B-X
did	B-X
not	B-X
turn	B-X
off	B-X
their	B-X
VPF	B-X
production	B-X
and	B-X
instead	B-X
continued	B-X
to	B-X
make	B-X
large	B-X
amounts	B-X
of	B-X
VPF	B-X
,	B-X
allowing	B-X
malignant	B-X
cells	B-X
to	B-X
continue	B-X
to	B-X
induce	B-X
new	B-X
blood	B-X
vessels	B-X
and	B-X
so	B-X
to	B-X
grow	B-X
and	B-X
spread	B-X
.	B-X
Thus	B-X
,	B-X
tumors	B-X
behave	B-X
like	B-X
wounds	B-X
that	B-X
fail	B-X
to	B-X
heal	B-X
.	B-X
This	B-X
work	B-X
is	B-X
again	B-X
extremely	B-X
significant	B-X
for	B-X
patients	B-X
worldwide	B-X
,	B-X
as	B-X
Dvorak	B-X
's	B-X
scientific	B-X
research	B-X
is	B-X
leading	B-X
his	B-X
colleagues	B-X
all	B-X
over	B-X
the	B-X
world	B-X
to	B-X
examine	B-X
how	B-X
to	B-X
treat	B-X
a	B-X
tumor	B-X
through	B-X
its	B-X
blood	B-X
supply	B-X
.	B-X

Thus	O
,	O
tumors	O
behave	O
like	O
wounds	O
that	O
fail	O
to	O
heal	O
.	O
<EOS>	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
went	B-X
on	B-X
to	B-X
demonstrate	B-X
that	B-X
VPF	B-X
was	B-X
secreted	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
and	B-X
proposed	B-X
that	B-X
VPF	B-X
was	B-X
in	B-X
part	B-X
responsible	B-X
for	B-X
the	B-X
abnormal	B-X
vasculature	B-X
seen	B-X
in	B-X
human	B-X
tumors	B-X
.	B-X
In	B-X
1986	B-X
,	B-X
Dvorak	B-X
proposed	B-X
that	B-X
by	B-X
secreting	B-X
VPF	B-X
,	B-X
tumors	B-X
induce	B-X
angiogenesis	B-X
by	B-X
turning	B-X
on	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
He	B-X
noted	B-X
that	B-X
wounds	B-X
,	B-X
like	B-X
tumors	B-X
,	B-X
secrete	B-X
VPF	B-X
,	B-X
causing	B-X
blood	B-X
vessels	B-X
to	B-X
leak	B-X
plasma	B-X
fibrinogen	B-X
,	B-X
which	B-X
stimulates	B-X
blood	B-X
vessel	B-X
growth	B-X
and	B-X
provides	B-X
a	B-X
matrix	B-X
on	B-X
which	B-X
they	B-X
can	B-X
spread	B-X
.	B-X
Unlike	B-X
wounds	B-X
,	B-X
however	B-X
,	B-X
that	B-X
turn	B-X
off	B-X
VPF	B-X
production	B-X
after	B-X
healing	B-X
,	B-X
tumors	B-X
did	B-X
not	B-X
turn	B-X
off	B-X
their	B-X
VPF	B-X
production	B-X
and	B-X
instead	B-X
continued	B-X
to	B-X
make	B-X
large	B-X
amounts	B-X
of	B-X
VPF	B-X
,	B-X
allowing	B-X
malignant	B-X
cells	B-X
to	B-X
continue	B-X
to	B-X
induce	B-X
new	B-X
blood	B-X
vessels	B-X
and	B-X
so	B-X
to	B-X
grow	B-X
and	B-X
spread	B-X
.	B-X
Thus	B-X
,	B-X
tumors	B-X
behave	B-X
like	B-X
wounds	B-X
that	B-X
fail	B-X
to	B-X
heal	B-X
.	B-X

This	O
work	O
is	O
again	O
extremely	O
significant	O
for	O
patients	O
worldwide	O
,	O
as	O
Dvorak	O
'	O
s	O
scientific	O
research	O
is	O
leading	O
his	O
colleagues	O
all	O
over	O
the	O
world	O
to	O
examine	O
how	O
to	O
treat	O
a	O
tumor	O
through	O
its	O
blood	O
supply	O
.	O

Melissoidesin	O
G	O
,	O
a	O
diterpenoid	O
purified	O
from	O
Isodon	O
melissoides	O
,	O
induces	O
leukemic	O
-	O
cell	O
apoptosis	O
through	O
induction	O
of	O
redox	O
imbalance	O
and	O
exhibits	O
synergy	O
with	O
other	O
anticancer	O
agents	O
.	O
<EOS>	B-X
Melissoidesin	B-X
G	B-X
(	B-X
MOG	B-X
)	B-X
is	B-X
a	B-X
new	B-X
diterpenoid	B-X
purified	B-X
from	B-X
Isodon	B-X
melissoides	B-X
,	B-X
a	B-X
plant	B-X
used	B-X
in	B-X
Chinese	B-X
traditional	B-X
medicine	B-X
as	B-X
antitumor	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
In	B-X
our	B-X
study	B-X
,	B-X
MOG	B-X
was	B-X
shown	B-X
to	B-X
specifically	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
leukemia	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
production	B-X
,	B-X
caspases	B-X
activation	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thiol-containing	B-X
antioxidants	B-X
completely	B-X
blocked	B-X
MOG-induced	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
subsequent	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
by	B-X
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone	B-X
only	B-X
partially	B-X
attenuated	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
indicating	B-X
that	B-X
MOG-induced	B-X
redox	B-X
imbalance	B-X
is	B-X
an	B-X
early	B-X
event	B-X
upstream	B-X
to	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
caspase-3	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
MOG	B-X
rapidly	B-X
decreased	B-X
the	B-X
intracellular	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
content	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
GSH	B-X
depletion	B-X
in	B-X
MOG-induced	B-X
apoptosis	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
tert-butylhydroquinone	B-X
(	B-X
tBHQ	B-X
)	B-X
and	B-X
the	B-X
facilitative	B-X
effects	B-X
of	B-X
DL-buthionine	B-X
(	B-X
S	B-X
,	B-X
R	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
showed	B-X
that	B-X
GSH	B-X
depletion	B-X
induced	B-X
by	B-X
MOG	B-X
rendered	B-X
some	B-X
leukemia	B-X
cell	B-X
lines	B-X
more	B-X
sensitive	B-X
to	B-X
arsenic	B-X
trioxide	B-X
(	B-X
As2O3	B-X
)	B-X
,	B-X
doxorubicin	B-X
or	B-X
cisplatin	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
synergistic	B-X
apoptotic	B-X
effects	B-X
of	B-X
MOG	B-X
with	B-X
As2O3	B-X
were	B-X
detected	B-X
in	B-X
HL-60	B-X
and	B-X
primary	B-X
AML	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
selective	B-X
toxicity	B-X
of	B-X
their	B-X
combination	B-X
to	B-X
the	B-X
malignant	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
we	B-X
proposed	B-X
that	B-X
MOG	B-X
alone	B-X
or	B-X
administered	B-X
with	B-X
other	B-X
anticancer	B-X
agents	B-X
may	B-X
provide	B-X
a	B-X
novel	B-X
therapeutic	B-X
strategy	B-X
for	B-X
leukemia	B-X
.	B-X

Melissoidesin	O
G	O
(	O
MOG	O
)	O
is	O
a	O
new	O
diterpenoid	O
purified	O
from	O
Isodon	O
melissoides	O
,	O
a	O
plant	O
used	O
in	O
Chinese	O
traditional	O
medicine	O
as	O
antitumor	O
and	O
anti	O
-	O
inflammatory	O
agents	O
.	O
<EOS>	B-X
Melissoidesin	B-X
G	B-X
(	B-X
MOG	B-X
)	B-X
is	B-X
a	B-X
new	B-X
diterpenoid	B-X
purified	B-X
from	B-X
Isodon	B-X
melissoides	B-X
,	B-X
a	B-X
plant	B-X
used	B-X
in	B-X
Chinese	B-X
traditional	B-X
medicine	B-X
as	B-X
antitumor	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
In	B-X
our	B-X
study	B-X
,	B-X
MOG	B-X
was	B-X
shown	B-X
to	B-X
specifically	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
leukemia	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
production	B-X
,	B-X
caspases	B-X
activation	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thiol-containing	B-X
antioxidants	B-X
completely	B-X
blocked	B-X
MOG-induced	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
subsequent	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
by	B-X
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone	B-X
only	B-X
partially	B-X
attenuated	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
indicating	B-X
that	B-X
MOG-induced	B-X
redox	B-X
imbalance	B-X
is	B-X
an	B-X
early	B-X
event	B-X
upstream	B-X
to	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
caspase-3	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
MOG	B-X
rapidly	B-X
decreased	B-X
the	B-X
intracellular	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
content	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
GSH	B-X
depletion	B-X
in	B-X
MOG-induced	B-X
apoptosis	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
tert-butylhydroquinone	B-X
(	B-X
tBHQ	B-X
)	B-X
and	B-X
the	B-X
facilitative	B-X
effects	B-X
of	B-X
DL-buthionine	B-X
(	B-X
S	B-X
,	B-X
R	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
showed	B-X
that	B-X
GSH	B-X
depletion	B-X
induced	B-X
by	B-X
MOG	B-X
rendered	B-X
some	B-X
leukemia	B-X
cell	B-X
lines	B-X
more	B-X
sensitive	B-X
to	B-X
arsenic	B-X
trioxide	B-X
(	B-X
As2O3	B-X
)	B-X
,	B-X
doxorubicin	B-X
or	B-X
cisplatin	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
synergistic	B-X
apoptotic	B-X
effects	B-X
of	B-X
MOG	B-X
with	B-X
As2O3	B-X
were	B-X
detected	B-X
in	B-X
HL-60	B-X
and	B-X
primary	B-X
AML	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
selective	B-X
toxicity	B-X
of	B-X
their	B-X
combination	B-X
to	B-X
the	B-X
malignant	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
we	B-X
proposed	B-X
that	B-X
MOG	B-X
alone	B-X
or	B-X
administered	B-X
with	B-X
other	B-X
anticancer	B-X
agents	B-X
may	B-X
provide	B-X
a	B-X
novel	B-X
therapeutic	B-X
strategy	B-X
for	B-X
leukemia	B-X
.	B-X

In	O
our	O
study	O
,	O
MOG	O
was	O
shown	O
to	O
specifically	O
inhibit	O
the	O
growth	O
of	O
human	O
leukemia	O
cell	O
lines	O
and	O
primary	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
blasts	O
via	O
induction	O
of	O
apoptosis	O
,	O
with	O
the	O
evidence	O
of	O
mitochondrial	O
DeltaPsim	O
loss	O
,	O
reactive	O
oxygen	O
species	O
production	O
,	O
caspases	B-Gene_or_gene_product
activation	O
and	O
nuclear	O
fragmentation	O
.	O
<EOS>	B-X
Melissoidesin	B-X
G	B-X
(	B-X
MOG	B-X
)	B-X
is	B-X
a	B-X
new	B-X
diterpenoid	B-X
purified	B-X
from	B-X
Isodon	B-X
melissoides	B-X
,	B-X
a	B-X
plant	B-X
used	B-X
in	B-X
Chinese	B-X
traditional	B-X
medicine	B-X
as	B-X
antitumor	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
In	B-X
our	B-X
study	B-X
,	B-X
MOG	B-X
was	B-X
shown	B-X
to	B-X
specifically	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
leukemia	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
production	B-X
,	B-X
caspases	B-X
activation	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thiol-containing	B-X
antioxidants	B-X
completely	B-X
blocked	B-X
MOG-induced	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
subsequent	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
by	B-X
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone	B-X
only	B-X
partially	B-X
attenuated	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
indicating	B-X
that	B-X
MOG-induced	B-X
redox	B-X
imbalance	B-X
is	B-X
an	B-X
early	B-X
event	B-X
upstream	B-X
to	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
caspase-3	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
MOG	B-X
rapidly	B-X
decreased	B-X
the	B-X
intracellular	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
content	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
GSH	B-X
depletion	B-X
in	B-X
MOG-induced	B-X
apoptosis	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
tert-butylhydroquinone	B-X
(	B-X
tBHQ	B-X
)	B-X
and	B-X
the	B-X
facilitative	B-X
effects	B-X
of	B-X
DL-buthionine	B-X
(	B-X
S	B-X
,	B-X
R	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
showed	B-X
that	B-X
GSH	B-X
depletion	B-X
induced	B-X
by	B-X
MOG	B-X
rendered	B-X
some	B-X
leukemia	B-X
cell	B-X
lines	B-X
more	B-X
sensitive	B-X
to	B-X
arsenic	B-X
trioxide	B-X
(	B-X
As2O3	B-X
)	B-X
,	B-X
doxorubicin	B-X
or	B-X
cisplatin	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
synergistic	B-X
apoptotic	B-X
effects	B-X
of	B-X
MOG	B-X
with	B-X
As2O3	B-X
were	B-X
detected	B-X
in	B-X
HL-60	B-X
and	B-X
primary	B-X
AML	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
selective	B-X
toxicity	B-X
of	B-X
their	B-X
combination	B-X
to	B-X
the	B-X
malignant	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
we	B-X
proposed	B-X
that	B-X
MOG	B-X
alone	B-X
or	B-X
administered	B-X
with	B-X
other	B-X
anticancer	B-X
agents	B-X
may	B-X
provide	B-X
a	B-X
novel	B-X
therapeutic	B-X
strategy	B-X
for	B-X
leukemia	B-X
.	B-X

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
thiol	O
-	O
containing	O
antioxidants	O
completely	O
blocked	O
MOG	O
-	O
induced	O
mitochondrial	O
DeltaPsim	O
loss	O
and	O
subsequent	O
cell	O
apoptosis	O
,	O
while	O
the	O
inhibition	O
of	O
apoptosis	O
by	O
benzyloxy	O
-	O
carbonyl	O
-	O
Val	O
-	O
Ala	O
-	O
Asp	O
-	O
fluoromethylketone	O
only	O
partially	O
attenuated	O
mitochondrial	O
DeltaPsim	O
loss	O
,	O
indicating	O
that	O
MOG	O
-	O
induced	O
redox	O
imbalance	O
is	O
an	O
early	O
event	O
upstream	O
to	O
mitochondrial	O
DeltaPsim	O
loss	O
and	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
activation	O
.	O
<EOS>	B-X
Melissoidesin	B-X
G	B-X
(	B-X
MOG	B-X
)	B-X
is	B-X
a	B-X
new	B-X
diterpenoid	B-X
purified	B-X
from	B-X
Isodon	B-X
melissoides	B-X
,	B-X
a	B-X
plant	B-X
used	B-X
in	B-X
Chinese	B-X
traditional	B-X
medicine	B-X
as	B-X
antitumor	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
In	B-X
our	B-X
study	B-X
,	B-X
MOG	B-X
was	B-X
shown	B-X
to	B-X
specifically	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
leukemia	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
production	B-X
,	B-X
caspases	B-X
activation	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thiol-containing	B-X
antioxidants	B-X
completely	B-X
blocked	B-X
MOG-induced	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
subsequent	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
by	B-X
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone	B-X
only	B-X
partially	B-X
attenuated	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
indicating	B-X
that	B-X
MOG-induced	B-X
redox	B-X
imbalance	B-X
is	B-X
an	B-X
early	B-X
event	B-X
upstream	B-X
to	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
caspase-3	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
MOG	B-X
rapidly	B-X
decreased	B-X
the	B-X
intracellular	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
content	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
GSH	B-X
depletion	B-X
in	B-X
MOG-induced	B-X
apoptosis	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
tert-butylhydroquinone	B-X
(	B-X
tBHQ	B-X
)	B-X
and	B-X
the	B-X
facilitative	B-X
effects	B-X
of	B-X
DL-buthionine	B-X
(	B-X
S	B-X
,	B-X
R	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
showed	B-X
that	B-X
GSH	B-X
depletion	B-X
induced	B-X
by	B-X
MOG	B-X
rendered	B-X
some	B-X
leukemia	B-X
cell	B-X
lines	B-X
more	B-X
sensitive	B-X
to	B-X
arsenic	B-X
trioxide	B-X
(	B-X
As2O3	B-X
)	B-X
,	B-X
doxorubicin	B-X
or	B-X
cisplatin	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
synergistic	B-X
apoptotic	B-X
effects	B-X
of	B-X
MOG	B-X
with	B-X
As2O3	B-X
were	B-X
detected	B-X
in	B-X
HL-60	B-X
and	B-X
primary	B-X
AML	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
selective	B-X
toxicity	B-X
of	B-X
their	B-X
combination	B-X
to	B-X
the	B-X
malignant	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
we	B-X
proposed	B-X
that	B-X
MOG	B-X
alone	B-X
or	B-X
administered	B-X
with	B-X
other	B-X
anticancer	B-X
agents	B-X
may	B-X
provide	B-X
a	B-X
novel	B-X
therapeutic	B-X
strategy	B-X
for	B-X
leukemia	B-X
.	B-X

Consistently	O
,	O
it	O
was	O
found	O
that	O
MOG	O
rapidly	O
decreased	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
content	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
significance	O
of	O
GSH	O
depletion	O
in	O
MOG	O
-	O
induced	O
apoptosis	O
was	O
further	O
supported	O
by	O
the	O
protective	O
effects	O
of	O
tert	O
-	O
butylhydroquinone	O
(	O
tBHQ	O
)	O
and	O
the	O
facilitative	O
effects	O
of	O
DL	O
-	O
buthionine	O
(	O
S	O
,	O
R	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
.	O

Furthermore	O
,	O
it	O
was	O
showed	O
that	O
GSH	O
depletion	O
induced	O
by	O
MOG	O
rendered	O
some	O
leukemia	O
cell	O
lines	O
more	O
sensitive	O
to	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
,	O
doxorubicin	O
or	O
cisplatin	O
.	O
<EOS>	B-X
However	B-X
,	B-X
side	B-X
effects	B-X
and	B-X
drug	B-X
resistance	B-X
are	B-X
the	B-X
two	B-X
inherent	B-X
challenges	B-X
of	B-X
cisplatin	B-X
which	B-X
limit	B-X
its	B-X
application	B-X
and	B-X
effectiveness	B-X
.	B-X
Reduction	B-X
of	B-X
drug	B-X
accumulation	B-X
inside	B-X
cancer	B-X
cells	B-X
,	B-X
inactivation	B-X
of	B-X
drug	B-X
by	B-X
reacting	B-X
with	B-X
glutathione	B-X
and	B-X
metallothioneins	B-X
and	B-X
faster	B-X
repairing	B-X
of	B-X
DNA	B-X
lesions	B-X
are	B-X
responsible	B-X
for	B-X
cisplatin	B-X
resistance	B-X
.	B-X
To	B-X
minimize	B-X
cisplatin	B-X
side	B-X
effects	B-X
and	B-X
resistance	B-X
,	B-X
combination	B-X
therapies	B-X
are	B-X
used	B-X
and	B-X
have	B-X
proven	B-X
more	B-X
effective	B-X
to	B-X
defect	B-X
cancers	B-X
.	B-X
This	B-X
article	B-X
highlights	B-X
a	B-X
systematic	B-X
description	B-X
on	B-X
cisplatin	B-X
which	B-X
includes	B-X
a	B-X
brief	B-X
history	B-X
,	B-X
synthesis	B-X
,	B-X
action	B-X
mechanism	B-X
,	B-X
resistance	B-X
,	B-X
uses	B-X
,	B-X
side	B-X
effects	B-X
and	B-X
modulation	B-X
of	B-X
side	B-X
effects	B-X
.	B-X
It	B-X
also	B-X
briefly	B-X
describes	B-X
development	B-X
of	B-X
platinum	B-X
drugs	B-X
from	B-X
very	B-X
small	B-X
cisplatin	B-X
complex	B-X
to	B-X
very	B-X
large	B-X
next	B-X
generation	B-X
nanocarriers	B-X
conjugated	B-X
platinum	B-X
complexes	B-X
.	B-X

Additionally	O
,	O
the	O
synergistic	O
apoptotic	O
effects	O
of	O
MOG	O
with	O
As2O3	O
were	O
detected	O
in	O
HL	O
-	O
60	O
and	O
primary	O
AML	O
cells	O
,	O
but	O
not	O
in	O
normal	O
cells	O
,	O
suggesting	O
the	O
selective	O
toxicity	O
of	O
their	O
combination	O
to	O
the	O
malignant	O
cells	O
.	O
<EOS>	B-X
Melissoidesin	B-X
G	B-X
(	B-X
MOG	B-X
)	B-X
is	B-X
a	B-X
new	B-X
diterpenoid	B-X
purified	B-X
from	B-X
Isodon	B-X
melissoides	B-X
,	B-X
a	B-X
plant	B-X
used	B-X
in	B-X
Chinese	B-X
traditional	B-X
medicine	B-X
as	B-X
antitumor	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
In	B-X
our	B-X
study	B-X
,	B-X
MOG	B-X
was	B-X
shown	B-X
to	B-X
specifically	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
leukemia	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
production	B-X
,	B-X
caspases	B-X
activation	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thiol-containing	B-X
antioxidants	B-X
completely	B-X
blocked	B-X
MOG-induced	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
subsequent	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
by	B-X
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone	B-X
only	B-X
partially	B-X
attenuated	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
indicating	B-X
that	B-X
MOG-induced	B-X
redox	B-X
imbalance	B-X
is	B-X
an	B-X
early	B-X
event	B-X
upstream	B-X
to	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
caspase-3	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
MOG	B-X
rapidly	B-X
decreased	B-X
the	B-X
intracellular	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
content	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
GSH	B-X
depletion	B-X
in	B-X
MOG-induced	B-X
apoptosis	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
tert-butylhydroquinone	B-X
(	B-X
tBHQ	B-X
)	B-X
and	B-X
the	B-X
facilitative	B-X
effects	B-X
of	B-X
DL-buthionine	B-X
(	B-X
S	B-X
,	B-X
R	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
showed	B-X
that	B-X
GSH	B-X
depletion	B-X
induced	B-X
by	B-X
MOG	B-X
rendered	B-X
some	B-X
leukemia	B-X
cell	B-X
lines	B-X
more	B-X
sensitive	B-X
to	B-X
arsenic	B-X
trioxide	B-X
(	B-X
As2O3	B-X
)	B-X
,	B-X
doxorubicin	B-X
or	B-X
cisplatin	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
synergistic	B-X
apoptotic	B-X
effects	B-X
of	B-X
MOG	B-X
with	B-X
As2O3	B-X
were	B-X
detected	B-X
in	B-X
HL-60	B-X
and	B-X
primary	B-X
AML	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
selective	B-X
toxicity	B-X
of	B-X
their	B-X
combination	B-X
to	B-X
the	B-X
malignant	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
we	B-X
proposed	B-X
that	B-X
MOG	B-X
alone	B-X
or	B-X
administered	B-X
with	B-X
other	B-X
anticancer	B-X
agents	B-X
may	B-X
provide	B-X
a	B-X
novel	B-X
therapeutic	B-X
strategy	B-X
for	B-X
leukemia	B-X
.	B-X

Together	O
,	O
we	O
proposed	O
that	O
MOG	O
alone	O
or	O
administered	O
with	O
other	O
anticancer	O
agents	O
may	O
provide	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
leukemia	O
.	O
<EOS>	B-X
Strategic	B-X
modalities	B-X
of	B-X
drug	B-X
delivery	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
greatly	B-X
improve	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
available	B-X
drugs	B-X
in	B-X
acute	B-X
myelogenous	B-X
leukaemia	B-X
(	B-X
AML	B-X
)	B-X
.	B-X
FR-beta	B-X
may	B-X
,	B-X
therefore	B-X
,	B-X
be	B-X
used	B-X
as	B-X
a	B-X
target	B-X
for	B-X
the	B-X
selective	B-X
delivery	B-X
of	B-X
chemotherapeutic	B-X
drugs	B-X
to	B-X
AML	B-X
cells	B-X
;	B-X
this	B-X
treatment	B-X
modality	B-X
appears	B-X
to	B-X
be	B-X
particularly	B-X
efficacious	B-X
when	B-X
administered	B-X
in	B-X
conjunction	B-X
with	B-X
retinoid-induction	B-X
of	B-X
FR-beta	B-X
.	B-X
The	B-X
rationale	B-X
and	B-X
merits	B-X
of	B-X
this	B-X
novel	B-X
experimental	B-X
treatment	B-X
for	B-X
AML	B-X
and	B-X
the	B-X
current	B-X
status	B-X
of	B-X
this	B-X
research	B-X
are	B-X
provided	B-X
.	B-X
Melissoidesin	B-X
G	B-X
(	B-X
MOG	B-X
)	B-X
is	B-X
a	B-X
new	B-X
diterpenoid	B-X
purified	B-X
from	B-X
Isodon	B-X
melissoides	B-X
,	B-X
a	B-X
plant	B-X
used	B-X
in	B-X
Chinese	B-X
traditional	B-X
medicine	B-X
as	B-X
antitumor	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
In	B-X
our	B-X
study	B-X
,	B-X
MOG	B-X
was	B-X
shown	B-X
to	B-X
specifically	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
leukemia	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
via	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
production	B-X
,	B-X
caspases	B-X
activation	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
thiol-containing	B-X
antioxidants	B-X
completely	B-X
blocked	B-X
MOG-induced	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
subsequent	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
by	B-X
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone	B-X
only	B-X
partially	B-X
attenuated	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
,	B-X
indicating	B-X
that	B-X
MOG-induced	B-X
redox	B-X
imbalance	B-X
is	B-X
an	B-X
early	B-X
event	B-X
upstream	B-X
to	B-X
mitochondrial	B-X
DeltaPsim	B-X
loss	B-X
and	B-X
caspase-3	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
MOG	B-X
rapidly	B-X
decreased	B-X
the	B-X
intracellular	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
content	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
GSH	B-X
depletion	B-X
in	B-X
MOG-induced	B-X
apoptosis	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
tert-butylhydroquinone	B-X
(	B-X
tBHQ	B-X
)	B-X
and	B-X
the	B-X
facilitative	B-X
effects	B-X
of	B-X
DL-buthionine	B-X
(	B-X
S	B-X
,	B-X
R	B-X
)	B-X
-sulfoximine	B-X
(	B-X
BSO	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
was	B-X
showed	B-X
that	B-X
GSH	B-X
depletion	B-X
induced	B-X
by	B-X
MOG	B-X
rendered	B-X
some	B-X
leukemia	B-X
cell	B-X
lines	B-X
more	B-X
sensitive	B-X
to	B-X
arsenic	B-X
trioxide	B-X
(	B-X
As2O3	B-X
)	B-X
,	B-X
doxorubicin	B-X
or	B-X
cisplatin	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
synergistic	B-X
apoptotic	B-X
effects	B-X
of	B-X
MOG	B-X
with	B-X
As2O3	B-X
were	B-X
detected	B-X
in	B-X
HL-60	B-X
and	B-X
primary	B-X
AML	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
suggesting	B-X
the	B-X
selective	B-X
toxicity	B-X
of	B-X
their	B-X
combination	B-X
to	B-X
the	B-X
malignant	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
we	B-X
proposed	B-X
that	B-X
MOG	B-X
alone	B-X
or	B-X
administered	B-X
with	B-X
other	B-X
anticancer	B-X
agents	B-X
may	B-X
provide	B-X
a	B-X
novel	B-X
therapeutic	B-X
strategy	B-X
for	B-X
leukemia	B-X
.	B-X

Hedgehog	B-Gene_or_gene_product
signaling	O
in	O
the	O
murine	O
melanoma	O
microenvironment	O
.	O
<EOS>	B-X
The	B-X
Hedgehog	B-X
intercellular	B-X
signaling	B-X
pathway	B-X
regulates	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
Shh	B-X
peptide	B-X
produced	B-X
by	B-X
melanoma	B-X
cells	B-X
induces	B-X
Patched	B-X
expression	B-X
in	B-X
fibroblasts	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

The	O
Hedgehog	B-Gene_or_gene_product
intercellular	O
signaling	O
pathway	O
regulates	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
retina	B-X
is	B-X
an	B-X
excellent	B-X
system	B-X
for	B-X
delving	B-X
into	B-X
the	B-X
question	B-X
of	B-X
how	B-X
cell	B-X
fate	B-X
,	B-X
number	B-X
and	B-X
organization	B-X
are	B-X
regulated	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
.	B-X
Multipotential	B-X
progenitor	B-X
cells	B-X
in	B-X
the	B-X
immature	B-X
retina	B-X
proliferate	B-X
,	B-X
exit	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
generate	B-X
neurons	B-X
and	B-X
one	B-X
glial	B-X
cell	B-X
type	B-X
in	B-X
a	B-X
prescribed	B-X
temporal	B-X
sequence	B-X
.	B-X
While	B-X
some	B-X
aspects	B-X
of	B-X
progenitor	B-X
behavior	B-X
are	B-X
controlled	B-X
cell	B-X
intrinsically	B-X
,	B-X
extrinsic	B-X
signals	B-X
present	B-X
in	B-X
the	B-X
retina	B-X
environment	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
impact	B-X
on	B-X
proliferation	B-X
,	B-X
differentiation	B-X
and	B-X
cell	B-X
fate	B-X
of	B-X
progenitors	B-X
.	B-X
Intercellular	B-X
signaling	B-X
proteins	B-X
of	B-X
the	B-X
Hedgehog	B-X
(	B-X
Hh	B-X
)	B-X
family	B-X
regulate	B-X
several	B-X
aspects	B-X
of	B-X
visual	B-X
system	B-X
development	B-X
in	B-X
vertebrates	B-X
--	B-X
ranging	B-X
from	B-X
early	B-X
eye	B-X
field	B-X
patterning	B-X
to	B-X
retinal	B-X
and	B-X
optic	B-X
nerve	B-X
development	B-X
.	B-X
This	B-X
review	B-X
highlights	B-X
the	B-X
role	B-X
of	B-X
Hh	B-X
signaling	B-X
on	B-X
retinal	B-X
progenitor	B-X
proliferation	B-X
and	B-X
diversification	B-X
.	B-X

This	O
pathway	O
has	O
been	O
implicated	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	O
and	O
in	O
embryonic	O
blood	O
vessel	O
development	O
.	O
<EOS>	B-X
Mitogen-activated	B-X
protein	B-X
kinases	B-X
play	B-X
an	B-X
integral	B-X
role	B-X
in	B-X
several	B-X
cellular	B-X
processes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
specific	B-X
role	B-X
that	B-X
one	B-X
member	B-X
of	B-X
this	B-X
family	B-X
of	B-X
phosphatases	B-X
,	B-X
dual-specific	B-X
phosphatase-5	B-X
(	B-X
Dusp-5	B-X
)	B-X
plays	B-X
in	B-X
vascular	B-X
development	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
that	B-X
dusp-5	B-X
is	B-X
expressed	B-X
in	B-X
angioblasts	B-X
and	B-X
in	B-X
established	B-X
vasculature	B-X
and	B-X
that	B-X
it	B-X
counteracts	B-X
the	B-X
function	B-X
of	B-X
a	B-X
serine	B-X
threonine	B-X
kinase	B-X
,	B-X
Snrk-1	B-X
,	B-X
which	B-X
also	B-X
plays	B-X
a	B-X
functional	B-X
role	B-X
in	B-X
angioblast	B-X
development	B-X
.	B-X
Importantly	B-X
,	B-X
mutations	B-X
in	B-X
dusp-5	B-X
and	B-X
snrk-1	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
affected	B-X
tissues	B-X
of	B-X
patients	B-X
with	B-X
vascular	B-X
anomalies	B-X
,	B-X
implicating	B-X
the	B-X
Snrk-1-Dusp-5	B-X
signaling	B-X
pathway	B-X
in	B-X
human	B-X
disease	B-X
.	B-X

In	O
the	O
current	O
study	O
,	O
Hedgehog	B-Gene_or_gene_product
signaling	O
in	O
tumor	O
related	O
vasculature	O
and	O
microenvironment	O
was	O
examined	O
using	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
and	O
B16F0	O
(	O
murine	O
melanoma	O
)	O
tumors	O
models	O
.	O
<EOS>	B-X
The	B-X
Hedgehog	B-X
intercellular	B-X
signaling	B-X
pathway	B-X
regulates	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
Use	B-X
of	B-X
exogenous	B-X
Sonic	B-X
hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
peptide	B-X
significantly	B-X
increased	B-X
BrdU	B-X
incorporation	B-X
in	B-X
endothelial	B-X
cells	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
Furthermore	B-X
,	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
B16F0	B-X
cells	B-X
to	B-X
express	B-X
Patched	B-X
in	B-X
a	B-X
co-culture	B-X
assay	B-X
system	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
Shh	B-X
peptide	B-X
produced	B-X
by	B-X
melanoma	B-X
cells	B-X
induces	B-X
Patched	B-X
expression	B-X
in	B-X
fibroblasts	B-X
.	B-X
To	B-X
study	B-X
tumor	B-X
related	B-X
angiogenesis	B-X
a	B-X
vascular	B-X
window	B-X
model	B-X
was	B-X
used	B-X
to	B-X
monitor	B-X
tumor	B-X
vascularity	B-X
.	B-X
Furthermore	B-X
,	B-X
cyclopamine	B-X
reduced	B-X
tumor	B-X
blood	B-X
vessel	B-X
permeability	B-X
to	B-X
FITC	B-X
labeled	B-X
dextran	B-X
while	B-X
having	B-X
no	B-X
effect	B-X
on	B-X
normal	B-X
blood	B-X
vessels	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

Use	O
of	O
exogenous	O
Sonic	B-Gene_or_gene_product
hedgehog	I-Gene_or_gene_product
(	O
Shh	B-Gene_or_gene_product
)	O
peptide	O
significantly	O
increased	O
BrdU	O
incorporation	O
in	O
endothelial	O
cells	O
in	O
vitro	O
by	O
a	O
factor	O
of	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

The	O
Hedgehog	B-Gene_or_gene_product
pathway	O
antagonist	O
cyclopamine	O
effectively	O
reduced	O
Shh	B-Gene_or_gene_product
-	O
induced	O
proliferation	O
to	O
control	O
levels	O
.	O
<EOS>	B-X
The	B-X
Hedgehog	B-X
intercellular	B-X
signaling	B-X
pathway	B-X
regulates	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
This	B-X
pathway	B-X
has	B-X
been	B-X
implicated	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
cancer	B-X
and	B-X
in	B-X
embryonic	B-X
blood	B-X
vessel	B-X
development	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
Use	B-X
of	B-X
exogenous	B-X
Sonic	B-X
hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
peptide	B-X
significantly	B-X
increased	B-X
BrdU	B-X
incorporation	B-X
in	B-X
endothelial	B-X
cells	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
Shh	B-X
peptide	B-X
produced	B-X
by	B-X
melanoma	B-X
cells	B-X
induces	B-X
Patched	B-X
expression	B-X
in	B-X
fibroblasts	B-X
.	B-X
Treatment	B-X
with	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
vascular	B-X
formation	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2.5	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
altered	B-X
vascular	B-X
morphology	B-X
.	B-X
Furthermore	B-X
,	B-X
cyclopamine	B-X
reduced	B-X
tumor	B-X
blood	B-X
vessel	B-X
permeability	B-X
to	B-X
FITC	B-X
labeled	B-X
dextran	B-X
while	B-X
having	B-X
no	B-X
effect	B-X
on	B-X
normal	B-X
blood	B-X
vessels	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

To	O
study	O
Hedgehog	B-Gene_or_gene_product
signaling	O
in	O
vivo	O
a	O
hind	O
limb	O
tumor	O
model	O
with	O
the	O
B16F0	O
cell	O
line	O
was	O
used	O
.	O
<EOS>	B-X
The	B-X
Hedgehog	B-X
intercellular	B-X
signaling	B-X
pathway	B-X
regulates	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
Use	B-X
of	B-X
exogenous	B-X
Sonic	B-X
hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
peptide	B-X
significantly	B-X
increased	B-X
BrdU	B-X
incorporation	B-X
in	B-X
endothelial	B-X
cells	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
Furthermore	B-X
,	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
B16F0	B-X
cells	B-X
to	B-X
express	B-X
Patched	B-X
in	B-X
a	B-X
co-culture	B-X
assay	B-X
system	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
Shh	B-X
peptide	B-X
produced	B-X
by	B-X
melanoma	B-X
cells	B-X
induces	B-X
Patched	B-X
expression	B-X
in	B-X
fibroblasts	B-X
.	B-X
To	B-X
study	B-X
tumor	B-X
related	B-X
angiogenesis	B-X
a	B-X
vascular	B-X
window	B-X
model	B-X
was	B-X
used	B-X
to	B-X
monitor	B-X
tumor	B-X
vascularity	B-X
.	B-X
Furthermore	B-X
,	B-X
cyclopamine	B-X
reduced	B-X
tumor	B-X
blood	B-X
vessel	B-X
permeability	B-X
to	B-X
FITC	B-X
labeled	B-X
dextran	B-X
while	B-X
having	B-X
no	B-X
effect	B-X
on	B-X
normal	B-X
blood	B-X
vessels	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

Treatment	O
with	O
25	O
mg	O
/	O
kg	O
cyclopamine	O
significantly	O
attenuated	O
BrdU	O
incorporation	O
in	O
tumor	O
cells	O
threefold	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
in	O
tumor	O
related	O
endothelial	O
cells	O
threefold	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
delayed	O
tumor	O
growth	O
by	O
4	O
days	O
.	O

Immunohistochemistry	O
revealed	O
that	O
the	O
Hedgehog	B-Gene_or_gene_product
receptor	O
Patched	B-Gene_or_gene_product
was	O
localized	O
to	O
the	O
tumor	O
stroma	O
and	O
that	O
B16F0	O
cells	O
expressed	O
Shh	B-Gene_or_gene_product
peptide	O
.	O

Furthermore	O
,	O
mouse	O
embryonic	O
fibroblasts	O
required	O
the	O
presence	O
of	O
B16F0	O
cells	O
to	O
express	O
Patched	B-Gene_or_gene_product
in	O
a	O
co	O
-	O
culture	O
assay	O
system	O
.	O

These	O
studies	O
indicate	O
that	O
Shh	B-Gene_or_gene_product
peptide	O
produced	O
by	O
melanoma	O
cells	O
induces	O
Patched	B-Gene_or_gene_product
expression	O
in	O
fibroblasts	O
.	O
<EOS>	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
Use	B-X
of	B-X
exogenous	B-X
Sonic	B-X
hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
peptide	B-X
significantly	B-X
increased	B-X
BrdU	B-X
incorporation	B-X
in	B-X
endothelial	B-X
cells	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
Furthermore	B-X
,	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
B16F0	B-X
cells	B-X
to	B-X
express	B-X
Patched	B-X
in	B-X
a	B-X
co-culture	B-X
assay	B-X
system	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
Shh	B-X
peptide	B-X
produced	B-X
by	B-X
melanoma	B-X
cells	B-X
induces	B-X
Patched	B-X
expression	B-X
in	B-X
fibroblasts	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

To	O
study	O
tumor	O
related	O
angiogenesis	O
a	O
vascular	O
window	O
model	O
was	O
used	O
to	O
monitor	O
tumor	O
vascularity	O
.	O
<EOS>	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
To	B-X
study	B-X
tumor	B-X
related	B-X
angiogenesis	B-X
a	B-X
vascular	B-X
window	B-X
model	B-X
was	B-X
used	B-X
to	B-X
monitor	B-X
tumor	B-X
vascularity	B-X
.	B-X
Treatment	B-X
with	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
vascular	B-X
formation	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2.5	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
altered	B-X
vascular	B-X
morphology	B-X
.	B-X
Furthermore	B-X
,	B-X
cyclopamine	B-X
reduced	B-X
tumor	B-X
blood	B-X
vessel	B-X
permeability	B-X
to	B-X
FITC	B-X
labeled	B-X
dextran	B-X
while	B-X
having	B-X
no	B-X
effect	B-X
on	B-X
normal	B-X
blood	B-X
vessels	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

Treatment	O
with	O
cyclopamine	O
significantly	O
attenuated	O
vascular	O
formation	O
by	O
a	O
factor	O
of	O
2	O
.	O
5	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
altered	O
vascular	O
morphology	O
.	O

Furthermore	O
,	O
cyclopamine	O
reduced	O
tumor	O
blood	O
vessel	O
permeability	O
to	O
FITC	O
labeled	O
dextran	O
while	O
having	O
no	O
effect	O
on	O
normal	O
blood	O
vessels	O
.	O
<EOS>	B-X
This	B-X
pathway	B-X
has	B-X
been	B-X
implicated	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
cancer	B-X
and	B-X
in	B-X
embryonic	B-X
blood	B-X
vessel	B-X
development	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
Furthermore	B-X
,	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
B16F0	B-X
cells	B-X
to	B-X
express	B-X
Patched	B-X
in	B-X
a	B-X
co-culture	B-X
assay	B-X
system	B-X
.	B-X
To	B-X
study	B-X
tumor	B-X
related	B-X
angiogenesis	B-X
a	B-X
vascular	B-X
window	B-X
model	B-X
was	B-X
used	B-X
to	B-X
monitor	B-X
tumor	B-X
vascularity	B-X
.	B-X
Treatment	B-X
with	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
vascular	B-X
formation	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2.5	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
altered	B-X
vascular	B-X
morphology	B-X
.	B-X
Furthermore	B-X
,	B-X
cyclopamine	B-X
reduced	B-X
tumor	B-X
blood	B-X
vessel	B-X
permeability	B-X
to	B-X
FITC	B-X
labeled	B-X
dextran	B-X
while	B-X
having	B-X
no	B-X
effect	B-X
on	B-X
normal	B-X
blood	B-X
vessels	B-X
.	B-X

These	O
studies	O
suggest	O
that	O
Hedgehog	B-Gene_or_gene_product
signaling	O
regulates	O
melanoma	O
related	O
vascular	O
formation	O
and	O
function	O
.	O
<EOS>	B-X
The	B-X
Hedgehog	B-X
intercellular	B-X
signaling	B-X
pathway	B-X
regulates	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
tumor	B-X
related	B-X
vasculature	B-X
and	B-X
microenvironment	B-X
was	B-X
examined	B-X
using	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
B16F0	B-X
(	B-X
murine	B-X
melanoma	B-X
)	B-X
tumors	B-X
models	B-X
.	B-X
The	B-X
Hedgehog	B-X
pathway	B-X
antagonist	B-X
cyclopamine	B-X
effectively	B-X
reduced	B-X
Shh-induced	B-X
proliferation	B-X
to	B-X
control	B-X
levels	B-X
.	B-X
To	B-X
study	B-X
Hedgehog	B-X
signaling	B-X
in	B-X
vivo	B-X
a	B-X
hind	B-X
limb	B-X
tumor	B-X
model	B-X
with	B-X
the	B-X
B16F0	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
.	B-X
Treatment	B-X
with	B-X
25	B-X
mg/kg	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
BrdU	B-X
incorporation	B-X
in	B-X
tumor	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
in	B-X
tumor	B-X
related	B-X
endothelial	B-X
cells	B-X
threefold	B-X
(	B-X
P	B-X
=	B-X
0.004	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
tumor	B-X
growth	B-X
by	B-X
4	B-X
days	B-X
.	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
the	B-X
Hedgehog	B-X
receptor	B-X
Patched	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
tumor	B-X
stroma	B-X
and	B-X
that	B-X
B16F0	B-X
cells	B-X
expressed	B-X
Shh	B-X
peptide	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
Shh	B-X
peptide	B-X
produced	B-X
by	B-X
melanoma	B-X
cells	B-X
induces	B-X
Patched	B-X
expression	B-X
in	B-X
fibroblasts	B-X
.	B-X
To	B-X
study	B-X
tumor	B-X
related	B-X
angiogenesis	B-X
a	B-X
vascular	B-X
window	B-X
model	B-X
was	B-X
used	B-X
to	B-X
monitor	B-X
tumor	B-X
vascularity	B-X
.	B-X
Treatment	B-X
with	B-X
cyclopamine	B-X
significantly	B-X
attenuated	B-X
vascular	B-X
formation	B-X
by	B-X
a	B-X
factor	B-X
of	B-X
2.5	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
altered	B-X
vascular	B-X
morphology	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
Hedgehog	B-X
signaling	B-X
regulates	B-X
melanoma	B-X
related	B-X
vascular	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

Expression	O
of	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
,	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
in	O
relationship	O
to	O
malignant	O
transformation	O
of	O
pleomorphic	O
adenoma	O
.	O
<EOS>	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
increased	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-alpha	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
early	B-X
events	B-X
in	B-X
malignant	B-X
transformation	B-X
of	B-X
pleomorphic	B-X
adenoma	B-X
(	B-X
PA	B-X
)	B-X
.	B-X

CONCLUSION	O
:	O
Quantitative	O
assessment	O
is	O
more	O
sensitive	O
as	O
a	O
measure	O
of	O
cellular	O
protein	O
content	O
as	O
compared	O
with	O
standard	O
optical	O
density	O
measurements	O
.	O
<EOS>	B-X
Quantitative	B-X
assessment	B-X
is	B-X
more	B-X
sensitive	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
cellular	B-X
protein	B-X
content	B-X
as	B-X
compared	B-X
with	B-X
standard	B-X
optical	B-X
density	B-X
measurements	B-X
.	B-X

The	O
data	O
support	O
the	O
hypothesis	O
that	O
increased	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
EGFR	B-Gene_or_gene_product
)	O
and	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
TGF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
expression	O
is	O
associated	O
with	O
early	O
events	O
in	O
malignant	O
transformation	O
of	O
pleomorphic	O
adenoma	O
(	O
PA	O
)	O
.	O
<EOS>	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
increased	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-alpha	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
early	B-X
events	B-X
in	B-X
malignant	B-X
transformation	B-X
of	B-X
pleomorphic	B-X
adenoma	B-X
(	B-X
PA	B-X
)	B-X
.	B-X

OBJECTIVE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
attempted	O
to	O
identify	O
EGFR	B-Gene_or_gene_product
and	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
expression	O
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
index	O
in	O
carcinoma	O
ex	O
-	O
pleomorphic	O
adenoma	O
(	O
Ca	O
ex	O
-	O
PA	O
)	O
and	O
PA	O
.	O
<EOS>	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
increased	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-alpha	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
early	B-X
events	B-X
in	B-X
malignant	B-X
transformation	B-X
of	B-X
pleomorphic	B-X
adenoma	B-X
(	B-X
PA	B-X
)	B-X
.	B-X

We	O
also	O
compared	O
the	O
presence	O
of	O
EGFR	B-Gene_or_gene_product
and	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
index	O
with	O
clinical	O
data	O
.	O
<EOS>	B-X
Quantitative	B-X
assessment	B-X
is	B-X
more	B-X
sensitive	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
cellular	B-X
protein	B-X
content	B-X
as	B-X
compared	B-X
with	B-X
standard	B-X
optical	B-X
density	B-X
measurements	B-X
.	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
increased	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-alpha	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
early	B-X
events	B-X
in	B-X
malignant	B-X
transformation	B-X
of	B-X
pleomorphic	B-X
adenoma	B-X
(	B-X
PA	B-X
)	B-X
.	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
tissues	O
were	O
stained	O
with	O
monoclonal	O
antibodies	O
to	O
EGFR	B-Gene_or_gene_product
,	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
increased	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-alpha	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
early	B-X
events	B-X
in	B-X
malignant	B-X
transformation	B-X
of	B-X
pleomorphic	B-X
adenoma	B-X
(	B-X
PA	B-X
)	B-X
.	B-X

The	O
results	O
were	O
analysed	O
using	O
quantitative	O
immunohistochemical	O
analysis	O
.	O
<EOS>	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
5-hydroxytryptamine	B-X
is	B-X
the	B-X
transmitter	B-X
of	B-X
a	B-X
set	B-X
of	B-X
amacrine	B-X
cells	B-X
in	B-X
cold-blooded	B-X
vertebrates	B-X
and	B-X
perhaps	B-X
also	B-X
in	B-X
birds	B-X
.	B-X
Developed	B-X
,	B-X
therefore	B-X
,	B-X
is	B-X
a	B-X
quantitative	B-X
,	B-X
image-analysis-based	B-X
immunohistochemical	B-X
technique	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
GSTM1	B-X
protein	B-X
in	B-X
paraffin-embedded	B-X
tissue	B-X
samples	B-X
.	B-X
It	B-X
was	B-X
applied	B-X
to	B-X
the	B-X
determination	B-X
of	B-X
the	B-X
GSTM1	B-X
phenotype	B-X
using	B-X
liver	B-X
biopsies	B-X
taken	B-X
from	B-X
70	B-X
patients	B-X
.	B-X
A	B-X
single	B-X
27	B-X
kD	B-X
band	B-X
characteristic	B-X
for	B-X
GSTM1	B-X
was	B-X
found	B-X
in	B-X
seven	B-X
of	B-X
16	B-X
cases	B-X
analysed	B-X
by	B-X
Western	B-X
blotting	B-X
using	B-X
the	B-X
same	B-X
GSTM1	B-X
antibody	B-X
as	B-X
in	B-X
the	B-X
immunohistochemical	B-X
analysis	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
this	B-X
quantitative	B-X
immunohistochemical	B-X
method	B-X
permits	B-X
accurate	B-X
determination	B-X
of	B-X
the	B-X
GSTM1	B-X
phenotype	B-X
and	B-X
is	B-X
well	B-X
suited	B-X
for	B-X
retrospective	B-X
analysis	B-X
of	B-X
GSTM1	B-X
expression	B-X
in	B-X
specific	B-X
tissues	B-X
in	B-X
situ	B-X
.	B-X

We	O
also	O
analysed	O
the	O
association	O
of	O
patients	O
'	O
prognosis	O
with	O
clinical	O
parameters	O
and	O
the	O
histological	O
classification	O
of	O
the	O
carcinomatous	O
component	O
.	O

RESULTS	O
:	O
As	O
regards	O
the	O
association	O
of	O
patients	O
'	O
prognosis	O
with	O
EGFR	B-Gene_or_gene_product
staining	O
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	I-Gene_or_gene_product
index	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
patients	O
who	O
died	O
or	O
had	O
residual	O
disease	O
compared	O
with	O
patients	O
who	O
were	O
alive	O
without	O
disease	O
.	O
<EOS>	B-X
Patients	B-X
who	B-X
have	B-X
residual	B-X
invasive	B-X
carcinoma	B-X
after	B-X
the	B-X
receipt	B-X
of	B-X
neoadjuvant	B-X
chemotherapy	B-X
for	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
HER2	B-X
)	B-X
-negative	B-X
breast	B-X
cancer	B-X
have	B-X
poor	B-X
prognoses	B-X
.	B-X
The	B-X
benefit	B-X
of	B-X
adjuvant	B-X
chemotherapy	B-X
in	B-X
these	B-X
patients	B-X
remains	B-X
unclear	B-X
.	B-X
Lenalidomide	B-X
plus	B-X
dexamethasone	B-X
is	B-X
a	B-X
standard	B-X
treatment	B-X
for	B-X
patients	B-X
with	B-X
newly	B-X
diagnosed	B-X
multiple	B-X
myeloma	B-X
who	B-X
are	B-X
ineligible	B-X
for	B-X
autologous	B-X
stem-cell	B-X
transplantation	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
addition	B-X
of	B-X
daratumumab	B-X
would	B-X
significantly	B-X
reduce	B-X
the	B-X
risk	B-X
of	B-X
disease	B-X
progression	B-X
or	B-X
death	B-X
in	B-X
this	B-X
population	B-X
.	B-X

In	O
the	O
immunohistochemical	O
analysis	O
of	O
EGFR	B-Gene_or_gene_product
and	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
and	O
Ki67	B-Gene_or_gene_product
index	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
Ca	O
ex	O
-	O
PA	O
,	O
especially	O
with	O
adenocarcinoma	O
,	O
compared	O
with	O
PA	O
and	O
sialadenitis	O
.	O
<EOS>	B-X
Quantitative	B-X
assessment	B-X
is	B-X
more	B-X
sensitive	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
cellular	B-X
protein	B-X
content	B-X
as	B-X
compared	B-X
with	B-X
standard	B-X
optical	B-X
density	B-X
measurements	B-X
.	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
increased	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-alpha	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
early	B-X
events	B-X
in	B-X
malignant	B-X
transformation	B-X
of	B-X
pleomorphic	B-X
adenoma	B-X
(	B-X
PA	B-X
)	B-X
.	B-X

CX3CR1	B-Gene_or_gene_product
-	O
dependent	O
subretinal	O
microglia	O
cell	O
accumulation	O
is	O
associated	O
with	O
cardinal	O
features	O
of	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X

The	O
role	O
of	O
retinal	O
microglial	O
cells	O
(	O
MCs	O
)	O
in	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
is	O
unclear	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
what	B-X
we	B-X
believe	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
pathogenic	B-X
process	B-X
with	B-X
important	B-X
implications	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
therapies	B-X
for	B-X
AMD	B-X
.	B-X

Here	O
we	O
demonstrated	O
that	O
all	O
retinal	O
MCs	O
express	O
CX3C	B-Gene_or_gene_product
chemokine	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
CX3CR1	B-Gene_or_gene_product
)	O
and	O
that	O
homozygosity	O
for	O
the	O
CX3CR1	B-Gene_or_gene_product
M280	O
allele	O
,	O
which	O
is	O
associated	O
with	O
impaired	O
cell	O
migration	O
,	O
increases	O
the	O
risk	O
of	O
AMD	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
what	B-X
we	B-X
believe	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
pathogenic	B-X
process	B-X
with	B-X
important	B-X
implications	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
therapies	B-X
for	B-X
AMD	B-X
.	B-X

In	O
humans	O
with	O
AMD	O
,	O
MCs	O
accumulated	O
in	O
the	O
subretinal	O
space	O
at	O
sites	O
of	O
retinal	O
degeneration	O
and	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
what	B-X
we	B-X
believe	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
pathogenic	B-X
process	B-X
with	B-X
important	B-X
implications	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
therapies	B-X
for	B-X
AMD	B-X
.	B-X

In	O
CX3CR1	B-Gene_or_gene_product
-	O
deficient	O
mice	O
,	O
MCs	O
accumulated	O
subretinally	O
with	O
age	O
and	O
albino	O
background	O
and	O
after	O
laser	O
impact	O
preceding	O
retinal	O
degeneration	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
Raising	B-X
the	B-X
albino	B-X
mice	B-X
in	B-X
the	B-X
dark	B-X
prevented	B-X
both	B-X
events	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X

Raising	O
the	O
albino	O
mice	O
in	O
the	O
dark	O
prevented	O
both	O
events	O
.	O
<EOS>	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
Raising	B-X
the	B-X
albino	B-X
mice	B-X
in	B-X
the	B-X
dark	B-X
prevented	B-X
both	B-X
events	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X

The	O
appearance	O
of	O
lipid	O
-	O
bloated	O
subretinal	O
MCs	O
was	O
drusen	O
-	O
like	O
on	O
funduscopy	O
of	O
senescent	O
mice	O
,	O
and	O
CX3CR1	B-Gene_or_gene_product
-	O
dependent	O
MC	O
accumulation	O
was	O
associated	O
with	O
an	O
exacerbation	O
of	O
experimental	O
CNV	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
Raising	B-X
the	B-X
albino	B-X
mice	B-X
in	B-X
the	B-X
dark	B-X
prevented	B-X
both	B-X
events	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X

These	O
results	O
show	O
that	O
CX3CR1	B-Gene_or_gene_product
-	O
dependent	O
accumulation	O
of	O
subretinal	O
MCs	O
evokes	O
cardinal	O
features	O
of	O
AMD	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
In	B-X
CX3CR1-deficient	B-X
mice	B-X
,	B-X
MCs	B-X
accumulated	B-X
subretinally	B-X
with	B-X
age	B-X
and	B-X
albino	B-X
background	B-X
and	B-X
after	B-X
laser	B-X
impact	B-X
preceding	B-X
retinal	B-X
degeneration	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
lipid-bloated	B-X
subretinal	B-X
MCs	B-X
was	B-X
drusen-like	B-X
on	B-X
funduscopy	B-X
of	B-X
senescent	B-X
mice	B-X
,	B-X
and	B-X
CX3CR1-dependent	B-X
MC	B-X
accumulation	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
exacerbation	B-X
of	B-X
experimental	B-X
CNV	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
what	B-X
we	B-X
believe	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
pathogenic	B-X
process	B-X
with	B-X
important	B-X
implications	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
therapies	B-X
for	B-X
AMD	B-X
.	B-X

These	O
findings	O
reveal	O
what	O
we	O
believe	O
to	O
be	O
a	O
novel	O
pathogenic	O
process	O
with	O
important	O
implications	O
for	O
the	O
development	O
of	O
new	O
therapies	O
for	O
AMD	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
retinal	B-X
microglial	B-X
cells	B-X
(	B-X
MCs	B-X
)	B-X
in	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
retinal	B-X
MCs	B-X
express	B-X
CX3C	B-X
chemokine	B-X
receptor	B-X
1	B-X
(	B-X
CX3CR1	B-X
)	B-X
and	B-X
that	B-X
homozygosity	B-X
for	B-X
the	B-X
CX3CR1	B-X
M280	B-X
allele	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
impaired	B-X
cell	B-X
migration	B-X
,	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
AMD	B-X
.	B-X
In	B-X
humans	B-X
with	B-X
AMD	B-X
,	B-X
MCs	B-X
accumulated	B-X
in	B-X
the	B-X
subretinal	B-X
space	B-X
at	B-X
sites	B-X
of	B-X
retinal	B-X
degeneration	B-X
and	B-X
choroidal	B-X
neovascularization	B-X
(	B-X
CNV	B-X
)	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
CX3CR1-dependent	B-X
accumulation	B-X
of	B-X
subretinal	B-X
MCs	B-X
evokes	B-X
cardinal	B-X
features	B-X
of	B-X
AMD	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
what	B-X
we	B-X
believe	B-X
to	B-X
be	B-X
a	B-X
novel	B-X
pathogenic	B-X
process	B-X
with	B-X
important	B-X
implications	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
therapies	B-X
for	B-X
AMD	B-X
.	B-X

Conditional	O
deletion	O
of	O
Smad1	B-Gene_or_gene_product
and	O
Smad5	B-Gene_or_gene_product
in	O
somatic	O
cells	O
of	O
male	O
and	O
female	O
gonads	O
leads	O
to	O
metastatic	O
tumor	O
development	O
in	O
mice	O
.	O
<EOS>	B-X
Using	B-X
tissue-specific	B-X
ablation	B-X
in	B-X
mice	B-X
,	B-X
we	B-X
deleted	B-X
the	B-X
BR-SMADs	B-X
from	B-X
somatic	B-X
cells	B-X
of	B-X
ovaries	B-X
and	B-X
testes	B-X
.	B-X
Single	B-X
conditional	B-X
knockouts	B-X
for	B-X
Smad1	B-X
or	B-X
Smad5	B-X
or	B-X
mice	B-X
homozygous	B-X
null	B-X
for	B-X
Smad8	B-X
are	B-X
viable	B-X
and	B-X
fertile	B-X
.	B-X
Female	B-X
double	B-X
Smad1	B-X
Smad5	B-X
and	B-X
triple	B-X
Smad1	B-X
Smad5	B-X
Smad8	B-X
conditional	B-X
knockout	B-X
mice	B-X
become	B-X
infertile	B-X
and	B-X
develop	B-X
metastatic	B-X
granulosa	B-X
cell	B-X
tumors	B-X
.	B-X
Male	B-X
double	B-X
Smad1	B-X
Smad5	B-X
conditional	B-X
knockout	B-X
mice	B-X
are	B-X
fertile	B-X
but	B-X
demonstrate	B-X
metastatic	B-X
testicular	B-X
tumor	B-X
development	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
implicate	B-X
the	B-X
BR-SMADs	B-X
as	B-X
part	B-X
of	B-X
a	B-X
critical	B-X
developmental	B-X
pathway	B-X
in	B-X
ovaries	B-X
and	B-X
testis	B-X
that	B-X
,	B-X
when	B-X
disrupted	B-X
,	B-X
leads	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X

The	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	O
TGFbeta	B-Gene_or_gene_product
)	O
family	O
has	O
critical	O
roles	O
in	O
the	O
regulation	O
of	O
fertility	O
.	O
<EOS>	B-X
Initially	B-X
identified	B-X
for	B-X
their	B-X
capability	B-X
to	B-X
induce	B-X
heterotopic	B-X
bone	B-X
formation	B-X
,	B-X
bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
are	B-X
multifunctional	B-X
growth	B-X
factors	B-X
that	B-X
belong	B-X
to	B-X
the	B-X
transforming	B-X
growth	B-X
factor	B-X
Î²	B-X
superfamily	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
physiological	B-X
role	B-X
and	B-X
molecular	B-X
determinants	B-X
of	B-X
these	B-X
ovarian	B-X
regulatory	B-X
factors	B-X
within	B-X
the	B-X
human	B-X
germline-somatic	B-X
regulatory	B-X
loop	B-X
.	B-X
Activin	B-X
A	B-X
,	B-X
a	B-X
transforming	B-X
growth	B-X
factor	B-X
beta	B-X
(	B-X
TGFbeta	B-X
)	B-X
superfamily	B-X
member	B-X
,	B-X
enhances	B-X
HESC	B-X
decidualization	B-X
and	B-X
localizes	B-X
to	B-X
decidual	B-X
cells	B-X
in	B-X
human	B-X
endometrium	B-X
.	B-X
Other	B-X
TGFbeta	B-X
superfamily	B-X
members	B-X
,	B-X
including	B-X
BMP2	B-X
,	B-X
BMP4	B-X
,	B-X
BMP7	B-X
,	B-X
GDF5	B-X
,	B-X
GDF8	B-X
,	B-X
GDF11	B-X
,	B-X
TGFbetas	B-X
and	B-X
Nodal	B-X
,	B-X
may	B-X
also	B-X
play	B-X
a	B-X
role	B-X
during	B-X
decidualization	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
identify	B-X
these	B-X
TGFbeta	B-X
family	B-X
members	B-X
in	B-X
human	B-X
endometrium	B-X
,	B-X
and	B-X
to	B-X
determine	B-X
whether	B-X
they	B-X
are	B-X
involved	B-X
in	B-X
human	B-X
decidualization	B-X
.	B-X

In	O
addition	O
,	O
the	O
pathogenesis	O
of	O
some	O
human	O
cancers	O
is	O
attributed	O
to	O
misregulation	O
of	O
TGFbeta	B-Gene_or_gene_product
function	O
and	O
SMAD2	B-Gene_or_gene_product
or	O
SMAD4	B-Gene_or_gene_product
mutations	O
.	O
<EOS>	B-X
SMAD4	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
the	B-X
central	B-X
mediator	B-X
of	B-X
TGF-Î²	B-X
signaling	B-X
,	B-X
is	B-X
specifically	B-X
inactivated	B-X
in	B-X
over	B-X
half	B-X
of	B-X
pancreatic	B-X
duct	B-X
adenocarcinoma	B-X
,	B-X
and	B-X
varying	B-X
degrees	B-X
in	B-X
many	B-X
other	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
In	B-X
the	B-X
past	B-X
two	B-X
decades	B-X
,	B-X
multiple	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
SMAD4	B-X
loss	B-X
on	B-X
its	B-X
own	B-X
does	B-X
not	B-X
initiate	B-X
tumor	B-X
formation	B-X
,	B-X
but	B-X
can	B-X
promote	B-X
tumor	B-X
progression	B-X
initiated	B-X
by	B-X
other	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
KRAS	B-X
activation	B-X
in	B-X
pancreatic	B-X
duct	B-X
adenocarcinoma	B-X
and	B-X
APC	B-X
inactivation	B-X
in	B-X
colorectal	B-X
cancer	B-X
.	B-X
In	B-X
other	B-X
cases	B-X
,	B-X
such	B-X
as	B-X
skin	B-X
cancer	B-X
,	B-X
loss	B-X
of	B-X
SMAD4	B-X
plays	B-X
an	B-X
important	B-X
initiating	B-X
role	B-X
by	B-X
disrupting	B-X
DNA	B-X
damage	B-X
response	B-X
and	B-X
repair	B-X
mechanisms	B-X
and	B-X
enhance	B-X
genomic	B-X
instability	B-X
,	B-X
suggesting	B-X
its	B-X
distinct	B-X
roles	B-X
in	B-X
different	B-X
types	B-X
of	B-X
tumors	B-X
.	B-X
This	B-X
review	B-X
lists	B-X
SMAD4	B-X
mutations	B-X
in	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
summarizes	B-X
recent	B-X
advances	B-X
on	B-X
SMAD4	B-X
with	B-X
focuses	B-X
on	B-X
the	B-X
function	B-X
,	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
the	B-X
possibility	B-X
of	B-X
SMAD4	B-X
as	B-X
a	B-X
prognostic	B-X
indicator	B-X
.	B-X

There	O
are	O
limited	O
mouse	O
models	O
for	O
the	O
BMP	B-Gene_or_gene_product
signaling	I-Gene_or_gene_product
SMADs	I-Gene_or_gene_product
(	I-Gene_or_gene_product
BR	I-Gene_or_gene_product
-	I-Gene_or_gene_product
SMADs	I-Gene_or_gene_product
)	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
5	B-Gene_or_gene_product
,	O
and	O
8	B-Gene_or_gene_product
because	O
of	O
embryonic	O
lethality	O
and	O
suspected	O
genetic	O
redundancy	O
.	O
<EOS>	B-X
There	B-X
are	B-X
limited	B-X
mouse	B-X
models	B-X
for	B-X
the	B-X
BMP	B-X
signaling	B-X
SMADs	B-X
(	B-X
BR-SMADs	B-X
)	B-X
1	B-X
,	B-X
5	B-X
,	B-X
and	B-X
8	B-X
because	B-X
of	B-X
embryonic	B-X
lethality	B-X
and	B-X
suspected	B-X
genetic	B-X
redundancy	B-X
.	B-X
Using	B-X
tissue-specific	B-X
ablation	B-X
in	B-X
mice	B-X
,	B-X
we	B-X
deleted	B-X
the	B-X
BR-SMADs	B-X
from	B-X
somatic	B-X
cells	B-X
of	B-X
ovaries	B-X
and	B-X
testes	B-X
.	B-X
Single	B-X
conditional	B-X
knockouts	B-X
for	B-X
Smad1	B-X
or	B-X
Smad5	B-X
or	B-X
mice	B-X
homozygous	B-X
null	B-X
for	B-X
Smad8	B-X
are	B-X
viable	B-X
and	B-X
fertile	B-X
.	B-X
Female	B-X
double	B-X
Smad1	B-X
Smad5	B-X
and	B-X
triple	B-X
Smad1	B-X
Smad5	B-X
Smad8	B-X
conditional	B-X
knockout	B-X
mice	B-X
become	B-X
infertile	B-X
and	B-X
develop	B-X
metastatic	B-X
granulosa	B-X
cell	B-X
tumors	B-X
.	B-X
Male	B-X
double	B-X
Smad1	B-X
Smad5	B-X
conditional	B-X
knockout	B-X
mice	B-X
are	B-X
fertile	B-X
but	B-X
demonstrate	B-X
metastatic	B-X
testicular	B-X
tumor	B-X
development	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
implicate	B-X
the	B-X
BR-SMADs	B-X
as	B-X
part	B-X
of	B-X
a	B-X
critical	B-X
developmental	B-X
pathway	B-X
in	B-X
ovaries	B-X
and	B-X
testis	B-X
that	B-X
,	B-X
when	B-X
disrupted	B-X
,	B-X
leads	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X

Using	O
tissue	O
-	O
specific	O
ablation	O
in	O
mice	O
,	O
we	O
deleted	O
the	O
BR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMADs	I-Gene_or_gene_product
from	O
somatic	O
cells	O
of	O
ovaries	O
and	O
testes	O
.	O
<EOS>	B-X
There	B-X
are	B-X
limited	B-X
mouse	B-X
models	B-X
for	B-X
the	B-X
BMP	B-X
signaling	B-X
SMADs	B-X
(	B-X
BR-SMADs	B-X
)	B-X
1	B-X
,	B-X
5	B-X
,	B-X
and	B-X
8	B-X
because	B-X
of	B-X
embryonic	B-X
lethality	B-X
and	B-X
suspected	B-X
genetic	B-X
redundancy	B-X
.	B-X
Using	B-X
tissue-specific	B-X
ablation	B-X
in	B-X
mice	B-X
,	B-X
we	B-X
deleted	B-X
the	B-X
BR-SMADs	B-X
from	B-X
somatic	B-X
cells	B-X
of	B-X
ovaries	B-X
and	B-X
testes	B-X
.	B-X
Single	B-X
conditional	B-X
knockouts	B-X
for	B-X
Smad1	B-X
or	B-X
Smad5	B-X
or	B-X
mice	B-X
homozygous	B-X
null	B-X
for	B-X
Smad8	B-X
are	B-X
viable	B-X
and	B-X
fertile	B-X
.	B-X
Female	B-X
double	B-X
Smad1	B-X
Smad5	B-X
and	B-X
triple	B-X
Smad1	B-X
Smad5	B-X
Smad8	B-X
conditional	B-X
knockout	B-X
mice	B-X
become	B-X
infertile	B-X
and	B-X
develop	B-X
metastatic	B-X
granulosa	B-X
cell	B-X
tumors	B-X
.	B-X
Male	B-X
double	B-X
Smad1	B-X
Smad5	B-X
conditional	B-X
knockout	B-X
mice	B-X
are	B-X
fertile	B-X
but	B-X
demonstrate	B-X
metastatic	B-X
testicular	B-X
tumor	B-X
development	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
implicate	B-X
the	B-X
BR-SMADs	B-X
as	B-X
part	B-X
of	B-X
a	B-X
critical	B-X
developmental	B-X
pathway	B-X
in	B-X
ovaries	B-X
and	B-X
testis	B-X
that	B-X
,	B-X
when	B-X
disrupted	B-X
,	B-X
leads	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X

Single	O
conditional	O
knockouts	O
for	O
Smad1	B-Gene_or_gene_product
or	O
Smad5	B-Gene_or_gene_product
or	O
mice	O
homozygous	O
null	O
for	O
Smad8	B-Gene_or_gene_product
are	O
viable	O
and	O
fertile	O
.	O
<EOS>	B-X
Mice	B-X
were	B-X
generated	B-X
to	B-X
contain	B-X
single	B-X
or	B-X
double	B-X
conditional	B-X
deletion	B-X
of	B-X
SMAD1/5	B-X
and	B-X
ACVR2A/ACVR2B	B-X
receptors	B-X
using	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
-cre	B-X
.	B-X
Female	B-X
mice	B-X
with	B-X
SMAD1/5	B-X
deletion	B-X
display	B-X
endometrial	B-X
defects	B-X
that	B-X
result	B-X
in	B-X
the	B-X
development	B-X
of	B-X
cystic	B-X
endometrial	B-X
glands	B-X
,	B-X
a	B-X
hyperproliferative	B-X
endometrial	B-X
epithelium	B-X
during	B-X
the	B-X
window	B-X
of	B-X
implantation	B-X
,	B-X
and	B-X
impaired	B-X
apicobasal	B-X
transformation	B-X
that	B-X
prevents	B-X
embryo	B-X
implantation	B-X
and	B-X
leads	B-X
to	B-X
infertility	B-X
.	B-X
Analysis	B-X
of	B-X
Acvr2a-PRcre	B-X
and	B-X
Acvr2b-PRcre	B-X
pregnant	B-X
mice	B-X
determined	B-X
that	B-X
BMP	B-X
signaling	B-X
occurs	B-X
via	B-X
ACVR2A	B-X
and	B-X
that	B-X
ACVR2B	B-X
is	B-X
dispensable	B-X
during	B-X
embryo	B-X
implantation	B-X
.	B-X
LUBAC	B-X
conjugates	B-X
linear	B-X
ubiquitin	B-X
chains	B-X
onto	B-X
Activin	B-X
receptor-like	B-X
kinase	B-X
1	B-X
(	B-X
ALK1	B-X
)	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
angiogenesis	B-X
defects	B-X
,	B-X
inhibiting	B-X
ALK1	B-X
enzyme	B-X
activity	B-X
and	B-X
Smad1/5	B-X
activation	B-X
.	B-X
Conversely	B-X
,	B-X
OTULIN	B-X
deubiquitinates	B-X
ALK1	B-X
to	B-X
promote	B-X
Smad1/5	B-X
activation	B-X
.	B-X
Consistently	B-X
,	B-X
embryonic	B-X
survival	B-X
of	B-X
Otulin-deficient	B-X
mice	B-X
was	B-X
prolonged	B-X
by	B-X
BMP9	B-X
pretreatment	B-X
or	B-X
EC-specific	B-X
ALK1	B-X

Female	O
double	O
Smad1	B-Gene_or_gene_product
Smad5	B-Gene_or_gene_product
and	O
triple	O
Smad1	B-Gene_or_gene_product
Smad5	B-Gene_or_gene_product
Smad8	B-Gene_or_gene_product
conditional	O
knockout	O
mice	O
become	O
infertile	O
and	O
develop	O
metastatic	O
granulosa	O
cell	O
tumors	O
.	O
<EOS>	B-X
Using	B-X
tissue-specific	B-X
ablation	B-X
in	B-X
mice	B-X
,	B-X
we	B-X
deleted	B-X
the	B-X
BR-SMADs	B-X
from	B-X
somatic	B-X
cells	B-X
of	B-X
ovaries	B-X
and	B-X
testes	B-X
.	B-X
Single	B-X
conditional	B-X
knockouts	B-X
for	B-X
Smad1	B-X
or	B-X
Smad5	B-X
or	B-X
mice	B-X
homozygous	B-X
null	B-X
for	B-X
Smad8	B-X
are	B-X
viable	B-X
and	B-X
fertile	B-X
.	B-X
Female	B-X
double	B-X
Smad1	B-X
Smad5	B-X
and	B-X
triple	B-X
Smad1	B-X
Smad5	B-X
Smad8	B-X
conditional	B-X
knockout	B-X
mice	B-X
become	B-X
infertile	B-X
and	B-X
develop	B-X
metastatic	B-X
granulosa	B-X
cell	B-X
tumors	B-X
.	B-X
Male	B-X
double	B-X
Smad1	B-X
Smad5	B-X
conditional	B-X
knockout	B-X
mice	B-X
are	B-X
fertile	B-X
but	B-X
demonstrate	B-X
metastatic	B-X
testicular	B-X
tumor	B-X
development	B-X
.	B-X
Microarray	B-X
analysis	B-X
indicated	B-X
significant	B-X
alterations	B-X
in	B-X
expression	B-X
of	B-X
genes	B-X
related	B-X
to	B-X
the	B-X
TGFbeta	B-X
pathway	B-X
,	B-X
as	B-X
well	B-X
as	B-X
genes	B-X
involved	B-X
in	B-X
infertility	B-X
and	B-X
extracellular	B-X
matrix	B-X
production	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
implicate	B-X
the	B-X
BR-SMADs	B-X
as	B-X
part	B-X
of	B-X
a	B-X
critical	B-X
developmental	B-X
pathway	B-X
in	B-X
ovaries	B-X
and	B-X
testis	B-X
that	B-X
,	B-X
when	B-X
disrupted	B-X
,	B-X
leads	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X

Male	O
double	O
Smad1	B-Gene_or_gene_product
Smad5	B-Gene_or_gene_product
conditional	O
knockout	O
mice	O
are	O
fertile	O
but	O
demonstrate	O
metastatic	O
testicular	O
tumor	O
development	O
.	O
<EOS>	B-X
Using	B-X
tissue-specific	B-X
ablation	B-X
in	B-X
mice	B-X
,	B-X
we	B-X
deleted	B-X
the	B-X
BR-SMADs	B-X
from	B-X
somatic	B-X
cells	B-X
of	B-X
ovaries	B-X
and	B-X
testes	B-X
.	B-X
Single	B-X
conditional	B-X
knockouts	B-X
for	B-X
Smad1	B-X
or	B-X
Smad5	B-X
or	B-X
mice	B-X
homozygous	B-X
null	B-X
for	B-X
Smad8	B-X
are	B-X
viable	B-X
and	B-X
fertile	B-X
.	B-X
Female	B-X
double	B-X
Smad1	B-X
Smad5	B-X
and	B-X
triple	B-X
Smad1	B-X
Smad5	B-X
Smad8	B-X
conditional	B-X
knockout	B-X
mice	B-X
become	B-X
infertile	B-X
and	B-X
develop	B-X
metastatic	B-X
granulosa	B-X
cell	B-X
tumors	B-X
.	B-X
Male	B-X
double	B-X
Smad1	B-X
Smad5	B-X
conditional	B-X
knockout	B-X
mice	B-X
are	B-X
fertile	B-X
but	B-X
demonstrate	B-X
metastatic	B-X
testicular	B-X
tumor	B-X
development	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
implicate	B-X
the	B-X
BR-SMADs	B-X
as	B-X
part	B-X
of	B-X
a	B-X
critical	B-X
developmental	B-X
pathway	B-X
in	B-X
ovaries	B-X
and	B-X
testis	B-X
that	B-X
,	B-X
when	B-X
disrupted	B-X
,	B-X
leads	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X

Microarray	O
analysis	O
indicated	O
significant	O
alterations	O
in	O
expression	O
of	O
genes	O
related	O
to	O
the	O
TGFbeta	B-Gene_or_gene_product
pathway	O
,	O
as	O
well	O
as	O
genes	O
involved	O
in	O
infertility	O
and	O
extracellular	O
matrix	O
production	O
.	O

These	O
data	O
strongly	O
implicate	O
the	O
BR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMADs	I-Gene_or_gene_product
as	O
part	O
of	O
a	O
critical	O
developmental	O
pathway	O
in	O
ovaries	O
and	O
testis	O
that	O
,	O
when	O
disrupted	O
,	O
leads	O
to	O
malignant	O
transformation	O
.	O
<EOS>	B-X
The	B-X
transforming	B-X
growth	B-X
factor	B-X
beta	B-X
(	B-X
TGFbeta	B-X
)	B-X
family	B-X
has	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
fertility	B-X
.	B-X
There	B-X
are	B-X
limited	B-X
mouse	B-X
models	B-X
for	B-X
the	B-X
BMP	B-X
signaling	B-X
SMADs	B-X
(	B-X
BR-SMADs	B-X
)	B-X
1	B-X
,	B-X
5	B-X
,	B-X
and	B-X
8	B-X
because	B-X
of	B-X
embryonic	B-X
lethality	B-X
and	B-X
suspected	B-X
genetic	B-X
redundancy	B-X
.	B-X
Using	B-X
tissue-specific	B-X
ablation	B-X
in	B-X
mice	B-X
,	B-X
we	B-X
deleted	B-X
the	B-X
BR-SMADs	B-X
from	B-X
somatic	B-X
cells	B-X
of	B-X
ovaries	B-X
and	B-X
testes	B-X
.	B-X
Microarray	B-X
analysis	B-X
indicated	B-X
significant	B-X
alterations	B-X
in	B-X
expression	B-X
of	B-X
genes	B-X
related	B-X
to	B-X
the	B-X
TGFbeta	B-X
pathway	B-X
,	B-X
as	B-X
well	B-X
as	B-X
genes	B-X
involved	B-X
in	B-X
infertility	B-X
and	B-X
extracellular	B-X
matrix	B-X
production	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
implicate	B-X
the	B-X
BR-SMADs	B-X
as	B-X
part	B-X
of	B-X
a	B-X
critical	B-X
developmental	B-X
pathway	B-X
in	B-X
ovaries	B-X
and	B-X
testis	B-X
that	B-X
,	B-X
when	B-X
disrupted	B-X
,	B-X
leads	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X

[	O
Clinical	O
significance	O
of	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
)	O
as	O
a	O
prognostic	O
factor	O
of	O
cancer	O
disease	O
]	O
<EOS>	B-X
Breast	B-X
cancer	B-X
is	B-X
the	B-X
most	B-X
common	B-X
cancer	B-X
in	B-X
Chinese	B-X
women	B-X
.	B-X
Inflammation	B-X
contributes	B-X
to	B-X
tumor	B-X
progression	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
excessive	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-Î±	B-X
(	B-X
TNF-Î±	B-X
)	B-X
.	B-X
However	B-X
,	B-X
how	B-X
their	B-X
levels	B-X
relate	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
estrogen	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
,	B-X
progesterone	B-X
receptors	B-X
(	B-X
PR	B-X
)	B-X
and	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
HER2	B-X
)	B-X
by	B-X
the	B-X
tumor	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
proinflammatory	B-X
cytokine	B-X
that	B-X
produces	B-X
multifunctional	B-X
effects	B-X
.	B-X
Interleukin-6	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
including	B-X
inhibition	B-X
of	B-X
cancer	B-X
cells	B-X
apoptosis	B-X
and	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
.	B-X
Anti-IL-6	B-X
therapy	B-X
is	B-X
a	B-X
new	B-X
strategy	B-X
in	B-X
the	B-X
inflammatory	B-X
autoimmune	B-X
diseases	B-X
and	B-X
cancer	B-X
.	B-X
Clinical	B-X
studies	B-X
have	B-X
shown	B-X
elevated	B-X
serum	B-X
IL-6	B-X
concentrations	B-X
in	B-X
patients	B-X
with	B-X
endometrial	B-X
cancer	B-X
,	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinoma	B-X
,	B-X
colorectal	B-X
cancer	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
,	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
.	B-X
Serum	B-X
IL-6	B-X
levels	B-X
correlate	B-X
with	B-X
tumor	B-X
stage	B-X
,	B-X
and	B-X
survival	B-X
of	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
have	B-X
focused	B-X
on	B-X
a	B-X
role	B-X
of	B-X
IL-6	B-X
as	B-X
a	B-X
prognostic	B-X
factor	B-X
in	B-X
several	B-X
malignancies	B-X
such	B-X
as	B-X
colorectal	B-X
cancer	B-X
,	B-X
breast	B-X
cancer	B-X
,	B-X
gastric	B-X
cancer	B-X
and	B-X
pancreatic	B-X
cancer	B-X
.	B-X

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
)	O
is	O
proinflammatory	O
cytokine	O
that	O
produces	O
multifunctional	O
effects	O
.	O
<EOS>	B-X
Proinflammatory	B-X
cytokines	B-X
have	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
preneoplastic	B-X
growth	B-X
during	B-X
CAC	B-X
tumorigenesis	B-X
.	B-X
Interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
a	B-X
multifunctional	B-X
NF-kappaB-regulated	B-X
cytokine	B-X
that	B-X
acts	B-X
on	B-X
epithelial	B-X
and	B-X
immune	B-X
cells	B-X
.	B-X
Using	B-X
genetic	B-X
tools	B-X
,	B-X
we	B-X
now	B-X
demonstrate	B-X
that	B-X
IL-6	B-X
is	B-X
a	B-X
critical	B-X
tumor	B-X
promoter	B-X
during	B-X
early	B-X
CAC	B-X
tumorigenesis	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
enhancing	B-X
proliferation	B-X
of	B-X
tumor-initiating	B-X
cells	B-X
,	B-X
IL-6	B-X
produced	B-X
by	B-X
lamina	B-X
propria	B-X
myeloid	B-X
cells	B-X
protects	B-X
normal	B-X
and	B-X
premalignant	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
(	B-X
IECs	B-X
)	B-X
from	B-X
apoptosis	B-X
.	B-X
The	B-X
proliferative	B-X
and	B-X
survival	B-X
effects	B-X
of	B-X
IL-6	B-X
are	B-X
largely	B-X
mediated	B-X
by	B-X
the	B-X
transcription	B-X
factor	B-X
Stat3	B-X
,	B-X
whose	B-X
IEC-specific	B-X
ablation	B-X
has	B-X
profound	B-X
impact	B-X
on	B-X
CAC	B-X
tumorigenesis	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
NF-kappaB-IL-6-Stat3	B-X
cascade	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
the	B-X
proliferation	B-X
and	B-X
survival	B-X
of	B-X
tumor-initiating	B-X
IECs	B-X
.	B-X

It	O
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
reactions	O
,	O
hematopoiesis	O
and	O
inflammatory	O
state	O
.	O
<EOS>	B-X
Immunological	B-X
reactions	B-X
are	B-X
propelled	B-X
by	B-X
ever-changing	B-X
signals	B-X
that	B-X
alter	B-X
the	B-X
translational	B-X
ability	B-X
of	B-X
the	B-X
RNA	B-X
in	B-X
the	B-X
cells	B-X
involved	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
RNA-binding	B-X
protein	B-X
(	B-X
RBP	B-X
)	B-X
assemblies	B-X
engaged	B-X
in	B-X
the	B-X
coordinative	B-X
regulation	B-X
of	B-X
state-specific	B-X
RNAs	B-X
indicates	B-X
alternative	B-X
and	B-X
exclusive	B-X
means	B-X
for	B-X
determining	B-X
the	B-X
activation	B-X
,	B-X
plasticity	B-X
and	B-X
tolerance	B-X
of	B-X
cells	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
current	B-X
knowledge	B-X
about	B-X
RBP-regulated	B-X
post-transcriptional	B-X
events	B-X
involved	B-X
in	B-X
the	B-X
reactivity	B-X
of	B-X
cells	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
their	B-X
alteration	B-X
during	B-X
chronic	B-X
inflammatory	B-X
pathology	B-X
and	B-X
autoimmunity	B-X
.	B-X
Anemia	B-X
of	B-X
chronic	B-X
disorders	B-X
(	B-X
ACD	B-X
)	B-X
is	B-X
a	B-X
mild	B-X
to	B-X
moderate	B-X
anemia	B-X
characterized	B-X
by	B-X
decreased	B-X
serum	B-X
iron	B-X
,	B-X
decreased	B-X
total	B-X
iron-binding	B-X
capacity	B-X
and	B-X
increased	B-X
iron	B-X
stores	B-X
that	B-X
occurs	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
diseases	B-X
including	B-X
cancer	B-X
,	B-X
chronic	B-X
infections	B-X
and	B-X
inflammatory	B-X
disorders	B-X
.	B-X
First	B-X
,	B-X
systemic	B-X
autoimmune	B-X
diseases	B-X
are	B-X
frequently	B-X
characterized	B-X
by	B-X
ACD	B-X
.	B-X
Second	B-X
,	B-X
advances	B-X
in	B-X
our	B-X
knowledge	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
systemic	B-X
autoimmune	B-X
diseases	B-X
as	B-X
well	B-X
as	B-X
pathogenesis	B-X
and	B-X
treatment	B-X
of	B-X
ACD	B-X
have	B-X
so	B-X
far	B-X
been	B-X
dealt	B-X
with	B-X
separately	B-X
.	B-X
Consequently	B-X
,	B-X
the	B-X
approach	B-X
to	B-X
the	B-X
evaluation	B-X
of	B-X
ACD	B-X
in	B-X
systemic	B-X
autoimmune	B-X
disorders	B-X
has	B-X
usually	B-X
been	B-X
either	B-X
immunology-	B-X
or	B-X
hematology-oriented	B-X
.	B-X

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
tumor	O
progression	O
including	O
inhibition	O
of	O
cancer	O
cells	O
apoptosis	O
and	O
stimulation	O
of	O
angiogenesis	O
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
a	B-X
multifunctional	B-X
cytokine	B-X
which	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biologic	B-X
activities	B-X
in	B-X
different	B-X
types	B-X
of	B-X
cell	B-X
including	B-X
tumor	B-X
cells	B-X
.	B-X
IL-6	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
host	B-X
immune	B-X
defense	B-X
mechanism	B-X
as	B-X
well	B-X
as	B-X
the	B-X
modulation	B-X
of	B-X
growth	B-X
and	B-X
differentiation	B-X
in	B-X
various	B-X
malignancies	B-X
.	B-X
There	B-X
exists	B-X
abundant	B-X
evidence	B-X
demonstrating	B-X
that	B-X
deregulated	B-X
overexpression	B-X
of	B-X
IL-6	B-X
was	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
through	B-X
inhibition	B-X
of	B-X
cancer	B-X
cell	B-X
apoptosis	B-X
,	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
,	B-X
and	B-X
drug	B-X
resistance	B-X
.	B-X
Clinical	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
increased	B-X
serum	B-X
IL-6	B-X
concentrations	B-X
in	B-X
patients	B-X
are	B-X
associated	B-X
with	B-X
advanced	B-X
tumor	B-X
stages	B-X
of	B-X
various	B-X
cancers	B-X
(	B-X
e.g.	B-X
,	B-X
multiple	B-X
myeloma	B-X
,	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinoma	B-X
,	B-X
colorectal	B-X
cancer	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
,	B-X
prostate	B-X
cancer	B-X
,	B-X
breast	B-X
cancer	B-X
and	B-X
ovarian	B-X
cancer	B-X
)	B-X
and	B-X
short	B-X
survival	B-X
in	B-X
patients	B-X
.	B-X
Therefore	B-X
,	B-X
blocking	B-X
IL-6	B-X
signaling	B-X
is	B-X
a	B-X
potential	B-X
therapeutic	B-X
strategy	B-X
for	B-X
cancer	B-X
(	B-X
i.e.	B-X
,	B-X
anti-IL-6	B-X
therapy	B-X
)	B-X
characterized	B-X
by	B-X
pathological	B-X
IL-6	B-X
overproduction	B-X
.	B-X
Preliminary	B-X
clinical	B-X
evidence	B-X
has	B-X
shown	B-X
that	B-X
antibody	B-X
targeted	B-X
IL-6	B-X
therapy	B-X
was	B-X
well	B-X
tolerated	B-X
in	B-X
cancer	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
detail	B-X
the	B-X
progress	B-X
of	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
IL-6	B-X
signaling	B-X
pathway	B-X
in	B-X
cancer	B-X
as	B-X
well	B-X
as	B-X
an	B-X
antibody	B-X
targeted	B-X
IL-6	B-X
therapy	B-X
for	B-X
human	B-X
cancer	B-X
.	B-X

Anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IL	I-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
therapy	O
is	O
a	O
new	O
strategy	O
in	O
the	O
inflammatory	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
a	B-X
pleiotropic	B-X
cytokine	B-X
with	B-X
significant	B-X
functions	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
As	B-X
a	B-X
potent	B-X
pro-inflammatory	B-X
cytokine	B-X
,	B-X
IL-6	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
host	B-X
defense	B-X
against	B-X
pathogens	B-X
and	B-X
acute	B-X
stress	B-X
.	B-X
However	B-X
,	B-X
increased	B-X
or	B-X
deregulated	B-X
expression	B-X
of	B-X
IL-6	B-X
significantly	B-X
contributes	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
human	B-X
diseases	B-X
.	B-X
Numerous	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
have	B-X
revealed	B-X
the	B-X
pathological	B-X
roles	B-X
of	B-X
the	B-X
IL-6	B-X
pathway	B-X
in	B-X
inflammation	B-X
,	B-X
autoimmunity	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
rich	B-X
body	B-X
of	B-X
studies	B-X
on	B-X
biological	B-X
activities	B-X
of	B-X
IL-6	B-X
and	B-X
its	B-X
pathological	B-X
roles	B-X
,	B-X
therapeutic	B-X
strategies	B-X
targeting	B-X
the	B-X
IL-6	B-X
pathway	B-X
are	B-X
in	B-X
development	B-X
for	B-X
cancers	B-X
,	B-X
inflammatory	B-X
and	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Several	B-X
anti-IL-6/IL-6	B-X
receptor	B-X
monoclonal	B-X
antibodies	B-X
developed	B-X
for	B-X
targeted	B-X
therapy	B-X
have	B-X
demonstrated	B-X
promising	B-X
results	B-X
in	B-X
both	B-X
preclinical	B-X
studies	B-X
and	B-X
clinical	B-X
trials	B-X
.	B-X
Tocilizumab	B-X
,	B-X
an	B-X
anti-IL-6	B-X
receptor	B-X
antibody	B-X
,	B-X
is	B-X
effective	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
various	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
conditions	B-X
notably	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
It	B-X
is	B-X
the	B-X
only	B-X
IL-6	B-X
pathway	B-X
targeting	B-X
agent	B-X
approved	B-X
by	B-X
the	B-X
regulatory	B-X
agencies	B-X
for	B-X
clinical	B-X
use	B-X
.	B-X
Siltuximab	B-X
,	B-X
an	B-X
anti-IL-6	B-X
antibody	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
have	B-X
potential	B-X
benefits	B-X
treating	B-X
various	B-X
human	B-X
cancers	B-X
either	B-X
as	B-X
a	B-X
single	B-X
agent	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
other	B-X
chemotherapy	B-X
drugs	B-X
.	B-X
Several	B-X
other	B-X
anti-IL-6-based	B-X
therapies	B-X
are	B-X
also	B-X
under	B-X
clinical	B-X
development	B-X
for	B-X
various	B-X
diseases	B-X
.	B-X
IL-6	B-X
antagonism	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
potential	B-X
therapy	B-X
for	B-X
these	B-X
disorders	B-X
refractory	B-X
to	B-X
conventional	B-X
drugs	B-X
.	B-X
New	B-X
strategies	B-X
,	B-X
such	B-X
as	B-X
combination	B-X
of	B-X
IL-6	B-X
blockade	B-X
with	B-X
inhibition	B-X
of	B-X
other	B-X
signaling	B-X
pathways	B-X
,	B-X
may	B-X
further	B-X
improve	B-X
IL-6-targeted	B-X
immunotherapy	B-X
of	B-X
human	B-X
diseases	B-X
.	B-X

Clinical	O
studies	O
have	O
shown	O
elevated	O
serum	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
concentrations	O
in	O
patients	O
with	O
endometrial	O
cancer	O
,	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
,	O
colorectal	O
cancer	O
,	O
renal	O
cell	O
carcinoma	O
,	O
breast	O
and	O
ovarian	O
cancer	O
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
proinflammatory	B-X
cytokine	B-X
that	B-X
produces	B-X
multifunctional	B-X
effects	B-X
.	B-X
Interleukin-6	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
including	B-X
inhibition	B-X
of	B-X
cancer	B-X
cells	B-X
apoptosis	B-X
and	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
.	B-X
Anti-IL-6	B-X
therapy	B-X
is	B-X
a	B-X
new	B-X
strategy	B-X
in	B-X
the	B-X
inflammatory	B-X
autoimmune	B-X
diseases	B-X
and	B-X
cancer	B-X
.	B-X
Clinical	B-X
studies	B-X
have	B-X
shown	B-X
elevated	B-X
serum	B-X
IL-6	B-X
concentrations	B-X
in	B-X
patients	B-X
with	B-X
endometrial	B-X
cancer	B-X
,	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinoma	B-X
,	B-X
colorectal	B-X
cancer	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
,	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
.	B-X
Serum	B-X
IL-6	B-X
levels	B-X
correlate	B-X
with	B-X
tumor	B-X
stage	B-X
,	B-X
and	B-X
survival	B-X
of	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
have	B-X
focused	B-X
on	B-X
a	B-X
role	B-X
of	B-X
IL-6	B-X
as	B-X
a	B-X
prognostic	B-X
factor	B-X
in	B-X
several	B-X
malignancies	B-X
such	B-X
as	B-X
colorectal	B-X
cancer	B-X
,	B-X
breast	B-X
cancer	B-X
,	B-X
gastric	B-X
cancer	B-X
and	B-X
pancreatic	B-X
cancer	B-X
.	B-X

Serum	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
levels	O
correlate	O
with	O
tumor	O
stage	O
,	O
and	O
survival	O
of	O
patients	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
correlate	B-X
serum	B-X
levels	B-X
of	B-X
IL-2	B-X
,	B-X
IL-5	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
TNF-Î±	B-X
with	B-X
clinical	B-X
,	B-X
laboratory	B-X
,	B-X
and	B-X
pathological	B-X
prognostic	B-X
factors	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
ovarian	B-X
malignancy	B-X
.	B-X
Patients	B-X
treated	B-X
at	B-X
the	B-X
Pelvic	B-X
Mass	B-X
Ambulatory	B-X
of	B-X
the	B-X
Discipline	B-X
of	B-X
Gynecology	B-X
and	B-X
Obstetrics/Oncology	B-X
Research	B-X
Institute	B-X
(	B-X
IPON	B-X
)	B-X
of	B-X
the	B-X
UFTM	B-X
with	B-X
confirmed	B-X
diagnosis	B-X
of	B-X
malignant	B-X
ovarian	B-X
neoplasia	B-X
(	B-X
n	B-X
=	B-X
26	B-X
)	B-X
were	B-X
evaluated	B-X
.	B-X
Serum	B-X
collection	B-X
was	B-X
performed	B-X
preoperatively	B-X
for	B-X
the	B-X
determination	B-X
of	B-X
tumor	B-X
markers	B-X
.	B-X
The	B-X
cytokines	B-X
IL-2	B-X
,	B-X
IL-5	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
TNF-Î±	B-X
were	B-X
assayed	B-X
by	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
.	B-X
When	B-X
evaluating	B-X
IL6	B-X
,	B-X
it	B-X
was	B-X
observed	B-X
that	B-X
higher	B-X
serum	B-X
levels	B-X
were	B-X
associated	B-X
with	B-X
overall	B-X
survival	B-X
less	B-X
than	B-X
60	B-X
months	B-X
(	B-X
p	B-X
=	B-X
0.0382	B-X
)	B-X
.	B-X
In	B-X
the	B-X
evaluation	B-X
of	B-X
IL8	B-X
,	B-X
higher	B-X
serum	B-X
levels	B-X
were	B-X
associated	B-X
with	B-X
neutrophil-to-lymphocyte	B-X
ratio	B-X
(	B-X
NLR	B-X
)	B-X
â¥	B-X
4	B-X
and	B-X
platelet-to-lymphocyte	B-X
ratio	B-X
(	B-X
PLR	B-X
)	B-X
â¥	B-X
200	B-X
(	B-X
p	B-X
=	B-X
0.0198	B-X
and	B-X
p	B-X
=	B-X
0.0072	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
altered	B-X
values	B-X
of	B-X
serum	B-X
CA125	B-X
(	B-X
p	B-X
=	B-X
0.0457	B-X
)	B-X
,	B-X
and	B-X
stage	B-X
IIIC	B-X
(	B-X
p	B-X
=	B-X
0.0486	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
IL-6	B-X
and	B-X
IL-8	B-X
are	B-X
associated	B-X
with	B-X
factors	B-X
of	B-X
worse	B-X
prognosis	B-X
in	B-X
ovarian	B-X
cancer	B-X
.	B-X
Additional	B-X
studies	B-X
with	B-X
a	B-X
larger	B-X
sample	B-X
of	B-X
patients	B-X
are	B-X
needed	B-X
to	B-X
confirm	B-X
the	B-X
role	B-X
of	B-X
cytokines	B-X
as	B-X
prognostic	B-X
factors	B-X
,	B-X
in	B-X
the	B-X
definition	B-X
of	B-X
treatment	B-X
,	B-X
and	B-X
in	B-X
the	B-X
development	B-X
of	B-X
future	B-X
target	B-X
therapies	B-X
.	B-X

In	O
this	O
article	O
we	O
have	O
focused	O
on	O
a	O
role	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	I-Gene_or_gene_product
as	O
a	O
prognostic	O
factor	O
in	O
several	O
malignancies	O
such	O
as	O
colorectal	O
cancer	O
,	O
breast	O
cancer	O
,	O
gastric	O
cancer	O
and	O
pancreatic	O
cancer	O
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
proinflammatory	B-X
cytokine	B-X
that	B-X
produces	B-X
multifunctional	B-X
effects	B-X
.	B-X
Interleukin-6	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
including	B-X
inhibition	B-X
of	B-X
cancer	B-X
cells	B-X
apoptosis	B-X
and	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
.	B-X
Anti-IL-6	B-X
therapy	B-X
is	B-X
a	B-X
new	B-X
strategy	B-X
in	B-X
the	B-X
inflammatory	B-X
autoimmune	B-X
diseases	B-X
and	B-X
cancer	B-X
.	B-X
Clinical	B-X
studies	B-X
have	B-X
shown	B-X
elevated	B-X
serum	B-X
IL-6	B-X
concentrations	B-X
in	B-X
patients	B-X
with	B-X
endometrial	B-X
cancer	B-X
,	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinoma	B-X
,	B-X
colorectal	B-X
cancer	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
,	B-X
breast	B-X
and	B-X
ovarian	B-X
cancer	B-X
.	B-X
Serum	B-X
IL-6	B-X
levels	B-X
correlate	B-X
with	B-X
tumor	B-X
stage	B-X
,	B-X
and	B-X
survival	B-X
of	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
have	B-X
focused	B-X
on	B-X
a	B-X
role	B-X
of	B-X
IL-6	B-X
as	B-X
a	B-X
prognostic	B-X
factor	B-X
in	B-X
several	B-X
malignancies	B-X
such	B-X
as	B-X
colorectal	B-X
cancer	B-X
,	B-X
breast	B-X
cancer	B-X
,	B-X
gastric	B-X
cancer	B-X
and	B-X
pancreatic	B-X
cancer	B-X
.	B-X

Expression	O
of	O
CDK4	B-Gene_or_gene_product
or	O
CDK2	B-Gene_or_gene_product
in	O
mouse	O
oral	O
cavity	O
is	O
retained	O
in	O
adult	O
pituitary	O
with	O
distinct	O
effects	O
on	O
tumorigenesis	O
.	O
<EOS>	B-X
Growing	B-X
evidence	B-X
has	B-X
proven	B-X
that	B-X
CDK4/6	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
tumor	B-X
immunity	B-X
and	B-X
the	B-X
prognosis	B-X
of	B-X
many	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CDK4/6	B-X
in	B-X
OC	B-X
remain	B-X
unclear	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
influence	B-X
of	B-X
CDK4/6	B-X
in	B-X
OC	B-X
,	B-X
especially	B-X
on	B-X
immunity	B-X
.	B-X
Mammalian	B-X
cells	B-X
encode	B-X
three	B-X
D	B-X
cyclins	B-X
(	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
and	B-X
D3	B-X
)	B-X
that	B-X
coordinately	B-X
function	B-X
as	B-X
allosteric	B-X
regulators	B-X
of	B-X
cyclin-dependent	B-X
kinase	B-X
4	B-X
(	B-X
CDK4	B-X
)	B-X
and	B-X
CDK6	B-X
to	B-X
regulate	B-X
cell	B-X
cycle	B-X
transition	B-X
from	B-X
G1	B-X
to	B-X
S	B-X
phase	B-X
.	B-X
Cyclin	B-X
expression	B-X
,	B-X
accumulation	B-X
,	B-X
and	B-X
degradation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
assembly	B-X
and	B-X
activation	B-X
of	B-X
CDK4/CDK6	B-X
are	B-X
governed	B-X
by	B-X
growth	B-X
factor	B-X
stimulation	B-X
.	B-X

The	O
keratin	B-Gene_or_gene_product
5	I-Gene_or_gene_product
(	O
K5	B-Gene_or_gene_product
)	O
promoter	O
drives	O
transgenic	O
expression	O
to	O
the	O
basal	O
cell	O
layer	O
of	O
stratified	O
epithelia	O
.	O

Surprisingly	O
,	O
analysis	O
of	O
K5CDK4	B-Gene_or_gene_product
and	O
K5CDK2	B-Gene_or_gene_product
transgenic	O
mouse	O
embryos	O
showed	O
CDK4	B-Gene_or_gene_product
and	O
CDK2	B-Gene_or_gene_product
expression	O
not	O
only	O
in	O
the	O
expected	O
tissues	O
,	O
but	O
also	O
in	O
the	O
adenohypophysis	O
.	O

This	O
organ	O
is	O
derived	O
from	O
an	O
upwards	O
growth	O
of	O
the	O
primitive	O
oropharynx	O
,	O
a	O
K5	B-Gene_or_gene_product
-	O
expressing	O
tissue	O
.	O
<EOS>	B-X
The	B-X
keratin	B-X
5	B-X
(	B-X
K5	B-X
)	B-X
promoter	B-X
drives	B-X
transgenic	B-X
expression	B-X
to	B-X
the	B-X
basal	B-X
cell	B-X
layer	B-X
of	B-X
stratified	B-X
epithelia	B-X
.	B-X
Surprisingly	B-X
,	B-X
analysis	B-X
of	B-X
K5CDK4	B-X
and	B-X
K5CDK2	B-X
transgenic	B-X
mouse	B-X
embryos	B-X
showed	B-X
CDK4	B-X
and	B-X
CDK2	B-X
expression	B-X
not	B-X
only	B-X
in	B-X
the	B-X
expected	B-X
tissues	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
adenohypophysis	B-X
.	B-X
This	B-X
organ	B-X
is	B-X
derived	B-X
from	B-X
an	B-X
upwards	B-X
growth	B-X
of	B-X
the	B-X
primitive	B-X
oropharynx	B-X
,	B-X
a	B-X
K5-expressing	B-X
tissue	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
K5CDK4	B-X
mice	B-X
show	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
pituitary	B-X
stem	B-X
cells	B-X
,	B-X
even	B-X
though	B-X
CDK4	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
the	B-X
stem	B-X
cells	B-X
but	B-X
in	B-X
transit-amplifying	B-X
(	B-X
TA	B-X
)	B-X
-like	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
CDK4-expressing	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
CDK2-expressing	B-X
cells	B-X
,	B-X
strongly	B-X
synergize	B-X
with	B-X
lack	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
generate	B-X
pituitary	B-X
carcinomas	B-X
that	B-X
appear	B-X
with	B-X
shortened	B-X
latency	B-X
and	B-X
are	B-X
drastically	B-X
more	B-X
aggressive	B-X
than	B-X
those	B-X
arising	B-X
in	B-X
p27	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deregulation	B-X
of	B-X
CDK	B-X
expression	B-X
in	B-X
the	B-X
primitive	B-X
oral	B-X
epithelium	B-X
plays	B-X
a	B-X
unique	B-X
function	B-X
,	B-X
providing	B-X
a	B-X
selective	B-X
advantage	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
transgene-positive	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
.	B-X

We	O
show	O
that	O
transgenic	O
expression	O
of	O
CDKs	B-Gene_or_gene_product
in	O
the	O
embryonic	O
oral	O
ectoderm	O
is	O
specifically	O
retained	O
in	O
undifferentiated	O
cells	O
from	O
the	O
pars	O
intermedia	O
of	O
the	O
adenohypophysis	O
.	O
<EOS>	B-X
The	B-X
keratin	B-X
5	B-X
(	B-X
K5	B-X
)	B-X
promoter	B-X
drives	B-X
transgenic	B-X
expression	B-X
to	B-X
the	B-X
basal	B-X
cell	B-X
layer	B-X
of	B-X
stratified	B-X
epithelia	B-X
.	B-X
Surprisingly	B-X
,	B-X
analysis	B-X
of	B-X
K5CDK4	B-X
and	B-X
K5CDK2	B-X
transgenic	B-X
mouse	B-X
embryos	B-X
showed	B-X
CDK4	B-X
and	B-X
CDK2	B-X
expression	B-X
not	B-X
only	B-X
in	B-X
the	B-X
expected	B-X
tissues	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
adenohypophysis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
transgenic	B-X
expression	B-X
of	B-X
CDKs	B-X
in	B-X
the	B-X
embryonic	B-X
oral	B-X
ectoderm	B-X
is	B-X
specifically	B-X
retained	B-X
in	B-X
undifferentiated	B-X
cells	B-X
from	B-X
the	B-X
pars	B-X
intermedia	B-X
of	B-X
the	B-X
adenohypophysis	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
K5CDK4	B-X
mice	B-X
show	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
pituitary	B-X
stem	B-X
cells	B-X
,	B-X
even	B-X
though	B-X
CDK4	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
the	B-X
stem	B-X
cells	B-X
but	B-X
in	B-X
transit-amplifying	B-X
(	B-X
TA	B-X
)	B-X
-like	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
CDK4-expressing	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
CDK2-expressing	B-X
cells	B-X
,	B-X
strongly	B-X
synergize	B-X
with	B-X
lack	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
generate	B-X
pituitary	B-X
carcinomas	B-X
that	B-X
appear	B-X
with	B-X
shortened	B-X
latency	B-X
and	B-X
are	B-X
drastically	B-X
more	B-X
aggressive	B-X
than	B-X
those	B-X
arising	B-X
in	B-X
p27	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deregulation	B-X
of	B-X
CDK	B-X
expression	B-X
in	B-X
the	B-X
primitive	B-X
oral	B-X
epithelium	B-X
plays	B-X
a	B-X
unique	B-X
function	B-X
,	B-X
providing	B-X
a	B-X
selective	B-X
advantage	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
transgene-positive	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
retention	B-X
of	B-X
CDK4	B-X
in	B-X
these	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
synergizes	B-X
with	B-X
loss	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
induce	B-X
pituitary	B-X
adenocarcinomas	B-X
.	B-X
This	B-X
model	B-X
suggests	B-X
that	B-X
forced	B-X
expression	B-X
of	B-X
CDK4	B-X
sensitizes	B-X
cells	B-X
and	B-X
synergizes	B-X
with	B-X
a	B-X
second	B-X
change	B-X
resulting	B-X
in	B-X
tumor	B-X
development	B-X
.	B-X

Interestingly	O
,	O
we	O
found	O
that	O
K5CDK4	B-Gene_or_gene_product
mice	O
show	O
a	O
decreased	O
number	O
of	O
pituitary	O
stem	O
cells	O
,	O
even	O
though	O
CDK4	B-Gene_or_gene_product
is	O
not	O
expressed	O
in	O
the	O
stem	O
cells	O
but	O
in	O
transit	O
-	O
amplifying	O
(	O
TA	O
)	O
-	O
like	O
cells	O
.	O

Interestingly	O
,	O
CDK4	B-Gene_or_gene_product
-	O
expressing	O
cells	O
,	O
but	O
not	O
CDK2	B-Gene_or_gene_product
-	O
expressing	O
cells	O
,	O
strongly	O
synergize	O
with	O
lack	O
of	O
p27	B-Gene_or_gene_product
(	O
Kip1	B-Gene_or_gene_product
)	O
to	O
generate	O
pituitary	O
carcinomas	O
that	O
appear	O
with	O
shortened	O
latency	O
and	O
are	O
drastically	O
more	O
aggressive	O
than	O
those	O
arising	O
in	O
p27	B-Gene_or_gene_product
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Thus	O
,	O
we	O
show	O
that	O
deregulation	O
of	O
CDK	B-Gene_or_gene_product
expression	O
in	O
the	O
primitive	O
oral	O
epithelium	O
plays	O
a	O
unique	O
function	O
,	O
providing	O
a	O
selective	O
advantage	O
that	O
gives	O
rise	O
to	O
transgene	O
-	O
positive	O
TA	O
-	O
like	O
pituitary	O
cells	O
.	O

Furthermore	O
,	O
retention	O
of	O
CDK4	B-Gene_or_gene_product
in	O
these	O
TA	O
-	O
like	O
pituitary	O
cells	O
synergizes	O
with	O
loss	O
of	O
p27	B-Gene_or_gene_product
(	O
Kip1	B-Gene_or_gene_product
)	O
to	O
induce	O
pituitary	O
adenocarcinomas	O
.	O
<EOS>	B-X
Surprisingly	B-X
,	B-X
analysis	B-X
of	B-X
K5CDK4	B-X
and	B-X
K5CDK2	B-X
transgenic	B-X
mouse	B-X
embryos	B-X
showed	B-X
CDK4	B-X
and	B-X
CDK2	B-X
expression	B-X
not	B-X
only	B-X
in	B-X
the	B-X
expected	B-X
tissues	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
adenohypophysis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
transgenic	B-X
expression	B-X
of	B-X
CDKs	B-X
in	B-X
the	B-X
embryonic	B-X
oral	B-X
ectoderm	B-X
is	B-X
specifically	B-X
retained	B-X
in	B-X
undifferentiated	B-X
cells	B-X
from	B-X
the	B-X
pars	B-X
intermedia	B-X
of	B-X
the	B-X
adenohypophysis	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
K5CDK4	B-X
mice	B-X
show	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
pituitary	B-X
stem	B-X
cells	B-X
,	B-X
even	B-X
though	B-X
CDK4	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
the	B-X
stem	B-X
cells	B-X
but	B-X
in	B-X
transit-amplifying	B-X
(	B-X
TA	B-X
)	B-X
-like	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
CDK4-expressing	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
CDK2-expressing	B-X
cells	B-X
,	B-X
strongly	B-X
synergize	B-X
with	B-X
lack	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
generate	B-X
pituitary	B-X
carcinomas	B-X
that	B-X
appear	B-X
with	B-X
shortened	B-X
latency	B-X
and	B-X
are	B-X
drastically	B-X
more	B-X
aggressive	B-X
than	B-X
those	B-X
arising	B-X
in	B-X
p27	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deregulation	B-X
of	B-X
CDK	B-X
expression	B-X
in	B-X
the	B-X
primitive	B-X
oral	B-X
epithelium	B-X
plays	B-X
a	B-X
unique	B-X
function	B-X
,	B-X
providing	B-X
a	B-X
selective	B-X
advantage	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
transgene-positive	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
retention	B-X
of	B-X
CDK4	B-X
in	B-X
these	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
synergizes	B-X
with	B-X
loss	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
induce	B-X
pituitary	B-X
adenocarcinomas	B-X
.	B-X
This	B-X
model	B-X
suggests	B-X
that	B-X
forced	B-X
expression	B-X
of	B-X
CDK4	B-X
sensitizes	B-X
cells	B-X
and	B-X
synergizes	B-X
with	B-X
a	B-X
second	B-X
change	B-X
resulting	B-X
in	B-X
tumor	B-X
development	B-X
.	B-X

This	O
model	O
suggests	O
that	O
forced	O
expression	O
of	O
CDK4	B-Gene_or_gene_product
sensitizes	O
cells	O
and	O
synergizes	O
with	O
a	O
second	O
change	O
resulting	O
in	O
tumor	O
development	O
.	O
<EOS>	B-X
The	B-X
keratin	B-X
5	B-X
(	B-X
K5	B-X
)	B-X
promoter	B-X
drives	B-X
transgenic	B-X
expression	B-X
to	B-X
the	B-X
basal	B-X
cell	B-X
layer	B-X
of	B-X
stratified	B-X
epithelia	B-X
.	B-X
Surprisingly	B-X
,	B-X
analysis	B-X
of	B-X
K5CDK4	B-X
and	B-X
K5CDK2	B-X
transgenic	B-X
mouse	B-X
embryos	B-X
showed	B-X
CDK4	B-X
and	B-X
CDK2	B-X
expression	B-X
not	B-X
only	B-X
in	B-X
the	B-X
expected	B-X
tissues	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
adenohypophysis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
transgenic	B-X
expression	B-X
of	B-X
CDKs	B-X
in	B-X
the	B-X
embryonic	B-X
oral	B-X
ectoderm	B-X
is	B-X
specifically	B-X
retained	B-X
in	B-X
undifferentiated	B-X
cells	B-X
from	B-X
the	B-X
pars	B-X
intermedia	B-X
of	B-X
the	B-X
adenohypophysis	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
K5CDK4	B-X
mice	B-X
show	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
pituitary	B-X
stem	B-X
cells	B-X
,	B-X
even	B-X
though	B-X
CDK4	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
the	B-X
stem	B-X
cells	B-X
but	B-X
in	B-X
transit-amplifying	B-X
(	B-X
TA	B-X
)	B-X
-like	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
CDK4-expressing	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
CDK2-expressing	B-X
cells	B-X
,	B-X
strongly	B-X
synergize	B-X
with	B-X
lack	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
generate	B-X
pituitary	B-X
carcinomas	B-X
that	B-X
appear	B-X
with	B-X
shortened	B-X
latency	B-X
and	B-X
are	B-X
drastically	B-X
more	B-X
aggressive	B-X
than	B-X
those	B-X
arising	B-X
in	B-X
p27	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
show	B-X
that	B-X
deregulation	B-X
of	B-X
CDK	B-X
expression	B-X
in	B-X
the	B-X
primitive	B-X
oral	B-X
epithelium	B-X
plays	B-X
a	B-X
unique	B-X
function	B-X
,	B-X
providing	B-X
a	B-X
selective	B-X
advantage	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
transgene-positive	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
retention	B-X
of	B-X
CDK4	B-X
in	B-X
these	B-X
TA-like	B-X
pituitary	B-X
cells	B-X
synergizes	B-X
with	B-X
loss	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
to	B-X
induce	B-X
pituitary	B-X
adenocarcinomas	B-X
.	B-X
This	B-X
model	B-X
suggests	B-X
that	B-X
forced	B-X
expression	B-X
of	B-X
CDK4	B-X
sensitizes	B-X
cells	B-X
and	B-X
synergizes	B-X
with	B-X
a	B-X
second	B-X
change	B-X
resulting	B-X
in	B-X
tumor	B-X
development	B-X
.	B-X

Survivin	B-Gene_or_gene_product
expression	O
in	O
breast	O
carcinoma	O
:	O
correlation	O
with	O
apoptosis	O
and	O
prognosis	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
commonly	B-X
detected	B-X
in	B-X
tissues	B-X
during	B-X
fetal	B-X
development	B-X
and	B-X
in	B-X
cancer	B-X
,	B-X
but	B-X
not	B-X
usually	B-X
in	B-X
normal	B-X
tissues	B-X
.	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
protein	B-X
may	B-X
be	B-X
of	B-X
prognostic	B-X
significance	B-X
in	B-X
gastric	B-X
,	B-X
colorectal	B-X
,	B-X
and	B-X
bladder	B-X
carcinomas	B-X
.	B-X
We	B-X
assessed	B-X
survivin	B-X
expression	B-X
in	B-X
breast	B-X
carcinomas	B-X
correlating	B-X
results	B-X
with	B-X
expression	B-X
of	B-X
other	B-X
antiapoptotic	B-X
(	B-X
bcl-2	B-X
,	B-X
bcl-x	B-X
)	B-X
and	B-X
proapoptotic	B-X
(	B-X
bax	B-X
)	B-X
markers	B-X
,	B-X
with	B-X
prognostic	B-X
parameters	B-X
,	B-X
and	B-X
with	B-X
prognosis	B-X
.	B-X
Immunohistochemically	B-X
,	B-X
we	B-X
evaluated	B-X
survivin	B-X
expression	B-X
in	B-X
19	B-X
cases	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
64	B-X
cases	B-X
of	B-X
lobular	B-X
breast	B-X
carcinoma	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
quantitative	B-X
differences	B-X
of	B-X
survivin	B-X
expression	B-X
between	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
carcinomas	B-X
.	B-X
We	B-X
also	B-X
correlated	B-X
survivin	B-X
expression	B-X
pattern	B-X
in	B-X
carcinomas	B-X
with	B-X
clinicomorphological	B-X
parameters	B-X
such	B-X
as	B-X
age	B-X
of	B-X
patients	B-X
,	B-X
grade	B-X
,	B-X
stage	B-X
and	B-X
size	B-X
of	B-X
primary	B-X
tumor	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
,	B-X
vascular	B-X
invasion	B-X
as	B-X
well	B-X
as	B-X
estrogen	B-X
and	B-X
progesterone	B-X
status	B-X
.	B-X
Survivin	B-X
was	B-X
detected	B-X
in	B-X
10/19	B-X
cases	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
(	B-X
52.6	B-X
%	B-X
)	B-X
and	B-X
in	B-X
55/64	B-X
cases	B-X
of	B-X
lobular	B-X
breast	B-X
carcinoma	B-X
(	B-X
86	B-X
%	B-X
)	B-X
.	B-X
The	B-X
statistical	B-X
analysis	B-X
confirmed	B-X
significant	B-X
correlations	B-X
between	B-X
the	B-X
assessed	B-X
parameters	B-X
in	B-X
normal	B-X
breast	B-X
and	B-X
lobular	B-X
carcinoma	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
estrogen	B-X
correlated	B-X
significantly	B-X
with	B-X
the	B-X
subcellular	B-X
localization	B-X
and	B-X
intensity	B-X
of	B-X
survivin	B-X
in	B-X
carcinoma	B-X
.	B-X
However	B-X
,	B-X
no	B-X
significant	B-X
correlation	B-X
was	B-X
shown	B-X
with	B-X
regard	B-X
to	B-X
other	B-X
clinicomorphological	B-X
parameters	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
survivin	B-X
may	B-X
be	B-X
a	B-X
valuable	B-X
diagnostic	B-X
marker	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
new	B-X
independent	B-X
prognostic	B-X
parameter	B-X
,	B-X
in	B-X
lobular	B-X
breast	B-X
carcinoma	B-X
.	B-X
Finally	B-X
,	B-X
our	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
lobular	B-X
and	B-X
ductal	B-X
breast	B-X
carcinomas	B-X
seem	B-X
to	B-X
be	B-X
different	B-X
clinicomorphological	B-X
entities	B-X
.	B-X

BACKGROUND	O
:	O
Survivin	B-Gene_or_gene_product
is	O
a	O
novel	O
inhibitor	O
of	O
apoptosis	O
commonly	O
detected	O
in	O
tissues	O
during	O
fetal	O
development	O
and	O
in	O
cancer	O
,	O
but	O
not	O
usually	O
in	O
normal	O
tissues	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
expression	O
of	O
this	O
protein	O
may	O
be	O
of	O
prognostic	O
significance	O
in	O
gastric	O
,	O
colorectal	O
,	O
and	O
bladder	O
carcinomas	O
.	O
<EOS>	B-X
O1	B-X
Regulation	B-X
of	B-X
genes	B-X
by	B-X
telomere	B-X
length	B-X
over	B-X
long	B-X
distances	B-X
Jerry	B-X
W.	B-X
Shay	B-X
O2	B-X
The	B-X
microtubule	B-X
destabilizer	B-X
KIF2A	B-X
regulates	B-X
the	B-X
postnatal	B-X
establishment	B-X
of	B-X
neuronal	B-X
circuits	B-X
in	B-X
addition	B-X
to	B-X
prenatal	B-X
cell	B-X
survival	B-X
,	B-X
cell	B-X
migration	B-X
,	B-X
and	B-X
axon	B-X
elongation	B-X
,	B-X
and	B-X
its	B-X
loss	B-X
leading	B-X
to	B-X
malformation	B-X
of	B-X
cortical	B-X
development	B-X
and	B-X
severe	B-X
epilepsy	B-X
Noriko	B-X
Homma	B-X
,	B-X
Ruyun	B-X
Zhou	B-X
,	B-X
Muhammad	B-X
Imran	B-X
Naseer	B-X
,	B-X
Adeel	B-X
G.	B-X
Chaudhary	B-X
,	B-X
Mohammed	B-X
Al-Qahtani	B-X
,	B-X
Nobutaka	B-X
Hirokawa	B-X
O3	B-X
Integration	B-X
of	B-X
metagenomics	B-X
and	B-X
metabolomics	B-X
in	B-X
gut	B-X
microbiome	B-X
research	B-X
Maryam	B-X
Goudarzi	B-X
,	B-X
Albert	B-X
J.	B-X
Fornace	B-X
Jr.	B-X
O4	B-X
A	B-X
unique	B-X
integrated	B-X
system	B-X
to	B-X
discern	B-X
pathogenesis	B-X
of	B-X
central	B-X
nervous	B-X
system	B-X
tumors	B-X
Saleh	B-X
Baeesa	B-X
,	B-X
Deema	B-X
Hussain	B-X
,	B-X
Mohammed	B-X
Bangash	B-X
,	B-X
Fahad	B-X
Alghamdi	B-X
,	B-X
Hans-Juergen	B-X
Schulten	B-X
,	B-X
Angel	B-X
Carracedo	B-X
,	B-X
Ishaq	B-X
Khan	B-X
,	B-X
Hanadi	B-X
Qashqari	B-X
,	B-X
Nawal	B-X
Madkhali	B-X
,	B-X
Mohamad	B-X
Saka	B-X
,	B-X
Kulvinder	B-X
S.	B-X
Saini	B-X
,	B-X
Awatif	B-X
Jamal	B-X
,	B-X
Jaudah	B-X
Al-Maghrabi	B-X
,	B-X
Adel	B-X
Abuzenadah	B-X
,	B-X
Adeel	B-X
Chaudhary	B-X
,	B-X
Mohammed	B-X
Al	B-X
Qahtani	B-X
,	B-X
Ghazi	B-X
Damanhouri	B-X
O5	B-X
RPL27A	B-X
is	B-X
a	B-X
target	B-X
of	B-X
miR-595	B-X
and	B-X
deficiency	B-X
contributes	B-X
to	B-X
ribosomal	B-X
dysgenesis	B-X
Heba	B-X
Alkhatabi	B-X
O6	B-X
Next	B-X
generation	B-X
DNA	B-X
sequencing	B-X
panels	B-X
for	B-X
haemostatic	B-X
and	B-X
platelet	B-X
disorders	B-X
and	B-X
for	B-X
Fanconi	B-X
anaemia	B-X
in	B-X
routine	B-X
diagnostic	B-X
service	B-X
Anne	B-X
Goodeve	B-X
,	B-X
Laura	B-X
Crookes	B-X
,	B-X
Nikolas	B-X
Niksic	B-X
,	B-X
Nicholas	B-X
Beauchamp	B-X
O7	B-X
Targeted	B-X
sequencing	B-X
panels	B-X
and	B-X
their	B-X
utilization	B-X
in	B-X
personalized	B-X
medicine	B-X
Adel	B-X
M.	B-X
Abuzenadah	B-X
O8	B-X
International	B-X
biobanking	B-X
in	B-X
the	B-X
era	B-X
of	B-X
precision	B-X
medicine	B-X
Jim	B-X
Vaught	B-X
O9	B-X
Biobank	B-X
and	B-X
biodata	B-X
for	B-X
clinical	B-X
and	B-X
forensic	B-X
applications	B-X
Bruce	B-X
Budowle	B-X
,	B-X
Mourad	B-X
Assidi	B-X
,	B-X
Abdelbaset	B-X
Buhmeida	B-X
O10	B-X
Tissue	B-X
microarray	B-X
technique	B-X
:	B-X
a	B-X
powerful	B-X
adjunct	B-X
tool	B-X
for	B-X
molecular	B-X
profiling	B-X
of	B-X
solid	B-X
tumors	B-X
Jaudah	B-X
Al-Maghrabi	B-X
O11	B-X
The	B-X
CEGMR	B-X
biobanking	B-X
unit	B-X
:	B-X
achievements	B-X
,	B-X
challenges	B-X
and	B-X
future	B-X
plans	B-X
Abdelbaset	B-X
Buhmeida	B-X
,	B-X
Mourad	B-X
Assidi	B-X
,	B-X
Leena	B-X
Merdad	B-X
O12	B-X
Phylomedicine	B-X
of	B-X
tumors	B-X
Sudhir	B-X
Kumar	B-X
,	B-X
Sayaka	B-X
Miura	B-X
,	B-X
Karen	B-X
Gomez	B-X
O13	B-X
Clinical	B-X
implementation	B-X
of	B-X
pharmacogenomics	B-X
for	B-X
colorectal	B-X
cancer	B-X
treatment	B-X
Angel	B-X
Carracedo	B-X
,	B-X
Mahmood	B-X
Rasool	B-X
O14	B-X
From	B-X
association	B-X
to	B-X
causality	B-X
:	B-X
translation	B-X
of	B-X
GWAS	B-X
findings	B-X
for	B-X
genomic	B-X
medicine	B-X
Ahmed	B-X
Rebai	B-X
O15	B-X
E-GRASP	B-X
:	B-X
an	B-X
interactive	B-X
database	B-X
and	B-X
web	B-X
application	B-X
for	B-X
efficient	B-X
analysis	B-X
of	B-X
disease-associated	B-X
genetic	B-X
information	B-X
Sajjad	B-X
Karim	B-X
,	B-X
Hend	B-X
F	B-X
Nour	B-X
Eldin	B-X
,	B-X
Heba	B-X
Abusamra	B-X
,	B-X
Elham	B-X
M	B-X
Alhathli	B-X
,	B-X
Nada	B-X
Salem	B-X
,	B-X
Mohammed	B-X
H	B-X
Al-Qahtani	B-X
,	B-X
Sudhir	B-X
Kumar	B-X
O16	B-X
The	B-X
supercomputer	B-X
facility	B-X
â	B-X
AZIZ	B-X
â	B-X
at	B-X
KAU	B-X
:	B-X
utility	B-X
and	B-X
future	B-X
prospects	B-X
Hossam	B-X
Faheem	B-X
O17	B-X
New	B-X
research	B-X
into	B-X
the	B-X
causes	B-X
of	B-X
male	B-X
infertility	B-X
Ashok	B-X
Agarwa	B-X
O18	B-X
The	B-X
Klinefelter	B-X
syndrome	B-X
:	B-X
recent	B-X
progress	B-X
in	B-X
pathophysiology	B-X
and	B-X
management	B-X
Eberhard	B-X
Nieschlag	B-X
,	B-X
Joachim	B-X
Wistuba	B-X
,	B-X
Oliver	B-X
S.	B-X
Damm	B-X
,	B-X
Mohd	B-X
A.	B-X
Beg	B-X
,	B-X
Taha	B-X
A.	B-X
Abdel-Meguid	B-X
,	B-X
Hisham	B-X
A.	B-X
Mosli	B-X
,	B-X
Osama	B-X
S.	B-X
Bajouh	B-X
,	B-X
Adel	B-X
M.	B-X
Abuzenadah	B-X
,	B-X
Mohammed	B-X
H.	B-X
Al-Qahtani	B-X
O19	B-X
A	B-X
new	B-X
look	B-X
to	B-X
reproductive	B-X
medicine	B-X
in	B-X
the	B-X
era	B-X
of	B-X
genomics	B-X
Serdar	B-X
Coskun	B-X
P1	B-X
Wnt	B-X
signalling	B-X
receptors	B-X
expression	B-X
in	B-X
Saudi	B-X
breast	B-X
cancer	B-X
patients	B-X
Muhammad	B-X
Abu-Elmagd	B-X
,	B-X
Abdelbaset	B-X
Buhmeida	B-X
,	B-X
Ashraf	B-X
Dallol	B-X
,	B-X
Jaudah	B-X
Al-Maghrabi	B-X
,	B-X
Sahar	B-X
Hakamy	B-X
,	B-X
Wejdan	B-X
Al-Qahtani	B-X
,	B-X
Asia	B-X
Al-Harbi	B-X
,	B-X
Shireen	B-X
Hussain	B-X
,	B-X
Mourad	B-X
Assidi	B-X
,	B-X
Mohammed	B-X
Al-Qahtani	B-X
,	B-X
Adel	B-X
Abuzenadah	B-X
P2	B-X
Analysis	B-X
of	B-X
oxidative	B-X
stress	B-X
interactome	B-X
during	B-X
spermatogenesis	B-X
:	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
to	B-X
reproduction	B-X
Burak	B-X
Ozkosem	B-X
,	B-X
Rick	B-X
DuBois	B-X
P3	B-X
Interleukin-18	B-X
gene	B-X
variants	B-X
are	B-X
strongly	B-X
associated	B-X
with	B-X
idiopathic	B-X
recurrent	B-X
pregnancy	B-X
loss	B-X
.	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
protein	B-X
may	B-X
be	B-X
of	B-X
prognostic	B-X
significance	B-X
in	B-X
gastric	B-X
,	B-X
colorectal	B-X
,	B-X
and	B-X
bladder	B-X
carcinomas	B-X
.	B-X
We	B-X
assessed	B-X
survivin	B-X
expression	B-X
in	B-X
breast	B-X
carcinomas	B-X
correlating	B-X
results	B-X
with	B-X
expression	B-X
of	B-X
other	B-X
antiapoptotic	B-X
(	B-X
bcl-2	B-X
,	B-X
bcl-x	B-X
)	B-X
and	B-X
proapoptotic	B-X
(	B-X
bax	B-X
)	B-X
markers	B-X
,	B-X
with	B-X
prognostic	B-X
parameters	B-X
,	B-X
and	B-X
with	B-X
prognosis	B-X
.	B-X

We	O
assessed	O
survivin	B-Gene_or_gene_product
expression	O
in	O
breast	O
carcinomas	O
correlating	O
results	O
with	O
expression	O
of	O
other	O
antiapoptotic	O
(	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
)	O
and	O
proapoptotic	O
(	O
bax	B-Gene_or_gene_product
)	O
markers	O
,	O
with	O
prognostic	O
parameters	O
,	O
and	O
with	O
prognosis	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
protein	B-X
may	B-X
be	B-X
of	B-X
prognostic	B-X
significance	B-X
in	B-X
gastric	B-X
,	B-X
colorectal	B-X
,	B-X
and	B-X
bladder	B-X
carcinomas	B-X
.	B-X
We	B-X
assessed	B-X
survivin	B-X
expression	B-X
in	B-X
breast	B-X
carcinomas	B-X
correlating	B-X
results	B-X
with	B-X
expression	B-X
of	B-X
other	B-X
antiapoptotic	B-X
(	B-X
bcl-2	B-X
,	B-X
bcl-x	B-X
)	B-X
and	B-X
proapoptotic	B-X
(	B-X
bax	B-X
)	B-X
markers	B-X
,	B-X
with	B-X
prognostic	B-X
parameters	B-X
,	B-X
and	B-X
with	B-X
prognosis	B-X
.	B-X

DESIGN	O
:	O
Paraffin	O
-	O
embedded	O
sections	O
of	O
37	O
breast	O
carcinomas	O
were	O
immunostained	O
for	O
survivin	B-Gene_or_gene_product
,	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
,	O
and	O
bax	B-Gene_or_gene_product
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
protein	B-X
may	B-X
be	B-X
of	B-X
prognostic	B-X
significance	B-X
in	B-X
gastric	B-X
,	B-X
colorectal	B-X
,	B-X
and	B-X
bladder	B-X
carcinomas	B-X
.	B-X
We	B-X
assessed	B-X
survivin	B-X
expression	B-X
in	B-X
breast	B-X
carcinomas	B-X
correlating	B-X
results	B-X
with	B-X
expression	B-X
of	B-X
other	B-X
antiapoptotic	B-X
(	B-X
bcl-2	B-X
,	B-X
bcl-x	B-X
)	B-X
and	B-X
proapoptotic	B-X
(	B-X
bax	B-X
)	B-X
markers	B-X
,	B-X
with	B-X
prognostic	B-X
parameters	B-X
,	B-X
and	B-X
with	B-X
prognosis	B-X
.	B-X

Expression	O
was	O
evaluated	O
in	O
normal	O
breast	O
tissue	O
and	O
carcinoma	O
,	O
nuclei	O
and	O
cytoplasm	O
,	O
as	O
intensity	O
(	O
0	O
to	O
3	O
+	O
)	O
,	O
and	O
percentage	O
of	O
positive	O
cells	O
.	O

RESULTS	O
:	O
Survivin	B-Gene_or_gene_product
expression	O
was	O
noted	O
in	O
30	O
(	O
81	O
%	O
)	O
of	O
breast	O
carcinomas	O
,	O
and	O
in	O
normal	O
breast	O
tissue	O
,	O
in	O
nuclei	O
,	O
and	O
cytoplasm	O
.	O
<EOS>	B-X
Survivin	B-X
is	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
commonly	B-X
detected	B-X
in	B-X
tissues	B-X
during	B-X
fetal	B-X
development	B-X
and	B-X
in	B-X
cancer	B-X
,	B-X
but	B-X
not	B-X
usually	B-X
in	B-X
normal	B-X
tissues	B-X
.	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
protein	B-X
may	B-X
be	B-X
of	B-X
prognostic	B-X
significance	B-X
in	B-X
gastric	B-X
,	B-X
colorectal	B-X
,	B-X
and	B-X
bladder	B-X
carcinomas	B-X
.	B-X
We	B-X
assessed	B-X
survivin	B-X
expression	B-X
in	B-X
breast	B-X
carcinomas	B-X
correlating	B-X
results	B-X
with	B-X
expression	B-X
of	B-X
other	B-X
antiapoptotic	B-X
(	B-X
bcl-2	B-X
,	B-X
bcl-x	B-X
)	B-X
and	B-X
proapoptotic	B-X
(	B-X
bax	B-X
)	B-X
markers	B-X
,	B-X
with	B-X
prognostic	B-X
parameters	B-X
,	B-X
and	B-X
with	B-X
prognosis	B-X
.	B-X

There	O
was	O
a	O
significant	O
correlation	O
(	O
P	O
=	O
0	O
.	O
022	O
)	O
between	O
survivin	B-Gene_or_gene_product
and	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
expression	O
;	O
survivin	B-Gene_or_gene_product
and	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
tended	O
to	O
correlate	O
with	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
072	O
and	O
0	O
.	O
075	O
,	O
respectively	O
)	O
,	O
but	O
not	O
with	O
disease	O
-	O
free	O
survival	O
(	O
P	O
=	O
0	O
.	O
19	O
and	O
0	O
.	O
18	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correlation	O
of	O
survivin	B-Gene_or_gene_product
with	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
or	O
bax	B-Gene_or_gene_product
expression	O
,	O
or	O
with	O
other	O
prognostic	O
parameters	O
(	O
age	O
,	O
tumor	O
size	O
,	O
histologic	O
type	O
,	O
histologic	O
grade	O
,	O
nodal	O
status	O
,	O
and	O
tumor	O
stage	O
)	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
majority	O
(	O
81	O
%	O
)	O
of	O
breast	O
carcinomas	O
show	O
survivin	B-Gene_or_gene_product
expression	O
which	O
correlates	O
with	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
x	I-Gene_or_gene_product
,	O
another	O
antiapoptotic	O
marker	O
,	O
and	O
both	O
markers	O
tend	O
to	O
correlate	O
with	O
prognosis	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
protein	B-X
may	B-X
be	B-X
of	B-X
prognostic	B-X
significance	B-X
in	B-X
gastric	B-X
,	B-X
colorectal	B-X
,	B-X
and	B-X
bladder	B-X
carcinomas	B-X
.	B-X
We	B-X
assessed	B-X
survivin	B-X
expression	B-X
in	B-X
breast	B-X
carcinomas	B-X
correlating	B-X
results	B-X
with	B-X
expression	B-X
of	B-X
other	B-X
antiapoptotic	B-X
(	B-X
bcl-2	B-X
,	B-X
bcl-x	B-X
)	B-X
and	B-X
proapoptotic	B-X
(	B-X
bax	B-X
)	B-X
markers	B-X
,	B-X
with	B-X
prognostic	B-X
parameters	B-X
,	B-X
and	B-X
with	B-X
prognosis	B-X
.	B-X

Functional	O
significance	O
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	I-Gene_or_gene_product
in	O
human	O
ovarian	O
carcinoma	O
:	O
role	O
in	O
vasculogenic	O
mimicry	O
.	O
<EOS>	B-X
The	B-X
microcirculation	B-X
of	B-X
most	B-X
tumors	B-X
includes	B-X
cooperation	B-X
of	B-X
pre-existing	B-X
vessels	B-X
,	B-X
intussusceptive	B-X
microvascular	B-X
growth	B-X
,	B-X
postnatal	B-X
vasculogenesis	B-X
,	B-X
glomeruloid	B-X
angiogenesis	B-X
and	B-X
vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
.	B-X
Our	B-X
studies	B-X
highlight	B-X
the	B-X
plasticity	B-X
of	B-X
aggressive	B-X
human	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
call	B-X
into	B-X
question	B-X
the	B-X
underlying	B-X
significance	B-X
of	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
VM	B-X
in	B-X
vitro	B-X
induced	B-X
by	B-X
VEGF-a	B-X
.	B-X
These	B-X
studies	B-X
also	B-X
show	B-X
their	B-X
clinicalpathological	B-X
features	B-X
of	B-X
the	B-X
cancers	B-X
with	B-X
human	B-X
Paraffin-embedded	B-X
tumor	B-X
tissue	B-X
samples	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
process	B-X
:	B-X
VEGF-a	B-X
--	B-X
>	B-X
EphA2	B-X
--	B-X
>	B-X
MMPs	B-X
--	B-X
>	B-X
VM	B-X
is	B-X
the	B-X
main	B-X
pathway	B-X
for	B-X
VM	B-X
formation	B-X
and	B-X
VEGF-a	B-X
appears	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VM	B-X
based	B-X
on	B-X
our	B-X
in	B-X
vitro	B-X
assays	B-X
and	B-X
clinical	B-X
immunohistochemical	B-X
analyses	B-X
.	B-X
VM-targeting	B-X
strategies	B-X
for	B-X
ovarian	B-X
cancer	B-X
include	B-X
anti-VEGF-a	B-X
treatment	B-X
,	B-X
knocking	B-X
down	B-X
the	B-X
EphA2	B-X
gene	B-X
and	B-X
using	B-X
antibodies	B-X
against	B-X
human	B-X
MMPs	B-X
if	B-X
the	B-X
tumor	B-X
is	B-X
VM	B-X
positive	B-X
.	B-X

Ovarian	O
cancer	O
is	O
a	O
silent	O
killer	O
,	O
and	O
shows	O
early	O
extensive	O
tumor	O
invasion	O
and	O
peritoneal	O
metastasis	O
.	O
<EOS>	B-X
Ovarian	B-X
cancer	B-X
is	B-X
a	B-X
silent	B-X
killer	B-X
,	B-X
and	B-X
shows	B-X
early	B-X
extensive	B-X
tumor	B-X
invasion	B-X
and	B-X
peritoneal	B-X
metastasis	B-X
.	B-X
The	B-X
microcirculation	B-X
of	B-X
most	B-X
tumors	B-X
includes	B-X
cooperation	B-X
of	B-X
pre-existing	B-X
vessels	B-X
,	B-X
intussusceptive	B-X
microvascular	B-X
growth	B-X
,	B-X
postnatal	B-X
vasculogenesis	B-X
,	B-X
glomeruloid	B-X
angiogenesis	B-X
and	B-X
vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
.	B-X
VM	B-X
is	B-X
critical	B-X
for	B-X
a	B-X
tumor	B-X
blood	B-X
supply	B-X
and	B-X
is	B-X
asscociated	B-X
with	B-X
aggressive	B-X
features	B-X
and	B-X
metastasis	B-X
.	B-X
These	B-X
studies	B-X
also	B-X
show	B-X
their	B-X
clinicalpathological	B-X
features	B-X
of	B-X
the	B-X
cancers	B-X
with	B-X
human	B-X
Paraffin-embedded	B-X
tumor	B-X
tissue	B-X
samples	B-X
.	B-X
VM-targeting	B-X
strategies	B-X
for	B-X
ovarian	B-X
cancer	B-X
include	B-X
anti-VEGF-a	B-X
treatment	B-X
,	B-X
knocking	B-X
down	B-X
the	B-X
EphA2	B-X
gene	B-X
and	B-X
using	B-X
antibodies	B-X
against	B-X
human	B-X
MMPs	B-X
if	B-X
the	B-X
tumor	B-X
is	B-X
VM	B-X
positive	B-X
.	B-X
This	B-X
strategy	B-X
may	B-X
be	B-X
of	B-X
significant	B-X
value	B-X
in	B-X
laying	B-X
the	B-X
foundation	B-X
for	B-X
a	B-X
more	B-X
explicit	B-X
anti-tumor	B-X
angiogenesis	B-X
therapy	B-X
.	B-X

The	O
microcirculation	O
of	O
most	O
tumors	O
includes	O
cooperation	O
of	O
pre	O
-	O
existing	O
vessels	O
,	O
intussusceptive	O
microvascular	O
growth	O
,	O
postnatal	O
vasculogenesis	O
,	O
glomeruloid	O
angiogenesis	O
and	O
vasculogenic	O
mimicry	O
(	O
VM	O
)	O
.	O
<EOS>	B-X
The	B-X
microcirculation	B-X
of	B-X
most	B-X
tumors	B-X
includes	B-X
cooperation	B-X
of	B-X
pre-existing	B-X
vessels	B-X
,	B-X
intussusceptive	B-X
microvascular	B-X
growth	B-X
,	B-X
postnatal	B-X
vasculogenesis	B-X
,	B-X
glomeruloid	B-X
angiogenesis	B-X
and	B-X
vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
.	B-X
VM	B-X
is	B-X
critical	B-X
for	B-X
a	B-X
tumor	B-X
blood	B-X
supply	B-X
and	B-X
is	B-X
asscociated	B-X
with	B-X
aggressive	B-X
features	B-X
and	B-X
metastasis	B-X
.	B-X
Our	B-X
studies	B-X
highlight	B-X
the	B-X
plasticity	B-X
of	B-X
aggressive	B-X
human	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
call	B-X
into	B-X
question	B-X
the	B-X
underlying	B-X
significance	B-X
of	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
VM	B-X
in	B-X
vitro	B-X
induced	B-X
by	B-X
VEGF-a	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
process	B-X
:	B-X
VEGF-a	B-X
--	B-X
>	B-X
EphA2	B-X
--	B-X
>	B-X
MMPs	B-X
--	B-X
>	B-X
VM	B-X
is	B-X
the	B-X
main	B-X
pathway	B-X
for	B-X
VM	B-X
formation	B-X
and	B-X
VEGF-a	B-X
appears	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VM	B-X
based	B-X
on	B-X
our	B-X
in	B-X
vitro	B-X
assays	B-X
and	B-X
clinical	B-X
immunohistochemical	B-X
analyses	B-X
.	B-X
VM-targeting	B-X
strategies	B-X
for	B-X
ovarian	B-X
cancer	B-X
include	B-X
anti-VEGF-a	B-X
treatment	B-X
,	B-X
knocking	B-X
down	B-X
the	B-X
EphA2	B-X
gene	B-X
and	B-X
using	B-X
antibodies	B-X
against	B-X
human	B-X
MMPs	B-X
if	B-X
the	B-X
tumor	B-X
is	B-X
VM	B-X
positive	B-X
.	B-X
This	B-X
strategy	B-X
may	B-X
be	B-X
of	B-X
significant	B-X
value	B-X
in	B-X
laying	B-X
the	B-X
foundation	B-X
for	B-X
a	B-X
more	B-X
explicit	B-X
anti-tumor	B-X
angiogenesis	B-X
therapy	B-X
.	B-X

VM	O
is	O
critical	O
for	O
a	O
tumor	O
blood	O
supply	O
and	O
is	O
asscociated	O
with	O
aggressive	O
features	O
and	O
metastasis	O
.	O
<EOS>	B-X
Ovarian	B-X
cancer	B-X
is	B-X
a	B-X
silent	B-X
killer	B-X
,	B-X
and	B-X
shows	B-X
early	B-X
extensive	B-X
tumor	B-X
invasion	B-X
and	B-X
peritoneal	B-X
metastasis	B-X
.	B-X
The	B-X
microcirculation	B-X
of	B-X
most	B-X
tumors	B-X
includes	B-X
cooperation	B-X
of	B-X
pre-existing	B-X
vessels	B-X
,	B-X
intussusceptive	B-X
microvascular	B-X
growth	B-X
,	B-X
postnatal	B-X
vasculogenesis	B-X
,	B-X
glomeruloid	B-X
angiogenesis	B-X
and	B-X
vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
.	B-X
VM	B-X
is	B-X
critical	B-X
for	B-X
a	B-X
tumor	B-X
blood	B-X
supply	B-X
and	B-X
is	B-X
asscociated	B-X
with	B-X
aggressive	B-X
features	B-X
and	B-X
metastasis	B-X
.	B-X
Our	B-X
studies	B-X
highlight	B-X
the	B-X
plasticity	B-X
of	B-X
aggressive	B-X
human	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
call	B-X
into	B-X
question	B-X
the	B-X
underlying	B-X
significance	B-X
of	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
VM	B-X
in	B-X
vitro	B-X
induced	B-X
by	B-X
VEGF-a	B-X
.	B-X
These	B-X
studies	B-X
also	B-X
show	B-X
their	B-X
clinicalpathological	B-X
features	B-X
of	B-X
the	B-X
cancers	B-X
with	B-X
human	B-X
Paraffin-embedded	B-X
tumor	B-X
tissue	B-X
samples	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
process	B-X
:	B-X
VEGF-a	B-X
--	B-X
>	B-X
EphA2	B-X
--	B-X
>	B-X
MMPs	B-X
--	B-X
>	B-X
VM	B-X
is	B-X
the	B-X
main	B-X
pathway	B-X
for	B-X
VM	B-X
formation	B-X
and	B-X
VEGF-a	B-X
appears	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VM	B-X
based	B-X
on	B-X
our	B-X
in	B-X
vitro	B-X
assays	B-X
and	B-X
clinical	B-X
immunohistochemical	B-X
analyses	B-X
.	B-X
VM-targeting	B-X
strategies	B-X
for	B-X
ovarian	B-X
cancer	B-X
include	B-X
anti-VEGF-a	B-X
treatment	B-X
,	B-X
knocking	B-X
down	B-X
the	B-X
EphA2	B-X
gene	B-X
and	B-X
using	B-X
antibodies	B-X
against	B-X
human	B-X
MMPs	B-X
if	B-X
the	B-X
tumor	B-X
is	B-X
VM	B-X
positive	B-X
.	B-X
This	B-X
strategy	B-X
may	B-X
be	B-X
of	B-X
significant	B-X
value	B-X
in	B-X
laying	B-X
the	B-X
foundation	B-X
for	B-X
a	B-X
more	B-X
explicit	B-X
anti-tumor	B-X
angiogenesis	B-X
therapy	B-X
.	B-X

Our	O
studies	O
highlight	O
the	O
plasticity	O
of	O
aggressive	O
human	O
ovarian	O
carcinoma	O
cells	O
and	O
call	O
into	O
question	O
the	O
underlying	O
significance	O
of	O
their	O
ability	O
to	O
form	O
VM	O
in	O
vitro	O
induced	O
by	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	I-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
microcirculation	B-X
of	B-X
most	B-X
tumors	B-X
includes	B-X
cooperation	B-X
of	B-X
pre-existing	B-X
vessels	B-X
,	B-X
intussusceptive	B-X
microvascular	B-X
growth	B-X
,	B-X
postnatal	B-X
vasculogenesis	B-X
,	B-X
glomeruloid	B-X
angiogenesis	B-X
and	B-X
vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
.	B-X
VM	B-X
is	B-X
critical	B-X
for	B-X
a	B-X
tumor	B-X
blood	B-X
supply	B-X
and	B-X
is	B-X
asscociated	B-X
with	B-X
aggressive	B-X
features	B-X
and	B-X
metastasis	B-X
.	B-X
Our	B-X
studies	B-X
highlight	B-X
the	B-X
plasticity	B-X
of	B-X
aggressive	B-X
human	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
call	B-X
into	B-X
question	B-X
the	B-X
underlying	B-X
significance	B-X
of	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
VM	B-X
in	B-X
vitro	B-X
induced	B-X
by	B-X
VEGF-a	B-X
.	B-X
These	B-X
studies	B-X
also	B-X
show	B-X
their	B-X
clinicalpathological	B-X
features	B-X
of	B-X
the	B-X
cancers	B-X
with	B-X
human	B-X
Paraffin-embedded	B-X
tumor	B-X
tissue	B-X
samples	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
process	B-X
:	B-X
VEGF-a	B-X
--	B-X
>	B-X
EphA2	B-X
--	B-X
>	B-X
MMPs	B-X
--	B-X
>	B-X
VM	B-X
is	B-X
the	B-X
main	B-X
pathway	B-X
for	B-X
VM	B-X
formation	B-X
and	B-X
VEGF-a	B-X
appears	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VM	B-X
based	B-X
on	B-X
our	B-X
in	B-X
vitro	B-X
assays	B-X
and	B-X
clinical	B-X
immunohistochemical	B-X
analyses	B-X
.	B-X
VM-targeting	B-X
strategies	B-X
for	B-X
ovarian	B-X
cancer	B-X
include	B-X
anti-VEGF-a	B-X
treatment	B-X
,	B-X
knocking	B-X
down	B-X
the	B-X
EphA2	B-X
gene	B-X
and	B-X
using	B-X
antibodies	B-X
against	B-X
human	B-X
MMPs	B-X
if	B-X
the	B-X
tumor	B-X
is	B-X
VM	B-X
positive	B-X
.	B-X

These	O
studies	O
also	O
show	O
their	O
clinicalpathological	O
features	O
of	O
the	O
cancers	O
with	O
human	O
Paraffin	O
-	O
embedded	O
tumor	O
tissue	O
samples	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
primary	B-X
soft	B-X
tissue	B-X
lymphomas	B-X
,	B-X
including	B-X
immunohistochemical	B-X
characterization	B-X
by	B-X
tissue	B-X
microarray	B-X
and	B-X
cytogenetic	B-X
profiling	B-X
.	B-X
Formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
tissue	B-X
samples	B-X
were	B-X
collected	B-X
from	B-X
patients	B-X
who	B-X
underwent	B-X
soft	B-X
tissue	B-X
biopsy	B-X
.	B-X
Cases	B-X
were	B-X
selected	B-X
according	B-X
to	B-X
the	B-X
definition	B-X
of	B-X
primary	B-X
soft	B-X
tissue	B-X
lymphoma	B-X
as	B-X
a	B-X
lymphoid	B-X
malignancy	B-X
arising	B-X
in	B-X
soft	B-X
tissues	B-X
without	B-X
evidence	B-X
of	B-X
other	B-X
nodal	B-X
or	B-X
extranodal	B-X
localization	B-X
for	B-X
a	B-X
period	B-X
of	B-X
at	B-X
least	B-X
6	B-X
months	B-X
.	B-X
There	B-X
were	B-X
three	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphomas	B-X
(	B-X
DLBCLs	B-X
)	B-X
;	B-X
one	B-X
B-cell	B-X
lymphoma	B-X
,	B-X
unclassifiable	B-X
,	B-X
with	B-X
features	B-X
intermediate	B-X
between	B-X
DLBCL	B-X
and	B-X
Burkitt	B-X
lymphoma	B-X
;	B-X
one	B-X
DLBCL	B-X
derived	B-X
from	B-X
follicular	B-X
lymphoma	B-X
;	B-X
one	B-X
ALK-negative	B-X
anaplastic	B-X
large	B-X
cell	B-X
lymphoma	B-X
;	B-X
and	B-X
one	B-X
follicular	B-X
lymphoma	B-X
.	B-X
We	B-X
present	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
the	B-X
complete	B-X
immunohistochemical	B-X
profile	B-X
and	B-X
molecular	B-X
cytogenetic	B-X
studies	B-X
of	B-X
these	B-X
lymphoid	B-X
neoplasms	B-X
.	B-X
A	B-X
rare	B-X
case	B-X
of	B-X
a	B-X
primary	B-X
soft	B-X
tissue	B-X
ALK-negative	B-X
anaplastic	B-X
large	B-X
cell	B-X
lymphoma	B-X
is	B-X
described	B-X
in	B-X
detail	B-X
.	B-X

Results	O
show	O
that	O
the	O
process	O
:	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	I-Gene_or_gene_product
-	O
-	O
greater	O
than	O
EphA2	B-Gene_or_gene_product
-	O
-	O
greater	O
than	O
MMPs	B-Gene_or_gene_product
-	O
-	O
greater	O
than	O
VM	O
is	O
the	O
main	O
pathway	O
for	O
VM	O
formation	O
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	I-Gene_or_gene_product
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
VM	O
based	O
on	O
our	O
in	O
vitro	O
assays	O
and	O
clinical	O
immunohistochemical	O
analyses	O
.	O

VM	O
-	O
targeting	O
strategies	O
for	O
ovarian	O
cancer	O
include	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
-	I-Gene_or_gene_product
a	I-Gene_or_gene_product
treatment	O
,	O
knocking	O
down	O
the	O
EphA2	B-Gene_or_gene_product
gene	O
and	O
using	O
antibodies	B-Gene_or_gene_product
against	I-Gene_or_gene_product
human	I-Gene_or_gene_product
MMPs	I-Gene_or_gene_product
if	O
the	O
tumor	O
is	O
VM	O
positive	O
.	O
<EOS>	B-X
Ovarian	B-X
cancer	B-X
is	B-X
a	B-X
silent	B-X
killer	B-X
,	B-X
and	B-X
shows	B-X
early	B-X
extensive	B-X
tumor	B-X
invasion	B-X
and	B-X
peritoneal	B-X
metastasis	B-X
.	B-X
The	B-X
microcirculation	B-X
of	B-X
most	B-X
tumors	B-X
includes	B-X
cooperation	B-X
of	B-X
pre-existing	B-X
vessels	B-X
,	B-X
intussusceptive	B-X
microvascular	B-X
growth	B-X
,	B-X
postnatal	B-X
vasculogenesis	B-X
,	B-X
glomeruloid	B-X
angiogenesis	B-X
and	B-X
vasculogenic	B-X
mimicry	B-X
(	B-X
VM	B-X
)	B-X
.	B-X
VM	B-X
is	B-X
critical	B-X
for	B-X
a	B-X
tumor	B-X
blood	B-X
supply	B-X
and	B-X
is	B-X
asscociated	B-X
with	B-X
aggressive	B-X
features	B-X
and	B-X
metastasis	B-X
.	B-X
Our	B-X
studies	B-X
highlight	B-X
the	B-X
plasticity	B-X
of	B-X
aggressive	B-X
human	B-X
ovarian	B-X
carcinoma	B-X
cells	B-X
and	B-X
call	B-X
into	B-X
question	B-X
the	B-X
underlying	B-X
significance	B-X
of	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
VM	B-X
in	B-X
vitro	B-X
induced	B-X
by	B-X
VEGF-a	B-X
.	B-X
These	B-X
studies	B-X
also	B-X
show	B-X
their	B-X
clinicalpathological	B-X
features	B-X
of	B-X
the	B-X
cancers	B-X
with	B-X
human	B-X
Paraffin-embedded	B-X
tumor	B-X
tissue	B-X
samples	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
process	B-X
:	B-X
VEGF-a	B-X
--	B-X
>	B-X
EphA2	B-X
--	B-X
>	B-X
MMPs	B-X
--	B-X
>	B-X
VM	B-X
is	B-X
the	B-X
main	B-X
pathway	B-X
for	B-X
VM	B-X
formation	B-X
and	B-X
VEGF-a	B-X
appears	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VM	B-X
based	B-X
on	B-X
our	B-X
in	B-X
vitro	B-X
assays	B-X
and	B-X
clinical	B-X
immunohistochemical	B-X
analyses	B-X
.	B-X
VM-targeting	B-X
strategies	B-X
for	B-X
ovarian	B-X
cancer	B-X
include	B-X
anti-VEGF-a	B-X
treatment	B-X
,	B-X
knocking	B-X
down	B-X
the	B-X
EphA2	B-X
gene	B-X
and	B-X
using	B-X
antibodies	B-X
against	B-X
human	B-X
MMPs	B-X
if	B-X
the	B-X
tumor	B-X
is	B-X
VM	B-X
positive	B-X
.	B-X
This	B-X
strategy	B-X
may	B-X
be	B-X
of	B-X
significant	B-X
value	B-X
in	B-X
laying	B-X
the	B-X
foundation	B-X
for	B-X
a	B-X
more	B-X
explicit	B-X
anti-tumor	B-X
angiogenesis	B-X
therapy	B-X
.	B-X

This	O
strategy	O
may	O
be	O
of	O
significant	O
value	O
in	O
laying	O
the	O
foundation	O
for	O
a	O
more	O
explicit	O
anti	O
-	O
tumor	O
angiogenesis	O
therapy	O
.	O

A	O
novel	O
role	O
of	O
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
in	O
cervical	O
carcinogenesis	O
:	O
inhibit	O
stroma	O
reaction	O
by	O
inhibiting	O
activated	O
fibroblasts	O
from	O
invading	O
cancer	O
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

Thrombospondin	B-Gene_or_gene_product
(	I-Gene_or_gene_product
TSP	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
a	O
potent	O
angiogenesis	O
inhibitor	O
,	O
has	O
been	O
shown	O
to	O
exert	O
different	O
biological	O
functions	O
on	O
various	O
cell	O
types	O
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
in	O
tumor	O
-	O
stroma	O
reaction	O
,	O
which	O
is	O
mainly	O
characterized	O
by	O
fibroblast	O
activation	O
to	O
create	O
a	O
permissive	O
microenvironment	O
for	O
tumor	O
progression	O
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

Immunohistochemistry	O
examinations	O
in	O
the	O
human	O
surgical	O
specimens	O
have	O
shown	O
that	O
a	O
downregulation	O
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
during	O
the	O
progression	O
of	O
cervical	O
carcinogenesis	O
was	O
accompanied	O
by	O
an	O
emergence	O
in	O
the	O
upregulation	O
of	O
stroma	B-Gene_or_gene_product
markers	I-Gene_or_gene_product
,	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
smooth	I-Gene_or_gene_product
muscle	I-Gene_or_gene_product
actin	I-Gene_or_gene_product
(	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	I-Gene_or_gene_product
)	O
and	O
desmin	B-Gene_or_gene_product
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

Transfection	O
of	O
SiHa	O
cervical	O
cancer	O
cells	O
with	O
a	O
plasmid	O
expressing	O
the	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
protein	O
exhibited	O
antiangiogenic	O
activity	O
in	O
vitro	O
and	O
resulted	O
in	O
reduced	O
tumor	O
growth	O
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
,	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
tumor	O
vascularization	O
and	O
lower	O
expressions	O
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	I-Gene_or_gene_product
and	O
desmin	B-Gene_or_gene_product
than	O
those	O
in	O
the	O
vector	O
controls	O
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

Transfection	O
with	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
purified	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
added	O
to	O
NIH3T3	O
cells	O
did	O
not	O
alter	O
the	O
protein	O
levels	O
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	I-Gene_or_gene_product
and	O
desmin	B-Gene_or_gene_product
but	O
significantly	O
inhibited	O
matrix	B-Gene_or_gene_product
metalloprotease	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
activity	O
.	O

Transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
)	O
,	O
a	O
major	O
factor	O
in	O
the	O
activation	O
of	O
fibroblasts	O
,	O
increased	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	I-Gene_or_gene_product
and	O
desmin	B-Gene_or_gene_product
expression	O
and	O
the	O
ability	O
of	O
cell	O
migration	O
and	O
invasion	O
in	O
NIH3T3	O
cells	O
.	O

The	O
increased	O
migration	O
ability	O
and	O
the	O
invasive	O
ability	O
into	O
tumor	O
cluster	O
of	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
-	O
treated	O
NIH3T3	O
cells	O
were	O
dose	O
dependently	O
inhibited	O
by	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

In	O
contrast	O
,	O
ectopic	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
expression	O
in	O
SiHa	O
cells	O
has	O
little	O
effect	O
on	O
the	O
invasive	O
ability	O
of	O
the	O
NIH3T3	O
cells	O
.	O
<EOS>	B-X
Thrombospondin	B-X
(	B-X
TSP	B-X
)	B-X
-1	B-X
,	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
different	B-X
biological	B-X
functions	B-X
on	B-X
various	B-X
cell	B-X
types	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
TSP-1	B-X
in	B-X
tumor-stroma	B-X
reaction	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
characterized	B-X
by	B-X
fibroblast	B-X
activation	B-X
to	B-X
create	B-X
a	B-X
permissive	B-X
microenvironment	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
Immunohistochemistry	B-X
examinations	B-X
in	B-X
the	B-X
human	B-X
surgical	B-X
specimens	B-X
have	B-X
shown	B-X
that	B-X
a	B-X
downregulation	B-X
of	B-X
TSP-1	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
cervical	B-X
carcinogenesis	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
emergence	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
stroma	B-X
markers	B-X
,	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
(	B-X
alpha-SMA	B-X
)	B-X
and	B-X
desmin	B-X
.	B-X
Transfection	B-X
of	B-X
SiHa	B-X
cervical	B-X
cancer	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
expressing	B-X
the	B-X
TSP-1	B-X
protein	B-X
exhibited	B-X
antiangiogenic	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
resulted	B-X
in	B-X
reduced	B-X
tumor	B-X
growth	B-X
in	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
vascularization	B-X
and	B-X
lower	B-X
expressions	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
than	B-X
those	B-X
in	B-X
the	B-X
vector	B-X
controls	B-X
.	B-X
Transfection	B-X
with	B-X
TSP-1	B-X
and	B-X
purified	B-X
TSP-1	B-X
added	B-X
to	B-X
NIH3T3	B-X
cells	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
but	B-X
significantly	B-X
inhibited	B-X
matrix	B-X
metalloprotease-2	B-X
activity	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
,	B-X
a	B-X
major	B-X
factor	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
fibroblasts	B-X
,	B-X
increased	B-X
alpha-SMA	B-X
and	B-X
desmin	B-X
expression	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
ability	B-X
and	B-X
the	B-X
invasive	B-X
ability	B-X
into	B-X
tumor	B-X
cluster	B-X
of	B-X
TGF-beta-treated	B-X
NIH3T3	B-X
cells	B-X
were	B-X
dose	B-X
dependently	B-X
inhibited	B-X
by	B-X
TSP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
ectopic	B-X
TSP-1	B-X
expression	B-X
in	B-X
SiHa	B-X
cells	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
invasive	B-X
ability	B-X
of	B-X
the	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
TSP-1	B-X
to	B-X
inhibit	B-X
tumor-stroma	B-X
reaction	B-X
that	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
blockage	B-X
of	B-X
activated	B-X
fibroblasts	B-X
from	B-X
invading	B-X
cancer	B-X
cells	B-X
.	B-X

Together	O
,	O
our	O
findings	O
demonstrate	O
a	O
novel	O
role	O
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
to	O
inhibit	O
tumor	O
-	O
stroma	O
reaction	O
that	O
could	O
be	O
attributed	O
to	O
the	O
blockage	O
of	O
activated	O
fibroblasts	O
from	O
invading	O
cancer	O
cells	O
.	O

Targeting	O
a	O
tumor	O
-	O
specific	O
laminin	B-Gene_or_gene_product
domain	O
critical	O
for	O
human	O
carcinogenesis	O
.	O
<EOS>	B-X
Laminin-332	B-X
is	B-X
critical	B-X
for	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
tumorigenesis	B-X
,	B-X
but	B-X
targeting	B-X
it	B-X
for	B-X
cancer	B-X
therapy	B-X
has	B-X
been	B-X
unachievable	B-X
due	B-X
to	B-X
key	B-X
role	B-X
of	B-X
laminin-332	B-X
in	B-X
promoting	B-X
tissue	B-X
integrity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

Laminin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
332	I-Gene_or_gene_product
is	O
critical	O
for	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
tumorigenesis	O
,	O
but	O
targeting	O
it	O
for	O
cancer	O
therapy	O
has	O
been	O
unachievable	O
due	O
to	O
key	O
role	O
of	O
laminin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
332	I-Gene_or_gene_product
in	O
promoting	O
tissue	O
integrity	O
.	O
<EOS>	B-X
Laminin-332	B-X
is	B-X
critical	B-X
for	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
tumorigenesis	B-X
,	B-X
but	B-X
targeting	B-X
it	B-X
for	B-X
cancer	B-X
therapy	B-X
has	B-X
been	B-X
unachievable	B-X
due	B-X
to	B-X
key	B-X
role	B-X
of	B-X
laminin-332	B-X
in	B-X
promoting	B-X
tissue	B-X
integrity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
a	O
portion	O
of	O
laminin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
332	I-Gene_or_gene_product
,	O
termed	O
G45	B-Gene_or_gene_product
,	O
which	O
is	O
proteolytically	O
removed	O
and	O
absent	O
in	O
normal	O
tissues	O
,	O
is	O
prominently	O
expressed	O
in	O
most	O
human	O
SCC	O
tumors	O
and	O
plays	O
an	O
important	O
role	O
in	O
human	O
SCC	O
tumorigenesis	O
.	O
<EOS>	B-X
Laminin-332	B-X
is	B-X
critical	B-X
for	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
tumorigenesis	B-X
,	B-X
but	B-X
targeting	B-X
it	B-X
for	B-X
cancer	B-X
therapy	B-X
has	B-X
been	B-X
unachievable	B-X
due	B-X
to	B-X
key	B-X
role	B-X
of	B-X
laminin-332	B-X
in	B-X
promoting	B-X
tissue	B-X
integrity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

Primary	O
human	O
keratinocytes	O
lacking	O
G45	B-Gene_or_gene_product
(	O
DeltaG45	O
)	O
showed	O
alterations	O
of	O
basal	O
receptor	O
organization	O
,	O
impaired	O
matrix	O
deposition	O
,	O
and	O
increased	O
migration	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

After	O
SCC	O
transformation	O
,	O
the	O
absence	O
of	O
G45	B-Gene_or_gene_product
domain	O
in	O
DeltaG45	B-Gene_or_gene_product
cells	O
was	O
associated	O
with	O
deficient	O
extracellular	B-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
and	O
phosphotidylinositol	B-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
PI3K	B-Gene_or_gene_product
)	O
pathway	O
activation	O
,	O
impaired	O
invasion	O
,	O
deficient	O
metalloproteinase	B-Gene_or_gene_product
activity	O
,	O
and	O
absent	O
tumorgenicity	O
in	O
vivo	O
.	O
<EOS>	B-X
Laminin-332	B-X
is	B-X
critical	B-X
for	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
tumorigenesis	B-X
,	B-X
but	B-X
targeting	B-X
it	B-X
for	B-X
cancer	B-X
therapy	B-X
has	B-X
been	B-X
unachievable	B-X
due	B-X
to	B-X
key	B-X
role	B-X
of	B-X
laminin-332	B-X
in	B-X
promoting	B-X
tissue	B-X
integrity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

Expression	O
of	O
G45	B-Gene_or_gene_product
or	O
activated	O
PI3K	B-Gene_or_gene_product
subunit	O
in	O
DeltaG45	B-Gene_or_gene_product
cells	O
reversed	O
these	O
abnormalities	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

G45	B-Gene_or_gene_product
antibody	O
treatment	O
induced	O
SCC	O
tumor	O
apoptosis	O
,	O
decreased	O
SCC	O
tumor	O
proliferation	O
,	O
and	O
markedly	O
impaired	O
human	O
SCC	O
tumorigenesis	O
in	O
vivo	O
without	O
affecting	O
normal	O
tissue	O
adhesion	O
.	O
<EOS>	B-X
Laminin-332	B-X
is	B-X
critical	B-X
for	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
tumorigenesis	B-X
,	B-X
but	B-X
targeting	B-X
it	B-X
for	B-X
cancer	B-X
therapy	B-X
has	B-X
been	B-X
unachievable	B-X
due	B-X
to	B-X
key	B-X
role	B-X
of	B-X
laminin-332	B-X
in	B-X
promoting	B-X
tissue	B-X
integrity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

These	O
results	O
show	O
a	O
remarkable	O
selectivity	O
of	O
expression	O
and	O
function	O
for	O
laminin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
332	I-Gene_or_gene_product
G45	B-Gene_or_gene_product
in	O
human	O
SCC	O
tumorigenesis	O
and	O
implicate	O
it	O
as	O
a	O
specific	O
target	O
for	O
anticancer	O
therapy	O
.	O
<EOS>	B-X
Laminin-332	B-X
is	B-X
critical	B-X
for	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
SCC	B-X
)	B-X
tumorigenesis	B-X
,	B-X
but	B-X
targeting	B-X
it	B-X
for	B-X
cancer	B-X
therapy	B-X
has	B-X
been	B-X
unachievable	B-X
due	B-X
to	B-X
key	B-X
role	B-X
of	B-X
laminin-332	B-X
in	B-X
promoting	B-X
tissue	B-X
integrity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
laminin-332	B-X
,	B-X
termed	B-X
G45	B-X
,	B-X
which	B-X
is	B-X
proteolytically	B-X
removed	B-X
and	B-X
absent	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
is	B-X
prominently	B-X
expressed	B-X
in	B-X
most	B-X
human	B-X
SCC	B-X
tumors	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
.	B-X
Primary	B-X
human	B-X
keratinocytes	B-X
lacking	B-X
G45	B-X
(	B-X
DeltaG45	B-X
)	B-X
showed	B-X
alterations	B-X
of	B-X
basal	B-X
receptor	B-X
organization	B-X
,	B-X
impaired	B-X
matrix	B-X
deposition	B-X
,	B-X
and	B-X
increased	B-X
migration	B-X
.	B-X
After	B-X
SCC	B-X
transformation	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
G45	B-X
domain	B-X
in	B-X
DeltaG45	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
deficient	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
and	B-X
phosphotidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
activation	B-X
,	B-X
impaired	B-X
invasion	B-X
,	B-X
deficient	B-X
metalloproteinase	B-X
activity	B-X
,	B-X
and	B-X
absent	B-X
tumorgenicity	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
G45	B-X
or	B-X
activated	B-X
PI3K	B-X
subunit	B-X
in	B-X
DeltaG45	B-X
cells	B-X
reversed	B-X
these	B-X
abnormalities	B-X
.	B-X
G45	B-X
antibody	B-X
treatment	B-X
induced	B-X
SCC	B-X
tumor	B-X
apoptosis	B-X
,	B-X
decreased	B-X
SCC	B-X
tumor	B-X
proliferation	B-X
,	B-X
and	B-X
markedly	B-X
impaired	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
in	B-X
vivo	B-X
without	B-X
affecting	B-X
normal	B-X
tissue	B-X
adhesion	B-X
.	B-X
These	B-X
results	B-X
show	B-X
a	B-X
remarkable	B-X
selectivity	B-X
of	B-X
expression	B-X
and	B-X
function	B-X
for	B-X
laminin-332	B-X
G45	B-X
in	B-X
human	B-X
SCC	B-X
tumorigenesis	B-X
and	B-X
implicate	B-X
it	B-X
as	B-X
a	B-X
specific	B-X
target	B-X
for	B-X
anticancer	B-X
therapy	B-X
.	B-X

Management	O
of	O
early	O
and	O
advanced	O
colorectal	O
cancer	O
:	O
therapeutic	O
issues	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
the	B-X
epidemiology	B-X
of	B-X
malnutrition/cachexia/sarcopenia	B-X
may	B-X
help	B-X
to	B-X
manage	B-X
these	B-X
complications	B-X
early	B-X
in	B-X
the	B-X
course	B-X
of	B-X
treatment	B-X
,	B-X
potentially	B-X
impacting	B-X
patient	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
treatment	B-X
intensity	B-X
,	B-X
and	B-X
disease	B-X
outcome	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
narrative	B-X
review	B-X
aimed	B-X
to	B-X
critically	B-X
evaluate	B-X
the	B-X
current	B-X
evidence	B-X
on	B-X
the	B-X
combined	B-X
impact	B-X
of	B-X
tumor-	B-X
and	B-X
treatment-related	B-X
factors	B-X
on	B-X
nutritional	B-X
status	B-X
and	B-X
to	B-X
draw	B-X
some	B-X
practical	B-X
conclusions	B-X
to	B-X
support	B-X
the	B-X
multidisciplinary	B-X
management	B-X
of	B-X
malnutrition	B-X
in	B-X
cancer	B-X
patients	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
prevalence	B-X
of	B-X
weight	B-X
loss	B-X
and	B-X
associated	B-X
symptoms	B-X
is	B-X
quite	B-X
heterogeneous	B-X
and	B-X
needs	B-X
to	B-X
be	B-X
assessed	B-X
with	B-X
recognized	B-X
criteria	B-X
,	B-X
thus	B-X
allowing	B-X
a	B-X
clear	B-X
classification	B-X
and	B-X
standardization	B-X
of	B-X
therapeutic	B-X
interventions	B-X
.	B-X
Tumor	B-X
subsite	B-X
is	B-X
one	B-X
of	B-X
the	B-X
major	B-X
determinants	B-X
of	B-X
malnutrition	B-X
,	B-X
with	B-X
pancreatic	B-X
,	B-X
esophageal	B-X
,	B-X
and	B-X
other	B-X
gastroenteric	B-X
cancers	B-X
,	B-X
head	B-X
and	B-X
neck	B-X
,	B-X
and	B-X
lung	B-X
cancers	B-X
having	B-X
the	B-X
highest	B-X
prevalence	B-X
.	B-X
The	B-X
advanced	B-X
stage	B-X
is	B-X
also	B-X
linked	B-X
to	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
developing	B-X
malnutrition	B-X
,	B-X
as	B-X
an	B-X
expression	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
tumor	B-X
burden	B-X
,	B-X
inflammatory	B-X
status	B-X
,	B-X
reduced	B-X
caloric	B-X
intake	B-X
,	B-X
and	B-X
malabsorption	B-X
.	B-X
Finally	B-X
,	B-X
treatment	B-X
type	B-X
influences	B-X
the	B-X
risk	B-X
of	B-X
nutritional	B-X
issues	B-X
,	B-X
both	B-X
for	B-X
locoregional	B-X
approaches	B-X
(	B-X
surgery	B-X
and	B-X
radiotherapy	B-X
)	B-X
and	B-X
for	B-X
systemic	B-X
treatment	B-X
.	B-X
Interestingly	B-X
,	B-X
personalized	B-X
approaches	B-X
based	B-X
on	B-X
the	B-X
selection	B-X
of	B-X
the	B-X
most	B-X
predictive	B-X
malnutrition	B-X
definitions	B-X
for	B-X
postoperative	B-X
complications	B-X
according	B-X
to	B-X
cancer	B-X
type	B-X
and	B-X
knowledge	B-X
of	B-X
specific	B-X
nutritional	B-X
problems	B-X
associated	B-X
with	B-X
some	B-X
new	B-X
agents	B-X
may	B-X
positively	B-X
impact	B-X
disease	B-X
course	B-X
.	B-X

PURPOSE	O
:	O
The	O
staging	O
of	O
colorectal	O
cancer	O
,	O
therapeutic	O
decision	O
making	O
in	O
the	O
management	O
of	O
early	O
and	O
advanced	O
colorectal	O
cancer	O
,	O
and	O
dilemmas	O
posed	O
by	O
drug	O
-	O
related	O
toxicity	O
are	O
discussed	O
.	O
<EOS>	B-X
The	B-X
staging	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
therapeutic	B-X
decision	B-X
making	B-X
in	B-X
the	B-X
management	B-X
of	B-X
early	B-X
and	B-X
advanced	B-X
colorectal	B-X
cancer	B-X
,	B-X
and	B-X
dilemmas	B-X
posed	B-X
by	B-X
drug-related	B-X
toxicity	B-X
are	B-X
discussed	B-X
.	B-X

SUMMARY	O
:	O
Staging	O
of	O
colorectal	O
cancer	O
occurs	O
after	O
surgery	O
and	O
is	O
based	O
on	O
the	O
extent	O
of	O
disease	O
invasiveness	O
and	O
dissemination	O
.	O
<EOS>	B-X
The	B-X
staging	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
therapeutic	B-X
decision	B-X
making	B-X
in	B-X
the	B-X
management	B-X
of	B-X
early	B-X
and	B-X
advanced	B-X
colorectal	B-X
cancer	B-X
,	B-X
and	B-X
dilemmas	B-X
posed	B-X
by	B-X
drug-related	B-X
toxicity	B-X
are	B-X
discussed	B-X
.	B-X

Surgery	O
is	O
the	O
primary	O
treatment	O
for	O
stage	O
I	O
disease	O
.	O

Adjuvant	O
chemotherapy	O
is	O
recommended	O
after	O
resection	O
in	O
selected	O
high	O
-	O
risk	O
patients	O
with	O
stage	O
II	O
disease	O
and	O
in	O
all	O
patients	O
with	O
stage	O
III	O
disease	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
these	B-X
guidelines	B-X
is	B-X
to	B-X
provide	B-X
clinicians	B-X
with	B-X
best	B-X
possible	B-X
evidence-based	B-X
recommendations	B-X
for	B-X
clinical	B-X
management	B-X
of	B-X
patients	B-X
with	B-X
ACC	B-X
based	B-X
on	B-X
the	B-X
GRADE	B-X
(	B-X
Grading	B-X
of	B-X
Recommendations	B-X
Assessment	B-X
,	B-X
Development	B-X
and	B-X
Evaluation	B-X
)	B-X
system	B-X
.	B-X
We	B-X
predefined	B-X
four	B-X
main	B-X
clinical	B-X
questions	B-X
,	B-X
which	B-X
we	B-X
judged	B-X
as	B-X
particularly	B-X
important	B-X
for	B-X
the	B-X
management	B-X
of	B-X
ACC	B-X
patients	B-X
and	B-X
performed	B-X
systematic	B-X
literature	B-X
searches	B-X
:	B-X
(	B-X
A	B-X
)	B-X
What	B-X
is	B-X
needed	B-X
to	B-X
diagnose	B-X
an	B-X
ACC	B-X
by	B-X
histopathology	B-X
?	B-X
(	B-X
C	B-X
)	B-X
Is	B-X
adjuvant	B-X
therapy	B-X
able	B-X
to	B-X
prevent	B-X
recurrent	B-X
disease	B-X
or	B-X
reduce	B-X
mortality	B-X
after	B-X
radical	B-X
resection	B-X
?	B-X
(	B-X
D	B-X
)	B-X
What	B-X
is	B-X
the	B-X
best	B-X
treatment	B-X
option	B-X
for	B-X
macroscopically	B-X
incompletely	B-X
resected	B-X
,	B-X
recurrent	B-X
or	B-X
metastatic	B-X
disease	B-X
?	B-X
Selected	B-X
Recommendations	B-X
:	B-X
(	B-X
i	B-X
)	B-X
We	B-X
recommend	B-X
that	B-X
all	B-X
patients	B-X
with	B-X
suspected	B-X
and	B-X
proven	B-X
ACC	B-X
are	B-X
discussed	B-X
in	B-X
a	B-X
multidisciplinary	B-X
expert	B-X
team	B-X
meeting	B-X
.	B-X
(	B-X
iii	B-X
)	B-X
We	B-X
recommend	B-X
that	B-X
adrenal	B-X
surgery	B-X
for	B-X
(	B-X
suspected	B-X
)	B-X
ACC	B-X
should	B-X
be	B-X
performed	B-X
only	B-X
by	B-X
surgeons	B-X
experienced	B-X
in	B-X
adrenal	B-X
and	B-X
oncological	B-X
surgery	B-X
aiming	B-X
at	B-X
a	B-X
complete	B-X
en	B-X
bloc	B-X
resection	B-X
(	B-X
including	B-X
resection	B-X
of	B-X
oligo-metastatic	B-X
disease	B-X
)	B-X
.	B-X
(	B-X
v	B-X
)	B-X
We	B-X
suggest	B-X
adjuvant	B-X
mitotane	B-X
treatment	B-X
in	B-X
patients	B-X
after	B-X
radical	B-X
surgery	B-X
that	B-X
have	B-X
a	B-X
perceived	B-X
high	B-X
risk	B-X
of	B-X
recurrence	B-X
(	B-X
ENSAT	B-X
stage	B-X
III	B-X
,	B-X
or	B-X
R1	B-X
resection	B-X
,	B-X
or	B-X
Ki67	B-X
>	B-X
10	B-X
%	B-X
)	B-X
.	B-X
(	B-X
vi	B-X
)	B-X
For	B-X
advanced	B-X
ACC	B-X
not	B-X
amenable	B-X
to	B-X
complete	B-X
surgical	B-X
resection	B-X
,	B-X
local	B-X
therapeutic	B-X
measures	B-X
(	B-X
e.g	B-X
.	B-X
However	B-X
,	B-X
we	B-X
suggest	B-X
against	B-X
the	B-X
routine	B-X
use	B-X
of	B-X
adrenal	B-X
surgery	B-X
in	B-X
case	B-X
of	B-X
widespread	B-X
metastatic	B-X
disease	B-X
.	B-X
In	B-X
these	B-X
patients	B-X
,	B-X
we	B-X
recommend	B-X
either	B-X
mitotane	B-X
monotherapy	B-X
or	B-X
mitotane	B-X
,	B-X
etoposide	B-X
,	B-X
doxorubicin	B-X
and	B-X
cisplatin	B-X
depending	B-X
on	B-X
prognostic	B-X
parameters	B-X
.	B-X
In	B-X
selected	B-X
patients	B-X
with	B-X
a	B-X
good	B-X
response	B-X
,	B-X
surgery	B-X
may	B-X
be	B-X
subsequently	B-X
considered	B-X
.	B-X
(	B-X
vii	B-X
)	B-X
In	B-X
patients	B-X
with	B-X
recurrent	B-X
disease	B-X
and	B-X
a	B-X
disease-free	B-X
interval	B-X
of	B-X
at	B-X
least	B-X
12	B-X
months	B-X
,	B-X
in	B-X
whom	B-X
a	B-X
complete	B-X
resection/ablation	B-X
seems	B-X
feasible	B-X
,	B-X
we	B-X
recommend	B-X
surgery	B-X
or	B-X
alternatively	B-X
other	B-X
local	B-X
therapies	B-X
.	B-X

Convenience	O
of	O
administration	O
,	O
tolerability	O
,	O
and	O
patient	O
factors	O
not	O
necessarily	O
age	O
may	O
be	O
considerations	O
in	O
decisions	O
about	O
adjuvant	O
therapy	O
after	O
resection	O
.	O
<EOS>	B-X
The	B-X
subcutaneous	B-X
administration	B-X
route	B-X
is	B-X
widely	B-X
used	B-X
to	B-X
administer	B-X
different	B-X
types	B-X
of	B-X
drugs	B-X
given	B-X
its	B-X
high	B-X
bioavailability	B-X
and	B-X
rapid	B-X
onset	B-X
of	B-X
action	B-X
.	B-X
However	B-X
,	B-X
the	B-X
sensation	B-X
of	B-X
pain	B-X
at	B-X
the	B-X
injection	B-X
site	B-X
might	B-X
reduce	B-X
patient	B-X
adherence	B-X
.	B-X
Apart	B-X
from	B-X
a	B-X
direct	B-X
effect	B-X
of	B-X
the	B-X
drug	B-X
itself	B-X
,	B-X
several	B-X
factors	B-X
can	B-X
influence	B-X
the	B-X
sensation	B-X
of	B-X
pain	B-X
:	B-X
needle	B-X
features	B-X
,	B-X
injection	B-X
site	B-X
,	B-X
volume	B-X
injected	B-X
,	B-X
injection	B-X
speed	B-X
,	B-X
osmolality	B-X
,	B-X
viscosity	B-X
and	B-X
pH	B-X
of	B-X
formulation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
kind	B-X
of	B-X
excipients	B-X
employed	B-X
,	B-X
including	B-X
buffers	B-X
and	B-X
preservatives	B-X
.	B-X
A	B-X
pH	B-X
close	B-X
to	B-X
the	B-X
physiological	B-X
one	B-X
is	B-X
recommended	B-X
to	B-X
minimize	B-X
pain	B-X
,	B-X
irritation	B-X
,	B-X
and	B-X
tissue	B-X
damage	B-X
.	B-X

Treatment	O
of	O
stage	O
IV	O
colorectal	O
cancer	O
is	O
based	O
on	O
the	O
type	O
of	O
prior	O
therapy	O
and	O
patient	O
-	O
specific	O
factors	O
.	O
<EOS>	B-X
The	B-X
staging	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
therapeutic	B-X
decision	B-X
making	B-X
in	B-X
the	B-X
management	B-X
of	B-X
early	B-X
and	B-X
advanced	B-X
colorectal	B-X
cancer	B-X
,	B-X
and	B-X
dilemmas	B-X
posed	B-X
by	B-X
drug-related	B-X
toxicity	B-X
are	B-X
discussed	B-X
.	B-X
In	B-X
February	B-X
2010	B-X
,	B-X
the	B-X
Medical	B-X
Advisory	B-X
Secretariat	B-X
(	B-X
MAS	B-X
)	B-X
began	B-X
work	B-X
on	B-X
evidence-based	B-X
reviews	B-X
of	B-X
the	B-X
literature	B-X
surrounding	B-X
three	B-X
pharmacogenomic	B-X
tests	B-X
.	B-X
This	B-X
project	B-X
came	B-X
about	B-X
when	B-X
Cancer	B-X
Care	B-X
Ontario	B-X
(	B-X
CCO	B-X
)	B-X
asked	B-X
MAS	B-X
to	B-X
provide	B-X
evidence-based	B-X
analyses	B-X
on	B-X
the	B-X
effectiveness	B-X
and	B-X
cost-effectiveness	B-X
of	B-X
three	B-X
oncology	B-X
pharmacogenomic	B-X
tests	B-X
currently	B-X
in	B-X
use	B-X
in	B-X
Ontario.Evidence-based	B-X
analyses	B-X
have	B-X
been	B-X
prepared	B-X
for	B-X
each	B-X
of	B-X
these	B-X
technologies	B-X
.	B-X
For	B-X
each	B-X
technology	B-X
,	B-X
an	B-X
economic	B-X
analysis	B-X
was	B-X
also	B-X
completed	B-X
by	B-X
the	B-X
Toronto	B-X
Health	B-X
Economics	B-X
and	B-X
Technology	B-X
Assessment	B-X
Collaborative	B-X
(	B-X
THETA	B-X
)	B-X
and	B-X
is	B-X
summarized	B-X
within	B-X
the	B-X
reports.THE	B-X
FOLLOWING	B-X
REPORTS	B-X
CAN	B-X
BE	B-X
PUBLICLY	B-X
ACCESSED	B-X
AT	B-X
THE	B-X
MAS	B-X
WEBSITE	B-X
AT	B-X
:	B-X
http	B-X
:	B-X
//www.health.gov.on.ca/mas	B-X
or	B-X
at	B-X
www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlGENE	B-X
EXPRESSION	B-X
PROFILING	B-X
FOR	B-X
GUIDING	B-X
ADJUVANT	B-X
CHEMOTHERAPY	B-X
DECISIONS	B-X
IN	B-X
WOMEN	B-X
WITH	B-X
EARLY	B-X
BREAST	B-X
CANCER	B-X
:	B-X
An	B-X
Evidence-Based	B-X
AnalysisEpidermal	B-X
Growth	B-X
Factor	B-X
Receptor	B-X
Mutation	B-X
(	B-X
EGFR	B-X
)	B-X
Testing	B-X
for	B-X
Prediction	B-X
of	B-X
Response	B-X
to	B-X
EGFR-Targeting	B-X
Tyrosine	B-X
Kinase	B-X
Inhibitor	B-X
(	B-X
TKI	B-X
)	B-X
Drugs	B-X
in	B-X
Patients	B-X
with	B-X
Advanced	B-X
Non-Small-Cell	B-X
Lung	B-X
Cancer	B-X
:	B-X
an	B-X
Evidence-Based	B-X
AnalysisK-RAS	B-X
testing	B-X
in	B-X
Treatment	B-X
Decisions	B-X
for	B-X
Advanced	B-X
Colorectal	B-X
Cancer	B-X
:	B-X
an	B-X
Evidence-Based	B-X
Analysis	B-X

Recently	O
,	O
significant	O
improvements	O
in	O
survival	O
have	O
been	O
achieved	O
through	O
the	O
use	O
of	O
combination	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
regimens	O
.	O
<EOS>	B-X
The	B-X
attempts	B-X
at	B-X
improving	B-X
the	B-X
results	B-X
by	B-X
combining	B-X
it	B-X
with	B-X
several	B-X
other	B-X
drugs	B-X
,	B-X
such	B-X
as	B-X
fluorouracil	B-X
,	B-X
cisplatin	B-X
,	B-X
irinotecan	B-X
,	B-X
oxaliplatin	B-X
,	B-X
or	B-X
pemetrexed	B-X
produced	B-X
no	B-X
clear	B-X
survival	B-X
benefit	B-X
.	B-X
Recently	B-X
,	B-X
however	B-X
,	B-X
new	B-X
combination	B-X
chemotherapy	B-X
regimens	B-X
(	B-X
e.g.	B-X
,	B-X
FOLFIRINOX	B-X
,	B-X
nab-paclitaxel	B-X
plus	B-X
gemcitabine	B-X
)	B-X
achieved	B-X
a	B-X
significant	B-X
survival	B-X
benefit	B-X
compared	B-X
to	B-X
gemcitabine	B-X
alone	B-X
.	B-X
Several	B-X
clinico-pathological	B-X
factors	B-X
are	B-X
used	B-X
to	B-X
discriminate	B-X
between	B-X
patients	B-X
at	B-X
low	B-X
(	B-X
<	B-X
10	B-X
%	B-X
)	B-X
,	B-X
average	B-X
(	B-X
10-40	B-X
%	B-X
)	B-X
and	B-X
high	B-X
risk	B-X
of	B-X
relapse	B-X
.	B-X
At	B-X
present	B-X
,	B-X
anastrozole	B-X
can	B-X
be	B-X
used	B-X
in	B-X
the	B-X
adjuvant	B-X
setting	B-X
in	B-X
cases	B-X
of	B-X
tamoxifen	B-X
intolerance	B-X
or	B-X
toxicity	B-X
.	B-X
Polychemotherapy	B-X
is	B-X
superior	B-X
to	B-X
single	B-X
agents	B-X
and	B-X
anthracycline-containing	B-X
regimens	B-X
are	B-X
superior	B-X
to	B-X
CMF	B-X
.	B-X
Six	B-X
courses	B-X
of	B-X
FEC	B-X
or	B-X
FAC	B-X
or	B-X
the	B-X
sequential	B-X
administration	B-X
of	B-X
four	B-X
doses	B-X
of	B-X
anthracycline	B-X
followed	B-X
by	B-X
four	B-X
of	B-X
CMF	B-X
are	B-X
the	B-X
recommended	B-X
regimens	B-X
.	B-X
New	B-X
regimens	B-X
including	B-X
the	B-X
taxanes	B-X
have	B-X
produced	B-X
a	B-X
further	B-X
improvement	B-X
in	B-X
risk	B-X
reduction	B-X
and	B-X
are	B-X
reasonable	B-X
therapeutic	B-X
options	B-X
.	B-X
Combined	B-X
endocrine-chemotherapy	B-X
is	B-X
the	B-X
standard	B-X
adjuvant	B-X
treatment	B-X
in	B-X
high-risk	B-X
patients	B-X
with	B-X
endocrine-responsive	B-X
tumours	B-X
.	B-X
Endocrine	B-X
manipulation	B-X
is	B-X
usually	B-X
administered	B-X
after	B-X
completion	B-X
of	B-X
the	B-X
chemotherapy	B-X
programme	B-X
.	B-X
For	B-X
HER2-neu	B-X
overexpressing	B-X
tumours	B-X
,	B-X
several	B-X
rapidly	B-X
accruing	B-X
trials	B-X
are	B-X
exploring	B-X
the	B-X
potential	B-X
additive	B-X
effect	B-X
of	B-X
trastuzumab	B-X
,	B-X
a	B-X
monoclonal	B-X
antibody	B-X
directed	B-X
against	B-X
the	B-X
extramembrane	B-X
portion	B-X
of	B-X
the	B-X
HER2	B-X
receptor	B-X
.	B-X
Primary	B-X
chemotherapy	B-X
is	B-X
increasingly	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
locally	B-X
advanced	B-X
and	B-X
operable	B-X
breast	B-X
cancer	B-X
,	B-X
with	B-X
increased	B-X
rates	B-X
of	B-X
breast-conserving	B-X
surgery	B-X
.	B-X
A	B-X
proportion	B-X
of	B-X
patients	B-X
achieve	B-X
a	B-X
pathological	B-X
complete	B-X
response	B-X
and	B-X
these	B-X
patients	B-X
have	B-X
significantly	B-X
better	B-X
long-term	B-X
outcomes	B-X
.	B-X
At	B-X
this	B-X
stage	B-X
the	B-X
disease	B-X
is	B-X
incurable	B-X
;	B-X
however	B-X
,	B-X
treatments	B-X
can	B-X
assure	B-X
a	B-X
significant	B-X
prolongation	B-X
of	B-X
survival	B-X
,	B-X
symptomatic	B-X
control	B-X
and	B-X
maintenance	B-X
of	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
Combination	B-X
regimens	B-X
are	B-X
usually	B-X
associated	B-X
with	B-X
higher	B-X
response	B-X
rates	B-X
and	B-X
sometimes	B-X
survival	B-X
prolongation	B-X
,	B-X
and	B-X
this	B-X
approach	B-X
should	B-X
be	B-X
recommended	B-X
in	B-X
young	B-X
patients	B-X
with	B-X
good	B-X
performance	B-X
status	B-X
and	B-X
visceral	B-X
disease	B-X
.	B-X
For	B-X
HER2-neu	B-X
positive	B-X
tumours	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
trastuzumab	B-X
and	B-X
chemotherapy	B-X
is	B-X
significantly	B-X
superior	B-X
to	B-X
chemotherapy	B-X
alone	B-X
in	B-X
terms	B-X
of	B-X
both	B-X
response	B-X
rates	B-X
and	B-X
survival	B-X
.	B-X
Other	B-X
useful	B-X
palliative	B-X
treatments	B-X
include	B-X
bisphosphonates	B-X
for	B-X
the	B-X
control	B-X
of	B-X
metastatic	B-X
bone	B-X
disease	B-X
and	B-X
radiotherapy	B-X
for	B-X
painful	B-X
bone	B-X
lesions	B-X
or	B-X
local	B-X
relapses	B-X
.	B-X

Bevacizumab	O
in	O
combination	O
with	O
chemotherapy	O
is	O
first	O
-	O
line	O
therapy	O
for	O
stage	O
IV	O
disease	O
.	O
<EOS>	B-X
Immune	B-X
checkpoint	B-X
inhibitors	B-X
(	B-X
ICIs	B-X
)	B-X
targeting	B-X
the	B-X
PD-1/PD-L1	B-X
axis	B-X
have	B-X
changed	B-X
the	B-X
first-line	B-X
treatment	B-X
of	B-X
people	B-X
with	B-X
advanced	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Single-agent	B-X
pembrolizumab	B-X
(	B-X
a	B-X
PD-1	B-X
inhibitor	B-X
)	B-X
is	B-X
currently	B-X
the	B-X
standard	B-X
of	B-X
care	B-X
as	B-X
monotherapy	B-X
in	B-X
patients	B-X
with	B-X
PD-L1	B-X
expression	B-X
â¥	B-X
50	B-X
%	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
when	B-X
PD-L1	B-X
expression	B-X
is	B-X
less	B-X
than	B-X
50	B-X
%	B-X
.	B-X
Atezolizumab	B-X
(	B-X
PD-L1	B-X
inhibitor	B-X
)	B-X
has	B-X
also	B-X
been	B-X
approved	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
and	B-X
bevacizumab	B-X
(	B-X
an	B-X
anti-angiogenic	B-X
antibody	B-X
)	B-X
in	B-X
first-line	B-X
NSCLC	B-X
regardless	B-X
of	B-X
PD-L1	B-X
expression	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
first-line	B-X
PD-1/PD-L1	B-X
inhibitors	B-X
with	B-X
anti-CTLA-4	B-X
antibodies	B-X
has	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
improve	B-X
survival	B-X
compared	B-X
to	B-X
platinum-based	B-X
chemotherapy	B-X
in	B-X
advanced	B-X
NSCLC	B-X
,	B-X
particularly	B-X
in	B-X
people	B-X
with	B-X
high	B-X
tumour	B-X
mutational	B-X
burden	B-X
(	B-X
TMB	B-X
)	B-X
.	B-X
Although	B-X
these	B-X
antibodies	B-X
are	B-X
currently	B-X
used	B-X
in	B-X
clinical	B-X
practice	B-X
,	B-X
some	B-X
questions	B-X
remain	B-X
unanswered	B-X
,	B-X
such	B-X
as	B-X
the	B-X
best-treatment	B-X
strategy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
different	B-X
biomarkers	B-X
for	B-X
treatment	B-X
selection	B-X
and	B-X
the	B-X
effectiveness	B-X
of	B-X
immunotherapy	B-X
according	B-X
to	B-X
specific	B-X
clinical	B-X
characteristics	B-X
.	B-X

Age	O
alone	O
should	O
not	O
preclude	O
the	O
use	O
of	O
chemotherapy	O
in	O
stage	O
IV	O
colorectal	O
cancer	O
,	O
although	O
the	O
ability	O
to	O
tolerate	O
drug	O
-	O
related	O
toxicity	O
may	O
be	O
a	O
consideration	O
.	O
<EOS>	B-X
Sociodemographic	B-X
associated	B-X
factors	B-X
of	B-X
sarcopenia	B-X
among	B-X
community-dwelling	B-X
older	B-X
adults	B-X
included	B-X
age	B-X
(	B-X
OR	B-X
=	B-X
1.12	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.10-1.13	B-X
)	B-X
,	B-X
marital	B-X
status	B-X
(	B-X
singled	B-X
,	B-X
divorced	B-X
,	B-X
or	B-X
widowed	B-X
)	B-X
(	B-X
OR	B-X
=	B-X
1.57	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.08-2.28	B-X
)	B-X
,	B-X
disability	B-X
for	B-X
activities	B-X
of	B-X
daily	B-X
living	B-X
(	B-X
ADL	B-X
)	B-X
(	B-X
OR	B-X
=	B-X
1.49	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.15-1.92	B-X
)	B-X
,	B-X
and	B-X
underweight	B-X
(	B-X
OR	B-X
=	B-X
3.78	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
2.55-5.60	B-X
)	B-X
.	B-X
Behavioral	B-X
associated	B-X
factors	B-X
included	B-X
smoking	B-X
(	B-X
OR	B-X
=	B-X
1.20	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.10-1.21	B-X
)	B-X
,	B-X
physical	B-X
inactivity	B-X
(	B-X
OR	B-X
=	B-X
1.73	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.48-2.01	B-X
)	B-X
,	B-X
malnutrition/malnutrition	B-X
risk	B-X
(	B-X
OR	B-X
=	B-X
2.99	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
2.40-3.72	B-X
)	B-X
,	B-X
long	B-X
(	B-X
OR	B-X
=	B-X
2.30	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.37-3.86	B-X
)	B-X
and	B-X
short	B-X
(	B-X
OR	B-X
=	B-X
3.32	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.86-5.93	B-X
)	B-X
sleeping	B-X
time	B-X
,	B-X
and	B-X
living	B-X
alone	B-X
(	B-X
OR	B-X
=	B-X
1.55	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.00-2.40	B-X
)	B-X
.	B-X
Disease-related	B-X
associated	B-X
factors	B-X
included	B-X
diabetes	B-X
(	B-X
OR	B-X
=	B-X
1.40	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.18-1.66	B-X
)	B-X
,	B-X
cognitive	B-X
impairment	B-X
(	B-X
OR	B-X
=	B-X
1.62	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.05-2.51	B-X
)	B-X
,	B-X
heart	B-X
diseases	B-X
(	B-X
OR	B-X
=	B-X
1.14	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.00-1.30	B-X
)	B-X
,	B-X
respiratory	B-X
diseases	B-X
(	B-X
OR	B-X
=	B-X
1.22	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.09-1.36	B-X
)	B-X
,	B-X
osteopenia/osteoporosis	B-X
(	B-X
OR	B-X
=	B-X
2.73	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.63-4.57	B-X
)	B-X
,	B-X
osteoarthritis	B-X
(	B-X
OR	B-X
=	B-X
1.33	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.23-1.44	B-X
)	B-X
,	B-X
depression	B-X
(	B-X
OR	B-X
=	B-X
1.46	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.17-1.83	B-X
)	B-X
,	B-X
falls	B-X
(	B-X
OR	B-X
=	B-X
1.28	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.14-1.44	B-X
)	B-X
,	B-X
anorexia	B-X
(	B-X
OR	B-X
=	B-X
1.50	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.14-1.96	B-X
)	B-X
,	B-X
and	B-X
anemia	B-X
(	B-X
OR	B-X
=	B-X
1.39	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.06-1.82	B-X
)	B-X
.	B-X
However	B-X
,	B-X
it	B-X
remained	B-X
unknown	B-X
whether	B-X
gender	B-X
(	B-X
female	B-X
:	B-X
OR	B-X
=	B-X
1.10	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.80-1.51	B-X
;	B-X
male	B-X
:	B-X
OR	B-X
=	B-X
1.50	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.96-2.34	B-X
)	B-X
,	B-X
overweight/obesity	B-X
(	B-X
OR	B-X
=	B-X
0.27	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.17-0.44	B-X
)	B-X
,	B-X
drinking	B-X
(	B-X
OR	B-X
=	B-X
0.92	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.84-1.01	B-X
)	B-X
,	B-X
hypertension	B-X
(	B-X
OR	B-X
=	B-X
0.98	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.84-1.14	B-X
)	B-X
,	B-X
hyperlipidemia	B-X
(	B-X
OR	B-X
=	B-X
1.14	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.89-1.47	B-X
)	B-X
,	B-X
stroke	B-X
(	B-X
OR	B-X
=	B-X
1.70	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.69-4.17	B-X
)	B-X
,	B-X
cancer	B-X
(	B-X
OR	B-X
=	B-X
0.88	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.85-0.92	B-X
)	B-X
,	B-X
pain	B-X
(	B-X
OR	B-X
=	B-X
1.08	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.98-1.20	B-X
)	B-X
,	B-X
liver	B-X
disease	B-X
(	B-X
OR	B-X
=	B-X
0.88	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.85-0.91	B-X
)	B-X
,	B-X
and	B-X
kidney	B-X
disease	B-X
(	B-X
OR	B-X
=	B-X
2.52	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.19-33.30	B-X
)	B-X
were	B-X
associated	B-X
with	B-X
sarcopenia	B-X
.	B-X
(	B-X
4	B-X
)	B-X
Conclusions	B-X
:	B-X
There	B-X
are	B-X
many	B-X
sociodemographic	B-X
,	B-X
behavioral	B-X
,	B-X
and	B-X
disease-related	B-X
associated	B-X
factors	B-X
of	B-X
sarcopenia	B-X
in	B-X
community-dwelling	B-X
older	B-X
adults	B-X
.	B-X

The	O
optimal	O
duration	O
of	O
chemotherapy	O
in	O
patients	O
with	O
early	O
and	O
metastatic	O
colorectal	O
cancer	O
is	O
unclear	O
.	O
<EOS>	B-X
The	B-X
staging	B-X
of	B-X
colorectal	B-X
cancer	B-X
,	B-X
therapeutic	B-X
decision	B-X
making	B-X
in	B-X
the	B-X
management	B-X
of	B-X
early	B-X
and	B-X
advanced	B-X
colorectal	B-X
cancer	B-X
,	B-X
and	B-X
dilemmas	B-X
posed	B-X
by	B-X
drug-related	B-X
toxicity	B-X
are	B-X
discussed	B-X
.	B-X

CONCLUSION	O
:	O
The	O
optimal	O
approach	O
to	O
the	O
treatment	O
of	O
colorectal	O
cancer	O
depends	O
on	O
several	O
considerations	O
,	O
including	O
patient	O
-	O
specific	O
factors	O
.	O

Serum	O
and	O
urine	O
levels	O
of	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
in	O
patients	O
with	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O
<EOS>	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
a	B-X
pro-inflammatory	B-X
and	B-X
pro-angiogenic	B-X
cytokine	B-X
,	B-X
and	B-X
IL-8	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
prognosis	B-X
and	B-X
survival	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
usefulness	B-X
of	B-X
measuring	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
.	B-X
We	B-X
developed	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
level	B-X
in	B-X
131	B-X
control	B-X
individuals	B-X
.	B-X
We	B-X
measured	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
,	B-X
and	B-X
we	B-X
compared	B-X
the	B-X
concentrations	B-X
with	B-X
those	B-X
of	B-X
control	B-X
individuals	B-X
.	B-X
The	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
corrected	B-X
by	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
were	B-X
15.9-430.3	B-X
pg/mL	B-X
and	B-X
0.0-28.4	B-X
pg/mg	B-X
Cr	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
urine	B-X
IL-8/Cr	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
48.9+/-194.4	B-X
vs.	B-X
5.2+/-13.8	B-X
pg/mg	B-X
Cr	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
serum	B-X
IL-8	B-X
concentrations	B-X
between	B-X
NHL	B-X
patients	B-X
and	B-X
controls	B-X
(	B-X
159.2+/-40.4	B-X
vs.	B-X
99.6+/-107.1	B-X
pg/mL	B-X
;	B-X
P=0.099	B-X
)	B-X
.	B-X
Receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
analysis	B-X
gave	B-X
0.83	B-X
and	B-X
0.43	B-X
ROC	B-X
area	B-X
values	B-X
for	B-X
urine	B-X
IL-8/Cr	B-X
and	B-X
serum	B-X
IL-8	B-X
,	B-X
respectively	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
serum	B-X
and	B-X
urine	B-X
concentrations	B-X
of	B-X
IL-8	B-X
and	B-X
clinical	B-X
variables	B-X
,	B-X
the	B-X
only	B-X
exception	B-X
being	B-X
the	B-X
international	B-X
prognostic	B-X
index	B-X
(	B-X
IPI	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
marginal	B-X
correlation	B-X
with	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
(	B-X
P=0.07	B-X
)	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
might	B-X
be	B-X
useful	B-X
as	B-X
a	B-X
diagnostic	B-X
marker	B-X
of	B-X
NHL	B-X
.	B-X

Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
many	O
types	O
of	O
cancer	O
.	O
<EOS>	B-X
Aberrant	B-X
activation	B-X
of	B-X
Notch	B-X
signaling	B-X
plays	B-X
an	B-X
oncogenic	B-X
role	B-X
in	B-X
cancer	B-X
development	B-X
.	B-X
Jagged1	B-X
(	B-X
JAG1	B-X
)	B-X
is	B-X
an	B-X
important	B-X
Notch	B-X
ligand	B-X
that	B-X
triggers	B-X
Notch	B-X
signaling	B-X
through	B-X
cell-cell	B-X
interactions	B-X
.	B-X
JAG1	B-X
overexpression	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
many	B-X
different	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
correlates	B-X
with	B-X
a	B-X
poor	B-X
clinical	B-X
prognosis	B-X
.	B-X
JAG1/Notch	B-X
signaling	B-X
controls	B-X
oncogenic	B-X
processes	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
and	B-X
cellular	B-X
contexts	B-X
.	B-X
To	B-X
suppress	B-X
the	B-X
severe	B-X
toxicity	B-X
of	B-X
pan-Notch	B-X
inhibitors	B-X
,	B-X
JAG1	B-X
is	B-X
attracting	B-X
increasing	B-X
attention	B-X
as	B-X
a	B-X
source	B-X
of	B-X
therapeutic	B-X
targets	B-X
for	B-X
cancers	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
oncogenic	B-X
role	B-X
of	B-X
JAG1/Notch	B-X
signaling	B-X
in	B-X
cancer	B-X
is	B-X
discussed	B-X
,	B-X
as	B-X
well	B-X
as	B-X
implications	B-X
of	B-X
strategies	B-X
to	B-X
inhibit	B-X
JAG1/Notch	B-X
signaling	B-X
activity	B-X
.	B-X

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
)	O
is	O
known	O
to	O
be	O
a	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
angiogenic	O
cytokine	O
,	O
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
tumor	O
progression	O
,	O
prognosis	O
and	O
survival	O
in	O
several	O
types	O
of	O
cancers	O
.	O
<EOS>	B-X
Angiogenesis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
many	B-X
types	B-X
of	B-X
cancer	B-X
.	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
a	B-X
pro-inflammatory	B-X
and	B-X
pro-angiogenic	B-X
cytokine	B-X
,	B-X
and	B-X
IL-8	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
prognosis	B-X
and	B-X
survival	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
usefulness	B-X
of	B-X
measuring	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
.	B-X
We	B-X
developed	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
level	B-X
in	B-X
131	B-X
control	B-X
individuals	B-X
.	B-X
We	B-X
measured	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
,	B-X
and	B-X
we	B-X
compared	B-X
the	B-X
concentrations	B-X
with	B-X
those	B-X
of	B-X
control	B-X
individuals	B-X
.	B-X
The	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
corrected	B-X
by	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
were	B-X
15.9-430.3	B-X
pg/mL	B-X
and	B-X
0.0-28.4	B-X
pg/mg	B-X
Cr	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
urine	B-X
IL-8/Cr	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
48.9+/-194.4	B-X
vs.	B-X
5.2+/-13.8	B-X
pg/mg	B-X
Cr	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
serum	B-X
IL-8	B-X
concentrations	B-X
between	B-X
NHL	B-X
patients	B-X
and	B-X
controls	B-X
(	B-X
159.2+/-40.4	B-X
vs.	B-X
99.6+/-107.1	B-X
pg/mL	B-X
;	B-X
P=0.099	B-X
)	B-X
.	B-X
Receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
analysis	B-X
gave	B-X
0.83	B-X
and	B-X
0.43	B-X
ROC	B-X
area	B-X
values	B-X
for	B-X
urine	B-X
IL-8/Cr	B-X
and	B-X
serum	B-X
IL-8	B-X
,	B-X
respectively	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
serum	B-X
and	B-X
urine	B-X
concentrations	B-X
of	B-X
IL-8	B-X
and	B-X
clinical	B-X
variables	B-X
,	B-X
the	B-X
only	B-X
exception	B-X
being	B-X
the	B-X
international	B-X
prognostic	B-X
index	B-X
(	B-X
IPI	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
marginal	B-X
correlation	B-X
with	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
(	B-X
P=0.07	B-X
)	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
might	B-X
be	B-X
useful	B-X
as	B-X
a	B-X
diagnostic	B-X
marker	B-X
of	B-X
NHL	B-X
.	B-X

However	O
,	O
the	O
role	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
in	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
has	O
not	O
been	O
fully	O
determined	O
.	O
<EOS>	B-X
More	B-X
than	B-X
30	B-X
%	B-X
of	B-X
patients	B-X
with	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
experience	B-X
treatment	B-X
failure	B-X
after	B-X
first-line	B-X
therapy	B-X
.	B-X
Neutrophil	B-X
extracellular	B-X
traps	B-X
(	B-X
NETs	B-X
)	B-X
,	B-X
a	B-X
pathogen-trapping	B-X
structure	B-X
in	B-X
tumor	B-X
microenvironment	B-X
,	B-X
can	B-X
promote	B-X
the	B-X
transition	B-X
of	B-X
autoimmunity	B-X
to	B-X
lymphomagenesis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
whether	B-X
NETs	B-X
play	B-X
a	B-X
novel	B-X
role	B-X
in	B-X
DLBCL	B-X
progression	B-X
and	B-X
its	B-X
underlying	B-X
mechanism	B-X
.	B-X
Anaplastic	B-X
large	B-X
cell	B-X
lymphoma	B-X
(	B-X
ALCL	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
,	B-X
aggressive	B-X
,	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
CD30	B-X
expression	B-X
and	B-X
disease	B-X
onset	B-X
in	B-X
young	B-X
patients	B-X
.	B-X
About	B-X
half	B-X
of	B-X
ALCL	B-X
patients	B-X
bear	B-X
the	B-X
t	B-X
(	B-X
2	B-X
;	B-X
5	B-X
)	B-X
(	B-X
p23	B-X
;	B-X
q35	B-X
)	B-X
translocation	B-X
,	B-X
which	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
nucleophosmin-anaplastic	B-X
lymphoma	B-X
tyrosine	B-X
kinase	B-X
(	B-X
NPM-ALK	B-X
)	B-X
fusion	B-X
protein	B-X
(	B-X
ALCL	B-X
ALK	B-X
(	B-X
+	B-X
)	B-X
)	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
features	B-X
and	B-X
tumour	B-X
drivers	B-X
in	B-X
ALK-negative	B-X
ALCL	B-X
(	B-X
ALCL	B-X
ALK	B-X
(	B-X
-	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
characterized	B-X
by	B-X
a	B-X
worse	B-X
prognosis	B-X
.	B-X
We	B-X
found	B-X
that	B-X
ALCL	B-X
ALK	B-X
(	B-X
-	B-X
)	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
ALCL	B-X
ALK	B-X
(	B-X
+	B-X
)	B-X
,	B-X
lymphomas	B-X
display	B-X
high	B-X
miR-155	B-X
expression	B-X
.	B-X
However	B-X
,	B-X
no	B-X
direct	B-X
effect	B-X
of	B-X
the	B-X
ALK	B-X
kinase	B-X
on	B-X
miR-155	B-X
levels	B-X
was	B-X
observed	B-X
.	B-X
Moreover	B-X
,	B-X
miR-155	B-X
induces	B-X
IL-22	B-X
expression	B-X
and	B-X
suppresses	B-X
the	B-X
C/EBPÎ²	B-X
target	B-X
IL-8	B-X
.	B-X

Here	O
,	O
we	O
evaluated	O
the	O
usefulness	O
of	O
measuring	O
serum	O
and	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
levels	O
in	O
patients	O
with	O
NHL	O
.	O
<EOS>	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
a	B-X
pro-inflammatory	B-X
and	B-X
pro-angiogenic	B-X
cytokine	B-X
,	B-X
and	B-X
IL-8	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
prognosis	B-X
and	B-X
survival	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
usefulness	B-X
of	B-X
measuring	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
.	B-X
We	B-X
developed	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
level	B-X
in	B-X
131	B-X
control	B-X
individuals	B-X
.	B-X
We	B-X
measured	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
,	B-X
and	B-X
we	B-X
compared	B-X
the	B-X
concentrations	B-X
with	B-X
those	B-X
of	B-X
control	B-X
individuals	B-X
.	B-X
The	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
corrected	B-X
by	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
were	B-X
15.9-430.3	B-X
pg/mL	B-X
and	B-X
0.0-28.4	B-X
pg/mg	B-X
Cr	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
urine	B-X
IL-8/Cr	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
48.9+/-194.4	B-X
vs.	B-X
5.2+/-13.8	B-X
pg/mg	B-X
Cr	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
serum	B-X
IL-8	B-X
concentrations	B-X
between	B-X
NHL	B-X
patients	B-X
and	B-X
controls	B-X
(	B-X
159.2+/-40.4	B-X
vs.	B-X
99.6+/-107.1	B-X
pg/mL	B-X
;	B-X
P=0.099	B-X
)	B-X
.	B-X
Receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
analysis	B-X
gave	B-X
0.83	B-X
and	B-X
0.43	B-X
ROC	B-X
area	B-X
values	B-X
for	B-X
urine	B-X
IL-8/Cr	B-X
and	B-X
serum	B-X
IL-8	B-X
,	B-X
respectively	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
serum	B-X
and	B-X
urine	B-X
concentrations	B-X
of	B-X
IL-8	B-X
and	B-X
clinical	B-X
variables	B-X
,	B-X
the	B-X
only	B-X
exception	B-X
being	B-X
the	B-X
international	B-X
prognostic	B-X
index	B-X
(	B-X
IPI	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
marginal	B-X
correlation	B-X
with	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
(	B-X
P=0.07	B-X
)	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
might	B-X
be	B-X
useful	B-X
as	B-X
a	B-X
diagnostic	B-X
marker	B-X
of	B-X
NHL	B-X
.	B-X

We	O
developed	O
reference	O
intervals	O
for	O
serum	O
and	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
level	O
in	O
131	O
control	O
individuals	O
.	O
<EOS>	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
a	B-X
pro-inflammatory	B-X
and	B-X
pro-angiogenic	B-X
cytokine	B-X
,	B-X
and	B-X
IL-8	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
prognosis	B-X
and	B-X
survival	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
usefulness	B-X
of	B-X
measuring	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
.	B-X
We	B-X
developed	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
level	B-X
in	B-X
131	B-X
control	B-X
individuals	B-X
.	B-X
We	B-X
measured	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
,	B-X
and	B-X
we	B-X
compared	B-X
the	B-X
concentrations	B-X
with	B-X
those	B-X
of	B-X
control	B-X
individuals	B-X
.	B-X
The	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
corrected	B-X
by	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
were	B-X
15.9-430.3	B-X
pg/mL	B-X
and	B-X
0.0-28.4	B-X
pg/mg	B-X
Cr	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
urine	B-X
IL-8/Cr	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
48.9+/-194.4	B-X
vs.	B-X
5.2+/-13.8	B-X
pg/mg	B-X
Cr	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
serum	B-X
IL-8	B-X
concentrations	B-X
between	B-X
NHL	B-X
patients	B-X
and	B-X
controls	B-X
(	B-X
159.2+/-40.4	B-X
vs.	B-X
99.6+/-107.1	B-X
pg/mL	B-X
;	B-X
P=0.099	B-X
)	B-X
.	B-X
Receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
analysis	B-X
gave	B-X
0.83	B-X
and	B-X
0.43	B-X
ROC	B-X
area	B-X
values	B-X
for	B-X
urine	B-X
IL-8/Cr	B-X
and	B-X
serum	B-X
IL-8	B-X
,	B-X
respectively	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
serum	B-X
and	B-X
urine	B-X
concentrations	B-X
of	B-X
IL-8	B-X
and	B-X
clinical	B-X
variables	B-X
,	B-X
the	B-X
only	B-X
exception	B-X
being	B-X
the	B-X
international	B-X
prognostic	B-X
index	B-X
(	B-X
IPI	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
marginal	B-X
correlation	B-X
with	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
(	B-X
P=0.07	B-X
)	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
might	B-X
be	B-X
useful	B-X
as	B-X
a	B-X
diagnostic	B-X
marker	B-X
of	B-X
NHL	B-X
.	B-X

We	O
measured	O
serum	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
and	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
levels	O
in	O
patients	O
with	O
NHL	O
,	O
and	O
we	O
compared	O
the	O
concentrations	O
with	O
those	O
of	O
control	O
individuals	O
.	O
<EOS>	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
a	B-X
pro-inflammatory	B-X
and	B-X
pro-angiogenic	B-X
cytokine	B-X
,	B-X
and	B-X
IL-8	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
prognosis	B-X
and	B-X
survival	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
usefulness	B-X
of	B-X
measuring	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
.	B-X
We	B-X
developed	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
level	B-X
in	B-X
131	B-X
control	B-X
individuals	B-X
.	B-X
We	B-X
measured	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
,	B-X
and	B-X
we	B-X
compared	B-X
the	B-X
concentrations	B-X
with	B-X
those	B-X
of	B-X
control	B-X
individuals	B-X
.	B-X
The	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
corrected	B-X
by	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
were	B-X
15.9-430.3	B-X
pg/mL	B-X
and	B-X
0.0-28.4	B-X
pg/mg	B-X
Cr	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
urine	B-X
IL-8/Cr	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
48.9+/-194.4	B-X
vs.	B-X
5.2+/-13.8	B-X
pg/mg	B-X
Cr	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
serum	B-X
IL-8	B-X
concentrations	B-X
between	B-X
NHL	B-X
patients	B-X
and	B-X
controls	B-X
(	B-X
159.2+/-40.4	B-X
vs.	B-X
99.6+/-107.1	B-X
pg/mL	B-X
;	B-X
P=0.099	B-X
)	B-X
.	B-X
Receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
analysis	B-X
gave	B-X
0.83	B-X
and	B-X
0.43	B-X
ROC	B-X
area	B-X
values	B-X
for	B-X
urine	B-X
IL-8/Cr	B-X
and	B-X
serum	B-X
IL-8	B-X
,	B-X
respectively	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
serum	B-X
and	B-X
urine	B-X
concentrations	B-X
of	B-X
IL-8	B-X
and	B-X
clinical	B-X
variables	B-X
,	B-X
the	B-X
only	B-X
exception	B-X
being	B-X
the	B-X
international	B-X
prognostic	B-X
index	B-X
(	B-X
IPI	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
marginal	B-X
correlation	B-X
with	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
(	B-X
P=0.07	B-X
)	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
might	B-X
be	B-X
useful	B-X
as	B-X
a	B-X
diagnostic	B-X
marker	B-X
of	B-X
NHL	B-X
.	B-X

The	O
reference	O
intervals	O
for	O
serum	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
and	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
corrected	O
by	O
creatinine	O
(	O
Cr	O
)	O
were	O
15	O
.	O
9	O
-	O
430	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
0	O
-	O
28	O
.	O
4	O
pg	O
/	O
mg	O
Cr	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
/	O
Cr	O
were	O
significantly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
48	O
.	O
9	O
+	O
/	O
-	O
194	O
.	O
4	O
vs	O
.	O
5	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
8	O
pg	O
/	O
mg	O
Cr	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
concentrations	O
between	O
NHL	O
patients	O
and	O
controls	O
(	O
159	O
.	O
2	O
+	O
/	O
-	O
40	O
.	O
4	O
vs	O
.	O
99	O
.	O
6	O
+	O
/	O
-	O
107	O
.	O
1	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
099	O
)	O
.	O
<EOS>	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
a	B-X
pro-inflammatory	B-X
and	B-X
pro-angiogenic	B-X
cytokine	B-X
,	B-X
and	B-X
IL-8	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
prognosis	B-X
and	B-X
survival	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
usefulness	B-X
of	B-X
measuring	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
.	B-X
We	B-X
developed	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
and	B-X
urine	B-X
IL-8	B-X
level	B-X
in	B-X
131	B-X
control	B-X
individuals	B-X
.	B-X
We	B-X
measured	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
levels	B-X
in	B-X
patients	B-X
with	B-X
NHL	B-X
,	B-X
and	B-X
we	B-X
compared	B-X
the	B-X
concentrations	B-X
with	B-X
those	B-X
of	B-X
control	B-X
individuals	B-X
.	B-X
The	B-X
reference	B-X
intervals	B-X
for	B-X
serum	B-X
IL-8	B-X
and	B-X
urine	B-X
IL-8	B-X
corrected	B-X
by	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
were	B-X
15.9-430.3	B-X
pg/mL	B-X
and	B-X
0.0-28.4	B-X
pg/mg	B-X
Cr	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
urine	B-X
IL-8/Cr	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
48.9+/-194.4	B-X
vs.	B-X
5.2+/-13.8	B-X
pg/mg	B-X
Cr	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
were	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
serum	B-X
IL-8	B-X
concentrations	B-X
between	B-X
NHL	B-X
patients	B-X
and	B-X
controls	B-X
(	B-X
159.2+/-40.4	B-X
vs.	B-X
99.6+/-107.1	B-X
pg/mL	B-X
;	B-X
P=0.099	B-X
)	B-X
.	B-X
Receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
analysis	B-X
gave	B-X
0.83	B-X
and	B-X
0.43	B-X
ROC	B-X
area	B-X
values	B-X
for	B-X
urine	B-X
IL-8/Cr	B-X
and	B-X
serum	B-X
IL-8	B-X
,	B-X
respectively	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
serum	B-X
and	B-X
urine	B-X
concentrations	B-X
of	B-X
IL-8	B-X
and	B-X
clinical	B-X
variables	B-X
,	B-X
the	B-X
only	B-X
exception	B-X
being	B-X
the	B-X
international	B-X
prognostic	B-X
index	B-X
(	B-X
IPI	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
marginal	B-X
correlation	B-X
with	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
(	B-X
P=0.07	B-X
)	B-X
.	B-X
This	B-X
study	B-X
indicated	B-X
that	B-X
urine	B-X
IL-8/Cr	B-X
levels	B-X
might	B-X
be	B-X
useful	B-X
as	B-X
a	B-X
diagnostic	B-X
marker	B-X
of	B-X
NHL	B-X
.	B-X

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
gave	O
0	O
.	O
83	O
and	O
0	O
.	O
43	O
ROC	O
area	O
values	O
for	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
/	O
Cr	O
and	O
serum	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
,	O
respectively	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
serum	O
and	O
urine	O
concentrations	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
and	O
clinical	O
variables	O
,	O
the	O
only	O
exception	O
being	O
the	O
international	O
prognostic	O
index	O
(	O
IPI	O
)	O
,	O
which	O
showed	O
a	O
marginal	O
correlation	O
with	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
/	O
Cr	O
levels	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

This	O
study	O
indicated	O
that	O
urine	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
/	O
Cr	O
levels	O
might	O
be	O
useful	O
as	O
a	O
diagnostic	O
marker	O
of	O
NHL	O
.	O

Microscopic	O
technique	O
for	O
the	O
detection	O
of	O
nitric	O
oxide	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
vascular	O
homeostasis	O
.	O
<EOS>	B-X
The	B-X
vascular	B-X
endothelium	B-X
is	B-X
a	B-X
monolayer	B-X
of	B-X
cells	B-X
between	B-X
the	B-X
vessel	B-X
lumen	B-X
and	B-X
the	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
is	B-X
a	B-X
soluble	B-X
gas	B-X
continuously	B-X
synthesized	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
L-arginine	B-X
in	B-X
endothelial	B-X
cells	B-X
by	B-X
the	B-X
constitutive	B-X
calcium-calmodulin-dependent	B-X
enzyme	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
NOS	B-X
)	B-X
.	B-X
This	B-X
substance	B-X
has	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
properties	B-X
that	B-X
maintain	B-X
vascular	B-X
homeostasis	B-X
,	B-X
including	B-X
modulation	B-X
of	B-X
vascular	B-X
dilator	B-X
tone	B-X
,	B-X
regulation	B-X
of	B-X
local	B-X
cell	B-X
growth	B-X
,	B-X
and	B-X
protection	B-X
of	B-X
the	B-X
vessel	B-X
from	B-X
injurious	B-X
consequences	B-X
of	B-X
platelets	B-X
and	B-X
cells	B-X
circulating	B-X
in	B-X
blood	B-X
,	B-X
playing	B-X
in	B-X
this	B-X
way	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
normal	B-X
endothelial	B-X
function	B-X
.	B-X
A	B-X
growing	B-X
list	B-X
of	B-X
conditions	B-X
,	B-X
including	B-X
those	B-X
commonly	B-X
associated	B-X
as	B-X
risk	B-X
factors	B-X
for	B-X
atherosclerosis	B-X
such	B-X
as	B-X
hypertension	B-X
,	B-X
hypercholesterolemia	B-X
,	B-X
smoking	B-X
,	B-X
diabetes	B-X
mellitus	B-X
and	B-X
heart	B-X
failure	B-X
are	B-X
associated	B-X
with	B-X
diminished	B-X
release	B-X
of	B-X
nitric	B-X
oxide	B-X
into	B-X
the	B-X
arterial	B-X
wall	B-X
either	B-X
because	B-X
of	B-X
impaired	B-X
synthesis	B-X
or	B-X
excessive	B-X
oxidative	B-X
degradation	B-X
.	B-X
The	B-X
decreased	B-X
production	B-X
of	B-X
NO	B-X
in	B-X
these	B-X
pathological	B-X
states	B-X
causes	B-X
serious	B-X
problems	B-X
in	B-X
endothelial	B-X
equilibrium	B-X
and	B-X
that	B-X
is	B-X
the	B-X
reason	B-X
why	B-X
numerous	B-X
therapies	B-X
have	B-X
been	B-X
investigated	B-X
to	B-X
assess	B-X
the	B-X
possibility	B-X
of	B-X
reversing	B-X
endothelial	B-X
dysfunction	B-X
by	B-X
enhancing	B-X
the	B-X
release	B-X
of	B-X
nitric	B-X
oxide	B-X
from	B-X
the	B-X
endothelium	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
important	B-X
role	B-X
of	B-X
nitric	B-X
oxide	B-X
in	B-X
physiological	B-X
endothelium	B-X
and	B-X
we	B-X
will	B-X
pinpoint	B-X
the	B-X
significance	B-X
of	B-X
this	B-X
molecule	B-X
in	B-X
pathological	B-X
states	B-X
altering	B-X
the	B-X
endothelial	B-X
function	B-X
.	B-X

The	O
importance	O
of	O
NO	O
in	O
the	O
vasculature	O
is	O
demonstrated	O
by	O
several	O
experimental	O
conditions	O
,	O
such	O
as	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
-	O
induced	O
angiogenesis	O
.	O
<EOS>	B-X
Nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
maintaining	B-X
vascular	B-X
homeostasis	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
NO	B-X
in	B-X
the	B-X
vasculature	B-X
is	B-X
demonstrated	B-X
by	B-X
several	B-X
experimental	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
-induced	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
NO	B-X
metabolic	B-X
pathway	B-X
in	B-X
endothelial	B-X
cells	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
main	B-X
contributing	B-X
factors	B-X
for	B-X
angiogenesis	B-X
.	B-X
Although	B-X
several	B-X
methods	B-X
have	B-X
been	B-X
used	B-X
for	B-X
measuring	B-X
in	B-X
vitro	B-X
angiogenesis	B-X
,	B-X
a	B-X
proper	B-X
technique	B-X
has	B-X
not	B-X
been	B-X
developed	B-X
for	B-X
identifying	B-X
in	B-X
vivo	B-X
NO-dependent	B-X
angiogenesis	B-X
.	B-X
This	B-X
chapter	B-X
provides	B-X
a	B-X
new	B-X
intravital	B-X
microscopic	B-X
method	B-X
for	B-X
detecting	B-X
and	B-X
measuring	B-X
NO-dependent	B-X
angiogenesis	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
.	B-X
This	B-X
technique	B-X
showed	B-X
strong	B-X
abdominal	B-X
neovascularization	B-X
in	B-X
wild-type	B-X
mice	B-X
,	B-X
but	B-X
not	B-X
eNOS	B-X
knockout	B-X
mice	B-X
,	B-X
locally	B-X
injected	B-X
with	B-X
VEGF	B-X
,	B-X
as	B-X
well	B-X
as	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
NO	B-X
donor-injected	B-X
mice	B-X
.	B-X
This	B-X
technique	B-X
also	B-X
revealed	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
the	B-X
NOS	B-X
inhibitor	B-X
N	B-X
(	B-X
G	B-X
)	B-X
-iminoethyl-L-ornithine	B-X
in	B-X
VEGF-mediated	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
.	B-X
This	B-X
chapter	B-X
describes	B-X
intravital	B-X
microscopy	B-X
as	B-X
a	B-X
new	B-X
imaging	B-X
technique	B-X
for	B-X
detecting	B-X
NO-dependent	B-X
angiogenesis	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
.	B-X

Thus	O
,	O
the	O
NO	O
metabolic	O
pathway	O
in	O
endothelial	O
cells	O
could	O
be	O
one	O
of	O
the	O
main	O
contributing	O
factors	O
for	O
angiogenesis	O
.	O
<EOS>	B-X
Nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
maintaining	B-X
vascular	B-X
homeostasis	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
NO	B-X
in	B-X
the	B-X
vasculature	B-X
is	B-X
demonstrated	B-X
by	B-X
several	B-X
experimental	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
-induced	B-X
angiogenesis	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
NO	B-X
metabolic	B-X
pathway	B-X
in	B-X
endothelial	B-X
cells	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
main	B-X
contributing	B-X
factors	B-X
for	B-X
angiogenesis	B-X
.	B-X
Although	B-X
several	B-X
methods	B-X
have	B-X
been	B-X
used	B-X
for	B-X
measuring	B-X
in	B-X
vitro	B-X
angiogenesis	B-X
,	B-X
a	B-X
proper	B-X
technique	B-X
has	B-X
not	B-X
been	B-X
developed	B-X
for	B-X
identifying	B-X
in	B-X
vivo	B-X
NO-dependent	B-X
angiogenesis	B-X
.	B-X
This	B-X
chapter	B-X
provides	B-X
a	B-X
new	B-X
intravital	B-X
microscopic	B-X
method	B-X
for	B-X
detecting	B-X
and	B-X
measuring	B-X
NO-dependent	B-X
angiogenesis	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
.	B-X
This	B-X
technique	B-X
showed	B-X
strong	B-X
abdominal	B-X
neovascularization	B-X
in	B-X
wild-type	B-X
mice	B-X
,	B-X
but	B-X
not	B-X
eNOS	B-X
knockout	B-X
mice	B-X
,	B-X
locally	B-X
injected	B-X
with	B-X
VEGF	B-X
,	B-X
as	B-X
well	B-X
as	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
NO	B-X
donor-injected	B-X
mice	B-X
.	B-X
This	B-X
technique	B-X
also	B-X
revealed	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
the	B-X
NOS	B-X
inhibitor	B-X
N	B-X
(	B-X
G	B-X
)	B-X
-iminoethyl-L-ornithine	B-X
in	B-X
VEGF-mediated	B-X
in	B-X
vivo	B-X
angiogenesis	B-X
.	B-X
This	B-X
chapter	B-X
describes	B-X
intravital	B-X
microscopy	B-X
as	B-X
a	B-X
new	B-X
imaging	B-X
technique	B-X
for	B-X
detecting	B-X
NO-dependent	B-X
angiogenesis	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
.	B-X

Although	O
several	O
methods	O
have	O
been	O
used	O
for	O
measuring	O
in	O
vitro	O
angiogenesis	O
,	O
a	O
proper	O
technique	O
has	O
not	O
been	O
developed	O
for	O
identifying	O
in	O
vivo	O
NO	O
-	O
dependent	O
angiogenesis	O
.	O
<EOS>	B-X
Although	B-X
numerous	B-X
factors	B-X
involved	B-X
in	B-X
this	B-X
multi-step	B-X
process	B-X
are	B-X
still	B-X
unknown	B-X
to	B-X
date	B-X
,	B-X
an	B-X
ever-increasing	B-X
number	B-X
of	B-X
mutated/altered	B-X
candidate	B-X
genes	B-X
are	B-X
being	B-X
identified	B-X
within	B-X
large-scale	B-X
cancer	B-X
genomic	B-X
projects	B-X
.	B-X
Therefore	B-X
,	B-X
investigators	B-X
need	B-X
to	B-X
be	B-X
aware	B-X
of	B-X
available	B-X
and	B-X
appropriate	B-X
techniques	B-X
capable	B-X
of	B-X
determining	B-X
characteristic	B-X
features	B-X
of	B-X
each	B-X
hallmark	B-X
.	B-X
We	B-X
review	B-X
the	B-X
methods	B-X
tailored	B-X
to	B-X
experimental	B-X
cancer	B-X
researchers	B-X
to	B-X
evaluate	B-X
cell	B-X
proliferation	B-X
,	B-X
programmed	B-X
cell	B-X
death	B-X
,	B-X
replicative	B-X
immortality	B-X
,	B-X
induction	B-X
of	B-X
angiogenesis	B-X
,	B-X
invasion	B-X
and	B-X
metastasis	B-X
,	B-X
genome	B-X
instability	B-X
,	B-X
and	B-X
reprogramming	B-X
of	B-X
energy	B-X
metabolism	B-X
.	B-X
Multiplexing	B-X
strategies	B-X
enable	B-X
a	B-X
more	B-X
in-depth	B-X
data	B-X
collection	B-X
from	B-X
a	B-X
single	B-X
experiment	B-X
-	B-X
obtaining	B-X
several	B-X
results	B-X
from	B-X
a	B-X
single	B-X
procedure	B-X
reduces	B-X
variability	B-X
and	B-X
saves	B-X
time	B-X
and	B-X
relative	B-X
cost	B-X
,	B-X
leading	B-X
to	B-X
more	B-X
robust	B-X
conclusions	B-X
compared	B-X
to	B-X
a	B-X
single	B-X
end	B-X
point	B-X
measurement	B-X
.	B-X
In	B-X
general	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
multiwell	B-X
readers	B-X
are	B-X
extremely	B-X
versatile	B-X
tools	B-X
and	B-X
,	B-X
with	B-X
proper	B-X
sample	B-X
preparation	B-X
,	B-X
allow	B-X
the	B-X
detection	B-X
of	B-X
a	B-X
vast	B-X
number	B-X
of	B-X
hallmark	B-X
features	B-X
.	B-X
Although	B-X
our	B-X
list	B-X
is	B-X
not	B-X
exhaustive	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
snapshot	B-X
of	B-X
the	B-X
most	B-X
widely	B-X
used	B-X
methods	B-X
,	B-X
with	B-X
an	B-X
emphasis	B-X
on	B-X
methods	B-X
enabling	B-X
the	B-X
simultaneous	B-X
evaluation	B-X
of	B-X
multiple	B-X
hallmark	B-X
features	B-X
.	B-X

This	O
chapter	O
provides	O
a	O
new	O
intravital	O
microscopic	O
method	O
for	O
detecting	O
and	O
measuring	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
a	O
mouse	O
model	O
.	O

This	O
technique	O
showed	O
strong	O
abdominal	O
neovascularization	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
not	O
eNOS	B-Gene_or_gene_product
knockout	O
mice	O
,	O
locally	O
injected	O
with	O
VEGF	B-Gene_or_gene_product
,	O
as	O
well	O
as	O
stimulation	O
of	O
angiogenesis	O
in	O
NO	O
donor	O
-	O
injected	O
mice	O
.	O

This	O
technique	O
also	O
revealed	O
the	O
inhibitory	O
effect	O
of	O
the	O
NOS	B-Gene_or_gene_product
inhibitor	O
N	O
(	O
G	O
)	O
-	O
iminoethyl	O
-	O
L	O
-	O
ornithine	O
in	O
VEGF	B-Gene_or_gene_product
-	O
mediated	O
in	O
vivo	O
angiogenesis	O
.	O

This	O
chapter	O
describes	O
intravital	O
microscopy	O
as	O
a	O
new	O
imaging	O
technique	O
for	O
detecting	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O

Effects	O
of	O
cyclooxygenase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
non	O
-	O
selective	O
and	O
selective	O
inhibitors	O
on	O
proliferation	O
inhibition	O
and	O
apoptosis	O
induction	O
of	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
on	B-X
cell	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
and	B-X
its	B-X
potential	B-X
mechanisms	B-X
in	B-X
EC9706	B-X
and	B-X
EC109	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
EC9706	B-X
and	B-X
EC109	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
varying	B-X
concentrations	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
were	B-X
monitored	B-X
by	B-X
3-	B-X
(	B-X
4,5-dimethyl-thiazol-2yl	B-X
)	B-X
-2,5-diphenyltetrazolium	B-X
bromide	B-X
and	B-X
flow	B-X
cytometry	B-X
.	B-X
Reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
Western	B-X
blot	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
expression	B-X
of	B-X
Bcl-2	B-X
and	B-X
Bax	B-X
.	B-X
Prostaglandin	B-X
E2	B-X
production	B-X
was	B-X
measured	B-X
by	B-X
enzyme	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
.	B-X
Pretreatment	B-X
with	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
inhibited	B-X
EC9706	B-X
and	B-X
EC109	B-X
cell	B-X
growth	B-X
in	B-X
a	B-X
time	B-X
and	B-X
dose-dependent	B-X
manner	B-X
,	B-X
accompanied	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
prostaglandin	B-X
E2	B-X
production	B-X
.	B-X
In	B-X
EC9706	B-X
cells	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
induced	B-X
growth	B-X
inhibition	B-X
was	B-X
a	B-X
consequence	B-X
of	B-X
cell	B-X
cycle	B-X
arrest	B-X
at	B-X
the	B-X
G	B-X
(	B-X
0	B-X
)	B-X
/G	B-X
(	B-X
1	B-X
)	B-X
check	B-X
point	B-X
.	B-X
In	B-X
EC109	B-X
cells	B-X
,	B-X
growth	B-X
arrest	B-X
was	B-X
by	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
downregulation	B-X
of	B-X
Bcl-2	B-X
,	B-X
but	B-X
not	B-X
Bax	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
could	B-X
inhibit	B-X
cell	B-X
proliferation	B-X
and	B-X
induce	B-X
apoptosis	B-X
in	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
Cyclooxygenase-2	B-X
inhibitor	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
agent	B-X
for	B-X
human	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
aspirin	O
and	O
nimesulide	O
on	O
cell	O
proliferation	O
,	O
apoptosis	O
and	O
its	O
potential	O
mechanisms	O
in	O
EC9706	O
and	O
EC109	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

EC9706	O
and	O
EC109	O
cells	O
were	O
incubated	O
with	O
varying	O
concentrations	O
of	O
aspirin	O
and	O
nimesulide	O
,	O
and	O
the	O
effects	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
were	O
monitored	O
by	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethyl	O
-	O
thiazol	O
-	O
2yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
and	O
flow	O
cytometry	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
on	B-X
cell	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
and	B-X
its	B-X
potential	B-X
mechanisms	B-X
in	B-X
EC9706	B-X
and	B-X
EC109	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
EC9706	B-X
and	B-X
EC109	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
varying	B-X
concentrations	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
were	B-X
monitored	B-X
by	B-X
3-	B-X
(	B-X
4,5-dimethyl-thiazol-2yl	B-X
)	B-X
-2,5-diphenyltetrazolium	B-X
bromide	B-X
and	B-X
flow	B-X
cytometry	B-X
.	B-X
Reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
Western	B-X
blot	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
expression	B-X
of	B-X
Bcl-2	B-X
and	B-X
Bax	B-X
.	B-X
Prostaglandin	B-X
E2	B-X
production	B-X
was	B-X
measured	B-X
by	B-X
enzyme	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
.	B-X
Pretreatment	B-X
with	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
inhibited	B-X
EC9706	B-X
and	B-X
EC109	B-X
cell	B-X
growth	B-X
in	B-X
a	B-X
time	B-X
and	B-X
dose-dependent	B-X
manner	B-X
,	B-X
accompanied	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
prostaglandin	B-X
E2	B-X
production	B-X
.	B-X
In	B-X
EC9706	B-X
cells	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
induced	B-X
growth	B-X
inhibition	B-X
was	B-X
a	B-X
consequence	B-X
of	B-X
cell	B-X
cycle	B-X
arrest	B-X
at	B-X
the	B-X
G	B-X
(	B-X
0	B-X
)	B-X
/G	B-X
(	B-X
1	B-X
)	B-X
check	B-X
point	B-X
.	B-X
In	B-X
EC109	B-X
cells	B-X
,	B-X
growth	B-X
arrest	B-X
was	B-X
by	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
downregulation	B-X
of	B-X
Bcl-2	B-X
,	B-X
but	B-X
not	B-X
Bax	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
could	B-X
inhibit	B-X
cell	B-X
proliferation	B-X
and	B-X
induce	B-X
apoptosis	B-X
in	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
Cyclooxygenase-2	B-X
inhibitor	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
agent	B-X
for	B-X
human	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
assays	O
were	O
used	O
to	O
investigate	O
expression	O
of	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
Bax	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
IL-27	B-X
on	B-X
chemotherapy	B-X
resistance	B-X
in	B-X
lung	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
analyze	B-X
its	B-X
potential	B-X
molecular	B-X
mechanism	B-X
in	B-X
lung	B-X
cancer	B-X
tissues	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
and	B-X
reverse	B-X
transcription-quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
were	B-X
performed	B-X
to	B-X
examine	B-X
the	B-X
RNA	B-X
and	B-X
protein	B-X
expression	B-X
levels	B-X
of	B-X
IL-27	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
revealed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
IL-27	B-X
with	B-X
cisplatin	B-X
,	B-X
significantly	B-X
suppressed	B-X
the	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
of	B-X
A549	B-X
cells	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
cisplatin	B-X
treatment	B-X
group	B-X
alone	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
Akt	B-X
and	B-X
apoptosis	B-X
factors	B-X
such	B-X
as	B-X
Caspase-3	B-X
and	B-X
Bcl-2/Bax	B-X
also	B-X
ascertained	B-X
that	B-X
upregulated	B-X
IL-27	B-X
inhibited	B-X
the	B-X
development	B-X
of	B-X
cancer	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
the	B-X
A549	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
IL-27	B-X
may	B-X
represent	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
antitumor	B-X
therapy	B-X
,	B-X
especially	B-X
when	B-X
considering	B-X
the	B-X
clinical	B-X
challenges	B-X
presented	B-X
by	B-X
the	B-X
development	B-X
of	B-X
chemoresistance	B-X
in	B-X
tumors	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
IL-27	B-X
is	B-X
a	B-X
promising	B-X
biomarker	B-X
and	B-X
represents	B-X
a	B-X
novel	B-X
treatment	B-X
strategy	B-X
for	B-X
patients	B-X
with	B-X
lung	B-X
cancer	B-X
.	B-X

Prostaglandin	B-Gene_or_gene_product
E2	I-Gene_or_gene_product
production	O
was	O
measured	O
by	O
enzyme	O
linked	O
immunosorbent	O
assay	O
.	O
<EOS>	B-X
Nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
was	B-X
determined	B-X
using	B-X
the	B-X
Griess	B-X
method	B-X
.	B-X
Production	B-X
of	B-X
prostaglandin	B-X
E2	B-X
(	B-X
PGE2	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-Î±	B-X
(	B-X
TNF-Î±	B-X
)	B-X
,	B-X
and	B-X
matrix	B-X
metalloproteinase-2	B-X
,	B-X
-8	B-X
,	B-X
and	B-X
-9	B-X
(	B-X
MMP-2	B-X
,	B-X
MMP-8	B-X
and	B-X
MMP-9	B-X
)	B-X
was	B-X
measured	B-X
by	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
luteolin	B-X
considerably	B-X
reduced	B-X
the	B-X
IL-1Î²-induced	B-X
production	B-X
of	B-X
NO	B-X
,	B-X
PGE2	B-X
,	B-X
TNF-Î±	B-X
,	B-X
MMP-2	B-X
,	B-X
MMP-8	B-X
and	B-X
MMP-9	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
COX-2	B-X
,	B-X
iNOS	B-X
,	B-X
MMP-1	B-X
,	B-X
MMP-3	B-X
and	B-X
MMP-13	B-X
.	B-X
BALf	B-X
's	B-X
eosinophil	B-X
Counting	B-X
,	B-X
The	B-X
levels	B-X
of	B-X
IL-4	B-X
,	B-X
-5	B-X
,	B-X
-13	B-X
,	B-X
-25	B-X
,	B-X
-33	B-X
,	B-X
INF-Î³	B-X
,	B-X
Cys-LT	B-X
,	B-X
LTB4	B-X
,	B-X
LTC4	B-X
,	B-X
mitochondria	B-X
genes	B-X
expression	B-X
of	B-X
COX-1	B-X
,	B-X
COX-2	B-X
,	B-X
ND1	B-X
,	B-X
Nrf2	B-X
,	B-X
Cytb	B-X
were	B-X
measured	B-X
and	B-X
lung	B-X
histopathological	B-X
study	B-X
were	B-X
done	B-X
.	B-X
BALf	B-X
's	B-X
eosinophils	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
IL-4	B-X
,	B-X
-5	B-X
,	B-X
-13	B-X
,	B-X
-25	B-X
,	B-X
-33	B-X
,	B-X
LTB4	B-X
,	B-X
LTC4	B-X
,	B-X
Cys-LT	B-X
,	B-X
the	B-X
mitochondria	B-X
genes	B-X
expression	B-X
(	B-X
COX-1	B-X
,	B-X
COX-2	B-X
,	B-X
Cytb	B-X
and	B-X
ND-1	B-X
)	B-X
,	B-X
perivascular	B-X
and	B-X
peribronchial	B-X
inflammation	B-X
,	B-X
mucus	B-X
hyper-production	B-X
and	B-X
hyperplasia	B-X
of	B-X
the	B-X
goblet	B-X
cell	B-X
in	B-X
pathological	B-X
study	B-X
were	B-X
significantly	B-X
decreased	B-X
in	B-X
MSCs-treated	B-X
asthma	B-X
mice	B-X
and	B-X
reverse	B-X
trend	B-X
was	B-X
found	B-X
about	B-X
Nrf-2	B-X
gene	B-X
expression	B-X
,	B-X
IFN-Î³	B-X
level	B-X
and	B-X
ratio	B-X
of	B-X
the	B-X
INF-Î³/IL-4	B-X
.	B-X

Pretreatment	O
with	O
aspirin	O
and	O
nimesulide	O
inhibited	O
EC9706	O
and	O
EC109	O
cell	O
growth	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
accompanied	O
with	O
a	O
decrease	O
of	O
prostaglandin	B-Gene_or_gene_product
E2	I-Gene_or_gene_product
production	O
.	O

In	O
EC9706	O
cells	O
,	O
the	O
mechanism	O
of	O
aspirin	O
and	O
nimesulide	O
induced	O
growth	O
inhibition	O
was	O
a	O
consequence	O
of	O
cell	O
cycle	O
arrest	O
at	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
check	O
point	O
.	O

In	O
EC109	O
cells	O
,	O
growth	O
arrest	O
was	O
by	O
induction	O
of	O
apoptosis	O
,	O
associated	O
with	O
downregulation	O
of	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
but	O
not	O
Bax	B-Gene_or_gene_product
.	O

In	O
conclusion	O
,	O
aspirin	O
and	O
nimesulide	O
could	O
inhibit	O
cell	O
proliferation	O
and	O
induce	O
apoptosis	O
in	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
on	B-X
cell	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
and	B-X
its	B-X
potential	B-X
mechanisms	B-X
in	B-X
EC9706	B-X
and	B-X
EC109	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
EC9706	B-X
and	B-X
EC109	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
varying	B-X
concentrations	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
were	B-X
monitored	B-X
by	B-X
3-	B-X
(	B-X
4,5-dimethyl-thiazol-2yl	B-X
)	B-X
-2,5-diphenyltetrazolium	B-X
bromide	B-X
and	B-X
flow	B-X
cytometry	B-X
.	B-X
Pretreatment	B-X
with	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
inhibited	B-X
EC9706	B-X
and	B-X
EC109	B-X
cell	B-X
growth	B-X
in	B-X
a	B-X
time	B-X
and	B-X
dose-dependent	B-X
manner	B-X
,	B-X
accompanied	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
prostaglandin	B-X
E2	B-X
production	B-X
.	B-X
In	B-X
EC9706	B-X
cells	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
induced	B-X
growth	B-X
inhibition	B-X
was	B-X
a	B-X
consequence	B-X
of	B-X
cell	B-X
cycle	B-X
arrest	B-X
at	B-X
the	B-X
G	B-X
(	B-X
0	B-X
)	B-X
/G	B-X
(	B-X
1	B-X
)	B-X
check	B-X
point	B-X
.	B-X
In	B-X
EC109	B-X
cells	B-X
,	B-X
growth	B-X
arrest	B-X
was	B-X
by	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
downregulation	B-X
of	B-X
Bcl-2	B-X
,	B-X
but	B-X
not	B-X
Bax	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
could	B-X
inhibit	B-X
cell	B-X
proliferation	B-X
and	B-X
induce	B-X
apoptosis	B-X
in	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
Cyclooxygenase-2	B-X
inhibitor	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
agent	B-X
for	B-X
human	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X

Cyclooxygenase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
inhibitor	O
may	O
be	O
a	O
promising	O
therapeutic	O
agent	O
for	O
human	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
on	B-X
cell	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
and	B-X
its	B-X
potential	B-X
mechanisms	B-X
in	B-X
EC9706	B-X
and	B-X
EC109	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
EC9706	B-X
and	B-X
EC109	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
varying	B-X
concentrations	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
were	B-X
monitored	B-X
by	B-X
3-	B-X
(	B-X
4,5-dimethyl-thiazol-2yl	B-X
)	B-X
-2,5-diphenyltetrazolium	B-X
bromide	B-X
and	B-X
flow	B-X
cytometry	B-X
.	B-X
Reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
Western	B-X
blot	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
expression	B-X
of	B-X
Bcl-2	B-X
and	B-X
Bax	B-X
.	B-X
Prostaglandin	B-X
E2	B-X
production	B-X
was	B-X
measured	B-X
by	B-X
enzyme	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
.	B-X
Pretreatment	B-X
with	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
inhibited	B-X
EC9706	B-X
and	B-X
EC109	B-X
cell	B-X
growth	B-X
in	B-X
a	B-X
time	B-X
and	B-X
dose-dependent	B-X
manner	B-X
,	B-X
accompanied	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
prostaglandin	B-X
E2	B-X
production	B-X
.	B-X
In	B-X
EC9706	B-X
cells	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
induced	B-X
growth	B-X
inhibition	B-X
was	B-X
a	B-X
consequence	B-X
of	B-X
cell	B-X
cycle	B-X
arrest	B-X
at	B-X
the	B-X
G	B-X
(	B-X
0	B-X
)	B-X
/G	B-X
(	B-X
1	B-X
)	B-X
check	B-X
point	B-X
.	B-X
In	B-X
EC109	B-X
cells	B-X
,	B-X
growth	B-X
arrest	B-X
was	B-X
by	B-X
induction	B-X
of	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
downregulation	B-X
of	B-X
Bcl-2	B-X
,	B-X
but	B-X
not	B-X
Bax	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
aspirin	B-X
and	B-X
nimesulide	B-X
could	B-X
inhibit	B-X
cell	B-X
proliferation	B-X
and	B-X
induce	B-X
apoptosis	B-X
in	B-X
esophageal	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
.	B-X
Cyclooxygenase-2	B-X
inhibitor	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
agent	B-X
for	B-X
human	B-X
esophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X

Neurotrophin	B-Gene_or_gene_product
p75	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
p75NTR	B-Gene_or_gene_product
)	O
promotes	O
endothelial	O
cell	O
apoptosis	O
and	O
inhibits	O
angiogenesis	O
:	O
implications	O
for	O
diabetes	O
-	O
induced	O
impaired	O
neovascularization	O
in	O
ischemic	O
limb	O
muscles	O
.	O
<EOS>	B-X
Diabetes	B-X
impairs	B-X
endothelial	B-X
function	B-X
and	B-X
reparative	B-X
neovascularization	B-X
.	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
intramuscular	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
gene	B-X
delivery	B-X
impairs	B-X
neovascularization	B-X
and	B-X
blood	B-X
flow	B-X
recovery	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
limb	B-X
ischemia	B-X
.	B-X
These	B-X
disturbed	B-X
functions	B-X
are	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
signaling	B-X
mechanisms	B-X
implicated	B-X
in	B-X
EC	B-X
survival	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
depresses	B-X
the	B-X
VEGF-A/Akt/eNOS/NO	B-X
pathway	B-X
and	B-X
additionally	B-X
reduces	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
ITGB1	B-X
[	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
integrin	B-X
]	B-X
,	B-X
BIRC5	B-X
(	B-X
survivin	B-X
)	B-X
,	B-X
PTTG1	B-X
(	B-X
securin	B-X
)	B-X
and	B-X
VEZF1	B-X
.	B-X
Diabetic	B-X
mice	B-X
,	B-X
which	B-X
typically	B-X
show	B-X
impaired	B-X
postischemic	B-X
muscular	B-X
neovascularization	B-X
and	B-X
blood	B-X
perfusion	B-X
recovery	B-X
,	B-X
have	B-X
these	B-X
defects	B-X
corrected	B-X
by	B-X
intramuscular	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
form	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
newly	B-X
demonstrate	B-X
the	B-X
antiangiogenic	B-X
action	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
and	B-X
open	B-X
new	B-X
avenues	B-X
for	B-X
the	B-X
therapeutic	B-X
use	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
inhibition	B-X
to	B-X
combat	B-X
diabetes-induced	B-X
microvascular	B-X
liabilities	B-X
.	B-X

Diabetes	O
impairs	O
endothelial	O
function	O
and	O
reparative	O
neovascularization	O
.	O
<EOS>	B-X
Diabetes	B-X
impairs	B-X
cardioprotective	B-X
function	B-X
of	B-X
endothelial	B-X
progenitor	B-X
cell-derived	B-X
extracellular	B-X
vesicles	B-X
via	B-X
H3K9Ac	B-X
inhibition	B-X
.	B-X
Diabetes	B-X
mellitus	B-X
impairs	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
function	B-X
and	B-X
postischemic	B-X
reparative	B-X
neovascularization	B-X
by	B-X
molecular	B-X
mechanisms	B-X
that	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
Diabetes	B-X
impairs	B-X
endothelial	B-X
function	B-X
and	B-X
reparative	B-X
neovascularization	B-X
.	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
intramuscular	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
gene	B-X
delivery	B-X
impairs	B-X
neovascularization	B-X
and	B-X
blood	B-X
flow	B-X
recovery	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
limb	B-X
ischemia	B-X
.	B-X
These	B-X
disturbed	B-X
functions	B-X
are	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
signaling	B-X
mechanisms	B-X
implicated	B-X
in	B-X
EC	B-X
survival	B-X
and	B-X
angiogenesis	B-X
.	B-X
Diabetic	B-X
mice	B-X
,	B-X
which	B-X
typically	B-X
show	B-X
impaired	B-X
postischemic	B-X
muscular	B-X
neovascularization	B-X
and	B-X
blood	B-X
perfusion	B-X
recovery	B-X
,	B-X
have	B-X
these	B-X
defects	B-X
corrected	B-X
by	B-X
intramuscular	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
form	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
.	B-X

The	O
p75	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
neurotrophins	I-Gene_or_gene_product
(	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
)	O
,	O
which	O
is	O
scarcely	O
present	O
in	O
healthy	O
endothelial	O
cells	O
(	O
ECs	O
)	O
,	O
becomes	O
strongly	O
expressed	O
by	O
capillary	O
ECs	O
after	O
induction	O
of	O
peripheral	O
ischemia	O
in	O
type	O
-	O
1	O
diabetic	O
mice	O
.	O
<EOS>	B-X
Diabetes	B-X
impairs	B-X
endothelial	B-X
function	B-X
and	B-X
reparative	B-X
neovascularization	B-X
.	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
intramuscular	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
gene	B-X
delivery	B-X
impairs	B-X
neovascularization	B-X
and	B-X
blood	B-X
flow	B-X
recovery	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
limb	B-X
ischemia	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
depresses	B-X
the	B-X
VEGF-A/Akt/eNOS/NO	B-X
pathway	B-X
and	B-X
additionally	B-X
reduces	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
ITGB1	B-X
[	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
integrin	B-X
]	B-X
,	B-X
BIRC5	B-X
(	B-X
survivin	B-X
)	B-X
,	B-X
PTTG1	B-X
(	B-X
securin	B-X
)	B-X
and	B-X
VEZF1	B-X
.	B-X
Diabetic	B-X
mice	B-X
,	B-X
which	B-X
typically	B-X
show	B-X
impaired	B-X
postischemic	B-X
muscular	B-X
neovascularization	B-X
and	B-X
blood	B-X
perfusion	B-X
recovery	B-X
,	B-X
have	B-X
these	B-X
defects	B-X
corrected	B-X
by	B-X
intramuscular	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
form	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
newly	B-X
demonstrate	B-X
the	B-X
antiangiogenic	B-X
action	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
and	B-X
open	B-X
new	B-X
avenues	B-X
for	B-X
the	B-X
therapeutic	B-X
use	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
inhibition	B-X
to	B-X
combat	B-X
diabetes-induced	B-X
microvascular	B-X
liabilities	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
gene	O
transfer	O
-	O
induced	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
expression	O
impairs	O
the	O
survival	O
,	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
capacities	O
of	O
cultured	O
ECs	O
and	O
endothelial	O
progenitor	O
cells	O
(	O
EPCs	O
)	O
and	O
inhibits	O
angiogenesis	O
in	O
vitro	O
.	O
<EOS>	B-X
Diabetes	B-X
impairs	B-X
endothelial	B-X
function	B-X
and	B-X
reparative	B-X
neovascularization	B-X
.	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
intramuscular	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
gene	B-X
delivery	B-X
impairs	B-X
neovascularization	B-X
and	B-X
blood	B-X
flow	B-X
recovery	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
limb	B-X
ischemia	B-X
.	B-X
These	B-X
disturbed	B-X
functions	B-X
are	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
signaling	B-X
mechanisms	B-X
implicated	B-X
in	B-X
EC	B-X
survival	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
depresses	B-X
the	B-X
VEGF-A/Akt/eNOS/NO	B-X
pathway	B-X
and	B-X
additionally	B-X
reduces	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
ITGB1	B-X
[	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
integrin	B-X
]	B-X
,	B-X
BIRC5	B-X
(	B-X
survivin	B-X
)	B-X
,	B-X
PTTG1	B-X
(	B-X
securin	B-X
)	B-X
and	B-X
VEZF1	B-X
.	B-X
Diabetic	B-X
mice	B-X
,	B-X
which	B-X
typically	B-X
show	B-X
impaired	B-X
postischemic	B-X
muscular	B-X
neovascularization	B-X
and	B-X
blood	B-X
perfusion	B-X
recovery	B-X
,	B-X
have	B-X
these	B-X
defects	B-X
corrected	B-X
by	B-X
intramuscular	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
form	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
newly	B-X
demonstrate	B-X
the	B-X
antiangiogenic	B-X
action	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
and	B-X
open	B-X
new	B-X
avenues	B-X
for	B-X
the	B-X
therapeutic	B-X
use	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
inhibition	B-X
to	B-X
combat	B-X
diabetes-induced	B-X
microvascular	B-X
liabilities	B-X
.	B-X

Moreover	O
,	O
intramuscular	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
gene	O
delivery	O
impairs	O
neovascularization	O
and	O
blood	O
flow	O
recovery	O
in	O
a	O
mouse	O
model	O
of	O
limb	O
ischemia	O
.	O

These	O
disturbed	O
functions	O
are	O
associated	O
with	O
suppression	O
of	O
signaling	O
mechanisms	O
implicated	O
in	O
EC	O
survival	O
and	O
angiogenesis	O
.	O
<EOS>	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
disturbed	B-X
functions	B-X
are	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
signaling	B-X
mechanisms	B-X
implicated	B-X
in	B-X
EC	B-X
survival	B-X
and	B-X
angiogenesis	B-X
.	B-X

In	O
fact	O
,	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
depresses	O
the	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	I-Gene_or_gene_product
/	O
Akt	B-Gene_or_gene_product
/	O
eNOS	B-Gene_or_gene_product
/	O
NO	O
pathway	O
and	O
additionally	O
reduces	O
the	O
mRNA	O
levels	O
of	O
ITGB1	B-Gene_or_gene_product
[	O
beta	B-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	I-Gene_or_gene_product
]	O
,	O
BIRC5	B-Gene_or_gene_product
(	O
survivin	B-Gene_or_gene_product
)	O
,	O
PTTG1	B-Gene_or_gene_product
(	O
securin	B-Gene_or_gene_product
)	O
and	O
VEZF1	B-Gene_or_gene_product
.	O

Diabetic	O
mice	O
,	O
which	O
typically	O
show	O
impaired	O
postischemic	O
muscular	O
neovascularization	O
and	O
blood	O
perfusion	O
recovery	O
,	O
have	O
these	O
defects	O
corrected	O
by	O
intramuscular	O
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
.	O
<EOS>	B-X
Diabetes	B-X
impairs	B-X
endothelial	B-X
function	B-X
and	B-X
reparative	B-X
neovascularization	B-X
.	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
intramuscular	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
gene	B-X
delivery	B-X
impairs	B-X
neovascularization	B-X
and	B-X
blood	B-X
flow	B-X
recovery	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
limb	B-X
ischemia	B-X
.	B-X
These	B-X
disturbed	B-X
functions	B-X
are	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
signaling	B-X
mechanisms	B-X
implicated	B-X
in	B-X
EC	B-X
survival	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
depresses	B-X
the	B-X
VEGF-A/Akt/eNOS/NO	B-X
pathway	B-X
and	B-X
additionally	B-X
reduces	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
ITGB1	B-X
[	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
integrin	B-X
]	B-X
,	B-X
BIRC5	B-X
(	B-X
survivin	B-X
)	B-X
,	B-X
PTTG1	B-X
(	B-X
securin	B-X
)	B-X
and	B-X
VEZF1	B-X
.	B-X
Diabetic	B-X
mice	B-X
,	B-X
which	B-X
typically	B-X
show	B-X
impaired	B-X
postischemic	B-X
muscular	B-X
neovascularization	B-X
and	B-X
blood	B-X
perfusion	B-X
recovery	B-X
,	B-X
have	B-X
these	B-X
defects	B-X
corrected	B-X
by	B-X
intramuscular	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
form	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
newly	B-X
demonstrate	B-X
the	B-X
antiangiogenic	B-X
action	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
and	B-X
open	B-X
new	B-X
avenues	B-X
for	B-X
the	B-X
therapeutic	B-X
use	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
inhibition	B-X
to	B-X
combat	B-X
diabetes-induced	B-X
microvascular	B-X
liabilities	B-X
.	B-X

Collectively	O
,	O
our	O
data	O
newly	O
demonstrate	O
the	O
antiangiogenic	O
action	O
of	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
and	O
open	O
new	O
avenues	O
for	O
the	O
therapeutic	O
use	O
of	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
inhibition	O
to	O
combat	O
diabetes	O
-	O
induced	O
microvascular	O
liabilities	O
.	O
<EOS>	B-X
The	B-X
p75	B-X
receptor	B-X
of	B-X
neurotrophins	B-X
(	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
)	B-X
,	B-X
which	B-X
is	B-X
scarcely	B-X
present	B-X
in	B-X
healthy	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
,	B-X
becomes	B-X
strongly	B-X
expressed	B-X
by	B-X
capillary	B-X
ECs	B-X
after	B-X
induction	B-X
of	B-X
peripheral	B-X
ischemia	B-X
in	B-X
type-1	B-X
diabetic	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
gene	B-X
transfer-induced	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
expression	B-X
impairs	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
adhesion	B-X
capacities	B-X
of	B-X
cultured	B-X
ECs	B-X
and	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
(	B-X
EPCs	B-X
)	B-X
and	B-X
inhibits	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
intramuscular	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
gene	B-X
delivery	B-X
impairs	B-X
neovascularization	B-X
and	B-X
blood	B-X
flow	B-X
recovery	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
limb	B-X
ischemia	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
depresses	B-X
the	B-X
VEGF-A/Akt/eNOS/NO	B-X
pathway	B-X
and	B-X
additionally	B-X
reduces	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
ITGB1	B-X
[	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
integrin	B-X
]	B-X
,	B-X
BIRC5	B-X
(	B-X
survivin	B-X
)	B-X
,	B-X
PTTG1	B-X
(	B-X
securin	B-X
)	B-X
and	B-X
VEZF1	B-X
.	B-X
Diabetic	B-X
mice	B-X
,	B-X
which	B-X
typically	B-X
show	B-X
impaired	B-X
postischemic	B-X
muscular	B-X
neovascularization	B-X
and	B-X
blood	B-X
perfusion	B-X
recovery	B-X
,	B-X
have	B-X
these	B-X
defects	B-X
corrected	B-X
by	B-X
intramuscular	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
form	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
newly	B-X
demonstrate	B-X
the	B-X
antiangiogenic	B-X
action	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
and	B-X
open	B-X
new	B-X
avenues	B-X
for	B-X
the	B-X
therapeutic	B-X
use	B-X
of	B-X
p75	B-X
(	B-X
NTR	B-X
)	B-X
inhibition	B-X
to	B-X
combat	B-X
diabetes-induced	B-X
microvascular	B-X
liabilities	B-X
.	B-X

Tumor	O
endothelial	O
cell	O
targeted	O
cyclic	O
RGD	O
-	O
modified	O
heparin	O
derivative	O
:	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O
<EOS>	B-X
We	B-X
prepared	B-X
tumor	B-X
endothelium	B-X
targeted	B-X
cRGD-modified	B-X
heparin	B-X
derivative	B-X
(	B-X
cRGD-HL	B-X
)	B-X
by	B-X
coupling	B-X
heparin-lithocholic	B-X
acid	B-X
(	B-X
HL	B-X
)	B-X
with	B-X
cRGDyK	B-X
,	B-X
and	B-X
evaluated	B-X
inhibition	B-X
effects	B-X
of	B-X
cRGD-HL	B-X
on	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X

PURPOSE	O
:	O
We	O
prepared	O
tumor	O
endothelium	O
targeted	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
(	O
cRGD	O
-	O
HL	O
)	O
by	O
coupling	O
heparin	O
-	O
lithocholic	O
acid	O
(	O
HL	O
)	O
with	O
cRGDyK	O
,	O
and	O
evaluated	O
inhibition	O
effects	O
of	O
cRGD	O
-	O
HL	O
on	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O
<EOS>	B-X
We	B-X
prepared	B-X
tumor	B-X
endothelium	B-X
targeted	B-X
cRGD-modified	B-X
heparin	B-X
derivative	B-X
(	B-X
cRGD-HL	B-X
)	B-X
by	B-X
coupling	B-X
heparin-lithocholic	B-X
acid	B-X
(	B-X
HL	B-X
)	B-X
with	B-X
cRGDyK	B-X
,	B-X
and	B-X
evaluated	B-X
inhibition	B-X
effects	B-X
of	B-X
cRGD-HL	B-X
on	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X

METHODS	O
:	O
To	O
evaluate	O
antiangiogenic	O
activity	O
of	O
cRGD	O
-	O
HL	O
,	O
we	O
performed	O
tests	O
on	O
endothelial	O
cell	O
adhesion	O
and	O
migration	O
to	O
vitronectin	B-Gene_or_gene_product
,	O
tube	O
formation	O
,	O
binding	O
affinity	O
to	O
purified	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	I-Gene_or_gene_product
,	O
and	O
in	O
vivo	O
Matrigel	O
plug	O
assay	O
.	O

The	O
antitumor	O
activity	O
of	O
cRGD	O
-	O
HL	O
was	O
also	O
evaluated	O
by	O
monitoring	O
tumor	O
growth	O
and	O
microvessel	O
formation	O
in	O
squamous	O
cell	O
carcinoma	O
(	O
SCC7	O
)	O
tumor	O
.	O
<EOS>	B-X
We	B-X
prepared	B-X
tumor	B-X
endothelium	B-X
targeted	B-X
cRGD-modified	B-X
heparin	B-X
derivative	B-X
(	B-X
cRGD-HL	B-X
)	B-X
by	B-X
coupling	B-X
heparin-lithocholic	B-X
acid	B-X
(	B-X
HL	B-X
)	B-X
with	B-X
cRGDyK	B-X
,	B-X
and	B-X
evaluated	B-X
inhibition	B-X
effects	B-X
of	B-X
cRGD-HL	B-X
on	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X

RESULTS	O
:	O
The	O
cRGD	O
-	O
HL	O
significantly	O
inhibited	O
adhesion	O
and	O
migration	O
of	O
endothelial	O
cells	O
to	O
vitronectin	B-Gene_or_gene_product
,	O
and	O
tubular	O
structures	O
of	O
endothelial	O
cells	O
.	O
<EOS>	B-X
We	B-X
prepared	B-X
tumor	B-X
endothelium	B-X
targeted	B-X
cRGD-modified	B-X
heparin	B-X
derivative	B-X
(	B-X
cRGD-HL	B-X
)	B-X
by	B-X
coupling	B-X
heparin-lithocholic	B-X
acid	B-X
(	B-X
HL	B-X
)	B-X
with	B-X
cRGDyK	B-X
,	B-X
and	B-X
evaluated	B-X
inhibition	B-X
effects	B-X
of	B-X
cRGD-HL	B-X
on	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X

Compared	O
to	O
cRGDyK	O
and	O
HL	O
,	O
cRGD	O
-	O
HL	O
has	O
high	O
binding	O
affinity	O
to	O
purified	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	I-Gene_or_gene_product
.	O

The	O
enhanced	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
confirmed	O
in	O
Matrigel	O
assay	O
by	O
showing	O
the	O
significant	O
inhibition	O
of	O
bFGF	B-Gene_or_gene_product
-	O
driven	O
angiogenesis	O
and	O
blood	O
vessel	O
formation	O
.	O
<EOS>	B-X
We	B-X
prepared	B-X
tumor	B-X
endothelium	B-X
targeted	B-X
cRGD-modified	B-X
heparin	B-X
derivative	B-X
(	B-X
cRGD-HL	B-X
)	B-X
by	B-X
coupling	B-X
heparin-lithocholic	B-X
acid	B-X
(	B-X
HL	B-X
)	B-X
with	B-X
cRGDyK	B-X
,	B-X
and	B-X
evaluated	B-X
inhibition	B-X
effects	B-X
of	B-X
cRGD-HL	B-X
on	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X

It	O
was	O
thought	O
that	O
potent	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
probably	O
due	O
to	O
the	O
interference	O
of	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	O
mediated	O
interaction	O
,	O
resulting	O
in	O
the	O
enhanced	O
antitumoral	O
activity	O
against	O
SCC7	O
tumor	O
.	O

CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
enhanced	O
anti	O
-	O
angiotherapeutic	O
effects	O
against	O
solid	O
tumor	O
,	O
and	O
therefore	O
,	O
it	O
could	O
be	O
applied	O
to	O
treat	O
various	O
cancers	O
and	O
angiogenic	O
diseases	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O
<EOS>	B-X
We	B-X
prepared	B-X
tumor	B-X
endothelium	B-X
targeted	B-X
cRGD-modified	B-X
heparin	B-X
derivative	B-X
(	B-X
cRGD-HL	B-X
)	B-X
by	B-X
coupling	B-X
heparin-lithocholic	B-X
acid	B-X
(	B-X
HL	B-X
)	B-X
with	B-X
cRGDyK	B-X
,	B-X
and	B-X
evaluated	B-X
inhibition	B-X
effects	B-X
of	B-X
cRGD-HL	B-X
on	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X

[	O
Inhibitory	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	B-Gene_or_gene_product
gene	O
transfer	O
on	O
transplanted	O
lung	O
carcinoma	O
in	O
mice	O
]	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
adenovirus-mediated	B-X
endostatin	B-X
gene	B-X
transfer	B-X
on	B-X
transplanted	B-X
lung	B-X
cancer	B-X
in	B-X
mice	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	B-Gene_or_gene_product
gene	O
transfer	O
on	O
transplanted	O
lung	O
cancer	O
in	O
mice	O
and	O
its	O
mechanism	O
of	O
action	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
adenovirus-mediated	B-X
endostatin	B-X
gene	B-X
transfer	B-X
on	B-X
transplanted	B-X
lung	B-X
cancer	B-X
in	B-X
mice	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X

METHODS	O
:	O
Transplant	O
tumor	O
model	O
was	O
induced	O
by	O
subcutaneous	O
inoculation	O
of	O
2	O
x	O
10	O
(	O
6	O
)	O
Lewis	O
lung	O
cancer	O
(	O
LLC	O
)	O
cells	O
into	O
the	O
back	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
mice	O
were	O
treated	O
by	O
intratumoral	O
injection	O
of	O
2	O
x	O
10	O
(	O
9	O
)	O
pfu	O
Ad	B-Gene_or_gene_product
-	I-Gene_or_gene_product
mEndostatin	I-Gene_or_gene_product
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
adenovirus-mediated	B-X
endostatin	B-X
gene	B-X
transfer	B-X
on	B-X
transplanted	B-X
lung	B-X
cancer	B-X
in	B-X
mice	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X

The	O
expression	O
of	O
endostatin	B-Gene_or_gene_product
in	O
situ	O
and	O
its	O
maintaining	O
time	O
were	O
detected	O
by	O
immunohistochemistry	O
and	O
Western	O
Blot	O
,	O
respectively	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
adenovirus-mediated	B-X
endostatin	B-X
gene	B-X
transfer	B-X
on	B-X
transplanted	B-X
lung	B-X
cancer	B-X
in	B-X
mice	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X

The	O
endostatin	B-Gene_or_gene_product
level	O
in	O
serum	O
was	O
determined	O
by	O
ELISA	O
.	O
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
relationship	B-X
between	B-X
serum	B-X
endostatin	B-X
(	B-X
ES	B-X
)	B-X
and	B-X
coronary	B-X
artery	B-X
calcification	B-X
(	B-X
CAC	B-X
)	B-X
in	B-X
type	B-X
2	B-X
diabetic	B-X
(	B-X
T2DM	B-X
)	B-X
patients	B-X
.	B-X
Increased	B-X
levels	B-X
of	B-X
tumor	B-X
angiogenesis	B-X
have	B-X
been	B-X
demonstrated	B-X
in	B-X
variety	B-X
of	B-X
solid	B-X
tumors	B-X
and	B-X
hematological	B-X
malignancies	B-X
including	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
serum	B-X
level	B-X
of	B-X
endostatin	B-X
in	B-X
newly	B-X
diagnosed	B-X
patients	B-X
with	B-X
AML	B-X
before	B-X
chemotherapy	B-X
and	B-X
after	B-X
achieving	B-X
complete	B-X
remission	B-X
(	B-X
CR	B-X
)	B-X
.	B-X
Endostatin	B-X
levels	B-X
were	B-X
measured	B-X
using	B-X
ChemiKine	B-X
sandwich	B-X
ELISA	B-X
kit	B-X
(	B-X
Chemicon	B-X
International	B-X
)	B-X
.	B-X
Endostatin	B-X
serum	B-X
levels	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
untreated	B-X
AML	B-X
patients	B-X
than	B-X
in	B-X
the	B-X
normal	B-X
controls	B-X
.	B-X
In	B-X
AML	B-X
patients	B-X
baseline	B-X
endostatin	B-X
levels	B-X
were	B-X
significantly	B-X
lower	B-X
than	B-X
in	B-X
CR	B-X
.	B-X
We	B-X
did	B-X
not	B-X
found	B-X
any	B-X
correlation	B-X
between	B-X
white	B-X
cell	B-X
count	B-X
or	B-X
percentage	B-X
of	B-X
blasts	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
and	B-X
endostatin	B-X
level	B-X
.	B-X
Moreover	B-X
endostatin	B-X
levels	B-X
did	B-X
not	B-X
differ	B-X
statistically	B-X
among	B-X
AML	B-X
FAB	B-X
subgroups	B-X
.	B-X
Increased	B-X
endostatin	B-X
plasma	B-X
levels	B-X
may	B-X
reflect	B-X
intensity	B-X
of	B-X
inhibition	B-X
of	B-X
angiogenesis	B-X
and	B-X
may	B-X
by	B-X
useful	B-X
in	B-X
prognosis	B-X
of	B-X
CR	B-X
in	B-X
AML	B-X
.	B-X

The	O
inhibition	O
of	O
tumor	O
growth	O
and	O
changes	O
of	O
survival	O
were	O
recorded	O
and	O
the	O
microvessel	O
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
histochemical	O
stainingwith	O
CD31	B-Gene_or_gene_product
and	O
CD105	B-Gene_or_gene_product
antibodies	I-Gene_or_gene_product
.	O

The	O
tumor	O
apoptosis	O
was	O
observed	O
by	O
electron	O
microscopy	O
.	O
<EOS>	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
chemoresistance	B-X
of	B-X
various	B-X
tumors	B-X
.	B-X
The	B-X
present	B-X
study	B-X
assessed	B-X
the	B-X
antitumor	B-X
effect	B-X
of	B-X
artesunate	B-X
(	B-X
ART	B-X
)	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
well	B-X
as	B-X
its	B-X
underlying	B-X
mechanism	B-X
of	B-X
action	B-X
in	B-X
HCT116	B-X
colon	B-X
cancer	B-X
cells	B-X
.	B-X
An	B-X
MTT	B-X
assay	B-X
,	B-X
DAPI	B-X
staining	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
western	B-X
blotting	B-X
,	B-X
immunohistochemistry	B-X
,	B-X
transmission	B-X
electron	B-X
microscopy	B-X
and	B-X
TUNEL	B-X
assay	B-X
were	B-X
performed	B-X
to	B-X
study	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
the	B-X
antitumor	B-X
effects	B-X
of	B-X
ART	B-X
in	B-X
HCT116	B-X
colon	B-X
cancer	B-X
cells	B-X
.	B-X
ART	B-X
was	B-X
observed	B-X
to	B-X
inhibit	B-X
proliferation	B-X
by	B-X
inducing	B-X
the	B-X
apoptosis	B-X
of	B-X
HCT116	B-X
cells	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Flow	B-X
cytometry	B-X
analysis	B-X
demonstrated	B-X
that	B-X
treatment	B-X
with	B-X
2	B-X
and	B-X
4	B-X
Âµg/ml	B-X
ART	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
early	B-X
apoptosis	B-X
in	B-X
22.7	B-X
and	B-X
33.8	B-X
%	B-X
of	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
the	B-X
xenograft	B-X
tumors	B-X
of	B-X
BALB/c	B-X
nude	B-X
mice	B-X
,	B-X
TUNELâpositive	B-X
cells	B-X
increased	B-X
in	B-X
the	B-X
ART	B-X
group	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
normal	B-X
saline	B-X
group	B-X
.	B-X
Notably	B-X
,	B-X
pharmacological	B-X
blockade	B-X
of	B-X
autophagy	B-X
activation	B-X
using	B-X
hydroxychloroquine	B-X
markedly	B-X
enhanced	B-X
ARTâinduced	B-X
apoptosis	B-X
and	B-X
increased	B-X
the	B-X
protein	B-X
levels	B-X
of	B-X
cleaved	B-X
caspase	B-X
3	B-X
and	B-X
PARP	B-X
,	B-X
while	B-X
decreasing	B-X
the	B-X
levels	B-X
of	B-X
LC3	B-X
and	B-X
beclinâ1	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
the	B-X
ARTâinduced	B-X
autophagy	B-X
may	B-X
have	B-X
a	B-X
cytoprotective	B-X
effect	B-X
by	B-X
suppressing	B-X
apoptosis	B-X
.	B-X

RESULTS	O
:	O
In	O
comparison	O
with	O
controls	O
,	O
intratumoral	O
injection	O
of	O
Ad	B-Gene_or_gene_product
-	I-Gene_or_gene_product
mEndostatin	I-Gene_or_gene_product
significantly	O
inhibited	O
the	O
tumor	O
growth	O
and	O
metastasis	O
,	O
and	O
prolonged	O
the	O
survival	O
rate	O
of	O
mice	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Strong	O
positive	O
expression	O
of	O
mEndostatin	B-Gene_or_gene_product
was	O
seen	O
in	O
the	O
tumor	O
tissue	O
after	O
injection	O
of	O
Ad	B-Gene_or_gene_product
-	I-Gene_or_gene_product
mEndostatin	I-Gene_or_gene_product
,	O
immunhistochemically	O
ostained	O
by	O
mouse	O
endostatin	B-Gene_or_gene_product
monoclonal	I-Gene_or_gene_product
antibody	I-Gene_or_gene_product
,	O
while	O
the	O
control	O
groups	O
showed	O
only	O
very	O
low	O
expression	O
or	O
absence	O
.	O
<EOS>	B-X
Childhood	B-X
absence	B-X
epilepsy	B-X
(	B-X
CAE	B-X
)	B-X
is	B-X
a	B-X
common	B-X
pediatric	B-X
generalized	B-X
epileptic	B-X
syndrome	B-X
.	B-X
Traditional	B-X
anticonvulsant	B-X
therapy	B-X
of	B-X
CAE	B-X
that	B-X
is	B-X
still	B-X
in	B-X
use	B-X
is	B-X
based	B-X
on	B-X
three	B-X
antiepileptic	B-X
drugs	B-X
:	B-X
ethosuximide	B-X
which	B-X
is	B-X
the	B-X
drug	B-X
of	B-X
choice	B-X
,	B-X
followed	B-X
by	B-X
valproic	B-X
acid	B-X
and	B-X
lamotrigine	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
absence	B-X
seizures	B-X
that	B-X
are	B-X
refractory	B-X
to	B-X
traditional	B-X
treatment	B-X
,	B-X
other	B-X
antiepileptic	B-X
drugs	B-X
may	B-X
be	B-X
introduced	B-X
such	B-X
as	B-X
levetiracetam	B-X
,	B-X
topiramate	B-X
and	B-X
zonisamide	B-X
.	B-X
Idiopathic	B-X
generalized	B-X
epilepsies	B-X
(	B-X
IGE	B-X
)	B-X
are	B-X
characterized	B-X
by	B-X
normal	B-X
background	B-X
EEG	B-X
activity	B-X
and	B-X
generalized	B-X
interictal	B-X
spike-and-wave	B-X
discharges	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
evidence	B-X
of	B-X
brain	B-X
lesion	B-X
.	B-X
In	B-X
childhood	B-X
and	B-X
juvenile	B-X
absence	B-X
epilepsies	B-X
,	B-X
by	B-X
definition	B-X
,	B-X
all	B-X
patients	B-X
manifest	B-X
absence	B-X
seizures	B-X
associated	B-X
with	B-X
an	B-X
EEG	B-X
pattern	B-X
of	B-X
generalized	B-X
spike-wave	B-X
(	B-X
GSW	B-X
)	B-X
discharges	B-X
.	B-X

Serum	O
endostatin	B-Gene_or_gene_product
concentration	O
was	O
1540	O
+	O
/	O
-	O
560	O
ng	O
/	O
ml	O
at	O
the	O
second	O
week	O
of	O
administration	O
,	O
the	O
expression	O
of	O
endostatin	B-Gene_or_gene_product
diminished	O
a	O
month	O
later	O
.	O

The	O
microvessel	O
density	O
(	O
MVD	O
)	O
)	O
decreased	O
from	O
42	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
10	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
2	O
per	O
x	O
200	O
magnificetion	O
microscopic	O
field	O
by	O
CD10	B-Gene_or_gene_product
staining	O
and	O
from	O
68	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
5	O
to	O
37	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
6	O
by	O
CD31	B-Gene_or_gene_product
staining	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

More	O
apoptotic	O
tumor	O
cells	O
were	O
seen	O
under	O
the	O
transmission	O
electron	O
microscope	O
.	O
<EOS>	B-X
Fructose-1,6-bisphosphatase	B-X
1	B-X
,	B-X
a	B-X
rate-limiting	B-X
enzyme	B-X
in	B-X
gluconeogenesis	B-X
,	B-X
was	B-X
recently	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
fructose-1,6-bisphosphatase	B-X
1	B-X
on	B-X
mitophagy	B-X
and	B-X
apoptosis	B-X
as	B-X
well	B-X
as	B-X
their	B-X
underlying	B-X
mechanisms	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
levels	B-X
of	B-X
cellular	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
apoptotic	B-X
index	B-X
were	B-X
detected	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Subcellular	B-X
structures	B-X
were	B-X
observed	B-X
under	B-X
a	B-X
transmission	B-X
electron	B-X
microscope	B-X
.	B-X
Additionally	B-X
,	B-X
fructose-1,6-bisphosphatase	B-X
1	B-X
promoted	B-X
cell	B-X
apoptosis	B-X
by	B-X
upregulating	B-X
the	B-X
levels	B-X
of	B-X
intracellular	B-X
ROS	B-X
and	B-X
expression	B-X
of	B-X
pro-apoptotic	B-X
proteins	B-X
such	B-X
as	B-X
cleaved	B-X
PARP	B-X
,	B-X
cleaved	B-X
Caspase	B-X
3	B-X
,	B-X
and	B-X
Bax	B-X
and	B-X
downregulating	B-X
the	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
proteins	B-X
such	B-X
as	B-X
PARP	B-X
,	B-X
Caspase	B-X
3	B-X
,	B-X
and	B-X
Bcl-2	B-X
.	B-X

CONCLUSION	O
:	O
Endostatin	B-Gene_or_gene_product
gene	O
therapy	O
mediated	O
by	O
adenoviral	O
vector	O
efficiently	O
induces	O
expression	O
of	O
endostatin	B-Gene_or_gene_product
in	O
vivo	O
,	O
and	O
inhibits	O
the	O
growth	O
and	O
metastasis	O
of	O
tumor	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
adenovirus-mediated	B-X
endostatin	B-X
gene	B-X
transfer	B-X
on	B-X
transplanted	B-X
lung	B-X
cancer	B-X
in	B-X
mice	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X

It	O
is	O
concluded	O
that	O
its	O
action	O
is	O
targeted	O
to	O
tumor	O
neovasculature	O
and	O
the	O
mechanism	O
is	O
inhibition	O
of	O
tumor	O
angiogenesis	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
adenovirus-mediated	B-X
endostatin	B-X
gene	B-X
transfer	B-X
on	B-X
transplanted	B-X
lung	B-X
cancer	B-X
in	B-X
mice	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X

The	O
role	O
of	O
p53	B-Gene_or_gene_product
in	O
pigmentation	O
,	O
tanning	O
and	O
melanoma	O
.	O
<EOS>	B-X
p53	B-X
has	B-X
a	B-X
central	B-X
role	B-X
in	B-X
skin	B-X
pigmentation	B-X
and	B-X
may	B-X
impact	B-X
on	B-X
melanoma	B-X
at	B-X
all	B-X
stages	B-X
,	B-X
however	B-X
,	B-X
as	B-X
it	B-X
's	B-X
mutation	B-X
frequency	B-X
in	B-X
melanoma	B-X
is	B-X
low	B-X
,	B-X
it	B-X
's	B-X
role	B-X
has	B-X
been	B-X
somewhat	B-X
under-appreciated	B-X
.	B-X
During	B-X
normal	B-X
skin	B-X
function	B-X
,	B-X
p53	B-X
in	B-X
the	B-X
keratinocyte	B-X
is	B-X
a	B-X
transducer	B-X
of	B-X
the	B-X
skin	B-X
tanning	B-X
signal	B-X
and	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
what	B-X
is	B-X
effectively	B-X
a	B-X
keratinocyte-melanocyte	B-X
signaling	B-X
cycle	B-X
that	B-X
regulates	B-X
skin	B-X
pigmentation	B-X
.	B-X
It	B-X
is	B-X
clear	B-X
that	B-X
this	B-X
cycle	B-X
functions	B-X
optimally	B-X
in	B-X
skin	B-X
of	B-X
dark	B-X
pigmentation	B-X
.	B-X
The	B-X
cell	B-X
autonomous	B-X
function	B-X
of	B-X
p53	B-X
in	B-X
melanocytes	B-X
is	B-X
not	B-X
well	B-X
described	B-X
,	B-X
however	B-X
,	B-X
the	B-X
balance	B-X
of	B-X
the	B-X
evidence	B-X
suggests	B-X
that	B-X
p53	B-X
is	B-X
an	B-X
effective	B-X
tumor	B-X
suppressor	B-X
and	B-X
the	B-X
myriad	B-X
of	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
p53	B-X
pathway	B-X
may	B-X
be	B-X
dysregulated	B-X
in	B-X
tumors	B-X
attests	B-X
to	B-X
it	B-X
importance	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
outline	B-X
the	B-X
known	B-X
mechanisms	B-X
that	B-X
impair	B-X
p53	B-X
itself	B-X
and	B-X
its	B-X
immediate	B-X
regulators	B-X
or	B-X
target	B-X
genes	B-X
during	B-X
melanomagenesis	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
it	B-X
is	B-X
clear	B-X
that	B-X
p53	B-X
disruptions	B-X
may	B-X
relate	B-X
directly	B-X
to	B-X
a	B-X
patient	B-X
's	B-X
prognosis	B-X
.	B-X

p53	B-Gene_or_gene_product
has	O
a	O
central	O
role	O
in	O
skin	O
pigmentation	O
and	O
may	O
impact	O
on	O
melanoma	O
at	O
all	O
stages	O
,	O
however	O
,	O
as	O
it	O
'	O
s	O
mutation	O
frequency	O
in	O
melanoma	O
is	O
low	O
,	O
it	O
'	O
s	O
role	O
has	O
been	O
somewhat	O
under	O
-	O
appreciated	O
.	O

During	O
normal	O
skin	O
function	O
,	O
p53	B-Gene_or_gene_product
in	O
the	O
keratinocyte	O
is	O
a	O
transducer	O
of	O
the	O
skin	O
tanning	O
signal	O
and	O
an	O
essential	O
component	O
of	O
what	O
is	O
effectively	O
a	O
keratinocyte	O
-	O
melanocyte	O
signaling	O
cycle	O
that	O
regulates	O
skin	O
pigmentation	O
.	O

It	O
is	O
clear	O
that	O
this	O
cycle	O
functions	O
optimally	O
in	O
skin	O
of	O
dark	O
pigmentation	O
.	O
<EOS>	B-X
p53	B-X
has	B-X
a	B-X
central	B-X
role	B-X
in	B-X
skin	B-X
pigmentation	B-X
and	B-X
may	B-X
impact	B-X
on	B-X
melanoma	B-X
at	B-X
all	B-X
stages	B-X
,	B-X
however	B-X
,	B-X
as	B-X
it	B-X
's	B-X
mutation	B-X
frequency	B-X
in	B-X
melanoma	B-X
is	B-X
low	B-X
,	B-X
it	B-X
's	B-X
role	B-X
has	B-X
been	B-X
somewhat	B-X
under-appreciated	B-X
.	B-X
During	B-X
normal	B-X
skin	B-X
function	B-X
,	B-X
p53	B-X
in	B-X
the	B-X
keratinocyte	B-X
is	B-X
a	B-X
transducer	B-X
of	B-X
the	B-X
skin	B-X
tanning	B-X
signal	B-X
and	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
what	B-X
is	B-X
effectively	B-X
a	B-X
keratinocyte-melanocyte	B-X
signaling	B-X
cycle	B-X
that	B-X
regulates	B-X
skin	B-X
pigmentation	B-X
.	B-X
It	B-X
is	B-X
clear	B-X
that	B-X
this	B-X
cycle	B-X
functions	B-X
optimally	B-X
in	B-X
skin	B-X
of	B-X
dark	B-X
pigmentation	B-X
.	B-X
When	B-X
melanin	B-X
biosynthesis	B-X
is	B-X
genetically	B-X
disrupted	B-X
in	B-X
skin	B-X
of	B-X
white	B-X
complexion	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
this	B-X
cycle	B-X
operates	B-X
as	B-X
a	B-X
promoter	B-X
of	B-X
melanocyte	B-X
proliferation	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
it	B-X
is	B-X
clear	B-X
that	B-X
p53	B-X
disruptions	B-X
may	B-X
relate	B-X
directly	B-X
to	B-X
a	B-X
patient	B-X
's	B-X
prognosis	B-X
.	B-X

When	O
melanin	O
biosynthesis	O
is	O
genetically	O
disrupted	O
in	O
skin	O
of	O
white	O
complexion	O
,	O
we	O
propose	O
that	O
this	O
cycle	O
operates	O
as	O
a	O
promoter	O
of	O
melanocyte	O
proliferation	O
.	O
<EOS>	B-X
p53	B-X
has	B-X
a	B-X
central	B-X
role	B-X
in	B-X
skin	B-X
pigmentation	B-X
and	B-X
may	B-X
impact	B-X
on	B-X
melanoma	B-X
at	B-X
all	B-X
stages	B-X
,	B-X
however	B-X
,	B-X
as	B-X
it	B-X
's	B-X
mutation	B-X
frequency	B-X
in	B-X
melanoma	B-X
is	B-X
low	B-X
,	B-X
it	B-X
's	B-X
role	B-X
has	B-X
been	B-X
somewhat	B-X
under-appreciated	B-X
.	B-X
During	B-X
normal	B-X
skin	B-X
function	B-X
,	B-X
p53	B-X
in	B-X
the	B-X
keratinocyte	B-X
is	B-X
a	B-X
transducer	B-X
of	B-X
the	B-X
skin	B-X
tanning	B-X
signal	B-X
and	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
what	B-X
is	B-X
effectively	B-X
a	B-X
keratinocyte-melanocyte	B-X
signaling	B-X
cycle	B-X
that	B-X
regulates	B-X
skin	B-X
pigmentation	B-X
.	B-X
It	B-X
is	B-X
clear	B-X
that	B-X
this	B-X
cycle	B-X
functions	B-X
optimally	B-X
in	B-X
skin	B-X
of	B-X
dark	B-X
pigmentation	B-X
.	B-X
When	B-X
melanin	B-X
biosynthesis	B-X
is	B-X
genetically	B-X
disrupted	B-X
in	B-X
skin	B-X
of	B-X
white	B-X
complexion	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
this	B-X
cycle	B-X
operates	B-X
as	B-X
a	B-X
promoter	B-X
of	B-X
melanocyte	B-X
proliferation	B-X
.	B-X
The	B-X
cell	B-X
autonomous	B-X
function	B-X
of	B-X
p53	B-X
in	B-X
melanocytes	B-X
is	B-X
not	B-X
well	B-X
described	B-X
,	B-X
however	B-X
,	B-X
the	B-X
balance	B-X
of	B-X
the	B-X
evidence	B-X
suggests	B-X
that	B-X
p53	B-X
is	B-X
an	B-X
effective	B-X
tumor	B-X
suppressor	B-X
and	B-X
the	B-X
myriad	B-X
of	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
p53	B-X
pathway	B-X
may	B-X
be	B-X
dysregulated	B-X
in	B-X
tumors	B-X
attests	B-X
to	B-X
it	B-X
importance	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X

The	O
cell	O
autonomous	O
function	O
of	O
p53	B-Gene_or_gene_product
in	O
melanocytes	O
is	O
not	O
well	O
described	O
,	O
however	O
,	O
the	O
balance	O
of	O
the	O
evidence	O
suggests	O
that	O
p53	B-Gene_or_gene_product
is	O
an	O
effective	O
tumor	O
suppressor	O
and	O
the	O
myriad	O
of	O
mechanisms	O
by	O
which	O
the	O
p53	B-Gene_or_gene_product
pathway	O
may	O
be	O
dysregulated	O
in	O
tumors	O
attests	O
to	O
it	O
importance	O
as	O
a	O
tumor	O
suppressor	O
.	O
<EOS>	B-X
S1	B-X
Health	B-X
literacy	B-X
and	B-X
health	B-X
education	B-X
in	B-X
adolescence	B-X
Catarina	B-X
Cardoso	B-X
TomÃ¡s	B-X
S2	B-X
The	B-X
effect	B-X
of	B-X
a	B-X
walking	B-X
program	B-X
on	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
well-being	B-X
of	B-X
people	B-X
with	B-X
schizophrenia	B-X
Emanuel	B-X
Oliveira	B-X
,	B-X
D.	B-X
Sousa	B-X
,	B-X
M.	B-X
Uba-Chupel	B-X
,	B-X
G.	B-X
Furtado	B-X
,	B-X
C.	B-X
Rocha	B-X
,	B-X
A.	B-X
Teixeira	B-X
,	B-X
P.	B-X
Ferreira	B-X
S3	B-X
Diagnosis	B-X
and	B-X
innovative	B-X
treatments	B-X
-	B-X
the	B-X
way	B-X
to	B-X
a	B-X
better	B-X
medical	B-X
practice	B-X
Celeste	B-X
Alves	B-X
S4	B-X
Simulation-based	B-X
learning	B-X
and	B-X
how	B-X
it	B-X
is	B-X
a	B-X
high	B-X
contribution	B-X
Stefan	B-X
Gisin	B-X
S5	B-X
Formative	B-X
research	B-X
about	B-X
acceptability	B-X
,	B-X
utilization	B-X
and	B-X
promotion	B-X
of	B-X
a	B-X
home	B-X
fortification	B-X
programme	B-X
with	B-X
micronutrient	B-X
powders	B-X
(	B-X
MNP	B-X
)	B-X
in	B-X
the	B-X
Autonomous	B-X
Region	B-X
of	B-X
PrÃ­ncipe	B-X
,	B-X
SÃ£o	B-X
TomÃ©	B-X
and	B-X
PrÃ­ncipe	B-X
Elisabete	B-X
Catarino	B-X
,	B-X
Nelma	B-X
Carvalho	B-X
,	B-X
Tiago	B-X
Coucelo	B-X
,	B-X
LuÃ­s	B-X
Bonfim	B-X
,	B-X
Carina	B-X
Silva	B-X
S6	B-X
Safety	B-X
culture	B-X
of	B-X
the	B-X
patient	B-X
:	B-X
a	B-X
reflexion	B-X
about	B-X
the	B-X
therapeutic	B-X
approach	B-X
on	B-X
the	B-X
patient	B-X
with	B-X
vocal	B-X
pathology	B-X
DÃ©bora	B-X
Franco	B-X
S7	B-X
About	B-X
wine	B-X
,	B-X
fortune	B-X
cookies	B-X
and	B-X
patient	B-X
experience	B-X
JesÃºs	B-X
Alcoba	B-X
GonzÃ¡lez	B-X
O1	B-X
The	B-X
psychological	B-X
impact	B-X
on	B-X
the	B-X
emergency	B-X
crews	B-X
after	B-X
the	B-X
disaster	B-X
event	B-X
on	B-X
February	B-X
20	B-X
,	B-X
2010	B-X
Helena	B-X
G.	B-X
Jardim	B-X
,	B-X
Rita	B-X
Silva	B-X
O2	B-X
Musculoskeletal	B-X
disorders	B-X
in	B-X
midwives	B-X
Cristina	B-X
L.	B-X
Baixinho	B-X
,	B-X
MÂª	B-X
Helena	B-X
Presado	B-X
,	B-X
MÂª	B-X
FÃ¡tima	B-X
Marques	B-X
,	B-X
MÃ¡rio	B-X
E.	B-X
Cardoso	B-X
O3	B-X
Negative	B-X
childhood	B-X
experiences	B-X
and	B-X
fears	B-X
of	B-X
compassion	B-X
:	B-X
Implications	B-X
for	B-X
psychological	B-X
difficulties	B-X
in	B-X
adolescence	B-X
Marina	B-X
Cunha	B-X
,	B-X
Joana	B-X
Mendes	B-X
,	B-X
Ana	B-X
Xavier	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Margarida	B-X
Couto	B-X
O4	B-X
Optimal	B-X
age	B-X
to	B-X
give	B-X
the	B-X
first	B-X
dose	B-X
of	B-X
measles	B-X
vaccine	B-X
in	B-X
Portugal	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Carla	B-X
Nunes	B-X
,	B-X
JoÃ£o	B-X
R.	B-X
Mesquita	B-X
,	B-X
Maria	B-X
S.	B-X
Nascimento	B-X
,	B-X
Guilherme	B-X
GonÃ§alves	B-X
O5	B-X
Functional	B-X
assessment	B-X
of	B-X
elderly	B-X
in	B-X
primary	B-X
care	B-X
ConceiÃ§Ã£o	B-X
Castro	B-X
,	B-X
Alice	B-X
MÃ¡rtires	B-X
,	B-X
MÂª	B-X
JoÃ£o	B-X
Monteiro	B-X
,	B-X
ConceiÃ§Ã£o	B-X
Rainho	B-X
O6	B-X
Smoking	B-X
and	B-X
coronary	B-X
events	B-X
in	B-X
a	B-X
population	B-X
of	B-X
Spanish	B-X
health-care	B-X
centre	B-X
:	B-X
An	B-X
observational	B-X
study	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Fatima	B-X
M.	B-X
Monago	B-X
,	B-X
Jose	B-X
T.	B-X
Guerrero	B-X
,	B-X
Rocio	B-X
M.	B-X
Monago	B-X
,	B-X
Africa	B-X
P.	B-X
Trigo	B-X
,	B-X
Milagros	B-X
L.	B-X
Gutierrez	B-X
,	B-X
Gemma	B-X
M.	B-X
MilanÃ©s	B-X
,	B-X
Mercedes	B-X
G.	B-X
Reina	B-X
,	B-X
Ana	B-X
G.	B-X
Villanueva	B-X
,	B-X
Ana	B-X
S.	B-X
PiÃ±ero	B-X
,	B-X
Isabel	B-X
R.	B-X
Aliseda	B-X
,	B-X
Francisco	B-X
B.	B-X
Ramirez	B-X
O7	B-X
Prevalence	B-X
of	B-X
musculoskeletal	B-X
injuries	B-X
in	B-X
Portuguese	B-X
musicians	B-X
Andrea	B-X
Ribeiro	B-X
,	B-X
Ana	B-X
Quelhas	B-X
,	B-X
ConceiÃ§Ã£o	B-X
Manso	B-X
O8	B-X
Hip	B-X
fractures	B-X
,	B-X
psychotropic	B-X
drug	B-X
consumption	B-X
and	B-X
comorbidity	B-X
in	B-X
patients	B-X
of	B-X
a	B-X
primary	B-X
care	B-X
practice	B-X
in	B-X
Spain	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Jose	B-X
T.	B-X
Guerrero	B-X
,	B-X
Fatima	B-X
M.	B-X
Monago	B-X
,	B-X
Rafael	B-X
B.	B-X
Santos	B-X
,	B-X
Nuria	B-X
R.	B-X
Jimenez	B-X
,	B-X
Cristina	B-X
G.	B-X
NuÃ±ez	B-X
,	B-X
Inmaculada	B-X
R.	B-X
Gomez	B-X
,	B-X
MÂª	B-X
Jose	B-X
L.	B-X
Fernandez	B-X
,	B-X
Laura	B-X
A.	B-X
Marquez	B-X
,	B-X
Ana	B-X
L.	B-X
Moreno	B-X
,	B-X
MÂª	B-X
Jesus	B-X
Tena	B-X
Huertas	B-X
,	B-X
Francisco	B-X
B.	B-X
Ramirez	B-X
O9	B-X
The	B-X
role	B-X
of	B-X
self-criticism	B-X
and	B-X
shame	B-X
in	B-X
social	B-X
anxiety	B-X
in	B-X
a	B-X
clinical	B-X
SAD	B-X
sample	B-X
Daniel	B-X
Seabra	B-X
,	B-X
MÂª	B-X
CÃ©u	B-X
Salvador	B-X
O10	B-X
Obstruction	B-X
and	B-X
infiltration	B-X
:	B-X
a	B-X
proposal	B-X
of	B-X
a	B-X
quality	B-X
indicator	B-X
Luciene	B-X
Braga	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Cristina	B-X
Arreguy-Sena	B-X
,	B-X
Bibiana	B-X
F.	B-X
Oliveira	B-X
,	B-X
MÂª	B-X
Adriana	B-X
Henriques	B-X
O11	B-X
Balance	B-X
and	B-X
anxiety	B-X
and	B-X
depression	B-X
symptoms	B-X
in	B-X
old	B-X
age	B-X
people	B-X
Joana	B-X
Santos	B-X
,	B-X
Sara	B-X
Lebre	B-X
,	B-X
Alda	B-X
Marques	B-X
O12	B-X
Prevalence	B-X
of	B-X
postural	B-X
changes	B-X
and	B-X
risk	B-X
factors	B-X
in	B-X
school	B-X
children	B-X
and	B-X
adolescents	B-X
in	B-X
a	B-X
northern	B-X
region	B-X
(	B-X
Porto	B-X
)	B-X
Clarinda	B-X
Festas	B-X
,	B-X
Sandra	B-X
Rodrigues	B-X
,	B-X
Andrea	B-X
Ribeiro	B-X
,	B-X
JosÃ©	B-X
Lumini	B-X
O13	B-X
Ischemic	B-X
stroke	B-X
vs.	B-X
haemorrhagic	B-X
stroke	B-X
survival	B-X
rate	B-X
Ana	B-X
G.	B-X
Figueiredo	B-X
O14	B-X
Chronobiological	B-X
factors	B-X
as	B-X
responsible	B-X
for	B-X
the	B-X
appearance	B-X
of	B-X
locomotor	B-X
pathology	B-X
in	B-X
adolescents	B-X
Francisco	B-X
J.	B-X
Hernandez-Martinez	B-X
,	B-X
Liliana	B-X
Campi	B-X
,	B-X
MÂª	B-X
Pino	B-X
Quintana-Montesdeoca	B-X
,	B-X
Juan	B-X
F.	B-X
Jimenez-Diaz	B-X
,	B-X
Bienvenida	B-X
C.	B-X
Rodriguez-De-Vera	B-X
O15	B-X
Risk	B-X
of	B-X
malnutrition	B-X
in	B-X
the	B-X
elderly	B-X
of	B-X
BraganÃ§a	B-X
Alexandra	B-X
Parente	B-X
,	B-X
MÂª	B-X
Augusta	B-X
Mata	B-X
,	B-X
Ana	B-X
MÂª	B-X
Pereira	B-X
,	B-X
AdÃ­lia	B-X
Fernandes	B-X
,	B-X
Manuel	B-X
BrÃ¡s	B-X
O16	B-X
A	B-X
Lifestyle	B-X
Educational	B-X
Programme	B-X
for	B-X
primary	B-X
care	B-X
diabetic	B-X
patients	B-X
:	B-X
the	B-X
design	B-X
of	B-X
a	B-X
complex	B-X
nursing	B-X
intervention	B-X
MÂª	B-X
RosÃ¡rio	B-X
Pinto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
L.	B-X
Basto	B-X
,	B-X
Ana	B-X
C.	B-X
Rei	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
O17	B-X
Medication	B-X
adherence	B-X
in	B-X
elderly	B-X
people	B-X
Gilberta	B-X
Sousa	B-X
,	B-X
Clementina	B-X
Morna	B-X
,	B-X
OtÃ­lia	B-X
Freitas	B-X
,	B-X
GregÃ³rio	B-X
Freitas	B-X
,	B-X
Ana	B-X
Jardim	B-X
,	B-X
Rita	B-X
Vasconcelos	B-X
O18	B-X
Hospitalization	B-X
for	B-X
cervical	B-X
cancer	B-X
of	B-X
residents	B-X
in	B-X
the	B-X
metropolitan	B-X
region	B-X
of	B-X
Porto	B-X
Alegre	B-X
,	B-X
Southern	B-X
Brazil	B-X
,	B-X
2012	B-X
to	B-X
2014	B-X
Lina	B-X
G.	B-X
Horta	B-X
,	B-X
Roger	B-X
S.	B-X
Rosa	B-X
,	B-X
LuÃ­s	B-X
F.	B-X
Kranz	B-X
,	B-X
Rita	B-X
C.	B-X
Nugem	B-X
,	B-X
Mariana	B-X
S.	B-X
Siqueira	B-X
,	B-X
Ronaldo	B-X
Bordin	B-X
O19	B-X
Oncologic	B-X
assistance	B-X
of	B-X
high	B-X
complexity	B-X
:	B-X
evaluation	B-X
of	B-X
regulating	B-X
accesses	B-X
Rosiane	B-X
Kniess	B-X
,	B-X
Josimari	B-X
T.	B-X
Lacerda	B-X
O20	B-X
Perceived	B-X
barriers	B-X
for	B-X
using	B-X
health	B-X
care	B-X
services	B-X
by	B-X
the	B-X
older	B-X
population	B-X
as	B-X
seen	B-X
by	B-X
the	B-X
social	B-X
sector	B-X
:	B-X
findings	B-X
from	B-X
the	B-X
Vila	B-X
Nova	B-X
de	B-X
Gaia	B-X
Gerontological	B-X
Plan	B-X
Joana	B-X
Guedes	B-X
,	B-X
Idalina	B-X
Machado	B-X
,	B-X
Sidalina	B-X
Almeida	B-X
,	B-X
Adriano	B-X
ZilhÃ£o	B-X
,	B-X
Helder	B-X
Alves	B-X
,	B-X
Ãscar	B-X
Ribeiro	B-X
O21	B-X
Sleep	B-X
difficulties	B-X
and	B-X
depressive	B-X
symptoms	B-X
in	B-X
college	B-X
students	B-X
Ana	B-X
P.	B-X
Amaral	B-X
,	B-X
Ana	B-X
Santos	B-X
,	B-X
Joana	B-X
Monteiro	B-X
,	B-X
MÂª	B-X
Clara	B-X
Rocha	B-X
,	B-X
Rui	B-X
Cruz	B-X
O22	B-X
Psychopathological	B-X
symptoms	B-X
and	B-X
medication	B-X
use	B-X
in	B-X
higher	B-X
education	B-X
Ana	B-X
P.	B-X
Amaral	B-X
,	B-X
Marina	B-X
LourenÃ§o	B-X
,	B-X
MÂª	B-X
Clara	B-X
Rocha	B-X
,	B-X
Rui	B-X
Cruz	B-X
O23	B-X
Sexually	B-X
transmitted	B-X
diseases	B-X
in	B-X
higher	B-X
education	B-X
institutions	B-X
Sandra	B-X
Antunes	B-X
,	B-X
VerÃ³nica	B-X
MendonÃ§a	B-X
,	B-X
Isabel	B-X
Andrade	B-X
,	B-X
NÃ¡dia	B-X
OsÃ³rio	B-X
,	B-X
Ana	B-X
Valado	B-X
,	B-X
Armando	B-X
Caseiro	B-X
,	B-X
AntÃ³nio	B-X
Gabriel	B-X
,	B-X
Anabela	B-X
C.	B-X
Martins	B-X
,	B-X
Fernando	B-X
Mendes	B-X
O24	B-X
Alcohol	B-X
consumption	B-X
and	B-X
suicide	B-X
ideation	B-X
in	B-X
higher	B-X
education	B-X
students	B-X
LÃ­dia	B-X
Cabral	B-X
,	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Amadeu	B-X
GonÃ§alves	B-X
O25	B-X
Quality	B-X
of	B-X
life	B-X
in	B-X
university	B-X
students	B-X
Tatiana	B-X
D.	B-X
Luz	B-X
,	B-X
Leonardo	B-X
Luz	B-X
,	B-X
Raul	B-X
Martins	B-X
O26	B-X
Male	B-X
and	B-X
female	B-X
adolescent	B-X
antisocial	B-X
behaviour	B-X
:	B-X
characterizing	B-X
vulnerabilities	B-X
in	B-X
a	B-X
Portuguese	B-X
sample	B-X
Alice	B-X
Morgado	B-X
,	B-X
Maria	B-X
L.	B-X
Vale-Dias	B-X
O27	B-X
Risk	B-X
factors	B-X
for	B-X
mental	B-X
health	B-X
in	B-X
higher	B-X
education	B-X
students	B-X
of	B-X
health	B-X
sciences	B-X
Rui	B-X
Porta-Nova	B-X
O28	B-X
International	B-X
classification	B-X
of	B-X
functioning	B-X
disability	B-X
and	B-X
health	B-X
as	B-X
reflexive	B-X
reasoning	B-X
in	B-X
primary	B-X
attention	B-X
in	B-X
health	B-X
TÃ¢nia	B-X
C.	B-X
Fleig	B-X
,	B-X
Ãboni	B-X
M.	B-X
Reuter	B-X
,	B-X
Miriam	B-X
B.	B-X
Froemming	B-X
,	B-X
Sabrina	B-X
L.	B-X
Guerreiro	B-X
,	B-X
Lisiane	B-X
L.	B-X
Carvalho	B-X
O29	B-X
Risk	B-X
factors	B-X
and	B-X
cardiovascular	B-X
disease	B-X
in	B-X
Portalegre	B-X
Daniel	B-X
Guedelha	B-X
,	B-X
P.	B-X
Coelho	B-X
,	B-X
A.	B-X
Pereira	B-X
O30	B-X
Health	B-X
status	B-X
of	B-X
the	B-X
elderly	B-X
population	B-X
living	B-X
in	B-X
Portalegre	B-X
historic	B-X
city	B-X
centre	B-X
:	B-X
A	B-X
longitudinal	B-X
study	B-X
AntÃ³nio	B-X
Calha	B-X
,	B-X
Raul	B-X
Cordeiro	B-X
O31	B-X
Student	B-X
â	B-X
s	B-X
sleep	B-X
in	B-X
higher	B-X
education	B-X
:	B-X
sleep	B-X
quality	B-X
among	B-X
students	B-X
of	B-X
the	B-X
IPB	B-X
Ana	B-X
GonÃ§alves	B-X
,	B-X
Ana	B-X
Certo	B-X
,	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
MÂª	B-X
Augusta	B-X
Mata	B-X
O32	B-X
Trend	B-X
in	B-X
mortality	B-X
from	B-X
cervical	B-X
cancer	B-X
in	B-X
the	B-X
metropolitan	B-X
area	B-X
of	B-X
FlorianÃ³polis	B-X
,	B-X
state	B-X
of	B-X
Santa	B-X
Catarina	B-X
,	B-X
Brazil	B-X
,	B-X
2000	B-X
to	B-X
2013	B-X
Aline	B-X
Welter	B-X
,	B-X
Elayne	B-X
Pereira	B-X
,	B-X
Sandra	B-X
Ribeiro	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
O33	B-X
Adherence	B-X
to	B-X
treatment	B-X
in	B-X
the	B-X
elderly	B-X
in	B-X
an	B-X
urban	B-X
environment	B-X
in	B-X
Spain	B-X
Juan-Fernando	B-X
JimÃ©nez-DÃ­az	B-X
,	B-X
Carla	B-X
JimÃ©nez-RodrÃ­guez	B-X
,	B-X
Francisco-JosÃ©	B-X
HernÃ¡ndez-MartÃ­nez	B-X
,	B-X
Bienvenida-Del-Carmen	B-X
RodrÃ­guez-De-Vera	B-X
,	B-X
Alexandre	B-X
Marques-Rodrigues	B-X
O34	B-X
Beira	B-X
Baixa	B-X
Blood	B-X
Pressure	B-X
Study	B-X
(	B-X
Study	B-X
PABB	B-X
)	B-X
PatrÃ­cia	B-X
Coelho	B-X
,	B-X
Tiago	B-X
Bernardes	B-X
,	B-X
Alexandre	B-X
Pereira	B-X
O35	B-X
Trends	B-X
in	B-X
cervical	B-X
cancer	B-X
mortality	B-X
statistics	B-X
in	B-X
Santa	B-X
Catarina	B-X
State	B-X
,	B-X
Brazil	B-X
,	B-X
by	B-X
age	B-X
group	B-X
and	B-X
macro-region	B-X
,	B-X
from	B-X
2000	B-X
to	B-X
2013	B-X
PatrÃ­cia	B-X
Sousa	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Filho	B-X
,	B-X
Nazare	B-X
Nazario	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
O36	B-X
Sleep	B-X
problems	B-X
among	B-X
Portuguese	B-X
adolescents	B-X
:	B-X
a	B-X
public	B-X
health	B-X
issue	B-X
Odete	B-X
Amaral	B-X
,	B-X
AntÃ³nio	B-X
Garrido	B-X
,	B-X
NÃ©lio	B-X
Veiga	B-X
,	B-X
Carla	B-X
Nunes	B-X
,	B-X
Ana	B-X
R.	B-X
Pedro	B-X
,	B-X
Carlos	B-X
Pereira	B-X
O37	B-X
Association	B-X
between	B-X
body	B-X
fat	B-X
and	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
AntÃ³nio	B-X
Almeia	B-X
,	B-X
Helder	B-X
M.	B-X
Fernandes	B-X
,	B-X
Carlos	B-X
Vasconcelos	B-X
,	B-X
Nelson	B-X
Sousa	B-X
,	B-X
Victor	B-X
M.	B-X
Reis	B-X
,	B-X
M.	B-X
JoÃ£o	B-X
Monteiro	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O38	B-X
Therapy	B-X
adherence	B-X
and	B-X
polypharmacy	B-X
in	B-X
non-institutionalized	B-X
elderly	B-X
from	B-X
Amares	B-X
county	B-X
,	B-X
Portugal	B-X
Isabel	B-X
C.	B-X
Pinto	B-X
,	B-X
TÃ¢nia	B-X
Pires	B-X
,	B-X
JoÃ£o	B-X
Gama	B-X
O39	B-X
Prevalence	B-X
of	B-X
surgical	B-X
site	B-X
infection	B-X
in	B-X
adults	B-X
at	B-X
a	B-X
hospital	B-X
unit	B-X
in	B-X
the	B-X
North	B-X
of	B-X
Portugal	B-X
Vera	B-X
Preto	B-X
,	B-X
Norberto	B-X
Silva	B-X
,	B-X
Carlos	B-X
MagalhÃ£es	B-X
,	B-X
Matilde	B-X
Martins	B-X
O40	B-X
Frailty	B-X
phenotype	B-X
in	B-X
old	B-X
age	B-X
:	B-X
implications	B-X
to	B-X
intervention	B-X
Mafalda	B-X
Duarte	B-X
,	B-X
ConstanÃ§a	B-X
PaÃºl	B-X
,	B-X
IgnÃ¡cio	B-X
MartÃ­n	B-X
O41	B-X
Portuguese	B-X
women	B-X
:	B-X
sexual	B-X
symptoms	B-X
in	B-X
perimenopause	B-X
Arminda	B-X
A.	B-X
Pinheiro	B-X
O42	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Perinatal	B-X
Depression	B-X
Screening	B-X
and	B-X
Prevention	B-X
Tool	B-X
â	B-X
preliminary	B-X
results	B-X
of	B-X
the	B-X
categorical	B-X
approach	B-X
Sandra	B-X
Xavier	B-X
,	B-X
Julieta	B-X
Azevedo	B-X
,	B-X
Elisabete	B-X
Bento	B-X
,	B-X
Cristiana	B-X
Marques	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
AntÃ³nio	B-X
Macedo	B-X
,	B-X
Ana	B-X
T.	B-X
Pereira	B-X
O43	B-X
Aging	B-X
and	B-X
muscle	B-X
strength	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
:	B-X
cross	B-X
sectional	B-X
analysis	B-X
JosÃ©	B-X
P.	B-X
Almeida	B-X
,	B-X
AntÃ³nio	B-X
Almeida	B-X
,	B-X
Josiane	B-X
Alves	B-X
,	B-X
Nelson	B-X
Sousa	B-X
,	B-X
Francisco	B-X
Saavedra	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O44	B-X
Accessibility	B-X
of	B-X
the	B-X
elderly	B-X
in	B-X
the	B-X
prevention	B-X
of	B-X
hypertension	B-X
in	B-X
a	B-X
family	B-X
health	B-X
unit	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
Luci	B-X
S.	B-X
Lopes	B-X
,	B-X
Eujcely	B-X
C.	B-X
Santiago	B-X
O45	B-X
Community	B-X
Health	B-X
screenings	B-X
and	B-X
self-reported	B-X
chronic	B-X
diseases	B-X
SÃ­lvia	B-X
Monteiro	B-X
,	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Armanda	B-X
ColaÃ§o	B-X
,	B-X
AntÃ³nio	B-X
Carvalho	B-X
,	B-X
Rita	B-X
P.	B-X
Silva	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
O46	B-X
Evaluation	B-X
of	B-X
indoor	B-X
air	B-X
quality	B-X
in	B-X
Kindergartens	B-X
Ana	B-X
Ferreira	B-X
,	B-X
Catarina	B-X
Marques	B-X
,	B-X
JoÃ£o	B-X
P.	B-X
Figueiredo	B-X
,	B-X
Susana	B-X
PaixÃ£o	B-X
O47	B-X
Atmospheric	B-X
exposure	B-X
to	B-X
chemical	B-X
agents	B-X
under	B-X
the	B-X
occupational	B-X
activity	B-X
of	B-X
pathology	B-X
technicians	B-X
Ana	B-X
Ferreira	B-X
,	B-X
Carla	B-X
Lopes	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
JoÃ£o	B-X
P.	B-X
Figueiredo	B-X
O48	B-X
Occupational	B-X
exposure	B-X
to	B-X
air	B-X
pollutants	B-X
in	B-X
night	B-X
entertainment	B-X
venues	B-X
workers	B-X
Ana	B-X
Ferreira	B-X
,	B-X
Diana	B-X
Ribeiro	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
JoÃ£o	B-X
P.	B-X
Figueiredo	B-X
,	B-X
Susana	B-X
PaixÃ£o	B-X
O49	B-X
Beliefs	B-X
and	B-X
attitudes	B-X
of	B-X
young	B-X
people	B-X
towards	B-X
breastfeeding	B-X
Telma	B-X
Fernandes	B-X
,	B-X
Diogo	B-X
Amado	B-X
,	B-X
JÃ©ssica	B-X
Leal	B-X
,	B-X
Marcelo	B-X
Azevedo	B-X
,	B-X
SÃ³nia	B-X
Ramalho	B-X
O50	B-X
Profiling	B-X
informal	B-X
caregivers	B-X
:	B-X
surveying	B-X
needs	B-X
in	B-X
the	B-X
care	B-X
of	B-X
the	B-X
elderly	B-X
Catarina	B-X
Mangas	B-X
,	B-X
Jaime	B-X
Ribeiro	B-X
,	B-X
Rita	B-X
GonÃ§alves	B-X
O51	B-X
Visual	B-X
health	B-X
in	B-X
teenagers	B-X
AmÃ©lia	B-X
F	B-X
Nunes	B-X
,	B-X
Ana	B-X
R.	B-X
Tuna	B-X
,	B-X
Carlos	B-X
R.	B-X
Martins	B-X
,	B-X
Henriqueta	B-X
D.	B-X
Forte	B-X
O52	B-X
Amenable	B-X
mortality	B-X
and	B-X
the	B-X
geographic	B-X
accessibility	B-X
to	B-X
healthcare	B-X
in	B-X
Portugal	B-X
ClÃ¡udia	B-X
Costa	B-X
,	B-X
JosÃ©	B-X
A.	B-X
TenedÃ³rio	B-X
,	B-X
Paula	B-X
Santana	B-X
O53	B-X
Bacterial	B-X
contamination	B-X
of	B-X
door	B-X
handles	B-X
in	B-X
a	B-X
SÃ£o	B-X
Paulo	B-X
See	B-X
Metropolitan	B-X
Cathedral	B-X
public	B-X
restrooms	B-X
in	B-X
Brazil	B-X
J	B-X
.	B-X
A	B-X
global	B-X
overview	B-X
using	B-X
census	B-X
data	B-X
Daniela	B-X
BrandÃ£o	B-X
,	B-X
Ãscar	B-X
Ribeiro	B-X
,	B-X
Lia	B-X
AraÃºjo	B-X
,	B-X
ConstanÃ§a	B-X
PaÃºl	B-X
P3	B-X
Prevalence	B-X
of	B-X
injuries	B-X
in	B-X
senior	B-X
amateur	B-X
volleyball	B-X
athletes	B-X
in	B-X
Alentejo	B-X
and	B-X
Algarve	B-X
clubs	B-X
,	B-X
Portugal	B-X
:	B-X
factors	B-X
associated	B-X
Beatriz	B-X
Minghelli	B-X
,	B-X
Sylvina	B-X
Richaud	B-X
P4	B-X
Shame	B-X
feelings	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
:	B-X
the	B-X
role	B-X
of	B-X
acceptance	B-X
and	B-X
decentring	B-X
Ana	B-X
L.	B-X
Mendes	B-X
,	B-X
Joana	B-X
Marta-SimÃµes	B-X
,	B-X
InÃªs	B-X
A.	B-X
Trindade	B-X
,	B-X
ClÃ¡udia	B-X
Ferreira	B-X
P5	B-X
Assessment	B-X
of	B-X
social	B-X
support	B-X
during	B-X
deployment	B-X
in	B-X
portuguese	B-X
colonial	B-X
war	B-X
veterans	B-X
Teresa	B-X
Carvalho	B-X
,	B-X
Marina	B-X
Cunha	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
P6	B-X
Hospitalization	B-X
for	B-X
acute	B-X
viral	B-X
bronchiolitis	B-X
of	B-X
residents	B-X
in	B-X
the	B-X
metropolitan	B-X
region	B-X
of	B-X
Porto	B-X
Alegre	B-X
,	B-X
Southern	B-X
Brazil	B-X
,	B-X
2012	B-X
to	B-X
2014	B-X
Morgana	B-X
C.	B-X
Fernandes	B-X
,	B-X
Roger	B-X
S.	B-X
Rosa	B-X
,	B-X
Rita	B-X
C.	B-X
Nugem	B-X
,	B-X
LuÃ­s	B-X
F.	B-X
Kranz	B-X
,	B-X
Mariana	B-X
S.	B-X
Siqueira	B-X
,	B-X
Ronaldo	B-X
Bordin	B-X
P7	B-X
Falls-risk	B-X
screening	B-X
â	B-X
an	B-X
opportunity	B-X
for	B-X
preventing	B-X
falls	B-X
in	B-X
the	B-X
elderly	B-X
from	B-X
Nordeste	B-X
Anabela	B-X
C.	B-X
Martins	B-X
,	B-X
Anabela	B-X
Medeiros	B-X
,	B-X
Rafaela	B-X
Pimentel	B-X
,	B-X
Andreia	B-X
Fernandes	B-X
,	B-X
Carlos	B-X
MendonÃ§a	B-X
,	B-X
Isabel	B-X
Andrade	B-X
,	B-X
Susana	B-X
Andrade	B-X
,	B-X
Ruth	B-X
L.	B-X
Menezes	B-X
P8	B-X
Aging	B-X
provokes	B-X
chronodisruption	B-X
in	B-X
mature	B-X
people	B-X
in	B-X
temperature	B-X
circadian	B-X
rhythm	B-X
Rafael	B-X
Bravo	B-X
,	B-X
Marta	B-X
Miranda	B-X
,	B-X
Lierni	B-X
Ugartemendia	B-X
,	B-X
JosÃ©	B-X
MÂª	B-X
Tena	B-X
,	B-X
Francisco	B-X
L.	B-X
PÃ©rez-Caballero	B-X
,	B-X
Lorena	B-X
Fuentes-Broto	B-X
,	B-X
Ana	B-X
B.	B-X
RodrÃ­guez	B-X
,	B-X
Barriga	B-X
Carmen	B-X
P9	B-X
The	B-X
influence	B-X
of	B-X
climate	B-X
and	B-X
pollution	B-X
factors	B-X
in	B-X
dengue	B-X
cases	B-X
of	B-X
great	B-X
ABC	B-X
region	B-X
,	B-X
SÃ£o	B-X
Paulo	B-X
M.	B-X
A.	B-X
Carneiro	B-X
,	B-X
J.	B-X
N.	B-X
Domingues	B-X
,	B-X
S.	B-X
PaixÃ£o	B-X
,	B-X
J.	B-X
Figueiredo	B-X
,	B-X
V.	B-X
B.	B-X
Nascimento	B-X
,	B-X
C.	B-X
Jesus	B-X
,	B-X
F	B-X
Mendes	B-X
,	B-X
F.	B-X
Gehrke	B-X
,	B-X
B.	B-X
Alves	B-X
,	B-X
L.	B-X
Azzalis	B-X
,	B-X
F.	B-X
Fonseca	B-X
P10	B-X
Visual	B-X
function	B-X
and	B-X
impact	B-X
of	B-X
visual	B-X
therapy	B-X
in	B-X
children	B-X
with	B-X
learning	B-X
disabilities	B-X
:	B-X
a	B-X
pilot	B-X
study	B-X
Ana	B-X
R.	B-X
Martins	B-X
,	B-X
AmÃ©lia	B-X
Nunes	B-X
,	B-X
Arminda	B-X
Jorge	B-X
P11	B-X
Edentulism	B-X
and	B-X
the	B-X
need	B-X
of	B-X
oral	B-X
rehabilitation	B-X
among	B-X
institutionalized	B-X
elderly	B-X
NÃ©lio	B-X
Veiga	B-X
,	B-X
Ana	B-X
Amorim	B-X
,	B-X
AndrÃ©	B-X
Silva	B-X
,	B-X
Liliana	B-X
Martinho	B-X
,	B-X
LuÃ­s	B-X
Monteiro	B-X
,	B-X
Rafael	B-X
Silva	B-X
,	B-X
Carina	B-X
Coelho	B-X
,	B-X
Odete	B-X
Amaral	B-X
,	B-X
InÃªs	B-X
Coelho	B-X
,	B-X
Carlos	B-X
Pereira	B-X
,	B-X
AndrÃ©	B-X
Correia	B-X
P12	B-X
Therapy	B-X
adherence	B-X
of	B-X
outpatients	B-X
in	B-X
the	B-X
pharmacy	B-X
services	B-X
of	B-X
a	B-X
hospital	B-X
unit	B-X
Diana	B-X
Rodrigues	B-X
,	B-X
NÃ­dia	B-X
Marante	B-X
,	B-X
Pedro	B-X
Silva	B-X
,	B-X
Sara	B-X
Carvalho	B-X
,	B-X
AndrÃ©	B-X
Rts	B-X
Araujo	B-X
,	B-X
Maximiano	B-X
Ribeiro	B-X
,	B-X
Paula	B-X
Coutinho	B-X
,	B-X
Sandra	B-X
Ventura	B-X
,	B-X
FÃ¡tima	B-X
Roque	B-X
P13	B-X
Universal	B-X
access	B-X
and	B-X
comprehensive	B-X
care	B-X
of	B-X
oral	B-X
health	B-X
:	B-X
an	B-X
availability	B-X
study	B-X
Cristina	B-X
Calvo	B-X
,	B-X
Manoela	B-X
Reses	B-X
P14	B-X
Is	B-X
the	B-X
respiratory	B-X
function	B-X
of	B-X
children	B-X
a	B-X
predictor	B-X
of	B-X
air	B-X
quality	B-X
?	B-X
Coimbra	B-X
as	B-X
a	B-X
case	B-X
study	B-X
Jorge	B-X
Conde	B-X
,	B-X
Ana	B-X
Ferreira	B-X
,	B-X
JoÃ£o	B-X
Figueiredo	B-X
P15	B-X
Meaning-in-life	B-X
of	B-X
college	B-X
students	B-X
David	B-X
Silva	B-X
,	B-X
LuÃ­s	B-X
SeiÃ§a	B-X
,	B-X
Raquel	B-X
Soares	B-X
,	B-X
Ricardo	B-X
MourÃ£o	B-X
,	B-X
Teresa	B-X
Kraus	B-X
O57	B-X
Training	B-X
needs	B-X
for	B-X
nurses	B-X
in	B-X
palliative	B-X
care	B-X
Ana	B-X
C.	B-X
Abreu	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
,	B-X
JÃºlia	B-X
M.	B-X
Alves	B-X
O58	B-X
Impact	B-X
of	B-X
computerized	B-X
information	B-X
systems	B-X
in	B-X
the	B-X
global	B-X
nurses	B-X
â	B-X
workload	B-X
:	B-X
nurses	B-X
â	B-X
perceptions	B-X
and	B-X
real-time	B-X
Paulino	B-X
Sousa	B-X
,	B-X
Manuel	B-X
Oliveira	B-X
,	B-X
Joana	B-X
Sousa	B-X
O59	B-X
The	B-X
perspective	B-X
of	B-X
health	B-X
care	B-X
professionals	B-X
on	B-X
self-care	B-X
in	B-X
hereditary	B-X
neurodegenerative	B-X
disease	B-X
:	B-X
a	B-X
qualitative	B-X
study	B-X
SÃ³nia	B-X
Novais	B-X
,	B-X
Felismina	B-X
Mendes	B-X
O60	B-X
Contribution	B-X
for	B-X
health-related	B-X
physical	B-X
fitness	B-X
reference	B-X
values	B-X
in	B-X
healthy	B-X
adolescents	B-X
Joana	B-X
Pinto	B-X
,	B-X
Joana	B-X
Cruz	B-X
,	B-X
Alda	B-X
Marques	B-X
School	B-X
of	B-X
Health	B-X
Sciences	B-X
,	B-X
University	B-X
of	B-X
Aveiro	B-X
,	B-X
3810-193	B-X
Aveiro	B-X
,	B-X
Portugal	B-X
O61	B-X
Perception	B-X
of	B-X
learning	B-X
,	B-X
satisfaction	B-X
and	B-X
self-efficacy	B-X
of	B-X
nursing	B-X
students	B-X
about	B-X
High-Fidelity	B-X
Simulation	B-X
Hugo	B-X
Duarte	B-X
,	B-X
Maria	B-X
Dos	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Pedro	B-X
Sousa	B-X
O62	B-X
Analysis	B-X
of	B-X
statements	B-X
of	B-X
diagnosis	B-X
about	B-X
health	B-X
deviation	B-X
in	B-X
self-care	B-X
requisites	B-X
customized	B-X
in	B-X
a	B-X
Nursing	B-X
Practice	B-X
Support	B-X
System	B-X
(	B-X
SAPEÂ®	B-X
)	B-X
:	B-X
Management	B-X
of	B-X
therapeutic	B-X
regimen	B-X
InÃªs	B-X
Cruz	B-X
,	B-X
Fernanda	B-X
Bastos	B-X
,	B-X
Filipe	B-X
Pereira	B-X
O63	B-X
Hybrid	B-X
management	B-X
and	B-X
hospital	B-X
governance	B-X
:	B-X
doctors	B-X
and	B-X
nurses	B-X
as	B-X
managers	B-X
Francisco	B-X
L.	B-X
Carvalho	B-X
,	B-X
Teresa	B-X
T.	B-X
Oliveira	B-X
,	B-X
VÃ­tor	B-X
R.	B-X
Raposo	B-X
O64	B-X
Time	B-X
management	B-X
in	B-X
health	B-X
professionals	B-X
ConceiÃ§Ã£o	B-X
Rainho	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Ribeiro	B-X
,	B-X
Isabel	B-X
Barroso	B-X
,	B-X
VÃ­tor	B-X
Rodrigues	B-X
O65	B-X
Financial	B-X
rewards	B-X
and	B-X
wellbeing	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
Carmo	B-X
Neves	B-X
,	B-X
Teresa	B-X
C.	B-X
Oliveira	B-X
O66	B-X
Patient	B-X
safety	B-X
promotion	B-X
in	B-X
the	B-X
operating	B-X
room	B-X
BÃ¡rbara	B-X
Oliveira	B-X
,	B-X
MÂª	B-X
Carminda	B-X
Morais	B-X
,	B-X
Pilar	B-X
Baylina	B-X
O67	B-X
Difficulties	B-X
and	B-X
needs	B-X
of	B-X
pre-graduate	B-X
nursing	B-X
students	B-X
in	B-X
the	B-X
area	B-X
of	B-X
Geriatrics/Gerontology	B-X
RogÃ©rio	B-X
Rodrigues	B-X
,	B-X
Zaida	B-X
Azeredo	B-X
,	B-X
CorÃ¡lia	B-X
Vicente	B-X
O68	B-X
Teaching	B-X
and	B-X
learning	B-X
sexuality	B-X
in	B-X
nursing	B-X
education	B-X
HÃ©lia	B-X
Dias	B-X
,	B-X
Margarida	B-X
Sim-Sim	B-X
O69	B-X
Entrepreneurial	B-X
Motivations	B-X
Questionnaire	B-X
:	B-X
AFC	B-X
and	B-X
CFA	B-X
in	B-X
academy	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
JosÃ©	B-X
Gomes	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Lisete	B-X
MÃ³nico	B-X
,	B-X
Nuno	B-X
Brito	B-X
O70	B-X
Nursing	B-X
intervention	B-X
to	B-X
patient	B-X
with	B-X
Permanent	B-X
Pacemakers	B-X
and	B-X
Implantable	B-X
Cardioverter	B-X
Defibrillators	B-X
:	B-X
a	B-X
qualitative	B-X
analysis	B-X
Cassilda	B-X
Sarroeira	B-X
,	B-X
JosÃ©	B-X
Amendoeira	B-X
,	B-X
FÃ¡tima	B-X
Cunha	B-X
,	B-X
Anabela	B-X
CÃ¢ndido	B-X
,	B-X
PatrÃ­cia	B-X
Fernandes	B-X
,	B-X
Helena	B-X
R.	B-X
Silva	B-X
,	B-X
Elsa	B-X
Silva	B-X
O71	B-X
Alcohol	B-X
consumption	B-X
among	B-X
nursing	B-X
students	B-X
:	B-X
where	B-X
does	B-X
education	B-X
fail	B-X
?	B-X
Isabel	B-X
Barroso	B-X
,	B-X
Leila	B-X
Lapa	B-X
,	B-X
Cristina	B-X
Antunes	B-X
O72	B-X
Labour	B-X
stress	B-X
in	B-X
nursing	B-X
Ana	B-X
GonÃ§alves	B-X
,	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
MÂª	B-X
JosÃ©	B-X
Gomes	B-X
,	B-X
Susana	B-X
R.	B-X
Escanciano	B-X
O73	B-X
The	B-X
influence	B-X
of	B-X
safe	B-X
staff	B-X
nursing	B-X
in	B-X
patient	B-X
satisfaction	B-X
with	B-X
nursing	B-X
care	B-X
Maria	B-X
Freitas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
JoÃ£o	B-X
MarÃ´co	B-X
O74	B-X
Intention	B-X
to	B-X
use	B-X
eHealth	B-X
strategies	B-X
with	B-X
nursing	B-X
students	B-X
Ana	B-X
R.	B-X
Fernandes	B-X
,	B-X
Cremilde	B-X
Cabral	B-X
,	B-X
Samuel	B-X
Alves	B-X
,	B-X
Pedro	B-X
Sousa	B-X
O75	B-X
Community	B-X
Based	B-X
Mental	B-X
Health	B-X
:	B-X
contributions	B-X
of	B-X
an	B-X
interdisciplinary	B-X
international	B-X
program	B-X
for	B-X
students	B-X
in	B-X
higher	B-X
health	B-X
education	B-X
AntÃ³nio	B-X
Ferreira	B-X
,	B-X
Fernanda	B-X
PrÃ­ncipe	B-X
,	B-X
Ulla-Maija	B-X
SeppÃ¤nen	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Maribel	B-X
Carvalhais	B-X
,	B-X
Marilene	B-X
Silva	B-X
O76	B-X
Study	B-X
of	B-X
satisfaction	B-X
at	B-X
work	B-X
of	B-X
graduates	B-X
in	B-X
nursing	B-X
:	B-X
2002-2014	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Joana	B-X
Silva	B-X
,	B-X
JÃ©ssica	B-X
Neves	B-X
,	B-X
Diana	B-X
Costa	B-X
,	B-X
Bruno	B-X
Santos	B-X
,	B-X
Soraia	B-X
Duarte	B-X
O77	B-X
Health	B-X
professionals	B-X
â	B-X
attitudes	B-X
towards	B-X
breastfeeding	B-X
SÃ­lvia	B-X
Marques	B-X
,	B-X
SÃ³nia	B-X
Ramalho	B-X
,	B-X
Isabel	B-X
Mendes	B-X
O78	B-X
Continuity	B-X
of	B-X
nursing	B-X
care	B-X
to	B-X
person	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
Clarisse	B-X
Louro	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Maria	B-X
Dixe	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
O79	B-X
Stigma	B-X
toward	B-X
mental	B-X
illness	B-X
among	B-X
future	B-X
health	B-X
professionals	B-X
Marina	B-X
Cordeiro	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
O80	B-X
Working	B-X
with	B-X
fears	B-X
and	B-X
anxieties	B-X
of	B-X
medical	B-X
students	B-X
in	B-X
search	B-X
of	B-X
a	B-X
humanized	B-X
care	B-X
Frederico	B-X
C.	B-X
Valim	B-X
,	B-X
Joyce	B-X
O.	B-X
Costa	B-X
,	B-X
LÃºcia	B-X
G.	B-X
Bernardes	B-X
P16	B-X
Surgical	B-X
paediatrics	B-X
patients	B-X
â	B-X
psycho	B-X
prophylaxis	B-X
at	B-X
a	B-X
teaching	B-X
hospital	B-X
Helena	B-X
Prebianchi	B-X
P17	B-X
Patient-perceived	B-X
outcomes	B-X
in	B-X
physiotherapy	B-X
â	B-X
a	B-X
pilot	B-X
study	B-X
Marlene	B-X
Cristina	B-X
Rosa	B-X
P18	B-X
Building	B-X
competencies	B-X
for	B-X
managers	B-X
in	B-X
nursing	B-X
Narcisa	B-X
GonÃ§alves	B-X
,	B-X
Maria	B-X
M.	B-X
Martins	B-X
,	B-X
Paulina	B-X
Kurcgant	B-X
P19	B-X
Theoretical	B-X
basis	B-X
underlying	B-X
physiotherapy	B-X
practice	B-X
in	B-X
stroke	B-X
rehabilitation	B-X
AndrÃ©	B-X
Vieira	B-X
P20	B-X
When	B-X
the	B-X
life-cycle	B-X
ends	B-X
:	B-X
the	B-X
nurse	B-X
â	B-X
s	B-X
confrontation	B-X
with	B-X
death	B-X
Sandrina	B-X
Bento	B-X
,	B-X
SÃ©rgio	B-X
Deodato	B-X
,	B-X
Isabel	B-X
Rabiais	B-X
P21	B-X
Nursing	B-X
students	B-X
â	B-X
opinion	B-X
about	B-X
the	B-X
supervision	B-X
relationship	B-X
during	B-X
their	B-X
first	B-X
clinical	B-X
experience	B-X
Laura	B-X
Reis	B-X
P22	B-X
Nursing	B-X
Relational	B-X
Laboratory	B-X
:	B-X
Pedagogical	B-X
,	B-X
dialogic	B-X
and	B-X
critical	B-X
project	B-X
Ana	B-X
Torres	B-X
,	B-X
SÃ©rgio	B-X
Soares	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Pedro	B-X
GraÃ§a	B-X
P23	B-X
Job	B-X
satisfaction	B-X
of	B-X
bioscientists	B-X
at	B-X
a	B-X
Lisbon	B-X
hospital	B-X
CÃ©u	B-X
LeitÃ£o	B-X
,	B-X
Renato	B-X
Abreu	B-X
,	B-X
Fernando	B-X
BellÃ©m	B-X
,	B-X
Ana	B-X
Almeida	B-X
,	B-X
Edna	B-X
Ribeiro-Varandas	B-X
,	B-X
Ana	B-X
Tavares	B-X
P24	B-X
Sociodemographic	B-X
and	B-X
professional	B-X
profile	B-X
of	B-X
nurses	B-X
and	B-X
its	B-X
relation	B-X
with	B-X
the	B-X
importance	B-X
of	B-X
family	B-X
in	B-X
nursing	B-X
practices	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Carolina	B-X
Henriques	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Clarisse	B-X
Louro	B-X
,	B-X
CÃ©lia	B-X
JordÃ£o	B-X
P25	B-X
Professional	B-X
satisfaction	B-X
of	B-X
rehabilitation	B-X
nurses	B-X
Sofia	B-X
Neco	B-X
,	B-X
Carminda	B-X
Morais	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
P26	B-X
The	B-X
person	B-X
living	B-X
with	B-X
a	B-X
stoma	B-X
:	B-X
the	B-X
formalization	B-X
of	B-X
knowledge	B-X
in	B-X
nursing	B-X
Carla	B-X
R.	B-X
Silva	B-X
,	B-X
Alice	B-X
Brito	B-X
,	B-X
AntÃ³nia	B-X
Silva	B-X
P27	B-X
Validation	B-X
of	B-X
the	B-X
Portuguese	B-X
versions	B-X
of	B-X
the	B-X
nursing	B-X
students	B-X
â	B-X
perceptions	B-X
of	B-X
learning	B-X
and	B-X
learner	B-X
satisfaction	B-X
with	B-X
simulation	B-X
tool	B-X
Hugo	B-X
Duarte	B-X
,	B-X
Maria	B-X
Dos	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Pedro	B-X
Sousa	B-X
P28	B-X
Physiotherapists	B-X
â	B-X
perceived	B-X
knowledge	B-X
on	B-X
technologies	B-X
for	B-X
electronic	B-X
health	B-X
records	B-X
for	B-X
physiotherapy	B-X
Gabriela	B-X
Postolache	B-X
,	B-X
Raul	B-X
Oliveira	B-X
,	B-X
Isabel	B-X
Moreira	B-X
,	B-X
LuÃ­sa	B-X
Pedro	B-X
,	B-X
SÃ³nia	B-X
Vicente	B-X
,	B-X
Samuel	B-X
Domingos	B-X
,	B-X
Octavian	B-X
Postolache	B-X
P29	B-X
Quality	B-X
of	B-X
life	B-X
and	B-X
physical	B-X
activity	B-X
of	B-X
medicine	B-X
undergraduate	B-X
students	B-X
in	B-X
the	B-X
University	B-X
of	B-X
Southern	B-X
Santa	B-X
Catarina	B-X
,	B-X
Brazil	B-X
Darlen	B-X
Silva	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Filho	B-X
,	B-X
Nazare	B-X
Nazario	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
,	B-X
Dulcineia	B-X
Schneider	B-X
P30	B-X
The	B-X
curricular	B-X
skills	B-X
for	B-X
decision	B-X
making	B-X
education	B-X
in	B-X
a	B-X
Nursing	B-X
Degree	B-X
FÃ¡tima	B-X
M.	B-X
Marques	B-X
P31	B-X
Effect	B-X
of	B-X
nurses	B-X
â	B-X
mobilization	B-X
in	B-X
satisfaction	B-X
at	B-X
work	B-X
and	B-X
turnover	B-X
:	B-X
An	B-X
empirical	B-X
study	B-X
in	B-X
the	B-X
hospital	B-X
setting	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Carlos	B-X
Pinto	B-X
,	B-X
Sara	B-X
Vicente	B-X
,	B-X
SÃ£o	B-X
JoÃ£o	B-X
Breda	B-X
P32	B-X
Entrepreneurial	B-X
skills	B-X
of	B-X
students	B-X
of	B-X
polytechnic	B-X
higher	B-X
education	B-X
in	B-X
Portugal	B-X
:	B-X
Business	B-X
influences	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
P33	B-X
Design	B-X
and	B-X
assessment	B-X
of	B-X
e-learning	B-X
modules	B-X
for	B-X
Pharmacology	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Nuno	B-X
Duarte	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Lopes	B-X
,	B-X
HÃ©lder	B-X
Nunes	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
P34	B-X
Perspective	B-X
of	B-X
nurses	B-X
involved	B-X
in	B-X
an	B-X
action-research	B-X
study	B-X
on	B-X
the	B-X
changes	B-X
observed	B-X
in	B-X
care	B-X
provision	B-X
:	B-X
results	B-X
from	B-X
a	B-X
focus	B-X
group	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
L.	B-X
Basto	B-X
,	B-X
Luciene	B-X
M.	B-X
Braga	B-X
P35	B-X
Use	B-X
of	B-X
peer	B-X
feedback	B-X
by	B-X
nursing	B-X
students	B-X
during	B-X
clinical	B-X
training	B-X
:	B-X
teacher	B-X
â	B-X
s	B-X
perception	B-X
AntÃ³nio	B-X
Ferreira	B-X
,	B-X
Beatriz	B-X
AraÃºjo	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Alves	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Maribel	B-X
Carvalhais	B-X
,	B-X
Marilene	B-X
Silva	B-X
,	B-X
SÃ³nia	B-X
Novais	B-X
P36	B-X
What	B-X
â	B-X
s	B-X
new	B-X
on	B-X
endotracheal	B-X
suctioning	B-X
recommendations	B-X
Ana	B-X
S.	B-X
Sousa	B-X
,	B-X
CÃ¢ndida	B-X
Ferrito	B-X
P37	B-X
Assessment	B-X
of	B-X
the	B-X
nurses	B-X
satisfaction	B-X
on	B-X
the	B-X
Central	B-X
Region	B-X
of	B-X
Portugal	B-X
Pedro	B-X
L.	B-X
Ferreira	B-X
,	B-X
Alexandre	B-X
Rodrigues	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Isabel	B-X
Oliveira	B-X
P38	B-X
Study	B-X
of	B-X
graduate	B-X
â	B-X
s	B-X
satisfaction	B-X
with	B-X
the	B-X
school	B-X
of	B-X
nursing	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
JÃ©ssica	B-X
Neves	B-X
,	B-X
Diana	B-X
Costa	B-X
,	B-X
Soraia	B-X
Duarte	B-X
,	B-X
Joana	B-X
Silva	B-X
,	B-X
Bruno	B-X
Santos	B-X
P39	B-X
Partnership	B-X
between	B-X
the	B-X
school	B-X
of	B-X
nursing	B-X
and	B-X
the	B-X
hospital	B-X
:	B-X
SupervisorsÂ´	B-X
perspectives	B-X
Cristina	B-X
Martins	B-X
,	B-X
Ana	B-X
P.	B-X
Macedo	B-X
,	B-X
Odete	B-X
AraÃºjo	B-X
,	B-X
ClÃ¡udia	B-X
Augusto	B-X
,	B-X
FÃ¡tima	B-X
Braga	B-X
,	B-X
Lisa	B-X
Gomes	B-X
,	B-X
Maria	B-X
A.	B-X
Silva	B-X
,	B-X
Rafaela	B-X
RosÃ¡rio	B-X
P40	B-X
Coping	B-X
strategies	B-X
of	B-X
college	B-X
students	B-X
LuÃ­s	B-X
Pimenta	B-X
,	B-X
Diana	B-X
Carreira	B-X
,	B-X
PatrÃ­cia	B-X
Teles	B-X
,	B-X
Teresa	B-X
Barros	B-X
P41	B-X
Emotional	B-X
intelligence	B-X
and	B-X
mental	B-X
health	B-X
stigma	B-X
in	B-X
health	B-X
students	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
P42	B-X
Stigma	B-X
of	B-X
mental	B-X
health	B-X
assessment	B-X
:	B-X
Comparison	B-X
between	B-X
health	B-X
courses	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
O81	B-X
Short-	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
pulmonary	B-X
rehabilitation	B-X
in	B-X
mild	B-X
COPD	B-X
Cristina	B-X
JÃ¡come	B-X
,	B-X
Alda	B-X
Marques	B-X
O82	B-X
Phonological	B-X
awareness	B-X
programme	B-X
for	B-X
preschool	B-X
children	B-X
Sylvie	B-X
Capelas	B-X
,	B-X
Andreia	B-X
Hall	B-X
,	B-X
Dina	B-X
Alves	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O83	B-X
REforma	B-X
ATIVA	B-X
:	B-X
An	B-X
efficient	B-X
health	B-X
promotion	B-X
program	B-X
to	B-X
be	B-X
implemented	B-X
during	B-X
retirement	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
,	B-X
Ana	B-X
Camarneiro	B-X
,	B-X
Margarida	B-X
Silva	B-X
,	B-X
Aida	B-X
Mendes	B-X
,	B-X
Ana	B-X
Pedreiro	B-X
O84	B-X
Intervention	B-X
for	B-X
men	B-X
who	B-X
batter	B-X
women	B-X
,	B-X
a	B-X
case	B-X
report	B-X
Anne	B-X
G.Silva	B-X
,	B-X
Elza	B-X
S.	B-X
Coelho	B-X
O85	B-X
Immediate	B-X
effects	B-X
of	B-X
Bowen	B-X
Therapy	B-X
on	B-X
muscle	B-X
tone	B-X
and	B-X
flexibility	B-X
FlÃ¡vio	B-X
Melo	B-X
,	B-X
Fernando	B-X
Ribeiro	B-X
,	B-X
Rui	B-X
Torres	B-X
,	B-X
Rui	B-X
Costa	B-X
O86	B-X
Predictive	B-X
equation	B-X
for	B-X
incremental	B-X
shuttle	B-X
walk	B-X
test	B-X
in	B-X
adolescents	B-X
TÃ¢nia	B-X
Pinho	B-X
,	B-X
Cristina	B-X
JÃ¡come	B-X
,	B-X
Alda	B-X
Marques	B-X
O87	B-X
Life	B-X
satisfaction	B-X
and	B-X
psychopathology	B-X
in	B-X
institutionalized	B-X
elderly	B-X
people	B-X
:	B-X
The	B-X
results	B-X
of	B-X
an	B-X
adapted	B-X
Mindfulness-Based	B-X
Stress	B-X
Reduction	B-X
program	B-X
BÃ¡rbara	B-X
Cruz	B-X
,	B-X
Daniel	B-X
Seabra	B-X
,	B-X
Diogo	B-X
Carreira	B-X
,	B-X
Maria	B-X
Ventura	B-X
O88	B-X
Outcome	B-X
changes	B-X
in	B-X
COPD	B-X
rehabilitation	B-X
:	B-X
exploring	B-X
the	B-X
relationship	B-X
between	B-X
physical	B-X
activity	B-X
and	B-X
health-related	B-X
outcomes	B-X
Joana	B-X
Cruz	B-X
,	B-X
Dina	B-X
Brooks	B-X
,	B-X
Alda	B-X
Marques	B-X
O89	B-X
Assessing	B-X
the	B-X
effectiveness	B-X
of	B-X
a	B-X
Complex	B-X
Nursing	B-X
Intervention	B-X
M	B-X
RosÃ¡rio	B-X
Pinto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
Lima-Basto	B-X
,	B-X
Miguel	B-X
Neves	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
O90	B-X
Psychotherapeutic	B-X
intervention	B-X
in	B-X
addiction	B-X
disorders	B-X
:	B-X
Change	B-X
in	B-X
psychopathological	B-X
symptoms	B-X
and	B-X
emotional	B-X
states	B-X
Carla	B-X
Bizarro	B-X
,	B-X
Marina	B-X
Cunha	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Couto	B-X
Margarida	B-X
,	B-X
Ana	B-X
P.	B-X
Amorim	B-X
,	B-X
Eduardo	B-X
Silva	B-X
O91	B-X
Economic	B-X
impact	B-X
of	B-X
a	B-X
nursing	B-X
intervention	B-X
program	B-X
to	B-X
promote	B-X
self-management	B-X
in	B-X
COPD	B-X
Susana	B-X
Cruz	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
,	B-X
Jorge	B-X
Valente	B-X
O92	B-X
Multimodal	B-X
acute	B-X
pain	B-X
management	B-X
during	B-X
uterine	B-X
artery	B-X
embolization	B-X
in	B-X
treatment	B-X
of	B-X
uterine	B-X
myomas	B-X
JosÃ©	B-X
T.	B-X
Guerrero	B-X
,	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Rafael	B-X
B.	B-X
Santos	B-X
,	B-X
Estefania	B-X
P.	B-X
Gonzalez	B-X
,	B-X
FÃ¡tima	B-X
M.	B-X
Monago	B-X
,	B-X
Lierni	B-X
U.	B-X
Ugalde	B-X
,	B-X
Marta	B-X
M.	B-X
VÃ©lez	B-X
,	B-X
Maria	B-X
J.	B-X
Tena	B-X
O93	B-X
Fluid	B-X
administration	B-X
strategies	B-X
in	B-X
major	B-X
surgery	B-X
:	B-X
Goal-directed	B-X
therapy	B-X
JosÃ©	B-X
T.	B-X
Guerrero	B-X
,	B-X
Rafael	B-X
Bravo	B-X
,	B-X
Francisco	B-X
L.	B-X
PÃ©rez-Caballero	B-X
,	B-X
Isabel	B-X
A.	B-X
Becerra	B-X
,	B-X
MÂª	B-X
Elizabeth	B-X
Agudelo	B-X
,	B-X
Guadalupe	B-X
Acedo	B-X
,	B-X
Roberto	B-X
Bajo	B-X
O94	B-X
Development	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
self-management	B-X
educational	B-X
programme	B-X
using	B-X
lay-led	B-X
â	B-X
s	B-X
in	B-X
adolescents	B-X
Spina	B-X
Bifida	B-X
:	B-X
A	B-X
pilot	B-X
study	B-X
Isabel	B-X
Malheiro	B-X
,	B-X
Filomena	B-X
Gaspar	B-X
,	B-X
LuÃ­sa	B-X
Barros	B-X
O95	B-X
Influence	B-X
of	B-X
chair-based	B-X
yoga	B-X
exercises	B-X
on	B-X
salivary	B-X
anti-microbial	B-X
proteins	B-X
in	B-X
institutionalized	B-X
frail-elderly	B-X
women	B-X
:	B-X
a	B-X
preliminary	B-X
study	B-X
Guilherme	B-X
Furtado	B-X
,	B-X
Mateus	B-X
Uba-Chupel	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
LuÃ­s	B-X
Rama	B-X
,	B-X
Margarida	B-X
Braga	B-X
,	B-X
JosÃ©	B-X
P.	B-X
Ferreira	B-X
,	B-X
Ana	B-X
MÂª	B-X
Teixeira	B-X
O96	B-X
High	B-X
intensity	B-X
interval	B-X
training	B-X
vs	B-X
moderate	B-X
intensity	B-X
continuous	B-X
training	B-X
impact	B-X
on	B-X
diabetes	B-X
2	B-X
JoÃ£o	B-X
Cruz	B-X
,	B-X
Tiago	B-X
Barbosa	B-X
,	B-X
Ãngela	B-X
SimÃµes	B-X
,	B-X
LuÃ­s	B-X
Coelho	B-X
O97	B-X
Family	B-X
caregiver	B-X
of	B-X
people	B-X
with	B-X
pressure	B-X
ulcer	B-X
:	B-X
Nursing	B-X
intervention	B-X
plan	B-X
Alexandre	B-X
Rodrigues	B-X
,	B-X
Juan-Fernando	B-X
JimÃ©nez-DÃ­az	B-X
,	B-X
Francisco	B-X
Martinez-HernÃ¡ndez	B-X
,	B-X
Bienvenida	B-X
Rodriguez-De-Vera	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Alexandrina	B-X
Rodrigues	B-X
O98	B-X
Chronic	B-X
effects	B-X
of	B-X
exercise	B-X
on	B-X
motor	B-X
memory	B-X
consolidation	B-X
in	B-X
elderly	B-X
people	B-X
AndrÃ©	B-X
Ramalho	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
InÃªs	B-X
Santo	B-X
,	B-X
AntÃ³nio	B-X
Rosado	B-X
O99	B-X
Impression	B-X
cytology	B-X
of	B-X
the	B-X
ocular	B-X
surface	B-X
:	B-X
Collection	B-X
technique	B-X
and	B-X
sample	B-X
processing	B-X
Paula	B-X
MendonÃ§a	B-X
,	B-X
KÃ¡tia	B-X
Freitas	B-X
O100	B-X
Does	B-X
sport	B-X
practice	B-X
affect	B-X
the	B-X
reaction	B-X
time	B-X
in	B-X
neuromuscular	B-X
activity	B-X
?	B-X
Dora	B-X
Ferreira	B-X
,	B-X
AntÃ³nio	B-X
Brito	B-X
,	B-X
Renato	B-X
Fernandes	B-X
O101	B-X
Efficiency	B-X
of	B-X
the	B-X
enteral	B-X
administration	B-X
of	B-X
fibbers	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
chronic	B-X
obstipation	B-X
Sofia	B-X
Gomes	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
Rita	B-X
Oliveira	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
O102	B-X
Fast	B-X
decalcifier	B-X
in	B-X
compact	B-X
bone	B-X
and	B-X
spongy	B-X
bone	B-X
Paula	B-X
MendonÃ§a	B-X
,	B-X
Ana	B-X
P.	B-X
Casimiro	B-X
,	B-X
PatrÃ­cia	B-X
Martins	B-X
,	B-X
Iryna	B-X
Silva	B-X
O103	B-X
Health	B-X
promotion	B-X
in	B-X
the	B-X
elderly	B-X
â	B-X
Intervention	B-X
project	B-X
in	B-X
dementia	B-X
Diana	B-X
Evangelista	B-X
O104	B-X
Prevention	B-X
of	B-X
musculoskeletal	B-X
disorders	B-X
through	B-X
an	B-X
exercise	B-X
protocol	B-X
held	B-X
in	B-X
labour	B-X
context	B-X
Catarina	B-X
LeitÃ£o	B-X
,	B-X
FÃ¡bia	B-X
Velosa	B-X
,	B-X
NÃ©lio	B-X
Carecho	B-X
,	B-X
LuÃ­s	B-X
Coelho	B-X
O105	B-X
Knowledge	B-X
of	B-X
teachers	B-X
and	B-X
other	B-X
education	B-X
agents	B-X
on	B-X
diabetes	B-X
type	B-X
1	B-X
:	B-X
Effectiveness	B-X
of	B-X
an	B-X
intervention	B-X
program	B-X
Eva	B-X
Menino	B-X
,	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
FÃ¡tima	B-X
Soares	B-X
,	B-X
Ester	B-X
Gama	B-X
,	B-X
Clementina	B-X
Gordo	B-X
O106	B-X
Treatment	B-X
of	B-X
diabetic	B-X
peripheral	B-X
neuropathic	B-X
pain	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
clinical	B-X
trials	B-X
of	B-X
phase	B-X
II	B-X
and	B-X
III	B-X
Eliana	B-X
Moreira	B-X
,	B-X
Cristiana	B-X
MidÃµes	B-X
,	B-X
Marlene	B-X
Santos	B-X
O107	B-X
New	B-X
drugs	B-X
for	B-X
osteoporosis	B-X
treatment	B-X
:	B-X
Systematic	B-X
review	B-X
of	B-X
clinical	B-X
trials	B-X
of	B-X
phase	B-X
II	B-X
and	B-X
III	B-X
Sara	B-X
Machado	B-X
,	B-X
VÃ¢nia	B-X
P.	B-X
Oliveira	B-X
,	B-X
Marlene	B-X
Santos	B-X
O108	B-X
Promoting	B-X
hope	B-X
at	B-X
the	B-X
end	B-X
of	B-X
life	B-X
:	B-X
Effectiveness	B-X
of	B-X
an	B-X
Intervention	B-X
Programme	B-X
Ana	B-X
Querido	B-X
,	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Rita	B-X
Marques	B-X
,	B-X
Zaida	B-X
Charepe	B-X
P43	B-X
Psychomotor	B-X
therapy	B-X
effects	B-X
on	B-X
adaptive	B-X
behaviour	B-X
and	B-X
motor	B-X
proficiency	B-X
of	B-X
adults	B-X
with	B-X
intellectual	B-X
disability	B-X
Ana	B-X
Antunes	B-X
,	B-X
Sofia	B-X
Santos	B-X
P44	B-X
The	B-X
effect	B-X
of	B-X
exercise	B-X
therapy	B-X
in	B-X
multiple	B-X
sclerosis	B-X
â	B-X
a	B-X
single	B-X
study	B-X
case	B-X
Marlene	B-X
C.	B-X
Rosa	B-X
P45	B-X
Physical	B-X
condition	B-X
and	B-X
self-efficacy	B-X
in	B-X
people	B-X
with	B-X
fall	B-X
risk	B-X
â	B-X
a	B-X
preliminary	B-X
study	B-X
Marlene	B-X
C.	B-X
Rosa	B-X
,	B-X
Silvana	B-X
F.	B-X
Marques	B-X
P46	B-X
Shock	B-X
waves	B-X
:	B-X
their	B-X
effectiveness	B-X
in	B-X
improving	B-X
the	B-X
symptoms	B-X
of	B-X
calcifying	B-X
tendinitis	B-X
of	B-X
the	B-X
shoulder	B-X
Beatriz	B-X
Minghelli	B-X
,	B-X
EulÃ¡lia	B-X
Caro	B-X
P47	B-X
Pacifier	B-X
â	B-X
construction	B-X
and	B-X
pilot	B-X
application	B-X
of	B-X
a	B-X
parenting	B-X
intervention	B-X
for	B-X
parents	B-X
of	B-X
babies	B-X
until	B-X
six	B-X
months	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
MÂª	B-X
JosÃ©	B-X
LuÃ­s	B-X
,	B-X
Teresa	B-X
BrandÃ£o	B-X
P48	B-X
The	B-X
influence	B-X
of	B-X
Motor	B-X
Imagery	B-X
in	B-X
fine	B-X
motor	B-X
skills	B-X
of	B-X
individuals	B-X
with	B-X
disabilities	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Daniel	B-X
Marinho	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
Diogo	B-X
Monteiro	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
InÃªs	B-X
Santo	B-X
P49	B-X
Evaluation	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
walking	B-X
programme	B-X
on	B-X
the	B-X
fall	B-X
risk	B-X
factors	B-X
in	B-X
older	B-X
people	B-X
â	B-X
a	B-X
longitudinal	B-X
pilot	B-X
study	B-X
Lina	B-X
Monteiro	B-X
,	B-X
FÃ¡tima	B-X
Ramalho	B-X
,	B-X
Rita	B-X
Santos-Rocha	B-X
,	B-X
SÃ³nia	B-X
Morgado	B-X
,	B-X
Teresa	B-X
Bento	B-X
P50	B-X
Nursing	B-X
intervention	B-X
programme	B-X
in	B-X
lifestyles	B-X
of	B-X
adolescents	B-X
Gilberta	B-X
Sousa	B-X
,	B-X
OtÃ­lia	B-X
Freitas	B-X
,	B-X
Isabel	B-X
Silva	B-X
,	B-X
GregÃ³rio	B-X
Freitas	B-X
,	B-X
Clementina	B-X
Morna	B-X
,	B-X
Rita	B-X
Vasconcelos	B-X
P51	B-X
The	B-X
person	B-X
submitted	B-X
to	B-X
hip	B-X
replacement	B-X
rehabilitation	B-X
,	B-X
at	B-X
home	B-X
Tatiana	B-X
Azevedo	B-X
,	B-X
Salete	B-X
Soares	B-X
,	B-X
Jacinta	B-X
Pisco	B-X
P52	B-X
Effects	B-X
of	B-X
Melatonin	B-X
use	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
neurovegetative	B-X
diseases	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
Efrain	B-X
O.	B-X
Olszewer	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
SebastiÃ£o	B-X
T.	B-X
Oliveira	B-X
P53	B-X
Review	B-X
of	B-X
Phytotherapy	B-X
and	B-X
other	B-X
natural	B-X
substances	B-X
in	B-X
alcohol	B-X
abuse	B-X
and	B-X
alcoholism	B-X
Erica	B-X
Santos	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
Carla	B-X
Maia	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
Joana	B-X
Santos	B-X
,	B-X
Maria	B-X
F.	B-X
Mendes	B-X
,	B-X
Rita	B-X
F.	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
P54	B-X
Dietary	B-X
programme	B-X
impact	B-X
on	B-X
biochemical	B-X
markers	B-X
in	B-X
diabetics	B-X
:	B-X
systematic	B-X
review	B-X
Eduarda	B-X
Barreira	B-X
,	B-X
Ana	B-X
Pereira	B-X
,	B-X
Josiana	B-X
A.	B-X
Vaz	B-X
,	B-X
AndrÃ©	B-X
Novo	B-X
P55	B-X
Biological	B-X
approaches	B-X
to	B-X
knee	B-X
osteoarthritis	B-X
:	B-X
platelet-rich	B-X
plasma	B-X
and	B-X
hyaluronic	B-X
acid	B-X
LuÃ­s	B-X
D.	B-X
Silva	B-X
,	B-X
Bruno	B-X
Maia	B-X
,	B-X
Eduardo	B-X
Ferreira	B-X
,	B-X
Filipa	B-X
Pires	B-X
,	B-X
Renato	B-X
Andrade	B-X
,	B-X
LuÃ­s	B-X
Camarinha	B-X
P56	B-X
Platelet-rich	B-X
plasma	B-X
and	B-X
hyaluronic	B-X
acid	B-X
intra-articular	B-X
injections	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
ankle	B-X
osteoarthritis	B-X
LuÃ­s	B-X
D.	B-X
Silva	B-X
,	B-X
Bruno	B-X
Maia	B-X
,	B-X
Eduardo	B-X
Ferreira	B-X
,	B-X
Filipa	B-X
Pires	B-X
,	B-X
Renato	B-X
Andrade	B-X
,	B-X
LuÃ­s	B-X
Camarinha	B-X
P57	B-X
The	B-X
impact	B-X
of	B-X
preventive	B-X
measures	B-X
in	B-X
the	B-X
incidence	B-X
of	B-X
diabetic	B-X
foot	B-X
ulcers	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
Ana	B-X
F.	B-X
CÃ©sar	B-X
,	B-X
Mariana	B-X
PoÃ§o	B-X
,	B-X
David	B-X
Ventura	B-X
,	B-X
Raquel	B-X
Loura	B-X
,	B-X
Pedro	B-X
Gomes	B-X
,	B-X
Catarina	B-X
Gomes	B-X
,	B-X
ClÃ¡udia	B-X
Silva	B-X
,	B-X
Elsa	B-X
Melo	B-X
,	B-X
JoÃ£o	B-X
Lindo	B-X
P58	B-X
Dating	B-X
violence	B-X
among	B-X
young	B-X
adolescents	B-X
Joana	B-X
Domingos	B-X
,	B-X
Zaida	B-X
Mendes	B-X
,	B-X
Susana	B-X
Poeta	B-X
,	B-X
Tiago	B-X
Carvalho	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
P59	B-X
Physical	B-X
activity	B-X
and	B-X
motor	B-X
memory	B-X
in	B-X
pedal	B-X
dexterity	B-X
AndrÃ©	B-X
Ramalho	B-X
,	B-X
AntÃ³nio	B-X
Rosado	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
InÃªs	B-X
Garcia	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
P60	B-X
The	B-X
effects	B-X
of	B-X
whole	B-X
body	B-X
vibration	B-X
on	B-X
the	B-X
electromyographic	B-X
activity	B-X
of	B-X
thigh	B-X
muscles	B-X
Sandra	B-X
Rodrigues	B-X
,	B-X
Rui	B-X
Meneses	B-X
,	B-X
Carlos	B-X
Afonso	B-X
,	B-X
LuÃ­s	B-X
Faria	B-X
,	B-X
AdÃ©rito	B-X
Seixas	B-X
P61	B-X
Mental	B-X
health	B-X
promotion	B-X
in	B-X
the	B-X
workplace	B-X
Marina	B-X
Cordeiro	B-X
,	B-X
Paulo	B-X
Granjo	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Gomes	B-X
P62	B-X
Influence	B-X
of	B-X
physical	B-X
exercise	B-X
on	B-X
the	B-X
self-perception	B-X
of	B-X
body	B-X
image	B-X
in	B-X
elderly	B-X
women	B-X
:	B-X
A	B-X
systematic	B-X
review	B-X
of	B-X
qualitative	B-X
studies	B-X
Nelba	B-X
R.	B-X
Souza	B-X
,	B-X
Guilherme	B-X
E.	B-X
Furtado	B-X
,	B-X
Saulo	B-X
V.	B-X
Rocha	B-X
,	B-X
Paula	B-X
Silva	B-X
,	B-X
Joana	B-X
Carvalho	B-X
O109	B-X
Psychometric	B-X
properties	B-X
of	B-X
the	B-X
Portuguese	B-X
version	B-X
of	B-X
the	B-X
Ãxamen	B-X
Geronto-Psychomoteur	B-X
(	B-X
P-EGP	B-X
)	B-X
Marina	B-X
Ana	B-X
Morais	B-X
,	B-X
Sofia	B-X
Santos	B-X
,	B-X
Paula	B-X
Lebre	B-X
,	B-X
Ana	B-X
Antunes	B-X
O110	B-X
Symptoms	B-X
of	B-X
depression	B-X
in	B-X
the	B-X
elderly	B-X
population	B-X
of	B-X
Portugal	B-X
,	B-X
Spain	B-X
and	B-X
Italy	B-X
AntÃ³nio	B-X
Calha	B-X
O111	B-X
Emotion	B-X
regulation	B-X
strategies	B-X
and	B-X
psychopathology	B-X
symptoms	B-X
:	B-X
A	B-X
comparison	B-X
between	B-X
adolescents	B-X
with	B-X
and	B-X
without	B-X
deliberate	B-X
self-harm	B-X
Ana	B-X
Xavier	B-X
,	B-X
Marina	B-X
Cunha	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
O112	B-X
Prevalence	B-X
of	B-X
physical	B-X
disability	B-X
in	B-X
people	B-X
with	B-X
leprosy	B-X
Liana	B-X
Alencar	B-X
,	B-X
Madalena	B-X
Cunha	B-X
,	B-X
AntÃ³nio	B-X
Madureira	B-X
O113	B-X
Quality	B-X
of	B-X
life	B-X
and	B-X
self-esteem	B-X
in	B-X
type	B-X
1	B-X
and	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
patients	B-X
Ilda	B-X
Cardoso	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Fernanda	B-X
Daniel	B-X
,	B-X
VÃ­tor	B-X
Rodrigues	B-X
O114	B-X
Cross-cultural	B-X
comparison	B-X
of	B-X
gross	B-X
motor	B-X
coordination	B-X
in	B-X
children	B-X
from	B-X
Brazil	B-X
and	B-X
Portugal	B-X
Leonardo	B-X
Luz	B-X
,	B-X
Tatiana	B-X
Luz	B-X
,	B-X
MaurÃ­cio	B-X
R.	B-X
Ramos	B-X
,	B-X
Dayse	B-X
C.	B-X
Medeiros	B-X
,	B-X
Bruno	B-X
M.	B-X
Carmo	B-X
,	B-X
AndrÃ©	B-X
Seabra	B-X
,	B-X
Cristina	B-X
Padez	B-X
,	B-X
Manuel	B-X
C.	B-X
Silva	B-X
O115	B-X
Electrocardiographic	B-X
differences	B-X
between	B-X
African	B-X
and	B-X
Caucasian	B-X
people	B-X
AntÃ³nio	B-X
Rodrigues	B-X
,	B-X
PatrÃ­cia	B-X
Coelho	B-X
,	B-X
Alexandre	B-X
Coelho	B-X
O116	B-X
Factors	B-X
associated	B-X
with	B-X
domestic	B-X
,	B-X
sexual	B-X
and	B-X
other	B-X
types	B-X
of	B-X
violence	B-X
in	B-X
the	B-X
city	B-X
of	B-X
PalhoÃ§a	B-X
-	B-X
Brazil	B-X
Madson	B-X
Caminha	B-X
,	B-X
Filipe	B-X
Matheus	B-X
,	B-X
Elenice	B-X
Mendes	B-X
,	B-X
Jony	B-X
Correia	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
O117	B-X
Tinnitus	B-X
prevalence	B-X
study	B-X
of	B-X
users	B-X
of	B-X
a	B-X
hospital	B-X
of	B-X
public	B-X
management	B-X
-	B-X
Spain	B-X
Francisco	B-X
J.	B-X
Hernandez-Martinez	B-X
,	B-X
Juan	B-X
F.	B-X
Jimenez-Diaz	B-X
,	B-X
Bienvendida	B-X
C.	B-X
Rodriguez-De-Vera	B-X
,	B-X
Carla	B-X
Jimenez-Rodriguez	B-X
,	B-X
Yadira	B-X
Armas-Gonzalez	B-X
O118	B-X
Difficulties	B-X
experienced	B-X
by	B-X
parents	B-X
of	B-X
children	B-X
with	B-X
diabetes	B-X
mellitus	B-X
of	B-X
preschool	B-X
age	B-X
in	B-X
therapeutic	B-X
and	B-X
nutritional	B-X
management	B-X
CÃ¡tia	B-X
Rodrigues	B-X
,	B-X
Rosa	B-X
Pedroso	B-X
O119	B-X
E-mental	B-X
health	B-X
-	B-X
â	B-X
nice	B-X
to	B-X
have	B-X
â	B-X
or	B-X
â	B-X
must	B-X
have	B-X
â	B-X
?	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Valentim	B-X
R.	B-X
Alferes	B-X
,	B-X
MÂª	B-X
SÃ£o	B-X
JoÃ£o	B-X
BrÃªda	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
O124	B-X
Empowerment	B-X
,	B-X
knowledge	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
of	B-X
people	B-X
with	B-X
diabetes	B-X
type	B-X
2	B-X
in	B-X
the	B-X
Alto	B-X
Minho	B-X
Health	B-X
Local	B-X
Unit	B-X
MÂª	B-X
Carminda	B-X
Morais	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Rui	B-X
Pimenta	B-X
,	B-X
JosÃ©	B-X
Boavida	B-X
O125	B-X
Antihypertensive	B-X
therapy	B-X
adherence	B-X
among	B-X
hypertensive	B-X
patients	B-X
from	B-X
BraganÃ§a	B-X
county	B-X
,	B-X
Portugal	B-X
Isabel	B-X
C.	B-X
Pinto	B-X
,	B-X
TÃ¢nia	B-X
Pires	B-X
,	B-X
Catarina	B-X
Silva	B-X
O126	B-X
Subjective	B-X
perception	B-X
of	B-X
sexual	B-X
achievement	B-X
-	B-X
An	B-X
exploratory	B-X
study	B-X
on	B-X
people	B-X
with	B-X
overweight	B-X
Maria	B-X
Ribeiro	B-X
,	B-X
Maria	B-X
Viega-Branco	B-X
,	B-X
Filomena	B-X
Pereira	B-X
,	B-X
Ana	B-X
MÂª	B-X
Pereira	B-X
O127	B-X
Physical	B-X
activity	B-X
level	B-X
and	B-X
associated	B-X
factors	B-X
in	B-X
hypertensive	B-X
individuals	B-X
registered	B-X
in	B-X
the	B-X
family	B-X
health	B-X
strategy	B-X
of	B-X
a	B-X
basic	B-X
health	B-X
unit	B-X
from	B-X
the	B-X
city	B-X
of	B-X
PalhoÃ§a	B-X
,	B-X
Santa	B-X
Catarina	B-X
,	B-X
Brazil	B-X
FabrÃ­cia	B-X
M.	B-X
Almeida	B-X
,	B-X
Gustavo	B-X
L.	B-X
Estevez	B-X
,	B-X
Sandra	B-X
Ribeiro	B-X
,	B-X
Marcia	B-X
R.	B-X
Kretzer	B-X
O128	B-X
Perception	B-X
of	B-X
functional	B-X
fitness	B-X
and	B-X
health	B-X
in	B-X
non-institutionalised	B-X
elderly	B-X
from	B-X
rural	B-X
areas	B-X
Paulo	B-X
V.	B-X
JoÃ£o	B-X
,	B-X
Paulo	B-X
Nogueira	B-X
,	B-X
Sandra	B-X
Novais	B-X
,	B-X
Ana	B-X
Pereira	B-X
,	B-X
Lara	B-X
Carneiro	B-X
,	B-X
Maria	B-X
Mota	B-X
O129	B-X
Medication	B-X
adherence	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
treated	B-X
at	B-X
primary	B-X
health	B-X
care	B-X
in	B-X
Coimbra	B-X
Rui	B-X
Cruz	B-X
,	B-X
Luiz	B-X
Santiago	B-X
,	B-X
Carlos	B-X
Fontes-Ribeiro	B-X
O130	B-X
Multivariate	B-X
association	B-X
between	B-X
body	B-X
mass	B-X
index	B-X
and	B-X
multi-comorbidities	B-X
in	B-X
elderly	B-X
people	B-X
living	B-X
in	B-X
low	B-X
socio-economic	B-X
status	B-X
context	B-X
Guilherme	B-X
Furtado	B-X
,	B-X
Saulo	B-X
V.	B-X
Rocha	B-X
,	B-X
AndrÃ©	B-X
P.	B-X
Coutinho	B-X
,	B-X
JoÃ£o	B-X
S.	B-X
Neto	B-X
,	B-X
LÃ©lia	B-X
R.	B-X
Vasconcelos	B-X
,	B-X
Nelba	B-X
R.	B-X
Souza	B-X
,	B-X
EstÃ©lio	B-X
Dantas	B-X
O131	B-X
Metacognition	B-X
,	B-X
rumination	B-X
and	B-X
experiential	B-X
avoidance	B-X
in	B-X
Borderline	B-X
Personality	B-X
Disorder	B-X
Alexandra	B-X
Dinis	B-X
,	B-X
SÃ©rgio	B-X
Carvalho	B-X
,	B-X
Paula	B-X
Castilho	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
O132	B-X
Health	B-X
issues	B-X
in	B-X
a	B-X
vulnerable	B-X
population	B-X
:	B-X
nursing	B-X
consultation	B-X
in	B-X
a	B-X
public	B-X
bathhouse	B-X
in	B-X
Lisbon	B-X
Alexandra	B-X
Sarreira-Santos	B-X
,	B-X
AmÃ©lia	B-X
Figueiredo	B-X
,	B-X
Lurdes	B-X
Medeiros-Garcia	B-X
,	B-X
Paulo	B-X
Seabra	B-X
O133	B-X
The	B-X
perception	B-X
of	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
people	B-X
with	B-X
multiple	B-X
sclerosis	B-X
accompanied	B-X
in	B-X
External	B-X
Consultation	B-X
of	B-X
the	B-X
Local	B-X
Health	B-X
Unit	B-X
of	B-X
Alto	B-X
Minho	B-X
Rosa	B-X
Rodrigues	B-X
,	B-X
MÂª	B-X
Carminda	B-X
Morais	B-X
,	B-X
Paula	B-X
O.	B-X
Fernandes	B-X
O134	B-X
Representation	B-X
of	B-X
interaction	B-X
established	B-X
between	B-X
immigrant	B-X
women	B-X
and	B-X
nurse	B-X
during	B-X
pregnancy	B-X
to	B-X
postpartum	B-X
,	B-X
from	B-X
the	B-X
perspective	B-X
of	B-X
immigrant	B-X
women	B-X
ConceiÃ§Ã£o	B-X
Santiago	B-X
,	B-X
MÂª	B-X
Henriqueta	B-X
Figueiredo	B-X
,	B-X
Marta	B-X
L.	B-X
Basto	B-X
O135	B-X
Illness	B-X
perceptions	B-X
and	B-X
medication	B-X
adherence	B-X
in	B-X
hypertension	B-X
Teresa	B-X
GuimarÃ£es	B-X
,	B-X
AndrÃ©	B-X
Coelho	B-X
,	B-X
Anabela	B-X
GraÃ§a	B-X
,	B-X
Ana	B-X
M.	B-X
Silva	B-X
,	B-X
Ana	B-X
R.	B-X
Fonseca	B-X
O136	B-X
A	B-X
Portuguese	B-X
study	B-X
on	B-X
adults	B-X
â	B-X
intimate	B-X
partner	B-X
violence	B-X
,	B-X
interpersonal	B-X
trust	B-X
and	B-X
hope	B-X
Luz	B-X
Vale-Dias	B-X
,	B-X
BÃ¡rbara	B-X
Minas	B-X
,	B-X
Graciete	B-X
Franco-Borges	B-X
P63	B-X
QOL	B-X
â	B-X
predictors	B-X
of	B-X
people	B-X
with	B-X
intellectual	B-X
disability	B-X
and	B-X
general	B-X
population	B-X
Cristina	B-X
SimÃµes	B-X
,	B-X
Sofia	B-X
Santos	B-X
P64	B-X
Content	B-X
validation	B-X
of	B-X
the	B-X
Communication	B-X
Disability	B-X
Profile	B-X
(	B-X
CDP	B-X
)	B-X
-	B-X
Portuguese	B-X
Version	B-X
Ana	B-X
Serra	B-X
,	B-X
Maria	B-X
Matos	B-X
,	B-X
LuÃ­s	B-X
Jesus	B-X
P65	B-X
Study	B-X
of	B-X
biochemical	B-X
and	B-X
haematological	B-X
changes	B-X
in	B-X
football	B-X
players	B-X
Ana	B-X
S.	B-X
Tavares	B-X
,	B-X
Ana	B-X
Almeida	B-X
,	B-X
CÃ©u	B-X
LeitÃ£o	B-X
,	B-X
Edna	B-X
Varandas	B-X
,	B-X
Renato	B-X
Abreu	B-X
,	B-X
Fernando	B-X
BellÃ©m	B-X
P66	B-X
Body	B-X
image	B-X
dissatisfaction	B-X
in	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
:	B-X
exploring	B-X
the	B-X
role	B-X
of	B-X
chronic	B-X
illness-related	B-X
shame	B-X
InÃªs	B-X
A.	B-X
Trindade	B-X
,	B-X
ClÃ¡udia	B-X
Ferreira	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
,	B-X
Joana	B-X
Marta-SimÃµes	B-X
P67	B-X
Obesity	B-X
and	B-X
sleep	B-X
in	B-X
the	B-X
adult	B-X
population	B-X
-	B-X
a	B-X
systematic	B-X
review	B-X
Odete	B-X
Amaral	B-X
,	B-X
Cristiana	B-X
Miranda	B-X
,	B-X
Pedro	B-X
GuimarÃ£es	B-X
,	B-X
Rodrigo	B-X
GonÃ§alves	B-X
,	B-X
NÃ©lio	B-X
Veiga	B-X
,	B-X
Carlos	B-X
Pereira	B-X
P68	B-X
Frequency	B-X
of	B-X
daytime	B-X
sleepiness	B-X
and	B-X
obstructive	B-X
sleep	B-X
apnea	B-X
risk	B-X
in	B-X
COPD	B-X
patients	B-X
TÃ¢nia	B-X
C.	B-X
Fleig	B-X
,	B-X
Elisabete	B-X
A.	B-X
San-Martin	B-X
,	B-X
CÃ¡ssia	B-X
L.	B-X
Goulart	B-X
,	B-X
Paloma	B-X
B.	B-X
Schneiders	B-X
,	B-X
Natacha	B-X
F.	B-X
Miranda	B-X
,	B-X
Lisiane	B-X
L.	B-X
Carvalho	B-X
,	B-X
Andrea	B-X
G.	B-X
Silva	B-X
P69	B-X
Working	B-X
with	B-X
immigrant-origin	B-X
clients	B-X
:	B-X
discourses	B-X
and	B-X
practices	B-X
of	B-X
health	B-X
professionals	B-X
Joana	B-X
Topa	B-X
,	B-X
ConceiÃ§Ã£o	B-X
Nogueira	B-X
,	B-X
Sofia	B-X
Neves	B-X
P70	B-X
Systemic	B-X
Lupus	B-X
Erythematosus	B-X
â	B-X
what	B-X
are	B-X
audiovestibular	B-X
changes	B-X
?	B-X
Rita	B-X
Ventura	B-X
,	B-X
Cristina	B-X
NazarÃ©	B-X
P71	B-X
Mental	B-X
disorders	B-X
in	B-X
the	B-X
oldest	B-X
old	B-X
:	B-X
findings	B-X
from	B-X
the	B-X
Portuguese	B-X
national	B-X
hospitalization	B-X
database	B-X
Daniela	B-X
BrandÃ£o	B-X
,	B-X
Alberto	B-X
Freitas	B-X
,	B-X
Ãscar	B-X
Ribeiro	B-X
,	B-X
ConstanÃ§a	B-X
PaÃºl	B-X
P72	B-X
Recurrence	B-X
analysis	B-X
in	B-X
postural	B-X
control	B-X
in	B-X
children	B-X
with	B-X
cerebral	B-X
palsy	B-X
Cristiana	B-X
MercÃª	B-X
,	B-X
Marco	B-X
Branco	B-X
,	B-X
Pedro	B-X
Almeida	B-X
,	B-X
Daniela	B-X
Nascimento	B-X
,	B-X
Juliana	B-X
Pereira	B-X
,	B-X
David	B-X
Catela	B-X
P73	B-X
The	B-X
experience	B-X
of	B-X
self-care	B-X
in	B-X
the	B-X
elderly	B-X
with	B-X
COPD	B-X
:	B-X
contributions	B-X
to	B-X
reflect	B-X
proximity	B-X
care	B-X
Helga	B-X
Rafael	B-X
P74	B-X
Culturally	B-X
competent	B-X
nurses	B-X
:	B-X
managing	B-X
unpredictability	B-X
in	B-X
clinical	B-X
practice	B-X
with	B-X
immigrants	B-X
Alcinda	B-X
C.	B-X
Reis	B-X
O137	B-X
Paediatric	B-X
speech	B-X
and	B-X
language	B-X
screening	B-X
:	B-X
An	B-X
instrument	B-X
for	B-X
health	B-X
professionals	B-X
Ana	B-X
Mendes	B-X
,	B-X
Ana	B-X
R.	B-X
Valente	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O138	B-X
Anthropometric	B-X
and	B-X
nutritional	B-X
assessment	B-X
in	B-X
bodybuilders	B-X
Diana	B-X
Sousa	B-X
,	B-X
Ana	B-X
L.	B-X
Baltazar	B-X
,	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
O139	B-X
Computerized	B-X
adventitious	B-X
respiratory	B-X
sounds	B-X
in	B-X
children	B-X
with	B-X
lower	B-X
respiratory	B-X
tract	B-X
infections	B-X
Ana	B-X
Oliveira	B-X
,	B-X
JosÃ©	B-X
AparÃ­cio	B-X
,	B-X
Alda	B-X
Marques	B-X
O140	B-X
Role	B-X
of	B-X
computerized	B-X
respiratory	B-X
sounds	B-X
as	B-X
a	B-X
marker	B-X
in	B-X
LRTI	B-X
Alda	B-X
Marques	B-X
,	B-X
Ana	B-X
Oliveira	B-X
,	B-X
Joana	B-X
Neves	B-X
,	B-X
Rodrigo	B-X
Ayoub	B-X
O141	B-X
Confirmatory	B-X
factor	B-X
analysis	B-X
of	B-X
the	B-X
Personal	B-X
Wellbeing	B-X
Index	B-X
in	B-X
people	B-X
with	B-X
chronic	B-X
kidney	B-X
disease	B-X
LuÃ­s	B-X
Sousa	B-X
,	B-X
Cristina	B-X
Marques-Vieira	B-X
,	B-X
Sandy	B-X
Severino	B-X
,	B-X
Helena	B-X
JosÃ©	B-X
O142	B-X
Phonological	B-X
awareness	B-X
skills	B-X
in	B-X
school	B-X
aged	B-X
children	B-X
InÃªs	B-X
Cadorio	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O143	B-X
Assessment	B-X
of	B-X
early	B-X
memories	B-X
of	B-X
warmth	B-X
and	B-X
safeness	B-X
in	B-X
interaction	B-X
with	B-X
peers	B-X
:	B-X
its	B-X
relationship	B-X
with	B-X
psychopathology	B-X
in	B-X
adolescence	B-X
Marina	B-X
Cunha	B-X
,	B-X
Diogo	B-X
Andrade	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Margarida	B-X
Couto	B-X
O144	B-X
The	B-X
molecular	B-X
effects	B-X
induced	B-X
by	B-X
single	B-X
shot	B-X
irradiation	B-X
on	B-X
a	B-X
diffuse	B-X
large	B-X
B	B-X
cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
Fernando	B-X
Mendes	B-X
,	B-X
CÃ¡tia	B-X
Domingues	B-X
,	B-X
Susann	B-X
Schukg	B-X
,	B-X
Ana	B-X
M.	B-X
Abrantes	B-X
,	B-X
Ana	B-X
C.	B-X
GonÃ§alves	B-X
,	B-X
Tiago	B-X
Sales	B-X
,	B-X
Ricardo	B-X
Teixo	B-X
,	B-X
Rita	B-X
Silva	B-X
,	B-X
JÃ©ssica	B-X
Estrela	B-X
,	B-X
Mafalda	B-X
Laranjo	B-X
,	B-X
JoÃ£o	B-X
Casalta-Lopes	B-X
,	B-X
Clara	B-X
Rocha	B-X
,	B-X
Paulo	B-X
C.	B-X
SimÃµes	B-X
,	B-X
Ana	B-X
B.	B-X
Sarmento-Ribeiro	B-X
,	B-X
MÂª	B-X
Filomena	B-X
Botelho	B-X
,	B-X
Manuel	B-X
S.	B-X
Rosa	B-X
O145	B-X
Morpho-functional	B-X
characterization	B-X
of	B-X
cardiac	B-X
chambers	B-X
by	B-X
Transthoracic	B-X
Echocardiography	B-X
,	B-X
in	B-X
young	B-X
athletes	B-X
of	B-X
gymnastics	B-X
competition	B-X
VirgÃ­nia	B-X
Fonseca	B-X
,	B-X
Diogo	B-X
ColaÃ§o	B-X
,	B-X
Vanessa	B-X
Neves	B-X
O146	B-X
Prevalence	B-X
of	B-X
the	B-X
antibodies	B-X
of	B-X
the	B-X
new	B-X
histo-blood	B-X
system	B-X
â	B-X
FORS	B-X
system	B-X
Carlos	B-X
Jesus	B-X
,	B-X
Camilla	B-X
Hesse	B-X
,	B-X
Clara	B-X
Rocha	B-X
,	B-X
NÃ¡dia	B-X
OsÃ³rio	B-X
,	B-X
Ana	B-X
Valado	B-X
,	B-X
Armando	B-X
Caseiro	B-X
,	B-X
AntÃ³nio	B-X
Gabriel	B-X
,	B-X
Lola	B-X
Svensson	B-X
,	B-X
Fernando	B-X
Mendes	B-X
,	B-X
Wafa	B-X
A.	B-X
Siba	B-X
,	B-X
Cristina	B-X
Pereira	B-X
,	B-X
Jorge	B-X
Tomaz	B-X
O147	B-X
Assessment	B-X
of	B-X
the	B-X
war-related	B-X
perceived	B-X
threat	B-X
in	B-X
Portuguese	B-X
Colonial	B-X
War	B-X
Veterans	B-X
Teresa	B-X
Carvalho	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
,	B-X
Marina	B-X
Cunha	B-X
O148	B-X
Pulse	B-X
transit	B-X
time	B-X
estimation	B-X
for	B-X
continuous	B-X
blood	B-X
pressure	B-X
measurement	B-X
:	B-X
A	B-X
comparative	B-X
study	B-X
Diana	B-X
Duarte	B-X
,	B-X
Nuno	B-X
V.	B-X
Lopes	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
O149	B-X
Blood	B-X
pressure	B-X
assessment	B-X
during	B-X
standard	B-X
clinical	B-X
manoeuvres	B-X
:	B-X
A	B-X
non-invasive	B-X
PPT	B-X
based	B-X
approach	B-X
Diana	B-X
Duarte	B-X
,	B-X
Nuno	B-X
V.	B-X
Lopes	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
O150	B-X
Development	B-X
and	B-X
initial	B-X
validation	B-X
of	B-X
the	B-X
Activities	B-X
and	B-X
Participation	B-X
Profile	B-X
related	B-X
to	B-X
Mobility	B-X
(	B-X
APPM	B-X
)	B-X
Anabela	B-X
C.	B-X
Martins	B-X
O151	B-X
MEASYCare-2010	B-X
StandardâA	B-X
geriatric	B-X
evaluation	B-X
system	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
:	B-X
Reliability	B-X
and	B-X
validity	B-X
of	B-X
the	B-X
latest	B-X
version	B-X
in	B-X
Portugal	B-X
Piedade	B-X
BrandÃ£o	B-X
,	B-X
Laura	B-X
Martins	B-X
,	B-X
Margarida	B-X
Cardoso	B-X
O152	B-X
Interrater	B-X
and	B-X
intrarater	B-X
reliability	B-X
and	B-X
agreement	B-X
of	B-X
the	B-X
range	B-X
of	B-X
shoulder	B-X
flexion	B-X
in	B-X
the	B-X
standing	B-X
upright	B-X
position	B-X
through	B-X
photographic	B-X
assessment	B-X
Nuno	B-X
Morais	B-X
,	B-X
Joana	B-X
Cruz	B-X
O153	B-X
Three-dimensional	B-X
biofabrication	B-X
techniques	B-X
for	B-X
tissue	B-X
regeneration	B-X
Nuno	B-X
Alves	B-X
,	B-X
Paula	B-X
Faria	B-X
,	B-X
Artur	B-X
Mateus	B-X
,	B-X
Pedro	B-X
MorouÃ§o	B-X
O154	B-X
A	B-X
new	B-X
computer	B-X
tool	B-X
for	B-X
biofabrication	B-X
applied	B-X
to	B-X
tissue	B-X
engineering	B-X
Nuno	B-X
Alves	B-X
,	B-X
Nelson	B-X
Ferreira	B-X
,	B-X
Artur	B-X
Mateus	B-X
,	B-X
Paula	B-X
Faria	B-X
,	B-X
Pedro	B-X
MorouÃ§o	B-X
O155	B-X
Development	B-X
and	B-X
psychometric	B-X
qualities	B-X
of	B-X
a	B-X
scale	B-X
to	B-X
measure	B-X
the	B-X
functional	B-X
independence	B-X
of	B-X
adolescents	B-X
with	B-X
motor	B-X
impairment	B-X
Isabel	B-X
Malheiro	B-X
,	B-X
Filomena	B-X
Gaspar	B-X
,	B-X
LuÃ­sa	B-X
Barros	B-X
O156	B-X
Organizational	B-X
Trust	B-X
in	B-X
Health	B-X
services	B-X
:	B-X
Exploratory	B-X
and	B-X
Confirmatory	B-X
factor	B-X
analysis	B-X
of	B-X
the	B-X
Organizational	B-X
Trust	B-X
Inventory-	B-X
Short	B-X
Form	B-X
(	B-X
OTI-SF	B-X
)	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Andreia	B-X
Cardoso	B-X
,	B-X
Lisete	B-X
MÃ³nico	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Albino	B-X
Lopes	B-X
,	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
O157	B-X
Thermal	B-X
symmetry	B-X
:	B-X
An	B-X
indicator	B-X
of	B-X
occupational	B-X
task	B-X
asymmetries	B-X
in	B-X
physiotherapy	B-X
AdÃ©rito	B-X
Seixas	B-X
,	B-X
Valter	B-X
Soares	B-X
,	B-X
Tiago	B-X
Dias	B-X
,	B-X
Ricardo	B-X
Vardasca	B-X
,	B-X
Joaquim	B-X
Gabriel	B-X
,	B-X
Sandra	B-X
Rodrigues	B-X
O158	B-X
A	B-X
study	B-X
of	B-X
ICT	B-X
active	B-X
monitoring	B-X
adoption	B-X
in	B-X
stroke	B-X
rehabilitation	B-X
Hugo	B-X
Paredes	B-X
,	B-X
ArsÃ©nio	B-X
Reis	B-X
,	B-X
Sara	B-X
Marinho	B-X
,	B-X
VÃ­tor	B-X
Filipe	B-X
,	B-X
JoÃ£o	B-X
Barroso	B-X
O159	B-X
Paranoia	B-X
Checklist	B-X
(	B-X
Portuguese	B-X
Version	B-X
)	B-X
:	B-X
Preliminary	B-X
studies	B-X
in	B-X
a	B-X
mixed	B-X
sample	B-X
of	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
Carolina	B-X
Da	B-X
Motta	B-X
,	B-X
CÃ©lia	B-X
B.	B-X
Carvalho	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
,	B-X
Ermelindo	B-X
Peixoto	B-X
O160	B-X
Reliability	B-X
and	B-X
validity	B-X
of	B-X
the	B-X
Composite	B-X
Scale	B-X
on	B-X
Morningness	B-X
:	B-X
European	B-X
Portuguese	B-X
version	B-X
,	B-X
in	B-X
adolescents	B-X
and	B-X
young	B-X
adults	B-X
Ana	B-X
A.	B-X
Gomes	B-X
,	B-X
Vanessa	B-X
Costa	B-X
,	B-X
Diana	B-X
Couto	B-X
,	B-X
Daniel	B-X
R.	B-X
Marques	B-X
,	B-X
JosÃ©	B-X
A.	B-X
LeitÃ£o	B-X
,	B-X
JosÃ©	B-X
Tavares	B-X
,	B-X
Maria	B-X
H.	B-X
Azevedo	B-X
,	B-X
Carlos	B-X
F.	B-X
Silva	B-X
O161	B-X
Evaluation	B-X
scale	B-X
of	B-X
patient	B-X
satisfaction	B-X
with	B-X
nursing	B-X
care	B-X
:	B-X
Psychometric	B-X
properties	B-X
evaluation	B-X
JoÃ£o	B-X
Freitas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
JoÃ£o	B-X
MarÃ´co	B-X
O162	B-X
Impact	B-X
of	B-X
fibromyalgia	B-X
on	B-X
quality	B-X
of	B-X
life	B-X
:	B-X
Comparing	B-X
results	B-X
from	B-X
generic	B-X
instruments	B-X
and	B-X
FIQR	B-X
Miguel	B-X
A.	B-X
Garcia-Gordillo	B-X
,	B-X
Daniel	B-X
Collado-Mateo	B-X
,	B-X
Gang	B-X
Chen	B-X
,	B-X
Angelo	B-X
Iezzi	B-X
,	B-X
JosÃ©	B-X
A.	B-X
Sala	B-X
,	B-X
JosÃ©	B-X
A.	B-X
ParraÃ§a	B-X
,	B-X
Narcis	B-X
Gusi	B-X
O163	B-X
Preliminary	B-X
study	B-X
of	B-X
the	B-X
adaptation	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
Rating	B-X
Scale	B-X
of	B-X
Resilient	B-X
Self	B-X
:	B-X
Resilience	B-X
,	B-X
self-harm	B-X
and	B-X
suicidal	B-X
ideation	B-X
in	B-X
adolescents	B-X
Jani	B-X
Sousa	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
Jacinto	B-X
Jardim	B-X
,	B-X
Anabela	B-X
Pereira	B-X
,	B-X
SÃ³nia	B-X
SimÃµes	B-X
,	B-X
Marina	B-X
Cunha	B-X
O164	B-X
Development	B-X
of	B-X
the	B-X
first	B-X
pressure	B-X
ulcer	B-X
in	B-X
inpatient	B-X
setting	B-X
:	B-X
Focus	B-X
on	B-X
length	B-X
of	B-X
stay	B-X
Pedro	B-X
Sardo	B-X
,	B-X
Jenifer	B-X
Guedes	B-X
,	B-X
JoÃ£o	B-X
Lindo	B-X
,	B-X
Paulo	B-X
Machado	B-X
,	B-X
Elsa	B-X
Melo	B-X
O165	B-X
Forms	B-X
of	B-X
Self-Criticizing	B-X
and	B-X
Self-Reassuring	B-X
Scale	B-X
:	B-X
Adaptation	B-X
and	B-X
early	B-X
findings	B-X
in	B-X
a	B-X
sample	B-X
of	B-X
Portuguese	B-X
children	B-X
CÃ©lia	B-X
B.	B-X
Carvalho	B-X
,	B-X
Joana	B-X
Benevides	B-X
,	B-X
Marina	B-X
Sousa	B-X
,	B-X
Joana	B-X
Cabral	B-X
,	B-X
Carolina	B-X
Da	B-X
Motta	B-X
O166	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Perinatal	B-X
Depression	B-X
Screening	B-X
and	B-X
Prevention	B-X
Tool	B-X
â	B-X
Preliminary	B-X
results	B-X
of	B-X
the	B-X
dimensional	B-X
approach	B-X
Ana	B-X
T.	B-X
Pereira	B-X
,	B-X
Sandra	B-X
Xavier	B-X
,	B-X
Julieta	B-X
Azevedo	B-X
,	B-X
Elisabete	B-X
Bento	B-X
,	B-X
Cristiana	B-X
Marques	B-X
,	B-X
Rosa	B-X
Carvalho	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
AntÃ³nio	B-X
Macedo	B-X
O167	B-X
Psychometric	B-X
properties	B-X
of	B-X
the	B-X
BaSIQS-Basic	B-X
Scale	B-X
on	B-X
insomnia	B-X
symptoms	B-X
and	B-X
quality	B-X
of	B-X
sleep	B-X
,	B-X
in	B-X
adults	B-X
and	B-X
in	B-X
the	B-X
elderly	B-X
Ana	B-X
M.	B-X
Silva	B-X
,	B-X
Juliana	B-X
Alves	B-X
,	B-X
Ana	B-X
A.	B-X
Gomes	B-X
,	B-X
Daniel	B-X
R.	B-X
Marques	B-X
,	B-X
MÂª	B-X
Helena	B-X
Azevedo	B-X
,	B-X
Carlos	B-X
Silva	B-X
O168	B-X
Enlightening	B-X
the	B-X
human	B-X
decision	B-X
in	B-X
health	B-X
:	B-X
The	B-X
skin	B-X
melanocytic	B-X
classification	B-X
challenge	B-X
Ana	B-X
Mendes	B-X
,	B-X
Huei	B-X
D.	B-X
Lee	B-X
,	B-X
Newton	B-X
SpolaÃ´r	B-X
,	B-X
Jefferson	B-X
T.	B-X
Oliva	B-X
,	B-X
Wu	B-X
F.	B-X
Chung	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
O169	B-X
Test-retest	B-X
reliability	B-X
household	B-X
life	B-X
study	B-X
and	B-X
health	B-X
questionnaire	B-X
Pomerode	B-X
(	B-X
SHIP-BRAZIL	B-X
)	B-X
Keila	B-X
Bairros	B-X
,	B-X
ClÃ¡udia	B-X
D.	B-X
Silva	B-X
,	B-X
ClÃ³vis	B-X
A.	B-X
Souza	B-X
,	B-X
Silvana	B-X
S.	B-X
Schroeder	B-X
O170	B-X
Characterization	B-X
of	B-X
sun	B-X
exposure	B-X
behaviours	B-X
among	B-X
medical	B-X
students	B-X
from	B-X
Nova	B-X
Medical	B-X
School	B-X
Elsa	B-X
AraÃºjo	B-X
,	B-X
Helena	B-X
Monteiro	B-X
,	B-X
Ricardo	B-X
Costa	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
,	B-X
Jorge	B-X
Torgal	B-X
O171	B-X
Spirituality	B-X
in	B-X
pregnant	B-X
women	B-X
Carolina	B-X
G.	B-X
Henriques	B-X
,	B-X
LuÃ­sa	B-X
Santos	B-X
,	B-X
Elisa	B-X
F.	B-X
Caceiro	B-X
,	B-X
SÃ³nia	B-X
A.	B-X
Ramalho	B-X
O172	B-X
Polypharmacy	B-X
in	B-X
older	B-X
patients	B-X
with	B-X
cancer	B-X
Rita	B-X
Oliveira	B-X
,	B-X
Vera	B-X
Afreixo	B-X
,	B-X
JoÃ£o	B-X
Santos	B-X
,	B-X
Priscilla	B-X
Mota	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
,	B-X
Francisco	B-X
Pimentel	B-X
O173	B-X
Quality	B-X
of	B-X
life	B-X
of	B-X
caregivers	B-X
of	B-X
people	B-X
with	B-X
advanced	B-X
chronic	B-X
disease	B-X
:	B-X
Translation	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
life	B-X
threatening	B-X
illness	B-X
-	B-X
family	B-X
carer	B-X
version	B-X
(	B-X
QOLLTI-C-PT	B-X
)	B-X
Rita	B-X
Marques	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
PatrÃ­cia	B-X
Sousa	B-X
O174	B-X
The	B-X
psychometric	B-X
properties	B-X
of	B-X
the	B-X
brief	B-X
Other	B-X
as	B-X
Shamer	B-X
Scale	B-X
for	B-X
Children	B-X
(	B-X
OAS-C	B-X
)	B-X
:	B-X
preliminary	B-X
validation	B-X
studies	B-X
in	B-X
a	B-X
sample	B-X
of	B-X
Portuguese	B-X
children	B-X
Joana	B-X
Benevides	B-X
,	B-X
Carolina	B-X
Da	B-X
Motta	B-X
,	B-X
Marina	B-X
Sousa	B-X
,	B-X
Suzana	B-X
N.	B-X
Caldeira	B-X
,	B-X
CÃ©lia	B-X
B.	B-X
Carvalho	B-X
O175	B-X
Measuring	B-X
emotional	B-X
intelligence	B-X
in	B-X
health	B-X
care	B-X
students	B-X
â	B-X
Revalidation	B-X
of	B-X
WLEIS-P	B-X
Ana	B-X
Querido	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
O176	B-X
Health	B-X
indicators	B-X
in	B-X
prenatal	B-X
assistance	B-X
:	B-X
The	B-X
impact	B-X
of	B-X
computerization	B-X
and	B-X
of	B-X
under-production	B-X
in	B-X
basic	B-X
health	B-X
centres	B-X
Joyce	B-X
O.	B-X
Costa	B-X
,	B-X
Frederico	B-X
C.	B-X
Valim	B-X
,	B-X
LÃ­gia	B-X
C.	B-X
Ribeiro	B-X
O177	B-X
Hope	B-X
genogram	B-X
:	B-X
Assessment	B-X
of	B-X
resources	B-X
and	B-X
interaction	B-X
patterns	B-X
in	B-X
the	B-X
family	B-X
of	B-X
the	B-X
child	B-X
with	B-X
cerebral	B-X
palsy	B-X
Zaida	B-X
Charepe	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
MÂª	B-X
Henriqueta	B-X
Figueiredo	B-X
O178	B-X
The	B-X
influence	B-X
of	B-X
childbirth	B-X
type	B-X
in	B-X
postpartum	B-X
quality	B-X
of	B-X
life	B-X
Priscila	B-X
S.	B-X
Aquino	B-X
,	B-X
Samila	B-X
G.	B-X
Ribeiro	B-X
,	B-X
Ana	B-X
B.	B-X
Pinheiro	B-X
,	B-X
Paula	B-X
A.	B-X
Lessa	B-X
,	B-X
Mirna	B-X
F.	B-X
Oliveira	B-X
,	B-X
LuÃ­sa	B-X
S.	B-X
Brito	B-X
,	B-X
Ãtalo	B-X
N.	B-X
Pinto	B-X
,	B-X
Alessandra	B-X
S.	B-X
Furtado	B-X
,	B-X
RÃ©gia	B-X
B.	B-X
Castro	B-X
,	B-X
Caroline	B-X
Q.	B-X
Aquino	B-X
,	B-X
Eveliny	B-X
S.	B-X
Martins	B-X
O179	B-X
Women	B-X
â	B-X
s	B-X
beliefs	B-X
about	B-X
pap	B-X
smear	B-X
test	B-X
and	B-X
cervical	B-X
cancer	B-X
:	B-X
influence	B-X
of	B-X
social	B-X
determinants	B-X
Ana	B-X
B	B-X
Pinheiro	B-X
,	B-X
Priscila	B-X
S.	B-X
Aquino	B-X
,	B-X
Lara	B-X
L.	B-X
Oliveira	B-X
,	B-X
PatrÃ­cia	B-X
C.	B-X
Pinheiro	B-X
,	B-X
Caroline	B-X
R.	B-X
Sousa	B-X
,	B-X
VÃ­vien	B-X
A.	B-X
Freitas	B-X
,	B-X
Tatiane	B-X
M.	B-X
Silva	B-X
,	B-X
Adman	B-X
S.	B-X
Lima	B-X
,	B-X
Caroline	B-X
Q.	B-X
Aquino	B-X
,	B-X
Karizia	B-X
V.	B-X
Andrade	B-X
,	B-X
Camila	B-X
A.	B-X
Oliveira	B-X
,	B-X
Eglidia	B-X
F.	B-X
Vidal	B-X
O180	B-X
Validity	B-X
of	B-X
the	B-X
Portuguese	B-X
version	B-X
of	B-X
the	B-X
ASI-3	B-X
:	B-X
Is	B-X
anxiety	B-X
sensitivity	B-X
a	B-X
unidimensional	B-X
or	B-X
multidimensional	B-X
construct	B-X
?	B-X
Ana	B-X
Ganho-Ãvila	B-X
,	B-X
Mariana	B-X
Moura-Ramos	B-X
,	B-X
Ãscar	B-X
GonÃ§alves	B-X
,	B-X
Jorge	B-X
Almeida	B-X
O181	B-X
Lifestyles	B-X
of	B-X
higher	B-X
education	B-X
students	B-X
:	B-X
the	B-X
influence	B-X
of	B-X
self-esteem	B-X
and	B-X
psychological	B-X
well-being	B-X
Armando	B-X
Silva	B-X
,	B-X
Irma	B-X
Brito	B-X
,	B-X
JoÃ£o	B-X
Amado	B-X
P75	B-X
Assessing	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
of	B-X
persons	B-X
with	B-X
significant	B-X
intellectual	B-X
disability	B-X
:	B-X
Portuguese	B-X
version	B-X
of	B-X
Escala	B-X
de	B-X
San	B-X
MartÃ­n	B-X
AntÃ³nio	B-X
Rodrigo	B-X
,	B-X
Sofia	B-X
Santos	B-X
,	B-X
Fernando	B-X
Gomes	B-X
P76	B-X
Childhood	B-X
obesity	B-X
and	B-X
breastfeeding	B-X
-	B-X
A	B-X
systematic	B-X
review	B-X
Marlene	B-X
C.	B-X
Rosa	B-X
,	B-X
Silvana	B-X
F.	B-X
Marques	B-X
P77	B-X
Cross-cultural	B-X
adaptation	B-X
of	B-X
the	B-X
Foot	B-X
and	B-X
Ankle	B-X
Ability	B-X
Measure	B-X
(	B-X
FAAM	B-X
)	B-X
for	B-X
the	B-X
Portuguese	B-X
population	B-X
Sara	B-X
LuÃ­s	B-X
,	B-X
LuÃ­s	B-X
Cavalheiro	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Rui	B-X
GonÃ§alves	B-X
P78	B-X
Cross-cultural	B-X
adaptation	B-X
of	B-X
the	B-X
Patient-Rated	B-X
Wrist	B-X
Evaluation	B-X
score	B-X
(	B-X
PRWE	B-X
)	B-X
for	B-X
the	B-X
Portuguese	B-X
population	B-X
Rui	B-X
S.	B-X
Lopes	B-X
,	B-X
LuÃ­s	B-X
Cavalheiro	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Rui	B-X
GonÃ§alves	B-X
P79	B-X
Cross-cultural	B-X
adaptation	B-X
of	B-X
the	B-X
Myocardial	B-X
Infraction	B-X
Dimensional	B-X
Assessment	B-X
Scale	B-X
(	B-X
MIDAS	B-X
)	B-X
for	B-X
Brazilian	B-X
Portuguese	B-X
language	B-X
Bruno	B-X
H.	B-X
Fiorin	B-X
,	B-X
Marina	B-X
S.	B-X
Santos	B-X
,	B-X
Edmar	B-X
S.	B-X
Oliveira	B-X
,	B-X
Rita	B-X
L.	B-X
Moreira	B-X
,	B-X
Elizabete	B-X
A.	B-X
Oliveira	B-X
,	B-X
Braulio	B-X
L.	B-X
Filho	B-X
P80	B-X
The	B-X
revised	B-X
Portuguese	B-X
version	B-X
of	B-X
the	B-X
Three-Factor	B-X
Eating	B-X
Questionnaire	B-X
:	B-X
A	B-X
confirmatory	B-X
factor	B-X
analysis	B-X
Lara	B-X
Palmeira	B-X
,	B-X
Teresa	B-X
Garcia	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
,	B-X
Marina	B-X
Cunha	B-X
P81	B-X
Assessing	B-X
weight-related	B-X
psychological	B-X
inflexibility	B-X
:	B-X
An	B-X
exploratory	B-X
factor	B-X
analysis	B-X
of	B-X
the	B-X
AAQW	B-X
â	B-X
s	B-X
Portuguese	B-X
version	B-X
Sara	B-X
Cardoso	B-X
,	B-X
Lara	B-X
Palmeira	B-X
,	B-X
Marina	B-X
Cunha	B-X
;	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
P82	B-X
Validation	B-X
of	B-X
the	B-X
Body	B-X
Appreciation	B-X
Scale-2	B-X
for	B-X
Portuguese	B-X
women	B-X
Joana	B-X
Marta-SimÃµes	B-X
,	B-X
Ana	B-X
L.	B-X
Mendes	B-X
,	B-X
InÃªs	B-X
A.	B-X
Trindade	B-X
,	B-X
Sara	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Ferreira	B-X
P83	B-X
The	B-X
Portuguese	B-X
validation	B-X
of	B-X
the	B-X
Dietary	B-X
Intent	B-X
Scale	B-X
Ana	B-X
L.	B-X
Mendes	B-X
,	B-X
Joana	B-X
Marta-SimÃµes	B-X
,	B-X
InÃªs	B-X
A.	B-X
Trindade	B-X
,	B-X
ClÃ¡udia	B-X
Ferreira	B-X
P84	B-X
Construction	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
Inventory	B-X
of	B-X
Marital	B-X
Violence	B-X
(	B-X
IVC	B-X
)	B-X
Filipe	B-X
Nave	B-X
P85	B-X
Portable	B-X
continuous	B-X
blood	B-X
pressure	B-X
monitor	B-X
system	B-X
Mariana	B-X
Campos	B-X
,	B-X
Iris	B-X
GaudÃªncio	B-X
,	B-X
Fernando	B-X
Martins	B-X
,	B-X
Lino	B-X
Ferreira	B-X
,	B-X
Nuno	B-X
Lopes	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
P86	B-X
Construction	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
Scale	B-X
of	B-X
Perception	B-X
of	B-X
the	B-X
Difficulties	B-X
in	B-X
Caring	B-X
for	B-X
the	B-X
Elderly	B-X
(	B-X
SPDCE	B-X
)	B-X
RogÃ©rio	B-X
Rodrigues	B-X
,	B-X
Zaida	B-X
Azeredo	B-X
,	B-X
CorÃ¡lia	B-X
Vicente	B-X
P87	B-X
Development	B-X
and	B-X
validation	B-X
of	B-X
a	B-X
comfort	B-X
rating	B-X
scale	B-X
for	B-X
the	B-X
elderly	B-X
hospitalized	B-X
with	B-X
chronic	B-X
illness	B-X
Joana	B-X
Silva	B-X
,	B-X
PatrÃ­cia	B-X
Sousa	B-X
,	B-X
Rita	B-X
Marques	B-X
P88	B-X
Construction	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
Postpartum	B-X
Paternal	B-X
Quality	B-X
of	B-X
Life	B-X
Questionnaire	B-X
(	B-X
PP-QOL	B-X
)	B-X
Isabel	B-X
Mendes	B-X
,	B-X
RogÃ©rio	B-X
Rodrigues	B-X
,	B-X
Zaida	B-X
Azeredo	B-X
,	B-X
CorÃ¡lia	B-X
Vicente	B-X
P89	B-X
Infrared	B-X
thermal	B-X
imaging	B-X
:	B-X
A	B-X
tool	B-X
for	B-X
assessing	B-X
diabetic	B-X
foot	B-X
ulcers	B-X
Ricardo	B-X
Vardasca	B-X
,	B-X
Ana	B-X
R.	B-X
Marques	B-X
,	B-X
AdÃ©rito	B-X
Seixas	B-X
,	B-X
Rui	B-X
Carvalho	B-X
,	B-X
Joaquim	B-X
Gabriel	B-X
P90	B-X
Pressure	B-X
ulcers	B-X
in	B-X
an	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
An	B-X
experience	B-X
report	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
SebastiÃ£o	B-X
T.	B-X
Oliveira	B-X
,	B-X
Pablo	B-X
O.	B-X
Costa	B-X
,	B-X
Maiza	B-X
M.	B-X
Silva	B-X
P91	B-X
Validation	B-X
of	B-X
figures	B-X
used	B-X
in	B-X
evocations	B-X
:	B-X
instrument	B-X
to	B-X
capture	B-X
representations	B-X
Cristina	B-X
Arreguy-Sena	B-X
,	B-X
NathÃ¡lia	B-X
Alvarenga-Martins	B-X
,	B-X
Paulo	B-X
F.	B-X
Pinto	B-X
,	B-X
Denize	B-X
C.	B-X
Oliveira	B-X
,	B-X
Pedro	B-X
D.	B-X
Parreira	B-X
,	B-X
AntÃ´nio	B-X
T.	B-X
Gomes	B-X
,	B-X
Luciene	B-X
M.	B-X
Braga	B-X
P92	B-X
Telephone	B-X
assistance	B-X
to	B-X
decrease	B-X
burden	B-X
in	B-X
informal	B-X
caregivers	B-X
of	B-X
stroke	B-X
older	B-X
people	B-X
:	B-X
Monitoring	B-X
and	B-X
diagnostic	B-X
evaluation	B-X
Odete	B-X
AraÃºjo	B-X
,	B-X
Isabel	B-X
Lage	B-X
,	B-X
JosÃ©	B-X
Cabrita	B-X
,	B-X
Laetitia	B-X
Teixeira	B-X
P93	B-X
Hope	B-X
of	B-X
informal	B-X
caregivers	B-X
of	B-X
people	B-X
with	B-X
chronic	B-X
and	B-X
advanced	B-X
disease	B-X
Rita	B-X
Marques	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
PatrÃ­cia	B-X
Sousa	B-X
P94	B-X
Functionality	B-X
and	B-X
quality	B-X
information	B-X
from	B-X
the	B-X
Portuguese	B-X
National	B-X
Epidemiological	B-X
Surveillance	B-X
System	B-X
Sara	B-X
Silva	B-X
,	B-X
EugÃ©nio	B-X
Cordeiro	B-X
,	B-X
JoÃ£o	B-X
Pimentel	B-X
P95	B-X
Resting	B-X
metabolic	B-X
rate	B-X
objectively	B-X
measured	B-X
vs.	B-X
Harris	B-X
and	B-X
Benedict	B-X
formula	B-X
Vera	B-X
Ferro-Lebres	B-X
,	B-X
Juliana	B-X
A.	B-X
Souza	B-X
,	B-X
Mariline	B-X
Tavares	B-X
O182	B-X
Characteristics	B-X
of	B-X
non-urgent	B-X
patients	B-X
:	B-X
Cross-sectional	B-X
study	B-X
of	B-X
an	B-X
emergency	B-X
department	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Pedro	B-X
Sousa	B-X
,	B-X
Rui	B-X
Passadouro	B-X
,	B-X
Teresa	B-X
Peralta	B-X
,	B-X
Carlos	B-X
Ferreira	B-X
,	B-X
Georgina	B-X
LourenÃ§o	B-X
O183	B-X
Physical	B-X
fitness	B-X
and	B-X
health	B-X
in	B-X
children	B-X
of	B-X
the	B-X
1st	B-X
Cycle	B-X
of	B-X
Education	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
,	B-X
Pedro	B-X
Mendes	B-X
O184	B-X
The	B-X
impact	B-X
of	B-X
physical	B-X
activity	B-X
on	B-X
sleep	B-X
quality	B-X
,	B-X
in	B-X
children	B-X
Alexandra	B-X
SimÃµes	B-X
,	B-X
Lucinda	B-X
Carvalho	B-X
,	B-X
Alexandre	B-X
Pereira	B-X
O185	B-X
What	B-X
is	B-X
the	B-X
potential	B-X
for	B-X
using	B-X
Information	B-X
and	B-X
Communication	B-X
Technologies	B-X
in	B-X
Arterial	B-X
Hypertension	B-X
self-management	B-X
?	B-X
Zaida	B-X
Azeredo	B-X
,	B-X
Carlos	B-X
Laranjeira	B-X
,	B-X
Magda	B-X
Guerra	B-X
,	B-X
Ana	B-X
P.	B-X
Barbeiro	B-X
O195	B-X
The	B-X
therapeutic	B-X
self-care	B-X
as	B-X
a	B-X
nursing-sensitive	B-X
outcome	B-X
:	B-X
A	B-X
correlational	B-X
study	B-X
Regina	B-X
Ferreira	B-X
O196	B-X
Phonetic-phonological	B-X
acquisition	B-X
for	B-X
the	B-X
European	B-X
Portuguese	B-X
from	B-X
18	B-X
months	B-X
to	B-X
6	B-X
years	B-X
and	B-X
12	B-X
months	B-X
Sara	B-X
Lopes	B-X
,	B-X
Liliana	B-X
Nunes	B-X
,	B-X
Ana	B-X
Mendes	B-X
O197	B-X
Quality	B-X
of	B-X
life	B-X
of	B-X
patients	B-X
undergoing	B-X
liver	B-X
transplant	B-X
surgery	B-X
Julian	B-X
Martins	B-X
,	B-X
Dulcineia	B-X
Schneider	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
,	B-X
FlÃ¡vio	B-X
Magajewski	B-X
O198	B-X
Professional	B-X
competences	B-X
in	B-X
health	B-X
:	B-X
views	B-X
of	B-X
older	B-X
people	B-X
from	B-X
different	B-X
European	B-X
Countries	B-X
CÃ©lia	B-X
Soares	B-X
,	B-X
AntÃ³nio	B-X
Marques	B-X
O199	B-X
Life	B-X
satisfaction	B-X
of	B-X
working	B-X
adults	B-X
due	B-X
to	B-X
the	B-X
number	B-X
of	B-X
hours	B-X
of	B-X
weekly	B-X
exercise	B-X
Marco	B-X
Batista	B-X
,	B-X
Ruth	B-X
J.	B-X
Castuera	B-X
,	B-X
Helena	B-X
Mesquita	B-X
,	B-X
AntÃ³nio	B-X
Faustino	B-X
,	B-X
Jorge	B-X
Santos	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
O200	B-X
Therapeutic	B-X
itinerary	B-X
of	B-X
women	B-X
with	B-X
breast	B-X
cancer	B-X
in	B-X
Santa	B-X
Maria	B-X
City/RS	B-X
Betina	B-X
P.	B-X
Vizzotto	B-X
,	B-X
Leticia	B-X
Frigo	B-X
,	B-X
Hedioneia	B-X
F.	B-X
Pivetta	B-X
O201	B-X
The	B-X
breastfeeding	B-X
prevalence	B-X
at	B-X
4	B-X
months	B-X
:	B-X
Maternal	B-X
experience	B-X
as	B-X
a	B-X
determining	B-X
factor	B-X
Dolores	B-X
Sardo	B-X
O202	B-X
The	B-X
impact	B-X
of	B-X
the	B-X
transition	B-X
to	B-X
parenthood	B-X
in	B-X
health	B-X
and	B-X
well-being	B-X
Cristina	B-X
Martins	B-X
,	B-X
Wilson	B-X
Abreu	B-X
,	B-X
MÂª	B-X
CÃ©u	B-X
Figueiredo	B-X
P96	B-X
Self-determined	B-X
motivation	B-X
and	B-X
well-being	B-X
in	B-X
Portuguese	B-X
active	B-X
adults	B-X
of	B-X
both	B-X
genders	B-X
Marco	B-X
Batista	B-X
,	B-X
Ruth	B-X
Jimenez-Castuera	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
Pedro	B-X
Mendes	B-X
P97	B-X
The	B-X
geriatric	B-X
care	B-X
:	B-X
ways	B-X
and	B-X
means	B-X
of	B-X
comforting	B-X
PatrÃ­cia	B-X
Sousa	B-X
,	B-X
Rita	B-X
Marques	B-X
P98	B-X
The	B-X
influence	B-X
of	B-X
relative	B-X
age	B-X
,	B-X
subcutaneous	B-X
adiposity	B-X
and	B-X
physical	B-X
growth	B-X
on	B-X
Castelo	B-X
Branco	B-X
under-15	B-X
soccer	B-X
players	B-X
2015	B-X
AntÃ³nio	B-X
Faustino	B-X
,	B-X
Paulo	B-X
Silveira	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
P99	B-X
Data	B-X
for	B-X
the	B-X
diagnostic	B-X
process	B-X
focused	B-X
on	B-X
self-care	B-X
â	B-X
managing	B-X
medication	B-X
regime	B-X
:	B-X
An	B-X
integrative	B-X
literature	B-X
review	B-X
Catarina	B-X
Oliveira	B-X
,	B-X
Fernanda	B-X
Bastos	B-X
,	B-X
InÃªs	B-X
Cruz	B-X
P100	B-X
Art	B-X
therapy	B-X
as	B-X
mental	B-X
health	B-X
promotion	B-X
for	B-X
children	B-X
ClÃ¡udia	B-X
K.	B-X
Rodriguez	B-X
,	B-X
MÃ¡rcia	B-X
R.	B-X
Kretzer	B-X
,	B-X
NazarÃ©	B-X
O.	B-X
NazÃ¡rio	B-X
P101	B-X
Chemical	B-X
characterization	B-X
of	B-X
fungal	B-X
chitosan	B-X
for	B-X
industrial	B-X
applications	B-X
Pedro	B-X
Cruz	B-X
,	B-X
Daniela	B-X
C.	B-X
Vaz	B-X
,	B-X
Rui	B-X
B.	B-X
Ruben	B-X
,	B-X
Francisco	B-X
Avelelas	B-X
,	B-X
Susana	B-X
Silva	B-X
,	B-X
MÂª	B-X
Jorge	B-X
Campos	B-X
P102	B-X
The	B-X
impact	B-X
of	B-X
caring	B-X
older	B-X
people	B-X
at	B-X
home	B-X
Maria	B-X
Almeida	B-X
,	B-X
Liliana	B-X
GonÃ§alves	B-X
,	B-X
LÃ­gia	B-X
Antunes	B-X
P103	B-X
Development	B-X
of	B-X
the	B-X
first	B-X
pressure	B-X
ulcer	B-X
in	B-X
an	B-X
inpatient	B-X
setting	B-X
:	B-X
Focus	B-X
on	B-X
patients	B-X
â	B-X
characteristics	B-X
Pedro	B-X
Sardo	B-X
,	B-X
Jenifer	B-X
Guedes	B-X
,	B-X
JoÃ£o	B-X
SimÃµes	B-X
,	B-X
Paulo	B-X
Machado	B-X
,	B-X
Elsa	B-X
Melo	B-X
P104	B-X
Association	B-X
between	B-X
General	B-X
Self-efficacy	B-X
and	B-X
Physical	B-X
Activity	B-X
among	B-X
Adolescents	B-X
Susana	B-X
Cardoso	B-X
,	B-X
Osvaldo	B-X
Santos	B-X
,	B-X
Carla	B-X
Nunes	B-X
,	B-X
Isabel	B-X
Loureiro	B-X
O203	B-X
Characterization	B-X
of	B-X
the	B-X
habits	B-X
of	B-X
online	B-X
acquisition	B-X
of	B-X
medicinal	B-X
products	B-X
in	B-X
Portugal	B-X
FlÃ¡via	B-X
Santos	B-X
,	B-X
Gilberto	B-X
Alves	B-X
O204	B-X
Waiting	B-X
room	B-X
â	B-X
A	B-X
space	B-X
for	B-X
health	B-X
education	B-X
ClÃ¡udia	B-X
Soar	B-X
,	B-X
Teresa	B-X
O.	B-X
Marsi	B-X
O205	B-X
Safey	B-X
culture	B-X
evaluation	B-X
in	B-X
hospitalized	B-X
children	B-X
Ernestina	B-X
Silva	B-X
,	B-X
Dora	B-X
Pedrosa	B-X
,	B-X
Andrea	B-X
LeÃ§a	B-X
,	B-X
Daniel	B-X
Silva	B-X
O206	B-X
Sexual	B-X
Self-awareness	B-X
and	B-X
Body	B-X
Image	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
Maria	B-X
Gomes	B-X
,	B-X
Paula	B-X
Fernandes	B-X
,	B-X
Ana	B-X
NonÃ©	B-X
O207	B-X
Perception	B-X
of	B-X
a	B-X
Portuguese	B-X
population	B-X
regarding	B-X
the	B-X
acquisition	B-X
and	B-X
consumption	B-X
of	B-X
functional	B-X
foods	B-X
Jaime	B-X
CombadÃ£o	B-X
,	B-X
CÃ¡tia	B-X
Ramalhete	B-X
,	B-X
Paulo	B-X
Figueiredo	B-X
,	B-X
PatrÃ­cia	B-X
Caeiro	B-X
O208	B-X
The	B-X
work	B-X
process	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
:	B-X
evaluation	B-X
in	B-X
municipalities	B-X
of	B-X
southern	B-X
Brazil	B-X
Karine	B-X
C.	B-X
Fontana	B-X
,	B-X
Josimari	B-X
T.	B-X
Lacerda	B-X
,	B-X
PatrÃ­cia	B-X
O.	B-X
Machado	B-X
O209	B-X
Exploration	B-X
and	B-X
evaluation	B-X
of	B-X
potential	B-X
probiotic	B-X
lactic	B-X
acid	B-X
bacteria	B-X
isolated	B-X
from	B-X
Amazon	B-X
buffalo	B-X
milk	B-X
Raphaelle	B-X
Borges	B-X
,	B-X
FlÃ¡vio	B-X
Barbosa	B-X
,	B-X
Dayse	B-X
SÃ¡	B-X
O210	B-X
Road	B-X
safety	B-X
for	B-X
children	B-X
:	B-X
Using	B-X
children	B-X
â	B-X
s	B-X
observation	B-X
,	B-X
as	B-X
a	B-X
passenger	B-X
Germana	B-X
Brunhoso	B-X
,	B-X
GraÃ§a	B-X
AparÃ­cio	B-X
,	B-X
AmÃ¢ncio	B-X
Carvalho	B-X
O211	B-X
Perception	B-X
and	B-X
application	B-X
of	B-X
quality-by-design	B-X
by	B-X
the	B-X
Pharmaceutical	B-X
industry	B-X
in	B-X
Portugal	B-X
Ana	B-X
P.	B-X
Garcia	B-X
,	B-X
Paula	B-X
O.	B-X
Fernandes	B-X
,	B-X
Adriana	B-X
Santos	B-X
O212	B-X
Oral	B-X
health	B-X
among	B-X
Portuguese	B-X
children	B-X
and	B-X
adolescents	B-X
:	B-X
a	B-X
public	B-X
health	B-X
issue	B-X
NÃ©lio	B-X
Veiga	B-X
,	B-X
Carina	B-X
BrÃ¡s	B-X
,	B-X
InÃªs	B-X
Carvalho	B-X
,	B-X
Joana	B-X
Batalha	B-X
,	B-X
Margarida	B-X
GlÃ³ria	B-X
,	B-X
Filipa	B-X
Bexiga	B-X
,	B-X
InÃªs	B-X
Coelho	B-X
,	B-X
Odete	B-X
Amaral	B-X
,	B-X
Carlos	B-X
Pereira	B-X
O213	B-X
Plant	B-X
species	B-X
as	B-X
a	B-X
medicinal	B-X
resource	B-X
in	B-X
Igatu-Chapada	B-X
Diamantina	B-X
(	B-X
Bahia	B-X
,	B-X
Brazil	B-X
)	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
Nilson	B-X
ParaÃ­so	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
CristÃ³vÃ£o	B-X
F.	B-X
Lima	B-X
,	B-X
Alberto	B-X
P.	B-X
Dias	B-X
O214	B-X
Characterization	B-X
of	B-X
cognitive	B-X
and	B-X
functional	B-X
performance	B-X
in	B-X
everyday	B-X
tasks	B-X
:	B-X
Implications	B-X
for	B-X
health	B-X
in	B-X
institutionalised	B-X
older	B-X
adults	B-X
Pedro	B-X
Silva	B-X
,	B-X
MÃ¡rio	B-X
Espada	B-X
,	B-X
MÃ¡rio	B-X
Marques	B-X
,	B-X
Ana	B-X
Pereira	B-X
O215	B-X
BMI	B-X
and	B-X
the	B-X
perception	B-X
of	B-X
the	B-X
importance	B-X
given	B-X
to	B-X
sexuality	B-X
in	B-X
obese	B-X
and	B-X
overweight	B-X
people	B-X
Ana	B-X
MÂª	B-X
Pereira	B-X
,	B-X
MÂª	B-X
Veiga-Branco	B-X
,	B-X
Filomena	B-X
Pereira	B-X
,	B-X
Maria	B-X
Ribeiro	B-X
O216	B-X
Analysis	B-X
and	B-X
comparison	B-X
of	B-X
microbiological	B-X
contaminations	B-X
of	B-X
two	B-X
different	B-X
composition	B-X
pacifiers	B-X
Vera	B-X
Lima	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
GraÃ§a	B-X
Cruz	B-X
,	B-X
Rita	B-X
F.	B-X
Oliveira	B-X
,	B-X
LuÃ­sa	B-X
Barreiros	B-X
,	B-X
Fernando	B-X
Moreira	B-X
O217	B-X
Experiences	B-X
of	B-X
couple	B-X
relationships	B-X
in	B-X
the	B-X
transition	B-X
to	B-X
retirement	B-X
Ana	B-X
Camarneiro	B-X
,	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
,	B-X
Margarida	B-X
Silva	B-X
O218	B-X
Preventive	B-X
and	B-X
corrective	B-X
treatment	B-X
of	B-X
drug-induced	B-X
calcium	B-X
deficiency	B-X
:	B-X
an	B-X
analysis	B-X
in	B-X
a	B-X
community	B-X
pharmacy	B-X
setting	B-X
Catarina	B-X
Duarte	B-X
,	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
O219	B-X
Profile	B-X
of	B-X
mood	B-X
states	B-X
in	B-X
physically	B-X
active	B-X
elderly	B-X
subjects	B-X
:	B-X
Is	B-X
there	B-X
a	B-X
relation	B-X
with	B-X
health	B-X
perception	B-X
?	B-X
Maria	B-X
Mota	B-X
,	B-X
Sandra	B-X
Novais	B-X
,	B-X
Paulo	B-X
Nogueira	B-X
,	B-X
Ana	B-X
Pereira	B-X
,	B-X
Lara	B-X
Carneiro	B-X
,	B-X
Paulo	B-X
V.	B-X
JoÃ£o	B-X
O220	B-X
(	B-X
Un	B-X
)	B-X
Safety	B-X
behaviour	B-X
at	B-X
work	B-X
:	B-X
the	B-X
role	B-X
of	B-X
education	B-X
towards	B-X
a	B-X
health	B-X
and	B-X
safety	B-X
culture	B-X
Teresa	B-X
Maneca	B-X
Lima	B-X
O221	B-X
Analysis	B-X
of	B-X
the	B-X
entrepreneurial	B-X
profile	B-X
of	B-X
students	B-X
attending	B-X
higher	B-X
education	B-X
in	B-X
Portugal	B-X
:	B-X
the	B-X
Carland	B-X
Entrepreneurship	B-X
Index	B-X
application	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
,	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
O222	B-X
Evaluation	B-X
of	B-X
welfare	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
of	B-X
pregnant	B-X
working	B-X
women	B-X
regarding	B-X
the	B-X
age	B-X
of	B-X
the	B-X
pregnant	B-X
MarÃ­a	B-X
S.	B-X
Medina	B-X
,	B-X
Valeriana	B-X
G.	B-X
Blanco	B-X
O223	B-X
Psychological	B-X
wellbeing	B-X
protection	B-X
among	B-X
unemployed	B-X
and	B-X
temporary	B-X
workers	B-X
:	B-X
Uncovering	B-X
effective	B-X
community-based	B-X
interventions	B-X
with	B-X
a	B-X
Delphi	B-X
panel	B-X
Osvaldo	B-X
Santos	B-X
,	B-X
Elisa	B-X
Lopes	B-X
,	B-X
Ana	B-X
Virgolino	B-X
,	B-X
Alexandra	B-X
Dinis	B-X
,	B-X
Sara	B-X
AmbrÃ³sio	B-X
,	B-X
InÃªs	B-X
Almeida	B-X
,	B-X
Tatiana	B-X
Marques	B-X
,	B-X
MÂª	B-X
JoÃ£o	B-X
Heitor	B-X
O224	B-X
Chilean	B-X
population	B-X
norms	B-X
derived	B-X
from	B-X
the	B-X
Health-related	B-X
quality	B-X
of	B-X
life	B-X
SF-6D	B-X
Miguel	B-X
A.	B-X
Garcia-Gordillo	B-X
,	B-X
Daniel	B-X
Collado-Mateo	B-X
,	B-X
Pedro	B-X
R.	B-X
Olivares	B-X
,	B-X
JosÃ©	B-X
A.	B-X
ParraÃ§a	B-X
,	B-X
JosÃ©	B-X
A.	B-X
Sala	B-X
O225	B-X
Motivation	B-X
of	B-X
college	B-X
students	B-X
toward	B-X
Entrepreneurship	B-X
:	B-X
The	B-X
influence	B-X
of	B-X
social	B-X
and	B-X
economic	B-X
instability	B-X
AmÃ©lia	B-X
Castilho	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Oliveira	B-X
,	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
O226	B-X
Use	B-X
of	B-X
aromatic	B-X
and	B-X
medicinal	B-X
plants	B-X
,	B-X
drugs	B-X
and	B-X
herbal	B-X
products	B-X
in	B-X
BraganÃ§a	B-X
city	B-X
MÃ³nia	B-X
Cheio	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
,	B-X
OlÃ­via	B-X
R.	B-X
Pereira	B-X
O227	B-X
Edible	B-X
flowers	B-X
as	B-X
new	B-X
novel	B-X
foods	B-X
concept	B-X
for	B-X
health	B-X
promotion	B-X
Sara	B-X
Pinto	B-X
,	B-X
Adriana	B-X
Oliveira	B-X
,	B-X
M.	B-X
ConceiÃ§Ã£o	B-X
Manso	B-X
,	B-X
Carla	B-X
Sousa	B-X
,	B-X
Ana	B-X
F.	B-X
Vinha	B-X
O228	B-X
The	B-X
influence	B-X
of	B-X
leisure	B-X
activities	B-X
on	B-X
the	B-X
health	B-X
and	B-X
welfare	B-X
of	B-X
older	B-X
people	B-X
living	B-X
in	B-X
nursing	B-X
homes	B-X
MÂª	B-X
Manuela	B-X
Machado	B-X
,	B-X
Margarida	B-X
Vieira	B-X
O229	B-X
Risk	B-X
of	B-X
falling	B-X
,	B-X
fear	B-X
of	B-X
falling	B-X
and	B-X
functionality	B-X
in	B-X
community-dwelling	B-X
older	B-X
adults	B-X
Beatriz	B-X
Fernandes	B-X
,	B-X
Teresa	B-X
TomÃ¡s	B-X
,	B-X
Diogo	B-X
Quirino	B-X
O230	B-X
Musculoskeletal	B-X
pain	B-X
and	B-X
postural	B-X
habits	B-X
in	B-X
children	B-X
and	B-X
teenage	B-X
students	B-X
Gustavo	B-X
Desouzart	B-X
,	B-X
Rui	B-X
Matos	B-X
,	B-X
Magali	B-X
Bordini	B-X
,	B-X
Pedro	B-X
MouroÃ§o	B-X
O231	B-X
What	B-X
's	B-X
different	B-X
in	B-X
Southern	B-X
Europe	B-X
?	B-X
Inmaculada	B-X
Z.	B-X
Martin	B-X
,	B-X
Anita	B-X
BjÃ¶rklund	B-X
P105	B-X
Pay-for-performance	B-X
satisfaction	B-X
and	B-X
quality	B-X
in	B-X
primary	B-X
care	B-X
Aida	B-X
I.	B-X
Tavares	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Rui	B-X
Passadouro	B-X
P106	B-X
Economic	B-X
development	B-X
through	B-X
life	B-X
expectancy	B-X
lenses	B-X
SÃ³nia	B-X
Morgado	B-X
P107	B-X
What	B-X
is	B-X
the	B-X
effectiveness	B-X
of	B-X
exercise	B-X
on	B-X
smoking	B-X
cessation	B-X
to	B-X
prevent	B-X
clinical	B-X
complications	B-X
of	B-X
smoking	B-X
?	B-X
Nuno	B-X
Tavares	B-X
,	B-X
JoÃ£o	B-X
Valente	B-X
,	B-X
Anabela	B-X
C.	B-X
Martins	B-X
P108	B-X
A	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
yoga	B-X
on	B-X
mental	B-X
health	B-X
PatrÃ­cia	B-X
AraÃºjo	B-X
,	B-X
Rosina	B-X
Fernandes	B-X
,	B-X
Francisco	B-X
Mendes	B-X
,	B-X
CÃ¡tia	B-X
MagalhÃ£es	B-X
,	B-X
EmÃ­lia	B-X
Martins	B-X
P109	B-X
Healthy	B-X
lifestyle	B-X
:	B-X
comparison	B-X
between	B-X
higher	B-X
education	B-X
students	B-X
that	B-X
lived	B-X
until	B-X
adult	B-X
age	B-X
in	B-X
rural	B-X
and	B-X
urban	B-X
environment	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
AntÃ³nio	B-X
Faustino	B-X
,	B-X
Helena	B-X
Mesquita	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
,	B-X
Marco	B-X
Batista	B-X
P110	B-X
Evaluation	B-X
of	B-X
the	B-X
Mobile	B-X
Emergency	B-X
Care	B-X
Service	B-X
(	B-X
SAMU	B-X
)	B-X
in	B-X
Brazil	B-X
Josimari	B-X
T.	B-X
Lacerda	B-X
,	B-X
Angela	B-X
B.	B-X
Ortiga	B-X
,	B-X
MÂª	B-X
Cristina	B-X
Calvo	B-X
,	B-X
SÃ´nia	B-X
Natal	B-X
P111	B-X
Bioactive	B-X
compounds	B-X
-	B-X
antioxidant	B-X
activity	B-X
of	B-X
tropical	B-X
fruits	B-X
Marta	B-X
Pereira	B-X
P112	B-X
Use	B-X
of	B-X
non-pharmacological	B-X
methods	B-X
to	B-X
relieve	B-X
pain	B-X
in	B-X
labour	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Ana	B-X
R.	B-X
Prata	B-X
,	B-X
Paula	B-X
Nelas	B-X
,	B-X
JoÃ£o	B-X
Duarte	B-X
P113	B-X
Mechanical	B-X
safety	B-X
of	B-X
pacifiers	B-X
sold	B-X
in	B-X
Portuguese	B-X
pharmacies	B-X
and	B-X
childcare	B-X
stores	B-X
Juliana	B-X
Carneiro	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
Cristina	B-X
Couto	B-X
,	B-X
Rita	B-X
F.	B-X
Oliveira	B-X
,	B-X
Fernando	B-X
Moreira	B-X
P114	B-X
The	B-X
importance	B-X
of	B-X
prenatal	B-X
consultation	B-X
:	B-X
Information	B-X
to	B-X
pregnant	B-X
women	B-X
given	B-X
on	B-X
a	B-X
unit	B-X
of	B-X
primary	B-X
care	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
GÃ©ssica	B-X
M.	B-X
Souza	B-X
,	B-X
LÃ­via	B-X
F.	B-X
Almada	B-X
,	B-X
Milena	B-X
A.	B-X
ConceiÃ§Ã£o	B-X
,	B-X
Eujcely	B-X
C.	B-X
Santiago	B-X
P115	B-X
Influence	B-X
of	B-X
different	B-X
backpack	B-X
loading	B-X
conditions	B-X
on	B-X
neck	B-X
and	B-X
lumbar	B-X
muscles	B-X
activity	B-X
of	B-X
elementary	B-X
school	B-X
children	B-X
Sandra	B-X
Rodrigues	B-X
,	B-X
Gabriela	B-X
Domingues	B-X
,	B-X
Irina	B-X
Ferreira	B-X
,	B-X
LuÃ­s	B-X
Faria	B-X
,	B-X
AdÃ©rito	B-X
Seixas	B-X
P116	B-X
Efficacy	B-X
and	B-X
safety	B-X
of	B-X
dry	B-X
extract	B-X
Hedera	B-X
helix	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
productive	B-X
cough	B-X
Ana	B-X
R.	B-X
Costa	B-X
,	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
AmÃ©rico	B-X
Cardoso	B-X
,	B-X
Alexandra	B-X
Meireles	B-X
,	B-X
Armanda	B-X
ColaÃ§o	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
P117	B-X
A	B-X
portrait	B-X
of	B-X
the	B-X
evaluation	B-X
processes	B-X
of	B-X
education	B-X
groups	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
Viviane	B-X
L.	B-X
Vieira	B-X
,	B-X
Kellem	B-X
R.	B-X
Vincha	B-X
,	B-X
Ana	B-X
MÂª	B-X
Cervato-Mancuso	B-X
P118	B-X
Benefits	B-X
of	B-X
vitamins	B-X
C	B-X
and	B-X
E	B-X
in	B-X
sensorineural	B-X
hearing	B-X
loss	B-X
:	B-X
a	B-X
review	B-X
Melissa	B-X
Faria	B-X
,	B-X
ClÃ¡udia	B-X
Reis	B-X
P119	B-X
BODY	B-X
SNAPSHOT	B-X
â	B-X
a	B-X
web-integrated	B-X
anthropometric	B-X
evaluation	B-X
system	B-X
Marco	B-X
P.	B-X
Cova	B-X
,	B-X
Rita	B-X
T.	B-X
Ascenso	B-X
,	B-X
Henrique	B-X
A.	B-X
Almeida	B-X
,	B-X
Eunice	B-X
G.	B-X
Oliveira	B-X
P120	B-X
Anthropometric	B-X
evaluation	B-X
and	B-X
variation	B-X
during	B-X
pregnancy	B-X
Miguel	B-X
Santana	B-X
,	B-X
Rafael	B-X
Pereira	B-X
,	B-X
Eunice	B-X
G.	B-X
Oliveira	B-X
,	B-X
Henrique	B-X
A.	B-X
Almeida	B-X
,	B-X
Rita	B-X
T.	B-X
Ascenso	B-X
P121	B-X
Knowledge	B-X
of	B-X
college	B-X
students	B-X
on	B-X
the	B-X
amendments	B-X
of	B-X
their	B-X
eating	B-X
habits	B-X
and	B-X
physical	B-X
activity	B-X
index	B-X
in	B-X
the	B-X
transition	B-X
to	B-X
higher	B-X
education	B-X
Rita	B-X
Jesus	B-X
,	B-X
Rodrigo	B-X
Tapadas	B-X
,	B-X
Carolina	B-X
Tim-Tim	B-X
,	B-X
Catarina	B-X
Cezanne	B-X
,	B-X
Matilde	B-X
Lagoa	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
,	B-X
Jorge	B-X
Torgal	B-X
P122	B-X
Muscular	B-X
activity	B-X
of	B-X
a	B-X
rally	B-X
race	B-X
car	B-X
driver	B-X
JoÃ£o	B-X
Lopes	B-X
,	B-X
Henrique	B-X
Almeida	B-X
,	B-X
Sandra	B-X
Amado	B-X
,	B-X
LuÃ­s	B-X
CarrÃ£o	B-X
O234	B-X
Literacy	B-X
and	B-X
results	B-X
in	B-X
health	B-X
Madalena	B-X
Cunha	B-X
,	B-X
LuÃ­s	B-X
Saboga-Nunes	B-X
,	B-X
Carlos	B-X
Albuquerque	B-X
,	B-X
OlivÃ©rio	B-X
Ribeiro	B-X
O235	B-X
Literacy	B-X
promotion	B-X
and	B-X
empowerment	B-X
of	B-X
type	B-X
2	B-X
diabetics	B-X
elderly	B-X
in	B-X
four	B-X
family	B-X
health	B-X
units	B-X
of	B-X
the	B-X
group	B-X
of	B-X
health	B-X
centers	B-X
of	B-X
DÃ£o	B-X
LafÃµes	B-X
Suzete	B-X
Oliveira	B-X
,	B-X
MÂª	B-X
Carminda	B-X
Morais	B-X
O236	B-X
Mediterranean	B-X
diet	B-X
,	B-X
health	B-X
and	B-X
life	B-X
quality	B-X
among	B-X
Portuguese	B-X
children	B-X
EmÃ­lia	B-X
Martins	B-X
,	B-X
Francisco	B-X
Mendes	B-X
,	B-X
Rosina	B-X
Fernandes	B-X
,	B-X
CÃ¡tia	B-X
MagalhÃ£es	B-X
,	B-X
PatrÃ­cia	B-X
AraÃºjo	B-X
O237	B-X
Health	B-X
literacy	B-X
,	B-X
from	B-X
data	B-X
to	B-X
action	B-X
-	B-X
translation	B-X
,	B-X
validation	B-X
and	B-X
application	B-X
of	B-X
the	B-X
European	B-X
Health	B-X
Literacy	B-X
Survey	B-X
in	B-X
Portugal	B-X
(	B-X
HLS-EU-PT	B-X
)	B-X
Ana	B-X
R.	B-X
Pedro	B-X
,	B-X
Odete	B-X
Amaral	B-X
,	B-X
Ana	B-X
Escoval	B-X
O238	B-X
Oral	B-X
health	B-X
literacy	B-X
evaluation	B-X
in	B-X
a	B-X
Portuguese	B-X
military	B-X
population	B-X
Victor	B-X
AssunÃ§Ã£o	B-X
,	B-X
Henrique	B-X
LuÃ­s	B-X
,	B-X
LuÃ­s	B-X
LuÃ­s	B-X
O239	B-X
Preferences	B-X
to	B-X
Internet-based	B-X
cognitive	B-X
behavioural	B-X
therapy	B-X
â	B-X
do	B-X
attachment	B-X
orientations	B-X
matter	B-X
?	B-X
Paula	B-X
A.	B-X
Silva	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
,	B-X
Carla	B-X
Carvalho	B-X
O243	B-X
Work-life	B-X
balance	B-X
in	B-X
health	B-X
professionals	B-X
and	B-X
professors	B-X
:	B-X
comparative	B-X
study	B-X
of	B-X
workers	B-X
with	B-X
shift	B-X
work	B-X
and	B-X
fixed	B-X
schedule	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Joana	B-X
Ruivo	B-X
O244	B-X
Technology	B-X
literacy	B-X
in	B-X
self-management	B-X
of	B-X
diabetes	B-X
VÃ¢nia	B-X
Silva	B-X
,	B-X
Paulino	B-X
Sousa	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
O245	B-X
Satisfaction	B-X
with	B-X
therapeutic	B-X
education	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
clinical	B-X
variables	B-X
in	B-X
children	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
Vera	B-X
Ferraz	B-X
,	B-X
GraÃ§a	B-X
AparÃ­cio	B-X
,	B-X
JoÃ£o	B-X
Duarte	B-X
O246	B-X
Nutrition-related	B-X
knowledge	B-X
in	B-X
middle-age	B-X
and	B-X
older	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
Carlos	B-X
Vasconcelos	B-X
,	B-X
AntÃ³nio	B-X
Almeida	B-X
,	B-X
Joel	B-X
Neves	B-X
,	B-X
Telma	B-X
Correia	B-X
,	B-X
Helena	B-X
Amorim	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O247	B-X
Validating	B-X
the	B-X
HLS-EU-	B-X
(	B-X
PT	B-X
)	B-X
questionnaire	B-X
to	B-X
measure	B-X
health	B-X
literacy	B-X
in	B-X
adolescents	B-X
(	B-X
CrAdLiSa	B-X
project	B-X
:	B-X
HLS-EU-PT	B-X
)	B-X
LuÃ­s	B-X
Saboga-Nunes	B-X
,	B-X
Madalena	B-X
Cunha	B-X
,	B-X
Carlos	B-X
Albuquerque	B-X
O248	B-X
Health	B-X
education	B-X
in	B-X
people	B-X
with	B-X
coronary	B-X
heart	B-X
disease	B-X
:	B-X
Experience	B-X
of	B-X
the	B-X
cardiology	B-X
department	B-X
of	B-X
a	B-X
hospital	B-X
on	B-X
the	B-X
outskirts	B-X
of	B-X
Lisbon	B-X
Elsa	B-X
S.	B-X
Pereira	B-X
,	B-X
Leonino	B-X
S.	B-X
Santos	B-X
,	B-X
Ana	B-X
S.	B-X
Reis	B-X
,	B-X
Helena	B-X
R.	B-X
Silva	B-X
,	B-X
JoÃ£o	B-X
Rombo	B-X
,	B-X
Jorge	B-X
C.	B-X
Fernandes	B-X
,	B-X
PatrÃ­cia	B-X
Fernandes	B-X
O249	B-X
Information	B-X
and	B-X
training	B-X
needs	B-X
of	B-X
informal	B-X
caregivers	B-X
of	B-X
individuals	B-X
with	B-X
stroke	B-X
sequelae	B-X
:	B-X
a	B-X
qualitative	B-X
survey	B-X
Jaime	B-X
Ribeiro	B-X
,	B-X
Catarina	B-X
Mangas	B-X
,	B-X
Ana	B-X
Freire	B-X
O250	B-X
Prevention	B-X
of	B-X
psychoactive	B-X
substances	B-X
consumption	B-X
in	B-X
students	B-X
from	B-X
6th	B-X
grade	B-X
of	B-X
Albergaria-a-VelhaÂ´s	B-X
School	B-X
Group	B-X
Sara	B-X
Silva	B-X
,	B-X
Irene	B-X
Francisco	B-X
,	B-X
Ana	B-X
Oliveira	B-X
O251	B-X
Promoting	B-X
healthy	B-X
sexuality	B-X
:	B-X
shared	B-X
responsibility	B-X
for	B-X
family	B-X
,	B-X
youth	B-X
and	B-X
educators	B-X
Helena	B-X
Catarino	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
MÂª	B-X
Clarisse	B-X
Louro	B-X
O252	B-X
Sexual	B-X
risk	B-X
behaviour	B-X
in	B-X
adolescents	B-X
and	B-X
young	B-X
people	B-X
Saudade	B-X
Lopes	B-X
,	B-X
Anjos	B-X
Dixe	B-X
O253	B-X
Knowledge	B-X
of	B-X
school	B-X
staff	B-X
on	B-X
type	B-X
1	B-X
diabetes	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
FÃ¡tima	B-X
Soares	B-X
,	B-X
Ana	B-X
P.	B-X
Oliveira	B-X
,	B-X
Sara	B-X
Gordo	B-X
,	B-X
Teresa	B-X
Kraus	B-X
O254	B-X
Sexual	B-X
health	B-X
in	B-X
adolescents	B-X
:	B-X
the	B-X
impact	B-X
of	B-X
information	B-X
search	B-X
in	B-X
literacy	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Paulo	B-X
QueirÃ³s	B-X
,	B-X
Teresa	B-X
Rodrigues	B-X
P123	B-X
Improving	B-X
basic	B-X
life	B-X
support	B-X
skills	B-X
in	B-X
adolescents	B-X
through	B-X
a	B-X
training	B-X
programme	B-X
Pedro	B-X
Sousa	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Catarina	B-X
LobÃ£o	B-X
P124	B-X
Difficulties	B-X
in	B-X
sexual	B-X
education	B-X
reported	B-X
by	B-X
basic	B-X
education	B-X
teachers	B-X
in	B-X
the	B-X
city	B-X
of	B-X
Foz	B-X
do	B-X
IguaÃ§u	B-X
-	B-X
Brazil	B-X
Cynthia	B-X
B.	B-X
Moura	B-X
,	B-X
Laysa	B-X
C.	B-X
Dreyer	B-X
,	B-X
Vanize	B-X
Meneghetti	B-X
,	B-X
Priscila	B-X
P.	B-X
Cabral	B-X
P125	B-X
Breast	B-X
cancer	B-X
survivors	B-X
:	B-X
subjects	B-X
and	B-X
resources	B-X
for	B-X
information	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
outline	O
the	O
known	O
mechanisms	O
that	O
impair	O
p53	B-Gene_or_gene_product
itself	O
and	O
its	O
immediate	O
regulators	O
or	O
target	O
genes	O
during	O
melanomagenesis	O
.	O
<EOS>	B-X
The	B-X
PI3K-PTEN-AKT	B-X
signaling	B-X
pathway	B-X
is	B-X
involved	B-X
in	B-X
various	B-X
cellular	B-X
activities	B-X
,	B-X
including	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
cell	B-X
growth	B-X
,	B-X
cell	B-X
survival	B-X
and	B-X
differentiation	B-X
during	B-X
adult	B-X
homeostasis	B-X
as	B-X
well	B-X
as	B-X
in	B-X
tumorigenesis	B-X
.	B-X
PI3K	B-X
signaling	B-X
activation	B-X
,	B-X
via	B-X
loss	B-X
of	B-X
PTEN	B-X
function	B-X
,	B-X
can	B-X
inhibit	B-X
proapoptotic	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
FoxO	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
while	B-X
inducing	B-X
cell	B-X
growth-	B-X
and	B-X
cell	B-X
survival-related	B-X
elements	B-X
such	B-X
as	B-X
p70S6K	B-X
and	B-X
AKT	B-X
.	B-X
Determining	B-X
how	B-X
the	B-X
PI3K-PTEN-AKT	B-X
signaling	B-X
pathway	B-X
,	B-X
alone	B-X
or	B-X
in	B-X
cooperation	B-X
with	B-X
other	B-X
pathways	B-X
,	B-X
orchestrates	B-X
the	B-X
induction	B-X
of	B-X
target	B-X
genes	B-X
involved	B-X
in	B-X
a	B-X
diverse	B-X
range	B-X
of	B-X
activities	B-X
is	B-X
a	B-X
major	B-X
challenge	B-X
in	B-X
research	B-X
into	B-X
melanoma	B-X
initiation	B-X
and	B-X
progression	B-X
.	B-X
Signaling	B-X
cascades	B-X
such	B-X
as	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
and	B-X
PI3K/AKT	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
crucial	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
processes	B-X
that	B-X
are	B-X
commonly	B-X
dysregulated	B-X
during	B-X
cancer	B-X
development	B-X
such	B-X
as	B-X
aberrant	B-X
proliferation	B-X
,	B-X
loss	B-X
of	B-X
cell	B-X
cycle	B-X
control	B-X
,	B-X
impaired	B-X
apoptosis	B-X
,	B-X
and	B-X
altered	B-X
drug	B-X
metabolism	B-X
.	B-X
With	B-X
advances	B-X
in	B-X
technology	B-X
and	B-X
especially	B-X
in	B-X
next	B-X
generation	B-X
sequencing	B-X
,	B-X
we	B-X
have	B-X
been	B-X
able	B-X
to	B-X
explore	B-X
melanoma	B-X
genomes	B-X
and	B-X
exomes	B-X
leading	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
previously	B-X
unknown	B-X
genes	B-X
with	B-X
functions	B-X
in	B-X
melanomagenesis	B-X
such	B-X
as	B-X
GRIN2A	B-X
and	B-X
PREX2	B-X
.	B-X
The	B-X
therapeutic	B-X
potential	B-X
of	B-X
these	B-X
novel	B-X
candidate	B-X
genes	B-X
is	B-X
actively	B-X
being	B-X
pursued	B-X
with	B-X
some	B-X
presenting	B-X
as	B-X
druggable	B-X
targets	B-X
while	B-X
others	B-X
serve	B-X
as	B-X
indicators	B-X
of	B-X
therapeutic	B-X
responses	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
analysis	B-X
of	B-X
the	B-X
mutational	B-X
signatures	B-X
of	B-X
melanoma	B-X
tumors	B-X
continues	B-X
to	B-X
cement	B-X
the	B-X
causative	B-X
role	B-X
of	B-X
UV	B-X
exposure	B-X
in	B-X
melanoma	B-X
pathogenesis	B-X
.	B-X

Due	O
to	O
the	O
importance	O
of	O
this	O
pathway	O
,	O
it	O
is	O
clear	O
that	O
p53	B-Gene_or_gene_product
disruptions	O
may	O
relate	O
directly	O
to	O
a	O
patient	O
'	O
s	O
prognosis	O
.	O

This	O
pathway	O
will	O
continue	O
to	O
be	O
a	O
focus	O
of	O
investigation	O
,	O
particularly	O
with	O
respect	O
to	O
targeted	O
experimental	O
chemotherapeutics	O
.	O
<EOS>	B-X
The	B-X
cell	B-X
autonomous	B-X
function	B-X
of	B-X
p53	B-X
in	B-X
melanocytes	B-X
is	B-X
not	B-X
well	B-X
described	B-X
,	B-X
however	B-X
,	B-X
the	B-X
balance	B-X
of	B-X
the	B-X
evidence	B-X
suggests	B-X
that	B-X
p53	B-X
is	B-X
an	B-X
effective	B-X
tumor	B-X
suppressor	B-X
and	B-X
the	B-X
myriad	B-X
of	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
p53	B-X
pathway	B-X
may	B-X
be	B-X
dysregulated	B-X
in	B-X
tumors	B-X
attests	B-X
to	B-X
it	B-X
importance	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
it	B-X
is	B-X
clear	B-X
that	B-X
p53	B-X
disruptions	B-X
may	B-X
relate	B-X
directly	B-X
to	B-X
a	B-X
patient	B-X
's	B-X
prognosis	B-X
.	B-X
This	B-X
pathway	B-X
will	B-X
continue	B-X
to	B-X
be	B-X
a	B-X
focus	B-X
of	B-X
investigation	B-X
,	B-X
particularly	B-X
with	B-X
respect	B-X
to	B-X
targeted	B-X
experimental	B-X
chemotherapeutics	B-X
.	B-X

Enhancement	O
of	O
docetaxel	O
-	O
induced	O
cytotoxicity	O
and	O
apoptosis	O
by	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
through	O
downregulation	O
of	O
survivin	B-Gene_or_gene_product
(	O
BIRC5	B-Gene_or_gene_product
)	O
,	O
MCL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
LTbeta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
R	I-Gene_or_gene_product
in	O
hormone	O
-	O
and	O
drug	O
resistant	O
prostate	O
cancer	O
cell	O
line	O
,	O
DU	O
-	O
145	O
.	O
<EOS>	B-X
The	B-X
management	B-X
of	B-X
hormone-refractory	B-X
prostate	B-X
cancer	B-X
(	B-X
HRPC	B-X
)	B-X
still	B-X
remains	B-X
as	B-X
an	B-X
important	B-X
challenge	B-X
of	B-X
daily	B-X
oncology	B-X
practice	B-X
.	B-X
Docetaxel	B-X
has	B-X
proved	B-X
to	B-X
be	B-X
a	B-X
first	B-X
line	B-X
treatment	B-X
choice	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
searched	B-X
for	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
apoptosis	B-X
by	B-X
demonstrating	B-X
apoptosis-related	B-X
genes	B-X
.	B-X

BACKGROUND	O
:	O
The	O
management	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
still	O
remains	O
as	O
an	O
important	O
challenge	O
of	O
daily	O
oncology	O
practice	O
.	O
<EOS>	B-X
The	B-X
management	B-X
of	B-X
hormone-refractory	B-X
prostate	B-X
cancer	B-X
(	B-X
HRPC	B-X
)	B-X
still	B-X
remains	B-X
as	B-X
an	B-X
important	B-X
challenge	B-X
of	B-X
daily	B-X
oncology	B-X
practice	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X

Docetaxel	O
has	O
proved	O
to	O
be	O
a	O
first	O
line	O
treatment	O
choice	O
.	O
<EOS>	B-X
Chemotherapy	B-X
is	B-X
the	B-X
treatment	B-X
of	B-X
choice	B-X
in	B-X
metastatic	B-X
stage	B-X
of	B-X
small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
SCLC	B-X
)	B-X
.	B-X
Radiation	B-X
therapy	B-X
,	B-X
surgery	B-X
and	B-X
other	B-X
forms	B-X
of	B-X
therapy	B-X
are	B-X
only	B-X
included	B-X
in	B-X
special	B-X
treatment	B-X
situations	B-X
,	B-X
particularly	B-X
for	B-X
different	B-X
local	B-X
problems	B-X
.	B-X
However	B-X
,	B-X
treatment	B-X
results	B-X
could	B-X
not	B-X
be	B-X
improved	B-X
over	B-X
the	B-X
last	B-X
10	B-X
years	B-X
and	B-X
the	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
metastatic	B-X
disease	B-X
is	B-X
limited	B-X
to	B-X
7-10	B-X
months	B-X
.	B-X
Yet	B-X
,	B-X
no	B-X
evidence	B-X
is	B-X
provided	B-X
from	B-X
randomized	B-X
trials	B-X
to	B-X
employ	B-X
these	B-X
drugs	B-X
in	B-X
first	B-X
line	B-X
treatment	B-X
.	B-X
Clearly	B-X
,	B-X
polychemotherapy	B-X
is	B-X
superior	B-X
to	B-X
single	B-X
agent	B-X
treatment	B-X
.	B-X
Compared	B-X
to	B-X
the	B-X
combination	B-X
of	B-X
cisplatin	B-X
and	B-X
etoposide	B-X
,	B-X
no	B-X
other	B-X
combination	B-X
has	B-X
clearly	B-X
shown	B-X
improved	B-X
results	B-X
in	B-X
large	B-X
phase-III	B-X
randomised	B-X
trials	B-X
,	B-X
yet	B-X
.	B-X
Neither	B-X
extending	B-X
the	B-X
initial	B-X
treatment	B-X
beyond	B-X
the	B-X
median	B-X
number	B-X
of	B-X
six	B-X
cycles	B-X
,	B-X
nor	B-X
maintenance	B-X
treatment	B-X
have-so	B-X
far-resulted	B-X
in	B-X
any	B-X
increase	B-X
in	B-X
survival	B-X
results	B-X
for	B-X
patients	B-X
with	B-X
metastasised	B-X
SCLC	B-X
.	B-X
Second-line	B-X
treatment	B-X
should	B-X
always	B-X
be	B-X
considered	B-X
in	B-X
patients	B-X
with	B-X
relapse	B-X
or	B-X
failure	B-X
to	B-X
first-line	B-X
therapy	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
a	B-X
rechallenging	B-X
with	B-X
the	B-X
prior	B-X
drug	B-X
combination	B-X
or	B-X
selecting	B-X
a	B-X
different	B-X
potentially	B-X
non-cross	B-X
resistant	B-X
one	B-X
,	B-X
monotherapy	B-X
with	B-X
topotecan	B-X
proved	B-X
to	B-X
be	B-X
effective	B-X
as	B-X
well	B-X
.	B-X

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
could	O
potently	O
inhibit	O
the	O
growth	O
of	O
prostate	O
cancer	O
cells	O
in	O
vitro	O
and	O
its	O
combination	O
with	O
various	O
anticancer	O
agents	O
results	O
in	O
increased	O
cytotoxicity	O
.	O
<EOS>	B-X
The	B-X
management	B-X
of	B-X
hormone-refractory	B-X
prostate	B-X
cancer	B-X
(	B-X
HRPC	B-X
)	B-X
still	B-X
remains	B-X
as	B-X
an	B-X
important	B-X
challenge	B-X
of	B-X
daily	B-X
oncology	B-X
practice	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X

Based	O
on	O
these	O
data	O
,	O
our	O
aim	O
was	O
to	O
examine	O
the	O
synergistic	O
/	O
additive	O
cytotoxic	O
and	O
apoptotic	O
effects	O
of	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
,	O
in	O
hormone	O
-	O
and	O
drug	O
refractory	O
human	O
DU	O
-	O
145	O
prostate	O
cancer	O
cells	O
.	O
<EOS>	B-X
The	B-X
management	B-X
of	B-X
hormone-refractory	B-X
prostate	B-X
cancer	B-X
(	B-X
HRPC	B-X
)	B-X
still	B-X
remains	B-X
as	B-X
an	B-X
important	B-X
challenge	B-X
of	B-X
daily	B-X
oncology	B-X
practice	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
we	O
have	O
searched	O
for	O
the	O
underlying	O
mechanisms	O
of	O
apoptosis	O
by	O
demonstrating	O
apoptosis	O
-	O
related	O
genes	O
.	O
<EOS>	B-X
Although	B-X
advances	B-X
in	B-X
identifying	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
to	B-X
delineate	B-X
these	B-X
fibroids	B-X
have	B-X
already	B-X
been	B-X
made	B-X
,	B-X
only	B-X
recently	B-X
has	B-X
the	B-X
role	B-X
of	B-X
epigenomics	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
this	B-X
disease	B-X
been	B-X
considered	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
searched	B-X
for	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
apoptosis	B-X
by	B-X
demonstrating	B-X
apoptosis-related	B-X
genes	B-X
.	B-X
The	B-X
search	B-X
for	B-X
new	B-X
medicines	B-X
that	B-X
modulate	B-X
the	B-X
formation	B-X
and	B-X
function	B-X
of	B-X
osteoclasts	B-X
is	B-X
a	B-X
potential	B-X
approach	B-X
for	B-X
treating	B-X
osteoclast-related	B-X
bone	B-X
diseases	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
RAW264.7	B-X
,	B-X
an	B-X
osteoclast	B-X
lineage	B-X
of	B-X
cells	B-X
of	B-X
murine	B-X
macrophages	B-X
,	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
and	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
PIC	B-X
on	B-X
osteoclasts	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
PIC	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
decrease	B-X
of	B-X
osteoclast-specific	B-X
genes	B-X
.	B-X
Besides	B-X
,	B-X
PIC	B-X
promoted	B-X
the	B-X
apoptosis	B-X
of	B-X
mature	B-X
osteoclasts	B-X
by	B-X
inducing	B-X
caspase-3	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
suggested	B-X
that	B-X
PIC	B-X
inhibited	B-X
RANKL-induced	B-X
osteoclastogenesis	B-X
and	B-X
bone	B-X
resorption	B-X
by	B-X
suppressing	B-X
MAPK	B-X
,	B-X
NF-ÎºB	B-X
and	B-X
AKT	B-X
signalling	B-X
pathways	B-X
and	B-X
promoted	B-X
caspase3-mediated	B-X
apoptosis	B-X
of	B-X
mature	B-X
osteoclasts	B-X
,	B-X
which	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
treatment	B-X
of	B-X
bone	B-X
diseases	B-X
characterized	B-X
by	B-X
excessive	B-X
bone	B-X
resorption	B-X
.	B-X

METHODS	O
:	O
XTT	O
cell	O
proliferation	O
assay	O
was	O
used	O
for	O
showing	O
cytotoxicity	O
.	O
<EOS>	B-X
This	B-X
in	B-X
vitro	B-X
study	B-X
evaluated	B-X
and	B-X
correlated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
leaching	B-X
residual	B-X
MMA	B-X
concentrations	B-X
(	B-X
[	B-X
MMA	B-X
]	B-X
r	B-X
)	B-X
on	B-X
in	B-X
vitro	B-X
cytotoxicity	B-X
of	B-X
L-929	B-X
fibroblasts	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
SCLC	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
aggressive	B-X
malignancies	B-X
implying	B-X
a	B-X
very	B-X
poor	B-X
prognosis	B-X
for	B-X
patients	B-X
even	B-X
under	B-X
therapy	B-X
.	B-X
Since	B-X
it	B-X
is	B-X
known	B-X
that	B-X
SCLC	B-X
cells	B-X
exhibit	B-X
neurone-like	B-X
characteristics	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
a	B-X
neuronal	B-X
induction	B-X
medium	B-X
(	B-X
NID	B-X
)	B-X
consisting	B-X
of	B-X
indomethacin	B-X
(	B-X
200	B-X
Î¼M	B-X
)	B-X
,	B-X
3-isobutyl-1-methylxanthine	B-X
(	B-X
IBMX	B-X
,	B-X
500	B-X
Î¼M	B-X
)	B-X
and	B-X
insulin	B-X
(	B-X
5	B-X
Î¼g/ml	B-X
)	B-X
induces	B-X
neuronal	B-X
differentiation	B-X
and	B-X
by	B-X
this	B-X
reduces	B-X
malignancy	B-X
of	B-X
SCLC	B-X
in	B-X
vitro	B-X
.	B-X

For	O
verifying	O
apoptosis	O
,	O
both	O
DNA	O
Fragmentation	O
by	O
ELISA	O
assay	O
and	O
caspase	B-Gene_or_gene_product
3	I-Gene_or_gene_product
/	O
7	B-Gene_or_gene_product
activity	O
measurement	O
were	O
used	O
.	O
<EOS>	B-X
Although	B-X
,	B-X
platinum	B-X
based	B-X
treatments	B-X
are	B-X
widely	B-X
used	B-X
,	B-X
the	B-X
disease	B-X
becomes	B-X
treatment	B-X
refractory	B-X
within	B-X
two	B-X
years	B-X
,	B-X
and	B-X
novel	B-X
treatment	B-X
options	B-X
should	B-X
be	B-X
searched	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
additive/synergistic	B-X
effect	B-X
of	B-X
both	B-X
agents	B-X
in	B-X
OVCAR-3	B-X
and	B-X
MDAH-2774	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
,	B-X
since	B-X
both	B-X
agents	B-X
show	B-X
superiority	B-X
to	B-X
conventional	B-X
cytotoxics	B-X
in	B-X
terms	B-X
of	B-X
adverse	B-X
events	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
searched	B-X
for	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
apoptosis	B-X
by	B-X
demonstrating	B-X
apoptosis-related	B-X
genes	B-X
.	B-X
OBJECTIVE	B-X
To	B-X
evaluate	B-X
the	B-X
effects	B-X
of	B-X
combined	B-X
treatment	B-X
with	B-X
docetaxel	B-X
and	B-X
octreotide	B-X
,	B-X
a	B-X
somatostatin	B-X
analogue	B-X
,	B-X
on	B-X
human	B-X
hormone-	B-X
and	B-X
drug-refractory	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
,	B-X
PC-3	B-X
and	B-X
DU-145	B-X
,	B-X
and	B-X
on	B-X
some	B-X
growth	B-X
factors	B-X
related	B-X
to	B-X
tumour	B-X
growth	B-X
and	B-X
angiogenesis	B-X
in	B-X
prostate	B-X
cancer	B-X
.	B-X
MATERIALS	B-X
AND	B-X
METHODS	B-X
A	B-X
cell	B-X
proliferation	B-X
assay	B-X
was	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
cytotoxicity	B-X
of	B-X
the	B-X
drugs	B-X
.	B-X
To	B-X
verify	B-X
apoptosis	B-X
,	B-X
both	B-X
DNA	B-X
fragmentation	B-X
(	B-X
by	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
)	B-X
and	B-X
caspase	B-X
3/7	B-X
activity	B-X
were	B-X
measured	B-X
.	B-X
RESULTS	B-X
The	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
octreotide	B-X
resulted	B-X
in	B-X
significant	B-X
synergistic	B-X
cytotoxic	B-X
activity	B-X
and	B-X
apoptosis	B-X
,	B-X
which	B-X
was	B-X
dose-	B-X
and	B-X
time-dependent	B-X
.	B-X
The	B-X
combined	B-X
treatment	B-X
also	B-X
resulted	B-X
in	B-X
significantly	B-X
less	B-X
secretion	B-X
of	B-X
stem	B-X
cell	B-X
factor	B-X
and	B-X
platelet-derived	B-X
growth	B-X
factor-AB	B-X
in	B-X
PC-3	B-X
cells	B-X
,	B-X
and	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
in	B-X
DU-145	B-X
cells	B-X
,	B-X
than	B-X
in	B-X
untreated	B-X
controls	B-X
.	B-X

For	O
detecting	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
docetaxel	O
-	O
ATRA	O
combination	O
,	O
OligoGeArray	O
which	O
consists	O
of	O
112	O
apoptosis	O
related	O
genes	O
was	O
used	O
.	O
<EOS>	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
searched	B-X
for	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
apoptosis	B-X
by	B-X
demonstrating	B-X
apoptosis-related	B-X
genes	B-X
.	B-X

RESULTS	O
:	O
Our	O
results	O
revealed	O
that	O
docetaxel	O
and	O
ATRA	O
were	O
synergistically	O
cytotoxic	O
and	O
apoptotic	O
in	O
DU	O
-	O
145	O
cells	O
,	O
in	O
a	O
dose	O
-	O
and	O
time	O
dependent	O
manner	O
.	O

It	O
was	O
also	O
shown	O
by	O
our	O
studies	O
that	O
apoptosis	O
was	O
induced	O
in	O
DU	O
-	O
145	O
prostate	O
carcinoma	O
cells	O
with	O
significant	O
cytotoxicity	O
,	O
no	O
matter	O
which	O
agent	O
applied	O
first	O
.	O
<EOS>	B-X
The	B-X
management	B-X
of	B-X
hormone-refractory	B-X
prostate	B-X
cancer	B-X
(	B-X
HRPC	B-X
)	B-X
still	B-X
remains	B-X
as	B-X
an	B-X
important	B-X
challenge	B-X
of	B-X
daily	B-X
oncology	B-X
practice	B-X
.	B-X
Docetaxel	B-X
has	B-X
proved	B-X
to	B-X
be	B-X
a	B-X
first	B-X
line	B-X
treatment	B-X
choice	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
searched	B-X
for	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
apoptosis	B-X
by	B-X
demonstrating	B-X
apoptosis-related	B-X
genes	B-X
.	B-X

We	O
have	O
found	O
out	O
that	O
docetaxel	O
-	O
ATRA	O
combination	O
significantly	O
downregulates	O
survivin	B-Gene_or_gene_product
(	O
BIRC5	B-Gene_or_gene_product
)	O
,	O
myeloid	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
leukemia	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
MCL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
and	O
lymphotoxin	B-Gene_or_gene_product
beta	I-Gene_or_gene_product
-	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
LTbetaR	B-Gene_or_gene_product
)	O
genes	O
,	O
which	O
all	O
three	O
have	O
pivotal	O
roles	O
in	O
regulation	O
of	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
.	O
<EOS>	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
searched	B-X
for	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
apoptosis	B-X
by	B-X
demonstrating	B-X
apoptosis-related	B-X
genes	B-X
.	B-X

CONCLUSION	O
:	O
In	O
conclusion	O
,	O
we	O
strongly	O
suggest	O
that	O
docetaxel	O
and	O
ATRA	O
combination	O
is	O
a	O
good	O
candidate	O
for	O
this	O
challenging	O
era	O
of	O
daily	O
oncologic	O
practice	O
.	O
<EOS>	B-X
The	B-X
management	B-X
of	B-X
hormone-refractory	B-X
prostate	B-X
cancer	B-X
(	B-X
HRPC	B-X
)	B-X
still	B-X
remains	B-X
as	B-X
an	B-X
important	B-X
challenge	B-X
of	B-X
daily	B-X
oncology	B-X
practice	B-X
.	B-X
All-trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
could	B-X
potently	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
prostate	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
various	B-X
anticancer	B-X
agents	B-X
results	B-X
in	B-X
increased	B-X
cytotoxicity	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
synergistic/additive	B-X
cytotoxic	B-X
and	B-X
apoptotic	B-X
effects	B-X
of	B-X
combination	B-X
of	B-X
docetaxel	B-X
and	B-X
ATRA	B-X
,	B-X
in	B-X
hormone-	B-X
and	B-X
drug	B-X
refractory	B-X
human	B-X
DU-145	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X

Also	O
,	O
the	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
might	O
allow	O
a	O
reduction	O
in	O
docetaxel	O
doses	O
and	O
by	O
this	O
way	O
may	O
diminish	O
docetaxel	O
adverse	O
effects	O
while	O
maintaining	O
the	O
therapeutic	O
effect	O
in	O
patients	O
with	O
HRPC	O
.	O

Diverse	O
cell	O
signaling	O
events	O
modulated	O
by	O
perlecan	B-Gene_or_gene_product
.	O
<EOS>	B-X
Perlecan	B-X
is	B-X
a	B-X
ubiquitous	B-X
pericellular	B-X
proteoglycan	B-X
ideally	B-X
placed	B-X
to	B-X
mediate	B-X
cell	B-X
signaling	B-X
events	B-X
controlling	B-X
migration	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
differentiation	B-X
.	B-X
Its	B-X
control	B-X
of	B-X
growth	B-X
factor	B-X
signaling	B-X
usually	B-X
involves	B-X
interactions	B-X
with	B-X
the	B-X
heparan	B-X
sulfate	B-X
chains	B-X
covalently	B-X
coupled	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
's	B-X
N-terminus	B-X
.	B-X
However	B-X
,	B-X
this	B-X
modular	B-X
protein	B-X
core	B-X
also	B-X
binds	B-X
with	B-X
relatively	B-X
high	B-X
affinity	B-X
to	B-X
a	B-X
number	B-X
of	B-X
growth	B-X
factors	B-X
and	B-X
surface	B-X
receptors	B-X
,	B-X
thereby	B-X
stabilizing	B-X
cell-matrix	B-X
links	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
perlecan-growth	B-X
factor	B-X
interactions	B-X
and	B-X
describe	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
this	B-X
highly	B-X
conserved	B-X
proteoglycan	B-X
during	B-X
development	B-X
,	B-X
cancer	B-X
growth	B-X
,	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
pro-angiogenic	B-X
capacities	B-X
of	B-X
perlecan	B-X
that	B-X
involve	B-X
proliferative	B-X
and	B-X
migratory	B-X
signals	B-X
in	B-X
response	B-X
to	B-X
bound	B-X
growth	B-X
factors	B-X
will	B-X
be	B-X
explored	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
anti-angiogenic	B-X
signals	B-X
resulting	B-X
from	B-X
interactions	B-X
between	B-X
the	B-X
C-terminal	B-X
domain	B-X
known	B-X
as	B-X
endorepellin	B-X
and	B-X
integrins	B-X
that	B-X
control	B-X
adhesion	B-X
of	B-X
cells	B-X
to	B-X
the	B-X
extracellular	B-X
matrix	B-X
.	B-X
These	B-X
two	B-X
somewhat	B-X
diametrically	B-X
opposed	B-X
roles	B-X
will	B-X
be	B-X
discussed	B-X
in	B-X
light	B-X
of	B-X
new	B-X
data	B-X
emerging	B-X
from	B-X
various	B-X
fields	B-X
which	B-X
converge	B-X
on	B-X
perlecan	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X

Perlecan	B-Gene_or_gene_product
is	O
a	O
ubiquitous	O
pericellular	O
proteoglycan	O
ideally	O
placed	O
to	O
mediate	O
cell	O
signaling	O
events	O
controlling	O
migration	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O
<EOS>	B-X
Perlecan	B-X
is	B-X
a	B-X
ubiquitous	B-X
pericellular	B-X
proteoglycan	B-X
ideally	B-X
placed	B-X
to	B-X
mediate	B-X
cell	B-X
signaling	B-X
events	B-X
controlling	B-X
migration	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
differentiation	B-X
.	B-X
Its	B-X
control	B-X
of	B-X
growth	B-X
factor	B-X
signaling	B-X
usually	B-X
involves	B-X
interactions	B-X
with	B-X
the	B-X
heparan	B-X
sulfate	B-X
chains	B-X
covalently	B-X
coupled	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
's	B-X
N-terminus	B-X
.	B-X
However	B-X
,	B-X
this	B-X
modular	B-X
protein	B-X
core	B-X
also	B-X
binds	B-X
with	B-X
relatively	B-X
high	B-X
affinity	B-X
to	B-X
a	B-X
number	B-X
of	B-X
growth	B-X
factors	B-X
and	B-X
surface	B-X
receptors	B-X
,	B-X
thereby	B-X
stabilizing	B-X
cell-matrix	B-X
links	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
perlecan-growth	B-X
factor	B-X
interactions	B-X
and	B-X
describe	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
this	B-X
highly	B-X
conserved	B-X
proteoglycan	B-X
during	B-X
development	B-X
,	B-X
cancer	B-X
growth	B-X
,	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
pro-angiogenic	B-X
capacities	B-X
of	B-X
perlecan	B-X
that	B-X
involve	B-X
proliferative	B-X
and	B-X
migratory	B-X
signals	B-X
in	B-X
response	B-X
to	B-X
bound	B-X
growth	B-X
factors	B-X
will	B-X
be	B-X
explored	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
anti-angiogenic	B-X
signals	B-X
resulting	B-X
from	B-X
interactions	B-X
between	B-X
the	B-X
C-terminal	B-X
domain	B-X
known	B-X
as	B-X
endorepellin	B-X
and	B-X
integrins	B-X
that	B-X
control	B-X
adhesion	B-X
of	B-X
cells	B-X
to	B-X
the	B-X
extracellular	B-X
matrix	B-X
.	B-X
These	B-X
two	B-X
somewhat	B-X
diametrically	B-X
opposed	B-X
roles	B-X
will	B-X
be	B-X
discussed	B-X
in	B-X
light	B-X
of	B-X
new	B-X
data	B-X
emerging	B-X
from	B-X
various	B-X
fields	B-X
which	B-X
converge	B-X
on	B-X
perlecan	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X

Its	O
control	O
of	O
growth	O
factor	O
signaling	O
usually	O
involves	O
interactions	O
with	O
the	O
heparan	O
sulfate	O
chains	O
covalently	O
coupled	O
to	O
the	O
protein	O
core	O
'	O
s	O
N	O
-	O
terminus	O
.	O

However	O
,	O
this	O
modular	O
protein	O
core	O
also	O
binds	O
with	O
relatively	O
high	O
affinity	O
to	O
a	O
number	O
of	O
growth	O
factors	O
and	O
surface	O
receptors	O
,	O
thereby	O
stabilizing	O
cell	O
-	O
matrix	O
links	O
.	O
<EOS>	B-X
Perlecan	B-X
is	B-X
a	B-X
ubiquitous	B-X
pericellular	B-X
proteoglycan	B-X
ideally	B-X
placed	B-X
to	B-X
mediate	B-X
cell	B-X
signaling	B-X
events	B-X
controlling	B-X
migration	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
differentiation	B-X
.	B-X
Its	B-X
control	B-X
of	B-X
growth	B-X
factor	B-X
signaling	B-X
usually	B-X
involves	B-X
interactions	B-X
with	B-X
the	B-X
heparan	B-X
sulfate	B-X
chains	B-X
covalently	B-X
coupled	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
's	B-X
N-terminus	B-X
.	B-X
However	B-X
,	B-X
this	B-X
modular	B-X
protein	B-X
core	B-X
also	B-X
binds	B-X
with	B-X
relatively	B-X
high	B-X
affinity	B-X
to	B-X
a	B-X
number	B-X
of	B-X
growth	B-X
factors	B-X
and	B-X
surface	B-X
receptors	B-X
,	B-X
thereby	B-X
stabilizing	B-X
cell-matrix	B-X
links	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
perlecan-growth	B-X
factor	B-X
interactions	B-X
and	B-X
describe	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
this	B-X
highly	B-X
conserved	B-X
proteoglycan	B-X
during	B-X
development	B-X
,	B-X
cancer	B-X
growth	B-X
,	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
pro-angiogenic	B-X
capacities	B-X
of	B-X
perlecan	B-X
that	B-X
involve	B-X
proliferative	B-X
and	B-X
migratory	B-X
signals	B-X
in	B-X
response	B-X
to	B-X
bound	B-X
growth	B-X
factors	B-X
will	B-X
be	B-X
explored	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
anti-angiogenic	B-X
signals	B-X
resulting	B-X
from	B-X
interactions	B-X
between	B-X
the	B-X
C-terminal	B-X
domain	B-X
known	B-X
as	B-X
endorepellin	B-X
and	B-X
integrins	B-X
that	B-X
control	B-X
adhesion	B-X
of	B-X
cells	B-X
to	B-X
the	B-X
extracellular	B-X
matrix	B-X
.	B-X
These	B-X
two	B-X
somewhat	B-X
diametrically	B-X
opposed	B-X
roles	B-X
will	B-X
be	B-X
discussed	B-X
in	B-X
light	B-X
of	B-X
new	B-X
data	B-X
emerging	B-X
from	B-X
various	B-X
fields	B-X
which	B-X
converge	B-X
on	B-X
perlecan	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X

This	O
review	O
will	O
focus	O
on	O
perlecan	B-Gene_or_gene_product
-	O
growth	O
factor	O
interactions	O
and	O
describe	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
this	O
highly	O
conserved	O
proteoglycan	O
during	O
development	O
,	O
cancer	O
growth	O
,	O
and	O
angiogenesis	O
.	O
<EOS>	B-X
Perlecan	B-X
is	B-X
a	B-X
ubiquitous	B-X
pericellular	B-X
proteoglycan	B-X
ideally	B-X
placed	B-X
to	B-X
mediate	B-X
cell	B-X
signaling	B-X
events	B-X
controlling	B-X
migration	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
differentiation	B-X
.	B-X
Its	B-X
control	B-X
of	B-X
growth	B-X
factor	B-X
signaling	B-X
usually	B-X
involves	B-X
interactions	B-X
with	B-X
the	B-X
heparan	B-X
sulfate	B-X
chains	B-X
covalently	B-X
coupled	B-X
to	B-X
the	B-X
protein	B-X
core	B-X
's	B-X
N-terminus	B-X
.	B-X
However	B-X
,	B-X
this	B-X
modular	B-X
protein	B-X
core	B-X
also	B-X
binds	B-X
with	B-X
relatively	B-X
high	B-X
affinity	B-X
to	B-X
a	B-X
number	B-X
of	B-X
growth	B-X
factors	B-X
and	B-X
surface	B-X
receptors	B-X
,	B-X
thereby	B-X
stabilizing	B-X
cell-matrix	B-X
links	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
perlecan-growth	B-X
factor	B-X
interactions	B-X
and	B-X
describe	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
this	B-X
highly	B-X
conserved	B-X
proteoglycan	B-X
during	B-X
development	B-X
,	B-X
cancer	B-X
growth	B-X
,	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
pro-angiogenic	B-X
capacities	B-X
of	B-X
perlecan	B-X
that	B-X
involve	B-X
proliferative	B-X
and	B-X
migratory	B-X
signals	B-X
in	B-X
response	B-X
to	B-X
bound	B-X
growth	B-X
factors	B-X
will	B-X
be	B-X
explored	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
anti-angiogenic	B-X
signals	B-X
resulting	B-X
from	B-X
interactions	B-X
between	B-X
the	B-X
C-terminal	B-X
domain	B-X
known	B-X
as	B-X
endorepellin	B-X
and	B-X
integrins	B-X
that	B-X
control	B-X
adhesion	B-X
of	B-X
cells	B-X
to	B-X
the	B-X
extracellular	B-X
matrix	B-X
.	B-X
These	B-X
two	B-X
somewhat	B-X
diametrically	B-X
opposed	B-X
roles	B-X
will	B-X
be	B-X
discussed	B-X
in	B-X
light	B-X
of	B-X
new	B-X
data	B-X
emerging	B-X
from	B-X
various	B-X
fields	B-X
which	B-X
converge	B-X
on	B-X
perlecan	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
cell	B-X
growth	B-X
and	B-X
angiogenesis	B-X
.	B-X

The	O
pro	O
-	O
angiogenic	O
capacities	O
of	O
perlecan	B-Gene_or_gene_product
that	O
involve	O
proliferative	O
and	O
migratory	O
signals	O
in	O
response	O
to	O
bound	O
growth	O
factors	O
will	O
be	O
explored	O
,	O
as	O
well	O
as	O
the	O
anti	O
-	O
angiogenic	O
signals	O
resulting	O
from	O
interactions	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
known	O
as	O
endorepellin	B-Gene_or_gene_product
and	O
integrins	B-Gene_or_gene_product
that	O
control	O
adhesion	O
of	O
cells	O
to	O
the	O
extracellular	O
matrix	O
.	O

These	O
two	O
somewhat	O
diametrically	O
opposed	O
roles	O
will	O
be	O
discussed	O
in	O
light	O
of	O
new	O
data	O
emerging	O
from	O
various	O
fields	O
which	O
converge	O
on	O
perlecan	B-Gene_or_gene_product
as	O
a	O
key	O
regulator	O
of	O
cell	O
growth	O
and	O
angiogenesis	O
.	O

Activation	O
of	O
signal	B-Gene_or_gene_product
transducer	I-Gene_or_gene_product
and	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
of	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
3	I-Gene_or_gene_product
through	O
a	O
phosphomimetic	O
serine	O
727	O
promotes	O
prostate	O
tumorigenesis	O
independent	O
of	O
tyrosine	O
705	O
phosphorylation	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

Aberrantly	O
activated	O
signal	B-Gene_or_gene_product
transducer	I-Gene_or_gene_product
and	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
of	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
3	I-Gene_or_gene_product
(	O
Stat3	B-Gene_or_gene_product
)	O
is	O
implicated	O
in	O
the	O
development	O
of	O
various	O
human	O
cancers	O
.	O
<EOS>	B-X
The	B-X
JAK/STAT3	B-X
signaling	B-X
pathway	B-X
may	B-X
be	B-X
aberrantly	B-X
activated	B-X
and	B-X
have	B-X
various	B-X
and	B-X
conflicting	B-X
roles	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
The	B-X
current	B-X
study	B-X
explored	B-X
prognostic	B-X
implications	B-X
of	B-X
activated	B-X
STAT3	B-X
in	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
HER2	B-X
)	B-X
-positive	B-X
primary	B-X
breast	B-X
cancers	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
large	B-X
prospective	B-X
study	B-X
(	B-X
ALTTO	B-X
)	B-X
.	B-X
Activated	B-X
STAT3	B-X
was	B-X
determined	B-X
by	B-X
immunohistochemical	B-X
analysis	B-X
of	B-X
STAT3	B-X
phosphorylation	B-X
(	B-X
Y705	B-X
)	B-X
performed	B-X
on	B-X
the	B-X
primary	B-X
tumors	B-X
.	B-X
This	B-X
analysis	B-X
evaluated	B-X
whether	B-X
patients	B-X
with	B-X
activated	B-X
STAT3	B-X
had	B-X
disease-free	B-X
survival	B-X
(	B-X
DFS	B-X
)	B-X
and	B-X
overall	B-X
survival	B-X
(	B-X
OS	B-X
)	B-X
different	B-X
from	B-X
patients	B-X
without	B-X
activated	B-X
STAT3	B-X
.	B-X
A	B-X
total	B-X
of	B-X
5694	B-X
patients	B-X
out	B-X
of	B-X
the	B-X
8381	B-X
patients	B-X
enrolled	B-X
in	B-X
ALTTO	B-X
were	B-X
included	B-X
in	B-X
this	B-X
analysis	B-X
(	B-X
67.9	B-X
%	B-X
)	B-X
,	B-X
and	B-X
2634	B-X
of	B-X
them	B-X
(	B-X
46	B-X
%	B-X
)	B-X
had	B-X
evidence	B-X
of	B-X
STAT3	B-X
activation	B-X
(	B-X
minimum	B-X
tumor	B-X
Allred	B-X
score	B-X
â¥2	B-X
)	B-X
.	B-X
The	B-X
median	B-X
follow-up	B-X
was	B-X
6.93	B-X
years	B-X
(	B-X
6.85-6.97	B-X
years	B-X
)	B-X
,	B-X
at	B-X
the	B-X
end	B-X
of	B-X
which	B-X
1035	B-X
(	B-X
18.18	B-X
%	B-X
)	B-X
and	B-X
520	B-X
(	B-X
9.13	B-X
%	B-X
)	B-X
patients	B-X
experienced	B-X
DFS	B-X
and	B-X
OS	B-X
events	B-X
,	B-X
respectively	B-X
.	B-X
Patients	B-X
with	B-X
STAT3	B-X
activation	B-X
experienced	B-X
improved	B-X
DFS	B-X
compared	B-X
to	B-X
those	B-X
without	B-X
it	B-X
(	B-X
multivariable	B-X
hazard	B-X
ratio	B-X
[	B-X
HR	B-X
]	B-X
,	B-X
0.84	B-X
;	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
[	B-X
CI	B-X
]	B-X
0.74-0.95	B-X
;	B-X
P	B-X
=	B-X
.006	B-X
)	B-X
.	B-X
There	B-X
were	B-X
no	B-X
group	B-X
differences	B-X
in	B-X
OS	B-X
(	B-X
multivariable	B-X
HR	B-X
,	B-X
0.92	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
0.78-1.10	B-X
;	B-X
P	B-X
=	B-X
.37	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
these	B-X
findings	B-X
support	B-X
the	B-X
role	B-X
of	B-X
STAT3	B-X
activation	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
favorable	B-X
outcome	B-X
in	B-X
ER-positive/HER2-positive	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X

Y705	O
phosphorylation	O
is	O
conventionally	O
thought	O
to	O
be	O
required	O
for	O
Stat3	B-Gene_or_gene_product
signal	O
-	O
dependent	O
activation	O
and	O
seems	O
to	O
play	O
an	O
essential	O
role	O
in	O
some	O
malignancies	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

Recently	O
,	O
it	O
was	O
shown	O
that	O
Stat3	B-Gene_or_gene_product
is	O
activated	O
through	O
novel	O
and	O
noncanonical	O
mechanisms	O
,	O
including	O
phosphorylation	O
at	O
S727	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

Here	O
,	O
we	O
investigate	O
S727	O
phosphorylation	O
of	O
Stat3	B-Gene_or_gene_product
and	O
its	O
subsequent	O
effects	O
in	O
prostate	O
cancer	O
development	O
,	O
independent	O
of	O
Y705	O
phosphorylation	O
,	O
using	O
mutated	O
Stat3	B-Gene_or_gene_product
in	O
the	O
human	O
prostate	O
cancer	O
cell	O
line	O
LNCaP	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

We	O
show	O
mutation	O
of	O
S727	O
to	O
the	O
phosphomimetic	O
residue	O
Glu	O
,	O
and	O
inactivation	O
of	O
Y705	O
(	O
Y705F	O
/	O
S727E	O
)	O
resulted	O
in	O
a	O
remarkable	O
growth	O
advantage	O
in	O
low	O
-	O
serum	O
,	O
enhanced	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
,	O
and	O
increased	O
tumorigenicity	O
in	O
nonobese	O
diabetic	O
/	O
severe	O
combined	O
immunodeficient	O
(	O
NOD	O
/	O
SCID	O
)	O
mice	O
,	O
possibly	O
by	O
direct	O
activation	O
of	O
downstream	O
proto	O
-	O
oncogenes	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
,	O
mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
and	O
survivin	B-Gene_or_gene_product
.	O

Y705F	O
/	O
S727E	O
mutant	O
cells	O
were	O
more	O
invasive	O
than	O
Y705F	O
/	O
S727A	O
(	O
inactivation	O
of	O
Y705	O
and	O
S727	O
)	O
mutant	O
cells	O
,	O
and	O
more	O
Y705F	O
/	O
S727E	O
mutant	O
Stat3	B-Gene_or_gene_product
was	O
localized	O
in	O
the	O
nuclei	O
relative	O
to	O
Y705F	O
/	O
S727A	O
mutant	O
Stat3	B-Gene_or_gene_product
at	O
the	O
steady	O
state	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

Furthermore	O
,	O
the	O
Y705F	O
/	O
S727E	O
but	O
not	O
the	O
Y705F	O
/	O
S727A	O
mutant	O
induced	O
anchorage	O
-	O
independent	O
growth	O
of	O
noncancerous	O
prostate	O
epithelial	O
cells	O
(	O
RWPE	O
-	O
1	O
)	O
.	O

We	O
further	O
show	O
that	O
Stat3	B-Gene_or_gene_product
is	O
phosphorylated	O
at	O
S727	O
in	O
65	O
%	O
of	O
malignant	O
prostate	O
tissues	O
(	O
n	O
=	O
20	O
)	O
relative	O
to	O
25	O
%	O
of	O
normal	O
prostate	O
tissues	O
(	O
n	O
=	O
4	O
)	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

Moreover	O
,	O
there	O
is	O
a	O
positive	O
correlation	O
between	O
phosphoS727	O
-	O
Stat3	B-Gene_or_gene_product
expression	O
and	O
Gleason	O
score	O
in	O
these	O
prostate	O
cancer	O
tissues	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
S727	O
phosphorylation	O
is	O
sufficient	O
to	O
activate	O
Stat3	B-Gene_or_gene_product
,	O
thereby	O
driving	O
prostate	O
tumorigenesis	O
independent	O
of	O
Y705	O
phosphorylation	O
.	O
<EOS>	B-X
Aberrantly	B-X
activated	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
Stat3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
human	B-X
cancers	B-X
.	B-X
Y705	B-X
phosphorylation	B-X
is	B-X
conventionally	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
Stat3	B-X
signal-dependent	B-X
activation	B-X
and	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
some	B-X
malignancies	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
Stat3	B-X
is	B-X
activated	B-X
through	B-X
novel	B-X
and	B-X
noncanonical	B-X
mechanisms	B-X
,	B-X
including	B-X
phosphorylation	B-X
at	B-X
S727	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
S727	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
and	B-X
its	B-X
subsequent	B-X
effects	B-X
in	B-X
prostate	B-X
cancer	B-X
development	B-X
,	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
,	B-X
using	B-X
mutated	B-X
Stat3	B-X
in	B-X
the	B-X
human	B-X
prostate	B-X
cancer	B-X
cell	B-X
line	B-X
LNCaP	B-X
.	B-X
We	B-X
show	B-X
mutation	B-X
of	B-X
S727	B-X
to	B-X
the	B-X
phosphomimetic	B-X
residue	B-X
Glu	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
Y705	B-X
(	B-X
Y705F/S727E	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
remarkable	B-X
growth	B-X
advantage	B-X
in	B-X
low-serum	B-X
,	B-X
enhanced	B-X
anchorage-independent	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
increased	B-X
tumorigenicity	B-X
in	B-X
nonobese	B-X
diabetic/severe	B-X
combined	B-X
immunodeficient	B-X
(	B-X
NOD/SCID	B-X
)	B-X
mice	B-X
,	B-X
possibly	B-X
by	B-X
direct	B-X
activation	B-X
of	B-X
downstream	B-X
proto-oncogenes	B-X
c-myc	B-X
,	B-X
mcl-1	B-X
,	B-X
and	B-X
survivin	B-X
.	B-X
Y705F/S727E	B-X
mutant	B-X
cells	B-X
were	B-X
more	B-X
invasive	B-X
than	B-X
Y705F/S727A	B-X
(	B-X
inactivation	B-X
of	B-X
Y705	B-X
and	B-X
S727	B-X
)	B-X
mutant	B-X
cells	B-X
,	B-X
and	B-X
more	B-X
Y705F/S727E	B-X
mutant	B-X
Stat3	B-X
was	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
relative	B-X
to	B-X
Y705F/S727A	B-X
mutant	B-X
Stat3	B-X
at	B-X
the	B-X
steady	B-X
state	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
Y705F/S727E	B-X
but	B-X
not	B-X
the	B-X
Y705F/S727A	B-X
mutant	B-X
induced	B-X
anchorage-independent	B-X
growth	B-X
of	B-X
noncancerous	B-X
prostate	B-X
epithelial	B-X
cells	B-X
(	B-X
RWPE-1	B-X
)	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Stat3	B-X
is	B-X
phosphorylated	B-X
at	B-X
S727	B-X
in	B-X
65	B-X
%	B-X
of	B-X
malignant	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
relative	B-X
to	B-X
25	B-X
%	B-X
of	B-X
normal	B-X
prostate	B-X
tissues	B-X
(	B-X
n	B-X
=	B-X
4	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
is	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
phosphoS727-Stat3	B-X
expression	B-X
and	B-X
Gleason	B-X
score	B-X
in	B-X
these	B-X
prostate	B-X
cancer	B-X
tissues	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
S727	B-X
phosphorylation	B-X
is	B-X
sufficient	B-X
to	B-X
activate	B-X
Stat3	B-X
,	B-X
thereby	B-X
driving	B-X
prostate	B-X
tumorigenesis	B-X
independent	B-X
of	B-X
Y705	B-X
phosphorylation	B-X
.	B-X

Allergic	O
pulmonary	O
inflammation	O
promotes	O
the	O
recruitment	O
of	O
circulating	O
tumor	O
cells	O
to	O
the	O
lung	O
.	O

Allergen	O
-	O
induced	O
respiratory	O
inflammation	O
facilitates	O
and	O
/	O
or	O
elicits	O
the	O
extravasation	O
of	O
proinflammatory	O
leukocytes	O
by	O
well	O
-	O
understood	O
mechanisms	O
that	O
mediate	O
the	O
movement	O
of	O
multiple	O
cell	O
types	O
.	O
<EOS>	B-X
Environmental	B-X
factors	B-X
which	B-X
cause	B-X
asthma	B-X
are	B-X
those	B-X
that	B-X
induce	B-X
airway	B-X
inflammation	B-X
with	B-X
eosinophils	B-X
(	B-X
more	B-X
common	B-X
)	B-X
or	B-X
neutrophils	B-X
along	B-X
with	B-X
airway	B-X
hyperresponsiveness	B-X
(	B-X
AHR	B-X
)	B-X
.	B-X
The	B-X
most	B-X
common	B-X
of	B-X
these	B-X
(	B-X
indeed	B-X
the	B-X
most	B-X
common	B-X
cause	B-X
of	B-X
asthma	B-X
)	B-X
are	B-X
IgE-mediated	B-X
inhalant	B-X
allergen	B-X
exposures	B-X
.	B-X
Allergen-induced	B-X
AHR	B-X
and	B-X
inflammation	B-X
are	B-X
both	B-X
associated	B-X
with	B-X
the	B-X
allergen-induced	B-X
late	B-X
asthmatic	B-X
response	B-X
(	B-X
LAR	B-X
)	B-X
.	B-X
Acute	B-X
irritant-induced	B-X
asthma	B-X
(	B-X
reactive	B-X
airways	B-X
dysfunction	B-X
syndrome	B-X
)	B-X
following	B-X
a	B-X
very	B-X
heavy	B-X
irritant	B-X
exposure	B-X
and	B-X
chronic	B-X
irritant-induced	B-X
asthma	B-X
following	B-X
repeated	B-X
high	B-X
exposures	B-X
can	B-X
also	B-X
induce	B-X
persistent	B-X
or	B-X
permanent	B-X
changes	B-X
(	B-X
inflammation	B-X
and	B-X
AHR	B-X
)	B-X
consistent	B-X
with	B-X
asthma	B-X
.	B-X
Environmental	B-X
exposure	B-X
to	B-X
tobacco	B-X
smoke	B-X
facilitates	B-X
the	B-X
development	B-X
of	B-X
asthma	B-X
in	B-X
children	B-X
.	B-X

The	O
nonspecific	O
character	O
of	O
these	O
pathways	O
led	O
us	O
to	O
hypothesize	O
that	O
circulating	O
cancer	O
cells	O
use	O
similar	O
mechanisms	O
,	O
promoting	O
secondary	O
tumor	O
formation	O
at	O
distal	O
sites	O
.	O
<EOS>	B-X
Allergen-induced	B-X
respiratory	B-X
inflammation	B-X
facilitates	B-X
and/or	B-X
elicits	B-X
the	B-X
extravasation	B-X
of	B-X
proinflammatory	B-X
leukocytes	B-X
by	B-X
well-understood	B-X
mechanisms	B-X
that	B-X
mediate	B-X
the	B-X
movement	B-X
of	B-X
multiple	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
nonspecific	B-X
character	B-X
of	B-X
these	B-X
pathways	B-X
led	B-X
us	B-X
to	B-X
hypothesize	B-X
that	B-X
circulating	B-X
cancer	B-X
cells	B-X
use	B-X
similar	B-X
mechanisms	B-X
,	B-X
promoting	B-X
secondary	B-X
tumor	B-X
formation	B-X
at	B-X
distal	B-X
sites	B-X
.	B-X
injection	B-X
of	B-X
B16-F10	B-X
melanoma	B-X
cells	B-X
in	B-X
mice	B-X
.	B-X
Interventional	B-X
strategies	B-X
showed	B-X
that	B-X
existing	B-X
therapeutic	B-X
modalities	B-X
for	B-X
asthma	B-X
,	B-X
such	B-X
as	B-X
inhaled	B-X
corticosteroids	B-X
,	B-X
were	B-X
sufficient	B-X
to	B-X
block	B-X
the	B-X
enhanced	B-X
pulmonary	B-X
recruitment	B-X
of	B-X
cancer	B-X
cells	B-X
from	B-X
circulation	B-X
.	B-X
Additional	B-X
mechanistic	B-X
studies	B-X
further	B-X
suggested	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
circulating	B-X
cancer	B-X
cells	B-X
to	B-X
extravasate	B-X
to	B-X
surrounding	B-X
lung	B-X
tissues	B-X
was	B-X
linked	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
vascular	B-X
endothelium	B-X
via	B-X
one	B-X
or	B-X
more	B-X
Galpha	B-X
(	B-X
i	B-X
)	B-X
-coupled	B-X
receptors	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
survey	B-X
of	B-X
a	B-X
clinical	B-X
breast	B-X
cancer	B-X
surgical	B-X
database	B-X
showed	B-X
that	B-X
the	B-X
incidence	B-X
of	B-X
asthma	B-X
was	B-X
higher	B-X
among	B-X
patients	B-X
with	B-X
lung	B-X
metastases	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
allergic	B-X
respiratory	B-X
inflammation	B-X
may	B-X
represent	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
the	B-X
development	B-X
of	B-X
lung	B-X
metastases	B-X
and	B-X
suggest	B-X
that	B-X
amelioration	B-X
of	B-X
the	B-X
pulmonary	B-X
inflammation	B-X
associated	B-X
with	B-X
asthma	B-X
will	B-X
have	B-X
a	B-X
direct	B-X
and	B-X
immediate	B-X
benefit	B-X
to	B-X
the	B-X
7	B-X
%	B-X
to	B-X
8	B-X
%	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
with	B-X
this	B-X
lung	B-X
disease	B-X
.	B-X

To	O
test	O
this	O
hypothesis	O
,	O
the	O
frequency	O
of	O
metastasis	O
to	O
the	O
lung	O
as	O
a	O
function	O
of	O
allergic	O
pulmonary	O
inflammation	O
was	O
assessed	O
following	O
the	O
i	O
.	O
v	O
.	O
injection	O
of	O
B16	O
-	O
F10	O
melanoma	O
cells	O
in	O
mice	O
.	O

These	O
studies	O
showed	O
that	O
allergen	O
-	O
induced	O
pulmonary	O
inflammation	O
resulted	O
in	O
a	O
>	O
3	O
-	O
fold	O
increase	O
in	O
lung	O
metastases	O
.	O

This	O
increase	O
was	O
dependent	O
on	O
CD4	B-Gene_or_gene_product
(	O
+	O
)	O
T	O
-	O
cell	O
activities	O
;	O
however	O
,	O
it	O
occurred	O
independent	O
of	O
the	O
induced	O
eosinophilia	O
associated	O
with	O
allergen	O
provocation	O
.	O
<EOS>	B-X
While	B-X
stimulator	B-X
of	B-X
interferon	B-X
genes	B-X
(	B-X
STING	B-X
)	B-X
activation	B-X
in	B-X
innate	B-X
immune	B-X
cells	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
can	B-X
result	B-X
in	B-X
CD8	B-X
T	B-X
cell-dependent	B-X
antitumor	B-X
immunity	B-X
,	B-X
whether	B-X
STING	B-X
signaling	B-X
affects	B-X
CD4	B-X
T-cell	B-X
responses	B-X
remains	B-X
elusive	B-X
.	B-X
CD4	B-X
The	B-X
gateway	B-X
reflex	B-X
explains	B-X
how	B-X
autoreactive	B-X
CD4+	B-X
T	B-X
cells	B-X
cause	B-X
inflammation	B-X
in	B-X
tissues	B-X
that	B-X
have	B-X
blood-barriers	B-X
,	B-X
such	B-X
as	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
retina	B-X
.	B-X
Noradrenaline	B-X
activates	B-X
NFkB	B-X
at	B-X
these	B-X
vessels	B-X
,	B-X
followed	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
chemokine	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
a	B-X
reduction	B-X
of	B-X
tight	B-X
junction	B-X
molecules	B-X
to	B-X
accumulate	B-X
autoreactive	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
breach	B-X
blood-barriers	B-X
.	B-X

Interventional	O
strategies	O
showed	O
that	O
existing	O
therapeutic	O
modalities	O
for	O
asthma	O
,	O
such	O
as	O
inhaled	O
corticosteroids	O
,	O
were	O
sufficient	O
to	O
block	O
the	O
enhanced	O
pulmonary	O
recruitment	O
of	O
cancer	O
cells	O
from	O
circulation	O
.	O
<EOS>	B-X
The	B-X
nonspecific	B-X
character	B-X
of	B-X
these	B-X
pathways	B-X
led	B-X
us	B-X
to	B-X
hypothesize	B-X
that	B-X
circulating	B-X
cancer	B-X
cells	B-X
use	B-X
similar	B-X
mechanisms	B-X
,	B-X
promoting	B-X
secondary	B-X
tumor	B-X
formation	B-X
at	B-X
distal	B-X
sites	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
metastasis	B-X
to	B-X
the	B-X
lung	B-X
as	B-X
a	B-X
function	B-X
of	B-X
allergic	B-X
pulmonary	B-X
inflammation	B-X
was	B-X
assessed	B-X
following	B-X
the	B-X
i.v	B-X
.	B-X
injection	B-X
of	B-X
B16-F10	B-X
melanoma	B-X
cells	B-X
in	B-X
mice	B-X
.	B-X
These	B-X
studies	B-X
showed	B-X
that	B-X
allergen-induced	B-X
pulmonary	B-X
inflammation	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
3-fold	B-X
increase	B-X
in	B-X
lung	B-X
metastases	B-X
.	B-X
Interventional	B-X
strategies	B-X
showed	B-X
that	B-X
existing	B-X
therapeutic	B-X
modalities	B-X
for	B-X
asthma	B-X
,	B-X
such	B-X
as	B-X
inhaled	B-X
corticosteroids	B-X
,	B-X
were	B-X
sufficient	B-X
to	B-X
block	B-X
the	B-X
enhanced	B-X
pulmonary	B-X
recruitment	B-X
of	B-X
cancer	B-X
cells	B-X
from	B-X
circulation	B-X
.	B-X
Additional	B-X
mechanistic	B-X
studies	B-X
further	B-X
suggested	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
circulating	B-X
cancer	B-X
cells	B-X
to	B-X
extravasate	B-X
to	B-X
surrounding	B-X
lung	B-X
tissues	B-X
was	B-X
linked	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
vascular	B-X
endothelium	B-X
via	B-X
one	B-X
or	B-X
more	B-X
Galpha	B-X
(	B-X
i	B-X
)	B-X
-coupled	B-X
receptors	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
survey	B-X
of	B-X
a	B-X
clinical	B-X
breast	B-X
cancer	B-X
surgical	B-X
database	B-X
showed	B-X
that	B-X
the	B-X
incidence	B-X
of	B-X
asthma	B-X
was	B-X
higher	B-X
among	B-X
patients	B-X
with	B-X
lung	B-X
metastases	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
allergic	B-X
respiratory	B-X
inflammation	B-X
may	B-X
represent	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
the	B-X
development	B-X
of	B-X
lung	B-X
metastases	B-X
and	B-X
suggest	B-X
that	B-X
amelioration	B-X
of	B-X
the	B-X
pulmonary	B-X
inflammation	B-X
associated	B-X
with	B-X
asthma	B-X
will	B-X
have	B-X
a	B-X
direct	B-X
and	B-X
immediate	B-X
benefit	B-X
to	B-X
the	B-X
7	B-X
%	B-X
to	B-X
8	B-X
%	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
with	B-X
this	B-X
lung	B-X
disease	B-X
.	B-X

Additional	O
mechanistic	O
studies	O
further	O
suggested	O
that	O
the	O
ability	O
of	O
circulating	O
cancer	O
cells	O
to	O
extravasate	O
to	O
surrounding	O
lung	O
tissues	O
was	O
linked	O
to	O
the	O
activation	O
of	O
the	O
vascular	O
endothelium	O
via	O
one	O
or	O
more	O
Galpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
i	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	O
coupled	O
receptors	O
.	O
<EOS>	B-X
Obesity-Associated	B-X
In	B-X
light	B-X
of	B-X
the	B-X
current	B-X
COVID-19	B-X
pandemic	B-X
,	B-X
during	B-X
which	B-X
the	B-X
world	B-X
is	B-X
confronted	B-X
with	B-X
a	B-X
new	B-X
,	B-X
highly	B-X
contagious	B-X
virus	B-X
that	B-X
suppresses	B-X
innate	B-X
immunity	B-X
as	B-X
one	B-X
of	B-X
its	B-X
initial	B-X
virulence	B-X
mechanisms	B-X
,	B-X
thus	B-X
escaping	B-X
from	B-X
first-line	B-X
human	B-X
defense	B-X
mechanisms	B-X
,	B-X
enhancing	B-X
innate	B-X
immunity	B-X
seems	B-X
a	B-X
good	B-X
preventive	B-X
strategy	B-X
.	B-X
Upon	B-X
acute	B-X
inflammation	B-X
,	B-X
gingival	B-X
fibroblasts	B-X
release	B-X
cytokines	B-X
to	B-X
recruit	B-X
immune	B-X
cells	B-X
to	B-X
counter	B-X
environmental	B-X
stimuli	B-X
.	B-X
Nonetheless	B-X
,	B-X
how	B-X
inflammation	B-X
is	B-X
resolved	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
elucidated	B-X
.	B-X

Interestingly	O
,	O
a	O
survey	O
of	O
a	O
clinical	O
breast	O
cancer	O
surgical	O
database	O
showed	O
that	O
the	O
incidence	O
of	O
asthma	O
was	O
higher	O
among	O
patients	O
with	O
lung	O
metastases	O
.	O
<EOS>	B-X
The	B-X
nonspecific	B-X
character	B-X
of	B-X
these	B-X
pathways	B-X
led	B-X
us	B-X
to	B-X
hypothesize	B-X
that	B-X
circulating	B-X
cancer	B-X
cells	B-X
use	B-X
similar	B-X
mechanisms	B-X
,	B-X
promoting	B-X
secondary	B-X
tumor	B-X
formation	B-X
at	B-X
distal	B-X
sites	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
metastasis	B-X
to	B-X
the	B-X
lung	B-X
as	B-X
a	B-X
function	B-X
of	B-X
allergic	B-X
pulmonary	B-X
inflammation	B-X
was	B-X
assessed	B-X
following	B-X
the	B-X
i.v	B-X
.	B-X
These	B-X
studies	B-X
showed	B-X
that	B-X
allergen-induced	B-X
pulmonary	B-X
inflammation	B-X
resulted	B-X
in	B-X
a	B-X
>	B-X
3-fold	B-X
increase	B-X
in	B-X
lung	B-X
metastases	B-X
.	B-X
Interventional	B-X
strategies	B-X
showed	B-X
that	B-X
existing	B-X
therapeutic	B-X
modalities	B-X
for	B-X
asthma	B-X
,	B-X
such	B-X
as	B-X
inhaled	B-X
corticosteroids	B-X
,	B-X
were	B-X
sufficient	B-X
to	B-X
block	B-X
the	B-X
enhanced	B-X
pulmonary	B-X
recruitment	B-X
of	B-X
cancer	B-X
cells	B-X
from	B-X
circulation	B-X
.	B-X
Additional	B-X
mechanistic	B-X
studies	B-X
further	B-X
suggested	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
circulating	B-X
cancer	B-X
cells	B-X
to	B-X
extravasate	B-X
to	B-X
surrounding	B-X
lung	B-X
tissues	B-X
was	B-X
linked	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
vascular	B-X
endothelium	B-X
via	B-X
one	B-X
or	B-X
more	B-X
Galpha	B-X
(	B-X
i	B-X
)	B-X
-coupled	B-X
receptors	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
survey	B-X
of	B-X
a	B-X
clinical	B-X
breast	B-X
cancer	B-X
surgical	B-X
database	B-X
showed	B-X
that	B-X
the	B-X
incidence	B-X
of	B-X
asthma	B-X
was	B-X
higher	B-X
among	B-X
patients	B-X
with	B-X
lung	B-X
metastases	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
allergic	B-X
respiratory	B-X
inflammation	B-X
may	B-X
represent	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
the	B-X
development	B-X
of	B-X
lung	B-X
metastases	B-X
and	B-X
suggest	B-X
that	B-X
amelioration	B-X
of	B-X
the	B-X
pulmonary	B-X
inflammation	B-X
associated	B-X
with	B-X
asthma	B-X
will	B-X
have	B-X
a	B-X
direct	B-X
and	B-X
immediate	B-X
benefit	B-X
to	B-X
the	B-X
7	B-X
%	B-X
to	B-X
8	B-X
%	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
with	B-X
this	B-X
lung	B-X
disease	B-X
.	B-X

Thus	O
,	O
our	O
data	O
show	O
that	O
allergic	O
respiratory	O
inflammation	O
may	O
represent	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
lung	O
metastases	O
and	O
suggest	O
that	O
amelioration	O
of	O
the	O
pulmonary	O
inflammation	O
associated	O
with	O
asthma	O
will	O
have	O
a	O
direct	O
and	O
immediate	O
benefit	O
to	O
the	O
7	O
%	O
to	O
8	O
%	O
of	O
breast	O
cancer	O
patients	O
with	O
this	O
lung	O
disease	O
.	O

Inhibition	O
of	O
energy	O
-	O
producing	O
pathways	O
of	O
HepG2	O
cells	O
by	O
3	O
-	O
bromopyruvate	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

3	O
-	O
BrPA	O
(	O
3	O
-	O
bromopyruvate	O
)	O
is	O
an	O
alkylating	O
agent	O
with	O
anti	O
-	O
tumoral	O
activity	O
on	O
hepatocellular	O
carcinoma	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

This	O
compound	O
inhibits	O
cellular	O
ATP	O
production	O
owing	O
to	O
its	O
action	O
on	O
glycolysis	O
and	O
oxidative	O
phosphorylation	O
;	O
however	O
,	O
the	O
specific	O
metabolic	O
steps	O
and	O
mechanisms	O
of	O
3	O
-	O
BrPA	O
action	O
in	O
human	O
hepatocellular	O
carcinomas	O
,	O
particularly	O
its	O
effects	O
on	O
mitochondrial	O
energetics	O
,	O
are	O
poorly	O
understood	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

In	O
the	O
present	O
study	O
it	O
was	O
found	O
that	O
incubation	O
of	O
HepG2	O
cells	O
with	O
a	O
low	O
concentration	O
of	O
3	O
-	O
BrPA	O
for	O
a	O
short	O
period	O
(	O
150	O
microM	O
for	O
30	O
min	O
)	O
significantly	O
affected	O
both	O
glycolysis	O
and	O
mitochondrial	O
respiratory	O
functions	O
.	O

The	O
activity	O
of	O
mitochondrial	O
hexokinase	B-Gene_or_gene_product
was	O
not	O
inhibited	O
by	O
150	O
microM	O
3	O
-	O
BrPA	O
,	O
but	O
this	O
concentration	O
caused	O
more	O
than	O
70	O
%	O
inhibition	O
of	O
GAPDH	B-Gene_or_gene_product
(	O
glyceraldehyde	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
phosphate	I-Gene_or_gene_product
dehydrogenase	I-Gene_or_gene_product
)	O
and	O
3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
phosphoglycerate	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
activities	O
.	O
<EOS>	B-X
Triptolide	B-X
(	B-X
TPL	B-X
)	B-X
is	B-X
a	B-X
natural	B-X
product	B-X
isolated	B-X
from	B-X
the	B-X
traditional	B-X
Chinese	B-X
herb	B-X
which	B-X
possesses	B-X
potent	B-X
anti-tumor	B-X
activity	B-X
in	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
product	B-X
of	B-X
hexokinase	B-X
(	B-X
HK	B-X
)	B-X
enzymes	B-X
,	B-X
glucose-6-phosphate	B-X
,	B-X
can	B-X
be	B-X
metabolized	B-X
through	B-X
glycolysis	B-X
or	B-X
directed	B-X
to	B-X
alternative	B-X
metabolic	B-X
routes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
pentose	B-X
phosphate	B-X
pathway	B-X
(	B-X
PPP	B-X
)	B-X
to	B-X
generate	B-X
anabolic	B-X
intermediates	B-X
.	B-X
HK1	B-X
contains	B-X
an	B-X
N-terminal	B-X
mitochondrial	B-X
binding	B-X
domain	B-X
(	B-X
MBD	B-X
)	B-X
,	B-X
but	B-X
its	B-X
physiologic	B-X
significance	B-X
remains	B-X
unclear	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
effect	B-X
of	B-X
HK1	B-X
mitochondrial	B-X
dissociation	B-X
on	B-X
cellular	B-X
metabolism	B-X
,	B-X
we	B-X
generated	B-X
mice	B-X
lacking	B-X
the	B-X
HK1	B-X
MBD	B-X
(	B-X
ÎE1HK1	B-X
)	B-X
.	B-X
Additionally	B-X
,	B-X
there	B-X
was	B-X
decreased	B-X
glucose	B-X
flux	B-X
below	B-X
the	B-X
level	B-X
of	B-X
GAPDH	B-X
and	B-X
increased	B-X
upstream	B-X
flux	B-X
through	B-X
the	B-X
PPP	B-X
.	B-X
The	B-X
glycolytic	B-X
block	B-X
below	B-X
GAPDH	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
binding	B-X
of	B-X
cytosolic	B-X
HK1	B-X
with	B-X
S100A8/A9	B-X
,	B-X
resulting	B-X
in	B-X
GAPDH	B-X
nitrosylation	B-X
through	B-X
iNOS	B-X
.	B-X
Additionally	B-X
,	B-X
human	B-X
and	B-X
mouse	B-X
macrophages	B-X
from	B-X
conditions	B-X
of	B-X
low-grade	B-X
inflammation	B-X
,	B-X
such	B-X
as	B-X
aging	B-X
and	B-X
diabetes	B-X
,	B-X
displayed	B-X
increased	B-X
cytosolic	B-X
HK1	B-X
and	B-X
reduced	B-X
GAPDH	B-X
activity	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
HK1	B-X
mitochondrial	B-X
binding	B-X
alters	B-X
glucose	B-X
metabolism	B-X
through	B-X
regulation	B-X
of	B-X
GAPDH	B-X
.	B-X

Additionally	O
,	O
3	O
-	O
BrPA	O
treatment	O
significantly	O
impaired	O
lactate	O
production	O
by	O
HepG2	O
cells	O
,	O
even	O
when	O
glucose	O
was	O
withdrawn	O
from	O
the	O
incubation	O
medium	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

Oxygen	O
consumption	O
of	O
HepG2	O
cells	O
supported	O
by	O
either	O
pyruvate	O
/	O
malate	O
or	O
succinate	O
was	O
inhibited	O
when	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
3	O
-	O
BrPA	O
in	O
glucose	O
-	O
free	O
medium	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
when	O
cells	O
were	O
pre	O
-	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
oxygen	O
consumption	O
was	O
affected	O
only	O
when	O
succinate	O
was	O
used	O
as	O
the	O
oxidizable	O
substrate	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

An	O
increase	O
in	O
oligomycin	O
-	O
independent	O
respiration	O
was	O
observed	O
in	O
HepG2	O
cells	O
treated	O
with	O
3	O
-	O
BrPA	O
only	O
when	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
indicating	O
that	O
3	O
-	O
BrPA	O
induces	O
mitochondrial	O
proton	O
leakage	O
as	O
well	O
as	O
blocking	O
the	O
electron	O
transport	O
system	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

The	O
activity	O
of	O
succinate	B-Gene_or_gene_product
dehydrogenase	I-Gene_or_gene_product
was	O
inhibited	O
by	O
70	O
%	O
by	O
3	O
-	O
BrPA	O
treatment	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

These	O
results	O
suggest	O
that	O
the	O
combined	O
action	O
of	O
3	O
-	O
BrPA	O
on	O
succinate	B-Gene_or_gene_product
dehydrogenase	I-Gene_or_gene_product
and	O
on	O
glycolysis	O
,	O
inhibiting	O
steps	O
downstream	O
of	O
the	O
phosphorylation	O
of	O
glucose	O
,	O
play	O
an	O
important	O
role	O
in	O
HepG2	O
cell	O
death	O
.	O
<EOS>	B-X
3-BrPA	B-X
(	B-X
3-bromopyruvate	B-X
)	B-X
is	B-X
an	B-X
alkylating	B-X
agent	B-X
with	B-X
anti-tumoral	B-X
activity	B-X
on	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
This	B-X
compound	B-X
inhibits	B-X
cellular	B-X
ATP	B-X
production	B-X
owing	B-X
to	B-X
its	B-X
action	B-X
on	B-X
glycolysis	B-X
and	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
specific	B-X
metabolic	B-X
steps	B-X
and	B-X
mechanisms	B-X
of	B-X
3-BrPA	B-X
action	B-X
in	B-X
human	B-X
hepatocellular	B-X
carcinomas	B-X
,	B-X
particularly	B-X
its	B-X
effects	B-X
on	B-X
mitochondrial	B-X
energetics	B-X
,	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
incubation	B-X
of	B-X
HepG2	B-X
cells	B-X
with	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
3-BrPA	B-X
for	B-X
a	B-X
short	B-X
period	B-X
(	B-X
150	B-X
microM	B-X
for	B-X
30	B-X
min	B-X
)	B-X
significantly	B-X
affected	B-X
both	B-X
glycolysis	B-X
and	B-X
mitochondrial	B-X
respiratory	B-X
functions	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
mitochondrial	B-X
hexokinase	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
150	B-X
microM	B-X
3-BrPA	B-X
,	B-X
but	B-X
this	B-X
concentration	B-X
caused	B-X
more	B-X
than	B-X
70	B-X
%	B-X
inhibition	B-X
of	B-X
GAPDH	B-X
(	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
)	B-X
and	B-X
3-phosphoglycerate	B-X
kinase	B-X
activities	B-X
.	B-X
Additionally	B-X
,	B-X
3-BrPA	B-X
treatment	B-X
significantly	B-X
impaired	B-X
lactate	B-X
production	B-X
by	B-X
HepG2	B-X
cells	B-X
,	B-X
even	B-X
when	B-X
glucose	B-X
was	B-X
withdrawn	B-X
from	B-X
the	B-X
incubation	B-X
medium	B-X
.	B-X
Oxygen	B-X
consumption	B-X
of	B-X
HepG2	B-X
cells	B-X
supported	B-X
by	B-X
either	B-X
pyruvate/malate	B-X
or	B-X
succinate	B-X
was	B-X
inhibited	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
with	B-X
3-BrPA	B-X
in	B-X
glucose-free	B-X
medium	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
when	B-X
cells	B-X
were	B-X
pre-incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
oxygen	B-X
consumption	B-X
was	B-X
affected	B-X
only	B-X
when	B-X
succinate	B-X
was	B-X
used	B-X
as	B-X
the	B-X
oxidizable	B-X
substrate	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
oligomycin-independent	B-X
respiration	B-X
was	B-X
observed	B-X
in	B-X
HepG2	B-X
cells	B-X
treated	B-X
with	B-X
3-BrPA	B-X
only	B-X
when	B-X
incubated	B-X
in	B-X
glucose-supplemented	B-X
medium	B-X
,	B-X
indicating	B-X
that	B-X
3-BrPA	B-X
induces	B-X
mitochondrial	B-X
proton	B-X
leakage	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
the	B-X
electron	B-X
transport	B-X
system	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
succinate	B-X
dehydrogenase	B-X
was	B-X
inhibited	B-X
by	B-X
70	B-X
%	B-X
by	B-X
3-BrPA	B-X
treatment	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
3-BrPA	B-X
on	B-X
succinate	B-X
dehydrogenase	B-X
and	B-X
on	B-X
glycolysis	B-X
,	B-X
inhibiting	B-X
steps	B-X
downstream	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
glucose	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
HepG2	B-X
cell	B-X
death	B-X
.	B-X

[	O
Retinochoroidopathy	O
after	O
intravitreal	O
anti	O
-	O
VEGF	B-Gene_or_gene_product
treatment	O
]	O
<EOS>	B-X
A	B-X
74-year-old	B-X
man	B-X
presented	B-X
with	B-X
persistent	B-X
metamorphopsias	B-X
of	B-X
the	B-X
right	B-X
eye	B-X
2	B-X
weeks	B-X
after	B-X
intravitreal	B-X
injection	B-X
of	B-X
bevacizumab	B-X
to	B-X
treat	B-X
choroidal	B-X
neovascularization	B-X
due	B-X
to	B-X
exudative	B-X
age-related	B-X
macular	B-X
degeneration	B-X
.	B-X
The	B-X
diagnosis	B-X
reached	B-X
was	B-X
retinochoroiditis	B-X
as	B-X
an	B-X
occult	B-X
manifestation	B-X
of	B-X
sarcoidosis	B-X
,	B-X
possibly	B-X
resulting	B-X
from	B-X
an	B-X
intravitreal	B-X
injection	B-X
of	B-X
bevacizumab	B-X
.	B-X

A	O
74	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
metamorphopsias	O
of	O
the	O
right	O
eye	O
2	O
weeks	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	O
to	O
treat	O
choroidal	O
neovascularization	O
due	O
to	O
exudative	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O
<EOS>	B-X
A	B-X
74-year-old	B-X
man	B-X
presented	B-X
with	B-X
persistent	B-X
metamorphopsias	B-X
of	B-X
the	B-X
right	B-X
eye	B-X
2	B-X
weeks	B-X
after	B-X
intravitreal	B-X
injection	B-X
of	B-X
bevacizumab	B-X
to	B-X
treat	B-X
choroidal	B-X
neovascularization	B-X
due	B-X
to	B-X
exudative	B-X
age-related	B-X
macular	B-X
degeneration	B-X
.	B-X
The	B-X
diagnosis	B-X
reached	B-X
was	B-X
retinochoroiditis	B-X
as	B-X
an	B-X
occult	B-X
manifestation	B-X
of	B-X
sarcoidosis	B-X
,	B-X
possibly	B-X
resulting	B-X
from	B-X
an	B-X
intravitreal	B-X
injection	B-X
of	B-X
bevacizumab	B-X
.	B-X

The	O
diagnosis	O
reached	O
was	O
retinochoroiditis	O
as	O
an	O
occult	O
manifestation	O
of	O
sarcoidosis	O
,	O
possibly	O
resulting	O
from	O
an	O
intravitreal	O
injection	O
of	O
bevacizumab	O
.	O
<EOS>	B-X
A	B-X
74-year-old	B-X
man	B-X
presented	B-X
with	B-X
persistent	B-X
metamorphopsias	B-X
of	B-X
the	B-X
right	B-X
eye	B-X
2	B-X
weeks	B-X
after	B-X
intravitreal	B-X
injection	B-X
of	B-X
bevacizumab	B-X
to	B-X
treat	B-X
choroidal	B-X
neovascularization	B-X
due	B-X
to	B-X
exudative	B-X
age-related	B-X
macular	B-X
degeneration	B-X
.	B-X
The	B-X
diagnosis	B-X
reached	B-X
was	B-X
retinochoroiditis	B-X
as	B-X
an	B-X
occult	B-X
manifestation	B-X
of	B-X
sarcoidosis	B-X
,	B-X
possibly	B-X
resulting	B-X
from	B-X
an	B-X
intravitreal	B-X
injection	B-X
of	B-X
bevacizumab	B-X
.	B-X

The	O
patient	O
received	O
a	O
prescription	O
for	O
100	O
mg	O
Ultralan	O
to	O
be	O
taken	O
daily	O
for	O
3	O
days	O
and	O
then	O
tapered	O
in	O
3	O
day	O
steps	O
.	O
<EOS>	B-X
The	B-X
patient	B-X
received	B-X
a	B-X
prescription	B-X
for	B-X
100	B-X
mg	B-X
Ultralan	B-X
to	B-X
be	B-X
taken	B-X
daily	B-X
for	B-X
3	B-X
days	B-X
and	B-X
then	B-X
tapered	B-X
in	B-X
3	B-X
day	B-X
steps	B-X
.	B-X

During	O
the	O
further	O
course	O
no	O
deterioration	O
of	O
the	O
condition	O
was	O
observed	O
.	O
<EOS>	B-X
As	B-X
pregnancy	B-X
is	B-X
characterized	B-X
by	B-X
significant	B-X
changes	B-X
in	B-X
cardiovascular	B-X
,	B-X
respiratory	B-X
,	B-X
endocrine	B-X
,	B-X
and	B-X
immunological	B-X
systems	B-X
,	B-X
there	B-X
are	B-X
concerns	B-X
on	B-X
issues	B-X
like	B-X
the	B-X
course	B-X
of	B-X
disease	B-X
in	B-X
pregnant	B-X
women	B-X
,	B-X
safety	B-X
of	B-X
medications	B-X
,	B-X
route	B-X
of	B-X
delivery	B-X
and	B-X
risk	B-X
of	B-X
obstetric	B-X
complications	B-X
.	B-X
Although	B-X
more	B-X
than	B-X
90	B-X
%	B-X
of	B-X
pregnant	B-X
women	B-X
with	B-X
COVID-19	B-X
recover	B-X
without	B-X
serious	B-X
morbidity	B-X
,	B-X
rapid	B-X
deterioration	B-X
of	B-X
disease	B-X
and	B-X
higher	B-X
rates	B-X
of	B-X
obstetric	B-X
complications	B-X
may	B-X
be	B-X
observed	B-X
.	B-X
Timing	B-X
of	B-X
delivery	B-X
should	B-X
be	B-X
decided	B-X
based	B-X
on	B-X
maternal	B-X
health	B-X
condition	B-X
,	B-X
accompanying	B-X
obstetric	B-X
complications	B-X
and	B-X
gestational	B-X
age	B-X
.	B-X
During	B-X
the	B-X
course	B-X
of	B-X
surgical	B-X
interventions	B-X
,	B-X
complications	B-X
mostly	B-X
occur	B-X
in	B-X
the	B-X
postoperative	B-X
period	B-X
.	B-X
Slight	B-X
clinical	B-X
indications	B-X
can	B-X
be	B-X
observed	B-X
,	B-X
which	B-X
precede	B-X
a	B-X
significant	B-X
deterioration	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
condition	B-X
.	B-X
These	B-X
systems	B-X
can	B-X
alert	B-X
and	B-X
alarm	B-X
ward	B-X
personnel	B-X
if	B-X
the	B-X
patient	B-X
's	B-X
condition	B-X
deteriorates	B-X
.	B-X

Silencing	O
of	O
directional	O
migration	O
in	O
roundabout4	B-Gene_or_gene_product
knockdown	O
endothelial	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

BACKGROUND	O
:	O
Roundabouts	B-Gene_or_gene_product
are	O
axon	O
guidance	O
molecules	O
that	O
have	O
recently	O
been	O
identified	O
to	O
play	O
a	O
role	O
in	O
vascular	O
guidance	O
as	O
well	O
.	O
<EOS>	B-X
Roundabouts	B-X
are	B-X
axon	B-X
guidance	B-X
molecules	B-X
that	B-X
have	B-X
recently	B-X
been	B-X
identified	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
vascular	B-X
guidance	B-X
as	B-X
well	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
gene	O
knockdown	O
analysis	O
of	O
endothelial	O
Robos	B-Gene_or_gene_product
,	O
in	O
particular	O
roundabout	B-Gene_or_gene_product
4	I-Gene_or_gene_product
(	O
robo4	B-Gene_or_gene_product
)	O
,	O
the	O
predominant	O
Robo	B-Gene_or_gene_product
in	O
endothelial	O
cells	O
using	O
small	O
interfering	O
RNA	O
technology	O
in	O
vitro	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

RESULTS	O
:	O
Robo1	B-Gene_or_gene_product
and	O
Robo4	B-Gene_or_gene_product
knockdown	O
cells	O
display	O
distinct	O
activity	O
in	O
endothelial	O
cell	O
migration	O
assay	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

The	O
knockdown	O
of	O
robo4	B-Gene_or_gene_product
abrogated	O
the	O
chemotactic	O
response	O
of	O
endothelial	O
cells	O
to	O
serum	O
but	O
enhanced	O
a	O
chemokinetic	O
response	O
to	O
Slit2	B-Gene_or_gene_product
,	O
while	O
robo1	B-Gene_or_gene_product
knockdown	O
cells	O
do	O
not	O
display	O
chemotactic	O
response	O
to	O
serum	O
or	O
VEGF	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
discovery	B-X
of	B-X
vascular	B-X
endothelial-derived	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
has	B-X
revolutionized	B-X
our	B-X
understanding	B-X
of	B-X
vasculogenesis	B-X
and	B-X
angiogenesis	B-X
during	B-X
development	B-X
and	B-X
physiological	B-X
homeostasis	B-X
.	B-X
Over	B-X
a	B-X
short	B-X
span	B-X
of	B-X
two	B-X
decades	B-X
,	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
VEGF	B-X
coordinates	B-X
neurovascular	B-X
homeostasis	B-X
has	B-X
become	B-X
more	B-X
sophisticated	B-X
.	B-X
The	B-X
central	B-X
role	B-X
of	B-X
VEGF	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
diverse	B-X
cancers	B-X
and	B-X
blinding	B-X
eye	B-X
diseases	B-X
has	B-X
also	B-X
become	B-X
evident	B-X
.	B-X
Elucidation	B-X
of	B-X
the	B-X
molecular	B-X
regulation	B-X
of	B-X
VEGF	B-X
and	B-X
the	B-X
transformative	B-X
development	B-X
of	B-X
multiple	B-X
therapeutic	B-X
pathways	B-X
targeting	B-X
VEGF	B-X
directly	B-X
or	B-X
indirectly	B-X
is	B-X
a	B-X
powerful	B-X
case	B-X
study	B-X
of	B-X
how	B-X
fundamental	B-X
research	B-X
can	B-X
guide	B-X
innovation	B-X
and	B-X
translation	B-X
.	B-X
This	B-X
review	B-X
will	B-X
highlight	B-X
critical	B-X
nodal	B-X
points	B-X
in	B-X
VEGF	B-X
biology	B-X
,	B-X
including	B-X
recent	B-X
developments	B-X
in	B-X
immunotherapy	B-X
for	B-X
cancer	B-X
and	B-X
multitarget	B-X
approaches	B-X
in	B-X
neovascular	B-X
eye	B-X
disease	B-X
.	B-X

Robo4	B-Gene_or_gene_product
knockdown	O
endothelial	O
cells	O
unexpectedly	O
show	O
up	O
regulation	O
of	O
Rho	B-Gene_or_gene_product
GTPases	I-Gene_or_gene_product
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

Zebrafish	O
Robo4	B-Gene_or_gene_product
rescues	O
both	O
Rho	B-Gene_or_gene_product
GTPase	I-Gene_or_gene_product
homeostasis	O
and	O
serum	O
reduced	O
chemotaxis	O
in	O
robo4	B-Gene_or_gene_product
knockdown	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

Robo1	B-Gene_or_gene_product
and	O
Robo4	B-Gene_or_gene_product
interact	O
and	O
share	O
molecules	O
such	O
as	O
Slit2	B-Gene_or_gene_product
,	O
Mena	B-Gene_or_gene_product
and	O
Vilse	B-Gene_or_gene_product
,	O
a	O
Cdc42	B-Gene_or_gene_product
-	I-Gene_or_gene_product
GAP	I-Gene_or_gene_product
.	O
<EOS>	B-X
Roundabouts	B-X
are	B-X
axon	B-X
guidance	B-X
molecules	B-X
that	B-X
have	B-X
recently	B-X
been	B-X
identified	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
vascular	B-X
guidance	B-X
as	B-X
well	B-X
.	B-X

In	O
addition	O
,	O
this	O
study	O
mechanistically	O
implicates	O
IRSp53	B-Gene_or_gene_product
in	O
the	O
signaling	O
nexus	O
between	O
activated	O
Cdc42	B-Gene_or_gene_product
and	O
Mena	B-Gene_or_gene_product
,	O
both	O
of	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
involved	O
with	O
Robo4	B-Gene_or_gene_product
signaling	O
in	O
endothelial	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

CONCLUSION	O
:	O
This	O
study	O
identifies	O
specific	O
components	O
of	O
the	O
Robo	B-Gene_or_gene_product
signaling	O
apparatus	O
that	O
work	O
together	O
to	O
guide	O
directional	O
migration	O
of	O
endothelial	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
gene	B-X
knockdown	B-X
analysis	B-X
of	B-X
endothelial	B-X
Robos	B-X
,	B-X
in	B-X
particular	B-X
roundabout	B-X
4	B-X
(	B-X
robo4	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
Robo	B-X
in	B-X
endothelial	B-X
cells	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
technology	B-X
in	B-X
vitro	B-X
.	B-X

p53	B-Gene_or_gene_product
hot	O
-	O
spot	O
mutants	O
increase	O
tumor	O
vascularization	O
via	O
ROS	O
-	O
mediated	O
activation	O
of	O
the	O
HIF1	B-Gene_or_gene_product
/	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	I-Gene_or_gene_product
pathway	O
.	O
<EOS>	B-X
The	B-X
function	B-X
of	B-X
p53	B-X
tumor	B-X
suppressor	B-X
is	B-X
often	B-X
altered	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
predominantly	B-X
through	B-X
missense-mutations	B-X
resulting	B-X
in	B-X
accumulation	B-X
of	B-X
mutant	B-X
proteins	B-X
.	B-X
We	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
p53	B-X
proteins	B-X
with	B-X
amino-acid	B-X
substitutions	B-X
at	B-X
codons	B-X
175	B-X
(	B-X
R175H	B-X
)	B-X
,	B-X
248	B-X
(	B-X
R248W	B-X
)	B-X
,	B-X
and	B-X
273	B-X
(	B-X
R273H	B-X
)	B-X
,	B-X
representing	B-X
the	B-X
hot-spots	B-X
of	B-X
mutations	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
,	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
vessels	B-X
in	B-X
HCT116	B-X
human	B-X
colon	B-X
carcinoma	B-X
xenografts	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
,	B-X
accelerated	B-X
their	B-X
growth	B-X
.	B-X
Stimulation	B-X
of	B-X
tumor	B-X
angiogenesis	B-X
was	B-X
connected	B-X
with	B-X
about	B-X
2-fold	B-X
increase	B-X
in	B-X
intracellular	B-X
level	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
.	B-X
Antioxidant	B-X
N-acetyl-l-aspartate	B-X
(	B-X
NAC	B-X
)	B-X
decreased	B-X
vessels	B-X
number	B-X
in	B-X
tumors	B-X
formed	B-X
by	B-X
cells	B-X
with	B-X
inactivated	B-X
p53	B-X
and	B-X
inhibited	B-X
their	B-X
growth	B-X
.	B-X
Effect	B-X
of	B-X
ROS	B-X
on	B-X
angiogenesis	B-X
in	B-X
tumors	B-X
expressing	B-X
hot-spot	B-X
p53	B-X
mutants	B-X
was	B-X
correlated	B-X
with	B-X
their	B-X
ability	B-X
to	B-X
increase	B-X
a	B-X
content	B-X
of	B-X
HIF1	B-X
transcriptional	B-X
factor	B-X
responsible	B-X
for	B-X
up-regulation	B-X
of	B-X
VEGF-A	B-X
mRNAs	B-X
.	B-X

The	O
function	O
of	O
p53	B-Gene_or_gene_product
tumor	O
suppressor	O
is	O
often	O
altered	O
in	O
various	O
human	O
tumors	O
predominantly	O
through	O
missense	O
-	O
mutations	O
resulting	O
in	O
accumulation	O
of	O
mutant	O
proteins	O
.	O
<EOS>	B-X
The	B-X
function	B-X
of	B-X
p53	B-X
tumor	B-X
suppressor	B-X
is	B-X
often	B-X
altered	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
predominantly	B-X
through	B-X
missense-mutations	B-X
resulting	B-X
in	B-X
accumulation	B-X
of	B-X
mutant	B-X
proteins	B-X
.	B-X
We	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
p53	B-X
proteins	B-X
with	B-X
amino-acid	B-X
substitutions	B-X
at	B-X
codons	B-X
175	B-X
(	B-X
R175H	B-X
)	B-X
,	B-X
248	B-X
(	B-X
R248W	B-X
)	B-X
,	B-X
and	B-X
273	B-X
(	B-X
R273H	B-X
)	B-X
,	B-X
representing	B-X
the	B-X
hot-spots	B-X
of	B-X
mutations	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
,	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
vessels	B-X
in	B-X
HCT116	B-X
human	B-X
colon	B-X
carcinoma	B-X
xenografts	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
,	B-X
accelerated	B-X
their	B-X
growth	B-X
.	B-X
Stimulation	B-X
of	B-X
tumor	B-X
angiogenesis	B-X
was	B-X
connected	B-X
with	B-X
about	B-X
2-fold	B-X
increase	B-X
in	B-X
intracellular	B-X
level	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
.	B-X
Antioxidant	B-X
N-acetyl-l-aspartate	B-X
(	B-X
NAC	B-X
)	B-X
decreased	B-X
vessels	B-X
number	B-X
in	B-X
tumors	B-X
formed	B-X
by	B-X
cells	B-X
with	B-X
inactivated	B-X
p53	B-X
and	B-X
inhibited	B-X
their	B-X
growth	B-X
.	B-X
Effect	B-X
of	B-X
ROS	B-X
on	B-X
angiogenesis	B-X
in	B-X
tumors	B-X
expressing	B-X
hot-spot	B-X
p53	B-X
mutants	B-X
was	B-X
correlated	B-X
with	B-X
their	B-X
ability	B-X
to	B-X
increase	B-X
a	B-X
content	B-X
of	B-X
HIF1	B-X
transcriptional	B-X
factor	B-X
responsible	B-X
for	B-X
up-regulation	B-X
of	B-X
VEGF-A	B-X
mRNAs	B-X
.	B-X

We	O
revealed	O
that	O
expression	O
of	O
p53	B-Gene_or_gene_product
proteins	O
with	O
amino	O
-	O
acid	O
substitutions	O
at	O
codons	O
175	O
(	O
R175H	O
)	O
,	O
248	O
(	O
R248W	O
)	O
,	O
and	O
273	O
(	O
R273H	O
)	O
,	O
representing	O
the	O
hot	O
-	O
spots	O
of	O
mutations	O
in	O
various	O
human	O
tumors	O
,	O
increased	O
the	O
number	O
of	O
vessels	O
in	O
HCT116	O
human	O
colon	O
carcinoma	O
xenografts	O
and	O
,	O
as	O
a	O
result	O
,	O
accelerated	O
their	O
growth	O
.	O

Stimulation	O
of	O
tumor	O
angiogenesis	O
was	O
connected	O
with	O
about	O
2	O
-	O
fold	O
increase	O
in	O
intracellular	O
level	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
<EOS>	B-X
The	B-X
function	B-X
of	B-X
p53	B-X
tumor	B-X
suppressor	B-X
is	B-X
often	B-X
altered	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
predominantly	B-X
through	B-X
missense-mutations	B-X
resulting	B-X
in	B-X
accumulation	B-X
of	B-X
mutant	B-X
proteins	B-X
.	B-X
We	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
p53	B-X
proteins	B-X
with	B-X
amino-acid	B-X
substitutions	B-X
at	B-X
codons	B-X
175	B-X
(	B-X
R175H	B-X
)	B-X
,	B-X
248	B-X
(	B-X
R248W	B-X
)	B-X
,	B-X
and	B-X
273	B-X
(	B-X
R273H	B-X
)	B-X
,	B-X
representing	B-X
the	B-X
hot-spots	B-X
of	B-X
mutations	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
,	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
vessels	B-X
in	B-X
HCT116	B-X
human	B-X
colon	B-X
carcinoma	B-X
xenografts	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
,	B-X
accelerated	B-X
their	B-X
growth	B-X
.	B-X
Stimulation	B-X
of	B-X
tumor	B-X
angiogenesis	B-X
was	B-X
connected	B-X
with	B-X
about	B-X
2-fold	B-X
increase	B-X
in	B-X
intracellular	B-X
level	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
.	B-X
Antioxidant	B-X
N-acetyl-l-aspartate	B-X
(	B-X
NAC	B-X
)	B-X
decreased	B-X
vessels	B-X
number	B-X
in	B-X
tumors	B-X
formed	B-X
by	B-X
cells	B-X
with	B-X
inactivated	B-X
p53	B-X
and	B-X
inhibited	B-X
their	B-X
growth	B-X
.	B-X
Effect	B-X
of	B-X
ROS	B-X
on	B-X
angiogenesis	B-X
in	B-X
tumors	B-X
expressing	B-X
hot-spot	B-X
p53	B-X
mutants	B-X
was	B-X
correlated	B-X
with	B-X
their	B-X
ability	B-X
to	B-X
increase	B-X
a	B-X
content	B-X
of	B-X
HIF1	B-X
transcriptional	B-X
factor	B-X
responsible	B-X
for	B-X
up-regulation	B-X
of	B-X
VEGF-A	B-X
mRNAs	B-X
.	B-X

Antioxidant	O
N	O
-	O
acetyl	O
-	O
l	O
-	O
aspartate	O
(	O
NAC	O
)	O
decreased	O
vessels	O
number	O
in	O
tumors	O
formed	O
by	O
cells	O
with	O
inactivated	O
p53	B-Gene_or_gene_product
and	O
inhibited	O
their	O
growth	O
.	O
<EOS>	B-X
The	B-X
function	B-X
of	B-X
p53	B-X
tumor	B-X
suppressor	B-X
is	B-X
often	B-X
altered	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
predominantly	B-X
through	B-X
missense-mutations	B-X
resulting	B-X
in	B-X
accumulation	B-X
of	B-X
mutant	B-X
proteins	B-X
.	B-X
We	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
p53	B-X
proteins	B-X
with	B-X
amino-acid	B-X
substitutions	B-X
at	B-X
codons	B-X
175	B-X
(	B-X
R175H	B-X
)	B-X
,	B-X
248	B-X
(	B-X
R248W	B-X
)	B-X
,	B-X
and	B-X
273	B-X
(	B-X
R273H	B-X
)	B-X
,	B-X
representing	B-X
the	B-X
hot-spots	B-X
of	B-X
mutations	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
,	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
vessels	B-X
in	B-X
HCT116	B-X
human	B-X
colon	B-X
carcinoma	B-X
xenografts	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
,	B-X
accelerated	B-X
their	B-X
growth	B-X
.	B-X
Stimulation	B-X
of	B-X
tumor	B-X
angiogenesis	B-X
was	B-X
connected	B-X
with	B-X
about	B-X
2-fold	B-X
increase	B-X
in	B-X
intracellular	B-X
level	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
.	B-X
Antioxidant	B-X
N-acetyl-l-aspartate	B-X
(	B-X
NAC	B-X
)	B-X
decreased	B-X
vessels	B-X
number	B-X
in	B-X
tumors	B-X
formed	B-X
by	B-X
cells	B-X
with	B-X
inactivated	B-X
p53	B-X
and	B-X
inhibited	B-X
their	B-X
growth	B-X
.	B-X
Effect	B-X
of	B-X
ROS	B-X
on	B-X
angiogenesis	B-X
in	B-X
tumors	B-X
expressing	B-X
hot-spot	B-X
p53	B-X
mutants	B-X
was	B-X
correlated	B-X
with	B-X
their	B-X
ability	B-X
to	B-X
increase	B-X
a	B-X
content	B-X
of	B-X
HIF1	B-X
transcriptional	B-X
factor	B-X
responsible	B-X
for	B-X
up-regulation	B-X
of	B-X
VEGF-A	B-X
mRNAs	B-X
.	B-X

Effect	O
of	O
ROS	O
on	O
angiogenesis	O
in	O
tumors	O
expressing	O
hot	O
-	O
spot	O
p53	B-Gene_or_gene_product
mutants	O
was	O
correlated	O
with	O
their	O
ability	O
to	O
increase	O
a	O
content	O
of	O
HIF1	B-Gene_or_gene_product
transcriptional	O
factor	O
responsible	O
for	O
up	O
-	O
regulation	O
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	I-Gene_or_gene_product
mRNAs	O
.	O
<EOS>	B-X
The	B-X
function	B-X
of	B-X
p53	B-X
tumor	B-X
suppressor	B-X
is	B-X
often	B-X
altered	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
predominantly	B-X
through	B-X
missense-mutations	B-X
resulting	B-X
in	B-X
accumulation	B-X
of	B-X
mutant	B-X
proteins	B-X
.	B-X
We	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
p53	B-X
proteins	B-X
with	B-X
amino-acid	B-X
substitutions	B-X
at	B-X
codons	B-X
175	B-X
(	B-X
R175H	B-X
)	B-X
,	B-X
248	B-X
(	B-X
R248W	B-X
)	B-X
,	B-X
and	B-X
273	B-X
(	B-X
R273H	B-X
)	B-X
,	B-X
representing	B-X
the	B-X
hot-spots	B-X
of	B-X
mutations	B-X
in	B-X
various	B-X
human	B-X
tumors	B-X
,	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
vessels	B-X
in	B-X
HCT116	B-X
human	B-X
colon	B-X
carcinoma	B-X
xenografts	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
,	B-X
accelerated	B-X
their	B-X
growth	B-X
.	B-X
Stimulation	B-X
of	B-X
tumor	B-X
angiogenesis	B-X
was	B-X
connected	B-X
with	B-X
about	B-X
2-fold	B-X
increase	B-X
in	B-X
intracellular	B-X
level	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
.	B-X
Antioxidant	B-X
N-acetyl-l-aspartate	B-X
(	B-X
NAC	B-X
)	B-X
decreased	B-X
vessels	B-X
number	B-X
in	B-X
tumors	B-X
formed	B-X
by	B-X
cells	B-X
with	B-X
inactivated	B-X
p53	B-X
and	B-X
inhibited	B-X
their	B-X
growth	B-X
.	B-X
Effect	B-X
of	B-X
ROS	B-X
on	B-X
angiogenesis	B-X
in	B-X
tumors	B-X
expressing	B-X
hot-spot	B-X
p53	B-X
mutants	B-X
was	B-X
correlated	B-X
with	B-X
their	B-X
ability	B-X
to	B-X
increase	B-X
a	B-X
content	B-X
of	B-X
HIF1	B-X
transcriptional	B-X
factor	B-X
responsible	B-X
for	B-X
up-regulation	B-X
of	B-X
VEGF-A	B-X
mRNAs	B-X
.	B-X

The	O
Akt	B-Gene_or_gene_product
/	O
mTOR	B-Gene_or_gene_product
pathway	O
assures	O
the	O
synthesis	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
protein	O
in	O
a	O
glucose	O
-	O
and	O
reoxygenation	O
-	O
dependent	O
manner	O
in	O
irradiated	O
tumors	O
.	O

Transcriptional	O
activity	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
has	O
been	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
solid	O
tumors	O
after	O
ionizing	O
radiation	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
response	O
remains	O
to	O
be	O
elucidated	O
.	O
<EOS>	B-X
Transcriptional	B-X
activity	B-X
of	B-X
HIF-1	B-X
(	B-X
hypoxia-inducible	B-X
factor-1	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
solid	B-X
tumors	B-X
after	B-X
ionizing	B-X
radiation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
the	B-X
response	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
series	B-X
of	B-X
molecular	B-X
imaging	B-X
experiments	B-X
using	B-X
a	B-X
HIF-1-dependent	B-X
reporter	B-X
gene	B-X
,	B-X
5HREp-ODD-luc	B-X
,	B-X
and	B-X
found	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
.	B-X
Hypoxic	B-X
tumor	B-X
cells	B-X
distant	B-X
from	B-X
blood	B-X
vessels	B-X
were	B-X
dramatically	B-X
reoxygenated	B-X
at	B-X
24	B-X
h	B-X
postirradiation	B-X
,	B-X
and	B-X
HIF-1	B-X
activity	B-X
increased	B-X
as	B-X
HIF-1alpha	B-X
accumulated	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
The	B-X
accumulation	B-X
was	B-X
inhibited	B-X
with	B-X
a	B-X
nonmetabolizable	B-X
glucose	B-X
analog	B-X
,	B-X
2-deoxy-d-glucose	B-X
,	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
radiation-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
Akt	B-X
knockdown	B-X
and	B-X
an	B-X
mTOR	B-X
inhibitor	B-X
revealed	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
in	B-X
the	B-X
postirradiation	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
vitro	B-X
experiments	B-X
confirmed	B-X
that	B-X
an	B-X
increase	B-X
in	B-X
glucose	B-X
availability	B-X
induced	B-X
Akt	B-X
phosphorylation	B-X
under	B-X
reoxygenated	B-X
conditions	B-X
and	B-X
consequently	B-X
up-regulated	B-X
HIF-1alpha	B-X
translation	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
the	B-X
accelerated	B-X
translation	B-X
and	B-X
the	B-X
previously	B-X
reported	B-X
reactive	B-X
oxygen	B-X
species-mediated	B-X
stabilization	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
were	B-X
essential	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
HIF-1	B-X
.	B-X
All	B-X
of	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
Akt/mTOR-dependent	B-X
translation	B-X
of	B-X
HIF-1alpha	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
postirradiation	B-X
up-regulation	B-X
of	B-X
intratumoral	B-X
HIF-1	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
radiation-induced	B-X
alterations	B-X
of	B-X
glucose	B-X
and	B-X
oxygen	B-X
availability	B-X
in	B-X
a	B-X
solid	B-X
tumor	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
a	O
series	O
of	O
molecular	O
imaging	O
experiments	O
using	O
a	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
dependent	O
reporter	O
gene	O
,	O
5HREp	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ODD	I-Gene_or_gene_product
-	I-Gene_or_gene_product
luc	I-Gene_or_gene_product
,	O
and	O
found	O
an	O
essential	O
role	O
of	O
the	O
Akt	B-Gene_or_gene_product
/	O
mTOR	B-Gene_or_gene_product
pathway	O
.	O
<EOS>	B-X
Transcriptional	B-X
activity	B-X
of	B-X
HIF-1	B-X
(	B-X
hypoxia-inducible	B-X
factor-1	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
solid	B-X
tumors	B-X
after	B-X
ionizing	B-X
radiation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
the	B-X
response	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
series	B-X
of	B-X
molecular	B-X
imaging	B-X
experiments	B-X
using	B-X
a	B-X
HIF-1-dependent	B-X
reporter	B-X
gene	B-X
,	B-X
5HREp-ODD-luc	B-X
,	B-X
and	B-X
found	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
.	B-X
Hypoxic	B-X
tumor	B-X
cells	B-X
distant	B-X
from	B-X
blood	B-X
vessels	B-X
were	B-X
dramatically	B-X
reoxygenated	B-X
at	B-X
24	B-X
h	B-X
postirradiation	B-X
,	B-X
and	B-X
HIF-1	B-X
activity	B-X
increased	B-X
as	B-X
HIF-1alpha	B-X
accumulated	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
The	B-X
accumulation	B-X
was	B-X
inhibited	B-X
with	B-X
a	B-X
nonmetabolizable	B-X
glucose	B-X
analog	B-X
,	B-X
2-deoxy-d-glucose	B-X
,	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
radiation-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
Akt	B-X
knockdown	B-X
and	B-X
an	B-X
mTOR	B-X
inhibitor	B-X
revealed	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
in	B-X
the	B-X
postirradiation	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
vitro	B-X
experiments	B-X
confirmed	B-X
that	B-X
an	B-X
increase	B-X
in	B-X
glucose	B-X
availability	B-X
induced	B-X
Akt	B-X
phosphorylation	B-X
under	B-X
reoxygenated	B-X
conditions	B-X
and	B-X
consequently	B-X
up-regulated	B-X
HIF-1alpha	B-X
translation	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
the	B-X
accelerated	B-X
translation	B-X
and	B-X
the	B-X
previously	B-X
reported	B-X
reactive	B-X
oxygen	B-X
species-mediated	B-X
stabilization	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
were	B-X
essential	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
HIF-1	B-X
.	B-X
All	B-X
of	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
Akt/mTOR-dependent	B-X
translation	B-X
of	B-X
HIF-1alpha	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
postirradiation	B-X
up-regulation	B-X
of	B-X
intratumoral	B-X
HIF-1	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
radiation-induced	B-X
alterations	B-X
of	B-X
glucose	B-X
and	B-X
oxygen	B-X
availability	B-X
in	B-X
a	B-X
solid	B-X
tumor	B-X
.	B-X

Hypoxic	O
tumor	O
cells	O
distant	O
from	O
blood	O
vessels	O
were	O
dramatically	O
reoxygenated	O
at	O
24	O
h	O
postirradiation	O
,	O
and	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
activity	O
increased	O
as	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
accumulated	O
in	O
the	O
reoxygenated	O
regions	O
.	O
<EOS>	B-X
Transcriptional	B-X
activity	B-X
of	B-X
HIF-1	B-X
(	B-X
hypoxia-inducible	B-X
factor-1	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
solid	B-X
tumors	B-X
after	B-X
ionizing	B-X
radiation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
the	B-X
response	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
series	B-X
of	B-X
molecular	B-X
imaging	B-X
experiments	B-X
using	B-X
a	B-X
HIF-1-dependent	B-X
reporter	B-X
gene	B-X
,	B-X
5HREp-ODD-luc	B-X
,	B-X
and	B-X
found	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
.	B-X
Hypoxic	B-X
tumor	B-X
cells	B-X
distant	B-X
from	B-X
blood	B-X
vessels	B-X
were	B-X
dramatically	B-X
reoxygenated	B-X
at	B-X
24	B-X
h	B-X
postirradiation	B-X
,	B-X
and	B-X
HIF-1	B-X
activity	B-X
increased	B-X
as	B-X
HIF-1alpha	B-X
accumulated	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
The	B-X
accumulation	B-X
was	B-X
inhibited	B-X
with	B-X
a	B-X
nonmetabolizable	B-X
glucose	B-X
analog	B-X
,	B-X
2-deoxy-d-glucose	B-X
,	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
radiation-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
Akt	B-X
knockdown	B-X
and	B-X
an	B-X
mTOR	B-X
inhibitor	B-X
revealed	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
in	B-X
the	B-X
postirradiation	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
vitro	B-X
experiments	B-X
confirmed	B-X
that	B-X
an	B-X
increase	B-X
in	B-X
glucose	B-X
availability	B-X
induced	B-X
Akt	B-X
phosphorylation	B-X
under	B-X
reoxygenated	B-X
conditions	B-X
and	B-X
consequently	B-X
up-regulated	B-X
HIF-1alpha	B-X
translation	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
the	B-X
accelerated	B-X
translation	B-X
and	B-X
the	B-X
previously	B-X
reported	B-X
reactive	B-X
oxygen	B-X
species-mediated	B-X
stabilization	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
were	B-X
essential	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
HIF-1	B-X
.	B-X
All	B-X
of	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
Akt/mTOR-dependent	B-X
translation	B-X
of	B-X
HIF-1alpha	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
postirradiation	B-X
up-regulation	B-X
of	B-X
intratumoral	B-X
HIF-1	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
radiation-induced	B-X
alterations	B-X
of	B-X
glucose	B-X
and	B-X
oxygen	B-X
availability	B-X
in	B-X
a	B-X
solid	B-X
tumor	B-X
.	B-X

The	O
accumulation	O
was	O
inhibited	O
with	O
a	O
nonmetabolizable	O
glucose	O
analog	O
,	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
,	O
through	O
the	O
suppression	O
of	O
radiation	O
-	O
induced	O
phosphorylation	O
of	O
Akt	B-Gene_or_gene_product
in	O
the	O
reoxygenated	O
regions	O
.	O
<EOS>	B-X
Transcriptional	B-X
activity	B-X
of	B-X
HIF-1	B-X
(	B-X
hypoxia-inducible	B-X
factor-1	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
solid	B-X
tumors	B-X
after	B-X
ionizing	B-X
radiation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
the	B-X
response	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
series	B-X
of	B-X
molecular	B-X
imaging	B-X
experiments	B-X
using	B-X
a	B-X
HIF-1-dependent	B-X
reporter	B-X
gene	B-X
,	B-X
5HREp-ODD-luc	B-X
,	B-X
and	B-X
found	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
.	B-X
Hypoxic	B-X
tumor	B-X
cells	B-X
distant	B-X
from	B-X
blood	B-X
vessels	B-X
were	B-X
dramatically	B-X
reoxygenated	B-X
at	B-X
24	B-X
h	B-X
postirradiation	B-X
,	B-X
and	B-X
HIF-1	B-X
activity	B-X
increased	B-X
as	B-X
HIF-1alpha	B-X
accumulated	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
The	B-X
accumulation	B-X
was	B-X
inhibited	B-X
with	B-X
a	B-X
nonmetabolizable	B-X
glucose	B-X
analog	B-X
,	B-X
2-deoxy-d-glucose	B-X
,	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
radiation-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
Akt	B-X
knockdown	B-X
and	B-X
an	B-X
mTOR	B-X
inhibitor	B-X
revealed	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
in	B-X
the	B-X
postirradiation	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
vitro	B-X
experiments	B-X
confirmed	B-X
that	B-X
an	B-X
increase	B-X
in	B-X
glucose	B-X
availability	B-X
induced	B-X
Akt	B-X
phosphorylation	B-X
under	B-X
reoxygenated	B-X
conditions	B-X
and	B-X
consequently	B-X
up-regulated	B-X
HIF-1alpha	B-X
translation	B-X
.	B-X
All	B-X
of	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
Akt/mTOR-dependent	B-X
translation	B-X
of	B-X
HIF-1alpha	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
postirradiation	B-X
up-regulation	B-X
of	B-X
intratumoral	B-X
HIF-1	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
radiation-induced	B-X
alterations	B-X
of	B-X
glucose	B-X
and	B-X
oxygen	B-X
availability	B-X
in	B-X
a	B-X
solid	B-X
tumor	B-X
.	B-X

Akt	B-Gene_or_gene_product
knockdown	O
and	O
an	O
mTOR	B-Gene_or_gene_product
inhibitor	O
revealed	O
the	O
importance	O
of	O
the	O
Akt	B-Gene_or_gene_product
/	O
mTOR	B-Gene_or_gene_product
pathway	O
in	O
the	O
postirradiation	O
accumulation	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
.	O

In	O
vitro	O
experiments	O
confirmed	O
that	O
an	O
increase	O
in	O
glucose	O
availability	O
induced	O
Akt	B-Gene_or_gene_product
phosphorylation	O
under	O
reoxygenated	O
conditions	O
and	O
consequently	O
up	O
-	O
regulated	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
translation	O
.	O
<EOS>	B-X
Transcriptional	B-X
activity	B-X
of	B-X
HIF-1	B-X
(	B-X
hypoxia-inducible	B-X
factor-1	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
solid	B-X
tumors	B-X
after	B-X
ionizing	B-X
radiation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
underlying	B-X
the	B-X
response	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
series	B-X
of	B-X
molecular	B-X
imaging	B-X
experiments	B-X
using	B-X
a	B-X
HIF-1-dependent	B-X
reporter	B-X
gene	B-X
,	B-X
5HREp-ODD-luc	B-X
,	B-X
and	B-X
found	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
.	B-X
Hypoxic	B-X
tumor	B-X
cells	B-X
distant	B-X
from	B-X
blood	B-X
vessels	B-X
were	B-X
dramatically	B-X
reoxygenated	B-X
at	B-X
24	B-X
h	B-X
postirradiation	B-X
,	B-X
and	B-X
HIF-1	B-X
activity	B-X
increased	B-X
as	B-X
HIF-1alpha	B-X
accumulated	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
The	B-X
accumulation	B-X
was	B-X
inhibited	B-X
with	B-X
a	B-X
nonmetabolizable	B-X
glucose	B-X
analog	B-X
,	B-X
2-deoxy-d-glucose	B-X
,	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
radiation-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
reoxygenated	B-X
regions	B-X
.	B-X
Akt	B-X
knockdown	B-X
and	B-X
an	B-X
mTOR	B-X
inhibitor	B-X
revealed	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
in	B-X
the	B-X
postirradiation	B-X
accumulation	B-X
of	B-X
HIF-1alpha	B-X
.	B-X
In	B-X
vitro	B-X
experiments	B-X
confirmed	B-X
that	B-X
an	B-X
increase	B-X
in	B-X
glucose	B-X
availability	B-X
induced	B-X
Akt	B-X
phosphorylation	B-X
under	B-X
reoxygenated	B-X
conditions	B-X
and	B-X
consequently	B-X
up-regulated	B-X
HIF-1alpha	B-X
translation	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
the	B-X
accelerated	B-X
translation	B-X
and	B-X
the	B-X
previously	B-X
reported	B-X
reactive	B-X
oxygen	B-X
species-mediated	B-X
stabilization	B-X
of	B-X
HIF-1alpha	B-X
protein	B-X
were	B-X
essential	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
HIF-1	B-X
.	B-X
All	B-X
of	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
Akt/mTOR-dependent	B-X
translation	B-X
of	B-X
HIF-1alpha	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
postirradiation	B-X
up-regulation	B-X
of	B-X
intratumoral	B-X
HIF-1	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
radiation-induced	B-X
alterations	B-X
of	B-X
glucose	B-X
and	B-X
oxygen	B-X
availability	B-X
in	B-X
a	B-X
solid	B-X
tumor	B-X
.	B-X

Moreover	O
,	O
both	O
the	O
accelerated	O
translation	O
and	O
the	O
previously	O
reported	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
stabilization	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
protein	O
were	O
essential	O
to	O
the	O
activation	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O

All	O
of	O
these	O
results	O
indicate	O
that	O
Akt	B-Gene_or_gene_product
/	O
mTOR	B-Gene_or_gene_product
-	O
dependent	O
translation	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
plays	O
a	O
critical	O
role	O
in	O
the	O
postirradiation	O
up	O
-	O
regulation	O
of	O
intratumoral	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
activity	O
in	O
response	O
to	O
radiation	O
-	O
induced	O
alterations	O
of	O
glucose	O
and	O
oxygen	O
availability	O
in	O
a	O
solid	O
tumor	O
.	O

Estradiol	O
increases	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
secretion	O
of	O
normal	O
human	O
breast	O
tissue	O
and	O
breast	O
cancer	O
in	O
vivo	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Estrogen	B-X
is	B-X
crucial	B-X
in	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
or	O
CXCL8	B-Gene_or_gene_product
has	O
been	O
associated	O
with	O
tumor	O
angiogenesis	O
,	O
metastasis	O
,	O
and	O
poor	O
prognosis	O
in	O
breast	O
cancer	O
.	O
<EOS>	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
belongs	B-X
to	B-X
a	B-X
family	B-X
of	B-X
small	B-X
,	B-X
structurally	B-X
related	B-X
cytokines	B-X
similar	B-X
to	B-X
platelet	B-X
factor	B-X
4	B-X
.	B-X
It	B-X
is	B-X
produced	B-X
by	B-X
phagocytes	B-X
and	B-X
mesenchymal	B-X
cells	B-X
exposed	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
(	B-X
e.g.	B-X
,	B-X
interleukin-1	B-X
or	B-X
tumor	B-X
necrosis	B-X
factor	B-X
)	B-X
and	B-X
activates	B-X
neutrophils	B-X
inducing	B-X
chemotaxis	B-X
,	B-X
exocytosis	B-X
and	B-X
the	B-X
respiratory	B-X
burst	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
IL-8	B-X
elicits	B-X
a	B-X
massive	B-X
neutrophil	B-X
accumulation	B-X
at	B-X
the	B-X
site	B-X
of	B-X
injection	B-X
.	B-X
Five	B-X
neutrophil-activating	B-X
cytokines	B-X
similar	B-X
to	B-X
IL-8	B-X
in	B-X
structure	B-X
and	B-X
function	B-X
have	B-X
been	B-X
identified	B-X
recently	B-X
.	B-X
IL-8	B-X
and	B-X
the	B-X
related	B-X
cytokines	B-X
are	B-X
produced	B-X
in	B-X
several	B-X
tissues	B-X
upon	B-X
infection	B-X
,	B-X
inflammation	B-X
,	B-X
ischemia	B-X
,	B-X
trauma	B-X
etc.	B-X
,	B-X
and	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
the	B-X
main	B-X
cause	B-X
of	B-X
local	B-X
neutrophil	B-X
accumulation	B-X
.	B-X

Estrogen	O
is	O
crucial	O
in	O
breast	O
carcinogenesis	O
and	O
tumor	O
progression	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
breast	B-X
cancer	B-X
remains	B-X
poorly	B-X
defined	B-X
due	B-X
to	B-X
its	B-X
heterogeneity	B-X
.	B-X
Several	B-X
studies	B-X
have	B-X
reported	B-X
that	B-X
G	B-X
Protein-Coupled	B-X
Estrogen	B-X
Receptor	B-X
1	B-X
(	B-X
GPER1	B-X
)	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
breast	B-X
cancer	B-X
progression	B-X
,	B-X
by	B-X
binding	B-X
to	B-X
estrogens	B-X
or	B-X
synthetic	B-X
agonists	B-X
,	B-X
like	B-X
G-1	B-X
,	B-X
thus	B-X
modulating	B-X
genes	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
events	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
has	B-X
been	B-X
established	B-X
that	B-X
the	B-X
dysregulation	B-X
of	B-X
short	B-X
sequences	B-X
of	B-X
non-coding	B-X
RNA	B-X
,	B-X
named	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
various	B-X
pathophysiological	B-X
conditions	B-X
,	B-X
including	B-X
breast	B-X
cancer	B-X
.	B-X
Recent	B-X
evidence	B-X
has	B-X
indicated	B-X
that	B-X
estrogens	B-X
may	B-X
regulate	B-X
miRNA	B-X
expression	B-X
and	B-X
therefore	B-X
modulate	B-X
the	B-X
levels	B-X
of	B-X
their	B-X
target	B-X
genes	B-X
,	B-X
not	B-X
only	B-X
through	B-X
the	B-X
classical	B-X
estrogen	B-X
receptors	B-X
(	B-X
ERs	B-X
)	B-X
,	B-X
but	B-X
also	B-X
activating	B-X
GPER1	B-X
signalling	B-X
,	B-X
hence	B-X
suggesting	B-X
an	B-X
alternative	B-X
molecular	B-X
pathway	B-X
involved	B-X
in	B-X
breast	B-X
tumor	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
current	B-X
knowledge	B-X
about	B-X
GPER1	B-X
and	B-X
miRNA	B-X
action	B-X
in	B-X
breast	B-X
cancer	B-X
is	B-X
recapitulated	B-X
,	B-X
reporting	B-X
recent	B-X
evidence	B-X
on	B-X
the	B-X
liaison	B-X
of	B-X
these	B-X
two	B-X
players	B-X
in	B-X
triggering	B-X
breast	B-X
tumorogenic	B-X
effects	B-X
.	B-X
Elucidating	B-X
the	B-X
role	B-X
of	B-X
GPER1	B-X
and	B-X
miRNAs	B-X
in	B-X
breast	B-X
cancer	B-X
might	B-X
provide	B-X
new	B-X
tools	B-X
for	B-X
innovative	B-X
approaches	B-X
in	B-X
anti-cancer	B-X
therapy	B-X
.	B-X

Whether	O
sex	O
steroids	O
affect	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
secretion	O
of	O
normal	O
breast	O
tissue	O
or	O
breast	O
cancer	O
is	O
not	O
known	O
.	O
<EOS>	B-X
Breast	B-X
cancer	B-X
is	B-X
the	B-X
most	B-X
common	B-X
global	B-X
malignancy	B-X
and	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
cancer	B-X
deaths	B-X
.	B-X
Despite	B-X
this	B-X
,	B-X
undergraduate	B-X
and	B-X
postgraduate	B-X
exposure	B-X
to	B-X
breast	B-X
cancer	B-X
is	B-X
limited	B-X
,	B-X
impacting	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
clinicians	B-X
to	B-X
accurately	B-X
recognise	B-X
,	B-X
assess	B-X
and	B-X
refer	B-X
appropriate	B-X
patients	B-X
.	B-X
This	B-X
article	B-X
provides	B-X
a	B-X
comprehensive	B-X
review	B-X
of	B-X
the	B-X
pathology	B-X
,	B-X
epidemiology	B-X
,	B-X
clinical	B-X
presentation	B-X
,	B-X
referral	B-X
pathways	B-X
and	B-X
management	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
the	B-X
UK	B-X
.	B-X
It	B-X
also	B-X
describes	B-X
how	B-X
to	B-X
conduct	B-X
a	B-X
thorough	B-X
clinical	B-X
breast	B-X
examination	B-X
.	B-X

Several	O
cell	O
types	O
in	O
a	O
tissue	O
secrete	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
.	O

Hence	O
,	O
regulatory	O
mechanisms	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
need	O
to	O
be	O
investigated	O
in	O
whole	O
tissue	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

We	O
used	O
microdialysis	O
to	O
sample	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
in	O
normal	O
human	O
breast	O
tissue	O
in	O
situ	O
in	O
pre	O
-	O
and	O
postmenopausal	O
women	O
,	O
preoperatively	O
in	O
breast	O
cancers	O
of	O
women	O
,	O
and	O
in	O
experimental	O
breast	O
cancer	O
in	O
mice	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Estrogen	B-X
is	B-X
crucial	B-X
in	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

We	O
found	O
a	O
significant	O
positive	O
correlation	O
between	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
and	O
estradiol	O
in	O
normal	O
breast	O
tissue	O
and	O
hormone	O
-	O
dependent	O
breast	O
cancer	O
in	O
vivo	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Estrogen	B-X
is	B-X
crucial	B-X
in	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

Ex	O
vivo	O
,	O
estradiol	O
exposure	O
increased	O
the	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
secretion	O
of	O
normal	O
whole	O
breast	O
tissue	O
in	O
culture	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Estrogen	B-X
is	B-X
crucial	B-X
in	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

In	O
experimental	O
breast	O
cancer	O
,	O
estradiol	O
increased	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
whereas	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
inhibited	O
the	O
secretion	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
both	O
in	O
vitro	O
and	O
extracellularly	O
in	O
vivo	O
in	O
tumors	O
of	O
nude	O
mice	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Estrogen	B-X
is	B-X
crucial	B-X
in	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

An	O
anti	O
-	O
IL	O
-	O
8	O
Ab	O
inhibited	O
endothelial	O
cell	O
proliferation	O
induced	O
by	O
cancer	O
cell	O
produced	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
and	O
tumors	O
with	O
low	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
levels	O
exhibited	O
decreased	O
angiogenesis	O
.	O
<EOS>	B-X
IL-8	B-X
or	B-X
CXCL8	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
tumor	B-X
angiogenesis	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Whether	B-X
sex	B-X
steroids	B-X
affect	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
breast	B-X
tissue	B-X
or	B-X
breast	B-X
cancer	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Several	B-X
cell	B-X
types	B-X
in	B-X
a	B-X
tissue	B-X
secrete	B-X
IL-8	B-X
.	B-X
Hence	B-X
,	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
IL-8	B-X
need	B-X
to	B-X
be	B-X
investigated	B-X
in	B-X
whole	B-X
tissue	B-X
.	B-X
We	B-X
used	B-X
microdialysis	B-X
to	B-X
sample	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
in	B-X
situ	B-X
in	B-X
pre-	B-X
and	B-X
postmenopausal	B-X
women	B-X
,	B-X
preoperatively	B-X
in	B-X
breast	B-X
cancers	B-X
of	B-X
women	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
breast	B-X
cancer	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
found	B-X
a	B-X
significant	B-X
positive	B-X
correlation	B-X
between	B-X
IL-8	B-X
and	B-X
estradiol	B-X
in	B-X
normal	B-X
breast	B-X
tissue	B-X
and	B-X
hormone-dependent	B-X
breast	B-X
cancer	B-X
in	B-X
vivo	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
estradiol	B-X
exposure	B-X
increased	B-X
the	B-X
IL-8	B-X
secretion	B-X
of	B-X
normal	B-X
whole	B-X
breast	B-X
tissue	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
experimental	B-X
breast	B-X
cancer	B-X
,	B-X
estradiol	B-X
increased	B-X
IL-8	B-X
whereas	B-X
the	B-X
anti-estrogen	B-X
tamoxifen	B-X
inhibited	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
extracellularly	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
of	B-X
nude	B-X
mice	B-X
.	B-X
An	B-X
anti-IL-8	B-X
Ab	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
induced	B-X
by	B-X
cancer	B-X
cell	B-X
produced	B-X
IL-8	B-X
and	B-X
tumors	B-X
with	B-X
low	B-X
IL-8	B-X
levels	B-X
exhibited	B-X
decreased	B-X
angiogenesis	B-X
.	B-X
Our	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
estradiol	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-8	B-X
in	B-X
normal	B-X
human	B-X
breast	B-X
tissue	B-X
and	B-X
human	B-X
breast	B-X
cancer	B-X
.	B-X
IL-8	B-X
may	B-X
present	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
estrogen	B-X
driven	B-X
breast	B-X
carcinogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X

Our	O
results	O
strongly	O
suggest	O
that	O
estradiol	O
has	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
in	O
normal	O
human	O
breast	O
tissue	O
and	O
human	O
breast	O
cancer	O
.	O

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
may	O
present	O
a	O
novel	O
therapeutic	O
target	O
for	O
estrogen	O
driven	O
breast	O
carcinogenesis	O
and	O
tumor	O
progression	O
.	O

Chemokine	O
receptor	O
CXCR4	B-Gene_or_gene_product
expression	O
,	O
function	O
,	O
and	O
clinical	O
implications	O
in	O
gastric	O
cancer	O
.	O
<EOS>	B-X
Gastric	B-X
cancer	B-X
is	B-X
the	B-X
second	B-X
leading	B-X
cause	B-X
of	B-X
cancer	B-X
deaths	B-X
worldwide	B-X
.	B-X
Despite	B-X
the	B-X
extensive	B-X
body	B-X
of	B-X
research	B-X
on	B-X
gastric	B-X
cancer	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
gastric	B-X
cancer	B-X
remains	B-X
poor	B-X
,	B-X
and	B-X
therapy	B-X
for	B-X
advanced	B-X
gastric	B-X
cancer	B-X
relies	B-X
largely	B-X
on	B-X
cytotoxic	B-X
chemotherapy	B-X
.	B-X
The	B-X
chemokine	B-X
CXCL12	B-X
and	B-X
its	B-X
receptor	B-X
CXCR4	B-X
are	B-X
now	B-X
known	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
cancer	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
and	B-X
CXCL12	B-X
,	B-X
as	B-X
well	B-X
as	B-X
their	B-X
clinical	B-X
relevance	B-X
in	B-X
gastric	B-X
cancer	B-X
.	B-X
We	B-X
also	B-X
cover	B-X
the	B-X
current	B-X
molecular	B-X
mechanism	B-X
,	B-X
specifically	B-X
the	B-X
cell-signaling	B-X
pathway	B-X
,	B-X
by	B-X
which	B-X
gastric	B-X
cancer	B-X
progresses	B-X
through	B-X
the	B-X
CXCR4/CXCL12	B-X
axis	B-X
,	B-X
and	B-X
discuss	B-X
the	B-X
potential	B-X
of	B-X
that	B-X
axis	B-X
as	B-X
a	B-X
therapeutic	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
gastric	B-X
cancer	B-X
.	B-X

The	O
chemokine	O
receptor	O
CXCR4	B-Gene_or_gene_product
is	O
associated	O
with	O
the	O
biological	O
behavior	O
of	O
cancer	O
,	O
but	O
few	O
studies	O
have	O
addressed	O
the	O
expression	O
and	O
function	O
of	O
CXCR4	B-Gene_or_gene_product
in	O
human	O
gastric	O
cancer	O
and	O
its	O
impact	O
on	O
disease	O
prognosis	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

We	O
studied	O
the	O
expression	O
of	O
CXCR4	B-Gene_or_gene_product
using	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
,	O
flow	O
cytometry	O
,	O
and	O
confocal	O
microscopy	O
in	O
five	O
gastric	O
cancer	O
cell	O
lines	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

We	O
also	O
examined	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
anti	O
-	O
apoptotic	O
activity	O
in	O
response	O
to	O
stromal	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
SDF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
and	O
evaluated	O
SDF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
/	O
CXCR4	B-Gene_or_gene_product
signaling	O
pathways	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
SDF-1alpha	B-X
induced	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
Erk1/2	B-X
MAPK	B-X
but	B-X
did	B-X
not	B-X
promote	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
or	B-X
Akt	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

Furthermore	O
,	O
we	O
investigated	O
the	O
correlation	O
between	O
CXCR4	B-Gene_or_gene_product
expression	O
and	O
the	O
clinical	O
features	O
of	O
221	O
gastric	O
cancer	O
tissue	O
samples	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

CXCR4	B-Gene_or_gene_product
transcripts	O
and	O
proteins	O
were	O
detectable	O
in	O
all	O
five	O
gastric	O
cancer	O
cell	O
lines	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

However	O
,	O
MKN	O
-	O
28	O
,	O
MKN	O
-	O
45	O
,	O
MKN	O
-	O
74	O
,	O
and	O
SNU16	O
cells	O
did	O
not	O
express	O
membrane	O
CXCR4	B-Gene_or_gene_product
.	O

In	O
contrast	O
,	O
KATO	O
III	O
cells	O
expressed	O
membrane	O
CXCR4	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

In	O
these	O
cells	O
,	O
SDF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
-	O
induced	O
migration	O
was	O
observed	O
and	O
was	O
blocked	O
by	O
AMD3100	O
,	O
a	O
specific	O
inhibitor	O
of	O
CXCR4	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
SDF-1alpha	B-X
induced	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
Erk1/2	B-X
MAPK	B-X
but	B-X
did	B-X
not	B-X
promote	B-X
phosphorylation	B-X
of	B-X
Stat3	B-X
or	B-X
Akt	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

SDF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
induced	O
rapid	O
phosphorylation	O
of	O
Erk1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	I-Gene_or_gene_product
MAPK	I-Gene_or_gene_product
but	O
did	O
not	O
promote	O
phosphorylation	O
of	O
Stat3	B-Gene_or_gene_product
or	O
Akt	B-Gene_or_gene_product
.	O
<EOS>	B-X
Akt	B-X
is	B-X
a	B-X
serine/threonine	B-X
kinase	B-X
and	B-X
it	B-X
participates	B-X
in	B-X
the	B-X
key	B-X
role	B-X
of	B-X
the	B-X
PI3K	B-X
signaling	B-X
pathway	B-X
.	B-X
The	B-X
Akt	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
growth	B-X
signals	B-X
and	B-X
the	B-X
biochemical	B-X
mechanisms	B-X
leading	B-X
to	B-X
Akt	B-X
activation	B-X
are	B-X
well	B-X
defined	B-X
.	B-X
Once	B-X
activated	B-X
,	B-X
Akt	B-X
modulates	B-X
the	B-X
function	B-X
of	B-X
many	B-X
downstream	B-X
proteins	B-X
involved	B-X
in	B-X
cellular	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
metabolism	B-X
,	B-X
and	B-X
angiogenesis	B-X
.	B-X
The	B-X
Akt	B-X
is	B-X
a	B-X
central	B-X
node	B-X
of	B-X
many	B-X
signaling	B-X
pathways	B-X
and	B-X
it	B-X
is	B-X
frequently	B-X
deregulated	B-X
in	B-X
many	B-X
types	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
Akt	B-X
function	B-X
and	B-X
its	B-X
role	B-X
in	B-X
the	B-X
hallmarks	B-X
of	B-X
human	B-X
cancer	B-X
.	B-X
We	B-X
also	B-X
discussed	B-X
various	B-X
mechanisms	B-X
of	B-X
Akt	B-X
dysregulation	B-X
in	B-X
cancers	B-X
,	B-X
including	B-X
epigenetic	B-X
modifications	B-X
like	B-X
methylation	B-X
,	B-X
post-transcriptional	B-X
non-coding	B-X
RNAs-mediated	B-X
regulation	B-X
,	B-X
and	B-X
the	B-X
overexpression	B-X
and	B-X
mutation	B-X
.	B-X

Gastric	O
cancer	O
tissue	O
samples	O
expressed	O
CXCR4	B-Gene_or_gene_product
with	O
variable	O
intensities	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

Strong	O
CXCR4	B-Gene_or_gene_product
expression	O
was	O
significantly	O
associated	O
with	O
lymph	O
node	O
metastases	O
(	O
P	O
=	O
0	O
.	O
028	O
)	O
and	O
higher	O
stages	O
III	O
/	O
IV	O
(	O
P	O
=	O
0	O
.	O
047	O
)	O
,	O
and	O
further	O
tended	O
to	O
be	O
correlated	O
with	O
a	O
reduced	O
5	O
-	O
year	O
survival	O
rate	O
(	O
42	O
.	O
6	O
%	O
vs	O
.	O
53	O
.	O
9	O
%	O
;	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

In	O
conclusion	O
,	O
CXCR4	B-Gene_or_gene_product
expression	O
is	O
associated	O
with	O
gastric	O
cancer	O
cell	O
migration	O
in	O
vitro	O
,	O
and	O
strong	O
expression	O
of	O
CXCR4	B-Gene_or_gene_product
by	O
gastric	O
cancer	O
cells	O
is	O
significantly	O
associated	O
with	O
lymphatic	O
metastasis	O
in	O
patients	O
with	O
gastric	O
cancer	O
,	O
suggesting	O
that	O
CXCR4	B-Gene_or_gene_product
plays	O
an	O
important	O
role	O
during	O
gastric	O
cancer	O
progression	O
.	O
<EOS>	B-X
The	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
cancer	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
expression	B-X
and	B-X
function	B-X
of	B-X
CXCR4	B-X
in	B-X
human	B-X
gastric	B-X
cancer	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
disease	B-X
prognosis	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
CXCR4	B-X
using	B-X
RT-PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
and	B-X
confocal	B-X
microscopy	B-X
in	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
(	B-X
SDF	B-X
)	B-X
-1alpha	B-X
and	B-X
evaluated	B-X
SDF-1alpha/CXCR4	B-X
signaling	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
CXCR4	B-X
expression	B-X
and	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
221	B-X
gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
.	B-X
CXCR4	B-X
transcripts	B-X
and	B-X
proteins	B-X
were	B-X
detectable	B-X
in	B-X
all	B-X
five	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
MKN-28	B-X
,	B-X
MKN-45	B-X
,	B-X
MKN-74	B-X
,	B-X
and	B-X
SNU16	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KATO	B-X
III	B-X
cells	B-X
expressed	B-X
membrane	B-X
CXCR4	B-X
.	B-X
In	B-X
these	B-X
cells	B-X
,	B-X
SDF-1alpha-induced	B-X
migration	B-X
was	B-X
observed	B-X
and	B-X
was	B-X
blocked	B-X
by	B-X
AMD3100	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
CXCR4	B-X
.	B-X
Gastric	B-X
cancer	B-X
tissue	B-X
samples	B-X
expressed	B-X
CXCR4	B-X
with	B-X
variable	B-X
intensities	B-X
.	B-X
Strong	B-X
CXCR4	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
lymph	B-X
node	B-X
metastases	B-X
(	B-X
P=0.028	B-X
)	B-X
and	B-X
higher	B-X
stages	B-X
III/IV	B-X
(	B-X
P=0.047	B-X
)	B-X
,	B-X
and	B-X
further	B-X
tended	B-X
to	B-X
be	B-X
correlated	B-X
with	B-X
a	B-X
reduced	B-X
5-year	B-X
survival	B-X
rate	B-X
(	B-X
42.6	B-X
%	B-X
vs.	B-X
53.9	B-X
%	B-X
;	B-X
P=0.1	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CXCR4	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
gastric	B-X
cancer	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
CXCR4	B-X
by	B-X
gastric	B-X
cancer	B-X
cells	B-X
is	B-X
significantly	B-X
associated	B-X
with	B-X
lymphatic	B-X
metastasis	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
,	B-X
suggesting	B-X
that	B-X
CXCR4	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
during	B-X
gastric	B-X
cancer	B-X
progression	B-X
.	B-X

Effect	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	O
activation	O
during	O
wound	O
healing	O
.	O
<EOS>	B-X
Age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
leads	B-X
to	B-X
substantial	B-X
morbidity	B-X
and	B-X
mortality	B-X
along	B-X
with	B-X
a	B-X
large	B-X
financial	B-X
burden	B-X
to	B-X
health	B-X
services	B-X
.	B-X
There	B-X
is	B-X
accumulating	B-X
evidence	B-X
that	B-X
the	B-X
tissue	B-X
damage	B-X
associated	B-X
with	B-X
chronic	B-X
wounds	B-X
is	B-X
initiated	B-X
and	B-X
propagated	B-X
by	B-X
an	B-X
inappropriately	B-X
excessive	B-X
inflammatory	B-X
response	B-X
.	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Topical	B-X
and	B-X
systemic	B-X
estrogen	B-X
treatments	B-X
have	B-X
shown	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
healing	B-X
by	B-X
reducing	B-X
inflammation	B-X
,	B-X
however	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
little	B-X
understood	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
also	B-X
suggest	B-X
progesterone	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
modulating	B-X
inflammation	B-X
.	B-X
Macrophages	B-X
are	B-X
essential	B-X
mediators	B-X
of	B-X
inflammation	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
following	B-X
ovariectomy	B-X
,	B-X
alternatively	B-X
activated	B-X
macrophage	B-X
markers	B-X
(	B-X
Fizz1	B-X
and	B-X
Ym1	B-X
)	B-X
were	B-X
reduced	B-X
,	B-X
with	B-X
this	B-X
effect	B-X
being	B-X
reversed	B-X
with	B-X
the	B-X
administration	B-X
of	B-X
estrogen	B-X
or	B-X
progesterone	B-X
;	B-X
suggesting	B-X
that	B-X
with	B-X
the	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
macrophages	B-X
are	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
manner	B-X
,	B-X
promoting	B-X
inflammation	B-X
,	B-X
whereas	B-X
estrogen	B-X
or	B-X
progesterone	B-X
are	B-X
contributing	B-X
toward	B-X
macrophage	B-X
activation	B-X
in	B-X
an	B-X
alternative	B-X
manner	B-X
,	B-X
driving	B-X
wound	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
remodeling	B-X
.	B-X

Age	O
-	O
related	O
impaired	O
wound	O
healing	O
leads	O
to	O
substantial	O
morbidity	O
and	O
mortality	O
along	O
with	O
a	O
large	O
financial	O
burden	O
to	O
health	O
services	O
.	O
<EOS>	B-X
Age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
leads	B-X
to	B-X
substantial	B-X
morbidity	B-X
and	B-X
mortality	B-X
along	B-X
with	B-X
a	B-X
large	B-X
financial	B-X
burden	B-X
to	B-X
health	B-X
services	B-X
.	B-X
There	B-X
is	B-X
accumulating	B-X
evidence	B-X
that	B-X
the	B-X
tissue	B-X
damage	B-X
associated	B-X
with	B-X
chronic	B-X
wounds	B-X
is	B-X
initiated	B-X
and	B-X
propagated	B-X
by	B-X
an	B-X
inappropriately	B-X
excessive	B-X
inflammatory	B-X
response	B-X
.	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Topical	B-X
and	B-X
systemic	B-X
estrogen	B-X
treatments	B-X
have	B-X
shown	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
healing	B-X
by	B-X
reducing	B-X
inflammation	B-X
,	B-X
however	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
little	B-X
understood	B-X
.	B-X
Macrophages	B-X
are	B-X
essential	B-X
mediators	B-X
of	B-X
inflammation	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
following	B-X
ovariectomy	B-X
,	B-X
alternatively	B-X
activated	B-X
macrophage	B-X
markers	B-X
(	B-X
Fizz1	B-X
and	B-X
Ym1	B-X
)	B-X
were	B-X
reduced	B-X
,	B-X
with	B-X
this	B-X
effect	B-X
being	B-X
reversed	B-X
with	B-X
the	B-X
administration	B-X
of	B-X
estrogen	B-X
or	B-X
progesterone	B-X
;	B-X
suggesting	B-X
that	B-X
with	B-X
the	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
macrophages	B-X
are	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
manner	B-X
,	B-X
promoting	B-X
inflammation	B-X
,	B-X
whereas	B-X
estrogen	B-X
or	B-X
progesterone	B-X
are	B-X
contributing	B-X
toward	B-X
macrophage	B-X
activation	B-X
in	B-X
an	B-X
alternative	B-X
manner	B-X
,	B-X
driving	B-X
wound	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
remodeling	B-X
.	B-X

There	O
is	O
accumulating	O
evidence	O
that	O
the	O
tissue	O
damage	O
associated	O
with	O
chronic	O
wounds	O
is	O
initiated	O
and	O
propagated	O
by	O
an	O
inappropriately	O
excessive	O
inflammatory	O
response	O
.	O
<EOS>	B-X
There	B-X
is	B-X
accumulating	B-X
evidence	B-X
that	B-X
the	B-X
tissue	B-X
damage	B-X
associated	B-X
with	B-X
chronic	B-X
wounds	B-X
is	B-X
initiated	B-X
and	B-X
propagated	B-X
by	B-X
an	B-X
inappropriately	B-X
excessive	B-X
inflammatory	B-X
response	B-X
.	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X

Research	O
on	O
age	O
-	O
related	O
impaired	O
wound	O
healing	O
suggests	O
that	O
the	O
decline	O
in	O
sex	O
steroid	O
hormones	O
with	O
age	O
may	O
have	O
a	O
substantial	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
vivo	O
.	O
<EOS>	B-X
Age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
leads	B-X
to	B-X
substantial	B-X
morbidity	B-X
and	B-X
mortality	B-X
along	B-X
with	B-X
a	B-X
large	B-X
financial	B-X
burden	B-X
to	B-X
health	B-X
services	B-X
.	B-X
There	B-X
is	B-X
accumulating	B-X
evidence	B-X
that	B-X
the	B-X
tissue	B-X
damage	B-X
associated	B-X
with	B-X
chronic	B-X
wounds	B-X
is	B-X
initiated	B-X
and	B-X
propagated	B-X
by	B-X
an	B-X
inappropriately	B-X
excessive	B-X
inflammatory	B-X
response	B-X
.	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Topical	B-X
and	B-X
systemic	B-X
estrogen	B-X
treatments	B-X
have	B-X
shown	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
healing	B-X
by	B-X
reducing	B-X
inflammation	B-X
,	B-X
however	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
little	B-X
understood	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
also	B-X
suggest	B-X
progesterone	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
modulating	B-X
inflammation	B-X
.	B-X
Macrophages	B-X
are	B-X
essential	B-X
mediators	B-X
of	B-X
inflammation	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Macrophages	B-X
can	B-X
be	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
or	B-X
alternative	B-X
manner	B-X
in	B-X
parallel	B-X
with	B-X
the	B-X
T	B-X
(	B-X
H	B-X
)	B-X
1/T	B-X
(	B-X
H	B-X
)	B-X
2	B-X
dichotomy	B-X
,	B-X
respectively	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
following	B-X
ovariectomy	B-X
,	B-X
alternatively	B-X
activated	B-X
macrophage	B-X
markers	B-X
(	B-X
Fizz1	B-X
and	B-X
Ym1	B-X
)	B-X
were	B-X
reduced	B-X
,	B-X
with	B-X
this	B-X
effect	B-X
being	B-X
reversed	B-X
with	B-X
the	B-X
administration	B-X
of	B-X
estrogen	B-X
or	B-X
progesterone	B-X
;	B-X
suggesting	B-X
that	B-X
with	B-X
the	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
macrophages	B-X
are	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
manner	B-X
,	B-X
promoting	B-X
inflammation	B-X
,	B-X
whereas	B-X
estrogen	B-X
or	B-X
progesterone	B-X
are	B-X
contributing	B-X
toward	B-X
macrophage	B-X
activation	B-X
in	B-X
an	B-X
alternative	B-X
manner	B-X
,	B-X
driving	B-X
wound	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
remodeling	B-X
.	B-X

Topical	O
and	O
systemic	O
estrogen	O
treatments	O
have	O
shown	O
an	O
increased	O
rate	O
of	O
healing	O
by	O
reducing	O
inflammation	O
,	O
however	O
the	O
underlying	O
mechanisms	O
are	O
little	O
understood	O
.	O
<EOS>	B-X
Age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
leads	B-X
to	B-X
substantial	B-X
morbidity	B-X
and	B-X
mortality	B-X
along	B-X
with	B-X
a	B-X
large	B-X
financial	B-X
burden	B-X
to	B-X
health	B-X
services	B-X
.	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Topical	B-X
and	B-X
systemic	B-X
estrogen	B-X
treatments	B-X
have	B-X
shown	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
healing	B-X
by	B-X
reducing	B-X
inflammation	B-X
,	B-X
however	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
little	B-X
understood	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
also	B-X
suggest	B-X
progesterone	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
modulating	B-X
inflammation	B-X
.	B-X
Macrophages	B-X
are	B-X
essential	B-X
mediators	B-X
of	B-X
inflammation	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
following	B-X
ovariectomy	B-X
,	B-X
alternatively	B-X
activated	B-X
macrophage	B-X
markers	B-X
(	B-X
Fizz1	B-X
and	B-X
Ym1	B-X
)	B-X
were	B-X
reduced	B-X
,	B-X
with	B-X
this	B-X
effect	B-X
being	B-X
reversed	B-X
with	B-X
the	B-X
administration	B-X
of	B-X
estrogen	B-X
or	B-X
progesterone	B-X
;	B-X
suggesting	B-X
that	B-X
with	B-X
the	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
macrophages	B-X
are	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
manner	B-X
,	B-X
promoting	B-X
inflammation	B-X
,	B-X
whereas	B-X
estrogen	B-X
or	B-X
progesterone	B-X
are	B-X
contributing	B-X
toward	B-X
macrophage	B-X
activation	B-X
in	B-X
an	B-X
alternative	B-X
manner	B-X
,	B-X
driving	B-X
wound	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
remodeling	B-X
.	B-X

In	O
vitro	O
studies	O
also	O
suggest	O
progesterone	O
may	O
play	O
a	O
role	O
in	O
modulating	O
inflammation	O
.	O
<EOS>	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Topical	B-X
and	B-X
systemic	B-X
estrogen	B-X
treatments	B-X
have	B-X
shown	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
healing	B-X
by	B-X
reducing	B-X
inflammation	B-X
,	B-X
however	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
little	B-X
understood	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
also	B-X
suggest	B-X
progesterone	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
modulating	B-X
inflammation	B-X
.	B-X
Macrophages	B-X
are	B-X
essential	B-X
mediators	B-X
of	B-X
inflammation	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
following	B-X
ovariectomy	B-X
,	B-X
alternatively	B-X
activated	B-X
macrophage	B-X
markers	B-X
(	B-X
Fizz1	B-X
and	B-X
Ym1	B-X
)	B-X
were	B-X
reduced	B-X
,	B-X
with	B-X
this	B-X
effect	B-X
being	B-X
reversed	B-X
with	B-X
the	B-X
administration	B-X
of	B-X
estrogen	B-X
or	B-X
progesterone	B-X
;	B-X
suggesting	B-X
that	B-X
with	B-X
the	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
macrophages	B-X
are	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
manner	B-X
,	B-X
promoting	B-X
inflammation	B-X
,	B-X
whereas	B-X
estrogen	B-X
or	B-X
progesterone	B-X
are	B-X
contributing	B-X
toward	B-X
macrophage	B-X
activation	B-X
in	B-X
an	B-X
alternative	B-X
manner	B-X
,	B-X
driving	B-X
wound	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
remodeling	B-X
.	B-X

Macrophages	O
are	O
essential	O
mediators	O
of	O
inflammation	O
and	O
wound	O
healing	O
.	O
<EOS>	B-X
Many	B-X
instances	B-X
lead	B-X
to	B-X
inadequate	B-X
wound	B-X
healing	B-X
which	B-X
necessitates	B-X
medical	B-X
intervention	B-X
.	B-X
Chronic	B-X
conditions	B-X
such	B-X
as	B-X
diabetes	B-X
mellitus	B-X
or	B-X
peripheral	B-X
vascular	B-X
disease	B-X
can	B-X
lead	B-X
to	B-X
impaired	B-X
wound	B-X
healing	B-X
.	B-X
Mononuclear	B-X
phagocyte	B-X
plasticity	B-X
includes	B-X
the	B-X
expression	B-X
of	B-X
functions	B-X
related	B-X
to	B-X
the	B-X
resolution	B-X
of	B-X
inflammation	B-X
,	B-X
tissue	B-X
repair	B-X
and	B-X
remodelling	B-X
,	B-X
particularly	B-X
when	B-X
these	B-X
cells	B-X
are	B-X
set	B-X
in	B-X
an	B-X
M2	B-X
or	B-X
an	B-X
M2-like	B-X
activation	B-X
mode	B-X
.	B-X
Macrophages	B-X
are	B-X
credited	B-X
with	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
remodelling	B-X
during	B-X
ontogenesis	B-X
.	B-X
In	B-X
pathology	B-X
,	B-X
macrophages	B-X
are	B-X
key	B-X
components	B-X
of	B-X
tissue	B-X
repair	B-X
and	B-X
remodelling	B-X
that	B-X
occur	B-X
during	B-X
wound	B-X
healing	B-X
,	B-X
allergy	B-X
,	B-X
parasite	B-X
infection	B-X
and	B-X
cancer	B-X
.	B-X

Macrophages	O
can	O
be	O
activated	O
in	O
a	O
classical	O
or	O
alternative	O
manner	O
in	O
parallel	O
with	O
the	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
dichotomy	O
,	O
respectively	O
.	O

Using	O
a	O
murine	O
incisional	O
wound	O
healing	O
model	O
this	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
roles	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	O
activation	O
during	O
the	O
wound	O
healing	O
response	O
.	O
<EOS>	B-X
Age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
leads	B-X
to	B-X
substantial	B-X
morbidity	B-X
and	B-X
mortality	B-X
along	B-X
with	B-X
a	B-X
large	B-X
financial	B-X
burden	B-X
to	B-X
health	B-X
services	B-X
.	B-X
There	B-X
is	B-X
accumulating	B-X
evidence	B-X
that	B-X
the	B-X
tissue	B-X
damage	B-X
associated	B-X
with	B-X
chronic	B-X
wounds	B-X
is	B-X
initiated	B-X
and	B-X
propagated	B-X
by	B-X
an	B-X
inappropriately	B-X
excessive	B-X
inflammatory	B-X
response	B-X
.	B-X
Research	B-X
on	B-X
age-related	B-X
impaired	B-X
wound	B-X
healing	B-X
suggests	B-X
that	B-X
the	B-X
decline	B-X
in	B-X
sex	B-X
steroid	B-X
hormones	B-X
with	B-X
age	B-X
may	B-X
have	B-X
a	B-X
substantial	B-X
influence	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Topical	B-X
and	B-X
systemic	B-X
estrogen	B-X
treatments	B-X
have	B-X
shown	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
healing	B-X
by	B-X
reducing	B-X
inflammation	B-X
,	B-X
however	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
little	B-X
understood	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
also	B-X
suggest	B-X
progesterone	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
modulating	B-X
inflammation	B-X
.	B-X
Macrophages	B-X
are	B-X
essential	B-X
mediators	B-X
of	B-X
inflammation	B-X
and	B-X
wound	B-X
healing	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
incisional	B-X
wound	B-X
healing	B-X
model	B-X
this	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
on	B-X
macrophage	B-X
activation	B-X
during	B-X
the	B-X
wound	B-X
healing	B-X
response	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
following	B-X
ovariectomy	B-X
,	B-X
alternatively	B-X
activated	B-X
macrophage	B-X
markers	B-X
(	B-X
Fizz1	B-X
and	B-X
Ym1	B-X
)	B-X
were	B-X
reduced	B-X
,	B-X
with	B-X
this	B-X
effect	B-X
being	B-X
reversed	B-X
with	B-X
the	B-X
administration	B-X
of	B-X
estrogen	B-X
or	B-X
progesterone	B-X
;	B-X
suggesting	B-X
that	B-X
with	B-X
the	B-X
reduction	B-X
of	B-X
steroid	B-X
hormones	B-X
macrophages	B-X
are	B-X
activated	B-X
in	B-X
a	B-X
classical	B-X
manner	B-X
,	B-X
promoting	B-X
inflammation	B-X
,	B-X
whereas	B-X
estrogen	B-X
or	B-X
progesterone	B-X
are	B-X
contributing	B-X
toward	B-X
macrophage	B-X
activation	B-X
in	B-X
an	B-X
alternative	B-X
manner	B-X
,	B-X
driving	B-X
wound	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
remodeling	B-X
.	B-X

Our	O
findings	O
suggest	O
with	O
a	O
reduction	O
of	O
steroid	O
hormones	O
following	O
ovariectomy	O
,	O
alternatively	O
activated	O
macrophage	O
markers	O
(	O
Fizz1	B-Gene_or_gene_product
and	O
Ym1	B-Gene_or_gene_product
)	O
were	O
reduced	O
,	O
with	O
this	O
effect	O
being	O
reversed	O
with	O
the	O
administration	O
of	O
estrogen	O
or	O
progesterone	O
;	O
suggesting	O
that	O
with	O
the	O
reduction	O
of	O
steroid	O
hormones	O
macrophages	O
are	O
activated	O
in	O
a	O
classical	O
manner	O
,	O
promoting	O
inflammation	O
,	O
whereas	O
estrogen	O
or	O
progesterone	O
are	O
contributing	O
toward	O
macrophage	O
activation	O
in	O
an	O
alternative	O
manner	O
,	O
driving	O
wound	O
repair	O
,	O
angiogenesis	O
,	O
and	O
remodeling	O
.	O
<EOS>	B-X
This	B-X
chapter	B-X
explores	B-X
the	B-X
role	B-X
of	B-X
progesterone	B-X
and	B-X
progestogens	B-X
in	B-X
the	B-X
management	B-X
of	B-X
abnormal	B-X
uterine	B-X
bleeding	B-X
(	B-X
AUB	B-X
)	B-X
.	B-X
In	B-X
menopausal	B-X
women	B-X
,	B-X
progesterones	B-X
and	B-X
progestogens	B-X
prevent	B-X
endometrial	B-X
hyperplasia	B-X
and	B-X
aim	B-X
to	B-X
reduce	B-X
the	B-X
development	B-X
of	B-X
endometrial	B-X
cancer	B-X
.	B-X
Progesterone	B-X
also	B-X
acts	B-X
in	B-X
concert	B-X
with	B-X
other	B-X
hormones	B-X
to	B-X
affect	B-X
breast	B-X
,	B-X
cardiovascular	B-X
system	B-X
,	B-X
lipid	B-X
profile	B-X
and	B-X
bone	B-X
.	B-X
We	B-X
hope	B-X
to	B-X
explain	B-X
how	B-X
its	B-X
unintended	B-X
side	B-X
effects	B-X
may	B-X
be	B-X
used	B-X
beneficially	B-X
or	B-X
may	B-X
cause	B-X
intended	B-X
side	B-X
effects	B-X
.	B-X

Effect	O
of	O
platelet	O
-	O
rich	O
plasma	O
and	O
fibrin	B-Gene_or_gene_product
glue	O
on	O
healing	O
of	O
critical	O
-	O
size	O
calvarial	O
bone	O
defects	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
insufficient	B-X
number	B-X
of	B-X
experimental	B-X
studies	B-X
,	B-X
platelet-rich	B-X
plasma	B-X
(	B-X
PRP	B-X
)	B-X
including	B-X
high	B-X
amounts	B-X
of	B-X
growth	B-X
factors	B-X
is	B-X
introduced	B-X
to	B-X
clinical	B-X
use	B-X
rapidly	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
and	B-X
platelet-poor	B-X
plasma	B-X
(	B-X
PPP	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
critical-size	B-X
bone	B-X
defects.Bilateral	B-X
full-thickness	B-X
,	B-X
critical-size	B-X
bone	B-X
defects	B-X
were	B-X
created	B-X
in	B-X
the	B-X
parietal	B-X
bones	B-X
of	B-X
32	B-X
rabbits	B-X
,	B-X
which	B-X
had	B-X
been	B-X
studied	B-X
in	B-X
4	B-X
groups	B-X
.	B-X
Saline	B-X
,	B-X
thrombin	B-X
solution	B-X
,	B-X
PPP	B-X
,	B-X
and	B-X
PRP	B-X
were	B-X
applied	B-X
to	B-X
the	B-X
created	B-X
defects	B-X
before	B-X
closure	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
densities	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
bones	B-X
at	B-X
16th	B-X
week	B-X
were	B-X
studied	B-X
.	B-X
Histologic	B-X
parameters	B-X
(	B-X
primary	B-X
and	B-X
secondary	B-X
bone	B-X
trabecula	B-X
,	B-X
neovascularization	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
and	B-X
connective	B-X
tissue	B-X
formation	B-X
)	B-X
were	B-X
compared	B-X
between	B-X
4-	B-X
and	B-X
16-week	B-X
groups.More	B-X
rapid	B-X
decrease	B-X
in	B-X
defect	B-X
size	B-X
was	B-X
observed	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
than	B-X
in	B-X
groups	B-X
1	B-X
and	B-X
2	B-X
,	B-X
both	B-X
in	B-X
the	B-X
4th	B-X
and	B-X
16th	B-X
weeks	B-X
.	B-X
Newly	B-X
formed	B-X
bone	B-X
densities	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
these	B-X
2	B-X
groups	B-X
.	B-X
New	B-X
bone	B-X
formation	B-X
was	B-X
detected	B-X
to	B-X
be	B-X
more	B-X
rapid	B-X
considering	B-X
histologic	B-X
parameters	B-X
,	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
at	B-X
4th	B-X
and	B-X
16th	B-X
weeks.Study	B-X
demonstrates	B-X
that	B-X
PRP	B-X
and	B-X
PPP	B-X
might	B-X
have	B-X
favorable	B-X
effects	B-X
on	B-X
bone	B-X
healing	B-X
.	B-X
Although	B-X
we	B-X
can	B-X
not	B-X
reveal	B-X
any	B-X
statistical	B-X
difference	B-X
between	B-X
these	B-X
2	B-X
substances	B-X
considering	B-X
osteoinductive	B-X
potential	B-X
,	B-X
PRP	B-X
group	B-X
has	B-X
demonstrated	B-X
superior	B-X
results	B-X
compared	B-X
with	B-X
fibrin	B-X
glue	B-X
group	B-X
.	B-X
Higher	B-X
platelet	B-X
concentrations	B-X
may	B-X
expose	B-X
beneficial	B-X
effects	B-X
of	B-X
PRP	B-X
.	B-X

Despite	O
the	O
insufficient	O
number	O
of	O
experimental	O
studies	O
,	O
platelet	O
-	O
rich	O
plasma	O
(	O
PRP	O
)	O
including	O
high	O
amounts	O
of	O
growth	O
factors	O
is	O
introduced	O
to	O
clinical	O
use	O
rapidly	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
insufficient	B-X
number	B-X
of	B-X
experimental	B-X
studies	B-X
,	B-X
platelet-rich	B-X
plasma	B-X
(	B-X
PRP	B-X
)	B-X
including	B-X
high	B-X
amounts	B-X
of	B-X
growth	B-X
factors	B-X
is	B-X
introduced	B-X
to	B-X
clinical	B-X
use	B-X
rapidly	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
and	B-X
platelet-poor	B-X
plasma	B-X
(	B-X
PPP	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
critical-size	B-X
bone	B-X
defects.Bilateral	B-X
full-thickness	B-X
,	B-X
critical-size	B-X
bone	B-X
defects	B-X
were	B-X
created	B-X
in	B-X
the	B-X
parietal	B-X
bones	B-X
of	B-X
32	B-X
rabbits	B-X
,	B-X
which	B-X
had	B-X
been	B-X
studied	B-X
in	B-X
4	B-X
groups	B-X
.	B-X
Saline	B-X
,	B-X
thrombin	B-X
solution	B-X
,	B-X
PPP	B-X
,	B-X
and	B-X
PRP	B-X
were	B-X
applied	B-X
to	B-X
the	B-X
created	B-X
defects	B-X
before	B-X
closure	B-X
.	B-X
Newly	B-X
formed	B-X
bone	B-X
densities	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
these	B-X
2	B-X
groups	B-X
.	B-X
New	B-X
bone	B-X
formation	B-X
was	B-X
detected	B-X
to	B-X
be	B-X
more	B-X
rapid	B-X
considering	B-X
histologic	B-X
parameters	B-X
,	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
at	B-X
4th	B-X
and	B-X
16th	B-X
weeks.Study	B-X
demonstrates	B-X
that	B-X
PRP	B-X
and	B-X
PPP	B-X
might	B-X
have	B-X
favorable	B-X
effects	B-X
on	B-X
bone	B-X
healing	B-X
.	B-X
Although	B-X
we	B-X
can	B-X
not	B-X
reveal	B-X
any	B-X
statistical	B-X
difference	B-X
between	B-X
these	B-X
2	B-X
substances	B-X
considering	B-X
osteoinductive	B-X
potential	B-X
,	B-X
PRP	B-X
group	B-X
has	B-X
demonstrated	B-X
superior	B-X
results	B-X
compared	B-X
with	B-X
fibrin	B-X
glue	B-X
group	B-X
.	B-X
Higher	B-X
platelet	B-X
concentrations	B-X
may	B-X
expose	B-X
beneficial	B-X
effects	B-X
of	B-X
PRP	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
PRP	O
and	O
platelet	O
-	O
poor	O
plasma	O
(	O
PPP	O
)	O
on	O
healing	O
of	O
critical	O
-	O
size	O
bone	O
defects	O
.	O
Bilateral	O
full	O
-	O
thickness	O
,	O
critical	O
-	O
size	O
bone	O
defects	O
were	O
created	O
in	O
the	O
parietal	O
bones	O
of	O
32	O
rabbits	O
,	O
which	O
had	O
been	O
studied	O
in	O
4	O
groups	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
insufficient	B-X
number	B-X
of	B-X
experimental	B-X
studies	B-X
,	B-X
platelet-rich	B-X
plasma	B-X
(	B-X
PRP	B-X
)	B-X
including	B-X
high	B-X
amounts	B-X
of	B-X
growth	B-X
factors	B-X
is	B-X
introduced	B-X
to	B-X
clinical	B-X
use	B-X
rapidly	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
and	B-X
platelet-poor	B-X
plasma	B-X
(	B-X
PPP	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
critical-size	B-X
bone	B-X
defects.Bilateral	B-X
full-thickness	B-X
,	B-X
critical-size	B-X
bone	B-X
defects	B-X
were	B-X
created	B-X
in	B-X
the	B-X
parietal	B-X
bones	B-X
of	B-X
32	B-X
rabbits	B-X
,	B-X
which	B-X
had	B-X
been	B-X
studied	B-X
in	B-X
4	B-X
groups	B-X
.	B-X
Saline	B-X
,	B-X
thrombin	B-X
solution	B-X
,	B-X
PPP	B-X
,	B-X
and	B-X
PRP	B-X
were	B-X
applied	B-X
to	B-X
the	B-X
created	B-X
defects	B-X
before	B-X
closure	B-X
.	B-X
Radiologic	B-X
defect	B-X
area	B-X
measurement	B-X
results	B-X
at	B-X
0	B-X
,	B-X
4	B-X
,	B-X
and	B-X
16	B-X
weeks	B-X
were	B-X
compared	B-X
between	B-X
the	B-X
groups	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
densities	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
bones	B-X
at	B-X
16th	B-X
week	B-X
were	B-X
studied	B-X
.	B-X
Histologic	B-X
parameters	B-X
(	B-X
primary	B-X
and	B-X
secondary	B-X
bone	B-X
trabecula	B-X
,	B-X
neovascularization	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
and	B-X
connective	B-X
tissue	B-X
formation	B-X
)	B-X
were	B-X
compared	B-X
between	B-X
4-	B-X
and	B-X
16-week	B-X
groups.More	B-X
rapid	B-X
decrease	B-X
in	B-X
defect	B-X
size	B-X
was	B-X
observed	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
than	B-X
in	B-X
groups	B-X
1	B-X
and	B-X
2	B-X
,	B-X
both	B-X
in	B-X
the	B-X
4th	B-X
and	B-X
16th	B-X
weeks	B-X
.	B-X
Newly	B-X
formed	B-X
bone	B-X
densities	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
these	B-X
2	B-X
groups	B-X
.	B-X
New	B-X
bone	B-X
formation	B-X
was	B-X
detected	B-X
to	B-X
be	B-X
more	B-X
rapid	B-X
considering	B-X
histologic	B-X
parameters	B-X
,	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
at	B-X
4th	B-X
and	B-X
16th	B-X
weeks.Study	B-X
demonstrates	B-X
that	B-X
PRP	B-X
and	B-X
PPP	B-X
might	B-X
have	B-X
favorable	B-X
effects	B-X
on	B-X
bone	B-X
healing	B-X
.	B-X
Although	B-X
we	B-X
can	B-X
not	B-X
reveal	B-X
any	B-X
statistical	B-X
difference	B-X
between	B-X
these	B-X
2	B-X
substances	B-X
considering	B-X
osteoinductive	B-X
potential	B-X
,	B-X
PRP	B-X
group	B-X
has	B-X
demonstrated	B-X
superior	B-X
results	B-X
compared	B-X
with	B-X
fibrin	B-X
glue	B-X
group	B-X
.	B-X
Higher	B-X
platelet	B-X
concentrations	B-X
may	B-X
expose	B-X
beneficial	B-X
effects	B-X
of	B-X
PRP	B-X
.	B-X

Saline	O
,	O
thrombin	B-Gene_or_gene_product
solution	O
,	O
PPP	O
,	O
and	O
PRP	O
were	O
applied	O
to	O
the	O
created	O
defects	O
before	O
closure	O
.	O

Radiologic	O
defect	O
area	O
measurement	O
results	O
at	O
0	O
,	O
4	O
,	O
and	O
16	O
weeks	O
were	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
densities	O
of	O
the	O
newly	O
formed	O
bones	O
at	O
16th	O
week	O
were	O
studied	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
and	B-X
platelet-poor	B-X
plasma	B-X
(	B-X
PPP	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
critical-size	B-X
bone	B-X
defects.Bilateral	B-X
full-thickness	B-X
,	B-X
critical-size	B-X
bone	B-X
defects	B-X
were	B-X
created	B-X
in	B-X
the	B-X
parietal	B-X
bones	B-X
of	B-X
32	B-X
rabbits	B-X
,	B-X
which	B-X
had	B-X
been	B-X
studied	B-X
in	B-X
4	B-X
groups	B-X
.	B-X
Radiologic	B-X
defect	B-X
area	B-X
measurement	B-X
results	B-X
at	B-X
0	B-X
,	B-X
4	B-X
,	B-X
and	B-X
16	B-X
weeks	B-X
were	B-X
compared	B-X
between	B-X
the	B-X
groups	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
densities	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
bones	B-X
at	B-X
16th	B-X
week	B-X
were	B-X
studied	B-X
.	B-X
Histologic	B-X
parameters	B-X
(	B-X
primary	B-X
and	B-X
secondary	B-X
bone	B-X
trabecula	B-X
,	B-X
neovascularization	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
and	B-X
connective	B-X
tissue	B-X
formation	B-X
)	B-X
were	B-X
compared	B-X
between	B-X
4-	B-X
and	B-X
16-week	B-X
groups.More	B-X
rapid	B-X
decrease	B-X
in	B-X
defect	B-X
size	B-X
was	B-X
observed	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
than	B-X
in	B-X
groups	B-X
1	B-X
and	B-X
2	B-X
,	B-X
both	B-X
in	B-X
the	B-X
4th	B-X
and	B-X
16th	B-X
weeks	B-X
.	B-X
Newly	B-X
formed	B-X
bone	B-X
densities	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
these	B-X
2	B-X
groups	B-X
.	B-X
New	B-X
bone	B-X
formation	B-X
was	B-X
detected	B-X
to	B-X
be	B-X
more	B-X
rapid	B-X
considering	B-X
histologic	B-X
parameters	B-X
,	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
at	B-X
4th	B-X
and	B-X
16th	B-X
weeks.Study	B-X
demonstrates	B-X
that	B-X
PRP	B-X
and	B-X
PPP	B-X
might	B-X
have	B-X
favorable	B-X
effects	B-X
on	B-X
bone	B-X
healing	B-X
.	B-X

Histologic	O
parameters	O
(	O
primary	O
and	O
secondary	O
bone	O
trabecula	O
,	O
neovascularization	O
,	O
and	O
bone	O
marrow	O
and	O
connective	O
tissue	O
formation	O
)	O
were	O
compared	O
between	O
4	O
-	O
and	O
16	O
-	O
week	O
groups	O
.	O
More	O
rapid	O
decrease	O
in	O
defect	O
size	O
was	O
observed	O
in	O
groups	O
3	O
and	O
4	O
than	O
in	O
groups	O
1	O
and	O
2	O
,	O
both	O
in	O
the	O
4th	O
and	O
16th	O
weeks	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
insufficient	B-X
number	B-X
of	B-X
experimental	B-X
studies	B-X
,	B-X
platelet-rich	B-X
plasma	B-X
(	B-X
PRP	B-X
)	B-X
including	B-X
high	B-X
amounts	B-X
of	B-X
growth	B-X
factors	B-X
is	B-X
introduced	B-X
to	B-X
clinical	B-X
use	B-X
rapidly	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
and	B-X
platelet-poor	B-X
plasma	B-X
(	B-X
PPP	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
critical-size	B-X
bone	B-X
defects.Bilateral	B-X
full-thickness	B-X
,	B-X
critical-size	B-X
bone	B-X
defects	B-X
were	B-X
created	B-X
in	B-X
the	B-X
parietal	B-X
bones	B-X
of	B-X
32	B-X
rabbits	B-X
,	B-X
which	B-X
had	B-X
been	B-X
studied	B-X
in	B-X
4	B-X
groups	B-X
.	B-X
Saline	B-X
,	B-X
thrombin	B-X
solution	B-X
,	B-X
PPP	B-X
,	B-X
and	B-X
PRP	B-X
were	B-X
applied	B-X
to	B-X
the	B-X
created	B-X
defects	B-X
before	B-X
closure	B-X
.	B-X
Radiologic	B-X
defect	B-X
area	B-X
measurement	B-X
results	B-X
at	B-X
0	B-X
,	B-X
4	B-X
,	B-X
and	B-X
16	B-X
weeks	B-X
were	B-X
compared	B-X
between	B-X
the	B-X
groups	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
densities	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
bones	B-X
at	B-X
16th	B-X
week	B-X
were	B-X
studied	B-X
.	B-X
Histologic	B-X
parameters	B-X
(	B-X
primary	B-X
and	B-X
secondary	B-X
bone	B-X
trabecula	B-X
,	B-X
neovascularization	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
and	B-X
connective	B-X
tissue	B-X
formation	B-X
)	B-X
were	B-X
compared	B-X
between	B-X
4-	B-X
and	B-X
16-week	B-X
groups.More	B-X
rapid	B-X
decrease	B-X
in	B-X
defect	B-X
size	B-X
was	B-X
observed	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
than	B-X
in	B-X
groups	B-X
1	B-X
and	B-X
2	B-X
,	B-X
both	B-X
in	B-X
the	B-X
4th	B-X
and	B-X
16th	B-X
weeks	B-X
.	B-X
Newly	B-X
formed	B-X
bone	B-X
densities	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
these	B-X
2	B-X
groups	B-X
.	B-X
New	B-X
bone	B-X
formation	B-X
was	B-X
detected	B-X
to	B-X
be	B-X
more	B-X
rapid	B-X
considering	B-X
histologic	B-X
parameters	B-X
,	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
at	B-X
4th	B-X
and	B-X
16th	B-X
weeks.Study	B-X
demonstrates	B-X
that	B-X
PRP	B-X
and	B-X
PPP	B-X
might	B-X
have	B-X
favorable	B-X
effects	B-X
on	B-X
bone	B-X
healing	B-X
.	B-X
Although	B-X
we	B-X
can	B-X
not	B-X
reveal	B-X
any	B-X
statistical	B-X
difference	B-X
between	B-X
these	B-X
2	B-X
substances	B-X
considering	B-X
osteoinductive	B-X
potential	B-X
,	B-X
PRP	B-X
group	B-X
has	B-X
demonstrated	B-X
superior	B-X
results	B-X
compared	B-X
with	B-X
fibrin	B-X
glue	B-X
group	B-X
.	B-X

Newly	O
formed	O
bone	O
densities	O
were	O
also	O
found	O
to	O
be	O
higher	O
in	O
these	O
2	O
groups	O
.	O
<EOS>	B-X
Many	B-X
biomaterials	B-X
are	B-X
used	B-X
for	B-X
Bone	B-X
Morphogenetic	B-X
Proteins	B-X
(	B-X
BMPs	B-X
)	B-X
delivery	B-X
in	B-X
bone	B-X
tissue	B-X
engineering	B-X
.	B-X
The	B-X
BMP	B-X
carrier	B-X
system	B-X
's	B-X
primary	B-X
function	B-X
is	B-X
to	B-X
hold	B-X
these	B-X
growth	B-X
factors	B-X
at	B-X
the	B-X
wound	B-X
's	B-X
site	B-X
for	B-X
a	B-X
prolonged	B-X
time	B-X
and	B-X
provide	B-X
initial	B-X
support	B-X
for	B-X
cells	B-X
to	B-X
attach	B-X
and	B-X
elaborate	B-X
the	B-X
extracellular	B-X
matrix	B-X
for	B-X
bone	B-X
regeneration	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
nanostructured	B-X
carbonated	B-X
hydroxyapatite	B-X
microspheres	B-X
(	B-X
nCHA	B-X
)	B-X
as	B-X
an	B-X
rhBMP-2	B-X
carrier	B-X
on	B-X
rats	B-X
calvaria	B-X
.	B-X
A	B-X
total	B-X
of	B-X
fifteen	B-X
male	B-X
Wistar	B-X
rats	B-X
were	B-X
randomly	B-X
divided	B-X
into	B-X
three	B-X
groups	B-X
(	B-X

New	O
bone	O
formation	O
was	O
detected	O
to	O
be	O
more	O
rapid	O
considering	O
histologic	O
parameters	O
,	O
in	O
groups	O
3	O
and	O
4	O
at	O
4th	O
and	O
16th	O
weeks	O
.	O
Study	O
demonstrates	O
that	O
PRP	O
and	O
PPP	O
might	O
have	O
favorable	O
effects	O
on	O
bone	O
healing	O
.	O

Although	O
we	O
cannot	O
reveal	O
any	O
statistical	O
difference	O
between	O
these	O
2	O
substances	O
considering	O
osteoinductive	O
potential	O
,	O
PRP	O
group	O
has	O
demonstrated	O
superior	O
results	O
compared	O
with	O
fibrin	B-Gene_or_gene_product
glue	O
group	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
insufficient	B-X
number	B-X
of	B-X
experimental	B-X
studies	B-X
,	B-X
platelet-rich	B-X
plasma	B-X
(	B-X
PRP	B-X
)	B-X
including	B-X
high	B-X
amounts	B-X
of	B-X
growth	B-X
factors	B-X
is	B-X
introduced	B-X
to	B-X
clinical	B-X
use	B-X
rapidly	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
and	B-X
platelet-poor	B-X
plasma	B-X
(	B-X
PPP	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
critical-size	B-X
bone	B-X
defects.Bilateral	B-X
full-thickness	B-X
,	B-X
critical-size	B-X
bone	B-X
defects	B-X
were	B-X
created	B-X
in	B-X
the	B-X
parietal	B-X
bones	B-X
of	B-X
32	B-X
rabbits	B-X
,	B-X
which	B-X
had	B-X
been	B-X
studied	B-X
in	B-X
4	B-X
groups	B-X
.	B-X
Saline	B-X
,	B-X
thrombin	B-X
solution	B-X
,	B-X
PPP	B-X
,	B-X
and	B-X
PRP	B-X
were	B-X
applied	B-X
to	B-X
the	B-X
created	B-X
defects	B-X
before	B-X
closure	B-X
.	B-X
Radiologic	B-X
defect	B-X
area	B-X
measurement	B-X
results	B-X
at	B-X
0	B-X
,	B-X
4	B-X
,	B-X
and	B-X
16	B-X
weeks	B-X
were	B-X
compared	B-X
between	B-X
the	B-X
groups	B-X
.	B-X
Histologic	B-X
parameters	B-X
(	B-X
primary	B-X
and	B-X
secondary	B-X
bone	B-X
trabecula	B-X
,	B-X
neovascularization	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
and	B-X
connective	B-X
tissue	B-X
formation	B-X
)	B-X
were	B-X
compared	B-X
between	B-X
4-	B-X
and	B-X
16-week	B-X
groups.More	B-X
rapid	B-X
decrease	B-X
in	B-X
defect	B-X
size	B-X
was	B-X
observed	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
than	B-X
in	B-X
groups	B-X
1	B-X
and	B-X
2	B-X
,	B-X
both	B-X
in	B-X
the	B-X
4th	B-X
and	B-X
16th	B-X
weeks	B-X
.	B-X
Newly	B-X
formed	B-X
bone	B-X
densities	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
these	B-X
2	B-X
groups	B-X
.	B-X
New	B-X
bone	B-X
formation	B-X
was	B-X
detected	B-X
to	B-X
be	B-X
more	B-X
rapid	B-X
considering	B-X
histologic	B-X
parameters	B-X
,	B-X
in	B-X
groups	B-X
3	B-X
and	B-X
4	B-X
at	B-X
4th	B-X
and	B-X
16th	B-X
weeks.Study	B-X
demonstrates	B-X
that	B-X
PRP	B-X
and	B-X
PPP	B-X
might	B-X
have	B-X
favorable	B-X
effects	B-X
on	B-X
bone	B-X
healing	B-X
.	B-X
Although	B-X
we	B-X
can	B-X
not	B-X
reveal	B-X
any	B-X
statistical	B-X
difference	B-X
between	B-X
these	B-X
2	B-X
substances	B-X
considering	B-X
osteoinductive	B-X
potential	B-X
,	B-X
PRP	B-X
group	B-X
has	B-X
demonstrated	B-X
superior	B-X
results	B-X
compared	B-X
with	B-X
fibrin	B-X
glue	B-X
group	B-X
.	B-X
Higher	B-X
platelet	B-X
concentrations	B-X
may	B-X
expose	B-X
beneficial	B-X
effects	B-X
of	B-X
PRP	B-X
.	B-X

Higher	O
platelet	O
concentrations	O
may	O
expose	O
beneficial	O
effects	O
of	O
PRP	O
.	O
<EOS>	B-X
Platelet-rich	B-X
plasma	B-X
(	B-X
PRP	B-X
)	B-X
is	B-X
an	B-X
emerging	B-X
therapeutic	B-X
application	B-X
because	B-X
PRP	B-X
contains	B-X
various	B-X
growth	B-X
factors	B-X
that	B-X
have	B-X
beneficial	B-X
effects	B-X
on	B-X
tissue	B-X
regeneration	B-X
and	B-X
engineering	B-X
.	B-X
Mesenchymal	B-X
stem	B-X
cells	B-X
and	B-X
PRP	B-X
derived	B-X
from	B-X
peripheral	B-X
blood	B-X
have	B-X
been	B-X
well	B-X
studied	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
PRP	B-X
derived	B-X
from	B-X
human	B-X
umbilical	B-X
cord	B-X
blood	B-X
(	B-X
UCB-PRP	B-X
)	B-X
on	B-X
proliferation	B-X
,	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
ALP	B-X
)	B-X
activity	B-X
,	B-X
and	B-X
osteogenic	B-X
differentiation	B-X
of	B-X
stem	B-X
cells	B-X
from	B-X
human	B-X
exfoliated	B-X
deciduous	B-X
teeth	B-X
(	B-X
SHEDs	B-X
)	B-X
,	B-X
dental	B-X
pulp	B-X
stem	B-X
cells	B-X
(	B-X
DPSCs	B-X
)	B-X
,	B-X
and	B-X
periodontal	B-X
ligament	B-X
stem	B-X
cells	B-X
(	B-X
PDLSCs	B-X
)	B-X
.	B-X
Dental	B-X
stem	B-X
cells	B-X
were	B-X
exposed	B-X
to	B-X
various	B-X
concentrations	B-X
of	B-X
UCB-PRP	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
the	B-X
proliferation	B-X
of	B-X
dental	B-X
stem	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
2	B-X
%	B-X
UCB-PRP	B-X
resulted	B-X
in	B-X
the	B-X
highest	B-X
level	B-X
of	B-X
proliferation	B-X
.	B-X
The	B-X
ALP	B-X
activity	B-X
of	B-X
DPSCs	B-X
and	B-X
PDLSCs	B-X
increased	B-X
following	B-X
treatment	B-X
with	B-X
UCB-PRP	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
up	B-X
to	B-X
a	B-X
concentration	B-X
of	B-X
2	B-X
%	B-X
.	B-X
ALP	B-X
activity	B-X
decreased	B-X
with	B-X
higher	B-X
concentration	B-X
of	B-X
UCB-PRP	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
UCB-PRP	B-X
on	B-X
calcium	B-X
deposition	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
on	B-X
proliferation	B-X
and	B-X
ALP	B-X
activity	B-X
.	B-X
Treatment	B-X
with	B-X
2	B-X
%	B-X
UCB-PRP	B-X
resulted	B-X
in	B-X
the	B-X
highest	B-X
calcium	B-X
depositions	B-X
in	B-X
DPSCs	B-X
and	B-X
PDLSCs	B-X
;	B-X
however	B-X
,	B-X
treatment	B-X
with	B-X
1	B-X
%	B-X
UCB-PRP	B-X
resulted	B-X
in	B-X
the	B-X
highest	B-X
calcium	B-X
deposition	B-X
in	B-X
SHEDs	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
platelet-derived	B-X
growth	B-X
factor-AB	B-X
and	B-X
transforming	B-X
growth	B-X
factor-Î²1	B-X
in	B-X
UCB-PRP	B-X
were	B-X
investigated	B-X
and	B-X
found	B-X
to	B-X
be	B-X
comparable	B-X
to	B-X
the	B-X
amounts	B-X
in	B-X
peripheral	B-X
blood	B-X
.	B-X
Overall	B-X
,	B-X
UCB-PRP	B-X
had	B-X
beneficial	B-X
effects	B-X
on	B-X
the	B-X
proliferation	B-X
and	B-X
osteogenic	B-X
differentiation	B-X
of	B-X
dental	B-X
stem	B-X
cells	B-X
.	B-X
Determination	B-X
of	B-X
the	B-X
optimal	B-X
concentration	B-X
of	B-X
UCB-PRP	B-X
requires	B-X
further	B-X
investigation	B-X
for	B-X
clinical	B-X
applications	B-X
.	B-X

Host	O
-	O
derived	O
angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
affects	O
early	O
stages	O
of	O
tumor	O
development	O
and	O
vessel	O
maturation	O
but	O
is	O
dispensable	O
for	O
later	O
stages	O
of	O
tumor	O
growth	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

The	O
angiopoietin	B-Gene_or_gene_product
/	O
Tie2	B-Gene_or_gene_product
system	O
has	O
been	O
identified	O
as	O
the	O
second	O
vascular	O
-	O
specific	O
receptor	O
tyrosine	O
kinase	O
system	O
controlling	O
vessel	O
assembly	O
,	O
maturation	O
,	O
and	O
quiescence	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X

Angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
(	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	O
is	O
prominently	O
up	O
-	O
regulated	O
in	O
the	O
host	O
-	O
derived	O
vasculature	O
of	O
most	O
tumors	O
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
antiangiogenic	O
intervention	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Yet	O
,	O
the	O
net	O
outcome	O
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
functions	O
on	O
tumor	O
angiogenesis	O
is	O
believed	O
to	O
be	O
contextual	O
depending	O
on	O
the	O
local	O
cytokine	O
milieu	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Correspondingly	O
,	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
manipulatory	O
therapies	O
have	O
been	O
shown	O
to	O
exert	O
protumorigenic	O
as	O
well	O
as	O
antitumorigenic	O
effects	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

To	O
clarify	O
the	O
role	O
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
for	O
angiogenesis	O
and	O
tumor	O
growth	O
in	O
a	O
definite	O
genetic	O
experimental	O
setting	O
,	O
the	O
present	O
study	O
was	O
aimed	O
at	O
comparatively	O
studying	O
the	O
growth	O
of	O
different	O
tumors	O
in	O
wild	O
-	O
type	O
and	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	O
deficient	O
mice	O
.	O

Lewis	O
lung	O
carcinomas	O
,	O
MT	O
-	O
ret	O
melanomas	O
,	O
and	O
B16F10	O
melanomas	O
all	O
grew	O
slower	O
in	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	O
deficient	O
mice	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Yet	O
,	O
tumor	O
growth	O
in	O
wild	O
-	O
type	O
and	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	O
deficient	O
mice	O
dissociated	O
during	O
early	O
stages	O
of	O
tumor	O
development	O
,	O
whereas	O
tumor	O
growth	O
rates	O
during	O
later	O
stages	O
of	O
primary	O
tumor	O
progression	O
were	O
similar	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Analysis	O
of	O
the	O
intratumoral	O
vascular	O
architecture	O
revealed	O
no	O
major	O
differences	O
in	O
microvessel	O
density	O
and	O
perfusion	O
characteristics	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X

However	O
,	O
diameters	O
of	O
intratumoral	O
microvessels	O
were	O
smaller	O
in	O
tumors	O
grown	O
in	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	O
deficient	O
mice	O
,	O
and	O
the	O
vasculature	O
had	O
an	O
altered	O
pattern	O
of	O
pericyte	O
recruitment	O
and	O
maturation	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	O
deficient	O
tumor	O
vessels	O
had	O
higher	O
pericyte	O
coverage	O
indices	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Recruited	O
pericytes	O
were	O
desmin	B-Gene_or_gene_product
and	O
NG2	B-Gene_or_gene_product
positive	O
and	O
predominately	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
smooth	I-Gene_or_gene_product
muscle	I-Gene_or_gene_product
actin	I-Gene_or_gene_product
negative	O
,	O
indicative	O
of	O
a	O
more	O
mature	O
pericyte	O
phenotype	O
.	O

Collectively	O
,	O
the	O
experiments	O
define	O
the	O
role	O
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
during	O
tumor	O
angiogenesis	O
and	O
establish	O
a	O
better	O
rationale	O
for	O
combination	O
therapies	O
involving	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
manipulatory	O
therapies	O
.	O
<EOS>	B-X
The	B-X
angiopoietin/Tie2	B-X
system	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
second	B-X
vascular-specific	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
system	B-X
controlling	B-X
vessel	B-X
assembly	B-X
,	B-X
maturation	B-X
,	B-X
and	B-X
quiescence	B-X
.	B-X
Angiopoietin-2	B-X
(	B-X
Ang-2	B-X
)	B-X
is	B-X
prominently	B-X
up-regulated	B-X
in	B-X
the	B-X
host-derived	B-X
vasculature	B-X
of	B-X
most	B-X
tumors	B-X
,	B-X
making	B-X
it	B-X
an	B-X
attractive	B-X
candidate	B-X
for	B-X
antiangiogenic	B-X
intervention	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
net	B-X
outcome	B-X
of	B-X
Ang-2	B-X
functions	B-X
on	B-X
tumor	B-X
angiogenesis	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
contextual	B-X
depending	B-X
on	B-X
the	B-X
local	B-X
cytokine	B-X
milieu	B-X
.	B-X
Correspondingly	B-X
,	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
protumorigenic	B-X
as	B-X
well	B-X
as	B-X
antitumorigenic	B-X
effects	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
for	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
definite	B-X
genetic	B-X
experimental	B-X
setting	B-X
,	B-X
the	B-X
present	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
comparatively	B-X
studying	B-X
the	B-X
growth	B-X
of	B-X
different	B-X
tumors	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
,	B-X
MT-ret	B-X
melanomas	B-X
,	B-X
and	B-X
B16F10	B-X
melanomas	B-X
all	B-X
grew	B-X
slower	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
.	B-X
Yet	B-X
,	B-X
tumor	B-X
growth	B-X
in	B-X
wild-type	B-X
and	B-X
Ang-2-deficient	B-X
mice	B-X
dissociated	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
,	B-X
whereas	B-X
tumor	B-X
growth	B-X
rates	B-X
during	B-X
later	B-X
stages	B-X
of	B-X
primary	B-X
tumor	B-X
progression	B-X
were	B-X
similar	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
intratumoral	B-X
vascular	B-X
architecture	B-X
revealed	B-X
no	B-X
major	B-X
differences	B-X
in	B-X
microvessel	B-X
density	B-X
and	B-X
perfusion	B-X
characteristics	B-X
.	B-X
However	B-X
,	B-X
diameters	B-X
of	B-X
intratumoral	B-X
microvessels	B-X
were	B-X
smaller	B-X
in	B-X
tumors	B-X
grown	B-X
in	B-X
Ang-2-deficient	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
vasculature	B-X
had	B-X
an	B-X
altered	B-X
pattern	B-X
of	B-X
pericyte	B-X
recruitment	B-X
and	B-X
maturation	B-X
.	B-X
Ang-2-deficient	B-X
tumor	B-X
vessels	B-X
had	B-X
higher	B-X
pericyte	B-X
coverage	B-X
indices	B-X
.	B-X
Recruited	B-X
pericytes	B-X
were	B-X
desmin	B-X
and	B-X
NG2	B-X
positive	B-X
and	B-X
predominately	B-X
alpha-smooth	B-X
muscle	B-X
actin	B-X
negative	B-X
,	B-X
indicative	B-X
of	B-X
a	B-X
more	B-X
mature	B-X
pericyte	B-X
phenotype	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
experiments	B-X
define	B-X
the	B-X
role	B-X
of	B-X
Ang-2	B-X
during	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
establish	B-X
a	B-X
better	B-X
rationale	B-X
for	B-X
combination	B-X
therapies	B-X
involving	B-X
Ang-2	B-X
manipulatory	B-X
therapies	B-X
.	B-X

Liposomal	O
honokiol	O
inhibits	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
D	I-Gene_or_gene_product
-	O
induced	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
xenograft	O
tumor	O
model	O
.	O
<EOS>	B-X
Lymph	B-X
nodes	B-X
metastasis	B-X
of	B-X
tumor	B-X
could	B-X
be	B-X
a	B-X
crucial	B-X
early	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
.	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Honokiol	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
potent	B-X
antiangiogenesis	B-X
and	B-X
antitumor	B-X
properties	B-X
in	B-X
several	B-X
cell	B-X
lines	B-X
and	B-X
xenograft	B-X
tumor	B-X
models	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
A	B-X
remarkable	B-X
delay	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
life	B-X
span	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

Lymph	O
nodes	O
metastasis	O
of	O
tumor	O
could	O
be	O
a	O
crucial	O
early	O
step	O
in	O
the	O
metastatic	O
process	O
.	O
<EOS>	B-X
Lymph	B-X
nodes	B-X
metastasis	B-X
of	B-X
tumor	B-X
could	B-X
be	B-X
a	B-X
crucial	B-X
early	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
.	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Honokiol	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
potent	B-X
antiangiogenesis	B-X
and	B-X
antitumor	B-X
properties	B-X
in	B-X
several	B-X
cell	B-X
lines	B-X
and	B-X
xenograft	B-X
tumor	B-X
models	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
A	B-X
remarkable	B-X
delay	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
life	B-X
span	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

Induction	O
of	O
tumor	O
lymphangiogenesis	O
by	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
D	I-Gene_or_gene_product
may	O
play	O
an	O
important	O
role	O
in	O
promoting	O
tumor	O
metastasis	O
to	O
regional	O
lymph	O
nodes	O
and	O
these	O
processes	O
can	O
be	O
inhibited	O
by	O
inactivation	O
of	O
the	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
signaling	O
pathway	O
.	O
<EOS>	B-X
Lymph	B-X
nodes	B-X
metastasis	B-X
of	B-X
tumor	B-X
could	B-X
be	B-X
a	B-X
crucial	B-X
early	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
.	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Honokiol	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
potent	B-X
antiangiogenesis	B-X
and	B-X
antitumor	B-X
properties	B-X
in	B-X
several	B-X
cell	B-X
lines	B-X
and	B-X
xenograft	B-X
tumor	B-X
models	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
A	B-X
remarkable	B-X
delay	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
life	B-X
span	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

Honokiol	O
has	O
been	O
reported	O
to	O
possess	O
potent	O
antiangiogenesis	O
and	O
antitumor	O
properties	O
in	O
several	O
cell	O
lines	O
and	O
xenograft	O
tumor	O
models	O
.	O
<EOS>	B-X
Lymph	B-X
nodes	B-X
metastasis	B-X
of	B-X
tumor	B-X
could	B-X
be	B-X
a	B-X
crucial	B-X
early	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
.	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Honokiol	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
potent	B-X
antiangiogenesis	B-X
and	B-X
antitumor	B-X
properties	B-X
in	B-X
several	B-X
cell	B-X
lines	B-X
and	B-X
xenograft	B-X
tumor	B-X
models	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
A	B-X
remarkable	B-X
delay	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
life	B-X
span	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X

However	O
,	O
its	O
role	O
in	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
lymphatic	O
metastasis	O
remains	O
unclear	O
.	O
<EOS>	B-X
Lymph	B-X
node	B-X
metastasis	B-X
(	B-X
LNM	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
cause	B-X
for	B-X
disease	B-X
progression	B-X
and	B-X
treatment	B-X
failure	B-X
in	B-X
cervical	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
cervical	B-X
cancer	B-X
LNM	B-X
remains	B-X
unclear	B-X
.	B-X
Meanwhile	B-X
,	B-X
HN1	B-X
promotes	B-X
lymphangiogenesis	B-X
of	B-X
cervical	B-X
cancer	B-X
in	B-X
vitro	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
study	B-X
suggests	B-X
that	B-X
HN1	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
promoting	B-X
LNM	B-X
and	B-X
acts	B-X
as	B-X
a	B-X
prognostic	B-X
biomarker	B-X
in	B-X
cervical	B-X
cancer	B-X
.	B-X

Here	O
,	O
we	O
established	O
lymph	O
node	O
metastasis	O
models	O
by	O
injecting	O
overexpressing	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
D	I-Gene_or_gene_product
Lewis	O
lung	O
carcinoma	O
cells	O
into	O
C57BL	O
/	O
6	O
mice	O
to	O
explore	O
the	O
effect	O
of	O
honokiol	O
on	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
related	O
lymph	O
node	O
metastasis	O
.	O
<EOS>	B-X
Lymph	B-X
nodes	B-X
metastasis	B-X
of	B-X
tumor	B-X
could	B-X
be	B-X
a	B-X
crucial	B-X
early	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
.	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Honokiol	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
potent	B-X
antiangiogenesis	B-X
and	B-X
antitumor	B-X
properties	B-X
in	B-X
several	B-X
cell	B-X
lines	B-X
and	B-X
xenograft	B-X
tumor	B-X
models	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
A	B-X
remarkable	B-X
delay	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
life	B-X
span	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

The	O
underlying	O
mechanisms	O
were	O
systematically	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
the	B-X
relationship	B-X
between	B-X
calcium	B-X
channelopathies	B-X
(	B-X
CCs	B-X
)	B-X
and	B-X
intellectual	B-X
disability	B-X
(	B-X
ID	B-X
)	B-X
/global	B-X
developmental	B-X
delay	B-X
(	B-X
GDD	B-X
)	B-X
has	B-X
been	B-X
poorly	B-X
investigated	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
systematic	B-X
review	B-X
to	B-X
investigate	B-X
the	B-X
contribution	B-X
of	B-X
CCs	B-X
,	B-X
potential	B-X
mechanisms	B-X
underlying	B-X
their	B-X
involvement	B-X
in	B-X
ID/GDD	B-X
,	B-X
advancements	B-X
in	B-X
cell	B-X
and	B-X
animal	B-X
models	B-X
,	B-X
treatments	B-X
,	B-X
brain	B-X
anomalies	B-X
in	B-X
patients	B-X
with	B-X
CCs	B-X
,	B-X
and	B-X
the	B-X
existing	B-X
gaps	B-X
in	B-X
the	B-X
knowledge	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
investigate	B-X
whether	B-X
caffeine	B-X
,	B-X
a	B-X
well-known	B-X
purine	B-X
alkaloid	B-X
,	B-X
is	B-X
able	B-X
to	B-X
prevent	B-X
skin	B-X
from	B-X
oxidative	B-X
stress-induced	B-X
senescence	B-X
,	B-X
and	B-X
to	B-X
explore	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
of	B-X
BBR	B-X
also	B-X
will	B-X
be	B-X
explored	B-X
systematically	B-X
.	B-X

In	O
in	O
vivo	O
study	O
,	O
liposomal	O
honokiol	O
significantly	O
inhibited	O
the	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
Lewis	O
lung	O
carcinoma	O
model	O
.	O
<EOS>	B-X
Lymph	B-X
nodes	B-X
metastasis	B-X
of	B-X
tumor	B-X
could	B-X
be	B-X
a	B-X
crucial	B-X
early	B-X
step	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
.	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Honokiol	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
potent	B-X
antiangiogenesis	B-X
and	B-X
antitumor	B-X
properties	B-X
in	B-X
several	B-X
cell	B-X
lines	B-X
and	B-X
xenograft	B-X
tumor	B-X
models	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
The	B-X
underlying	B-X
mechanisms	B-X
were	B-X
systematically	B-X
investigated	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
A	B-X
remarkable	B-X
delay	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
prolonged	B-X
life	B-X
span	B-X
were	B-X
also	B-X
observed	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

A	O
remarkable	O
delay	O
of	O
tumor	O
growth	O
and	O
prolonged	O
life	O
span	O
were	O
also	O
observed	O
.	O
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
neutrophils	B-X
in	B-X
tumor	B-X
immune	B-X
surveillance	B-X
,	B-X
invasive	B-X
growth	B-X
and	B-X
angiogenesis	B-X
becomes	B-X
increasingly	B-X
clear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
endogenous	B-X
IFN-Î²	B-X
is	B-X
regulating	B-X
the	B-X
apoptosis	B-X
of	B-X
pro-angiogenic	B-X
tumor	B-X
infiltrating	B-X
neutrophils	B-X
by	B-X
influencing	B-X
both	B-X
,	B-X
the	B-X
extrinsic	B-X
as	B-X
well	B-X
as	B-X
the	B-X
intrinsic	B-X
apoptosis	B-X
pathways	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
life	B-X
span	B-X
of	B-X
tumor	B-X
associated	B-X
neutrophils	B-X
(	B-X
TANs	B-X
)	B-X
is	B-X
remarkably	B-X
prolonged	B-X
in	B-X
tumor	B-X
bearing	B-X
Ifnb1	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
wild	B-X
type	B-X
controls	B-X
.	B-X
Lower	B-X
expression	B-X
of	B-X
Fas	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
active	B-X
Caspase	B-X
3	B-X
and	B-X
9	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
change	B-X
in	B-X
expression	B-X
pattern	B-X
of	B-X
proapoptotic	B-X
and	B-X
antiapoptotic	B-X
members	B-X
of	B-X
the	B-X
Bcl-2	B-X
family	B-X
and	B-X
the	B-X
major	B-X
apoptosome	B-X
constituent	B-X
Apaf-1	B-X
is	B-X
observed	B-X
under	B-X
such	B-X
conditions	B-X
.	B-X
In	B-X
line	B-X
with	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
and	B-X
the	B-X
prolonged	B-X
neutrophil	B-X
survival	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
endogenous	B-X
IFN-Î²	B-X
,	B-X
a	B-X
strong	B-X
enhancement	B-X
of	B-X
G-CSF	B-X
expression	B-X
and	B-X
PI3	B-X
Kinase	B-X
phosphorylation	B-X
is	B-X
detected	B-X
.	B-X
These	B-X
data	B-X
explain	B-X
the	B-X
increased	B-X
longevity	B-X
of	B-X
tumor	B-X
infiltrating	B-X
neutrophils	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
such	B-X
cells	B-X
in	B-X
tumors	B-X
.	B-X

In	O
in	O
vitro	O
study	O
,	O
honokiol	O
inhibited	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
D	I-Gene_or_gene_product
-	O
induced	O
survival	O
,	O
proliferation	O
and	O
tube	O
-	O
formation	O
of	O
both	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
lymphatic	O
vascular	O
endothelial	O
cells	O
(	O
HLECs	O
)	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
The	B-X
underlying	B-X
mechanisms	B-X
were	B-X
systematically	B-X
investigated	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

Western	O
blotting	O
analysis	O
showed	O
that	O
liposomal	O
honokiol	O
-	O
inhibited	O
Akt	B-Gene_or_gene_product
and	O
MAPK	B-Gene_or_gene_product
phosphorylation	O
in	O
2	O
endothelial	O
cells	O
,	O
and	O
downregulated	O
expressions	O
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
of	O
human	O
vascular	O
endothelial	O
cells	O
and	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
of	O
lymphatic	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
lymphatic	B-X
metastasis	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

Thus	O
,	O
we	O
identified	O
for	O
the	O
first	O
time	O
that	O
honokiol	O
provided	O
therapeutic	O
benefit	O
not	O
only	O
by	O
direct	O
effects	O
on	O
tumor	O
cells	O
and	O
antiangiogenesis	O
but	O
also	O
by	O
inhibiting	O
lymphangiogenesis	O
and	O
metastasis	O
via	O
the	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
pathway	O
.	O

The	O
present	O
findings	O
may	O
be	O
of	O
importance	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
spread	O
of	O
cancer	O
via	O
the	O
lymphatics	O
and	O
explore	O
the	O
therapeutical	O
strategy	O
of	O
honokiol	O
on	O
antilymphangiogenesis	O
and	O
antimetastasis	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
tumor	B-X
lymphangiogenesis	B-X
by	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-D	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
promoting	B-X
tumor	B-X
metastasis	B-X
to	B-X
regional	B-X
lymph	B-X
nodes	B-X
and	B-X
these	B-X
processes	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
inactivation	B-X
of	B-X
the	B-X
VEGFR-3	B-X
signaling	B-X
pathway	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
established	B-X
lymph	B-X
node	B-X
metastasis	B-X
models	B-X
by	B-X
injecting	B-X
overexpressing	B-X
VEGF-D	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
into	B-X
C57BL/6	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
honokiol	B-X
on	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
related	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
The	B-X
underlying	B-X
mechanisms	B-X
were	B-X
systematically	B-X
investigated	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
in	B-X
vivo	B-X
study	B-X
,	B-X
liposomal	B-X
honokiol	B-X
significantly	B-X
inhibited	B-X
the	B-X
tumor-associated	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
in	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X
In	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
honokiol	B-X
inhibited	B-X
VEGF-D-induced	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
tube-formation	B-X
of	B-X
both	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
and	B-X
lymphatic	B-X
vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HLECs	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
showed	B-X
that	B-X
liposomal	B-X
honokiol-inhibited	B-X
Akt	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
in	B-X
2	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
downregulated	B-X
expressions	B-X
of	B-X
VEGFR-2	B-X
of	B-X
human	B-X
vascular	B-X
endothelial	B-X
cells	B-X
and	B-X
VEGFR-3	B-X
of	B-X
lymphatic	B-X
endothelial	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
identified	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
honokiol	B-X
provided	B-X
therapeutic	B-X
benefit	B-X
not	B-X
only	B-X
by	B-X
direct	B-X
effects	B-X
on	B-X
tumor	B-X
cells	B-X
and	B-X
antiangiogenesis	B-X
but	B-X
also	B-X
by	B-X
inhibiting	B-X
lymphangiogenesis	B-X
and	B-X
metastasis	B-X
via	B-X
the	B-X
VEGFR-3	B-X
pathway	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
spread	B-X
of	B-X
cancer	B-X
via	B-X
the	B-X
lymphatics	B-X
and	B-X
explore	B-X
the	B-X
therapeutical	B-X
strategy	B-X
of	B-X
honokiol	B-X
on	B-X
antilymphangiogenesis	B-X
and	B-X
antimetastasis	B-X
.	B-X

Short	B-Gene_or_gene_product
pigment	I-Gene_or_gene_product
epithelial	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
peptide	I-Gene_or_gene_product
inhibits	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
,	B-X
a	B-X
50	B-X
kDa	B-X
secreted	B-X
glycoprotein	B-X
,	B-X
exhibits	B-X
distinct	B-X
effects	B-X
on	B-X
a	B-X
range	B-X
of	B-X
cell	B-X
types	B-X
.	B-X
PEDF	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
-mediated	B-X
angiogenesis	B-X
and	B-X
widely	B-X
accepted	B-X
as	B-X
a	B-X
promising	B-X
agent	B-X
for	B-X
treatment	B-X
eye	B-X
diseases	B-X
related	B-X
to	B-X
neovascularization	B-X
.	B-X
A	B-X
pool	B-X
of	B-X
short	B-X
peptide	B-X
fragments	B-X
derived	B-X
from	B-X
PEDF	B-X
reportedly	B-X
manifests	B-X
angioinhibitory	B-X
activity	B-X
.	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

PURPOSE	O
:	O
Pigment	B-Gene_or_gene_product
epithelial	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
PEDF	B-Gene_or_gene_product
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
with	O
multiple	O
other	O
functions	O
,	O
some	O
of	O
which	O
enhance	O
tumor	O
growth	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

Our	O
previous	O
studies	O
mapped	O
PEDF	B-Gene_or_gene_product
antiangiogenic	O
and	O
prosurvival	O
activities	O
to	O
distinct	O
epitopes	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
minimal	O
fragment	O
of	O
PEDF	B-Gene_or_gene_product
,	O
which	O
maintains	O
antiangiogenic	O
and	O
antitumor	O
efficacy	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
antigenicity	O
,	O
hydrophilicity	O
,	O
and	O
charge	O
distribution	O
of	O
the	O
angioinhibitory	O
epitope	O
(	O
the	O
34	O
-	O
mer	O
)	O
and	O
designed	O
three	O
peptides	O
covering	O
its	O
COOH	O
terminus	O
,	O
P14	B-Gene_or_gene_product
,	O
P18	B-Gene_or_gene_product
,	O
and	O
P23	B-Gene_or_gene_product
.	O
<EOS>	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X

We	O
analyzed	O
their	O
ability	O
to	O
block	O
endothelial	O
cell	O
chemotaxis	O
and	O
induce	O
apoptosis	O
in	O
vitro	O
and	O
their	O
antiangiogenic	O
activity	O
in	O
vivo	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

The	O
selected	O
peptide	O
was	O
tested	O
for	O
the	O
antitumor	O
activity	O
against	O
mildly	O
aggressive	O
xenografted	O
prostate	O
carcinoma	O
and	O
highly	O
aggressive	O
renal	O
cell	O
carcinoma	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

To	O
verify	O
that	O
P18	B-Gene_or_gene_product
acts	O
in	O
the	O
same	O
manner	O
as	O
PEDF	B-Gene_or_gene_product
,	O
we	O
used	O
immunohistochemistry	O
to	O
measure	O
PEDF	B-Gene_or_gene_product
targets	I-Gene_or_gene_product
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
and	O
CD95	B-Gene_or_gene_product
ligand	I-Gene_or_gene_product
expression	O
in	O
P18	B-Gene_or_gene_product
-	O
treated	O
vasculature	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

RESULTS	O
:	O
P14	B-Gene_or_gene_product
and	O
P18	B-Gene_or_gene_product
blocked	O
endothelial	O
cell	O
chemotaxis	O
;	O
P18	B-Gene_or_gene_product
and	O
P23	B-Gene_or_gene_product
induced	O
apoptosis	O
.	O

P18	B-Gene_or_gene_product
showed	O
the	O
highest	O
IC50	O
and	O
blocked	O
angiogenesis	O
in	O
vivo	O
:	O
P23	B-Gene_or_gene_product
was	O
inactive	O
and	O
P14	B-Gene_or_gene_product
was	O
proangiogenic	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X

P18	B-Gene_or_gene_product
increased	O
the	O
production	O
of	O
CD95	B-Gene_or_gene_product
ligand	I-Gene_or_gene_product
and	O
reduced	O
the	O
expression	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	I-Gene_or_gene_product
by	O
the	O
endothelial	O
cells	O
in	O
vivo	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X

In	O
tumor	O
studies	O
,	O
P18	B-Gene_or_gene_product
was	O
more	O
effective	O
in	O
blocking	O
the	O
angiogenesis	O
and	O
growth	O
of	O
the	O
prostate	O
cancer	O
than	O
parental	B-Gene_or_gene_product
34	I-Gene_or_gene_product
-	I-Gene_or_gene_product
mer	I-Gene_or_gene_product
;	O
in	O
the	O
renal	O
cell	O
carcinoma	O
,	O
P18	B-Gene_or_gene_product
strongly	O
decreased	O
angiogenesis	O
and	O
halted	O
the	O
progression	O
of	O
established	O
tumors	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

CONCLUSIONS	O
:	O
P18	B-Gene_or_gene_product
is	O
a	O
novel	O
and	O
potent	O
antiangiogenic	O
biotherapeutic	O
agent	O
that	O
has	O
potential	O
to	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
prostate	O
and	O
renal	O
cancer	O
.	O
<EOS>	B-X
Pigment	B-X
epithelial-derived	B-X
factor	B-X
(	B-X
PEDF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
angiogenesis	B-X
inhibitor	B-X
with	B-X
multiple	B-X
other	B-X
functions	B-X
,	B-X
some	B-X
of	B-X
which	B-X
enhance	B-X
tumor	B-X
growth	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
mapped	B-X
PEDF	B-X
antiangiogenic	B-X
and	B-X
prosurvival	B-X
activities	B-X
to	B-X
distinct	B-X
epitopes	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
minimal	B-X
fragment	B-X
of	B-X
PEDF	B-X
,	B-X
which	B-X
maintains	B-X
antiangiogenic	B-X
and	B-X
antitumor	B-X
efficacy	B-X
.	B-X

Distinct	O
role	O
of	O
PLCbeta3	B-Gene_or_gene_product
in	O
VEGF	B-Gene_or_gene_product
-	O
mediated	O
directional	O
migration	O
and	O
vascular	O
sprouting	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
migration	B-X
is	B-X
essential	B-X
to	B-X
angiogenesis	B-X
.	B-X
Typically	B-X
,	B-X
proliferation	B-X
and	B-X
chemotaxis	B-X
of	B-X
endothelial	B-X
cells	B-X
is	B-X
driven	B-X
by	B-X
growth	B-X
factors	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
VEGF	B-X
activates	B-X
phospholipases	B-X
(	B-X
PLCs	B-X
)	B-X
-	B-X
specifically	B-X
PLCgamma1	B-X
-	B-X
that	B-X
are	B-X
important	B-X
for	B-X
tubulogenesis	B-X
,	B-X
differentiation	B-X
and	B-X
DNA	B-X
synthesis	B-X
.	B-X
However	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
VEGF	B-X
,	B-X
specifically	B-X
through	B-X
VEGFR2	B-X
,	B-X
induces	B-X
phosphorylation	B-X
of	B-X
two	B-X
serine	B-X
residues	B-X
on	B-X
PLCbeta3	B-X
,	B-X
and	B-X
this	B-X
was	B-X
confirmed	B-X
in	B-X
an	B-X
ex	B-X
vivo	B-X
embryoid	B-X
body	B-X
model	B-X
.	B-X
Knockdown	B-X
of	B-X
PLCbeta3	B-X
in	B-X
HUVEC	B-X
cells	B-X
affects	B-X
IP3	B-X
production	B-X
,	B-X
actin	B-X
reorganization	B-X
,	B-X
migration	B-X
and	B-X
proliferation	B-X
;	B-X
whereas	B-X
migration	B-X
is	B-X
inhibited	B-X
,	B-X
proliferation	B-X
is	B-X
enhanced	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhanced	B-X
proliferation	B-X
is	B-X
precipitated	B-X
by	B-X
an	B-X
accelerated	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
decreased	B-X
migration	B-X
by	B-X
an	B-X
inability	B-X
to	B-X
activate	B-X
CDC42	B-X
.	B-X
Given	B-X
that	B-X
PLCbeta3	B-X
is	B-X
typically	B-X
known	B-X
as	B-X
an	B-X
effector	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
a	B-X
unique	B-X
crosstalk	B-X
between	B-X
the	B-X
G-protein	B-X
and	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
(	B-X
RTK	B-X
)	B-X
axes	B-X
and	B-X
reveal	B-X
a	B-X
novel	B-X
molecular	B-X
mechanism	B-X
of	B-X
VEGF	B-X
signaling	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
angiogenesis	B-X
.	B-X

Endothelial	O
cell	O
proliferation	O
and	O
migration	O
is	O
essential	O
to	O
angiogenesis	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
BACH1	B-X
(	B-X
BTB	B-X
and	B-X
CNC	B-X
homology	B-X
1	B-X
)	B-X
suppressed	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
proliferation	B-X
and	B-X
migration	B-X
and	B-X
impaired	B-X
angiogenesis	B-X
in	B-X
the	B-X
ischemic	B-X
hindlimbs	B-X
of	B-X
adult	B-X
mice	B-X
.	B-X
This	B-X
pathway	B-X
is	B-X
known	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
numerous	B-X
cellular	B-X
functions	B-X
including	B-X
proliferation	B-X
,	B-X
adhesion	B-X
,	B-X
migration	B-X
,	B-X
invasion	B-X
,	B-X
metabolism	B-X
,	B-X
and	B-X
survival	B-X
,	B-X
but	B-X
in	B-X
the	B-X
current	B-X
review	B-X
we	B-X
focus	B-X
on	B-X
its	B-X
role	B-X
in	B-X
angiogenesis	B-X
.	B-X
There	B-X
is	B-X
a	B-X
connection	B-X
between	B-X
the	B-X
PI3K	B-X
pathway	B-X
and	B-X
angiogenesis	B-X
.	B-X
Hypoxia	B-X
leads	B-X
to	B-X
HIF-1Î±	B-X
stabilization	B-X
and	B-X
is	B-X
a	B-X
major	B-X
stimulus	B-X
for	B-X
increased	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
production	B-X
by	B-X
tumor	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
PI3K/AKT	B-X
pathway	B-X
in	B-X
tumor	B-X
cells	B-X
can	B-X
also	B-X
increase	B-X
VEGF	B-X
secretion	B-X
,	B-X
both	B-X
by	B-X
hypoxia-inducible	B-X
factor	B-X
1	B-X
(	B-X
HIF-1	B-X
)	B-X
dependent	B-X
and	B-X
independent	B-X
mechanisms	B-X
.	B-X
Numerous	B-X
inhibitors	B-X
targeting	B-X
the	B-X
PI3K/AKT/mTOR	B-X
pathway	B-X
have	B-X
been	B-X
developed	B-X
,	B-X
and	B-X
these	B-X
agents	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
decrease	B-X
VEGF	B-X
secretion	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
importance	B-X
in	B-X
cancer	B-X
,	B-X
the	B-X
PI3K	B-X
pathway	B-X
also	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
normal	B-X
blood	B-X
vessels	B-X
during	B-X
development	B-X
.	B-X
Stimulation	B-X
of	B-X
endothelial	B-X
cells	B-X
by	B-X
VEGF	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
PI3K	B-X
pathway	B-X
within	B-X
these	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
cell	B-X
migration	B-X
.	B-X
Hence	B-X
,	B-X
the	B-X
PI3K	B-X
pathway	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
angiogenesis	B-X
both	B-X
in	B-X
normal	B-X
tissues	B-X
and	B-X
in	B-X
cancers	B-X
.	B-X

Typically	O
,	O
proliferation	O
and	O
chemotaxis	O
of	O
endothelial	O
cells	O
is	O
driven	O
by	O
growth	O
factors	O
such	O
as	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
and	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
bFGF	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
migration	B-X
is	B-X
essential	B-X
to	B-X
angiogenesis	B-X
.	B-X
Typically	B-X
,	B-X
proliferation	B-X
and	B-X
chemotaxis	B-X
of	B-X
endothelial	B-X
cells	B-X
is	B-X
driven	B-X
by	B-X
growth	B-X
factors	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
VEGF	B-X
activates	B-X
phospholipases	B-X
(	B-X
PLCs	B-X
)	B-X
-	B-X
specifically	B-X
PLCgamma1	B-X
-	B-X
that	B-X
are	B-X
important	B-X
for	B-X
tubulogenesis	B-X
,	B-X
differentiation	B-X
and	B-X
DNA	B-X
synthesis	B-X
.	B-X
However	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
VEGF	B-X
,	B-X
specifically	B-X
through	B-X
VEGFR2	B-X
,	B-X
induces	B-X
phosphorylation	B-X
of	B-X
two	B-X
serine	B-X
residues	B-X
on	B-X
PLCbeta3	B-X
,	B-X
and	B-X
this	B-X
was	B-X
confirmed	B-X
in	B-X
an	B-X
ex	B-X
vivo	B-X
embryoid	B-X
body	B-X
model	B-X
.	B-X
Knockdown	B-X
of	B-X
PLCbeta3	B-X
in	B-X
HUVEC	B-X
cells	B-X
affects	B-X
IP3	B-X
production	B-X
,	B-X
actin	B-X
reorganization	B-X
,	B-X
migration	B-X
and	B-X
proliferation	B-X
;	B-X
whereas	B-X
migration	B-X
is	B-X
inhibited	B-X
,	B-X
proliferation	B-X
is	B-X
enhanced	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhanced	B-X
proliferation	B-X
is	B-X
precipitated	B-X
by	B-X
an	B-X
accelerated	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
decreased	B-X
migration	B-X
by	B-X
an	B-X
inability	B-X
to	B-X
activate	B-X
CDC42	B-X
.	B-X
Given	B-X
that	B-X
PLCbeta3	B-X
is	B-X
typically	B-X
known	B-X
as	B-X
an	B-X
effector	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
a	B-X
unique	B-X
crosstalk	B-X
between	B-X
the	B-X
G-protein	B-X
and	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
(	B-X
RTK	B-X
)	B-X
axes	B-X
and	B-X
reveal	B-X
a	B-X
novel	B-X
molecular	B-X
mechanism	B-X
of	B-X
VEGF	B-X
signaling	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
angiogenesis	B-X
.	B-X

VEGF	B-Gene_or_gene_product
activates	O
phospholipases	B-Gene_or_gene_product
(	O
PLCs	B-Gene_or_gene_product
)	O
-	O
specifically	O
PLCgamma1	B-Gene_or_gene_product
-	O
that	O
are	O
important	O
for	O
tubulogenesis	O
,	O
differentiation	O
and	O
DNA	O
synthesis	O
.	O
<EOS>	B-X
Typically	B-X
,	B-X
proliferation	B-X
and	B-X
chemotaxis	B-X
of	B-X
endothelial	B-X
cells	B-X
is	B-X
driven	B-X
by	B-X
growth	B-X
factors	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
VEGF	B-X
activates	B-X
phospholipases	B-X
(	B-X
PLCs	B-X
)	B-X
-	B-X
specifically	B-X
PLCgamma1	B-X
-	B-X
that	B-X
are	B-X
important	B-X
for	B-X
tubulogenesis	B-X
,	B-X
differentiation	B-X
and	B-X
DNA	B-X
synthesis	B-X
.	B-X
However	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
VEGF	B-X
,	B-X
specifically	B-X
through	B-X
VEGFR2	B-X
,	B-X
induces	B-X
phosphorylation	B-X
of	B-X
two	B-X
serine	B-X
residues	B-X
on	B-X
PLCbeta3	B-X
,	B-X
and	B-X
this	B-X
was	B-X
confirmed	B-X
in	B-X
an	B-X
ex	B-X
vivo	B-X
embryoid	B-X
body	B-X
model	B-X
.	B-X
Given	B-X
that	B-X
PLCbeta3	B-X
is	B-X
typically	B-X
known	B-X
as	B-X
an	B-X
effector	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
a	B-X
unique	B-X
crosstalk	B-X
between	B-X
the	B-X
G-protein	B-X
and	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
(	B-X
RTK	B-X
)	B-X
axes	B-X
and	B-X
reveal	B-X
a	B-X
novel	B-X
molecular	B-X
mechanism	B-X
of	B-X
VEGF	B-X
signaling	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
angiogenesis	B-X
.	B-X

However	O
,	O
we	O
show	O
here	O
that	O
VEGF	B-Gene_or_gene_product
,	O
specifically	O
through	O
VEGFR2	B-Gene_or_gene_product
,	O
induces	O
phosphorylation	O
of	O
two	O
serine	O
residues	O
on	O
PLCbeta3	B-Gene_or_gene_product
,	O
and	O
this	O
was	O
confirmed	O
in	O
an	O
ex	O
vivo	O
embryoid	O
body	O
model	O
.	O

Knockdown	O
of	O
PLCbeta3	B-Gene_or_gene_product
in	O
HUVEC	O
cells	O
affects	O
IP3	B-Gene_or_gene_product
production	O
,	O
actin	B-Gene_or_gene_product
reorganization	O
,	O
migration	O
and	O
proliferation	O
;	O
whereas	O
migration	O
is	O
inhibited	O
,	O
proliferation	O
is	O
enhanced	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
migration	B-X
is	B-X
essential	B-X
to	B-X
angiogenesis	B-X
.	B-X
Typically	B-X
,	B-X
proliferation	B-X
and	B-X
chemotaxis	B-X
of	B-X
endothelial	B-X
cells	B-X
is	B-X
driven	B-X
by	B-X
growth	B-X
factors	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
However	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
VEGF	B-X
,	B-X
specifically	B-X
through	B-X
VEGFR2	B-X
,	B-X
induces	B-X
phosphorylation	B-X
of	B-X
two	B-X
serine	B-X
residues	B-X
on	B-X
PLCbeta3	B-X
,	B-X
and	B-X
this	B-X
was	B-X
confirmed	B-X
in	B-X
an	B-X
ex	B-X
vivo	B-X
embryoid	B-X
body	B-X
model	B-X
.	B-X
Knockdown	B-X
of	B-X
PLCbeta3	B-X
in	B-X
HUVEC	B-X
cells	B-X
affects	B-X
IP3	B-X
production	B-X
,	B-X
actin	B-X
reorganization	B-X
,	B-X
migration	B-X
and	B-X
proliferation	B-X
;	B-X
whereas	B-X
migration	B-X
is	B-X
inhibited	B-X
,	B-X
proliferation	B-X
is	B-X
enhanced	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhanced	B-X
proliferation	B-X
is	B-X
precipitated	B-X
by	B-X
an	B-X
accelerated	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
decreased	B-X
migration	B-X
by	B-X
an	B-X
inability	B-X
to	B-X
activate	B-X
CDC42	B-X
.	B-X
Given	B-X
that	B-X
PLCbeta3	B-X
is	B-X
typically	B-X
known	B-X
as	B-X
an	B-X
effector	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
a	B-X
unique	B-X
crosstalk	B-X
between	B-X
the	B-X
G-protein	B-X
and	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
(	B-X
RTK	B-X
)	B-X
axes	B-X
and	B-X
reveal	B-X
a	B-X
novel	B-X
molecular	B-X
mechanism	B-X
of	B-X
VEGF	B-X
signaling	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
angiogenesis	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
enhanced	O
proliferation	O
is	O
precipitated	O
by	O
an	O
accelerated	O
cell	O
cycle	O
,	O
and	O
decreased	O
migration	O
by	O
an	O
inability	O
to	O
activate	O
CDC42	B-Gene_or_gene_product
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
migration	B-X
is	B-X
essential	B-X
to	B-X
angiogenesis	B-X
.	B-X
Typically	B-X
,	B-X
proliferation	B-X
and	B-X
chemotaxis	B-X
of	B-X
endothelial	B-X
cells	B-X
is	B-X
driven	B-X
by	B-X
growth	B-X
factors	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
VEGF	B-X
activates	B-X
phospholipases	B-X
(	B-X
PLCs	B-X
)	B-X
-	B-X
specifically	B-X
PLCgamma1	B-X
-	B-X
that	B-X
are	B-X
important	B-X
for	B-X
tubulogenesis	B-X
,	B-X
differentiation	B-X
and	B-X
DNA	B-X
synthesis	B-X
.	B-X
Knockdown	B-X
of	B-X
PLCbeta3	B-X
in	B-X
HUVEC	B-X
cells	B-X
affects	B-X
IP3	B-X
production	B-X
,	B-X
actin	B-X
reorganization	B-X
,	B-X
migration	B-X
and	B-X
proliferation	B-X
;	B-X
whereas	B-X
migration	B-X
is	B-X
inhibited	B-X
,	B-X
proliferation	B-X
is	B-X
enhanced	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhanced	B-X
proliferation	B-X
is	B-X
precipitated	B-X
by	B-X
an	B-X
accelerated	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
decreased	B-X
migration	B-X
by	B-X
an	B-X
inability	B-X
to	B-X
activate	B-X
CDC42	B-X
.	B-X
Given	B-X
that	B-X
PLCbeta3	B-X
is	B-X
typically	B-X
known	B-X
as	B-X
an	B-X
effector	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
a	B-X
unique	B-X
crosstalk	B-X
between	B-X
the	B-X
G-protein	B-X
and	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
(	B-X
RTK	B-X
)	B-X
axes	B-X
and	B-X
reveal	B-X
a	B-X
novel	B-X
molecular	B-X
mechanism	B-X
of	B-X
VEGF	B-X
signaling	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
angiogenesis	B-X
.	B-X

Given	O
that	O
PLCbeta3	B-Gene_or_gene_product
is	O
typically	O
known	O
as	O
an	O
effector	O
of	O
heterotrimeric	B-Gene_or_gene_product
G	I-Gene_or_gene_product
-	I-Gene_or_gene_product
proteins	I-Gene_or_gene_product
,	O
our	O
data	O
demonstrate	O
a	O
unique	O
crosstalk	O
between	O
the	O
G	B-Gene_or_gene_product
-	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
and	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
axes	O
and	O
reveal	O
a	O
novel	O
molecular	O
mechanism	O
of	O
VEGF	B-Gene_or_gene_product
signaling	O
and	O
,	O
thus	O
,	O
angiogenesis	O
.	O

Antivascular	O
actions	O
of	O
microtubule	O
-	O
binding	O
drugs	O
.	O
<EOS>	B-X
Microtubule-binding	B-X
drugs	B-X
(	B-X
MBD	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
cancer	B-X
chemotherapy	B-X
and	B-X
also	B-X
have	B-X
clinically	B-X
relevant	B-X
antiangiogenic	B-X
and	B-X
vascular-disrupting	B-X
properties	B-X
.	B-X
These	B-X
antivascular	B-X
actions	B-X
are	B-X
due	B-X
in	B-X
part	B-X
to	B-X
direct	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
all	B-X
MBDs	B-X
(	B-X
both	B-X
microtubule-stabilizing	B-X
and	B-X
microtubule-destabilizing	B-X
)	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
,	B-X
actions	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
correspond	B-X
to	B-X
therapeutic	B-X
antiangiogenic	B-X
actions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
microtubule-destabilizing	B-X
agents	B-X
cause	B-X
prominent	B-X
changes	B-X
in	B-X
endothelial	B-X
cell	B-X
morphology	B-X
,	B-X
an	B-X
action	B-X
associated	B-X
with	B-X
rapid	B-X
vascular	B-X
collapse	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
occur	B-X
in	B-X
vitro	B-X
at	B-X
low	B-X
drug	B-X
concentrations	B-X
,	B-X
which	B-X
do	B-X
not	B-X
affect	B-X
microtubule	B-X
gross	B-X
morphology	B-X
,	B-X
do	B-X
not	B-X
cause	B-X
microtubule	B-X
bundling	B-X
or	B-X
microtubule	B-X
loss	B-X
and	B-X
do	B-X
not	B-X
induce	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
apoptosis	B-X
,	B-X
or	B-X
cell	B-X
death	B-X
.	B-X
Rather	B-X
,	B-X
it	B-X
has	B-X
been	B-X
hypothesized	B-X
that	B-X
,	B-X
at	B-X
low	B-X
concentrations	B-X
,	B-X
MBDs	B-X
produce	B-X
more	B-X
subtle	B-X
effects	B-X
on	B-X
microtubule	B-X
dynamics	B-X
,	B-X
block	B-X
critical	B-X
cell	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
prevent	B-X
the	B-X
microtubules	B-X
from	B-X
properly	B-X
interacting	B-X
with	B-X
transient	B-X
subcellular	B-X
assemblies	B-X
(	B-X
focal	B-X
adhesions	B-X
and	B-X
adherens	B-X
junctions	B-X
)	B-X
whose	B-X
subsequent	B-X
stabilization	B-X
and/or	B-X
maturation	B-X
are	B-X
required	B-X
for	B-X
cell	B-X
motility	B-X
and	B-X
cell-cell	B-X
interactions	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
studies	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
mechanisms	B-X
for	B-X
the	B-X
antivascular	B-X
actions	B-X
of	B-X
the	B-X
MBDs	B-X
,	B-X
information	B-X
that	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
the	B-X
identification	B-X
or	B-X
design	B-X
of	B-X
agents	B-X
whose	B-X
actions	B-X
more	B-X
selectively	B-X
target	B-X
the	B-X
tumor	B-X
vasculature	B-X
.	B-X

Microtubule	O
-	O
binding	O
drugs	O
(	O
MBD	O
)	O
are	O
widely	O
used	O
in	O
cancer	O
chemotherapy	O
and	O
also	O
have	O
clinically	O
relevant	O
antiangiogenic	O
and	O
vascular	O
-	O
disrupting	O
properties	O
.	O
<EOS>	B-X
Microtubule-binding	B-X
drugs	B-X
(	B-X
MBD	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
cancer	B-X
chemotherapy	B-X
and	B-X
also	B-X
have	B-X
clinically	B-X
relevant	B-X
antiangiogenic	B-X
and	B-X
vascular-disrupting	B-X
properties	B-X
.	B-X
These	B-X
antivascular	B-X
actions	B-X
are	B-X
due	B-X
in	B-X
part	B-X
to	B-X
direct	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
all	B-X
MBDs	B-X
(	B-X
both	B-X
microtubule-stabilizing	B-X
and	B-X
microtubule-destabilizing	B-X
)	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
,	B-X
actions	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
correspond	B-X
to	B-X
therapeutic	B-X
antiangiogenic	B-X
actions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
microtubule-destabilizing	B-X
agents	B-X
cause	B-X
prominent	B-X
changes	B-X
in	B-X
endothelial	B-X
cell	B-X
morphology	B-X
,	B-X
an	B-X
action	B-X
associated	B-X
with	B-X
rapid	B-X
vascular	B-X
collapse	B-X
in	B-X
vivo	B-X
.	B-X
Rather	B-X
,	B-X
it	B-X
has	B-X
been	B-X
hypothesized	B-X
that	B-X
,	B-X
at	B-X
low	B-X
concentrations	B-X
,	B-X
MBDs	B-X
produce	B-X
more	B-X
subtle	B-X
effects	B-X
on	B-X
microtubule	B-X
dynamics	B-X
,	B-X
block	B-X
critical	B-X
cell	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
prevent	B-X
the	B-X
microtubules	B-X
from	B-X
properly	B-X
interacting	B-X
with	B-X
transient	B-X
subcellular	B-X
assemblies	B-X
(	B-X
focal	B-X
adhesions	B-X
and	B-X
adherens	B-X
junctions	B-X
)	B-X
whose	B-X
subsequent	B-X
stabilization	B-X
and/or	B-X
maturation	B-X
are	B-X
required	B-X
for	B-X
cell	B-X
motility	B-X
and	B-X
cell-cell	B-X
interactions	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
studies	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
mechanisms	B-X
for	B-X
the	B-X
antivascular	B-X
actions	B-X
of	B-X
the	B-X
MBDs	B-X
,	B-X
information	B-X
that	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
the	B-X
identification	B-X
or	B-X
design	B-X
of	B-X
agents	B-X
whose	B-X
actions	B-X
more	B-X
selectively	B-X
target	B-X
the	B-X
tumor	B-X
vasculature	B-X
.	B-X

These	O
antivascular	O
actions	O
are	O
due	O
in	O
part	O
to	O
direct	O
effects	O
on	O
endothelial	O
cells	O
,	O
and	O
all	O
MBDs	O
(	O
both	O
microtubule	O
-	O
stabilizing	O
and	O
microtubule	O
-	O
destabilizing	O
)	O
inhibit	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
tube	O
formation	O
in	O
vitro	O
,	O
actions	O
that	O
are	O
thought	O
to	O
correspond	O
to	O
therapeutic	O
antiangiogenic	O
actions	O
.	O
<EOS>	B-X
Microtubule-binding	B-X
drugs	B-X
(	B-X
MBD	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
cancer	B-X
chemotherapy	B-X
and	B-X
also	B-X
have	B-X
clinically	B-X
relevant	B-X
antiangiogenic	B-X
and	B-X
vascular-disrupting	B-X
properties	B-X
.	B-X
These	B-X
antivascular	B-X
actions	B-X
are	B-X
due	B-X
in	B-X
part	B-X
to	B-X
direct	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
all	B-X
MBDs	B-X
(	B-X
both	B-X
microtubule-stabilizing	B-X
and	B-X
microtubule-destabilizing	B-X
)	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
,	B-X
actions	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
correspond	B-X
to	B-X
therapeutic	B-X
antiangiogenic	B-X
actions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
microtubule-destabilizing	B-X
agents	B-X
cause	B-X
prominent	B-X
changes	B-X
in	B-X
endothelial	B-X
cell	B-X
morphology	B-X
,	B-X
an	B-X
action	B-X
associated	B-X
with	B-X
rapid	B-X
vascular	B-X
collapse	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
occur	B-X
in	B-X
vitro	B-X
at	B-X
low	B-X
drug	B-X
concentrations	B-X
,	B-X
which	B-X
do	B-X
not	B-X
affect	B-X
microtubule	B-X
gross	B-X
morphology	B-X
,	B-X
do	B-X
not	B-X
cause	B-X
microtubule	B-X
bundling	B-X
or	B-X
microtubule	B-X
loss	B-X
and	B-X
do	B-X
not	B-X
induce	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
apoptosis	B-X
,	B-X
or	B-X
cell	B-X
death	B-X
.	B-X
Rather	B-X
,	B-X
it	B-X
has	B-X
been	B-X
hypothesized	B-X
that	B-X
,	B-X
at	B-X
low	B-X
concentrations	B-X
,	B-X
MBDs	B-X
produce	B-X
more	B-X
subtle	B-X
effects	B-X
on	B-X
microtubule	B-X
dynamics	B-X
,	B-X
block	B-X
critical	B-X
cell	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
prevent	B-X
the	B-X
microtubules	B-X
from	B-X
properly	B-X
interacting	B-X
with	B-X
transient	B-X
subcellular	B-X
assemblies	B-X
(	B-X
focal	B-X
adhesions	B-X
and	B-X
adherens	B-X
junctions	B-X
)	B-X
whose	B-X
subsequent	B-X
stabilization	B-X
and/or	B-X
maturation	B-X
are	B-X
required	B-X
for	B-X
cell	B-X
motility	B-X
and	B-X
cell-cell	B-X
interactions	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
studies	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
mechanisms	B-X
for	B-X
the	B-X
antivascular	B-X
actions	B-X
of	B-X
the	B-X
MBDs	B-X
,	B-X
information	B-X
that	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
the	B-X
identification	B-X
or	B-X
design	B-X
of	B-X
agents	B-X
whose	B-X
actions	B-X
more	B-X
selectively	B-X
target	B-X
the	B-X
tumor	B-X
vasculature	B-X
.	B-X

In	O
addition	O
,	O
the	O
microtubule	O
-	O
destabilizing	O
agents	O
cause	O
prominent	O
changes	O
in	O
endothelial	O
cell	O
morphology	O
,	O
an	O
action	O
associated	O
with	O
rapid	O
vascular	O
collapse	O
in	O
vivo	O
.	O
<EOS>	B-X
Microtubule-binding	B-X
drugs	B-X
(	B-X
MBD	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
cancer	B-X
chemotherapy	B-X
and	B-X
also	B-X
have	B-X
clinically	B-X
relevant	B-X
antiangiogenic	B-X
and	B-X
vascular-disrupting	B-X
properties	B-X
.	B-X
These	B-X
antivascular	B-X
actions	B-X
are	B-X
due	B-X
in	B-X
part	B-X
to	B-X
direct	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
all	B-X
MBDs	B-X
(	B-X
both	B-X
microtubule-stabilizing	B-X
and	B-X
microtubule-destabilizing	B-X
)	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
,	B-X
actions	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
correspond	B-X
to	B-X
therapeutic	B-X
antiangiogenic	B-X
actions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
microtubule-destabilizing	B-X
agents	B-X
cause	B-X
prominent	B-X
changes	B-X
in	B-X
endothelial	B-X
cell	B-X
morphology	B-X
,	B-X
an	B-X
action	B-X
associated	B-X
with	B-X
rapid	B-X
vascular	B-X
collapse	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
occur	B-X
in	B-X
vitro	B-X
at	B-X
low	B-X
drug	B-X
concentrations	B-X
,	B-X
which	B-X
do	B-X
not	B-X
affect	B-X
microtubule	B-X
gross	B-X
morphology	B-X
,	B-X
do	B-X
not	B-X
cause	B-X
microtubule	B-X
bundling	B-X
or	B-X
microtubule	B-X
loss	B-X
and	B-X
do	B-X
not	B-X
induce	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
apoptosis	B-X
,	B-X
or	B-X
cell	B-X
death	B-X
.	B-X
Rather	B-X
,	B-X
it	B-X
has	B-X
been	B-X
hypothesized	B-X
that	B-X
,	B-X
at	B-X
low	B-X
concentrations	B-X
,	B-X
MBDs	B-X
produce	B-X
more	B-X
subtle	B-X
effects	B-X
on	B-X
microtubule	B-X
dynamics	B-X
,	B-X
block	B-X
critical	B-X
cell	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
prevent	B-X
the	B-X
microtubules	B-X
from	B-X
properly	B-X
interacting	B-X
with	B-X
transient	B-X
subcellular	B-X
assemblies	B-X
(	B-X
focal	B-X
adhesions	B-X
and	B-X
adherens	B-X
junctions	B-X
)	B-X
whose	B-X
subsequent	B-X
stabilization	B-X
and/or	B-X
maturation	B-X
are	B-X
required	B-X
for	B-X
cell	B-X
motility	B-X
and	B-X
cell-cell	B-X
interactions	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
studies	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
mechanisms	B-X
for	B-X
the	B-X
antivascular	B-X
actions	B-X
of	B-X
the	B-X
MBDs	B-X
,	B-X
information	B-X
that	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
the	B-X
identification	B-X
or	B-X
design	B-X
of	B-X
agents	B-X
whose	B-X
actions	B-X
more	B-X
selectively	B-X
target	B-X
the	B-X
tumor	B-X
vasculature	B-X
.	B-X

The	O
effects	O
on	O
endothelial	O
cells	O
occur	O
in	O
vitro	O
at	O
low	O
drug	O
concentrations	O
,	O
which	O
do	O
not	O
affect	O
microtubule	O
gross	O
morphology	O
,	O
do	O
not	O
cause	O
microtubule	O
bundling	O
or	O
microtubule	O
loss	O
and	O
do	O
not	O
induce	O
cell	O
cycle	O
arrest	O
,	O
apoptosis	O
,	O
or	O
cell	O
death	O
.	O
<EOS>	B-X
It	B-X
is	B-X
accompanied	B-X
by	B-X
the	B-X
shortening	B-X
of	B-X
kinetochore-attached	B-X
microtubules	B-X
.	B-X
The	B-X
requisite	B-X
tubulin	B-X
depolymerization	B-X
may	B-X
occur	B-X
at	B-X
kinetochores	B-X
,	B-X
at	B-X
poles	B-X
,	B-X
or	B-X
both	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
species	B-X
and/or	B-X
the	B-X
time	B-X
in	B-X
mitosis	B-X
.	B-X
These	B-X
depolymerization	B-X
events	B-X
are	B-X
local	B-X
and	B-X
suggest	B-X
that	B-X
cells	B-X
regulate	B-X
microtubule	B-X
dynamics	B-X
in	B-X
specific	B-X
places	B-X
,	B-X
presumably	B-X
by	B-X
the	B-X
localization	B-X
of	B-X
relevant	B-X
enzymes	B-X
and	B-X
microtubule-associated	B-X
proteins	B-X
to	B-X
specific	B-X
loci	B-X
,	B-X
such	B-X
as	B-X
pericentriolar	B-X
material	B-X
and	B-X
outer	B-X
kinetochores	B-X
.	B-X
Motor	B-X
enzymes	B-X
can	B-X
contribute	B-X
to	B-X
anaphase	B-X
A	B-X
,	B-X
both	B-X
by	B-X
altering	B-X
microtubule	B-X
stability	B-X
and	B-X
by	B-X
pushing	B-X
or	B-X
pulling	B-X
microtubules	B-X
through	B-X
the	B-X
cell	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
force	B-X
on	B-X
chromosomes	B-X
requires	B-X
couplings	B-X
that	B-X
can	B-X
both	B-X
withstand	B-X
the	B-X
considerable	B-X
force	B-X
that	B-X
spindles	B-X
can	B-X
generate	B-X
and	B-X
simultaneously	B-X
permit	B-X
tubulin	B-X
addition	B-X
and	B-X
loss	B-X
.	B-X
This	B-X
chapter	B-X
reviews	B-X
literature	B-X
on	B-X
the	B-X
molecules	B-X
that	B-X
regulate	B-X
anaphase	B-X
microtubule	B-X
dynamics	B-X
,	B-X
couple	B-X
dynamic	B-X
microtubules	B-X
to	B-X
kinetochores	B-X
and	B-X
poles	B-X
,	B-X
and	B-X
generate	B-X
forces	B-X
for	B-X
microtubule	B-X
and	B-X
chromosome	B-X
motion	B-X
.	B-X

Rather	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
,	O
at	O
low	O
concentrations	O
,	O
MBDs	O
produce	O
more	O
subtle	O
effects	O
on	O
microtubule	O
dynamics	O
,	O
block	O
critical	O
cell	O
signaling	O
pathways	O
,	O
and	O
prevent	O
the	O
microtubules	O
from	O
properly	O
interacting	O
with	O
transient	O
subcellular	O
assemblies	O
(	O
focal	O
adhesions	O
and	O
adherens	O
junctions	O
)	O
whose	O
subsequent	O
stabilization	O
and	O
/	O
or	O
maturation	O
are	O
required	O
for	O
cell	O
motility	O
and	O
cell	O
-	O
cell	O
interactions	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
extracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
levels	B-X
impact	B-X
on	B-X
distinct	B-X
processes	B-X
in	B-X
mammalian	B-X
reproduction	B-X
.	B-X
The	B-X
calcium-sensing	B-X
receptor	B-X
(	B-X
CaSR	B-X
)	B-X
translates	B-X
changes	B-X
in	B-X
extracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-concentrations	B-X
into	B-X
cellular	B-X
reactions	B-X
.	B-X
CaSR	B-X
was	B-X
detected	B-X
in	B-X
placental	B-X
cells	B-X
mediating	B-X
materno-fetal	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-transport	B-X
such	B-X
as	B-X
the	B-X
murine	B-X
intraplacental	B-X
yolk	B-X
sac	B-X
(	B-X
IPYS	B-X
)	B-X
and	B-X
the	B-X
human	B-X
syncytiotrophoblast	B-X
.	B-X
Receptor	B-X
expression	B-X
was	B-X
reported	B-X
in	B-X
human	B-X
and	B-X
rat	B-X
ovarian	B-X
surface	B-X
epithelial	B-X
(	B-X
ROSE	B-X
)	B-X
cells	B-X
,	B-X
where	B-X
CaSR	B-X
activation	B-X
stimulates	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
follicles	B-X
of	B-X
various	B-X
species	B-X
a	B-X
role	B-X
of	B-X
CaSR	B-X
activation	B-X
in	B-X
oocyte	B-X
maturation	B-X
was	B-X
suggested	B-X
.	B-X
Based	B-X
on	B-X
studies	B-X
in	B-X
avian	B-X
follicles	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
CaSR	B-X
expressed	B-X
in	B-X
granulosa	B-X
cells	B-X
may	B-X
support	B-X
the	B-X
survival	B-X
of	B-X
follicles	B-X
after	B-X
their	B-X
selection	B-X
.	B-X
CaSR	B-X
in	B-X
rat	B-X
and	B-X
equine	B-X
sperms	B-X
was	B-X
functionally	B-X
linked	B-X
to	B-X
sperm	B-X
motility	B-X
and	B-X
sperm	B-X
capacitation	B-X
.	B-X
Implantation	B-X
involves	B-X
complex	B-X
interactions	B-X
between	B-X
the	B-X
blastocyst	B-X
and	B-X
the	B-X
uterine	B-X
epithelium	B-X
.	B-X
During	B-X
early	B-X
pregnancy	B-X
,	B-X
CaSR	B-X
expression	B-X
at	B-X
the	B-X
implantation	B-X
site	B-X
as	B-X
well	B-X
as	B-X
in	B-X
decidual	B-X
cells	B-X
indicates	B-X
that	B-X
CaSR	B-X
is	B-X
important	B-X
for	B-X
blastocyst	B-X
implantation	B-X
and	B-X
decidualization	B-X
in	B-X
the	B-X
rat	B-X
uterus	B-X
.	B-X
Moreover	B-X
,	B-X
several	B-X
studies	B-X
reported	B-X
altered	B-X
expression	B-X
of	B-X
CaSR	B-X
in	B-X
cells	B-X
of	B-X
reproductive	B-X
tissues	B-X
under	B-X
pathologic	B-X
conditions	B-X
.	B-X
However	B-X
,	B-X
in	B-X
many	B-X
tissues	B-X
we	B-X
still	B-X
lack	B-X
knowledge	B-X
on	B-X
physiological	B-X
ligands	B-X
activating	B-X
CaSR	B-X
,	B-X
CaSR-linked	B-X
G-proteins	B-X
,	B-X
activated	B-X
intracellular	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
functional	B-X
relevance	B-X
of	B-X
CaSR	B-X
activation	B-X
.	B-X
Clearly	B-X
,	B-X
more	B-X
work	B-X
is	B-X
required	B-X
in	B-X
the	B-X
future	B-X
to	B-X
decode	B-X
the	B-X
complex	B-X
physiologic	B-X
and	B-X
pathophysiologic	B-X
relationship	B-X
of	B-X
CaSR	B-X
and	B-X
the	B-X
mammalian	B-X
reproductive	B-X
system	B-X
.	B-X

This	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
to	O
define	O
the	O
molecular	O
mechanisms	O
for	O
the	O
antivascular	O
actions	O
of	O
the	O
MBDs	O
,	O
information	O
that	O
could	O
be	O
useful	O
in	O
the	O
identification	O
or	O
design	O
of	O
agents	O
whose	O
actions	O
more	O
selectively	O
target	O
the	O
tumor	O
vasculature	O
.	O
<EOS>	B-X
These	B-X
antivascular	B-X
actions	B-X
are	B-X
due	B-X
in	B-X
part	B-X
to	B-X
direct	B-X
effects	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
all	B-X
MBDs	B-X
(	B-X
both	B-X
microtubule-stabilizing	B-X
and	B-X
microtubule-destabilizing	B-X
)	B-X
inhibit	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
,	B-X
actions	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
correspond	B-X
to	B-X
therapeutic	B-X
antiangiogenic	B-X
actions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
microtubule-destabilizing	B-X
agents	B-X
cause	B-X
prominent	B-X
changes	B-X
in	B-X
endothelial	B-X
cell	B-X
morphology	B-X
,	B-X
an	B-X
action	B-X
associated	B-X
with	B-X
rapid	B-X
vascular	B-X
collapse	B-X
in	B-X
vivo	B-X
.	B-X
Rather	B-X
,	B-X
it	B-X
has	B-X
been	B-X
hypothesized	B-X
that	B-X
,	B-X
at	B-X
low	B-X
concentrations	B-X
,	B-X
MBDs	B-X
produce	B-X
more	B-X
subtle	B-X
effects	B-X
on	B-X
microtubule	B-X
dynamics	B-X
,	B-X
block	B-X
critical	B-X
cell	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
prevent	B-X
the	B-X
microtubules	B-X
from	B-X
properly	B-X
interacting	B-X
with	B-X
transient	B-X
subcellular	B-X
assemblies	B-X
(	B-X
focal	B-X
adhesions	B-X
and	B-X
adherens	B-X
junctions	B-X
)	B-X
whose	B-X
subsequent	B-X
stabilization	B-X
and/or	B-X
maturation	B-X
are	B-X
required	B-X
for	B-X
cell	B-X
motility	B-X
and	B-X
cell-cell	B-X
interactions	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
studies	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
mechanisms	B-X
for	B-X
the	B-X
antivascular	B-X
actions	B-X
of	B-X
the	B-X
MBDs	B-X
,	B-X
information	B-X
that	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
the	B-X
identification	B-X
or	B-X
design	B-X
of	B-X
agents	B-X
whose	B-X
actions	B-X
more	B-X
selectively	B-X
target	B-X
the	B-X
tumor	B-X
vasculature	B-X
.	B-X

Neurovascular	O
effects	O
of	O
CD47	B-Gene_or_gene_product
signaling	O
:	O
promotion	O
of	O
cell	O
death	O
,	O
inflammation	O
,	O
and	O
suppression	O
of	O
angiogenesis	O
in	O
brain	O
endothelial	O
cells	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
emphasizes	B-X
that	B-X
common	B-X
signals	B-X
and	B-X
substrates	B-X
underlie	B-X
the	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
of	B-X
neuronal	B-X
and	B-X
endothelial	B-X
compartments	B-X
in	B-X
brain	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
integrin-associated	B-X
protein	B-X
CD47	B-X
promotes	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Is	B-X
it	B-X
possible	B-X
that	B-X
CD47	B-X
may	B-X
also	B-X
negatively	B-X
affect	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
?	B-X
Exposure	B-X
of	B-X
wild-type	B-X
primary	B-X
mouse	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin	B-X
1	B-X
(	B-X
TSP-1	B-X
)	B-X
induced	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
derived	B-X
from	B-X
CD47	B-X
knockout	B-X
mice	B-X
.	B-X
The	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
,	B-X
4N1K	B-X
,	B-X
similarly	B-X
induced	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
brain	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Promotion	B-X
of	B-X
inflammation	B-X
was	B-X
also	B-X
involved	B-X
because	B-X
lower	B-X
TSP-1	B-X
was	B-X
able	B-X
to	B-X
up-regulate	B-X
the	B-X
adhesion	B-X
molecules	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule-1	B-X
.	B-X
Finally	B-X
,	B-X
CD47	B-X
signaling	B-X
may	B-X
suppress	B-X
angiogenesis	B-X
because	B-X
4N1K	B-X
significantly	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
signaling	B-X
can	B-X
negatively	B-X
affect	B-X
the	B-X
viability	B-X
and	B-X
function	B-X
of	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
notion	B-X
that	B-X
CD47	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
neurovascular	B-X
target	B-X
for	B-X
stroke	B-X
and	B-X
brain	B-X
injury	B-X
.	B-X

The	O
concept	O
of	O
the	O
neurovascular	O
unit	O
emphasizes	O
that	O
common	O
signals	O
and	O
substrates	O
underlie	O
the	O
physiology	O
and	O
pathophysiology	O
of	O
neuronal	O
and	O
endothelial	O
compartments	O
in	O
brain	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
emphasizes	B-X
that	B-X
common	B-X
signals	B-X
and	B-X
substrates	B-X
underlie	B-X
the	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
of	B-X
neuronal	B-X
and	B-X
endothelial	B-X
compartments	B-X
in	B-X
brain	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
integrin-associated	B-X
protein	B-X
CD47	B-X
promotes	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Is	B-X
it	B-X
possible	B-X
that	B-X
CD47	B-X
may	B-X
also	B-X
negatively	B-X
affect	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
?	B-X
Exposure	B-X
of	B-X
wild-type	B-X
primary	B-X
mouse	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin	B-X
1	B-X
(	B-X
TSP-1	B-X
)	B-X
induced	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
derived	B-X
from	B-X
CD47	B-X
knockout	B-X
mice	B-X
.	B-X
The	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
,	B-X
4N1K	B-X
,	B-X
similarly	B-X
induced	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
brain	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Finally	B-X
,	B-X
CD47	B-X
signaling	B-X
may	B-X
suppress	B-X
angiogenesis	B-X
because	B-X
4N1K	B-X
significantly	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
signaling	B-X
can	B-X
negatively	B-X
affect	B-X
the	B-X
viability	B-X
and	B-X
function	B-X
of	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
notion	B-X
that	B-X
CD47	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
neurovascular	B-X
target	B-X
for	B-X
stroke	B-X
and	B-X
brain	B-X
injury	B-X
.	B-X

Recent	O
data	O
suggest	O
that	O
activation	O
of	O
the	O
integrin	B-Gene_or_gene_product
-	O
associated	O
protein	O
CD47	B-Gene_or_gene_product
promotes	O
neuronal	O
cell	O
death	O
.	O
<EOS>	B-X
CD47	B-X
or	B-X
integrin-associated	B-X
protein	B-X
promotes	B-X
cell	B-X
death	B-X
in	B-X
blood	B-X
and	B-X
tumor	B-X
cells	B-X
.	B-X
Recently	B-X
,	B-X
CD47	B-X
signaling	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
neurons	B-X
as	B-X
well	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
CD47	B-X
in	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Exposure	B-X
of	B-X
primary	B-X
mouse	B-X
cortical	B-X
neurons	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin-1	B-X
or	B-X
the	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
4N1K	B-X
induced	B-X
cell	B-X
death	B-X
.	B-X
Activation	B-X
of	B-X
CD47	B-X
elevated	B-X
levels	B-X
of	B-X
active	B-X
caspase	B-X
3	B-X
and	B-X
increased	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
in	B-X
a	B-X
time-dependent	B-X
manner	B-X
.	B-X
Both	B-X
ROS	B-X
scavengers	B-X
and	B-X
caspase	B-X
inhibitors	B-X
attenuated	B-X
cell	B-X
death	B-X
.	B-X
But	B-X
ROS	B-X
scavenging	B-X
did	B-X
not	B-X
reduce	B-X
the	B-X
activation	B-X
of	B-X
caspase	B-X
3	B-X
,	B-X
and	B-X
combination	B-X
treatments	B-X
with	B-X
a	B-X
caspase	B-X
inhibitor	B-X
plus	B-X
free	B-X
radical	B-X
scavenger	B-X
did	B-X
not	B-X
yield	B-X
additive	B-X
protection	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
parallel	B-X
and	B-X
redundant	B-X
pathways	B-X
of	B-X
oxidative	B-X
stress	B-X
and	B-X
caspase-mediated	B-X
cell	B-X
death	B-X
are	B-X
involved	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
mediates	B-X
neuronal	B-X
cell	B-X
death	B-X
through	B-X
caspase-dependent	B-X
and	B-X
caspase-independent	B-X
pathways	B-X
.	B-X

Is	O
it	O
possible	O
that	O
CD47	B-Gene_or_gene_product
may	O
also	O
negatively	O
affect	O
cerebral	O
endothelial	O
cells	O
?	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
emphasizes	B-X
that	B-X
common	B-X
signals	B-X
and	B-X
substrates	B-X
underlie	B-X
the	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
of	B-X
neuronal	B-X
and	B-X
endothelial	B-X
compartments	B-X
in	B-X
brain	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
integrin-associated	B-X
protein	B-X
CD47	B-X
promotes	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Is	B-X
it	B-X
possible	B-X
that	B-X
CD47	B-X
may	B-X
also	B-X
negatively	B-X
affect	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
?	B-X
Exposure	B-X
of	B-X
wild-type	B-X
primary	B-X
mouse	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin	B-X
1	B-X
(	B-X
TSP-1	B-X
)	B-X
induced	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
derived	B-X
from	B-X
CD47	B-X
knockout	B-X
mice	B-X
.	B-X
The	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
,	B-X
4N1K	B-X
,	B-X
similarly	B-X
induced	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
brain	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Promotion	B-X
of	B-X
inflammation	B-X
was	B-X
also	B-X
involved	B-X
because	B-X
lower	B-X
TSP-1	B-X
was	B-X
able	B-X
to	B-X
up-regulate	B-X
the	B-X
adhesion	B-X
molecules	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule-1	B-X
.	B-X
Finally	B-X
,	B-X
CD47	B-X
signaling	B-X
may	B-X
suppress	B-X
angiogenesis	B-X
because	B-X
4N1K	B-X
significantly	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
signaling	B-X
can	B-X
negatively	B-X
affect	B-X
the	B-X
viability	B-X
and	B-X
function	B-X
of	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
notion	B-X
that	B-X
CD47	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
neurovascular	B-X
target	B-X
for	B-X
stroke	B-X
and	B-X
brain	B-X
injury	B-X
.	B-X

Exposure	O
of	O
wild	O
-	O
type	O
primary	O
mouse	O
cerebral	O
endothelial	O
cells	O
to	O
the	O
CD47	B-Gene_or_gene_product
ligand	O
thrombospondin	B-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
induced	O
an	O
increasing	O
amount	O
of	O
cell	O
death	O
,	O
whereas	O
cytotoxicity	O
was	O
significantly	O
decreased	O
in	O
cerebral	O
endothelial	O
cells	O
derived	O
from	O
CD47	B-Gene_or_gene_product
knockout	O
mice	O
.	O

The	O
specific	O
CD47	B-Gene_or_gene_product
-	O
activating	O
peptide	O
,	O
4N1K	B-Gene_or_gene_product
,	O
similarly	O
induced	O
cell	O
death	O
in	O
human	O
brain	O
microvascular	O
endothelial	O
cells	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
emphasizes	B-X
that	B-X
common	B-X
signals	B-X
and	B-X
substrates	B-X
underlie	B-X
the	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
of	B-X
neuronal	B-X
and	B-X
endothelial	B-X
compartments	B-X
in	B-X
brain	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
integrin-associated	B-X
protein	B-X
CD47	B-X
promotes	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Is	B-X
it	B-X
possible	B-X
that	B-X
CD47	B-X
may	B-X
also	B-X
negatively	B-X
affect	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
?	B-X
Exposure	B-X
of	B-X
wild-type	B-X
primary	B-X
mouse	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin	B-X
1	B-X
(	B-X
TSP-1	B-X
)	B-X
induced	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
derived	B-X
from	B-X
CD47	B-X
knockout	B-X
mice	B-X
.	B-X
The	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
,	B-X
4N1K	B-X
,	B-X
similarly	B-X
induced	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
brain	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Promotion	B-X
of	B-X
inflammation	B-X
was	B-X
also	B-X
involved	B-X
because	B-X
lower	B-X
TSP-1	B-X
was	B-X
able	B-X
to	B-X
up-regulate	B-X
the	B-X
adhesion	B-X
molecules	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule-1	B-X
.	B-X
Finally	B-X
,	B-X
CD47	B-X
signaling	B-X
may	B-X
suppress	B-X
angiogenesis	B-X
because	B-X
4N1K	B-X
significantly	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
signaling	B-X
can	B-X
negatively	B-X
affect	B-X
the	B-X
viability	B-X
and	B-X
function	B-X
of	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
notion	B-X
that	B-X
CD47	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
neurovascular	B-X
target	B-X
for	B-X
stroke	B-X
and	B-X
brain	B-X
injury	B-X
.	B-X

Promotion	O
of	O
inflammation	O
was	O
also	O
involved	O
because	O
lower	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
was	O
able	O
to	O
up	O
-	O
regulate	O
the	O
adhesion	O
molecules	O
intercellular	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O

Finally	O
,	O
CD47	B-Gene_or_gene_product
signaling	O
may	O
suppress	O
angiogenesis	O
because	O
4N1K	B-Gene_or_gene_product
significantly	O
inhibited	O
endothelial	O
cell	O
migration	O
and	O
tube	O
formation	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
emphasizes	B-X
that	B-X
common	B-X
signals	B-X
and	B-X
substrates	B-X
underlie	B-X
the	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
of	B-X
neuronal	B-X
and	B-X
endothelial	B-X
compartments	B-X
in	B-X
brain	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
integrin-associated	B-X
protein	B-X
CD47	B-X
promotes	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Is	B-X
it	B-X
possible	B-X
that	B-X
CD47	B-X
may	B-X
also	B-X
negatively	B-X
affect	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
?	B-X
Exposure	B-X
of	B-X
wild-type	B-X
primary	B-X
mouse	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin	B-X
1	B-X
(	B-X
TSP-1	B-X
)	B-X
induced	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
derived	B-X
from	B-X
CD47	B-X
knockout	B-X
mice	B-X
.	B-X
The	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
,	B-X
4N1K	B-X
,	B-X
similarly	B-X
induced	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
brain	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Promotion	B-X
of	B-X
inflammation	B-X
was	B-X
also	B-X
involved	B-X
because	B-X
lower	B-X
TSP-1	B-X
was	B-X
able	B-X
to	B-X
up-regulate	B-X
the	B-X
adhesion	B-X
molecules	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule-1	B-X
.	B-X
Finally	B-X
,	B-X
CD47	B-X
signaling	B-X
may	B-X
suppress	B-X
angiogenesis	B-X
because	B-X
4N1K	B-X
significantly	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
signaling	B-X
can	B-X
negatively	B-X
affect	B-X
the	B-X
viability	B-X
and	B-X
function	B-X
of	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
notion	B-X
that	B-X
CD47	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
neurovascular	B-X
target	B-X
for	B-X
stroke	B-X
and	B-X
brain	B-X
injury	B-X
.	B-X

We	O
conclude	O
that	O
CD47	B-Gene_or_gene_product
signaling	O
can	O
negatively	O
affect	O
the	O
viability	O
and	O
function	O
of	O
cerebral	O
endothelial	O
cells	O
,	O
further	O
supporting	O
the	O
notion	O
that	O
CD47	B-Gene_or_gene_product
may	O
be	O
a	O
potential	O
neurovascular	O
target	O
for	O
stroke	O
and	O
brain	O
injury	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
emphasizes	B-X
that	B-X
common	B-X
signals	B-X
and	B-X
substrates	B-X
underlie	B-X
the	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
of	B-X
neuronal	B-X
and	B-X
endothelial	B-X
compartments	B-X
in	B-X
brain	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
integrin-associated	B-X
protein	B-X
CD47	B-X
promotes	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Is	B-X
it	B-X
possible	B-X
that	B-X
CD47	B-X
may	B-X
also	B-X
negatively	B-X
affect	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
?	B-X
Exposure	B-X
of	B-X
wild-type	B-X
primary	B-X
mouse	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
to	B-X
the	B-X
CD47	B-X
ligand	B-X
thrombospondin	B-X
1	B-X
(	B-X
TSP-1	B-X
)	B-X
induced	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
derived	B-X
from	B-X
CD47	B-X
knockout	B-X
mice	B-X
.	B-X
The	B-X
specific	B-X
CD47-activating	B-X
peptide	B-X
,	B-X
4N1K	B-X
,	B-X
similarly	B-X
induced	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
brain	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Finally	B-X
,	B-X
CD47	B-X
signaling	B-X
may	B-X
suppress	B-X
angiogenesis	B-X
because	B-X
4N1K	B-X
significantly	B-X
inhibited	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
tube	B-X
formation	B-X
in	B-X
vitro	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
CD47	B-X
signaling	B-X
can	B-X
negatively	B-X
affect	B-X
the	B-X
viability	B-X
and	B-X
function	B-X
of	B-X
cerebral	B-X
endothelial	B-X
cells	B-X
,	B-X
further	B-X
supporting	B-X
the	B-X
notion	B-X
that	B-X
CD47	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
neurovascular	B-X
target	B-X
for	B-X
stroke	B-X
and	B-X
brain	B-X
injury	B-X
.	B-X

Cisplatin	O
reduces	O
endothelial	O
cell	O
migration	O
via	O
regulation	O
of	O
type	B-Gene_or_gene_product
2	I-Gene_or_gene_product
-	I-Gene_or_gene_product
matrix	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
activity	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cisplatin	B-X
on	B-X
endothelial	B-X
cell	B-X
migration	B-X
,	B-X
an	B-X
essential	B-X
process	B-X
for	B-X
vascular	B-X
remodeling	B-X
and	B-X
regeneration	B-X
in	B-X
several	B-X
physiological	B-X
and	B-X
pathological	B-X
situations	B-X
.	B-X

AIMS	O
:	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	O
on	O
endothelial	O
cell	O
migration	O
,	O
an	O
essential	O
process	O
for	O
vascular	O
remodeling	O
and	O
regeneration	O
in	O
several	O
physiological	O
and	O
pathological	O
situations	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cisplatin	B-X
on	B-X
endothelial	B-X
cell	B-X
migration	B-X
,	B-X
an	B-X
essential	B-X
process	B-X
for	B-X
vascular	B-X
remodeling	B-X
and	B-X
regeneration	B-X
in	B-X
several	B-X
physiological	B-X
and	B-X
pathological	B-X
situations	B-X
.	B-X

MATERIAL	O
AND	O
METHODS	O
:	O
Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
were	O
treated	O
with	O
cisplatin	O
and	O
endothelial	O
cell	O
migration	O
analyzed	O
by	O
fluorescence	O
and	O
scratch	O
-	O
wound	O
migration	O
assay	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cisplatin	B-X
on	B-X
endothelial	B-X
cell	B-X
migration	B-X
,	B-X
an	B-X
essential	B-X
process	B-X
for	B-X
vascular	B-X
remodeling	B-X
and	B-X
regeneration	B-X
in	B-X
several	B-X
physiological	B-X
and	B-X
pathological	B-X
situations	B-X
.	B-X

MMP2	B-Gene_or_gene_product
and	O
MMP9	B-Gene_or_gene_product
activity	O
were	O
determined	O
by	O
zymographic	O
assay	O
,	O
and	O
MAPK	B-Gene_or_gene_product
activation	O
by	O
Western	O
blotting	O
analysis	O
.	O
<EOS>	B-X
Wound	B-X
healing	B-X
assay	B-X
and	B-X
Boyden	B-X
chamber	B-X
assays	B-X
indicated	B-X
that	B-X
propofol	B-X
inhibited	B-X
the	B-X
migration	B-X
and	B-X
invasion	B-X
of	B-X
A549	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Gelatin	B-X
zymographic	B-X
analysis	B-X
showed	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
propofol	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
expression	B-X
MMP-2	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
also	B-X
indicated	B-X
that	B-X
propofol	B-X
suppressed	B-X
the	B-X
protein	B-X
expiration	B-X
of	B-X
growth	B-X
factor	B-X
receptor-bound	B-X
protein	B-X
2	B-X
(	B-X
GRB2	B-X
)	B-X
,	B-X
Jun	B-X
N-terminal	B-X
kinases	B-X
1/2	B-X
(	B-X
p-JNK1/2	B-X
)	B-X
,	B-X
p-p38	B-X
,	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X
Results	B-X
from	B-X
real-time	B-X
PCR	B-X
assay	B-X
also	B-X
showed	B-X
that	B-X
propofol	B-X
inhibited	B-X
the	B-X
mRNA	B-X
gene	B-X
expression	B-X
of	B-X
MMP-2	B-X
,	B-X
-7	B-X
and	B-X
-9	B-X
,	B-X
and	B-X
enhanced	B-X
that	B-X
of	B-X
tissue	B-X
inhibitor	B-X
of	B-X
metalloproteinase	B-X
1	B-X
(	B-X
TIMP1	B-X
)	B-X
and	B-X
TIMP2	B-X
in	B-X
A549	B-X
cells	B-X
.	B-X

RESULTS	O
:	O
We	O
demonstrated	O
that	O
cisplatin	O
provoked	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
decrease	O
of	O
HUVEC	O
migration	O
;	O
this	O
effect	O
was	O
clearly	O
independent	O
from	O
its	O
well	O
known	O
cytotoxic	O
activity	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cisplatin	B-X
on	B-X
endothelial	B-X
cell	B-X
migration	B-X
,	B-X
an	B-X
essential	B-X
process	B-X
for	B-X
vascular	B-X
remodeling	B-X
and	B-X
regeneration	B-X
in	B-X
several	B-X
physiological	B-X
and	B-X
pathological	B-X
situations	B-X
.	B-X

In	O
addition	O
,	O
cisplatin	O
markedly	O
reduced	O
MMP2	B-Gene_or_gene_product
activity	O
in	O
both	O
conditioned	O
media	O
and	O
cell	O
lysates	O
,	O
increased	O
p38	B-Gene_or_gene_product
MAPK	I-Gene_or_gene_product
and	O
JNK	B-Gene_or_gene_product
phosphorylation	O
,	O
but	O
did	O
not	O
affect	O
ERK	B-Gene_or_gene_product
phosphorylation	O
.	O

Endothelial	O
cell	O
migration	O
was	O
attenuated	O
by	O
treatment	O
of	O
cells	O
with	O
GM6001	O
,	O
a	O
non	O
-	O
specific	O
inhibitor	O
of	O
MMPs	B-Gene_or_gene_product
,	O
or	O
by	O
a	O
selective	O
anti	O
-	O
MMP2	B-Gene_or_gene_product
antibody	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
showed	B-X
abnormal	B-X
vascularization	B-X
in	B-X
the	B-X
endometrium	B-X
in	B-X
patients	B-X
with	B-X
adenomyosis	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
pathophysiology	B-X
of	B-X
AUB	B-X
and	B-X
subfertility	B-X
in	B-X
adenomyosis	B-X
and	B-X
providing	B-X
a	B-X
possible	B-X
treatment	B-X
target	B-X
.	B-X
Non-genetic	B-X
MMP-2	B-X
insufficiency	B-X
is	B-X
a	B-X
relatively	B-X
unexplored	B-X
condition	B-X
which	B-X
could	B-X
be	B-X
induced	B-X
by	B-X
pathological	B-X
overexpression	B-X
of	B-X
endogenous	B-X
MMP-2	B-X
inhibitors	B-X
such	B-X
as	B-X
TIMPs	B-X
and/or	B-X
the	B-X
acute	B-X
phase	B-X
reactant	B-X
alpha-2-macroglobulin	B-X
.	B-X
Following	B-X
an	B-X
unexpected	B-X
observation	B-X
where	B-X
sera	B-X
from	B-X
human	B-X
donors	B-X
including	B-X
arthritis	B-X
patients	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
serum	B-X
FBG	B-X
exhibited	B-X
reduced	B-X
binding	B-X
of	B-X
serum	B-X
proMMP-2	B-X
to	B-X
gelatin	B-X
,	B-X
we	B-X
found	B-X
that	B-X
human	B-X
FBG	B-X
(	B-X
0	B-X
to	B-X
3.6	B-X
mg/mL	B-X
i.e.	B-X
,	B-X
0	B-X
to	B-X
10.6	B-X
Î¼M	B-X
)	B-X
concentration-dependently	B-X
inhibited	B-X
human	B-X
proMMP-2	B-X
and	B-X
MMP2	B-X
from	B-X
binding	B-X
to	B-X
gelatin	B-X
.	B-X
Indicative	B-X
of	B-X
a	B-X
mixed-type	B-X
(	B-X
combination	B-X
of	B-X
competitive	B-X
and	B-X
non-competitive	B-X
)	B-X
inhibition	B-X
mechanism	B-X
,	B-X
FBG	B-X
reduced	B-X
the	B-X
V	B-X

However	O
,	O
treatment	O
of	O
cells	O
with	O
SB202190	O
or	O
SP600125	O
,	O
inhibitors	O
of	O
p38	B-Gene_or_gene_product
MAPK	I-Gene_or_gene_product
and	O
JNK	B-Gene_or_gene_product
respectively	O
,	O
did	O
not	O
affect	O
HUVEC	O
migration	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
concentration	B-X
of	B-X
IL-15	B-X
in	B-X
follicular	B-X
fluid	B-X
of	B-X
patients	B-X
with	B-X
PCOS	B-X
has	B-X
yet	B-X
been	B-X
evaluated	B-X
.	B-X
Cryptococcosis	B-X
is	B-X
a	B-X
potentially	B-X
lethal	B-X
disease	B-X
that	B-X
is	B-X
primarily	B-X
caused	B-X
by	B-X
the	B-X
fungus	B-X
Cryptococcus	B-X
neoformans	B-X
,	B-X
treatment	B-X
options	B-X
for	B-X
cryptococcosis	B-X
are	B-X
limited	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
glucuronoxylomannan	B-X
,	B-X
the	B-X
major	B-X
polysaccharide	B-X
component	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
induces	B-X
the	B-X
recruitment	B-X
of	B-X
neutrophilic	B-X
myeloid-derived	B-X
suppressor	B-X
cells	B-X
in	B-X
mice	B-X
and	B-X
patients	B-X
with	B-X
cryptococcosis	B-X
.	B-X
Depletion	B-X
of	B-X
neutrophilic	B-X
myeloid-derived	B-X
suppressor	B-X
cells	B-X
enhances	B-X
host	B-X
defense	B-X
against	B-X
C.	B-X
neoformans	B-X
infection	B-X
.	B-X
We	B-X
identify	B-X
C-type	B-X
lectin	B-X
receptor-2d	B-X
recognizes	B-X
glucuronoxylomannan	B-X
to	B-X
potentiate	B-X
the	B-X
immunosuppressive	B-X
activity	B-X
of	B-X
neutrophilic	B-X
myeloid-derived	B-X
suppressor	B-X
cells	B-X
by	B-X
initiating	B-X
p38-mediated	B-X
production	B-X
of	B-X
the	B-X
enzyme	B-X
arginase-1	B-X
,	B-X
which	B-X
inhibits	B-X
T-cell	B-X
mediated	B-X
antifungal	B-X
responses	B-X
.	B-X
Notably	B-X
,	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
arginase-1	B-X
expression	B-X
by	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
p38	B-X
,	B-X
SB202190	B-X
,	B-X
or	B-X
an	B-X
orally	B-X
available	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
,	B-X
vandetanib	B-X
,	B-X
significantly	B-X
enhances	B-X
T-cell	B-X
mediated	B-X
antifungal	B-X
responses	B-X
against	B-X
cryptococcosis	B-X
.	B-X
These	B-X
data	B-X
reveal	B-X
a	B-X
crucial	B-X
suppressive	B-X
role	B-X
of	B-X
neutrophilic	B-X
myeloid-derived	B-X
suppressor	B-X
cells	B-X
during	B-X
cryptococcosis	B-X
and	B-X
highlight	B-X
a	B-X
promising	B-X
immunotherapeutic	B-X
application	B-X
by	B-X
inhibiting	B-X
arginase-1	B-X
production	B-X
to	B-X
combat	B-X
infectious	B-X
diseases	B-X
.	B-X

CONCLUSION	O
:	O
These	O
results	O
suggested	O
that	O
cisplatin	O
induced	O
a	O
reduction	O
of	O
endothelial	O
cell	O
migration	O
through	O
an	O
inhibition	O
of	O
MMP2	B-Gene_or_gene_product
activity	O
by	O
downstream	O
signal	O
transduction	O
pathways	O
independent	O
of	O
JNK	B-Gene_or_gene_product
and	O
p38	B-Gene_or_gene_product
MAPK	I-Gene_or_gene_product
activation	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cisplatin	B-X
on	B-X
endothelial	B-X
cell	B-X
migration	B-X
,	B-X
an	B-X
essential	B-X
process	B-X
for	B-X
vascular	B-X
remodeling	B-X
and	B-X
regeneration	B-X
in	B-X
several	B-X
physiological	B-X
and	B-X
pathological	B-X
situations	B-X
.	B-X

The	O
modulation	O
of	O
platelet	O
and	O
endothelial	O
cell	O
adhesion	O
to	O
vascular	O
graft	O
materials	O
by	O
perlecan	B-Gene_or_gene_product
.	O
<EOS>	B-X
Controlled	B-X
neo-endothelialisation	B-X
is	B-X
critical	B-X
to	B-X
the	B-X
patency	B-X
of	B-X
small	B-X
diameter	B-X
vascular	B-X
grafts	B-X
.	B-X
Endothelialisation	B-X
and	B-X
platelet	B-X
adhesion	B-X
to	B-X
purified	B-X
endothelial	B-X
cell-derived	B-X
perlecan	B-X
,	B-X
the	B-X
major	B-X
heparan	B-X
sulfate	B-X
(	B-X
HS	B-X
)	B-X
proteoglycan	B-X
in	B-X
basement	B-X
membranes	B-X
,	B-X
were	B-X
investigated	B-X
using	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
assays	B-X
.	B-X
Expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
were	B-X
coated	B-X
with	B-X
perlecan	B-X
and	B-X
tested	B-X
in	B-X
an	B-X
ovine	B-X
carotid	B-X
interposition	B-X
model	B-X
for	B-X
a	B-X
period	B-X
of	B-X
6	B-X
weeks	B-X
and	B-X
assessed	B-X
using	B-X
light	B-X
and	B-X
scanning	B-X
microscopy	B-X
.	B-X
Enhanced	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
reduced	B-X
platelet	B-X
adhesion	B-X
were	B-X
observed	B-X
on	B-X
the	B-X
perlecan	B-X
coated	B-X
grafts	B-X
when	B-X
compared	B-X
to	B-X
uncoated	B-X
controls	B-X
implanted	B-X
in	B-X
the	B-X
same	B-X
sheep	B-X
(	B-X
n=5	B-X
)	B-X
.	B-X
Perlecan	B-X
was	B-X
also	B-X
found	B-X
to	B-X
stimulate	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
over	B-X
a	B-X
period	B-X
of	B-X
6	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
plasma	B-X
proteins	B-X
and	B-X
fibroblastic	B-X
growth	B-X
factor	B-X
2	B-X
(	B-X
FGF-2	B-X
)	B-X
,	B-X
however	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
FGF-2	B-X
endothelial	B-X
cell	B-X
growth	B-X
could	B-X
not	B-X
be	B-X
maintained	B-X
during	B-X
this	B-X
period	B-X
.	B-X
Perlecan	B-X
was	B-X
found	B-X
to	B-X
be	B-X
anti-adhesive	B-X
for	B-X
platelets	B-X
,	B-X
however	B-X
after	B-X
removal	B-X
of	B-X
the	B-X
HS	B-X
chains	B-X
attached	B-X
to	B-X
perlecan	B-X
,	B-X
platelet	B-X
adhesion	B-X
and	B-X
aggregation	B-X
were	B-X
supported	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
HS	B-X
chains	B-X
of	B-X
perlecan	B-X
in	B-X
improving	B-X
graft	B-X
patency	B-X
by	B-X
selectively	B-X
promoting	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
while	B-X
modulating	B-X
platelet	B-X
adhesion	B-X
.	B-X

Controlled	O
neo	O
-	O
endothelialisation	O
is	O
critical	O
to	O
the	O
patency	O
of	O
small	O
diameter	O
vascular	O
grafts	O
.	O

Endothelialisation	O
and	O
platelet	O
adhesion	O
to	O
purified	O
endothelial	O
cell	O
-	O
derived	O
perlecan	B-Gene_or_gene_product
,	O
the	O
major	O
heparan	B-Gene_or_gene_product
sulfate	I-Gene_or_gene_product
(	I-Gene_or_gene_product
HS	I-Gene_or_gene_product
)	I-Gene_or_gene_product
proteoglycan	I-Gene_or_gene_product
in	O
basement	O
membranes	O
,	O
were	O
investigated	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
.	O
<EOS>	B-X
Controlled	B-X
neo-endothelialisation	B-X
is	B-X
critical	B-X
to	B-X
the	B-X
patency	B-X
of	B-X
small	B-X
diameter	B-X
vascular	B-X
grafts	B-X
.	B-X
Endothelialisation	B-X
and	B-X
platelet	B-X
adhesion	B-X
to	B-X
purified	B-X
endothelial	B-X
cell-derived	B-X
perlecan	B-X
,	B-X
the	B-X
major	B-X
heparan	B-X
sulfate	B-X
(	B-X
HS	B-X
)	B-X
proteoglycan	B-X
in	B-X
basement	B-X
membranes	B-X
,	B-X
were	B-X
investigated	B-X
using	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
assays	B-X
.	B-X
Expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
were	B-X
coated	B-X
with	B-X
perlecan	B-X
and	B-X
tested	B-X
in	B-X
an	B-X
ovine	B-X
carotid	B-X
interposition	B-X
model	B-X
for	B-X
a	B-X
period	B-X
of	B-X
6	B-X
weeks	B-X
and	B-X
assessed	B-X
using	B-X
light	B-X
and	B-X
scanning	B-X
microscopy	B-X
.	B-X
Enhanced	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
reduced	B-X
platelet	B-X
adhesion	B-X
were	B-X
observed	B-X
on	B-X
the	B-X
perlecan	B-X
coated	B-X
grafts	B-X
when	B-X
compared	B-X
to	B-X
uncoated	B-X
controls	B-X
implanted	B-X
in	B-X
the	B-X
same	B-X
sheep	B-X
(	B-X
n=5	B-X
)	B-X
.	B-X
Perlecan	B-X
was	B-X
also	B-X
found	B-X
to	B-X
stimulate	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
over	B-X
a	B-X
period	B-X
of	B-X
6	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
plasma	B-X
proteins	B-X
and	B-X
fibroblastic	B-X
growth	B-X
factor	B-X
2	B-X
(	B-X
FGF-2	B-X
)	B-X
,	B-X
however	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
FGF-2	B-X
endothelial	B-X
cell	B-X
growth	B-X
could	B-X
not	B-X
be	B-X
maintained	B-X
during	B-X
this	B-X
period	B-X
.	B-X
Perlecan	B-X
was	B-X
found	B-X
to	B-X
be	B-X
anti-adhesive	B-X
for	B-X
platelets	B-X
,	B-X
however	B-X
after	B-X
removal	B-X
of	B-X
the	B-X
HS	B-X
chains	B-X
attached	B-X
to	B-X
perlecan	B-X
,	B-X
platelet	B-X
adhesion	B-X
and	B-X
aggregation	B-X
were	B-X
supported	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
HS	B-X
chains	B-X
of	B-X
perlecan	B-X
in	B-X
improving	B-X
graft	B-X
patency	B-X
by	B-X
selectively	B-X
promoting	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
while	B-X
modulating	B-X
platelet	B-X
adhesion	B-X
.	B-X

Expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
were	O
coated	O
with	O
perlecan	B-Gene_or_gene_product
and	O
tested	O
in	O
an	O
ovine	O
carotid	O
interposition	O
model	O
for	O
a	O
period	O
of	O
6	O
weeks	O
and	O
assessed	O
using	O
light	O
and	O
scanning	O
microscopy	O
.	O

Enhanced	O
endothelial	O
cell	O
growth	O
and	O
reduced	O
platelet	O
adhesion	O
were	O
observed	O
on	O
the	O
perlecan	B-Gene_or_gene_product
coated	O
grafts	O
when	O
compared	O
to	O
uncoated	O
controls	O
implanted	O
in	O
the	O
same	O
sheep	O
(	O
n	O
=	O
5	O
)	O
.	O
<EOS>	B-X
Controlled	B-X
neo-endothelialisation	B-X
is	B-X
critical	B-X
to	B-X
the	B-X
patency	B-X
of	B-X
small	B-X
diameter	B-X
vascular	B-X
grafts	B-X
.	B-X
Endothelialisation	B-X
and	B-X
platelet	B-X
adhesion	B-X
to	B-X
purified	B-X
endothelial	B-X
cell-derived	B-X
perlecan	B-X
,	B-X
the	B-X
major	B-X
heparan	B-X
sulfate	B-X
(	B-X
HS	B-X
)	B-X
proteoglycan	B-X
in	B-X
basement	B-X
membranes	B-X
,	B-X
were	B-X
investigated	B-X
using	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
assays	B-X
.	B-X
Expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
were	B-X
coated	B-X
with	B-X
perlecan	B-X
and	B-X
tested	B-X
in	B-X
an	B-X
ovine	B-X
carotid	B-X
interposition	B-X
model	B-X
for	B-X
a	B-X
period	B-X
of	B-X
6	B-X
weeks	B-X
and	B-X
assessed	B-X
using	B-X
light	B-X
and	B-X
scanning	B-X
microscopy	B-X
.	B-X
Enhanced	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
reduced	B-X
platelet	B-X
adhesion	B-X
were	B-X
observed	B-X
on	B-X
the	B-X
perlecan	B-X
coated	B-X
grafts	B-X
when	B-X
compared	B-X
to	B-X
uncoated	B-X
controls	B-X
implanted	B-X
in	B-X
the	B-X
same	B-X
sheep	B-X
(	B-X
n=5	B-X
)	B-X
.	B-X
Perlecan	B-X
was	B-X
also	B-X
found	B-X
to	B-X
stimulate	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
over	B-X
a	B-X
period	B-X
of	B-X
6	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
plasma	B-X
proteins	B-X
and	B-X
fibroblastic	B-X
growth	B-X
factor	B-X
2	B-X
(	B-X
FGF-2	B-X
)	B-X
,	B-X
however	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
FGF-2	B-X
endothelial	B-X
cell	B-X
growth	B-X
could	B-X
not	B-X
be	B-X
maintained	B-X
during	B-X
this	B-X
period	B-X
.	B-X
Perlecan	B-X
was	B-X
found	B-X
to	B-X
be	B-X
anti-adhesive	B-X
for	B-X
platelets	B-X
,	B-X
however	B-X
after	B-X
removal	B-X
of	B-X
the	B-X
HS	B-X
chains	B-X
attached	B-X
to	B-X
perlecan	B-X
,	B-X
platelet	B-X
adhesion	B-X
and	B-X
aggregation	B-X
were	B-X
supported	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
HS	B-X
chains	B-X
of	B-X
perlecan	B-X
in	B-X
improving	B-X
graft	B-X
patency	B-X
by	B-X
selectively	B-X
promoting	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
while	B-X
modulating	B-X
platelet	B-X
adhesion	B-X
.	B-X

Perlecan	B-Gene_or_gene_product
was	O
also	O
found	O
to	O
stimulate	O
endothelial	O
cell	O
proliferation	O
in	O
vitro	O
over	O
a	O
period	O
of	O
6	O
days	O
in	O
the	O
presence	O
of	O
plasma	O
proteins	O
and	O
fibroblastic	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
2	I-Gene_or_gene_product
(	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	O
,	O
however	O
in	O
the	O
absence	O
of	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
endothelial	O
cell	O
growth	O
could	O
not	O
be	O
maintained	O
during	O
this	O
period	O
.	O

Perlecan	B-Gene_or_gene_product
was	O
found	O
to	O
be	O
anti	O
-	O
adhesive	O
for	O
platelets	O
,	O
however	O
after	O
removal	O
of	O
the	O
HS	O
chains	O
attached	O
to	O
perlecan	B-Gene_or_gene_product
,	O
platelet	O
adhesion	O
and	O
aggregation	O
were	O
supported	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
HS	O
chains	O
of	O
perlecan	B-Gene_or_gene_product
in	O
improving	O
graft	O
patency	O
by	O
selectively	O
promoting	O
endothelial	O
cell	O
proliferation	O
while	O
modulating	O
platelet	O
adhesion	O
.	O
<EOS>	B-X
Controlled	B-X
neo-endothelialisation	B-X
is	B-X
critical	B-X
to	B-X
the	B-X
patency	B-X
of	B-X
small	B-X
diameter	B-X
vascular	B-X
grafts	B-X
.	B-X
Endothelialisation	B-X
and	B-X
platelet	B-X
adhesion	B-X
to	B-X
purified	B-X
endothelial	B-X
cell-derived	B-X
perlecan	B-X
,	B-X
the	B-X
major	B-X
heparan	B-X
sulfate	B-X
(	B-X
HS	B-X
)	B-X
proteoglycan	B-X
in	B-X
basement	B-X
membranes	B-X
,	B-X
were	B-X
investigated	B-X
using	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
assays	B-X
.	B-X
Expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
were	B-X
coated	B-X
with	B-X
perlecan	B-X
and	B-X
tested	B-X
in	B-X
an	B-X
ovine	B-X
carotid	B-X
interposition	B-X
model	B-X
for	B-X
a	B-X
period	B-X
of	B-X
6	B-X
weeks	B-X
and	B-X
assessed	B-X
using	B-X
light	B-X
and	B-X
scanning	B-X
microscopy	B-X
.	B-X
Enhanced	B-X
endothelial	B-X
cell	B-X
growth	B-X
and	B-X
reduced	B-X
platelet	B-X
adhesion	B-X
were	B-X
observed	B-X
on	B-X
the	B-X
perlecan	B-X
coated	B-X
grafts	B-X
when	B-X
compared	B-X
to	B-X
uncoated	B-X
controls	B-X
implanted	B-X
in	B-X
the	B-X
same	B-X
sheep	B-X
(	B-X
n=5	B-X
)	B-X
.	B-X
Perlecan	B-X
was	B-X
also	B-X
found	B-X
to	B-X
stimulate	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
over	B-X
a	B-X
period	B-X
of	B-X
6	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
plasma	B-X
proteins	B-X
and	B-X
fibroblastic	B-X
growth	B-X
factor	B-X
2	B-X
(	B-X
FGF-2	B-X
)	B-X
,	B-X
however	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
FGF-2	B-X
endothelial	B-X
cell	B-X
growth	B-X
could	B-X
not	B-X
be	B-X
maintained	B-X
during	B-X
this	B-X
period	B-X
.	B-X
Perlecan	B-X
was	B-X
found	B-X
to	B-X
be	B-X
anti-adhesive	B-X
for	B-X
platelets	B-X
,	B-X
however	B-X
after	B-X
removal	B-X
of	B-X
the	B-X
HS	B-X
chains	B-X
attached	B-X
to	B-X
perlecan	B-X
,	B-X
platelet	B-X
adhesion	B-X
and	B-X
aggregation	B-X
were	B-X
supported	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
HS	B-X
chains	B-X
of	B-X
perlecan	B-X
in	B-X
improving	B-X
graft	B-X
patency	B-X
by	B-X
selectively	B-X
promoting	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
while	B-X
modulating	B-X
platelet	B-X
adhesion	B-X
.	B-X

Tumour	O
angiogenesis	O
:	O
its	O
mechanism	O
and	O
therapeutic	O
implications	O
in	O
malignant	O
gliomas	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
a	B-X
key	B-X
event	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X
Tumour	B-X
angiogenesis	B-X
involves	B-X
multiple	B-X
cellular	B-X
processes	B-X
including	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
reorganisation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
tube	B-X
formation	B-X
.	B-X
Other	B-X
anti-angiogenic	B-X
therapies	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
and	B-X
endogeneous	B-X
angiogenesis	B-X
inhibitor	B-X
levels	B-X
.	B-X
Most	B-X
anti-angiogenic	B-X
therapies	B-X
for	B-X
malignant	B-X
gliomas	B-X
are	B-X
in	B-X
Phase	B-X
I/II	B-X
trials	B-X
and	B-X
only	B-X
modest	B-X
efficacies	B-X
are	B-X
reported	B-X
for	B-X
monotherapies	B-X
.	B-X
The	B-X
greatest	B-X
potential	B-X
for	B-X
angiogenesis	B-X
inhibitors	B-X
may	B-X
lie	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
combine	B-X
safely	B-X
with	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X

Angiogenesis	O
is	O
a	O
key	O
event	O
in	O
the	O
progression	O
of	O
malignant	O
gliomas	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
a	B-X
key	B-X
process	B-X
in	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
and	B-X
in	B-X
the	B-X
retina	B-X
during	B-X
postnatal	B-X
life	B-X
.	B-X
Although	B-X
an	B-X
increasing	B-X
number	B-X
of	B-X
studies	B-X
have	B-X
addressed	B-X
the	B-X
role	B-X
of	B-X
endothelial	B-X
cells	B-X
in	B-X
this	B-X
event	B-X
,	B-X
the	B-X
astrocytes	B-X
contribution	B-X
in	B-X
angiogenesis	B-X
has	B-X
received	B-X
less	B-X
attention	B-X
.	B-X
Further	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
astrocytes	B-X
phenotype	B-X
are	B-X
addressed	B-X
in	B-X
glioblastoma	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
devastating	B-X
types	B-X
of	B-X
brain	B-X
cancer	B-X
,	B-X
in	B-X
order	B-X
to	B-X
provide	B-X
potential	B-X
targets	B-X
involved	B-X
in	B-X
the	B-X
cross	B-X
signaling	B-X
between	B-X
endothelial	B-X
cells	B-X
,	B-X
astrocytes	B-X
and	B-X
glioma	B-X
cells	B-X
,	B-X
that	B-X
mediate	B-X
tumor	B-X
progression	B-X
and	B-X
pathological	B-X
angiogenesis	B-X
.	B-X
Angiogenesis	B-X
is	B-X
a	B-X
key	B-X
event	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X
Angiogenesis	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
interrupt	B-X
the	B-X
angiogenic	B-X
process	B-X
at	B-X
the	B-X
growth	B-X
factor	B-X
,	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
and	B-X
intracellular	B-X
kinase	B-X
levels	B-X
.	B-X
Most	B-X
anti-angiogenic	B-X
therapies	B-X
for	B-X
malignant	B-X
gliomas	B-X
are	B-X
in	B-X
Phase	B-X
I/II	B-X
trials	B-X
and	B-X
only	B-X
modest	B-X
efficacies	B-X
are	B-X
reported	B-X
for	B-X
monotherapies	B-X
.	B-X

The	O
presence	O
of	O
microvascular	O
proliferation	O
leads	O
to	O
the	O
histological	O
diagnosis	O
of	O
glioblastoma	O
multiforme	O
.	O

Tumour	O
angiogenesis	O
involves	O
multiple	O
cellular	O
processes	O
including	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
reorganisation	O
of	O
extracellular	O
matrix	O
and	O
tube	O
formation	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
microvascular	B-X
proliferation	B-X
leads	B-X
to	B-X
the	B-X
histological	B-X
diagnosis	B-X
of	B-X
glioblastoma	B-X
multiforme	B-X
.	B-X
Tumour	B-X
angiogenesis	B-X
involves	B-X
multiple	B-X
cellular	B-X
processes	B-X
including	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
reorganisation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
tube	B-X
formation	B-X
.	B-X
These	B-X
processes	B-X
are	B-X
regulated	B-X
by	B-X
numerous	B-X
pro-angiogenic	B-X
and	B-X
anti-angiogenic	B-X
growth	B-X
factors	B-X
.	B-X
Angiogenesis	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
interrupt	B-X
the	B-X
angiogenic	B-X
process	B-X
at	B-X
the	B-X
growth	B-X
factor	B-X
,	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
and	B-X
intracellular	B-X
kinase	B-X
levels	B-X
.	B-X
Other	B-X
anti-angiogenic	B-X
therapies	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
and	B-X
endogeneous	B-X
angiogenesis	B-X
inhibitor	B-X
levels	B-X
.	B-X
The	B-X
greatest	B-X
potential	B-X
for	B-X
angiogenesis	B-X
inhibitors	B-X
may	B-X
lie	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
combine	B-X
safely	B-X
with	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X

These	O
processes	O
are	O
regulated	O
by	O
numerous	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
growth	O
factors	O
.	O
<EOS>	B-X
Pathological	B-X
neovascularization	B-X
in	B-X
ocular	B-X
tissues	B-X
can	B-X
lead	B-X
to	B-X
vision-threatening	B-X
vascular	B-X
diseases	B-X
,	B-X
including	B-X
proliferative	B-X
diabetic	B-X
retinopathy	B-X
,	B-X
retinal	B-X
vein	B-X
occlusion	B-X
,	B-X
retinopathy	B-X
of	B-X
prematurity	B-X
,	B-X
choroidal	B-X
neovascularization	B-X
,	B-X
and	B-X
corneal	B-X
neovascularization	B-X
.	B-X
Neovascularization	B-X
involves	B-X
various	B-X
cellular	B-X
processes	B-X
and	B-X
signaling	B-X
pathways	B-X
and	B-X
is	B-X
regulated	B-X
by	B-X
angiogenic	B-X
factors	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
.	B-X
Modulating	B-X
these	B-X
circuits	B-X
may	B-X
represent	B-X
a	B-X
promising	B-X
strategy	B-X
to	B-X
treat	B-X
ocular	B-X
neovascular	B-X
diseases	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
glycerophospholipids	B-X
,	B-X
sphingolipids	B-X
,	B-X
and	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
exert	B-X
potent	B-X
pro-angiogenic	B-X
or	B-X
anti-angiogenic	B-X
effects	B-X
,	B-X
according	B-X
to	B-X
the	B-X
findings	B-X
of	B-X
numerous	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
.	B-X
A	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
lipid	B-X
signaling	B-X
in	B-X
neovascularization	B-X
may	B-X
provide	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
to	B-X
treat	B-X
ocular	B-X
neovascular	B-X
diseases	B-X
and	B-X
other	B-X
human	B-X
disorders	B-X
.	B-X

Angiogenesis	O
inhibitors	O
have	O
been	O
developed	O
to	O
interrupt	O
the	O
angiogenic	O
process	O
at	O
the	O
growth	O
factor	O
,	O
receptor	O
tyrosine	O
kinase	O
and	O
intracellular	O
kinase	O
levels	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
a	B-X
key	B-X
event	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X
Tumour	B-X
angiogenesis	B-X
involves	B-X
multiple	B-X
cellular	B-X
processes	B-X
including	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
reorganisation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
tube	B-X
formation	B-X
.	B-X
These	B-X
processes	B-X
are	B-X
regulated	B-X
by	B-X
numerous	B-X
pro-angiogenic	B-X
and	B-X
anti-angiogenic	B-X
growth	B-X
factors	B-X
.	B-X
Angiogenesis	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
interrupt	B-X
the	B-X
angiogenic	B-X
process	B-X
at	B-X
the	B-X
growth	B-X
factor	B-X
,	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
and	B-X
intracellular	B-X
kinase	B-X
levels	B-X
.	B-X
Other	B-X
anti-angiogenic	B-X
therapies	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
and	B-X
endogeneous	B-X
angiogenesis	B-X
inhibitor	B-X
levels	B-X
.	B-X
Most	B-X
anti-angiogenic	B-X
therapies	B-X
for	B-X
malignant	B-X
gliomas	B-X
are	B-X
in	B-X
Phase	B-X
I/II	B-X
trials	B-X
and	B-X
only	B-X
modest	B-X
efficacies	B-X
are	B-X
reported	B-X
for	B-X
monotherapies	B-X
.	B-X
The	B-X
greatest	B-X
potential	B-X
for	B-X
angiogenesis	B-X
inhibitors	B-X
may	B-X
lie	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
combine	B-X
safely	B-X
with	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X

Other	O
anti	O
-	O
angiogenic	O
therapies	O
alter	O
the	O
immune	O
response	O
and	O
endogeneous	O
angiogenesis	O
inhibitor	O
levels	O
.	O
<EOS>	B-X
Tumour	B-X
angiogenesis	B-X
involves	B-X
multiple	B-X
cellular	B-X
processes	B-X
including	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
reorganisation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
tube	B-X
formation	B-X
.	B-X
These	B-X
processes	B-X
are	B-X
regulated	B-X
by	B-X
numerous	B-X
pro-angiogenic	B-X
and	B-X
anti-angiogenic	B-X
growth	B-X
factors	B-X
.	B-X
Angiogenesis	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
interrupt	B-X
the	B-X
angiogenic	B-X
process	B-X
at	B-X
the	B-X
growth	B-X
factor	B-X
,	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
and	B-X
intracellular	B-X
kinase	B-X
levels	B-X
.	B-X
Other	B-X
anti-angiogenic	B-X
therapies	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
and	B-X
endogeneous	B-X
angiogenesis	B-X
inhibitor	B-X
levels	B-X
.	B-X
Most	B-X
anti-angiogenic	B-X
therapies	B-X
for	B-X
malignant	B-X
gliomas	B-X
are	B-X
in	B-X
Phase	B-X
I/II	B-X
trials	B-X
and	B-X
only	B-X
modest	B-X
efficacies	B-X
are	B-X
reported	B-X
for	B-X
monotherapies	B-X
.	B-X
The	B-X
greatest	B-X
potential	B-X
for	B-X
angiogenesis	B-X
inhibitors	B-X
may	B-X
lie	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
combine	B-X
safely	B-X
with	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X

Most	O
anti	O
-	O
angiogenic	O
therapies	O
for	O
malignant	O
gliomas	O
are	O
in	O
Phase	O
I	O
/	O
II	O
trials	O
and	O
only	O
modest	O
efficacies	O
are	O
reported	O
for	O
monotherapies	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
a	B-X
key	B-X
event	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
malignant	B-X
gliomas	B-X
.	B-X
These	B-X
processes	B-X
are	B-X
regulated	B-X
by	B-X
numerous	B-X
pro-angiogenic	B-X
and	B-X
anti-angiogenic	B-X
growth	B-X
factors	B-X
.	B-X
Angiogenesis	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
interrupt	B-X
the	B-X
angiogenic	B-X
process	B-X
at	B-X
the	B-X
growth	B-X
factor	B-X
,	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
and	B-X
intracellular	B-X
kinase	B-X
levels	B-X
.	B-X
Other	B-X
anti-angiogenic	B-X
therapies	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
and	B-X
endogeneous	B-X
angiogenesis	B-X
inhibitor	B-X
levels	B-X
.	B-X
Most	B-X
anti-angiogenic	B-X
therapies	B-X
for	B-X
malignant	B-X
gliomas	B-X
are	B-X
in	B-X
Phase	B-X
I/II	B-X
trials	B-X
and	B-X
only	B-X
modest	B-X
efficacies	B-X
are	B-X
reported	B-X
for	B-X
monotherapies	B-X
.	B-X

The	O
greatest	O
potential	O
for	O
angiogenesis	O
inhibitors	O
may	O
lie	O
in	O
their	O
ability	O
to	O
combine	O
safely	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O
<EOS>	B-X
Tumour	B-X
angiogenesis	B-X
involves	B-X
multiple	B-X
cellular	B-X
processes	B-X
including	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
reorganisation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
tube	B-X
formation	B-X
.	B-X
Angiogenesis	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
interrupt	B-X
the	B-X
angiogenic	B-X
process	B-X
at	B-X
the	B-X
growth	B-X
factor	B-X
,	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
and	B-X
intracellular	B-X
kinase	B-X
levels	B-X
.	B-X
Other	B-X
anti-angiogenic	B-X
therapies	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
and	B-X
endogeneous	B-X
angiogenesis	B-X
inhibitor	B-X
levels	B-X
.	B-X
The	B-X
greatest	B-X
potential	B-X
for	B-X
angiogenesis	B-X
inhibitors	B-X
may	B-X
lie	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
combine	B-X
safely	B-X
with	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X

Regulation	O
of	O
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
by	O
natural	O
and	O
synthetic	O
progestins	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O
<EOS>	B-X
Our	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
progestins	B-X
induce	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
express	B-X
mutant	B-X
p53	B-X
protein	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
natural	B-X
and	B-X
synthetic	B-X
progestins	B-X
also	B-X
induce	B-X
thrombospondin-1	B-X
(	B-X
TSP-1	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
in	B-X
T47-D	B-X
and	B-X
BT-474	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Antiprogestin	B-X
RU-486	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
VEGF	B-X
and	B-X
TSP-1	B-X
by	B-X
progestins	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
effect	B-X
of	B-X
progestin	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
Actinomycin-D	B-X
,	B-X
but	B-X
not	B-X
puromycin	B-X
,	B-X
also	B-X
blocks	B-X
progestin-dependent	B-X
induction	B-X
of	B-X
TSP-1	B-X
.	B-X
A	B-X
putative	B-X
progestin-response	B-X
element	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
human	B-X
TSP-1	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
a	B-X
progestin-PR	B-X
complex	B-X
might	B-X
directly	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TSP-1	B-X
gene	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Conditioned	B-X
medium	B-X
from	B-X
progestin-treated	B-X
breast	B-X
cancer	B-X
cells	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
though	B-X
not	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antibody	B-X
to	B-X
TSP-1	B-X
,	B-X
indicating	B-X
that	B-X
TSP-1	B-X
secreted	B-X
by	B-X
breast	B-X
cancer	B-X
cells	B-X
could	B-X
be	B-X
pro-angiogenic	B-X
.	B-X
Since	B-X
tumor	B-X
cell-derived	B-X
TSP-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
promote	B-X
angiogenesis	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
.	B-X

Our	O
recent	O
studies	O
show	O
that	O
progestins	O
induce	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
in	O
breast	O
cancer	O
cells	O
that	O
express	O
mutant	O
p53	B-Gene_or_gene_product
protein	O
.	O
<EOS>	B-X
Our	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
progestins	B-X
induce	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
express	B-X
mutant	B-X
p53	B-X
protein	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
natural	B-X
and	B-X
synthetic	B-X
progestins	B-X
also	B-X
induce	B-X
thrombospondin-1	B-X
(	B-X
TSP-1	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
in	B-X
T47-D	B-X
and	B-X
BT-474	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Antiprogestin	B-X
RU-486	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
VEGF	B-X
and	B-X
TSP-1	B-X
by	B-X
progestins	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
effect	B-X
of	B-X
progestin	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
A	B-X
putative	B-X
progestin-response	B-X
element	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
human	B-X
TSP-1	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
a	B-X
progestin-PR	B-X
complex	B-X
might	B-X
directly	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TSP-1	B-X
gene	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Conditioned	B-X
medium	B-X
from	B-X
progestin-treated	B-X
breast	B-X
cancer	B-X
cells	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
though	B-X
not	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antibody	B-X
to	B-X
TSP-1	B-X
,	B-X
indicating	B-X
that	B-X
TSP-1	B-X
secreted	B-X
by	B-X
breast	B-X
cancer	B-X
cells	B-X
could	B-X
be	B-X
pro-angiogenic	B-X
.	B-X
Since	B-X
tumor	B-X
cell-derived	B-X
TSP-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
promote	B-X
angiogenesis	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
natural	O
and	O
synthetic	O
progestins	O
also	O
induce	O
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
mRNA	O
and	O
protein	O
in	O
T47	O
-	O
D	O
and	O
BT	O
-	O
474	O
breast	O
cancer	O
cells	O
.	O
<EOS>	B-X
Our	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
progestins	B-X
induce	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
express	B-X
mutant	B-X
p53	B-X
protein	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
natural	B-X
and	B-X
synthetic	B-X
progestins	B-X
also	B-X
induce	B-X
thrombospondin-1	B-X
(	B-X
TSP-1	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
in	B-X
T47-D	B-X
and	B-X
BT-474	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Antiprogestin	B-X
RU-486	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
VEGF	B-X
and	B-X
TSP-1	B-X
by	B-X
progestins	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
effect	B-X
of	B-X
progestin	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
Actinomycin-D	B-X
,	B-X
but	B-X
not	B-X
puromycin	B-X
,	B-X
also	B-X
blocks	B-X
progestin-dependent	B-X
induction	B-X
of	B-X
TSP-1	B-X
.	B-X
A	B-X
putative	B-X
progestin-response	B-X
element	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
human	B-X
TSP-1	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
a	B-X
progestin-PR	B-X
complex	B-X
might	B-X
directly	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TSP-1	B-X
gene	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Conditioned	B-X
medium	B-X
from	B-X
progestin-treated	B-X
breast	B-X
cancer	B-X
cells	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
though	B-X
not	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antibody	B-X
to	B-X
TSP-1	B-X
,	B-X
indicating	B-X
that	B-X
TSP-1	B-X
secreted	B-X
by	B-X
breast	B-X
cancer	B-X
cells	B-X
could	B-X
be	B-X
pro-angiogenic	B-X
.	B-X
Since	B-X
tumor	B-X
cell-derived	B-X
TSP-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
promote	B-X
angiogenesis	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
.	B-X

Antiprogestin	O
RU	O
-	O
486	O
inhibits	O
the	O
induction	O
of	O
VEGF	B-Gene_or_gene_product
and	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
by	O
progestins	O
,	O
suggesting	O
that	O
this	O
effect	O
of	O
progestin	O
is	O
mediated	O
by	O
the	O
progesterone	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
PR	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
Our	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
progestins	B-X
induce	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
express	B-X
mutant	B-X
p53	B-X
protein	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
natural	B-X
and	B-X
synthetic	B-X
progestins	B-X
also	B-X
induce	B-X
thrombospondin-1	B-X
(	B-X
TSP-1	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
in	B-X
T47-D	B-X
and	B-X
BT-474	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Antiprogestin	B-X
RU-486	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
VEGF	B-X
and	B-X
TSP-1	B-X
by	B-X
progestins	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
effect	B-X
of	B-X
progestin	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
Actinomycin-D	B-X
,	B-X
but	B-X
not	B-X
puromycin	B-X
,	B-X
also	B-X
blocks	B-X
progestin-dependent	B-X
induction	B-X
of	B-X
TSP-1	B-X
.	B-X
A	B-X
putative	B-X
progestin-response	B-X
element	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
human	B-X
TSP-1	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
a	B-X
progestin-PR	B-X
complex	B-X
might	B-X
directly	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TSP-1	B-X
gene	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Conditioned	B-X
medium	B-X
from	B-X
progestin-treated	B-X
breast	B-X
cancer	B-X
cells	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
though	B-X
not	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antibody	B-X
to	B-X
TSP-1	B-X
,	B-X
indicating	B-X
that	B-X
TSP-1	B-X
secreted	B-X
by	B-X
breast	B-X
cancer	B-X
cells	B-X
could	B-X
be	B-X
pro-angiogenic	B-X
.	B-X
Since	B-X
tumor	B-X
cell-derived	B-X
TSP-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
promote	B-X
angiogenesis	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
.	B-X

Actinomycin	O
-	O
D	O
,	O
but	O
not	O
puromycin	O
,	O
also	O
blocks	O
progestin	O
-	O
dependent	O
induction	O
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
DNA	B-X
thermal	B-X
denaturation	B-X
was	B-X
evaluated	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
the	B-X
effect	B-X
of	B-X
antitumor	B-X
drug	B-X
actinomycin	B-X
D	B-X
on	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
double	B-X
helix	B-X
and	B-X
also	B-X
the	B-X
effect	B-X
of	B-X
SDS	B-X
micelles	B-X
on	B-X
actinomycin	B-X
D	B-X
-	B-X
DNA	B-X
complexes	B-X
.	B-X
The	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
melting	B-X
temperature	B-X
of	B-X
DNA	B-X
was	B-X
dependent	B-X
on	B-X
drug	B-X
concentration	B-X
,	B-X
increasing	B-X
with	B-X
actinomycin	B-X
D	B-X
concentration	B-X
.	B-X
High	B-X
thermal	B-X
stabilization	B-X
(	B-X
about	B-X
10	B-X
Â°C	B-X
)	B-X
of	B-X
the	B-X
DNA	B-X
helix	B-X
after	B-X
the	B-X
association	B-X
with	B-X
actinomycin	B-X
D	B-X
clearly	B-X
demonstrates	B-X
the	B-X
intercalative	B-X
binding	B-X
mode	B-X
.	B-X
Actinomycin	B-X
D	B-X
,	B-X
together	B-X
with	B-X
7-amino-actinomycin	B-X
D	B-X
,	B-X
also	B-X
became	B-X
a	B-X
useful	B-X
tool	B-X
in	B-X
biochemistry	B-X
and	B-X
molecular	B-X
biology	B-X
.	B-X
Many	B-X
derivatives	B-X
of	B-X
actinomycins	B-X
,	B-X
differing	B-X
in	B-X
chemical	B-X
structure	B-X
as	B-X
well	B-X
as	B-X
biological	B-X
activity	B-X
,	B-X
have	B-X
been	B-X
isolated	B-X
and	B-X
synthesized	B-X
and	B-X
their	B-X
modifications	B-X
involved	B-X
not	B-X
only	B-X
the	B-X
chromphoric	B-X
phenoxazone	B-X
ring	B-X
,	B-X
but	B-X
also	B-X
two	B-X
cyclic	B-X
pentapeptide	B-X
lacton	B-X
rings	B-X
.	B-X
Modifications	B-X
of	B-X
the	B-X
actinomycins	B-X
'	B-X
chromophore	B-X
mainly	B-X
concerned	B-X
introducing	B-X
an	B-X
amino	B-X
group	B-X
in	B-X
position	B-X
2	B-X
and	B-X
a	B-X
carbon	B-X
atom	B-X
in	B-X
position	B-X
7	B-X
,	B-X
but	B-X
also	B-X
modifications	B-X
in	B-X
positions	B-X
4	B-X
,	B-X
6	B-X
,	B-X
and	B-X
8	B-X
of	B-X
the	B-X
phenoxazone	B-X
ring	B-X
.	B-X
The	B-X
actinomycin	B-X
peptide	B-X
moiety	B-X
was	B-X
mainly	B-X
modified	B-X
by	B-X
replacement	B-X
of	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
pentapeptide	B-X
rings	B-X
and	B-X
also	B-X
by	B-X
the	B-X
synthesis	B-X
of	B-X
actinomycin	B-X
derivatives	B-X
with	B-X
open	B-X
peptide	B-X
lacton	B-X
rings	B-X
.	B-X

A	O
putative	O
progestin	O
-	O
response	O
element	O
was	O
identified	O
in	O
the	O
human	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
promoter	O
,	O
which	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
a	O
progestin	O
-	O
PR	B-Gene_or_gene_product
complex	O
might	O
directly	O
regulate	O
transcription	O
of	O
the	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
gene	O
in	O
human	O
cells	O
.	O
<EOS>	B-X
Our	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
progestins	B-X
induce	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
express	B-X
mutant	B-X
p53	B-X
protein	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
natural	B-X
and	B-X
synthetic	B-X
progestins	B-X
also	B-X
induce	B-X
thrombospondin-1	B-X
(	B-X
TSP-1	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
in	B-X
T47-D	B-X
and	B-X
BT-474	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Antiprogestin	B-X
RU-486	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
VEGF	B-X
and	B-X
TSP-1	B-X
by	B-X
progestins	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
effect	B-X
of	B-X
progestin	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
Actinomycin-D	B-X
,	B-X
but	B-X
not	B-X
puromycin	B-X
,	B-X
also	B-X
blocks	B-X
progestin-dependent	B-X
induction	B-X
of	B-X
TSP-1	B-X
.	B-X
A	B-X
putative	B-X
progestin-response	B-X
element	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
human	B-X
TSP-1	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
a	B-X
progestin-PR	B-X
complex	B-X
might	B-X
directly	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TSP-1	B-X
gene	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Conditioned	B-X
medium	B-X
from	B-X
progestin-treated	B-X
breast	B-X
cancer	B-X
cells	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
though	B-X
not	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antibody	B-X
to	B-X
TSP-1	B-X
,	B-X
indicating	B-X
that	B-X
TSP-1	B-X
secreted	B-X
by	B-X
breast	B-X
cancer	B-X
cells	B-X
could	B-X
be	B-X
pro-angiogenic	B-X
.	B-X
Since	B-X
tumor	B-X
cell-derived	B-X
TSP-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
promote	B-X
angiogenesis	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
.	B-X

Conditioned	O
medium	O
from	O
progestin	O
-	O
treated	O
breast	O
cancer	O
cells	O
stimulates	O
endothelial	O
cell	O
proliferation	O
in	O
the	O
absence	O
though	O
not	O
in	O
the	O
presence	O
of	O
antibody	B-Gene_or_gene_product
to	I-Gene_or_gene_product
TSP	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
indicating	O
that	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
secreted	O
by	O
breast	O
cancer	O
cells	O
could	O
be	O
pro	O
-	O
angiogenic	O
.	O

Since	O
tumor	O
cell	O
-	O
derived	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
has	O
the	O
potential	O
to	O
promote	O
angiogenesis	O
in	O
the	O
tumor	O
microenvironment	O
,	O
it	O
could	O
be	O
a	O
potential	O
target	O
for	O
breast	O
cancer	O
therapy	O
.	O
<EOS>	B-X
Our	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
progestins	B-X
induce	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
express	B-X
mutant	B-X
p53	B-X
protein	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
natural	B-X
and	B-X
synthetic	B-X
progestins	B-X
also	B-X
induce	B-X
thrombospondin-1	B-X
(	B-X
TSP-1	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
in	B-X
T47-D	B-X
and	B-X
BT-474	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Antiprogestin	B-X
RU-486	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
VEGF	B-X
and	B-X
TSP-1	B-X
by	B-X
progestins	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
effect	B-X
of	B-X
progestin	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
Actinomycin-D	B-X
,	B-X
but	B-X
not	B-X
puromycin	B-X
,	B-X
also	B-X
blocks	B-X
progestin-dependent	B-X
induction	B-X
of	B-X
TSP-1	B-X
.	B-X
A	B-X
putative	B-X
progestin-response	B-X
element	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
human	B-X
TSP-1	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
a	B-X
progestin-PR	B-X
complex	B-X
might	B-X
directly	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TSP-1	B-X
gene	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Conditioned	B-X
medium	B-X
from	B-X
progestin-treated	B-X
breast	B-X
cancer	B-X
cells	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
though	B-X
not	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antibody	B-X
to	B-X
TSP-1	B-X
,	B-X
indicating	B-X
that	B-X
TSP-1	B-X
secreted	B-X
by	B-X
breast	B-X
cancer	B-X
cells	B-X
could	B-X
be	B-X
pro-angiogenic	B-X
.	B-X
Since	B-X
tumor	B-X
cell-derived	B-X
TSP-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
promote	B-X
angiogenesis	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
.	B-X

WNT	B-Gene_or_gene_product
/	O
TCF	B-Gene_or_gene_product
signaling	O
through	O
LEF1	B-Gene_or_gene_product
and	O
HOXB9	B-Gene_or_gene_product
mediates	O
lung	O
adenocarcinoma	O
metastasis	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

Metastasis	O
from	O
lung	O
adenocarcinoma	O
can	O
occur	O
swiftly	O
to	O
multiple	O
organs	O
within	O
months	O
of	O
diagnosis	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

The	O
mechanisms	O
that	O
confer	O
this	O
rapid	O
metastatic	O
capacity	O
to	O
lung	O
tumors	O
are	O
unknown	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

Activation	O
of	O
the	O
canonical	O
WNT	B-Gene_or_gene_product
/	O
TCF	B-Gene_or_gene_product
pathway	O
is	O
identified	O
here	O
as	O
a	O
determinant	O
of	O
metastasis	O
to	O
brain	O
and	O
bone	O
during	O
lung	O
adenocarcinoma	O
progression	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

Gene	O
expression	O
signatures	O
denoting	O
WNT	B-Gene_or_gene_product
/	O
TCF	B-Gene_or_gene_product
activation	O
are	O
associated	O
with	O
relapse	O
to	O
multiple	O
organs	O
in	O
primary	O
lung	O
adenocarcinoma	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

Metastatic	O
subpopulations	O
isolated	O
from	O
independent	O
lymph	O
node	O
-	O
derived	O
lung	O
adenocarcinoma	O
cell	O
lines	O
harbor	O
a	O
hyperactive	O
WNT	B-Gene_or_gene_product
/	O
TCF	B-Gene_or_gene_product
pathway	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

Reduction	O
of	O
TCF	B-Gene_or_gene_product
activity	O
in	O
these	O
cells	O
attenuates	O
their	O
ability	O
to	O
form	O
brain	O
and	O
bone	O
metastases	O
in	O
mice	O
,	O
independently	O
of	O
effects	O
on	O
tumor	O
growth	O
in	O
the	O
lungs	O
.	O
<EOS>	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

The	O
WNT	B-Gene_or_gene_product
/	O
TCF	B-Gene_or_gene_product
target	O
genes	O
HOXB9	B-Gene_or_gene_product
and	O
LEF1	B-Gene_or_gene_product
are	O
identified	O
as	O
mediators	O
of	O
chemotactic	O
invasion	O
and	O
colony	O
outgrowth	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

Thus	O
,	O
a	O
distinct	O
WNT	B-Gene_or_gene_product
/	O
TCF	B-Gene_or_gene_product
signaling	O
program	O
through	O
LEF1	B-Gene_or_gene_product
and	O
HOXB9	B-Gene_or_gene_product
enhances	O
the	O
competence	O
of	O
lung	O
adenocarcinoma	O
cells	O
to	O
colonize	O
the	O
bones	O
and	O
the	O
brain	O
.	O
<EOS>	B-X
Metastasis	B-X
from	B-X
lung	B-X
adenocarcinoma	B-X
can	B-X
occur	B-X
swiftly	B-X
to	B-X
multiple	B-X
organs	B-X
within	B-X
months	B-X
of	B-X
diagnosis	B-X
.	B-X
The	B-X
mechanisms	B-X
that	B-X
confer	B-X
this	B-X
rapid	B-X
metastatic	B-X
capacity	B-X
to	B-X
lung	B-X
tumors	B-X
are	B-X
unknown	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
canonical	B-X
WNT/TCF	B-X
pathway	B-X
is	B-X
identified	B-X
here	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
metastasis	B-X
to	B-X
brain	B-X
and	B-X
bone	B-X
during	B-X
lung	B-X
adenocarcinoma	B-X
progression	B-X
.	B-X
Gene	B-X
expression	B-X
signatures	B-X
denoting	B-X
WNT/TCF	B-X
activation	B-X
are	B-X
associated	B-X
with	B-X
relapse	B-X
to	B-X
multiple	B-X
organs	B-X
in	B-X
primary	B-X
lung	B-X
adenocarcinoma	B-X
.	B-X
Metastatic	B-X
subpopulations	B-X
isolated	B-X
from	B-X
independent	B-X
lymph	B-X
node-derived	B-X
lung	B-X
adenocarcinoma	B-X
cell	B-X
lines	B-X
harbor	B-X
a	B-X
hyperactive	B-X
WNT/TCF	B-X
pathway	B-X
.	B-X
Reduction	B-X
of	B-X
TCF	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
attenuates	B-X
their	B-X
ability	B-X
to	B-X
form	B-X
brain	B-X
and	B-X
bone	B-X
metastases	B-X
in	B-X
mice	B-X
,	B-X
independently	B-X
of	B-X
effects	B-X
on	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
The	B-X
WNT/TCF	B-X
target	B-X
genes	B-X
HOXB9	B-X
and	B-X
LEF1	B-X
are	B-X
identified	B-X
as	B-X
mediators	B-X
of	B-X
chemotactic	B-X
invasion	B-X
and	B-X
colony	B-X
outgrowth	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
distinct	B-X
WNT/TCF	B-X
signaling	B-X
program	B-X
through	B-X
LEF1	B-X
and	B-X
HOXB9	B-X
enhances	B-X
the	B-X
competence	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
colonize	B-X
the	B-X
bones	B-X
and	B-X
the	B-X
brain	B-X
.	B-X

For	O
a	O
video	O
summary	O
of	O
this	O
article	O
,	O
see	O
the	O
PaperFlick	O
file	O
available	O
with	O
the	O
online	O
Supplemental	O
Data	O
.	O
<EOS>	B-X
For	B-X
a	B-X
video	B-X
summary	B-X
of	B-X
this	B-X
article	B-X
,	B-X
see	B-X
the	B-X
PaperFlick	B-X
file	B-X
with	B-X
the	B-X
Supplemental	B-X
Data	B-X
available	B-X
online	B-X
.	B-X
For	B-X
a	B-X
video	B-X
summary	B-X
of	B-X
this	B-X
article	B-X
,	B-X
see	B-X
the	B-X
PaperFlick	B-X
file	B-X
with	B-X
the	B-X
Supplemental	B-X
Data	B-X
available	B-X
online	B-X
.	B-X
For	B-X
a	B-X
video	B-X
summary	B-X
of	B-X
this	B-X
article	B-X
,	B-X
see	B-X
the	B-X
PaperFlick	B-X
file	B-X
available	B-X
with	B-X
the	B-X
online	B-X
Supplemental	B-X
Data	B-X
.	B-X
For	B-X
a	B-X
video	B-X
summary	B-X
of	B-X
this	B-X
article	B-X
,	B-X
see	B-X
the	B-X
PaperFlick	B-X
file	B-X
available	B-X
with	B-X
the	B-X
online	B-X
Supplemental	B-X
Data	B-X
.	B-X

Angiogenesis	O
-	O
a	O
novel	O
therapeutic	O
approach	O
for	O
ischemic	O
heart	O
disease	O
.	O
<EOS>	B-X
The	B-X
prevalence	B-X
of	B-X
peripheral	B-X
arterial	B-X
disease	B-X
(	B-X
PAD	B-X
)	B-X
in	B-X
the	B-X
United	B-X
States	B-X
exceeds	B-X
10	B-X
million	B-X
people	B-X
,	B-X
and	B-X
PAD	B-X
is	B-X
a	B-X
significant	B-X
cause	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
across	B-X
the	B-X
globe	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
,	B-X
relieving	B-X
obstructive	B-X
disease	B-X
in	B-X
the	B-X
large	B-X
conduit	B-X
arteries	B-X
does	B-X
not	B-X
assure	B-X
complete	B-X
limb	B-X
salvage	B-X
because	B-X
of	B-X
severe	B-X
microvascular	B-X
disease	B-X
.	B-X
Experimental	B-X
approaches	B-X
to	B-X
improve	B-X
limb	B-X
outcomes	B-X
have	B-X
included	B-X
the	B-X
administration	B-X
of	B-X
angiogenic	B-X
cytokines	B-X
(	B-X
either	B-X
as	B-X
recombinant	B-X
protein	B-X
or	B-X
as	B-X
gene	B-X
therapy	B-X
)	B-X
as	B-X
well	B-X
as	B-X
cell	B-X
therapy	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
what	B-X
has	B-X
been	B-X
learned	B-X
to	B-X
advance	B-X
medical	B-X
revascularization	B-X
for	B-X
PAD	B-X
and	B-X
how	B-X
that	B-X
information	B-X
might	B-X
lead	B-X
to	B-X
novel	B-X
approaches	B-X
for	B-X
therapeutic	B-X
angiogenesis	B-X
and	B-X
arteriogenesis	B-X
for	B-X
PAD	B-X
.	B-X

Angiogenesis	O
is	O
the	O
biologic	O
process	O
of	O
forming	O
new	O
blood	O
vessels	O
.	O
<EOS>	B-X
Angiogenesis	B-X
,	B-X
or	B-X
the	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
in	B-X
the	B-X
body	B-X
is	B-X
a	B-X
well-coordinated	B-X
multi-step	B-X
process	B-X
.	B-X
Endothelial	B-X
cells	B-X
lining	B-X
the	B-X
blood	B-X
vessels	B-X
acquire	B-X
several	B-X
new	B-X
properties	B-X
such	B-X
as	B-X
front-rear	B-X
polarity	B-X
,	B-X
invasiveness	B-X
,	B-X
rapid	B-X
proliferation	B-X
and	B-X
motility	B-X
during	B-X
angiogenesis	B-X
.	B-X
Actin	B-X
regulators	B-X
at	B-X
endothelial	B-X
cell-cell	B-X
junctions	B-X
maintain	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
blood-tissue	B-X
barrier	B-X
while	B-X
permitting	B-X
trans-endothelial	B-X
leukocyte	B-X
migration	B-X
.	B-X
Angiogenesis	B-X
forms	B-X
new	B-X
vessels	B-X
from	B-X
existing	B-X
ones	B-X
.	B-X
Abnormal	B-X
angiogenesis	B-X
,	B-X
which	B-X
is	B-X
what	B-X
gives	B-X
tumor	B-X
microenvironments	B-X
their	B-X
distinctive	B-X
features	B-X
,	B-X
is	B-X
characterised	B-X
by	B-X
convoluted	B-X
,	B-X
permeable	B-X
blood	B-X
vessels	B-X
with	B-X
a	B-X
variety	B-X
of	B-X
shapes	B-X
and	B-X
high	B-X
perfusion	B-X
efficiency	B-X
.	B-X
Numerous	B-X
pathways	B-X
regulate	B-X
angiogenesis	B-X
,	B-X
and	B-X
when	B-X
one	B-X
of	B-X
those	B-X
processes	B-X
is	B-X
blocked	B-X
,	B-X
the	B-X
other	B-X
pathways	B-X
may	B-X
step	B-X
in	B-X
to	B-X
help	B-X
.	B-X
For	B-X
the	B-X
treatment	B-X
of	B-X
advanced	B-X
solid	B-X
tumors	B-X
,	B-X
there	B-X
are	B-X
also	B-X
new	B-X
,	B-X
emerging	B-X
medicines	B-X
that	B-X
target	B-X
multiple	B-X
angiogenic	B-X
pathways	B-X
.	B-X

Undoubtedly	O
,	O
blood	O
vessels	O
growth	O
regulation	O
is	O
a	O
vital	O
aspect	O
in	O
health	O
and	O
disease	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
the	B-X
biologic	B-X
process	B-X
of	B-X
forming	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Undoubtedly	B-X
,	B-X
blood	B-X
vessels	B-X
growth	B-X
regulation	B-X
is	B-X
a	B-X
vital	B-X
aspect	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X
In	B-X
many	B-X
diseases	B-X
state	B-X
body	B-X
loses	B-X
control	B-X
over	B-X
angiogenesis	B-X
.	B-X
Angiogenesis-dependent	B-X
diseases	B-X
result	B-X
when	B-X
new	B-X
blood	B-X
vessels	B-X
either	B-X
grow	B-X
excessively	B-X
or	B-X
insufficiently	B-X
.	B-X
Insufficient	B-X
angiogenesis	B-X
occurs	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
coronary	B-X
artery	B-X
disease	B-X
,	B-X
stroke	B-X
and	B-X
chronic	B-X
wounds	B-X
.	B-X
Therapeutic	B-X
angiogenesis	B-X
is	B-X
the	B-X
biological	B-X
agents	B-X
or	B-X
bioactive	B-X
material	B-X
to	B-X
stimulate	B-X
the	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Traditional	B-X
coronary	B-X
revascularization	B-X
therapies	B-X
such	B-X
as	B-X
coronary	B-X
angioplasty	B-X
or	B-X
bypass	B-X
graft	B-X
surgery	B-X
,	B-X
act	B-X
by	B-X
restoring	B-X
blood	B-X
flow	B-X
through	B-X
the	B-X
preexisting	B-X
coronary	B-X
vessels	B-X
.	B-X
One	B-X
limitation	B-X
of	B-X
these	B-X
approaches	B-X
,	B-X
however	B-X
,	B-X
may	B-X
be	B-X
the	B-X
failure	B-X
to	B-X
normalize	B-X
myocardial	B-X
perfusion	B-X
,	B-X
due	B-X
to	B-X
the	B-X
concomitant	B-X
presence	B-X
or	B-X
small	B-X
of	B-X
resistance	B-X
vessel	B-X
disease	B-X
.	B-X
Studies	B-X
,	B-X
both	B-X
in	B-X
human	B-X
and	B-X
animal	B-X
models	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
,	B-X
various	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
progenitor	B-X
cells	B-X
can	B-X
enhance	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
,	B-X
recombinant	B-X
proteins	B-X
and	B-X
bone	B-X
marrow	B-X
stem	B-X
cells	B-X
are	B-X
currently	B-X
used	B-X
therapeutic	B-X
stimulators	B-X
for	B-X
angiogenesis	B-X
.	B-X
As	B-X
coronary	B-X
artery	B-X
disease	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
in	B-X
the	B-X
developed	B-X
societies	B-X
and	B-X
also	B-X
an	B-X
emerging	B-X
health	B-X
problem	B-X
in	B-X
developing	B-X
countries	B-X
like	B-X
Bangladesh	B-X
therapeutic	B-X
angiogenesis	B-X
may	B-X
provide	B-X
hope	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
modality	B-X
for	B-X
ischemic	B-X
heart	B-X
disease	B-X
with	B-X
or	B-X
in	B-X
place	B-X
of	B-X
current	B-X
therapies	B-X
.	B-X

Under	O
physiological	O
conditions	O
,	O
angiogenesis	O
is	O
regulated	O
by	O
local	O
balance	O
between	O
endogenous	O
stimulators	O
and	O
inhibitors	O
of	O
this	O
process	O
.	O
<EOS>	B-X
Over	B-X
the	B-X
past	B-X
25	B-X
years	B-X
,	B-X
the	B-X
number	B-X
of	B-X
Medline	B-X
publications	B-X
dealing	B-X
with	B-X
angiogenesis	B-X
has	B-X
increased	B-X
in	B-X
a	B-X
nonlinear	B-X
fashion	B-X
,	B-X
reflecting	B-X
the	B-X
interest	B-X
among	B-X
basic	B-X
scientists	B-X
and	B-X
clinicians	B-X
in	B-X
this	B-X
field	B-X
.	B-X
Under	B-X
physiological	B-X
conditions	B-X
,	B-X
angiogenesis	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
local	B-X
balance	B-X
between	B-X
endogenous	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
of	B-X
this	B-X
process	B-X
.	B-X
In	B-X
tumor	B-X
growth	B-X
,	B-X
there	B-X
is	B-X
an	B-X
imbalance	B-X
between	B-X
endogenous	B-X
stimulator	B-X
and	B-X
inhibitor	B-X
levels	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
'angiogenic	B-X
switch	B-X
'	B-X
.	B-X
Starting	B-X
with	B-X
the	B-X
hypothesis	B-X
formulated	B-X
by	B-X
Judah	B-X
Folkman	B-X
that	B-X
tumor	B-X
growth	B-X
is	B-X
angiogenesis-dependent	B-X
,	B-X
this	B-X
area	B-X
of	B-X
research	B-X
has	B-X
a	B-X
solid	B-X
scientific	B-X
foundation	B-X
and	B-X
inhibition	B-X
of	B-X
angiogenesis	B-X
is	B-X
a	B-X
major	B-X
area	B-X
of	B-X
therapeutic	B-X
development	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
.	B-X

In	O
many	O
diseases	O
state	O
body	O
loses	O
control	O
over	O
angiogenesis	O
.	O
<EOS>	B-X
Under	B-X
physiological	B-X
conditions	B-X
,	B-X
angiogenesis	B-X
is	B-X
regulated	B-X
by	B-X
local	B-X
balance	B-X
between	B-X
endogenous	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
of	B-X
this	B-X
process	B-X
.	B-X
In	B-X
many	B-X
diseases	B-X
state	B-X
body	B-X
loses	B-X
control	B-X
over	B-X
angiogenesis	B-X
.	B-X
Angiogenesis-dependent	B-X
diseases	B-X
result	B-X
when	B-X
new	B-X
blood	B-X
vessels	B-X
either	B-X
grow	B-X
excessively	B-X
or	B-X
insufficiently	B-X
.	B-X
Insufficient	B-X
angiogenesis	B-X
occurs	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
coronary	B-X
artery	B-X
disease	B-X
,	B-X
stroke	B-X
and	B-X
chronic	B-X
wounds	B-X
.	B-X
Myocardial	B-X
ischemia	B-X
both	B-X
acute	B-X
and	B-X
chronic	B-X
has	B-X
been	B-X
clearly	B-X
shown	B-X
to	B-X
stimulate	B-X
angiogenesis	B-X
in	B-X
many	B-X
experimental	B-X
models	B-X
.	B-X
Therapeutic	B-X
angiogenesis	B-X
is	B-X
the	B-X
biological	B-X
agents	B-X
or	B-X
bioactive	B-X
material	B-X
to	B-X
stimulate	B-X
the	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
therapeutic	B-X
angiogenesis	B-X
is	B-X
based	B-X
on	B-X
the	B-X
concept	B-X
that	B-X
coronary	B-X
collateral	B-X
development	B-X
may	B-X
be	B-X
stimulated	B-X
by	B-X
pharmacological	B-X
or	B-X
molecular	B-X
means	B-X
and	B-X
can	B-X
limit	B-X
myocardial	B-X
ischemia	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
,	B-X
recombinant	B-X
proteins	B-X
and	B-X
bone	B-X
marrow	B-X
stem	B-X
cells	B-X
are	B-X
currently	B-X
used	B-X
therapeutic	B-X
stimulators	B-X
for	B-X
angiogenesis	B-X
.	B-X
As	B-X
coronary	B-X
artery	B-X
disease	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
in	B-X
the	B-X
developed	B-X
societies	B-X
and	B-X
also	B-X
an	B-X
emerging	B-X
health	B-X
problem	B-X
in	B-X
developing	B-X
countries	B-X
like	B-X
Bangladesh	B-X
therapeutic	B-X
angiogenesis	B-X
may	B-X
provide	B-X
hope	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
modality	B-X
for	B-X
ischemic	B-X
heart	B-X
disease	B-X
with	B-X
or	B-X
in	B-X
place	B-X
of	B-X
current	B-X
therapies	B-X
.	B-X

Angiogenesis	O
-	O
dependent	O
diseases	O
result	O
when	O
new	O
blood	O
vessels	O
either	O
grow	O
excessively	O
or	O
insufficiently	O
.	O
<EOS>	B-X
The	B-X
potential	B-X
impact	B-X
of	B-X
regular	B-X
sodium	B-X
bicarbonate	B-X
therapy	B-X
on	B-X
worsening	B-X
vascular	B-X
calcifications	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
kidney	B-X
disease	B-X
has	B-X
been	B-X
insufficiently	B-X
investigated	B-X
.	B-X
Sheehan	B-X
's	B-X
syndrome	B-X
(	B-X
SS	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
various	B-X
degrees	B-X
of	B-X
hypopituitarism	B-X
,	B-X
and	B-X
develops	B-X
as	B-X
a	B-X
result	B-X
of	B-X
ischemic	B-X
pituitary	B-X
necrosis	B-X
due	B-X
to	B-X
severe	B-X
postpartum	B-X
hemorrhage	B-X
.	B-X
The	B-X
most	B-X
frequent	B-X
endocrine	B-X
disorders	B-X
are	B-X
the	B-X
deficiencies	B-X
of	B-X
growth	B-X
hormone	B-X
and	B-X
prolactin	B-X
.	B-X
Short	B-X
term	B-X
cardiorespiratory	B-X
detraining	B-X
is	B-X
characterised	B-X
in	B-X
highly	B-X
trained	B-X
athletes	B-X
by	B-X
a	B-X
rapid	B-X
decline	B-X
in	B-X
maximal	B-X
oxygen	B-X
uptake	B-X
(	B-X
VO2max	B-X
)	B-X
and	B-X
blood	B-X
volume	B-X
.	B-X
Exercise	B-X
heart	B-X
rate	B-X
increases	B-X
insufficiently	B-X
to	B-X
counterbalance	B-X
the	B-X
decreased	B-X
stroke	B-X
volume	B-X
,	B-X
and	B-X
maximal	B-X
cardiac	B-X
output	B-X
is	B-X
thus	B-X
reduced	B-X
.	B-X
Hormonal	B-X
changes	B-X
include	B-X
a	B-X
reduced	B-X
insulin	B-X
sensitivity	B-X
,	B-X
a	B-X
possible	B-X
increase	B-X
in	B-X
testosterone	B-X
and	B-X
growth	B-X
hormone	B-X
levels	B-X
in	B-X
strength	B-X
athletes	B-X
,	B-X
and	B-X
a	B-X
reversal	B-X
of	B-X
short	B-X
term	B-X
training-induced	B-X
adaptations	B-X
in	B-X
fluid-electrolyte	B-X
regulating	B-X
hormones	B-X
.	B-X

Insufficient	O
angiogenesis	O
occurs	O
in	O
diseases	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
stroke	O
and	O
chronic	O
wounds	O
.	O
<EOS>	B-X
Undoubtedly	B-X
,	B-X
blood	B-X
vessels	B-X
growth	B-X
regulation	B-X
is	B-X
a	B-X
vital	B-X
aspect	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X
Under	B-X
physiological	B-X
conditions	B-X
,	B-X
angiogenesis	B-X
is	B-X
regulated	B-X
by	B-X
local	B-X
balance	B-X
between	B-X
endogenous	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
of	B-X
this	B-X
process	B-X
.	B-X
In	B-X
many	B-X
diseases	B-X
state	B-X
body	B-X
loses	B-X
control	B-X
over	B-X
angiogenesis	B-X
.	B-X
Angiogenesis-dependent	B-X
diseases	B-X
result	B-X
when	B-X
new	B-X
blood	B-X
vessels	B-X
either	B-X
grow	B-X
excessively	B-X
or	B-X
insufficiently	B-X
.	B-X
Insufficient	B-X
angiogenesis	B-X
occurs	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
coronary	B-X
artery	B-X
disease	B-X
,	B-X
stroke	B-X
and	B-X
chronic	B-X
wounds	B-X
.	B-X
Myocardial	B-X
ischemia	B-X
both	B-X
acute	B-X
and	B-X
chronic	B-X
has	B-X
been	B-X
clearly	B-X
shown	B-X
to	B-X
stimulate	B-X
angiogenesis	B-X
in	B-X
many	B-X
experimental	B-X
models	B-X
.	B-X
Therapeutic	B-X
angiogenesis	B-X
is	B-X
the	B-X
biological	B-X
agents	B-X
or	B-X
bioactive	B-X
material	B-X
to	B-X
stimulate	B-X
the	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Traditional	B-X
coronary	B-X
revascularization	B-X
therapies	B-X
such	B-X
as	B-X
coronary	B-X
angioplasty	B-X
or	B-X
bypass	B-X
graft	B-X
surgery	B-X
,	B-X
act	B-X
by	B-X
restoring	B-X
blood	B-X
flow	B-X
through	B-X
the	B-X
preexisting	B-X
coronary	B-X
vessels	B-X
.	B-X
One	B-X
limitation	B-X
of	B-X
these	B-X
approaches	B-X
,	B-X
however	B-X
,	B-X
may	B-X
be	B-X
the	B-X
failure	B-X
to	B-X
normalize	B-X
myocardial	B-X
perfusion	B-X
,	B-X
due	B-X
to	B-X
the	B-X
concomitant	B-X
presence	B-X
or	B-X
small	B-X
of	B-X
resistance	B-X
vessel	B-X
disease	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
therapeutic	B-X
angiogenesis	B-X
is	B-X
based	B-X
on	B-X
the	B-X
concept	B-X
that	B-X
coronary	B-X
collateral	B-X
development	B-X
may	B-X
be	B-X
stimulated	B-X
by	B-X
pharmacological	B-X
or	B-X
molecular	B-X
means	B-X
and	B-X
can	B-X
limit	B-X
myocardial	B-X
ischemia	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
,	B-X
recombinant	B-X
proteins	B-X
and	B-X
bone	B-X
marrow	B-X
stem	B-X
cells	B-X
are	B-X
currently	B-X
used	B-X
therapeutic	B-X
stimulators	B-X
for	B-X
angiogenesis	B-X
.	B-X
As	B-X
coronary	B-X
artery	B-X
disease	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
in	B-X
the	B-X
developed	B-X
societies	B-X
and	B-X
also	B-X
an	B-X
emerging	B-X
health	B-X
problem	B-X
in	B-X
developing	B-X
countries	B-X
like	B-X
Bangladesh	B-X
therapeutic	B-X
angiogenesis	B-X
may	B-X
provide	B-X
hope	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
modality	B-X
for	B-X
ischemic	B-X
heart	B-X
disease	B-X
with	B-X
or	B-X
in	B-X
place	B-X
of	B-X
current	B-X
therapies	B-X
.	B-X

Myocardial	O
ischemia	O
both	O
acute	O
and	O
chronic	O
has	O
been	O
clearly	O
shown	O
to	O
stimulate	O
angiogenesis	O
in	O
many	O
experimental	O
models	O
.	O
<EOS>	B-X
Under	B-X
physiological	B-X
conditions	B-X
,	B-X
angiogenesis	B-X
is	B-X
regulated	B-X
by	B-X
local	B-X
balance	B-X
between	B-X
endogenous	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
of	B-X
this	B-X
process	B-X
.	B-X
In	B-X
many	B-X
diseases	B-X
state	B-X
body	B-X
loses	B-X
control	B-X
over	B-X
angiogenesis	B-X
.	B-X
Insufficient	B-X
angiogenesis	B-X
occurs	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
coronary	B-X
artery	B-X
disease	B-X
,	B-X
stroke	B-X
and	B-X
chronic	B-X
wounds	B-X
.	B-X
Myocardial	B-X
ischemia	B-X
both	B-X
acute	B-X
and	B-X
chronic	B-X
has	B-X
been	B-X
clearly	B-X
shown	B-X
to	B-X
stimulate	B-X
angiogenesis	B-X
in	B-X
many	B-X
experimental	B-X
models	B-X
.	B-X
Therapeutic	B-X
angiogenesis	B-X
is	B-X
the	B-X
biological	B-X
agents	B-X
or	B-X
bioactive	B-X
material	B-X
to	B-X
stimulate	B-X
the	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
therapeutic	B-X
angiogenesis	B-X
is	B-X
based	B-X
on	B-X
the	B-X
concept	B-X
that	B-X
coronary	B-X
collateral	B-X
development	B-X
may	B-X
be	B-X
stimulated	B-X
by	B-X
pharmacological	B-X
or	B-X
molecular	B-X
means	B-X
and	B-X
can	B-X
limit	B-X
myocardial	B-X
ischemia	B-X
.	B-X
Studies	B-X
,	B-X
both	B-X
in	B-X
human	B-X
and	B-X
animal	B-X
models	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
,	B-X
various	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
progenitor	B-X
cells	B-X
can	B-X
enhance	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
,	B-X
recombinant	B-X
proteins	B-X
and	B-X
bone	B-X
marrow	B-X
stem	B-X
cells	B-X
are	B-X
currently	B-X
used	B-X
therapeutic	B-X
stimulators	B-X
for	B-X
angiogenesis	B-X
.	B-X
As	B-X
coronary	B-X
artery	B-X
disease	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
in	B-X
the	B-X
developed	B-X
societies	B-X
and	B-X
also	B-X
an	B-X
emerging	B-X
health	B-X
problem	B-X
in	B-X
developing	B-X
countries	B-X
like	B-X
Bangladesh	B-X
therapeutic	B-X
angiogenesis	B-X
may	B-X
provide	B-X
hope	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
modality	B-X
for	B-X
ischemic	B-X
heart	B-X
disease	B-X
with	B-X
or	B-X
in	B-X
place	B-X
of	B-X
current	B-X
therapies	B-X
.	B-X

Therapeutic	O
angiogenesis	O
is	O
the	O
biological	O
agents	O
or	O
bioactive	O
material	O
to	O
stimulate	O
the	O
growth	O
of	O
new	O
blood	O
vessels	O
.	O
<EOS>	B-X
Tumor	B-X
blood	B-X
vessels	B-X
are	B-X
a	B-X
key	B-X
target	B-X
for	B-X
cancer	B-X
therapeutic	B-X
management	B-X
.	B-X
Tumor	B-X
cells	B-X
secrete	B-X
high	B-X
levels	B-X
of	B-X
pro-angiogenic	B-X
factors	B-X
which	B-X
contribute	B-X
to	B-X
the	B-X
creation	B-X
of	B-X
an	B-X
abnormal	B-X
vascular	B-X
network	B-X
characterized	B-X
by	B-X
disorganized	B-X
,	B-X
immature	B-X
and	B-X
permeable	B-X
blood	B-X
vessels	B-X
,	B-X
resulting	B-X
in	B-X
poorly	B-X
perfused	B-X
tumors	B-X
.	B-X
To	B-X
fight	B-X
against	B-X
this	B-X
defective	B-X
phenotype	B-X
,	B-X
the	B-X
normalization	B-X
of	B-X
the	B-X
tumor	B-X
vasculature	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
new	B-X
therapeutic	B-X
strategy	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
and	B-X
describe	B-X
strategies	B-X
used	B-X
to	B-X
achieve	B-X
vascular	B-X
normalization	B-X
.	B-X

Traditional	O
coronary	O
revascularization	O
therapies	O
such	O
as	O
coronary	O
angioplasty	O
or	O
bypass	O
graft	O
surgery	O
,	O
act	O
by	O
restoring	O
blood	O
flow	O
through	O
the	O
preexisting	O
coronary	O
vessels	O
.	O
<EOS>	B-X
Exercise	B-X
program	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
improved	B-X
cardiovascular	B-X
outcomes	B-X
in	B-X
patients	B-X
sustaining	B-X
coronary	B-X
artery	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
role	B-X
of	B-X
exercise	B-X
after	B-X
percutaneous	B-X
coronary	B-X
intervention	B-X
(	B-X
PCI	B-X
)	B-X
.	B-X
Exercise	B-X
versus	B-X
no	B-X
exercise	B-X
following	B-X
PCI	B-X
in	B-X
the	B-X
patients	B-X
with	B-X
coronary	B-X
heart	B-X
disease	B-X
(	B-X
CHD	B-X
)	B-X
was	B-X
investigated	B-X
in	B-X
randomized	B-X
trials	B-X
.	B-X
Left	B-X
ventricular	B-X
end	B-X
diastolic	B-X
diameter	B-X
(	B-X
LVEDD	B-X
)	B-X
,	B-X
left	B-X
ventricular	B-X
ejection	B-X
fraction	B-X
(	B-X
LVEF	B-X
)	B-X
,	B-X
6-minute	B-X
walking	B-X
distance	B-X
(	B-X
6MWD	B-X
)	B-X
,	B-X
cardiac	B-X
death	B-X
,	B-X
myocardial	B-X
infarction	B-X
,	B-X
coronary	B-X
angioplasty	B-X
,	B-X
coronary	B-X
artery	B-X
bypass	B-X
surgery	B-X
(	B-X
CABG	B-X
)	B-X
,	B-X
and	B-X
angina	B-X
pectoris	B-X
or	B-X
restenosis	B-X
per	B-X
randomized	B-X
patients	B-X
were	B-X
analyzed	B-X
by	B-X
meta-analytic	B-X
procedure	B-X
to	B-X
compare	B-X
the	B-X
curative	B-X
effect	B-X
of	B-X
exercise	B-X
program	B-X
with	B-X
exclusive	B-X
exercise	B-X
program	B-X
after	B-X
PCI	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
incidence	B-X
rate	B-X
of	B-X
cardiac	B-X
death	B-X
(	B-X
RR	B-X
=	B-X
0.24	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
[	B-X
007	B-X
,	B-X
0.76	B-X
]	B-X
,	B-X
p	B-X
=	B-X
0.02	B-X
)	B-X
,	B-X
myocardial	B-X
infarction	B-X
(	B-X
RR	B-X
=	B-X
0.23	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
[	B-X
0.09	B-X
,	B-X
0.57	B-X
]	B-X
,	B-X
p	B-X
=	B-X
0.002	B-X
)	B-X
,	B-X
coronary	B-X
angioplasty	B-X
(	B-X
RR	B-X
=	B-X
0.47	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
[	B-X
0.26	B-X
,	B-X
0.84	B-X
]	B-X
,	B-X
p	B-X
=	B-X
0.01	B-X
)	B-X
,	B-X
angina	B-X
pectoris	B-X
(	B-X
RR	B-X
=	B-X
0.39	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
[	B-X
0.24	B-X
,	B-X
0.64	B-X
]	B-X
,	B-X
p	B-X
=	B-X
0.0002	B-X
)	B-X
and	B-X
restenosis	B-X
(	B-X
RR	B-X
=	B-X
0.36	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
[	B-X
0.16	B-X
,	B-X
0.83	B-X
]	B-X
,	B-X
p	B-X
=	B-X
0.02	B-X
)	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
exercise	B-X
group	B-X
.	B-X

One	O
limitation	O
of	O
these	O
approaches	O
,	O
however	O
,	O
may	O
be	O
the	O
failure	O
to	O
normalize	O
myocardial	O
perfusion	O
,	O
due	O
to	O
the	O
concomitant	O
presence	O
or	O
small	O
of	O
resistance	O
vessel	O
disease	O
.	O
<EOS>	B-X
The	B-X
endothelium	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
vascular	B-X
tone	B-X
by	B-X
synthesizing	B-X
and	B-X
liberating	B-X
endothelium-derived	B-X
relaxing	B-X
factors	B-X
inclusive	B-X
of	B-X
vasodilator	B-X
prostaglandins	B-X
(	B-X
eg	B-X
,	B-X
prostacyclin	B-X
)	B-X
,	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
,	B-X
and	B-X
endothelium-dependent	B-X
hyperpolarization	B-X
factors	B-X
in	B-X
a	B-X
distinct	B-X
blood	B-X
vessel	B-X
size-dependent	B-X
manner	B-X
.	B-X
Large	B-X
conduit	B-X
arteries	B-X
are	B-X
predominantly	B-X
regulated	B-X
by	B-X
NO	B-X
and	B-X
small	B-X
resistance	B-X
arteries	B-X
by	B-X
endothelium-dependent	B-X
hyperpolarization	B-X
factors	B-X
.	B-X
Accumulating	B-X
evidence	B-X
over	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
has	B-X
demonstrated	B-X
that	B-X
endothelial	B-X
dysfunction	B-X
and	B-X
coronary	B-X
vasomotion	B-X
abnormalities	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
cardiovascular	B-X
diseases	B-X
.	B-X
The	B-X
major	B-X
mechanisms	B-X
of	B-X
coronary	B-X
vasomotion	B-X
abnormalities	B-X
include	B-X
enhanced	B-X
coronary	B-X
vasoconstrictive	B-X
reactivity	B-X
at	B-X
epicardial	B-X
and	B-X
microvascular	B-X
levels	B-X
,	B-X
impaired	B-X
endothelium-dependent	B-X
and	B-X
endothelium-independent	B-X
coronary	B-X
vasodilator	B-X
capacities	B-X
,	B-X
and	B-X
elevated	B-X
coronary	B-X
microvascular	B-X
resistance	B-X
caused	B-X
by	B-X
structural	B-X
factors	B-X
.	B-X
Recent	B-X
experimental	B-X
and	B-X
clinical	B-X
research	B-X
has	B-X
highlighted	B-X
CMD	B-X
as	B-X
the	B-X
systemic	B-X
small	B-X
artery	B-X
disease	B-X
beyond	B-X
the	B-X
heart	B-X
,	B-X
emerging	B-X
modulators	B-X
of	B-X
vascular	B-X
functions	B-X
,	B-X
novel	B-X
insights	B-X
into	B-X
the	B-X
pathogenesis	B-X
of	B-X
cardiovascular	B-X
diseases	B-X
associated	B-X
with	B-X
CMD	B-X
,	B-X
and	B-X
potential	B-X
therapeutic	B-X
interventions	B-X
to	B-X
CMD	B-X
with	B-X
major	B-X
clinical	B-X
implications	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
will	B-X
summarize	B-X
the	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
endothelial	B-X
modulation	B-X
of	B-X
vascular	B-X
tone	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
coronary	B-X
macrovascular	B-X
and	B-X
microvascular	B-X
diseases	B-X
from	B-X
bench	B-X
to	B-X
bedside	B-X
,	B-X
with	B-X
a	B-X
special	B-X
emphasis	B-X
placed	B-X
on	B-X
the	B-X
mechanisms	B-X
and	B-X
clinical	B-X
implications	B-X
of	B-X
CMD	B-X
.	B-X

In	O
contrast	O
,	O
therapeutic	O
angiogenesis	O
is	O
based	O
on	O
the	O
concept	O
that	O
coronary	O
collateral	O
development	O
may	O
be	O
stimulated	O
by	O
pharmacological	O
or	O
molecular	O
means	O
and	O
can	O
limit	O
myocardial	O
ischemia	O
.	O
<EOS>	B-X
S1	B-X
Health	B-X
literacy	B-X
and	B-X
health	B-X
education	B-X
in	B-X
adolescence	B-X
Catarina	B-X
Cardoso	B-X
TomÃ¡s	B-X
S2	B-X
The	B-X
effect	B-X
of	B-X
a	B-X
walking	B-X
program	B-X
on	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
well-being	B-X
of	B-X
people	B-X
with	B-X
schizophrenia	B-X
Emanuel	B-X
Oliveira	B-X
,	B-X
D.	B-X
Sousa	B-X
,	B-X
M.	B-X
Uba-Chupel	B-X
,	B-X
G.	B-X
Furtado	B-X
,	B-X
C.	B-X
Rocha	B-X
,	B-X
A.	B-X
Teixeira	B-X
,	B-X
P.	B-X
Ferreira	B-X
S3	B-X
Diagnosis	B-X
and	B-X
innovative	B-X
treatments	B-X
-	B-X
the	B-X
way	B-X
to	B-X
a	B-X
better	B-X
medical	B-X
practice	B-X
Celeste	B-X
Alves	B-X
S4	B-X
Simulation-based	B-X
learning	B-X
and	B-X
how	B-X
it	B-X
is	B-X
a	B-X
high	B-X
contribution	B-X
Stefan	B-X
Gisin	B-X
S5	B-X
Formative	B-X
research	B-X
about	B-X
acceptability	B-X
,	B-X
utilization	B-X
and	B-X
promotion	B-X
of	B-X
a	B-X
home	B-X
fortification	B-X
programme	B-X
with	B-X
micronutrient	B-X
powders	B-X
(	B-X
MNP	B-X
)	B-X
in	B-X
the	B-X
Autonomous	B-X
Region	B-X
of	B-X
PrÃ­ncipe	B-X
,	B-X
SÃ£o	B-X
TomÃ©	B-X
and	B-X
PrÃ­ncipe	B-X
Elisabete	B-X
Catarino	B-X
,	B-X
Nelma	B-X
Carvalho	B-X
,	B-X
Tiago	B-X
Coucelo	B-X
,	B-X
LuÃ­s	B-X
Bonfim	B-X
,	B-X
Carina	B-X
Silva	B-X
S6	B-X
Safety	B-X
culture	B-X
of	B-X
the	B-X
patient	B-X
:	B-X
a	B-X
reflexion	B-X
about	B-X
the	B-X
therapeutic	B-X
approach	B-X
on	B-X
the	B-X
patient	B-X
with	B-X
vocal	B-X
pathology	B-X
DÃ©bora	B-X
Franco	B-X
S7	B-X
About	B-X
wine	B-X
,	B-X
fortune	B-X
cookies	B-X
and	B-X
patient	B-X
experience	B-X
JesÃºs	B-X
Alcoba	B-X
GonzÃ¡lez	B-X
O1	B-X
The	B-X
psychological	B-X
impact	B-X
on	B-X
the	B-X
emergency	B-X
crews	B-X
after	B-X
the	B-X
disaster	B-X
event	B-X
on	B-X
February	B-X
20	B-X
,	B-X
2010	B-X
Helena	B-X
G.	B-X
Jardim	B-X
,	B-X
Rita	B-X
Silva	B-X
O2	B-X
Musculoskeletal	B-X
disorders	B-X
in	B-X
midwives	B-X
Cristina	B-X
L.	B-X
Baixinho	B-X
,	B-X
MÂª	B-X
Helena	B-X
Presado	B-X
,	B-X
MÂª	B-X
FÃ¡tima	B-X
Marques	B-X
,	B-X
MÃ¡rio	B-X
E.	B-X
Cardoso	B-X
O3	B-X
Negative	B-X
childhood	B-X
experiences	B-X
and	B-X
fears	B-X
of	B-X
compassion	B-X
:	B-X
Implications	B-X
for	B-X
psychological	B-X
difficulties	B-X
in	B-X
adolescence	B-X
Marina	B-X
Cunha	B-X
,	B-X
Joana	B-X
Mendes	B-X
,	B-X
Ana	B-X
Xavier	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Margarida	B-X
Couto	B-X
O4	B-X
Optimal	B-X
age	B-X
to	B-X
give	B-X
the	B-X
first	B-X
dose	B-X
of	B-X
measles	B-X
vaccine	B-X
in	B-X
Portugal	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Carla	B-X
Nunes	B-X
,	B-X
JoÃ£o	B-X
R.	B-X
Mesquita	B-X
,	B-X
Maria	B-X
S.	B-X
Nascimento	B-X
,	B-X
Guilherme	B-X
GonÃ§alves	B-X
O5	B-X
Functional	B-X
assessment	B-X
of	B-X
elderly	B-X
in	B-X
primary	B-X
care	B-X
ConceiÃ§Ã£o	B-X
Castro	B-X
,	B-X
Alice	B-X
MÃ¡rtires	B-X
,	B-X
MÂª	B-X
JoÃ£o	B-X
Monteiro	B-X
,	B-X
ConceiÃ§Ã£o	B-X
Rainho	B-X
O6	B-X
Smoking	B-X
and	B-X
coronary	B-X
events	B-X
in	B-X
a	B-X
population	B-X
of	B-X
Spanish	B-X
health-care	B-X
centre	B-X
:	B-X
An	B-X
observational	B-X
study	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Fatima	B-X
M.	B-X
Monago	B-X
,	B-X
Jose	B-X
T.	B-X
Guerrero	B-X
,	B-X
Rocio	B-X
M.	B-X
Monago	B-X
,	B-X
Africa	B-X
P.	B-X
Trigo	B-X
,	B-X
Milagros	B-X
L.	B-X
Gutierrez	B-X
,	B-X
Gemma	B-X
M.	B-X
MilanÃ©s	B-X
,	B-X
Mercedes	B-X
G.	B-X
Reina	B-X
,	B-X
Ana	B-X
G.	B-X
Villanueva	B-X
,	B-X
Ana	B-X
S.	B-X
PiÃ±ero	B-X
,	B-X
Isabel	B-X
R.	B-X
Aliseda	B-X
,	B-X
Francisco	B-X
B.	B-X
Ramirez	B-X
O7	B-X
Prevalence	B-X
of	B-X
musculoskeletal	B-X
injuries	B-X
in	B-X
Portuguese	B-X
musicians	B-X
Andrea	B-X
Ribeiro	B-X
,	B-X
Ana	B-X
Quelhas	B-X
,	B-X
ConceiÃ§Ã£o	B-X
Manso	B-X
O8	B-X
Hip	B-X
fractures	B-X
,	B-X
psychotropic	B-X
drug	B-X
consumption	B-X
and	B-X
comorbidity	B-X
in	B-X
patients	B-X
of	B-X
a	B-X
primary	B-X
care	B-X
practice	B-X
in	B-X
Spain	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Jose	B-X
T.	B-X
Guerrero	B-X
,	B-X
Fatima	B-X
M.	B-X
Monago	B-X
,	B-X
Rafael	B-X
B.	B-X
Santos	B-X
,	B-X
Nuria	B-X
R.	B-X
Jimenez	B-X
,	B-X
Cristina	B-X
G.	B-X
NuÃ±ez	B-X
,	B-X
Inmaculada	B-X
R.	B-X
Gomez	B-X
,	B-X
MÂª	B-X
Jose	B-X
L.	B-X
Fernandez	B-X
,	B-X
Laura	B-X
A.	B-X
Marquez	B-X
,	B-X
Ana	B-X
L.	B-X
Moreno	B-X
,	B-X
MÂª	B-X
Jesus	B-X
Tena	B-X
Huertas	B-X
,	B-X
Francisco	B-X
B.	B-X
Ramirez	B-X
O9	B-X
The	B-X
role	B-X
of	B-X
self-criticism	B-X
and	B-X
shame	B-X
in	B-X
social	B-X
anxiety	B-X
in	B-X
a	B-X
clinical	B-X
SAD	B-X
sample	B-X
Daniel	B-X
Seabra	B-X
,	B-X
MÂª	B-X
CÃ©u	B-X
Salvador	B-X
O10	B-X
Obstruction	B-X
and	B-X
infiltration	B-X
:	B-X
a	B-X
proposal	B-X
of	B-X
a	B-X
quality	B-X
indicator	B-X
Luciene	B-X
Braga	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Cristina	B-X
Arreguy-Sena	B-X
,	B-X
Bibiana	B-X
F.	B-X
Oliveira	B-X
,	B-X
MÂª	B-X
Adriana	B-X
Henriques	B-X
O11	B-X
Balance	B-X
and	B-X
anxiety	B-X
and	B-X
depression	B-X
symptoms	B-X
in	B-X
old	B-X
age	B-X
people	B-X
Joana	B-X
Santos	B-X
,	B-X
Sara	B-X
Lebre	B-X
,	B-X
Alda	B-X
Marques	B-X
O12	B-X
Prevalence	B-X
of	B-X
postural	B-X
changes	B-X
and	B-X
risk	B-X
factors	B-X
in	B-X
school	B-X
children	B-X
and	B-X
adolescents	B-X
in	B-X
a	B-X
northern	B-X
region	B-X
(	B-X
Porto	B-X
)	B-X
Clarinda	B-X
Festas	B-X
,	B-X
Sandra	B-X
Rodrigues	B-X
,	B-X
Andrea	B-X
Ribeiro	B-X
,	B-X
JosÃ©	B-X
Lumini	B-X
O13	B-X
Ischemic	B-X
stroke	B-X
vs.	B-X
haemorrhagic	B-X
stroke	B-X
survival	B-X
rate	B-X
Ana	B-X
G.	B-X
Figueiredo	B-X
O14	B-X
Chronobiological	B-X
factors	B-X
as	B-X
responsible	B-X
for	B-X
the	B-X
appearance	B-X
of	B-X
locomotor	B-X
pathology	B-X
in	B-X
adolescents	B-X
Francisco	B-X
J.	B-X
Hernandez-Martinez	B-X
,	B-X
Liliana	B-X
Campi	B-X
,	B-X
MÂª	B-X
Pino	B-X
Quintana-Montesdeoca	B-X
,	B-X
Juan	B-X
F.	B-X
Jimenez-Diaz	B-X
,	B-X
Bienvenida	B-X
C.	B-X
Rodriguez-De-Vera	B-X
O15	B-X
Risk	B-X
of	B-X
malnutrition	B-X
in	B-X
the	B-X
elderly	B-X
of	B-X
BraganÃ§a	B-X
Alexandra	B-X
Parente	B-X
,	B-X
MÂª	B-X
Augusta	B-X
Mata	B-X
,	B-X
Ana	B-X
MÂª	B-X
Pereira	B-X
,	B-X
AdÃ­lia	B-X
Fernandes	B-X
,	B-X
Manuel	B-X
BrÃ¡s	B-X
O16	B-X
A	B-X
Lifestyle	B-X
Educational	B-X
Programme	B-X
for	B-X
primary	B-X
care	B-X
diabetic	B-X
patients	B-X
:	B-X
the	B-X
design	B-X
of	B-X
a	B-X
complex	B-X
nursing	B-X
intervention	B-X
MÂª	B-X
RosÃ¡rio	B-X
Pinto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
L.	B-X
Basto	B-X
,	B-X
Ana	B-X
C.	B-X
Rei	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
O17	B-X
Medication	B-X
adherence	B-X
in	B-X
elderly	B-X
people	B-X
Gilberta	B-X
Sousa	B-X
,	B-X
Clementina	B-X
Morna	B-X
,	B-X
OtÃ­lia	B-X
Freitas	B-X
,	B-X
GregÃ³rio	B-X
Freitas	B-X
,	B-X
Ana	B-X
Jardim	B-X
,	B-X
Rita	B-X
Vasconcelos	B-X
O18	B-X
Hospitalization	B-X
for	B-X
cervical	B-X
cancer	B-X
of	B-X
residents	B-X
in	B-X
the	B-X
metropolitan	B-X
region	B-X
of	B-X
Porto	B-X
Alegre	B-X
,	B-X
Southern	B-X
Brazil	B-X
,	B-X
2012	B-X
to	B-X
2014	B-X
Lina	B-X
G.	B-X
Horta	B-X
,	B-X
Roger	B-X
S.	B-X
Rosa	B-X
,	B-X
LuÃ­s	B-X
F.	B-X
Kranz	B-X
,	B-X
Rita	B-X
C.	B-X
Nugem	B-X
,	B-X
Mariana	B-X
S.	B-X
Siqueira	B-X
,	B-X
Ronaldo	B-X
Bordin	B-X
O19	B-X
Oncologic	B-X
assistance	B-X
of	B-X
high	B-X
complexity	B-X
:	B-X
evaluation	B-X
of	B-X
regulating	B-X
accesses	B-X
Rosiane	B-X
Kniess	B-X
,	B-X
Josimari	B-X
T.	B-X
Lacerda	B-X
O20	B-X
Perceived	B-X
barriers	B-X
for	B-X
using	B-X
health	B-X
care	B-X
services	B-X
by	B-X
the	B-X
older	B-X
population	B-X
as	B-X
seen	B-X
by	B-X
the	B-X
social	B-X
sector	B-X
:	B-X
findings	B-X
from	B-X
the	B-X
Vila	B-X
Nova	B-X
de	B-X
Gaia	B-X
Gerontological	B-X
Plan	B-X
Joana	B-X
Guedes	B-X
,	B-X
Idalina	B-X
Machado	B-X
,	B-X
Sidalina	B-X
Almeida	B-X
,	B-X
Adriano	B-X
ZilhÃ£o	B-X
,	B-X
Helder	B-X
Alves	B-X
,	B-X
Ãscar	B-X
Ribeiro	B-X
O21	B-X
Sleep	B-X
difficulties	B-X
and	B-X
depressive	B-X
symptoms	B-X
in	B-X
college	B-X
students	B-X
Ana	B-X
P.	B-X
Amaral	B-X
,	B-X
Ana	B-X
Santos	B-X
,	B-X
Joana	B-X
Monteiro	B-X
,	B-X
MÂª	B-X
Clara	B-X
Rocha	B-X
,	B-X
Rui	B-X
Cruz	B-X
O22	B-X
Psychopathological	B-X
symptoms	B-X
and	B-X
medication	B-X
use	B-X
in	B-X
higher	B-X
education	B-X
Ana	B-X
P.	B-X
Amaral	B-X
,	B-X
Marina	B-X
LourenÃ§o	B-X
,	B-X
MÂª	B-X
Clara	B-X
Rocha	B-X
,	B-X
Rui	B-X
Cruz	B-X
O23	B-X
Sexually	B-X
transmitted	B-X
diseases	B-X
in	B-X
higher	B-X
education	B-X
institutions	B-X
Sandra	B-X
Antunes	B-X
,	B-X
VerÃ³nica	B-X
MendonÃ§a	B-X
,	B-X
Isabel	B-X
Andrade	B-X
,	B-X
NÃ¡dia	B-X
OsÃ³rio	B-X
,	B-X
Ana	B-X
Valado	B-X
,	B-X
Armando	B-X
Caseiro	B-X
,	B-X
AntÃ³nio	B-X
Gabriel	B-X
,	B-X
Anabela	B-X
C.	B-X
Martins	B-X
,	B-X
Fernando	B-X
Mendes	B-X
O24	B-X
Alcohol	B-X
consumption	B-X
and	B-X
suicide	B-X
ideation	B-X
in	B-X
higher	B-X
education	B-X
students	B-X
LÃ­dia	B-X
Cabral	B-X
,	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Amadeu	B-X
GonÃ§alves	B-X
O25	B-X
Quality	B-X
of	B-X
life	B-X
in	B-X
university	B-X
students	B-X
Tatiana	B-X
D.	B-X
Luz	B-X
,	B-X
Leonardo	B-X
Luz	B-X
,	B-X
Raul	B-X
Martins	B-X
O26	B-X
Male	B-X
and	B-X
female	B-X
adolescent	B-X
antisocial	B-X
behaviour	B-X
:	B-X
characterizing	B-X
vulnerabilities	B-X
in	B-X
a	B-X
Portuguese	B-X
sample	B-X
Alice	B-X
Morgado	B-X
,	B-X
Maria	B-X
L.	B-X
Vale-Dias	B-X
O27	B-X
Risk	B-X
factors	B-X
for	B-X
mental	B-X
health	B-X
in	B-X
higher	B-X
education	B-X
students	B-X
of	B-X
health	B-X
sciences	B-X
Rui	B-X
Porta-Nova	B-X
O28	B-X
International	B-X
classification	B-X
of	B-X
functioning	B-X
disability	B-X
and	B-X
health	B-X
as	B-X
reflexive	B-X
reasoning	B-X
in	B-X
primary	B-X
attention	B-X
in	B-X
health	B-X
TÃ¢nia	B-X
C.	B-X
Fleig	B-X
,	B-X
Ãboni	B-X
M.	B-X
Reuter	B-X
,	B-X
Miriam	B-X
B.	B-X
Froemming	B-X
,	B-X
Sabrina	B-X
L.	B-X
Guerreiro	B-X
,	B-X
Lisiane	B-X
L.	B-X
Carvalho	B-X
O29	B-X
Risk	B-X
factors	B-X
and	B-X
cardiovascular	B-X
disease	B-X
in	B-X
Portalegre	B-X
Daniel	B-X
Guedelha	B-X
,	B-X
P.	B-X
Coelho	B-X
,	B-X
A.	B-X
Pereira	B-X
O30	B-X
Health	B-X
status	B-X
of	B-X
the	B-X
elderly	B-X
population	B-X
living	B-X
in	B-X
Portalegre	B-X
historic	B-X
city	B-X
centre	B-X
:	B-X
A	B-X
longitudinal	B-X
study	B-X
AntÃ³nio	B-X
Calha	B-X
,	B-X
Raul	B-X
Cordeiro	B-X
O31	B-X
Student	B-X
â	B-X
s	B-X
sleep	B-X
in	B-X
higher	B-X
education	B-X
:	B-X
sleep	B-X
quality	B-X
among	B-X
students	B-X
of	B-X
the	B-X
IPB	B-X
Ana	B-X
GonÃ§alves	B-X
,	B-X
Ana	B-X
Certo	B-X
,	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
MÂª	B-X
Augusta	B-X
Mata	B-X
O32	B-X
Trend	B-X
in	B-X
mortality	B-X
from	B-X
cervical	B-X
cancer	B-X
in	B-X
the	B-X
metropolitan	B-X
area	B-X
of	B-X
FlorianÃ³polis	B-X
,	B-X
state	B-X
of	B-X
Santa	B-X
Catarina	B-X
,	B-X
Brazil	B-X
,	B-X
2000	B-X
to	B-X
2013	B-X
Aline	B-X
Welter	B-X
,	B-X
Elayne	B-X
Pereira	B-X
,	B-X
Sandra	B-X
Ribeiro	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
O33	B-X
Adherence	B-X
to	B-X
treatment	B-X
in	B-X
the	B-X
elderly	B-X
in	B-X
an	B-X
urban	B-X
environment	B-X
in	B-X
Spain	B-X
Juan-Fernando	B-X
JimÃ©nez-DÃ­az	B-X
,	B-X
Carla	B-X
JimÃ©nez-RodrÃ­guez	B-X
,	B-X
Francisco-JosÃ©	B-X
HernÃ¡ndez-MartÃ­nez	B-X
,	B-X
Bienvenida-Del-Carmen	B-X
RodrÃ­guez-De-Vera	B-X
,	B-X
Alexandre	B-X
Marques-Rodrigues	B-X
O34	B-X
Beira	B-X
Baixa	B-X
Blood	B-X
Pressure	B-X
Study	B-X
(	B-X
Study	B-X
PABB	B-X
)	B-X
PatrÃ­cia	B-X
Coelho	B-X
,	B-X
Tiago	B-X
Bernardes	B-X
,	B-X
Alexandre	B-X
Pereira	B-X
O35	B-X
Trends	B-X
in	B-X
cervical	B-X
cancer	B-X
mortality	B-X
statistics	B-X
in	B-X
Santa	B-X
Catarina	B-X
State	B-X
,	B-X
Brazil	B-X
,	B-X
by	B-X
age	B-X
group	B-X
and	B-X
macro-region	B-X
,	B-X
from	B-X
2000	B-X
to	B-X
2013	B-X
PatrÃ­cia	B-X
Sousa	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Filho	B-X
,	B-X
Nazare	B-X
Nazario	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
O36	B-X
Sleep	B-X
problems	B-X
among	B-X
Portuguese	B-X
adolescents	B-X
:	B-X
a	B-X
public	B-X
health	B-X
issue	B-X
Odete	B-X
Amaral	B-X
,	B-X
AntÃ³nio	B-X
Garrido	B-X
,	B-X
NÃ©lio	B-X
Veiga	B-X
,	B-X
Carla	B-X
Nunes	B-X
,	B-X
Ana	B-X
R.	B-X
Pedro	B-X
,	B-X
Carlos	B-X
Pereira	B-X
O37	B-X
Association	B-X
between	B-X
body	B-X
fat	B-X
and	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
AntÃ³nio	B-X
Almeia	B-X
,	B-X
Helder	B-X
M.	B-X
Fernandes	B-X
,	B-X
Carlos	B-X
Vasconcelos	B-X
,	B-X
Nelson	B-X
Sousa	B-X
,	B-X
Victor	B-X
M.	B-X
Reis	B-X
,	B-X
M.	B-X
JoÃ£o	B-X
Monteiro	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O38	B-X
Therapy	B-X
adherence	B-X
and	B-X
polypharmacy	B-X
in	B-X
non-institutionalized	B-X
elderly	B-X
from	B-X
Amares	B-X
county	B-X
,	B-X
Portugal	B-X
Isabel	B-X
C.	B-X
Pinto	B-X
,	B-X
TÃ¢nia	B-X
Pires	B-X
,	B-X
JoÃ£o	B-X
Gama	B-X
O39	B-X
Prevalence	B-X
of	B-X
surgical	B-X
site	B-X
infection	B-X
in	B-X
adults	B-X
at	B-X
a	B-X
hospital	B-X
unit	B-X
in	B-X
the	B-X
North	B-X
of	B-X
Portugal	B-X
Vera	B-X
Preto	B-X
,	B-X
Norberto	B-X
Silva	B-X
,	B-X
Carlos	B-X
MagalhÃ£es	B-X
,	B-X
Matilde	B-X
Martins	B-X
O40	B-X
Frailty	B-X
phenotype	B-X
in	B-X
old	B-X
age	B-X
:	B-X
implications	B-X
to	B-X
intervention	B-X
Mafalda	B-X
Duarte	B-X
,	B-X
ConstanÃ§a	B-X
PaÃºl	B-X
,	B-X
IgnÃ¡cio	B-X
MartÃ­n	B-X
O41	B-X
Portuguese	B-X
women	B-X
:	B-X
sexual	B-X
symptoms	B-X
in	B-X
perimenopause	B-X
Arminda	B-X
A.	B-X
Pinheiro	B-X
O42	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Perinatal	B-X
Depression	B-X
Screening	B-X
and	B-X
Prevention	B-X
Tool	B-X
â	B-X
preliminary	B-X
results	B-X
of	B-X
the	B-X
categorical	B-X
approach	B-X
Sandra	B-X
Xavier	B-X
,	B-X
Julieta	B-X
Azevedo	B-X
,	B-X
Elisabete	B-X
Bento	B-X
,	B-X
Cristiana	B-X
Marques	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
AntÃ³nio	B-X
Macedo	B-X
,	B-X
Ana	B-X
T.	B-X
Pereira	B-X
O43	B-X
Aging	B-X
and	B-X
muscle	B-X
strength	B-X
in	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
:	B-X
cross	B-X
sectional	B-X
analysis	B-X
JosÃ©	B-X
P.	B-X
Almeida	B-X
,	B-X
AntÃ³nio	B-X
Almeida	B-X
,	B-X
Josiane	B-X
Alves	B-X
,	B-X
Nelson	B-X
Sousa	B-X
,	B-X
Francisco	B-X
Saavedra	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O44	B-X
Accessibility	B-X
of	B-X
the	B-X
elderly	B-X
in	B-X
the	B-X
prevention	B-X
of	B-X
hypertension	B-X
in	B-X
a	B-X
family	B-X
health	B-X
unit	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
Luci	B-X
S.	B-X
Lopes	B-X
,	B-X
Eujcely	B-X
C.	B-X
Santiago	B-X
O45	B-X
Community	B-X
Health	B-X
screenings	B-X
and	B-X
self-reported	B-X
chronic	B-X
diseases	B-X
SÃ­lvia	B-X
Monteiro	B-X
,	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Armanda	B-X
ColaÃ§o	B-X
,	B-X
AntÃ³nio	B-X
Carvalho	B-X
,	B-X
Rita	B-X
P.	B-X
Silva	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
O46	B-X
Evaluation	B-X
of	B-X
indoor	B-X
air	B-X
quality	B-X
in	B-X
Kindergartens	B-X
Ana	B-X
Ferreira	B-X
,	B-X
Catarina	B-X
Marques	B-X
,	B-X
JoÃ£o	B-X
P.	B-X
Figueiredo	B-X
,	B-X
Susana	B-X
PaixÃ£o	B-X
O47	B-X
Atmospheric	B-X
exposure	B-X
to	B-X
chemical	B-X
agents	B-X
under	B-X
the	B-X
occupational	B-X
activity	B-X
of	B-X
pathology	B-X
technicians	B-X
Ana	B-X
Ferreira	B-X
,	B-X
Carla	B-X
Lopes	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
JoÃ£o	B-X
P.	B-X
Figueiredo	B-X
O48	B-X
Occupational	B-X
exposure	B-X
to	B-X
air	B-X
pollutants	B-X
in	B-X
night	B-X
entertainment	B-X
venues	B-X
workers	B-X
Ana	B-X
Ferreira	B-X
,	B-X
Diana	B-X
Ribeiro	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
JoÃ£o	B-X
P.	B-X
Figueiredo	B-X
,	B-X
Susana	B-X
PaixÃ£o	B-X
O49	B-X
Beliefs	B-X
and	B-X
attitudes	B-X
of	B-X
young	B-X
people	B-X
towards	B-X
breastfeeding	B-X
Telma	B-X
Fernandes	B-X
,	B-X
Diogo	B-X
Amado	B-X
,	B-X
JÃ©ssica	B-X
Leal	B-X
,	B-X
Marcelo	B-X
Azevedo	B-X
,	B-X
SÃ³nia	B-X
Ramalho	B-X
O50	B-X
Profiling	B-X
informal	B-X
caregivers	B-X
:	B-X
surveying	B-X
needs	B-X
in	B-X
the	B-X
care	B-X
of	B-X
the	B-X
elderly	B-X
Catarina	B-X
Mangas	B-X
,	B-X
Jaime	B-X
Ribeiro	B-X
,	B-X
Rita	B-X
GonÃ§alves	B-X
O51	B-X
Visual	B-X
health	B-X
in	B-X
teenagers	B-X
AmÃ©lia	B-X
F	B-X
Nunes	B-X
,	B-X
Ana	B-X
R.	B-X
Tuna	B-X
,	B-X
Carlos	B-X
R.	B-X
Martins	B-X
,	B-X
Henriqueta	B-X
D.	B-X
Forte	B-X
O52	B-X
Amenable	B-X
mortality	B-X
and	B-X
the	B-X
geographic	B-X
accessibility	B-X
to	B-X
healthcare	B-X
in	B-X
Portugal	B-X
ClÃ¡udia	B-X
Costa	B-X
,	B-X
JosÃ©	B-X
A.	B-X
TenedÃ³rio	B-X
,	B-X
Paula	B-X
Santana	B-X
O53	B-X
Bacterial	B-X
contamination	B-X
of	B-X
door	B-X
handles	B-X
in	B-X
a	B-X
SÃ£o	B-X
Paulo	B-X
See	B-X
Metropolitan	B-X
Cathedral	B-X
public	B-X
restrooms	B-X
in	B-X
Brazil	B-X
J.	B-X
Coimbra	B-X
as	B-X
a	B-X
case	B-X
study	B-X
Jorge	B-X
Conde	B-X
,	B-X
Ana	B-X
Ferreira	B-X
,	B-X
JoÃ£o	B-X
Figueiredo	B-X
P15	B-X
Meaning-in-life	B-X
of	B-X
college	B-X
students	B-X
David	B-X
Silva	B-X
,	B-X
LuÃ­s	B-X
SeiÃ§a	B-X
,	B-X
Raquel	B-X
Soares	B-X
,	B-X
Ricardo	B-X
MourÃ£o	B-X
,	B-X
Teresa	B-X
Kraus	B-X
O57	B-X
Training	B-X
needs	B-X
for	B-X
nurses	B-X
in	B-X
palliative	B-X
care	B-X
Ana	B-X
C.	B-X
Abreu	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
,	B-X
JÃºlia	B-X
M.	B-X
Alves	B-X
O58	B-X
Impact	B-X
of	B-X
computerized	B-X
information	B-X
systems	B-X
in	B-X
the	B-X
global	B-X
nurses	B-X
â	B-X
workload	B-X
:	B-X
nurses	B-X
â	B-X
perceptions	B-X
and	B-X
real-time	B-X
Paulino	B-X
Sousa	B-X
,	B-X
Manuel	B-X
Oliveira	B-X
,	B-X
Joana	B-X
Sousa	B-X
O59	B-X
The	B-X
perspective	B-X
of	B-X
health	B-X
care	B-X
professionals	B-X
on	B-X
self-care	B-X
in	B-X
hereditary	B-X
neurodegenerative	B-X
disease	B-X
:	B-X
a	B-X
qualitative	B-X
study	B-X
SÃ³nia	B-X
Novais	B-X
,	B-X
Felismina	B-X
Mendes	B-X
O60	B-X
Contribution	B-X
for	B-X
health-related	B-X
physical	B-X
fitness	B-X
reference	B-X
values	B-X
in	B-X
healthy	B-X
adolescents	B-X
Joana	B-X
Pinto	B-X
,	B-X
Joana	B-X
Cruz	B-X
,	B-X
Alda	B-X
Marques	B-X
School	B-X
of	B-X
Health	B-X
Sciences	B-X
,	B-X
University	B-X
of	B-X
Aveiro	B-X
,	B-X
3810-193	B-X
Aveiro	B-X
,	B-X
Portugal	B-X
O61	B-X
Perception	B-X
of	B-X
learning	B-X
,	B-X
satisfaction	B-X
and	B-X
self-efficacy	B-X
of	B-X
nursing	B-X
students	B-X
about	B-X
High-Fidelity	B-X
Simulation	B-X
Hugo	B-X
Duarte	B-X
,	B-X
Maria	B-X
Dos	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Pedro	B-X
Sousa	B-X
O62	B-X
Analysis	B-X
of	B-X
statements	B-X
of	B-X
diagnosis	B-X
about	B-X
health	B-X
deviation	B-X
in	B-X
self-care	B-X
requisites	B-X
customized	B-X
in	B-X
a	B-X
Nursing	B-X
Practice	B-X
Support	B-X
System	B-X
(	B-X
SAPEÂ®	B-X
)	B-X
:	B-X
Management	B-X
of	B-X
therapeutic	B-X
regimen	B-X
InÃªs	B-X
Cruz	B-X
,	B-X
Fernanda	B-X
Bastos	B-X
,	B-X
Filipe	B-X
Pereira	B-X
O63	B-X
Hybrid	B-X
management	B-X
and	B-X
hospital	B-X
governance	B-X
:	B-X
doctors	B-X
and	B-X
nurses	B-X
as	B-X
managers	B-X
Francisco	B-X
L.	B-X
Carvalho	B-X
,	B-X
Teresa	B-X
T.	B-X
Oliveira	B-X
,	B-X
VÃ­tor	B-X
R.	B-X
Raposo	B-X
O64	B-X
Time	B-X
management	B-X
in	B-X
health	B-X
professionals	B-X
ConceiÃ§Ã£o	B-X
Rainho	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Ribeiro	B-X
,	B-X
Isabel	B-X
Barroso	B-X
,	B-X
VÃ­tor	B-X
Rodrigues	B-X
O65	B-X
Financial	B-X
rewards	B-X
and	B-X
wellbeing	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
Carmo	B-X
Neves	B-X
,	B-X
Teresa	B-X
C.	B-X
Oliveira	B-X
O66	B-X
Patient	B-X
safety	B-X
promotion	B-X
in	B-X
the	B-X
operating	B-X
room	B-X
BÃ¡rbara	B-X
Oliveira	B-X
,	B-X
MÂª	B-X
Carminda	B-X
Morais	B-X
,	B-X
Pilar	B-X
Baylina	B-X
O67	B-X
Difficulties	B-X
and	B-X
needs	B-X
of	B-X
pre-graduate	B-X
nursing	B-X
students	B-X
in	B-X
the	B-X
area	B-X
of	B-X
Geriatrics/Gerontology	B-X
RogÃ©rio	B-X
Rodrigues	B-X
,	B-X
Zaida	B-X
Azeredo	B-X
,	B-X
CorÃ¡lia	B-X
Vicente	B-X
O68	B-X
Teaching	B-X
and	B-X
learning	B-X
sexuality	B-X
in	B-X
nursing	B-X
education	B-X
HÃ©lia	B-X
Dias	B-X
,	B-X
Margarida	B-X
Sim-Sim	B-X
O69	B-X
Entrepreneurial	B-X
Motivations	B-X
Questionnaire	B-X
:	B-X
AFC	B-X
and	B-X
CFA	B-X
in	B-X
academy	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
JosÃ©	B-X
Gomes	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Lisete	B-X
MÃ³nico	B-X
,	B-X
Nuno	B-X
Brito	B-X
O70	B-X
Nursing	B-X
intervention	B-X
to	B-X
patient	B-X
with	B-X
Permanent	B-X
Pacemakers	B-X
and	B-X
Implantable	B-X
Cardioverter	B-X
Defibrillators	B-X
:	B-X
a	B-X
qualitative	B-X
analysis	B-X
Cassilda	B-X
Sarroeira	B-X
,	B-X
JosÃ©	B-X
Amendoeira	B-X
,	B-X
FÃ¡tima	B-X
Cunha	B-X
,	B-X
Anabela	B-X
CÃ¢ndido	B-X
,	B-X
PatrÃ­cia	B-X
Fernandes	B-X
,	B-X
Helena	B-X
R.	B-X
Silva	B-X
,	B-X
Elsa	B-X
Silva	B-X
O71	B-X
Alcohol	B-X
consumption	B-X
among	B-X
nursing	B-X
students	B-X
:	B-X
where	B-X
does	B-X
education	B-X
fail	B-X
?	B-X
Isabel	B-X
Barroso	B-X
,	B-X
Leila	B-X
Lapa	B-X
,	B-X
Cristina	B-X
Antunes	B-X
O72	B-X
Labour	B-X
stress	B-X
in	B-X
nursing	B-X
Ana	B-X
GonÃ§alves	B-X
,	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
MÂª	B-X
JosÃ©	B-X
Gomes	B-X
,	B-X
Susana	B-X
R.	B-X
Escanciano	B-X
O73	B-X
The	B-X
influence	B-X
of	B-X
safe	B-X
staff	B-X
nursing	B-X
in	B-X
patient	B-X
satisfaction	B-X
with	B-X
nursing	B-X
care	B-X
Maria	B-X
Freitas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
JoÃ£o	B-X
MarÃ´co	B-X
O74	B-X
Intention	B-X
to	B-X
use	B-X
eHealth	B-X
strategies	B-X
with	B-X
nursing	B-X
students	B-X
Ana	B-X
R.	B-X
Fernandes	B-X
,	B-X
Cremilde	B-X
Cabral	B-X
,	B-X
Samuel	B-X
Alves	B-X
,	B-X
Pedro	B-X
Sousa	B-X
O75	B-X
Community	B-X
Based	B-X
Mental	B-X
Health	B-X
:	B-X
contributions	B-X
of	B-X
an	B-X
interdisciplinary	B-X
international	B-X
program	B-X
for	B-X
students	B-X
in	B-X
higher	B-X
health	B-X
education	B-X
AntÃ³nio	B-X
Ferreira	B-X
,	B-X
Fernanda	B-X
PrÃ­ncipe	B-X
,	B-X
Ulla-Maija	B-X
SeppÃ¤nen	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Maribel	B-X
Carvalhais	B-X
,	B-X
Marilene	B-X
Silva	B-X
O76	B-X
Study	B-X
of	B-X
satisfaction	B-X
at	B-X
work	B-X
of	B-X
graduates	B-X
in	B-X
nursing	B-X
:	B-X
2002-2014	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Joana	B-X
Silva	B-X
,	B-X
JÃ©ssica	B-X
Neves	B-X
,	B-X
Diana	B-X
Costa	B-X
,	B-X
Bruno	B-X
Santos	B-X
,	B-X
Soraia	B-X
Duarte	B-X
O77	B-X
Health	B-X
professionals	B-X
â	B-X
attitudes	B-X
towards	B-X
breastfeeding	B-X
SÃ­lvia	B-X
Marques	B-X
,	B-X
SÃ³nia	B-X
Ramalho	B-X
,	B-X
Isabel	B-X
Mendes	B-X
O78	B-X
Continuity	B-X
of	B-X
nursing	B-X
care	B-X
to	B-X
person	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
Clarisse	B-X
Louro	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Maria	B-X
Dixe	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
O79	B-X
Stigma	B-X
toward	B-X
mental	B-X
illness	B-X
among	B-X
future	B-X
health	B-X
professionals	B-X
Marina	B-X
Cordeiro	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
O80	B-X
Working	B-X
with	B-X
fears	B-X
and	B-X
anxieties	B-X
of	B-X
medical	B-X
students	B-X
in	B-X
search	B-X
of	B-X
a	B-X
humanized	B-X
care	B-X
Frederico	B-X
C.	B-X
Valim	B-X
,	B-X
Joyce	B-X
O.	B-X
Costa	B-X
,	B-X
LÃºcia	B-X
G.	B-X
Bernardes	B-X
P16	B-X
Surgical	B-X
paediatrics	B-X
patients	B-X
â	B-X
psycho	B-X
prophylaxis	B-X
at	B-X
a	B-X
teaching	B-X
hospital	B-X
Helena	B-X
Prebianchi	B-X
P17	B-X
Patient-perceived	B-X
outcomes	B-X
in	B-X
physiotherapy	B-X
â	B-X
a	B-X
pilot	B-X
study	B-X
Marlene	B-X
Cristina	B-X
Rosa	B-X
P18	B-X
Building	B-X
competencies	B-X
for	B-X
managers	B-X
in	B-X
nursing	B-X
Narcisa	B-X
GonÃ§alves	B-X
,	B-X
Maria	B-X
M.	B-X
Martins	B-X
,	B-X
Paulina	B-X
Kurcgant	B-X
P19	B-X
Theoretical	B-X
basis	B-X
underlying	B-X
physiotherapy	B-X
practice	B-X
in	B-X
stroke	B-X
rehabilitation	B-X
AndrÃ©	B-X
Vieira	B-X
P20	B-X
When	B-X
the	B-X
life-cycle	B-X
ends	B-X
:	B-X
the	B-X
nurse	B-X
â	B-X
s	B-X
confrontation	B-X
with	B-X
death	B-X
Sandrina	B-X
Bento	B-X
,	B-X
SÃ©rgio	B-X
Deodato	B-X
,	B-X
Isabel	B-X
Rabiais	B-X
P21	B-X
Nursing	B-X
students	B-X
â	B-X
opinion	B-X
about	B-X
the	B-X
supervision	B-X
relationship	B-X
during	B-X
their	B-X
first	B-X
clinical	B-X
experience	B-X
Laura	B-X
Reis	B-X
P22	B-X
Nursing	B-X
Relational	B-X
Laboratory	B-X
:	B-X
Pedagogical	B-X
,	B-X
dialogic	B-X
and	B-X
critical	B-X
project	B-X
Ana	B-X
Torres	B-X
,	B-X
SÃ©rgio	B-X
Soares	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Pedro	B-X
GraÃ§a	B-X
P23	B-X
Job	B-X
satisfaction	B-X
of	B-X
bioscientists	B-X
at	B-X
a	B-X
Lisbon	B-X
hospital	B-X
CÃ©u	B-X
LeitÃ£o	B-X
,	B-X
Renato	B-X
Abreu	B-X
,	B-X
Fernando	B-X
BellÃ©m	B-X
,	B-X
Ana	B-X
Almeida	B-X
,	B-X
Edna	B-X
Ribeiro-Varandas	B-X
,	B-X
Ana	B-X
Tavares	B-X
P24	B-X
Sociodemographic	B-X
and	B-X
professional	B-X
profile	B-X
of	B-X
nurses	B-X
and	B-X
its	B-X
relation	B-X
with	B-X
the	B-X
importance	B-X
of	B-X
family	B-X
in	B-X
nursing	B-X
practices	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Carolina	B-X
Henriques	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Clarisse	B-X
Louro	B-X
,	B-X
CÃ©lia	B-X
JordÃ£o	B-X
P25	B-X
Professional	B-X
satisfaction	B-X
of	B-X
rehabilitation	B-X
nurses	B-X
Sofia	B-X
Neco	B-X
,	B-X
Carminda	B-X
Morais	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
P26	B-X
The	B-X
person	B-X
living	B-X
with	B-X
a	B-X
stoma	B-X
:	B-X
the	B-X
formalization	B-X
of	B-X
knowledge	B-X
in	B-X
nursing	B-X
Carla	B-X
R.	B-X
Silva	B-X
,	B-X
Alice	B-X
Brito	B-X
,	B-X
AntÃ³nia	B-X
Silva	B-X
P27	B-X
Validation	B-X
of	B-X
the	B-X
Portuguese	B-X
versions	B-X
of	B-X
the	B-X
nursing	B-X
students	B-X
â	B-X
perceptions	B-X
of	B-X
learning	B-X
and	B-X
learner	B-X
satisfaction	B-X
with	B-X
simulation	B-X
tool	B-X
Hugo	B-X
Duarte	B-X
,	B-X
Maria	B-X
Dos	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Pedro	B-X
Sousa	B-X
P28	B-X
Physiotherapists	B-X
â	B-X
perceived	B-X
knowledge	B-X
on	B-X
technologies	B-X
for	B-X
electronic	B-X
health	B-X
records	B-X
for	B-X
physiotherapy	B-X
Gabriela	B-X
Postolache	B-X
,	B-X
Raul	B-X
Oliveira	B-X
,	B-X
Isabel	B-X
Moreira	B-X
,	B-X
LuÃ­sa	B-X
Pedro	B-X
,	B-X
SÃ³nia	B-X
Vicente	B-X
,	B-X
Samuel	B-X
Domingos	B-X
,	B-X
Octavian	B-X
Postolache	B-X
P29	B-X
Quality	B-X
of	B-X
life	B-X
and	B-X
physical	B-X
activity	B-X
of	B-X
medicine	B-X
undergraduate	B-X
students	B-X
in	B-X
the	B-X
University	B-X
of	B-X
Southern	B-X
Santa	B-X
Catarina	B-X
,	B-X
Brazil	B-X
Darlen	B-X
Silva	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Filho	B-X
,	B-X
Nazare	B-X
Nazario	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
,	B-X
Dulcineia	B-X
Schneider	B-X
P30	B-X
The	B-X
curricular	B-X
skills	B-X
for	B-X
decision	B-X
making	B-X
education	B-X
in	B-X
a	B-X
Nursing	B-X
Degree	B-X
FÃ¡tima	B-X
M.	B-X
Marques	B-X
P31	B-X
Effect	B-X
of	B-X
nurses	B-X
â	B-X
mobilization	B-X
in	B-X
satisfaction	B-X
at	B-X
work	B-X
and	B-X
turnover	B-X
:	B-X
An	B-X
empirical	B-X
study	B-X
in	B-X
the	B-X
hospital	B-X
setting	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Carlos	B-X
Pinto	B-X
,	B-X
Sara	B-X
Vicente	B-X
,	B-X
SÃ£o	B-X
JoÃ£o	B-X
Breda	B-X
P32	B-X
Entrepreneurial	B-X
skills	B-X
of	B-X
students	B-X
of	B-X
polytechnic	B-X
higher	B-X
education	B-X
in	B-X
Portugal	B-X
:	B-X
Business	B-X
influences	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
P33	B-X
Design	B-X
and	B-X
assessment	B-X
of	B-X
e-learning	B-X
modules	B-X
for	B-X
Pharmacology	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Nuno	B-X
Duarte	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Lopes	B-X
,	B-X
HÃ©lder	B-X
Nunes	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
P34	B-X
Perspective	B-X
of	B-X
nurses	B-X
involved	B-X
in	B-X
an	B-X
action-research	B-X
study	B-X
on	B-X
the	B-X
changes	B-X
observed	B-X
in	B-X
care	B-X
provision	B-X
:	B-X
results	B-X
from	B-X
a	B-X
focus	B-X
group	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
L.	B-X
Basto	B-X
,	B-X
Luciene	B-X
M.	B-X
Braga	B-X
P35	B-X
Use	B-X
of	B-X
peer	B-X
feedback	B-X
by	B-X
nursing	B-X
students	B-X
during	B-X
clinical	B-X
training	B-X
:	B-X
teacher	B-X
â	B-X
s	B-X
perception	B-X
AntÃ³nio	B-X
Ferreira	B-X
,	B-X
Beatriz	B-X
AraÃºjo	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Alves	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Maribel	B-X
Carvalhais	B-X
,	B-X
Marilene	B-X
Silva	B-X
,	B-X
SÃ³nia	B-X
Novais	B-X
P36	B-X
What	B-X
â	B-X
s	B-X
new	B-X
on	B-X
endotracheal	B-X
suctioning	B-X
recommendations	B-X
Ana	B-X
S.	B-X
Sousa	B-X
,	B-X
CÃ¢ndida	B-X
Ferrito	B-X
P37	B-X
Assessment	B-X
of	B-X
the	B-X
nurses	B-X
satisfaction	B-X
on	B-X
the	B-X
Central	B-X
Region	B-X
of	B-X
Portugal	B-X
Pedro	B-X
L.	B-X
Ferreira	B-X
,	B-X
Alexandre	B-X
Rodrigues	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Isabel	B-X
Oliveira	B-X
P38	B-X
Study	B-X
of	B-X
graduate	B-X
â	B-X
s	B-X
satisfaction	B-X
with	B-X
the	B-X
school	B-X
of	B-X
nursing	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
JÃ©ssica	B-X
Neves	B-X
,	B-X
Diana	B-X
Costa	B-X
,	B-X
Soraia	B-X
Duarte	B-X
,	B-X
Joana	B-X
Silva	B-X
,	B-X
Bruno	B-X
Santos	B-X
P39	B-X
Partnership	B-X
between	B-X
the	B-X
school	B-X
of	B-X
nursing	B-X
and	B-X
the	B-X
hospital	B-X
:	B-X
SupervisorsÂ´	B-X
perspectives	B-X
Cristina	B-X
Martins	B-X
,	B-X
Ana	B-X
P.	B-X
Macedo	B-X
,	B-X
Odete	B-X
AraÃºjo	B-X
,	B-X
ClÃ¡udia	B-X
Augusto	B-X
,	B-X
FÃ¡tima	B-X
Braga	B-X
,	B-X
Lisa	B-X
Gomes	B-X
,	B-X
Maria	B-X
A.	B-X
Silva	B-X
,	B-X
Rafaela	B-X
RosÃ¡rio	B-X
P40	B-X
Coping	B-X
strategies	B-X
of	B-X
college	B-X
students	B-X
LuÃ­s	B-X
Pimenta	B-X
,	B-X
Diana	B-X
Carreira	B-X
,	B-X
PatrÃ­cia	B-X
Teles	B-X
,	B-X
Teresa	B-X
Barros	B-X
P41	B-X
Emotional	B-X
intelligence	B-X
and	B-X
mental	B-X
health	B-X
stigma	B-X
in	B-X
health	B-X
students	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
P42	B-X
Stigma	B-X
of	B-X
mental	B-X
health	B-X
assessment	B-X
:	B-X
Comparison	B-X
between	B-X
health	B-X
courses	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
O81	B-X
Short-	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
pulmonary	B-X
rehabilitation	B-X
in	B-X
mild	B-X
COPD	B-X
Cristina	B-X
JÃ¡come	B-X
,	B-X
Alda	B-X
Marques	B-X
O82	B-X
Phonological	B-X
awareness	B-X
programme	B-X
for	B-X
preschool	B-X
children	B-X
Sylvie	B-X
Capelas	B-X
,	B-X
Andreia	B-X
Hall	B-X
,	B-X
Dina	B-X
Alves	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O83	B-X
REforma	B-X
ATIVA	B-X
:	B-X
An	B-X
efficient	B-X
health	B-X
promotion	B-X
program	B-X
to	B-X
be	B-X
implemented	B-X
during	B-X
retirement	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
,	B-X
Ana	B-X
Camarneiro	B-X
,	B-X
Margarida	B-X
Silva	B-X
,	B-X
Aida	B-X
Mendes	B-X
,	B-X
Ana	B-X
Pedreiro	B-X
O84	B-X
Intervention	B-X
for	B-X
men	B-X
who	B-X
batter	B-X
women	B-X
,	B-X
a	B-X
case	B-X
report	B-X
Anne	B-X
G.Silva	B-X
,	B-X
Elza	B-X
S.	B-X
Coelho	B-X
O85	B-X
Immediate	B-X
effects	B-X
of	B-X
Bowen	B-X
Therapy	B-X
on	B-X
muscle	B-X
tone	B-X
and	B-X
flexibility	B-X
FlÃ¡vio	B-X
Melo	B-X
,	B-X
Fernando	B-X
Ribeiro	B-X
,	B-X
Rui	B-X
Torres	B-X
,	B-X
Rui	B-X
Costa	B-X
O86	B-X
Predictive	B-X
equation	B-X
for	B-X
incremental	B-X
shuttle	B-X
walk	B-X
test	B-X
in	B-X
adolescents	B-X
TÃ¢nia	B-X
Pinho	B-X
,	B-X
Cristina	B-X
JÃ¡come	B-X
,	B-X
Alda	B-X
Marques	B-X
O87	B-X
Life	B-X
satisfaction	B-X
and	B-X
psychopathology	B-X
in	B-X
institutionalized	B-X
elderly	B-X
people	B-X
:	B-X
The	B-X
results	B-X
of	B-X
an	B-X
adapted	B-X
Mindfulness-Based	B-X
Stress	B-X
Reduction	B-X
program	B-X
BÃ¡rbara	B-X
Cruz	B-X
,	B-X
Daniel	B-X
Seabra	B-X
,	B-X
Diogo	B-X
Carreira	B-X
,	B-X
Maria	B-X
Ventura	B-X
O88	B-X
Outcome	B-X
changes	B-X
in	B-X
COPD	B-X
rehabilitation	B-X
:	B-X
exploring	B-X
the	B-X
relationship	B-X
between	B-X
physical	B-X
activity	B-X
and	B-X
health-related	B-X
outcomes	B-X
Joana	B-X
Cruz	B-X
,	B-X
Dina	B-X
Brooks	B-X
,	B-X
Alda	B-X
Marques	B-X
O89	B-X
Assessing	B-X
the	B-X
effectiveness	B-X
of	B-X
a	B-X
Complex	B-X
Nursing	B-X
Intervention	B-X
M	B-X
RosÃ¡rio	B-X
Pinto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
Lima-Basto	B-X
,	B-X
Miguel	B-X
Neves	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
O90	B-X
Psychotherapeutic	B-X
intervention	B-X
in	B-X
addiction	B-X
disorders	B-X
:	B-X
Change	B-X
in	B-X
psychopathological	B-X
symptoms	B-X
and	B-X
emotional	B-X
states	B-X
Carla	B-X
Bizarro	B-X
,	B-X
Marina	B-X
Cunha	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Couto	B-X
Margarida	B-X
,	B-X
Ana	B-X
P.	B-X
Amorim	B-X
,	B-X
Eduardo	B-X
Silva	B-X
O91	B-X
Economic	B-X
impact	B-X
of	B-X
a	B-X
nursing	B-X
intervention	B-X
program	B-X
to	B-X
promote	B-X
self-management	B-X
in	B-X
COPD	B-X
Susana	B-X
Cruz	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
,	B-X
Jorge	B-X
Valente	B-X
O92	B-X
Multimodal	B-X
acute	B-X
pain	B-X
management	B-X
during	B-X
uterine	B-X
artery	B-X
embolization	B-X
in	B-X
treatment	B-X
of	B-X
uterine	B-X
myomas	B-X
JosÃ©	B-X
T.	B-X
Guerrero	B-X
,	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Rafael	B-X
B.	B-X
Santos	B-X
,	B-X
Estefania	B-X
P.	B-X
Gonzalez	B-X
,	B-X
FÃ¡tima	B-X
M.	B-X
Monago	B-X
,	B-X
Lierni	B-X
U.	B-X
Ugalde	B-X
,	B-X
Marta	B-X
M.	B-X
VÃ©lez	B-X
,	B-X
Maria	B-X
J.	B-X
Tena	B-X
O93	B-X
Fluid	B-X
administration	B-X
strategies	B-X
in	B-X
major	B-X
surgery	B-X
:	B-X
Goal-directed	B-X
therapy	B-X
JosÃ©	B-X
T.	B-X
Guerrero	B-X
,	B-X
Rafael	B-X
Bravo	B-X
,	B-X
Francisco	B-X
L.	B-X
PÃ©rez-Caballero	B-X
,	B-X
Isabel	B-X
A.	B-X
Becerra	B-X
,	B-X
MÂª	B-X
Elizabeth	B-X
Agudelo	B-X
,	B-X
Guadalupe	B-X
Acedo	B-X
,	B-X
Roberto	B-X
Bajo	B-X
O94	B-X
Development	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
self-management	B-X
educational	B-X
programme	B-X
using	B-X
lay-led	B-X
â	B-X
s	B-X
in	B-X
adolescents	B-X
Spina	B-X
Bifida	B-X
:	B-X
A	B-X
pilot	B-X
study	B-X
Isabel	B-X
Malheiro	B-X
,	B-X
Filomena	B-X
Gaspar	B-X
,	B-X
LuÃ­sa	B-X
Barros	B-X
O95	B-X
Influence	B-X
of	B-X
chair-based	B-X
yoga	B-X
exercises	B-X
on	B-X
salivary	B-X
anti-microbial	B-X
proteins	B-X
in	B-X
institutionalized	B-X
frail-elderly	B-X
women	B-X
:	B-X
a	B-X
preliminary	B-X
study	B-X
Guilherme	B-X
Furtado	B-X
,	B-X
Mateus	B-X
Uba-Chupel	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
LuÃ­s	B-X
Rama	B-X
,	B-X
Margarida	B-X
Braga	B-X
,	B-X
JosÃ©	B-X
P.	B-X
Ferreira	B-X
,	B-X
Ana	B-X
MÂª	B-X
Teixeira	B-X
O96	B-X
High	B-X
intensity	B-X
interval	B-X
training	B-X
vs	B-X
moderate	B-X
intensity	B-X
continuous	B-X
training	B-X
impact	B-X
on	B-X
diabetes	B-X
2	B-X
JoÃ£o	B-X
Cruz	B-X
,	B-X
Tiago	B-X
Barbosa	B-X
,	B-X
Ãngela	B-X
SimÃµes	B-X
,	B-X
LuÃ­s	B-X
Coelho	B-X
O97	B-X
Family	B-X
caregiver	B-X
of	B-X
people	B-X
with	B-X
pressure	B-X
ulcer	B-X
:	B-X
Nursing	B-X
intervention	B-X
plan	B-X
Alexandre	B-X
Rodrigues	B-X
,	B-X
Juan-Fernando	B-X
JimÃ©nez-DÃ­az	B-X
,	B-X
Francisco	B-X
Martinez-HernÃ¡ndez	B-X
,	B-X
Bienvenida	B-X
Rodriguez-De-Vera	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Alexandrina	B-X
Rodrigues	B-X
O98	B-X
Chronic	B-X
effects	B-X
of	B-X
exercise	B-X
on	B-X
motor	B-X
memory	B-X
consolidation	B-X
in	B-X
elderly	B-X
people	B-X
AndrÃ©	B-X
Ramalho	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
InÃªs	B-X
Santo	B-X
,	B-X
AntÃ³nio	B-X
Rosado	B-X
O99	B-X
Impression	B-X
cytology	B-X
of	B-X
the	B-X
ocular	B-X
surface	B-X
:	B-X
Collection	B-X
technique	B-X
and	B-X
sample	B-X
processing	B-X
Paula	B-X
MendonÃ§a	B-X
,	B-X
KÃ¡tia	B-X
Freitas	B-X
O100	B-X
Does	B-X
sport	B-X
practice	B-X
affect	B-X
the	B-X
reaction	B-X
time	B-X
in	B-X
neuromuscular	B-X
activity	B-X
?	B-X
Dora	B-X
Ferreira	B-X
,	B-X
AntÃ³nio	B-X
Brito	B-X
,	B-X
Renato	B-X
Fernandes	B-X
O101	B-X
Efficiency	B-X
of	B-X
the	B-X
enteral	B-X
administration	B-X
of	B-X
fibbers	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
chronic	B-X
obstipation	B-X
Sofia	B-X
Gomes	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
Rita	B-X
Oliveira	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
O102	B-X
Fast	B-X
decalcifier	B-X
in	B-X
compact	B-X
bone	B-X
and	B-X
spongy	B-X
bone	B-X
Paula	B-X
MendonÃ§a	B-X
,	B-X
Ana	B-X
P.	B-X
Casimiro	B-X
,	B-X
PatrÃ­cia	B-X
Martins	B-X
,	B-X
Iryna	B-X
Silva	B-X
O103	B-X
Health	B-X
promotion	B-X
in	B-X
the	B-X
elderly	B-X
â	B-X
Intervention	B-X
project	B-X
in	B-X
dementia	B-X
Diana	B-X
Evangelista	B-X
O104	B-X
Prevention	B-X
of	B-X
musculoskeletal	B-X
disorders	B-X
through	B-X
an	B-X
exercise	B-X
protocol	B-X
held	B-X
in	B-X
labour	B-X
context	B-X
Catarina	B-X
LeitÃ£o	B-X
,	B-X
FÃ¡bia	B-X
Velosa	B-X
,	B-X
NÃ©lio	B-X
Carecho	B-X
,	B-X
LuÃ­s	B-X
Coelho	B-X
O105	B-X
Knowledge	B-X
of	B-X
teachers	B-X
and	B-X
other	B-X
education	B-X
agents	B-X
on	B-X
diabetes	B-X
type	B-X
1	B-X
:	B-X
Effectiveness	B-X
of	B-X
an	B-X
intervention	B-X
program	B-X
Eva	B-X
Menino	B-X
,	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
FÃ¡tima	B-X
Soares	B-X
,	B-X
Ester	B-X
Gama	B-X
,	B-X
Clementina	B-X
Gordo	B-X
O106	B-X
Treatment	B-X
of	B-X
diabetic	B-X
peripheral	B-X
neuropathic	B-X
pain	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
clinical	B-X
trials	B-X
of	B-X
phase	B-X
II	B-X
and	B-X
III	B-X
Eliana	B-X
Moreira	B-X
,	B-X
Cristiana	B-X
MidÃµes	B-X
,	B-X
Marlene	B-X
Santos	B-X
O107	B-X
New	B-X
drugs	B-X
for	B-X
osteoporosis	B-X
treatment	B-X
:	B-X
Systematic	B-X
review	B-X
of	B-X
clinical	B-X
trials	B-X
of	B-X
phase	B-X
II	B-X
and	B-X
III	B-X
Sara	B-X
Machado	B-X
,	B-X
VÃ¢nia	B-X
P.	B-X
Oliveira	B-X
,	B-X
Marlene	B-X
Santos	B-X
O108	B-X
Promoting	B-X
hope	B-X
at	B-X
the	B-X
end	B-X
of	B-X
life	B-X
:	B-X
Effectiveness	B-X
of	B-X
an	B-X
Intervention	B-X
Programme	B-X
Ana	B-X
Querido	B-X
,	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Rita	B-X
Marques	B-X
,	B-X
Zaida	B-X
Charepe	B-X
P43	B-X
Psychomotor	B-X
therapy	B-X
effects	B-X
on	B-X
adaptive	B-X
behaviour	B-X
and	B-X
motor	B-X
proficiency	B-X
of	B-X
adults	B-X
with	B-X
intellectual	B-X
disability	B-X
Ana	B-X
Antunes	B-X
,	B-X
Sofia	B-X
Santos	B-X
P44	B-X
The	B-X
effect	B-X
of	B-X
exercise	B-X
therapy	B-X
in	B-X
multiple	B-X
sclerosis	B-X
â	B-X
a	B-X
single	B-X
study	B-X
case	B-X
Marlene	B-X
C.	B-X
Rosa	B-X
P45	B-X
Physical	B-X
condition	B-X
and	B-X
self-efficacy	B-X
in	B-X
people	B-X
with	B-X
fall	B-X
risk	B-X
â	B-X
a	B-X
preliminary	B-X
study	B-X
Marlene	B-X
C.	B-X
Rosa	B-X
,	B-X
Silvana	B-X
F.	B-X
Marques	B-X
P46	B-X
Shock	B-X
waves	B-X
:	B-X
their	B-X
effectiveness	B-X
in	B-X
improving	B-X
the	B-X
symptoms	B-X
of	B-X
calcifying	B-X
tendinitis	B-X
of	B-X
the	B-X
shoulder	B-X
Beatriz	B-X
Minghelli	B-X
,	B-X
EulÃ¡lia	B-X
Caro	B-X
P47	B-X
Pacifier	B-X
â	B-X
construction	B-X
and	B-X
pilot	B-X
application	B-X
of	B-X
a	B-X
parenting	B-X
intervention	B-X
for	B-X
parents	B-X
of	B-X
babies	B-X
until	B-X
six	B-X
months	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
MÂª	B-X
JosÃ©	B-X
LuÃ­s	B-X
,	B-X
Teresa	B-X
BrandÃ£o	B-X
P48	B-X
The	B-X
influence	B-X
of	B-X
Motor	B-X
Imagery	B-X
in	B-X
fine	B-X
motor	B-X
skills	B-X
of	B-X
individuals	B-X
with	B-X
disabilities	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Daniel	B-X
Marinho	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
Diogo	B-X
Monteiro	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
InÃªs	B-X
Santo	B-X
P49	B-X
Evaluation	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
walking	B-X
programme	B-X
on	B-X
the	B-X
fall	B-X
risk	B-X
factors	B-X
in	B-X
older	B-X
people	B-X
â	B-X
a	B-X
longitudinal	B-X
pilot	B-X
study	B-X
Lina	B-X
Monteiro	B-X
,	B-X
FÃ¡tima	B-X
Ramalho	B-X
,	B-X
Rita	B-X
Santos-Rocha	B-X
,	B-X
SÃ³nia	B-X
Morgado	B-X
,	B-X
Teresa	B-X
Bento	B-X
P50	B-X
Nursing	B-X
intervention	B-X
programme	B-X
in	B-X
lifestyles	B-X
of	B-X
adolescents	B-X
Gilberta	B-X
Sousa	B-X
,	B-X
OtÃ­lia	B-X
Freitas	B-X
,	B-X
Isabel	B-X
Silva	B-X
,	B-X
GregÃ³rio	B-X
Freitas	B-X
,	B-X
Clementina	B-X
Morna	B-X
,	B-X
Rita	B-X
Vasconcelos	B-X
P51	B-X
The	B-X
person	B-X
submitted	B-X
to	B-X
hip	B-X
replacement	B-X
rehabilitation	B-X
,	B-X
at	B-X
home	B-X
Tatiana	B-X
Azevedo	B-X
,	B-X
Salete	B-X
Soares	B-X
,	B-X
Jacinta	B-X
Pisco	B-X
P52	B-X
Effects	B-X
of	B-X
Melatonin	B-X
use	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
neurovegetative	B-X
diseases	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
Efrain	B-X
O.	B-X
Olszewer	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
SebastiÃ£o	B-X
T.	B-X
Oliveira	B-X
P53	B-X
Review	B-X
of	B-X
Phytotherapy	B-X
and	B-X
other	B-X
natural	B-X
substances	B-X
in	B-X
alcohol	B-X
abuse	B-X
and	B-X
alcoholism	B-X
Erica	B-X
Santos	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
Carla	B-X
Maia	B-X
,	B-X
Fernando	B-X
Moreira	B-X
,	B-X
Joana	B-X
Santos	B-X
,	B-X
Maria	B-X
F.	B-X
Mendes	B-X
,	B-X
Rita	B-X
F.	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
P54	B-X
Dietary	B-X
programme	B-X
impact	B-X
on	B-X
biochemical	B-X
markers	B-X
in	B-X
diabetics	B-X
:	B-X
systematic	B-X
review	B-X
Eduarda	B-X
Barreira	B-X
,	B-X
Ana	B-X
Pereira	B-X
,	B-X
Josiana	B-X
A.	B-X
Vaz	B-X
,	B-X
AndrÃ©	B-X
Novo	B-X
P55	B-X
Biological	B-X
approaches	B-X
to	B-X
knee	B-X
osteoarthritis	B-X
:	B-X
platelet-rich	B-X
plasma	B-X
and	B-X
hyaluronic	B-X
acid	B-X
LuÃ­s	B-X
D.	B-X
Silva	B-X
,	B-X
Bruno	B-X
Maia	B-X
,	B-X
Eduardo	B-X
Ferreira	B-X
,	B-X
Filipa	B-X
Pires	B-X
,	B-X
Renato	B-X
Andrade	B-X
,	B-X
LuÃ­s	B-X
Camarinha	B-X
P56	B-X
Platelet-rich	B-X
plasma	B-X
and	B-X
hyaluronic	B-X
acid	B-X
intra-articular	B-X
injections	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
ankle	B-X
osteoarthritis	B-X
LuÃ­s	B-X
D.	B-X
Silva	B-X
,	B-X
Bruno	B-X
Maia	B-X
,	B-X
Eduardo	B-X
Ferreira	B-X
,	B-X
Filipa	B-X
Pires	B-X
,	B-X
Renato	B-X
Andrade	B-X
,	B-X
LuÃ­s	B-X
Camarinha	B-X
P57	B-X
The	B-X
impact	B-X
of	B-X
preventive	B-X
measures	B-X
in	B-X
the	B-X
incidence	B-X
of	B-X
diabetic	B-X
foot	B-X
ulcers	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
Ana	B-X
F.	B-X
CÃ©sar	B-X
,	B-X
Mariana	B-X
PoÃ§o	B-X
,	B-X
David	B-X
Ventura	B-X
,	B-X
Raquel	B-X
Loura	B-X
,	B-X
Pedro	B-X
Gomes	B-X
,	B-X
Catarina	B-X
Gomes	B-X
,	B-X
ClÃ¡udia	B-X
Silva	B-X
,	B-X
Elsa	B-X
Melo	B-X
,	B-X
JoÃ£o	B-X
Lindo	B-X
P58	B-X
Dating	B-X
violence	B-X
among	B-X
young	B-X
adolescents	B-X
Joana	B-X
Domingos	B-X
,	B-X
Zaida	B-X
Mendes	B-X
,	B-X
Susana	B-X
Poeta	B-X
,	B-X
Tiago	B-X
Carvalho	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
P59	B-X
Physical	B-X
activity	B-X
and	B-X
motor	B-X
memory	B-X
in	B-X
pedal	B-X
dexterity	B-X
AndrÃ©	B-X
Ramalho	B-X
,	B-X
AntÃ³nio	B-X
Rosado	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
InÃªs	B-X
Garcia	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
P60	B-X
The	B-X
effects	B-X
of	B-X
whole	B-X
body	B-X
vibration	B-X
on	B-X
the	B-X
electromyographic	B-X
activity	B-X
of	B-X
thigh	B-X
muscles	B-X
Sandra	B-X
Rodrigues	B-X
,	B-X
Rui	B-X
Meneses	B-X
,	B-X
Carlos	B-X
Afonso	B-X
,	B-X
LuÃ­s	B-X
Faria	B-X
,	B-X
AdÃ©rito	B-X
Seixas	B-X
P61	B-X
Mental	B-X
health	B-X
promotion	B-X
in	B-X
the	B-X
workplace	B-X
Marina	B-X
Cordeiro	B-X
,	B-X
Paulo	B-X
Granjo	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Gomes	B-X
P62	B-X
Influence	B-X
of	B-X
physical	B-X
exercise	B-X
on	B-X
the	B-X
self-perception	B-X
of	B-X
body	B-X
image	B-X
in	B-X
elderly	B-X
women	B-X
:	B-X
A	B-X
systematic	B-X
review	B-X
of	B-X
qualitative	B-X
studies	B-X
Nelba	B-X
R.	B-X
Souza	B-X
,	B-X
Guilherme	B-X
E.	B-X
Furtado	B-X
,	B-X
Saulo	B-X
V.	B-X
Rocha	B-X
,	B-X
Paula	B-X
Silva	B-X
,	B-X
Joana	B-X
Carvalho	B-X
O109	B-X
Psychometric	B-X
properties	B-X
of	B-X
the	B-X
Portuguese	B-X
version	B-X
of	B-X
the	B-X
Ãxamen	B-X
Geronto-Psychomoteur	B-X
(	B-X
P-EGP	B-X
)	B-X
Marina	B-X
Ana	B-X
Morais	B-X
,	B-X
Sofia	B-X
Santos	B-X
,	B-X
Paula	B-X
Lebre	B-X
,	B-X
Ana	B-X
Antunes	B-X
O110	B-X
Symptoms	B-X
of	B-X
depression	B-X
in	B-X
the	B-X
elderly	B-X
population	B-X
of	B-X
Portugal	B-X
,	B-X
Spain	B-X
and	B-X
Italy	B-X
AntÃ³nio	B-X
Calha	B-X
O111	B-X
Emotion	B-X
regulation	B-X
strategies	B-X
and	B-X
psychopathology	B-X
symptoms	B-X
:	B-X
A	B-X
comparison	B-X
between	B-X
adolescents	B-X
with	B-X
and	B-X
without	B-X
deliberate	B-X
self-harm	B-X
Ana	B-X
Xavier	B-X
,	B-X
Marina	B-X
Cunha	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
O112	B-X
Prevalence	B-X
of	B-X
physical	B-X
disability	B-X
in	B-X
people	B-X
with	B-X
leprosy	B-X
Liana	B-X
Alencar	B-X
,	B-X
Madalena	B-X
Cunha	B-X
,	B-X
AntÃ³nio	B-X
Madureira	B-X
O113	B-X
Quality	B-X
of	B-X
life	B-X
and	B-X
self-esteem	B-X
in	B-X
type	B-X
1	B-X
and	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
patients	B-X
Ilda	B-X
Cardoso	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Fernanda	B-X
Daniel	B-X
,	B-X
VÃ­tor	B-X
Rodrigues	B-X
O114	B-X
Cross-cultural	B-X
comparison	B-X
of	B-X
gross	B-X
motor	B-X
coordination	B-X
in	B-X
children	B-X
from	B-X
Brazil	B-X
and	B-X
Portugal	B-X
Leonardo	B-X
Luz	B-X
,	B-X
Tatiana	B-X
Luz	B-X
,	B-X
MaurÃ­cio	B-X
R.	B-X
Ramos	B-X
,	B-X
Dayse	B-X
C.	B-X
Medeiros	B-X
,	B-X
Bruno	B-X
M.	B-X
Carmo	B-X
,	B-X
AndrÃ©	B-X
Seabra	B-X
,	B-X
Cristina	B-X
Padez	B-X
,	B-X
Manuel	B-X
C.	B-X
Silva	B-X
O115	B-X
Electrocardiographic	B-X
differences	B-X
between	B-X
African	B-X
and	B-X
Caucasian	B-X
people	B-X
AntÃ³nio	B-X
Rodrigues	B-X
,	B-X
PatrÃ­cia	B-X
Coelho	B-X
,	B-X
Alexandre	B-X
Coelho	B-X
O116	B-X
Factors	B-X
associated	B-X
with	B-X
domestic	B-X
,	B-X
sexual	B-X
and	B-X
other	B-X
types	B-X
of	B-X
violence	B-X
in	B-X
the	B-X
city	B-X
of	B-X
PalhoÃ§a	B-X
-	B-X
Brazil	B-X
Madson	B-X
Caminha	B-X
,	B-X
Filipe	B-X
Matheus	B-X
,	B-X
Elenice	B-X
Mendes	B-X
,	B-X
Jony	B-X
Correia	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
O117	B-X
Tinnitus	B-X
prevalence	B-X
study	B-X
of	B-X
users	B-X
of	B-X
a	B-X
hospital	B-X
of	B-X
public	B-X
management	B-X
-	B-X
Spain	B-X
Francisco	B-X
J.	B-X
Hernandez-Martinez	B-X
,	B-X
Juan	B-X
F.	B-X
Jimenez-Diaz	B-X
,	B-X
Bienvendida	B-X
C.	B-X
Rodriguez-De-Vera	B-X
,	B-X
Carla	B-X
Jimenez-Rodriguez	B-X
,	B-X
Yadira	B-X
Armas-Gonzalez	B-X
O118	B-X
Difficulties	B-X
experienced	B-X
by	B-X
parents	B-X
of	B-X
children	B-X
with	B-X
diabetes	B-X
mellitus	B-X
of	B-X
preschool	B-X
age	B-X
in	B-X
therapeutic	B-X
and	B-X
nutritional	B-X
management	B-X
CÃ¡tia	B-X
Rodrigues	B-X
,	B-X
Rosa	B-X
Pedroso	B-X
O119	B-X
E-mental	B-X
health	B-X
-	B-X
â	B-X
nice	B-X
to	B-X
have	B-X
â	B-X
or	B-X
â	B-X
must	B-X
have	B-X
â	B-X
?	B-X
Rita	B-X
Ventura	B-X
,	B-X
Cristina	B-X
NazarÃ©	B-X
P71	B-X
Mental	B-X
disorders	B-X
in	B-X
the	B-X
oldest	B-X
old	B-X
:	B-X
findings	B-X
from	B-X
the	B-X
Portuguese	B-X
national	B-X
hospitalization	B-X
database	B-X
Daniela	B-X
BrandÃ£o	B-X
,	B-X
Alberto	B-X
Freitas	B-X
,	B-X
Ãscar	B-X
Ribeiro	B-X
,	B-X
ConstanÃ§a	B-X
PaÃºl	B-X
P72	B-X
Recurrence	B-X
analysis	B-X
in	B-X
postural	B-X
control	B-X
in	B-X
children	B-X
with	B-X
cerebral	B-X
palsy	B-X
Cristiana	B-X
MercÃª	B-X
,	B-X
Marco	B-X
Branco	B-X
,	B-X
Pedro	B-X
Almeida	B-X
,	B-X
Daniela	B-X
Nascimento	B-X
,	B-X
Juliana	B-X
Pereira	B-X
,	B-X
David	B-X
Catela	B-X
P73	B-X
The	B-X
experience	B-X
of	B-X
self-care	B-X
in	B-X
the	B-X
elderly	B-X
with	B-X
COPD	B-X
:	B-X
contributions	B-X
to	B-X
reflect	B-X
proximity	B-X
care	B-X
Helga	B-X
Rafael	B-X
P74	B-X
Culturally	B-X
competent	B-X
nurses	B-X
:	B-X
managing	B-X
unpredictability	B-X
in	B-X
clinical	B-X
practice	B-X
with	B-X
immigrants	B-X
Alcinda	B-X
C.	B-X
Reis	B-X
O137	B-X
Paediatric	B-X
speech	B-X
and	B-X
language	B-X
screening	B-X
:	B-X
An	B-X
instrument	B-X
for	B-X
health	B-X
professionals	B-X
Ana	B-X
Mendes	B-X
,	B-X
Ana	B-X
R.	B-X
Valente	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O138	B-X
Anthropometric	B-X
and	B-X
nutritional	B-X
assessment	B-X
in	B-X
bodybuilders	B-X
Diana	B-X
Sousa	B-X
,	B-X
Ana	B-X
L.	B-X
Baltazar	B-X
,	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
O139	B-X
Computerized	B-X
adventitious	B-X
respiratory	B-X
sounds	B-X
in	B-X
children	B-X
with	B-X
lower	B-X
respiratory	B-X
tract	B-X
infections	B-X
Ana	B-X
Oliveira	B-X
,	B-X
JosÃ©	B-X
AparÃ­cio	B-X
,	B-X
Alda	B-X
Marques	B-X
O140	B-X
Role	B-X
of	B-X
computerized	B-X
respiratory	B-X
sounds	B-X
as	B-X
a	B-X
marker	B-X
in	B-X
LRTI	B-X
Alda	B-X
Marques	B-X
,	B-X
Ana	B-X
Oliveira	B-X
,	B-X
Joana	B-X
Neves	B-X
,	B-X
Rodrigo	B-X
Ayoub	B-X
O141	B-X
Confirmatory	B-X
factor	B-X
analysis	B-X
of	B-X
the	B-X
Personal	B-X
Wellbeing	B-X
Index	B-X
in	B-X
people	B-X
with	B-X
chronic	B-X
kidney	B-X
disease	B-X
LuÃ­s	B-X
Sousa	B-X
,	B-X
Cristina	B-X
Marques-Vieira	B-X
,	B-X
Sandy	B-X
Severino	B-X
,	B-X
Helena	B-X
JosÃ©	B-X
O142	B-X
Phonological	B-X
awareness	B-X
skills	B-X
in	B-X
school	B-X
aged	B-X
children	B-X
InÃªs	B-X
Cadorio	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O143	B-X
Assessment	B-X
of	B-X
early	B-X
memories	B-X
of	B-X
warmth	B-X
and	B-X
safeness	B-X
in	B-X
interaction	B-X
with	B-X
peers	B-X
:	B-X
its	B-X
relationship	B-X
with	B-X
psychopathology	B-X
in	B-X
adolescence	B-X
Marina	B-X
Cunha	B-X
,	B-X
Diogo	B-X
Andrade	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Margarida	B-X
Couto	B-X
O144	B-X
The	B-X
molecular	B-X
effects	B-X
induced	B-X
by	B-X
single	B-X
shot	B-X
irradiation	B-X
on	B-X
a	B-X
diffuse	B-X
large	B-X
B	B-X
cell	B-X
lymphoma	B-X
cell	B-X
line	B-X
Fernando	B-X
Mendes	B-X
,	B-X
CÃ¡tia	B-X
Domingues	B-X
,	B-X
Susann	B-X
Schukg	B-X
,	B-X
Ana	B-X
M.	B-X
Abrantes	B-X
,	B-X
Ana	B-X
C.	B-X
GonÃ§alves	B-X
,	B-X
Tiago	B-X
Sales	B-X
,	B-X
Ricardo	B-X
Teixo	B-X
,	B-X
Rita	B-X
Silva	B-X
,	B-X
JÃ©ssica	B-X
Estrela	B-X
,	B-X
Mafalda	B-X
Laranjo	B-X
,	B-X
JoÃ£o	B-X
Casalta-Lopes	B-X
,	B-X
Clara	B-X
Rocha	B-X
,	B-X
Paulo	B-X
C.	B-X
SimÃµes	B-X
,	B-X
Ana	B-X
B.	B-X
Sarmento-Ribeiro	B-X
,	B-X
MÂª	B-X
Filomena	B-X
Botelho	B-X
,	B-X
Manuel	B-X
S.	B-X
Rosa	B-X
O145	B-X
Morpho-functional	B-X
characterization	B-X
of	B-X
cardiac	B-X
chambers	B-X
by	B-X
Transthoracic	B-X
Echocardiography	B-X
,	B-X
in	B-X
young	B-X
athletes	B-X
of	B-X
gymnastics	B-X
competition	B-X
VirgÃ­nia	B-X
Fonseca	B-X
,	B-X
Diogo	B-X
ColaÃ§o	B-X
,	B-X
Vanessa	B-X
Neves	B-X
O146	B-X
Prevalence	B-X
of	B-X
the	B-X
antibodies	B-X
of	B-X
the	B-X
new	B-X
histo-blood	B-X
system	B-X
â	B-X
FORS	B-X
system	B-X
Carlos	B-X
Jesus	B-X
,	B-X
Camilla	B-X
Hesse	B-X
,	B-X
Clara	B-X
Rocha	B-X
,	B-X
NÃ¡dia	B-X
OsÃ³rio	B-X
,	B-X
Ana	B-X
Valado	B-X
,	B-X
Armando	B-X
Caseiro	B-X
,	B-X
AntÃ³nio	B-X
Gabriel	B-X
,	B-X
Lola	B-X
Svensson	B-X
,	B-X
Fernando	B-X
Mendes	B-X
,	B-X
Wafa	B-X
A.	B-X
Siba	B-X
,	B-X
Cristina	B-X
Pereira	B-X
,	B-X
Jorge	B-X
Tomaz	B-X
O147	B-X
Assessment	B-X
of	B-X
the	B-X
war-related	B-X
perceived	B-X
threat	B-X
in	B-X
Portuguese	B-X
Colonial	B-X
War	B-X
Veterans	B-X
Teresa	B-X
Carvalho	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
,	B-X
Marina	B-X
Cunha	B-X
O148	B-X
Pulse	B-X
transit	B-X
time	B-X
estimation	B-X
for	B-X
continuous	B-X
blood	B-X
pressure	B-X
measurement	B-X
:	B-X
A	B-X
comparative	B-X
study	B-X
Diana	B-X
Duarte	B-X
,	B-X
Nuno	B-X
V.	B-X
Lopes	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
O149	B-X
Blood	B-X
pressure	B-X
assessment	B-X
during	B-X
standard	B-X
clinical	B-X
manoeuvres	B-X
:	B-X
A	B-X
non-invasive	B-X
PPT	B-X
based	B-X
approach	B-X
Diana	B-X
Duarte	B-X
,	B-X
Nuno	B-X
V.	B-X
Lopes	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
O150	B-X
Development	B-X
and	B-X
initial	B-X
validation	B-X
of	B-X
the	B-X
Activities	B-X
and	B-X
Participation	B-X
Profile	B-X
related	B-X
to	B-X
Mobility	B-X
(	B-X
APPM	B-X
)	B-X
Anabela	B-X
C.	B-X
Martins	B-X
O151	B-X
MEASYCare-2010	B-X
StandardâA	B-X
geriatric	B-X
evaluation	B-X
system	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
:	B-X
Reliability	B-X
and	B-X
validity	B-X
of	B-X
the	B-X
latest	B-X
version	B-X
in	B-X
Portugal	B-X
Piedade	B-X
BrandÃ£o	B-X
,	B-X
Laura	B-X
Martins	B-X
,	B-X
Margarida	B-X
Cardoso	B-X
O152	B-X
Interrater	B-X
and	B-X
intrarater	B-X
reliability	B-X
and	B-X
agreement	B-X
of	B-X
the	B-X
range	B-X
of	B-X
shoulder	B-X
flexion	B-X
in	B-X
the	B-X
standing	B-X
upright	B-X
position	B-X
through	B-X
photographic	B-X
assessment	B-X
Nuno	B-X
Morais	B-X
,	B-X
Joana	B-X
Cruz	B-X
O153	B-X
Three-dimensional	B-X
biofabrication	B-X
techniques	B-X
for	B-X
tissue	B-X
regeneration	B-X
Nuno	B-X
Alves	B-X
,	B-X
Paula	B-X
Faria	B-X
,	B-X
Artur	B-X
Mateus	B-X
,	B-X
Pedro	B-X
MorouÃ§o	B-X
O154	B-X
A	B-X
new	B-X
computer	B-X
tool	B-X
for	B-X
biofabrication	B-X
applied	B-X
to	B-X
tissue	B-X
engineering	B-X
Nuno	B-X
Alves	B-X
,	B-X
Nelson	B-X
Ferreira	B-X
,	B-X
Artur	B-X
Mateus	B-X
,	B-X
Paula	B-X
Faria	B-X
,	B-X
Pedro	B-X
MorouÃ§o	B-X
O155	B-X
Development	B-X
and	B-X
psychometric	B-X
qualities	B-X
of	B-X
a	B-X
scale	B-X
to	B-X
measure	B-X
the	B-X
functional	B-X
independence	B-X
of	B-X
adolescents	B-X
with	B-X
motor	B-X
impairment	B-X
Isabel	B-X
Malheiro	B-X
,	B-X
Filomena	B-X
Gaspar	B-X
,	B-X
LuÃ­sa	B-X
Barros	B-X
O156	B-X
Organizational	B-X
Trust	B-X
in	B-X
Health	B-X
services	B-X
:	B-X
Exploratory	B-X
and	B-X
Confirmatory	B-X
factor	B-X
analysis	B-X
of	B-X
the	B-X
Organizational	B-X
Trust	B-X
Inventory-	B-X
Short	B-X
Form	B-X
(	B-X
OTI-SF	B-X
)	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Andreia	B-X
Cardoso	B-X
,	B-X
Lisete	B-X
MÃ³nico	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Albino	B-X
Lopes	B-X
,	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
O157	B-X
Thermal	B-X
symmetry	B-X
:	B-X
An	B-X
indicator	B-X
of	B-X
occupational	B-X
task	B-X
asymmetries	B-X
in	B-X
physiotherapy	B-X
AdÃ©rito	B-X
Seixas	B-X
,	B-X
Valter	B-X
Soares	B-X
,	B-X
Tiago	B-X
Dias	B-X
,	B-X
Ricardo	B-X
Vardasca	B-X
,	B-X
Joaquim	B-X
Gabriel	B-X
,	B-X
Sandra	B-X
Rodrigues	B-X
O158	B-X
A	B-X
study	B-X
of	B-X
ICT	B-X
active	B-X
monitoring	B-X
adoption	B-X
in	B-X
stroke	B-X
rehabilitation	B-X
Hugo	B-X
Paredes	B-X
,	B-X
ArsÃ©nio	B-X
Reis	B-X
,	B-X
Sara	B-X
Marinho	B-X
,	B-X
VÃ­tor	B-X
Filipe	B-X
,	B-X
JoÃ£o	B-X
Barroso	B-X
O159	B-X
Paranoia	B-X
Checklist	B-X
(	B-X
Portuguese	B-X
Version	B-X
)	B-X
:	B-X
Preliminary	B-X
studies	B-X
in	B-X
a	B-X
mixed	B-X
sample	B-X
of	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
Carolina	B-X
Da	B-X
Motta	B-X
,	B-X
CÃ©lia	B-X
B.	B-X
Carvalho	B-X
,	B-X
JosÃ©	B-X
Pinto-Gouveia	B-X
,	B-X
Ermelindo	B-X
Peixoto	B-X
O160	B-X
Reliability	B-X
and	B-X
validity	B-X
of	B-X
the	B-X
Composite	B-X
Scale	B-X
on	B-X
Morningness	B-X
:	B-X
European	B-X
Portuguese	B-X
version	B-X
,	B-X
in	B-X
adolescents	B-X
and	B-X
young	B-X
adults	B-X
Ana	B-X
A.	B-X
Gomes	B-X
,	B-X
Vanessa	B-X
Costa	B-X
,	B-X
Diana	B-X
Couto	B-X
,	B-X
Daniel	B-X
R.	B-X
Marques	B-X
,	B-X
JosÃ©	B-X
A.	B-X
LeitÃ£o	B-X
,	B-X
JosÃ©	B-X
Tavares	B-X
,	B-X
Maria	B-X
H.	B-X
Azevedo	B-X
,	B-X
Carlos	B-X
F.	B-X
Silva	B-X
O161	B-X
Evaluation	B-X
scale	B-X
of	B-X
patient	B-X
satisfaction	B-X
with	B-X
nursing	B-X
care	B-X
:	B-X
Psychometric	B-X
properties	B-X
evaluation	B-X
JoÃ£o	B-X
Freitas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
JoÃ£o	B-X
MarÃ´co	B-X
O162	B-X
Impact	B-X
of	B-X
fibromyalgia	B-X
on	B-X
quality	B-X
of	B-X
life	B-X
:	B-X
Comparing	B-X
results	B-X
from	B-X
generic	B-X
instruments	B-X
and	B-X
FIQR	B-X
Miguel	B-X
A.	B-X
Garcia-Gordillo	B-X
,	B-X
Daniel	B-X
Collado-Mateo	B-X
,	B-X
Gang	B-X
Chen	B-X
,	B-X
Angelo	B-X
Iezzi	B-X
,	B-X
JosÃ©	B-X
A.	B-X
Sala	B-X
,	B-X
JosÃ©	B-X
A.	B-X
ParraÃ§a	B-X
,	B-X
Narcis	B-X
Gusi	B-X
O163	B-X
Preliminary	B-X
study	B-X
of	B-X
the	B-X
adaptation	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
Rating	B-X
Scale	B-X
of	B-X
Resilient	B-X
Self	B-X
:	B-X
Resilience	B-X
,	B-X
self-harm	B-X
and	B-X
suicidal	B-X
ideation	B-X
in	B-X
adolescents	B-X
Jani	B-X
Sousa	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
Jacinto	B-X
Jardim	B-X
,	B-X
Anabela	B-X
Pereira	B-X
,	B-X
SÃ³nia	B-X
SimÃµes	B-X
,	B-X
Marina	B-X
Cunha	B-X
O164	B-X
Development	B-X
of	B-X
the	B-X
first	B-X
pressure	B-X
ulcer	B-X
in	B-X
inpatient	B-X
setting	B-X
:	B-X
Focus	B-X
on	B-X
length	B-X
of	B-X
stay	B-X
Pedro	B-X
Sardo	B-X
,	B-X
Jenifer	B-X
Guedes	B-X
,	B-X
JoÃ£o	B-X
Lindo	B-X
,	B-X
Paulo	B-X
Machado	B-X
,	B-X
Elsa	B-X
Melo	B-X
O165	B-X
Forms	B-X
of	B-X
Self-Criticizing	B-X
and	B-X
Self-Reassuring	B-X
Scale	B-X
:	B-X
Adaptation	B-X
and	B-X
early	B-X
findings	B-X
in	B-X
a	B-X
sample	B-X
of	B-X
Portuguese	B-X
children	B-X
CÃ©lia	B-X
B.	B-X
Carvalho	B-X
,	B-X
Joana	B-X
Benevides	B-X
,	B-X
Marina	B-X
Sousa	B-X
,	B-X
Joana	B-X
Cabral	B-X
,	B-X
Carolina	B-X
Da	B-X
Motta	B-X
O166	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Perinatal	B-X
Depression	B-X
Screening	B-X
and	B-X
Prevention	B-X
Tool	B-X
â	B-X
Preliminary	B-X
results	B-X
of	B-X
the	B-X
dimensional	B-X
approach	B-X
Ana	B-X
T.	B-X
Pereira	B-X
,	B-X
Sandra	B-X
Xavier	B-X
,	B-X
Julieta	B-X
Azevedo	B-X
,	B-X
Elisabete	B-X
Bento	B-X
,	B-X
Cristiana	B-X
Marques	B-X
,	B-X
Rosa	B-X
Carvalho	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
AntÃ³nio	B-X
Macedo	B-X
O167	B-X
Psychometric	B-X
properties	B-X
of	B-X
the	B-X
BaSIQS-Basic	B-X
Scale	B-X
on	B-X
insomnia	B-X
symptoms	B-X
and	B-X
quality	B-X
of	B-X
sleep	B-X
,	B-X
in	B-X
adults	B-X
and	B-X
in	B-X
the	B-X
elderly	B-X
Ana	B-X
M.	B-X
Silva	B-X
,	B-X
Juliana	B-X
Alves	B-X
,	B-X
Ana	B-X
A.	B-X
Gomes	B-X
,	B-X
Daniel	B-X
R.	B-X
Marques	B-X
,	B-X
MÂª	B-X
Helena	B-X
Azevedo	B-X
,	B-X
Carlos	B-X
Silva	B-X
O168	B-X
Enlightening	B-X
the	B-X
human	B-X
decision	B-X
in	B-X
health	B-X
:	B-X
The	B-X
skin	B-X
melanocytic	B-X
classification	B-X
challenge	B-X
Ana	B-X
Mendes	B-X
,	B-X
Huei	B-X
D.	B-X
Lee	B-X
,	B-X
Newton	B-X
SpolaÃ´r	B-X
,	B-X
Jefferson	B-X
T.	B-X
Oliva	B-X
,	B-X
Wu	B-X
F.	B-X
Chung	B-X
,	B-X
Rui	B-X
Fonseca-Pinto	B-X
O169	B-X
Test-retest	B-X
reliability	B-X
household	B-X
life	B-X
study	B-X
and	B-X
health	B-X
questionnaire	B-X
Pomerode	B-X
(	B-X
SHIP-BRAZIL	B-X
)	B-X
Keila	B-X
Bairros	B-X
,	B-X
ClÃ¡udia	B-X
D.	B-X
Silva	B-X
,	B-X
ClÃ³vis	B-X
A.	B-X
Souza	B-X
,	B-X
Silvana	B-X
S.	B-X
Schroeder	B-X
O170	B-X
Characterization	B-X
of	B-X
sun	B-X
exposure	B-X
behaviours	B-X
among	B-X
medical	B-X
students	B-X
from	B-X
Nova	B-X
Medical	B-X
School	B-X
Elsa	B-X
AraÃºjo	B-X
,	B-X
Helena	B-X
Monteiro	B-X
,	B-X
Ricardo	B-X
Costa	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
,	B-X
Jorge	B-X
Torgal	B-X
O171	B-X
Spirituality	B-X
in	B-X
pregnant	B-X
women	B-X
Carolina	B-X
G.	B-X
Henriques	B-X
,	B-X
LuÃ­sa	B-X
Santos	B-X
,	B-X
Elisa	B-X
F.	B-X
Caceiro	B-X
,	B-X
SÃ³nia	B-X
A.	B-X
Ramalho	B-X
O172	B-X
Polypharmacy	B-X
in	B-X
older	B-X
patients	B-X
with	B-X
cancer	B-X
Rita	B-X
Oliveira	B-X
,	B-X
Vera	B-X
Afreixo	B-X
,	B-X
JoÃ£o	B-X
Santos	B-X
,	B-X
Priscilla	B-X
Mota	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
,	B-X
Francisco	B-X
Pimentel	B-X
O173	B-X
Quality	B-X
of	B-X
life	B-X
of	B-X
caregivers	B-X
of	B-X
people	B-X
with	B-X
advanced	B-X
chronic	B-X
disease	B-X
:	B-X
Translation	B-X
and	B-X
validation	B-X
of	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
life	B-X
threatening	B-X
illness	B-X
-	B-X
family	B-X
carer	B-X
version	B-X
(	B-X
QOLLTI-C-PT	B-X
)	B-X
Rita	B-X
Marques	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
PatrÃ­cia	B-X
Sousa	B-X
O174	B-X
The	B-X
psychometric	B-X
properties	B-X
of	B-X
the	B-X
brief	B-X
Other	B-X
as	B-X
Shamer	B-X
Scale	B-X
for	B-X
Children	B-X
(	B-X
OAS-C	B-X
)	B-X
:	B-X
preliminary	B-X
validation	B-X
studies	B-X
in	B-X
a	B-X
sample	B-X
of	B-X
Portuguese	B-X
children	B-X
Joana	B-X
Benevides	B-X
,	B-X
Carolina	B-X
Da	B-X
Motta	B-X
,	B-X
Marina	B-X
Sousa	B-X
,	B-X
Suzana	B-X
N.	B-X
Caldeira	B-X
,	B-X
CÃ©lia	B-X
B.	B-X
Carvalho	B-X
O175	B-X
Measuring	B-X
emotional	B-X
intelligence	B-X
in	B-X
health	B-X
care	B-X
students	B-X
â	B-X
Revalidation	B-X
of	B-X
WLEIS-P	B-X
Ana	B-X
Querido	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
O176	B-X
Health	B-X
indicators	B-X
in	B-X
prenatal	B-X
assistance	B-X
:	B-X
The	B-X
impact	B-X
of	B-X
computerization	B-X
and	B-X
of	B-X
under-production	B-X
in	B-X
basic	B-X
health	B-X
centres	B-X
Joyce	B-X
O.	B-X
Costa	B-X
,	B-X
Frederico	B-X
C.	B-X
Valim	B-X
,	B-X
LÃ­gia	B-X
C.	B-X
Ribeiro	B-X
O177	B-X
Hope	B-X
genogram	B-X
:	B-X
Assessment	B-X
of	B-X
resources	B-X
and	B-X
interaction	B-X
patterns	B-X
in	B-X
the	B-X
family	B-X
of	B-X
the	B-X
child	B-X
with	B-X
cerebral	B-X
palsy	B-X
Zaida	B-X
Charepe	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
MÂª	B-X
Henriqueta	B-X
Figueiredo	B-X
O178	B-X
The	B-X
influence	B-X
of	B-X
childbirth	B-X
type	B-X
in	B-X
postpartum	B-X
quality	B-X
of	B-X
life	B-X
Priscila	B-X
S.	B-X
Aquino	B-X
,	B-X
Samila	B-X
G.	B-X
Ribeiro	B-X
,	B-X
Ana	B-X
B.	B-X
Pinheiro	B-X
,	B-X
Paula	B-X
A.	B-X
Lessa	B-X
,	B-X
Mirna	B-X
F.	B-X
Oliveira	B-X
,	B-X
LuÃ­sa	B-X
S.	B-X
Brito	B-X
,	B-X
Ãtalo	B-X
N.	B-X
Pinto	B-X
,	B-X
Alessandra	B-X
S.	B-X
Furtado	B-X
,	B-X
RÃ©gia	B-X
B.	B-X
Castro	B-X
,	B-X
Caroline	B-X
Q.	B-X
Aquino	B-X
,	B-X
Eveliny	B-X
S.	B-X
Martins	B-X
O179	B-X
Women	B-X
â	B-X
s	B-X
beliefs	B-X
about	B-X
pap	B-X
smear	B-X
test	B-X
and	B-X
cervical	B-X
cancer	B-X
:	B-X
influence	B-X
of	B-X
social	B-X
determinants	B-X
Ana	B-X
B	B-X
Pinheiro	B-X
,	B-X
Priscila	B-X
S.	B-X
Aquino	B-X
,	B-X
Lara	B-X
L.	B-X
Oliveira	B-X
,	B-X
PatrÃ­cia	B-X
C.	B-X
Pinheiro	B-X
,	B-X
Caroline	B-X
R.	B-X
Sousa	B-X
,	B-X
VÃ­vien	B-X
A.	B-X
Freitas	B-X
,	B-X
Tatiane	B-X
M.	B-X
Silva	B-X
,	B-X
Adman	B-X
S.	B-X
Lima	B-X
,	B-X
Caroline	B-X
Q.	B-X
Aquino	B-X
,	B-X
Karizia	B-X
V.	B-X
Andrade	B-X
,	B-X
Camila	B-X
A.	B-X
Oliveira	B-X
,	B-X
Eglidia	B-X
F.	B-X
Vidal	B-X
O180	B-X
Validity	B-X
of	B-X
the	B-X
Portuguese	B-X
version	B-X
of	B-X
the	B-X
ASI-3	B-X
:	B-X
Is	B-X
anxiety	B-X
sensitivity	B-X
a	B-X
unidimensional	B-X
or	B-X
multidimensional	B-X
construct	B-X
?	B-X
Zaida	B-X
Azeredo	B-X
,	B-X
Carlos	B-X
Laranjeira	B-X
,	B-X
Magda	B-X
Guerra	B-X
,	B-X
Ana	B-X
P.	B-X
Barbeiro	B-X
O195	B-X
The	B-X
therapeutic	B-X
self-care	B-X
as	B-X
a	B-X
nursing-sensitive	B-X
outcome	B-X
:	B-X
A	B-X
correlational	B-X
study	B-X
Regina	B-X
Ferreira	B-X
O196	B-X
Phonetic-phonological	B-X
acquisition	B-X
for	B-X
the	B-X
European	B-X
Portuguese	B-X
from	B-X
18	B-X
months	B-X
to	B-X
6	B-X
years	B-X
and	B-X
12	B-X
months	B-X
Sara	B-X
Lopes	B-X
,	B-X
Liliana	B-X
Nunes	B-X
,	B-X
Ana	B-X
Mendes	B-X
O197	B-X
Quality	B-X
of	B-X
life	B-X
of	B-X
patients	B-X
undergoing	B-X
liver	B-X
transplant	B-X
surgery	B-X
Julian	B-X
Martins	B-X
,	B-X
Dulcineia	B-X
Schneider	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
,	B-X
FlÃ¡vio	B-X
Magajewski	B-X
O198	B-X
Professional	B-X
competences	B-X
in	B-X
health	B-X
:	B-X
views	B-X
of	B-X
older	B-X
people	B-X
from	B-X
different	B-X
European	B-X
Countries	B-X
CÃ©lia	B-X
Soares	B-X
,	B-X
AntÃ³nio	B-X
Marques	B-X
O199	B-X
Life	B-X
satisfaction	B-X
of	B-X
working	B-X
adults	B-X
due	B-X
to	B-X
the	B-X
number	B-X
of	B-X
hours	B-X
of	B-X
weekly	B-X
exercise	B-X
Marco	B-X
Batista	B-X
,	B-X
Ruth	B-X
J.	B-X
Castuera	B-X
,	B-X
Helena	B-X
Mesquita	B-X
,	B-X
AntÃ³nio	B-X
Faustino	B-X
,	B-X
Jorge	B-X
Santos	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
O200	B-X
Therapeutic	B-X
itinerary	B-X
of	B-X
women	B-X
with	B-X
breast	B-X
cancer	B-X
in	B-X
Santa	B-X
Maria	B-X
City/RS	B-X
Betina	B-X
P.	B-X
Vizzotto	B-X
,	B-X
Leticia	B-X
Frigo	B-X
,	B-X
Hedioneia	B-X
F.	B-X
Pivetta	B-X
O201	B-X
The	B-X
breastfeeding	B-X
prevalence	B-X
at	B-X
4	B-X
months	B-X
:	B-X
Maternal	B-X
experience	B-X
as	B-X
a	B-X
determining	B-X
factor	B-X
Dolores	B-X
Sardo	B-X
O202	B-X
The	B-X
impact	B-X
of	B-X
the	B-X
transition	B-X
to	B-X
parenthood	B-X
in	B-X
health	B-X
and	B-X
well-being	B-X
Cristina	B-X
Martins	B-X
,	B-X
Wilson	B-X
Abreu	B-X
,	B-X
MÂª	B-X
CÃ©u	B-X
Figueiredo	B-X
P96	B-X
Self-determined	B-X
motivation	B-X
and	B-X
well-being	B-X
in	B-X
Portuguese	B-X
active	B-X
adults	B-X
of	B-X
both	B-X
genders	B-X
Marco	B-X
Batista	B-X
,	B-X
Ruth	B-X
Jimenez-Castuera	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
Pedro	B-X
Mendes	B-X
P97	B-X
The	B-X
geriatric	B-X
care	B-X
:	B-X
ways	B-X
and	B-X
means	B-X
of	B-X
comforting	B-X
PatrÃ­cia	B-X
Sousa	B-X
,	B-X
Rita	B-X
Marques	B-X
P98	B-X
The	B-X
influence	B-X
of	B-X
relative	B-X
age	B-X
,	B-X
subcutaneous	B-X
adiposity	B-X
and	B-X
physical	B-X
growth	B-X
on	B-X
Castelo	B-X
Branco	B-X
under-15	B-X
soccer	B-X
players	B-X
2015	B-X
AntÃ³nio	B-X
Faustino	B-X
,	B-X
Paulo	B-X
Silveira	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
P99	B-X
Data	B-X
for	B-X
the	B-X
diagnostic	B-X
process	B-X
focused	B-X
on	B-X
self-care	B-X
â	B-X
managing	B-X
medication	B-X
regime	B-X
:	B-X
An	B-X
integrative	B-X
literature	B-X
review	B-X
Catarina	B-X
Oliveira	B-X
,	B-X
Fernanda	B-X
Bastos	B-X
,	B-X
InÃªs	B-X
Cruz	B-X
P100	B-X
Art	B-X
therapy	B-X
as	B-X
mental	B-X
health	B-X
promotion	B-X
for	B-X
children	B-X
ClÃ¡udia	B-X
K.	B-X
Rodriguez	B-X
,	B-X
MÃ¡rcia	B-X
R.	B-X
Kretzer	B-X
,	B-X
NazarÃ©	B-X
O.	B-X
NazÃ¡rio	B-X
P101	B-X
Chemical	B-X
characterization	B-X
of	B-X
fungal	B-X
chitosan	B-X
for	B-X
industrial	B-X
applications	B-X
Pedro	B-X
Cruz	B-X
,	B-X
Daniela	B-X
C.	B-X
Vaz	B-X
,	B-X
Rui	B-X
B.	B-X
Ruben	B-X
,	B-X
Francisco	B-X
Avelelas	B-X
,	B-X
Susana	B-X
Silva	B-X
,	B-X
MÂª	B-X
Jorge	B-X
Campos	B-X
P102	B-X
The	B-X
impact	B-X
of	B-X
caring	B-X
older	B-X
people	B-X
at	B-X
home	B-X
Maria	B-X
Almeida	B-X
,	B-X
Liliana	B-X
GonÃ§alves	B-X
,	B-X
LÃ­gia	B-X
Antunes	B-X
P103	B-X
Development	B-X
of	B-X
the	B-X
first	B-X
pressure	B-X
ulcer	B-X
in	B-X
an	B-X
inpatient	B-X
setting	B-X
:	B-X
Focus	B-X
on	B-X
patients	B-X
â	B-X
characteristics	B-X
Pedro	B-X
Sardo	B-X
,	B-X
Jenifer	B-X
Guedes	B-X
,	B-X
JoÃ£o	B-X
SimÃµes	B-X
,	B-X
Paulo	B-X
Machado	B-X
,	B-X
Elsa	B-X
Melo	B-X
P104	B-X
Association	B-X
between	B-X
General	B-X
Self-efficacy	B-X
and	B-X
Physical	B-X
Activity	B-X
among	B-X
Adolescents	B-X
Susana	B-X
Cardoso	B-X
,	B-X
Osvaldo	B-X
Santos	B-X
,	B-X
Carla	B-X
Nunes	B-X
,	B-X
Isabel	B-X
Loureiro	B-X
O203	B-X
Characterization	B-X
of	B-X
the	B-X
habits	B-X
of	B-X
online	B-X
acquisition	B-X
of	B-X
medicinal	B-X
products	B-X
in	B-X
Portugal	B-X
FlÃ¡via	B-X
Santos	B-X
,	B-X
Gilberto	B-X
Alves	B-X
O204	B-X
Waiting	B-X
room	B-X
â	B-X
A	B-X
space	B-X
for	B-X
health	B-X
education	B-X
ClÃ¡udia	B-X
Soar	B-X
,	B-X
Teresa	B-X
O.	B-X
Marsi	B-X
O205	B-X
Safey	B-X
culture	B-X
evaluation	B-X
in	B-X
hospitalized	B-X
children	B-X
Ernestina	B-X
Silva	B-X
,	B-X
Dora	B-X
Pedrosa	B-X
,	B-X
Andrea	B-X
LeÃ§a	B-X
,	B-X
Daniel	B-X
Silva	B-X
O206	B-X
Sexual	B-X
Self-awareness	B-X
and	B-X
Body	B-X
Image	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
Maria	B-X
Gomes	B-X
,	B-X
Paula	B-X
Fernandes	B-X
,	B-X
Ana	B-X
NonÃ©	B-X
O207	B-X
Perception	B-X
of	B-X
a	B-X
Portuguese	B-X
population	B-X
regarding	B-X
the	B-X
acquisition	B-X
and	B-X
consumption	B-X
of	B-X
functional	B-X
foods	B-X
Jaime	B-X
CombadÃ£o	B-X
,	B-X
CÃ¡tia	B-X
Ramalhete	B-X
,	B-X
Paulo	B-X
Figueiredo	B-X
,	B-X
PatrÃ­cia	B-X
Caeiro	B-X
O208	B-X
The	B-X
work	B-X
process	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
:	B-X
evaluation	B-X
in	B-X
municipalities	B-X
of	B-X
southern	B-X
Brazil	B-X
Karine	B-X
C.	B-X
Fontana	B-X
,	B-X
Josimari	B-X
T.	B-X
Lacerda	B-X
,	B-X
PatrÃ­cia	B-X
O.	B-X
Machado	B-X
O209	B-X
Exploration	B-X
and	B-X
evaluation	B-X
of	B-X
potential	B-X
probiotic	B-X
lactic	B-X
acid	B-X
bacteria	B-X
isolated	B-X
from	B-X
Amazon	B-X
buffalo	B-X
milk	B-X
Raphaelle	B-X
Borges	B-X
,	B-X
FlÃ¡vio	B-X
Barbosa	B-X
,	B-X
Dayse	B-X
SÃ¡	B-X
O210	B-X
Road	B-X
safety	B-X
for	B-X
children	B-X
:	B-X
Using	B-X
children	B-X
â	B-X
s	B-X
observation	B-X
,	B-X
as	B-X
a	B-X
passenger	B-X
Germana	B-X
Brunhoso	B-X
,	B-X
GraÃ§a	B-X
AparÃ­cio	B-X
,	B-X
AmÃ¢ncio	B-X
Carvalho	B-X
O211	B-X
Perception	B-X
and	B-X
application	B-X
of	B-X
quality-by-design	B-X
by	B-X
the	B-X
Pharmaceutical	B-X
industry	B-X
in	B-X
Portugal	B-X
Ana	B-X
P.	B-X
Garcia	B-X
,	B-X
Paula	B-X
O.	B-X
Fernandes	B-X
,	B-X
Adriana	B-X
Santos	B-X
O212	B-X
Oral	B-X
health	B-X
among	B-X
Portuguese	B-X
children	B-X
and	B-X
adolescents	B-X
:	B-X
a	B-X
public	B-X
health	B-X
issue	B-X
NÃ©lio	B-X
Veiga	B-X
,	B-X
Carina	B-X
BrÃ¡s	B-X
,	B-X
InÃªs	B-X
Carvalho	B-X
,	B-X
Joana	B-X
Batalha	B-X
,	B-X
Margarida	B-X
GlÃ³ria	B-X
,	B-X
Filipa	B-X
Bexiga	B-X
,	B-X
InÃªs	B-X
Coelho	B-X
,	B-X
Odete	B-X
Amaral	B-X
,	B-X
Carlos	B-X
Pereira	B-X
O213	B-X
Plant	B-X
species	B-X
as	B-X
a	B-X
medicinal	B-X
resource	B-X
in	B-X
Igatu-Chapada	B-X
Diamantina	B-X
(	B-X
Bahia	B-X
,	B-X
Brazil	B-X
)	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
Nilson	B-X
ParaÃ­so	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
CristÃ³vÃ£o	B-X
F.	B-X
Lima	B-X
,	B-X
Alberto	B-X
P.	B-X
Dias	B-X
O214	B-X
Characterization	B-X
of	B-X
cognitive	B-X
and	B-X
functional	B-X
performance	B-X
in	B-X
everyday	B-X
tasks	B-X
:	B-X
Implications	B-X
for	B-X
health	B-X
in	B-X
institutionalised	B-X
older	B-X
adults	B-X
Pedro	B-X
Silva	B-X
,	B-X
MÃ¡rio	B-X
Espada	B-X
,	B-X
MÃ¡rio	B-X
Marques	B-X
,	B-X
Ana	B-X
Pereira	B-X
O215	B-X
BMI	B-X
and	B-X
the	B-X
perception	B-X
of	B-X
the	B-X
importance	B-X
given	B-X
to	B-X
sexuality	B-X
in	B-X
obese	B-X
and	B-X
overweight	B-X
people	B-X
Ana	B-X
MÂª	B-X
Pereira	B-X
,	B-X
MÂª	B-X
Veiga-Branco	B-X
,	B-X
Filomena	B-X
Pereira	B-X
,	B-X
Maria	B-X
Ribeiro	B-X
O216	B-X
Analysis	B-X
and	B-X
comparison	B-X
of	B-X
microbiological	B-X
contaminations	B-X
of	B-X
two	B-X
different	B-X
composition	B-X
pacifiers	B-X
Vera	B-X
Lima	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
GraÃ§a	B-X
Cruz	B-X
,	B-X
Rita	B-X
F.	B-X
Oliveira	B-X
,	B-X
LuÃ­sa	B-X
Barreiros	B-X
,	B-X
Fernando	B-X
Moreira	B-X
O217	B-X
Experiences	B-X
of	B-X
couple	B-X
relationships	B-X
in	B-X
the	B-X
transition	B-X
to	B-X
retirement	B-X
Ana	B-X
Camarneiro	B-X
,	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
,	B-X
Margarida	B-X
Silva	B-X
O218	B-X
Preventive	B-X
and	B-X
corrective	B-X
treatment	B-X
of	B-X
drug-induced	B-X
calcium	B-X
deficiency	B-X
:	B-X
an	B-X
analysis	B-X
in	B-X
a	B-X
community	B-X
pharmacy	B-X
setting	B-X
Catarina	B-X
Duarte	B-X
,	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
O219	B-X
Profile	B-X
of	B-X
mood	B-X
states	B-X
in	B-X
physically	B-X
active	B-X
elderly	B-X
subjects	B-X
:	B-X
Is	B-X
there	B-X
a	B-X
relation	B-X
with	B-X
health	B-X
perception	B-X
?	B-X
Maria	B-X
Mota	B-X
,	B-X
Sandra	B-X
Novais	B-X
,	B-X
Paulo	B-X
Nogueira	B-X
,	B-X
Ana	B-X
Pereira	B-X
,	B-X
Lara	B-X
Carneiro	B-X
,	B-X
Paulo	B-X
V.	B-X
JoÃ£o	B-X
O220	B-X
(	B-X
Un	B-X
)	B-X
Safety	B-X
behaviour	B-X
at	B-X
work	B-X
:	B-X
the	B-X
role	B-X
of	B-X
education	B-X
towards	B-X
a	B-X
health	B-X
and	B-X
safety	B-X
culture	B-X
Teresa	B-X
Maneca	B-X
Lima	B-X
O221	B-X
Analysis	B-X
of	B-X
the	B-X
entrepreneurial	B-X
profile	B-X
of	B-X
students	B-X
attending	B-X
higher	B-X
education	B-X
in	B-X
Portugal	B-X
:	B-X
the	B-X
Carland	B-X
Entrepreneurship	B-X
Index	B-X
application	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
,	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
O222	B-X
Evaluation	B-X
of	B-X
welfare	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
of	B-X
pregnant	B-X
working	B-X
women	B-X
regarding	B-X
the	B-X
age	B-X
of	B-X
the	B-X
pregnant	B-X
MarÃ­a	B-X
S.	B-X
Medina	B-X
,	B-X
Valeriana	B-X
G.	B-X
Blanco	B-X
O223	B-X
Psychological	B-X
wellbeing	B-X
protection	B-X
among	B-X
unemployed	B-X
and	B-X
temporary	B-X
workers	B-X
:	B-X
Uncovering	B-X
effective	B-X
community-based	B-X
interventions	B-X
with	B-X
a	B-X
Delphi	B-X
panel	B-X
Osvaldo	B-X
Santos	B-X
,	B-X
Elisa	B-X
Lopes	B-X
,	B-X
Ana	B-X
Virgolino	B-X
,	B-X
Alexandra	B-X
Dinis	B-X
,	B-X
Sara	B-X
AmbrÃ³sio	B-X
,	B-X
InÃªs	B-X
Almeida	B-X
,	B-X
Tatiana	B-X
Marques	B-X
,	B-X
MÂª	B-X
JoÃ£o	B-X
Heitor	B-X
O224	B-X
Chilean	B-X
population	B-X
norms	B-X
derived	B-X
from	B-X
the	B-X
Health-related	B-X
quality	B-X
of	B-X
life	B-X
SF-6D	B-X
Miguel	B-X
A.	B-X
Garcia-Gordillo	B-X
,	B-X
Daniel	B-X
Collado-Mateo	B-X
,	B-X
Pedro	B-X
R.	B-X
Olivares	B-X
,	B-X
JosÃ©	B-X
A.	B-X
ParraÃ§a	B-X
,	B-X
JosÃ©	B-X
A.	B-X
Sala	B-X
O225	B-X
Motivation	B-X
of	B-X
college	B-X
students	B-X
toward	B-X
Entrepreneurship	B-X
:	B-X
The	B-X
influence	B-X
of	B-X
social	B-X
and	B-X
economic	B-X
instability	B-X
AmÃ©lia	B-X
Castilho	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Oliveira	B-X
,	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
O226	B-X
Use	B-X
of	B-X
aromatic	B-X
and	B-X
medicinal	B-X
plants	B-X
,	B-X
drugs	B-X
and	B-X
herbal	B-X
products	B-X
in	B-X
BraganÃ§a	B-X
city	B-X
MÃ³nia	B-X
Cheio	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
,	B-X
OlÃ­via	B-X
R.	B-X
Pereira	B-X
O227	B-X
Edible	B-X
flowers	B-X
as	B-X
new	B-X
novel	B-X
foods	B-X
concept	B-X
for	B-X
health	B-X
promotion	B-X
Sara	B-X
Pinto	B-X
,	B-X
Adriana	B-X
Oliveira	B-X
,	B-X
M.	B-X
ConceiÃ§Ã£o	B-X
Manso	B-X
,	B-X
Carla	B-X
Sousa	B-X
,	B-X
Ana	B-X
F.	B-X
Vinha	B-X
O228	B-X
The	B-X
influence	B-X
of	B-X
leisure	B-X
activities	B-X
on	B-X
the	B-X
health	B-X
and	B-X
welfare	B-X
of	B-X
older	B-X
people	B-X
living	B-X
in	B-X
nursing	B-X
homes	B-X
MÂª	B-X
Manuela	B-X
Machado	B-X
,	B-X
Margarida	B-X
Vieira	B-X
O229	B-X
Risk	B-X
of	B-X
falling	B-X
,	B-X
fear	B-X
of	B-X
falling	B-X
and	B-X
functionality	B-X
in	B-X
community-dwelling	B-X
older	B-X
adults	B-X
Beatriz	B-X
Fernandes	B-X
,	B-X
Teresa	B-X
TomÃ¡s	B-X
,	B-X
Diogo	B-X
Quirino	B-X
O230	B-X
Musculoskeletal	B-X
pain	B-X
and	B-X
postural	B-X
habits	B-X
in	B-X
children	B-X
and	B-X
teenage	B-X
students	B-X
Gustavo	B-X
Desouzart	B-X
,	B-X
Rui	B-X
Matos	B-X
,	B-X
Magali	B-X
Bordini	B-X
,	B-X
Pedro	B-X
MouroÃ§o	B-X
O231	B-X
What	B-X
's	B-X
different	B-X
in	B-X
Southern	B-X
Europe	B-X
?	B-X
Inmaculada	B-X
Z.	B-X
Martin	B-X
,	B-X
Anita	B-X
BjÃ¶rklund	B-X
P105	B-X
Pay-for-performance	B-X
satisfaction	B-X
and	B-X
quality	B-X
in	B-X
primary	B-X
care	B-X
Aida	B-X
I.	B-X
Tavares	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Rui	B-X
Passadouro	B-X
P106	B-X
Economic	B-X
development	B-X
through	B-X
life	B-X
expectancy	B-X
lenses	B-X
SÃ³nia	B-X
Morgado	B-X
P107	B-X
What	B-X
is	B-X
the	B-X
effectiveness	B-X
of	B-X
exercise	B-X
on	B-X
smoking	B-X
cessation	B-X
to	B-X
prevent	B-X
clinical	B-X
complications	B-X
of	B-X
smoking	B-X
?	B-X
Nuno	B-X
Tavares	B-X
,	B-X
JoÃ£o	B-X
Valente	B-X
,	B-X
Anabela	B-X
C.	B-X
Martins	B-X
P108	B-X
A	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
yoga	B-X
on	B-X
mental	B-X
health	B-X
PatrÃ­cia	B-X
AraÃºjo	B-X
,	B-X
Rosina	B-X
Fernandes	B-X
,	B-X
Francisco	B-X
Mendes	B-X
,	B-X
CÃ¡tia	B-X
MagalhÃ£es	B-X
,	B-X
EmÃ­lia	B-X
Martins	B-X
P109	B-X
Healthy	B-X
lifestyle	B-X
:	B-X
comparison	B-X
between	B-X
higher	B-X
education	B-X
students	B-X
that	B-X
lived	B-X
until	B-X
adult	B-X
age	B-X
in	B-X
rural	B-X
and	B-X
urban	B-X
environment	B-X
Pedro	B-X
Mendes	B-X
,	B-X
Rui	B-X
Paulo	B-X
,	B-X
AntÃ³nio	B-X
Faustino	B-X
,	B-X
Helena	B-X
Mesquita	B-X
,	B-X
Samuel	B-X
HonÃ³rio	B-X
,	B-X
Marco	B-X
Batista	B-X
P110	B-X
Evaluation	B-X
of	B-X
the	B-X
Mobile	B-X
Emergency	B-X
Care	B-X
Service	B-X
(	B-X
SAMU	B-X
)	B-X
in	B-X
Brazil	B-X
Josimari	B-X
T.	B-X
Lacerda	B-X
,	B-X
Angela	B-X
B.	B-X
Ortiga	B-X
,	B-X
MÂª	B-X
Cristina	B-X
Calvo	B-X
,	B-X
SÃ´nia	B-X
Natal	B-X
P111	B-X
Bioactive	B-X
compounds	B-X
-	B-X
antioxidant	B-X
activity	B-X
of	B-X
tropical	B-X
fruits	B-X
Marta	B-X
Pereira	B-X
P112	B-X
Use	B-X
of	B-X
non-pharmacological	B-X
methods	B-X
to	B-X
relieve	B-X
pain	B-X
in	B-X
labour	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Ana	B-X
R.	B-X
Prata	B-X
,	B-X
Paula	B-X
Nelas	B-X
,	B-X
JoÃ£o	B-X
Duarte	B-X
P113	B-X
Mechanical	B-X
safety	B-X
of	B-X
pacifiers	B-X
sold	B-X
in	B-X
Portuguese	B-X
pharmacies	B-X
and	B-X
childcare	B-X
stores	B-X
Juliana	B-X
Carneiro	B-X
,	B-X
Ana	B-X
I.	B-X
Oliveira	B-X
,	B-X
ClÃ¡udia	B-X
Pinho	B-X
,	B-X
Cristina	B-X
Couto	B-X
,	B-X
Rita	B-X
F.	B-X
Oliveira	B-X
,	B-X
Fernando	B-X
Moreira	B-X
P114	B-X
The	B-X
importance	B-X
of	B-X
prenatal	B-X
consultation	B-X
:	B-X
Information	B-X
to	B-X
pregnant	B-X
women	B-X
given	B-X
on	B-X
a	B-X
unit	B-X
of	B-X
primary	B-X
care	B-X
Ana	B-X
S.	B-X
Maia	B-X
,	B-X
Michelle	B-X
T.	B-X
Oliveira	B-X
,	B-X
Anderson	B-X
R.	B-X
Sousa	B-X
,	B-X
Paulo	B-X
P.	B-X
Ferreira	B-X
,	B-X
GÃ©ssica	B-X
M.	B-X
Souza	B-X
,	B-X
LÃ­via	B-X
F.	B-X
Almada	B-X
,	B-X
Milena	B-X
A.	B-X
ConceiÃ§Ã£o	B-X
,	B-X
Eujcely	B-X
C.	B-X
Santiago	B-X
P115	B-X
Influence	B-X
of	B-X
different	B-X
backpack	B-X
loading	B-X
conditions	B-X
on	B-X
neck	B-X
and	B-X
lumbar	B-X
muscles	B-X
activity	B-X
of	B-X
elementary	B-X
school	B-X
children	B-X
Sandra	B-X
Rodrigues	B-X
,	B-X
Gabriela	B-X
Domingues	B-X
,	B-X
Irina	B-X
Ferreira	B-X
,	B-X
LuÃ­s	B-X
Faria	B-X
,	B-X
AdÃ©rito	B-X
Seixas	B-X
P116	B-X
Efficacy	B-X
and	B-X
safety	B-X
of	B-X
dry	B-X
extract	B-X
Hedera	B-X
helix	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
productive	B-X
cough	B-X
Ana	B-X
R.	B-X
Costa	B-X
,	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
AmÃ©rico	B-X
Cardoso	B-X
,	B-X
Alexandra	B-X
Meireles	B-X
,	B-X
Armanda	B-X
ColaÃ§o	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
P117	B-X
A	B-X
portrait	B-X
of	B-X
the	B-X
evaluation	B-X
processes	B-X
of	B-X
education	B-X
groups	B-X
in	B-X
primary	B-X
health	B-X
care	B-X
Viviane	B-X
L.	B-X
Vieira	B-X
,	B-X
Kellem	B-X
R.	B-X
Vincha	B-X
,	B-X
Ana	B-X
MÂª	B-X
Cervato-Mancuso	B-X
P118	B-X
Benefits	B-X
of	B-X
vitamins	B-X
C	B-X
and	B-X
E	B-X
in	B-X
sensorineural	B-X
hearing	B-X
loss	B-X
:	B-X
a	B-X
review	B-X
Melissa	B-X
Faria	B-X
,	B-X
ClÃ¡udia	B-X
Reis	B-X
P119	B-X
BODY	B-X
SNAPSHOT	B-X
â	B-X
a	B-X
web-integrated	B-X
anthropometric	B-X
evaluation	B-X
system	B-X
Marco	B-X
P.	B-X
Cova	B-X
,	B-X
Rita	B-X
T.	B-X
Ascenso	B-X
,	B-X
Henrique	B-X
A.	B-X
Almeida	B-X
,	B-X
Eunice	B-X
G.	B-X
Oliveira	B-X
P120	B-X
Anthropometric	B-X
evaluation	B-X
and	B-X
variation	B-X
during	B-X
pregnancy	B-X
Miguel	B-X
Santana	B-X
,	B-X
Rafael	B-X
Pereira	B-X
,	B-X
Eunice	B-X
G.	B-X
Oliveira	B-X
,	B-X
Henrique	B-X
A.	B-X
Almeida	B-X
,	B-X
Rita	B-X
T.	B-X
Ascenso	B-X
P121	B-X
Knowledge	B-X
of	B-X
college	B-X
students	B-X
on	B-X
the	B-X
amendments	B-X
of	B-X
their	B-X
eating	B-X
habits	B-X
and	B-X
physical	B-X
activity	B-X
index	B-X
in	B-X
the	B-X
transition	B-X
to	B-X
higher	B-X
education	B-X
Rita	B-X
Jesus	B-X
,	B-X
Rodrigo	B-X
Tapadas	B-X
,	B-X
Carolina	B-X
Tim-Tim	B-X
,	B-X
Catarina	B-X
Cezanne	B-X
,	B-X
Matilde	B-X
Lagoa	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
,	B-X
Jorge	B-X
Torgal	B-X
P122	B-X
Muscular	B-X
activity	B-X
of	B-X
a	B-X
rally	B-X
race	B-X
car	B-X
driver	B-X
JoÃ£o	B-X
Lopes	B-X
,	B-X
Henrique	B-X
Almeida	B-X
,	B-X
Sandra	B-X
Amado	B-X
,	B-X
LuÃ­s	B-X
CarrÃ£o	B-X
O234	B-X
Literacy	B-X
and	B-X
results	B-X
in	B-X
health	B-X
Madalena	B-X
Cunha	B-X
,	B-X
LuÃ­s	B-X
Saboga-Nunes	B-X
,	B-X
Carlos	B-X
Albuquerque	B-X
,	B-X
OlivÃ©rio	B-X
Ribeiro	B-X
O235	B-X
Literacy	B-X
promotion	B-X
and	B-X
empowerment	B-X
of	B-X
type	B-X
2	B-X
diabetics	B-X
elderly	B-X
in	B-X
four	B-X
family	B-X
health	B-X
units	B-X
of	B-X
the	B-X
group	B-X
of	B-X
health	B-X
centers	B-X
of	B-X
DÃ£o	B-X
LafÃµes	B-X
Suzete	B-X
Oliveira	B-X
,	B-X
MÂª	B-X
Carminda	B-X
Morais	B-X
O236	B-X
Mediterranean	B-X
diet	B-X
,	B-X
health	B-X
and	B-X
life	B-X
quality	B-X
among	B-X
Portuguese	B-X
children	B-X
EmÃ­lia	B-X
Martins	B-X
,	B-X
Francisco	B-X
Mendes	B-X
,	B-X
Rosina	B-X
Fernandes	B-X
,	B-X
CÃ¡tia	B-X
MagalhÃ£es	B-X
,	B-X
PatrÃ­cia	B-X
AraÃºjo	B-X
O237	B-X
Health	B-X
literacy	B-X
,	B-X
from	B-X
data	B-X
to	B-X
action	B-X
-	B-X
translation	B-X
,	B-X
validation	B-X
and	B-X
application	B-X
of	B-X
the	B-X
European	B-X
Health	B-X
Literacy	B-X
Survey	B-X
in	B-X
Portugal	B-X
(	B-X
HLS-EU-PT	B-X
)	B-X
Ana	B-X
R.	B-X
Pedro	B-X
,	B-X
Odete	B-X
Amaral	B-X
,	B-X
Ana	B-X
Escoval	B-X
O238	B-X
Oral	B-X
health	B-X
literacy	B-X
evaluation	B-X
in	B-X
a	B-X
Portuguese	B-X
military	B-X
population	B-X
Victor	B-X
AssunÃ§Ã£o	B-X
,	B-X
Henrique	B-X
LuÃ­s	B-X
,	B-X
LuÃ­s	B-X
LuÃ­s	B-X
O239	B-X
Preferences	B-X
to	B-X
Internet-based	B-X
cognitive	B-X
behavioural	B-X
therapy	B-X
â	B-X
do	B-X
attachment	B-X
orientations	B-X
matter	B-X
?	B-X
Paula	B-X
A.	B-X
Silva	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
,	B-X
Carla	B-X
Carvalho	B-X
O243	B-X
Work-life	B-X
balance	B-X
in	B-X
health	B-X
professionals	B-X
and	B-X
professors	B-X
:	B-X
comparative	B-X
study	B-X
of	B-X
workers	B-X
with	B-X
shift	B-X
work	B-X
and	B-X
fixed	B-X
schedule	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Joana	B-X
Ruivo	B-X
O244	B-X
Technology	B-X
literacy	B-X
in	B-X
self-management	B-X
of	B-X
diabetes	B-X
VÃ¢nia	B-X
Silva	B-X
,	B-X
Paulino	B-X
Sousa	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
O245	B-X
Satisfaction	B-X
with	B-X
therapeutic	B-X
education	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
clinical	B-X
variables	B-X
in	B-X
children	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
Vera	B-X
Ferraz	B-X
,	B-X
GraÃ§a	B-X
AparÃ­cio	B-X
,	B-X
JoÃ£o	B-X
Duarte	B-X
O246	B-X
Nutrition-related	B-X
knowledge	B-X
in	B-X
middle-age	B-X
and	B-X
older	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
Carlos	B-X
Vasconcelos	B-X
,	B-X
AntÃ³nio	B-X
Almeida	B-X
,	B-X
Joel	B-X
Neves	B-X
,	B-X
Telma	B-X
Correia	B-X
,	B-X
Helena	B-X
Amorim	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O247	B-X
Validating	B-X
the	B-X
HLS-EU-	B-X
(	B-X
PT	B-X
)	B-X
questionnaire	B-X
to	B-X
measure	B-X
health	B-X
literacy	B-X
in	B-X
adolescents	B-X
(	B-X
CrAdLiSa	B-X
project	B-X
:	B-X
HLS-EU-PT	B-X
)	B-X
LuÃ­s	B-X
Saboga-Nunes	B-X
,	B-X
Madalena	B-X
Cunha	B-X
,	B-X
Carlos	B-X
Albuquerque	B-X
O248	B-X
Health	B-X
education	B-X
in	B-X
people	B-X
with	B-X
coronary	B-X
heart	B-X
disease	B-X
:	B-X
Experience	B-X
of	B-X
the	B-X
cardiology	B-X
department	B-X
of	B-X
a	B-X
hospital	B-X
on	B-X
the	B-X
outskirts	B-X
of	B-X
Lisbon	B-X
Elsa	B-X
S.	B-X
Pereira	B-X
,	B-X
Leonino	B-X
S.	B-X
Santos	B-X
,	B-X
Ana	B-X
S.	B-X
Reis	B-X
,	B-X
Helena	B-X
R.	B-X
Silva	B-X
,	B-X
JoÃ£o	B-X
Rombo	B-X
,	B-X
Jorge	B-X
C.	B-X
Fernandes	B-X
,	B-X
PatrÃ­cia	B-X
Fernandes	B-X
O249	B-X
Information	B-X
and	B-X
training	B-X
needs	B-X
of	B-X
informal	B-X
caregivers	B-X
of	B-X
individuals	B-X
with	B-X
stroke	B-X
sequelae	B-X
:	B-X
a	B-X
qualitative	B-X
survey	B-X
Jaime	B-X
Ribeiro	B-X
,	B-X
Catarina	B-X
Mangas	B-X
,	B-X
Ana	B-X
Freire	B-X
O250	B-X
Prevention	B-X
of	B-X
psychoactive	B-X
substances	B-X
consumption	B-X
in	B-X
students	B-X
from	B-X
6th	B-X
grade	B-X
of	B-X
Albergaria-a-VelhaÂ´s	B-X
School	B-X
Group	B-X
Sara	B-X
Silva	B-X
,	B-X
Irene	B-X
Francisco	B-X
,	B-X
Ana	B-X
Oliveira	B-X
O251	B-X
Promoting	B-X
healthy	B-X
sexuality	B-X
:	B-X
shared	B-X
responsibility	B-X
for	B-X
family	B-X
,	B-X
youth	B-X
and	B-X
educators	B-X
Helena	B-X
Catarino	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
MÂª	B-X
Clarisse	B-X
Louro	B-X
O252	B-X
Sexual	B-X
risk	B-X
behaviour	B-X
in	B-X
adolescents	B-X
and	B-X
young	B-X
people	B-X
Saudade	B-X
Lopes	B-X
,	B-X
Anjos	B-X
Dixe	B-X
O253	B-X
Knowledge	B-X
of	B-X
school	B-X
staff	B-X
on	B-X
type	B-X
1	B-X
diabetes	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
FÃ¡tima	B-X
Soares	B-X
,	B-X
Ana	B-X
P.	B-X
Oliveira	B-X
,	B-X
Sara	B-X
Gordo	B-X
,	B-X
Teresa	B-X
Kraus	B-X
O254	B-X
Sexual	B-X
health	B-X
in	B-X
adolescents	B-X
:	B-X
the	B-X
impact	B-X
of	B-X
information	B-X
search	B-X
in	B-X
literacy	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Paulo	B-X
QueirÃ³s	B-X
,	B-X
Teresa	B-X
Rodrigues	B-X
P123	B-X
Improving	B-X
basic	B-X
life	B-X
support	B-X
skills	B-X
in	B-X
adolescents	B-X
through	B-X
a	B-X
training	B-X
programme	B-X
Pedro	B-X
Sousa	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Catarina	B-X
LobÃ£o	B-X
P124	B-X
Difficulties	B-X
in	B-X
sexual	B-X
education	B-X
reported	B-X
by	B-X
basic	B-X
education	B-X
teachers	B-X
in	B-X
the	B-X
city	B-X
of	B-X
Foz	B-X
do	B-X
IguaÃ§u	B-X
-	B-X
Brazil	B-X
Cynthia	B-X
B.	B-X
Moura	B-X
,	B-X
Laysa	B-X
C.	B-X
Dreyer	B-X
,	B-X
Vanize	B-X
Meneghetti	B-X
,	B-X
Priscila	B-X
P.	B-X
Cabral	B-X
P125	B-X
Breast	B-X
cancer	B-X
survivors	B-X
:	B-X
subjects	B-X
and	B-X
resources	B-X
for	B-X
information	B-X
.	B-X

Studies	O
,	O
both	O
in	O
human	O
and	O
animal	O
models	O
support	O
the	O
notion	O
that	O
,	O
various	O
angiogenic	O
growth	O
factors	O
and	O
progenitor	O
cells	O
can	O
enhance	O
new	O
blood	O
vessels	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
the	B-X
biologic	B-X
process	B-X
of	B-X
forming	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Undoubtedly	B-X
,	B-X
blood	B-X
vessels	B-X
growth	B-X
regulation	B-X
is	B-X
a	B-X
vital	B-X
aspect	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X
Angiogenesis-dependent	B-X
diseases	B-X
result	B-X
when	B-X
new	B-X
blood	B-X
vessels	B-X
either	B-X
grow	B-X
excessively	B-X
or	B-X
insufficiently	B-X
.	B-X
Myocardial	B-X
ischemia	B-X
both	B-X
acute	B-X
and	B-X
chronic	B-X
has	B-X
been	B-X
clearly	B-X
shown	B-X
to	B-X
stimulate	B-X
angiogenesis	B-X
in	B-X
many	B-X
experimental	B-X
models	B-X
.	B-X
Therapeutic	B-X
angiogenesis	B-X
is	B-X
the	B-X
biological	B-X
agents	B-X
or	B-X
bioactive	B-X
material	B-X
to	B-X
stimulate	B-X
the	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Traditional	B-X
coronary	B-X
revascularization	B-X
therapies	B-X
such	B-X
as	B-X
coronary	B-X
angioplasty	B-X
or	B-X
bypass	B-X
graft	B-X
surgery	B-X
,	B-X
act	B-X
by	B-X
restoring	B-X
blood	B-X
flow	B-X
through	B-X
the	B-X
preexisting	B-X
coronary	B-X
vessels	B-X
.	B-X
Studies	B-X
,	B-X
both	B-X
in	B-X
human	B-X
and	B-X
animal	B-X
models	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
,	B-X
various	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
progenitor	B-X
cells	B-X
can	B-X
enhance	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
,	B-X
recombinant	B-X
proteins	B-X
and	B-X
bone	B-X
marrow	B-X
stem	B-X
cells	B-X
are	B-X
currently	B-X
used	B-X
therapeutic	B-X
stimulators	B-X
for	B-X
angiogenesis	B-X
.	B-X
As	B-X
coronary	B-X
artery	B-X
disease	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
in	B-X
the	B-X
developed	B-X
societies	B-X
and	B-X
also	B-X
an	B-X
emerging	B-X
health	B-X
problem	B-X
in	B-X
developing	B-X
countries	B-X
like	B-X
Bangladesh	B-X
therapeutic	B-X
angiogenesis	B-X
may	B-X
provide	B-X
hope	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
modality	B-X
for	B-X
ischemic	B-X
heart	B-X
disease	B-X
with	B-X
or	B-X
in	B-X
place	B-X
of	B-X
current	B-X
therapies	B-X
.	B-X

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
,	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
FGF	B-Gene_or_gene_product
)	O
,	O
recombinant	O
proteins	O
and	O
bone	O
marrow	O
stem	O
cells	O
are	O
currently	O
used	O
therapeutic	O
stimulators	O
for	O
angiogenesis	O
.	O
<EOS>	B-X
Undoubtedly	B-X
,	B-X
blood	B-X
vessels	B-X
growth	B-X
regulation	B-X
is	B-X
a	B-X
vital	B-X
aspect	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X
Under	B-X
physiological	B-X
conditions	B-X
,	B-X
angiogenesis	B-X
is	B-X
regulated	B-X
by	B-X
local	B-X
balance	B-X
between	B-X
endogenous	B-X
stimulators	B-X
and	B-X
inhibitors	B-X
of	B-X
this	B-X
process	B-X
.	B-X
In	B-X
many	B-X
diseases	B-X
state	B-X
body	B-X
loses	B-X
control	B-X
over	B-X
angiogenesis	B-X
.	B-X
Insufficient	B-X
angiogenesis	B-X
occurs	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
coronary	B-X
artery	B-X
disease	B-X
,	B-X
stroke	B-X
and	B-X
chronic	B-X
wounds	B-X
.	B-X
Myocardial	B-X
ischemia	B-X
both	B-X
acute	B-X
and	B-X
chronic	B-X
has	B-X
been	B-X
clearly	B-X
shown	B-X
to	B-X
stimulate	B-X
angiogenesis	B-X
in	B-X
many	B-X
experimental	B-X
models	B-X
.	B-X
Therapeutic	B-X
angiogenesis	B-X
is	B-X
the	B-X
biological	B-X
agents	B-X
or	B-X
bioactive	B-X
material	B-X
to	B-X
stimulate	B-X
the	B-X
growth	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
therapeutic	B-X
angiogenesis	B-X
is	B-X
based	B-X
on	B-X
the	B-X
concept	B-X
that	B-X
coronary	B-X
collateral	B-X
development	B-X
may	B-X
be	B-X
stimulated	B-X
by	B-X
pharmacological	B-X
or	B-X
molecular	B-X
means	B-X
and	B-X
can	B-X
limit	B-X
myocardial	B-X
ischemia	B-X
.	B-X
Studies	B-X
,	B-X
both	B-X
in	B-X
human	B-X
and	B-X
animal	B-X
models	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
,	B-X
various	B-X
angiogenic	B-X
growth	B-X
factors	B-X
and	B-X
progenitor	B-X
cells	B-X
can	B-X
enhance	B-X
new	B-X
blood	B-X
vessels	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
FGF	B-X
)	B-X
,	B-X
recombinant	B-X
proteins	B-X
and	B-X
bone	B-X
marrow	B-X
stem	B-X
cells	B-X
are	B-X
currently	B-X
used	B-X
therapeutic	B-X
stimulators	B-X
for	B-X
angiogenesis	B-X
.	B-X
As	B-X
coronary	B-X
artery	B-X
disease	B-X
is	B-X
the	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
in	B-X
the	B-X
developed	B-X
societies	B-X
and	B-X
also	B-X
an	B-X
emerging	B-X
health	B-X
problem	B-X
in	B-X
developing	B-X
countries	B-X
like	B-X
Bangladesh	B-X
therapeutic	B-X
angiogenesis	B-X
may	B-X
provide	B-X
hope	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
modality	B-X
for	B-X
ischemic	B-X
heart	B-X
disease	B-X
with	B-X
or	B-X
in	B-X
place	B-X
of	B-X
current	B-X
therapies	B-X
.	B-X

As	O
coronary	O
artery	O
disease	O
is	O
the	O
major	O
cause	O
of	O
death	O
in	O
the	O
developed	O
societies	O
and	O
also	O
an	O
emerging	O
health	O
problem	O
in	O
developing	O
countries	O
like	O
Bangladesh	O
therapeutic	O
angiogenesis	O
may	O
provide	O
hope	O
as	O
a	O
new	O
treatment	O
modality	O
for	O
ischemic	O
heart	O
disease	O
with	O
or	O
in	O
place	O
of	O
current	O
therapies	O
.	O
<EOS>	B-X
Neuromodulation	B-X
is	B-X
an	B-X
expanding	B-X
area	B-X
of	B-X
pain	B-X
medicine	B-X
that	B-X
incorporates	B-X
an	B-X
array	B-X
of	B-X
non-invasive	B-X
,	B-X
minimally	B-X
invasive	B-X
,	B-X
and	B-X
surgical	B-X
electrical	B-X
therapies	B-X
.	B-X
In	B-X
this	B-X
Series	B-X
paper	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
spinal	B-X
cord	B-X
stimulation	B-X
(	B-X
SCS	B-X
)	B-X
therapies	B-X
discussed	B-X
within	B-X
the	B-X
framework	B-X
of	B-X
other	B-X
invasive	B-X
,	B-X
minimally	B-X
invasive	B-X
,	B-X
and	B-X
non-invasive	B-X
neuromodulation	B-X
therapies	B-X
.	B-X
These	B-X
therapies	B-X
include	B-X
deep	B-X
brain	B-X
and	B-X
motor	B-X
cortex	B-X
stimulation	B-X
,	B-X
peripheral	B-X
nerve	B-X
stimulation	B-X
,	B-X
and	B-X
the	B-X
non-invasive	B-X
treatments	B-X
of	B-X
repetitive	B-X
transcranial	B-X
magnetic	B-X
stimulation	B-X
,	B-X
transcranial	B-X
direct	B-X
current	B-X
stimulation	B-X
,	B-X
and	B-X
transcutaneous	B-X
electrical	B-X
nerve	B-X
stimulation	B-X
.	B-X
Although	B-X
methods	B-X
devoid	B-X
of	B-X
paraesthesias	B-X
(	B-X
eg	B-X
,	B-X
high	B-X
frequency	B-X
)	B-X
should	B-X
theoretically	B-X
allow	B-X
for	B-X
placebo-controlled	B-X
trials	B-X
,	B-X
few	B-X
have	B-X
been	B-X
done	B-X
.	B-X
Peripheral	B-X
nerve	B-X
stimulation	B-X
technologies	B-X
have	B-X
also	B-X
undergone	B-X
rapid	B-X
development	B-X
and	B-X
become	B-X
less	B-X
invasive	B-X
,	B-X
including	B-X
many	B-X
that	B-X
are	B-X
placed	B-X
percutaneously	B-X
.	B-X
Regarding	B-X
non-invasive	B-X
modalities	B-X
,	B-X
there	B-X
is	B-X
moderate	B-X
quality	B-X
evidence	B-X
that	B-X
repetitive	B-X
transcranial	B-X
magnetic	B-X
stimulation	B-X
does	B-X
not	B-X
provide	B-X
meaningful	B-X
benefit	B-X
for	B-X
chronic	B-X
pain	B-X
in	B-X
general	B-X
,	B-X
but	B-X
conflicting	B-X
evidence	B-X
regarding	B-X
pain	B-X
relief	B-X
for	B-X
neuropathic	B-X
pain	B-X
and	B-X
headaches	B-X
.	B-X
For	B-X
transcranial	B-X
direct	B-X
current	B-X
stimulation	B-X
,	B-X
there	B-X
is	B-X
low-quality	B-X
evidence	B-X
supporting	B-X
its	B-X
benefit	B-X
for	B-X
chronic	B-X
pain	B-X
,	B-X
but	B-X
conflicting	B-X
evidence	B-X
regarding	B-X
a	B-X
small	B-X
treatment	B-X
effect	B-X
for	B-X
neuropathic	B-X
pain	B-X
and	B-X
headaches	B-X
.	B-X
For	B-X
transcutaneous	B-X
electrical	B-X
nerve	B-X
stimulation	B-X
,	B-X
there	B-X
is	B-X
low-quality	B-X
evidence	B-X
that	B-X
it	B-X
is	B-X
superior	B-X
to	B-X
sham	B-X
or	B-X
no	B-X
treatment	B-X
for	B-X
neuropathic	B-X
pain	B-X
,	B-X
but	B-X
conflicting	B-X
evidence	B-X
for	B-X
non-neuropathic	B-X
pain	B-X
.	B-X
Future	B-X
research	B-X
should	B-X
focus	B-X
on	B-X
better	B-X
evaluating	B-X
the	B-X
short-term	B-X
and	B-X
long-term	B-X
effectiveness	B-X
of	B-X
all	B-X
neuromodulation	B-X
modalities	B-X
and	B-X
whether	B-X
they	B-X
decrease	B-X
health-care	B-X
use	B-X
,	B-X
and	B-X
on	B-X
refining	B-X
selection	B-X
criteria	B-X
and	B-X
treatment	B-X
variables	B-X
.	B-X

Use	O
of	O
uteroglobin	B-Gene_or_gene_product
for	O
the	O
engineering	O
of	O
polyvalent	O
,	O
polyspecific	O
fusion	O
proteins	O
.	O
<EOS>	B-X
We	B-X
report	B-X
a	B-X
novel	B-X
strategy	B-X
to	B-X
engineer	B-X
and	B-X
express	B-X
stable	B-X
and	B-X
soluble	B-X
human	B-X
recombinant	B-X
polyvalent/polyspecific	B-X
fusion	B-X
proteins	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
the	B-X
use	B-X
of	B-X
a	B-X
central	B-X
skeleton	B-X
of	B-X
uteroglobin	B-X
,	B-X
a	B-X
small	B-X
and	B-X
very	B-X
soluble	B-X
covalently	B-X
linked	B-X
homodimeric	B-X
protein	B-X
that	B-X
is	B-X
very	B-X
resistant	B-X
to	B-X
proteolytic	B-X
enzymes	B-X
and	B-X
to	B-X
pH	B-X
variations	B-X
.	B-X
Using	B-X
a	B-X
human	B-X
recombinant	B-X
antibody	B-X
(	B-X
scFv	B-X
)	B-X
specific	B-X
for	B-X
the	B-X
angiogenesis	B-X
marker	B-X
domain	B-X
B	B-X
of	B-X
fibronectin	B-X
,	B-X
interleukin	B-X
2	B-X
,	B-X
and	B-X
an	B-X
scFv	B-X
able	B-X
to	B-X
neutralize	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
we	B-X
expressed	B-X
various	B-X
biologically	B-X
active	B-X
uteroglobin	B-X
fusion	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
similar	B-X
fusion	B-X
proteins	B-X
in	B-X
which	B-X
uteroglobin	B-X
was	B-X
not	B-X
used	B-X
,	B-X
the	B-X
use	B-X
of	B-X
uteroglobin	B-X
improved	B-X
properties	B-X
of	B-X
solubility	B-X
and	B-X
stability	B-X
.	B-X
Indeed	B-X
,	B-X
in	B-X
the	B-X
reported	B-X
cases	B-X
it	B-X
was	B-X
possible	B-X
to	B-X
vacuum	B-X
dry	B-X
and	B-X
reconstitute	B-X
the	B-X
proteins	B-X
without	B-X
any	B-X
aggregation	B-X
or	B-X
loss	B-X
in	B-X
protein	B-X
and	B-X
biological	B-X
activity	B-X
.	B-X

We	O
report	O
a	O
novel	O
strategy	O
to	O
engineer	O
and	O
express	O
stable	O
and	O
soluble	O
human	O
recombinant	O
polyvalent	O
/	O
polyspecific	O
fusion	O
proteins	O
.	O
<EOS>	B-X
We	B-X
report	B-X
a	B-X
novel	B-X
strategy	B-X
to	B-X
engineer	B-X
and	B-X
express	B-X
stable	B-X
and	B-X
soluble	B-X
human	B-X
recombinant	B-X
polyvalent/polyspecific	B-X
fusion	B-X
proteins	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
the	B-X
use	B-X
of	B-X
a	B-X
central	B-X
skeleton	B-X
of	B-X
uteroglobin	B-X
,	B-X
a	B-X
small	B-X
and	B-X
very	B-X
soluble	B-X
covalently	B-X
linked	B-X
homodimeric	B-X
protein	B-X
that	B-X
is	B-X
very	B-X
resistant	B-X
to	B-X
proteolytic	B-X
enzymes	B-X
and	B-X
to	B-X
pH	B-X
variations	B-X
.	B-X
Using	B-X
a	B-X
human	B-X
recombinant	B-X
antibody	B-X
(	B-X
scFv	B-X
)	B-X
specific	B-X
for	B-X
the	B-X
angiogenesis	B-X
marker	B-X
domain	B-X
B	B-X
of	B-X
fibronectin	B-X
,	B-X
interleukin	B-X
2	B-X
,	B-X
and	B-X
an	B-X
scFv	B-X
able	B-X
to	B-X
neutralize	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
we	B-X
expressed	B-X
various	B-X
biologically	B-X
active	B-X
uteroglobin	B-X
fusion	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
similar	B-X
fusion	B-X
proteins	B-X
in	B-X
which	B-X
uteroglobin	B-X
was	B-X
not	B-X
used	B-X
,	B-X
the	B-X
use	B-X
of	B-X
uteroglobin	B-X
improved	B-X
properties	B-X
of	B-X
solubility	B-X
and	B-X
stability	B-X
.	B-X
Indeed	B-X
,	B-X
in	B-X
the	B-X
reported	B-X
cases	B-X
it	B-X
was	B-X
possible	B-X
to	B-X
vacuum	B-X
dry	B-X
and	B-X
reconstitute	B-X
the	B-X
proteins	B-X
without	B-X
any	B-X
aggregation	B-X
or	B-X
loss	B-X
in	B-X
protein	B-X
and	B-X
biological	B-X
activity	B-X
.	B-X

The	O
procedure	O
is	O
based	O
on	O
the	O
use	O
of	O
a	O
central	O
skeleton	O
of	O
uteroglobin	B-Gene_or_gene_product
,	O
a	O
small	O
and	O
very	O
soluble	O
covalently	O
linked	O
homodimeric	O
protein	O
that	O
is	O
very	O
resistant	O
to	O
proteolytic	O
enzymes	O
and	O
to	O
pH	O
variations	O
.	O
<EOS>	B-X
We	B-X
report	B-X
a	B-X
novel	B-X
strategy	B-X
to	B-X
engineer	B-X
and	B-X
express	B-X
stable	B-X
and	B-X
soluble	B-X
human	B-X
recombinant	B-X
polyvalent/polyspecific	B-X
fusion	B-X
proteins	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
the	B-X
use	B-X
of	B-X
a	B-X
central	B-X
skeleton	B-X
of	B-X
uteroglobin	B-X
,	B-X
a	B-X
small	B-X
and	B-X
very	B-X
soluble	B-X
covalently	B-X
linked	B-X
homodimeric	B-X
protein	B-X
that	B-X
is	B-X
very	B-X
resistant	B-X
to	B-X
proteolytic	B-X
enzymes	B-X
and	B-X
to	B-X
pH	B-X
variations	B-X
.	B-X
Using	B-X
a	B-X
human	B-X
recombinant	B-X
antibody	B-X
(	B-X
scFv	B-X
)	B-X
specific	B-X
for	B-X
the	B-X
angiogenesis	B-X
marker	B-X
domain	B-X
B	B-X
of	B-X
fibronectin	B-X
,	B-X
interleukin	B-X
2	B-X
,	B-X
and	B-X
an	B-X
scFv	B-X
able	B-X
to	B-X
neutralize	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
we	B-X
expressed	B-X
various	B-X
biologically	B-X
active	B-X
uteroglobin	B-X
fusion	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
similar	B-X
fusion	B-X
proteins	B-X
in	B-X
which	B-X
uteroglobin	B-X
was	B-X
not	B-X
used	B-X
,	B-X
the	B-X
use	B-X
of	B-X
uteroglobin	B-X
improved	B-X
properties	B-X
of	B-X
solubility	B-X
and	B-X
stability	B-X
.	B-X
Indeed	B-X
,	B-X
in	B-X
the	B-X
reported	B-X
cases	B-X
it	B-X
was	B-X
possible	B-X
to	B-X
vacuum	B-X
dry	B-X
and	B-X
reconstitute	B-X
the	B-X
proteins	B-X
without	B-X
any	B-X
aggregation	B-X
or	B-X
loss	B-X
in	B-X
protein	B-X
and	B-X
biological	B-X
activity	B-X
.	B-X

Using	O
a	O
human	O
recombinant	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
angiogenesis	O
marker	O
domain	O
B	O
of	O
fibronectin	B-Gene_or_gene_product
,	O
interleukin	B-Gene_or_gene_product
2	I-Gene_or_gene_product
,	O
and	O
an	O
scFv	O
able	O
to	O
neutralize	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
,	O
we	O
expressed	O
various	O
biologically	O
active	O
uteroglobin	B-Gene_or_gene_product
fusion	O
proteins	O
.	O

The	O
results	O
demonstrate	O
the	O
possibility	O
to	O
generate	O
monospecific	O
divalent	O
and	O
tetravalent	O
antibodies	O
,	O
immunocytokines	O
,	O
and	O
dual	O
specificity	O
tetravalent	O
antibodies	O
.	O
<EOS>	B-X
The	B-X
results	B-X
demonstrate	B-X
the	B-X
possibility	B-X
to	B-X
generate	B-X
monospecific	B-X
divalent	B-X
and	B-X
tetravalent	B-X
antibodies	B-X
,	B-X
immunocytokines	B-X
,	B-X
and	B-X
dual	B-X
specificity	B-X
tetravalent	B-X
antibodies	B-X
.	B-X

Furthermore	O
,	O
compared	O
with	O
similar	O
fusion	O
proteins	O
in	O
which	O
uteroglobin	B-Gene_or_gene_product
was	O
not	O
used	O
,	O
the	O
use	O
of	O
uteroglobin	B-Gene_or_gene_product
improved	O
properties	O
of	O
solubility	O
and	O
stability	O
.	O

Indeed	O
,	O
in	O
the	O
reported	O
cases	O
it	O
was	O
possible	O
to	O
vacuum	O
dry	O
and	O
reconstitute	O
the	O
proteins	O
without	O
any	O
aggregation	O
or	O
loss	O
in	O
protein	O
and	O
biological	O
activity	O
.	O
<EOS>	B-X
The	B-X
term	B-X
was	B-X
first	B-X
used	B-X
to	B-X
designate	B-X
the	B-X
loss	B-X
of	B-X
muscle	B-X
mass	B-X
and	B-X
performance	B-X
associated	B-X
with	B-X
aging	B-X
.	B-X
Now	B-X
,	B-X
recognized	B-X
causes	B-X
of	B-X
sarcopenia	B-X
also	B-X
include	B-X
chronic	B-X
disease	B-X
,	B-X
a	B-X
physically	B-X
inactive	B-X
lifestyle	B-X
,	B-X
loss	B-X
of	B-X
mobility	B-X
,	B-X
and	B-X
malnutrition	B-X
.	B-X
Sarcopenia	B-X
should	B-X
be	B-X
differentiated	B-X
from	B-X
cachexia	B-X
,	B-X
which	B-X
is	B-X
characterized	B-X
not	B-X
only	B-X
by	B-X
low	B-X
muscle	B-X
mass	B-X
but	B-X
also	B-X
by	B-X
weight	B-X
loss	B-X
and	B-X
anorexia	B-X
.	B-X
Sarcopenia	B-X
results	B-X
from	B-X
complex	B-X
and	B-X
interdependent	B-X
pathophysiological	B-X
mechanisms	B-X
that	B-X
include	B-X
aging	B-X
,	B-X
physical	B-X
inactivity	B-X
,	B-X
neuromuscular	B-X
compromise	B-X
,	B-X
resistance	B-X
to	B-X
postprandial	B-X
anabolism	B-X
,	B-X
insulin	B-X
resistance	B-X
,	B-X
lipotoxicity	B-X
,	B-X
endocrine	B-X
factors	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
mitochondrial	B-X
dysfunction	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X
The	B-X
management	B-X
of	B-X
sarcopenia	B-X
requires	B-X
a	B-X
multimodal	B-X
approach	B-X
combining	B-X
a	B-X
sufficient	B-X
intake	B-X
of	B-X
high-quality	B-X
protein	B-X
and	B-X
fatty	B-X
acids	B-X
,	B-X
physical	B-X
exercise	B-X
,	B-X
and	B-X
antiinflammatory	B-X
medications	B-X
.	B-X

Netrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
up	O
-	O
regulation	O
in	O
inflammatory	O
bowel	O
diseases	O
is	O
required	O
for	O
colorectal	O
cancer	O
progression	O
.	O
<EOS>	B-X
Chronic	B-X
inflammation	B-X
and	B-X
cancer	B-X
are	B-X
intimately	B-X
associated	B-X
.	B-X
This	B-X
is	B-X
particularly	B-X
true	B-X
for	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
(	B-X
IBD	B-X
)	B-X
,	B-X
such	B-X
as	B-X
ulcerative	B-X
colitis	B-X
and	B-X
Crohn	B-X
's	B-X
disease	B-X
,	B-X
which	B-X
show	B-X
a	B-X
major	B-X
increased	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
.	B-X
While	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
IBD	B-X
has	B-X
recently	B-X
improved	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
these	B-X
chronic	B-X
inflammatory	B-X
states	B-X
to	B-X
colorectal	B-X
cancer	B-X
development	B-X
are	B-X
in	B-X
large	B-X
part	B-X
unknown	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
observation	B-X
that	B-X
netrin-1	B-X
,	B-X
the	B-X
anti-apoptotic	B-X
ligand	B-X
for	B-X
the	B-X
dependence	B-X
receptors	B-X
DCC	B-X
and	B-X
UNC5H	B-X
is	B-X
up-regulated	B-X
in	B-X
colonic	B-X
crypts	B-X
in	B-X
response	B-X
to	B-X
NF-kappaB	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
colorectal	B-X
cancers	B-X
from	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
patients	B-X
have	B-X
selected	B-X
up-regulation	B-X
of	B-X
netrin-1	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
this	B-X
inflammation-driven	B-X
netrin-1	B-X
up-regulation	B-X
is	B-X
causal	B-X
for	B-X
colorectal	B-X
cancer	B-X
development	B-X
as	B-X
interference	B-X
with	B-X
netrin-1	B-X
autocrine	B-X
loop	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
for	B-X
ulcerative	B-X
colitis-associated	B-X
colorectal	B-X
cancer	B-X
,	B-X
while	B-X
showing	B-X
no	B-X
effect	B-X
on	B-X
inflammation	B-X
,	B-X
inhibits	B-X
colorectal	B-X
cancer	B-X
progression	B-X
.	B-X

Chronic	O
inflammation	O
and	O
cancer	O
are	O
intimately	O
associated	O
.	O
<EOS>	B-X
It	B-X
is	B-X
also	B-X
intimately	B-X
linked	B-X
with	B-X
the	B-X
progression	B-X
of	B-X
COVID-19	B-X
disease	B-X
as	B-X
well	B-X
as	B-X
associated	B-X
complications	B-X
and	B-X
mortality	B-X
.	B-X
Therefore	B-X
,	B-X
targeting	B-X
the	B-X
cytokine	B-X
storm	B-X
might	B-X
help	B-X
in	B-X
reducing	B-X
COVID-19-associated	B-X
health	B-X
complications	B-X
.	B-X
The	B-X
number	B-X
of	B-X
COVID-19	B-X
associated	B-X
deaths	B-X
(	B-X
as	B-X
of	B-X
January	B-X
15	B-X
,	B-X
2021	B-X
;	B-X
https	B-X
:	B-X
//www.worldometers.info/coronavirus/	B-X
)	B-X
in	B-X
the	B-X
USA	B-X
is	B-X
high	B-X
(	B-X
1199/million	B-X
)	B-X
as	B-X
compared	B-X
to	B-X
countries	B-X
like	B-X
India	B-X
(	B-X
110/million	B-X
)	B-X
.	B-X
Recent	B-X
evidence	B-X
has	B-X
accumulated	B-X
that	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
intimately	B-X
intertwined	B-X
with	B-X
cancer	B-X
development	B-X
.	B-X
Two	B-X
key	B-X
characteristics	B-X
of	B-X
carcinogens	B-X
in	B-X
which	B-X
the	B-X
immune	B-X
system	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
are	B-X
chronic	B-X
inflammation	B-X
and	B-X
immunosuppression	B-X
.	B-X
Benzene	B-X
has	B-X
been	B-X
confirmed	B-X
to	B-X
cause	B-X
acute	B-X
myeloid	B-X
leukaemia	B-X
and	B-X
suspected	B-X
to	B-X
cause	B-X
non-Hodgkin	B-X
lymphoma	B-X
,	B-X
two	B-X
cancers	B-X
of	B-X
the	B-X
blood-forming	B-X
system	B-X
that	B-X
affect	B-X
immune	B-X
cells	B-X
.	B-X

This	O
is	O
particularly	O
true	O
for	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
,	O
such	O
as	O
ulcerative	O
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
,	O
which	O
show	O
a	O
major	O
increased	O
risk	O
for	O
colorectal	O
cancer	O
.	O

While	O
the	O
understanding	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
IBD	O
has	O
recently	O
improved	O
,	O
the	O
mechanisms	O
that	O
link	O
these	O
chronic	O
inflammatory	O
states	O
to	O
colorectal	O
cancer	O
development	O
are	O
in	O
large	O
part	O
unknown	O
.	O
<EOS>	B-X
Chronic	B-X
inflammation	B-X
and	B-X
cancer	B-X
are	B-X
intimately	B-X
associated	B-X
.	B-X
This	B-X
is	B-X
particularly	B-X
true	B-X
for	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
(	B-X
IBD	B-X
)	B-X
,	B-X
such	B-X
as	B-X
ulcerative	B-X
colitis	B-X
and	B-X
Crohn	B-X
's	B-X
disease	B-X
,	B-X
which	B-X
show	B-X
a	B-X
major	B-X
increased	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
.	B-X
While	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
IBD	B-X
has	B-X
recently	B-X
improved	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
these	B-X
chronic	B-X
inflammatory	B-X
states	B-X
to	B-X
colorectal	B-X
cancer	B-X
development	B-X
are	B-X
in	B-X
large	B-X
part	B-X
unknown	B-X
.	B-X
One	B-X
of	B-X
these	B-X
mechanisms	B-X
is	B-X
NF-kappaB	B-X
pathway	B-X
activation	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
contribute	B-X
to	B-X
tumor	B-X
formation	B-X
by	B-X
providing	B-X
anti-apoptotic	B-X
survival	B-X
signals	B-X
to	B-X
the	B-X
epithelial	B-X
cells	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
observation	B-X
that	B-X
netrin-1	B-X
,	B-X
the	B-X
anti-apoptotic	B-X
ligand	B-X
for	B-X
the	B-X
dependence	B-X
receptors	B-X
DCC	B-X
and	B-X
UNC5H	B-X
is	B-X
up-regulated	B-X
in	B-X
colonic	B-X
crypts	B-X
in	B-X
response	B-X
to	B-X
NF-kappaB	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
colorectal	B-X
cancers	B-X
from	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
patients	B-X
have	B-X
selected	B-X
up-regulation	B-X
of	B-X
netrin-1	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
this	B-X
inflammation-driven	B-X
netrin-1	B-X
up-regulation	B-X
is	B-X
causal	B-X
for	B-X
colorectal	B-X
cancer	B-X
development	B-X
as	B-X
interference	B-X
with	B-X
netrin-1	B-X
autocrine	B-X
loop	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
for	B-X
ulcerative	B-X
colitis-associated	B-X
colorectal	B-X
cancer	B-X
,	B-X
while	B-X
showing	B-X
no	B-X
effect	B-X
on	B-X
inflammation	B-X
,	B-X
inhibits	B-X
colorectal	B-X
cancer	B-X
progression	B-X
.	B-X

One	O
of	O
these	O
mechanisms	O
is	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
pathway	O
activation	O
which	O
in	O
turn	O
may	O
contribute	O
to	O
tumor	O
formation	O
by	O
providing	O
anti	O
-	O
apoptotic	O
survival	O
signals	O
to	O
the	O
epithelial	O
cells	O
.	O

Based	O
on	O
the	O
observation	O
that	O
netrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
the	O
anti	O
-	O
apoptotic	O
ligand	O
for	O
the	O
dependence	O
receptors	O
DCC	B-Gene_or_gene_product
and	O
UNC5H	B-Gene_or_gene_product
is	O
up	O
-	O
regulated	O
in	O
colonic	O
crypts	O
in	O
response	O
to	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	I-Gene_or_gene_product
,	O
we	O
show	O
here	O
that	O
colorectal	O
cancers	O
from	O
inflammatory	O
bowel	O
diseases	O
patients	O
have	O
selected	O
up	O
-	O
regulation	O
of	O
netrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
This	B-X
is	B-X
particularly	B-X
true	B-X
for	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
(	B-X
IBD	B-X
)	B-X
,	B-X
such	B-X
as	B-X
ulcerative	B-X
colitis	B-X
and	B-X
Crohn	B-X
's	B-X
disease	B-X
,	B-X
which	B-X
show	B-X
a	B-X
major	B-X
increased	B-X
risk	B-X
for	B-X
colorectal	B-X
cancer	B-X
.	B-X
While	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
IBD	B-X
has	B-X
recently	B-X
improved	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
these	B-X
chronic	B-X
inflammatory	B-X
states	B-X
to	B-X
colorectal	B-X
cancer	B-X
development	B-X
are	B-X
in	B-X
large	B-X
part	B-X
unknown	B-X
.	B-X
One	B-X
of	B-X
these	B-X
mechanisms	B-X
is	B-X
NF-kappaB	B-X
pathway	B-X
activation	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
contribute	B-X
to	B-X
tumor	B-X
formation	B-X
by	B-X
providing	B-X
anti-apoptotic	B-X
survival	B-X
signals	B-X
to	B-X
the	B-X
epithelial	B-X
cells	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
observation	B-X
that	B-X
netrin-1	B-X
,	B-X
the	B-X
anti-apoptotic	B-X
ligand	B-X
for	B-X
the	B-X
dependence	B-X
receptors	B-X
DCC	B-X
and	B-X
UNC5H	B-X
is	B-X
up-regulated	B-X
in	B-X
colonic	B-X
crypts	B-X
in	B-X
response	B-X
to	B-X
NF-kappaB	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
colorectal	B-X
cancers	B-X
from	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
patients	B-X
have	B-X
selected	B-X
up-regulation	B-X
of	B-X
netrin-1	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
this	B-X
inflammation-driven	B-X
netrin-1	B-X
up-regulation	B-X
is	B-X
causal	B-X
for	B-X
colorectal	B-X
cancer	B-X
development	B-X
as	B-X
interference	B-X
with	B-X
netrin-1	B-X
autocrine	B-X
loop	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
for	B-X
ulcerative	B-X
colitis-associated	B-X
colorectal	B-X
cancer	B-X
,	B-X
while	B-X
showing	B-X
no	B-X
effect	B-X
on	B-X
inflammation	B-X
,	B-X
inhibits	B-X
colorectal	B-X
cancer	B-X
progression	B-X
.	B-X

Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inflammation	O
-	O
driven	O
netrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
up	O
-	O
regulation	O
is	O
causal	O
for	O
colorectal	O
cancer	O
development	O
as	O
interference	O
with	O
netrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
autocrine	O
loop	O
in	O
a	O
mouse	O
model	O
for	O
ulcerative	O
colitis	O
-	O
associated	O
colorectal	O
cancer	O
,	O
while	O
showing	O
no	O
effect	O
on	O
inflammation	O
,	O
inhibits	O
colorectal	O
cancer	O
progression	O
.	O

[	O
Prognostic	O
significance	O
of	O
cellular	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
expression	O
in	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
]	O
<EOS>	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
is	B-X
unknown	B-X
.	B-X
By	B-X
radioimmunoassay	B-X
,	B-X
we	B-X
measured	B-X
pretreatment	B-X
cellular	B-X
VEGF	B-X
protein	B-X
in	B-X
bone	B-X
marrow	B-X
samples	B-X
from	B-X
184	B-X
(	B-X
148	B-X
chronic	B-X
and	B-X
36	B-X
accelerated/blastic	B-X
phases	B-X
)	B-X
CML	B-X
patients	B-X
and	B-X
found	B-X
the	B-X
levels	B-X
to	B-X
be	B-X
1.6-fold	B-X
higher	B-X
than	B-X
in	B-X
31	B-X
normal	B-X
control	B-X
bone	B-X
marrow	B-X
samples	B-X
(	B-X
P	B-X
=.000	B-X
01	B-X
)	B-X
.	B-X
No	B-X
significant	B-X
differences	B-X
were	B-X
found	B-X
in	B-X
VEGF	B-X
levels	B-X
by	B-X
different	B-X
phases	B-X
of	B-X
CML	B-X
(	B-X
P	B-X
=.1	B-X
)	B-X
.	B-X
VEGF	B-X
levels	B-X
correlated	B-X
with	B-X
older	B-X
age	B-X
(	B-X
P	B-X
=.01	B-X
)	B-X
and	B-X
higher	B-X
platelet	B-X
count	B-X
(	B-X
P	B-X
=.0003	B-X
)	B-X
,	B-X
but	B-X
also	B-X
with	B-X
smaller	B-X
spleen	B-X
size	B-X
(	B-X
P	B-X
=.004	B-X
)	B-X
,	B-X
lower	B-X
white	B-X
blood	B-X
cell	B-X
count	B-X
(	B-X
P	B-X
=.0006	B-X
)	B-X
,	B-X
and	B-X
lower	B-X
percentage	B-X
of	B-X
peripheral	B-X
blasts	B-X
(	B-X
P	B-X
=.04	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
Cox	B-X
proportional	B-X
hazard	B-X
model	B-X
and	B-X
VEGF	B-X
levels	B-X
as	B-X
a	B-X
continuous	B-X
variable	B-X
,	B-X
high	B-X
VEGF	B-X
levels	B-X
correlated	B-X
with	B-X
shorter	B-X
survival	B-X
of	B-X
patients	B-X
in	B-X
chronic	B-X
CML	B-X
(	B-X
P	B-X
=.008	B-X
)	B-X
.	B-X
Multivariate	B-X
analysis	B-X
showed	B-X
that	B-X
VEGF	B-X
was	B-X
not	B-X
independent	B-X
of	B-X
the	B-X
synthesis	B-X
stage	B-X
(	B-X
P	B-X
=.09	B-X
)	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
VEGF	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
biology	B-X
of	B-X
CML	B-X
and	B-X
that	B-X
VEGF	B-X
inhibitors	B-X
should	B-X
be	B-X
investigated	B-X
in	B-X
CML	B-X
.	B-X

INTRODUCTION	O
:	O
Increased	O
angiogenesis	O
in	O
bone	O
marrow	O
is	O
one	O
of	O
the	O
characteristics	O
of	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
,	O
a	O
clonal	O
myeloproliferative	O
disorder	O
that	O
expresses	O
a	O
chimeric	O
bcr	B-Gene_or_gene_product
/	I-Gene_or_gene_product
abl	I-Gene_or_gene_product
protein	O
.	O
<EOS>	B-X
Increased	B-X
angiogenesis	B-X
in	B-X
bone	B-X
marrow	B-X
is	B-X
one	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
clonal	B-X
myeloproliferative	B-X
disorder	B-X
that	B-X
expresses	B-X
a	B-X
chimeric	B-X
bcr/abl	B-X
protein	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
and	B-X
a	B-X
specific	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
which	B-X
principally	B-X
targets	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
several	B-X
of	B-X
their	B-X
functions	B-X
,	B-X
including	B-X
mitogenesis	B-X
,	B-X
permeability	B-X
and	B-X
migration	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
VEGF	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
is	B-X
unknown	B-X
.	B-X

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
is	O
one	O
of	O
the	O
most	O
potent	O
and	O
a	O
specific	O
regulator	O
of	O
angiogenesis	O
which	O
principally	O
targets	O
endothelial	O
cells	O
and	O
regulates	O
several	O
of	O
their	O
functions	O
,	O
including	O
mitogenesis	O
,	O
permeability	O
and	O
migration	O
.	O

The	O
impact	O
of	O
elevated	O
VEGF	B-Gene_or_gene_product
expression	O
on	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
is	O
unknown	O
.	O
<EOS>	B-X
Increased	B-X
angiogenesis	B-X
in	B-X
bone	B-X
marrow	B-X
is	B-X
one	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
clonal	B-X
myeloproliferative	B-X
disorder	B-X
that	B-X
expresses	B-X
a	B-X
chimeric	B-X
bcr/abl	B-X
protein	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
and	B-X
a	B-X
specific	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
which	B-X
principally	B-X
targets	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
several	B-X
of	B-X
their	B-X
functions	B-X
,	B-X
including	B-X
mitogenesis	B-X
,	B-X
permeability	B-X
and	B-X
migration	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
VEGF	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
is	B-X
unknown	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
is	B-X
unknown	B-X
.	B-X
By	B-X
radioimmunoassay	B-X
,	B-X
we	B-X
measured	B-X
pretreatment	B-X
cellular	B-X
VEGF	B-X
protein	B-X
in	B-X
bone	B-X
marrow	B-X
samples	B-X
from	B-X
184	B-X
(	B-X
148	B-X
chronic	B-X
and	B-X
36	B-X
accelerated/blastic	B-X
phases	B-X
)	B-X
CML	B-X
patients	B-X
and	B-X
found	B-X
the	B-X
levels	B-X
to	B-X
be	B-X
1.6-fold	B-X
higher	B-X
than	B-X
in	B-X
31	B-X
normal	B-X
control	B-X
bone	B-X
marrow	B-X
samples	B-X
(	B-X
P	B-X
=.000	B-X
01	B-X
)	B-X
.	B-X
No	B-X
significant	B-X
differences	B-X
were	B-X
found	B-X
in	B-X
VEGF	B-X
levels	B-X
by	B-X
different	B-X
phases	B-X
of	B-X
CML	B-X
(	B-X
P	B-X
=.1	B-X
)	B-X
.	B-X
VEGF	B-X
levels	B-X
correlated	B-X
with	B-X
older	B-X
age	B-X
(	B-X
P	B-X
=.01	B-X
)	B-X
and	B-X
higher	B-X
platelet	B-X
count	B-X
(	B-X
P	B-X
=.0003	B-X
)	B-X
,	B-X
but	B-X
also	B-X
with	B-X
smaller	B-X
spleen	B-X
size	B-X
(	B-X
P	B-X
=.004	B-X
)	B-X
,	B-X
lower	B-X
white	B-X
blood	B-X
cell	B-X
count	B-X
(	B-X
P	B-X
=.0006	B-X
)	B-X
,	B-X
and	B-X
lower	B-X
percentage	B-X
of	B-X
peripheral	B-X
blasts	B-X
(	B-X
P	B-X
=.04	B-X
)	B-X
.	B-X
With	B-X
the	B-X
use	B-X
of	B-X
Cox	B-X
proportional	B-X
hazard	B-X
model	B-X
and	B-X
VEGF	B-X
levels	B-X
as	B-X
a	B-X
continuous	B-X
variable	B-X
,	B-X
high	B-X
VEGF	B-X
levels	B-X
correlated	B-X
with	B-X
shorter	B-X
survival	B-X
of	B-X
patients	B-X
in	B-X
chronic	B-X
CML	B-X
(	B-X
P	B-X
=.008	B-X
)	B-X
.	B-X
Multivariate	B-X
analysis	B-X
showed	B-X
that	B-X
VEGF	B-X
was	B-X
not	B-X
independent	B-X
of	B-X
the	B-X
synthesis	B-X
stage	B-X
(	B-X
P	B-X
=.09	B-X
)	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
VEGF	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
biology	B-X
of	B-X
CML	B-X
and	B-X
that	B-X
VEGF	B-X
inhibitors	B-X
should	B-X
be	B-X
investigated	B-X
in	B-X
CML	B-X
.	B-X

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
follow	O
-	O
up	O
of	O
VEGF	B-Gene_or_gene_product
expression	O
during	O
the	O
course	O
of	O
CML	O
.	O
<EOS>	B-X
Increased	B-X
angiogenesis	B-X
in	B-X
bone	B-X
marrow	B-X
is	B-X
one	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
clonal	B-X
myeloproliferative	B-X
disorder	B-X
that	B-X
expresses	B-X
a	B-X
chimeric	B-X
bcr/abl	B-X
protein	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
and	B-X
a	B-X
specific	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
which	B-X
principally	B-X
targets	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
several	B-X
of	B-X
their	B-X
functions	B-X
,	B-X
including	B-X
mitogenesis	B-X
,	B-X
permeability	B-X
and	B-X
migration	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
VEGF	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
is	B-X
unknown	B-X
.	B-X

METHODS	O
:	O
We	O
studied	O
VEGF	B-Gene_or_gene_product
expression	O
of	O
85	O
CML	O
patients	O
(	O
median	O
age	O
50	O
years	O
,	O
range	O
16	O
-	O
75	O
years	O
)	O
.	O
<EOS>	B-X
Increased	B-X
angiogenesis	B-X
in	B-X
bone	B-X
marrow	B-X
is	B-X
one	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
clonal	B-X
myeloproliferative	B-X
disorder	B-X
that	B-X
expresses	B-X
a	B-X
chimeric	B-X
bcr/abl	B-X
protein	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
and	B-X
a	B-X
specific	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
which	B-X
principally	B-X
targets	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
several	B-X
of	B-X
their	B-X
functions	B-X
,	B-X
including	B-X
mitogenesis	B-X
,	B-X
permeability	B-X
and	B-X
migration	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
VEGF	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
is	B-X
unknown	B-X
.	B-X

At	O
the	O
commencement	O
of	O
the	O
study	O
,	O
29	O
patients	O
were	O
in	O
chronic	O
phase	O
(	O
CP	O
)	O
,	O
25	O
in	O
an	O
accelerated	O
phase	O
(	O
AP	O
)	O
,	O
and	O
31	O
in	O
the	O
blast	O
crisis	O
(	O
BC	O
)	O
.	O

The	O
temporal	O
expression	O
(	O
percentage	O
positivity	O
per	O
1000	O
analysed	O
cells	O
)	O
VEGF	B-Gene_or_gene_product
proteins	O
over	O
the	O
course	O
of	O
CML	O
were	O
studied	O
using	O
the	O
immunohistochemical	O
technique	O
utilizing	O
relevant	O
monoclonal	O
antibodies	O
.	O
<EOS>	B-X
Increased	B-X
angiogenesis	B-X
in	B-X
bone	B-X
marrow	B-X
is	B-X
one	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
clonal	B-X
myeloproliferative	B-X
disorder	B-X
that	B-X
expresses	B-X
a	B-X
chimeric	B-X
bcr/abl	B-X
protein	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
and	B-X
a	B-X
specific	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
which	B-X
principally	B-X
targets	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
several	B-X
of	B-X
their	B-X
functions	B-X
,	B-X
including	B-X
mitogenesis	B-X
,	B-X
permeability	B-X
and	B-X
migration	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
VEGF	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
is	B-X
unknown	B-X
.	B-X

It	O
was	O
correlated	O
with	O
the	O
laboratory	O
(	O
Hb	B-Gene_or_gene_product
,	O
WBC	O
and	O
platelet	O
counts	O
,	O
and	O
the	O
percentage	O
of	O
blasts	O
)	O
and	O
clinical	O
parameters	O
(	O
organomegaly	O
,	O
duration	O
of	O
CP	O
,	O
AP	O
,	O
and	O
BC	O
)	O
of	O
disease	O
progression	O
.	O

RESULTS	O
:	O
The	O
expression	O
ofVEGF	B-Gene_or_gene_product
protein	O
was	O
most	O
pronounced	O
in	O
AP	O
(	O
ANOVA	O
,	O
p	O
=	O
0	O
.	O
033	O
)	O
.	O

The	O
level	O
of	O
VEGF	B-Gene_or_gene_product
expression	O
correlated	O
inversely	O
with	O
the	O
degree	O
of	O
splenomegaly	O
(	O
Pearson	O
,	O
r	O
=	O
-	O
0	O
.	O
400	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

High	O
expression	O
of	O
VEGF	B-Gene_or_gene_product
correlated	O
with	O
a	O
shorter	O
overall	O
survival	O
(	O
log	O
rank	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
.	O

CONCLUSION	O
:	O
Immunohistochemically	O
confirmed	O
significance	O
of	O
the	O
expression	O
of	O
VEGF	B-Gene_or_gene_product
in	O
dependence	O
of	O
the	O
CML	O
stage	O
could	O
be	O
of	O
clinical	O
importance	O
in	O
deciding	O
on	O
the	O
timing	O
therapy	O
.	O
<EOS>	B-X
Increased	B-X
angiogenesis	B-X
in	B-X
bone	B-X
marrow	B-X
is	B-X
one	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
clonal	B-X
myeloproliferative	B-X
disorder	B-X
that	B-X
expresses	B-X
a	B-X
chimeric	B-X
bcr/abl	B-X
protein	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
and	B-X
a	B-X
specific	B-X
regulator	B-X
of	B-X
angiogenesis	B-X
which	B-X
principally	B-X
targets	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
several	B-X
of	B-X
their	B-X
functions	B-X
,	B-X
including	B-X
mitogenesis	B-X
,	B-X
permeability	B-X
and	B-X
migration	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
elevated	B-X
VEGF	B-X
expression	B-X
on	B-X
the	B-X
course	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukaemia	B-X
is	B-X
unknown	B-X
.	B-X

These	O
data	O
suggest	O
that	O
VEGF	B-Gene_or_gene_product
plays	O
a	O
role	O
in	O
the	O
biology	O
of	O
CML	O
and	O
that	O
VEGF	B-Gene_or_gene_product
inhibitors	O
should	O
be	O
investigated	O
in	O
CML	O
.	O

Pbx1	B-Gene_or_gene_product
is	O
a	O
downstream	O
target	O
of	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
in	O
hematopoietic	O
stem	O
/	O
progenitors	O
and	O
leukemic	O
cells	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

Ecotropic	B-Gene_or_gene_product
viral	I-Gene_or_gene_product
integration	I-Gene_or_gene_product
site	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
is	O
a	O
nuclear	O
transcription	O
factor	O
,	O
which	O
is	O
essential	O
for	O
the	O
proliferation	O
/	O
maintenance	O
of	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

Aberrant	O
expression	O
of	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
has	O
been	O
frequently	O
found	O
in	O
myeloid	O
leukemia	O
,	O
and	O
is	O
associated	O
with	O
a	O
poor	O
patient	O
survival	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

Recently	O
,	O
we	O
reported	O
candidate	O
target	O
genes	O
of	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
shared	O
in	O
HSCs	O
and	O
leukemic	O
cells	O
using	O
gene	O
expression	O
profiling	O
analysis	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
identified	O
Pbx1	B-Gene_or_gene_product
,	O
a	O
proto	O
-	O
oncogene	O
in	O
hematopoietic	O
malignancy	O
,	O
as	O
a	O
target	O
gene	O
of	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

Overexpression	O
of	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
increased	O
Pbx1	B-Gene_or_gene_product
expression	O
in	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

An	O
analysis	O
of	O
the	O
Pbx1	B-Gene_or_gene_product
promoter	O
region	O
revealed	O
that	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
upregulates	O
Pbx1	B-Gene_or_gene_product
transcription	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

Furthermore	O
,	O
reduction	O
of	O
Pbx1	B-Gene_or_gene_product
levels	O
through	O
RNAi	O
-	O
mediated	O
knockdown	O
significantly	O
inhibited	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
induced	O
transformation	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

In	O
contrast	O
,	O
knockdown	O
of	O
Pbx1	B-Gene_or_gene_product
did	O
not	O
impair	O
bone	O
marrow	O
transformation	O
by	O
E2A	B-Gene_or_gene_product
/	O
HLF	B-Gene_or_gene_product
or	O
AML1	B-Gene_or_gene_product
/	O
ETO	B-Gene_or_gene_product
,	O
suggesting	O
that	O
Pbx1	B-Gene_or_gene_product
is	O
specifically	O
required	O
for	O
the	O
maintenance	O
of	O
bone	O
marrow	O
transformation	O
mediated	O
by	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

These	O
results	O
indicate	O
that	O
Pbx1	B-Gene_or_gene_product
is	O
a	O
target	O
gene	O
of	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
involved	O
in	O
Evi	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
mediated	O
leukemogenesis	O
.	O
<EOS>	B-X
Ecotropic	B-X
viral	B-X
integration	B-X
site-1	B-X
(	B-X
Evi-1	B-X
)	B-X
is	B-X
a	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proliferation/maintenance	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
Evi-1	B-X
has	B-X
been	B-X
frequently	B-X
found	B-X
in	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
poor	B-X
patient	B-X
survival	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
candidate	B-X
target	B-X
genes	B-X
of	B-X
Evi-1	B-X
shared	B-X
in	B-X
HSCs	B-X
and	B-X
leukemic	B-X
cells	B-X
using	B-X
gene	B-X
expression	B-X
profiling	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
Pbx1	B-X
,	B-X
a	B-X
proto-oncogene	B-X
in	B-X
hematopoietic	B-X
malignancy	B-X
,	B-X
as	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
.	B-X
Overexpression	B-X
of	B-X
Evi-1	B-X
increased	B-X
Pbx1	B-X
expression	B-X
in	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
Pbx1	B-X
promoter	B-X
region	B-X
revealed	B-X
that	B-X
Evi-1	B-X
upregulates	B-X
Pbx1	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
reduction	B-X
of	B-X
Pbx1	B-X
levels	B-X
through	B-X
RNAi-mediated	B-X
knockdown	B-X
significantly	B-X
inhibited	B-X
Evi-1-induced	B-X
transformation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
knockdown	B-X
of	B-X
Pbx1	B-X
did	B-X
not	B-X
impair	B-X
bone	B-X
marrow	B-X
transformation	B-X
by	B-X
E2A/HLF	B-X
or	B-X
AML1/ETO	B-X
,	B-X
suggesting	B-X
that	B-X
Pbx1	B-X
is	B-X
specifically	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
bone	B-X
marrow	B-X
transformation	B-X
mediated	B-X
by	B-X
Evi-1	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Pbx1	B-X
is	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
Evi-1	B-X
involved	B-X
in	B-X
Evi-1-mediated	B-X
leukemogenesis	B-X
.	B-X

Tumor	O
Angiogenesis	O
:	O
Initiation	O
and	O
Targeting	O
-	O
Therapeutic	O
Targeting	O
of	O
an	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Binding	I-Gene_or_gene_product
Protein	I-Gene_or_gene_product
,	O
an	O
Angiogenic	O
Switch	O
Molecule	O
,	O
and	O
Indicator	O
of	O
Early	O
Stages	O
of	O
Gastrointestinal	O
Adenocarcinomas	O
-	O
.	O
<EOS>	B-X
Tumor	B-X
angiogenesis	B-X
has	B-X
been	B-X
related	B-X
to	B-X
the	B-X
initiation	B-X
as	B-X
well	B-X
as	B-X
progression	B-X
toward	B-X
more	B-X
aggressive	B-X
behavior	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
secreted	B-X
FGF-BP	B-X
protein	B-X
during	B-X
early	B-X
phases	B-X
of	B-X
pancreas	B-X
and	B-X
colon	B-X
cancer	B-X
could	B-X
make	B-X
this	B-X
protein	B-X
a	B-X
possible	B-X
serum	B-X
marker	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
high-risk	B-X
premalignant	B-X
lesions	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
FGF-BP	B-X
is	B-X
neutralized	B-X
by	B-X
monoclonal	B-X
antibodies	B-X
suggesting	B-X
the	B-X
potential	B-X
for	B-X
antibody-based	B-X
therapeutic	B-X
targeting	B-X
.	B-X

Tumor	O
angiogenesis	O
has	O
been	O
related	O
to	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
toward	O
more	O
aggressive	O
behavior	O
of	O
human	O
tumors	O
.	O

In	O
particular	O
,	O
the	O
activity	O
of	O
angiogenic	O
factors	O
is	O
crucial	O
for	O
tumor	O
progression	O
.	O
<EOS>	B-X
Upon	B-X
activation	B-X
,	B-X
platelets	B-X
release	B-X
many	B-X
molecules	B-X
,	B-X
including	B-X
growth	B-X
and	B-X
angiogenic	B-X
factors	B-X
,	B-X
lipids	B-X
,	B-X
and	B-X
extracellular	B-X
vesicles	B-X
,	B-X
and	B-X
activate	B-X
numerous	B-X
cell	B-X
types	B-X
,	B-X
including	B-X
vascular	B-X
and	B-X
immune	B-X
cells	B-X
,	B-X
fibroblasts	B-X
,	B-X
and	B-X
cancer	B-X
cells	B-X
.	B-X
Hence	B-X
,	B-X
platelets	B-X
are	B-X
a	B-X
crucial	B-X
component	B-X
of	B-X
cell-cell	B-X
communication	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
their	B-X
interaction	B-X
with	B-X
cancer	B-X
cells	B-X
can	B-X
enhance	B-X
their	B-X
malignancy	B-X
and	B-X
facilitate	B-X
the	B-X
invasion	B-X
and	B-X
colonization	B-X
of	B-X
distant	B-X
organs	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
the	B-X
use	B-X
of	B-X
antiplatelet	B-X
agents	B-X
to	B-X
restrain	B-X
cancer	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Thus	B-X
,	B-X
cancer-patient	B-X
platelets	B-X
show	B-X
specific	B-X
proteomic	B-X
and	B-X
transcriptomic	B-X
expression	B-X
patterns	B-X
,	B-X
a	B-X
phenomenon	B-X
called	B-X
tumor-educated	B-X
platelets	B-X
(	B-X
TEP	B-X
)	B-X
.	B-X
Platelet	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
tumor	B-X
cells	B-X
and	B-X
transfer	B-X
their	B-X
molecular	B-X
cargo	B-X
has	B-X
been	B-X
exploited	B-X
to	B-X
design	B-X
platelet-mediated	B-X
drug	B-X
delivery	B-X
systems	B-X
to	B-X
enhance	B-X
the	B-X
efficacy	B-X
and	B-X
reduce	B-X
toxicity	B-X
often	B-X
associated	B-X
with	B-X
traditional	B-X
chemotherapy	B-X
.	B-X

We	O
previously	O
characterized	O
a	O
secreted	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
(	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
)	O
as	O
a	O
chaperone	O
molecule	O
,	O
which	O
binds	O
to	O
various	O
FGFs	B-Gene_or_gene_product
,	O
enhances	O
FGF	B-Gene_or_gene_product
-	O
mediated	O
biochemical	O
and	O
biologic	O
events	O
and	O
importantly	O
is	O
a	O
crucial	O
rate	O
-	O
limiting	O
factor	O
for	O
tumor	O
-	O
dependent	O
angiogenesis	O
.	O
<EOS>	B-X
Tumor	B-X
angiogenesis	B-X
has	B-X
been	B-X
related	B-X
to	B-X
the	B-X
initiation	B-X
as	B-X
well	B-X
as	B-X
progression	B-X
toward	B-X
more	B-X
aggressive	B-X
behavior	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
angiogenic	B-X
factors	B-X
is	B-X
crucial	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
Crucial	B-X
genetic	B-X
events	B-X
underlying	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
angiogenesis	B-X
and	B-X
antiangiogenic	B-X
therapies	B-X
are	B-X
discussed	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
secreted	B-X
FGF-BP	B-X
protein	B-X
during	B-X
early	B-X
phases	B-X
of	B-X
pancreas	B-X
and	B-X
colon	B-X
cancer	B-X
could	B-X
make	B-X
this	B-X
protein	B-X
a	B-X
possible	B-X
serum	B-X
marker	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
high-risk	B-X
premalignant	B-X
lesions	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
FGF-BP	B-X
is	B-X
neutralized	B-X
by	B-X
monoclonal	B-X
antibodies	B-X
suggesting	B-X
the	B-X
potential	B-X
for	B-X
antibody-based	B-X
therapeutic	B-X
targeting	B-X
.	B-X

We	O
generated	O
monoclonal	O
antibodies	O
that	O
target	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
protein	O
and	O
used	O
them	O
as	O
a	O
tool	O
to	O
evaluate	O
frequency	O
and	O
pattern	O
of	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
expression	O
during	O
the	O
malignant	O
progression	O
of	O
pancreas	O
and	O
colorectal	O
carcinoma	O
in	O
archival	O
tissue	O
samples	O
.	O
<EOS>	B-X
Tumor	B-X
angiogenesis	B-X
has	B-X
been	B-X
related	B-X
to	B-X
the	B-X
initiation	B-X
as	B-X
well	B-X
as	B-X
progression	B-X
toward	B-X
more	B-X
aggressive	B-X
behavior	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
angiogenic	B-X
factors	B-X
is	B-X
crucial	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
Crucial	B-X
genetic	B-X
events	B-X
underlying	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
angiogenesis	B-X
and	B-X
antiangiogenic	B-X
therapies	B-X
are	B-X
discussed	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
secreted	B-X
FGF-BP	B-X
protein	B-X
during	B-X
early	B-X
phases	B-X
of	B-X
pancreas	B-X
and	B-X
colon	B-X
cancer	B-X
could	B-X
make	B-X
this	B-X
protein	B-X
a	B-X
possible	B-X
serum	B-X
marker	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
high-risk	B-X
premalignant	B-X
lesions	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
FGF-BP	B-X
is	B-X
neutralized	B-X
by	B-X
monoclonal	B-X
antibodies	B-X
suggesting	B-X
the	B-X
potential	B-X
for	B-X
antibody-based	B-X
therapeutic	B-X
targeting	B-X
.	B-X

We	O
found	O
that	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
is	O
dramatically	O
upregulated	O
during	O
the	O
initiation	O
of	O
colorectal	O
and	O
pancreatic	O
adenocarcinoma	O
.	O
<EOS>	B-X
Tumor	B-X
angiogenesis	B-X
has	B-X
been	B-X
related	B-X
to	B-X
the	B-X
initiation	B-X
as	B-X
well	B-X
as	B-X
progression	B-X
toward	B-X
more	B-X
aggressive	B-X
behavior	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
Crucial	B-X
genetic	B-X
events	B-X
underlying	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
angiogenesis	B-X
and	B-X
antiangiogenic	B-X
therapies	B-X
are	B-X
discussed	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
secreted	B-X
FGF-BP	B-X
protein	B-X
during	B-X
early	B-X
phases	B-X
of	B-X
pancreas	B-X
and	B-X
colon	B-X
cancer	B-X
could	B-X
make	B-X
this	B-X
protein	B-X
a	B-X
possible	B-X
serum	B-X
marker	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
high-risk	B-X
premalignant	B-X
lesions	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
FGF-BP	B-X
is	B-X
neutralized	B-X
by	B-X
monoclonal	B-X
antibodies	B-X
suggesting	B-X
the	B-X
potential	B-X
for	B-X
antibody-based	B-X
therapeutic	B-X
targeting	B-X
.	B-X

Crucial	O
genetic	O
events	O
underlying	O
the	O
initiation	O
and	O
progression	O
of	O
colorectal	O
and	O
pancreatic	O
adenocarcinoma	O
with	O
a	O
particular	O
focus	O
on	O
the	O
modulation	O
of	O
angiogenesis	O
and	O
antiangiogenic	O
therapies	O
are	O
discussed	O
.	O
<EOS>	B-X
Tumor	B-X
angiogenesis	B-X
has	B-X
been	B-X
related	B-X
to	B-X
the	B-X
initiation	B-X
as	B-X
well	B-X
as	B-X
progression	B-X
toward	B-X
more	B-X
aggressive	B-X
behavior	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
angiogenic	B-X
factors	B-X
is	B-X
crucial	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
Crucial	B-X
genetic	B-X
events	B-X
underlying	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
angiogenesis	B-X
and	B-X
antiangiogenic	B-X
therapies	B-X
are	B-X
discussed	B-X
.	B-X

We	O
propose	O
that	O
the	O
upregulation	O
of	O
the	O
secreted	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
protein	O
during	O
early	O
phases	O
of	O
pancreas	O
and	O
colon	O
cancer	O
could	O
make	O
this	O
protein	O
a	O
possible	O
serum	O
marker	O
indicating	O
the	O
presence	O
of	O
high	O
-	O
risk	O
premalignant	O
lesions	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
secreted	B-X
FGF-BP	B-X
protein	B-X
during	B-X
early	B-X
phases	B-X
of	B-X
pancreas	B-X
and	B-X
colon	B-X
cancer	B-X
could	B-X
make	B-X
this	B-X
protein	B-X
a	B-X
possible	B-X
serum	B-X
marker	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
high-risk	B-X
premalignant	B-X
lesions	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
FGF-BP	B-X
is	B-X
neutralized	B-X
by	B-X
monoclonal	B-X
antibodies	B-X
suggesting	B-X
the	B-X
potential	B-X
for	B-X
antibody-based	B-X
therapeutic	B-X
targeting	B-X
.	B-X

Furthermore	O
,	O
the	O
biological	O
activity	O
of	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
is	O
neutralized	O
by	O
monoclonal	O
antibodies	O
suggesting	O
the	O
potential	O
for	O
antibody	O
-	O
based	O
therapeutic	O
targeting	O
.	O
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
angiogenic	B-X
factors	B-X
is	B-X
crucial	B-X
for	B-X
tumor	B-X
progression	B-X
.	B-X
We	B-X
previously	B-X
characterized	B-X
a	B-X
secreted	B-X
fibroblast	B-X
growth	B-X
factor-binding	B-X
protein	B-X
(	B-X
FGF-BP	B-X
)	B-X
as	B-X
a	B-X
chaperone	B-X
molecule	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
various	B-X
FGFs	B-X
,	B-X
enhances	B-X
FGF-mediated	B-X
biochemical	B-X
and	B-X
biologic	B-X
events	B-X
and	B-X
importantly	B-X
is	B-X
a	B-X
crucial	B-X
rate-limiting	B-X
factor	B-X
for	B-X
tumor-dependent	B-X
angiogenesis	B-X
.	B-X
We	B-X
generated	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
target	B-X
FGF-BP	B-X
protein	B-X
and	B-X
used	B-X
them	B-X
as	B-X
a	B-X
tool	B-X
to	B-X
evaluate	B-X
frequency	B-X
and	B-X
pattern	B-X
of	B-X
FGF-BP	B-X
expression	B-X
during	B-X
the	B-X
malignant	B-X
progression	B-X
of	B-X
pancreas	B-X
and	B-X
colorectal	B-X
carcinoma	B-X
in	B-X
archival	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
that	B-X
FGF-BP	B-X
is	B-X
dramatically	B-X
upregulated	B-X
during	B-X
the	B-X
initiation	B-X
of	B-X
colorectal	B-X
and	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
secreted	B-X
FGF-BP	B-X
protein	B-X
during	B-X
early	B-X
phases	B-X
of	B-X
pancreas	B-X
and	B-X
colon	B-X
cancer	B-X
could	B-X
make	B-X
this	B-X
protein	B-X
a	B-X
possible	B-X
serum	B-X
marker	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
high-risk	B-X
premalignant	B-X
lesions	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
FGF-BP	B-X
is	B-X
neutralized	B-X
by	B-X
monoclonal	B-X
antibodies	B-X
suggesting	B-X
the	B-X
potential	B-X
for	B-X
antibody-based	B-X
therapeutic	B-X
targeting	B-X
.	B-X

The	O
role	O
of	O
hypoxia	O
in	O
2	O
-	O
butoxyethanol	O
-	O
induced	O
hemangiosarcoma	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
immunohistochemistry	B-X
method	B-X
(	B-X
Hypoxyprobe	B-X
)	B-X
demonstrated	B-X
that	B-X
tissue	B-X
hypoxia	B-X
was	B-X
present	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

To	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
compound	O
-	O
induced	O
hemangiosarcomas	O
in	O
mice	O
,	O
and	O
therefore	O
,	O
their	O
human	O
relevance	O
,	O
a	O
systems	O
biology	O
approach	O
was	O
undertaken	O
using	O
transcriptomics	O
and	O
Causal	O
Network	O
Modeling	O
from	O
mice	O
treated	O
with	O
2	O
-	O
butoxyethanol	O
(	O
2	O
-	O
BE	O
)	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

2	O
-	O
BE	O
is	O
a	O
hemolytic	O
agent	O
that	O
induces	O
hemangiosarcomas	O
in	O
mice	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

We	O
hypothesized	O
that	O
the	O
hemolysis	O
induced	O
by	O
2	O
-	O
BE	O
would	O
result	O
in	O
local	O
tissue	O
hypoxia	O
,	O
a	O
well	O
-	O
documented	O
trigger	O
for	O
endothelial	O
cell	O
proliferation	O
leading	O
to	O
hemangiosarcoma	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
immunohistochemistry	B-X
method	B-X
(	B-X
Hypoxyprobe	B-X
)	B-X
demonstrated	B-X
that	B-X
tissue	B-X
hypoxia	B-X
was	B-X
present	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

Gene	O
expression	O
data	O
from	O
bone	O
marrow	O
(	O
BM	O
)	O
,	O
liver	O
,	O
and	O
spleen	O
of	O
mice	O
exposed	O
to	O
a	O
single	O
dose	O
(	O
4	O
h	O
)	O
or	O
seven	O
daily	O
doses	O
of	O
2	O
-	O
BE	O
were	O
used	O
to	O
develop	O
a	O
mechanistic	O
model	O
of	O
hemangiosarcoma	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
immunohistochemistry	B-X
method	B-X
(	B-X
Hypoxyprobe	B-X
)	B-X
demonstrated	B-X
that	B-X
tissue	B-X
hypoxia	B-X
was	B-X
present	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

The	O
resulting	O
mechanistic	O
model	O
confirms	O
previous	O
work	O
proposing	O
that	O
2	O
-	O
BE	O
induces	O
macrophage	O
activation	O
and	O
inflammation	O
in	O
the	O
liver	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

In	O
addition	O
,	O
the	O
model	O
supports	O
local	O
tissue	O
hypoxia	O
in	O
the	O
liver	O
and	O
spleen	O
,	O
coupled	O
with	O
increased	O
erythropoeitin	B-Gene_or_gene_product
signaling	O
and	O
erythropoiesis	O
in	O
the	O
spleen	O
and	O
BM	O
,	O
and	O
suppression	O
of	O
mechanisms	O
that	O
contribute	O
to	O
genomic	O
stability	O
,	O
events	O
that	O
could	O
be	O
contributing	O
factors	O
to	O
hemangiosarcoma	O
formation	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
immunohistochemistry	B-X
method	B-X
(	B-X
Hypoxyprobe	B-X
)	B-X
demonstrated	B-X
that	B-X
tissue	B-X
hypoxia	B-X
was	B-X
present	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

Finally	O
,	O
an	O
immunohistochemistry	O
method	O
(	O
Hypoxyprobe	O
)	O
demonstrated	O
that	O
tissue	O
hypoxia	O
was	O
present	O
in	O
the	O
spleen	O
and	O
BM	O
.	O
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
immunohistochemistry	B-X
method	B-X
(	B-X
Hypoxyprobe	B-X
)	B-X
demonstrated	B-X
that	B-X
tissue	B-X
hypoxia	B-X
was	B-X
present	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

Together	O
,	O
the	O
results	O
of	O
this	O
study	O
identify	O
molecular	O
mechanisms	O
that	O
initiate	O
hemangiosarcoma	O
,	O
a	O
key	O
step	O
in	O
understanding	O
safety	O
concerns	O
that	O
can	O
impact	O
drug	O
decision	O
processes	O
,	O
and	O
identified	O
hypoxia	O
as	O
a	O
possible	O
contributing	O
factor	O
for	O
2	O
-	O
BE	O
-	O
induced	O
hemangiosarcoma	O
in	O
mice	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
compound-induced	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
their	B-X
human	B-X
relevance	B-X
,	B-X
a	B-X
systems	B-X
biology	B-X
approach	B-X
was	B-X
undertaken	B-X
using	B-X
transcriptomics	B-X
and	B-X
Causal	B-X
Network	B-X
Modeling	B-X
from	B-X
mice	B-X
treated	B-X
with	B-X
2-butoxyethanol	B-X
(	B-X
2-BE	B-X
)	B-X
.	B-X
2-BE	B-X
is	B-X
a	B-X
hemolytic	B-X
agent	B-X
that	B-X
induces	B-X
hemangiosarcomas	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
hemolysis	B-X
induced	B-X
by	B-X
2-BE	B-X
would	B-X
result	B-X
in	B-X
local	B-X
tissue	B-X
hypoxia	B-X
,	B-X
a	B-X
well-documented	B-X
trigger	B-X
for	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
leading	B-X
to	B-X
hemangiosarcoma	B-X
.	B-X
Gene	B-X
expression	B-X
data	B-X
from	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
single	B-X
dose	B-X
(	B-X
4	B-X
h	B-X
)	B-X
or	B-X
seven	B-X
daily	B-X
doses	B-X
of	B-X
2-BE	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
a	B-X
mechanistic	B-X
model	B-X
of	B-X
hemangiosarcoma	B-X
.	B-X
The	B-X
resulting	B-X
mechanistic	B-X
model	B-X
confirms	B-X
previous	B-X
work	B-X
proposing	B-X
that	B-X
2-BE	B-X
induces	B-X
macrophage	B-X
activation	B-X
and	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
model	B-X
supports	B-X
local	B-X
tissue	B-X
hypoxia	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
,	B-X
coupled	B-X
with	B-X
increased	B-X
erythropoeitin	B-X
signaling	B-X
and	B-X
erythropoiesis	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
,	B-X
and	B-X
suppression	B-X
of	B-X
mechanisms	B-X
that	B-X
contribute	B-X
to	B-X
genomic	B-X
stability	B-X
,	B-X
events	B-X
that	B-X
could	B-X
be	B-X
contributing	B-X
factors	B-X
to	B-X
hemangiosarcoma	B-X
formation	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
immunohistochemistry	B-X
method	B-X
(	B-X
Hypoxyprobe	B-X
)	B-X
demonstrated	B-X
that	B-X
tissue	B-X
hypoxia	B-X
was	B-X
present	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
BM	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
identify	B-X
molecular	B-X
mechanisms	B-X
that	B-X
initiate	B-X
hemangiosarcoma	B-X
,	B-X
a	B-X
key	B-X
step	B-X
in	B-X
understanding	B-X
safety	B-X
concerns	B-X
that	B-X
can	B-X
impact	B-X
drug	B-X
decision	B-X
processes	B-X
,	B-X
and	B-X
identified	B-X
hypoxia	B-X
as	B-X
a	B-X
possible	B-X
contributing	B-X
factor	B-X
for	B-X
2-BE-induced	B-X
hemangiosarcoma	B-X
in	B-X
mice	B-X
.	B-X

Pancreatic	O
endocrine	O
tumors	O
:	O
expression	O
profiling	O
evidences	O
a	O
role	O
for	O
AKT	B-Gene_or_gene_product
-	O
mTOR	B-Gene_or_gene_product
pathway	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
large	B-X
panel	B-X
of	B-X
pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
aimed	B-X
at	B-X
identifying	B-X
new	B-X
potential	B-X
targets	B-X
for	B-X
therapy	B-X
and	B-X
biomarkers	B-X
to	B-X
predict	B-X
patient	B-X
outcome	B-X
.	B-X

PURPOSE	O
:	O
We	O
investigated	O
the	O
global	O
gene	O
expression	O
in	O
a	O
large	O
panel	O
of	O
pancreatic	O
endocrine	O
tumors	O
(	O
PETs	O
)	O
aimed	O
at	O
identifying	O
new	O
potential	O
targets	O
for	O
therapy	O
and	O
biomarkers	O
to	O
predict	O
patient	O
outcome	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Using	O
a	O
custom	O
microarray	O
,	O
we	O
analyzed	O
72	O
primary	O
PETs	O
,	O
seven	O
matched	O
metastases	O
,	O
and	O
10	O
normal	O
pancreatic	O
samples	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
large	B-X
panel	B-X
of	B-X
pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
aimed	B-X
at	B-X
identifying	B-X
new	B-X
potential	B-X
targets	B-X
for	B-X
therapy	B-X
and	B-X
biomarkers	B-X
to	B-X
predict	B-X
patient	B-X
outcome	B-X
.	B-X

Relevant	O
differentially	O
expressed	O
genes	O
were	O
validated	O
by	O
either	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
on	O
tissue	O
microarrays	O
.	O
<EOS>	B-X
In	B-X
the	B-X
last	B-X
decade	B-X
,	B-X
the	B-X
ability	B-X
to	B-X
detect	B-X
antigens	B-X
(	B-X
Ags	B-X
)	B-X
in	B-X
tissue	B-X
sections	B-X
has	B-X
improved	B-X
dramatically	B-X
,	B-X
mainly	B-X
by	B-X
countering	B-X
the	B-X
deleterious	B-X
effects	B-X
of	B-X
formaldehyde	B-X
with	B-X
antigen	B-X
retrieval	B-X
(	B-X
AR	B-X
)	B-X
and	B-X
increasing	B-X
sensitivity	B-X
of	B-X
the	B-X
detection	B-X
systems	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
I	B-X
address	B-X
these	B-X
topics	B-X
and	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
technical	B-X
aspects	B-X
of	B-X
immunohistochemistry	B-X
,	B-X
including	B-X
those	B-X
related	B-X
to	B-X
antibodies	B-X
(	B-X
Abs	B-X
)	B-X
and	B-X
Ags	B-X
,	B-X
fixation	B-X
,	B-X
AR	B-X
,	B-X
detection	B-X
methods	B-X
,	B-X
background	B-X
,	B-X
and	B-X
troubleshooting	B-X
.	B-X
Microarray	B-X
technology	B-X
and	B-X
the	B-X
use	B-X
of	B-X
rabbit	B-X
monoclonal	B-X
Abs	B-X
in	B-X
immunohistochemistry	B-X
are	B-X
also	B-X
discussed	B-X
.	B-X
Advances	B-X
in	B-X
quantitative	B-X
immunohistochemistry	B-X
and	B-X
their	B-X
contribution	B-X
to	B-X
breast	B-X
cancer	B-X
.	B-X

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
:	O
tuberous	B-Gene_or_gene_product
sclerosis	I-Gene_or_gene_product
2	I-Gene_or_gene_product
(	O
TSC2	B-Gene_or_gene_product
)	O
and	O
phosphatase	B-Gene_or_gene_product
and	I-Gene_or_gene_product
tensin	I-Gene_or_gene_product
homolog	I-Gene_or_gene_product
(	O
PTEN	B-Gene_or_gene_product
)	O
were	O
downregulated	O
in	O
most	O
of	O
the	O
primary	O
tumors	O
,	O
and	O
their	O
low	O
expression	O
was	O
significantly	O
associated	O
with	O
shorter	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
;	O
somatostatin	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	I-Gene_or_gene_product
(	O
SSTR2	B-Gene_or_gene_product
)	O
was	O
absent	O
or	O
very	O
low	O
in	O
insulinomas	O
compared	O
with	O
nonfunctioning	O
tumors	O
;	O
and	O
expression	O
of	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
13	I-Gene_or_gene_product
(	O
FGF13	B-Gene_or_gene_product
)	O
gene	O
was	O
significantly	O
associated	O
with	O
the	O
occurrence	O
of	O
liver	O
metastasis	O
and	O
shorter	O
disease	O
-	O
free	O
survival	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
large	B-X
panel	B-X
of	B-X
pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
aimed	B-X
at	B-X
identifying	B-X
new	B-X
potential	B-X
targets	B-X
for	B-X
therapy	B-X
and	B-X
biomarkers	B-X
to	B-X
predict	B-X
patient	B-X
outcome	B-X
.	B-X

TSC2	B-Gene_or_gene_product
and	O
PTEN	B-Gene_or_gene_product
are	O
two	O
key	O
inhibitors	O
of	O
the	O
Akt	B-Gene_or_gene_product
/	O
mammalian	B-Gene_or_gene_product
target	I-Gene_or_gene_product
of	I-Gene_or_gene_product
rapamycin	I-Gene_or_gene_product
(	O
mTOR	B-Gene_or_gene_product
)	O
pathway	O
and	O
the	O
specific	O
inhibition	O
of	O
mTOR	B-Gene_or_gene_product
with	O
rapamycin	O
or	O
RAD001	O
inhibited	O
cell	O
proliferation	O
of	O
PET	O
cell	O
lines	O
.	O
<EOS>	B-X
Pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
are	B-X
characterised	B-X
by	B-X
an	B-X
indolent	B-X
behaviour	B-X
in	B-X
terms	B-X
of	B-X
tumor	B-X
growth	B-X
.	B-X
Since	B-X
the	B-X
PI3K/AKT/mTOR	B-X
axis	B-X
is	B-X
deregulated	B-X
in	B-X
PETs	B-X
,	B-X
the	B-X
mTOR	B-X
inhibitor	B-X
RAD001	B-X
represents	B-X
the	B-X
first	B-X
line	B-X
treatment	B-X
.	B-X
Inhibition	B-X
of	B-X
mTOR	B-X
leads	B-X
to	B-X
feedback	B-X
re-activation	B-X
of	B-X
PI3K	B-X
activity	B-X
,	B-X
which	B-X
may	B-X
promote	B-X
resistance	B-X
to	B-X
RAD001	B-X
.	B-X
Thus	B-X
,	B-X
PI3K	B-X
represents	B-X
a	B-X
novel	B-X
potential	B-X
target	B-X
for	B-X
PETs	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
impact	B-X
of	B-X
three	B-X
novel	B-X
PI3K	B-X
inhibitors	B-X
(	B-X
BEZ235	B-X
,	B-X
BKM120	B-X
and	B-X
BYL719	B-X
)	B-X
on	B-X
proliferation	B-X
of	B-X
PET	B-X
cells	B-X
that	B-X
are	B-X
responsive	B-X
(	B-X
BON-1	B-X
)	B-X
or	B-X
unresponsive	B-X
(	B-X
QGP-1	B-X
)	B-X
to	B-X
RAD001	B-X
.	B-X
BEZ235	B-X
was	B-X
the	B-X
most	B-X
efficient	B-X
in	B-X
inhibiting	B-X
proliferation	B-X
in	B-X
PET	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
combined	B-X
treatment	B-X
with	B-X
BEZ235	B-X
and	B-X
RAD001	B-X
exhibited	B-X
synergic	B-X
effects	B-X
and	B-X
was	B-X
also	B-X
effective	B-X
in	B-X
BON-1	B-X
that	B-X
acquired	B-X
resistance	B-X
to	B-X
RAD001	B-X
(	B-X
BON-1	B-X
RR	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
PI3K/AKT/mTOR	B-X
pathway	B-X
showed	B-X
that	B-X
RAD001	B-X
and	B-X
BEZ235	B-X
only	B-X
partially	B-X
inhibited	B-X
mTOR-dependent	B-X
phosphorylation	B-X
of	B-X
4EBP1	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
combined	B-X
therapy	B-X
with	B-X
the	B-X
two	B-X
inhibitors	B-X
strongly	B-X
inhibited	B-X
phosphorylation	B-X
of	B-X
4EBP1	B-X
,	B-X
assembly	B-X
of	B-X
the	B-X
translational	B-X
initiation	B-X
complex	B-X
and	B-X
protein	B-X
synthesis	B-X
.	B-X
Thus	B-X
,	B-X
combined	B-X
treatment	B-X
with	B-X
BEZ235	B-X
may	B-X
represent	B-X
suitable	B-X
therapy	B-X
to	B-X
counteract	B-X
primary	B-X
and	B-X
acquired	B-X
resistance	B-X
to	B-X
RAD001	B-X
in	B-X
PETs	B-X
.	B-X

CONCLUSION	O
:	O
Our	O
results	O
strongly	O
support	O
a	O
role	O
for	O
PI3K	B-Gene_or_gene_product
/	O
Akt	B-Gene_or_gene_product
/	O
mTOR	B-Gene_or_gene_product
pathway	O
in	O
PET	O
,	O
which	O
ties	O
in	O
with	O
the	O
fact	O
that	O
mTOR	B-Gene_or_gene_product
inhibitors	O
have	O
reached	O
phase	O
III	O
trials	O
in	O
neuroendocrine	O
tumors	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
large	B-X
panel	B-X
of	B-X
pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
aimed	B-X
at	B-X
identifying	B-X
new	B-X
potential	B-X
targets	B-X
for	B-X
therapy	B-X
and	B-X
biomarkers	B-X
to	B-X
predict	B-X
patient	B-X
outcome	B-X
.	B-X

The	O
finding	O
of	O
differential	O
SSTR	B-Gene_or_gene_product
expression	O
raises	O
the	O
potential	O
for	O
SSTR	B-Gene_or_gene_product
expression	O
to	O
be	O
evaluated	O
as	O
a	O
marker	O
of	O
response	O
to	O
somatostatin	B-Gene_or_gene_product
analogs	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
large	B-X
panel	B-X
of	B-X
pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
aimed	B-X
at	B-X
identifying	B-X
new	B-X
potential	B-X
targets	B-X
for	B-X
therapy	B-X
and	B-X
biomarkers	B-X
to	B-X
predict	B-X
patient	B-X
outcome	B-X
.	B-X

Finally	O
,	O
we	O
identified	O
FGF13	B-Gene_or_gene_product
as	O
a	O
new	O
prognostic	O
marker	O
that	O
predicted	O
poorer	O
outcome	O
in	O
patients	O
who	O
were	O
clinically	O
considered	O
free	O
from	O
disease	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
large	B-X
panel	B-X
of	B-X
pancreatic	B-X
endocrine	B-X
tumors	B-X
(	B-X
PETs	B-X
)	B-X
aimed	B-X
at	B-X
identifying	B-X
new	B-X
potential	B-X
targets	B-X
for	B-X
therapy	B-X
and	B-X
biomarkers	B-X
to	B-X
predict	B-X
patient	B-X
outcome	B-X
.	B-X

ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
enhances	O
the	O
migratory	O
and	O
invasive	O
potential	O
of	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
by	O
inducing	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
via	O
Akt	B-Gene_or_gene_product
and	O
CREB	B-Gene_or_gene_product
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
CREB	B-X
functions	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
between	B-X
Akt	B-X
and	B-X
MMP	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

We	O
have	O
previously	O
reported	O
that	O
intercellular	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
(	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	O
is	O
associated	O
with	O
an	O
increase	O
of	O
cellular	O
radio	O
-	O
resistance	O
and	O
cancer	O
cell	O
proliferation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
hypothesized	O
that	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
has	O
an	O
additional	O
effect	O
on	O
cancer	O
cell	O
migration	O
and	O
invasion	O
because	O
molecules	O
induced	O
by	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
are	O
known	O
as	O
regulators	O
of	O
cell	O
migration	O
and	O
invasion	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
used	O
NCI	O
-	O
H1299	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
cell	O
line	O
(	O
p53	B-Gene_or_gene_product
and	O
PTEN	B-Gene_or_gene_product
null	O
cell	O
)	O
and	O
constructed	O
an	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	O
over	O
-	O
expressing	O
stable	O
transfectant	O
,	O
which	O
exhibited	O
increased	O
cell	O
migration	O
and	O
invasion	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

The	O
increased	O
migration	O
and	O
invasion	O
resulted	O
from	O
up	O
-	O
regulation	O
of	O
expression	O
and	O
activities	O
of	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
.	O
<EOS>	B-X
In	B-X
human	B-X
tumors	B-X
,	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
expression	B-X
is	B-X
positively	B-X
associated	B-X
with	B-X
tumor	B-X
metastatic	B-X
potential	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
(	B-X
MMP	B-X
)	B-X
secretion	B-X
.	B-X
Additionally	B-X
,	B-X
tissue	B-X
transglutaminase	B-X
(	B-X
TG2	B-X
)	B-X
is	B-X
implicated	B-X
as	B-X
playing	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
,	B-X
and	B-X
acts	B-X
as	B-X
a	B-X
co-receptor	B-X
for	B-X
integrin-mediated	B-X
cell	B-X
binding	B-X
to	B-X
FN	B-X
.	B-X
This	B-X
study	B-X
explored	B-X
the	B-X
involvement	B-X
of	B-X
FN	B-X
and	B-X
TG2	B-X
in	B-X
cancer	B-X
cell	B-X
metastasis	B-X
using	B-X
the	B-X
recently	B-X
established	B-X
highly	B-X
invasive	B-X
A431-III	B-X
subline	B-X
.	B-X
A431-III	B-X
cells	B-X
expressed	B-X
significantly	B-X
higher	B-X
levels	B-X
of	B-X
FN	B-X
and	B-X
TG2	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
parental	B-X
line	B-X
(	B-X
A431-P	B-X
)	B-X
.	B-X
Knockdown	B-X
of	B-X
endogenous	B-X
FN	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
resulted	B-X
in	B-X
dramatic	B-X
suppression	B-X
of	B-X
the	B-X
migratory	B-X
and	B-X
invasive	B-X
activity	B-X
,	B-X
and	B-X
the	B-X
secreted	B-X
MMP-9	B-X
activity	B-X
(	B-X
but	B-X
not	B-X
MMP-2	B-X
)	B-X
in	B-X
A431-III	B-X
subline	B-X
.	B-X
Exogenous	B-X
administration	B-X
of	B-X
FN	B-X
to	B-X
A431-III	B-X
cells	B-X
also	B-X
increased	B-X
the	B-X
secreted	B-X
activity	B-X
of	B-X
MMP-9	B-X
but	B-X
not	B-X
MMP-2	B-X
.	B-X
Interestingly	B-X
,	B-X
knockdown	B-X
of	B-X
TG2	B-X
by	B-X
siRNA	B-X
dramatically	B-X
reduced	B-X
the	B-X
cell	B-X
attachment	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
,	B-X
and	B-X
the	B-X
secretion	B-X
of	B-X
MMP-9	B-X
and	B-X
MMP-1	B-X
(	B-X
but	B-X
not	B-X
MMP-2	B-X
and	B-X
MMP-3	B-X
)	B-X
in	B-X
A431-III	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
A431-P	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
A431-III	B-X
cells	B-X
exhibited	B-X
increased	B-X
association	B-X
of	B-X
integrin	B-X
Î²1	B-X
and	B-X
Î²3	B-X
with	B-X
FN	B-X
and	B-X
TG2	B-X
,	B-X
and	B-X
knockdown	B-X
of	B-X
TG2	B-X
markedly	B-X
suppressed	B-X
integrin	B-X
Î²1	B-X
interaction	B-X
with	B-X
FN	B-X
.	B-X
Together	B-X
,	B-X
this	B-X
study	B-X
suggests	B-X
that	B-X
FN	B-X
and	B-X
TG2	B-X
facilitate	B-X
the	B-X
metastatic	B-X
activity	B-X
of	B-X
A431	B-X
tumor	B-X
cells	B-X
,	B-X
and	B-X
this	B-X
may	B-X
be	B-X
partly	B-X
attributed	B-X
to	B-X
TG2	B-X
enhancement	B-X
of	B-X
the	B-X
association	B-X
of	B-X
FN	B-X
and	B-X
Î²	B-X
integrin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
combined	B-X
targeting	B-X
of	B-X
TG2	B-X
and	B-X
FN	B-X
may	B-X
be	B-X
an	B-X
effective	B-X
therapeutic	B-X
strategy	B-X
for	B-X
cancer	B-X
displaying	B-X
increased	B-X
expression	B-X
of	B-X
both	B-X
proteins	B-X
.	B-X

ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
also	O
increased	O
Akt	B-Gene_or_gene_product
phosphorylation	O
,	O
which	O
caused	O
an	O
increase	O
in	O
cellular	O
migration	O
/	O
invasion	O
and	O
MMP	B-Gene_or_gene_product
activities	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
CREB	B-X
functions	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
between	B-X
Akt	B-X
and	B-X
MMP	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

Activity	O
of	O
several	O
transcriptional	O
factors	O
located	O
downstream	O
in	O
the	O
Akt	B-Gene_or_gene_product
pathway	O
was	O
also	O
tested	O
,	O
and	O
constitutive	O
activation	O
of	O
adenosine	B-Gene_or_gene_product
3	I-Gene_or_gene_product
'	I-Gene_or_gene_product
,	I-Gene_or_gene_product
5	I-Gene_or_gene_product
'	I-Gene_or_gene_product
-	I-Gene_or_gene_product
monophosphate	I-Gene_or_gene_product
response	I-Gene_or_gene_product
element	I-Gene_or_gene_product
-	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
(	O
CREB	B-Gene_or_gene_product
)	O
by	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
was	O
detected	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
CREB	B-X
functions	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
between	B-X
Akt	B-X
and	B-X
MMP	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

Blockage	O
of	O
the	O
Akt	B-Gene_or_gene_product
pathway	O
attenuated	O
CREB	B-Gene_or_gene_product
activation	O
,	O
and	O
a	O
decrease	O
in	O
CREB	B-Gene_or_gene_product
expression	O
reduced	O
cellular	O
migration	O
/	O
invasion	O
and	O
activity	O
of	O
MMPs	B-Gene_or_gene_product
.	O

This	O
result	O
indicates	O
that	O
CREB	B-Gene_or_gene_product
functions	O
in	O
the	O
signaling	O
pathway	O
between	O
Akt	B-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
.	O
<EOS>	B-X
Blood	B-X
levels	B-X
of	B-X
triglyceride-rich	B-X
lipoproteins	B-X
(	B-X
TRL	B-X
)	B-X
increase	B-X
postprandially	B-X
,	B-X
and	B-X
a	B-X
delay	B-X
in	B-X
their	B-X
clearance	B-X
results	B-X
in	B-X
postprandial	B-X
hyperlipidemia	B-X
,	B-X
an	B-X
important	B-X
risk	B-X
factor	B-X
in	B-X
atherosclerosis	B-X
development	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
provided	B-X
insights	B-X
into	B-X
the	B-X
mechanisms	B-X
of	B-X
uptake	B-X
and	B-X
the	B-X
signal	B-X
transduction	B-X
pathways	B-X
mediating	B-X
the	B-X
interactions	B-X
of	B-X
TRL	B-X
with	B-X
leukocytes	B-X
and	B-X
vascular	B-X
cells	B-X
,	B-X
and	B-X
how	B-X
they	B-X
are	B-X
modified	B-X
by	B-X
dietary	B-X
lipids	B-X
.	B-X
Multiple	B-X
receptor	B-X
and	B-X
non-receptor	B-X
mediated	B-X
pathways	B-X
function	B-X
in	B-X
macrophage	B-X
uptake	B-X
of	B-X
TRL	B-X
.	B-X
TRL	B-X
also	B-X
induce	B-X
expression	B-X
of	B-X
adhesion	B-X
molecules	B-X
,	B-X
cyclooxygenase-2	B-X
and	B-X
heme-oxygenase-1	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
and	B-X
activate	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
involving	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
,	B-X
NF-ÎºB	B-X
and	B-X
Nrf2	B-X
.	B-X

We	O
also	O
showed	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	O
induced	O
cell	O
migration	O
and	O
invasion	O
in	O
NCI	O
-	O
H460	O
NSCLC	O
cells	O
(	O
wild	O
-	O
type	O
p53	B-Gene_or_gene_product
and	O
PTEN	B-Gene_or_gene_product
cell	O
)	O
through	O
the	O
same	O
signaling	O
pathway	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
CREB	B-X
functions	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
between	B-X
Akt	B-X
and	B-X
MMP	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
stimulates	O
cancer	O
cell	O
migration	O
/	O
invasion	O
via	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
/	O
Akt	B-Gene_or_gene_product
/	O
CREB	B-Gene_or_gene_product
/	O
MMP	B-Gene_or_gene_product
pathway	O
regardless	O
of	O
p53	B-Gene_or_gene_product
and	O
PTEN	B-Gene_or_gene_product
status	O
,	O
and	O
this	O
reflects	O
the	O
possibility	O
that	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
could	O
be	O
considered	O
as	O
a	O
candidate	O
for	O
anti	O
-	O
cancer	O
drug	O
development	O
and	O
as	O
a	O
cancer	O
diagnostic	O
marker	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule-3	B-X
(	B-X
ICAM-3	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
cellular	B-X
radio-resistance	B-X
and	B-X
cancer	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
ICAM-3	B-X
has	B-X
an	B-X
additional	B-X
effect	B-X
on	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
because	B-X
molecules	B-X
induced	B-X
by	B-X
ICAM-3	B-X
are	B-X
known	B-X
as	B-X
regulators	B-X
of	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
To	B-X
examine	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
used	B-X
NCI-H1299	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
(	B-X
p53	B-X
and	B-X
PTEN	B-X
null	B-X
cell	B-X
)	B-X
and	B-X
constructed	B-X
an	B-X
ICAM-3-over-expressing	B-X
stable	B-X
transfectant	B-X
,	B-X
which	B-X
exhibited	B-X
increased	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
The	B-X
increased	B-X
migration	B-X
and	B-X
invasion	B-X
resulted	B-X
from	B-X
up-regulation	B-X
of	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
.	B-X
ICAM-3	B-X
also	B-X
increased	B-X
Akt	B-X
phosphorylation	B-X
,	B-X
which	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
MMP	B-X
activities	B-X
.	B-X
Activity	B-X
of	B-X
several	B-X
transcriptional	B-X
factors	B-X
located	B-X
downstream	B-X
in	B-X
the	B-X
Akt	B-X
pathway	B-X
was	B-X
also	B-X
tested	B-X
,	B-X
and	B-X
constitutive	B-X
activation	B-X
of	B-X
adenosine	B-X
3	B-X
'	B-X
,	B-X
5'-monophosphate	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
by	B-X
ICAM-3	B-X
was	B-X
detected	B-X
.	B-X
Blockage	B-X
of	B-X
the	B-X
Akt	B-X
pathway	B-X
attenuated	B-X
CREB	B-X
activation	B-X
,	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
CREB	B-X
expression	B-X
reduced	B-X
cellular	B-X
migration/invasion	B-X
and	B-X
activity	B-X
of	B-X
MMPs	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
CREB	B-X
functions	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
between	B-X
Akt	B-X
and	B-X
MMP	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
ICAM-3-induced	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
in	B-X
NCI-H460	B-X
NSCLC	B-X
cells	B-X
(	B-X
wild-type	B-X
p53	B-X
and	B-X
PTEN	B-X
cell	B-X
)	B-X
through	B-X
the	B-X
same	B-X
signaling	B-X
pathway	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
ICAM-3	B-X
stimulates	B-X
cancer	B-X
cell	B-X
migration/invasion	B-X
via	B-X
ICAM-3/Akt/CREB/MMP	B-X
pathway	B-X
regardless	B-X
of	B-X
p53	B-X
and	B-X
PTEN	B-X
status	B-X
,	B-X
and	B-X
this	B-X
reflects	B-X
the	B-X
possibility	B-X
that	B-X
ICAM-3	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
candidate	B-X
for	B-X
anti-cancer	B-X
drug	B-X
development	B-X
and	B-X
as	B-X
a	B-X
cancer	B-X
diagnostic	B-X
marker	B-X
.	B-X

The	O
role	O
of	O
p53	B-Gene_or_gene_product
in	O
glucose	O
metabolism	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
classic	B-X
activities	B-X
of	B-X
p53	B-X
including	B-X
induction	B-X
of	B-X
cell-cycle	B-X
arrest	B-X
,	B-X
senescence	B-X
,	B-X
and	B-X
apoptosis	B-X
are	B-X
well	B-X
accepted	B-X
as	B-X
critical	B-X
barriers	B-X
to	B-X
cancer	B-X
development	B-X
,	B-X
accumulating	B-X
evidence	B-X
suggests	B-X
that	B-X
loss	B-X
of	B-X
these	B-X
classic	B-X
activities	B-X
is	B-X
not	B-X
sufficient	B-X
to	B-X
abrogate	B-X
the	B-X
tumor	B-X
suppression	B-X
activity	B-X
of	B-X
p53	B-X
.	B-X
Cancer	B-X
cells	B-X
rewire	B-X
cellular	B-X
metabolism	B-X
to	B-X
meet	B-X
the	B-X
energetic	B-X
and	B-X
substrate	B-X
demands	B-X
of	B-X
tumor	B-X
development	B-X
.	B-X
It	B-X
is	B-X
well	B-X
established	B-X
that	B-X
p53	B-X
suppresses	B-X
glycolysis	B-X
and	B-X
promotes	B-X
mitochondrial	B-X
oxidative	B-X
phosphorylation	B-X
through	B-X
a	B-X
number	B-X
of	B-X
downstream	B-X
targets	B-X
against	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
The	B-X
role	B-X
of	B-X
p53-mediated	B-X
metabolic	B-X
regulation	B-X
in	B-X
tumor	B-X
suppression	B-X
is	B-X
complexed	B-X
by	B-X
its	B-X
function	B-X
to	B-X
promote	B-X
both	B-X
cell	B-X
survival	B-X
and	B-X
cell	B-X
death	B-X
under	B-X
different	B-X
physiological	B-X
settings	B-X
.	B-X
Indeed	B-X
,	B-X
p53	B-X
can	B-X
regulate	B-X
both	B-X
pro-oxidant	B-X
and	B-X
antioxidant	B-X
target	B-X
genes	B-X
for	B-X
complete	B-X
opposite	B-X
effects	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
summarize	B-X
the	B-X
roles	B-X
of	B-X
p53	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
glucose	B-X
,	B-X
lipid	B-X
,	B-X
amino	B-X
acid	B-X
,	B-X
nucleotide	B-X
,	B-X
iron	B-X
metabolism	B-X
,	B-X
and	B-X
ROS	B-X
production	B-X
.	B-X
We	B-X
will	B-X
highlight	B-X
the	B-X
mechanisms	B-X
underlying	B-X
p53-mediated	B-X
ferroptosis	B-X
,	B-X
AKT/mTOR	B-X
signaling	B-X
as	B-X
well	B-X
as	B-X
autophagy	B-X
and	B-X
discuss	B-X
the	B-X
complexity	B-X
of	B-X
p53-metabolic	B-X
regulation	B-X
in	B-X
tumor	B-X
development	B-X
.	B-X

The	O
p53	B-Gene_or_gene_product
protein	O
functions	O
to	O
prevent	O
tumour	O
development	O
by	O
inhibiting	O
the	O
outgrowth	O
of	O
stressed	O
or	O
damaged	O
cells	O
.	O
<EOS>	B-X
Autophagy	B-X
is	B-X
the	B-X
process	B-X
by	B-X
which	B-X
cells	B-X
can	B-X
selectively	B-X
or	B-X
non-selectively	B-X
remove	B-X
damaged	B-X
proteins	B-X
and	B-X
organelles	B-X
.	B-X
As	B-X
the	B-X
cell	B-X
's	B-X
main	B-X
means	B-X
of	B-X
sequestering	B-X
damaged	B-X
mitochondria	B-X
for	B-X
removal	B-X
,	B-X
mitophagy	B-X
is	B-X
central	B-X
to	B-X
cellular	B-X
function	B-X
and	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
summarize	B-X
key	B-X
signaling	B-X
molecules	B-X
that	B-X
consign	B-X
damaged	B-X
mitochondria	B-X
for	B-X
autophagic	B-X
degradation	B-X
,	B-X
describe	B-X
the	B-X
relationship	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
PD	B-X
to	B-X
autophagy/mitophagy	B-X
dysfunction	B-X
,	B-X
and	B-X
discuss	B-X
additional	B-X
roles	B-X
of	B-X
both	B-X
mitochondrial	B-X
and	B-X
cytosolic	B-X
pools	B-X
of	B-X
PTEN-induced	B-X
kinase	B-X
1	B-X
(	B-X
PINK1	B-X
)	B-X
in	B-X
mitochondrial	B-X
homeostasis	B-X
,	B-X
dendritic	B-X
morphogenesis	B-X
and	B-X
inflammation	B-X
.	B-X
cGAS	B-X
is	B-X
localized	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
nondividing	B-X
cells	B-X
but	B-X
enters	B-X
the	B-X
nucleus	B-X
and	B-X
associates	B-X
with	B-X
chromatin	B-X
DNA	B-X
during	B-X
mitosis	B-X
in	B-X
proliferating	B-X
cells	B-X
.	B-X
DNA	B-X
damage	B-X
leads	B-X
to	B-X
accumulation	B-X
of	B-X
damaged	B-X
DNA	B-X
in	B-X
cytoplasmic	B-X
foci	B-X
that	B-X
contain	B-X
cGAS	B-X
.	B-X

In	O
addition	O
to	O
well	O
established	O
functions	O
to	O
block	O
cell	O
proliferation	O
,	O
recent	O
studies	O
have	O
revealed	O
a	O
role	O
for	O
p53	B-Gene_or_gene_product
in	O
the	O
regulation	O
of	O
pathways	O
involved	O
in	O
glucose	O
metabolism	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
protein	B-X
functions	B-X
to	B-X
prevent	B-X
tumour	B-X
development	B-X
by	B-X
inhibiting	B-X
the	B-X
outgrowth	B-X
of	B-X
stressed	B-X
or	B-X
damaged	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
well	B-X
established	B-X
functions	B-X
to	B-X
block	B-X
cell	B-X
proliferation	B-X
,	B-X
recent	B-X
studies	B-X
have	B-X
revealed	B-X
a	B-X
role	B-X
for	B-X
p53	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pathways	B-X
involved	B-X
in	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
metabolic	B-X
functions	B-X
of	B-X
p53	B-X
resist	B-X
the	B-X
shift	B-X
to	B-X
glycolysis	B-X
that	B-X
is	B-X
characteristically	B-X
seen	B-X
in	B-X
cancers	B-X
,	B-X
and	B-X
also	B-X
help	B-X
cells	B-X
adapt	B-X
to	B-X
and	B-X
survive	B-X
limited	B-X
periods	B-X
of	B-X
metabolic	B-X
stress	B-X
.	B-X
Such	B-X
activities	B-X
of	B-X
p53	B-X
would	B-X
not	B-X
only	B-X
help	B-X
to	B-X
prevent	B-X
cancer	B-X
development	B-X
,	B-X
but	B-X
might	B-X
also	B-X
contribute	B-X
to	B-X
non-tumour	B-X
related	B-X
roles	B-X
for	B-X
p53	B-X
,	B-X
such	B-X
as	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
longevity	B-X
.	B-X
These	B-X
new	B-X
functions	B-X
of	B-X
p53	B-X
are	B-X
providing	B-X
interesting	B-X
possibilities	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapies	B-X
.	B-X

The	O
metabolic	O
functions	O
of	O
p53	B-Gene_or_gene_product
resist	O
the	O
shift	O
to	O
glycolysis	O
that	O
is	O
characteristically	O
seen	O
in	O
cancers	O
,	O
and	O
also	O
help	O
cells	O
adapt	O
to	O
and	O
survive	O
limited	O
periods	O
of	O
metabolic	O
stress	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
protein	B-X
functions	B-X
to	B-X
prevent	B-X
tumour	B-X
development	B-X
by	B-X
inhibiting	B-X
the	B-X
outgrowth	B-X
of	B-X
stressed	B-X
or	B-X
damaged	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
well	B-X
established	B-X
functions	B-X
to	B-X
block	B-X
cell	B-X
proliferation	B-X
,	B-X
recent	B-X
studies	B-X
have	B-X
revealed	B-X
a	B-X
role	B-X
for	B-X
p53	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pathways	B-X
involved	B-X
in	B-X
glucose	B-X
metabolism	B-X
.	B-X
The	B-X
metabolic	B-X
functions	B-X
of	B-X
p53	B-X
resist	B-X
the	B-X
shift	B-X
to	B-X
glycolysis	B-X
that	B-X
is	B-X
characteristically	B-X
seen	B-X
in	B-X
cancers	B-X
,	B-X
and	B-X
also	B-X
help	B-X
cells	B-X
adapt	B-X
to	B-X
and	B-X
survive	B-X
limited	B-X
periods	B-X
of	B-X
metabolic	B-X
stress	B-X
.	B-X
Such	B-X
activities	B-X
of	B-X
p53	B-X
would	B-X
not	B-X
only	B-X
help	B-X
to	B-X
prevent	B-X
cancer	B-X
development	B-X
,	B-X
but	B-X
might	B-X
also	B-X
contribute	B-X
to	B-X
non-tumour	B-X
related	B-X
roles	B-X
for	B-X
p53	B-X
,	B-X
such	B-X
as	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
longevity	B-X
.	B-X
These	B-X
new	B-X
functions	B-X
of	B-X
p53	B-X
are	B-X
providing	B-X
interesting	B-X
possibilities	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapies	B-X
.	B-X

Such	O
activities	O
of	O
p53	B-Gene_or_gene_product
would	O
not	O
only	O
help	O
to	O
prevent	O
cancer	O
development	O
,	O
but	O
might	O
also	O
contribute	O
to	O
non	O
-	O
tumour	O
related	O
roles	O
for	O
p53	B-Gene_or_gene_product
,	O
such	O
as	O
in	O
the	O
regulation	O
of	O
longevity	O
.	O
<EOS>	B-X
p53	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
protein	B-X
involved	B-X
in	B-X
regulating	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
signaling	B-X
pathways	B-X
.	B-X
The	B-X
role	B-X
of	B-X
p53	B-X
in	B-X
the	B-X
cell	B-X
is	B-X
determined	B-X
by	B-X
the	B-X
type	B-X
of	B-X
imposed	B-X
oxidative	B-X
stress	B-X
,	B-X
its	B-X
intensity	B-X
and	B-X
duration	B-X
.	B-X
The	B-X
last	B-X
decade	B-X
of	B-X
research	B-X
has	B-X
unravelled	B-X
a	B-X
dual	B-X
nature	B-X
in	B-X
the	B-X
function	B-X
of	B-X
p53	B-X
in	B-X
mediating	B-X
the	B-X
oxidative	B-X
stress	B-X
burden	B-X
.	B-X
As	B-X
a	B-X
genome	B-X
guardian	B-X
,	B-X
p53	B-X
maintains	B-X
genome	B-X
stability	B-X
by	B-X
arresting	B-X
cells	B-X
for	B-X
damage	B-X
repair	B-X
or	B-X
inducing	B-X
cell	B-X
apoptosis	B-X
to	B-X
eliminate	B-X
the	B-X
damaged	B-X
cells	B-X
in	B-X
stress	B-X
response	B-X
.	B-X
Several	B-X
nucleolar	B-X
proteins	B-X
stabilize	B-X
p53	B-X
by	B-X
interfering	B-X
Mdm2-p53	B-X
interaction	B-X
upon	B-X
cellular	B-X
stress	B-X
,	B-X
while	B-X
other	B-X
mechanisms	B-X
by	B-X
which	B-X
nucleolar	B-X
proteins	B-X
activate	B-X
p53	B-X
remain	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
NAT10	B-X
as	B-X
a	B-X
novel	B-X
regulator	B-X
for	B-X
p53	B-X
activation	B-X
.	B-X
NAT10	B-X
acetylates	B-X
p53	B-X
at	B-X
K120	B-X
and	B-X
stabilizes	B-X
p53	B-X
by	B-X
counteracting	B-X
Mdm2	B-X
action	B-X
.	B-X
After	B-X
DNA	B-X
damage	B-X
,	B-X
NAT10	B-X
translocates	B-X
to	B-X
nucleoplasm	B-X
and	B-X
activates	B-X
p53-mediated	B-X
cell	B-X
cycle	B-X
control	B-X
and	B-X
apoptosis	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
NAT10	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
p53	B-X
activation	B-X
via	B-X
acetylating	B-X
p53	B-X
and	B-X
counteracting	B-X
Mdm2	B-X
action	B-X
,	B-X
providing	B-X
a	B-X
novel	B-X
pathway	B-X
by	B-X
which	B-X
nucleolar	B-X
protein	B-X
activates	B-X
p53	B-X
as	B-X
a	B-X
cellular	B-X
stress	B-X
sensor	B-X
.	B-X

These	O
new	O
functions	O
of	O
p53	B-Gene_or_gene_product
are	O
providing	O
interesting	O
possibilities	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
.	O
<EOS>	B-X
Mouse	B-X
Double	B-X
Minute	B-X
2	B-X
protein	B-X
(	B-X
MDM2	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
regulator	B-X
of	B-X
p53	B-X
tumor	B-X
suppressor	B-X
(	B-X
p53	B-X
)	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
MDM2	B-X
and	B-X
p53	B-X
proteins	B-X
is	B-X
a	B-X
promising	B-X
anticancer	B-X
therapy	B-X
.	B-X
Therefore	B-X
,	B-X
novel	B-X
and	B-X
more	B-X
effective	B-X
therapies	B-X
for	B-X
these	B-X
aggressive	B-X
neoplasias	B-X
are	B-X
urgently	B-X
needed	B-X
.	B-X
To	B-X
date	B-X
,	B-X
one	B-X
of	B-X
the	B-X
best-characterized	B-X
genetic	B-X
alterations	B-X
leading	B-X
to	B-X
the	B-X
development	B-X
of	B-X
poorly	B-X
differentiated	B-X
thyroid	B-X
tumors	B-X
is	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
p53	B-X
tumor	B-X
suppressor	B-X
gene	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
complex	B-X
network	B-X
among	B-X
p53	B-X
family	B-X
members	B-X
(	B-X
p63	B-X
and	B-X
p73	B-X
)	B-X
and	B-X
their	B-X
interactions	B-X
with	B-X
other	B-X
factors	B-X
that	B-X
promote	B-X
thyroid	B-X
cancer	B-X
progression	B-X
has	B-X
been	B-X
well	B-X
documented	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
update	B-X
on	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
the	B-X
role	B-X
of	B-X
p53	B-X
family	B-X
proteins	B-X
in	B-X
thyroid	B-X
cancer	B-X
and	B-X
their	B-X
possible	B-X
use	B-X
as	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
the	B-X
most	B-X
aggressive	B-X
variants	B-X
of	B-X
this	B-X
disease	B-X
.	B-X

14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
Overexpression	O
and	O
abnormal	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
expression	O
are	O
associated	O
with	O
poor	O
differentiation	O
and	O
progression	O
in	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
interacted	O
with	O
other	O
key	O
cellular	O
proteins	O
involved	O
in	O
the	O
tumor	O
development	O
and	O
progression	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

Knowledge	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
and	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
expression	O
and	O
clinical	O
significance	O
in	O
the	O
same	O
tumor	O
tissues	O
is	O
limited	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Specimens	B-X
of	B-X
NSCLC	B-X
and	B-X
adjacent	B-X
normal	B-X
lung	B-X
tissues	B-X
were	B-X
collected	B-X
from	B-X
110	B-X
patients	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
significance	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
and	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
in	O
stage	O
I	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Specimens	O
of	O
NSCLC	O
and	O
adjacent	O
normal	O
lung	O
tissues	O
were	O
collected	O
from	O
110	O
patients	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Specimens	B-X
of	B-X
NSCLC	B-X
and	B-X
adjacent	B-X
normal	B-X
lung	B-X
tissues	B-X
were	B-X
collected	B-X
from	B-X
110	B-X
patients	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

The	O
expressions	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
and	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
were	O
detected	O
by	O
western	O
blotting	O
,	O
double	O
labeling	O
immunofluorescence	O
,	O
confocal	O
laser	O
scanning	O
microscopy	O
and	O
immunohistochemistry	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

The	O
expression	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
was	O
upregulated	O
in	O
stage	O
I	O
NSCLC	O
.	O

Further	O
,	O
the	O
overexpression	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
correlated	O
with	O
histological	O
grades	O
,	O
lymph	O
node	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

Further	O
,	O
the	O
overexpression	O
of	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
correlated	O
with	O
histological	O
grades	O
,	O
lymph	O
node	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

Abnormal	O
expression	O
of	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
was	O
significantly	O
correlated	O
with	O
poor	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Î²-catenin	B-X
immunohistochemical	B-X
expression	B-X
on	B-X
the	B-X
prognosis	B-X
of	B-X
gastric	B-X
cancer	B-X
(	B-X
GC	B-X
)	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X

Abnormal	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
expression	O
was	O
associated	O
significantly	O
with	O
positive	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

In	O
conclusion	O
,	O
14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
and	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
might	O
have	O
an	O
important	O
role	O
in	O
development	O
,	O
progression	O
and	O
metastatic	O
process	O
of	O
NSCLC	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
14-3-3Î¶	B-X
interacted	B-X
with	B-X
other	B-X
key	B-X
cellular	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
tumor	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Knowledge	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
expression	B-X
and	B-X
clinical	B-X
significance	B-X
in	B-X
the	B-X
same	B-X
tumor	B-X
tissues	B-X
is	B-X
limited	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
significance	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
in	B-X
stage	B-X
I	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Specimens	B-X
of	B-X
NSCLC	B-X
and	B-X
adjacent	B-X
normal	B-X
lung	B-X
tissues	B-X
were	B-X
collected	B-X
from	B-X
110	B-X
patients	B-X
.	B-X
The	B-X
expressions	B-X
of	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blotting	B-X
,	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
confocal	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
immunohistochemistry	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
14-3-3Î¶	B-X
was	B-X
upregulated	B-X
in	B-X
stage	B-X
I	B-X
NSCLC	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
14-3-3Î¶	B-X
correlated	B-X
with	B-X
histological	B-X
grades	B-X
,	B-X
lymph	B-X
node	B-X
metastasis	B-X
and	B-X
poor	B-X
clinical	B-X
outcome	B-X
.	B-X
Abnormal	B-X
expression	B-X
of	B-X
Î²-catenin	B-X
was	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
differentiation	B-X
and	B-X
lymph	B-X
node	B-X
metastasis	B-X
.	B-X
Abnormal	B-X
Î²-catenin	B-X
expression	B-X
was	B-X
associated	B-X
significantly	B-X
with	B-X
positive	B-X
14-3-3Î¶	B-X
expression	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
14-3-3Î¶	B-X
and	B-X
Î²-catenin	B-X
might	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
development	B-X
,	B-X
progression	B-X
and	B-X
metastatic	B-X
process	B-X
of	B-X
NSCLC	B-X
.	B-X
14-3-3Î¶	B-X
might	B-X
be	B-X
used	B-X
as	B-X
prognostic	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
.	B-X

14	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3zeta	I-Gene_or_gene_product
might	O
be	O
used	O
as	O
prognostic	O
biomarkers	O
for	O
NSCLC	O
.	O
<EOS>	B-X
A	B-X
functional	B-X
genomic	B-X
approach	B-X
integrating	B-X
microarray	B-X
and	B-X
proteomic	B-X
analyses	B-X
done	B-X
in	B-X
our	B-X
laboratory	B-X
has	B-X
identified	B-X
14-3-3zeta	B-X
as	B-X
a	B-X
putative	B-X
oncogene	B-X
whose	B-X
activation	B-X
was	B-X
common	B-X
and	B-X
driven	B-X
by	B-X
its	B-X
genomic	B-X
amplification	B-X
in	B-X
lung	B-X
adenocarcinomas	B-X
.	B-X
14-3-3zeta	B-X
is	B-X
believed	B-X
to	B-X
function	B-X
in	B-X
cell	B-X
signaling	B-X
,	B-X
cycle	B-X
control	B-X
,	B-X
and	B-X
apoptotic	B-X
death	B-X
.	B-X
Following	B-X
our	B-X
initial	B-X
finding	B-X
,	B-X
here	B-X
,	B-X
we	B-X
analyzed	B-X
its	B-X
expression	B-X
in	B-X
lung	B-X
tumor	B-X
tissues	B-X
obtained	B-X
from	B-X
205	B-X
patients	B-X
with	B-X
various	B-X
histologic	B-X
and	B-X
stage	B-X
non-small	B-X
cell	B-X
lung	B-X
cancers	B-X
(	B-X
NSCLC	B-X
)	B-X
using	B-X
immunohistochemistry	B-X
and	B-X
then	B-X
explored	B-X
the	B-X
effects	B-X
of	B-X
specific	B-X
suppression	B-X
of	B-X
the	B-X
gene	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
a	B-X
xenograft	B-X
model	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
.	B-X
The	B-X
increased	B-X
14-3-3zeta	B-X
expression	B-X
was	B-X
positively	B-X
correlated	B-X
with	B-X
a	B-X
more	B-X
advanced	B-X
pathologic	B-X
stage	B-X
and	B-X
grade	B-X
of	B-X
NSCLCs	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
and	B-X
P	B-X
=	B-X
0.006	B-X
,	B-X
respectively	B-X
)	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
overall	B-X
and	B-X
cancer-specific	B-X
survival	B-X
rates	B-X
of	B-X
the	B-X
patients	B-X
(	B-X
P	B-X
=	B-X
0.022	B-X
and	B-X
P	B-X
=	B-X
0.018	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Down-regulation	B-X
of	B-X
14-3-3zeta	B-X
in	B-X
lung	B-X
cancer	B-X
cells	B-X
led	B-X
to	B-X
a	B-X
dose-dependent	B-X
increased	B-X
sensitivity	B-X
to	B-X
cisplatin-induced	B-X
cell	B-X
death	B-X
,	B-X
which	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
increased	B-X
G2-M	B-X
arrest	B-X
and	B-X
apoptosis	B-X
.	B-X
The	B-X
result	B-X
was	B-X
further	B-X
confirmed	B-X
in	B-X
the	B-X
animal	B-X
model	B-X
,	B-X
which	B-X
showed	B-X
that	B-X
the	B-X
A549	B-X
lung	B-X
cancer	B-X
cells	B-X
with	B-X
reduced	B-X
14-3-3zeta	B-X
grew	B-X
significantly	B-X
slower	B-X
than	B-X
the	B-X
wild-type	B-X
A549	B-X
cells	B-X
after	B-X
cisplatin	B-X
treatment	B-X
(	B-X
P	B-X
=	B-X
0.008	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
14-3-3zeta	B-X
is	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
developing	B-X
a	B-X
prognostic	B-X
biomarker	B-X
and	B-X
therapeutics	B-X
that	B-X
can	B-X
enhance	B-X
the	B-X
antitumor	B-X
activity	B-X
of	B-X
cisplatin	B-X
for	B-X
NSCLC	B-X
.	B-X

p24	B-Gene_or_gene_product
family	I-Gene_or_gene_product
type	I-Gene_or_gene_product
1	I-Gene_or_gene_product
transmembrane	I-Gene_or_gene_product
proteins	I-Gene_or_gene_product
are	O
required	O
for	O
insulin	B-Gene_or_gene_product
biosynthesis	O
and	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O
<EOS>	B-X
The	B-X
p24	B-X
protein	B-X
family	B-X
have	B-X
multiple	B-X
functions	B-X
in	B-X
protein	B-X
transport	B-X
in	B-X
the	B-X
early	B-X
secretory	B-X
pathway	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
p24	B-X
proteins	B-X
in	B-X
insulin	B-X
transport	B-X
.	B-X
Several	B-X
members	B-X
were	B-X
detected	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
and	B-X
rat	B-X
islets	B-X
and	B-X
expression	B-X
levels	B-X
positively	B-X
correlated	B-X
with	B-X
insulin	B-X
abundance	B-X
,	B-X
particularly	B-X
for	B-X
p24delta1	B-X
and	B-X
p24beta1	B-X
.	B-X
Knocking	B-X
down	B-X
p24delta1	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
also	B-X
resulted	B-X
in	B-X
the	B-X
concomitant	B-X
knock-down	B-X
of	B-X
other	B-X
family	B-X
members	B-X
,	B-X
impaired	B-X
glucose-stimulated	B-X
insulin	B-X
secretion	B-X
,	B-X
decreased	B-X
total	B-X
cellular	B-X
insulin	B-X
content	B-X
and	B-X
reduced	B-X
proinsulin	B-X
biosynthesis	B-X
.	B-X
There	B-X
was	B-X
no	B-X
effect	B-X
on	B-X
overall	B-X
protein	B-X
biosynthesis	B-X
or	B-X
ER	B-X
stress	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p24delta1	B-X
and	B-X
possibly	B-X
other	B-X
p24	B-X
family	B-X
proteins	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
insulin	B-X
biosynthesis	B-X
and	B-X
subsequent	B-X
secretion	B-X
in	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X

The	O
p24	B-Gene_or_gene_product
protein	I-Gene_or_gene_product
family	I-Gene_or_gene_product
have	O
multiple	O
functions	O
in	O
protein	O
transport	O
in	O
the	O
early	O
secretory	O
pathway	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
show	B-X
that	B-X
small	B-X
trans-membrane	B-X
proteins	B-X
of	B-X
approximately	B-X
22-24	B-X
kDa	B-X
(	B-X
the	B-X
p24	B-X
family	B-X
)	B-X
,	B-X
which	B-X
are	B-X
grouped	B-X
into	B-X
4	B-X
sub-families	B-X
by	B-X
sequence	B-X
homology	B-X
(	B-X
p23	B-X
,	B-X
p24	B-X
,	B-X
p25	B-X
and	B-X
p26	B-X
)	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
early	B-X
secretory	B-X
pathway	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
the	B-X
mutual	B-X
requirements	B-X
of	B-X
ectopically	B-X
expressed	B-X
members	B-X
of	B-X
the	B-X
p24	B-X
family	B-X
for	B-X
targeting	B-X
to	B-X
their	B-X
proper	B-X
cellular	B-X
destination	B-X
.	B-X
We	B-X
find	B-X
that	B-X
coexpression	B-X
of	B-X
p23	B-X
and	B-X
p24	B-X
is	B-X
both	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
each	B-X
protein	B-X
to	B-X
be	B-X
transported	B-X
to	B-X
the	B-X
cis-Golgi	B-X
network/Golgi	B-X
complex	B-X
.	B-X
Proteins	B-X
from	B-X
other	B-X
subfamilies	B-X
did	B-X
not	B-X
substitute	B-X
for	B-X
either	B-X
p23	B-X
or	B-X
p24	B-X
,	B-X
even	B-X
after	B-X
multiple	B-X
coexpression	B-X
.	B-X
However	B-X
,	B-X
trafficking	B-X
of	B-X
the	B-X
p23/p24	B-X
couple	B-X
was	B-X
facilitated	B-X
by	B-X
coexpression	B-X
of	B-X
proteins	B-X
from	B-X
other	B-X
sub-families	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
sequence	B-X
resembling	B-X
an	B-X
endoplasmic	B-X
reticulum	B-X
retrieval	B-X
signal	B-X
present	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
p23	B-X
(	B-X
but	B-X
not	B-X
p24	B-X
)	B-X
is	B-X
dispensable	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
conserved	B-X
coiled-coil	B-X
region	B-X
in	B-X
the	B-X
lumenal	B-X
domain	B-X
is	B-X
absolutely	B-X
required	B-X
in	B-X
both	B-X
p23	B-X
and	B-X
p24	B-X
for	B-X
proper	B-X
targeting	B-X
of	B-X
the	B-X
p23/p24	B-X
couple	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
p23	B-X
and	B-X
p24	B-X
must	B-X
interact	B-X
with	B-X
each	B-X
other	B-X
to	B-X
reach	B-X
their	B-X
destination	B-X
,	B-X
but	B-X
that	B-X
this	B-X
strict	B-X
requirement	B-X
is	B-X
combined	B-X
with	B-X
a	B-X
mutual	B-X
dependence	B-X
amongst	B-X
p24	B-X
proteins	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
p24	B-X
proteins	B-X
can	B-X
form	B-X
different	B-X
oligomeric	B-X
complexes	B-X
,	B-X
which	B-X
contribute	B-X
to	B-X
confer	B-X
specialized	B-X
sorting/trafficking	B-X
properties	B-X
to	B-X
membranes	B-X
of	B-X
the	B-X
early	B-X
secretory	B-X
pathway	B-X
,	B-X
perhaps	B-X
serving	B-X
as	B-X
membrane	B-X
organizers	B-X
.	B-X

In	O
this	O
study	O
we	O
examined	O
the	O
role	O
of	O
p24	B-Gene_or_gene_product
proteins	I-Gene_or_gene_product
in	O
insulin	B-Gene_or_gene_product
transport	O
.	O
<EOS>	B-X
The	B-X
p24	B-X
protein	B-X
family	B-X
have	B-X
multiple	B-X
functions	B-X
in	B-X
protein	B-X
transport	B-X
in	B-X
the	B-X
early	B-X
secretory	B-X
pathway	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
p24	B-X
proteins	B-X
in	B-X
insulin	B-X
transport	B-X
.	B-X
Several	B-X
members	B-X
were	B-X
detected	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
and	B-X
rat	B-X
islets	B-X
and	B-X
expression	B-X
levels	B-X
positively	B-X
correlated	B-X
with	B-X
insulin	B-X
abundance	B-X
,	B-X
particularly	B-X
for	B-X
p24delta1	B-X
and	B-X
p24beta1	B-X
.	B-X
Knocking	B-X
down	B-X
p24delta1	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
also	B-X
resulted	B-X
in	B-X
the	B-X
concomitant	B-X
knock-down	B-X
of	B-X
other	B-X
family	B-X
members	B-X
,	B-X
impaired	B-X
glucose-stimulated	B-X
insulin	B-X
secretion	B-X
,	B-X
decreased	B-X
total	B-X
cellular	B-X
insulin	B-X
content	B-X
and	B-X
reduced	B-X
proinsulin	B-X
biosynthesis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p24delta1	B-X
and	B-X
possibly	B-X
other	B-X
p24	B-X
family	B-X
proteins	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
insulin	B-X
biosynthesis	B-X
and	B-X
subsequent	B-X
secretion	B-X
in	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X

Several	O
members	O
were	O
detected	O
in	O
insulinoma	O
cell	O
lines	O
and	O
rat	O
islets	O
and	O
expression	O
levels	O
positively	O
correlated	O
with	O
insulin	B-Gene_or_gene_product
abundance	O
,	O
particularly	O
for	O
p24delta1	B-Gene_or_gene_product
and	O
p24beta1	B-Gene_or_gene_product
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
p24	B-X
proteins	B-X
in	B-X
insulin	B-X
transport	B-X
.	B-X
Several	B-X
members	B-X
were	B-X
detected	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
and	B-X
rat	B-X
islets	B-X
and	B-X
expression	B-X
levels	B-X
positively	B-X
correlated	B-X
with	B-X
insulin	B-X
abundance	B-X
,	B-X
particularly	B-X
for	B-X
p24delta1	B-X
and	B-X
p24beta1	B-X
.	B-X
Knocking	B-X
down	B-X
p24delta1	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
also	B-X
resulted	B-X
in	B-X
the	B-X
concomitant	B-X
knock-down	B-X
of	B-X
other	B-X
family	B-X
members	B-X
,	B-X
impaired	B-X
glucose-stimulated	B-X
insulin	B-X
secretion	B-X
,	B-X
decreased	B-X
total	B-X
cellular	B-X
insulin	B-X
content	B-X
and	B-X
reduced	B-X
proinsulin	B-X
biosynthesis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p24delta1	B-X
and	B-X
possibly	B-X
other	B-X
p24	B-X
family	B-X
proteins	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
insulin	B-X
biosynthesis	B-X
and	B-X
subsequent	B-X
secretion	B-X
in	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X

Knocking	O
down	O
p24delta1	B-Gene_or_gene_product
in	O
insulinoma	O
cell	O
lines	O
,	O
which	O
also	O
resulted	O
in	O
the	O
concomitant	O
knock	O
-	O
down	O
of	O
other	O
family	O
members	O
,	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	B-Gene_or_gene_product
secretion	O
,	O
decreased	O
total	O
cellular	O
insulin	B-Gene_or_gene_product
content	O
and	O
reduced	O
proinsulin	B-Gene_or_gene_product
biosynthesis	O
.	O
<EOS>	B-X
The	B-X
p24	B-X
protein	B-X
family	B-X
have	B-X
multiple	B-X
functions	B-X
in	B-X
protein	B-X
transport	B-X
in	B-X
the	B-X
early	B-X
secretory	B-X
pathway	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
p24	B-X
proteins	B-X
in	B-X
insulin	B-X
transport	B-X
.	B-X
Several	B-X
members	B-X
were	B-X
detected	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
and	B-X
rat	B-X
islets	B-X
and	B-X
expression	B-X
levels	B-X
positively	B-X
correlated	B-X
with	B-X
insulin	B-X
abundance	B-X
,	B-X
particularly	B-X
for	B-X
p24delta1	B-X
and	B-X
p24beta1	B-X
.	B-X
Knocking	B-X
down	B-X
p24delta1	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
also	B-X
resulted	B-X
in	B-X
the	B-X
concomitant	B-X
knock-down	B-X
of	B-X
other	B-X
family	B-X
members	B-X
,	B-X
impaired	B-X
glucose-stimulated	B-X
insulin	B-X
secretion	B-X
,	B-X
decreased	B-X
total	B-X
cellular	B-X
insulin	B-X
content	B-X
and	B-X
reduced	B-X
proinsulin	B-X
biosynthesis	B-X
.	B-X
There	B-X
was	B-X
no	B-X
effect	B-X
on	B-X
overall	B-X
protein	B-X
biosynthesis	B-X
or	B-X
ER	B-X
stress	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p24delta1	B-X
and	B-X
possibly	B-X
other	B-X
p24	B-X
family	B-X
proteins	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
insulin	B-X
biosynthesis	B-X
and	B-X
subsequent	B-X
secretion	B-X
in	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X

There	O
was	O
no	O
effect	O
on	O
overall	O
protein	O
biosynthesis	O
or	O
ER	B-Gene_or_gene_product
stress	O
.	O
<EOS>	B-X
Cancer	B-X
cells	B-X
encounter	B-X
numerous	B-X
stresses	B-X
that	B-X
pose	B-X
a	B-X
threat	B-X
to	B-X
their	B-X
survival	B-X
.	B-X
Tumor	B-X
microenviroment	B-X
stresses	B-X
that	B-X
perturb	B-X
protein	B-X
homeostasis	B-X
can	B-X
produce	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress	B-X
,	B-X
which	B-X
can	B-X
be	B-X
counterbalanced	B-X
by	B-X
triggering	B-X
the	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
which	B-X
is	B-X
considered	B-X
the	B-X
canonical	B-X
ER	B-X
stress	B-X
response	B-X
.	B-X
The	B-X
UPR	B-X
is	B-X
characterized	B-X
by	B-X
three	B-X
major	B-X
proteins	B-X
that	B-X
lead	B-X
to	B-X
specific	B-X
changes	B-X
in	B-X
transcriptional	B-X
and	B-X
translational	B-X
programs	B-X
in	B-X
stressed	B-X
cells	B-X
.	B-X
More	B-X
recently	B-X
several	B-X
new	B-X
pathways	B-X
that	B-X
connect	B-X
cell	B-X
stresses	B-X
,	B-X
components	B-X
of	B-X
the	B-X
UPR	B-X
and	B-X
autophagy	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
which	B-X
together	B-X
can	B-X
be	B-X
viewed	B-X
as	B-X
non-canonical	B-X
ER	B-X
stress	B-X
responses	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
recent	B-X
findings	B-X
on	B-X
the	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
canonical	B-X
and	B-X
non-canonical	B-X
ER	B-X
stress	B-X
responses	B-X
can	B-X
activate	B-X
cytoprotective	B-X
autophagy	B-X
and	B-X
contribute	B-X
to	B-X
tumor	B-X
growth	B-X
and	B-X
therapy	B-X
resistance	B-X
.	B-X
It	B-X
may	B-X
be	B-X
the	B-X
case	B-X
that	B-X
targeting	B-X
the	B-X
UPR	B-X
or	B-X
non-canonical	B-X
ER	B-X
stress	B-X
programs	B-X
can	B-X
more	B-X
effectively	B-X
block	B-X
cytoprotective	B-X
autophagy	B-X
to	B-X
enhance	B-X
cancer	B-X
therapy	B-X
.	B-X

These	O
results	O
suggest	O
that	O
p24delta1	B-Gene_or_gene_product
and	O
possibly	O
other	O
p24	B-Gene_or_gene_product
family	I-Gene_or_gene_product
proteins	I-Gene_or_gene_product
are	O
required	O
for	O
normal	O
insulin	B-Gene_or_gene_product
biosynthesis	O
and	O
subsequent	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O
<EOS>	B-X
The	B-X
p24	B-X
protein	B-X
family	B-X
have	B-X
multiple	B-X
functions	B-X
in	B-X
protein	B-X
transport	B-X
in	B-X
the	B-X
early	B-X
secretory	B-X
pathway	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
p24	B-X
proteins	B-X
in	B-X
insulin	B-X
transport	B-X
.	B-X
Several	B-X
members	B-X
were	B-X
detected	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
and	B-X
rat	B-X
islets	B-X
and	B-X
expression	B-X
levels	B-X
positively	B-X
correlated	B-X
with	B-X
insulin	B-X
abundance	B-X
,	B-X
particularly	B-X
for	B-X
p24delta1	B-X
and	B-X
p24beta1	B-X
.	B-X
Knocking	B-X
down	B-X
p24delta1	B-X
in	B-X
insulinoma	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
also	B-X
resulted	B-X
in	B-X
the	B-X
concomitant	B-X
knock-down	B-X
of	B-X
other	B-X
family	B-X
members	B-X
,	B-X
impaired	B-X
glucose-stimulated	B-X
insulin	B-X
secretion	B-X
,	B-X
decreased	B-X
total	B-X
cellular	B-X
insulin	B-X
content	B-X
and	B-X
reduced	B-X
proinsulin	B-X
biosynthesis	B-X
.	B-X
There	B-X
was	B-X
no	B-X
effect	B-X
on	B-X
overall	B-X
protein	B-X
biosynthesis	B-X
or	B-X
ER	B-X
stress	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p24delta1	B-X
and	B-X
possibly	B-X
other	B-X
p24	B-X
family	B-X
proteins	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
insulin	B-X
biosynthesis	B-X
and	B-X
subsequent	B-X
secretion	B-X
in	B-X
pancreatic	B-X
beta-cells	B-X
.	B-X

Expression	O
of	O
KISS1	B-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
their	O
relations	O
to	O
metastasis	O
and	O
survival	O
.	O
<EOS>	B-X
KISS1	B-X
and	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
may	B-X
play	B-X
important	B-X
roles	B-X
as	B-X
metastasis	B-X
suppressor	B-X
and	B-X
metastasis	B-X
promoter	B-X
genes	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
little	B-X
information	B-X
about	B-X
their	B-X
possible	B-X
roles	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
goals	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
in	B-X
NSCLC	B-X
and	B-X
their	B-X
relations	B-X
to	B-X
metastasis	B-X
and	B-X
prognosis	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
of	B-X
MMP-9	B-X
protein	B-X
were	B-X
detected	B-X
by	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
immunohistochemistry	B-X
respectively	B-X
in	B-X
85	B-X
cases	B-X
of	B-X
NSCLC	B-X
,	B-X
and	B-X
their	B-X
matched	B-X
lymph	B-X
node	B-X
metastases	B-X
.	B-X
Expressions	B-X
of	B-X
KISS1	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
low	B-X
TNM	B-X
stages	B-X
of	B-X
NSCLC	B-X
(	B-X
I-II	B-X
)	B-X
compared	B-X
to	B-X
more	B-X
advanced	B-X
stages	B-X
(	B-X
III-IV	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
advanced	B-X
TNM	B-X
stages	B-X
,	B-X
cases	B-X
without	B-X
metastasis	B-X
had	B-X
higher	B-X
KISS1	B-X
gene	B-X
expression	B-X
compared	B-X
to	B-X
those	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
MMP-9	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
stage	B-X
III-IV	B-X
NSCLC	B-X
cases	B-X
compared	B-X
to	B-X
stage	B-X
I-II	B-X
tumors	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
higher	B-X
in	B-X
NSCLC	B-X
cases	B-X
with	B-X
metastasis	B-X
than	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
There	B-X
was	B-X
negative	B-X
correction	B-X
between	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
protein	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
5-year	B-X
survival	B-X
rate	B-X
in	B-X
cases	B-X
with	B-X
higher	B-X
KISS1	B-X
protein	B-X
expression	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
20.9	B-X
vs.	B-X
2.4	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
5-year	B-X
survival	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
high	B-X
MMP-9	B-X
protein	B-X
expression	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
19	B-X
vs.	B-X
4.7	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
may	B-X
serve	B-X
as	B-X
potential	B-X
prognostic	B-X
and	B-X
therapeutic	B-X
markers	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X

KISS1	B-Gene_or_gene_product
and	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
(	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
)	O
may	O
play	O
important	O
roles	O
as	O
metastasis	O
suppressor	O
and	O
metastasis	O
promoter	O
genes	O
,	O
respectively	O
,	O
in	O
a	O
variety	O
of	O
malignancies	O
.	O

However	O
,	O
there	O
is	O
little	O
information	O
about	O
their	O
possible	O
roles	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O
<EOS>	B-X
KISS1	B-X
and	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
may	B-X
play	B-X
important	B-X
roles	B-X
as	B-X
metastasis	B-X
suppressor	B-X
and	B-X
metastasis	B-X
promoter	B-X
genes	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
little	B-X
information	B-X
about	B-X
their	B-X
possible	B-X
roles	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
goals	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
in	B-X
NSCLC	B-X
and	B-X
their	B-X
relations	B-X
to	B-X
metastasis	B-X
and	B-X
prognosis	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
of	B-X
MMP-9	B-X
protein	B-X
were	B-X
detected	B-X
by	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
immunohistochemistry	B-X
respectively	B-X
in	B-X
85	B-X
cases	B-X
of	B-X
NSCLC	B-X
,	B-X
and	B-X
their	B-X
matched	B-X
lymph	B-X
node	B-X
metastases	B-X
.	B-X
Expressions	B-X
of	B-X
KISS1	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
low	B-X
TNM	B-X
stages	B-X
of	B-X
NSCLC	B-X
(	B-X
I-II	B-X
)	B-X
compared	B-X
to	B-X
more	B-X
advanced	B-X
stages	B-X
(	B-X
III-IV	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
MMP-9	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
stage	B-X
III-IV	B-X
NSCLC	B-X
cases	B-X
compared	B-X
to	B-X
stage	B-X
I-II	B-X
tumors	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
higher	B-X
in	B-X
NSCLC	B-X
cases	B-X
with	B-X
metastasis	B-X
than	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
5-year	B-X
survival	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
high	B-X
MMP-9	B-X
protein	B-X
expression	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
19	B-X
vs.	B-X
4.7	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
may	B-X
serve	B-X
as	B-X
potential	B-X
prognostic	B-X
and	B-X
therapeutic	B-X
markers	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X

The	O
goals	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	B-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
in	O
NSCLC	O
and	O
their	O
relations	O
to	O
metastasis	O
and	O
prognosis	O
.	O
<EOS>	B-X
KISS1	B-X
and	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
may	B-X
play	B-X
important	B-X
roles	B-X
as	B-X
metastasis	B-X
suppressor	B-X
and	B-X
metastasis	B-X
promoter	B-X
genes	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
little	B-X
information	B-X
about	B-X
their	B-X
possible	B-X
roles	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
goals	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
in	B-X
NSCLC	B-X
and	B-X
their	B-X
relations	B-X
to	B-X
metastasis	B-X
and	B-X
prognosis	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
of	B-X
MMP-9	B-X
protein	B-X
were	B-X
detected	B-X
by	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
immunohistochemistry	B-X
respectively	B-X
in	B-X
85	B-X
cases	B-X
of	B-X
NSCLC	B-X
,	B-X
and	B-X
their	B-X
matched	B-X
lymph	B-X
node	B-X
metastases	B-X
.	B-X
Expressions	B-X
of	B-X
KISS1	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
low	B-X
TNM	B-X
stages	B-X
of	B-X
NSCLC	B-X
(	B-X
I-II	B-X
)	B-X
compared	B-X
to	B-X
more	B-X
advanced	B-X
stages	B-X
(	B-X
III-IV	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
advanced	B-X
TNM	B-X
stages	B-X
,	B-X
cases	B-X
without	B-X
metastasis	B-X
had	B-X
higher	B-X
KISS1	B-X
gene	B-X
expression	B-X
compared	B-X
to	B-X
those	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
MMP-9	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
stage	B-X
III-IV	B-X
NSCLC	B-X
cases	B-X
compared	B-X
to	B-X
stage	B-X
I-II	B-X
tumors	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
higher	B-X
in	B-X
NSCLC	B-X
cases	B-X
with	B-X
metastasis	B-X
than	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
There	B-X
was	B-X
negative	B-X
correction	B-X
between	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
protein	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
5-year	B-X
survival	B-X
rate	B-X
in	B-X
cases	B-X
with	B-X
higher	B-X
KISS1	B-X
protein	B-X
expression	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
20.9	B-X
vs.	B-X
2.4	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
5-year	B-X
survival	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
high	B-X
MMP-9	B-X
protein	B-X
expression	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
19	B-X
vs.	B-X
4.7	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
may	B-X
serve	B-X
as	B-X
potential	B-X
prognostic	B-X
and	B-X
therapeutic	B-X
markers	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X

The	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	B-Gene_or_gene_product
and	O
of	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
protein	O
were	O
detected	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
respectively	O
in	O
85	O
cases	O
of	O
NSCLC	O
,	O
and	O
their	O
matched	O
lymph	O
node	O
metastases	O
.	O
<EOS>	B-X
KISS1	B-X
and	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
may	B-X
play	B-X
important	B-X
roles	B-X
as	B-X
metastasis	B-X
suppressor	B-X
and	B-X
metastasis	B-X
promoter	B-X
genes	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
little	B-X
information	B-X
about	B-X
their	B-X
possible	B-X
roles	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
goals	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
in	B-X
NSCLC	B-X
and	B-X
their	B-X
relations	B-X
to	B-X
metastasis	B-X
and	B-X
prognosis	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
of	B-X
MMP-9	B-X
protein	B-X
were	B-X
detected	B-X
by	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
immunohistochemistry	B-X
respectively	B-X
in	B-X
85	B-X
cases	B-X
of	B-X
NSCLC	B-X
,	B-X
and	B-X
their	B-X
matched	B-X
lymph	B-X
node	B-X
metastases	B-X
.	B-X
Expressions	B-X
of	B-X
KISS1	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
low	B-X
TNM	B-X
stages	B-X
of	B-X
NSCLC	B-X
(	B-X
I-II	B-X
)	B-X
compared	B-X
to	B-X
more	B-X
advanced	B-X
stages	B-X
(	B-X
III-IV	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
advanced	B-X
TNM	B-X
stages	B-X
,	B-X
cases	B-X
without	B-X
metastasis	B-X
had	B-X
higher	B-X
KISS1	B-X
gene	B-X
expression	B-X
compared	B-X
to	B-X
those	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
MMP-9	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
stage	B-X
III-IV	B-X
NSCLC	B-X
cases	B-X
compared	B-X
to	B-X
stage	B-X
I-II	B-X
tumors	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
higher	B-X
in	B-X
NSCLC	B-X
cases	B-X
with	B-X
metastasis	B-X
than	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
There	B-X
was	B-X
negative	B-X
correction	B-X
between	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
protein	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
5-year	B-X
survival	B-X
rate	B-X
in	B-X
cases	B-X
with	B-X
higher	B-X
KISS1	B-X
protein	B-X
expression	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
20.9	B-X
vs.	B-X
2.4	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
5-year	B-X
survival	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
high	B-X
MMP-9	B-X
protein	B-X
expression	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
19	B-X
vs.	B-X
4.7	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
may	B-X
serve	B-X
as	B-X
potential	B-X
prognostic	B-X
and	B-X
therapeutic	B-X
markers	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X

Expressions	O
of	O
KISS1	B-Gene_or_gene_product
mRNA	O
and	O
protein	O
were	O
significantly	O
higher	O
in	O
low	O
TNM	O
stages	O
of	O
NSCLC	O
(	O
I	O
-	O
II	O
)	O
compared	O
to	O
more	O
advanced	O
stages	O
(	O
III	O
-	O
IV	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Moreover	O
,	O
in	O
advanced	O
TNM	O
stages	O
,	O
cases	O
without	O
metastasis	O
had	O
higher	O
KISS1	B-Gene_or_gene_product
gene	O
expression	O
compared	O
to	O
those	O
with	O
lymph	O
node	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
contrast	O
,	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
expression	O
was	O
higher	O
in	O
stage	O
III	O
-	O
IV	O
NSCLC	O
cases	O
compared	O
to	O
stage	O
I	O
-	O
II	O
tumors	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
higher	O
in	O
NSCLC	O
cases	O
with	O
metastasis	O
than	O
those	O
without	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
negative	O
correction	O
between	O
KISS1	B-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
protein	O
expression	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
5	O
-	O
year	O
survival	O
rate	O
in	O
cases	O
with	O
higher	O
KISS1	B-Gene_or_gene_product
protein	O
expression	O
was	O
significantly	O
higher	O
than	O
in	O
those	O
with	O
low	O
expression	O
(	O
20	O
.	O
9	O
vs	O
.	O
2	O
.	O
4	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
the	O
5	O
-	O
year	O
survival	O
rate	O
of	O
patients	O
with	O
high	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
protein	O
expression	O
were	O
lower	O
than	O
those	O
with	O
low	O
expression	O
(	O
19	O
vs	O
.	O
4	O
.	O
7	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
KISS1	B-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	I-Gene_or_gene_product
may	O
serve	O
as	O
potential	O
prognostic	O
and	O
therapeutic	O
markers	O
in	O
lung	O
cancer	O
.	O
<EOS>	B-X
KISS1	B-X
and	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
may	B-X
play	B-X
important	B-X
roles	B-X
as	B-X
metastasis	B-X
suppressor	B-X
and	B-X
metastasis	B-X
promoter	B-X
genes	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
little	B-X
information	B-X
about	B-X
their	B-X
possible	B-X
roles	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
The	B-X
goals	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
in	B-X
NSCLC	B-X
and	B-X
their	B-X
relations	B-X
to	B-X
metastasis	B-X
and	B-X
prognosis	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
expressions	B-X
of	B-X
KISS1	B-X
and	B-X
of	B-X
MMP-9	B-X
protein	B-X
were	B-X
detected	B-X
by	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
immunohistochemistry	B-X
respectively	B-X
in	B-X
85	B-X
cases	B-X
of	B-X
NSCLC	B-X
,	B-X
and	B-X
their	B-X
matched	B-X
lymph	B-X
node	B-X
metastases	B-X
.	B-X
Expressions	B-X
of	B-X
KISS1	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
low	B-X
TNM	B-X
stages	B-X
of	B-X
NSCLC	B-X
(	B-X
I-II	B-X
)	B-X
compared	B-X
to	B-X
more	B-X
advanced	B-X
stages	B-X
(	B-X
III-IV	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
advanced	B-X
TNM	B-X
stages	B-X
,	B-X
cases	B-X
without	B-X
metastasis	B-X
had	B-X
higher	B-X
KISS1	B-X
gene	B-X
expression	B-X
compared	B-X
to	B-X
those	B-X
with	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
MMP-9	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
stage	B-X
III-IV	B-X
NSCLC	B-X
cases	B-X
compared	B-X
to	B-X
stage	B-X
I-II	B-X
tumors	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
higher	B-X
in	B-X
NSCLC	B-X
cases	B-X
with	B-X
metastasis	B-X
than	B-X
those	B-X
without	B-X
metastasis	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
There	B-X
was	B-X
negative	B-X
correction	B-X
between	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
protein	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
5-year	B-X
survival	B-X
rate	B-X
in	B-X
cases	B-X
with	B-X
higher	B-X
KISS1	B-X
protein	B-X
expression	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
in	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
20.9	B-X
vs.	B-X
2.4	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
5-year	B-X
survival	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
high	B-X
MMP-9	B-X
protein	B-X
expression	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
with	B-X
low	B-X
expression	B-X
(	B-X
19	B-X
vs.	B-X
4.7	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
KISS1	B-X
and	B-X
MMP-9	B-X
may	B-X
serve	B-X
as	B-X
potential	B-X
prognostic	B-X
and	B-X
therapeutic	B-X
markers	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X

Relationship	O
and	O
prognostic	O
significance	O
of	O
SPARC	B-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
protein	O
expression	O
in	O
colon	O
cancer	O
.	O
<EOS>	B-X
SPARC	B-X
(	B-X
secreted	B-X
protein	B-X
,	B-X
acidic	B-X
and	B-X
rich	B-X
in	B-X
cysteine	B-X
)	B-X
is	B-X
closely	B-X
related	B-X
with	B-X
the	B-X
progress	B-X
,	B-X
invasion	B-X
and	B-X
metastasis	B-X
of	B-X
malignant	B-X
tumor	B-X
and	B-X
angiogenesis	B-X
.	B-X

BACKGROUND	O
:	O
SPARC	B-Gene_or_gene_product
(	O
secreted	B-Gene_or_gene_product
protein	I-Gene_or_gene_product
,	I-Gene_or_gene_product
acidic	I-Gene_or_gene_product
and	I-Gene_or_gene_product
rich	I-Gene_or_gene_product
in	I-Gene_or_gene_product
cysteine	I-Gene_or_gene_product
)	O
is	O
closely	O
related	O
with	O
the	O
progress	O
,	O
invasion	O
and	O
metastasis	O
of	O
malignant	O
tumor	O
and	O
angiogenesis	O
.	O

METHODS	O
:	O
Using	O
human	O
colon	O
adenocarcinoma	O
tissues	O
(	O
hereinafter	O
referred	O
to	O
as	O
colon	O
cancer	O
)	O
and	O
their	O
corresponding	O
non	O
-	O
diseased	O
colon	O
from	O
114	O
patients	O
'	O
biopsies	O
,	O
the	O
expression	O
of	O
SPARC	B-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
)	O
were	O
investigated	O
by	O
immunohistochemistry	O
staining	O
to	O
assessment	O
the	O
relationship	O
between	O
SPARC	B-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
,	O
as	O
well	O
as	O
their	O
prognostic	O
significance	O
in	O
patients	O
.	O

Evaluation	O
of	O
VEGF	B-Gene_or_gene_product
expression	O
level	O
with	O
the	O
same	O
tissues	O
was	O
used	O
to	O
establish	O
the	O
antigenic	O
profiles	O
,	O
and	O
the	O
marker	O
of	O
CD34	B-Gene_or_gene_product
staining	O
was	O
used	O
as	O
an	O
indicator	O
of	O
microvessel	O
density	O
(	O
MVD	O
)	O
.	O

RESULTS	O
:	O
SPARC	B-Gene_or_gene_product
expression	O
was	O
mainly	O
in	O
the	O
stromal	O
cells	O
surrounding	O
the	O
colon	O
cancer	O
,	O
and	O
was	O
significant	O
difference	O
in	O
those	O
tissues	O
with	O
the	O
lymph	O
node	O
metastasis	O
and	O
differentiation	O
degree	O
of	O
tumor	O
.	O
<EOS>	B-X
SPARC	B-X
(	B-X
secreted	B-X
protein	B-X
,	B-X
acidic	B-X
and	B-X
rich	B-X
in	B-X
cysteine	B-X
)	B-X
is	B-X
closely	B-X
related	B-X
with	B-X
the	B-X
progress	B-X
,	B-X
invasion	B-X
and	B-X
metastasis	B-X
of	B-X
malignant	B-X
tumor	B-X
and	B-X
angiogenesis	B-X
.	B-X

Expression	O
of	O
SPARC	B-Gene_or_gene_product
was	O
significantly	O
correlated	O
with	O
the	O
expression	O
of	O
VEGF	B-Gene_or_gene_product
and	O
MVD	B-Gene_or_gene_product
in	O
colon	O
cancer	O
tissues	O
.	O
<EOS>	B-X
SPARC	B-X
(	B-X
secreted	B-X
protein	B-X
,	B-X
acidic	B-X
and	B-X
rich	B-X
in	B-X
cysteine	B-X
)	B-X
is	B-X
closely	B-X
related	B-X
with	B-X
the	B-X
progress	B-X
,	B-X
invasion	B-X
and	B-X
metastasis	B-X
of	B-X
malignant	B-X
tumor	B-X
and	B-X
angiogenesis	B-X
.	B-X

Patients	O
with	O
low	O
or	O
absence	O
expressing	O
SPARC	B-Gene_or_gene_product
had	O
significantly	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
a	O
Single	O
Factor	O
Analysis	O
;	O
Cox	O
Regression	O
Analysis	O
,	O
SPARC	B-Gene_or_gene_product
emerged	O
as	O
an	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
independent	O
prognostic	O
factor	O
for	O
colon	O
cancer	O
.	O
<EOS>	B-X
The	B-X
shift	B-X
from	B-X
routine	B-X
antibiotics	B-X
towards	B-X
omitting	B-X
antibiotics	B-X
for	B-X
uncomplicated	B-X
acute	B-X
diverticulitis	B-X
opens	B-X
up	B-X
the	B-X
possibility	B-X
for	B-X
outpatient	B-X
instead	B-X
of	B-X
inpatient	B-X
treatment	B-X
,	B-X
potentially	B-X
reducing	B-X
the	B-X
burden	B-X
of	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
gastrointestinal	B-X
diseases	B-X
in	B-X
the	B-X
Western	B-X
world	B-X
.	B-X
Patients	B-X
with	B-X
serious	B-X
or	B-X
life-threatening	B-X
illness	B-X
are	B-X
frequently	B-X
asked	B-X
to	B-X
make	B-X
complex	B-X
,	B-X
high-stakes	B-X
medical	B-X
decisions	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
anxiety	B-X
,	B-X
low	B-X
health	B-X
literacy	B-X
,	B-X
asymmetric	B-X
information	B-X
and	B-X
inadequate	B-X
communication	B-X
between	B-X
patients	B-X
and	B-X
health	B-X
care	B-X
providers	B-X
,	B-X
family	B-X
pressures	B-X
,	B-X
rational	B-X
apathy	B-X
by	B-X
health	B-X
care	B-X
providers	B-X
,	B-X
cognitive	B-X
biases	B-X
of	B-X
both	B-X
patients	B-X
and	B-X
health	B-X
care	B-X
providers	B-X
,	B-X
and	B-X
other	B-X
factors	B-X
make	B-X
it	B-X
quite	B-X
difficult	B-X
for	B-X
patients	B-X
in	B-X
these	B-X
circumstances	B-X
to	B-X
process	B-X
and	B-X
comprehend	B-X
the	B-X
strategic	B-X
uncertainty	B-X
and	B-X
resultant	B-X
risks	B-X
and	B-X
benefits	B-X
of	B-X
,	B-X
and	B-X
alternatives	B-X
to	B-X
,	B-X
whatever	B-X
therapeutic	B-X
or	B-X
life-prolonging	B-X
treatment	B-X
physicians	B-X
are	B-X
offering	B-X
.	B-X
All	B-X
of	B-X
these	B-X
factors	B-X
render	B-X
the	B-X
classic	B-X
goal	B-X
of	B-X
``	B-X
informed	B-X
consent	B-X
''	B-X
unachievable	B-X
in	B-X
all	B-X
but	B-X
the	B-X
rarest	B-X
of	B-X
circumstances	B-X
:	B-X
The	B-X
effort	B-X
to	B-X
discuss	B-X
and	B-X
evaluate	B-X
strategic	B-X
uncertainty	B-X
,	B-X
its	B-X
rational	B-X
reduction	B-X
into	B-X
risks	B-X
and	B-X
benefits	B-X
,	B-X
and	B-X
alternatives	B-X
of	B-X
treatment	B-X
for	B-X
purposes	B-X
of	B-X
optimizing	B-X
decisional	B-X
outcomes	B-X
will	B-X
have	B-X
genuine	B-X
intrinsic	B-X
value	B-X
only	B-X
for	B-X
ultra-rational	B-X
patients	B-X
(	B-X
and	B-X
physicians	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
alterable	B-X
barriers	B-X
to	B-X
rational	B-X
decision-making	B-X
--	B-X
i.e.	B-X
,	B-X
barriers	B-X
that	B-X
can	B-X
,	B-X
in	B-X
theory	B-X
,	B-X
be	B-X
overcome	B-X
by	B-X
ultra-rational	B-X
patients	B-X
and	B-X
physicians	B-X
with	B-X
sufficient	B-X
time	B-X
and	B-X
persistent	B-X
inquiry	B-X
--	B-X
there	B-X
is	B-X
a	B-X
second	B-X
decision-making	B-X
realm	B-X
in	B-X
which	B-X
the	B-X
added	B-X
complexities	B-X
of	B-X
bounded	B-X
rationality	B-X
,	B-X
clinical	B-X
uncertainty	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
of	B-X
overall	B-X
Knightian	B-X
uncertainty	B-X
provide	B-X
insurmountable	B-X
,	B-X
unalterable	B-X
barriers	B-X
to	B-X
confident	B-X
rational	B-X
decision-making	B-X
.	B-X
In	B-X
the	B-X
context	B-X
of	B-X
this	B-X
persistent	B-X
patient	B-X
avoidance	B-X
of	B-X
substantive	B-X
decision-making	B-X
,	B-X
empirical	B-X
evidence	B-X
demonstrates	B-X
frequent	B-X
reversion	B-X
to	B-X
a	B-X
quantity-over-quality	B-X
approach	B-X
,	B-X
allowing	B-X
health	B-X
care	B-X
providers	B-X
to	B-X
``	B-X
do	B-X
everything	B-X
''	B-X
until	B-X
continued	B-X
medical	B-X
intervention	B-X
reaches	B-X
the	B-X
point	B-X
of	B-X
obvious	B-X
medical	B-X
or	B-X
economic	B-X
futility	B-X
.	B-X

CONCLUSION	O
:	O
The	O
low	O
expression	O
or	O
absence	O
of	O
stromal	O
SPARC	B-Gene_or_gene_product
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
poor	O
prognosis	O
of	O
colon	O
cancer	O
.	O
<EOS>	B-X
Lung	B-X
adenocarcinoma	B-X
(	B-X
LUAD	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
subtype	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
identify	B-X
novel	B-X
molecular	B-X
markers	B-X
associated	B-X
with	B-X
LUAD	B-X
prognosis	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
research	B-X
was	B-X
to	B-X
confirm	B-X
the	B-X
prognostic	B-X
value	B-X
of	B-X
bestrophin-2	B-X
(	B-X
BEST2	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
hub	B-X
genes	B-X
in	B-X
colon	B-X
cancer	B-X
,	B-X
via	B-X
bioinformatics	B-X
analysis	B-X
and	B-X
validation	B-X
in	B-X
public	B-X
databases	B-X
and	B-X
immunohistochemistry	B-X
detection	B-X
.	B-X
Selecting	B-X
an	B-X
appropriate	B-X
workflow	B-X
has	B-X
become	B-X
an	B-X
important	B-X
issue	B-X
for	B-X
researchers	B-X
in	B-X
the	B-X
field	B-X
.	B-X

SPARC	B-Gene_or_gene_product
maybe	O
involved	O
in	O
the	O
regulation	O
of	O
anti	O
-	O
angiogenesis	O
by	O
which	O
it	O
may	O
serve	O
as	O
a	O
novel	O
target	O
for	O
colon	O
cancer	O
treatment	O
as	O
well	O
as	O
a	O
novel	O
distinctive	O
marker	O
.	O
<EOS>	B-X
SPARC	B-X
(	B-X
secreted	B-X
protein	B-X
,	B-X
acidic	B-X
and	B-X
rich	B-X
in	B-X
cysteine	B-X
)	B-X
is	B-X
closely	B-X
related	B-X
with	B-X
the	B-X
progress	B-X
,	B-X
invasion	B-X
and	B-X
metastasis	B-X
of	B-X
malignant	B-X
tumor	B-X
and	B-X
angiogenesis	B-X
.	B-X

The	O
neural	O
stem	O
cell	O
fate	O
determinant	O
TLX	B-Gene_or_gene_product
promotes	O
tumorigenesis	O
and	O
genesis	O
of	O
cells	O
resembling	O
glioma	O
stem	O
cells	O
.	O
<EOS>	B-X
A	B-X
growing	B-X
body	B-X
of	B-X
evidence	B-X
indicates	B-X
that	B-X
deregulation	B-X
of	B-X
stem	B-X
cell	B-X
fate	B-X
determinants	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
many	B-X
types	B-X
of	B-X
malignancies	B-X
.	B-X
The	B-X
neural	B-X
stem	B-X
cell	B-X
fate	B-X
determinant	B-X
TLX	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
neurogenesis	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
by	B-X
maintaining	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
a	B-X
tumorigenic	B-X
role	B-X
of	B-X
TLX	B-X
in	B-X
brain	B-X
tumor	B-X
initiation	B-X
and	B-X
progression	B-X
.	B-X
Increased	B-X
TLX	B-X
expression	B-X
was	B-X
observed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
glioma	B-X
cells	B-X
and	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
correlated	B-X
with	B-X
poor	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
gliomas	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
TLX	B-X
in	B-X
the	B-X
U87MG	B-X
glioma	B-X
cell	B-X
line	B-X
and	B-X
Ink4a/Arf-deficient	B-X
mouse	B-X
astrocytes	B-X
(	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
)	B-X
induced	B-X
cell	B-X
proliferation	B-X
with	B-X
a	B-X
concomitant	B-X
increase	B-X
in	B-X
cyclin	B-X
D	B-X
expression	B-X
,	B-X
and	B-X
accelerated	B-X
foci	B-X
formation	B-X
in	B-X
soft	B-X
agar	B-X
and	B-X
tumor	B-X
formation	B-X
in	B-X
in	B-X
vivo	B-X
transplantation	B-X
assays	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
TLX	B-X
in	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
inhibited	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
and	B-X
promoted	B-X
neurosphere	B-X
formation	B-X
and	B-X
Nestin	B-X
expression	B-X
,	B-X
which	B-X
are	B-X
hallmark	B-X
characteristics	B-X
of	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
under	B-X
stem	B-X
cell	B-X
culture	B-X
conditions	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
TLX	B-X
is	B-X
involved	B-X
in	B-X
glioma	B-X
stem	B-X
cell	B-X
genesis	B-X
and	B-X
represents	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
this	B-X
type	B-X
of	B-X
malignancy	B-X
.	B-X

A	O
growing	O
body	O
of	O
evidence	O
indicates	O
that	O
deregulation	O
of	O
stem	O
cell	O
fate	O
determinants	O
is	O
a	O
hallmark	O
of	O
many	O
types	O
of	O
malignancies	O
.	O
<EOS>	B-X
A	B-X
growing	B-X
body	B-X
of	B-X
evidence	B-X
indicates	B-X
that	B-X
deregulation	B-X
of	B-X
stem	B-X
cell	B-X
fate	B-X
determinants	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
many	B-X
types	B-X
of	B-X
malignancies	B-X
.	B-X
The	B-X
neural	B-X
stem	B-X
cell	B-X
fate	B-X
determinant	B-X
TLX	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
neurogenesis	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
by	B-X
maintaining	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Increased	B-X
TLX	B-X
expression	B-X
was	B-X
observed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
glioma	B-X
cells	B-X
and	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
correlated	B-X
with	B-X
poor	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
gliomas	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
TLX	B-X
in	B-X
the	B-X
U87MG	B-X
glioma	B-X
cell	B-X
line	B-X
and	B-X
Ink4a/Arf-deficient	B-X
mouse	B-X
astrocytes	B-X
(	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
)	B-X
induced	B-X
cell	B-X
proliferation	B-X
with	B-X
a	B-X
concomitant	B-X
increase	B-X
in	B-X
cyclin	B-X
D	B-X
expression	B-X
,	B-X
and	B-X
accelerated	B-X
foci	B-X
formation	B-X
in	B-X
soft	B-X
agar	B-X
and	B-X
tumor	B-X
formation	B-X
in	B-X
in	B-X
vivo	B-X
transplantation	B-X
assays	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
TLX	B-X
in	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
inhibited	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
and	B-X
promoted	B-X
neurosphere	B-X
formation	B-X
and	B-X
Nestin	B-X
expression	B-X
,	B-X
which	B-X
are	B-X
hallmark	B-X
characteristics	B-X
of	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
under	B-X
stem	B-X
cell	B-X
culture	B-X
conditions	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
TLX	B-X
is	B-X
involved	B-X
in	B-X
glioma	B-X
stem	B-X
cell	B-X
genesis	B-X
and	B-X
represents	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
this	B-X
type	B-X
of	B-X
malignancy	B-X
.	B-X

The	O
neural	O
stem	O
cell	O
fate	O
determinant	O
TLX	B-Gene_or_gene_product
plays	O
a	O
pivotal	O
role	O
in	O
neurogenesis	O
in	O
the	O
adult	O
brain	O
by	O
maintaining	O
neural	O
stem	O
cells	O
.	O

Here	O
,	O
we	O
report	O
a	O
tumorigenic	O
role	O
of	O
TLX	B-Gene_or_gene_product
in	O
brain	O
tumor	O
initiation	O
and	O
progression	O
.	O
<EOS>	B-X
The	B-X
neural	B-X
stem	B-X
cell	B-X
fate	B-X
determinant	B-X
TLX	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
neurogenesis	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
by	B-X
maintaining	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
a	B-X
tumorigenic	B-X
role	B-X
of	B-X
TLX	B-X
in	B-X
brain	B-X
tumor	B-X
initiation	B-X
and	B-X
progression	B-X
.	B-X
Increased	B-X
TLX	B-X
expression	B-X
was	B-X
observed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
glioma	B-X
cells	B-X
and	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
correlated	B-X
with	B-X
poor	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
gliomas	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
TLX	B-X
in	B-X
the	B-X
U87MG	B-X
glioma	B-X
cell	B-X
line	B-X
and	B-X
Ink4a/Arf-deficient	B-X
mouse	B-X
astrocytes	B-X
(	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
)	B-X
induced	B-X
cell	B-X
proliferation	B-X
with	B-X
a	B-X
concomitant	B-X
increase	B-X
in	B-X
cyclin	B-X
D	B-X
expression	B-X
,	B-X
and	B-X
accelerated	B-X
foci	B-X
formation	B-X
in	B-X
soft	B-X
agar	B-X
and	B-X
tumor	B-X
formation	B-X
in	B-X
in	B-X
vivo	B-X
transplantation	B-X
assays	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
TLX	B-X
in	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
inhibited	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
and	B-X
promoted	B-X
neurosphere	B-X
formation	B-X
and	B-X
Nestin	B-X
expression	B-X
,	B-X
which	B-X
are	B-X
hallmark	B-X
characteristics	B-X
of	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
under	B-X
stem	B-X
cell	B-X
culture	B-X
conditions	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
TLX	B-X
is	B-X
involved	B-X
in	B-X
glioma	B-X
stem	B-X
cell	B-X
genesis	B-X
and	B-X
represents	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
this	B-X
type	B-X
of	B-X
malignancy	B-X
.	B-X

Increased	O
TLX	B-Gene_or_gene_product
expression	O
was	O
observed	O
in	O
a	O
number	O
of	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
,	O
and	O
correlated	O
with	O
poor	O
survival	O
of	O
patients	O
with	O
gliomas	O
.	O

Ectopic	O
expression	O
of	O
TLX	B-Gene_or_gene_product
in	O
the	O
U87MG	O
glioma	O
cell	O
line	O
and	O
Ink4a	B-Gene_or_gene_product
/	O
Arf	B-Gene_or_gene_product
-	O
deficient	O
mouse	O
astrocytes	O
(	O
Ink4a	B-Gene_or_gene_product
/	O
Arf	B-Gene_or_gene_product
(	O
-	O
/	O
-	O
)	O
astrocytes	O
)	O
induced	O
cell	O
proliferation	O
with	O
a	O
concomitant	O
increase	O
in	O
cyclin	B-Gene_or_gene_product
D	I-Gene_or_gene_product
expression	O
,	O
and	O
accelerated	O
foci	O
formation	O
in	O
soft	O
agar	O
and	O
tumor	O
formation	O
in	O
in	O
vivo	O
transplantation	O
assays	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
TLX	B-Gene_or_gene_product
in	O
Ink4a	B-Gene_or_gene_product
/	O
Arf	B-Gene_or_gene_product
(	O
-	O
/	O
-	O
)	O
astrocytes	O
inhibited	O
cell	O
migration	O
and	O
invasion	O
and	O
promoted	O
neurosphere	O
formation	O
and	O
Nestin	B-Gene_or_gene_product
expression	O
,	O
which	O
are	O
hallmark	O
characteristics	O
of	O
glioma	O
stem	O
cells	O
,	O
under	O
stem	O
cell	O
culture	O
conditions	O
.	O
<EOS>	B-X
A	B-X
growing	B-X
body	B-X
of	B-X
evidence	B-X
indicates	B-X
that	B-X
deregulation	B-X
of	B-X
stem	B-X
cell	B-X
fate	B-X
determinants	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
many	B-X
types	B-X
of	B-X
malignancies	B-X
.	B-X
The	B-X
neural	B-X
stem	B-X
cell	B-X
fate	B-X
determinant	B-X
TLX	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
neurogenesis	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
by	B-X
maintaining	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
a	B-X
tumorigenic	B-X
role	B-X
of	B-X
TLX	B-X
in	B-X
brain	B-X
tumor	B-X
initiation	B-X
and	B-X
progression	B-X
.	B-X
Increased	B-X
TLX	B-X
expression	B-X
was	B-X
observed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
glioma	B-X
cells	B-X
and	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
correlated	B-X
with	B-X
poor	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
gliomas	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
TLX	B-X
in	B-X
the	B-X
U87MG	B-X
glioma	B-X
cell	B-X
line	B-X
and	B-X
Ink4a/Arf-deficient	B-X
mouse	B-X
astrocytes	B-X
(	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
)	B-X
induced	B-X
cell	B-X
proliferation	B-X
with	B-X
a	B-X
concomitant	B-X
increase	B-X
in	B-X
cyclin	B-X
D	B-X
expression	B-X
,	B-X
and	B-X
accelerated	B-X
foci	B-X
formation	B-X
in	B-X
soft	B-X
agar	B-X
and	B-X
tumor	B-X
formation	B-X
in	B-X
in	B-X
vivo	B-X
transplantation	B-X
assays	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
TLX	B-X
in	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
inhibited	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
and	B-X
promoted	B-X
neurosphere	B-X
formation	B-X
and	B-X
Nestin	B-X
expression	B-X
,	B-X
which	B-X
are	B-X
hallmark	B-X
characteristics	B-X
of	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
under	B-X
stem	B-X
cell	B-X
culture	B-X
conditions	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
TLX	B-X
is	B-X
involved	B-X
in	B-X
glioma	B-X
stem	B-X
cell	B-X
genesis	B-X
and	B-X
represents	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
this	B-X
type	B-X
of	B-X
malignancy	B-X
.	B-X

Our	O
results	O
indicate	O
that	O
TLX	B-Gene_or_gene_product
is	O
involved	O
in	O
glioma	O
stem	O
cell	O
genesis	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
for	O
this	O
type	O
of	O
malignancy	O
.	O
<EOS>	B-X
A	B-X
growing	B-X
body	B-X
of	B-X
evidence	B-X
indicates	B-X
that	B-X
deregulation	B-X
of	B-X
stem	B-X
cell	B-X
fate	B-X
determinants	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
many	B-X
types	B-X
of	B-X
malignancies	B-X
.	B-X
The	B-X
neural	B-X
stem	B-X
cell	B-X
fate	B-X
determinant	B-X
TLX	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
neurogenesis	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
by	B-X
maintaining	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
a	B-X
tumorigenic	B-X
role	B-X
of	B-X
TLX	B-X
in	B-X
brain	B-X
tumor	B-X
initiation	B-X
and	B-X
progression	B-X
.	B-X
Increased	B-X
TLX	B-X
expression	B-X
was	B-X
observed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
glioma	B-X
cells	B-X
and	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
correlated	B-X
with	B-X
poor	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
gliomas	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
TLX	B-X
in	B-X
the	B-X
U87MG	B-X
glioma	B-X
cell	B-X
line	B-X
and	B-X
Ink4a/Arf-deficient	B-X
mouse	B-X
astrocytes	B-X
(	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
)	B-X
induced	B-X
cell	B-X
proliferation	B-X
with	B-X
a	B-X
concomitant	B-X
increase	B-X
in	B-X
cyclin	B-X
D	B-X
expression	B-X
,	B-X
and	B-X
accelerated	B-X
foci	B-X
formation	B-X
in	B-X
soft	B-X
agar	B-X
and	B-X
tumor	B-X
formation	B-X
in	B-X
in	B-X
vivo	B-X
transplantation	B-X
assays	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
TLX	B-X
in	B-X
Ink4a/Arf	B-X
(	B-X
-/-	B-X
)	B-X
astrocytes	B-X
inhibited	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
and	B-X
promoted	B-X
neurosphere	B-X
formation	B-X
and	B-X
Nestin	B-X
expression	B-X
,	B-X
which	B-X
are	B-X
hallmark	B-X
characteristics	B-X
of	B-X
glioma	B-X
stem	B-X
cells	B-X
,	B-X
under	B-X
stem	B-X
cell	B-X
culture	B-X
conditions	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
TLX	B-X
is	B-X
involved	B-X
in	B-X
glioma	B-X
stem	B-X
cell	B-X
genesis	B-X
and	B-X
represents	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
this	B-X
type	B-X
of	B-X
malignancy	B-X
.	B-X

Expression	O
profiling	O
in	O
progressive	O
stages	O
of	O
fumarate	B-Gene_or_gene_product
-	I-Gene_or_gene_product
hydratase	I-Gene_or_gene_product
deficiency	O
:	O
the	O
contribution	O
of	O
metabolic	O
changes	O
to	O
tumorigenesis	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
``	B-X
pseudohypoxic	B-X
''	B-X
stabilization	B-X
of	B-X
hypoxia-inducible	B-X
factor-Î±	B-X
(	B-X
HIF-Î±	B-X
)	B-X
by	B-X
fumarate	B-X
accumulation	B-X
contributes	B-X
to	B-X
tumorigenesis	B-X
in	B-X
HLRCC	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
an	B-X
additional	B-X
direct	B-X
consequence	B-X
of	B-X
FH	B-X
deficiency	B-X
is	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
biosynthetic	B-X
milieu	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
detailed	B-X
metabolic	B-X
assessment	B-X
of	B-X
these	B-X
MEFs	B-X
confirmed	B-X
their	B-X
dependence	B-X
on	B-X
glycolysis	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
rate	B-X
of	B-X
lactate	B-X
efflux	B-X
,	B-X
associated	B-X
with	B-X
the	B-X
upregulation	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Correspondingly	B-X
,	B-X
Fh1-deficient	B-X
benign	B-X
murine	B-X
renal	B-X
cysts	B-X
and	B-X
an	B-X
advanced	B-X
human	B-X
HLRCC-related	B-X
renal	B-X
cell	B-X
carcinoma	B-X
manifested	B-X
a	B-X
prominent	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
HIF-Î±	B-X
target	B-X
genes	B-X
and	B-X
in	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
relevant	B-X
to	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
our	B-X
hypothesis	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
FH-deficient	B-X
tissues	B-X
,	B-X
including	B-X
a	B-X
novel	B-X
murine	B-X
model	B-X
of	B-X
Fh1-deficient	B-X
smooth	B-X
muscle	B-X
,	B-X
we	B-X
show	B-X
a	B-X
striking	B-X
and	B-X
progressive	B-X
upregulation	B-X
of	B-X
a	B-X
tumorigenic	B-X
metabolic	B-X
profile	B-X
,	B-X
as	B-X
manifested	B-X
by	B-X
increased	B-X
PKM2	B-X
and	B-X
LDHA	B-X
protein	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
models	B-X
assessed	B-X
herein	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
that	B-X
FH	B-X
deficiency	B-X
compels	B-X
cells	B-X
to	B-X
adopt	B-X
an	B-X
early	B-X
,	B-X
reversible	B-X
,	B-X
and	B-X
progressive	B-X
protumorigenic	B-X
metabolic	B-X
milieu	B-X
that	B-X
is	B-X
reminiscent	B-X
of	B-X
that	B-X
driving	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
Targets	B-X
identified	B-X
in	B-X
these	B-X
novel	B-X
and	B-X
diverse	B-X
FH-deficient	B-X
models	B-X
represent	B-X
excellent	B-X
potential	B-X
candidates	B-X
for	B-X
further	B-X
mechanistic	B-X
investigation	B-X
and	B-X
therapeutic	B-X
metabolic	B-X
manipulation	B-X
in	B-X
tumors	B-X
.	B-X

Hereditary	O
leiomyomatosis	O
and	O
renal	O
cell	O
carcinoma	O
(	O
HLRCC	O
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Krebs	O
cycle	O
enzyme	O
fumarate	B-Gene_or_gene_product
hydratase	I-Gene_or_gene_product
(	O
FH	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
cancer	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
condition	B-X
in	B-X
which	B-X
susceptible	B-X
individuals	B-X
are	B-X
at	B-X
risk	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cutaneous	B-X
leiomyomas	B-X
,	B-X
early	B-X
onset	B-X
multiple	B-X
uterine	B-X
leiomyomas	B-X
and	B-X
an	B-X
aggressive	B-X
form	B-X
of	B-X
type	B-X
2	B-X
papillary	B-X
renal	B-X
cell	B-X
cancer	B-X
.	B-X
HLRCC	B-X
is	B-X
caused	B-X
by	B-X
germline	B-X
mutations	B-X
in	B-X
the	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
gene	B-X
which	B-X
inactivate	B-X
the	B-X
enzyme	B-X
and	B-X
alters	B-X
the	B-X
function	B-X
of	B-X
the	B-X
tricarboxylic	B-X
acid	B-X
(	B-X
Krebs	B-X
)	B-X
cycle	B-X
.	B-X
Issues	B-X
surrounding	B-X
surveillance	B-X
and	B-X
treatment	B-X
for	B-X
HLRCC-associated	B-X
renal	B-X
cell	B-X
cancer	B-X
were	B-X
considered	B-X
as	B-X
part	B-X
of	B-X
a	B-X
recent	B-X
international	B-X
symposium	B-X
on	B-X
HLRCC	B-X
.	B-X
The	B-X
lifetime	B-X
renal	B-X
cancer	B-X
risk	B-X
for	B-X
FH	B-X
mutation	B-X
carriers	B-X
is	B-X
estimated	B-X
to	B-X
be	B-X
15	B-X
%	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
potential	B-X
for	B-X
early	B-X
onset	B-X
of	B-X
RCC	B-X
in	B-X
HLRCC	B-X
,	B-X
periodic	B-X
renal	B-X
imaging	B-X
and	B-X
,	B-X
when	B-X
available	B-X
,	B-X
predictive	B-X
testing	B-X
for	B-X
a	B-X
FH	B-X
mutation	B-X
is	B-X
recommended	B-X
from	B-X
8	B-X
to	B-X
10	B-X
years	B-X
of	B-X
age	B-X
.	B-X
However	B-X
,	B-X
the	B-X
small	B-X
risk	B-X
of	B-X
renal	B-X
cell	B-X
cancer	B-X
in	B-X
the	B-X
10-20	B-X
years	B-X
age	B-X
range	B-X
and	B-X
the	B-X
potential	B-X
drawbacks	B-X
of	B-X
screening	B-X
should	B-X
be	B-X
carefully	B-X
discussed	B-X
on	B-X
an	B-X
individual	B-X
basis	B-X
.	B-X
Treatment	B-X
of	B-X
renal	B-X
tumours	B-X
should	B-X
be	B-X
prompt	B-X
and	B-X
generally	B-X
consist	B-X
of	B-X
wide-margin	B-X
surgical	B-X
excision	B-X
and	B-X
consideration	B-X
of	B-X
retroperitoneal	B-X
lymph	B-X
node	B-X
dissection	B-X
.	B-X
Screening	B-X
procedures	B-X
in	B-X
HLRCC	B-X
families	B-X
should	B-X
preferably	B-X
be	B-X
evaluated	B-X
in	B-X
large	B-X
cohorts	B-X
of	B-X
families	B-X
.	B-X

It	O
has	O
been	O
proposed	O
that	O
"	O
pseudohypoxic	O
"	O
stabilization	O
of	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
)	O
by	O
fumarate	O
accumulation	O
contributes	O
to	O
tumorigenesis	O
in	O
HLRCC	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
``	B-X
pseudohypoxic	B-X
''	B-X
stabilization	B-X
of	B-X
hypoxia-inducible	B-X
factor-Î±	B-X
(	B-X
HIF-Î±	B-X
)	B-X
by	B-X
fumarate	B-X
accumulation	B-X
contributes	B-X
to	B-X
tumorigenesis	B-X
in	B-X
HLRCC	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
detailed	B-X
metabolic	B-X
assessment	B-X
of	B-X
these	B-X
MEFs	B-X
confirmed	B-X
their	B-X
dependence	B-X
on	B-X
glycolysis	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
rate	B-X
of	B-X
lactate	B-X
efflux	B-X
,	B-X
associated	B-X
with	B-X
the	B-X
upregulation	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Correspondingly	B-X
,	B-X
Fh1-deficient	B-X
benign	B-X
murine	B-X
renal	B-X
cysts	B-X
and	B-X
an	B-X
advanced	B-X
human	B-X
HLRCC-related	B-X
renal	B-X
cell	B-X
carcinoma	B-X
manifested	B-X
a	B-X
prominent	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
HIF-Î±	B-X
target	B-X
genes	B-X
and	B-X
in	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
relevant	B-X
to	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X

We	O
hypothesized	O
that	O
an	O
additional	O
direct	O
consequence	O
of	O
FH	B-Gene_or_gene_product
deficiency	O
is	O
the	O
establishment	O
of	O
a	O
biosynthetic	O
milieu	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
an	B-X
additional	B-X
direct	B-X
consequence	B-X
of	B-X
FH	B-X
deficiency	B-X
is	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
biosynthetic	B-X
milieu	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
our	B-X
hypothesis	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
FH-deficient	B-X
tissues	B-X
,	B-X
including	B-X
a	B-X
novel	B-X
murine	B-X
model	B-X
of	B-X
Fh1-deficient	B-X
smooth	B-X
muscle	B-X
,	B-X
we	B-X
show	B-X
a	B-X
striking	B-X
and	B-X
progressive	B-X
upregulation	B-X
of	B-X
a	B-X
tumorigenic	B-X
metabolic	B-X
profile	B-X
,	B-X
as	B-X
manifested	B-X
by	B-X
increased	B-X
PKM2	B-X
and	B-X
LDHA	B-X
protein	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
models	B-X
assessed	B-X
herein	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
that	B-X
FH	B-X
deficiency	B-X
compels	B-X
cells	B-X
to	B-X
adopt	B-X
an	B-X
early	B-X
,	B-X
reversible	B-X
,	B-X
and	B-X
progressive	B-X
protumorigenic	B-X
metabolic	B-X
milieu	B-X
that	B-X
is	B-X
reminiscent	B-X
of	B-X
that	B-X
driving	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
Targets	B-X
identified	B-X
in	B-X
these	B-X
novel	B-X
and	B-X
diverse	B-X
FH-deficient	B-X
models	B-X
represent	B-X
excellent	B-X
potential	B-X
candidates	B-X
for	B-X
further	B-X
mechanistic	B-X
investigation	B-X
and	B-X
therapeutic	B-X
metabolic	B-X
manipulation	B-X
in	B-X
tumors	B-X
.	B-X

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
isolated	O
primary	O
mouse	O
embryonic	O
fibroblast	O
(	O
MEF	O
)	O
lines	O
from	O
Fh1	B-Gene_or_gene_product
-	O
deficient	O
mice	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
isolated	B-X
primary	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
(	B-X
MEF	B-X
)	B-X
lines	B-X
from	B-X
Fh1-deficient	B-X
mice	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
detailed	B-X
metabolic	B-X
assessment	B-X
of	B-X
these	B-X
MEFs	B-X
confirmed	B-X
their	B-X
dependence	B-X
on	B-X
glycolysis	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
rate	B-X
of	B-X
lactate	B-X
efflux	B-X
,	B-X
associated	B-X
with	B-X
the	B-X
upregulation	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Correspondingly	B-X
,	B-X
Fh1-deficient	B-X
benign	B-X
murine	B-X
renal	B-X
cysts	B-X
and	B-X
an	B-X
advanced	B-X
human	B-X
HLRCC-related	B-X
renal	B-X
cell	B-X
carcinoma	B-X
manifested	B-X
a	B-X
prominent	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
HIF-Î±	B-X
target	B-X
genes	B-X
and	B-X
in	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
relevant	B-X
to	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
our	B-X
hypothesis	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
FH-deficient	B-X
tissues	B-X
,	B-X
including	B-X
a	B-X
novel	B-X
murine	B-X
model	B-X
of	B-X
Fh1-deficient	B-X
smooth	B-X
muscle	B-X
,	B-X
we	B-X
show	B-X
a	B-X
striking	B-X
and	B-X
progressive	B-X
upregulation	B-X
of	B-X
a	B-X
tumorigenic	B-X
metabolic	B-X
profile	B-X
,	B-X
as	B-X
manifested	B-X
by	B-X
increased	B-X
PKM2	B-X
and	B-X
LDHA	B-X
protein	B-X
.	B-X
Targets	B-X
identified	B-X
in	B-X
these	B-X
novel	B-X
and	B-X
diverse	B-X
FH-deficient	B-X
models	B-X
represent	B-X
excellent	B-X
potential	B-X
candidates	B-X
for	B-X
further	B-X
mechanistic	B-X
investigation	B-X
and	B-X
therapeutic	B-X
metabolic	B-X
manipulation	B-X
in	B-X
tumors	B-X
.	B-X

As	O
predicted	O
,	O
these	O
MEFs	O
upregulated	O
Hif	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
and	O
HIF	B-Gene_or_gene_product
target	O
genes	O
directly	O
as	O
a	O
result	O
of	O
FH	B-Gene_or_gene_product
deficiency	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
``	B-X
pseudohypoxic	B-X
''	B-X
stabilization	B-X
of	B-X
hypoxia-inducible	B-X
factor-Î±	B-X
(	B-X
HIF-Î±	B-X
)	B-X
by	B-X
fumarate	B-X
accumulation	B-X
contributes	B-X
to	B-X
tumorigenesis	B-X
in	B-X
HLRCC	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
an	B-X
additional	B-X
direct	B-X
consequence	B-X
of	B-X
FH	B-X
deficiency	B-X
is	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
biosynthetic	B-X
milieu	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
detailed	B-X
metabolic	B-X
assessment	B-X
of	B-X
these	B-X
MEFs	B-X
confirmed	B-X
their	B-X
dependence	B-X
on	B-X
glycolysis	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
rate	B-X
of	B-X
lactate	B-X
efflux	B-X
,	B-X
associated	B-X
with	B-X
the	B-X
upregulation	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Correspondingly	B-X
,	B-X
Fh1-deficient	B-X
benign	B-X
murine	B-X
renal	B-X
cysts	B-X
and	B-X
an	B-X
advanced	B-X
human	B-X
HLRCC-related	B-X
renal	B-X
cell	B-X
carcinoma	B-X
manifested	B-X
a	B-X
prominent	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
HIF-Î±	B-X
target	B-X
genes	B-X
and	B-X
in	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
relevant	B-X
to	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
our	B-X
hypothesis	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
FH-deficient	B-X
tissues	B-X
,	B-X
including	B-X
a	B-X
novel	B-X
murine	B-X
model	B-X
of	B-X
Fh1-deficient	B-X
smooth	B-X
muscle	B-X
,	B-X
we	B-X
show	B-X
a	B-X
striking	B-X
and	B-X
progressive	B-X
upregulation	B-X
of	B-X
a	B-X
tumorigenic	B-X
metabolic	B-X
profile	B-X
,	B-X
as	B-X
manifested	B-X
by	B-X
increased	B-X
PKM2	B-X
and	B-X
LDHA	B-X
protein	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
models	B-X
assessed	B-X
herein	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
that	B-X
FH	B-X
deficiency	B-X
compels	B-X
cells	B-X
to	B-X
adopt	B-X
an	B-X
early	B-X
,	B-X
reversible	B-X
,	B-X
and	B-X
progressive	B-X
protumorigenic	B-X
metabolic	B-X
milieu	B-X
that	B-X
is	B-X
reminiscent	B-X
of	B-X
that	B-X
driving	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
Targets	B-X
identified	B-X
in	B-X
these	B-X
novel	B-X
and	B-X
diverse	B-X
FH-deficient	B-X
models	B-X
represent	B-X
excellent	B-X
potential	B-X
candidates	B-X
for	B-X
further	B-X
mechanistic	B-X
investigation	B-X
and	B-X
therapeutic	B-X
metabolic	B-X
manipulation	B-X
in	B-X
tumors	B-X
.	B-X

In	O
addition	O
,	O
detailed	O
metabolic	O
assessment	O
of	O
these	O
MEFs	O
confirmed	O
their	O
dependence	O
on	O
glycolysis	O
,	O
and	O
an	O
elevated	O
rate	O
of	O
lactate	O
efflux	O
,	O
associated	O
with	O
the	O
upregulation	O
of	O
glycolytic	B-Gene_or_gene_product
enzymes	I-Gene_or_gene_product
known	O
to	O
be	O
associated	O
with	O
tumorigenesis	O
.	O

Correspondingly	O
,	O
Fh1	B-Gene_or_gene_product
-	O
deficient	O
benign	O
murine	O
renal	O
cysts	O
and	O
an	O
advanced	O
human	O
HLRCC	O
-	O
related	O
renal	O
cell	O
carcinoma	O
manifested	O
a	O
prominent	O
and	O
progressive	O
increase	O
in	O
the	O
expression	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
target	O
genes	O
and	O
in	O
genes	O
known	O
to	O
be	O
relevant	O
to	O
tumorigenesis	O
and	O
metastasis	O
.	O

In	O
accord	O
with	O
our	O
hypothesis	O
,	O
in	O
a	O
variety	O
of	O
different	O
FH	B-Gene_or_gene_product
-	O
deficient	O
tissues	O
,	O
including	O
a	O
novel	O
murine	O
model	O
of	O
Fh1	B-Gene_or_gene_product
-	O
deficient	O
smooth	O
muscle	O
,	O
we	O
show	O
a	O
striking	O
and	O
progressive	O
upregulation	O
of	O
a	O
tumorigenic	O
metabolic	O
profile	O
,	O
as	O
manifested	O
by	O
increased	O
PKM2	B-Gene_or_gene_product
and	O
LDHA	B-Gene_or_gene_product
protein	O
.	O

Based	O
on	O
the	O
models	O
assessed	O
herein	O
,	O
we	O
infer	O
that	O
that	O
FH	B-Gene_or_gene_product
deficiency	O
compels	O
cells	O
to	O
adopt	O
an	O
early	O
,	O
reversible	O
,	O
and	O
progressive	O
protumorigenic	O
metabolic	O
milieu	O
that	O
is	O
reminiscent	O
of	O
that	O
driving	O
the	O
Warburg	O
effect	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
an	B-X
additional	B-X
direct	B-X
consequence	B-X
of	B-X
FH	B-X
deficiency	B-X
is	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
biosynthetic	B-X
milieu	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
detailed	B-X
metabolic	B-X
assessment	B-X
of	B-X
these	B-X
MEFs	B-X
confirmed	B-X
their	B-X
dependence	B-X
on	B-X
glycolysis	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
rate	B-X
of	B-X
lactate	B-X
efflux	B-X
,	B-X
associated	B-X
with	B-X
the	B-X
upregulation	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Correspondingly	B-X
,	B-X
Fh1-deficient	B-X
benign	B-X
murine	B-X
renal	B-X
cysts	B-X
and	B-X
an	B-X
advanced	B-X
human	B-X
HLRCC-related	B-X
renal	B-X
cell	B-X
carcinoma	B-X
manifested	B-X
a	B-X
prominent	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
HIF-Î±	B-X
target	B-X
genes	B-X
and	B-X
in	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
relevant	B-X
to	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
our	B-X
hypothesis	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
FH-deficient	B-X
tissues	B-X
,	B-X
including	B-X
a	B-X
novel	B-X
murine	B-X
model	B-X
of	B-X
Fh1-deficient	B-X
smooth	B-X
muscle	B-X
,	B-X
we	B-X
show	B-X
a	B-X
striking	B-X
and	B-X
progressive	B-X
upregulation	B-X
of	B-X
a	B-X
tumorigenic	B-X
metabolic	B-X
profile	B-X
,	B-X
as	B-X
manifested	B-X
by	B-X
increased	B-X
PKM2	B-X
and	B-X
LDHA	B-X
protein	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
models	B-X
assessed	B-X
herein	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
that	B-X
FH	B-X
deficiency	B-X
compels	B-X
cells	B-X
to	B-X
adopt	B-X
an	B-X
early	B-X
,	B-X
reversible	B-X
,	B-X
and	B-X
progressive	B-X
protumorigenic	B-X
metabolic	B-X
milieu	B-X
that	B-X
is	B-X
reminiscent	B-X
of	B-X
that	B-X
driving	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
Targets	B-X
identified	B-X
in	B-X
these	B-X
novel	B-X
and	B-X
diverse	B-X
FH-deficient	B-X
models	B-X
represent	B-X
excellent	B-X
potential	B-X
candidates	B-X
for	B-X
further	B-X
mechanistic	B-X
investigation	B-X
and	B-X
therapeutic	B-X
metabolic	B-X
manipulation	B-X
in	B-X
tumors	B-X
.	B-X

Targets	O
identified	O
in	O
these	O
novel	O
and	O
diverse	O
FH	B-Gene_or_gene_product
-	O
deficient	O
models	O
represent	O
excellent	O
potential	O
candidates	O
for	O
further	O
mechanistic	O
investigation	O
and	O
therapeutic	O
metabolic	O
manipulation	O
in	O
tumors	O
.	O
<EOS>	B-X
Hereditary	B-X
leiomyomatosis	B-X
and	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
HLRCC	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
fumarate	B-X
hydratase	B-X
(	B-X
FH	B-X
)	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
an	B-X
additional	B-X
direct	B-X
consequence	B-X
of	B-X
FH	B-X
deficiency	B-X
is	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
biosynthetic	B-X
milieu	B-X
.	B-X
To	B-X
investigate	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
isolated	B-X
primary	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
(	B-X
MEF	B-X
)	B-X
lines	B-X
from	B-X
Fh1-deficient	B-X
mice	B-X
.	B-X
As	B-X
predicted	B-X
,	B-X
these	B-X
MEFs	B-X
upregulated	B-X
Hif-1Î±	B-X
and	B-X
HIF	B-X
target	B-X
genes	B-X
directly	B-X
as	B-X
a	B-X
result	B-X
of	B-X
FH	B-X
deficiency	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
detailed	B-X
metabolic	B-X
assessment	B-X
of	B-X
these	B-X
MEFs	B-X
confirmed	B-X
their	B-X
dependence	B-X
on	B-X
glycolysis	B-X
,	B-X
and	B-X
an	B-X
elevated	B-X
rate	B-X
of	B-X
lactate	B-X
efflux	B-X
,	B-X
associated	B-X
with	B-X
the	B-X
upregulation	B-X
of	B-X
glycolytic	B-X
enzymes	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Correspondingly	B-X
,	B-X
Fh1-deficient	B-X
benign	B-X
murine	B-X
renal	B-X
cysts	B-X
and	B-X
an	B-X
advanced	B-X
human	B-X
HLRCC-related	B-X
renal	B-X
cell	B-X
carcinoma	B-X
manifested	B-X
a	B-X
prominent	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
HIF-Î±	B-X
target	B-X
genes	B-X
and	B-X
in	B-X
genes	B-X
known	B-X
to	B-X
be	B-X
relevant	B-X
to	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
our	B-X
hypothesis	B-X
,	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
FH-deficient	B-X
tissues	B-X
,	B-X
including	B-X
a	B-X
novel	B-X
murine	B-X
model	B-X
of	B-X
Fh1-deficient	B-X
smooth	B-X
muscle	B-X
,	B-X
we	B-X
show	B-X
a	B-X
striking	B-X
and	B-X
progressive	B-X
upregulation	B-X
of	B-X
a	B-X
tumorigenic	B-X
metabolic	B-X
profile	B-X
,	B-X
as	B-X
manifested	B-X
by	B-X
increased	B-X
PKM2	B-X
and	B-X
LDHA	B-X
protein	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
models	B-X
assessed	B-X
herein	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
that	B-X
FH	B-X
deficiency	B-X
compels	B-X
cells	B-X
to	B-X
adopt	B-X
an	B-X
early	B-X
,	B-X
reversible	B-X
,	B-X
and	B-X
progressive	B-X
protumorigenic	B-X
metabolic	B-X
milieu	B-X
that	B-X
is	B-X
reminiscent	B-X
of	B-X
that	B-X
driving	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
Targets	B-X
identified	B-X
in	B-X
these	B-X
novel	B-X
and	B-X
diverse	B-X
FH-deficient	B-X
models	B-X
represent	B-X
excellent	B-X
potential	B-X
candidates	B-X
for	B-X
further	B-X
mechanistic	B-X
investigation	B-X
and	B-X
therapeutic	B-X
metabolic	B-X
manipulation	B-X
in	B-X
tumors	B-X
.	B-X

A	O
STAT3	B-Gene_or_gene_product
-	O
mediated	O
metabolic	O
switch	O
is	O
involved	O
in	O
tumour	O
transformation	O
and	O
STAT3	B-Gene_or_gene_product
addiction	O
.	O
<EOS>	B-X
The	B-X
pro-oncogenic	B-X
transcription	B-X
factor	B-X
STAT3	B-X
is	B-X
constitutively	B-X
activated	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumours	B-X
that	B-X
often	B-X
become	B-X
addicted	B-X
to	B-X
its	B-X
activity	B-X
,	B-X
but	B-X
no	B-X
unifying	B-X
view	B-X
of	B-X
a	B-X
core	B-X
function	B-X
determining	B-X
this	B-X
widespread	B-X
STAT3-dependence	B-X
has	B-X
yet	B-X
emerged	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
constitutively	B-X
active	B-X
STAT3	B-X
acts	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cell	B-X
metabolism	B-X
,	B-X
inducing	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
down-regulating	B-X
mitochondrial	B-X
activity	B-X
both	B-X
in	B-X
primary	B-X
fibroblasts	B-X
and	B-X
in	B-X
STAT3-dependent	B-X
tumour	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
show	B-X
that	B-X
enhanced	B-X
glycolysis	B-X
is	B-X
dependent	B-X
on	B-X
HIF-1Î±	B-X
up-regulation	B-X
,	B-X
while	B-X
reduced	B-X
mitochondrial	B-X
activity	B-X
is	B-X
HIF-1Î±-independent	B-X
and	B-X
likely	B-X
caused	B-X
by	B-X
STAT3-mediated	B-X
down-regulation	B-X
of	B-X
mitochondrial	B-X
proteins	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
aerobic	B-X
glycolysis	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
STAT3	B-X
pro-oncogenic	B-X
activities	B-X
,	B-X
since	B-X
inhibition	B-X
of	B-X
STAT3	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
the	B-X
tumour	B-X
cell	B-X
lines	B-X
down-regulates	B-X
glycolysis	B-X
prior	B-X
to	B-X
leading	B-X
to	B-X
growth	B-X
arrest	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
novel	B-X
,	B-X
central	B-X
metabolic	B-X
role	B-X
is	B-X
at	B-X
the	B-X
core	B-X
of	B-X
the	B-X
addiction	B-X
for	B-X
STAT3	B-X
shown	B-X
by	B-X
so	B-X
many	B-X
biologically	B-X
different	B-X
tumours	B-X
.	B-X

The	O
pro	O
-	O
oncogenic	O
transcription	O
factor	O
STAT3	B-Gene_or_gene_product
is	O
constitutively	O
activated	O
in	O
a	O
wide	O
variety	O
of	O
tumours	O
that	O
often	O
become	O
addicted	O
to	O
its	O
activity	O
,	O
but	O
no	O
unifying	O
view	O
of	O
a	O
core	O
function	O
determining	O
this	O
widespread	O
STAT3	B-Gene_or_gene_product
-	O
dependence	O
has	O
yet	O
emerged	O
.	O

We	O
show	O
here	O
that	O
constitutively	O
active	O
STAT3	B-Gene_or_gene_product
acts	O
as	O
a	O
master	O
regulator	O
of	O
cell	O
metabolism	O
,	O
inducing	O
aerobic	O
glycolysis	O
and	O
down	O
-	O
regulating	O
mitochondrial	O
activity	O
both	O
in	O
primary	O
fibroblasts	O
and	O
in	O
STAT3	B-Gene_or_gene_product
-	O
dependent	O
tumour	O
cell	O
lines	O
.	O
<EOS>	B-X
The	B-X
pro-oncogenic	B-X
transcription	B-X
factor	B-X
STAT3	B-X
is	B-X
constitutively	B-X
activated	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumours	B-X
that	B-X
often	B-X
become	B-X
addicted	B-X
to	B-X
its	B-X
activity	B-X
,	B-X
but	B-X
no	B-X
unifying	B-X
view	B-X
of	B-X
a	B-X
core	B-X
function	B-X
determining	B-X
this	B-X
widespread	B-X
STAT3-dependence	B-X
has	B-X
yet	B-X
emerged	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
constitutively	B-X
active	B-X
STAT3	B-X
acts	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cell	B-X
metabolism	B-X
,	B-X
inducing	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
down-regulating	B-X
mitochondrial	B-X
activity	B-X
both	B-X
in	B-X
primary	B-X
fibroblasts	B-X
and	B-X
in	B-X
STAT3-dependent	B-X
tumour	B-X
cell	B-X
lines	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
cells	B-X
are	B-X
protected	B-X
from	B-X
apoptosis	B-X
and	B-X
senescence	B-X
while	B-X
becoming	B-X
highly	B-X
sensitive	B-X
to	B-X
glucose	B-X
deprivation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
enhanced	B-X
glycolysis	B-X
is	B-X
dependent	B-X
on	B-X
HIF-1Î±	B-X
up-regulation	B-X
,	B-X
while	B-X
reduced	B-X
mitochondrial	B-X
activity	B-X
is	B-X
HIF-1Î±-independent	B-X
and	B-X
likely	B-X
caused	B-X
by	B-X
STAT3-mediated	B-X
down-regulation	B-X
of	B-X
mitochondrial	B-X
proteins	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
aerobic	B-X
glycolysis	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
STAT3	B-X
pro-oncogenic	B-X
activities	B-X
,	B-X
since	B-X
inhibition	B-X
of	B-X
STAT3	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
the	B-X
tumour	B-X
cell	B-X
lines	B-X
down-regulates	B-X
glycolysis	B-X
prior	B-X
to	B-X
leading	B-X
to	B-X
growth	B-X
arrest	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
novel	B-X
,	B-X
central	B-X
metabolic	B-X
role	B-X
is	B-X
at	B-X
the	B-X
core	B-X
of	B-X
the	B-X
addiction	B-X
for	B-X
STAT3	B-X
shown	B-X
by	B-X
so	B-X
many	B-X
biologically	B-X
different	B-X
tumours	B-X
.	B-X

As	O
a	O
result	O
,	O
cells	O
are	O
protected	O
from	O
apoptosis	O
and	O
senescence	O
while	O
becoming	O
highly	O
sensitive	O
to	O
glucose	O
deprivation	O
.	O
<EOS>	B-X
As	B-X
a	B-X
result	B-X
,	B-X
cells	B-X
are	B-X
protected	B-X
from	B-X
apoptosis	B-X
and	B-X
senescence	B-X
while	B-X
becoming	B-X
highly	B-X
sensitive	B-X
to	B-X
glucose	B-X
deprivation	B-X
.	B-X

We	O
show	O
that	O
enhanced	O
glycolysis	O
is	O
dependent	O
on	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
up	O
-	O
regulation	O
,	O
while	O
reduced	O
mitochondrial	O
activity	O
is	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	I-Gene_or_gene_product
-	O
independent	O
and	O
likely	O
caused	O
by	O
STAT3	B-Gene_or_gene_product
-	O
mediated	O
down	O
-	O
regulation	O
of	O
mitochondrial	O
proteins	O
.	O
<EOS>	B-X
The	B-X
pro-oncogenic	B-X
transcription	B-X
factor	B-X
STAT3	B-X
is	B-X
constitutively	B-X
activated	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumours	B-X
that	B-X
often	B-X
become	B-X
addicted	B-X
to	B-X
its	B-X
activity	B-X
,	B-X
but	B-X
no	B-X
unifying	B-X
view	B-X
of	B-X
a	B-X
core	B-X
function	B-X
determining	B-X
this	B-X
widespread	B-X
STAT3-dependence	B-X
has	B-X
yet	B-X
emerged	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
constitutively	B-X
active	B-X
STAT3	B-X
acts	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cell	B-X
metabolism	B-X
,	B-X
inducing	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
down-regulating	B-X
mitochondrial	B-X
activity	B-X
both	B-X
in	B-X
primary	B-X
fibroblasts	B-X
and	B-X
in	B-X
STAT3-dependent	B-X
tumour	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
show	B-X
that	B-X
enhanced	B-X
glycolysis	B-X
is	B-X
dependent	B-X
on	B-X
HIF-1Î±	B-X
up-regulation	B-X
,	B-X
while	B-X
reduced	B-X
mitochondrial	B-X
activity	B-X
is	B-X
HIF-1Î±-independent	B-X
and	B-X
likely	B-X
caused	B-X
by	B-X
STAT3-mediated	B-X
down-regulation	B-X
of	B-X
mitochondrial	B-X
proteins	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
aerobic	B-X
glycolysis	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
STAT3	B-X
pro-oncogenic	B-X
activities	B-X
,	B-X
since	B-X
inhibition	B-X
of	B-X
STAT3	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
the	B-X
tumour	B-X
cell	B-X
lines	B-X
down-regulates	B-X
glycolysis	B-X
prior	B-X
to	B-X
leading	B-X
to	B-X
growth	B-X
arrest	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
novel	B-X
,	B-X
central	B-X
metabolic	B-X
role	B-X
is	B-X
at	B-X
the	B-X
core	B-X
of	B-X
the	B-X
addiction	B-X
for	B-X
STAT3	B-X
shown	B-X
by	B-X
so	B-X
many	B-X
biologically	B-X
different	B-X
tumours	B-X
.	B-X

The	O
induction	O
of	O
aerobic	O
glycolysis	O
is	O
an	O
important	O
component	O
of	O
STAT3	B-Gene_or_gene_product
pro	O
-	O
oncogenic	O
activities	O
,	O
since	O
inhibition	O
of	O
STAT3	B-Gene_or_gene_product
tyrosine	O
phosphorylation	O
in	O
the	O
tumour	O
cell	O
lines	O
down	O
-	O
regulates	O
glycolysis	O
prior	O
to	O
leading	O
to	O
growth	O
arrest	O
and	O
cell	O
death	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
pro-oncogenic	B-X
transcription	B-X
factor	B-X
STAT3	B-X
is	B-X
constitutively	B-X
activated	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
tumours	B-X
that	B-X
often	B-X
become	B-X
addicted	B-X
to	B-X
its	B-X
activity	B-X
,	B-X
but	B-X
no	B-X
unifying	B-X
view	B-X
of	B-X
a	B-X
core	B-X
function	B-X
determining	B-X
this	B-X
widespread	B-X
STAT3-dependence	B-X
has	B-X
yet	B-X
emerged	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
constitutively	B-X
active	B-X
STAT3	B-X
acts	B-X
as	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
cell	B-X
metabolism	B-X
,	B-X
inducing	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
down-regulating	B-X
mitochondrial	B-X
activity	B-X
both	B-X
in	B-X
primary	B-X
fibroblasts	B-X
and	B-X
in	B-X
STAT3-dependent	B-X
tumour	B-X
cell	B-X
lines	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
cells	B-X
are	B-X
protected	B-X
from	B-X
apoptosis	B-X
and	B-X
senescence	B-X
while	B-X
becoming	B-X
highly	B-X
sensitive	B-X
to	B-X
glucose	B-X
deprivation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
enhanced	B-X
glycolysis	B-X
is	B-X
dependent	B-X
on	B-X
HIF-1Î±	B-X
up-regulation	B-X
,	B-X
while	B-X
reduced	B-X
mitochondrial	B-X
activity	B-X
is	B-X
HIF-1Î±-independent	B-X
and	B-X
likely	B-X
caused	B-X
by	B-X
STAT3-mediated	B-X
down-regulation	B-X
of	B-X
mitochondrial	B-X
proteins	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
aerobic	B-X
glycolysis	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
STAT3	B-X
pro-oncogenic	B-X
activities	B-X
,	B-X
since	B-X
inhibition	B-X
of	B-X
STAT3	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
the	B-X
tumour	B-X
cell	B-X
lines	B-X
down-regulates	B-X
glycolysis	B-X
prior	B-X
to	B-X
leading	B-X
to	B-X
growth	B-X
arrest	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
novel	B-X
,	B-X
central	B-X
metabolic	B-X
role	B-X
is	B-X
at	B-X
the	B-X
core	B-X
of	B-X
the	B-X
addiction	B-X
for	B-X
STAT3	B-X
shown	B-X
by	B-X
so	B-X
many	B-X
biologically	B-X
different	B-X
tumours	B-X
.	B-X

We	O
propose	O
that	O
this	O
novel	O
,	O
central	O
metabolic	O
role	O
is	O
at	O
the	O
core	O
of	O
the	O
addiction	O
for	O
STAT3	B-Gene_or_gene_product
shown	O
by	O
so	O
many	O
biologically	O
different	O
tumours	O
.	O

Roles	O
of	O
brca2	B-Gene_or_gene_product
(	O
fancd1	B-Gene_or_gene_product
)	O
in	O
oocyte	O
nuclear	O
architecture	O
,	O
gametogenesis	O
,	O
gonad	O
tumors	O
,	O
and	O
genome	O
stability	O
in	O
zebrafish	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
zebrafish	B-X
brca2	B-X
insertional	B-X
mutant	B-X
that	B-X
shares	B-X
phenotypes	B-X
with	B-X
human	B-X
patients	B-X
and	B-X
identifies	B-X
a	B-X
novel	B-X
brca2	B-X
function	B-X
in	B-X
oogenesis	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
The	B-X
construction	B-X
of	B-X
animals	B-X
doubly	B-X
mutant	B-X
for	B-X
brca2	B-X
and	B-X
the	B-X
apoptotic	B-X
gene	B-X
tp53	B-X
(	B-X
p53	B-X
)	B-X
rescued	B-X
brca2-dependent	B-X
sex	B-X
reversal	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X
Mutating	B-X
tp53	B-X
did	B-X
not	B-X
rescue	B-X
the	B-X
infertility	B-X
phenotype	B-X
in	B-X
brca2	B-X
mutant	B-X
males	B-X
,	B-X
suggesting	B-X
that	B-X
brca2	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
zebrafish	B-X
spermatogenesis	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
work	B-X
verified	B-X
zebrafish	B-X
as	B-X
a	B-X
model	B-X
for	B-X
the	B-X
role	B-X
of	B-X
Brca2	B-X
in	B-X
human	B-X
disease	B-X
and	B-X
uncovered	B-X
a	B-X
novel	B-X
function	B-X
of	B-X
Brca2	B-X
in	B-X
vertebrate	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X

Mild	O
mutations	O
in	O
BRCA2	B-Gene_or_gene_product
(	O
FANCD1	B-Gene_or_gene_product
)	O
cause	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
when	O
homozygous	O
,	O
while	O
severe	O
mutations	O
cause	O
common	O
cancers	O
including	O
breast	O
,	O
ovarian	O
,	O
and	O
prostate	O
cancers	O
when	O
heterozygous	O
.	O
<EOS>	B-X
Mild	B-X
mutations	B-X
in	B-X
BRCA2	B-X
(	B-X
FANCD1	B-X
)	B-X
cause	B-X
Fanconi	B-X
anemia	B-X
(	B-X
FA	B-X
)	B-X
when	B-X
homozygous	B-X
,	B-X
while	B-X
severe	B-X
mutations	B-X
cause	B-X
common	B-X
cancers	B-X
including	B-X
breast	B-X
,	B-X
ovarian	B-X
,	B-X
and	B-X
prostate	B-X
cancers	B-X
when	B-X
heterozygous	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X

Here	O
we	O
report	O
a	O
zebrafish	O
brca2	B-Gene_or_gene_product
insertional	O
mutant	O
that	O
shares	O
phenotypes	O
with	O
human	O
patients	O
and	O
identifies	O
a	O
novel	O
brca2	B-Gene_or_gene_product
function	O
in	O
oogenesis	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
zebrafish	B-X
brca2	B-X
insertional	B-X
mutant	B-X
that	B-X
shares	B-X
phenotypes	B-X
with	B-X
human	B-X
patients	B-X
and	B-X
identifies	B-X
a	B-X
novel	B-X
brca2	B-X
function	B-X
in	B-X
oogenesis	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
The	B-X
construction	B-X
of	B-X
animals	B-X
doubly	B-X
mutant	B-X
for	B-X
brca2	B-X
and	B-X
the	B-X
apoptotic	B-X
gene	B-X
tp53	B-X
(	B-X
p53	B-X
)	B-X
rescued	B-X
brca2-dependent	B-X
sex	B-X
reversal	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X
Mutating	B-X
tp53	B-X
did	B-X
not	B-X
rescue	B-X
the	B-X
infertility	B-X
phenotype	B-X
in	B-X
brca2	B-X
mutant	B-X
males	B-X
,	B-X
suggesting	B-X
that	B-X
brca2	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
zebrafish	B-X
spermatogenesis	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
work	B-X
verified	B-X
zebrafish	B-X
as	B-X
a	B-X
model	B-X
for	B-X
the	B-X
role	B-X
of	B-X
Brca2	B-X
in	B-X
human	B-X
disease	B-X
and	B-X
uncovered	B-X
a	B-X
novel	B-X
function	B-X
of	B-X
Brca2	B-X
in	B-X
vertebrate	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X

Experiments	O
showed	O
that	O
mutant	O
embryos	O
and	O
mutant	O
cells	O
in	O
culture	O
experienced	O
genome	O
instability	O
,	O
as	O
do	O
cells	O
in	O
FA	O
patients	O
.	O
<EOS>	B-X
Mild	B-X
mutations	B-X
in	B-X
BRCA2	B-X
(	B-X
FANCD1	B-X
)	B-X
cause	B-X
Fanconi	B-X
anemia	B-X
(	B-X
FA	B-X
)	B-X
when	B-X
homozygous	B-X
,	B-X
while	B-X
severe	B-X
mutations	B-X
cause	B-X
common	B-X
cancers	B-X
including	B-X
breast	B-X
,	B-X
ovarian	B-X
,	B-X
and	B-X
prostate	B-X
cancers	B-X
when	B-X
heterozygous	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
zebrafish	B-X
brca2	B-X
insertional	B-X
mutant	B-X
that	B-X
shares	B-X
phenotypes	B-X
with	B-X
human	B-X
patients	B-X
and	B-X
identifies	B-X
a	B-X
novel	B-X
brca2	B-X
function	B-X
in	B-X
oogenesis	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
The	B-X
construction	B-X
of	B-X
animals	B-X
doubly	B-X
mutant	B-X
for	B-X
brca2	B-X
and	B-X
the	B-X
apoptotic	B-X
gene	B-X
tp53	B-X
(	B-X
p53	B-X
)	B-X
rescued	B-X
brca2-dependent	B-X
sex	B-X
reversal	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X
Mutating	B-X
tp53	B-X
did	B-X
not	B-X
rescue	B-X
the	B-X
infertility	B-X
phenotype	B-X
in	B-X
brca2	B-X
mutant	B-X
males	B-X
,	B-X
suggesting	B-X
that	B-X
brca2	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
zebrafish	B-X
spermatogenesis	B-X
.	B-X

In	O
wild	O
-	O
type	O
zebrafish	O
,	O
meiotic	O
cells	O
expressed	O
brca2	B-Gene_or_gene_product
;	O
and	O
,	O
unexpectedly	O
,	O
transcripts	O
in	O
oocytes	O
localized	O
asymmetrically	O
to	O
the	O
animal	O
pole	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
zebrafish	B-X
brca2	B-X
insertional	B-X
mutant	B-X
that	B-X
shares	B-X
phenotypes	B-X
with	B-X
human	B-X
patients	B-X
and	B-X
identifies	B-X
a	B-X
novel	B-X
brca2	B-X
function	B-X
in	B-X
oogenesis	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
The	B-X
construction	B-X
of	B-X
animals	B-X
doubly	B-X
mutant	B-X
for	B-X
brca2	B-X
and	B-X
the	B-X
apoptotic	B-X
gene	B-X
tp53	B-X
(	B-X
p53	B-X
)	B-X
rescued	B-X
brca2-dependent	B-X
sex	B-X
reversal	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X
Mutating	B-X
tp53	B-X
did	B-X
not	B-X
rescue	B-X
the	B-X
infertility	B-X
phenotype	B-X
in	B-X
brca2	B-X
mutant	B-X
males	B-X
,	B-X
suggesting	B-X
that	B-X
brca2	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
zebrafish	B-X
spermatogenesis	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
work	B-X
verified	B-X
zebrafish	B-X
as	B-X
a	B-X
model	B-X
for	B-X
the	B-X
role	B-X
of	B-X
Brca2	B-X
in	B-X
human	B-X
disease	B-X
and	B-X
uncovered	B-X
a	B-X
novel	B-X
function	B-X
of	B-X
Brca2	B-X
in	B-X
vertebrate	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X

In	O
juvenile	O
brca2	B-Gene_or_gene_product
mutants	O
,	O
oocytes	O
failed	O
to	O
progress	O
through	O
meiosis	O
,	O
leading	O
to	O
female	O
-	O
to	O
-	O
male	O
sex	O
reversal	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
zebrafish	B-X
brca2	B-X
insertional	B-X
mutant	B-X
that	B-X
shares	B-X
phenotypes	B-X
with	B-X
human	B-X
patients	B-X
and	B-X
identifies	B-X
a	B-X
novel	B-X
brca2	B-X
function	B-X
in	B-X
oogenesis	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
The	B-X
construction	B-X
of	B-X
animals	B-X
doubly	B-X
mutant	B-X
for	B-X
brca2	B-X
and	B-X
the	B-X
apoptotic	B-X
gene	B-X
tp53	B-X
(	B-X
p53	B-X
)	B-X
rescued	B-X
brca2-dependent	B-X
sex	B-X
reversal	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X
Mutating	B-X
tp53	B-X
did	B-X
not	B-X
rescue	B-X
the	B-X
infertility	B-X
phenotype	B-X
in	B-X
brca2	B-X
mutant	B-X
males	B-X
,	B-X
suggesting	B-X
that	B-X
brca2	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
zebrafish	B-X
spermatogenesis	B-X
.	B-X

Adult	O
mutants	O
became	O
sterile	O
males	O
due	O
to	O
the	O
meiotic	O
arrest	O
of	O
spermatocytes	O
,	O
which	O
then	O
died	O
by	O
apoptosis	O
,	O
followed	O
by	O
neoplastic	O
proliferation	O
of	O
gonad	O
somatic	O
cells	O
that	O
was	O
similar	O
to	O
neoplasia	O
observed	O
in	O
ageing	O
dead	B-Gene_or_gene_product
end	I-Gene_or_gene_product
(	O
dnd	B-Gene_or_gene_product
)	O
-	O
knockdown	O
males	O
,	O
which	O
lack	O
germ	O
cells	O
.	O

The	O
construction	O
of	O
animals	O
doubly	O
mutant	O
for	O
brca2	B-Gene_or_gene_product
and	O
the	O
apoptotic	O
gene	O
tp53	B-Gene_or_gene_product
(	O
p53	B-Gene_or_gene_product
)	O
rescued	O
brca2	B-Gene_or_gene_product
-	O
dependent	O
sex	O
reversal	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
zebrafish	B-X
brca2	B-X
insertional	B-X
mutant	B-X
that	B-X
shares	B-X
phenotypes	B-X
with	B-X
human	B-X
patients	B-X
and	B-X
identifies	B-X
a	B-X
novel	B-X
brca2	B-X
function	B-X
in	B-X
oogenesis	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
The	B-X
construction	B-X
of	B-X
animals	B-X
doubly	B-X
mutant	B-X
for	B-X
brca2	B-X
and	B-X
the	B-X
apoptotic	B-X
gene	B-X
tp53	B-X
(	B-X
p53	B-X
)	B-X
rescued	B-X
brca2-dependent	B-X
sex	B-X
reversal	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X
Mutating	B-X
tp53	B-X
did	B-X
not	B-X
rescue	B-X
the	B-X
infertility	B-X
phenotype	B-X
in	B-X
brca2	B-X
mutant	B-X
males	B-X
,	B-X
suggesting	B-X
that	B-X
brca2	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
zebrafish	B-X
spermatogenesis	B-X
.	B-X

Double	O
mutants	O
developed	O
oocytes	O
and	O
became	O
sterile	O
females	O
that	O
produced	O
only	O
aberrant	O
embryos	O
and	O
showed	O
elevated	O
risk	O
for	O
invasive	O
ovarian	O
tumors	O
.	O
<EOS>	B-X
Mild	B-X
mutations	B-X
in	B-X
BRCA2	B-X
(	B-X
FANCD1	B-X
)	B-X
cause	B-X
Fanconi	B-X
anemia	B-X
(	B-X
FA	B-X
)	B-X
when	B-X
homozygous	B-X
,	B-X
while	B-X
severe	B-X
mutations	B-X
cause	B-X
common	B-X
cancers	B-X
including	B-X
breast	B-X
,	B-X
ovarian	B-X
,	B-X
and	B-X
prostate	B-X
cancers	B-X
when	B-X
heterozygous	B-X
.	B-X
Experiments	B-X
showed	B-X
that	B-X
mutant	B-X
embryos	B-X
and	B-X
mutant	B-X
cells	B-X
in	B-X
culture	B-X
experienced	B-X
genome	B-X
instability	B-X
,	B-X
as	B-X
do	B-X
cells	B-X
in	B-X
FA	B-X
patients	B-X
.	B-X
In	B-X
wild-type	B-X
zebrafish	B-X
,	B-X
meiotic	B-X
cells	B-X
expressed	B-X
brca2	B-X
;	B-X
and	B-X
,	B-X
unexpectedly	B-X
,	B-X
transcripts	B-X
in	B-X
oocytes	B-X
localized	B-X
asymmetrically	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
.	B-X
In	B-X
juvenile	B-X
brca2	B-X
mutants	B-X
,	B-X
oocytes	B-X
failed	B-X
to	B-X
progress	B-X
through	B-X
meiosis	B-X
,	B-X
leading	B-X
to	B-X
female-to-male	B-X
sex	B-X
reversal	B-X
.	B-X
Adult	B-X
mutants	B-X
became	B-X
sterile	B-X
males	B-X
due	B-X
to	B-X
the	B-X
meiotic	B-X
arrest	B-X
of	B-X
spermatocytes	B-X
,	B-X
which	B-X
then	B-X
died	B-X
by	B-X
apoptosis	B-X
,	B-X
followed	B-X
by	B-X
neoplastic	B-X
proliferation	B-X
of	B-X
gonad	B-X
somatic	B-X
cells	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
neoplasia	B-X
observed	B-X
in	B-X
ageing	B-X
dead	B-X
end	B-X
(	B-X
dnd	B-X
)	B-X
-knockdown	B-X
males	B-X
,	B-X
which	B-X
lack	B-X
germ	B-X
cells	B-X
.	B-X
Double	B-X
mutants	B-X
developed	B-X
oocytes	B-X
and	B-X
became	B-X
sterile	B-X
females	B-X
that	B-X
produced	B-X
only	B-X
aberrant	B-X
embryos	B-X
and	B-X
showed	B-X
elevated	B-X
risk	B-X
for	B-X
invasive	B-X
ovarian	B-X
tumors	B-X
.	B-X
Oocytes	B-X
in	B-X
double-mutant	B-X
females	B-X
showed	B-X
normal	B-X
localization	B-X
of	B-X
brca2	B-X
and	B-X
pou5f1	B-X
transcripts	B-X
to	B-X
the	B-X
animal	B-X
pole	B-X
and	B-X
vasa	B-X
transcripts	B-X
to	B-X
the	B-X
vegetal	B-X
pole	B-X
,	B-X
but	B-X
had	B-X
a	B-X
polarized	B-X
rather	B-X
than	B-X
symmetrical	B-X
nucleus	B-X
with	B-X
the	B-X
distribution	B-X
of	B-X
nucleoli	B-X
and	B-X
chromosomes	B-X
to	B-X
opposite	B-X
nuclear	B-X
poles	B-X
;	B-X
this	B-X
result	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
Brca2	B-X
in	B-X
establishing	B-X
or	B-X
maintaining	B-X
oocyte	B-X
nuclear	B-X
architecture	B-X
.	B-X

Oocytes	O
in	O
double	O
-	O
mutant	O
females	O
showed	O
normal	O
localization	O
of	O
brca2	B-Gene_or_gene_product
and	O
pou5f1	B-Gene_or_gene_product
transcripts	O
to	O
the	O
animal	O
pole	O
and	O
vasa	O
transcripts	O
to	O
the	O
vegetal	O
pole	O
,	O
but	O
had	O
a	O
polarized	O
rather	O
than	O
symmetrical	O
nucleus	O
with	O
the	O
distribution	O
of	O
nucleoli	O
and	O
chromosomes	O
to	O
opposite	O
nuclear	O
poles	O
;	O
this	O
result	O
revealed	O
a	O
novel	O
role	O
for	O
Brca2	B-Gene_or_gene_product
in	O
establishing	O
or	O
maintaining	O
oocyte	O
nuclear	O
architecture	O
.	O

Mutating	O
tp53	B-Gene_or_gene_product
did	O
not	O
rescue	O
the	O
infertility	O
phenotype	O
in	O
brca2	B-Gene_or_gene_product
mutant	O
males	O
,	O
suggesting	O
that	O
brca2	B-Gene_or_gene_product
plays	O
an	O
essential	O
role	O
in	O
zebrafish	O
spermatogenesis	O
.	O
<EOS>	B-X
Majority	B-X
of	B-X
these	B-X
restore	B-X
p53/TP53	B-X
function	B-X
by	B-X
targeting	B-X
negative	B-X
regulators	B-X
of	B-X
p53/TP53	B-X
,	B-X
wtp53/TP53	B-X
(	B-X
wild-type	B-X
)	B-X
and	B-X
mtp53/TP53	B-X
(	B-X
mutant	B-X
)	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
mutations	B-X
have	B-X
been	B-X
invaluable	B-X
for	B-X
bettering	B-X
our	B-X
knowledge	B-X
on	B-X
the	B-X
structure-function	B-X
relationships	B-X
within	B-X
the	B-X
TP53	B-X
protein	B-X
and	B-X
the	B-X
high	B-X
degree	B-X
of	B-X
heterogeneity	B-X
of	B-X
the	B-X
various	B-X
TP53	B-X
mutants	B-X
in	B-X
human	B-X
cancer	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
how	B-X
with	B-X
the	B-X
release	B-X
of	B-X
the	B-X
sequences	B-X
of	B-X
thousands	B-X
of	B-X
tumor	B-X
genomes	B-X
issued	B-X
from	B-X
high-throughput	B-X
sequencing	B-X
,	B-X
the	B-X
description	B-X
of	B-X
novel	B-X
TP53	B-X
mutants	B-X
is	B-X
now	B-X
reaching	B-X
a	B-X
plateau	B-X
indicating	B-X
that	B-X
we	B-X
are	B-X
close	B-X
to	B-X
the	B-X
full	B-X
set	B-X
of	B-X
mutants	B-X
that	B-X
target	B-X
the	B-X
elusive	B-X
tumor-suppressive	B-X
activity	B-X
of	B-X
this	B-X
protein	B-X
.	B-X
Acute	B-X
erythroleukemia	B-X
(	B-X
AEL	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
form	B-X
of	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
recognized	B-X
by	B-X
erythroblastic	B-X
proliferation	B-X
.	B-X

Overall	O
,	O
this	O
work	O
verified	O
zebrafish	O
as	O
a	O
model	O
for	O
the	O
role	O
of	O
Brca2	B-Gene_or_gene_product
in	O
human	O
disease	O
and	O
uncovered	O
a	O
novel	O
function	O
of	O
Brca2	B-Gene_or_gene_product
in	O
vertebrate	O
oocyte	O
nuclear	O
architecture	O
.	O

KISS1	B-Gene_or_gene_product
methylation	O
and	O
expression	O
as	O
tumor	O
stratification	O
biomarkers	O
and	O
clinical	O
outcome	O
prognosticators	O
for	O
bladder	O
cancer	O
patients	O
.	O
<EOS>	B-X
KISS1	B-X
is	B-X
a	B-X
metastasis	B-X
suppressor	B-X
gene	B-X
that	B-X
is	B-X
lost	B-X
in	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
bladder	B-X
cancer	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
epigenetic	B-X
silencing	B-X
hypothesis	B-X
and	B-X
evaluated	B-X
the	B-X
biological	B-X
influence	B-X
of	B-X
KISS1	B-X
methylation	B-X
on	B-X
its	B-X
expression	B-X
and	B-X
clinical	B-X
relevance	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
frequent	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
analyzed	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
and	B-X
bisulfite	B-X
sequencing	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
gene	B-X
expression	B-X
,	B-X
being	B-X
restored	B-X
in	B-X
vitro	B-X
by	B-X
demethylating	B-X
azacytidine	B-X
.	B-X
Hypermethylation	B-X
was	B-X
also	B-X
frequently	B-X
observed	B-X
in	B-X
a	B-X
large	B-X
series	B-X
of	B-X
bladder	B-X
tumors	B-X
(	B-X
83.1	B-X
%	B-X
,	B-X
n	B-X
=	B-X
804	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
increasing	B-X
stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
and	B-X
tumor	B-X
grade	B-X
(	B-X
P	B-X
=	B-X
0.010	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
KISS1	B-X
transcript	B-X
expression	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
(	B-X
P	B-X
=	B-X
0.037	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
histopathological	B-X
tumor	B-X
stage	B-X
(	B-X
P	B-X
<	B-X
0.0005	B-X
)	B-X
.	B-X
Low	B-X
transcript	B-X
expression	B-X
alone	B-X
(	B-X
P	B-X
=	B-X
0.003	B-X
)	B-X
or	B-X
combined	B-X
with	B-X
methylation	B-X
(	B-X
P	B-X
=	B-X
0.019	B-X
)	B-X
was	B-X
associated	B-X
with	B-X
poor	B-X
disease-specific	B-X
survival	B-X
(	B-X
n	B-X
=	B-X
205	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
remained	B-X
an	B-X
independent	B-X
prognosticator	B-X
in	B-X
multivariate	B-X
analyses	B-X
(	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
identified	B-X
in	B-X
bladder	B-X
cancer	B-X
,	B-X
providing	B-X
a	B-X
potential	B-X
mechanistic	B-X
explanation	B-X
(	B-X
epigenetic	B-X
silencing	B-X
)	B-X
for	B-X
the	B-X
observed	B-X
loss	B-X
of	B-X
KISS1	B-X
in	B-X
uroepithelial	B-X
malignancies	B-X
.	B-X
Associations	B-X
of	B-X
KISS1	B-X
methylation	B-X
and	B-X
its	B-X
expression	B-X
with	B-X
histopathological	B-X
variables	B-X
and	B-X
poor	B-X
survival	B-X
suggest	B-X
the	B-X
utility	B-X
of	B-X
incorporating	B-X
KISS1	B-X
measurement	B-X
using	B-X
paraffin-embedded	B-X
material	B-X
for	B-X
tumor	B-X
stratification	B-X
and	B-X
clinical	B-X
outcome	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
uroepithelial	B-X
neoplasias	B-X
.	B-X

KISS1	B-Gene_or_gene_product
is	O
a	O
metastasis	O
suppressor	O
gene	O
that	O
is	O
lost	O
in	O
several	O
malignancies	O
,	O
including	O
bladder	O
cancer	O
.	O
<EOS>	B-X
KISS1	B-X
is	B-X
a	B-X
metastasis	B-X
suppressor	B-X
gene	B-X
that	B-X
is	B-X
lost	B-X
in	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
bladder	B-X
cancer	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
epigenetic	B-X
silencing	B-X
hypothesis	B-X
and	B-X
evaluated	B-X
the	B-X
biological	B-X
influence	B-X
of	B-X
KISS1	B-X
methylation	B-X
on	B-X
its	B-X
expression	B-X
and	B-X
clinical	B-X
relevance	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
frequent	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
analyzed	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
and	B-X
bisulfite	B-X
sequencing	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
gene	B-X
expression	B-X
,	B-X
being	B-X
restored	B-X
in	B-X
vitro	B-X
by	B-X
demethylating	B-X
azacytidine	B-X
.	B-X
Hypermethylation	B-X
was	B-X
also	B-X
frequently	B-X
observed	B-X
in	B-X
a	B-X
large	B-X
series	B-X
of	B-X
bladder	B-X
tumors	B-X
(	B-X
83.1	B-X
%	B-X
,	B-X
n	B-X
=	B-X
804	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
increasing	B-X
stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
and	B-X
tumor	B-X
grade	B-X
(	B-X
P	B-X
=	B-X
0.010	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
KISS1	B-X
transcript	B-X
expression	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
(	B-X
P	B-X
=	B-X
0.037	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
histopathological	B-X
tumor	B-X
stage	B-X
(	B-X
P	B-X
<	B-X
0.0005	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
remained	B-X
an	B-X
independent	B-X
prognosticator	B-X
in	B-X
multivariate	B-X
analyses	B-X
(	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
identified	B-X
in	B-X
bladder	B-X
cancer	B-X
,	B-X
providing	B-X
a	B-X
potential	B-X
mechanistic	B-X
explanation	B-X
(	B-X
epigenetic	B-X
silencing	B-X
)	B-X
for	B-X
the	B-X
observed	B-X
loss	B-X
of	B-X
KISS1	B-X
in	B-X
uroepithelial	B-X
malignancies	B-X
.	B-X
Associations	B-X
of	B-X
KISS1	B-X
methylation	B-X
and	B-X
its	B-X
expression	B-X
with	B-X
histopathological	B-X
variables	B-X
and	B-X
poor	B-X
survival	B-X
suggest	B-X
the	B-X
utility	B-X
of	B-X
incorporating	B-X
KISS1	B-X
measurement	B-X
using	B-X
paraffin-embedded	B-X
material	B-X
for	B-X
tumor	B-X
stratification	B-X
and	B-X
clinical	B-X
outcome	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
uroepithelial	B-X
neoplasias	B-X
.	B-X

We	O
tested	O
the	O
epigenetic	O
silencing	O
hypothesis	O
and	O
evaluated	O
the	O
biological	O
influence	O
of	O
KISS1	B-Gene_or_gene_product
methylation	O
on	O
its	O
expression	O
and	O
clinical	O
relevance	O
in	O
bladder	O
cancer	O
.	O
<EOS>	B-X
KISS1	B-X
is	B-X
a	B-X
metastasis	B-X
suppressor	B-X
gene	B-X
that	B-X
is	B-X
lost	B-X
in	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
bladder	B-X
cancer	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
epigenetic	B-X
silencing	B-X
hypothesis	B-X
and	B-X
evaluated	B-X
the	B-X
biological	B-X
influence	B-X
of	B-X
KISS1	B-X
methylation	B-X
on	B-X
its	B-X
expression	B-X
and	B-X
clinical	B-X
relevance	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
frequent	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
analyzed	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
and	B-X
bisulfite	B-X
sequencing	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
gene	B-X
expression	B-X
,	B-X
being	B-X
restored	B-X
in	B-X
vitro	B-X
by	B-X
demethylating	B-X
azacytidine	B-X
.	B-X
Hypermethylation	B-X
was	B-X
also	B-X
frequently	B-X
observed	B-X
in	B-X
a	B-X
large	B-X
series	B-X
of	B-X
bladder	B-X
tumors	B-X
(	B-X
83.1	B-X
%	B-X
,	B-X
n	B-X
=	B-X
804	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
increasing	B-X
stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
and	B-X
tumor	B-X
grade	B-X
(	B-X
P	B-X
=	B-X
0.010	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
KISS1	B-X
transcript	B-X
expression	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
(	B-X
P	B-X
=	B-X
0.037	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
histopathological	B-X
tumor	B-X
stage	B-X
(	B-X
P	B-X
<	B-X
0.0005	B-X
)	B-X
.	B-X
Low	B-X
transcript	B-X
expression	B-X
alone	B-X
(	B-X
P	B-X
=	B-X
0.003	B-X
)	B-X
or	B-X
combined	B-X
with	B-X
methylation	B-X
(	B-X
P	B-X
=	B-X
0.019	B-X
)	B-X
was	B-X
associated	B-X
with	B-X
poor	B-X
disease-specific	B-X
survival	B-X
(	B-X
n	B-X
=	B-X
205	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
remained	B-X
an	B-X
independent	B-X
prognosticator	B-X
in	B-X
multivariate	B-X
analyses	B-X
(	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
identified	B-X
in	B-X
bladder	B-X
cancer	B-X
,	B-X
providing	B-X
a	B-X
potential	B-X
mechanistic	B-X
explanation	B-X
(	B-X
epigenetic	B-X
silencing	B-X
)	B-X
for	B-X
the	B-X
observed	B-X
loss	B-X
of	B-X
KISS1	B-X
in	B-X
uroepithelial	B-X
malignancies	B-X
.	B-X
Associations	B-X
of	B-X
KISS1	B-X
methylation	B-X
and	B-X
its	B-X
expression	B-X
with	B-X
histopathological	B-X
variables	B-X
and	B-X
poor	B-X
survival	B-X
suggest	B-X
the	B-X
utility	B-X
of	B-X
incorporating	B-X
KISS1	B-X
measurement	B-X
using	B-X
paraffin-embedded	B-X
material	B-X
for	B-X
tumor	B-X
stratification	B-X
and	B-X
clinical	B-X
outcome	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
uroepithelial	B-X
neoplasias	B-X
.	B-X

KISS1	B-Gene_or_gene_product
hypermethylation	O
was	O
frequent	O
in	O
bladder	O
cancer	O
cells	O
analyzed	O
by	O
methylation	O
-	O
specific	O
PCR	O
and	O
bisulfite	O
sequencing	O
and	O
was	O
associated	O
with	O
low	O
gene	O
expression	O
,	O
being	O
restored	O
in	O
vitro	O
by	O
demethylating	O
azacytidine	O
.	O
<EOS>	B-X
KISS1	B-X
is	B-X
a	B-X
metastasis	B-X
suppressor	B-X
gene	B-X
that	B-X
is	B-X
lost	B-X
in	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
bladder	B-X
cancer	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
epigenetic	B-X
silencing	B-X
hypothesis	B-X
and	B-X
evaluated	B-X
the	B-X
biological	B-X
influence	B-X
of	B-X
KISS1	B-X
methylation	B-X
on	B-X
its	B-X
expression	B-X
and	B-X
clinical	B-X
relevance	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
frequent	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
analyzed	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
and	B-X
bisulfite	B-X
sequencing	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
gene	B-X
expression	B-X
,	B-X
being	B-X
restored	B-X
in	B-X
vitro	B-X
by	B-X
demethylating	B-X
azacytidine	B-X
.	B-X
Hypermethylation	B-X
was	B-X
also	B-X
frequently	B-X
observed	B-X
in	B-X
a	B-X
large	B-X
series	B-X
of	B-X
bladder	B-X
tumors	B-X
(	B-X
83.1	B-X
%	B-X
,	B-X
n	B-X
=	B-X
804	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
increasing	B-X
stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
and	B-X
tumor	B-X
grade	B-X
(	B-X
P	B-X
=	B-X
0.010	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
KISS1	B-X
transcript	B-X
expression	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
(	B-X
P	B-X
=	B-X
0.037	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
histopathological	B-X
tumor	B-X
stage	B-X
(	B-X
P	B-X
<	B-X
0.0005	B-X
)	B-X
.	B-X
Low	B-X
transcript	B-X
expression	B-X
alone	B-X
(	B-X
P	B-X
=	B-X
0.003	B-X
)	B-X
or	B-X
combined	B-X
with	B-X
methylation	B-X
(	B-X
P	B-X
=	B-X
0.019	B-X
)	B-X
was	B-X
associated	B-X
with	B-X
poor	B-X
disease-specific	B-X
survival	B-X
(	B-X
n	B-X
=	B-X
205	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
remained	B-X
an	B-X
independent	B-X
prognosticator	B-X
in	B-X
multivariate	B-X
analyses	B-X
(	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
identified	B-X
in	B-X
bladder	B-X
cancer	B-X
,	B-X
providing	B-X
a	B-X
potential	B-X
mechanistic	B-X
explanation	B-X
(	B-X
epigenetic	B-X
silencing	B-X
)	B-X
for	B-X
the	B-X
observed	B-X
loss	B-X
of	B-X
KISS1	B-X
in	B-X
uroepithelial	B-X
malignancies	B-X
.	B-X
Associations	B-X
of	B-X
KISS1	B-X
methylation	B-X
and	B-X
its	B-X
expression	B-X
with	B-X
histopathological	B-X
variables	B-X
and	B-X
poor	B-X
survival	B-X
suggest	B-X
the	B-X
utility	B-X
of	B-X
incorporating	B-X
KISS1	B-X
measurement	B-X
using	B-X
paraffin-embedded	B-X
material	B-X
for	B-X
tumor	B-X
stratification	B-X
and	B-X
clinical	B-X
outcome	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
uroepithelial	B-X
neoplasias	B-X
.	B-X

Hypermethylation	O
was	O
also	O
frequently	O
observed	O
in	O
a	O
large	O
series	O
of	O
bladder	O
tumors	O
(	O
83	O
.	O
1	O
%	O
,	O
n	O
=	O
804	O
)	O
.	O

KISS1	B-Gene_or_gene_product
methylation	O
was	O
associated	O
with	O
increasing	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
tumor	O
grade	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O

KISS1	B-Gene_or_gene_product
methylation	O
was	O
associated	O
with	O
low	O
KISS1	B-Gene_or_gene_product
transcript	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
(	O
P	O
=	O
0	O
.	O
037	O
)	O
.	O

KISS1	B-Gene_or_gene_product
transcript	O
expression	O
was	O
also	O
associated	O
with	O
histopathological	O
tumor	O
stage	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O

Low	O
transcript	O
expression	O
alone	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
or	O
combined	O
with	O
methylation	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
was	O
associated	O
with	O
poor	O
disease	O
-	O
specific	O
survival	O
(	O
n	O
=	O
205	O
)	O
.	O

KISS1	B-Gene_or_gene_product
transcript	O
expression	O
remained	O
an	O
independent	O
prognosticator	O
in	O
multivariate	O
analyses	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

KISS1	B-Gene_or_gene_product
hypermethylation	O
was	O
identified	O
in	O
bladder	O
cancer	O
,	O
providing	O
a	O
potential	O
mechanistic	O
explanation	O
(	O
epigenetic	O
silencing	O
)	O
for	O
the	O
observed	O
loss	O
of	O
KISS1	B-Gene_or_gene_product
in	O
uroepithelial	O
malignancies	O
.	O
<EOS>	B-X
KISS1	B-X
is	B-X
a	B-X
metastasis	B-X
suppressor	B-X
gene	B-X
that	B-X
is	B-X
lost	B-X
in	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
bladder	B-X
cancer	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
epigenetic	B-X
silencing	B-X
hypothesis	B-X
and	B-X
evaluated	B-X
the	B-X
biological	B-X
influence	B-X
of	B-X
KISS1	B-X
methylation	B-X
on	B-X
its	B-X
expression	B-X
and	B-X
clinical	B-X
relevance	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
frequent	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
analyzed	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
and	B-X
bisulfite	B-X
sequencing	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
gene	B-X
expression	B-X
,	B-X
being	B-X
restored	B-X
in	B-X
vitro	B-X
by	B-X
demethylating	B-X
azacytidine	B-X
.	B-X
Hypermethylation	B-X
was	B-X
also	B-X
frequently	B-X
observed	B-X
in	B-X
a	B-X
large	B-X
series	B-X
of	B-X
bladder	B-X
tumors	B-X
(	B-X
83.1	B-X
%	B-X
,	B-X
n	B-X
=	B-X
804	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
increasing	B-X
stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
and	B-X
tumor	B-X
grade	B-X
(	B-X
P	B-X
=	B-X
0.010	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
KISS1	B-X
transcript	B-X
expression	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
(	B-X
P	B-X
=	B-X
0.037	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
histopathological	B-X
tumor	B-X
stage	B-X
(	B-X
P	B-X
<	B-X
0.0005	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
remained	B-X
an	B-X
independent	B-X
prognosticator	B-X
in	B-X
multivariate	B-X
analyses	B-X
(	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
identified	B-X
in	B-X
bladder	B-X
cancer	B-X
,	B-X
providing	B-X
a	B-X
potential	B-X
mechanistic	B-X
explanation	B-X
(	B-X
epigenetic	B-X
silencing	B-X
)	B-X
for	B-X
the	B-X
observed	B-X
loss	B-X
of	B-X
KISS1	B-X
in	B-X
uroepithelial	B-X
malignancies	B-X
.	B-X
Associations	B-X
of	B-X
KISS1	B-X
methylation	B-X
and	B-X
its	B-X
expression	B-X
with	B-X
histopathological	B-X
variables	B-X
and	B-X
poor	B-X
survival	B-X
suggest	B-X
the	B-X
utility	B-X
of	B-X
incorporating	B-X
KISS1	B-X
measurement	B-X
using	B-X
paraffin-embedded	B-X
material	B-X
for	B-X
tumor	B-X
stratification	B-X
and	B-X
clinical	B-X
outcome	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
uroepithelial	B-X
neoplasias	B-X
.	B-X

Associations	O
of	O
KISS1	B-Gene_or_gene_product
methylation	O
and	O
its	O
expression	O
with	O
histopathological	O
variables	O
and	O
poor	O
survival	O
suggest	O
the	O
utility	O
of	O
incorporating	O
KISS1	B-Gene_or_gene_product
measurement	O
using	O
paraffin	O
-	O
embedded	O
material	O
for	O
tumor	O
stratification	O
and	O
clinical	O
outcome	O
prognosis	O
of	O
patients	O
with	O
uroepithelial	O
neoplasias	O
.	O
<EOS>	B-X
KISS1	B-X
is	B-X
a	B-X
metastasis	B-X
suppressor	B-X
gene	B-X
that	B-X
is	B-X
lost	B-X
in	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
bladder	B-X
cancer	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
epigenetic	B-X
silencing	B-X
hypothesis	B-X
and	B-X
evaluated	B-X
the	B-X
biological	B-X
influence	B-X
of	B-X
KISS1	B-X
methylation	B-X
on	B-X
its	B-X
expression	B-X
and	B-X
clinical	B-X
relevance	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
frequent	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
analyzed	B-X
by	B-X
methylation-specific	B-X
PCR	B-X
and	B-X
bisulfite	B-X
sequencing	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
gene	B-X
expression	B-X
,	B-X
being	B-X
restored	B-X
in	B-X
vitro	B-X
by	B-X
demethylating	B-X
azacytidine	B-X
.	B-X
Hypermethylation	B-X
was	B-X
also	B-X
frequently	B-X
observed	B-X
in	B-X
a	B-X
large	B-X
series	B-X
of	B-X
bladder	B-X
tumors	B-X
(	B-X
83.1	B-X
%	B-X
,	B-X
n	B-X
=	B-X
804	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
increasing	B-X
stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
and	B-X
tumor	B-X
grade	B-X
(	B-X
P	B-X
=	B-X
0.010	B-X
)	B-X
.	B-X
KISS1	B-X
methylation	B-X
was	B-X
associated	B-X
with	B-X
low	B-X
KISS1	B-X
transcript	B-X
expression	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
(	B-X
P	B-X
=	B-X
0.037	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
histopathological	B-X
tumor	B-X
stage	B-X
(	B-X
P	B-X
<	B-X
0.0005	B-X
)	B-X
.	B-X
Low	B-X
transcript	B-X
expression	B-X
alone	B-X
(	B-X
P	B-X
=	B-X
0.003	B-X
)	B-X
or	B-X
combined	B-X
with	B-X
methylation	B-X
(	B-X
P	B-X
=	B-X
0.019	B-X
)	B-X
was	B-X
associated	B-X
with	B-X
poor	B-X
disease-specific	B-X
survival	B-X
(	B-X
n	B-X
=	B-X
205	B-X
)	B-X
.	B-X
KISS1	B-X
transcript	B-X
expression	B-X
remained	B-X
an	B-X
independent	B-X
prognosticator	B-X
in	B-X
multivariate	B-X
analyses	B-X
(	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
KISS1	B-X
hypermethylation	B-X
was	B-X
identified	B-X
in	B-X
bladder	B-X
cancer	B-X
,	B-X
providing	B-X
a	B-X
potential	B-X
mechanistic	B-X
explanation	B-X
(	B-X
epigenetic	B-X
silencing	B-X
)	B-X
for	B-X
the	B-X
observed	B-X
loss	B-X
of	B-X
KISS1	B-X
in	B-X
uroepithelial	B-X
malignancies	B-X
.	B-X
Associations	B-X
of	B-X
KISS1	B-X
methylation	B-X
and	B-X
its	B-X
expression	B-X
with	B-X
histopathological	B-X
variables	B-X
and	B-X
poor	B-X
survival	B-X
suggest	B-X
the	B-X
utility	B-X
of	B-X
incorporating	B-X
KISS1	B-X
measurement	B-X
using	B-X
paraffin-embedded	B-X
material	B-X
for	B-X
tumor	B-X
stratification	B-X
and	B-X
clinical	B-X
outcome	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
uroepithelial	B-X
neoplasias	B-X
.	B-X

Correlation	O
of	O
lymphatic	O
vessel	O
density	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
with	O
nodal	O
metastasis	O
in	O
papillary	O
thyroid	O
microcarcinoma	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
not	B-X
only	B-X
the	B-X
intratumoral	B-X
and	B-X
peritumoral	B-X
lymphatic	B-X
vessel	B-X
density	B-X
(	B-X
ILD	B-X
and	B-X
PLD	B-X
)	B-X
but	B-X
also	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
to	B-X
test	B-X
their	B-X
correlation	B-X
with	B-X
regional	B-X
lymph	B-X
nodal	B-X
metastases	B-X
in	B-X
papillary	B-X
thyroid	B-X
microcarcinoma	B-X
(	B-X
PTMC	B-X
)	B-X
.	B-X

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
not	O
only	O
the	O
intratumoral	O
and	O
peritumoral	O
lymphatic	O
vessel	O
density	O
(	O
ILD	O
and	O
PLD	O
)	O
but	O
also	O
the	O
expression	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	I-Gene_or_gene_product
(	O
VEGFs	B-Gene_or_gene_product
)	O
and	O
to	O
test	O
their	O
correlation	O
with	O
regional	O
lymph	O
nodal	O
metastases	O
in	O
papillary	O
thyroid	O
microcarcinoma	O
(	O
PTMC	O
)	O
.	O

METHODS	O
:	O
A	O
clinicopathologic	O
data	O
review	O
was	O
performed	O
in	O
60	O
patients	O
with	O
PTMC	O
treated	O
with	O
total	O
thyroidectomies	O
involving	O
neck	O
dissections	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
not	B-X
only	B-X
the	B-X
intratumoral	B-X
and	B-X
peritumoral	B-X
lymphatic	B-X
vessel	B-X
density	B-X
(	B-X
ILD	B-X
and	B-X
PLD	B-X
)	B-X
but	B-X
also	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
to	B-X
test	B-X
their	B-X
correlation	B-X
with	B-X
regional	B-X
lymph	B-X
nodal	B-X
metastases	B-X
in	B-X
papillary	B-X
thyroid	B-X
microcarcinoma	B-X
(	B-X
PTMC	B-X
)	B-X
.	B-X

The	O
patterns	O
of	O
lymphatic	O
vessels	O
,	O
the	O
expression	O
of	O
VEGFs	B-Gene_or_gene_product
,	O
and	O
their	O
correlation	O
with	O
neck	O
metastases	O
were	O
assessed	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
not	B-X
only	B-X
the	B-X
intratumoral	B-X
and	B-X
peritumoral	B-X
lymphatic	B-X
vessel	B-X
density	B-X
(	B-X
ILD	B-X
and	B-X
PLD	B-X
)	B-X
but	B-X
also	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
to	B-X
test	B-X
their	B-X
correlation	B-X
with	B-X
regional	B-X
lymph	B-X
nodal	B-X
metastases	B-X
in	B-X
papillary	B-X
thyroid	B-X
microcarcinoma	B-X
(	B-X
PTMC	B-X
)	B-X
.	B-X

RESULTS	O
:	O
PLD	O
was	O
significantly	O
higher	O
than	O
ILD	O
(	O
p	O
<	O
.	O
001	O
)	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
not	B-X
only	B-X
the	B-X
intratumoral	B-X
and	B-X
peritumoral	B-X
lymphatic	B-X
vessel	B-X
density	B-X
(	B-X
ILD	B-X
and	B-X
PLD	B-X
)	B-X
but	B-X
also	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
to	B-X
test	B-X
their	B-X
correlation	B-X
with	B-X
regional	B-X
lymph	B-X
nodal	B-X
metastases	B-X
in	B-X
papillary	B-X
thyroid	B-X
microcarcinoma	B-X
(	B-X
PTMC	B-X
)	B-X
.	B-X

Patients	O
with	O
high	O
PLD	O
(	O
>	O
8	O
.	O
0	O
)	O
showed	O
higher	O
rates	O
of	O
neck	O
metastases	O
than	O
low	O
PLD	O
(	O
<	O
=	O
8	O
.	O
0	O
)	O
(	O
74	O
.	O
0	O
%	O
vs	O
46	O
.	O
8	O
%	O
,	O
p	O
=	O
.	O
03	O
)	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
revealed	O
high	O
PLD	O
as	O
the	O
only	O
independent	O
variable	O
predictive	O
of	O
neck	O
metastasis	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
not	B-X
only	B-X
the	B-X
intratumoral	B-X
and	B-X
peritumoral	B-X
lymphatic	B-X
vessel	B-X
density	B-X
(	B-X
ILD	B-X
and	B-X
PLD	B-X
)	B-X
but	B-X
also	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
to	B-X
test	B-X
their	B-X
correlation	B-X
with	B-X
regional	B-X
lymph	B-X
nodal	B-X
metastases	B-X
in	B-X
papillary	B-X
thyroid	B-X
microcarcinoma	B-X
(	B-X
PTMC	B-X
)	B-X
.	B-X

The	O
expression	O
of	O
VEGFs	B-Gene_or_gene_product
did	O
not	O
correlate	O
with	O
either	O
lymphatic	O
density	O
or	O
neck	O
metastasis	O
.	O
<EOS>	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
their	B-X
receptors	B-X
(	B-X
VEGFRs	B-X
)	B-X
are	B-X
quintessential	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
blood	B-X
and	B-X
lymphatic	B-X
vessels	B-X
.	B-X
This	B-X
article	B-X
presents	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
evaluation	B-X
and	B-X
staging	B-X
of	B-X
the	B-X
neck	B-X
in	B-X
the	B-X
context	B-X
of	B-X
malignant	B-X
disease	B-X
.	B-X
The	B-X
current	B-X
tumor-nodes-metastasis	B-X
(	B-X
TNM	B-X
)	B-X
nodal	B-X
classification	B-X
is	B-X
reviewed	B-X
followed	B-X
by	B-X
a	B-X
brief	B-X
discussion	B-X
of	B-X
the	B-X
common	B-X
malignant	B-X
processes	B-X
encountered	B-X
in	B-X
the	B-X
head	B-X
and	B-X
neck	B-X
and	B-X
their	B-X
associated	B-X
risk	B-X
factors	B-X
for	B-X
cervical	B-X
metastasis	B-X
.	B-X
Common	B-X
imaging	B-X
modalities	B-X
,	B-X
such	B-X
as	B-X
ultrasound	B-X
,	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
,	B-X
Computed	B-X
tomography	B-X
,	B-X
and	B-X
positron	B-X
emission	B-X
tomography	B-X
,	B-X
for	B-X
the	B-X
investigation	B-X
of	B-X
the	B-X
neck	B-X
are	B-X
also	B-X
summarized	B-X
.	B-X

CONCLUSIONS	O
:	O
PLD	O
may	O
be	O
of	O
potential	O
benefit	O
in	O
the	O
prediction	O
of	O
neck	O
metastasis	O
in	O
PTMC	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
not	B-X
only	B-X
the	B-X
intratumoral	B-X
and	B-X
peritumoral	B-X
lymphatic	B-X
vessel	B-X
density	B-X
(	B-X
ILD	B-X
and	B-X
PLD	B-X
)	B-X
but	B-X
also	B-X
the	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factors	B-X
(	B-X
VEGFs	B-X
)	B-X
and	B-X
to	B-X
test	B-X
their	B-X
correlation	B-X
with	B-X
regional	B-X
lymph	B-X
nodal	B-X
metastases	B-X
in	B-X
papillary	B-X
thyroid	B-X
microcarcinoma	B-X
(	B-X
PTMC	B-X
)	B-X
.	B-X

Inhibition	O
of	O
autophagy	O
potentiates	O
the	O
antitumor	O
effect	O
of	O
the	O
multikinase	O
inhibitor	O
sorafenib	O
in	O
hepatocellular	O
carcinoma	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

Multikinase	O
inhibitor	O
sorafenib	O
inhibits	O
proliferation	O
and	O
angiogenesis	O
of	O
tumors	O
by	O
suppressing	O
the	O
Raf	B-Gene_or_gene_product
/	O
MEK	B-Gene_or_gene_product
/	O
ERK	B-Gene_or_gene_product
signaling	O
pathway	O
and	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
tyrosine	O
kinase	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

It	O
significantly	O
prolongs	O
median	O
survival	O
of	O
patients	O
with	O
advanced	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
but	O
the	O
response	O
is	O
disease	O
-	O
stabilizing	O
and	O
cytostatic	O
rather	O
than	O
one	O
of	O
tumor	O
regression	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

To	O
examine	O
the	O
mechanisms	O
underlying	O
the	O
relative	O
resistance	O
in	O
HCC	O
,	O
we	O
investigated	O
the	O
role	O
of	O
autophagy	O
,	O
an	O
evolutionarily	O
conserved	O
self	O
-	O
digestion	O
pathway	O
,	O
in	O
hepatoma	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

Sorafenib	O
treatment	O
led	O
to	O
accumulation	O
of	O
autophagosomes	O
as	O
evidenced	O
by	O
conversion	O
from	O
LC3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
to	O
LC3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	I-Gene_or_gene_product
observed	O
by	O
immunoblot	O
in	O
Huh7	O
,	O
HLF	O
and	O
PLC	O
/	O
PRF	O
/	O
5	O
cells	O
.	O
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Sorafenib	B-X
inhibited	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
and	B-X
its	B-X
inhibition	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
LC3-II	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X

This	O
induction	O
was	O
due	O
to	O
activation	O
of	O
autophagic	O
flux	O
,	O
as	O
there	O
was	O
further	O
increase	O
in	O
LC3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	I-Gene_or_gene_product
expression	O
upon	O
treatment	O
with	O
lysosomal	O
inhibitors	O
,	O
clear	O
decline	O
of	O
the	O
autophagy	O
substrate	O
p62	B-Gene_or_gene_product
,	O
and	O
an	O
mRFP	B-Gene_or_gene_product
-	O
GFP	B-Gene_or_gene_product
-	O
LC3	B-Gene_or_gene_product
fluorescence	O
change	O
in	O
sorafenib	O
-	O
treated	O
hepatoma	O
cells	O
.	O

Sorafenib	O
inhibited	O
the	O
mammalian	B-Gene_or_gene_product
target	I-Gene_or_gene_product
of	I-Gene_or_gene_product
rapamycin	I-Gene_or_gene_product
complex	I-Gene_or_gene_product
1	I-Gene_or_gene_product
and	O
its	O
inhibition	O
led	O
to	O
accumulation	O
of	O
LC3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	I-Gene_or_gene_product
.	O
<EOS>	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Sorafenib	B-X
inhibited	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
and	B-X
its	B-X
inhibition	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
LC3-II	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

Pharmacological	O
inhibition	O
of	O
autophagic	O
flux	O
by	O
chloroquine	O
increased	O
apoptosis	O
and	O
decreased	O
cell	O
viability	O
in	O
hepatoma	O
cells	O
.	O
<EOS>	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Sorafenib	B-X
inhibited	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
and	B-X
its	B-X
inhibition	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
LC3-II	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
ATG7	B-Gene_or_gene_product
gene	O
also	O
sensitized	O
hepatoma	O
cells	O
to	O
sorafenib	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

Finally	O
,	O
sorafenib	O
induced	O
autophagy	O
in	O
Huh7	O
xenograft	O
tumors	O
in	O
nude	O
mice	O
and	O
coadministration	O
with	O
chloroquine	O
significantly	O
suppressed	O
tumor	O
growth	O
compared	O
with	O
sorafenib	O
alone	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

In	O
conclusion	O
,	O
sorafenib	O
administration	O
induced	O
autophagosome	O
formation	O
and	O
enhanced	O
autophagic	O
activity	O
,	O
which	O
conferred	O
a	O
survival	O
advantage	O
to	O
hepatoma	O
cells	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Sorafenib	B-X
treatment	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
autophagosomes	B-X
as	B-X
evidenced	B-X
by	B-X
conversion	B-X
from	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
observed	B-X
by	B-X
immunoblot	B-X
in	B-X
Huh7	B-X
,	B-X
HLF	B-X
and	B-X
PLC/PRF/5	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

Concomitant	O
inhibition	O
of	O
autophagy	O
may	O
be	O
an	O
attractive	O
strategy	O
for	O
unlocking	O
the	O
antitumor	O
potential	O
of	O
sorafenib	O
in	O
HCC	O
.	O
<EOS>	B-X
Multikinase	B-X
inhibitor	B-X
sorafenib	B-X
inhibits	B-X
proliferation	B-X
and	B-X
angiogenesis	B-X
of	B-X
tumors	B-X
by	B-X
suppressing	B-X
the	B-X
Raf/MEK/ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
VEGF	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
It	B-X
significantly	B-X
prolongs	B-X
median	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
but	B-X
the	B-X
response	B-X
is	B-X
disease-stabilizing	B-X
and	B-X
cytostatic	B-X
rather	B-X
than	B-X
one	B-X
of	B-X
tumor	B-X
regression	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
relative	B-X
resistance	B-X
in	B-X
HCC	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
,	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
self-digestion	B-X
pathway	B-X
,	B-X
in	B-X
hepatoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
induction	B-X
was	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
autophagic	B-X
flux	B-X
,	B-X
as	B-X
there	B-X
was	B-X
further	B-X
increase	B-X
in	B-X
LC3-II	B-X
expression	B-X
upon	B-X
treatment	B-X
with	B-X
lysosomal	B-X
inhibitors	B-X
,	B-X
clear	B-X
decline	B-X
of	B-X
the	B-X
autophagy	B-X
substrate	B-X
p62	B-X
,	B-X
and	B-X
an	B-X
mRFP-GFP-LC3	B-X
fluorescence	B-X
change	B-X
in	B-X
sorafenib-treated	B-X
hepatoma	B-X
cells	B-X
.	B-X
Sorafenib	B-X
inhibited	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
and	B-X
its	B-X
inhibition	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
LC3-II	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
autophagic	B-X
flux	B-X
by	B-X
chloroquine	B-X
increased	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
hepatoma	B-X
cells	B-X
.	B-X
siRNA-mediated	B-X
knockdown	B-X
of	B-X
the	B-X
ATG7	B-X
gene	B-X
also	B-X
sensitized	B-X
hepatoma	B-X
cells	B-X
to	B-X
sorafenib	B-X
.	B-X
Finally	B-X
,	B-X
sorafenib	B-X
induced	B-X
autophagy	B-X
in	B-X
Huh7	B-X
xenograft	B-X
tumors	B-X
in	B-X
nude	B-X
mice	B-X
and	B-X
coadministration	B-X
with	B-X
chloroquine	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
compared	B-X
with	B-X
sorafenib	B-X
alone	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
sorafenib	B-X
administration	B-X
induced	B-X
autophagosome	B-X
formation	B-X
and	B-X
enhanced	B-X
autophagic	B-X
activity	B-X
,	B-X
which	B-X
conferred	B-X
a	B-X
survival	B-X
advantage	B-X
to	B-X
hepatoma	B-X
cells	B-X
.	B-X
Concomitant	B-X
inhibition	B-X
of	B-X
autophagy	B-X
may	B-X
be	B-X
an	B-X
attractive	B-X
strategy	B-X
for	B-X
unlocking	B-X
the	B-X
antitumor	B-X
potential	B-X
of	B-X
sorafenib	B-X
in	B-X
HCC	B-X
.	B-X

Desensitization	O
of	O
prostaglandin	O
F2	O
alpha	O
-	O
stimulated	O
inositol	O
phosphate	O
generation	O
in	O
NIH	O
-	O
3T3	O
fibroblasts	O
transformed	O
by	O
overexpression	O
of	O
normal	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ha	I-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
,	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ki	I-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
N	I-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
genes	O
.	O

The	O
stimulation	O
of	O
inositol	O
phosphate	O
generation	O
in	O
control	O
and	O
ras	B-Gene_or_gene_product
-	O
gene	O
-	O
transformed	O
NIH	O
-	O
3T3	O
cells	O
by	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
was	O
investigated	O
.	O
<EOS>	B-X
The	B-X
stimulation	B-X
of	B-X
inositol	B-X
phosphate	B-X
generation	B-X
in	B-X
control	B-X
and	B-X
ras-gene-transformed	B-X
NIH-3T3	B-X
cells	B-X
by	B-X
prostaglandin	B-X
F2	B-X
alpha	B-X
(	B-X
PGF2	B-X
alpha	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
control	B-X
cells	B-X
,	B-X
a	B-X
desensitization	B-X
of	B-X
the	B-X
response	B-X
was	B-X
observed	B-X
in	B-X
cells	B-X
transformed	B-X
by	B-X
the	B-X
overexpression	B-X
of	B-X
N-	B-X
,	B-X
Ha-	B-X
,	B-X
or	B-X
Ki-ras	B-X
genes	B-X
.	B-X
This	B-X
desensitization	B-X
was	B-X
without	B-X
effect	B-X
upon	B-X
the	B-X
concentration	B-X
causing	B-X
half-maximal	B-X
effect	B-X
(	B-X
EC50	B-X
)	B-X
,	B-X
dissociation	B-X
constant	B-X
(	B-X
Kd	B-X
)	B-X
or	B-X
number	B-X
of	B-X
PGF2	B-X
alpha	B-X
receptors	B-X
.	B-X
Desensitization	B-X
could	B-X
be	B-X
induced	B-X
in	B-X
NIH-3T3	B-X
cells	B-X
by	B-X
culturing	B-X
under	B-X
conditions	B-X
where	B-X
the	B-X
cells	B-X
were	B-X
all	B-X
in	B-X
the	B-X
exponential	B-X
growth	B-X
phase	B-X
,	B-X
or	B-X
by	B-X
a	B-X
12	B-X
h	B-X
exposure	B-X
to	B-X
a	B-X
C-kinase-activating	B-X
phorbol	B-X
ester	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
desensitization	B-X
of	B-X
certain	B-X
agonist-induced	B-X
inositol	B-X
phospholipid	B-X
responses	B-X
in	B-X
ras-transformed	B-X
cells	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
increased	B-X
cell	B-X
proliferation	B-X
and	B-X
associated	B-X
amplification	B-X
in	B-X
C-kinase	B-X
activity	B-X
and	B-X
is	B-X
an	B-X
indirect	B-X
consequence	B-X
of	B-X
transformation	B-X
by	B-X
ras	B-X
.	B-X

Compared	O
with	O
the	O
control	O
cells	O
,	O
a	O
desensitization	O
of	O
the	O
response	O
was	O
observed	O
in	O
cells	O
transformed	O
by	O
the	O
overexpression	O
of	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
,	O
Ha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
,	O
or	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
genes	O
.	O
<EOS>	B-X
What	B-X
level	B-X
of	B-X
Ras	B-X
genes	B-X
activity	B-X
leads	B-X
to	B-X
the	B-X
development	B-X
of	B-X
cancer	B-X
?	B-X
About	B-X
a	B-X
third	B-X
of	B-X
all	B-X
human	B-X
cancers	B-X
harbor	B-X
mutations	B-X
in	B-X
one	B-X
of	B-X
the	B-X
K-	B-X
,	B-X
N-	B-X
,	B-X
or	B-X
HRAS	B-X
genes	B-X
that	B-X
encode	B-X
an	B-X
abnormal	B-X
RAS	B-X
protein	B-X
locked	B-X
in	B-X
a	B-X
constitutively	B-X
activated	B-X
state	B-X
to	B-X
drive	B-X
malignant	B-X
transformation	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
These	B-X
reports	B-X
of	B-X
direct-acting	B-X
RAS	B-X
inhibitors	B-X
provide	B-X
valuable	B-X
insight	B-X
for	B-X
further	B-X
discovery	B-X
and	B-X
development	B-X
of	B-X
clinical	B-X
candidates	B-X
for	B-X
RAS-driven	B-X
cancers	B-X
involving	B-X
mutations	B-X
in	B-X
RAS	B-X
genes	B-X
or	B-X
otherwise	B-X
activated	B-X
RAS	B-X
proteins	B-X
.	B-X
On	B-X
the	B-X
PM	B-X
,	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
Ras	B-X
isoforms	B-X
,	B-X
H-	B-X
,	B-X
N-	B-X
,	B-X
and	B-X
K-Ras	B-X
,	B-X
spatially	B-X
segregate	B-X
to	B-X
nonoverlapping	B-X
nanometer-sized	B-X
domains	B-X
,	B-X
called	B-X
nanoclusters	B-X
,	B-X
with	B-X
further	B-X
lateral	B-X
segregation	B-X
into	B-X
nonoverlapping	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
-bound	B-X
and	B-X
guanosine	B-X
diphosphate	B-X
(	B-X
GDP	B-X
)	B-X
-bound	B-X
nanoclusters	B-X
.	B-X

This	O
desensitization	O
was	O
without	O
effect	O
upon	O
the	O
concentration	O
causing	O
half	O
-	O
maximal	O
effect	O
(	O
EC50	O
)	O
,	O
dissociation	O
constant	O
(	O
Kd	O
)	O
or	O
number	O
of	O
PGF2	B-Gene_or_gene_product
alpha	I-Gene_or_gene_product
receptors	I-Gene_or_gene_product
.	O
<EOS>	B-X
There	B-X
are	B-X
a	B-X
number	B-X
of	B-X
compounds	B-X
in	B-X
clinical	B-X
use	B-X
for	B-X
termination	B-X
of	B-X
pregnancy	B-X
.	B-X
PGF2	B-X
alpha	B-X
and	B-X
PGE2	B-X
as	B-X
well	B-X
as	B-X
different	B-X
prostaglandin	B-X
analogues	B-X
all	B-X
have	B-X
a	B-X
direct	B-X
stimulatory	B-X
effect	B-X
on	B-X
the	B-X
myometrium	B-X
,	B-X
while	B-X
other	B-X
compounds	B-X
such	B-X
as	B-X
hypertonic	B-X
saline	B-X
and	B-X
Rivanol	B-X
seem	B-X
to	B-X
act	B-X
mainly	B-X
through	B-X
a	B-X
stimulation	B-X
of	B-X
the	B-X
endogenous	B-X
production	B-X
of	B-X
PGF2	B-X
alpha	B-X
.	B-X
These	B-X
junctions	B-X
increase	B-X
in	B-X
number	B-X
prior	B-X
to	B-X
labor	B-X
.	B-X
Estrogen	B-X
,	B-X
via	B-X
alpha	B-X
adrenergic	B-X
receptors	B-X
,	B-X
causes	B-X
a	B-X
decrease	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
It	B-X
also	B-X
increases	B-X
the	B-X
number	B-X
of	B-X
oxytocin	B-X
receptors	B-X
.	B-X
Progesterone	B-X
,	B-X
via	B-X
beta	B-X
adrenergic	B-X
receptors	B-X
,	B-X
causes	B-X
an	B-X
increase	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
While	B-X
estrogen	B-X
leads	B-X
to	B-X
increased	B-X
production	B-X
of	B-X
PGF2alpha	B-X
,	B-X
progesterone	B-X
stimulates	B-X
the	B-X
production	B-X
of	B-X
prostacyclin	B-X
synthase	B-X
,	B-X
Mifepristone	B-X
,	B-X
which	B-X
blocks	B-X
progesterone	B-X
at	B-X
the	B-X
receptor	B-X
level	B-X
,	B-X
increases	B-X
uterine	B-X
activity	B-X
and	B-X
sensitivity	B-X
to	B-X
PG	B-X
.	B-X
The	B-X
decidua	B-X
produces	B-X
PGE2	B-X
and	B-X
PGF2alpha	B-X
.	B-X
Their	B-X
production	B-X
by	B-X
uterine	B-X
tissues	B-X
increases	B-X
during	B-X
pregnancy	B-X
,	B-X
as	B-X
does	B-X
their	B-X
concentration	B-X
in	B-X
amniotic	B-X
fluid	B-X
and	B-X
in	B-X
maternal	B-X
blood	B-X
and	B-X
urine	B-X
.	B-X
Although	B-X
PGE2	B-X
and	B-X
PGF2alpha	B-X
relax	B-X
cervical	B-X
smooth	B-X
muscle	B-X
,	B-X
they	B-X
contract	B-X
the	B-X
myometrium	B-X
by	B-X
acting	B-X
as	B-X
calcium	B-X
ionophpores	B-X
.	B-X
The	B-X
production	B-X
of	B-X
PGE2	B-X
,	B-X
PGF2alpha	B-X
,	B-X
and	B-X
other	B-X
eicosanoids	B-X
by	B-X
the	B-X
fetoplacental	B-X
production	B-X
of	B-X
PGE2	B-X
,	B-X
PGF2alpha	B-X
,	B-X
and	B-X
other	B-X
eicosanoids	B-X
by	B-X
the	B-X
fetoplacental	B-X
unit	B-X
is	B-X
related	B-X
to	B-X
increased	B-X
contractile	B-X
activity	B-X
during	B-X
labor	B-X
.	B-X
What	B-X
is	B-X
produced	B-X
in	B-X
the	B-X
eiconsanoid	B-X
pathway	B-X
changes	B-X
dynamically	B-X
with	B-X
the	B-X
phases	B-X
of	B-X
the	B-X
reproductive	B-X
cycle	B-X
and	B-X
the	B-X
local	B-X
concentrations	B-X
of	B-X
enzymes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
any	B-X
stimulus	B-X
facilitating	B-X
PGE2	B-X
synthesis	B-X
in	B-X
the	B-X
fetal	B-X
membrane	B-X
(	B-X
hypoxia	B-X
,	B-X
infection	B-X
,	B-X
exposure	B-X
to	B-X
oxytocin	B-X
,	B-X
hypertonic	B-X
solutions	B-X
,	B-X
prostaglandins	B-X
,	B-X
or	B-X
arachidonic	B-X
acid	B-X
)	B-X
would	B-X
induce	B-X
the	B-X
same	B-X
series	B-X
of	B-X
steps	B-X
leading	B-X
to	B-X
formation	B-X
of	B-X
PGF2alpha	B-X
in	B-X
the	B-X
decidua	B-X
and	B-X
the	B-X
myometrium	B-X
.	B-X

Inhibition	O
of	O
PG	O
synthesis	O
was	O
without	O
effect	O
upon	O
desensitization	O
,	O
demonstrating	O
that	O
the	O
effect	O
was	O
not	O
agonist	O
-	O
induced	O
.	O
<EOS>	B-X
Peimine	B-X
,	B-X
an	B-X
Anti-Inflammatory	B-X
Compound	B-X
from	B-X
Chinese	B-X
Herbal	B-X
Extracts	B-X
,	B-X
Modulates	B-X
Muscle-Type	B-X
Nicotinic	B-X
Receptors	B-X
.	B-X
Experimental	B-X
and	B-X
small	B-X
clinical	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
Î²2-adrenergic	B-X
receptor	B-X
(	B-X
Î²2AR	B-X
)	B-X
agonists	B-X
enhance	B-X
AFC	B-X
via	B-X
a	B-X
cAMP-dependent	B-X
mechanism	B-X
.	B-X
However	B-X
,	B-X
two	B-X
multicenter	B-X
phase	B-X
3	B-X
clinical	B-X
trials	B-X
failed	B-X
to	B-X
show	B-X
that	B-X
Î²2AR	B-X
agonists	B-X
provide	B-X
a	B-X
survival	B-X
advantage	B-X
in	B-X
patients	B-X
with	B-X
ALI	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
IL-8	B-X
,	B-X
an	B-X
important	B-X
mediator	B-X
of	B-X
ALI	B-X
,	B-X
directly	B-X
antagonizes	B-X
the	B-X
alveolar	B-X
epithelial	B-X
response	B-X
to	B-X
Î²2AR	B-X
agonists	B-X
.	B-X
Short-circuit	B-X
current	B-X
and	B-X
whole-cell	B-X
patch-clamping	B-X
experiments	B-X
revealed	B-X
that	B-X
IL-8	B-X
or	B-X
its	B-X
rat	B-X
analog	B-X
CINC-1	B-X
decreases	B-X
by	B-X
50	B-X
%	B-X
Î²2AR	B-X
agonist-stimulated	B-X
vectorial	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
and	B-X
net	B-X
fluid	B-X
transport	B-X
across	B-X
rat	B-X
and	B-X
human	B-X
alveolar	B-X
epithelial	B-X
type	B-X
II	B-X
cells	B-X
via	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
cystic	B-X
fibrosis	B-X
transmembrane	B-X
conductance	B-X
regulator	B-X
activity	B-X
and	B-X
biosynthesis	B-X
.	B-X
This	B-X
reduction	B-X
was	B-X
mediated	B-X
by	B-X
heterologous	B-X
Î²2AR	B-X
desensitization	B-X
and	B-X
down-regulation	B-X
(	B-X
50	B-X
%	B-X
)	B-X
via	B-X
the	B-X
G-protein-coupled	B-X
receptor	B-X
kinase	B-X
2	B-X
(	B-X
GRK2	B-X
)	B-X
/PI3K	B-X
signaling	B-X
pathway	B-X
.	B-X
Inhibition	B-X
of	B-X
CINC-1	B-X
restored	B-X
Î²2AR	B-X
agonist-stimulated	B-X
AFC	B-X
in	B-X
an	B-X
experimental	B-X
model	B-X
of	B-X
ALI	B-X
in	B-X
rats	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
IL-8	B-X
in	B-X
inhibiting	B-X
Î²2AR	B-X
agonist-stimulated	B-X
alveolar	B-X
epithelial	B-X
fluid	B-X
transport	B-X
via	B-X
GRK2/PI3K-dependent	B-X
mechanisms.-Roux	B-X
,	B-X
J.	B-X
,	B-X
McNicholas	B-X
,	B-X
C.	B-X
M.	B-X
,	B-X
Carles	B-X
,	B-X
M.	B-X
,	B-X
Goolaerts	B-X
,	B-X
A.	B-X
,	B-X
Houseman	B-X
,	B-X
B.	B-X
T.	B-X
,	B-X
Dickinson	B-X
,	B-X
D.	B-X
A.	B-X
,	B-X
Iles	B-X
,	B-X
K.	B-X
E.	B-X
,	B-X
Ware	B-X
,	B-X
L.	B-X
B.	B-X
,	B-X
Matthay	B-X
,	B-X
M.	B-X
A.	B-X
,	B-X
Pittet	B-X
,	B-X
J.-F.	B-X
IL-8	B-X
inhibits	B-X
cAMP-stimulated	B-X
alveolar	B-X
epithelial	B-X
fluid	B-X
transport	B-X
via	B-X
a	B-X
GRK2/PI3K-dependent	B-X
mechanism	B-X
.	B-X

Desensitization	O
could	O
be	O
induced	O
in	O
NIH	O
-	O
3T3	O
cells	O
by	O
culturing	O
under	O
conditions	O
where	O
the	O
cells	O
were	O
all	O
in	O
the	O
exponential	O
growth	O
phase	O
,	O
or	O
by	O
a	O
12	O
h	O
exposure	O
to	O
a	O
C	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
-	O
activating	O
phorbol	O
ester	O
.	O
<EOS>	B-X
The	B-X
stimulation	B-X
of	B-X
inositol	B-X
phosphate	B-X
generation	B-X
in	B-X
control	B-X
and	B-X
ras-gene-transformed	B-X
NIH-3T3	B-X
cells	B-X
by	B-X
prostaglandin	B-X
F2	B-X
alpha	B-X
(	B-X
PGF2	B-X
alpha	B-X
)	B-X
was	B-X
investigated	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
control	B-X
cells	B-X
,	B-X
a	B-X
desensitization	B-X
of	B-X
the	B-X
response	B-X
was	B-X
observed	B-X
in	B-X
cells	B-X
transformed	B-X
by	B-X
the	B-X
overexpression	B-X
of	B-X
N-	B-X
,	B-X
Ha-	B-X
,	B-X
or	B-X
Ki-ras	B-X
genes	B-X
.	B-X
This	B-X
desensitization	B-X
was	B-X
without	B-X
effect	B-X
upon	B-X
the	B-X
concentration	B-X
causing	B-X
half-maximal	B-X
effect	B-X
(	B-X
EC50	B-X
)	B-X
,	B-X
dissociation	B-X
constant	B-X
(	B-X
Kd	B-X
)	B-X
or	B-X
number	B-X
of	B-X
PGF2	B-X
alpha	B-X
receptors	B-X
.	B-X
Inhibition	B-X
of	B-X
PG	B-X
synthesis	B-X
was	B-X
without	B-X
effect	B-X
upon	B-X
desensitization	B-X
,	B-X
demonstrating	B-X
that	B-X
the	B-X
effect	B-X
was	B-X
not	B-X
agonist-induced	B-X
.	B-X
Desensitization	B-X
could	B-X
be	B-X
induced	B-X
in	B-X
NIH-3T3	B-X
cells	B-X
by	B-X
culturing	B-X
under	B-X
conditions	B-X
where	B-X
the	B-X
cells	B-X
were	B-X
all	B-X
in	B-X
the	B-X
exponential	B-X
growth	B-X
phase	B-X
,	B-X
or	B-X
by	B-X
a	B-X
12	B-X
h	B-X
exposure	B-X
to	B-X
a	B-X
C-kinase-activating	B-X
phorbol	B-X
ester	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
desensitization	B-X
of	B-X
certain	B-X
agonist-induced	B-X
inositol	B-X
phospholipid	B-X
responses	B-X
in	B-X
ras-transformed	B-X
cells	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
increased	B-X
cell	B-X
proliferation	B-X
and	B-X
associated	B-X
amplification	B-X
in	B-X
C-kinase	B-X
activity	B-X
and	B-X
is	B-X
an	B-X
indirect	B-X
consequence	B-X
of	B-X
transformation	B-X
by	B-X
ras	B-X
.	B-X

These	O
results	O
suggest	O
that	O
desensitization	O
of	O
certain	O
agonist	O
-	O
induced	O
inositol	O
phospholipid	O
responses	O
in	O
ras	B-Gene_or_gene_product
-	O
transformed	O
cells	O
is	O
a	O
consequence	O
of	O
increased	O
cell	O
proliferation	O
and	O
associated	O
amplification	O
in	O
C	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
activity	O
and	O
is	O
an	O
indirect	O
consequence	O
of	O
transformation	O
by	O
ras	B-Gene_or_gene_product
.	O

Relationship	O
between	O
of	O
blood	O
flow	O
,	O
glucose	O
metabolism	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
in	O
experimentally	O
-	O
induced	O
glioma	O
(	O
RG1	O
2	O
.	O
2	O
)	O
of	O
rat	O
brain	O
.	O
<EOS>	B-X
In	B-X
experimental	B-X
RG1	B-X
2.2	B-X
glioma	B-X
of	B-X
rat	B-X
brain	B-X
,	B-X
local	B-X
blood	B-X
flow	B-X
,	B-X
glucose	B-X
utilization	B-X
,	B-X
protein	B-X
synthesis	B-X
,	B-X
glucose	B-X
and	B-X
ATP	B-X
content	B-X
were	B-X
measured	B-X
by	B-X
means	B-X
of	B-X
triple	B-X
tracer	B-X
autoradiography	B-X
and	B-X
bioluminescence	B-X
technique	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
determine	B-X
hemodynamic	B-X
and	B-X
metabolic	B-X
thresholds	B-X
for	B-X
local	B-X
tumor	B-X
energy	B-X
failure	B-X
.	B-X
Perfusion	B-X
thresholds	B-X
were	B-X
estimated	B-X
at	B-X
tumor	B-X
blood	B-X
flow	B-X
values	B-X
of	B-X
69.0	B-X
+/-	B-X
0.1	B-X
ml/100	B-X
g/min	B-X
(	B-X
estimate	B-X
+/-	B-X
standard	B-X
error	B-X
)	B-X
and	B-X
of	B-X
69	B-X
+/-	B-X
7.1	B-X
ml/100	B-X
g/min	B-X
for	B-X
the	B-X
beginning	B-X
of	B-X
the	B-X
decline	B-X
in	B-X
regional	B-X
ATP	B-X
and	B-X
glucose	B-X
content	B-X
,	B-X
respectively	B-X
.	B-X
Metabolic	B-X
thresholds	B-X
were	B-X
derived	B-X
at	B-X
tumor	B-X
glucose	B-X
utilization	B-X
values	B-X
of	B-X
70.6	B-X
+/-	B-X
8.3	B-X
mumol/100	B-X
g/min	B-X
for	B-X
reduced	B-X
protein	B-X
synthesis	B-X
,	B-X
of	B-X
55.0	B-X
+/-	B-X
0.2	B-X
mumol/100	B-X
g/min	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
glucose	B-X
content	B-X
,	B-X
and	B-X
34.7	B-X
+/-	B-X
4.7	B-X
mumol/100	B-X
g/min	B-X
for	B-X
decline	B-X
in	B-X
ATP	B-X
content	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
blood	B-X
flow	B-X
limits	B-X
glucose	B-X
supply	B-X
to	B-X
tumor	B-X
tissue	B-X
at	B-X
much	B-X
higher	B-X
flow	B-X
rates	B-X
than	B-X
in	B-X
normal	B-X
brain	B-X
which	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
glucose	B-X
utilization	B-X
.	B-X
A	B-X
reduction	B-X
and	B-X
not	B-X
an	B-X
increase	B-X
in	B-X
tumor	B-X
glucose	B-X
availability	B-X
could	B-X
be	B-X
a	B-X
more	B-X
appropriate	B-X
strategy	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
energy	B-X
failure	B-X
in	B-X
tumors	B-X
.	B-X

In	O
experimental	O
RG1	O
2	O
.	O
2	O
glioma	O
of	O
rat	O
brain	O
,	O
local	O
blood	O
flow	O
,	O
glucose	O
utilization	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
were	O
measured	O
by	O
means	O
of	O
triple	O
tracer	O
autoradiography	O
and	O
bioluminescence	O
technique	O
,	O
respectively	O
,	O
to	O
determine	O
hemodynamic	O
and	O
metabolic	O
thresholds	O
for	O
local	O
tumor	O
energy	O
failure	O
.	O
<EOS>	B-X
In	B-X
experimental	B-X
RG1	B-X
2.2	B-X
glioma	B-X
of	B-X
rat	B-X
brain	B-X
,	B-X
local	B-X
blood	B-X
flow	B-X
,	B-X
glucose	B-X
utilization	B-X
,	B-X
protein	B-X
synthesis	B-X
,	B-X
glucose	B-X
and	B-X
ATP	B-X
content	B-X
were	B-X
measured	B-X
by	B-X
means	B-X
of	B-X
triple	B-X
tracer	B-X
autoradiography	B-X
and	B-X
bioluminescence	B-X
technique	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
determine	B-X
hemodynamic	B-X
and	B-X
metabolic	B-X
thresholds	B-X
for	B-X
local	B-X
tumor	B-X
energy	B-X
failure	B-X
.	B-X
Perfusion	B-X
thresholds	B-X
were	B-X
estimated	B-X
at	B-X
tumor	B-X
blood	B-X
flow	B-X
values	B-X
of	B-X
69.0	B-X
+/-	B-X
0.1	B-X
ml/100	B-X
g/min	B-X
(	B-X
estimate	B-X
+/-	B-X
standard	B-X
error	B-X
)	B-X
and	B-X
of	B-X
69	B-X
+/-	B-X
7.1	B-X
ml/100	B-X
g/min	B-X
for	B-X
the	B-X
beginning	B-X
of	B-X
the	B-X
decline	B-X
in	B-X
regional	B-X
ATP	B-X
and	B-X
glucose	B-X
content	B-X
,	B-X
respectively	B-X
.	B-X
Metabolic	B-X
thresholds	B-X
were	B-X
derived	B-X
at	B-X
tumor	B-X
glucose	B-X
utilization	B-X
values	B-X
of	B-X
70.6	B-X
+/-	B-X
8.3	B-X
mumol/100	B-X
g/min	B-X
for	B-X
reduced	B-X
protein	B-X
synthesis	B-X
,	B-X
of	B-X
55.0	B-X
+/-	B-X
0.2	B-X
mumol/100	B-X
g/min	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
glucose	B-X
content	B-X
,	B-X
and	B-X
34.7	B-X
+/-	B-X
4.7	B-X
mumol/100	B-X
g/min	B-X
for	B-X
decline	B-X
in	B-X
ATP	B-X
content	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
blood	B-X
flow	B-X
limits	B-X
glucose	B-X
supply	B-X
to	B-X
tumor	B-X
tissue	B-X
at	B-X
much	B-X
higher	B-X
flow	B-X
rates	B-X
than	B-X
in	B-X
normal	B-X
brain	B-X
which	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
glucose	B-X
utilization	B-X
.	B-X
A	B-X
reduction	B-X
and	B-X
not	B-X
an	B-X
increase	B-X
in	B-X
tumor	B-X
glucose	B-X
availability	B-X
could	B-X
be	B-X
a	B-X
more	B-X
appropriate	B-X
strategy	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
energy	B-X
failure	B-X
in	B-X
tumors	B-X
.	B-X

Perfusion	O
thresholds	O
were	O
estimated	O
at	O
tumor	O
blood	O
flow	O
values	O
of	O
69	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
estimate	O
+	O
/	O
-	O
standard	O
error	O
)	O
and	O
of	O
69	O
+	O
/	O
-	O
7	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
beginning	O
of	O
the	O
decline	O
in	O
regional	O
ATP	O
and	O
glucose	O
content	O
,	O
respectively	O
.	O

Metabolic	O
thresholds	O
were	O
derived	O
at	O
tumor	O
glucose	O
utilization	O
values	O
of	O
70	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
3	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
reduced	O
protein	O
synthesis	O
,	O
of	O
55	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
decrease	O
in	O
glucose	O
content	O
,	O
and	O
34	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
7	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
decline	O
in	O
ATP	O
content	O
.	O

Our	O
results	O
suggest	O
that	O
blood	O
flow	O
limits	O
glucose	O
supply	O
to	O
tumor	O
tissue	O
at	O
much	O
higher	O
flow	O
rates	O
than	O
in	O
normal	O
brain	O
which	O
,	O
in	O
turn	O
,	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
tumor	O
glucose	O
utilization	O
.	O
<EOS>	B-X
In	B-X
experimental	B-X
RG1	B-X
2.2	B-X
glioma	B-X
of	B-X
rat	B-X
brain	B-X
,	B-X
local	B-X
blood	B-X
flow	B-X
,	B-X
glucose	B-X
utilization	B-X
,	B-X
protein	B-X
synthesis	B-X
,	B-X
glucose	B-X
and	B-X
ATP	B-X
content	B-X
were	B-X
measured	B-X
by	B-X
means	B-X
of	B-X
triple	B-X
tracer	B-X
autoradiography	B-X
and	B-X
bioluminescence	B-X
technique	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
determine	B-X
hemodynamic	B-X
and	B-X
metabolic	B-X
thresholds	B-X
for	B-X
local	B-X
tumor	B-X
energy	B-X
failure	B-X
.	B-X
Perfusion	B-X
thresholds	B-X
were	B-X
estimated	B-X
at	B-X
tumor	B-X
blood	B-X
flow	B-X
values	B-X
of	B-X
69.0	B-X
+/-	B-X
0.1	B-X
ml/100	B-X
g/min	B-X
(	B-X
estimate	B-X
+/-	B-X
standard	B-X
error	B-X
)	B-X
and	B-X
of	B-X
69	B-X
+/-	B-X
7.1	B-X
ml/100	B-X
g/min	B-X
for	B-X
the	B-X
beginning	B-X
of	B-X
the	B-X
decline	B-X
in	B-X
regional	B-X
ATP	B-X
and	B-X
glucose	B-X
content	B-X
,	B-X
respectively	B-X
.	B-X
Metabolic	B-X
thresholds	B-X
were	B-X
derived	B-X
at	B-X
tumor	B-X
glucose	B-X
utilization	B-X
values	B-X
of	B-X
70.6	B-X
+/-	B-X
8.3	B-X
mumol/100	B-X
g/min	B-X
for	B-X
reduced	B-X
protein	B-X
synthesis	B-X
,	B-X
of	B-X
55.0	B-X
+/-	B-X
0.2	B-X
mumol/100	B-X
g/min	B-X
for	B-X
the	B-X
decrease	B-X
in	B-X
glucose	B-X
content	B-X
,	B-X
and	B-X
34.7	B-X
+/-	B-X
4.7	B-X
mumol/100	B-X
g/min	B-X
for	B-X
decline	B-X
in	B-X
ATP	B-X
content	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
blood	B-X
flow	B-X
limits	B-X
glucose	B-X
supply	B-X
to	B-X
tumor	B-X
tissue	B-X
at	B-X
much	B-X
higher	B-X
flow	B-X
rates	B-X
than	B-X
in	B-X
normal	B-X
brain	B-X
which	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
tumor	B-X
glucose	B-X
utilization	B-X
.	B-X
A	B-X
reduction	B-X
and	B-X
not	B-X
an	B-X
increase	B-X
in	B-X
tumor	B-X
glucose	B-X
availability	B-X
could	B-X
be	B-X
a	B-X
more	B-X
appropriate	B-X
strategy	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
energy	B-X
failure	B-X
in	B-X
tumors	B-X
.	B-X

A	O
reduction	O
and	O
not	O
an	O
increase	O
in	O
tumor	O
glucose	O
availability	O
could	O
be	O
a	O
more	O
appropriate	O
strategy	O
for	O
the	O
induction	O
of	O
energy	O
failure	O
in	O
tumors	O
.	O
<EOS>	B-X
Yoga	B-X
as	B-X
an	B-X
Intervention	B-X
for	B-X
the	B-X
Reduction	B-X
of	B-X
Symptoms	B-X
of	B-X
Anxiety	B-X
and	B-X
Depression	B-X
in	B-X
Children	B-X
and	B-X
Adolescents	B-X
:	B-X
A	B-X
Systematic	B-X
Review	B-X
.	B-X
The	B-X
Vocal	B-X
Handicap	B-X
Index-10	B-X
(	B-X
VHI-10	B-X
)	B-X
was	B-X
designed	B-X
as	B-X
an	B-X
item	B-X
reduction	B-X
of	B-X
the	B-X
original	B-X
VHI	B-X
to	B-X
provide	B-X
a	B-X
quick	B-X
,	B-X
reliable	B-X
,	B-X
and	B-X
quantifiable	B-X
measure	B-X
of	B-X
patients	B-X
'	B-X
own	B-X
vocal	B-X
handicap	B-X
perception	B-X
.	B-X
This	B-X
article	B-X
examines	B-X
the	B-X
various	B-X
item	B-X
reductions	B-X
of	B-X
the	B-X
VHI-10	B-X
from	B-X
the	B-X
VHI	B-X
and	B-X
the	B-X
differing	B-X
methodologies	B-X
of	B-X
translation	B-X
of	B-X
the	B-X
VHI-10	B-X
.	B-X
Breast	B-X
reduction	B-X
has	B-X
a	B-X
well-chronicled	B-X
history	B-X
and	B-X
remains	B-X
a	B-X
common	B-X
reason	B-X
for	B-X
patients	B-X
to	B-X
seek	B-X
plastic	B-X
surgery	B-X
consultation	B-X
.	B-X
The	B-X
Wise	B-X
pattern	B-X
is	B-X
the	B-X
most	B-X
common	B-X
skin	B-X
reduction	B-X
pattern	B-X
in	B-X
the	B-X
United	B-X
States	B-X
.	B-X
Vertical	B-X
pattern	B-X
reduction	B-X
is	B-X
also	B-X
widely	B-X
used	B-X
and	B-X
offers	B-X
the	B-X
potential	B-X
for	B-X
decreased	B-X
scar	B-X
burden	B-X
.	B-X
There	B-X
is	B-X
a	B-X
preponderance	B-X
of	B-X
literature	B-X
on	B-X
breast	B-X
reduction	B-X
surgery	B-X
but	B-X
limited	B-X
comparative	B-X
data	B-X
on	B-X
the	B-X
safety	B-X
profile	B-X
of	B-X
these	B-X
patterns	B-X
.	B-X

Inactivation	O
of	O
androgen	O
-	O
induced	O
regulator	O
ARD1	B-Gene_or_gene_product
inhibits	O
androgen	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
acetylation	O
and	O
prostate	O
tumorigenesis	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

Androgen	O
signaling	O
through	O
androgen	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	O
AR	B-Gene_or_gene_product
)	O
is	O
critical	O
for	O
prostate	O
tumorigenesis	O
.	O
<EOS>	B-X
In	B-X
prostate	B-X
cancer	B-X
,	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
-targeting	B-X
agents	B-X
are	B-X
very	B-X
effective	B-X
in	B-X
various	B-X
disease	B-X
stages	B-X
.	B-X
However	B-X
,	B-X
therapy	B-X
resistance	B-X
inevitably	B-X
occurs	B-X
,	B-X
and	B-X
little	B-X
is	B-X
known	B-X
about	B-X
how	B-X
tumor	B-X
cells	B-X
adapt	B-X
to	B-X
bypass	B-X
AR	B-X
suppression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
performed	B-X
integrative	B-X
multiomics	B-X
analyses	B-X
on	B-X
tissues	B-X
isolated	B-X
before	B-X
and	B-X
after	B-X
3	B-X
months	B-X
of	B-X
AR-targeting	B-X
enzalutamide	B-X
monotherapy	B-X
from	B-X
patients	B-X
with	B-X
high-risk	B-X
prostate	B-X
cancer	B-X
enrolled	B-X
in	B-X
a	B-X
neoadjuvant	B-X
clinical	B-X
trial	B-X
.	B-X
Transcriptomic	B-X
analyses	B-X
demonstrated	B-X
that	B-X
AR	B-X
inhibition	B-X
drove	B-X
tumors	B-X
toward	B-X
a	B-X
neuroendocrine-like	B-X
disease	B-X
state	B-X
.	B-X
Notably	B-X
,	B-X
treatment-induced	B-X
FOXA1	B-X
sites	B-X
were	B-X
enriched	B-X
for	B-X
the	B-X
circadian	B-X
clock	B-X
component	B-X
ARNTL	B-X
.	B-X
Posttreatment	B-X
ARNTL	B-X
levels	B-X
were	B-X
associated	B-X
with	B-X
patients	B-X
'	B-X
clinical	B-X
outcomes	B-X
,	B-X
and	B-X
ARNTL	B-X
knockout	B-X
strongly	B-X
decreased	B-X
prostate	B-X
cancer	B-X
cell	B-X
growth	B-X
.	B-X
Our	B-X
data	B-X
highlight	B-X
a	B-X
remarkable	B-X
cistromic	B-X
plasticity	B-X
of	B-X
FOXA1	B-X
following	B-X
AR-targeted	B-X
therapy	B-X
and	B-X
revealed	B-X
an	B-X
acquired	B-X
dependency	B-X
on	B-X
the	B-X
circadian	B-X
regulator	B-X
ARNTL	B-X
,	B-X
a	B-X
novel	B-X
candidate	B-X
therapeutic	B-X
target	B-X
.	B-X

Given	O
that	O
AR	B-Gene_or_gene_product
-	O
mediated	O
gene	O
regulation	O
is	O
enhanced	O
by	O
AR	B-Gene_or_gene_product
coregulators	O
,	O
inactivation	O
of	O
those	O
coregulators	O
is	O
emerging	O
as	O
a	O
promising	O
therapy	O
for	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
the	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
acetyltransferase	I-Gene_or_gene_product
arrest	I-Gene_or_gene_product
-	I-Gene_or_gene_product
defect	I-Gene_or_gene_product
1	I-Gene_or_gene_product
protein	O
(	O
ARD1	B-Gene_or_gene_product
)	O
functions	O
as	O
a	O
unique	O
AR	B-Gene_or_gene_product
regulator	O
in	O
PCa	O
cells	O
.	O

ARD1	B-Gene_or_gene_product
is	O
up	O
-	O
regulated	O
in	O
human	O
PCa	O
cell	O
lines	O
and	O
primary	O
tumor	O
biopsies	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

The	O
expression	O
of	O
ARD1	B-Gene_or_gene_product
was	O
augmented	O
by	O
treatment	O
with	O
synthetic	O
androgen	O
(	O
R1881	O
)	O
unless	O
AR	B-Gene_or_gene_product
is	O
deficient	O
or	O
is	O
inhibited	O
by	O
AR	B-Gene_or_gene_product
-	O
specific	O
siRNA	O
or	O
androgen	O
inhibitor	O
bicalutamide	O
(	O
Casodex	O
)	O
.	O
<EOS>	B-X
Metastatic	B-X
prostate	B-X
cancer	B-X
is	B-X
treated	B-X
with	B-X
drugs	B-X
that	B-X
antagonize	B-X
androgen	B-X
action	B-X
,	B-X
but	B-X
most	B-X
patients	B-X
progress	B-X
to	B-X
a	B-X
more	B-X
aggressive	B-X
form	B-X
of	B-X
the	B-X
disease	B-X
called	B-X
castration-resistant	B-X
prostate	B-X
cancer	B-X
,	B-X
driven	B-X
by	B-X
elevated	B-X
expression	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
.	B-X
Here	B-X
we	B-X
characterize	B-X
the	B-X
diarylthiohydantoins	B-X
RD162	B-X
and	B-X
MDV3100	B-X
,	B-X
two	B-X
compounds	B-X
optimized	B-X
from	B-X
a	B-X
screen	B-X
for	B-X
nonsteroidal	B-X
antiandrogens	B-X
that	B-X
retain	B-X
activity	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
increased	B-X
androgen	B-X
receptor	B-X
expression	B-X
.	B-X
Both	B-X
compounds	B-X
bind	B-X
to	B-X
the	B-X
androgen	B-X
receptor	B-X
with	B-X
greater	B-X
relative	B-X
affinity	B-X
than	B-X
the	B-X
clinically	B-X
used	B-X
antiandrogen	B-X
bicalutamide	B-X
,	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
its	B-X
nuclear	B-X
translocation	B-X
,	B-X
and	B-X
impair	B-X
both	B-X
DNA	B-X
binding	B-X
to	B-X
androgen	B-X
response	B-X
elements	B-X
and	B-X
recruitment	B-X
of	B-X
coactivators	B-X
.	B-X
Of	B-X
the	B-X
first	B-X
30	B-X
patients	B-X
treated	B-X
with	B-X
MDV3100	B-X
in	B-X
a	B-X
Phase	B-X
I/II	B-X
clinical	B-X
trial	B-X
,	B-X
13	B-X
of	B-X
30	B-X
(	B-X
43	B-X
%	B-X
)	B-X
showed	B-X
sustained	B-X
declines	B-X
(	B-X
by	B-X
>	B-X
50	B-X
%	B-X
)	B-X
in	B-X
serum	B-X
concentrations	B-X
of	B-X
prostate-specific	B-X
antigen	B-X
,	B-X
a	B-X
biomarker	B-X
of	B-X
prostate	B-X
cancer	B-X
.	B-X
These	B-X
compounds	B-X
thus	B-X
appear	B-X
to	B-X
be	B-X
promising	B-X
candidates	B-X
for	B-X
treatment	B-X
of	B-X
advanced	B-X
prostate	B-X
cancer	B-X
.	B-X

Depletion	O
of	O
ARD1	B-Gene_or_gene_product
by	O
shRNA	O
suppressed	O
PCa	O
cell	O
proliferation	O
,	O
anchorage	O
-	O
independent	O
growth	O
,	O
and	O
xenograft	O
tumor	O
formation	O
in	O
SCID	O
mice	O
,	O
suggesting	O
that	O
AR	B-Gene_or_gene_product
-	O
dependent	O
ARD1	B-Gene_or_gene_product
expression	O
is	O
biologically	O
germane	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

Notably	O
,	O
ARD1	B-Gene_or_gene_product
was	O
critical	O
for	O
transcriptionally	O
regulating	O
a	O
number	O
of	O
AR	B-Gene_or_gene_product
target	O
genes	O
that	O
are	O
involved	O
in	O
prostate	O
tumorigenesis	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

Furthermore	O
,	O
ARD1	B-Gene_or_gene_product
interacted	O
physically	O
with	O
and	O
acetylated	O
the	O
AR	B-Gene_or_gene_product
protein	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

Because	O
AR	B-Gene_or_gene_product
-	O
ARD1	B-Gene_or_gene_product
interaction	O
facilitated	O
the	O
AR	B-Gene_or_gene_product
binding	O
to	O
its	O
targeted	O
promoters	O
for	O
gene	O
transcription	O
,	O
we	O
propose	O
that	O
ARD1	B-Gene_or_gene_product
functions	O
as	O
a	O
unique	O
AR	B-Gene_or_gene_product
regulator	O
and	O
forms	O
a	O
positive	O
feedback	O
loop	O
for	O
AR	B-Gene_or_gene_product
-	O
dependent	O
prostate	O
tumorigenesis	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

Disruption	O
of	O
AR	B-Gene_or_gene_product
-	O
ARD1	B-Gene_or_gene_product
interactions	O
may	O
be	O
a	O
potent	O
intervention	O
for	O
androgen	B-Gene_or_gene_product
-	O
dependent	O
PCa	O
therapy	O
.	O
<EOS>	B-X
Androgen	B-X
signaling	B-X
through	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Given	B-X
that	B-X
AR-mediated	B-X
gene	B-X
regulation	B-X
is	B-X
enhanced	B-X
by	B-X
AR	B-X
coregulators	B-X
,	B-X
inactivation	B-X
of	B-X
those	B-X
coregulators	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
promising	B-X
therapy	B-X
for	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
N-acetyltransferase	B-X
arrest-defect	B-X
1	B-X
protein	B-X
(	B-X
ARD1	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
in	B-X
PCa	B-X
cells	B-X
.	B-X
ARD1	B-X
is	B-X
up-regulated	B-X
in	B-X
human	B-X
PCa	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
tumor	B-X
biopsies	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
ARD1	B-X
was	B-X
augmented	B-X
by	B-X
treatment	B-X
with	B-X
synthetic	B-X
androgen	B-X
(	B-X
R1881	B-X
)	B-X
unless	B-X
AR	B-X
is	B-X
deficient	B-X
or	B-X
is	B-X
inhibited	B-X
by	B-X
AR-specific	B-X
siRNA	B-X
or	B-X
androgen	B-X
inhibitor	B-X
bicalutamide	B-X
(	B-X
Casodex	B-X
)	B-X
.	B-X
Depletion	B-X
of	B-X
ARD1	B-X
by	B-X
shRNA	B-X
suppressed	B-X
PCa	B-X
cell	B-X
proliferation	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
and	B-X
xenograft	B-X
tumor	B-X
formation	B-X
in	B-X
SCID	B-X
mice	B-X
,	B-X
suggesting	B-X
that	B-X
AR-dependent	B-X
ARD1	B-X
expression	B-X
is	B-X
biologically	B-X
germane	B-X
.	B-X
Notably	B-X
,	B-X
ARD1	B-X
was	B-X
critical	B-X
for	B-X
transcriptionally	B-X
regulating	B-X
a	B-X
number	B-X
of	B-X
AR	B-X
target	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Furthermore	B-X
,	B-X
ARD1	B-X
interacted	B-X
physically	B-X
with	B-X
and	B-X
acetylated	B-X
the	B-X
AR	B-X
protein	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Because	B-X
AR-ARD1	B-X
interaction	B-X
facilitated	B-X
the	B-X
AR	B-X
binding	B-X
to	B-X
its	B-X
targeted	B-X
promoters	B-X
for	B-X
gene	B-X
transcription	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
ARD1	B-X
functions	B-X
as	B-X
a	B-X
unique	B-X
AR	B-X
regulator	B-X
and	B-X
forms	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
for	B-X
AR-dependent	B-X
prostate	B-X
tumorigenesis	B-X
.	B-X
Disruption	B-X
of	B-X
AR-ARD1	B-X
interactions	B-X
may	B-X
be	B-X
a	B-X
potent	B-X
intervention	B-X
for	B-X
androgen-dependent	B-X
PCa	B-X
therapy	B-X
.	B-X

The	O
role	O
of	O
Hes	B-Gene_or_gene_product
genes	O
in	O
intestinal	O
development	O
,	O
homeostasis	O
and	O
tumor	O
formation	O
.	O
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
intestinal	B-X
development	B-X
,	B-X
homeostasis	B-X
and	B-X
tumorigenesis	B-X
,	B-X
but	B-X
its	B-X
precise	B-X
downstream	B-X
mechanism	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
inactivation	B-X
of	B-X
the	B-X
Notch	B-X
effectors	B-X
Hes1	B-X
,	B-X
Hes3	B-X
and	B-X
Hes5	B-X
,	B-X
but	B-X
not	B-X
Hes1	B-X
alone	B-X
,	B-X
led	B-X
to	B-X
reduced	B-X
cell	B-X
proliferation	B-X
,	B-X
increased	B-X
secretory	B-X
cell	B-X
formation	B-X
and	B-X
altered	B-X
intestinal	B-X
structures	B-X
in	B-X
adult	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
in	B-X
Apc	B-X
mutation-induced	B-X
intestinal	B-X
tumors	B-X
,	B-X
inactivation	B-X
of	B-X
Hes1	B-X
alone	B-X
was	B-X
sufficient	B-X
for	B-X
reducing	B-X
tumor	B-X
cell	B-X
proliferation	B-X
and	B-X
inducing	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
into	B-X
all	B-X
types	B-X
of	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
,	B-X
but	B-X
without	B-X
affecting	B-X
the	B-X
homeostasis	B-X
of	B-X
normal	B-X
crypts	B-X
owing	B-X
to	B-X
genetic	B-X
redundancy	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
Hes	B-X
genes	B-X
cooperatively	B-X
regulate	B-X
intestinal	B-X
development	B-X
and	B-X
homeostasis	B-X
and	B-X
raised	B-X
the	B-X
possibility	B-X
that	B-X
Hes1	B-X
is	B-X
a	B-X
promising	B-X
target	B-X
to	B-X
induce	B-X
the	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X

Notch	B-Gene_or_gene_product
signaling	O
regulates	O
intestinal	O
development	O
,	O
homeostasis	O
and	O
tumorigenesis	O
,	O
but	O
its	O
precise	O
downstream	O
mechanism	O
remains	O
largely	O
unknown	O
.	O
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
intestinal	B-X
development	B-X
,	B-X
homeostasis	B-X
and	B-X
tumorigenesis	B-X
,	B-X
but	B-X
its	B-X
precise	B-X
downstream	B-X
mechanism	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
inactivation	B-X
of	B-X
the	B-X
Notch	B-X
effectors	B-X
Hes1	B-X
,	B-X
Hes3	B-X
and	B-X
Hes5	B-X
,	B-X
but	B-X
not	B-X
Hes1	B-X
alone	B-X
,	B-X
led	B-X
to	B-X
reduced	B-X
cell	B-X
proliferation	B-X
,	B-X
increased	B-X
secretory	B-X
cell	B-X
formation	B-X
and	B-X
altered	B-X
intestinal	B-X
structures	B-X
in	B-X
adult	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
in	B-X
Apc	B-X
mutation-induced	B-X
intestinal	B-X
tumors	B-X
,	B-X
inactivation	B-X
of	B-X
Hes1	B-X
alone	B-X
was	B-X
sufficient	B-X
for	B-X
reducing	B-X
tumor	B-X
cell	B-X
proliferation	B-X
and	B-X
inducing	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
into	B-X
all	B-X
types	B-X
of	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
,	B-X
but	B-X
without	B-X
affecting	B-X
the	B-X
homeostasis	B-X
of	B-X
normal	B-X
crypts	B-X
owing	B-X
to	B-X
genetic	B-X
redundancy	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
Hes	B-X
genes	B-X
cooperatively	B-X
regulate	B-X
intestinal	B-X
development	B-X
and	B-X
homeostasis	B-X
and	B-X
raised	B-X
the	B-X
possibility	B-X
that	B-X
Hes1	B-X
is	B-X
a	B-X
promising	B-X
target	B-X
to	B-X
induce	B-X
the	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X

Here	O
we	O
found	O
that	O
inactivation	O
of	O
the	O
Notch	B-Gene_or_gene_product
effectors	O
Hes1	B-Gene_or_gene_product
,	O
Hes3	B-Gene_or_gene_product
and	O
Hes5	B-Gene_or_gene_product
,	O
but	O
not	O
Hes1	B-Gene_or_gene_product
alone	O
,	O
led	O
to	O
reduced	O
cell	O
proliferation	O
,	O
increased	O
secretory	O
cell	O
formation	O
and	O
altered	O
intestinal	O
structures	O
in	O
adult	O
mice	O
.	O
<EOS>	B-X
There	B-X
are	B-X
seven	B-X
members	B-X
in	B-X
the	B-X
human	B-X
Hes	B-X
family	B-X
,	B-X
Hes1-7	B-X
,	B-X
which	B-X
are	B-X
expressed	B-X
in	B-X
many	B-X
tissues	B-X
and	B-X
play	B-X
various	B-X
roles	B-X
mainly	B-X
in	B-X
development	B-X
.	B-X
The	B-X
basic	B-X
region	B-X
binds	B-X
to	B-X
target	B-X
DNA	B-X
sequences	B-X
,	B-X
while	B-X
the	B-X
HLH	B-X
region	B-X
forms	B-X
homo-	B-X
and	B-X
heterodimers	B-X
with	B-X
other	B-X
bHLH	B-X
proteins	B-X
,	B-X
the	B-X
Orange	B-X
domain	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
selection	B-X
of	B-X
partners	B-X
during	B-X
heterodimer	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
WRPW	B-X
domain	B-X
recruits	B-X
corepressors	B-X
.	B-X
Hes1	B-X
,	B-X
Hes5	B-X
,	B-X
and	B-X
Hes7	B-X
are	B-X
known	B-X
as	B-X
downstream	B-X
effectors	B-X
of	B-X
canonical	B-X
Notch	B-X
signaling	B-X
,	B-X
which	B-X
regulates	B-X
cell	B-X
differentiation	B-X
via	B-X
cell-cell	B-X
interaction	B-X
.	B-X
Hes	B-X
factors	B-X
regulate	B-X
many	B-X
events	B-X
in	B-X
development	B-X
by	B-X
repressing	B-X
the	B-X
expression	B-X
of	B-X
target	B-X
genes	B-X
,	B-X
many	B-X
of	B-X
which	B-X
encode	B-X
transcriptional	B-X
activators	B-X
that	B-X
promote	B-X
cell	B-X
differentiation	B-X
.	B-X
For	B-X
example	B-X
,	B-X
Hes1	B-X
,	B-X
Hes3	B-X
,	B-X
and	B-X
Hes5	B-X
are	B-X
highly	B-X
expressed	B-X
by	B-X
neural	B-X
stem	B-X
cells	B-X
,	B-X
and	B-X
inactivation	B-X
of	B-X
these	B-X
genes	B-X
results	B-X
in	B-X
insufficient	B-X
maintenance	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
and	B-X
prematurely	B-X
promotes	B-X
neuronal	B-X
differentiation	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
expression	B-X
dynamics	B-X
of	B-X
Hes1	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
proper	B-X
developmental	B-X
timings	B-X
and	B-X
fate-determination	B-X
steps	B-X
of	B-X
embryonic	B-X
stem	B-X
cells	B-X
and	B-X
neural	B-X
progenitor	B-X
cells	B-X
.	B-X

However	O
,	O
in	O
Apc	B-Gene_or_gene_product
mutation	O
-	O
induced	O
intestinal	O
tumors	O
,	O
inactivation	O
of	O
Hes1	B-Gene_or_gene_product
alone	O
was	O
sufficient	O
for	O
reducing	O
tumor	O
cell	O
proliferation	O
and	O
inducing	O
differentiation	O
of	O
tumor	O
cells	O
into	O
all	O
types	O
of	O
intestinal	O
epithelial	O
cells	O
,	O
but	O
without	O
affecting	O
the	O
homeostasis	O
of	O
normal	O
crypts	O
owing	O
to	O
genetic	O
redundancy	O
.	O
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
intestinal	B-X
development	B-X
,	B-X
homeostasis	B-X
and	B-X
tumorigenesis	B-X
,	B-X
but	B-X
its	B-X
precise	B-X
downstream	B-X
mechanism	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
inactivation	B-X
of	B-X
the	B-X
Notch	B-X
effectors	B-X
Hes1	B-X
,	B-X
Hes3	B-X
and	B-X
Hes5	B-X
,	B-X
but	B-X
not	B-X
Hes1	B-X
alone	B-X
,	B-X
led	B-X
to	B-X
reduced	B-X
cell	B-X
proliferation	B-X
,	B-X
increased	B-X
secretory	B-X
cell	B-X
formation	B-X
and	B-X
altered	B-X
intestinal	B-X
structures	B-X
in	B-X
adult	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
in	B-X
Apc	B-X
mutation-induced	B-X
intestinal	B-X
tumors	B-X
,	B-X
inactivation	B-X
of	B-X
Hes1	B-X
alone	B-X
was	B-X
sufficient	B-X
for	B-X
reducing	B-X
tumor	B-X
cell	B-X
proliferation	B-X
and	B-X
inducing	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
into	B-X
all	B-X
types	B-X
of	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
,	B-X
but	B-X
without	B-X
affecting	B-X
the	B-X
homeostasis	B-X
of	B-X
normal	B-X
crypts	B-X
owing	B-X
to	B-X
genetic	B-X
redundancy	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
Hes	B-X
genes	B-X
cooperatively	B-X
regulate	B-X
intestinal	B-X
development	B-X
and	B-X
homeostasis	B-X
and	B-X
raised	B-X
the	B-X
possibility	B-X
that	B-X
Hes1	B-X
is	B-X
a	B-X
promising	B-X
target	B-X
to	B-X
induce	B-X
the	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X

These	O
results	O
indicated	O
that	O
Hes	B-Gene_or_gene_product
genes	O
cooperatively	O
regulate	O
intestinal	O
development	O
and	O
homeostasis	O
and	O
raised	O
the	O
possibility	O
that	O
Hes1	B-Gene_or_gene_product
is	O
a	O
promising	O
target	O
to	O
induce	O
the	O
differentiation	O
of	O
tumor	O
cells	O
.	O
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
intestinal	B-X
development	B-X
,	B-X
homeostasis	B-X
and	B-X
tumorigenesis	B-X
,	B-X
but	B-X
its	B-X
precise	B-X
downstream	B-X
mechanism	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
inactivation	B-X
of	B-X
the	B-X
Notch	B-X
effectors	B-X
Hes1	B-X
,	B-X
Hes3	B-X
and	B-X
Hes5	B-X
,	B-X
but	B-X
not	B-X
Hes1	B-X
alone	B-X
,	B-X
led	B-X
to	B-X
reduced	B-X
cell	B-X
proliferation	B-X
,	B-X
increased	B-X
secretory	B-X
cell	B-X
formation	B-X
and	B-X
altered	B-X
intestinal	B-X
structures	B-X
in	B-X
adult	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
in	B-X
Apc	B-X
mutation-induced	B-X
intestinal	B-X
tumors	B-X
,	B-X
inactivation	B-X
of	B-X
Hes1	B-X
alone	B-X
was	B-X
sufficient	B-X
for	B-X
reducing	B-X
tumor	B-X
cell	B-X
proliferation	B-X
and	B-X
inducing	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
into	B-X
all	B-X
types	B-X
of	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
,	B-X
but	B-X
without	B-X
affecting	B-X
the	B-X
homeostasis	B-X
of	B-X
normal	B-X
crypts	B-X
owing	B-X
to	B-X
genetic	B-X
redundancy	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
Hes	B-X
genes	B-X
cooperatively	B-X
regulate	B-X
intestinal	B-X
development	B-X
and	B-X
homeostasis	B-X
and	B-X
raised	B-X
the	B-X
possibility	B-X
that	B-X
Hes1	B-X
is	B-X
a	B-X
promising	B-X
target	B-X
to	B-X
induce	B-X
the	B-X
differentiation	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X

Activation	B-Gene_or_gene_product
-	I-Gene_or_gene_product
induced	I-Gene_or_gene_product
cytidine	I-Gene_or_gene_product
deaminase	I-Gene_or_gene_product
in	O
antibody	O
diversification	O
and	O
chromosome	O
translocation	O
.	O
<EOS>	B-X
An	B-X
exception	B-X
is	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
where	B-X
lymphocytes	B-X
utilize	B-X
programmed	B-X
DNA	B-X
damage	B-X
to	B-X
effect	B-X
antigen	B-X
receptor	B-X
diversification	B-X
.	B-X
Both	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
diversify	B-X
their	B-X
antigen	B-X
receptors	B-X
through	B-X
RAG1/2	B-X
mediated	B-X
recombination	B-X
,	B-X
but	B-X
B	B-X
cells	B-X
undergo	B-X
two	B-X
additional	B-X
processes	B-X
--	B-X
somatic	B-X
hypermutation	B-X
(	B-X
SHM	B-X
)	B-X
and	B-X
class-switch	B-X
recombination	B-X
(	B-X
CSR	B-X
)	B-X
,	B-X
both	B-X
initiated	B-X
by	B-X
activation-induced	B-X
cytidine	B-X
deaminase	B-X
(	B-X
AID	B-X
)	B-X
.	B-X
AID	B-X
deaminates	B-X
cytidines	B-X
in	B-X
DNA	B-X
resulting	B-X
in	B-X
U	B-X
:	B-X
G	B-X
mismatches	B-X
that	B-X
are	B-X
processed	B-X
into	B-X
point	B-X
mutations	B-X
in	B-X
SHM	B-X
or	B-X
double-strand	B-X
breaks	B-X
in	B-X
CSR	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
AID	B-X
regulation	B-X
,	B-X
targeting	B-X
,	B-X
and	B-X
initiation	B-X
of	B-X
CSR	B-X
and	B-X
SHM	B-X
,	B-X
as	B-X
well	B-X
as	B-X
AID	B-X
's	B-X
role	B-X
in	B-X
generating	B-X
chromosome	B-X
translocations	B-X
that	B-X
contribute	B-X
to	B-X
lymphomagenesis	B-X
.	B-X

DNA	O
damage	O
,	O
rearrangement	O
,	O
and	O
mutation	O
of	O
the	O
human	O
genome	O
are	O
the	O
basis	O
of	O
carcinogenesis	O
and	O
thought	O
to	O
be	O
avoided	O
at	O
all	O
costs	O
.	O
<EOS>	B-X
DNA	B-X
damage	B-X
,	B-X
rearrangement	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
the	B-X
human	B-X
genome	B-X
are	B-X
the	B-X
basis	B-X
of	B-X
carcinogenesis	B-X
and	B-X
thought	B-X
to	B-X
be	B-X
avoided	B-X
at	B-X
all	B-X
costs	B-X
.	B-X
An	B-X
exception	B-X
is	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
where	B-X
lymphocytes	B-X
utilize	B-X
programmed	B-X
DNA	B-X
damage	B-X
to	B-X
effect	B-X
antigen	B-X
receptor	B-X
diversification	B-X
.	B-X
Both	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
diversify	B-X
their	B-X
antigen	B-X
receptors	B-X
through	B-X
RAG1/2	B-X
mediated	B-X
recombination	B-X
,	B-X
but	B-X
B	B-X
cells	B-X
undergo	B-X
two	B-X
additional	B-X
processes	B-X
--	B-X
somatic	B-X
hypermutation	B-X
(	B-X
SHM	B-X
)	B-X
and	B-X
class-switch	B-X
recombination	B-X
(	B-X
CSR	B-X
)	B-X
,	B-X
both	B-X
initiated	B-X
by	B-X
activation-induced	B-X
cytidine	B-X
deaminase	B-X
(	B-X
AID	B-X
)	B-X
.	B-X
AID	B-X
deaminates	B-X
cytidines	B-X
in	B-X
DNA	B-X
resulting	B-X
in	B-X
U	B-X
:	B-X
G	B-X
mismatches	B-X
that	B-X
are	B-X
processed	B-X
into	B-X
point	B-X
mutations	B-X
in	B-X
SHM	B-X
or	B-X
double-strand	B-X
breaks	B-X
in	B-X
CSR	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
AID	B-X
regulation	B-X
,	B-X
targeting	B-X
,	B-X
and	B-X
initiation	B-X
of	B-X
CSR	B-X
and	B-X
SHM	B-X
,	B-X
as	B-X
well	B-X
as	B-X
AID	B-X
's	B-X
role	B-X
in	B-X
generating	B-X
chromosome	B-X
translocations	B-X
that	B-X
contribute	B-X
to	B-X
lymphomagenesis	B-X
.	B-X

An	O
exception	O
is	O
the	O
adaptive	O
immune	O
system	O
where	O
lymphocytes	O
utilize	O
programmed	O
DNA	O
damage	O
to	O
effect	O
antigen	O
receptor	O
diversification	O
.	O
<EOS>	B-X
DNA	B-X
damage	B-X
,	B-X
rearrangement	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
the	B-X
human	B-X
genome	B-X
are	B-X
the	B-X
basis	B-X
of	B-X
carcinogenesis	B-X
and	B-X
thought	B-X
to	B-X
be	B-X
avoided	B-X
at	B-X
all	B-X
costs	B-X
.	B-X
An	B-X
exception	B-X
is	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
where	B-X
lymphocytes	B-X
utilize	B-X
programmed	B-X
DNA	B-X
damage	B-X
to	B-X
effect	B-X
antigen	B-X
receptor	B-X
diversification	B-X
.	B-X
Both	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
diversify	B-X
their	B-X
antigen	B-X
receptors	B-X
through	B-X
RAG1/2	B-X
mediated	B-X
recombination	B-X
,	B-X
but	B-X
B	B-X
cells	B-X
undergo	B-X
two	B-X
additional	B-X
processes	B-X
--	B-X
somatic	B-X
hypermutation	B-X
(	B-X
SHM	B-X
)	B-X
and	B-X
class-switch	B-X
recombination	B-X
(	B-X
CSR	B-X
)	B-X
,	B-X
both	B-X
initiated	B-X
by	B-X
activation-induced	B-X
cytidine	B-X
deaminase	B-X
(	B-X
AID	B-X
)	B-X
.	B-X
AID	B-X
deaminates	B-X
cytidines	B-X
in	B-X
DNA	B-X
resulting	B-X
in	B-X
U	B-X
:	B-X
G	B-X
mismatches	B-X
that	B-X
are	B-X
processed	B-X
into	B-X
point	B-X
mutations	B-X
in	B-X
SHM	B-X
or	B-X
double-strand	B-X
breaks	B-X
in	B-X
CSR	B-X
.	B-X

Both	O
B	O
and	O
T	O
lymphocytes	O
diversify	O
their	O
antigen	O
receptors	O
through	O
RAG1	B-Gene_or_gene_product
/	O
2	B-Gene_or_gene_product
mediated	O
recombination	O
,	O
but	O
B	O
cells	O
undergo	O
two	O
additional	O
processes	O
-	O
-	O
somatic	O
hypermutation	O
(	O
SHM	O
)	O
and	O
class	O
-	O
switch	O
recombination	O
(	O
CSR	O
)	O
,	O
both	O
initiated	O
by	O
activation	B-Gene_or_gene_product
-	I-Gene_or_gene_product
induced	I-Gene_or_gene_product
cytidine	I-Gene_or_gene_product
deaminase	I-Gene_or_gene_product
(	O
AID	B-Gene_or_gene_product
)	O
.	O

AID	B-Gene_or_gene_product
deaminates	O
cytidines	O
in	O
DNA	O
resulting	O
in	O
U	O
:	O
G	O
mismatches	O
that	O
are	O
processed	O
into	O
point	O
mutations	O
in	O
SHM	O
or	O
double	O
-	O
strand	O
breaks	O
in	O
CSR	O
.	O
<EOS>	B-X
The	B-X
recombinational	B-X
process	B-X
,	B-X
including	B-X
randomly	B-X
choosing	B-X
a	B-X
pair	B-X
of	B-X
V	B-X
,	B-X
D	B-X
,	B-X
J	B-X
segments	B-X
,	B-X
introducing	B-X
double-strand	B-X
breaks	B-X
adjacent	B-X
to	B-X
each	B-X
segment	B-X
,	B-X
deleting	B-X
(	B-X
or	B-X
inverting	B-X
in	B-X
some	B-X
cases	B-X
)	B-X
the	B-X
intervening	B-X
DNA	B-X
and	B-X
ligating	B-X
the	B-X
segments	B-X
together	B-X
,	B-X
is	B-X
defined	B-X
as	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombination	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
surprising	B-X
immunoglobulin	B-X
diversity	B-X
in	B-X
vertebrate	B-X
immune	B-X
systems	B-X
.	B-X
To	B-X
enhance	B-X
both	B-X
the	B-X
ability	B-X
of	B-X
immunoglobulins	B-X
to	B-X
recognize	B-X
and	B-X
bind	B-X
to	B-X
foreign	B-X
antigens	B-X
and	B-X
the	B-X
effector	B-X
capacities	B-X
of	B-X
the	B-X
expressed	B-X
antibodies	B-X
,	B-X
naive	B-X
B	B-X
cells	B-X
will	B-X
undergo	B-X
class	B-X
switching	B-X
recombination	B-X
(	B-X
CSR	B-X
)	B-X
and	B-X
somatic	B-X
hypermutation	B-X
(	B-X
SHM	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
genetics	B-X
mechanisms	B-X
of	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombination	B-X
,	B-X
CSR	B-X
and	B-X
SHM	B-X
are	B-X
not	B-X
clear	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
major	B-X
progress	B-X
in	B-X
mechanism	B-X
studies	B-X
of	B-X
immunoglobulin	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
gene	B-X
recombination	B-X
and	B-X
CSR	B-X
as	B-X
well	B-X
as	B-X
SHM	B-X
,	B-X
and	B-X
their	B-X
regulatory	B-X
mechanisms	B-X
.	B-X

Although	O
AID	B-Gene_or_gene_product
activity	O
is	O
focused	O
at	O
Immunoglobulin	B-Gene_or_gene_product
(	O
Ig	B-Gene_or_gene_product
)	O
gene	O
loci	O
,	O
it	O
also	O
targets	O
a	O
wide	O
array	O
of	O
non	O
-	O
Ig	B-Gene_or_gene_product
genes	O
including	O
oncogenes	O
associated	O
with	O
lymphomas	O
.	O
<EOS>	B-X
DNA	B-X
damage	B-X
,	B-X
rearrangement	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
the	B-X
human	B-X
genome	B-X
are	B-X
the	B-X
basis	B-X
of	B-X
carcinogenesis	B-X
and	B-X
thought	B-X
to	B-X
be	B-X
avoided	B-X
at	B-X
all	B-X
costs	B-X
.	B-X
Both	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
diversify	B-X
their	B-X
antigen	B-X
receptors	B-X
through	B-X
RAG1/2	B-X
mediated	B-X
recombination	B-X
,	B-X
but	B-X
B	B-X
cells	B-X
undergo	B-X
two	B-X
additional	B-X
processes	B-X
--	B-X
somatic	B-X
hypermutation	B-X
(	B-X
SHM	B-X
)	B-X
and	B-X
class-switch	B-X
recombination	B-X
(	B-X
CSR	B-X
)	B-X
,	B-X
both	B-X
initiated	B-X
by	B-X
activation-induced	B-X
cytidine	B-X
deaminase	B-X
(	B-X
AID	B-X
)	B-X
.	B-X
AID	B-X
deaminates	B-X
cytidines	B-X
in	B-X
DNA	B-X
resulting	B-X
in	B-X
U	B-X
:	B-X
G	B-X
mismatches	B-X
that	B-X
are	B-X
processed	B-X
into	B-X
point	B-X
mutations	B-X
in	B-X
SHM	B-X
or	B-X
double-strand	B-X
breaks	B-X
in	B-X
CSR	B-X
.	B-X
Although	B-X
AID	B-X
activity	B-X
is	B-X
focused	B-X
at	B-X
Immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
gene	B-X
loci	B-X
,	B-X
it	B-X
also	B-X
targets	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
non-Ig	B-X
genes	B-X
including	B-X
oncogenes	B-X
associated	B-X
with	B-X
lymphomas	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
AID	B-X
regulation	B-X
,	B-X
targeting	B-X
,	B-X
and	B-X
initiation	B-X
of	B-X
CSR	B-X
and	B-X
SHM	B-X
,	B-X
as	B-X
well	B-X
as	B-X
AID	B-X
's	B-X
role	B-X
in	B-X
generating	B-X
chromosome	B-X
translocations	B-X
that	B-X
contribute	B-X
to	B-X
lymphomagenesis	B-X
.	B-X

Here	O
,	O
we	O
review	O
the	O
molecular	O
basis	O
of	O
AID	B-Gene_or_gene_product
regulation	O
,	O
targeting	O
,	O
and	O
initiation	O
of	O
CSR	O
and	O
SHM	O
,	O
as	O
well	O
as	O
AID	B-Gene_or_gene_product
'	O
s	O
role	O
in	O
generating	O
chromosome	O
translocations	O
that	O
contribute	O
to	O
lymphomagenesis	O
.	O

Incidence	O
of	O
BRAF	B-Gene_or_gene_product
p	O
.	O
Val600Glu	O
and	O
p	O
.	O
Val600Lys	O
mutations	O
in	O
a	O
consecutive	O
series	O
of	O
183	O
metastatic	O
melanoma	O
patients	O
from	O
a	O
high	O
incidence	O
region	O
.	O

AIM	O
:	O
Approximately	O
40	O
-	O
60	O
%	O
of	O
melanomas	O
from	O
Caucasian	O
populations	O
carry	O
activating	O
mutations	O
in	O
the	O
BRAF	B-Gene_or_gene_product
oncogene	O
,	O
with	O
the	O
most	O
common	O
being	O
the	O
p	O
.	O
Val600Glu	O
(	O
V600E	O
)	O
hotspot	O
mutation	O
in	O
exon	O
15	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
of	O
the	O
less	O
common	O
p	O
.	O
Val600Lys	O
(	O
V600K	O
)	O
mutation	O
in	O
metastatic	O
melanoma	O
from	O
a	O
high	O
incidence	O
region	O
.	O
<EOS>	B-X
Approximately	B-X
40-60	B-X
%	B-X
of	B-X
melanomas	B-X
from	B-X
Caucasian	B-X
populations	B-X
carry	B-X
activating	B-X
mutations	B-X
in	B-X
the	B-X
BRAF	B-X
oncogene	B-X
,	B-X
with	B-X
the	B-X
most	B-X
common	B-X
being	B-X
the	B-X
p.Val600Glu	B-X
(	B-X
V600E	B-X
)	B-X
hotspot	B-X
mutation	B-X
in	B-X
exon	B-X
15	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
frequency	B-X
of	B-X
the	B-X
less	B-X
common	B-X
p.Val600Lys	B-X
(	B-X
V600K	B-X
)	B-X
mutation	B-X
in	B-X
metastatic	B-X
melanoma	B-X
from	B-X
a	B-X
high	B-X
incidence	B-X
region	B-X
.	B-X

METHOD	O
:	O
Dideoxy	O
sequencing	O
and	O
fluorescent	O
single	O
strand	O
conformation	O
analysis	O
were	O
used	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
15	O
of	O
BRAF	B-Gene_or_gene_product
in	O
183	O
cases	O
of	O
metastatic	O
melanoma	O
.	O
<EOS>	B-X
Approximately	B-X
40-60	B-X
%	B-X
of	B-X
melanomas	B-X
from	B-X
Caucasian	B-X
populations	B-X
carry	B-X
activating	B-X
mutations	B-X
in	B-X
the	B-X
BRAF	B-X
oncogene	B-X
,	B-X
with	B-X
the	B-X
most	B-X
common	B-X
being	B-X
the	B-X
p.Val600Glu	B-X
(	B-X
V600E	B-X
)	B-X
hotspot	B-X
mutation	B-X
in	B-X
exon	B-X
15	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
frequency	B-X
of	B-X
the	B-X
less	B-X
common	B-X
p.Val600Lys	B-X
(	B-X
V600K	B-X
)	B-X
mutation	B-X
in	B-X
metastatic	B-X
melanoma	B-X
from	B-X
a	B-X
high	B-X
incidence	B-X
region	B-X
.	B-X

RESULTS	O
:	O
The	O
overall	O
incidence	O
of	O
BRAF	B-Gene_or_gene_product
mutation	O
(	O
89	O
/	O
183	O
,	O
49	O
%	O
)	O
was	O
very	O
similar	O
to	O
other	O
large	O
studies	O
of	O
Caucasian	O
populations	O
.	O
<EOS>	B-X
Approximately	B-X
40-60	B-X
%	B-X
of	B-X
melanomas	B-X
from	B-X
Caucasian	B-X
populations	B-X
carry	B-X
activating	B-X
mutations	B-X
in	B-X
the	B-X
BRAF	B-X
oncogene	B-X
,	B-X
with	B-X
the	B-X
most	B-X
common	B-X
being	B-X
the	B-X
p.Val600Glu	B-X
(	B-X
V600E	B-X
)	B-X
hotspot	B-X
mutation	B-X
in	B-X
exon	B-X
15	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
frequency	B-X
of	B-X
the	B-X
less	B-X
common	B-X
p.Val600Lys	B-X
(	B-X
V600K	B-X
)	B-X
mutation	B-X
in	B-X
metastatic	B-X
melanoma	B-X
from	B-X
a	B-X
high	B-X
incidence	B-X
region	B-X
.	B-X

However	O
,	O
the	O
frequency	O
of	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
was	O
higher	O
than	O
in	O
most	O
other	O
studies	O
and	O
comprised	O
almost	O
one	O
-	O
third	O
of	O
all	O
BRAF	B-Gene_or_gene_product
mutations	O
in	O
our	O
cohort	O
(	O
27	O
/	O
89	O
,	O
30	O
%	O
)	O
.	O

CONCLUSION	O
:	O
BRAF	B-Gene_or_gene_product
p	O
.	O
Val600Lys	O
mutations	O
were	O
present	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
this	O
cohort	O
of	O
metastatic	O
melanoma	O
patients	O
(	O
27	O
/	O
183	O
,	O
15	O
%	O
)	O
.	O

Assays	O
used	O
to	O
screen	O
for	O
BRAF	B-Gene_or_gene_product
mutations	O
in	O
the	O
clinic	O
should	O
be	O
robust	O
enough	O
to	O
detect	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
,	O
as	O
this	O
may	O
have	O
therapeutic	O
implications	O
.	O

Alterations	O
in	O
carbohydrate	O
metabolism	O
in	O
canine	O
lymphoma	O
.	O
<EOS>	B-X
Following	B-X
an	B-X
overnight	B-X
fast	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
14	B-X
dogs	B-X
with	B-X
previously	B-X
untreated	B-X
lymphoma	B-X
before	B-X
and	B-X
5	B-X
,	B-X
15	B-X
,	B-X
30	B-X
,	B-X
45	B-X
,	B-X
60	B-X
,	B-X
and	B-X
90	B-X
minutes	B-X
following	B-X
an	B-X
intravenous	B-X
challenge	B-X
with	B-X
500	B-X
mg/kg	B-X
dextrose	B-X
.	B-X
Dogs	B-X
with	B-X
lymphoma	B-X
had	B-X
similar	B-X
glucose	B-X
tolerance	B-X
curves	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Lactate	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
all	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Rise	B-X
in	B-X
lactate	B-X
concentrations	B-X
over	B-X
baseline	B-X
levels	B-X
in	B-X
the	B-X
first	B-X
30	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.011	B-X
)	B-X
.	B-X
Insulin	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
the	B-X
5-	B-X
,	B-X
45-	B-X
,	B-X
60-	B-X
,	B-X
and	B-X
90-minute	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Rise	B-X
in	B-X
insulin	B-X
concentrations	B-X
over	B-X
baseline	B-X
in	B-X
the	B-X
first	B-X
5	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
also	B-X
significantly	B-X
greater	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.021	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
carbohydrate	B-X
metabolism	B-X
is	B-X
altered	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
alterations	B-X
parallel	B-X
those	B-X
observed	B-X
in	B-X
human	B-X
patients	B-X
suffering	B-X
from	B-X
cancer	B-X
cachexia	B-X
making	B-X
canine	B-X
lymphoma	B-X
a	B-X
potential	B-X
model	B-X
for	B-X
further	B-X
study	B-X
of	B-X
the	B-X
pathogenesis	B-X
and	B-X
therapy	B-X
of	B-X
cancer	B-X
cachexia	B-X
.	B-X

Following	O
an	O
overnight	O
fast	O
,	O
blood	O
samples	O
were	O
obtained	O
from	O
14	O
dogs	O
with	O
previously	O
untreated	O
lymphoma	O
before	O
and	O
5	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
and	O
90	O
minutes	O
following	O
an	O
intravenous	O
challenge	O
with	O
500	O
mg	O
/	O
kg	O
dextrose	O
.	O
<EOS>	B-X
Following	B-X
an	B-X
overnight	B-X
fast	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
14	B-X
dogs	B-X
with	B-X
previously	B-X
untreated	B-X
lymphoma	B-X
before	B-X
and	B-X
5	B-X
,	B-X
15	B-X
,	B-X
30	B-X
,	B-X
45	B-X
,	B-X
60	B-X
,	B-X
and	B-X
90	B-X
minutes	B-X
following	B-X
an	B-X
intravenous	B-X
challenge	B-X
with	B-X
500	B-X
mg/kg	B-X
dextrose	B-X
.	B-X
Samples	B-X
were	B-X
assayed	B-X
for	B-X
glucose	B-X
,	B-X
lactate	B-X
,	B-X
and	B-X
insulin	B-X
concentrations	B-X
and	B-X
compared	B-X
statistically	B-X
with	B-X
ten	B-X
control	B-X
dogs	B-X
of	B-X
similar	B-X
weight	B-X
and	B-X
age	B-X
undergoing	B-X
an	B-X
identical	B-X
dextrose	B-X
challenge	B-X
.	B-X
Dogs	B-X
with	B-X
lymphoma	B-X
had	B-X
similar	B-X
glucose	B-X
tolerance	B-X
curves	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Lactate	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
all	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Rise	B-X
in	B-X
lactate	B-X
concentrations	B-X
over	B-X
baseline	B-X
levels	B-X
in	B-X
the	B-X
first	B-X
30	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.011	B-X
)	B-X
.	B-X
Insulin	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
the	B-X
5-	B-X
,	B-X
45-	B-X
,	B-X
60-	B-X
,	B-X
and	B-X
90-minute	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Rise	B-X
in	B-X
insulin	B-X
concentrations	B-X
over	B-X
baseline	B-X
in	B-X
the	B-X
first	B-X
5	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
also	B-X
significantly	B-X
greater	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.021	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
carbohydrate	B-X
metabolism	B-X
is	B-X
altered	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
alterations	B-X
parallel	B-X
those	B-X
observed	B-X
in	B-X
human	B-X
patients	B-X
suffering	B-X
from	B-X
cancer	B-X
cachexia	B-X
making	B-X
canine	B-X
lymphoma	B-X
a	B-X
potential	B-X
model	B-X
for	B-X
further	B-X
study	B-X
of	B-X
the	B-X
pathogenesis	B-X
and	B-X
therapy	B-X
of	B-X
cancer	B-X
cachexia	B-X
.	B-X

Samples	O
were	O
assayed	O
for	O
glucose	O
,	O
lactate	O
,	O
and	O
insulin	B-Gene_or_gene_product
concentrations	O
and	O
compared	O
statistically	O
with	O
ten	O
control	O
dogs	O
of	O
similar	O
weight	O
and	O
age	O
undergoing	O
an	O
identical	O
dextrose	O
challenge	O
.	O
<EOS>	B-X
Following	B-X
an	B-X
overnight	B-X
fast	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
14	B-X
dogs	B-X
with	B-X
previously	B-X
untreated	B-X
lymphoma	B-X
before	B-X
and	B-X
5	B-X
,	B-X
15	B-X
,	B-X
30	B-X
,	B-X
45	B-X
,	B-X
60	B-X
,	B-X
and	B-X
90	B-X
minutes	B-X
following	B-X
an	B-X
intravenous	B-X
challenge	B-X
with	B-X
500	B-X
mg/kg	B-X
dextrose	B-X
.	B-X
Samples	B-X
were	B-X
assayed	B-X
for	B-X
glucose	B-X
,	B-X
lactate	B-X
,	B-X
and	B-X
insulin	B-X
concentrations	B-X
and	B-X
compared	B-X
statistically	B-X
with	B-X
ten	B-X
control	B-X
dogs	B-X
of	B-X
similar	B-X
weight	B-X
and	B-X
age	B-X
undergoing	B-X
an	B-X
identical	B-X
dextrose	B-X
challenge	B-X
.	B-X
Dogs	B-X
with	B-X
lymphoma	B-X
had	B-X
similar	B-X
glucose	B-X
tolerance	B-X
curves	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Lactate	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
all	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Rise	B-X
in	B-X
lactate	B-X
concentrations	B-X
over	B-X
baseline	B-X
levels	B-X
in	B-X
the	B-X
first	B-X
30	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.011	B-X
)	B-X
.	B-X
Insulin	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
the	B-X
5-	B-X
,	B-X
45-	B-X
,	B-X
60-	B-X
,	B-X
and	B-X
90-minute	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Rise	B-X
in	B-X
insulin	B-X
concentrations	B-X
over	B-X
baseline	B-X
in	B-X
the	B-X
first	B-X
5	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
also	B-X
significantly	B-X
greater	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.021	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
carbohydrate	B-X
metabolism	B-X
is	B-X
altered	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
alterations	B-X
parallel	B-X
those	B-X
observed	B-X
in	B-X
human	B-X
patients	B-X
suffering	B-X
from	B-X
cancer	B-X
cachexia	B-X
making	B-X
canine	B-X
lymphoma	B-X
a	B-X
potential	B-X
model	B-X
for	B-X
further	B-X
study	B-X
of	B-X
the	B-X
pathogenesis	B-X
and	B-X
therapy	B-X
of	B-X
cancer	B-X
cachexia	B-X
.	B-X

Dogs	O
with	O
lymphoma	O
had	O
similar	O
glucose	O
tolerance	O
curves	O
when	O
compared	O
with	O
controls	O
.	O
<EOS>	B-X
Following	B-X
an	B-X
overnight	B-X
fast	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
14	B-X
dogs	B-X
with	B-X
previously	B-X
untreated	B-X
lymphoma	B-X
before	B-X
and	B-X
5	B-X
,	B-X
15	B-X
,	B-X
30	B-X
,	B-X
45	B-X
,	B-X
60	B-X
,	B-X
and	B-X
90	B-X
minutes	B-X
following	B-X
an	B-X
intravenous	B-X
challenge	B-X
with	B-X
500	B-X
mg/kg	B-X
dextrose	B-X
.	B-X
Samples	B-X
were	B-X
assayed	B-X
for	B-X
glucose	B-X
,	B-X
lactate	B-X
,	B-X
and	B-X
insulin	B-X
concentrations	B-X
and	B-X
compared	B-X
statistically	B-X
with	B-X
ten	B-X
control	B-X
dogs	B-X
of	B-X
similar	B-X
weight	B-X
and	B-X
age	B-X
undergoing	B-X
an	B-X
identical	B-X
dextrose	B-X
challenge	B-X
.	B-X
Dogs	B-X
with	B-X
lymphoma	B-X
had	B-X
similar	B-X
glucose	B-X
tolerance	B-X
curves	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Lactate	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
all	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Rise	B-X
in	B-X
lactate	B-X
concentrations	B-X
over	B-X
baseline	B-X
levels	B-X
in	B-X
the	B-X
first	B-X
30	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.011	B-X
)	B-X
.	B-X
Insulin	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
the	B-X
5-	B-X
,	B-X
45-	B-X
,	B-X
60-	B-X
,	B-X
and	B-X
90-minute	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Rise	B-X
in	B-X
insulin	B-X
concentrations	B-X
over	B-X
baseline	B-X
in	B-X
the	B-X
first	B-X
5	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
also	B-X
significantly	B-X
greater	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.021	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
carbohydrate	B-X
metabolism	B-X
is	B-X
altered	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
alterations	B-X
parallel	B-X
those	B-X
observed	B-X
in	B-X
human	B-X
patients	B-X
suffering	B-X
from	B-X
cancer	B-X
cachexia	B-X
making	B-X
canine	B-X
lymphoma	B-X
a	B-X
potential	B-X
model	B-X
for	B-X
further	B-X
study	B-X
of	B-X
the	B-X
pathogenesis	B-X
and	B-X
therapy	B-X
of	B-X
cancer	B-X
cachexia	B-X
.	B-X

Lactate	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
all	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	O
when	O
compared	O
with	O
controls	O
.	O

Rise	O
in	O
lactate	O
concentrations	O
over	O
baseline	O
levels	O
in	O
the	O
first	O
30	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
significantly	O
higher	O
in	O
dogs	O
with	O
lymphoma	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Insulin	B-Gene_or_gene_product
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
at	O
the	O
5	O
-	O
,	O
45	O
-	O
,	O
60	O
-	O
,	O
and	O
90	O
-	O
minute	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	O
.	O

Rise	O
in	O
insulin	B-Gene_or_gene_product
concentrations	O
over	O
baseline	O
in	O
the	O
first	O
5	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
also	O
significantly	O
greater	O
in	O
dogs	O
with	O
lymphoma	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
.	O

These	O
results	O
indicate	O
carbohydrate	O
metabolism	O
is	O
altered	O
in	O
dogs	O
with	O
lymphoma	O
.	O
<EOS>	B-X
After	B-X
a	B-X
12-hour	B-X
fast	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
27	B-X
dogs	B-X
with	B-X
previously	B-X
untreated	B-X
lymphoma	B-X
before	B-X
and	B-X
5	B-X
,	B-X
15	B-X
,	B-X
30	B-X
,	B-X
45	B-X
,	B-X
and	B-X
60	B-X
minutes	B-X
after	B-X
an	B-X
intravenous	B-X
(	B-X
IV	B-X
)	B-X
challenge	B-X
with	B-X
500	B-X
mg/kg	B-X
dextrose	B-X
.	B-X
All	B-X
dogs	B-X
achieved	B-X
a	B-X
complete	B-X
remission	B-X
.	B-X
Samples	B-X
were	B-X
assayed	B-X
for	B-X
glucose	B-X
,	B-X
lactate	B-X
,	B-X
and	B-X
insulin	B-X
concentrations	B-X
,	B-X
and	B-X
results	B-X
were	B-X
compared	B-X
statistically	B-X
with	B-X
those	B-X
from	B-X
16	B-X
normal	B-X
control	B-X
dogs	B-X
of	B-X
similar	B-X
weight	B-X
and	B-X
age	B-X
undergoing	B-X
an	B-X
identical	B-X
dextrose	B-X
challenge	B-X
before	B-X
and	B-X
3	B-X
weeks	B-X
after	B-X
receiving	B-X
one	B-X
dose	B-X
of	B-X
IV	B-X
doxorubicin	B-X
(	B-X
30	B-X
mg/m2	B-X
)	B-X
.	B-X
Glucose	B-X
,	B-X
lactate	B-X
,	B-X
and	B-X
insulin	B-X
concentrations	B-X
did	B-X
not	B-X
change	B-X
significantly	B-X
in	B-X
response	B-X
to	B-X
glucose	B-X
challenge	B-X
in	B-X
control	B-X
dogs	B-X
after	B-X
doxorubicin	B-X
chemotherapy	B-X
.	B-X
Lactate	B-X
and	B-X
insulin	B-X
concentrations	B-X
in	B-X
untreated	B-X
dogs	B-X
with	B-X
lymphoma	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
controls	B-X
.	B-X
This	B-X
hyperlactatemia	B-X
and	B-X
hyperinsulinemia	B-X
did	B-X
not	B-X
improve	B-X
when	B-X
dogs	B-X
with	B-X
lymphoma	B-X
were	B-X
put	B-X
into	B-X
remission	B-X
with	B-X
doxorubicin	B-X
chemotherapy	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
carbohydrate	B-X
metabolism	B-X
is	B-X
altered	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
,	B-X
and	B-X
that	B-X
these	B-X
abnormalities	B-X
do	B-X
not	B-X
improve	B-X
when	B-X
a	B-X
complete	B-X
remission	B-X
is	B-X
obtained	B-X
with	B-X
doxorubicin	B-X
chemotherapy	B-X
.	B-X

Many	O
of	O
these	O
alterations	O
parallel	O
those	O
observed	O
in	O
human	O
patients	O
suffering	O
from	O
cancer	O
cachexia	O
making	O
canine	O
lymphoma	O
a	O
potential	O
model	O
for	O
further	O
study	O
of	O
the	O
pathogenesis	O
and	O
therapy	O
of	O
cancer	O
cachexia	O
.	O
<EOS>	B-X
Following	B-X
an	B-X
overnight	B-X
fast	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
14	B-X
dogs	B-X
with	B-X
previously	B-X
untreated	B-X
lymphoma	B-X
before	B-X
and	B-X
5	B-X
,	B-X
15	B-X
,	B-X
30	B-X
,	B-X
45	B-X
,	B-X
60	B-X
,	B-X
and	B-X
90	B-X
minutes	B-X
following	B-X
an	B-X
intravenous	B-X
challenge	B-X
with	B-X
500	B-X
mg/kg	B-X
dextrose	B-X
.	B-X
Dogs	B-X
with	B-X
lymphoma	B-X
had	B-X
similar	B-X
glucose	B-X
tolerance	B-X
curves	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Lactate	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
all	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
when	B-X
compared	B-X
with	B-X
controls	B-X
.	B-X
Rise	B-X
in	B-X
lactate	B-X
concentrations	B-X
over	B-X
baseline	B-X
levels	B-X
in	B-X
the	B-X
first	B-X
30	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.011	B-X
)	B-X
.	B-X
Insulin	B-X
concentrations	B-X
were	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0.001	B-X
)	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
the	B-X
5-	B-X
,	B-X
45-	B-X
,	B-X
60-	B-X
,	B-X
and	B-X
90-minute	B-X
time	B-X
periods	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Rise	B-X
in	B-X
insulin	B-X
concentrations	B-X
over	B-X
baseline	B-X
in	B-X
the	B-X
first	B-X
5	B-X
minutes	B-X
of	B-X
the	B-X
glucose	B-X
tolerance	B-X
test	B-X
were	B-X
also	B-X
significantly	B-X
greater	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
(	B-X
P	B-X
=	B-X
0.021	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
carbohydrate	B-X
metabolism	B-X
is	B-X
altered	B-X
in	B-X
dogs	B-X
with	B-X
lymphoma	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
alterations	B-X
parallel	B-X
those	B-X
observed	B-X
in	B-X
human	B-X
patients	B-X
suffering	B-X
from	B-X
cancer	B-X
cachexia	B-X
making	B-X
canine	B-X
lymphoma	B-X
a	B-X
potential	B-X
model	B-X
for	B-X
further	B-X
study	B-X
of	B-X
the	B-X
pathogenesis	B-X
and	B-X
therapy	B-X
of	B-X
cancer	B-X
cachexia	B-X
.	B-X

Members	O
of	O
the	O
src	B-Gene_or_gene_product
and	O
ras	B-Gene_or_gene_product
oncogene	O
families	O
supplant	O
the	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
requirement	O
of	O
BALB	O
/	O
MK	O
-	O
2	O
keratinocytes	O
and	O
induce	O
distinct	O
alterations	O
in	O
their	O
terminal	O
differentiation	O
program	O
.	O
<EOS>	B-X
BALB-/MK-2	B-X
mouse	B-X
epidermal	B-X
keratinocytes	B-X
required	B-X
epidermal	B-X
growth	B-X
factor	B-X
for	B-X
proliferation	B-X
and	B-X
terminally	B-X
differentiated	B-X
in	B-X
response	B-X
to	B-X
high	B-X
Ca2+	B-X
concentration	B-X
.	B-X
Infection	B-X
with	B-X
retroviruses	B-X
containing	B-X
transforming	B-X
genes	B-X
of	B-X
the	B-X
src	B-X
and	B-X
ras	B-X
oncogene	B-X
families	B-X
led	B-X
to	B-X
rapid	B-X
loss	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
dependence	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
accompanied	B-X
by	B-X
alterations	B-X
in	B-X
cellular	B-X
morphology	B-X
.	B-X
The	B-X
virus-altered	B-X
cells	B-X
continued	B-X
to	B-X
proliferate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
high	B-X
levels	B-X
of	B-X
extracellular	B-X
calcium	B-X
but	B-X
exhibited	B-X
alterations	B-X
in	B-X
normal	B-X
keratinocyte	B-X
terminal	B-X
differentiation	B-X
that	B-X
appear	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
the	B-X
particular	B-X
oncogene	B-X
.	B-X
These	B-X
alterations	B-X
bore	B-X
similarities	B-X
to	B-X
abnormalities	B-X
in	B-X
differentiation	B-X
observed	B-X
in	B-X
naturally	B-X
occurring	B-X
squamous	B-X
epithelial	B-X
malignancies	B-X
.	B-X

BALB	O
-	O
/	O
MK	O
-	O
2	O
mouse	O
epidermal	O
keratinocytes	O
required	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
for	O
proliferation	O
and	O
terminally	O
differentiated	O
in	O
response	O
to	O
high	O
Ca2	O
+	O
concentration	O
.	O
<EOS>	B-X
BALB-/MK-2	B-X
mouse	B-X
epidermal	B-X
keratinocytes	B-X
required	B-X
epidermal	B-X
growth	B-X
factor	B-X
for	B-X
proliferation	B-X
and	B-X
terminally	B-X
differentiated	B-X
in	B-X
response	B-X
to	B-X
high	B-X
Ca2+	B-X
concentration	B-X
.	B-X
Infection	B-X
with	B-X
retroviruses	B-X
containing	B-X
transforming	B-X
genes	B-X
of	B-X
the	B-X
src	B-X
and	B-X
ras	B-X
oncogene	B-X
families	B-X
led	B-X
to	B-X
rapid	B-X
loss	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
dependence	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
accompanied	B-X
by	B-X
alterations	B-X
in	B-X
cellular	B-X
morphology	B-X
.	B-X
The	B-X
virus-altered	B-X
cells	B-X
continued	B-X
to	B-X
proliferate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
high	B-X
levels	B-X
of	B-X
extracellular	B-X
calcium	B-X
but	B-X
exhibited	B-X
alterations	B-X
in	B-X
normal	B-X
keratinocyte	B-X
terminal	B-X
differentiation	B-X
that	B-X
appear	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
the	B-X
particular	B-X
oncogene	B-X
.	B-X

Infection	O
with	O
retroviruses	O
containing	O
transforming	O
genes	O
of	O
the	O
src	B-Gene_or_gene_product
and	O
ras	B-Gene_or_gene_product
oncogene	O
families	O
led	O
to	O
rapid	O
loss	O
of	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
dependence	O
,	O
in	O
some	O
cases	O
,	O
accompanied	O
by	O
alterations	O
in	O
cellular	O
morphology	O
.	O
<EOS>	B-X
BALB-/MK-2	B-X
mouse	B-X
epidermal	B-X
keratinocytes	B-X
required	B-X
epidermal	B-X
growth	B-X
factor	B-X
for	B-X
proliferation	B-X
and	B-X
terminally	B-X
differentiated	B-X
in	B-X
response	B-X
to	B-X
high	B-X
Ca2+	B-X
concentration	B-X
.	B-X
Infection	B-X
with	B-X
retroviruses	B-X
containing	B-X
transforming	B-X
genes	B-X
of	B-X
the	B-X
src	B-X
and	B-X
ras	B-X
oncogene	B-X
families	B-X
led	B-X
to	B-X
rapid	B-X
loss	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
dependence	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
accompanied	B-X
by	B-X
alterations	B-X
in	B-X
cellular	B-X
morphology	B-X
.	B-X
The	B-X
virus-altered	B-X
cells	B-X
continued	B-X
to	B-X
proliferate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
high	B-X
levels	B-X
of	B-X
extracellular	B-X
calcium	B-X
but	B-X
exhibited	B-X
alterations	B-X
in	B-X
normal	B-X
keratinocyte	B-X
terminal	B-X
differentiation	B-X
that	B-X
appear	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
the	B-X
particular	B-X
oncogene	B-X
.	B-X
These	B-X
alterations	B-X
bore	B-X
similarities	B-X
to	B-X
abnormalities	B-X
in	B-X
differentiation	B-X
observed	B-X
in	B-X
naturally	B-X
occurring	B-X
squamous	B-X
epithelial	B-X
malignancies	B-X
.	B-X

The	O
virus	O
-	O
altered	O
cells	O
continued	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
high	O
levels	O
of	O
extracellular	O
calcium	O
but	O
exhibited	O
alterations	O
in	O
normal	O
keratinocyte	O
terminal	O
differentiation	O
that	O
appear	O
to	O
be	O
specific	O
to	O
the	O
particular	O
oncogene	O
.	O

These	O
alterations	O
bore	O
similarities	O
to	O
abnormalities	O
in	O
differentiation	O
observed	O
in	O
naturally	O
occurring	O
squamous	O
epithelial	O
malignancies	O
.	O
<EOS>	B-X
Infection	B-X
with	B-X
retroviruses	B-X
containing	B-X
transforming	B-X
genes	B-X
of	B-X
the	B-X
src	B-X
and	B-X
ras	B-X
oncogene	B-X
families	B-X
led	B-X
to	B-X
rapid	B-X
loss	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
dependence	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
accompanied	B-X
by	B-X
alterations	B-X
in	B-X
cellular	B-X
morphology	B-X
.	B-X
The	B-X
virus-altered	B-X
cells	B-X
continued	B-X
to	B-X
proliferate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
high	B-X
levels	B-X
of	B-X
extracellular	B-X
calcium	B-X
but	B-X
exhibited	B-X
alterations	B-X
in	B-X
normal	B-X
keratinocyte	B-X
terminal	B-X
differentiation	B-X
that	B-X
appear	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
the	B-X
particular	B-X
oncogene	B-X
.	B-X
These	B-X
alterations	B-X
bore	B-X
similarities	B-X
to	B-X
abnormalities	B-X
in	B-X
differentiation	B-X
observed	B-X
in	B-X
naturally	B-X
occurring	B-X
squamous	B-X
epithelial	B-X
malignancies	B-X
.	B-X

Experimental	O
drug	O
therapy	O
of	O
peritumoral	O
brain	O
edema	O
.	O
<EOS>	B-X
Four	B-X
drugs	B-X
with	B-X
potential	B-X
anti-peritumoral	B-X
brain	B-X
edema	B-X
activity	B-X
were	B-X
studied	B-X
using	B-X
the	B-X
VX2	B-X
rabbit	B-X
brain	B-X
tumor	B-X
model	B-X
.	B-X
Meclofenamate	B-X
and	B-X
indomethacin	B-X
were	B-X
tested	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
confirm	B-X
recent	B-X
reports	B-X
of	B-X
anti-edema	B-X
activity	B-X
in	B-X
non	B-X
steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
(	B-X
NSAID	B-X
's	B-X
)	B-X
.	B-X
The	B-X
protein	B-X
and	B-X
water	B-X
component	B-X
of	B-X
brain	B-X
edema	B-X
were	B-X
indirectly	B-X
quantitated	B-X
.	B-X
None	B-X
of	B-X
the	B-X
test	B-X
drugs	B-X
demonstrated	B-X
significant	B-X
anti-edema	B-X
activity	B-X
.	B-X
This	B-X
work	B-X
does	B-X
not	B-X
confirm	B-X
reports	B-X
that	B-X
NSAID	B-X
's	B-X
have	B-X
anti-edema	B-X
activity	B-X
and	B-X
suggests	B-X
that	B-X
there	B-X
may	B-X
be	B-X
no	B-X
correlation	B-X
between	B-X
'angiostatic	B-X
'	B-X
and	B-X
anti-edema	B-X
activity	B-X
in	B-X
certain	B-X
steroid	B-X
compounds	B-X
.	B-X

Four	O
drugs	O
with	O
potential	O
anti	O
-	O
peritumoral	O
brain	O
edema	O
activity	O
were	O
studied	O
using	O
the	O
VX2	O
rabbit	O
brain	O
tumor	O
model	O
.	O
<EOS>	B-X
Four	B-X
drugs	B-X
with	B-X
potential	B-X
anti-peritumoral	B-X
brain	B-X
edema	B-X
activity	B-X
were	B-X
studied	B-X
using	B-X
the	B-X
VX2	B-X
rabbit	B-X
brain	B-X
tumor	B-X
model	B-X
.	B-X
Meclofenamate	B-X
and	B-X
indomethacin	B-X
were	B-X
tested	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
confirm	B-X
recent	B-X
reports	B-X
of	B-X
anti-edema	B-X
activity	B-X
in	B-X
non	B-X
steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
(	B-X
NSAID	B-X
's	B-X
)	B-X
.	B-X
The	B-X
protein	B-X
and	B-X
water	B-X
component	B-X
of	B-X
brain	B-X
edema	B-X
were	B-X
indirectly	B-X
quantitated	B-X
.	B-X
None	B-X
of	B-X
the	B-X
test	B-X
drugs	B-X
demonstrated	B-X
significant	B-X
anti-edema	B-X
activity	B-X
.	B-X
This	B-X
work	B-X
does	B-X
not	B-X
confirm	B-X
reports	B-X
that	B-X
NSAID	B-X
's	B-X
have	B-X
anti-edema	B-X
activity	B-X
and	B-X
suggests	B-X
that	B-X
there	B-X
may	B-X
be	B-X
no	B-X
correlation	B-X
between	B-X
'angiostatic	B-X
'	B-X
and	B-X
anti-edema	B-X
activity	B-X
in	B-X
certain	B-X
steroid	B-X
compounds	B-X
.	B-X

Meclofenamate	O
and	O
indomethacin	O
were	O
tested	O
in	O
an	O
attempt	O
to	O
confirm	O
recent	O
reports	O
of	O
anti	O
-	O
edema	O
activity	O
in	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
'	O
s	O
)	O
.	O

The	O
'	O
angiostatic	O
'	O
steroids	O
17	O
hydroxyprogesterone	O
and	O
epicortisol	O
were	O
tested	O
because	O
of	O
their	O
lack	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
effects	O
and	O
their	O
structural	O
similarity	O
to	O
glucocorticoids	O
.	O
<EOS>	B-X
Meclofenamate	B-X
and	B-X
indomethacin	B-X
were	B-X
tested	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
confirm	B-X
recent	B-X
reports	B-X
of	B-X
anti-edema	B-X
activity	B-X
in	B-X
non	B-X
steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
(	B-X
NSAID	B-X
's	B-X
)	B-X
.	B-X
The	B-X
'angiostatic	B-X
'	B-X
steroids	B-X
17	B-X
hydroxyprogesterone	B-X
and	B-X
epicortisol	B-X
were	B-X
tested	B-X
because	B-X
of	B-X
their	B-X
lack	B-X
of	B-X
glucocorticoid	B-X
and	B-X
mineralocorticoid	B-X
effects	B-X
and	B-X
their	B-X
structural	B-X
similarity	B-X
to	B-X
glucocorticoids	B-X
.	B-X
This	B-X
work	B-X
does	B-X
not	B-X
confirm	B-X
reports	B-X
that	B-X
NSAID	B-X
's	B-X
have	B-X
anti-edema	B-X
activity	B-X
and	B-X
suggests	B-X
that	B-X
there	B-X
may	B-X
be	B-X
no	B-X
correlation	B-X
between	B-X
'angiostatic	B-X
'	B-X
and	B-X
anti-edema	B-X
activity	B-X
in	B-X
certain	B-X
steroid	B-X
compounds	B-X
.	B-X

The	O
protein	O
and	O
water	O
component	O
of	O
brain	O
edema	O
were	O
indirectly	O
quantitated	O
.	O
<EOS>	B-X
Four	B-X
drugs	B-X
with	B-X
potential	B-X
anti-peritumoral	B-X
brain	B-X
edema	B-X
activity	B-X
were	B-X
studied	B-X
using	B-X
the	B-X
VX2	B-X
rabbit	B-X
brain	B-X
tumor	B-X
model	B-X
.	B-X
Meclofenamate	B-X
and	B-X
indomethacin	B-X
were	B-X
tested	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
confirm	B-X
recent	B-X
reports	B-X
of	B-X
anti-edema	B-X
activity	B-X
in	B-X
non	B-X
steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
(	B-X
NSAID	B-X
's	B-X
)	B-X
.	B-X
The	B-X
protein	B-X
and	B-X
water	B-X
component	B-X
of	B-X
brain	B-X
edema	B-X
were	B-X
indirectly	B-X
quantitated	B-X
.	B-X
None	B-X
of	B-X
the	B-X
test	B-X
drugs	B-X
demonstrated	B-X
significant	B-X
anti-edema	B-X
activity	B-X
.	B-X
This	B-X
work	B-X
does	B-X
not	B-X
confirm	B-X
reports	B-X
that	B-X
NSAID	B-X
's	B-X
have	B-X
anti-edema	B-X
activity	B-X
and	B-X
suggests	B-X
that	B-X
there	B-X
may	B-X
be	B-X
no	B-X
correlation	B-X
between	B-X
'angiostatic	B-X
'	B-X
and	B-X
anti-edema	B-X
activity	B-X
in	B-X
certain	B-X
steroid	B-X
compounds	B-X
.	B-X

None	O
of	O
the	O
test	O
drugs	O
demonstrated	O
significant	O
anti	O
-	O
edema	O
activity	O
.	O
<EOS>	B-X
Four	B-X
drugs	B-X
with	B-X
potential	B-X
anti-peritumoral	B-X
brain	B-X
edema	B-X
activity	B-X
were	B-X
studied	B-X
using	B-X
the	B-X
VX2	B-X
rabbit	B-X
brain	B-X
tumor	B-X
model	B-X
.	B-X
Meclofenamate	B-X
and	B-X
indomethacin	B-X
were	B-X
tested	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
confirm	B-X
recent	B-X
reports	B-X
of	B-X
anti-edema	B-X
activity	B-X
in	B-X
non	B-X
steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
(	B-X
NSAID	B-X
's	B-X
)	B-X
.	B-X
The	B-X
'angiostatic	B-X
'	B-X
steroids	B-X
17	B-X
hydroxyprogesterone	B-X
and	B-X
epicortisol	B-X
were	B-X
tested	B-X
because	B-X
of	B-X
their	B-X
lack	B-X
of	B-X
glucocorticoid	B-X
and	B-X
mineralocorticoid	B-X
effects	B-X
and	B-X
their	B-X
structural	B-X
similarity	B-X
to	B-X
glucocorticoids	B-X
.	B-X
The	B-X
protein	B-X
and	B-X
water	B-X
component	B-X
of	B-X
brain	B-X
edema	B-X
were	B-X
indirectly	B-X
quantitated	B-X
.	B-X
None	B-X
of	B-X
the	B-X
test	B-X
drugs	B-X
demonstrated	B-X
significant	B-X
anti-edema	B-X
activity	B-X
.	B-X
This	B-X
work	B-X
does	B-X
not	B-X
confirm	B-X
reports	B-X
that	B-X
NSAID	B-X
's	B-X
have	B-X
anti-edema	B-X
activity	B-X
and	B-X
suggests	B-X
that	B-X
there	B-X
may	B-X
be	B-X
no	B-X
correlation	B-X
between	B-X
'angiostatic	B-X
'	B-X
and	B-X
anti-edema	B-X
activity	B-X
in	B-X
certain	B-X
steroid	B-X
compounds	B-X
.	B-X

This	O
work	O
does	O
not	O
confirm	O
reports	O
that	O
NSAID	O
'	O
s	O
have	O
anti	O
-	O
edema	O
activity	O
and	O
suggests	O
that	O
there	O
may	O
be	O
no	O
correlation	O
between	O
'	O
angiostatic	O
'	O
and	O
anti	O
-	O
edema	O
activity	O
in	O
certain	O
steroid	O
compounds	O
.	O
<EOS>	B-X
Medication	B-X
administration	B-X
accounts	B-X
for	B-X
40	B-X
%	B-X
of	B-X
the	B-X
nursing	B-X
clinical	B-X
activity	B-X
in	B-X
hospitals	B-X
and	B-X
nurses	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
granting	B-X
the	B-X
patient	B-X
safety	B-X
,	B-X
as	B-X
they	B-X
are	B-X
directly	B-X
responsible	B-X
for	B-X
the	B-X
patient	B-X
care	B-X
.	B-X
This	B-X
review	B-X
aims	B-X
at	B-X
analyzing	B-X
the	B-X
correlation	B-X
between	B-X
the	B-X
clinical	B-X
risk	B-X
management	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
medication	B-X
errors	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
shift	B-X
work	B-X
(	B-X
such	B-X
as	B-X
excessive	B-X
fatigue	B-X
and	B-X
sleep	B-X
deprivation	B-X
after	B-X
a	B-X
shift	B-X
in	B-X
hospital	B-X
)	B-X
on	B-X
inpatient	B-X
nurses	B-X
.	B-X
Office	B-X
workers	B-X
are	B-X
exposed	B-X
to	B-X
high	B-X
levels	B-X
of	B-X
sedentary	B-X
time	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
cardio-vascular	B-X
and	B-X
metabolic	B-X
health	B-X
risks	B-X
,	B-X
this	B-X
sedentary	B-X
time	B-X
may	B-X
have	B-X
musculoskeletal	B-X
and/or	B-X
cognitive	B-X
impacts	B-X
on	B-X
office	B-X
workers	B-X
.	B-X
Participants	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
undertook	B-X
two	B-X
hours	B-X
of	B-X
laboratory-based	B-X
sitting	B-X
computer	B-X
work	B-X
to	B-X
investigate	B-X
changes	B-X
in	B-X
discomfort	B-X
and	B-X
cognitive	B-X
function	B-X
(	B-X
sustained	B-X
attention	B-X
and	B-X
problem	B-X
solving	B-X
)	B-X
,	B-X
along	B-X
with	B-X
muscle	B-X
fatigue	B-X
,	B-X
movement	B-X
and	B-X
mental	B-X
state	B-X
.	B-X
There	B-X
were	B-X
no	B-X
substantial	B-X
correlations	B-X
between	B-X
discomfort	B-X
and	B-X
cognitive	B-X
function	B-X
.	B-X
The	B-X
observed	B-X
changes	B-X
suggest	B-X
prolonged	B-X
sitting	B-X
may	B-X
have	B-X
consequences	B-X
for	B-X
musculoskeletal	B-X
discomfort	B-X
and	B-X
cognitive	B-X
function	B-X
and	B-X
breaks	B-X
to	B-X
interrupt	B-X
prolonged	B-X
sitting	B-X
are	B-X
recommended	B-X
.	B-X

Identification	O
of	O
a	O
small	O
region	O
of	O
the	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
gene	O
product	O
that	O
is	O
sufficient	O
for	O
transforming	O
potential	O
and	O
growth	O
-	O
stimulating	O
activity	O
.	O

To	O
analyze	O
the	O
structure	O
-	O
function	O
relationship	O
for	O
the	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
protein	O
,	O
we	O
constructed	O
in	O
-	O
frame	O
insertion	O
and	O
deletion	O
mutants	O
of	O
the	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
gene	O
carried	O
by	O
FBJ	O
-	O
MuSV	O
,	O
and	O
expressed	O
them	O
in	O
chicken	O
primary	O
cells	O
using	O
retrovirus	O
vectors	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
the	O
ability	O
of	O
the	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
protein	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
and	O
to	O
stimulate	O
cellular	O
proliferation	O
of	O
chicken	O
neuroretinal	O
cells	O
.	O

The	O
mutant	O
which	O
retains	O
only	O
the	O
central	O
region	O
of	O
the	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
protein	O
(	O
Met111	O
-	O
Ile206	O
)	O
have	O
both	O
activities	O
,	O
but	O
the	O
mutants	O
which	O
have	O
deletions	O
in	O
this	O
region	O
,	O
and	O
one	O
of	O
the	O
mutants	O
that	O
has	O
a	O
four	O
amino	O
acid	O
insertion	O
in	O
it	O
,	O
lost	O
both	O
activities	O
.	O

The	O
central	O
region	O
that	O
is	O
sufficient	O
for	O
these	O
activities	O
includes	O
the	O
evolutionarily	O
highly	O
conserved	O
region	O
among	O
human	O
,	O
mouse	O
and	O
chicken	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
proteins	O
.	O

Additionally	O
,	O
this	O
sequence	O
shares	O
some	O
homology	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GCN4	B-Gene_or_gene_product
and	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
jun	I-Gene_or_gene_product
protein	O
.	O

The	O
truncated	O
fos	B-Gene_or_gene_product
protein	O
that	O
contains	O
only	O
part	O
of	O
the	O
central	O
region	O
is	O
not	O
phosphorylated	O
in	O
chicken	O
embryo	O
fibroblasts	O
,	O
indicating	O
that	O
phosphorylation	O
of	O
the	O
fos	B-Gene_or_gene_product
protein	O
is	O
not	O
necessary	O
for	O
the	O
transforming	O
activity	O
.	O
<EOS>	B-X
Cytokines	B-X
such	B-X
as	B-X
interleukin-1	B-X
beta	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
alter	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
hypothalamic-pituitary-adrenal	B-X
(	B-X
HPA	B-X
)	B-X
and	B-X
hypothalamic-pituitary-gonadal	B-X
(	B-X
HPG	B-X
)	B-X
axes	B-X
in	B-X
the	B-X
rat	B-X
.	B-X
The	B-X
present	B-X
study	B-X
sought	B-X
to	B-X
identify	B-X
some	B-X
of	B-X
these	B-X
sites	B-X
,	B-X
using	B-X
c-fos	B-X
protein	B-X
expression	B-X
as	B-X
an	B-X
index	B-X
of	B-X
cellular	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
attempted	B-X
to	B-X
determine	B-X
possible	B-X
differences	B-X
between	B-X
the	B-X
effects	B-X
of	B-X
peripheral	B-X
and	B-X
central	B-X
injection	B-X
of	B-X
IL-1	B-X
beta	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
specific	B-X
brain	B-X
areas	B-X
.	B-X
Thirty-microns	B-X
frozen	B-X
sections	B-X
were	B-X
cut	B-X
and	B-X
approximately	B-X
every	B-X
fourth	B-X
tissue	B-X
section	B-X
was	B-X
processed	B-X
for	B-X
c-fos	B-X
expression	B-X
by	B-X
an	B-X
avidin-biotin-peroxidase	B-X
method	B-X
.	B-X
infusion	B-X
of	B-X
the	B-X
cytokine	B-X
markedly	B-X
augmented	B-X
c-fos	B-X
expression	B-X
in	B-X
the	B-X
paraventricular	B-X
nucleus	B-X
(	B-X
PVN	B-X
)	B-X
and	B-X
the	B-X
arcuate	B-X
nucleus	B-X
(	B-X
ARC	B-X
)	B-X
of	B-X
the	B-X
hypothalamus	B-X
.	B-X
A	B-X
large	B-X
amount	B-X
of	B-X
CRF	B-X
cells	B-X
in	B-X
the	B-X
PVN	B-X
contained	B-X
labelled	B-X
c-fos	B-X
protein	B-X
(	B-X
as	B-X
measured	B-X
by	B-X
a	B-X
double	B-X
labelling	B-X
technique	B-X
)	B-X
,	B-X
which	B-X
indicates	B-X
that	B-X
CRF	B-X
perikarya	B-X
in	B-X
this	B-X
hypothalamic	B-X
region	B-X
are	B-X
activated	B-X
by	B-X
the	B-X
central	B-X
administration	B-X
of	B-X
IL-1	B-X
beta	B-X
.	B-X
injection	B-X
of	B-X
IL-1	B-X
beta	B-X
did	B-X
not	B-X
significantly	B-X
alter	B-X
c-fos	B-X
expression	B-X
in	B-X
the	B-X
PVN	B-X
or	B-X
the	B-X
ARC	B-X
of	B-X
the	B-X
hypothalamus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
increased	B-X
HPA	B-X
axis	B-X
activity	B-X
which	B-X
follows	B-X
the	B-X
peripheral	B-X
IL-1	B-X
beta	B-X
administration	B-X
,	B-X
a	B-X
phenomenon	B-X
previously	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
endogenous	B-X
CRF	B-X
,	B-X
does	B-X
not	B-X
require	B-X
immediate	B-X
activation	B-X
of	B-X
hypothalamic	B-X
CRF	B-X
perikarya	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
i.c.v.-injected	B-X
IL-1	B-X
beta	B-X
appears	B-X
to	B-X
activate	B-X
the	B-X
HPA	B-X
axis	B-X
through	B-X
a	B-X
stimulation	B-X
of	B-X
CRF	B-X
neurons	B-X
within	B-X
the	B-X
parvocellular	B-X
part	B-X
of	B-X
PVN	B-X
.	B-X

Inhibition	O
by	O
retinoic	O
acid	O
of	O
type	O
IV	O
collagenolysis	O
and	O
invasion	O
through	O
reconstituted	O
basement	O
membrane	O
by	O
metastatic	O
rat	O
mammary	O
adenocarcinoma	O
cells	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X

The	O
activity	O
of	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagenase	I-Gene_or_gene_product
,	O
which	O
enables	O
tumor	O
cells	O
to	O
degrade	O
collagen	B-Gene_or_gene_product
type	I-Gene_or_gene_product
IV	I-Gene_or_gene_product
found	O
in	O
the	O
subendothelial	O
basement	O
membrane	O
,	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
in	O
several	O
tumor	O
types	O
,	O
including	O
the	O
rat	O
13762NF	O
mammary	O
adenocarcinoma	O
cell	O
line	O
and	O
its	O
clones	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
These	B-X
two	B-X
enzymes	B-X
were	B-X
also	B-X
found	B-X
to	B-X
have	B-X
specificity	B-X
for	B-X
gelatin	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
all	O
-	O
trans	O
-	O
RA	O
)	O
and	O
other	O
retinoids	O
,	O
which	O
exhibit	O
antitumor	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
affect	O
the	O
collagenolytic	O
activity	O
of	O
metastatic	O
rat	O
13762NF	O
mammary	O
adenocarcinoma	O
cells	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

Cells	O
of	O
the	O
highly	O
metastatic	O
lung	O
-	O
colonizing	O
clone	O
MTF7	O
.	O
T35	O
.	O
3	O
,	O
derived	O
from	O
the	O
13762NF	O
cell	O
line	O
,	O
were	O
treated	O
for	O
3	O
days	O
with	O
0	O
.	O
1	O
,	O
1	O
,	O
or	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
,	O
harvested	O
,	O
and	O
seeded	O
on	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
extracellular	O
matrix	O
deposited	O
by	O
cultured	O
rat	O
lung	O
endothelial	O
cells	O
or	O
on	O
a	O
film	O
of	O
purified	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagen	I-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

The	O
amount	O
of	O
radioactivity	O
released	O
into	O
the	O
medium	O
during	O
the	O
subsequent	O
24	O
to	O
72	O
h	O
was	O
measured	O
,	O
and	O
it	O
was	O
found	O
that	O
all	O
-	O
trans	O
-	O
RA	O
treatment	O
inhibited	O
degradation	O
of	O
extracellular	O
matrix	O
and	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagen	I-Gene_or_gene_product
by	O
50	O
to	O
60	O
%	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
These	B-X
two	B-X
enzymes	B-X
were	B-X
also	B-X
found	B-X
to	B-X
have	B-X
specificity	B-X
for	B-X
gelatin	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

This	O
effect	O
was	O
observed	O
whether	O
the	O
cells	O
had	O
been	O
treated	O
with	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	O
-	O
free	O
medium	O
or	O
in	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
or	O
acid	O
-	O
treated	O
fetal	O
bovine	O
serum	O
.	O
<EOS>	B-X
In	B-X
general	B-X
,	B-X
Bovine	B-X
Serum	B-X
Albumin	B-X
(	B-X
BSA	B-X
)	B-X
is	B-X
treated	B-X
as	B-X
comparable	B-X
to	B-X
its	B-X
human	B-X
homologue	B-X
and	B-X
used	B-X
as	B-X
a	B-X
model	B-X
protein	B-X
for	B-X
fundamental	B-X
studies	B-X
since	B-X
it	B-X
is	B-X
available	B-X
in	B-X
high	B-X
amounts	B-X
and	B-X
well	B-X
understood	B-X
.	B-X
Carnosic	B-X
acid	B-X
(	B-X
CA	B-X
)	B-X
is	B-X
a	B-X
natural	B-X
phenolic	B-X
compound	B-X
with	B-X
several	B-X
biomedical	B-X
actions	B-X
.	B-X
This	B-X
work	B-X
was	B-X
performed	B-X
to	B-X
study	B-X
the	B-X
use	B-X
of	B-X
CA-loaded	B-X
polymeric	B-X
nanoparticles	B-X
to	B-X
improve	B-X
the	B-X
antitumor	B-X
activity	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
MCF-7	B-X
)	B-X
and	B-X
colon	B-X
cancer	B-X
cells	B-X
(	B-X
Caco-2	B-X
)	B-X
.	B-X
CA	B-X
was	B-X
encapsulated	B-X
in	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
BSA	B-X
)	B-X
,	B-X
chitosan	B-X
(	B-X
CH	B-X
)	B-X
,	B-X
and	B-X
cellulose	B-X
(	B-X
CL	B-X
)	B-X
nanoparticles	B-X
.	B-X
The	B-X
CA-loaded	B-X
BSA	B-X
nanoparticles	B-X
(	B-X
CA-BSA-NPs	B-X
)	B-X
revealed	B-X
the	B-X
most	B-X
promising	B-X
formula	B-X
as	B-X
it	B-X
showed	B-X
good	B-X
loading	B-X
capacity	B-X
and	B-X
the	B-X
best	B-X
release	B-X
rate	B-X
profile	B-X
as	B-X
the	B-X
drug	B-X
reached	B-X
80	B-X
%	B-X
after	B-X
10	B-X
h.	B-X
The	B-X
physicochemical	B-X
characterization	B-X
of	B-X
the	B-X
CA-BSA-NPs	B-X
and	B-X
empty	B-X
carrier	B-X
(	B-X
BSA-NPs	B-X
)	B-X
was	B-X
performed	B-X
by	B-X
the	B-X
particle	B-X
size	B-X
distribution	B-X
analysis	B-X
,	B-X
transmission	B-X
electron	B-X
microscopy	B-X
(	B-X
TEM	B-X
)	B-X
,	B-X
and	B-X
zeta	B-X
potential	B-X
.	B-X
The	B-X
cytotoxicity	B-X
assay	B-X
(	B-X
MTT	B-X
)	B-X
showed	B-X
elevated	B-X
antitumor	B-X
activity	B-X
of	B-X
CA-BSA-NPs	B-X
against	B-X
MCF-7	B-X
and	B-X
Caco-2	B-X
compared	B-X
to	B-X
free	B-X
CA	B-X
and	B-X
BSA-NPs	B-X
.	B-X
Moreover	B-X
,	B-X
apoptosis	B-X
test	B-X
data	B-X
showed	B-X
an	B-X
arrest	B-X
of	B-X
the	B-X
Caco-2	B-X
cells	B-X
at	B-X
G	B-X

The	O
growth	O
of	O
the	O
cells	O
was	O
not	O
inhibited	O
under	O
these	O
conditions	O
,	O
except	O
after	O
treatment	O
with	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	O
-	O
free	O
medium	O
.	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
central	B-X
role	B-X
of	B-X
growth	B-X
processes	B-X
(	B-X
distinct	B-X
from	B-X
cell	B-X
proliferation	B-X
)	B-X
in	B-X
morphogenesis	B-X
is	B-X
highlighted	B-X
and	B-X
the	B-X
limitations	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
basic	B-X
mechanisms	B-X
of	B-X
plant	B-X
growth	B-X
control	B-X
are	B-X
highlighted	B-X
.	B-X
Finally	B-X
,	B-X
an	B-X
attempt	B-X
is	B-X
made	B-X
to	B-X
demonstrate	B-X
how	B-X
sequential	B-X
local	B-X
co-ordination	B-X
of	B-X
growth	B-X
might	B-X
provide	B-X
an	B-X
interpretation	B-X
of	B-X
some	B-X
of	B-X
the	B-X
recent	B-X
observations	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
leaf	B-X
morphogenesis	B-X
.	B-X
The	B-X
bewildering	B-X
morphological	B-X
diversity	B-X
found	B-X
in	B-X
cells	B-X
is	B-X
one	B-X
of	B-X
the	B-X
starkest	B-X
illustrations	B-X
of	B-X
life	B-X
's	B-X
ability	B-X
to	B-X
self-organize	B-X
.	B-X
Yet	B-X
the	B-X
morphogenetic	B-X
mechanisms	B-X
that	B-X
produce	B-X
the	B-X
multifarious	B-X
shapes	B-X
of	B-X
cells	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
The	B-X
shared	B-X
similarities	B-X
between	B-X
the	B-X
walled	B-X
cells	B-X
of	B-X
prokaryotes	B-X
,	B-X
many	B-X
protists	B-X
,	B-X
fungi	B-X
,	B-X
and	B-X
plants	B-X
make	B-X
these	B-X
groups	B-X
particularly	B-X
appealing	B-X
to	B-X
begin	B-X
investigating	B-X
how	B-X
morphological	B-X
diversity	B-X
is	B-X
generated	B-X
at	B-X
the	B-X
cell	B-X
level	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
I	B-X
attempt	B-X
a	B-X
first	B-X
classification	B-X
of	B-X
the	B-X
different	B-X
modes	B-X
of	B-X
surface	B-X
deformation	B-X
used	B-X
by	B-X
walled	B-X
cells	B-X
.	B-X
Five	B-X
modes	B-X
of	B-X
deformation	B-X
were	B-X
identified	B-X
:	B-X
inextensional	B-X
bending	B-X
,	B-X
equi-area	B-X
shear	B-X
,	B-X
elastic	B-X
stretching	B-X
,	B-X
processive	B-X
intussusception	B-X
,	B-X
and	B-X
chemorheological	B-X
growth	B-X
.	B-X
The	B-X
greatest	B-X
morphogenetic	B-X
power	B-X
is	B-X
reached	B-X
with	B-X
the	B-X
processive	B-X
intussusception	B-X
and	B-X
chemorheological	B-X
growth	B-X
mechanisms	B-X
that	B-X
underlie	B-X
the	B-X
expansive	B-X
growth	B-X
of	B-X
walled	B-X
cells	B-X
.	B-X
A	B-X
comparison	B-X
of	B-X
these	B-X
two	B-X
growth	B-X
mechanisms	B-X
suggests	B-X
a	B-X
possible	B-X
way	B-X
to	B-X
tackle	B-X
the	B-X
complexity	B-X
behind	B-X
wall	B-X
growth	B-X
.	B-X

The	O
reduction	O
in	O
collagenolytic	O
activity	O
was	O
observed	O
in	O
viable	O
cells	O
as	O
well	O
as	O
in	O
conditioned	O
medium	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X

A	O
24	O
-	O
h	O
exposure	O
of	O
cells	O
to	O
all	O
-	O
trans	O
-	O
RA	O
was	O
sufficient	O
to	O
cause	O
a	O
30	O
%	O
decrease	O
in	O
the	O
collagenolytic	O
activity	O
,	O
and	O
this	O
inhibitory	O
effect	O
was	O
reversible	O
.	O

The	O
direct	O
addition	O
of	O
all	O
-	O
trans	O
-	O
RA	O
to	O
conditioned	O
medium	O
had	O
no	O
effect	O
on	O
secreted	O
collagenase	B-Gene_or_gene_product
activity	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

The	O
apparent	O
molecular	O
weights	O
of	O
the	O
collagenolytic	O
enzymes	O
were	O
determined	O
by	O
electrophoresis	O
of	O
cell	O
extracts	O
and	O
concentrated	O
conditioned	O
medium	O
in	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagen	I-Gene_or_gene_product
-	O
embedded	O
polyacrylamide	O
gels	O
followed	O
by	O
renaturation	O
and	O
activation	O
of	O
the	O
enzymes	O
within	O
the	O
gels	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
These	B-X
two	B-X
enzymes	B-X
were	B-X
also	B-X
found	B-X
to	B-X
have	B-X
specificity	B-X
for	B-X
gelatin	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X

Two	O
major	O
type	O
IV	O
collagenolytic	O
metalloproteinases	B-Gene_or_gene_product
exhibiting	O
molecular	O
weights	O
of	O
64	O
,	O
000	O
and	O
88	O
,	O
000	O
,	O
respectively	O
,	O
were	O
detected	O
by	O
this	O
method	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X

These	O
two	O
enzymes	O
were	O
also	O
found	O
to	O
have	O
specificity	O
for	O
gelatin	O
.	O
<EOS>	B-X
The	B-X
gelatinases	B-X
,	B-X
a	B-X
subgroup	B-X
of	B-X
the	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
superfamily	B-X
are	B-X
composed	B-X
of	B-X
two	B-X
members	B-X
;	B-X
MMP2	B-X
and	B-X
MMP9	B-X
.	B-X
They	B-X
are	B-X
known	B-X
to	B-X
degrade	B-X
gelatin	B-X
among	B-X
other	B-X
components	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
two	B-X
gelatinases	B-X
were	B-X
found	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
neural	B-X
crest	B-X
cell	B-X
migration	B-X
and	B-X
to	B-X
compensate	B-X
for	B-X
each	B-X
other	B-X
loss	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Comprehensive	B-X
analysis	B-X
of	B-X
the	B-X
skeleton	B-X
morphological	B-X
and	B-X
mechanical	B-X
parameters	B-X
at	B-X
postnatal	B-X
day	B-X
(	B-X
P	B-X
)	B-X
0	B-X
,	B-X
P21	B-X
,	B-X
3	B-X
months	B-X
(	B-X
M	B-X
)	B-X
and	B-X
8M	B-X
of	B-X
age	B-X
,	B-X
revealed	B-X
an	B-X
unexpected	B-X
distinct	B-X
role	B-X
for	B-X
each	B-X
gelatinase	B-X
;	B-X
MMP2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
involved	B-X
merely	B-X
in	B-X
intramembranous	B-X
ossification	B-X
which	B-X
led	B-X
to	B-X
a	B-X
smaller	B-X
skull	B-X
and	B-X
inferior	B-X
cortical	B-X
parameters	B-X
upon	B-X
its	B-X
loss	B-X
,	B-X
while	B-X
MMP9	B-X
was	B-X
found	B-X
to	B-X
affect	B-X
only	B-X
the	B-X
endochondral	B-X
ossification	B-X
process	B-X
,	B-X
which	B-X
led	B-X
to	B-X
shorter	B-X
long-bones	B-X
in	B-X
its	B-X
absence	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
dKO	B-X
mice	B-X
demonstrated	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
the	B-X
skull	B-X
and	B-X
long	B-X
bone	B-X
phenotypes	B-X
as	B-X
found	B-X
in	B-X
the	B-X
single-KOs	B-X
,	B-X
and	B-X
not	B-X
a	B-X
severer	B-X
additive	B-X
phenotype	B-X
.	B-X
Transcriptome	B-X
analysis	B-X
on	B-X
the	B-X
cortical	B-X
bone	B-X
,	B-X
the	B-X
growth	B-X
plate	B-X
and	B-X
the	B-X
skull	B-X
frontal	B-X
bone	B-X
,	B-X
found	B-X
many	B-X
genes	B-X
that	B-X
were	B-X
differentially	B-X
expressed	B-X
as	B-X
a	B-X
direct	B-X
or	B-X
indirect	B-X
result	B-X
of	B-X
MMP-loss	B-X
,	B-X
and	B-X
reinforced	B-X
the	B-X
specific	B-X
and	B-X
distinct	B-X
role	B-X
of	B-X
each	B-X
gelatinase	B-X
in	B-X
each	B-X
bone	B-X
type	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
although	B-X
both	B-X
gelatinases	B-X
share	B-X
the	B-X
same	B-X
substrates	B-X
and	B-X
are	B-X
highly	B-X
expressed	B-X
in	B-X
flat	B-X
and	B-X
long	B-X
bones	B-X
,	B-X
they	B-X
are	B-X
indispensable	B-X
and	B-X
control	B-X
separately	B-X
the	B-X
development	B-X
of	B-X
different	B-X
bones	B-X
.	B-X

The	O
Mr	O
64	O
,	O
000	O
enzyme	O
could	O
be	O
extracted	O
from	O
viable	O
cells	O
(	O
presumably	O
from	O
the	O
cell	O
membrane	O
)	O
by	O
2	O
%	O
1	O
-	O
butanol	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
Two	B-X
major	B-X
type	B-X
IV	B-X
collagenolytic	B-X
metalloproteinases	B-X
exhibiting	B-X
molecular	B-X
weights	B-X
of	B-X
64,000	B-X
and	B-X
88,000	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
detected	B-X
by	B-X
this	B-X
method	B-X
.	B-X
These	B-X
two	B-X
enzymes	B-X
were	B-X
also	B-X
found	B-X
to	B-X
have	B-X
specificity	B-X
for	B-X
gelatin	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X

Treatment	O
with	O
all	O
-	O
trans	O
-	O
RA	O
decreased	O
the	O
level	O
of	O
these	O
enzymes	O
in	O
the	O
cellular	O
,	O
cell	O
membrane	O
,	O
and	O
conditioned	O
medium	O
compartments	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
,	B-X
which	B-X
enables	B-X
tumor	B-X
cells	B-X
to	B-X
degrade	B-X
collagen	B-X
type	B-X
IV	B-X
found	B-X
in	B-X
the	B-X
subendothelial	B-X
basement	B-X
membrane	B-X
,	B-X
has	B-X
been	B-X
correlated	B-X
with	B-X
the	B-X
metastatic	B-X
potential	B-X
in	B-X
several	B-X
tumor	B-X
types	B-X
,	B-X
including	B-X
the	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
clones	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
all-trans-retinoic	B-X
acid	B-X
(	B-X
all-trans-RA	B-X
)	B-X
and	B-X
other	B-X
retinoids	B-X
,	B-X
which	B-X
exhibit	B-X
antitumor	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
affect	B-X
the	B-X
collagenolytic	B-X
activity	B-X
of	B-X
metastatic	B-X
rat	B-X
13762NF	B-X
mammary	B-X
adenocarcinoma	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
highly	B-X
metastatic	B-X
lung-colonizing	B-X
clone	B-X
MTF7.T35.3	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
13762NF	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
treated	B-X
for	B-X
3	B-X
days	B-X
with	B-X
0.1	B-X
,	B-X
1	B-X
,	B-X
or	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
,	B-X
harvested	B-X
,	B-X
and	B-X
seeded	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
extracellular	B-X
matrix	B-X
deposited	B-X
by	B-X
cultured	B-X
rat	B-X
lung	B-X
endothelial	B-X
cells	B-X
or	B-X
on	B-X
a	B-X
film	B-X
of	B-X
purified	B-X
[	B-X
3H	B-X
]	B-X
proline-labeled	B-X
type	B-X
IV	B-X
collagen	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
radioactivity	B-X
released	B-X
into	B-X
the	B-X
medium	B-X
during	B-X
the	B-X
subsequent	B-X
24	B-X
to	B-X
72	B-X
h	B-X
was	B-X
measured	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
all-trans-RA	B-X
treatment	B-X
inhibited	B-X
degradation	B-X
of	B-X
extracellular	B-X
matrix	B-X
and	B-X
type	B-X
IV	B-X
collagen	B-X
by	B-X
50	B-X
to	B-X
60	B-X
%	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
observed	B-X
whether	B-X
the	B-X
cells	B-X
had	B-X
been	B-X
treated	B-X
with	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
or	B-X
in	B-X
medium	B-X
supplemented	B-X
with	B-X
heat-inactivated	B-X
or	B-X
acid-treated	B-X
fetal	B-X
bovine	B-X
serum	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
under	B-X
these	B-X
conditions	B-X
,	B-X
except	B-X
after	B-X
treatment	B-X
with	B-X
10	B-X
microM	B-X
all-trans-RA	B-X
in	B-X
serum-free	B-X
medium	B-X
.	B-X
The	B-X
reduction	B-X
in	B-X
collagenolytic	B-X
activity	B-X
was	B-X
observed	B-X
in	B-X
viable	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
conditioned	B-X
medium	B-X
.	B-X
A	B-X
24-h	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
all-trans-RA	B-X
was	B-X
sufficient	B-X
to	B-X
cause	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
collagenolytic	B-X
activity	B-X
,	B-X
and	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
reversible	B-X
.	B-X
The	B-X
direct	B-X
addition	B-X
of	B-X
all-trans-RA	B-X
to	B-X
conditioned	B-X
medium	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
secreted	B-X
collagenase	B-X
activity	B-X
.	B-X
The	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
the	B-X
collagenolytic	B-X
enzymes	B-X
were	B-X
determined	B-X
by	B-X
electrophoresis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
concentrated	B-X
conditioned	B-X
medium	B-X
in	B-X
type	B-X
IV	B-X
collagen-embedded	B-X
polyacrylamide	B-X
gels	B-X
followed	B-X
by	B-X
renaturation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzymes	B-X
within	B-X
the	B-X
gels	B-X
.	B-X
These	B-X
two	B-X
enzymes	B-X
were	B-X
also	B-X
found	B-X
to	B-X
have	B-X
specificity	B-X
for	B-X
gelatin	B-X
.	B-X
The	B-X
Mr	B-X
64,000	B-X
enzyme	B-X
could	B-X
be	B-X
extracted	B-X
from	B-X
viable	B-X
cells	B-X
(	B-X
presumably	B-X
from	B-X
the	B-X
cell	B-X
membrane	B-X
)	B-X
by	B-X
2	B-X
%	B-X
1-butanol	B-X
.	B-X
Treatment	B-X
with	B-X
all-trans-RA	B-X
decreased	B-X
the	B-X
level	B-X
of	B-X
these	B-X
enzymes	B-X
in	B-X
the	B-X
cellular	B-X
,	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
conditioned	B-X
medium	B-X
compartments	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

Malate	O
-	O
citrate	O
cycle	O
during	O
glycolysis	O
and	O
glutaminolysis	O
in	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O
<EOS>	B-X
The	B-X
malate-citrate	B-X
cycle	B-X
was	B-X
studied	B-X
during	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
glutaminolysis	B-X
in	B-X
a	B-X
strain	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
cells	B-X
which	B-X
showed	B-X
a	B-X
very	B-X
low	B-X
malate-aspartate	B-X
shuttle	B-X
system	B-X
activity	B-X
.	B-X
The	B-X
experimental	B-X
approach	B-X
includes	B-X
:	B-X
estimation	B-X
of	B-X
mitochondrial	B-X
NAD	B-X
[	B-X
P	B-X
]	B-X
+-dependent	B-X
malic	B-X
enzyme	B-X
activity	B-X
;	B-X
respiratory	B-X
activity	B-X
of	B-X
freshly	B-X
harvested	B-X
or	B-X
fasted	B-X
cells	B-X
,	B-X
and	B-X
of	B-X
isolated	B-X
mitochondria	B-X
;	B-X
and	B-X
determination	B-X
of	B-X
the	B-X
metabolites	B-X
involved	B-X
in	B-X
the	B-X
glycolytic	B-X
and	B-X
glutaminolytic	B-X
pathways	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
this	B-X
strain	B-X
,	B-X
the	B-X
malate-citrate	B-X
shuttle	B-X
is	B-X
not	B-X
an	B-X
effective	B-X
pathway	B-X
for	B-X
transferring	B-X
glycolytic	B-X
reducing	B-X
equivalents	B-X
from	B-X
cytosol	B-X
to	B-X
mitochondria	B-X
.	B-X
Less	B-X
than	B-X
15	B-X
%	B-X
of	B-X
the	B-X
glucose	B-X
uptake	B-X
was	B-X
affected	B-X
by	B-X
the	B-X
1,2,3-benzenetricarboxylate	B-X
inhibition	B-X
of	B-X
the	B-X
malate-citrate	B-X
shuttle	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
,	B-X
the	B-X
malate-citrate	B-X
cycle	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
glutaminolytic	B-X
process	B-X
.	B-X
The	B-X
present	B-X
work	B-X
supports	B-X
and	B-X
extends	B-X
the	B-X
finding	B-X
of	B-X
previous	B-X
studies	B-X
,	B-X
since	B-X
the	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
glucose	B-X
metabolism	B-X
depressed	B-X
the	B-X
oxidative	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
mitochondria	B-X
,	B-X
not	B-X
only	B-X
alone	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glutamine	B-X
.	B-X

The	O
malate	O
-	O
citrate	O
cycle	O
was	O
studied	O
during	O
aerobic	O
glycolysis	O
and	O
glutaminolysis	O
in	O
a	O
strain	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
which	O
showed	O
a	O
very	O
low	O
malate	O
-	O
aspartate	O
shuttle	O
system	O
activity	O
.	O

The	O
experimental	O
approach	O
includes	O
:	O
estimation	O
of	O
mitochondrial	O
NAD	O
[	O
P	O
]	O
+	O
-	O
dependent	O
malic	O
enzyme	O
activity	O
;	O
respiratory	O
activity	O
of	O
freshly	O
harvested	O
or	O
fasted	O
cells	O
,	O
and	O
of	O
isolated	O
mitochondria	O
;	O
and	O
determination	O
of	O
the	O
metabolites	O
involved	O
in	O
the	O
glycolytic	O
and	O
glutaminolytic	O
pathways	O
.	O
<EOS>	B-X
The	B-X
malate-citrate	B-X
cycle	B-X
was	B-X
studied	B-X
during	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
glutaminolysis	B-X
in	B-X
a	B-X
strain	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
cells	B-X
which	B-X
showed	B-X
a	B-X
very	B-X
low	B-X
malate-aspartate	B-X
shuttle	B-X
system	B-X
activity	B-X
.	B-X
The	B-X
experimental	B-X
approach	B-X
includes	B-X
:	B-X
estimation	B-X
of	B-X
mitochondrial	B-X
NAD	B-X
[	B-X
P	B-X
]	B-X
+-dependent	B-X
malic	B-X
enzyme	B-X
activity	B-X
;	B-X
respiratory	B-X
activity	B-X
of	B-X
freshly	B-X
harvested	B-X
or	B-X
fasted	B-X
cells	B-X
,	B-X
and	B-X
of	B-X
isolated	B-X
mitochondria	B-X
;	B-X
and	B-X
determination	B-X
of	B-X
the	B-X
metabolites	B-X
involved	B-X
in	B-X
the	B-X
glycolytic	B-X
and	B-X
glutaminolytic	B-X
pathways	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
this	B-X
strain	B-X
,	B-X
the	B-X
malate-citrate	B-X
shuttle	B-X
is	B-X
not	B-X
an	B-X
effective	B-X
pathway	B-X
for	B-X
transferring	B-X
glycolytic	B-X
reducing	B-X
equivalents	B-X
from	B-X
cytosol	B-X
to	B-X
mitochondria	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
,	B-X
the	B-X
malate-citrate	B-X
cycle	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
glutaminolytic	B-X
process	B-X
.	B-X
The	B-X
present	B-X
work	B-X
supports	B-X
and	B-X
extends	B-X
the	B-X
finding	B-X
of	B-X
previous	B-X
studies	B-X
,	B-X
since	B-X
the	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
glucose	B-X
metabolism	B-X
depressed	B-X
the	B-X
oxidative	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
mitochondria	B-X
,	B-X
not	B-X
only	B-X
alone	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glutamine	B-X
.	B-X

The	O
results	O
suggest	O
that	O
in	O
this	O
strain	O
,	O
the	O
malate	O
-	O
citrate	O
shuttle	O
is	O
not	O
an	O
effective	O
pathway	O
for	O
transferring	O
glycolytic	O
reducing	O
equivalents	O
from	O
cytosol	O
to	O
mitochondria	O
.	O
<EOS>	B-X
Fatty	B-X
acid	B-X
biosynthesis	B-X
in	B-X
oleaginous	B-X
fungi	B-X
requires	B-X
the	B-X
supply	B-X
of	B-X
reducing	B-X
power	B-X
,	B-X
NADPH	B-X
,	B-X
and	B-X
the	B-X
precursor	B-X
of	B-X
fatty	B-X
acids	B-X
,	B-X
acetyl-CoA	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
in	B-X
the	B-X
cytosol	B-X
being	B-X
produced	B-X
by	B-X
ATP	B-X
:	B-X
citrate	B-X
lyase	B-X
which	B-X
requires	B-X
citrate	B-X
to	B-X
be	B-X
,	B-X
transported	B-X
from	B-X
the	B-X
mitochondrion	B-X
by	B-X
the	B-X
citrate/malate/pyruvate	B-X
transporter	B-X
.	B-X
This	B-X
transporter	B-X
,	B-X
which	B-X
is	B-X
within	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
,	B-X
transports	B-X
cytosolic	B-X
malate	B-X
into	B-X
the	B-X
mitochondrion	B-X
in	B-X
exchange	B-X
for	B-X
mitochondrial	B-X
citrate	B-X
moving	B-X
into	B-X
the	B-X
cytosol	B-X
(	B-X
Fig.	B-X
1	B-X
)	B-X
.	B-X
The	B-X
role	B-X
of	B-X
malate	B-X
transporter	B-X
in	B-X
lipid	B-X
accumulation	B-X
in	B-X
oleaginous	B-X
fungi	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
,	B-X
however	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
the	B-X
mt	B-X
gene	B-X
,	B-X
coding	B-X
for	B-X
a	B-X
malate	B-X
transporter	B-X
,	B-X
was	B-X
manipulated	B-X
in	B-X
the	B-X
oleaginous	B-X
fungus	B-X
Mucor	B-X
circinelloides	B-X
to	B-X
analyze	B-X
its	B-X
effect	B-X
on	B-X
lipid	B-X
accumulation	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
mt	B-X
overexpression	B-X
increased	B-X
the	B-X
lipid	B-X
content	B-X
for	B-X
about	B-X
70	B-X
%	B-X
(	B-X
from	B-X
13	B-X
to	B-X
22	B-X
%	B-X
dry	B-X
cell	B-X
weight	B-X
,	B-X
CDW	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
lipid	B-X
content	B-X
in	B-X
mt	B-X
knockout	B-X
mutant	B-X
decreased	B-X
about	B-X
27	B-X
%	B-X
(	B-X
from	B-X
13	B-X
to	B-X
9.5	B-X
%	B-X
CDW	B-X
)	B-X
compared	B-X
with	B-X
the	B-X
control	B-X
strain	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
extracellular	B-X
malate	B-X
concentration	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
mt	B-X
overexpressing	B-X
strain	B-X
and	B-X
increased	B-X
in	B-X
the	B-X
mt	B-X
knockout	B-X
strain	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
strain	B-X
.	B-X
This	B-X
work	B-X
suggests	B-X
that	B-X
the	B-X
malate	B-X
transporter	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
lipid	B-X
accumulation	B-X
in	B-X
oleaginous	B-X
fungus	B-X
M.	B-X
circinelloides	B-X
.	B-X

Less	O
than	O
15	O
%	O
of	O
the	O
glucose	O
uptake	O
was	O
affected	O
by	O
the	O
1	O
,	O
2	O
,	O
3	O
-	O
benzenetricarboxylate	O
inhibition	O
of	O
the	O
malate	O
-	O
citrate	O
shuttle	O
.	O
<EOS>	B-X
The	B-X
malate-citrate	B-X
cycle	B-X
was	B-X
studied	B-X
during	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
glutaminolysis	B-X
in	B-X
a	B-X
strain	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
cells	B-X
which	B-X
showed	B-X
a	B-X
very	B-X
low	B-X
malate-aspartate	B-X
shuttle	B-X
system	B-X
activity	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
this	B-X
strain	B-X
,	B-X
the	B-X
malate-citrate	B-X
shuttle	B-X
is	B-X
not	B-X
an	B-X
effective	B-X
pathway	B-X
for	B-X
transferring	B-X
glycolytic	B-X
reducing	B-X
equivalents	B-X
from	B-X
cytosol	B-X
to	B-X
mitochondria	B-X
.	B-X
Less	B-X
than	B-X
15	B-X
%	B-X
of	B-X
the	B-X
glucose	B-X
uptake	B-X
was	B-X
affected	B-X
by	B-X
the	B-X
1,2,3-benzenetricarboxylate	B-X
inhibition	B-X
of	B-X
the	B-X
malate-citrate	B-X
shuttle	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
,	B-X
the	B-X
malate-citrate	B-X
cycle	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
glutaminolytic	B-X
process	B-X
.	B-X
The	B-X
present	B-X
work	B-X
supports	B-X
and	B-X
extends	B-X
the	B-X
finding	B-X
of	B-X
previous	B-X
studies	B-X
,	B-X
since	B-X
the	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
glucose	B-X
metabolism	B-X
depressed	B-X
the	B-X
oxidative	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
mitochondria	B-X
,	B-X
not	B-X
only	B-X
alone	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glutamine	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
high	B-X
glutamine	B-X
uptake	B-X
was	B-X
maintained	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
.	B-X

Moreover	O
,	O
in	O
the	O
presence	O
of	O
glucose	O
,	O
the	O
malate	O
-	O
citrate	O
cycle	O
did	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
glutaminolytic	O
process	O
.	O
<EOS>	B-X
Modulation	B-X
of	B-X
glucose	B-X
metabolic	B-X
capacity	B-X
of	B-X
human	B-X
preantral	B-X
follicles	B-X
in	B-X
vitro	B-X
by	B-X
gonadotropins	B-X
and	B-X
intraovarian	B-X
growth	B-X
factors	B-X
was	B-X
evaluated	B-X
by	B-X
monitoring	B-X
the	B-X
activities	B-X
of	B-X
phosphofructokinase	B-X
(	B-X
PFK	B-X
)	B-X
and	B-X
pyruvate	B-X
kinase	B-X
(	B-X
PK	B-X
)	B-X
,	B-X
two	B-X
regulatory	B-X
enzymes	B-X
of	B-X
the	B-X
glycolytic	B-X
pathway	B-X
,	B-X
and	B-X
malate	B-X
dehydrogenase	B-X
(	B-X
MDH	B-X
)	B-X
,	B-X
a	B-X
key	B-X
mitochondrial	B-X
enzyme	B-X
of	B-X
the	B-X
Krebs	B-X
cycle	B-X
.	B-X
Preantral	B-X
follicles	B-X
in	B-X
classes	B-X
1	B-X
and	B-X
2	B-X
from	B-X
premenopausal	B-X
women	B-X
were	B-X
cultured	B-X
separately	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
FSH	B-X
,	B-X
LH	B-X
,	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
,	B-X
insulin-like	B-X
growth	B-X
factor	B-X
(	B-X
IGF-I	B-X
)	B-X
,	B-X
or	B-X
transforming	B-X
growth	B-X
factor	B-X
beta1	B-X
(	B-X
TGFbeta1	B-X
)	B-X
for	B-X
24	B-X
h.	B-X
Mitochondrial	B-X
fraction	B-X
was	B-X
separated	B-X
from	B-X
the	B-X
cytosolic	B-X
fraction	B-X
,	B-X
and	B-X
both	B-X
fractions	B-X
were	B-X
used	B-X
for	B-X
enzyme	B-X
assays	B-X
.	B-X
Although	B-X
both	B-X
EGF	B-X
and	B-X
TGFbeta1	B-X
stimulated	B-X
glycolytic	B-X
and	B-X
Krebs	B-X
cycle	B-X
enzymes	B-X
for	B-X
class	B-X
1	B-X
preantral	B-X
follicles	B-X
,	B-X
TGFbeta1	B-X
consistently	B-X
stimulated	B-X
the	B-X
activities	B-X
of	B-X
both	B-X
glycolytic	B-X
enzymes	B-X
more	B-X
than	B-X
that	B-X
of	B-X
EGF	B-X
.	B-X
In	B-X
general	B-X
,	B-X
only	B-X
gonadotropins	B-X
consistently	B-X
stimulated	B-X
both	B-X
glycolytic	B-X
and	B-X
Krebs	B-X
cycle	B-X
enzyme	B-X
activities	B-X
several-fold	B-X
in	B-X
class	B-X
2	B-X
follicles	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
gonadotropins	B-X
and	B-X
ovarian	B-X
growth	B-X
factors	B-X
differentially	B-X
influence	B-X
follicular	B-X
energy-producing	B-X
capacity	B-X
from	B-X
glucose	B-X
.	B-X
Moreover	B-X
,	B-X
gonadotropins	B-X
may	B-X
either	B-X
directly	B-X
influence	B-X
glucose	B-X
metabolism	B-X
in	B-X
class	B-X
2	B-X
preantral	B-X
follicles	B-X
or	B-X
do	B-X
so	B-X
indirectly	B-X
through	B-X
factors	B-X
other	B-X
than	B-X
the	B-X
well-known	B-X
intraovarian	B-X
growth	B-X
factors	B-X
.	B-X
Because	B-X
growth	B-X
factors	B-X
modulate	B-X
granulosa	B-X
cell	B-X
mitosis	B-X
and	B-X
functionality	B-X
,	B-X
their	B-X
role	B-X
on	B-X
energy	B-X
production	B-X
may	B-X
be	B-X
related	B-X
to	B-X
specific	B-X
cellular	B-X
activities	B-X
.	B-X

The	O
present	O
work	O
supports	O
and	O
extends	O
the	O
finding	O
of	O
previous	O
studies	O
,	O
since	O
the	O
results	O
showed	O
that	O
the	O
glucose	O
metabolism	O
depressed	O
the	O
oxidative	O
processes	O
in	O
Ehrlich	O
ascites	O
tumor	O
mitochondria	O
,	O
not	O
only	O
alone	O
,	O
but	O
also	O
in	O
the	O
presence	O
of	O
glutamine	O
.	O

Interestingly	O
,	O
the	O
high	O
glutamine	O
uptake	O
was	O
maintained	O
in	O
the	O
presence	O
of	O
glucose	O
.	O
<EOS>	B-X
Less	B-X
than	B-X
15	B-X
%	B-X
of	B-X
the	B-X
glucose	B-X
uptake	B-X
was	B-X
affected	B-X
by	B-X
the	B-X
1,2,3-benzenetricarboxylate	B-X
inhibition	B-X
of	B-X
the	B-X
malate-citrate	B-X
shuttle	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
,	B-X
the	B-X
malate-citrate	B-X
cycle	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
glutaminolytic	B-X
process	B-X
.	B-X
The	B-X
present	B-X
work	B-X
supports	B-X
and	B-X
extends	B-X
the	B-X
finding	B-X
of	B-X
previous	B-X
studies	B-X
,	B-X
since	B-X
the	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
glucose	B-X
metabolism	B-X
depressed	B-X
the	B-X
oxidative	B-X
processes	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
tumor	B-X
mitochondria	B-X
,	B-X
not	B-X
only	B-X
alone	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glutamine	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
high	B-X
glutamine	B-X
uptake	B-X
was	B-X
maintained	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucose	B-X
.	B-X

N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
induced	O
transformation	O
of	O
rat	O
urothelial	O
cells	O
in	O
vitro	O
is	O
not	O
mediated	O
by	O
activation	O
of	O
ras	B-Gene_or_gene_product
oncogenes	O
.	O
<EOS>	B-X
Using	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
and	B-X
tumorigenicity	B-X
in	B-X
athymic	B-X
nude	B-X
mice	B-X
as	B-X
indices	B-X
of	B-X
transformation	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
H202	B-X
and	B-X
cytokines	B-X
on	B-X
the	B-X
enhancement	B-X
of	B-X
N-methyl-N-nitrosourea	B-X
(	B-X
MNU	B-X
)	B-X
-initiated	B-X
transformation	B-X
of	B-X
MYP3	B-X
cells	B-X
,	B-X
an	B-X
anchorage-dependent	B-X
nontumorigenic	B-X
rat	B-X
bladder	B-X
epithelial	B-X
cell	B-X
line	B-X
.	B-X
MYP3	B-X
cells	B-X
pretreated	B-X
with	B-X
or	B-X
without	B-X
MNU	B-X
were	B-X
exposed	B-X
to	B-X
H202	B-X
(	B-X
0.001	B-X
to	B-X
0.1	B-X
mM	B-X
)	B-X
daily	B-X
for	B-X
1	B-X
week	B-X
in	B-X
monolayer	B-X
culture	B-X
and	B-X
were	B-X
then	B-X
tested	B-X
for	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
A	B-X
marked	B-X
increase	B-X
in	B-X
colony	B-X
numbers	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
cells	B-X
that	B-X
were	B-X
MNU-initiated	B-X
and	B-X
exposed	B-X
to	B-X
H202	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
transformants	B-X
induced	B-X
by	B-X
MNU	B-X
plus	B-X
H202	B-X
or	B-X
H202	B-X
alone	B-X
formed	B-X
high-grade	B-X
transitional	B-X
cell	B-X
carcinomas	B-X
when	B-X
injected	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
these	B-X
transformants	B-X
was	B-X
stimulated	B-X
by	B-X
several	B-X
cytokines	B-X
(	B-X
interleukin	B-X
1alpha	B-X
,	B-X
interleukin	B-X
6	B-X
,	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
)	B-X
better	B-X
than	B-X
the	B-X
parental	B-X
cells	B-X
both	B-X
on	B-X
a	B-X
plastic	B-X
surface	B-X
and	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
H202	B-X
causes	B-X
genetic	B-X
change	B-X
(	B-X
s	B-X
)	B-X
to	B-X
induce	B-X
tumorigenic	B-X
conversion	B-X
in	B-X
urothelial	B-X
cells	B-X
and	B-X
that	B-X
the	B-X
transformants	B-X
are	B-X
stimulated	B-X
to	B-X
grow	B-X
because	B-X
of	B-X
their	B-X
selective	B-X
response	B-X
to	B-X
several	B-X
cytokines	B-X
.	B-X

Adult	O
rat	O
urothelial	O
cells	O
were	O
transformed	O
in	O
vitro	O
following	O
treatment	O
with	O
a	O
single	O
dose	O
of	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
MNU	O
)	O
or	O
MNU	O
treatment	O
followed	O
by	O
promotion	O
with	O
sodium	O
saccharin	O
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factors	B-X
alpha	B-X
and	B-X
beta	B-X
(	B-X
TGF-alpha	B-X
and	B-X
TGF-beta	B-X
)	B-X
isolated	B-X
from	B-X
normal	B-X
mouse	B-X
kidney	B-X
induced	B-X
gross	B-X
morphological	B-X
changes	B-X
in	B-X
rat	B-X
urothelial	B-X
cells	B-X
maintained	B-X
in	B-X
organ	B-X
culture	B-X
.	B-X
These	B-X
morphological	B-X
effects	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
observed	B-X
after	B-X
long-term	B-X
treatment	B-X
of	B-X
rat	B-X
bladder	B-X
organ	B-X
cultures	B-X
with	B-X
the	B-X
carcinogen	B-X
N-methyl-N-nitrosourea	B-X
(	B-X
MNU	B-X
)	B-X
or	B-X
the	B-X
promoting	B-X
agents	B-X
sodium	B-X
saccharin	B-X
and	B-X
sodium	B-X
cyclamate	B-X
.	B-X
Mature	B-X
superficial-type	B-X
cells	B-X
covered	B-X
most	B-X
of	B-X
the	B-X
surface	B-X
and	B-X
less	B-X
mature	B-X
forms	B-X
appeared	B-X
on	B-X
the	B-X
cut	B-X
sides	B-X
and	B-X
damaged	B-X
areas	B-X
where	B-X
cells	B-X
followed	B-X
the	B-X
normal	B-X
pattern	B-X
of	B-X
urothelial	B-X
differentiation	B-X
.	B-X
Crude	B-X
P-30-purified	B-X
TGFs	B-X
induced	B-X
a	B-X
series	B-X
of	B-X
dose-related	B-X
changes	B-X
from	B-X
4	B-X
days	B-X
,	B-X
which	B-X
were	B-X
maximal	B-X
at	B-X
8	B-X
days	B-X
and	B-X
persisted	B-X
or	B-X
decreased	B-X
between	B-X
8	B-X
and	B-X
14	B-X
days	B-X
.	B-X
These	B-X
included	B-X
hyperplasia	B-X
,	B-X
loss	B-X
of	B-X
epithelial	B-X
polarity	B-X
,	B-X
hyperchromasia	B-X
and	B-X
elongation	B-X
of	B-X
basal	B-X
cells	B-X
between	B-X
the	B-X
overlying	B-X
cell	B-X
layers	B-X
to	B-X
reach	B-X
the	B-X
culture	B-X
surface	B-X
.	B-X
Scanning	B-X
electron	B-X
microscopy	B-X
showed	B-X
the	B-X
appearance	B-X
at	B-X
the	B-X
culture	B-X
surface	B-X
of	B-X
immature	B-X
cells	B-X
with	B-X
gross	B-X
surface	B-X
abnormalities	B-X
including	B-X
large	B-X
numbers	B-X
of	B-X
blebs	B-X
,	B-X
stubby	B-X
microvilli	B-X
and	B-X
long	B-X
pleomorphic	B-X
microvilli	B-X
.	B-X
Immature	B-X
cells	B-X
on	B-X
the	B-X
sides	B-X
of	B-X
the	B-X
culture	B-X
and	B-X
in	B-X
damaged	B-X
areas	B-X
developed	B-X
similar	B-X
features	B-X
.	B-X
At	B-X
crude	B-X
TGF	B-X
doses	B-X
of	B-X
10	B-X
micrograms/ml	B-X
many	B-X
superficial	B-X
cells	B-X
were	B-X
rounded	B-X
,	B-X
some	B-X
became	B-X
cystic	B-X
and	B-X
epithelial	B-X
necrosis	B-X
was	B-X
observed	B-X
.	B-X
However	B-X
,	B-X
histological	B-X
changes	B-X
,	B-X
particularly	B-X
basal	B-X
cell	B-X
elongation	B-X
were	B-X
more	B-X
widespread	B-X
and	B-X
there	B-X
was	B-X
an	B-X
abnormal	B-X
development	B-X
of	B-X
globular	B-X
processes	B-X
between	B-X
the	B-X
membrane	B-X
ridges	B-X
of	B-X
mature	B-X
superficial	B-X
cells	B-X
.	B-X
Neither	B-X
crude	B-X
TGF	B-X
nor	B-X
EGF	B-X
stimulated	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
of	B-X
isolated	B-X
epithelial	B-X
cells	B-X
from	B-X
freshly	B-X
killed	B-X
rats	B-X
or	B-X
organ	B-X
cultures	B-X
pretreated	B-X
for	B-X
7	B-X
days	B-X
with	B-X
EGF	B-X
or	B-X
TGF	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

This	O
in	O
vitro	O
transformation	O
process	O
involves	O
multiple	O
steps	O
:	O
slow	O
-	O
growing	O
'	O
pre	O
-	O
neoplastic	O
'	O
epithelial	O
foci	O
are	O
induced	O
70	O
-	O
100	O
days	O
after	O
MNU	O
treatment	O
and	O
from	O
such	O
foci	O
rapidly	O
proliferating	O
immortal	O
cell	O
lines	O
were	O
established	O
,	O
some	O
of	O
which	O
became	O
tumorigenic	O
after	O
a	O
further	O
latent	O
period	O
.	O
<EOS>	B-X
Adult	B-X
rat	B-X
urothelial	B-X
cells	B-X
were	B-X
transformed	B-X
in	B-X
vitro	B-X
following	B-X
treatment	B-X
with	B-X
a	B-X
single	B-X
dose	B-X
of	B-X
N-methyl-N-nitrosourea	B-X
(	B-X
MNU	B-X
)	B-X
or	B-X
MNU	B-X
treatment	B-X
followed	B-X
by	B-X
promotion	B-X
with	B-X
sodium	B-X
saccharin	B-X
.	B-X
This	B-X
in	B-X
vitro	B-X
transformation	B-X
process	B-X
involves	B-X
multiple	B-X
steps	B-X
:	B-X
slow-growing	B-X
'pre-neoplastic	B-X
'	B-X
epithelial	B-X
foci	B-X
are	B-X
induced	B-X
70-100	B-X
days	B-X
after	B-X
MNU	B-X
treatment	B-X
and	B-X
from	B-X
such	B-X
foci	B-X
rapidly	B-X
proliferating	B-X
immortal	B-X
cell	B-X
lines	B-X
were	B-X
established	B-X
,	B-X
some	B-X
of	B-X
which	B-X
became	B-X
tumorigenic	B-X
after	B-X
a	B-X
further	B-X
latent	B-X
period	B-X
.	B-X
A	B-X
series	B-X
of	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
a	B-X
single	B-X
fibroblast	B-X
cell	B-X
line	B-X
established	B-X
in	B-X
this	B-X
way	B-X
were	B-X
analysed	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
transforming	B-X
genes	B-X
by	B-X
DNA	B-X
transfection	B-X
into	B-X
NIH3T3	B-X
cells	B-X
.	B-X
None	B-X
of	B-X
the	B-X
epithelial	B-X
cell	B-X
lines	B-X
induced	B-X
foci	B-X
in	B-X
a	B-X
focus	B-X
formation	B-X
assay	B-X
.	B-X
The	B-X
single	B-X
non-epithelial	B-X
line	B-X
induced	B-X
foci	B-X
and	B-X
was	B-X
found	B-X
to	B-X
contain	B-X
an	B-X
activated	B-X
c-Ki-ras	B-X
gene	B-X
with	B-X
a	B-X
G	B-X
--	B-X
--	B-X
A	B-X
transition	B-X
in	B-X
codon	B-X
12	B-X
.	B-X
To	B-X
assay	B-X
for	B-X
the	B-X
possible	B-X
presence	B-X
of	B-X
transforming	B-X
genes	B-X
which	B-X
were	B-X
not	B-X
active	B-X
in	B-X
a	B-X
focus	B-X
formation	B-X
assay	B-X
,	B-X
two	B-X
of	B-X
the	B-X
epithelial	B-X
lines	B-X
were	B-X
analysed	B-X
further	B-X
by	B-X
co-transfection	B-X
with	B-X
a	B-X
dominant	B-X
selectable	B-X
marker	B-X
,	B-X
followed	B-X
by	B-X
selection	B-X
and	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
No	B-X
tumours	B-X
were	B-X
induced	B-X
within	B-X
the	B-X
latent	B-X
period	B-X
for	B-X
tumour	B-X
production	B-X
by	B-X
control	B-X
cells	B-X
transfected	B-X
with	B-X
NIH3T3	B-X
cell	B-X
DNA	B-X
(	B-X
40-60	B-X
days	B-X
)	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
cell	B-X
type	B-X
specificity	B-X
for	B-X
oncogene	B-X
activation	B-X
during	B-X
in	B-X
vitro	B-X
rat	B-X
bladder	B-X
transformation	B-X
initiated	B-X
by	B-X
a	B-X
single	B-X
carcinogen	B-X
and	B-X
that	B-X
ras	B-X
gene	B-X
activation	B-X
is	B-X
not	B-X
a	B-X
necessary	B-X
step	B-X
in	B-X
urothelial	B-X
transformation	B-X
in	B-X
vitro	B-X
.	B-X

A	O
series	O
of	O
epithelial	O
cell	O
lines	O
and	O
a	O
single	O
fibroblast	O
cell	O
line	O
established	O
in	O
this	O
way	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
transforming	O
genes	O
by	O
DNA	O
transfection	O
into	O
NIH3T3	O
cells	O
.	O

None	O
of	O
the	O
epithelial	O
cell	O
lines	O
induced	O
foci	O
in	O
a	O
focus	O
formation	O
assay	O
.	O

The	O
single	O
non	O
-	O
epithelial	O
line	O
induced	O
foci	O
and	O
was	O
found	O
to	O
contain	O
an	O
activated	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ki	I-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
gene	O
with	O
a	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
in	O
codon	O
12	O
.	O

To	O
assay	O
for	O
the	O
possible	O
presence	O
of	O
transforming	O
genes	O
which	O
were	O
not	O
active	O
in	O
a	O
focus	O
formation	O
assay	O
,	O
two	O
of	O
the	O
epithelial	O
lines	O
were	O
analysed	O
further	O
by	O
co	O
-	O
transfection	O
with	O
a	O
dominant	O
selectable	O
marker	O
,	O
followed	O
by	O
selection	O
and	O
inoculation	O
into	O
nude	O
mice	O
.	O
<EOS>	B-X
TGFÎ²	B-X
signaling	B-X
plays	B-X
crucial	B-X
role	B-X
during	B-X
development	B-X
and	B-X
cancer	B-X
,	B-X
however	B-X
the	B-X
role	B-X
for	B-X
TGFÎ²	B-X
signaling	B-X
in	B-X
regulating	B-X
the	B-X
noncoding	B-X
part	B-X
of	B-X
the	B-X
human	B-X
genome	B-X
in	B-X
triple	B-X
negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
is	B-X
still	B-X
being	B-X
unraveled	B-X
.	B-X
Our	B-X
data	B-X
revealed	B-X
72	B-X
commonly	B-X
upregulated	B-X
[	B-X
fold	B-X
change	B-X
(	B-X
FC	B-X
)	B-X
â¥	B-X
2.0	B-X
]	B-X
,	B-X
including	B-X
PLAU	B-X
,	B-X
TPM1	B-X
,	B-X
TAGLN	B-X
,	B-X
COL1A1	B-X
,	B-X
TGFBI	B-X
,	B-X
and	B-X
SNAI1	B-X
,	B-X
and	B-X
53	B-X
downregulated	B-X
(	B-X
FC	B-X
â¤	B-X
2.0	B-X
)	B-X
protein	B-X
coding	B-X
genes	B-X
in	B-X
BT-549	B-X
and	B-X
MDA-MB-231	B-X
models	B-X
in	B-X
response	B-X
to	B-X
TGFÎ²1	B-X
activation	B-X
.	B-X
Alignment	B-X
to	B-X
the	B-X
geocode	B-X
(	B-X
V33	B-X
)	B-X
identified	B-X
41	B-X
upregulated	B-X
(	B-X
FC	B-X
â¥	B-X
2.0	B-X
)	B-X
and	B-X
22	B-X
downregulated	B-X
(	B-X
FC	B-X
â¤	B-X
2.0	B-X
)	B-X
long	B-X
non-coding	B-X
RNA	B-X
(	B-X
lncRNA	B-X
)	B-X
in	B-X
response	B-X
to	B-X
TGFÎ²1	B-X
activation	B-X
,	B-X
which	B-X
were	B-X
inhibited	B-X
by	B-X
concurrent	B-X
treatment	B-X
with	B-X
SB431542	B-X
.	B-X
To	B-X
place	B-X
our	B-X
data	B-X
from	B-X
the	B-X
in	B-X
vitro	B-X
models	B-X
into	B-X
their	B-X
clinical	B-X
context	B-X
,	B-X
we	B-X
identified	B-X
AC015909.1	B-X
,	B-X
AC013451.1	B-X
,	B-X
CYP1B1-AS1	B-X
,	B-X
AC004862.1	B-X
,	B-X
LINC01824	B-X
,	B-X
AL138828.1	B-X
,	B-X
B4GALT1-AS1	B-X
,	B-X
AL353751.1	B-X
,	B-X
AC090826.3	B-X
,	B-X
AC104695.4	B-X
,	B-X
ADORA2A-AS1	B-X
,	B-X
PTPRG-AS1	B-X
,	B-X
LINC01943	B-X
,	B-X
AC026954.3	B-X
,	B-X
TPM1-AS	B-X
,	B-X
ZFPM2-AS1	B-X
,	B-X
AC007362.1	B-X
,	B-X
AC112721.2	B-X
,	B-X
MALAT1	B-X
,	B-X
AL513314.2	B-X
,	B-X
AC112721.1	B-X
,	B-X
AC010343.3	B-X
,	B-X
LINC01711	B-X
,	B-X
and	B-X
MAP3K2-DT	B-X
lncRNA	B-X
expression	B-X
to	B-X
positively	B-X
correlate	B-X
with	B-X
TGFÎ²1	B-X
expression	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
360	B-X
TNBC	B-X
patients	B-X
.	B-X
Interestingly	B-X
,	B-X
AC112721.1	B-X
,	B-X
AC112721.2	B-X
exhibited	B-X
higher	B-X
expression	B-X
in	B-X
TNBC	B-X
compared	B-X
to	B-X
normal	B-X
breast	B-X
tissue	B-X
suggesting	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
those	B-X
lncRNA	B-X
in	B-X
TNBC	B-X
biology	B-X
.	B-X
Our	B-X
miRNA	B-X
analysis	B-X
in	B-X
the	B-X
BT-549	B-X
model	B-X
in	B-X
response	B-X
to	B-X
exogenous	B-X
TGFB1	B-X
revealed	B-X
several	B-X
affected	B-X
miRNAs	B-X
(	B-X
2.0	B-X
â¤	B-X
FC	B-X
â¤	B-X
2.0	B-X
)	B-X
,	B-X
whose	B-X
expression	B-X
pattern	B-X
was	B-X
reversed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
SB431542	B-X
,	B-X
suggesting	B-X
those	B-X
miRNA	B-X
as	B-X
plausible	B-X
targets	B-X
for	B-X
TGFÎ²	B-X
regulation	B-X
.	B-X

No	O
tumours	O
were	O
induced	O
within	O
the	O
latent	O
period	O
for	O
tumour	O
production	O
by	O
control	O
cells	O
transfected	O
with	O
NIH3T3	O
cell	O
DNA	O
(	O
40	O
-	O
60	O
days	O
)	O
.	O
<EOS>	B-X
Adult	B-X
rat	B-X
urothelial	B-X
cells	B-X
were	B-X
transformed	B-X
in	B-X
vitro	B-X
following	B-X
treatment	B-X
with	B-X
a	B-X
single	B-X
dose	B-X
of	B-X
N-methyl-N-nitrosourea	B-X
(	B-X
MNU	B-X
)	B-X
or	B-X
MNU	B-X
treatment	B-X
followed	B-X
by	B-X
promotion	B-X
with	B-X
sodium	B-X
saccharin	B-X
.	B-X
This	B-X
in	B-X
vitro	B-X
transformation	B-X
process	B-X
involves	B-X
multiple	B-X
steps	B-X
:	B-X
slow-growing	B-X
'pre-neoplastic	B-X
'	B-X
epithelial	B-X
foci	B-X
are	B-X
induced	B-X
70-100	B-X
days	B-X
after	B-X
MNU	B-X
treatment	B-X
and	B-X
from	B-X
such	B-X
foci	B-X
rapidly	B-X
proliferating	B-X
immortal	B-X
cell	B-X
lines	B-X
were	B-X
established	B-X
,	B-X
some	B-X
of	B-X
which	B-X
became	B-X
tumorigenic	B-X
after	B-X
a	B-X
further	B-X
latent	B-X
period	B-X
.	B-X
A	B-X
series	B-X
of	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
a	B-X
single	B-X
fibroblast	B-X
cell	B-X
line	B-X
established	B-X
in	B-X
this	B-X
way	B-X
were	B-X
analysed	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
transforming	B-X
genes	B-X
by	B-X
DNA	B-X
transfection	B-X
into	B-X
NIH3T3	B-X
cells	B-X
.	B-X
None	B-X
of	B-X
the	B-X
epithelial	B-X
cell	B-X
lines	B-X
induced	B-X
foci	B-X
in	B-X
a	B-X
focus	B-X
formation	B-X
assay	B-X
.	B-X
The	B-X
single	B-X
non-epithelial	B-X
line	B-X
induced	B-X
foci	B-X
and	B-X
was	B-X
found	B-X
to	B-X
contain	B-X
an	B-X
activated	B-X
c-Ki-ras	B-X
gene	B-X
with	B-X
a	B-X
G	B-X
--	B-X
--	B-X
A	B-X
transition	B-X
in	B-X
codon	B-X
12	B-X
.	B-X
No	B-X
tumours	B-X
were	B-X
induced	B-X
within	B-X
the	B-X
latent	B-X
period	B-X
for	B-X
tumour	B-X
production	B-X
by	B-X
control	B-X
cells	B-X
transfected	B-X
with	B-X
NIH3T3	B-X
cell	B-X
DNA	B-X
(	B-X
40-60	B-X
days	B-X
)	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
cell	B-X
type	B-X
specificity	B-X
for	B-X
oncogene	B-X
activation	B-X
during	B-X
in	B-X
vitro	B-X
rat	B-X
bladder	B-X
transformation	B-X
initiated	B-X
by	B-X
a	B-X
single	B-X
carcinogen	B-X
and	B-X
that	B-X
ras	B-X
gene	B-X
activation	B-X
is	B-X
not	B-X
a	B-X
necessary	B-X
step	B-X
in	B-X
urothelial	B-X
transformation	B-X
in	B-X
vitro	B-X
.	B-X

These	O
results	O
suggest	O
that	O
there	O
is	O
cell	O
type	O
specificity	O
for	O
oncogene	O
activation	O
during	O
in	O
vitro	O
rat	O
bladder	O
transformation	O
initiated	O
by	O
a	O
single	O
carcinogen	O
and	O
that	O
ras	B-Gene_or_gene_product
gene	O
activation	O
is	O
not	O
a	O
necessary	O
step	O
in	O
urothelial	O
transformation	O
in	O
vitro	O
.	O

Low	O
-	O
level	O
X	O
-	O
radiation	O
effects	O
on	O
functional	O
vascular	O
changes	O
in	O
Syrian	O
hamster	O
cheek	O
pouch	O
epithelium	O
during	O
hydrocarbon	O
carcinogenesis	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

Effects	O
of	O
repeated	O
low	O
-	O
level	O
X	O
radiation	O
on	O
functional	O
microvascular	O
changes	O
in	O
hamster	O
cheek	O
pouch	O
epithelium	O
during	O
and	O
following	O
carcinogenesis	O
by	O
7	O
,	O
12	O
-	O
dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
were	O
studied	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

Prior	O
studies	O
showed	O
enhancement	O
of	O
such	O
carcinogenesis	O
by	O
repeated	O
20	O
rad	O
head	O
and	O
neck	O
X	O
-	O
radiation	O
exposures	O
,	O
and	O
it	O
was	O
proposed	O
that	O
one	O
possible	O
mechanism	O
was	O
radiogenic	O
alteration	O
of	O
the	O
functional	O
microvasculature	O
in	O
a	O
manner	O
which	O
favored	O
subsequent	O
tumor	O
development	O
.	O

Hamsters	O
were	O
treated	O
with	O
either	O
radiation	O
,	O
DMBA	O
,	O
radiation	O
+	O
DMBA	O
,	O
or	O
no	O
treatment	O
.	O
<EOS>	B-X
For	B-X
more	B-X
than	B-X
30	B-X
years	B-X
,	B-X
hundreds	B-X
of	B-X
researchers	B-X
have	B-X
maintained	B-X
that	B-X
genetic	B-X
modifications	B-X
would	B-X
provide	B-X
effective	B-X
treatments	B-X
for	B-X
many	B-X
inherited	B-X
human	B-X
diseases	B-X
,	B-X
offering	B-X
durable	B-X
and	B-X
possibly	B-X
curative	B-X
clinical	B-X
benefit	B-X
with	B-X
a	B-X
single	B-X
treatment	B-X
.	B-X
There	B-X
are	B-X
now	B-X
five	B-X
treatments	B-X
approved	B-X
for	B-X
commercialization	B-X
and	B-X
currently	B-X
available	B-X
,	B-X
i.e.	B-X
,	B-X
Luxturna	B-X
,	B-X
Zolgensma	B-X
,	B-X
the	B-X
two	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
T	B-X
cell	B-X
(	B-X
CAR-T	B-X
)	B-X
therapies	B-X
(	B-X
Yescarta	B-X
and	B-X
Kymriah	B-X
)	B-X
,	B-X
and	B-X
Strimvelis	B-X
(	B-X
the	B-X
gammaretrovirus	B-X
approved	B-X
for	B-X
adenosine	B-X
deaminase-severe	B-X
combined	B-X
immunodeficiency	B-X
[	B-X
ADA-SCID	B-X
]	B-X
in	B-X
Europe	B-X
)	B-X
.	B-X
Dozens	B-X
of	B-X
other	B-X
treatments	B-X
are	B-X
under	B-X
clinical	B-X
trials	B-X
.	B-X
In	B-X
that	B-X
article	B-X
,	B-X
I	B-X
presented	B-X
evidence-based	B-X
algorithms	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
these	B-X
refractory	B-X
pathologic	B-X
scars	B-X
.	B-X

Animals	O
were	O
sacrificed	O
at	O
3	O
-	O
week	O
intervals	O
from	O
0	O
to	O
39	O
weeks	O
after	O
treatments	O
began	O
.	O

Pouch	O
vascular	O
volume	O
and	O
permeability	O
changes	O
were	O
studied	O
by	O
fractional	O
distributions	O
of	O
radiotracers	O
and	O
were	O
analyzed	O
by	O
a	O
variety	O
of	O
statistical	O
methods	O
which	O
explored	O
the	O
vascular	O
parameters	O
,	O
treatment	O
types	O
,	O
elapsed	O
time	O
,	O
presence	O
of	O
the	O
carcinogen	O
,	O
and	O
histopathologic	O
changes	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Animals	B-X
were	B-X
sacrificed	B-X
at	B-X
3-week	B-X
intervals	B-X
from	B-X
0	B-X
to	B-X
39	B-X
weeks	B-X
after	B-X
treatments	B-X
began	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

All	O
treatments	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	O
volume	O
with	O
time	O
,	O
while	O
only	O
DMBA	O
treatments	O
alone	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	O
permeability	O
with	O
time	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Animals	B-X
were	B-X
sacrificed	B-X
at	B-X
3-week	B-X
intervals	B-X
from	B-X
0	B-X
to	B-X
39	B-X
weeks	B-X
after	B-X
treatments	B-X
began	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

Prior	O
to	O
the	O
appearances	O
of	O
frank	O
neoplasms	O
,	O
volumetric	O
changes	O
in	O
DMBA	O
only	O
and	O
radiation	O
only	O
groups	O
were	O
similar	O
,	O
while	O
volume	O
changes	O
in	O
DMBA	O
+	O
radiation	O
groups	O
increased	O
slowly	O
to	O
a	O
peak	O
later	O
than	O
in	O
other	O
groups	O
and	O
then	O
declined	O
steadily	O
to	O
levels	O
similar	O
to	O
the	O
radiation	O
only	O
group	O
.	O

As	O
in	O
prior	O
studies	O
,	O
there	O
were	O
significant	O
vascular	O
volume	O
differences	O
between	O
DMBA	O
and	O
DMBA	O
+	O
radiation	O
groups	O
of	O
tumor	O
-	O
bearing	O
cheek	O
pouches	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

DMBA	O
maxima	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
DMBA	O
+	O
radiation	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

Radiation	O
significantly	O
affected	O
DMBA	O
-	O
associated	O
vascular	O
volume	O
and	O
permeability	O
changes	O
during	O
carcinogenesis	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

Several	O
possible	O
explanations	O
for	O
the	O
relationship	O
of	O
these	O
changes	O
to	O
the	O
enhancement	O
of	O
DMBA	O
carcinogenesis	O
include	O
:	O
radiation	O
blocking	O
normal	O
capillary	O
proliferative	O
and	O
/	O
or	O
dilatory	O
responses	O
to	O
inflammation	O
secondary	O
to	O
neoplastic	O
changes	O
;	O
radiation	O
-	O
induced	O
focal	O
increases	O
in	O
the	O
pericapillary	O
connective	O
tissue	O
histohematic	O
barrier	O
,	O
stimulating	O
angiogenesis	O
but	O
reducing	O
nutrient	O
diffusion	O
;	O
radiation	O
exposures	O
sensitizing	O
vascular	O
endothelium	O
to	O
subsequent	O
angiogenic	O
stimulation	O
from	O
premalignant	O
tissues	O
;	O
DMBA	O
vascular	O
and	O
epithelial	O
effects	O
partially	O
or	O
completely	O
blocking	O
radiation	O
effects	O
on	O
epithelial	O
and	O
/	O
or	O
endothelial	O
cells	O
;	O
and	O
radiation	O
damage	O
to	O
vessel	O
walls	O
partially	O
or	O
fully	O
inhibiting	O
normal	O
physiologic	O
mechanisms	O
of	O
repairing	O
DMBA	O
damage	O
to	O
the	O
vessels	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
repeated	B-X
low-level	B-X
X	B-X
radiation	B-X
on	B-X
functional	B-X
microvascular	B-X
changes	B-X
in	B-X
hamster	B-X
cheek	B-X
pouch	B-X
epithelium	B-X
during	B-X
and	B-X
following	B-X
carcinogenesis	B-X
by	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
were	B-X
studied	B-X
.	B-X
Prior	B-X
studies	B-X
showed	B-X
enhancement	B-X
of	B-X
such	B-X
carcinogenesis	B-X
by	B-X
repeated	B-X
20	B-X
rad	B-X
head	B-X
and	B-X
neck	B-X
X-radiation	B-X
exposures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
one	B-X
possible	B-X
mechanism	B-X
was	B-X
radiogenic	B-X
alteration	B-X
of	B-X
the	B-X
functional	B-X
microvasculature	B-X
in	B-X
a	B-X
manner	B-X
which	B-X
favored	B-X
subsequent	B-X
tumor	B-X
development	B-X
.	B-X
Hamsters	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
radiation	B-X
,	B-X
DMBA	B-X
,	B-X
radiation	B-X
+	B-X
DMBA	B-X
,	B-X
or	B-X
no	B-X
treatment	B-X
.	B-X
Pouch	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
were	B-X
studied	B-X
by	B-X
fractional	B-X
distributions	B-X
of	B-X
radiotracers	B-X
and	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
statistical	B-X
methods	B-X
which	B-X
explored	B-X
the	B-X
vascular	B-X
parameters	B-X
,	B-X
treatment	B-X
types	B-X
,	B-X
elapsed	B-X
time	B-X
,	B-X
presence	B-X
of	B-X
the	B-X
carcinogen	B-X
,	B-X
and	B-X
histopathologic	B-X
changes	B-X
.	B-X
All	B-X
treatments	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
volume	B-X
with	B-X
time	B-X
,	B-X
while	B-X
only	B-X
DMBA	B-X
treatments	B-X
alone	B-X
resulted	B-X
in	B-X
significant	B-X
changes	B-X
in	B-X
vascular	B-X
permeability	B-X
with	B-X
time	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
appearances	B-X
of	B-X
frank	B-X
neoplasms	B-X
,	B-X
volumetric	B-X
changes	B-X
in	B-X
DMBA	B-X
only	B-X
and	B-X
radiation	B-X
only	B-X
groups	B-X
were	B-X
similar	B-X
,	B-X
while	B-X
volume	B-X
changes	B-X
in	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
increased	B-X
slowly	B-X
to	B-X
a	B-X
peak	B-X
later	B-X
than	B-X
in	B-X
other	B-X
groups	B-X
and	B-X
then	B-X
declined	B-X
steadily	B-X
to	B-X
levels	B-X
similar	B-X
to	B-X
the	B-X
radiation	B-X
only	B-X
group	B-X
.	B-X
As	B-X
in	B-X
prior	B-X
studies	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
vascular	B-X
volume	B-X
differences	B-X
between	B-X
DMBA	B-X
and	B-X
DMBA	B-X
+	B-X
radiation	B-X
groups	B-X
of	B-X
tumor-bearing	B-X
cheek	B-X
pouches	B-X
.	B-X
DMBA	B-X
maxima	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
DMBA	B-X
+	B-X
radiation	B-X
.	B-X
Radiation	B-X
significantly	B-X
affected	B-X
DMBA-associated	B-X
vascular	B-X
volume	B-X
and	B-X
permeability	B-X
changes	B-X
during	B-X
carcinogenesis	B-X
.	B-X
Several	B-X
possible	B-X
explanations	B-X
for	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
changes	B-X
to	B-X
the	B-X
enhancement	B-X
of	B-X
DMBA	B-X
carcinogenesis	B-X
include	B-X
:	B-X
radiation	B-X
blocking	B-X
normal	B-X
capillary	B-X
proliferative	B-X
and/or	B-X
dilatory	B-X
responses	B-X
to	B-X
inflammation	B-X
secondary	B-X
to	B-X
neoplastic	B-X
changes	B-X
;	B-X
radiation-induced	B-X
focal	B-X
increases	B-X
in	B-X
the	B-X
pericapillary	B-X
connective	B-X
tissue	B-X
histohematic	B-X
barrier	B-X
,	B-X
stimulating	B-X
angiogenesis	B-X
but	B-X
reducing	B-X
nutrient	B-X
diffusion	B-X
;	B-X
radiation	B-X
exposures	B-X
sensitizing	B-X
vascular	B-X
endothelium	B-X
to	B-X
subsequent	B-X
angiogenic	B-X
stimulation	B-X
from	B-X
premalignant	B-X
tissues	B-X
;	B-X
DMBA	B-X
vascular	B-X
and	B-X
epithelial	B-X
effects	B-X
partially	B-X
or	B-X
completely	B-X
blocking	B-X
radiation	B-X
effects	B-X
on	B-X
epithelial	B-X
and/or	B-X
endothelial	B-X
cells	B-X
;	B-X
and	B-X
radiation	B-X
damage	B-X
to	B-X
vessel	B-X
walls	B-X
partially	B-X
or	B-X
fully	B-X
inhibiting	B-X
normal	B-X
physiologic	B-X
mechanisms	B-X
of	B-X
repairing	B-X
DMBA	B-X
damage	B-X
to	B-X
the	B-X
vessels	B-X
.	B-X

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
in	O
experimental	O
ocular	O
vasoproliferation	O
.	O
<EOS>	B-X
Scanning	B-X
electron	B-X
microscopy	B-X
of	B-X
vascular	B-X
casts	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
three	B-X
experimental	B-X
models	B-X
of	B-X
neovascularization	B-X
.	B-X
In	B-X
each	B-X
experimental	B-X
situation	B-X
,	B-X
the	B-X
casts	B-X
provided	B-X
a	B-X
valuable	B-X
three	B-X
dimensional	B-X
representation	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
blood	B-X
vessels	B-X
and	B-X
permitted	B-X
subclassification	B-X
of	B-X
the	B-X
vessels	B-X
within	B-X
normal	B-X
and	B-X
proliferating	B-X
vascular	B-X
networks	B-X
.	B-X
Although	B-X
vascular	B-X
casts	B-X
must	B-X
be	B-X
interpreted	B-X
with	B-X
caution	B-X
in	B-X
light	B-X
of	B-X
the	B-X
possibility	B-X
of	B-X
incomplete	B-X
filling	B-X
and	B-X
other	B-X
artifacts	B-X
,	B-X
they	B-X
are	B-X
a	B-X
valuable	B-X
tool	B-X
in	B-X
the	B-X
study	B-X
of	B-X
ocular	B-X
vasoproliferation	B-X
.	B-X

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
was	O
used	O
to	O
investigate	O
three	O
experimental	O
models	O
of	O
neovascularization	O
.	O
<EOS>	B-X
Scanning	B-X
electron	B-X
microscopy	B-X
of	B-X
vascular	B-X
casts	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
three	B-X
experimental	B-X
models	B-X
of	B-X
neovascularization	B-X
.	B-X
In	B-X
each	B-X
experimental	B-X
situation	B-X
,	B-X
the	B-X
casts	B-X
provided	B-X
a	B-X
valuable	B-X
three	B-X
dimensional	B-X
representation	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
blood	B-X
vessels	B-X
and	B-X
permitted	B-X
subclassification	B-X
of	B-X
the	B-X
vessels	B-X
within	B-X
normal	B-X
and	B-X
proliferating	B-X
vascular	B-X
networks	B-X
.	B-X
Although	B-X
vascular	B-X
casts	B-X
must	B-X
be	B-X
interpreted	B-X
with	B-X
caution	B-X
in	B-X
light	B-X
of	B-X
the	B-X
possibility	B-X
of	B-X
incomplete	B-X
filling	B-X
and	B-X
other	B-X
artifacts	B-X
,	B-X
they	B-X
are	B-X
a	B-X
valuable	B-X
tool	B-X
in	B-X
the	B-X
study	B-X
of	B-X
ocular	B-X
vasoproliferation	B-X
.	B-X
To	B-X
report	B-X
a	B-X
model	B-X
of	B-X
choroidal	B-X
neovascularization	B-X
feeder	B-X
vessels	B-X
that	B-X
reconciles	B-X
current	B-X
histologic	B-X
,	B-X
angiographic	B-X
,	B-X
and	B-X
clinical	B-X
data	B-X
,	B-X
and	B-X
to	B-X
report	B-X
experimental	B-X
studies	B-X
that	B-X
investigate	B-X
the	B-X
potential	B-X
of	B-X
indocyanine-green-dye-enhanced	B-X
photocoagulation	B-X
to	B-X
improve	B-X
feeder-vessel	B-X
treatment	B-X
.	B-X

In	O
each	O
experimental	O
situation	O
,	O
the	O
casts	O
provided	O
a	O
valuable	O
three	O
dimensional	O
representation	O
of	O
the	O
newly	O
formed	O
blood	O
vessels	O
and	O
permitted	O
subclassification	O
of	O
the	O
vessels	O
within	O
normal	O
and	O
proliferating	O
vascular	O
networks	O
.	O
<EOS>	B-X
Scanning	B-X
electron	B-X
microscopy	B-X
of	B-X
vascular	B-X
casts	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
three	B-X
experimental	B-X
models	B-X
of	B-X
neovascularization	B-X
.	B-X
In	B-X
each	B-X
experimental	B-X
situation	B-X
,	B-X
the	B-X
casts	B-X
provided	B-X
a	B-X
valuable	B-X
three	B-X
dimensional	B-X
representation	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
blood	B-X
vessels	B-X
and	B-X
permitted	B-X
subclassification	B-X
of	B-X
the	B-X
vessels	B-X
within	B-X
normal	B-X
and	B-X
proliferating	B-X
vascular	B-X
networks	B-X
.	B-X
They	B-X
defined	B-X
also	B-X
the	B-X
predominant	B-X
origin	B-X
of	B-X
new	B-X
vessels	B-X
from	B-X
venules	B-X
and	B-X
capillaries	B-X
,	B-X
and	B-X
enabled	B-X
the	B-X
evolution	B-X
of	B-X
proliferating	B-X
vessels	B-X
into	B-X
arterioles	B-X
and	B-X
venules	B-X
to	B-X
be	B-X
documented	B-X
.	B-X
Although	B-X
vascular	B-X
casts	B-X
must	B-X
be	B-X
interpreted	B-X
with	B-X
caution	B-X
in	B-X
light	B-X
of	B-X
the	B-X
possibility	B-X
of	B-X
incomplete	B-X
filling	B-X
and	B-X
other	B-X
artifacts	B-X
,	B-X
they	B-X
are	B-X
a	B-X
valuable	B-X
tool	B-X
in	B-X
the	B-X
study	B-X
of	B-X
ocular	B-X
vasoproliferation	B-X
.	B-X

They	O
defined	O
also	O
the	O
predominant	O
origin	O
of	O
new	O
vessels	O
from	O
venules	O
and	O
capillaries	O
,	O
and	O
enabled	O
the	O
evolution	O
of	O
proliferating	O
vessels	O
into	O
arterioles	O
and	O
venules	O
to	O
be	O
documented	O
.	O
<EOS>	B-X
In	B-X
each	B-X
experimental	B-X
situation	B-X
,	B-X
the	B-X
casts	B-X
provided	B-X
a	B-X
valuable	B-X
three	B-X
dimensional	B-X
representation	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
blood	B-X
vessels	B-X
and	B-X
permitted	B-X
subclassification	B-X
of	B-X
the	B-X
vessels	B-X
within	B-X
normal	B-X
and	B-X
proliferating	B-X
vascular	B-X
networks	B-X
.	B-X
They	B-X
defined	B-X
also	B-X
the	B-X
predominant	B-X
origin	B-X
of	B-X
new	B-X
vessels	B-X
from	B-X
venules	B-X
and	B-X
capillaries	B-X
,	B-X
and	B-X
enabled	B-X
the	B-X
evolution	B-X
of	B-X
proliferating	B-X
vessels	B-X
into	B-X
arterioles	B-X
and	B-X
venules	B-X
to	B-X
be	B-X
documented	B-X
.	B-X

Although	O
vascular	O
casts	O
must	O
be	O
interpreted	O
with	O
caution	O
in	O
light	O
of	O
the	O
possibility	O
of	O
incomplete	O
filling	O
and	O
other	O
artifacts	O
,	O
they	O
are	O
a	O
valuable	O
tool	O
in	O
the	O
study	O
of	O
ocular	O
vasoproliferation	O
.	O

Participation	O
of	O
p53	B-Gene_or_gene_product
cellular	O
tumour	O
antigen	O
in	O
transformation	O
of	O
normal	O
embryonic	O
cells	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
tumour	B-X
antigen	B-X
p53	B-X
is	B-X
found	B-X
at	B-X
elevated	B-X
levels	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
transformed	B-X
cells	B-X
(	B-X
for	B-X
reviews	B-X
see	B-X
refs	B-X
1	B-X
,	B-X
2	B-X
)	B-X
.	B-X
Very	B-X
little	B-X
is	B-X
yet	B-X
known	B-X
about	B-X
the	B-X
precise	B-X
relationship	B-X
of	B-X
p53	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X
Although	B-X
the	B-X
increase	B-X
in	B-X
p53	B-X
levels	B-X
could	B-X
be	B-X
a	B-X
secondary	B-X
by-product	B-X
of	B-X
the	B-X
transformed	B-X
state	B-X
,	B-X
it	B-X
is	B-X
equally	B-X
possible	B-X
that	B-X
p53	B-X
is	B-X
actively	B-X
involved	B-X
in	B-X
altering	B-X
cellular	B-X
growth	B-X
properties	B-X
,	B-X
especially	B-X
as	B-X
it	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
normal	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
test	B-X
whether	B-X
p53	B-X
could	B-X
behave	B-X
in	B-X
a	B-X
manner	B-X
similar	B-X
to	B-X
known	B-X
genes	B-X
in	B-X
a	B-X
biological	B-X
test	B-X
system	B-X
,	B-X
and	B-X
we	B-X
demonstrate	B-X
here	B-X
that	B-X
p53	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
activated	B-X
Ha-ras	B-X
oncogene	B-X
to	B-X
transform	B-X
normal	B-X
embryonic	B-X
cells	B-X
.	B-X
The	B-X
resultant	B-X
foci	B-X
contain	B-X
cells	B-X
of	B-X
a	B-X
markedly	B-X
altered	B-X
morphology	B-X
which	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
p53	B-X
.	B-X
Cell	B-X
lines	B-X
established	B-X
from	B-X
such	B-X
foci	B-X
elicit	B-X
tumours	B-X
in	B-X
syngeneic	B-X
animals	B-X
.	B-X

The	O
cellular	O
tumour	O
antigen	O
p53	B-Gene_or_gene_product
is	O
found	O
at	O
elevated	O
levels	O
in	O
a	O
wide	O
variety	O
of	O
transformed	O
cells	O
(	O
for	O
reviews	O
see	O
refs	O
1	O
,	O
2	O
)	O
.	O

Very	O
little	O
is	O
yet	O
known	O
about	O
the	O
precise	O
relationship	O
of	O
p53	B-Gene_or_gene_product
to	O
malignant	O
transformation	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
tumour	B-X
antigen	B-X
p53	B-X
is	B-X
found	B-X
at	B-X
elevated	B-X
levels	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
transformed	B-X
cells	B-X
(	B-X
for	B-X
reviews	B-X
see	B-X
refs	B-X
1	B-X
,	B-X
2	B-X
)	B-X
.	B-X
Very	B-X
little	B-X
is	B-X
yet	B-X
known	B-X
about	B-X
the	B-X
precise	B-X
relationship	B-X
of	B-X
p53	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X
Although	B-X
the	B-X
increase	B-X
in	B-X
p53	B-X
levels	B-X
could	B-X
be	B-X
a	B-X
secondary	B-X
by-product	B-X
of	B-X
the	B-X
transformed	B-X
state	B-X
,	B-X
it	B-X
is	B-X
equally	B-X
possible	B-X
that	B-X
p53	B-X
is	B-X
actively	B-X
involved	B-X
in	B-X
altering	B-X
cellular	B-X
growth	B-X
properties	B-X
,	B-X
especially	B-X
as	B-X
it	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
normal	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
test	B-X
whether	B-X
p53	B-X
could	B-X
behave	B-X
in	B-X
a	B-X
manner	B-X
similar	B-X
to	B-X
known	B-X
genes	B-X
in	B-X
a	B-X
biological	B-X
test	B-X
system	B-X
,	B-X
and	B-X
we	B-X
demonstrate	B-X
here	B-X
that	B-X
p53	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
activated	B-X
Ha-ras	B-X
oncogene	B-X
to	B-X
transform	B-X
normal	B-X
embryonic	B-X
cells	B-X
.	B-X
The	B-X
resultant	B-X
foci	B-X
contain	B-X
cells	B-X
of	B-X
a	B-X
markedly	B-X
altered	B-X
morphology	B-X
which	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
p53	B-X
.	B-X

Although	O
the	O
increase	O
in	O
p53	B-Gene_or_gene_product
levels	O
could	O
be	O
a	O
secondary	O
by	O
-	O
product	O
of	O
the	O
transformed	O
state	O
,	O
it	O
is	O
equally	O
possible	O
that	O
p53	B-Gene_or_gene_product
is	O
actively	O
involved	O
in	O
altering	O
cellular	O
growth	O
properties	O
,	O
especially	O
as	O
it	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
normal	O
cell	O
proliferation	O
.	O
<EOS>	B-X
The	B-X
cellular	B-X
tumour	B-X
antigen	B-X
p53	B-X
is	B-X
found	B-X
at	B-X
elevated	B-X
levels	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
transformed	B-X
cells	B-X
(	B-X
for	B-X
reviews	B-X
see	B-X
refs	B-X
1	B-X
,	B-X
2	B-X
)	B-X
.	B-X
Very	B-X
little	B-X
is	B-X
yet	B-X
known	B-X
about	B-X
the	B-X
precise	B-X
relationship	B-X
of	B-X
p53	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X
Although	B-X
the	B-X
increase	B-X
in	B-X
p53	B-X
levels	B-X
could	B-X
be	B-X
a	B-X
secondary	B-X
by-product	B-X
of	B-X
the	B-X
transformed	B-X
state	B-X
,	B-X
it	B-X
is	B-X
equally	B-X
possible	B-X
that	B-X
p53	B-X
is	B-X
actively	B-X
involved	B-X
in	B-X
altering	B-X
cellular	B-X
growth	B-X
properties	B-X
,	B-X
especially	B-X
as	B-X
it	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
normal	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
test	B-X
whether	B-X
p53	B-X
could	B-X
behave	B-X
in	B-X
a	B-X
manner	B-X
similar	B-X
to	B-X
known	B-X
genes	B-X
in	B-X
a	B-X
biological	B-X
test	B-X
system	B-X
,	B-X
and	B-X
we	B-X
demonstrate	B-X
here	B-X
that	B-X
p53	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
activated	B-X
Ha-ras	B-X
oncogene	B-X
to	B-X
transform	B-X
normal	B-X
embryonic	B-X
cells	B-X
.	B-X
The	B-X
resultant	B-X
foci	B-X
contain	B-X
cells	B-X
of	B-X
a	B-X
markedly	B-X
altered	B-X
morphology	B-X
which	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
p53	B-X
.	B-X

We	O
sought	O
to	O
test	O
whether	O
p53	B-Gene_or_gene_product
could	O
behave	O
in	O
a	O
manner	O
similar	O
to	O
known	O
genes	O
in	O
a	O
biological	O
test	O
system	O
,	O
and	O
we	O
demonstrate	O
here	O
that	O
p53	B-Gene_or_gene_product
can	O
cooperate	O
with	O
the	O
activated	O
Ha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
oncogene	O
to	O
transform	O
normal	O
embryonic	O
cells	O
.	O

The	O
resultant	O
foci	O
contain	O
cells	O
of	O
a	O
markedly	O
altered	O
morphology	O
which	O
produce	O
high	O
levels	O
of	O
p53	B-Gene_or_gene_product
.	O
<EOS>	B-X
The	B-X
cellular	B-X
tumour	B-X
antigen	B-X
p53	B-X
is	B-X
found	B-X
at	B-X
elevated	B-X
levels	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
transformed	B-X
cells	B-X
(	B-X
for	B-X
reviews	B-X
see	B-X
refs	B-X
1	B-X
,	B-X
2	B-X
)	B-X
.	B-X
Very	B-X
little	B-X
is	B-X
yet	B-X
known	B-X
about	B-X
the	B-X
precise	B-X
relationship	B-X
of	B-X
p53	B-X
to	B-X
malignant	B-X
transformation	B-X
.	B-X
Although	B-X
the	B-X
increase	B-X
in	B-X
p53	B-X
levels	B-X
could	B-X
be	B-X
a	B-X
secondary	B-X
by-product	B-X
of	B-X
the	B-X
transformed	B-X
state	B-X
,	B-X
it	B-X
is	B-X
equally	B-X
possible	B-X
that	B-X
p53	B-X
is	B-X
actively	B-X
involved	B-X
in	B-X
altering	B-X
cellular	B-X
growth	B-X
properties	B-X
,	B-X
especially	B-X
as	B-X
it	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
normal	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
test	B-X
whether	B-X
p53	B-X
could	B-X
behave	B-X
in	B-X
a	B-X
manner	B-X
similar	B-X
to	B-X
known	B-X
genes	B-X
in	B-X
a	B-X
biological	B-X
test	B-X
system	B-X
,	B-X
and	B-X
we	B-X
demonstrate	B-X
here	B-X
that	B-X
p53	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
activated	B-X
Ha-ras	B-X
oncogene	B-X
to	B-X
transform	B-X
normal	B-X
embryonic	B-X
cells	B-X
.	B-X
The	B-X
resultant	B-X
foci	B-X
contain	B-X
cells	B-X
of	B-X
a	B-X
markedly	B-X
altered	B-X
morphology	B-X
which	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
p53	B-X
.	B-X
Cell	B-X
lines	B-X
established	B-X
from	B-X
such	B-X
foci	B-X
elicit	B-X
tumours	B-X
in	B-X
syngeneic	B-X
animals	B-X
.	B-X

Cell	O
lines	O
established	O
from	O
such	O
foci	O
elicit	O
tumours	O
in	O
syngeneic	O
animals	O
.	O
<EOS>	B-X
The	B-X
resultant	B-X
foci	B-X
contain	B-X
cells	B-X
of	B-X
a	B-X
markedly	B-X
altered	B-X
morphology	B-X
which	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
p53	B-X
.	B-X
Cell	B-X
lines	B-X
established	B-X
from	B-X
such	B-X
foci	B-X
elicit	B-X
tumours	B-X
in	B-X
syngeneic	B-X
animals	B-X
.	B-X
Human	B-X
adenovirus	B-X
type	B-X
9	B-X
(	B-X
Ad9	B-X
)	B-X
elicits	B-X
exclusively	B-X
estrogen-dependent	B-X
mammary	B-X
tumors	B-X
in	B-X
rats	B-X
,	B-X
and	B-X
an	B-X
essential	B-X
oncogenic	B-X
determinant	B-X
for	B-X
this	B-X
virus	B-X
is	B-X
Ad9	B-X
E4	B-X
open	B-X
reading	B-X
frame	B-X
1	B-X
(	B-X
9ORF1	B-X
)	B-X
,	B-X
which	B-X
encodes	B-X
a	B-X
125-residue	B-X
cytoplasmic	B-X
protein	B-X
with	B-X
cellular	B-X
growth-transforming	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
engineered	B-X
48	B-X
different	B-X
mutant	B-X
9ORF1	B-X
genes	B-X
in	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
regions	B-X
of	B-X
this	B-X
viral	B-X
protein	B-X
essential	B-X
for	B-X
transformation	B-X
of	B-X
the	B-X
established	B-X
rat	B-X
embryo	B-X
fibroblast	B-X
cell	B-X
line	B-X
CREF	B-X
.	B-X
In	B-X
initial	B-X
assays	B-X
with	B-X
CREF	B-X
cells	B-X
,	B-X
17	B-X
of	B-X
the	B-X
48	B-X
mutant	B-X
9ORF1	B-X
genes	B-X
proved	B-X
to	B-X
be	B-X
severely	B-X
defective	B-X
for	B-X
generating	B-X
transformed	B-X
foci	B-X
but	B-X
only	B-X
7	B-X
of	B-X
these	B-X
defective	B-X
genes	B-X
expressed	B-X
detectable	B-X
amounts	B-X
of	B-X
protein	B-X
.	B-X
Compared	B-X
to	B-X
cell	B-X
pools	B-X
expressing	B-X
the	B-X
wild-type	B-X
9ORF1	B-X
protein	B-X
,	B-X
most	B-X
cell	B-X
pools	B-X
expressing	B-X
mutant	B-X
proteins	B-X
displayed	B-X
decreased	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
,	B-X
and	B-X
all	B-X
generated	B-X
significantly	B-X
smaller	B-X
tumors	B-X
in	B-X
syngeneic	B-X
animals	B-X
.	B-X

Interaction	O
between	O
cellular	O
and	O
viral	O
genes	O
in	O
the	O
expression	O
of	O
the	O
RSV	O
-	O
induced	O
transformation	O
-	O
specific	O
cell	O
-	O
surface	O
antigen	O
VCSA	B-Gene_or_gene_product
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
BHK	B-X
hamster	B-X
fibroblasts	B-X
by	B-X
an	B-X
env-	B-X
strain	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
(	B-X
RSV	B-X
)	B-X
leads	B-X
to	B-X
the	B-X
appearance	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
of	B-X
a	B-X
virus-induced	B-X
nonvirion	B-X
antigen	B-X
(	B-X
VCSA	B-X
)	B-X
,	B-X
specific	B-X
for	B-X
transformation	B-X
,	B-X
whose	B-X
expression	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
transforming	B-X
src	B-X
gene	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
a	B-X
rabbit	B-X
anti-VCSA	B-X
serum	B-X
lyses	B-X
specifically	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
,	B-X
51Cr-labelled	B-X
RSV-transformed	B-X
cells	B-X
from	B-X
different	B-X
animal	B-X
species	B-X
.	B-X
Now	B-X
,	B-X
by	B-X
competition	B-X
experiments	B-X
with	B-X
a	B-X
panel	B-X
of	B-X
different	B-X
unlabelled	B-X
cells	B-X
we	B-X
show	B-X
that	B-X
the	B-X
VCSA	B-X
expressed	B-X
on	B-X
RSV-transformed	B-X
hamster	B-X
fibroblasts	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
at	B-X
least	B-X
three	B-X
distinct	B-X
antigenic	B-X
specificities	B-X
:	B-X
(	B-X
1	B-X
)	B-X
one	B-X
expressed	B-X
on	B-X
all	B-X
RSV-transformed	B-X
fibroblasts	B-X
,	B-X
regardless	B-X
their	B-X
species	B-X
and	B-X
the	B-X
subgroup	B-X
or	B-X
strain	B-X
of	B-X
the	B-X
transforming	B-X
virus	B-X
;	B-X
(	B-X
2	B-X
)	B-X
one	B-X
cross-reacting	B-X
with	B-X
a	B-X
cell-surface	B-X
antigen	B-X
(	B-X
CSA	B-X
)	B-X
expressed	B-X
at	B-X
various	B-X
degrees	B-X
on	B-X
untransformed	B-X
avian	B-X
fibroblasts	B-X
,	B-X
but	B-X
not	B-X
on	B-X
mammalian	B-X
fibroblasts	B-X
;	B-X
(	B-X
3	B-X
)	B-X
one	B-X
species-specific	B-X
,	B-X
present	B-X
only	B-X
on	B-X
RSV-transformed	B-X
hamster	B-X
fibroblasts	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
VCSA	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
several	B-X
antigenic	B-X
determinants	B-X
,	B-X
and	B-X
that	B-X
some	B-X
of	B-X
these	B-X
differ	B-X
in	B-X
different	B-X
cells	B-X
transformed	B-X
by	B-X
RSV	B-X
.	B-X
This	B-X
observation	B-X
indicates	B-X
that	B-X
VCSA	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
viral	B-X
src	B-X
gene	B-X
product	B-X
pp60src	B-X
with	B-X
host	B-X
cell	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
or	B-X
gene	B-X
product	B-X
(	B-X
s	B-X
)	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
simple	B-X
expression	B-X
of	B-X
this	B-X
molecule	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Transformation	O
of	O
BHK	O
hamster	O
fibroblasts	O
by	O
an	O
env	O
-	O
strain	O
of	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
leads	O
to	O
the	O
appearance	O
at	O
the	O
cell	O
surface	O
of	O
a	O
virus	B-Gene_or_gene_product
-	I-Gene_or_gene_product
induced	I-Gene_or_gene_product
nonvirion	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
(	O
VCSA	B-Gene_or_gene_product
)	O
,	O
specific	O
for	O
transformation	O
,	O
whose	O
expression	O
is	O
controlled	O
by	O
the	O
transforming	O
src	B-Gene_or_gene_product
gene	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
a	O
rabbit	O
anti	O
-	O
VCSA	B-Gene_or_gene_product
serum	O
lyses	O
specifically	O
,	O
in	O
the	O
presence	O
of	O
complement	O
,	O
51Cr	O
-	O
labelled	O
RSV	O
-	O
transformed	O
cells	O
from	O
different	O
animal	O
species	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
BHK	B-X
hamster	B-X
fibroblasts	B-X
by	B-X
an	B-X
env-	B-X
strain	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
(	B-X
RSV	B-X
)	B-X
leads	B-X
to	B-X
the	B-X
appearance	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
of	B-X
a	B-X
virus-induced	B-X
nonvirion	B-X
antigen	B-X
(	B-X
VCSA	B-X
)	B-X
,	B-X
specific	B-X
for	B-X
transformation	B-X
,	B-X
whose	B-X
expression	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
transforming	B-X
src	B-X
gene	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
a	B-X
rabbit	B-X
anti-VCSA	B-X
serum	B-X
lyses	B-X
specifically	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
,	B-X
51Cr-labelled	B-X
RSV-transformed	B-X
cells	B-X
from	B-X
different	B-X
animal	B-X
species	B-X
.	B-X
Now	B-X
,	B-X
by	B-X
competition	B-X
experiments	B-X
with	B-X
a	B-X
panel	B-X
of	B-X
different	B-X
unlabelled	B-X
cells	B-X
we	B-X
show	B-X
that	B-X
the	B-X
VCSA	B-X
expressed	B-X
on	B-X
RSV-transformed	B-X
hamster	B-X
fibroblasts	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
at	B-X
least	B-X
three	B-X
distinct	B-X
antigenic	B-X
specificities	B-X
:	B-X
(	B-X
1	B-X
)	B-X
one	B-X
expressed	B-X
on	B-X
all	B-X
RSV-transformed	B-X
fibroblasts	B-X
,	B-X
regardless	B-X
their	B-X
species	B-X
and	B-X
the	B-X
subgroup	B-X
or	B-X
strain	B-X
of	B-X
the	B-X
transforming	B-X
virus	B-X
;	B-X
(	B-X
2	B-X
)	B-X
one	B-X
cross-reacting	B-X
with	B-X
a	B-X
cell-surface	B-X
antigen	B-X
(	B-X
CSA	B-X
)	B-X
expressed	B-X
at	B-X
various	B-X
degrees	B-X
on	B-X
untransformed	B-X
avian	B-X
fibroblasts	B-X
,	B-X
but	B-X
not	B-X
on	B-X
mammalian	B-X
fibroblasts	B-X
;	B-X
(	B-X
3	B-X
)	B-X
one	B-X
species-specific	B-X
,	B-X
present	B-X
only	B-X
on	B-X
RSV-transformed	B-X
hamster	B-X
fibroblasts	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
VCSA	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
several	B-X
antigenic	B-X
determinants	B-X
,	B-X
and	B-X
that	B-X
some	B-X
of	B-X
these	B-X
differ	B-X
in	B-X
different	B-X
cells	B-X
transformed	B-X
by	B-X
RSV	B-X
.	B-X
This	B-X
observation	B-X
indicates	B-X
that	B-X
VCSA	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
viral	B-X
src	B-X
gene	B-X
product	B-X
pp60src	B-X
with	B-X
host	B-X
cell	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
or	B-X
gene	B-X
product	B-X
(	B-X
s	B-X
)	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
simple	B-X
expression	B-X
of	B-X
this	B-X
molecule	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Now	O
,	O
by	O
competition	O
experiments	O
with	O
a	O
panel	O
of	O
different	O
unlabelled	O
cells	O
we	O
show	O
that	O
the	O
VCSA	B-Gene_or_gene_product
expressed	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	O
is	O
a	O
complex	O
of	O
at	O
least	O
three	O
distinct	O
antigenic	O
specificities	O
:	O
(	O
1	O
)	O
one	O
expressed	O
on	O
all	O
RSV	O
-	O
transformed	O
fibroblasts	O
,	O
regardless	O
their	O
species	O
and	O
the	O
subgroup	O
or	O
strain	O
of	O
the	O
transforming	O
virus	O
;	O
(	O
2	O
)	O
one	O
cross	O
-	O
reacting	O
with	O
a	O
cell	B-Gene_or_gene_product
-	I-Gene_or_gene_product
surface	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
(	O
CSA	B-Gene_or_gene_product
)	O
expressed	O
at	O
various	O
degrees	O
on	O
untransformed	O
avian	O
fibroblasts	O
,	O
but	O
not	O
on	O
mammalian	O
fibroblasts	O
;	O
(	O
3	O
)	O
one	O
species	O
-	O
specific	O
,	O
present	O
only	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
seroepidemiological	B-X
studies	B-X
,	B-X
human	B-X
herpes	B-X
simplex	B-X
virus	B-X
types	B-X
1	B-X
and	B-X
2	B-X
(	B-X
HSV-1	B-X
,	B-X
HSV-2	B-X
)	B-X
are	B-X
put	B-X
in	B-X
relation	B-X
with	B-X
a	B-X
number	B-X
of	B-X
cancer	B-X
diseases	B-X
;	B-X
however	B-X
,	B-X
they	B-X
do	B-X
not	B-X
appear	B-X
to	B-X
play	B-X
a	B-X
direct	B-X
role	B-X
,	B-X
being	B-X
only	B-X
considered	B-X
cofactors	B-X
.	B-X
Their	B-X
ability	B-X
to	B-X
transform	B-X
the	B-X
cells	B-X
in	B-X
vitro	B-X
could	B-X
be	B-X
demonstrated	B-X
experimentally	B-X
by	B-X
removing	B-X
their	B-X
high	B-X
lytic	B-X
ability	B-X
by	B-X
a	B-X
certain	B-X
dose	B-X
of	B-X
UV	B-X
radiation	B-X
or	B-X
by	B-X
photoinactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
photosensitizers	B-X
,	B-X
such	B-X
as	B-X
neutral	B-X
red	B-X
or	B-X
methylene	B-X
blue	B-X
,	B-X
or	B-X
culturing	B-X
under	B-X
conditions	B-X
suppressing	B-X
their	B-X
lytic	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
studies	B-X
indicate	B-X
that	B-X
UV	B-X
irradiated	B-X
or	B-X
photoinactivated	B-X
HSV-1	B-X
and	B-X
HSV-2	B-X
,	B-X
able	B-X
to	B-X
transform	B-X
non-transformed	B-X
cells	B-X
,	B-X
behave	B-X
differently	B-X
in	B-X
transformed	B-X
cells	B-X
suppressing	B-X
their	B-X
transformed	B-X
phenotype	B-X
.	B-X
Furthermore	B-X
,	B-X
both	B-X
transforming	B-X
and	B-X
transformed	B-X
phenotype	B-X
suppressing	B-X
activities	B-X
are	B-X
pertaining	B-X
only	B-X
to	B-X
non-syncytial	B-X
virus	B-X
strains	B-X
.	B-X
There	B-X
are	B-X
some	B-X
proposed	B-X
mechanisms	B-X
explaining	B-X
their	B-X
transforming	B-X
activity	B-X
.	B-X
According	B-X
to	B-X
the	B-X
``	B-X
hit	B-X
and	B-X
run	B-X
''	B-X
mechanism	B-X
,	B-X
viral	B-X
DNA	B-X
induces	B-X
only	B-X
initiation	B-X
of	B-X
transformation	B-X
by	B-X
interacting	B-X
with	B-X
cellular	B-X
DNA	B-X
bringing	B-X
about	B-X
mutations	B-X
and	B-X
epigenetic	B-X
changes	B-X
and	B-X
is	B-X
no	B-X
longer	B-X
involved	B-X
in	B-X
other	B-X
processes	B-X
of	B-X
neoplastic	B-X
progression	B-X
.	B-X
According	B-X
to	B-X
the	B-X
``	B-X
hijacking	B-X
''	B-X
mechanism	B-X
,	B-X
virus	B-X
products	B-X
in	B-X
infected	B-X
cells	B-X
may	B-X
activate	B-X
signalling	B-X
pathways	B-X
and	B-X
thus	B-X
induce	B-X
uncontrolled	B-X
proliferation	B-X
.	B-X
a	B-X
product	B-X
of	B-X
HSV-2	B-X
gene	B-X
designated	B-X
ICP10	B-X
that	B-X
encodes	B-X
an	B-X
oncoprotein	B-X
RR1PK	B-X
that	B-X
activates	B-X
the	B-X
Ras	B-X
pathway	B-X
.	B-X
In	B-X
two	B-X
cases	B-X
of	B-X
cancer	B-X
,	B-X
in	B-X
the	B-X
case	B-X
of	B-X
serous	B-X
ovarian	B-X
carcinoma	B-X
and	B-X
in	B-X
some	B-X
prostate	B-X
tumours	B-X
,	B-X
virus-encoded	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
were	B-X
detected	B-X
as	B-X
a	B-X
possible	B-X
cofactor	B-X
in	B-X
tumorigenesis	B-X
.	B-X
And	B-X
,	B-X
recently	B-X
described	B-X
herpes	B-X
virus-associated	B-X
growth	B-X
factors	B-X
with	B-X
transforming	B-X
and	B-X
transformation	B-X
repressing	B-X
activity	B-X
might	B-X
be	B-X
considered	B-X
important	B-X
factors	B-X
playing	B-X
a	B-X
role	B-X
in	B-X
tumour	B-X
formation	B-X
.	B-X
And	B-X
finally	B-X
,	B-X
there	B-X
is	B-X
a	B-X
number	B-X
of	B-X
evidence	B-X
that	B-X
HSV-2	B-X
may	B-X
increase	B-X
the	B-X
risk	B-X
of	B-X
cervical	B-X
cancer	B-X
after	B-X
infection	B-X
with	B-X
human	B-X
papillomaviruses	B-X
.	B-X
A	B-X
similar	B-X
situation	B-X
is	B-X
with	B-X
human	B-X
cytomegalovirus	B-X
;	B-X
however	B-X
,	B-X
here	B-X
,	B-X
a	B-X
novel	B-X
mechanism	B-X
named	B-X
oncomodulation	B-X
has	B-X
been	B-X
proposed	B-X
.	B-X
Oncomodulation	B-X
means	B-X
that	B-X
HCMV	B-X
infects	B-X
tumour	B-X
cells	B-X
and	B-X
modulates	B-X
their	B-X
malignant	B-X
properties	B-X
without	B-X
having	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
cell	B-X
transformation	B-X
.	B-X

It	O
is	O
concluded	O
that	O
VCSA	B-Gene_or_gene_product
is	O
a	O
complex	O
of	O
several	O
antigenic	O
determinants	O
,	O
and	O
that	O
some	O
of	O
these	O
differ	O
in	O
different	O
cells	O
transformed	O
by	O
RSV	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
BHK	B-X
hamster	B-X
fibroblasts	B-X
by	B-X
an	B-X
env-	B-X
strain	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
(	B-X
RSV	B-X
)	B-X
leads	B-X
to	B-X
the	B-X
appearance	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
of	B-X
a	B-X
virus-induced	B-X
nonvirion	B-X
antigen	B-X
(	B-X
VCSA	B-X
)	B-X
,	B-X
specific	B-X
for	B-X
transformation	B-X
,	B-X
whose	B-X
expression	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
transforming	B-X
src	B-X
gene	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
a	B-X
rabbit	B-X
anti-VCSA	B-X
serum	B-X
lyses	B-X
specifically	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
complement	B-X
,	B-X
51Cr-labelled	B-X
RSV-transformed	B-X
cells	B-X
from	B-X
different	B-X
animal	B-X
species	B-X
.	B-X
Now	B-X
,	B-X
by	B-X
competition	B-X
experiments	B-X
with	B-X
a	B-X
panel	B-X
of	B-X
different	B-X
unlabelled	B-X
cells	B-X
we	B-X
show	B-X
that	B-X
the	B-X
VCSA	B-X
expressed	B-X
on	B-X
RSV-transformed	B-X
hamster	B-X
fibroblasts	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
at	B-X
least	B-X
three	B-X
distinct	B-X
antigenic	B-X
specificities	B-X
:	B-X
(	B-X
1	B-X
)	B-X
one	B-X
expressed	B-X
on	B-X
all	B-X
RSV-transformed	B-X
fibroblasts	B-X
,	B-X
regardless	B-X
their	B-X
species	B-X
and	B-X
the	B-X
subgroup	B-X
or	B-X
strain	B-X
of	B-X
the	B-X
transforming	B-X
virus	B-X
;	B-X
(	B-X
2	B-X
)	B-X
one	B-X
cross-reacting	B-X
with	B-X
a	B-X
cell-surface	B-X
antigen	B-X
(	B-X
CSA	B-X
)	B-X
expressed	B-X
at	B-X
various	B-X
degrees	B-X
on	B-X
untransformed	B-X
avian	B-X
fibroblasts	B-X
,	B-X
but	B-X
not	B-X
on	B-X
mammalian	B-X
fibroblasts	B-X
;	B-X
(	B-X
3	B-X
)	B-X
one	B-X
species-specific	B-X
,	B-X
present	B-X
only	B-X
on	B-X
RSV-transformed	B-X
hamster	B-X
fibroblasts	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
VCSA	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
several	B-X
antigenic	B-X
determinants	B-X
,	B-X
and	B-X
that	B-X
some	B-X
of	B-X
these	B-X
differ	B-X
in	B-X
different	B-X
cells	B-X
transformed	B-X
by	B-X
RSV	B-X
.	B-X
This	B-X
observation	B-X
indicates	B-X
that	B-X
VCSA	B-X
expression	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
viral	B-X
src	B-X
gene	B-X
product	B-X
pp60src	B-X
with	B-X
host	B-X
cell	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
or	B-X
gene	B-X
product	B-X
(	B-X
s	B-X
)	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
simple	B-X
expression	B-X
of	B-X
this	B-X
molecule	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

This	O
observation	O
indicates	O
that	O
VCSA	B-Gene_or_gene_product
expression	O
at	O
the	O
cell	O
surface	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
the	O
viral	O
src	B-Gene_or_gene_product
gene	O
product	O
pp60src	B-Gene_or_gene_product
with	O
host	O
cell	O
gene	O
(	O
s	O
)	O
or	O
gene	O
product	O
(	O
s	O
)	O
,	O
rather	O
than	O
the	O
simple	O
expression	O
of	O
this	O
molecule	O
at	O
the	O
cell	O
surface	O
.	O

The	O
effect	O
of	O
translocations	O
on	O
the	O
cellular	O
myc	B-Gene_or_gene_product
gene	O
in	O
Burkitt	O
lymphomas	O
.	O
<EOS>	B-X
Chromosomal	B-X
translocations	B-X
are	B-X
found	B-X
to	B-X
be	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
Burkitt	B-X
lymphomas	B-X
.	B-X
Similar	B-X
translocations	B-X
are	B-X
found	B-X
in	B-X
mouse	B-X
plasmacytomas	B-X
and	B-X
both	B-X
diseases	B-X
involve	B-X
interchanges	B-X
between	B-X
one	B-X
of	B-X
the	B-X
immunoglobulin	B-X
loci	B-X
and	B-X
DNA	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
has	B-X
been	B-X
elucidated	B-X
from	B-X
studies	B-X
on	B-X
translocated	B-X
versions	B-X
of	B-X
the	B-X
gene	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
transformation	B-X
by	B-X
promoting	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
bearing	B-X
the	B-X
rearranged	B-X
chromosomes	B-X
.	B-X

Chromosomal	O
translocations	O
are	O
found	O
to	O
be	O
a	O
characteristic	O
feature	O
of	O
Burkitt	O
lymphomas	O
.	O
<EOS>	B-X
Chromosomal	B-X
translocations	B-X
are	B-X
found	B-X
to	B-X
be	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
Burkitt	B-X
lymphomas	B-X
.	B-X
Similar	B-X
translocations	B-X
are	B-X
found	B-X
in	B-X
mouse	B-X
plasmacytomas	B-X
and	B-X
both	B-X
diseases	B-X
involve	B-X
interchanges	B-X
between	B-X
one	B-X
of	B-X
the	B-X
immunoglobulin	B-X
loci	B-X
and	B-X
DNA	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
.	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
has	B-X
been	B-X
defined	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
its	B-X
characteristic	B-X
cytomorphology	B-X
.	B-X
Their	B-X
morphological	B-X
identity	B-X
probably	B-X
relates	B-X
to	B-X
similar	B-X
chromosomal	B-X
translocations	B-X
in	B-X
both	B-X
tumours	B-X
,	B-X
resulting	B-X
in	B-X
c-myc	B-X
de-regulation	B-X
and	B-X
consequent	B-X
unrestrained	B-X
proliferation	B-X
without	B-X
differentiation	B-X
.	B-X
Similar	B-X
gene	B-X
rearrangements	B-X
are	B-X
found	B-X
in	B-X
a	B-X
proportion	B-X
of	B-X
AIDS-related	B-X
lymphomas	B-X
that	B-X
are	B-X
predominantly	B-X
extranodal	B-X
and	B-X
have	B-X
the	B-X
cytomorphology	B-X
of	B-X
BL	B-X
.	B-X
The	B-X
term	B-X
``	B-X
Burkitt-like	B-X
lymphoma	B-X
''	B-X
(	B-X
BLL	B-X
)	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
a	B-X
group	B-X
of	B-X
high-grade	B-X
B-cell	B-X
lymphomas	B-X
that	B-X
appear	B-X
morphologically	B-X
intermediate	B-X
between	B-X
BL	B-X
and	B-X
centroblastic/immunoblastic	B-X
lymphomas	B-X
,	B-X
as	B-X
detailed	B-X
in	B-X
an	B-X
accompanying	B-X
paper	B-X
in	B-X
this	B-X
issue	B-X
.	B-X
The	B-X
association	B-X
of	B-X
Burkitt	B-X
's	B-X
name	B-X
with	B-X
such	B-X
a	B-X
disparate	B-X
group	B-X
of	B-X
tumours	B-X
is	B-X
confusing	B-X
and	B-X
new	B-X
terminology	B-X
for	B-X
sporadic	B-X
BL	B-X
,	B-X
AIDS-related	B-X
BL	B-X
and	B-X
BLL	B-X
is	B-X
desirable	B-X
.	B-X
It	B-X
is	B-X
important	B-X
that	B-X
clinico-anatomical	B-X
features	B-X
,	B-X
as	B-X
well	B-X
as	B-X
cytomorphology	B-X
,	B-X
should	B-X
be	B-X
taken	B-X
into	B-X
account	B-X
in	B-X
the	B-X
diagnosis	B-X
of	B-X
endemic	B-X
BL	B-X
.	B-X

Similar	O
translocations	O
are	O
found	O
in	O
mouse	O
plasmacytomas	O
and	O
both	O
diseases	O
involve	O
interchanges	O
between	O
one	O
of	O
the	O
immunoglobulin	B-Gene_or_gene_product
loci	O
and	O
DNA	O
in	O
the	O
vicinity	O
of	O
the	O
myc	B-Gene_or_gene_product
gene	O
.	O
<EOS>	B-X
Chromosomal	B-X
translocations	B-X
are	B-X
found	B-X
to	B-X
be	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
Burkitt	B-X
lymphomas	B-X
.	B-X
Similar	B-X
translocations	B-X
are	B-X
found	B-X
in	B-X
mouse	B-X
plasmacytomas	B-X
and	B-X
both	B-X
diseases	B-X
involve	B-X
interchanges	B-X
between	B-X
one	B-X
of	B-X
the	B-X
immunoglobulin	B-X
loci	B-X
and	B-X
DNA	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
has	B-X
been	B-X
elucidated	B-X
from	B-X
studies	B-X
on	B-X
translocated	B-X
versions	B-X
of	B-X
the	B-X
gene	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
transformation	B-X
by	B-X
promoting	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
bearing	B-X
the	B-X
rearranged	B-X
chromosomes	B-X
.	B-X

The	O
structure	O
of	O
the	O
myc	B-Gene_or_gene_product
gene	O
has	O
been	O
elucidated	O
from	O
studies	O
on	O
translocated	O
versions	O
of	O
the	O
gene	O
.	O
<EOS>	B-X
Similar	B-X
translocations	B-X
are	B-X
found	B-X
in	B-X
mouse	B-X
plasmacytomas	B-X
and	B-X
both	B-X
diseases	B-X
involve	B-X
interchanges	B-X
between	B-X
one	B-X
of	B-X
the	B-X
immunoglobulin	B-X
loci	B-X
and	B-X
DNA	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
has	B-X
been	B-X
elucidated	B-X
from	B-X
studies	B-X
on	B-X
translocated	B-X
versions	B-X
of	B-X
the	B-X
gene	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
transformation	B-X
by	B-X
promoting	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
bearing	B-X
the	B-X
rearranged	B-X
chromosomes	B-X
.	B-X

Activation	O
of	O
the	O
myc	B-Gene_or_gene_product
gene	O
may	O
play	O
a	O
role	O
in	O
transformation	O
by	O
promoting	O
growth	O
of	O
the	O
cells	O
bearing	O
the	O
rearranged	O
chromosomes	O
.	O
<EOS>	B-X
Similar	B-X
translocations	B-X
are	B-X
found	B-X
in	B-X
mouse	B-X
plasmacytomas	B-X
and	B-X
both	B-X
diseases	B-X
involve	B-X
interchanges	B-X
between	B-X
one	B-X
of	B-X
the	B-X
immunoglobulin	B-X
loci	B-X
and	B-X
DNA	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
has	B-X
been	B-X
elucidated	B-X
from	B-X
studies	B-X
on	B-X
translocated	B-X
versions	B-X
of	B-X
the	B-X
gene	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
myc	B-X
gene	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
transformation	B-X
by	B-X
promoting	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
bearing	B-X
the	B-X
rearranged	B-X
chromosomes	B-X
.	B-X

Inhibition	O
by	O
N	O
-	O
(	O
phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
of	O
Ehrlich	O
ascites	O
tumour	O
growth	O
and	O
glucose	O
transport	O
.	O

N	O
-	O
(	O
Phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
(	O
PALA	O
)	O
suppressed	O
the	O
growth	O
of	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
vivo	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Simultaneously	O
as	O
the	O
growth	O
rate	O
decreased	O
,	O
the	O
cellular	O
uptake	O
of	O
glucose	O
and	O
the	O
density	O
of	O
a	O
class	O
of	O
glucose	O
-	O
reversible	O
binding	O
sites	O
for	O
cytochalasin	O
B	O
on	O
the	O
cell	O
surface	O
were	O
also	O
found	O
to	O
be	O
reduced	O
.	O
<EOS>	B-X
N-	B-X
(	B-X
Phosphonacetyl	B-X
)	B-X
-L-aspartate	B-X
(	B-X
PALA	B-X
)	B-X
suppressed	B-X
the	B-X
growth	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
tumour	B-X
cells	B-X
in	B-X
vivo	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
Simultaneously	B-X
as	B-X
the	B-X
growth	B-X
rate	B-X
decreased	B-X
,	B-X
the	B-X
cellular	B-X
uptake	B-X
of	B-X
glucose	B-X
and	B-X
the	B-X
density	B-X
of	B-X
a	B-X
class	B-X
of	B-X
glucose-reversible	B-X
binding	B-X
sites	B-X
for	B-X
cytochalasin	B-X
B	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
reduced	B-X
.	B-X
There	B-X
is	B-X
a	B-X
highly	B-X
significant	B-X
correlation	B-X
between	B-X
the	B-X
magnitude	B-X
of	B-X
changes	B-X
in	B-X
the	B-X
number	B-X
of	B-X
cytochalasin	B-X
B	B-X
binding	B-X
sites	B-X
and	B-X
the	B-X
magnitude	B-X
of	B-X
changes	B-X
in	B-X
glucose	B-X
uptake	B-X
.	B-X

There	O
is	O
a	O
highly	O
significant	O
correlation	O
between	O
the	O
magnitude	O
of	O
changes	O
in	O
the	O
number	O
of	O
cytochalasin	O
B	O
binding	O
sites	O
and	O
the	O
magnitude	O
of	O
changes	O
in	O
glucose	O
uptake	O
.	O
<EOS>	B-X
Simultaneously	B-X
as	B-X
the	B-X
growth	B-X
rate	B-X
decreased	B-X
,	B-X
the	B-X
cellular	B-X
uptake	B-X
of	B-X
glucose	B-X
and	B-X
the	B-X
density	B-X
of	B-X
a	B-X
class	B-X
of	B-X
glucose-reversible	B-X
binding	B-X
sites	B-X
for	B-X
cytochalasin	B-X
B	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
reduced	B-X
.	B-X
There	B-X
is	B-X
a	B-X
highly	B-X
significant	B-X
correlation	B-X
between	B-X
the	B-X
magnitude	B-X
of	B-X
changes	B-X
in	B-X
the	B-X
number	B-X
of	B-X
cytochalasin	B-X
B	B-X
binding	B-X
sites	B-X
and	B-X
the	B-X
magnitude	B-X
of	B-X
changes	B-X
in	B-X
glucose	B-X
uptake	B-X
.	B-X

The	O
physiological	O
significance	O
of	O
these	O
observations	O
are	O
discussed	O
.	O
<EOS>	B-X
Subsequent	B-X
observations	B-X
of	B-X
dramatic	B-X
improvement	B-X
in	B-X
oxygenation	B-X
with	B-X
simple	B-X
patient	B-X
rotation	B-X
motivated	B-X
the	B-X
next	B-X
several	B-X
decades	B-X
of	B-X
research	B-X
.	B-X
This	B-X
work	B-X
elucidated	B-X
the	B-X
physiological	B-X
mechanisms	B-X
underlying	B-X
changes	B-X
in	B-X
gas	B-X
exchange	B-X
and	B-X
respiratory	B-X
mechanics	B-X
with	B-X
prone	B-X
ventilation	B-X
.	B-X
However	B-X
,	B-X
translating	B-X
physiological	B-X
improvements	B-X
into	B-X
a	B-X
clinical	B-X
benefit	B-X
has	B-X
proved	B-X
challenging	B-X
;	B-X
several	B-X
contemporary	B-X
trials	B-X
showed	B-X
no	B-X
major	B-X
clinical	B-X
benefits	B-X
with	B-X
prone	B-X
positioning	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
physiological	B-X
principles	B-X
,	B-X
clinical	B-X
evidence	B-X
,	B-X
and	B-X
practical	B-X
application	B-X
of	B-X
prone	B-X
ventilation	B-X
in	B-X
ARDS	B-X
.	B-X

Effects	O
of	O
3	O
-	O
chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
on	O
nucleic	O
acid	O
,	O
protein	O
,	O
and	O
aerobic	O
and	O
anaerobic	O
metabolism	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O
<EOS>	B-X
3-Chloromethylthiochromone-1,1-dioxide	B-X
was	B-X
observed	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
carcinoma	B-X
growth	B-X
and	B-X
a	B-X
moderate	B-X
inhibitor	B-X
of	B-X
P-388	B-X
lymphocytic	B-X
leukemia	B-X
growth	B-X
at	B-X
10	B-X
mg/kg/day	B-X
.	B-X
Preliminary	B-X
in	B-X
vitro	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
agents	B-X
significantly	B-X
inhibited	B-X
RNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
cells	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
after	B-X
dosing	B-X
on	B-X
Days	B-X
6	B-X
,	B-X
7	B-X
,	B-X
and	B-X
8	B-X
demonstrated	B-X
the	B-X
same	B-X
reductions	B-X
in	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
and	B-X
a	B-X
moderate	B-X
reduction	B-X
in	B-X
protein	B-X
synthesis	B-X
.	B-X
The	B-X
primary	B-X
site	B-X
of	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
,	B-X
which	B-X
was	B-X
blocked	B-X
by	B-X
3-chloromethylthiochromone	B-X
,	B-X
was	B-X
at	B-X
orotidine	B-X
monophosphate	B-X
decarboxylase	B-X
in	B-X
the	B-X
primidine	B-X
pathway	B-X
.	B-X
Other	B-X
enzymes	B-X
,	B-X
in	B-X
anaerobic	B-X
and	B-X
aerobic	B-X
glycolysis	B-X
,	B-X
which	B-X
were	B-X
blocked	B-X
include	B-X
hexokinase	B-X
,	B-X
phosphofructokinase	B-X
,	B-X
succinic	B-X
and	B-X
alpha-ketoglutarate	B-X
dehydrogenases	B-X
,	B-X
as	B-X
well	B-X
as	B-X
States	B-X
3	B-X
and	B-X
4	B-X
of	B-X
oxidative	B-X
phosphorylation	B-X
.	B-X

3	O
-	O
Chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
was	O
observed	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
Ehrlich	O
ascites	O
carcinoma	O
growth	O
and	O
a	O
moderate	O
inhibitor	O
of	O
P	O
-	O
388	O
lymphocytic	O
leukemia	O
growth	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Preliminary	O
in	O
vitro	O
studies	O
showed	O
that	O
the	O
agents	O
significantly	O
inhibited	O
RNA	O
and	O
DNA	O
synthesis	O
in	O
Ehrlich	O
ascites	O
cells	O
.	O
<EOS>	B-X
3-Chloromethylthiochromone-1,1-dioxide	B-X
was	B-X
observed	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
carcinoma	B-X
growth	B-X
and	B-X
a	B-X
moderate	B-X
inhibitor	B-X
of	B-X
P-388	B-X
lymphocytic	B-X
leukemia	B-X
growth	B-X
at	B-X
10	B-X
mg/kg/day	B-X
.	B-X
Preliminary	B-X
in	B-X
vitro	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
agents	B-X
significantly	B-X
inhibited	B-X
RNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
cells	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
after	B-X
dosing	B-X
on	B-X
Days	B-X
6	B-X
,	B-X
7	B-X
,	B-X
and	B-X
8	B-X
demonstrated	B-X
the	B-X
same	B-X
reductions	B-X
in	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
and	B-X
a	B-X
moderate	B-X
reduction	B-X
in	B-X
protein	B-X
synthesis	B-X
.	B-X
The	B-X
primary	B-X
site	B-X
of	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
,	B-X
which	B-X
was	B-X
blocked	B-X
by	B-X
3-chloromethylthiochromone	B-X
,	B-X
was	B-X
at	B-X
orotidine	B-X
monophosphate	B-X
decarboxylase	B-X
in	B-X
the	B-X
primidine	B-X
pathway	B-X
.	B-X

In	O
vivo	O
studies	O
after	O
dosing	O
on	O
Days	O
6	O
,	O
7	O
,	O
and	O
8	O
demonstrated	O
the	O
same	O
reductions	O
in	O
nucleic	O
acid	O
synthesis	O
and	O
a	O
moderate	O
reduction	O
in	O
protein	O
synthesis	O
.	O

The	O
primary	O
site	O
of	O
nucleic	O
acid	O
synthesis	O
,	O
which	O
was	O
blocked	O
by	O
3	O
-	O
chloromethylthiochromone	O
,	O
was	O
at	O
orotidine	B-Gene_or_gene_product
monophosphate	I-Gene_or_gene_product
decarboxylase	I-Gene_or_gene_product
in	O
the	O
primidine	O
pathway	O
.	O
<EOS>	B-X
3-Chloromethylthiochromone-1,1-dioxide	B-X
was	B-X
observed	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
carcinoma	B-X
growth	B-X
and	B-X
a	B-X
moderate	B-X
inhibitor	B-X
of	B-X
P-388	B-X
lymphocytic	B-X
leukemia	B-X
growth	B-X
at	B-X
10	B-X
mg/kg/day	B-X
.	B-X
Preliminary	B-X
in	B-X
vitro	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
agents	B-X
significantly	B-X
inhibited	B-X
RNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
Ehrlich	B-X
ascites	B-X
cells	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
after	B-X
dosing	B-X
on	B-X
Days	B-X
6	B-X
,	B-X
7	B-X
,	B-X
and	B-X
8	B-X
demonstrated	B-X
the	B-X
same	B-X
reductions	B-X
in	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
and	B-X
a	B-X
moderate	B-X
reduction	B-X
in	B-X
protein	B-X
synthesis	B-X
.	B-X
The	B-X
primary	B-X
site	B-X
of	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
,	B-X
which	B-X
was	B-X
blocked	B-X
by	B-X
3-chloromethylthiochromone	B-X
,	B-X
was	B-X
at	B-X
orotidine	B-X
monophosphate	B-X
decarboxylase	B-X
in	B-X
the	B-X
primidine	B-X
pathway	B-X
.	B-X
Other	B-X
enzymes	B-X
,	B-X
in	B-X
anaerobic	B-X
and	B-X
aerobic	B-X
glycolysis	B-X
,	B-X
which	B-X
were	B-X
blocked	B-X
include	B-X
hexokinase	B-X
,	B-X
phosphofructokinase	B-X
,	B-X
succinic	B-X
and	B-X
alpha-ketoglutarate	B-X
dehydrogenases	B-X
,	B-X
as	B-X
well	B-X
as	B-X
States	B-X
3	B-X
and	B-X
4	B-X
of	B-X
oxidative	B-X
phosphorylation	B-X
.	B-X

Other	O
enzymes	O
,	O
in	O
anaerobic	O
and	O
aerobic	O
glycolysis	O
,	O
which	O
were	O
blocked	O
include	O
hexokinase	B-Gene_or_gene_product
,	O
phosphofructokinase	B-Gene_or_gene_product
,	O
succinic	B-Gene_or_gene_product
and	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ketoglutarate	I-Gene_or_gene_product
dehydrogenases	I-Gene_or_gene_product
,	O
as	O
well	O
as	O
States	O
3	O
and	O
4	O
of	O
oxidative	O
phosphorylation	O
.	O
<EOS>	B-X
3-Chloromethylthiochromone-1,1-dioxide	B-X
was	B-X
observed	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
Ehrlich	B-X
ascites	B-X
carcinoma	B-X
growth	B-X
and	B-X
a	B-X
moderate	B-X
inhibitor	B-X
of	B-X
P-388	B-X
lymphocytic	B-X
leukemia	B-X
growth	B-X
at	B-X
10	B-X
mg/kg/day	B-X
.	B-X
The	B-X
primary	B-X
site	B-X
of	B-X
nucleic	B-X
acid	B-X
synthesis	B-X
,	B-X
which	B-X
was	B-X
blocked	B-X
by	B-X
3-chloromethylthiochromone	B-X
,	B-X
was	B-X
at	B-X
orotidine	B-X
monophosphate	B-X
decarboxylase	B-X
in	B-X
the	B-X
primidine	B-X
pathway	B-X
.	B-X
Other	B-X
enzymes	B-X
,	B-X
in	B-X
anaerobic	B-X
and	B-X
aerobic	B-X
glycolysis	B-X
,	B-X
which	B-X
were	B-X
blocked	B-X
include	B-X
hexokinase	B-X
,	B-X
phosphofructokinase	B-X
,	B-X
succinic	B-X
and	B-X
alpha-ketoglutarate	B-X
dehydrogenases	B-X
,	B-X
as	B-X
well	B-X
as	B-X
States	B-X
3	B-X
and	B-X
4	B-X
of	B-X
oxidative	B-X
phosphorylation	B-X
.	B-X

Mast	O
cell	O
heparin	O
stimulates	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
in	O
vitro	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
Heparin	B-X
preparations	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
sources	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
but	B-X
did	B-X
not	B-X
stimulate	B-X
migration	B-X
of	B-X
several	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

Migration	O
of	O
capillary	O
endothelial	O
cells	O
is	O
an	O
important	O
component	O
of	O
angiogenesis	O
in	O
vivo	O
.	O
<EOS>	B-X
Adipocytes	B-X
are	B-X
an	B-X
important	B-X
component	B-X
of	B-X
hepatic	B-X
microenvironment	B-X
in	B-X
nonalcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
(	B-X
NAFLD	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
significant	B-X
risk	B-X
factor	B-X
for	B-X
HCC	B-X
.	B-X
Given	B-X
the	B-X
global	B-X
prevalence	B-X
of	B-X
NAFLD	B-X
,	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
interplay	B-X
between	B-X
HCC	B-X
cells	B-X
and	B-X
adipocytes	B-X
is	B-X
urgently	B-X
needed	B-X
.	B-X
Exosomes	B-X
,	B-X
released	B-X
by	B-X
malignant	B-X
cells	B-X
,	B-X
represent	B-X
a	B-X
novel	B-X
way	B-X
of	B-X
cell-cell	B-X
interaction	B-X
and	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
cancer	B-X
cell	B-X
communication	B-X
with	B-X
their	B-X
microenvironment	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
HCC-derived	B-X
exosomes	B-X
in	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
conversion	B-X
of	B-X
adipocytes	B-X
into	B-X
tumor-promoting	B-X
cells	B-X
.	B-X

Increased	O
numbers	O
of	O
mast	O
cells	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
angiogenesis	O
.	O
<EOS>	B-X
Tumor	B-X
cells	B-X
are	B-X
surrounded	B-X
by	B-X
infiltrating	B-X
inflammatory	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
lymphocytes	B-X
,	B-X
neutrophils	B-X
,	B-X
macrophages	B-X
,	B-X
and	B-X
mast	B-X
cells	B-X
.	B-X
A	B-X
body	B-X
of	B-X
evidence	B-X
indicates	B-X
that	B-X
mast	B-X
cells	B-X
are	B-X
associated	B-X
with	B-X
various	B-X
types	B-X
of	B-X
tumors	B-X
.	B-X
Although	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
can	B-X
be	B-X
directly	B-X
related	B-X
to	B-X
their	B-X
granule	B-X
content	B-X
,	B-X
their	B-X
function	B-X
in	B-X
angiogenesis	B-X
and	B-X
tumor	B-X
progression	B-X
remains	B-X
obscure	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Phase	B-X
I	B-X
tumors	B-X
exhibited	B-X
a	B-X
large	B-X
number	B-X
of	B-X
mast	B-X
cells	B-X
,	B-X
which	B-X
increased	B-X
in	B-X
phase	B-X
II	B-X
and	B-X
remained	B-X
unchanged	B-X
in	B-X
phase	B-X
III	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
mouse	B-X
mast	B-X
cell	B-X
protease	B-X
(	B-X
mMCP	B-X
)	B-X
-4	B-X
,	B-X
mMCP-5	B-X
,	B-X
mMCP-6	B-X
,	B-X
mMCP-7	B-X
,	B-X
and	B-X
carboxypeptidase	B-X
A	B-X
were	B-X
analyzed	B-X
at	B-X
the	B-X
3	B-X
stages	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
mMCP-4	B-X
expression	B-X
of	B-X
these	B-X
mast	B-X
cell	B-X
chymase	B-X
(	B-X
mMCP-5	B-X
)	B-X
,	B-X
tryptases	B-X
(	B-X
mMCP-6	B-X
and	B-X
7	B-X
)	B-X
,	B-X
and	B-X
carboxypeptidase	B-X
A	B-X
(	B-X
mMC-CPA	B-X
)	B-X
increased	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
Chymase	B-X
and	B-X
tryptase	B-X
activity	B-X
increased	B-X
at	B-X
all	B-X
stages	B-X
of	B-X
tumor	B-X
progression	B-X
whereas	B-X
the	B-X
number	B-X
of	B-X
mast	B-X
cells	B-X
remained	B-X
constant	B-X
from	B-X
phase	B-X
II	B-X
to	B-X
III	B-X
.	B-X
The	B-X
present	B-X
study	B-X
suggests	B-X
that	B-X
mast	B-X
cells	B-X
are	B-X
involved	B-X
in	B-X
induction	B-X
of	B-X
angiogenesis	B-X
in	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
tumor	B-X
development	B-X
and	B-X
in	B-X
modulating	B-X
blood	B-X
vessel	B-X
growth	B-X
in	B-X
the	B-X
later	B-X
stages	B-X
of	B-X
tumor	B-X
progression	B-X
.	B-X

We	O
have	O
used	O
a	O
quantitative	O
assay	O
in	O
vitro	O
to	O
demonstrate	O
that	O
mast	O
cells	O
release	O
a	O
factor	O
that	O
significantly	O
increases	O
bovine	O
capillary	O
endothelial	O
cell	O
migration	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
Heparin	B-X
preparations	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
sources	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
but	B-X
did	B-X
not	B-X
stimulate	B-X
migration	B-X
of	B-X
several	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

The	O
factor	O
is	O
present	O
in	O
medium	O
conditioned	O
by	O
mast	O
cells	O
as	O
well	O
as	O
lysates	O
of	O
mast	O
cells	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

The	O
stimulatory	O
effect	O
of	O
mast	O
cells	O
on	O
migration	O
is	O
specific	O
for	O
capillary	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
Heparin	B-X
preparations	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
sources	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
but	B-X
did	B-X
not	B-X
stimulate	B-X
migration	B-X
of	B-X
several	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

Furthermore	O
,	O
mast	O
cells	O
have	O
no	O
mitogenic	O
activity	O
for	O
capillary	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
Heparin	B-X
preparations	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
sources	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
but	B-X
did	B-X
not	B-X
stimulate	B-X
migration	B-X
of	B-X
several	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

Of	O
all	O
the	O
secretory	O
products	O
of	O
mast	O
cells	O
tested	O
,	O
only	O
heparin	O
stimulated	O
capillary	O
endothelial	O
cell	O
migration	O
in	O
vitro	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
Heparin	B-X
preparations	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
sources	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
but	B-X
did	B-X
not	B-X
stimulate	B-X
migration	B-X
of	B-X
several	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

Heparin	O
preparations	O
from	O
a	O
variety	O
of	O
sources	O
stimulated	O
capillary	O
endothelial	O
cell	O
migration	O
to	O
the	O
same	O
degree	O
but	O
did	O
not	O
stimulate	O
migration	O
of	O
several	O
other	O
cell	O
types	O
.	O

The	O
migration	O
activity	O
of	O
heparin	O
and	O
mast	O
cell	O
conditioned	O
medium	O
was	O
blocked	O
by	O
specific	O
antagonists	O
of	O
heparin	O
(	O
protamine	B-Gene_or_gene_product
and	O
heparinase	B-Gene_or_gene_product
)	O
,	O
but	O
not	O
by	O
chondroitinase	B-Gene_or_gene_product
ABC	I-Gene_or_gene_product
.	O

The	O
migration	O
activity	O
of	O
mast	O
cell	O
conditioned	O
medium	O
was	O
resistant	O
to	O
heat	O
(	O
100	O
degrees	O
C	O
)	O
and	O
incubation	O
with	O
proteolytic	O
enzymes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
mast	O
cells	O
in	O
angiogenesis	O
may	O
be	O
to	O
enhance	O
migration	O
of	O
the	O
endothelial	O
cells	O
of	O
growing	O
capillaries	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
capillary	B-X
endothelial	B-X
cells	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
Increased	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
several	B-X
types	B-X
of	B-X
angiogenesis	B-X
.	B-X
We	B-X
have	B-X
used	B-X
a	B-X
quantitative	B-X
assay	B-X
in	B-X
vitro	B-X
to	B-X
demonstrate	B-X
that	B-X
mast	B-X
cells	B-X
release	B-X
a	B-X
factor	B-X
that	B-X
significantly	B-X
increases	B-X
bovine	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
.	B-X
The	B-X
factor	B-X
is	B-X
present	B-X
in	B-X
medium	B-X
conditioned	B-X
by	B-X
mast	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
lysates	B-X
of	B-X
mast	B-X
cells	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
mast	B-X
cells	B-X
on	B-X
migration	B-X
is	B-X
specific	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
mast	B-X
cells	B-X
have	B-X
no	B-X
mitogenic	B-X
activity	B-X
for	B-X
capillary	B-X
endothelial	B-X
cells	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
secretory	B-X
products	B-X
of	B-X
mast	B-X
cells	B-X
tested	B-X
,	B-X
only	B-X
heparin	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
in	B-X
vitro	B-X
.	B-X
Heparin	B-X
preparations	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
sources	B-X
stimulated	B-X
capillary	B-X
endothelial	B-X
cell	B-X
migration	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
but	B-X
did	B-X
not	B-X
stimulate	B-X
migration	B-X
of	B-X
several	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
heparin	B-X
and	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
blocked	B-X
by	B-X
specific	B-X
antagonists	B-X
of	B-X
heparin	B-X
(	B-X
protamine	B-X
and	B-X
heparinase	B-X
)	B-X
,	B-X
but	B-X
not	B-X
by	B-X
chondroitinase	B-X
ABC	B-X
.	B-X
The	B-X
migration	B-X
activity	B-X
of	B-X
mast	B-X
cell	B-X
conditioned	B-X
medium	B-X
was	B-X
resistant	B-X
to	B-X
heat	B-X
(	B-X
100	B-X
degrees	B-X
C	B-X
)	B-X
and	B-X
incubation	B-X
with	B-X
proteolytic	B-X
enzymes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
mast	B-X
cells	B-X
in	B-X
angiogenesis	B-X
may	B-X
be	B-X
to	B-X
enhance	B-X
migration	B-X
of	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
growing	B-X
capillaries	B-X
.	B-X

Cancer	O
progression	O
and	O
p53	B-Gene_or_gene_product
.	O
<EOS>	B-X
p53	B-X
is	B-X
a	B-X
key	B-X
tumor	B-X
suppressor	B-X
,	B-X
and	B-X
loss	B-X
of	B-X
p53	B-X
function	B-X
is	B-X
frequently	B-X
a	B-X
prerequisite	B-X
for	B-X
cancer	B-X
development	B-X
.	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
the	B-X
most	B-X
frequently	B-X
mutated	B-X
gene	B-X
in	B-X
human	B-X
cancers	B-X
;	B-X
p53	B-X
mutations	B-X
occur	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
all	B-X
human	B-X
cancers	B-X
and	B-X
in	B-X
almost	B-X
every	B-X
type	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
Most	B-X
of	B-X
p53	B-X
mutations	B-X
in	B-X
cancers	B-X
are	B-X
missense	B-X
mutations	B-X
,	B-X
which	B-X
produce	B-X
the	B-X
full-length	B-X
mutant	B-X
p53	B-X
(	B-X
mutp53	B-X
)	B-X
protein	B-X
with	B-X
only	B-X
one	B-X
amino	B-X
acid	B-X
difference	B-X
from	B-X
wild-type	B-X
p53	B-X
protein	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
loss	B-X
of	B-X
the	B-X
tumor-suppressive	B-X
function	B-X
of	B-X
wild-type	B-X
p53	B-X
,	B-X
many	B-X
mutp53	B-X
proteins	B-X
acquire	B-X
new	B-X
oncogenic	B-X
activities	B-X
independently	B-X
of	B-X
wild-type	B-X
p53	B-X
to	B-X
promote	B-X
cancer	B-X
progression	B-X
,	B-X
termed	B-X
gain-of-function	B-X
(	B-X
GOF	B-X
)	B-X
.	B-X
Mutp53	B-X
protein	B-X
often	B-X
accumulates	B-X
to	B-X
very	B-X
high	B-X
levels	B-X
in	B-X
cancer	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
GOF	B-X
.	B-X
Given	B-X
the	B-X
high	B-X
mutation	B-X
frequency	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
and	B-X
the	B-X
GOF	B-X
activities	B-X
of	B-X
mutp53	B-X
in	B-X
cancer	B-X
,	B-X
therapies	B-X
targeting	B-X
mutp53	B-X
have	B-X
attracted	B-X
great	B-X
interest	B-X
.	B-X
Further	B-X
understanding	B-X
the	B-X
mechanisms	B-X
underlying	B-X
mutp53	B-X
protein	B-X
accumulation	B-X
and	B-X
GOF	B-X
will	B-X
help	B-X
develop	B-X
effective	B-X
therapies	B-X
treating	B-X
human	B-X
cancers	B-X
containing	B-X
mutp53	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
studies	B-X
on	B-X
mutp53	B-X
regulation	B-X
and	B-X
GOF	B-X
as	B-X
well	B-X
as	B-X
therapies	B-X
targeting	B-X
mutp53	B-X
in	B-X
human	B-X
cancers	B-X
.	B-X

In	O
a	O
complex	O
organism	O
,	O
somatic	O
cells	O
are	O
under	O
intermittent	O
selection	O
pressure	O
for	O
the	O
emergence	O
of	O
mutants	O
that	O
can	O
survive	O
environmental	O
insults	O
and	O
that	O
can	O
grow	O
autonomously	O
despite	O
adverse	O
conditions	O
.	O

Repeated	O
rounds	O
of	O
mutation	O
,	O
selection	O
,	O
and	O
proliferation	O
may	O
lead	O
to	O
cancer	O
.	O
<EOS>	B-X
In	B-X
a	B-X
complex	B-X
organism	B-X
,	B-X
somatic	B-X
cells	B-X
are	B-X
under	B-X
intermittent	B-X
selection	B-X
pressure	B-X
for	B-X
the	B-X
emergence	B-X
of	B-X
mutants	B-X
that	B-X
can	B-X
survive	B-X
environmental	B-X
insults	B-X
and	B-X
that	B-X
can	B-X
grow	B-X
autonomously	B-X
despite	B-X
adverse	B-X
conditions	B-X
.	B-X
Repeated	B-X
rounds	B-X
of	B-X
mutation	B-X
,	B-X
selection	B-X
,	B-X
and	B-X
proliferation	B-X
may	B-X
lead	B-X
to	B-X
cancer	B-X
.	B-X
Disabling	B-X
mutations	B-X
and	B-X
deletions	B-X
of	B-X
p53	B-X
occur	B-X
in	B-X
50	B-X
%	B-X
of	B-X
human	B-X
tumours	B-X
.	B-X
p53-deficient	B-X
cancers	B-X
are	B-X
often	B-X
unstable	B-X
,	B-X
aggressive	B-X
,	B-X
and	B-X
resistant	B-X
to	B-X
therapy	B-X
.	B-X

The	O
organism	O
prevents	O
malignant	O
transformation	O
by	O
assuring	O
accurate	O
DNA	O
repair	O
before	O
cell	O
division	O
,	O
by	O
forcing	O
the	O
death	O
of	O
cells	O
with	O
excessive	O
DNA	O
damage	O
,	O
and	O
by	O
placing	O
limits	O
on	O
the	O
replicative	O
lifespans	O
of	O
most	O
somatic	O
cells	O
.	O
<EOS>	B-X
In	B-X
a	B-X
complex	B-X
organism	B-X
,	B-X
somatic	B-X
cells	B-X
are	B-X
under	B-X
intermittent	B-X
selection	B-X
pressure	B-X
for	B-X
the	B-X
emergence	B-X
of	B-X
mutants	B-X
that	B-X
can	B-X
survive	B-X
environmental	B-X
insults	B-X
and	B-X
that	B-X
can	B-X
grow	B-X
autonomously	B-X
despite	B-X
adverse	B-X
conditions	B-X
.	B-X
The	B-X
organism	B-X
prevents	B-X
malignant	B-X
transformation	B-X
by	B-X
assuring	B-X
accurate	B-X
DNA	B-X
repair	B-X
before	B-X
cell	B-X
division	B-X
,	B-X
by	B-X
forcing	B-X
the	B-X
death	B-X
of	B-X
cells	B-X
with	B-X
excessive	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
by	B-X
placing	B-X
limits	B-X
on	B-X
the	B-X
replicative	B-X
lifespans	B-X
of	B-X
most	B-X
somatic	B-X
cells	B-X
.	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
a	B-X
``	B-X
guardian	B-X
of	B-X
the	B-X
genome	B-X
''	B-X
--	B-X
it	B-X
regulates	B-X
multiple	B-X
components	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
control	B-X
response	B-X
and	B-X
promotes	B-X
cellular	B-X
senescence	B-X
.	B-X

The	O
p53	B-Gene_or_gene_product
gene	O
is	O
a	O
"	O
guardian	O
of	O
the	O
genome	O
"	O
-	O
-	O
it	O
regulates	O
multiple	O
components	O
of	O
the	O
DNA	O
damage	O
control	O
response	O
and	O
promotes	O
cellular	O
senescence	O
.	O
<EOS>	B-X
The	B-X
organism	B-X
prevents	B-X
malignant	B-X
transformation	B-X
by	B-X
assuring	B-X
accurate	B-X
DNA	B-X
repair	B-X
before	B-X
cell	B-X
division	B-X
,	B-X
by	B-X
forcing	B-X
the	B-X
death	B-X
of	B-X
cells	B-X
with	B-X
excessive	B-X
DNA	B-X
damage	B-X
,	B-X
and	B-X
by	B-X
placing	B-X
limits	B-X
on	B-X
the	B-X
replicative	B-X
lifespans	B-X
of	B-X
most	B-X
somatic	B-X
cells	B-X
.	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
a	B-X
``	B-X
guardian	B-X
of	B-X
the	B-X
genome	B-X
''	B-X
--	B-X
it	B-X
regulates	B-X
multiple	B-X
components	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
control	B-X
response	B-X
and	B-X
promotes	B-X
cellular	B-X
senescence	B-X
.	B-X
Disabling	B-X
mutations	B-X
and	B-X
deletions	B-X
of	B-X
p53	B-X
occur	B-X
in	B-X
50	B-X
%	B-X
of	B-X
human	B-X
tumours	B-X
.	B-X
p53-deficient	B-X
cancers	B-X
are	B-X
often	B-X
unstable	B-X
,	B-X
aggressive	B-X
,	B-X
and	B-X
resistant	B-X
to	B-X
therapy	B-X
.	B-X

Disabling	O
mutations	O
and	O
deletions	O
of	O
p53	B-Gene_or_gene_product
occur	O
in	O
50	O
%	O
of	O
human	O
tumours	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
a	B-X
``	B-X
guardian	B-X
of	B-X
the	B-X
genome	B-X
''	B-X
--	B-X
it	B-X
regulates	B-X
multiple	B-X
components	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
control	B-X
response	B-X
and	B-X
promotes	B-X
cellular	B-X
senescence	B-X
.	B-X
Disabling	B-X
mutations	B-X
and	B-X
deletions	B-X
of	B-X
p53	B-X
occur	B-X
in	B-X
50	B-X
%	B-X
of	B-X
human	B-X
tumours	B-X
.	B-X
p53-deficient	B-X
cancers	B-X
are	B-X
often	B-X
unstable	B-X
,	B-X
aggressive	B-X
,	B-X
and	B-X
resistant	B-X
to	B-X
therapy	B-X
.	B-X

p53	B-Gene_or_gene_product
-	O
deficient	O
cancers	O
are	O
often	O
unstable	O
,	O
aggressive	O
,	O
and	O
resistant	O
to	O
therapy	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
gene	B-X
is	B-X
a	B-X
``	B-X
guardian	B-X
of	B-X
the	B-X
genome	B-X
''	B-X
--	B-X
it	B-X
regulates	B-X
multiple	B-X
components	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
control	B-X
response	B-X
and	B-X
promotes	B-X
cellular	B-X
senescence	B-X
.	B-X
Disabling	B-X
mutations	B-X
and	B-X
deletions	B-X
of	B-X
p53	B-X
occur	B-X
in	B-X
50	B-X
%	B-X
of	B-X
human	B-X
tumours	B-X
.	B-X
p53-deficient	B-X
cancers	B-X
are	B-X
often	B-X
unstable	B-X
,	B-X
aggressive	B-X
,	B-X
and	B-X
resistant	B-X
to	B-X
therapy	B-X
.	B-X

The	O
Met	B-Gene_or_gene_product
proto	O
-	O
oncogene	O
mesenchymal	O
to	O
epithelial	O
cell	O
conversion	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
A549/CDDP	B-X
(	B-X
resistant	B-X
to	B-X
CDDP	B-X
)	B-X
cells	B-X
not	B-X
only	B-X
acquired	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
phenotype	B-X
,	B-X
but	B-X
also	B-X
showed	B-X
increased	B-X
NF-ÎºB	B-X
activity	B-X
compared	B-X
with	B-X
A549	B-X
cells	B-X
(	B-X
sensitive	B-X
to	B-X
CDDP	B-X
)	B-X
.	B-X
Baicalein	B-X
significantly	B-X
suppressed	B-X
the	B-X
PI3K/Akt/NF-ÎºB	B-X
pathway	B-X
,	B-X
leading	B-X
to	B-X
conversion	B-X
of	B-X
EMT	B-X
to	B-X
mesenchymal-epithelial	B-X
transition	B-X
(	B-X
MET	B-X
,	B-X
the	B-X
reciprocal	B-X
mesenchymal	B-X
to	B-X
epithelial	B-X
transition	B-X
)	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
NF-ÎºB-mediated	B-X
antiapoptotic	B-X
proteins	B-X
in	B-X
A549/CDDP	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
demonstrated	B-X
that	B-X
baicalein	B-X
reversed	B-X
the	B-X
resistance	B-X
of	B-X
human	B-X
A549	B-X
lung	B-X
adenocarcinoma	B-X
cells	B-X
to	B-X
cisplatin	B-X
by	B-X
inhibiting	B-X
EMT	B-X
and	B-X
attenuating	B-X
apoptosis	B-X
via	B-X
PI3K/Akt/NF-ÎºB	B-X
pathway	B-X
.	B-X
Cancer	B-X
cell	B-X
plasticity	B-X
facilitates	B-X
the	B-X
development	B-X
of	B-X
therapy	B-X
resistance	B-X
and	B-X
malignant	B-X
progression	B-X
.	B-X
De-differentiation	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
an	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
are	B-X
known	B-X
to	B-X
enhance	B-X
cellular	B-X
plasticity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
cancer	B-X
cell	B-X
plasticity	B-X
can	B-X
be	B-X
exploited	B-X
therapeutically	B-X
by	B-X
forcing	B-X
the	B-X
trans-differentiation	B-X
of	B-X
EMT-derived	B-X
breast	B-X
cancer	B-X
cells	B-X
into	B-X
post-mitotic	B-X
and	B-X
functional	B-X
adipocytes	B-X
.	B-X
This	B-X
combination	B-X
therapy	B-X
provokes	B-X
the	B-X
conversion	B-X
of	B-X
invasive	B-X
and	B-X
disseminating	B-X
cancer	B-X
cells	B-X
into	B-X
post-mitotic	B-X
adipocytes	B-X
leading	B-X
to	B-X
the	B-X
repression	B-X
of	B-X
primary	B-X
tumor	B-X
invasion	B-X
and	B-X
metastasis	B-X
formation	B-X
.	B-X

Coexpression	O
of	O
the	O
human	O
Met	B-Gene_or_gene_product
receptor	O
and	O
its	O
ligand	O
,	O
hepatocyte	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
/	O
scatter	B-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
HGF	B-Gene_or_gene_product
/	O
SF	B-Gene_or_gene_product
)	O
,	O
in	O
NIH	O
3T3	O
fibroblasts	O
causes	O
the	O
cells	O
to	O
become	O
tumorigenic	O
in	O
nude	O
mice	O
.	O
<EOS>	B-X
Coexpression	B-X
of	B-X
the	B-X
human	B-X
Met	B-X
receptor	B-X
and	B-X
its	B-X
ligand	B-X
,	B-X
hepatocyte	B-X
growth	B-X
factor/scatter	B-X
factor	B-X
(	B-X
HGF/SF	B-X
)	B-X
,	B-X
in	B-X
NIH	B-X
3T3	B-X
fibroblasts	B-X
causes	B-X
the	B-X
cells	B-X
to	B-X
become	B-X
tumorigenic	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
tumor	B-X
cells	B-X
also	B-X
display	B-X
enhanced	B-X
expression	B-X
of	B-X
desmosomal	B-X
and	B-X
tight-junction	B-X
proteins	B-X
.	B-X
The	B-X
apparent	B-X
mesenchymal	B-X
to	B-X
epithelial	B-X
conversion	B-X
of	B-X
the	B-X
tumor	B-X
cells	B-X
mimics	B-X
the	B-X
conversion	B-X
that	B-X
occurs	B-X
during	B-X
embryonic	B-X
kidney	B-X
development	B-X
,	B-X
suggesting	B-X
that	B-X
Met-HGF/SF	B-X
signaling	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
this	B-X
process	B-X
as	B-X
well	B-X
as	B-X
in	B-X
tumors	B-X
that	B-X
express	B-X
both	B-X
epithelial	B-X
and	B-X
mesenchymal	B-X
markers	B-X
.	B-X

The	O
resultant	O
tumors	O
display	O
lumen	O
-	O
like	O
morphology	O
,	O
contain	O
carcinoma	O
-	O
like	O
focal	O
areas	O
with	O
intercellular	O
junctions	O
resembling	O
desmosomes	O
,	O
and	O
coexpress	O
epithelial	O
(	O
cytokeratin	B-Gene_or_gene_product
)	O
and	O
mesenchymal	O
(	O
vimentin	B-Gene_or_gene_product
)	O
cytoskeletal	O
markers	O
.	O
<EOS>	B-X
The	B-X
resultant	B-X
tumors	B-X
display	B-X
lumen-like	B-X
morphology	B-X
,	B-X
contain	B-X
carcinoma-like	B-X
focal	B-X
areas	B-X
with	B-X
intercellular	B-X
junctions	B-X
resembling	B-X
desmosomes	B-X
,	B-X
and	B-X
coexpress	B-X
epithelial	B-X
(	B-X
cytokeratin	B-X
)	B-X
and	B-X
mesenchymal	B-X
(	B-X
vimentin	B-X
)	B-X
cytoskeletal	B-X
markers	B-X
.	B-X
The	B-X
tumor	B-X
cells	B-X
also	B-X
display	B-X
enhanced	B-X
expression	B-X
of	B-X
desmosomal	B-X
and	B-X
tight-junction	B-X
proteins	B-X
.	B-X
The	B-X
apparent	B-X
mesenchymal	B-X
to	B-X
epithelial	B-X
conversion	B-X
of	B-X
the	B-X
tumor	B-X
cells	B-X
mimics	B-X
the	B-X
conversion	B-X
that	B-X
occurs	B-X
during	B-X
embryonic	B-X
kidney	B-X
development	B-X
,	B-X
suggesting	B-X
that	B-X
Met-HGF/SF	B-X
signaling	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
this	B-X
process	B-X
as	B-X
well	B-X
as	B-X
in	B-X
tumors	B-X
that	B-X
express	B-X
both	B-X
epithelial	B-X
and	B-X
mesenchymal	B-X
markers	B-X
.	B-X

The	O
tumor	O
cells	O
also	O
display	O
enhanced	O
expression	O
of	O
desmosomal	O
and	O
tight	O
-	O
junction	O
proteins	O
.	O
<EOS>	B-X
Coexpression	B-X
of	B-X
the	B-X
human	B-X
Met	B-X
receptor	B-X
and	B-X
its	B-X
ligand	B-X
,	B-X
hepatocyte	B-X
growth	B-X
factor/scatter	B-X
factor	B-X
(	B-X
HGF/SF	B-X
)	B-X
,	B-X
in	B-X
NIH	B-X
3T3	B-X
fibroblasts	B-X
causes	B-X
the	B-X
cells	B-X
to	B-X
become	B-X
tumorigenic	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
resultant	B-X
tumors	B-X
display	B-X
lumen-like	B-X
morphology	B-X
,	B-X
contain	B-X
carcinoma-like	B-X
focal	B-X
areas	B-X
with	B-X
intercellular	B-X
junctions	B-X
resembling	B-X
desmosomes	B-X
,	B-X
and	B-X
coexpress	B-X
epithelial	B-X
(	B-X
cytokeratin	B-X
)	B-X
and	B-X
mesenchymal	B-X
(	B-X
vimentin	B-X
)	B-X
cytoskeletal	B-X
markers	B-X
.	B-X
The	B-X
tumor	B-X
cells	B-X
also	B-X
display	B-X
enhanced	B-X
expression	B-X
of	B-X
desmosomal	B-X
and	B-X
tight-junction	B-X
proteins	B-X
.	B-X
The	B-X
apparent	B-X
mesenchymal	B-X
to	B-X
epithelial	B-X
conversion	B-X
of	B-X
the	B-X
tumor	B-X
cells	B-X
mimics	B-X
the	B-X
conversion	B-X
that	B-X
occurs	B-X
during	B-X
embryonic	B-X
kidney	B-X
development	B-X
,	B-X
suggesting	B-X
that	B-X
Met-HGF/SF	B-X
signaling	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
this	B-X
process	B-X
as	B-X
well	B-X
as	B-X
in	B-X
tumors	B-X
that	B-X
express	B-X
both	B-X
epithelial	B-X
and	B-X
mesenchymal	B-X
markers	B-X
.	B-X

The	O
apparent	O
mesenchymal	O
to	O
epithelial	O
conversion	O
of	O
the	O
tumor	O
cells	O
mimics	O
the	O
conversion	O
that	O
occurs	O
during	O
embryonic	O
kidney	O
development	O
,	O
suggesting	O
that	O
Met	B-Gene_or_gene_product
-	O
HGF	B-Gene_or_gene_product
/	O
SF	B-Gene_or_gene_product
signaling	O
plays	O
a	O
role	O
in	O
this	O
process	O
as	O
well	O
as	O
in	O
tumors	O
that	O
express	O
both	O
epithelial	O
and	O
mesenchymal	O
markers	O
.	O

Ultraviolet	O
B	O
irradiation	O
promotes	O
tumorigenic	O
and	O
metastatic	O
properties	O
in	O
primary	O
cutaneous	O
melanoma	O
via	O
induction	O
of	O
interleukin	B-Gene_or_gene_product
8	I-Gene_or_gene_product
.	O
<EOS>	B-X
UV	B-X
radiation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
malignant	B-X
melanoma	B-X
to	B-X
the	B-X
metastatic	B-X
state	B-X
is	B-X
not	B-X
very	B-X
well	B-X
defined	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
concentrated	B-X
on	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
host	B-X
immune	B-X
response	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
tumor	B-X
cells	B-X
was	B-X
not	B-X
elucidated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
induce	B-X
interleukin	B-X
8	B-X
(	B-X
IL-8	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
with	B-X
negligible	B-X
expression	B-X
of	B-X
IL-8	B-X
.	B-X
UV-B-induced	B-X
IL-8	B-X
was	B-X
constitutively	B-X
expressed	B-X
60	B-X
days	B-X
after	B-X
irradiation	B-X
in	B-X
tumors	B-X
implanted	B-X
in	B-X
mice	B-X
.	B-X
Induction	B-X
of	B-X
IL-8	B-X
was	B-X
UV-B	B-X
dose	B-X
dependent	B-X
and	B-X
blocked	B-X
by	B-X
cyclohexamide	B-X
,	B-X
indicating	B-X
that	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
is	B-X
required	B-X
for	B-X
its	B-X
expression	B-X
.	B-X
The	B-X
UV-irradiated	B-X
cells	B-X
demonstrated	B-X
enhanced	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
potential	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
ability	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
increase	B-X
in	B-X
Mr	B-X
72,000	B-X
type	B-X
IV	B-X
collagenase	B-X
activity	B-X
and	B-X
angiogenesis	B-X
attributed	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
IL-8	B-X
after	B-X
irradiation	B-X
.	B-X
The	B-X
acquisition	B-X
of	B-X
the	B-X
metastatic	B-X
phenotype	B-X
induced	B-X
by	B-X
UV-B	B-X
could	B-X
not	B-X
be	B-X
attributed	B-X
to	B-X
abnormalities	B-X
in	B-X
the	B-X
p53	B-X
or	B-X
MTS-1	B-X
(	B-X
p16INK4	B-X
)	B-X
genes	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
increase	B-X
the	B-X
aggressiveness	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
for	B-X
growth	B-X
and	B-X
metastasis	B-X
.	B-X

UV	O
radiation	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
human	O
cutaneous	O
melanoma	O
,	O
but	O
its	O
role	O
in	O
the	O
development	O
of	O
malignant	O
melanoma	O
to	O
the	O
metastatic	O
state	O
is	O
not	O
very	O
well	O
defined	O
.	O

Although	O
previous	O
studies	O
have	O
concentrated	O
on	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
host	O
immune	O
response	O
,	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
tumor	O
cells	O
was	O
not	O
elucidated	O
.	O

Here	O
we	O
show	O
that	O
UV	O
-	O
B	O
can	O
induce	O
interleukin	B-Gene_or_gene_product
8	I-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
)	O
mRNA	O
and	O
protein	O
secretion	O
in	O
human	O
cutaneous	O
melanoma	O
with	O
negligible	O
expression	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
.	O
<EOS>	B-X
Expression	B-X
of	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
by	B-X
human	B-X
melanoma	B-X
cells	B-X
correlates	B-X
with	B-X
their	B-X
metastatic	B-X
potential	B-X
.	B-X
Moreover	B-X
,	B-X
UV-B	B-X
irradiation	B-X
of	B-X
primary	B-X
cutaneous	B-X
melanoma	B-X
cells	B-X
induces	B-X
IL-8	B-X
mRNA	B-X
and	B-X
protein	B-X
production	B-X
and	B-X
increases	B-X
both	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Although	B-X
IL-8	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
angiogenic	B-X
factor	B-X
,	B-X
the	B-X
biological	B-X
consequences	B-X
of	B-X
increased	B-X
IL-8	B-X
production	B-X
by	B-X
melanoma	B-X
cells	B-X
and	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
the	B-X
metastatic	B-X
process	B-X
remains	B-X
unclear	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
IL-8	B-X
in	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
of	B-X
human	B-X
melanoma	B-X
cells	B-X
.	B-X
Nonmetastatic	B-X
SB-2	B-X
melanoma	B-X
cells	B-X
with	B-X
negligible	B-X
levels	B-X
of	B-X
IL-8	B-X
were	B-X
transfected	B-X
with	B-X
IL-8	B-X
cDNA	B-X
and	B-X
subsequently	B-X
analyzed	B-X
for	B-X
changes	B-X
in	B-X
their	B-X
tumorigenic	B-X
and	B-X
metastatic	B-X
potential	B-X
.	B-X
Enforced	B-X
expression	B-X
of	B-X
IL-8	B-X
rendered	B-X
the	B-X
melanoma	B-X
cells	B-X
highly	B-X
tumorigenic	B-X
and	B-X
increased	B-X
their	B-X
metastatic	B-X
potential	B-X
as	B-X
compared	B-X
with	B-X
parental	B-X
and	B-X
control	B-X
transfected	B-X
cells	B-X
.	B-X
The	B-X
IL-8-transfected	B-X
cells	B-X
displayed	B-X
up-regulation	B-X
in	B-X
M	B-X
(	B-X
r	B-X
)	B-X
72,000	B-X
collagenase	B-X
type	B-X
IV	B-X
(	B-X
MMP-2	B-X
)	B-X
mRNA	B-X
and	B-X
collagenase	B-X
activity	B-X
and	B-X
increased	B-X
invasiveness	B-X
through	B-X
Matrigel-coated	B-X
filters	B-X
.	B-X
Moreover	B-X
,	B-X
when	B-X
the	B-X
MMP-2	B-X
promoter	B-X
was	B-X
linked	B-X
upstream	B-X
of	B-X
the	B-X
chloramphenicol	B-X
acetyltransferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X
gene	B-X
,	B-X
CAT	B-X
activity	B-X
was	B-X
up-regulated	B-X
in	B-X
IL-8	B-X
but	B-X
not	B-X
in	B-X
control	B-X
transfected	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
IL-8	B-X
is	B-X
involved	B-X
in	B-X
MMP-2	B-X
gene	B-X
transcription	B-X
.	B-X
Activation	B-X
of	B-X
type	B-X
IV	B-X
collagenase	B-X
by	B-X
IL-8	B-X
can	B-X
enhance	B-X
the	B-X
invasion	B-X
of	B-X
host	B-X
stroma	B-X
by	B-X
the	B-X
tumor	B-X
cells	B-X
and	B-X
increase	B-X
angiogenesis	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
metastasis	B-X
.	B-X

UV	O
-	O
B	O
-	O
induced	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
was	O
constitutively	O
expressed	O
60	O
days	O
after	O
irradiation	O
in	O
tumors	O
implanted	O
in	O
mice	O
.	O
<EOS>	B-X
UV	B-X
radiation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
malignant	B-X
melanoma	B-X
to	B-X
the	B-X
metastatic	B-X
state	B-X
is	B-X
not	B-X
very	B-X
well	B-X
defined	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
concentrated	B-X
on	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
host	B-X
immune	B-X
response	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
tumor	B-X
cells	B-X
was	B-X
not	B-X
elucidated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
induce	B-X
interleukin	B-X
8	B-X
(	B-X
IL-8	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
with	B-X
negligible	B-X
expression	B-X
of	B-X
IL-8	B-X
.	B-X
UV-B-induced	B-X
IL-8	B-X
was	B-X
constitutively	B-X
expressed	B-X
60	B-X
days	B-X
after	B-X
irradiation	B-X
in	B-X
tumors	B-X
implanted	B-X
in	B-X
mice	B-X
.	B-X
Induction	B-X
of	B-X
IL-8	B-X
was	B-X
UV-B	B-X
dose	B-X
dependent	B-X
and	B-X
blocked	B-X
by	B-X
cyclohexamide	B-X
,	B-X
indicating	B-X
that	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
is	B-X
required	B-X
for	B-X
its	B-X
expression	B-X
.	B-X
The	B-X
UV-irradiated	B-X
cells	B-X
demonstrated	B-X
enhanced	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
potential	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
ability	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
increase	B-X
in	B-X
Mr	B-X
72,000	B-X
type	B-X
IV	B-X
collagenase	B-X
activity	B-X
and	B-X
angiogenesis	B-X
attributed	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
IL-8	B-X
after	B-X
irradiation	B-X
.	B-X
The	B-X
acquisition	B-X
of	B-X
the	B-X
metastatic	B-X
phenotype	B-X
induced	B-X
by	B-X
UV-B	B-X
could	B-X
not	B-X
be	B-X
attributed	B-X
to	B-X
abnormalities	B-X
in	B-X
the	B-X
p53	B-X
or	B-X
MTS-1	B-X
(	B-X
p16INK4	B-X
)	B-X
genes	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
increase	B-X
the	B-X
aggressiveness	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
for	B-X
growth	B-X
and	B-X
metastasis	B-X
.	B-X

Induction	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
was	O
UV	O
-	O
B	O
dose	O
dependent	O
and	O
blocked	O
by	O
cyclohexamide	O
,	O
indicating	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
required	O
for	O
its	O
expression	O
.	O
<EOS>	B-X
UV	B-X
radiation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
malignant	B-X
melanoma	B-X
to	B-X
the	B-X
metastatic	B-X
state	B-X
is	B-X
not	B-X
very	B-X
well	B-X
defined	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
concentrated	B-X
on	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
host	B-X
immune	B-X
response	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
tumor	B-X
cells	B-X
was	B-X
not	B-X
elucidated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
induce	B-X
interleukin	B-X
8	B-X
(	B-X
IL-8	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
with	B-X
negligible	B-X
expression	B-X
of	B-X
IL-8	B-X
.	B-X
UV-B-induced	B-X
IL-8	B-X
was	B-X
constitutively	B-X
expressed	B-X
60	B-X
days	B-X
after	B-X
irradiation	B-X
in	B-X
tumors	B-X
implanted	B-X
in	B-X
mice	B-X
.	B-X
Induction	B-X
of	B-X
IL-8	B-X
was	B-X
UV-B	B-X
dose	B-X
dependent	B-X
and	B-X
blocked	B-X
by	B-X
cyclohexamide	B-X
,	B-X
indicating	B-X
that	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
is	B-X
required	B-X
for	B-X
its	B-X
expression	B-X
.	B-X
The	B-X
UV-irradiated	B-X
cells	B-X
demonstrated	B-X
enhanced	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
potential	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
ability	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
increase	B-X
in	B-X
Mr	B-X
72,000	B-X
type	B-X
IV	B-X
collagenase	B-X
activity	B-X
and	B-X
angiogenesis	B-X
attributed	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
IL-8	B-X
after	B-X
irradiation	B-X
.	B-X
The	B-X
acquisition	B-X
of	B-X
the	B-X
metastatic	B-X
phenotype	B-X
induced	B-X
by	B-X
UV-B	B-X
could	B-X
not	B-X
be	B-X
attributed	B-X
to	B-X
abnormalities	B-X
in	B-X
the	B-X
p53	B-X
or	B-X
MTS-1	B-X
(	B-X
p16INK4	B-X
)	B-X
genes	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
increase	B-X
the	B-X
aggressiveness	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
for	B-X
growth	B-X
and	B-X
metastasis	B-X
.	B-X

The	O
UV	O
-	O
irradiated	O
cells	O
demonstrated	O
enhanced	O
tumorigenicity	O
and	O
metastatic	O
potential	O
in	O
nude	O
mice	O
.	O
<EOS>	B-X
UV	B-X
radiation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
malignant	B-X
melanoma	B-X
to	B-X
the	B-X
metastatic	B-X
state	B-X
is	B-X
not	B-X
very	B-X
well	B-X
defined	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
concentrated	B-X
on	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
host	B-X
immune	B-X
response	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
UV-B	B-X
on	B-X
the	B-X
tumor	B-X
cells	B-X
was	B-X
not	B-X
elucidated	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
induce	B-X
interleukin	B-X
8	B-X
(	B-X
IL-8	B-X
)	B-X
mRNA	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
with	B-X
negligible	B-X
expression	B-X
of	B-X
IL-8	B-X
.	B-X
UV-B-induced	B-X
IL-8	B-X
was	B-X
constitutively	B-X
expressed	B-X
60	B-X
days	B-X
after	B-X
irradiation	B-X
in	B-X
tumors	B-X
implanted	B-X
in	B-X
mice	B-X
.	B-X
Induction	B-X
of	B-X
IL-8	B-X
was	B-X
UV-B	B-X
dose	B-X
dependent	B-X
and	B-X
blocked	B-X
by	B-X
cyclohexamide	B-X
,	B-X
indicating	B-X
that	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
is	B-X
required	B-X
for	B-X
its	B-X
expression	B-X
.	B-X
The	B-X
UV-irradiated	B-X
cells	B-X
demonstrated	B-X
enhanced	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
potential	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
ability	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
increase	B-X
in	B-X
Mr	B-X
72,000	B-X
type	B-X
IV	B-X
collagenase	B-X
activity	B-X
and	B-X
angiogenesis	B-X
attributed	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
IL-8	B-X
after	B-X
irradiation	B-X
.	B-X
The	B-X
acquisition	B-X
of	B-X
the	B-X
metastatic	B-X
phenotype	B-X
induced	B-X
by	B-X
UV-B	B-X
could	B-X
not	B-X
be	B-X
attributed	B-X
to	B-X
abnormalities	B-X
in	B-X
the	B-X
p53	B-X
or	B-X
MTS-1	B-X
(	B-X
p16INK4	B-X
)	B-X
genes	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
show	B-X
that	B-X
UV-B	B-X
can	B-X
increase	B-X
the	B-X
aggressiveness	B-X
of	B-X
human	B-X
cutaneous	B-X
melanoma	B-X
for	B-X
growth	B-X
and	B-X
metastasis	B-X
.	B-X

The	O
increase	O
in	O
tumorigenicity	O
and	O
metastatic	O
ability	O
could	O
be	O
explained	O
by	O
the	O
increase	O
in	O
Mr	O
72	O
,	O
000	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagenase	I-Gene_or_gene_product
activity	O
and	O
angiogenesis	O
attributed	O
to	O
the	O
induction	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	I-Gene_or_gene_product
after	O
irradiation	O
.	O

The	O
acquisition	O
of	O
the	O
metastatic	O
phenotype	O
induced	O
by	O
UV	O
-	O
B	O
could	O
not	O
be	O
attributed	O
to	O
abnormalities	O
in	O
the	O
p53	B-Gene_or_gene_product
or	O
MTS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
(	O
p16INK4	B-Gene_or_gene_product
)	O
genes	O
.	O
<EOS>	B-X
Since	B-X
its	B-X
discovery	B-X
as	B-X
a	B-X
CDKI	B-X
(	B-X
cyclin-dependent	B-X
kinase	B-X
inhibitor	B-X
)	B-X
in	B-X
1993	B-X
,	B-X
the	B-X
tumor	B-X
suppressor	B-X
p16	B-X
(	B-X
INK4A/MTS-1/CDKN2A	B-X
)	B-X
has	B-X
gained	B-X
widespread	B-X
importance	B-X
in	B-X
cancer	B-X
.	B-X
The	B-X
frequent	B-X
mutations	B-X
and	B-X
deletions	B-X
of	B-X
p16	B-X
in	B-X
human	B-X
cancer	B-X
cell	B-X
lines	B-X
first	B-X
suggested	B-X
an	B-X
important	B-X
role	B-X
for	B-X
p16	B-X
in	B-X
carcinogenesis	B-X
.	B-X
This	B-X
genetic	B-X
evidence	B-X
for	B-X
a	B-X
causal	B-X
role	B-X
was	B-X
significantly	B-X
strengthened	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
p16	B-X
was	B-X
frequently	B-X
inactivated	B-X
in	B-X
familial	B-X
melanoma	B-X
kindreds	B-X
.	B-X
Since	B-X
then	B-X
,	B-X
a	B-X
high	B-X
frequency	B-X
of	B-X
p16	B-X
gene	B-X
alterations	B-X
were	B-X
observed	B-X
in	B-X
many	B-X
primary	B-X
tumors	B-X
.	B-X
In	B-X
human	B-X
neoplasms	B-X
,	B-X
p16	B-X
is	B-X
silenced	B-X
in	B-X
at	B-X
least	B-X
three	B-X
ways	B-X
:	B-X
homozygous	B-X
deletion	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
promoter	B-X
,	B-X
and	B-X
point	B-X
mutation	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
p16	B-X
may	B-X
be	B-X
an	B-X
early	B-X
event	B-X
in	B-X
cancer	B-X
progression	B-X
,	B-X
because	B-X
deletion	B-X
of	B-X
at	B-X
least	B-X
one	B-X
copy	B-X
is	B-X
quite	B-X
high	B-X
in	B-X
some	B-X
premalignant	B-X
lesions	B-X
.	B-X
p16	B-X
is	B-X
a	B-X
major	B-X
target	B-X
in	B-X
carcinogenesis	B-X
,	B-X
rivaled	B-X
in	B-X
frequency	B-X
only	B-X
by	B-X
the	B-X
p53	B-X
tumor-suppressor	B-X
gene	B-X
.	B-X
Although	B-X
p16	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
cell	B-X
senescence	B-X
,	B-X
the	B-X
physiologic	B-X
role	B-X
of	B-X
p16	B-X
is	B-X
still	B-X
unclear	B-X
.	B-X
Future	B-X
work	B-X
will	B-X
focus	B-X
on	B-X
studies	B-X
of	B-X
the	B-X
upstream	B-X
events	B-X
that	B-X
lead	B-X
to	B-X
p16	B-X
expression	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
regulation	B-X
,	B-X
and	B-X
perhaps	B-X
lead	B-X
to	B-X
better	B-X
therapeutic	B-X
strategies	B-X
that	B-X
can	B-X
improve	B-X
the	B-X
clinical	B-X
course	B-X
of	B-X
many	B-X
lethal	B-X
cancers	B-X
.	B-X

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
to	O
show	O
that	O
UV	O
-	O
B	O
can	O
increase	O
the	O
aggressiveness	O
of	O
human	O
cutaneous	O
melanoma	O
for	O
growth	O
and	O
metastasis	O
.	O

Cancer	O
metastasis	O
:	O
negative	O
regulation	O
by	O
an	O
invasion	O
-	O
suppressor	O
complex	O
.	O
<EOS>	B-X
We	B-X
situate	B-X
invasion	B-X
within	B-X
microecosystems	B-X
comprising	B-X
neoplastic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
host	B-X
cells	B-X
.	B-X
Modulation	B-X
of	B-X
invasion	B-X
within	B-X
such	B-X
systems	B-X
is	B-X
ascribed	B-X
to	B-X
balances	B-X
between	B-X
promoter	B-X
and	B-X
suppressor	B-X
pathways	B-X
.	B-X
The	B-X
E-cadherin/alpha-	B-X
,	B-X
beta-	B-X
,	B-X
gamma-catenin	B-X
complex	B-X
has	B-X
an	B-X
invasion-suppressor	B-X
function	B-X
as	B-X
evidenced	B-X
by	B-X
transfections	B-X
either	B-X
with	B-X
sense	B-X
cDNA	B-X
encoding	B-X
these	B-X
molecules	B-X
or	B-X
with	B-X
antisense	B-X
cDNA	B-X
inhibiting	B-X
their	B-X
expression	B-X
.	B-X
Downregulation	B-X
of	B-X
E-cadherin	B-X
occurred	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
or	B-X
of	B-X
mRNA	B-X
stability	B-X
.	B-X
These	B-X
observations	B-X
have	B-X
led	B-X
to	B-X
the	B-X
idea	B-X
that	B-X
factors	B-X
in	B-X
the	B-X
host	B-X
downmodulate	B-X
the	B-X
E-cadherin	B-X
complex	B-X
and	B-X
promote	B-X
invasion	B-X
most	B-X
probably	B-X
in	B-X
a	B-X
transient	B-X
way	B-X
.	B-X

Invasion	O
is	O
the	O
hallmark	O
of	O
tumor	O
malignancy	O
.	O
<EOS>	B-X
The	B-X
hallmarks	B-X
of	B-X
cancer	B-X
comprise	B-X
six	B-X
biological	B-X
capabilities	B-X
acquired	B-X
during	B-X
the	B-X
multistep	B-X
development	B-X
of	B-X
human	B-X
tumors	B-X
.	B-X
The	B-X
hallmarks	B-X
constitute	B-X
an	B-X
organizing	B-X
principle	B-X
for	B-X
rationalizing	B-X
the	B-X
complexities	B-X
of	B-X
neoplastic	B-X
disease	B-X
.	B-X
Underlying	B-X
these	B-X
hallmarks	B-X
are	B-X
genome	B-X
instability	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
genetic	B-X
diversity	B-X
that	B-X
expedites	B-X
their	B-X
acquisition	B-X
,	B-X
and	B-X
inflammation	B-X
,	B-X
which	B-X
fosters	B-X
multiple	B-X
hallmark	B-X
functions	B-X
.	B-X
Conceptual	B-X
progress	B-X
in	B-X
the	B-X
last	B-X
decade	B-X
has	B-X
added	B-X
two	B-X
emerging	B-X
hallmarks	B-X
of	B-X
potential	B-X
generality	B-X
to	B-X
this	B-X
list-reprogramming	B-X
of	B-X
energy	B-X
metabolism	B-X
and	B-X
evading	B-X
immune	B-X
destruction	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
cancer	B-X
cells	B-X
,	B-X
tumors	B-X
exhibit	B-X
another	B-X
dimension	B-X
of	B-X
complexity	B-X
:	B-X
they	B-X
contain	B-X
a	B-X
repertoire	B-X
of	B-X
recruited	B-X
,	B-X
ostensibly	B-X
normal	B-X
cells	B-X
that	B-X
contribute	B-X
to	B-X
the	B-X
acquisition	B-X
of	B-X
hallmark	B-X
traits	B-X
by	B-X
creating	B-X
the	B-X
``	B-X
tumor	B-X
microenvironment	B-X
.	B-X
''	B-X

We	O
situate	O
invasion	O
within	O
microecosystems	O
comprising	O
neoplastic	O
cells	O
as	O
well	O
as	O
host	O
cells	O
.	O
<EOS>	B-X
We	B-X
situate	B-X
invasion	B-X
within	B-X
microecosystems	B-X
comprising	B-X
neoplastic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
host	B-X
cells	B-X
.	B-X
Modulation	B-X
of	B-X
invasion	B-X
within	B-X
such	B-X
systems	B-X
is	B-X
ascribed	B-X
to	B-X
balances	B-X
between	B-X
promoter	B-X
and	B-X
suppressor	B-X
pathways	B-X
.	B-X
The	B-X
E-cadherin/alpha-	B-X
,	B-X
beta-	B-X
,	B-X
gamma-catenin	B-X
complex	B-X
has	B-X
an	B-X
invasion-suppressor	B-X
function	B-X
as	B-X
evidenced	B-X
by	B-X
transfections	B-X
either	B-X
with	B-X
sense	B-X
cDNA	B-X
encoding	B-X
these	B-X
molecules	B-X
or	B-X
with	B-X
antisense	B-X
cDNA	B-X
inhibiting	B-X
their	B-X
expression	B-X
.	B-X
Ex	B-X
vivo	B-X
cultures	B-X
from	B-X
invasive	B-X
tumors	B-X
or	B-X
metastases	B-X
produced	B-X
cells	B-X
that	B-X
were	B-X
homogeneously	B-X
E-cadherin-positive	B-X
and	B-X
noninvasive	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
observations	B-X
have	B-X
led	B-X
to	B-X
the	B-X
idea	B-X
that	B-X
factors	B-X
in	B-X
the	B-X
host	B-X
downmodulate	B-X
the	B-X
E-cadherin	B-X
complex	B-X
and	B-X
promote	B-X
invasion	B-X
most	B-X
probably	B-X
in	B-X
a	B-X
transient	B-X
way	B-X
.	B-X

Modulation	O
of	O
invasion	O
within	O
such	O
systems	O
is	O
ascribed	O
to	O
balances	O
between	O
promoter	O
and	O
suppressor	O
pathways	O
.	O
<EOS>	B-X
We	B-X
situate	B-X
invasion	B-X
within	B-X
microecosystems	B-X
comprising	B-X
neoplastic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
host	B-X
cells	B-X
.	B-X
Modulation	B-X
of	B-X
invasion	B-X
within	B-X
such	B-X
systems	B-X
is	B-X
ascribed	B-X
to	B-X
balances	B-X
between	B-X
promoter	B-X
and	B-X
suppressor	B-X
pathways	B-X
.	B-X
The	B-X
E-cadherin/alpha-	B-X
,	B-X
beta-	B-X
,	B-X
gamma-catenin	B-X
complex	B-X
has	B-X
an	B-X
invasion-suppressor	B-X
function	B-X
as	B-X
evidenced	B-X
by	B-X
transfections	B-X
either	B-X
with	B-X
sense	B-X
cDNA	B-X
encoding	B-X
these	B-X
molecules	B-X
or	B-X
with	B-X
antisense	B-X
cDNA	B-X
inhibiting	B-X
their	B-X
expression	B-X
.	B-X
These	B-X
observations	B-X
have	B-X
led	B-X
to	B-X
the	B-X
idea	B-X
that	B-X
factors	B-X
in	B-X
the	B-X
host	B-X
downmodulate	B-X
the	B-X
E-cadherin	B-X
complex	B-X
and	B-X
promote	B-X
invasion	B-X
most	B-X
probably	B-X
in	B-X
a	B-X
transient	B-X
way	B-X
.	B-X

The	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
/	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
,	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
,	O
gamma	B-Gene_or_gene_product
-	I-Gene_or_gene_product
catenin	I-Gene_or_gene_product
complex	O
has	O
an	O
invasion	O
-	O
suppressor	O
function	O
as	O
evidenced	O
by	O
transfections	O
either	O
with	O
sense	O
cDNA	O
encoding	O
these	O
molecules	O
or	O
with	O
antisense	O
cDNA	O
inhibiting	O
their	O
expression	O
.	O
<EOS>	B-X
Oligonucleotides	B-X
can	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
ways	B-X
inhibit	B-X
gene	B-X
expression	B-X
by	B-X
interfering	B-X
with	B-X
translation	B-X
.	B-X
Oligonucleotides	B-X
that	B-X
are	B-X
complementary	B-X
to	B-X
a	B-X
target	B-X
mRNA	B-X
,	B-X
antisense	B-X
oligonucleotides	B-X
,	B-X
can	B-X
prevent	B-X
translation	B-X
either	B-X
by	B-X
cleaving	B-X
the	B-X
target	B-X
or	B-X
by	B-X
physically	B-X
blocking	B-X
the	B-X
process	B-X
.	B-X
Even	B-X
with	B-X
no	B-X
RNA	B-X
as	B-X
target	B-X
,	B-X
oligonucleotides	B-X
can	B-X
be	B-X
selected	B-X
as	B-X
aptamers	B-X
to	B-X
bind	B-X
to	B-X
any	B-X
protein	B-X
to	B-X
inhibit	B-X
its	B-X
activity	B-X
.	B-X
The	B-X
intercalating	B-X
agent	B-X
provides	B-X
an	B-X
additional	B-X
binding	B-X
energy	B-X
which	B-X
stabilizes	B-X
the	B-X
complex	B-X
.	B-X
Metal	B-X
complexes	B-X
of	B-X
EDTA	B-X
,	B-X
phenanthroline	B-X
or	B-X
porphyrins	B-X
induce	B-X
cleavage	B-X
reactions	B-X
of	B-X
the	B-X
phosphodiester	B-X
backbone	B-X
in	B-X
both	B-X
DNA	B-X
and	B-X
RNA	B-X
.	B-X
The	B-X
oligonucleotide	B-X
can	B-X
be	B-X
made	B-X
resistant	B-X
to	B-X
nuclease	B-X
digestion	B-X
by	B-X
substituting	B-X
the	B-X
synthetic	B-X
alpha-anomers	B-X
of	B-X
nucleosides	B-X
to	B-X
the	B-X
natural	B-X
beta-nucleosides	B-X
.	B-X

Loss	O
of	O
heterozygosity	O
at	O
the	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Cadherin	I-Gene_or_gene_product
(	O
uvo	O
)	O
locus	O
has	O
been	O
reported	O
,	O
but	O
mutations	O
in	O
the	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
gene	O
seem	O
to	O
be	O
rare	O
.	O

Downregulation	O
of	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
occurred	O
at	O
the	O
level	O
of	O
transcription	O
or	O
of	O
mRNA	O
stability	O
.	O
<EOS>	B-X
Many	B-X
studies	B-X
have	B-X
highlighted	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
tight	B-X
regulation	B-X
of	B-X
mRNA	B-X
stability	B-X
in	B-X
the	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
mRNA	B-X
stability	B-X
largely	B-X
depends	B-X
on	B-X
the	B-X
mRNA	B-X
nucleotide	B-X
sequence	B-X
,	B-X
which	B-X
affects	B-X
the	B-X
secondary	B-X
and	B-X
tertiary	B-X
structures	B-X
of	B-X
the	B-X
mRNAs	B-X
,	B-X
and	B-X
the	B-X
accessibility	B-X
of	B-X
various	B-X
RNA-binding	B-X
proteins	B-X
to	B-X
the	B-X
mRNAs	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
high-throughput	B-X
RNA-sequencing	B-X
techniques	B-X
have	B-X
resulted	B-X
in	B-X
the	B-X
elucidation	B-X
of	B-X
the	B-X
important	B-X
roles	B-X
played	B-X
by	B-X
mRNA	B-X
modifications	B-X
and	B-X
mRNA	B-X
nucleotide	B-X
sequences	B-X
in	B-X
regulating	B-X
mRNA	B-X
stability	B-X
.	B-X
Therapeutic	B-X
mRNAs	B-X
and	B-X
vaccines	B-X
are	B-X
being	B-X
developed	B-X
for	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
human	B-X
diseases	B-X
,	B-X
including	B-X
COVID-19	B-X
.	B-X
However	B-X
,	B-X
their	B-X
optimization	B-X
is	B-X
hindered	B-X
by	B-X
mRNA	B-X
instability	B-X
and	B-X
inefficient	B-X
protein	B-X
expression	B-X
.	B-X
We	B-X
develop	B-X
an	B-X
RNA	B-X
sequencing-based	B-X
platform	B-X
called	B-X
PERSIST-seq	B-X
to	B-X
systematically	B-X
delineate	B-X
in-cell	B-X
mRNA	B-X
stability	B-X
,	B-X
ribosome	B-X
load	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in-solution	B-X
stability	B-X
of	B-X
a	B-X
library	B-X
of	B-X
diverse	B-X
mRNAs	B-X
.	B-X
We	B-X
find	B-X
that	B-X
,	B-X
surprisingly	B-X
,	B-X
in-cell	B-X
stability	B-X
is	B-X
a	B-X
greater	B-X
driver	B-X
of	B-X
protein	B-X
output	B-X
than	B-X
high	B-X
ribosome	B-X
load	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
highly	B-X
structured	B-X
``	B-X
superfolder	B-X
''	B-X
mRNAs	B-X
can	B-X
be	B-X
designed	B-X
to	B-X
improve	B-X
both	B-X
stability	B-X
and	B-X
expression	B-X
with	B-X
further	B-X
enhancement	B-X
through	B-X
pseudouridine	B-X
nucleoside	B-X
modification	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
study	B-X
demonstrates	B-X
simultaneous	B-X
improvement	B-X
of	B-X
mRNA	B-X
stability	B-X
and	B-X
protein	B-X
expression	B-X
and	B-X
provides	B-X
a	B-X
computational-experimental	B-X
platform	B-X
for	B-X
the	B-X
enhancement	B-X
of	B-X
mRNA	B-X
medicines	B-X
.	B-X

Ex	O
vivo	O
cultures	O
from	O
invasive	O
tumors	O
or	O
metastases	O
produced	O
cells	O
that	O
were	O
homogeneously	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
-	O
positive	O
and	O
noninvasive	O
in	O
vitro	O
.	O
<EOS>	B-X
We	B-X
established	B-X
a	B-X
biorepository	B-X
of	B-X
65	B-X
patient-derived	B-X
RC	B-X
organoid	B-X
cultures	B-X
(	B-X
tumoroids	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
metastatic	B-X
or	B-X
recurrent	B-X
disease	B-X
.	B-X
RC	B-X
tumoroids	B-X
retained	B-X
molecular	B-X
features	B-X
of	B-X
the	B-X
tumors	B-X
from	B-X
which	B-X
they	B-X
were	B-X
derived	B-X
,	B-X
and	B-X
their	B-X
ex	B-X
vivo	B-X
responses	B-X
to	B-X
clinically	B-X
relevant	B-X
chemotherapy	B-X
and	B-X
radiation	B-X
treatment	B-X
correlated	B-X
with	B-X
the	B-X
clinical	B-X
responses	B-X
noted	B-X
in	B-X
individual	B-X
patients	B-X
'	B-X
tumors	B-X
.	B-X
Upon	B-X
engraftment	B-X
into	B-X
murine	B-X
rectal	B-X
mucosa	B-X
,	B-X
human	B-X
RC	B-X
tumoroids	B-X
gave	B-X
rise	B-X
to	B-X
invasive	B-X
RC	B-X
followed	B-X
by	B-X
metastasis	B-X
to	B-X
lung	B-X
and	B-X
liver	B-X
.	B-X
Importantly	B-X
,	B-X
engrafted	B-X
tumors	B-X
displayed	B-X
the	B-X
heterogenous	B-X
sensitivity	B-X
to	B-X
chemotherapy	B-X
observed	B-X
clinically	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
biology	B-X
and	B-X
drug	B-X
sensitivity	B-X
of	B-X
RC	B-X
clinical	B-X
isolates	B-X
can	B-X
be	B-X
efficiently	B-X
interrogated	B-X
using	B-X
an	B-X
organoid-based	B-X
,	B-X
ex	B-X
vivo	B-X
platform	B-X
coupled	B-X
with	B-X
in	B-X
vivo	B-X
endoluminal	B-X
propagation	B-X
in	B-X
animals	B-X
.	B-X

These	O
observations	O
have	O
led	O
to	O
the	O
idea	O
that	O
factors	O
in	O
the	O
host	O
downmodulate	O
the	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	I-Gene_or_gene_product
complex	O
and	O
promote	O
invasion	O
most	O
probably	O
in	O
a	O
transient	O
way	O
.	O

Heparin	O
-	O
steroid	O
conjugates	O
:	O
new	O
angiogenesis	O
inhibitors	O
with	O
antitumor	O
activity	O
in	O
mice	O
.	O
<EOS>	B-X
Inhibitors	B-X
of	B-X
angiogenesis	B-X
hold	B-X
potential	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
where	B-X
the	B-X
disease	B-X
is	B-X
caused	B-X
or	B-X
maintained	B-X
by	B-X
the	B-X
inappropriate	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
angiogenesis	B-X
was	B-X
synthesized	B-X
by	B-X
covalently	B-X
linking	B-X
a	B-X
nonanticoagulating	B-X
derivative	B-X
of	B-X
heparin	B-X
,	B-X
heparin	B-X
adipic	B-X
hydrazide	B-X
(	B-X
HAH	B-X
)	B-X
,	B-X
by	B-X
an	B-X
acid-labile	B-X
bond	B-X
to	B-X
the	B-X
antiangiogenic	B-X
steroid	B-X
,	B-X
cortisol	B-X
.	B-X
The	B-X
rationale	B-X
was	B-X
that	B-X
the	B-X
heparin	B-X
derivative	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
sulfated	B-X
polyanion	B-X
receptors	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
should	B-X
concentrate	B-X
the	B-X
steroid	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Endocytosis	B-X
of	B-X
the	B-X
conjugate	B-X
and	B-X
decomposition	B-X
of	B-X
the	B-X
acid-labile	B-X
linkage	B-X
inside	B-X
lysosomes	B-X
and	B-X
other	B-X
acidic	B-X
intracellular	B-X
compartments	B-X
should	B-X
then	B-X
lead	B-X
to	B-X
release	B-X
of	B-X
the	B-X
cortisol	B-X
and	B-X
expression	B-X
of	B-X
its	B-X
antiproliferative	B-X
activity	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
into	B-X
mice	B-X
bearing	B-X
s.c.	B-X
sponge	B-X
implants	B-X
retarded	B-X
vascularization	B-X
of	B-X
the	B-X
sponge	B-X
,	B-X
and	B-X
injections	B-X
directly	B-X
into	B-X
the	B-X
sponge	B-X
abolished	B-X
vascularization	B-X
for	B-X
as	B-X
long	B-X
as	B-X
the	B-X
injections	B-X
were	B-X
continued	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
at	B-X
doses	B-X
causing	B-X
no	B-X
apparent	B-X
toxicity	B-X
retarded	B-X
the	B-X
growth	B-X
of	B-X
solid	B-X
s.c.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
in	B-X
mice	B-X
by	B-X
up	B-X
to	B-X
65	B-X
%	B-X
.	B-X
The	B-X
antiproliferative	B-X
effect	B-X
of	B-X
HAH-cortisol	B-X
on	B-X
endothelial	B-X
cells	B-X
appeared	B-X
independent	B-X
of	B-X
the	B-X
glucocorticoid	B-X
activity	B-X
of	B-X
the	B-X
steroid	B-X
since	B-X
HAH	B-X
conjugated	B-X
to	B-X
5	B-X
beta-pregnane-3	B-X
alpha,17	B-X
alpha,21-triol-20-one	B-X
,	B-X
a	B-X
steroid	B-X
lacking	B-X
glucocorticoid	B-X
or	B-X
mineralocorticoid	B-X
activity	B-X
,	B-X
was	B-X
even	B-X
more	B-X
effective	B-X
at	B-X
inhibiting	B-X
DNA	B-X
synthesis	B-X
by	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
than	B-X
was	B-X
HAH-cortisol	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HAH-cortisol	B-X
represents	B-X
the	B-X
prototype	B-X
of	B-X
a	B-X
new	B-X
class	B-X
of	B-X
angiogenesis	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
angiogenic	B-X
diseases	B-X
.	B-X

Inhibitors	O
of	O
angiogenesis	O
hold	O
potential	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
diseases	O
where	O
the	O
disease	O
is	O
caused	O
or	O
maintained	O
by	O
the	O
inappropriate	O
growth	O
of	O
blood	O
vessels	O
.	O
<EOS>	B-X
These	B-X
may	B-X
include	B-X
autonomic	B-X
neuropathy	B-X
,	B-X
left	B-X
ventricular	B-X
hypertrophy	B-X
(	B-X
LVH	B-X
)	B-X
and	B-X
diastolic	B-X
dysfunction	B-X
,	B-X
inappropriate	B-X
activation	B-X
of	B-X
cardiovascular	B-X
reflexes	B-X
,	B-X
and	B-X
abnormal	B-X
vascular	B-X
compliance	B-X
.	B-X
Impaired	B-X
cardiac	B-X
filling	B-X
and	B-X
reduced	B-X
cardiac	B-X
output	B-X
do	B-X
not	B-X
fully	B-X
explain	B-X
dialysis	B-X
hypotension	B-X
;	B-X
in	B-X
most	B-X
subjects	B-X
the	B-X
response	B-X
is	B-X
reflex	B-X
sympathetic	B-X
activation	B-X
and	B-X
peripheral	B-X
vasoconstriction	B-X
,	B-X
with	B-X
maintenance	B-X
of	B-X
blood	B-X
pressure	B-X
.	B-X
Other	B-X
potential	B-X
factors	B-X
increasing	B-X
susceptibility	B-X
to	B-X
hypotension	B-X
include	B-X
impaired	B-X
venous	B-X
compliance	B-X
,	B-X
which	B-X
predisposes	B-X
to	B-X
reduced	B-X
venous	B-X
return	B-X
,	B-X
seen	B-X
particularly	B-X
in	B-X
elderly	B-X
hypertensive	B-X
and	B-X
diabetic	B-X
ESRD	B-X
patients	B-X
.	B-X
Despite	B-X
this	B-X
,	B-X
interdialytic	B-X
weight	B-X
gain	B-X
is	B-X
not	B-X
related	B-X
either	B-X
to	B-X
interdialytic	B-X
blood	B-X
pressure	B-X
change	B-X
,	B-X
nor	B-X
to	B-X
development	B-X
of	B-X
LVH	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
inhibitor	O
of	O
angiogenesis	O
was	O
synthesized	O
by	O
covalently	O
linking	O
a	O
nonanticoagulating	O
derivative	O
of	O
heparin	O
,	O
heparin	O
adipic	O
hydrazide	O
(	O
HAH	O
)	O
,	O
by	O
an	O
acid	O
-	O
labile	O
bond	O
to	O
the	O
antiangiogenic	O
steroid	O
,	O
cortisol	O
.	O

The	O
rationale	O
was	O
that	O
the	O
heparin	O
derivative	O
,	O
which	O
binds	O
to	O
sulfated	O
polyanion	O
receptors	O
on	O
endothelial	O
cells	O
,	O
should	O
concentrate	O
the	O
steroid	O
on	O
the	O
surface	O
of	O
vascular	O
endothelial	O
cells	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
angiogenesis	B-X
was	B-X
synthesized	B-X
by	B-X
covalently	B-X
linking	B-X
a	B-X
nonanticoagulating	B-X
derivative	B-X
of	B-X
heparin	B-X
,	B-X
heparin	B-X
adipic	B-X
hydrazide	B-X
(	B-X
HAH	B-X
)	B-X
,	B-X
by	B-X
an	B-X
acid-labile	B-X
bond	B-X
to	B-X
the	B-X
antiangiogenic	B-X
steroid	B-X
,	B-X
cortisol	B-X
.	B-X
The	B-X
rationale	B-X
was	B-X
that	B-X
the	B-X
heparin	B-X
derivative	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
sulfated	B-X
polyanion	B-X
receptors	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
should	B-X
concentrate	B-X
the	B-X
steroid	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
stability	B-X
of	B-X
HAH-cortisol	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
7.4	B-X
and	B-X
broke	B-X
down	B-X
rapidly	B-X
(	B-X
t1/2	B-X
15	B-X
min	B-X
)	B-X
at	B-X
pH	B-X
4.8	B-X
at	B-X
37	B-X
degrees	B-X
C.	B-X
Treatment	B-X
of	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
with	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
suppressed	B-X
their	B-X
DNA	B-X
synthesis	B-X
by	B-X
50	B-X
%	B-X
and	B-X
inhibited	B-X
their	B-X
migration	B-X
into	B-X
wounded	B-X
areas	B-X
of	B-X
confluent	B-X
monolayers	B-X
.	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
did	B-X
not	B-X
suppress	B-X
the	B-X
DNA	B-X
synthesis	B-X
of	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
into	B-X
mice	B-X
bearing	B-X
s.c.	B-X
sponge	B-X
implants	B-X
retarded	B-X
vascularization	B-X
of	B-X
the	B-X
sponge	B-X
,	B-X
and	B-X
injections	B-X
directly	B-X
into	B-X
the	B-X
sponge	B-X
abolished	B-X
vascularization	B-X
for	B-X
as	B-X
long	B-X
as	B-X
the	B-X
injections	B-X
were	B-X
continued	B-X
.	B-X
The	B-X
antiproliferative	B-X
effect	B-X
of	B-X
HAH-cortisol	B-X
on	B-X
endothelial	B-X
cells	B-X
appeared	B-X
independent	B-X
of	B-X
the	B-X
glucocorticoid	B-X
activity	B-X
of	B-X
the	B-X
steroid	B-X
since	B-X
HAH	B-X
conjugated	B-X
to	B-X
5	B-X
beta-pregnane-3	B-X
alpha,17	B-X
alpha,21-triol-20-one	B-X
,	B-X
a	B-X
steroid	B-X
lacking	B-X
glucocorticoid	B-X
or	B-X
mineralocorticoid	B-X
activity	B-X
,	B-X
was	B-X
even	B-X
more	B-X
effective	B-X
at	B-X
inhibiting	B-X
DNA	B-X
synthesis	B-X
by	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
than	B-X
was	B-X
HAH-cortisol	B-X
.	B-X

Endocytosis	O
of	O
the	O
conjugate	O
and	O
decomposition	O
of	O
the	O
acid	O
-	O
labile	O
linkage	O
inside	O
lysosomes	O
and	O
other	O
acidic	O
intracellular	O
compartments	O
should	O
then	O
lead	O
to	O
release	O
of	O
the	O
cortisol	O
and	O
expression	O
of	O
its	O
antiproliferative	O
activity	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
angiogenesis	B-X
was	B-X
synthesized	B-X
by	B-X
covalently	B-X
linking	B-X
a	B-X
nonanticoagulating	B-X
derivative	B-X
of	B-X
heparin	B-X
,	B-X
heparin	B-X
adipic	B-X
hydrazide	B-X
(	B-X
HAH	B-X
)	B-X
,	B-X
by	B-X
an	B-X
acid-labile	B-X
bond	B-X
to	B-X
the	B-X
antiangiogenic	B-X
steroid	B-X
,	B-X
cortisol	B-X
.	B-X
Endocytosis	B-X
of	B-X
the	B-X
conjugate	B-X
and	B-X
decomposition	B-X
of	B-X
the	B-X
acid-labile	B-X
linkage	B-X
inside	B-X
lysosomes	B-X
and	B-X
other	B-X
acidic	B-X
intracellular	B-X
compartments	B-X
should	B-X
then	B-X
lead	B-X
to	B-X
release	B-X
of	B-X
the	B-X
cortisol	B-X
and	B-X
expression	B-X
of	B-X
its	B-X
antiproliferative	B-X
activity	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
stability	B-X
of	B-X
HAH-cortisol	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
7.4	B-X
and	B-X
broke	B-X
down	B-X
rapidly	B-X
(	B-X
t1/2	B-X
15	B-X
min	B-X
)	B-X
at	B-X
pH	B-X
4.8	B-X
at	B-X
37	B-X
degrees	B-X
C.	B-X
Treatment	B-X
of	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
with	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
suppressed	B-X
their	B-X
DNA	B-X
synthesis	B-X
by	B-X
50	B-X
%	B-X
and	B-X
inhibited	B-X
their	B-X
migration	B-X
into	B-X
wounded	B-X
areas	B-X
of	B-X
confluent	B-X
monolayers	B-X
.	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
did	B-X
not	B-X
suppress	B-X
the	B-X
DNA	B-X
synthesis	B-X
of	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
into	B-X
mice	B-X
bearing	B-X
s.c.	B-X
sponge	B-X
implants	B-X
retarded	B-X
vascularization	B-X
of	B-X
the	B-X
sponge	B-X
,	B-X
and	B-X
injections	B-X
directly	B-X
into	B-X
the	B-X
sponge	B-X
abolished	B-X
vascularization	B-X
for	B-X
as	B-X
long	B-X
as	B-X
the	B-X
injections	B-X
were	B-X
continued	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
at	B-X
doses	B-X
causing	B-X
no	B-X
apparent	B-X
toxicity	B-X
retarded	B-X
the	B-X
growth	B-X
of	B-X
solid	B-X
s.c.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
in	B-X
mice	B-X
by	B-X
up	B-X
to	B-X
65	B-X
%	B-X
.	B-X
In	B-X
all	B-X
of	B-X
these	B-X
assays	B-X
,	B-X
equivalent	B-X
treatments	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
HAH	B-X
plus	B-X
cortisol	B-X
was	B-X
significantly	B-X
less	B-X
effective	B-X
.	B-X
The	B-X
antiproliferative	B-X
effect	B-X
of	B-X
HAH-cortisol	B-X
on	B-X
endothelial	B-X
cells	B-X
appeared	B-X
independent	B-X
of	B-X
the	B-X
glucocorticoid	B-X
activity	B-X
of	B-X
the	B-X
steroid	B-X
since	B-X
HAH	B-X
conjugated	B-X
to	B-X
5	B-X
beta-pregnane-3	B-X
alpha,17	B-X
alpha,21-triol-20-one	B-X
,	B-X
a	B-X
steroid	B-X
lacking	B-X
glucocorticoid	B-X
or	B-X
mineralocorticoid	B-X
activity	B-X
,	B-X
was	B-X
even	B-X
more	B-X
effective	B-X
at	B-X
inhibiting	B-X
DNA	B-X
synthesis	B-X
by	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
than	B-X
was	B-X
HAH-cortisol	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HAH-cortisol	B-X
represents	B-X
the	B-X
prototype	B-X
of	B-X
a	B-X
new	B-X
class	B-X
of	B-X
angiogenesis	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
angiogenic	B-X
diseases	B-X
.	B-X

Analysis	O
of	O
the	O
stability	O
of	O
HAH	O
-	O
cortisol	O
showed	O
that	O
it	O
was	O
stable	O
at	O
pH	O
7	O
.	O
4	O
and	O
broke	O
down	O
rapidly	O
(	O
t1	O
/	O
2	O
15	O
min	O
)	O
at	O
pH	O
4	O
.	O
8	O
at	O
37	O
degrees	O
C	O
.	O

Treatment	O
of	O
murine	O
pulmonary	O
capillary	O
endothelial	O
cells	O
with	O
HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
5	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
suppressed	O
their	O
DNA	O
synthesis	O
by	O
50	O
%	O
and	O
inhibited	O
their	O
migration	O
into	O
wounded	O
areas	O
of	O
confluent	O
monolayers	O
.	O

HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
4	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
did	O
not	O
suppress	O
the	O
DNA	O
synthesis	O
of	O
Lewis	O
lung	O
carcinoma	O
cells	O
.	O

Daily	O
i	O
.	O
p	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
into	O
mice	O
bearing	O
s	O
.	O
c	O
.	O
sponge	O
implants	O
retarded	O
vascularization	O
of	O
the	O
sponge	O
,	O
and	O
injections	O
directly	O
into	O
the	O
sponge	O
abolished	O
vascularization	O
for	O
as	O
long	O
as	O
the	O
injections	O
were	O
continued	O
.	O

Daily	O
i	O
.	O
v	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
at	O
doses	O
causing	O
no	O
apparent	O
toxicity	O
retarded	O
the	O
growth	O
of	O
solid	O
s	O
.	O
c	O
.	O

Lewis	O
lung	O
carcinomas	O
in	O
mice	O
by	O
up	O
to	O
65	O
%	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
analyze	B-X
the	B-X
mechanisms	B-X
for	B-X
cancer	B-X
metastasis	B-X
,	B-X
high	B-X
metastatic	B-X
sublines	B-X
(	B-X
H7-A	B-X
,	B-X
H7-Lu	B-X
,	B-X
H7-O	B-X
,	B-X
C4-sc	B-X
,	B-X
and	B-X
C4-ly	B-X
)	B-X
were	B-X
obtained	B-X
by	B-X
repeated	B-X
injection	B-X
of	B-X
mouse	B-X
Lewis	B-X
lung	B-X
cancer	B-X
sublines	B-X
H7	B-X
and	B-X
C4	B-X
into	B-X
C57BL/6	B-X
mice	B-X
.	B-X
Stable	B-X
silencing	B-X
of	B-X
endogenous	B-X
pp-GalNAc-T13	B-X
in	B-X
C4-sc	B-X
(	B-X
T13-KD	B-X
)	B-X
revealed	B-X
that	B-X
primary	B-X
tumors	B-X
generated	B-X
by	B-X
subcutaneous	B-X
injection	B-X
of	B-X
T13-KD	B-X
clones	B-X
showed	B-X
lower	B-X
coalescence	B-X
to	B-X
fascia	B-X
and	B-X
peritoneum	B-X
,	B-X
and	B-X
significantly	B-X
reduced	B-X
lung	B-X
metastasis	B-X
than	B-X
control	B-X
clones	B-X
.	B-X
We	B-X
demonstrated	B-X
previously	B-X
that	B-X
ppGalNAc-T13	B-X
(	B-X
T13	B-X
)	B-X
,	B-X
identified	B-X
as	B-X
an	B-X
up-regulated	B-X
gene	B-X
with	B-X
increased	B-X
metastasis	B-X
in	B-X
a	B-X
DNA	B-X
microarray	B-X
,	B-X
generated	B-X
trimeric	B-X
Tn	B-X
(	B-X
tTn	B-X
)	B-X
antigen	B-X
(	B-X
GalNAcÎ±1-Ser/Thr	B-X
)	B-X
3	B-X
on	B-X
Syndecan	B-X
1	B-X
in	B-X
highly	B-X
metastatic	B-X
sublines	B-X
of	B-X
Lewis	B-X
lung	B-X
cancer	B-X
.	B-X
C57Bl	B-X
mice	B-X
bearing	B-X
LLC	B-X
tumors	B-X
were	B-X
injected	B-X
i.p	B-X
.	B-X

In	O
all	O
of	O
these	O
assays	O
,	O
equivalent	O
treatments	O
with	O
a	O
mixture	O
of	O
the	O
HAH	O
plus	O
cortisol	O
was	O
significantly	O
less	O
effective	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
angiogenesis	B-X
was	B-X
synthesized	B-X
by	B-X
covalently	B-X
linking	B-X
a	B-X
nonanticoagulating	B-X
derivative	B-X
of	B-X
heparin	B-X
,	B-X
heparin	B-X
adipic	B-X
hydrazide	B-X
(	B-X
HAH	B-X
)	B-X
,	B-X
by	B-X
an	B-X
acid-labile	B-X
bond	B-X
to	B-X
the	B-X
antiangiogenic	B-X
steroid	B-X
,	B-X
cortisol	B-X
.	B-X
Endocytosis	B-X
of	B-X
the	B-X
conjugate	B-X
and	B-X
decomposition	B-X
of	B-X
the	B-X
acid-labile	B-X
linkage	B-X
inside	B-X
lysosomes	B-X
and	B-X
other	B-X
acidic	B-X
intracellular	B-X
compartments	B-X
should	B-X
then	B-X
lead	B-X
to	B-X
release	B-X
of	B-X
the	B-X
cortisol	B-X
and	B-X
expression	B-X
of	B-X
its	B-X
antiproliferative	B-X
activity	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
stability	B-X
of	B-X
HAH-cortisol	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
7.4	B-X
and	B-X
broke	B-X
down	B-X
rapidly	B-X
(	B-X
t1/2	B-X
15	B-X
min	B-X
)	B-X
at	B-X
pH	B-X
4.8	B-X
at	B-X
37	B-X
degrees	B-X
C.	B-X
Treatment	B-X
of	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
with	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
suppressed	B-X
their	B-X
DNA	B-X
synthesis	B-X
by	B-X
50	B-X
%	B-X
and	B-X
inhibited	B-X
their	B-X
migration	B-X
into	B-X
wounded	B-X
areas	B-X
of	B-X
confluent	B-X
monolayers	B-X
.	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
did	B-X
not	B-X
suppress	B-X
the	B-X
DNA	B-X
synthesis	B-X
of	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
into	B-X
mice	B-X
bearing	B-X
s.c.	B-X
sponge	B-X
implants	B-X
retarded	B-X
vascularization	B-X
of	B-X
the	B-X
sponge	B-X
,	B-X
and	B-X
injections	B-X
directly	B-X
into	B-X
the	B-X
sponge	B-X
abolished	B-X
vascularization	B-X
for	B-X
as	B-X
long	B-X
as	B-X
the	B-X
injections	B-X
were	B-X
continued	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
at	B-X
doses	B-X
causing	B-X
no	B-X
apparent	B-X
toxicity	B-X
retarded	B-X
the	B-X
growth	B-X
of	B-X
solid	B-X
s.c.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
in	B-X
mice	B-X
by	B-X
up	B-X
to	B-X
65	B-X
%	B-X
.	B-X
In	B-X
all	B-X
of	B-X
these	B-X
assays	B-X
,	B-X
equivalent	B-X
treatments	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
HAH	B-X
plus	B-X
cortisol	B-X
was	B-X
significantly	B-X
less	B-X
effective	B-X
.	B-X
The	B-X
antiproliferative	B-X
effect	B-X
of	B-X
HAH-cortisol	B-X
on	B-X
endothelial	B-X
cells	B-X
appeared	B-X
independent	B-X
of	B-X
the	B-X
glucocorticoid	B-X
activity	B-X
of	B-X
the	B-X
steroid	B-X
since	B-X
HAH	B-X
conjugated	B-X
to	B-X
5	B-X
beta-pregnane-3	B-X
alpha,17	B-X
alpha,21-triol-20-one	B-X
,	B-X
a	B-X
steroid	B-X
lacking	B-X
glucocorticoid	B-X
or	B-X
mineralocorticoid	B-X
activity	B-X
,	B-X
was	B-X
even	B-X
more	B-X
effective	B-X
at	B-X
inhibiting	B-X
DNA	B-X
synthesis	B-X
by	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
than	B-X
was	B-X
HAH-cortisol	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HAH-cortisol	B-X
represents	B-X
the	B-X
prototype	B-X
of	B-X
a	B-X
new	B-X
class	B-X
of	B-X
angiogenesis	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
angiogenic	B-X
diseases	B-X
.	B-X

The	O
antiproliferative	O
effect	O
of	O
HAH	O
-	O
cortisol	O
on	O
endothelial	O
cells	O
appeared	O
independent	O
of	O
the	O
glucocorticoid	O
activity	O
of	O
the	O
steroid	O
since	O
HAH	O
conjugated	O
to	O
5	O
beta	O
-	O
pregnane	O
-	O
3	O
alpha	O
,	O
17	O
alpha	O
,	O
21	O
-	O
triol	O
-	O
20	O
-	O
one	O
,	O
a	O
steroid	O
lacking	O
glucocorticoid	O
or	O
mineralocorticoid	O
activity	O
,	O
was	O
even	O
more	O
effective	O
at	O
inhibiting	O
DNA	O
synthesis	O
by	O
murine	O
pulmonary	O
capillary	O
endothelial	O
cells	O
than	O
was	O
HAH	O
-	O
cortisol	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
angiogenesis	B-X
was	B-X
synthesized	B-X
by	B-X
covalently	B-X
linking	B-X
a	B-X
nonanticoagulating	B-X
derivative	B-X
of	B-X
heparin	B-X
,	B-X
heparin	B-X
adipic	B-X
hydrazide	B-X
(	B-X
HAH	B-X
)	B-X
,	B-X
by	B-X
an	B-X
acid-labile	B-X
bond	B-X
to	B-X
the	B-X
antiangiogenic	B-X
steroid	B-X
,	B-X
cortisol	B-X
.	B-X
The	B-X
rationale	B-X
was	B-X
that	B-X
the	B-X
heparin	B-X
derivative	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
sulfated	B-X
polyanion	B-X
receptors	B-X
on	B-X
endothelial	B-X
cells	B-X
,	B-X
should	B-X
concentrate	B-X
the	B-X
steroid	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
.	B-X
Endocytosis	B-X
of	B-X
the	B-X
conjugate	B-X
and	B-X
decomposition	B-X
of	B-X
the	B-X
acid-labile	B-X
linkage	B-X
inside	B-X
lysosomes	B-X
and	B-X
other	B-X
acidic	B-X
intracellular	B-X
compartments	B-X
should	B-X
then	B-X
lead	B-X
to	B-X
release	B-X
of	B-X
the	B-X
cortisol	B-X
and	B-X
expression	B-X
of	B-X
its	B-X
antiproliferative	B-X
activity	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
stability	B-X
of	B-X
HAH-cortisol	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
7.4	B-X
and	B-X
broke	B-X
down	B-X
rapidly	B-X
(	B-X
t1/2	B-X
15	B-X
min	B-X
)	B-X
at	B-X
pH	B-X
4.8	B-X
at	B-X
37	B-X
degrees	B-X
C.	B-X
Treatment	B-X
of	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
with	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
suppressed	B-X
their	B-X
DNA	B-X
synthesis	B-X
by	B-X
50	B-X
%	B-X
and	B-X
inhibited	B-X
their	B-X
migration	B-X
into	B-X
wounded	B-X
areas	B-X
of	B-X
confluent	B-X
monolayers	B-X
.	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
did	B-X
not	B-X
suppress	B-X
the	B-X
DNA	B-X
synthesis	B-X
of	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
into	B-X
mice	B-X
bearing	B-X
s.c.	B-X
sponge	B-X
implants	B-X
retarded	B-X
vascularization	B-X
of	B-X
the	B-X
sponge	B-X
,	B-X
and	B-X
injections	B-X
directly	B-X
into	B-X
the	B-X
sponge	B-X
abolished	B-X
vascularization	B-X
for	B-X
as	B-X
long	B-X
as	B-X
the	B-X
injections	B-X
were	B-X
continued	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
at	B-X
doses	B-X
causing	B-X
no	B-X
apparent	B-X
toxicity	B-X
retarded	B-X
the	B-X
growth	B-X
of	B-X
solid	B-X
s.c.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
in	B-X
mice	B-X
by	B-X
up	B-X
to	B-X
65	B-X
%	B-X
.	B-X
In	B-X
all	B-X
of	B-X
these	B-X
assays	B-X
,	B-X
equivalent	B-X
treatments	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
HAH	B-X
plus	B-X
cortisol	B-X
was	B-X
significantly	B-X
less	B-X
effective	B-X
.	B-X
The	B-X
antiproliferative	B-X
effect	B-X
of	B-X
HAH-cortisol	B-X
on	B-X
endothelial	B-X
cells	B-X
appeared	B-X
independent	B-X
of	B-X
the	B-X
glucocorticoid	B-X
activity	B-X
of	B-X
the	B-X
steroid	B-X
since	B-X
HAH	B-X
conjugated	B-X
to	B-X
5	B-X
beta-pregnane-3	B-X
alpha,17	B-X
alpha,21-triol-20-one	B-X
,	B-X
a	B-X
steroid	B-X
lacking	B-X
glucocorticoid	B-X
or	B-X
mineralocorticoid	B-X
activity	B-X
,	B-X
was	B-X
even	B-X
more	B-X
effective	B-X
at	B-X
inhibiting	B-X
DNA	B-X
synthesis	B-X
by	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
than	B-X
was	B-X
HAH-cortisol	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HAH-cortisol	B-X
represents	B-X
the	B-X
prototype	B-X
of	B-X
a	B-X
new	B-X
class	B-X
of	B-X
angiogenesis	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
angiogenic	B-X
diseases	B-X
.	B-X

In	O
conclusion	O
,	O
HAH	O
-	O
cortisol	O
represents	O
the	O
prototype	O
of	O
a	O
new	O
class	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
angiogenic	O
diseases	O
.	O
<EOS>	B-X
Inhibitors	B-X
of	B-X
angiogenesis	B-X
hold	B-X
potential	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
where	B-X
the	B-X
disease	B-X
is	B-X
caused	B-X
or	B-X
maintained	B-X
by	B-X
the	B-X
inappropriate	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
novel	B-X
inhibitor	B-X
of	B-X
angiogenesis	B-X
was	B-X
synthesized	B-X
by	B-X
covalently	B-X
linking	B-X
a	B-X
nonanticoagulating	B-X
derivative	B-X
of	B-X
heparin	B-X
,	B-X
heparin	B-X
adipic	B-X
hydrazide	B-X
(	B-X
HAH	B-X
)	B-X
,	B-X
by	B-X
an	B-X
acid-labile	B-X
bond	B-X
to	B-X
the	B-X
antiangiogenic	B-X
steroid	B-X
,	B-X
cortisol	B-X
.	B-X
Endocytosis	B-X
of	B-X
the	B-X
conjugate	B-X
and	B-X
decomposition	B-X
of	B-X
the	B-X
acid-labile	B-X
linkage	B-X
inside	B-X
lysosomes	B-X
and	B-X
other	B-X
acidic	B-X
intracellular	B-X
compartments	B-X
should	B-X
then	B-X
lead	B-X
to	B-X
release	B-X
of	B-X
the	B-X
cortisol	B-X
and	B-X
expression	B-X
of	B-X
its	B-X
antiproliferative	B-X
activity	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
stability	B-X
of	B-X
HAH-cortisol	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
7.4	B-X
and	B-X
broke	B-X
down	B-X
rapidly	B-X
(	B-X
t1/2	B-X
15	B-X
min	B-X
)	B-X
at	B-X
pH	B-X
4.8	B-X
at	B-X
37	B-X
degrees	B-X
C.	B-X
Treatment	B-X
of	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
with	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
suppressed	B-X
their	B-X
DNA	B-X
synthesis	B-X
by	B-X
50	B-X
%	B-X
and	B-X
inhibited	B-X
their	B-X
migration	B-X
into	B-X
wounded	B-X
areas	B-X
of	B-X
confluent	B-X
monolayers	B-X
.	B-X
HAH-cortisol	B-X
at	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
M	B-X
(	B-X
with	B-X
respect	B-X
to	B-X
cortisol	B-X
)	B-X
did	B-X
not	B-X
suppress	B-X
the	B-X
DNA	B-X
synthesis	B-X
of	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
cells	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
into	B-X
mice	B-X
bearing	B-X
s.c.	B-X
sponge	B-X
implants	B-X
retarded	B-X
vascularization	B-X
of	B-X
the	B-X
sponge	B-X
,	B-X
and	B-X
injections	B-X
directly	B-X
into	B-X
the	B-X
sponge	B-X
abolished	B-X
vascularization	B-X
for	B-X
as	B-X
long	B-X
as	B-X
the	B-X
injections	B-X
were	B-X
continued	B-X
.	B-X
injections	B-X
of	B-X
HAH-cortisol	B-X
at	B-X
doses	B-X
causing	B-X
no	B-X
apparent	B-X
toxicity	B-X
retarded	B-X
the	B-X
growth	B-X
of	B-X
solid	B-X
s.c.	B-X
Lewis	B-X
lung	B-X
carcinomas	B-X
in	B-X
mice	B-X
by	B-X
up	B-X
to	B-X
65	B-X
%	B-X
.	B-X
In	B-X
all	B-X
of	B-X
these	B-X
assays	B-X
,	B-X
equivalent	B-X
treatments	B-X
with	B-X
a	B-X
mixture	B-X
of	B-X
the	B-X
HAH	B-X
plus	B-X
cortisol	B-X
was	B-X
significantly	B-X
less	B-X
effective	B-X
.	B-X
The	B-X
antiproliferative	B-X
effect	B-X
of	B-X
HAH-cortisol	B-X
on	B-X
endothelial	B-X
cells	B-X
appeared	B-X
independent	B-X
of	B-X
the	B-X
glucocorticoid	B-X
activity	B-X
of	B-X
the	B-X
steroid	B-X
since	B-X
HAH	B-X
conjugated	B-X
to	B-X
5	B-X
beta-pregnane-3	B-X
alpha,17	B-X
alpha,21-triol-20-one	B-X
,	B-X
a	B-X
steroid	B-X
lacking	B-X
glucocorticoid	B-X
or	B-X
mineralocorticoid	B-X
activity	B-X
,	B-X
was	B-X
even	B-X
more	B-X
effective	B-X
at	B-X
inhibiting	B-X
DNA	B-X
synthesis	B-X
by	B-X
murine	B-X
pulmonary	B-X
capillary	B-X
endothelial	B-X
cells	B-X
than	B-X
was	B-X
HAH-cortisol	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
HAH-cortisol	B-X
represents	B-X
the	B-X
prototype	B-X
of	B-X
a	B-X
new	B-X
class	B-X
of	B-X
angiogenesis	B-X
inhibitors	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
other	B-X
angiogenic	B-X
diseases	B-X
.	B-X

Selenoperoxidase	B-Gene_or_gene_product
-	O
dependent	O
glutathione	O
cycle	O
activity	O
in	O
peroxide	O
-	O
challenged	O
leukemia	O
cells	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Under	B-X
the	B-X
conditions	B-X
used	B-X
,	B-X
peroxide-induced	B-X
conversion	B-X
of	B-X
GSH	B-X
to	B-X
GSSG	B-X
could	B-X
be	B-X
stoichiometrically	B-X
reversed	B-X
by	B-X
resupplying	B-X
D-glucose	B-X
,	B-X
indicating	B-X
that	B-X
no	B-X
significant	B-X
lysis	B-X
or	B-X
GSSG	B-X
efflux	B-X
and/or	B-X
interchange	B-X
had	B-X
taken	B-X
place	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

Murine	O
leukemia	O
L1210	O
cells	O
rendered	O
deficient	O
in	O
glutathione	B-Gene_or_gene_product
peroxidase	I-Gene_or_gene_product
(	O
GPX	B-Gene_or_gene_product
)	O
and	O
phospholipid	B-Gene_or_gene_product
hydroperoxide	I-Gene_or_gene_product
glutathione	I-Gene_or_gene_product
peroxidase	I-Gene_or_gene_product
(	O
PHGPX	B-Gene_or_gene_product
)	O
by	O
Se	O
deprivation	O
(	O
L	O
.	O
Se	O
(	O
-	O
)	O
cells	O
)	O
were	O
found	O
to	O
be	O
more	O
sensitive	O
to	O
tert	O
-	O
butyl	O
hydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
cytotoxicity	O
than	O
Se	O
-	O
replete	O
controls	O
(	O
L	O
.	O
Se	O
(	O
+	O
)	O
cells	O
)	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

Human	O
K562	O
cells	O
,	O
which	O
express	O
PHGPX	B-Gene_or_gene_product
,	O
but	O
not	O
GPX	B-Gene_or_gene_product
,	O
were	O
also	O
more	O
sensitive	O
to	O
t	O
-	O
BuOOH	O
in	O
the	O
Se	O
-	O
deficient	O
(	O
K	O
.	O
Se	O
(	O
-	O
)	O
)	O
than	O
Se	O
-	O
satisfied	O
(	O
K	O
.	O
Se	O
(	O
+	O
)	O
)	O
condition	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Under	B-X
the	B-X
conditions	B-X
used	B-X
,	B-X
peroxide-induced	B-X
conversion	B-X
of	B-X
GSH	B-X
to	B-X
GSSG	B-X
could	B-X
be	B-X
stoichiometrically	B-X
reversed	B-X
by	B-X
resupplying	B-X
D-glucose	B-X
,	B-X
indicating	B-X
that	B-X
no	B-X
significant	B-X
lysis	B-X
or	B-X
GSSG	B-X
efflux	B-X
and/or	B-X
interchange	B-X
had	B-X
taken	B-X
place	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

In	O
examining	O
the	O
metabolic	O
basis	O
for	O
selenoperoxidase	B-Gene_or_gene_product
-	O
dependent	O
resistance	O
,	O
we	O
found	O
that	O
glucose	O
-	O
replete	O
Se	O
(	O
-	O
)	O
cells	O
reduce	O
t	O
-	O
BuOOH	O
to	O
t	O
-	O
butanol	O
far	O
more	O
slowly	O
than	O
Se	O
(	O
+	O
)	O
cells	O
,	O
the	O
ratio	O
of	O
the	O
first	O
-	O
order	O
rate	O
constants	O
approximating	O
that	O
of	O
the	O
GPX	B-Gene_or_gene_product
activities	O
(	O
L1210	O
cells	O
)	O
or	O
PHGPX	B-Gene_or_gene_product
activities	O
(	O
K562	O
cells	O
)	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Under	B-X
the	B-X
conditions	B-X
used	B-X
,	B-X
peroxide-induced	B-X
conversion	B-X
of	B-X
GSH	B-X
to	B-X
GSSG	B-X
could	B-X
be	B-X
stoichiometrically	B-X
reversed	B-X
by	B-X
resupplying	B-X
D-glucose	B-X
,	B-X
indicating	B-X
that	B-X
no	B-X
significant	B-X
lysis	B-X
or	B-X
GSSG	B-X
efflux	B-X
and/or	B-X
interchange	B-X
had	B-X
taken	B-X
place	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

Monitoring	O
peroxide	O
-	O
induced	O
changes	O
in	O
GSH	O
and	O
GSSG	O
gave	O
consistent	O
results	O
;	O
e	O
.	O
g	O
.	O
,	O
glucose	O
-	O
depleted	O
L	O
.	O
Se	O
(	O
+	O
)	O
cells	O
exhibited	O
a	O
first	O
order	O
loss	O
of	O
GSH	O
that	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
glucose	O
-	O
depleted	O
L	O
.	O
Se	O
(	O
-	O
)	O
cells	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Under	B-X
the	B-X
conditions	B-X
used	B-X
,	B-X
peroxide-induced	B-X
conversion	B-X
of	B-X
GSH	B-X
to	B-X
GSSG	B-X
could	B-X
be	B-X
stoichiometrically	B-X
reversed	B-X
by	B-X
resupplying	B-X
D-glucose	B-X
,	B-X
indicating	B-X
that	B-X
no	B-X
significant	B-X
lysis	B-X
or	B-X
GSSG	B-X
efflux	B-X
and/or	B-X
interchange	B-X
had	B-X
taken	B-X
place	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

Under	O
the	O
conditions	O
used	O
,	O
peroxide	O
-	O
induced	O
conversion	O
of	O
GSH	O
to	O
GSSG	O
could	O
be	O
stoichiometrically	O
reversed	O
by	O
resupplying	O
D	O
-	O
glucose	O
,	O
indicating	O
that	O
no	O
significant	O
lysis	O
or	O
GSSG	O
efflux	O
and	O
/	O
or	O
interchange	O
had	O
taken	O
place	O
.	O
<EOS>	B-X
Instead	B-X
,	B-X
a	B-X
representational	B-X
emptiness	B-X
occurs	B-X
,	B-X
such	B-X
that	B-X
what	B-X
has	B-X
taken	B-X
place	B-X
can	B-X
not	B-X
be	B-X
shared	B-X
or	B-X
transmitted	B-X
.	B-X
The	B-X
cathartic	B-X
word	B-X
becomes	B-X
a	B-X
robotic	B-X
mocking	B-X
of	B-X
the	B-X
interchange	B-X
between	B-X
human	B-X
beings	B-X
.	B-X
The	B-X
establishment	B-X
of	B-X
a	B-X
new	B-X
plastid	B-X
organelle	B-X
by	B-X
secondary	B-X
endosymbiosis	B-X
represents	B-X
a	B-X
series	B-X
of	B-X
events	B-X
of	B-X
massive	B-X
complexity	B-X
,	B-X
and	B-X
yet	B-X
we	B-X
know	B-X
it	B-X
has	B-X
taken	B-X
place	B-X
multiple	B-X
times	B-X
because	B-X
both	B-X
green	B-X
and	B-X
red	B-X
algae	B-X
have	B-X
been	B-X
taken	B-X
up	B-X
by	B-X
other	B-X
eukaryotic	B-X
lineages	B-X
.	B-X
Exactly	B-X
how	B-X
many	B-X
times	B-X
these	B-X
events	B-X
have	B-X
succeeded	B-X
,	B-X
however	B-X
,	B-X
has	B-X
been	B-X
a	B-X
matter	B-X
of	B-X
debate	B-X
that	B-X
significantly	B-X
impacts	B-X
how	B-X
we	B-X
view	B-X
plastid	B-X
evolution	B-X
,	B-X
protein	B-X
targeting	B-X
,	B-X
and	B-X
eukaryotic	B-X
relationships	B-X
.	B-X
How	B-X
many	B-X
times	B-X
red	B-X
algae	B-X
have	B-X
been	B-X
taken	B-X
up	B-X
is	B-X
less	B-X
clear	B-X
,	B-X
because	B-X
there	B-X
are	B-X
many	B-X
more	B-X
lineages	B-X
with	B-X
red	B-X
alga-derived	B-X
plastids	B-X
(	B-X
cryptomonads	B-X
,	B-X
haptophytes	B-X
,	B-X
heterokonts	B-X
,	B-X
dinoflagellates	B-X
and	B-X
apicomplexa	B-X
)	B-X
and	B-X
the	B-X
relationships	B-X
between	B-X
these	B-X
lineages	B-X
are	B-X
less	B-X
clear	B-X
.	B-X

The	O
apparent	O
first	O
-	O
order	O
rate	O
constant	O
for	O
GSH	O
decay	O
increased	O
progressively	O
for	O
L1210	O
cells	O
expressing	O
a	O
range	O
of	O
GPX	B-Gene_or_gene_product
activities	O
from	O
approximately	O
5	O
%	O
to	O
100	O
%	O
,	O
demonstrating	O
that	O
peroxide	O
detoxification	O
is	O
strictly	O
dependent	O
on	O
enzyme	O
content	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Under	B-X
the	B-X
conditions	B-X
used	B-X
,	B-X
peroxide-induced	B-X
conversion	B-X
of	B-X
GSH	B-X
to	B-X
GSSG	B-X
could	B-X
be	B-X
stoichiometrically	B-X
reversed	B-X
by	B-X
resupplying	B-X
D-glucose	B-X
,	B-X
indicating	B-X
that	B-X
no	B-X
significant	B-X
lysis	B-X
or	B-X
GSSG	B-X
efflux	B-X
and/or	B-X
interchange	B-X
had	B-X
taken	B-X
place	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

The	O
initial	O
rate	O
of	O
14CO2	O
release	O
from	O
D	O
-	O
[	O
1	O
-	O
14C	O
]	O
glucose	O
supplied	O
in	O
the	O
medium	O
was	O
much	O
greater	O
for	O
L	O
.	O
Se	O
(	O
+	O
)	O
or	O
K	O
.	O
Se	O
(	O
+	O
)	O
cells	O
than	O
for	O
their	O
respective	O
Se	O
(	O
-	O
)	O
counterparts	O
,	O
consistent	O
with	O
greater	O
hexose	O
monophosphate	O
shunt	O
activity	O
in	O
the	O
former	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Under	B-X
the	B-X
conditions	B-X
used	B-X
,	B-X
peroxide-induced	B-X
conversion	B-X
of	B-X
GSH	B-X
to	B-X
GSSG	B-X
could	B-X
be	B-X
stoichiometrically	B-X
reversed	B-X
by	B-X
resupplying	B-X
D-glucose	B-X
,	B-X
indicating	B-X
that	B-X
no	B-X
significant	B-X
lysis	B-X
or	B-X
GSSG	B-X
efflux	B-X
and/or	B-X
interchange	B-X
had	B-X
taken	B-X
place	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

These	O
results	O
highlight	O
the	O
importance	O
of	O
selenoperoxidase	B-Gene_or_gene_product
action	O
in	O
the	O
glutathione	O
cycle	O
as	O
a	O
means	O
by	O
which	O
tumor	O
cells	O
cope	O
with	O
hydroperoxide	O
stress	O
.	O
<EOS>	B-X
Murine	B-X
leukemia	B-X
L1210	B-X
cells	B-X
rendered	B-X
deficient	B-X
in	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
GPX	B-X
)	B-X
and	B-X
phospholipid	B-X
hydroperoxide	B-X
glutathione	B-X
peroxidase	B-X
(	B-X
PHGPX	B-X
)	B-X
by	B-X
Se	B-X
deprivation	B-X
(	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
sensitive	B-X
to	B-X
tert-butyl	B-X
hydroperoxide	B-X
(	B-X
t-BuOOH	B-X
)	B-X
cytotoxicity	B-X
than	B-X
Se-replete	B-X
controls	B-X
(	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
)	B-X
.	B-X
Human	B-X
K562	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
PHGPX	B-X
,	B-X
but	B-X
not	B-X
GPX	B-X
,	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
t-BuOOH	B-X
in	B-X
the	B-X
Se-deficient	B-X
(	B-X
K.Se	B-X
(	B-X
-	B-X
)	B-X
)	B-X
than	B-X
Se-satisfied	B-X
(	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
)	B-X
condition	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
metabolic	B-X
basis	B-X
for	B-X
selenoperoxidase-dependent	B-X
resistance	B-X
,	B-X
we	B-X
found	B-X
that	B-X
glucose-replete	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
reduce	B-X
t-BuOOH	B-X
to	B-X
t-butanol	B-X
far	B-X
more	B-X
slowly	B-X
than	B-X
Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
first-order	B-X
rate	B-X
constants	B-X
approximating	B-X
that	B-X
of	B-X
the	B-X
GPX	B-X
activities	B-X
(	B-X
L1210	B-X
cells	B-X
)	B-X
or	B-X
PHGPX	B-X
activities	B-X
(	B-X
K562	B-X
cells	B-X
)	B-X
.	B-X
Monitoring	B-X
peroxide-induced	B-X
changes	B-X
in	B-X
GSH	B-X
and	B-X
GSSG	B-X
gave	B-X
consistent	B-X
results	B-X
;	B-X
e.g.	B-X
,	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
exhibited	B-X
a	B-X
first	B-X
order	B-X
loss	B-X
of	B-X
GSH	B-X
that	B-X
was	B-X
substantially	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
glucose-depleted	B-X
L.Se	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
The	B-X
apparent	B-X
first-order	B-X
rate	B-X
constant	B-X
for	B-X
GSH	B-X
decay	B-X
increased	B-X
progressively	B-X
for	B-X
L1210	B-X
cells	B-X
expressing	B-X
a	B-X
range	B-X
of	B-X
GPX	B-X
activities	B-X
from	B-X
approximately	B-X
5	B-X
%	B-X
to	B-X
100	B-X
%	B-X
,	B-X
demonstrating	B-X
that	B-X
peroxide	B-X
detoxification	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
enzyme	B-X
content	B-X
.	B-X
The	B-X
initial	B-X
rate	B-X
of	B-X
14CO2	B-X
release	B-X
from	B-X
D-	B-X
[	B-X
1-14C	B-X
]	B-X
glucose	B-X
supplied	B-X
in	B-X
the	B-X
medium	B-X
was	B-X
much	B-X
greater	B-X
for	B-X
L.Se	B-X
(	B-X
+	B-X
)	B-X
or	B-X
K.Se	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
than	B-X
for	B-X
their	B-X
respective	B-X
Se	B-X
(	B-X
-	B-X
)	B-X
counterparts	B-X
,	B-X
consistent	B-X
with	B-X
greater	B-X
hexose	B-X
monophosphate	B-X
shunt	B-X
activity	B-X
in	B-X
the	B-X
former	B-X
.	B-X
These	B-X
results	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
selenoperoxidase	B-X
action	B-X
in	B-X
the	B-X
glutathione	B-X
cycle	B-X
as	B-X
a	B-X
means	B-X
by	B-X
which	B-X
tumor	B-X
cells	B-X
cope	B-X
with	B-X
hydroperoxide	B-X
stress	B-X
.	B-X

Differential	O
expression	O
and	O
mutation	O
of	O
NME	B-Gene_or_gene_product
genes	O
in	O
autologous	O
cultured	O
human	O
melanoma	O
cells	O
with	O
different	O
metastatic	O
potentials	O
.	O
<EOS>	B-X
The	B-X
putative	B-X
metastasis	B-X
suppressor	B-X
genes	B-X
,	B-X
NME1	B-X
(	B-X
nm23-1	B-X
)	B-X
and	B-X
NME2	B-X
(	B-X
nm23-2	B-X
)	B-X
,	B-X
were	B-X
examined	B-X
in	B-X
a	B-X
model	B-X
system	B-X
we	B-X
developed	B-X
to	B-X
approximate	B-X
the	B-X
dissemination	B-X
of	B-X
melanoma	B-X
from	B-X
a	B-X
primary	B-X
skin	B-X
tumor	B-X
.	B-X
We	B-X
utilized	B-X
two	B-X
autologous	B-X
human	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
IV	B-X
Cl	B-X
1	B-X
and	B-X
IV	B-X
Cl	B-X
3	B-X
,	B-X
which	B-X
displayed	B-X
qualitatively	B-X
different	B-X
metastatic	B-X
phenotypes	B-X
following	B-X
subdermal	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Highly	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
expressed	B-X
approximately	B-X
5	B-X
fold	B-X
lower	B-X
levels	B-X
of	B-X
protein	B-X
encoded	B-X
by	B-X
NME	B-X
genes	B-X
than	B-X
non-metastatic	B-X
IV	B-X
Cl	B-X
3	B-X
cells	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
We	B-X
found	B-X
a	B-X
ser122-pro	B-X
mutation	B-X
in	B-X
the	B-X
NME2	B-X
gene	B-X
of	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X
These	B-X
mutations	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
since	B-X
they	B-X
eliminate	B-X
potential	B-X
phosphorylation	B-X
sites	B-X
and	B-X
may	B-X
affect	B-X
the	B-X
tertiary	B-X
structure	B-X
of	B-X
mature	B-X
protein	B-X
complexes	B-X
.	B-X

The	O
putative	O
metastasis	O
suppressor	O
genes	O
,	O
NME1	B-Gene_or_gene_product
(	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
and	O
NME2	B-Gene_or_gene_product
(	O
nm23	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
)	O
,	O
were	O
examined	O
in	O
a	O
model	O
system	O
we	O
developed	O
to	O
approximate	O
the	O
dissemination	O
of	O
melanoma	O
from	O
a	O
primary	O
skin	O
tumor	O
.	O

We	O
utilized	O
two	O
autologous	O
human	O
melanoma	O
cell	O
lines	O
,	O
IV	O
Cl	O
1	O
and	O
IV	O
Cl	O
3	O
,	O
which	O
displayed	O
qualitatively	O
different	O
metastatic	O
phenotypes	O
following	O
subdermal	O
inoculation	O
into	O
nude	O
mice	O
.	O
<EOS>	B-X
The	B-X
putative	B-X
metastasis	B-X
suppressor	B-X
genes	B-X
,	B-X
NME1	B-X
(	B-X
nm23-1	B-X
)	B-X
and	B-X
NME2	B-X
(	B-X
nm23-2	B-X
)	B-X
,	B-X
were	B-X
examined	B-X
in	B-X
a	B-X
model	B-X
system	B-X
we	B-X
developed	B-X
to	B-X
approximate	B-X
the	B-X
dissemination	B-X
of	B-X
melanoma	B-X
from	B-X
a	B-X
primary	B-X
skin	B-X
tumor	B-X
.	B-X
We	B-X
utilized	B-X
two	B-X
autologous	B-X
human	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
IV	B-X
Cl	B-X
1	B-X
and	B-X
IV	B-X
Cl	B-X
3	B-X
,	B-X
which	B-X
displayed	B-X
qualitatively	B-X
different	B-X
metastatic	B-X
phenotypes	B-X
following	B-X
subdermal	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Highly	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
expressed	B-X
approximately	B-X
5	B-X
fold	B-X
lower	B-X
levels	B-X
of	B-X
protein	B-X
encoded	B-X
by	B-X
NME	B-X
genes	B-X
than	B-X
non-metastatic	B-X
IV	B-X
Cl	B-X
3	B-X
cells	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
We	B-X
found	B-X
a	B-X
ser122-pro	B-X
mutation	B-X
in	B-X
the	B-X
NME2	B-X
gene	B-X
of	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X

Highly	O
metastatic	O
IV	O
Cl	O
1	O
cells	O
expressed	O
approximately	O
5	O
fold	O
lower	O
levels	O
of	O
protein	O
encoded	O
by	O
NME	B-Gene_or_gene_product
genes	O
than	O
non	O
-	O
metastatic	O
IV	O
Cl	O
3	O
cells	O
.	O
<EOS>	B-X
The	B-X
putative	B-X
metastasis	B-X
suppressor	B-X
genes	B-X
,	B-X
NME1	B-X
(	B-X
nm23-1	B-X
)	B-X
and	B-X
NME2	B-X
(	B-X
nm23-2	B-X
)	B-X
,	B-X
were	B-X
examined	B-X
in	B-X
a	B-X
model	B-X
system	B-X
we	B-X
developed	B-X
to	B-X
approximate	B-X
the	B-X
dissemination	B-X
of	B-X
melanoma	B-X
from	B-X
a	B-X
primary	B-X
skin	B-X
tumor	B-X
.	B-X
We	B-X
utilized	B-X
two	B-X
autologous	B-X
human	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
IV	B-X
Cl	B-X
1	B-X
and	B-X
IV	B-X
Cl	B-X
3	B-X
,	B-X
which	B-X
displayed	B-X
qualitatively	B-X
different	B-X
metastatic	B-X
phenotypes	B-X
following	B-X
subdermal	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Highly	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
expressed	B-X
approximately	B-X
5	B-X
fold	B-X
lower	B-X
levels	B-X
of	B-X
protein	B-X
encoded	B-X
by	B-X
NME	B-X
genes	B-X
than	B-X
non-metastatic	B-X
IV	B-X
Cl	B-X
3	B-X
cells	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
We	B-X
found	B-X
a	B-X
ser122-pro	B-X
mutation	B-X
in	B-X
the	B-X
NME2	B-X
gene	B-X
of	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X
These	B-X
mutations	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
since	B-X
they	B-X
eliminate	B-X
potential	B-X
phosphorylation	B-X
sites	B-X
and	B-X
may	B-X
affect	B-X
the	B-X
tertiary	B-X
structure	B-X
of	B-X
mature	B-X
protein	B-X
complexes	B-X
.	B-X

Similar	O
differences	O
in	O
NME	B-Gene_or_gene_product
protein	O
levels	O
were	O
observed	O
in	O
tumors	O
induced	O
by	O
the	O
two	O
cell	O
lines	O
in	O
nude	O
mice	O
.	O
<EOS>	B-X
The	B-X
putative	B-X
metastasis	B-X
suppressor	B-X
genes	B-X
,	B-X
NME1	B-X
(	B-X
nm23-1	B-X
)	B-X
and	B-X
NME2	B-X
(	B-X
nm23-2	B-X
)	B-X
,	B-X
were	B-X
examined	B-X
in	B-X
a	B-X
model	B-X
system	B-X
we	B-X
developed	B-X
to	B-X
approximate	B-X
the	B-X
dissemination	B-X
of	B-X
melanoma	B-X
from	B-X
a	B-X
primary	B-X
skin	B-X
tumor	B-X
.	B-X
We	B-X
utilized	B-X
two	B-X
autologous	B-X
human	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
IV	B-X
Cl	B-X
1	B-X
and	B-X
IV	B-X
Cl	B-X
3	B-X
,	B-X
which	B-X
displayed	B-X
qualitatively	B-X
different	B-X
metastatic	B-X
phenotypes	B-X
following	B-X
subdermal	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Highly	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
expressed	B-X
approximately	B-X
5	B-X
fold	B-X
lower	B-X
levels	B-X
of	B-X
protein	B-X
encoded	B-X
by	B-X
NME	B-X
genes	B-X
than	B-X
non-metastatic	B-X
IV	B-X
Cl	B-X
3	B-X
cells	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
We	B-X
found	B-X
a	B-X
ser122-pro	B-X
mutation	B-X
in	B-X
the	B-X
NME2	B-X
gene	B-X
of	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X
These	B-X
mutations	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
since	B-X
they	B-X
eliminate	B-X
potential	B-X
phosphorylation	B-X
sites	B-X
and	B-X
may	B-X
affect	B-X
the	B-X
tertiary	B-X
structure	B-X
of	B-X
mature	B-X
protein	B-X
complexes	B-X
.	B-X

There	O
were	O
no	O
differences	O
in	O
NME	B-Gene_or_gene_product
mRNA	O
levels	O
between	O
these	O
two	O
cell	O
lines	O
,	O
suggesting	O
that	O
expression	O
of	O
these	O
proteins	O
is	O
regulated	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

We	O
found	O
a	O
ser122	O
-	O
pro	O
mutation	O
in	O
the	O
NME2	B-Gene_or_gene_product
gene	O
of	O
metastatic	O
IV	O
Cl	O
1	O
cells	O
.	O
<EOS>	B-X
The	B-X
putative	B-X
metastasis	B-X
suppressor	B-X
genes	B-X
,	B-X
NME1	B-X
(	B-X
nm23-1	B-X
)	B-X
and	B-X
NME2	B-X
(	B-X
nm23-2	B-X
)	B-X
,	B-X
were	B-X
examined	B-X
in	B-X
a	B-X
model	B-X
system	B-X
we	B-X
developed	B-X
to	B-X
approximate	B-X
the	B-X
dissemination	B-X
of	B-X
melanoma	B-X
from	B-X
a	B-X
primary	B-X
skin	B-X
tumor	B-X
.	B-X
We	B-X
utilized	B-X
two	B-X
autologous	B-X
human	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
IV	B-X
Cl	B-X
1	B-X
and	B-X
IV	B-X
Cl	B-X
3	B-X
,	B-X
which	B-X
displayed	B-X
qualitatively	B-X
different	B-X
metastatic	B-X
phenotypes	B-X
following	B-X
subdermal	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Highly	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
expressed	B-X
approximately	B-X
5	B-X
fold	B-X
lower	B-X
levels	B-X
of	B-X
protein	B-X
encoded	B-X
by	B-X
NME	B-X
genes	B-X
than	B-X
non-metastatic	B-X
IV	B-X
Cl	B-X
3	B-X
cells	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
We	B-X
found	B-X
a	B-X
ser122-pro	B-X
mutation	B-X
in	B-X
the	B-X
NME2	B-X
gene	B-X
of	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X
These	B-X
mutations	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
since	B-X
they	B-X
eliminate	B-X
potential	B-X
phosphorylation	B-X
sites	B-X
and	B-X
may	B-X
affect	B-X
the	B-X
tertiary	B-X
structure	B-X
of	B-X
mature	B-X
protein	B-X
complexes	B-X
.	B-X

A	O
similar	O
ser120	O
-	O
gly	O
mutation	O
in	O
NME1	B-Gene_or_gene_product
has	O
been	O
found	O
in	O
human	O
neuroblastoma	O
,	O
suggesting	O
that	O
mutation	O
in	O
this	O
region	O
may	O
be	O
a	O
general	O
phenomenon	O
related	O
to	O
tumor	O
progression	O
.	O
<EOS>	B-X
The	B-X
putative	B-X
metastasis	B-X
suppressor	B-X
genes	B-X
,	B-X
NME1	B-X
(	B-X
nm23-1	B-X
)	B-X
and	B-X
NME2	B-X
(	B-X
nm23-2	B-X
)	B-X
,	B-X
were	B-X
examined	B-X
in	B-X
a	B-X
model	B-X
system	B-X
we	B-X
developed	B-X
to	B-X
approximate	B-X
the	B-X
dissemination	B-X
of	B-X
melanoma	B-X
from	B-X
a	B-X
primary	B-X
skin	B-X
tumor	B-X
.	B-X
We	B-X
utilized	B-X
two	B-X
autologous	B-X
human	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
IV	B-X
Cl	B-X
1	B-X
and	B-X
IV	B-X
Cl	B-X
3	B-X
,	B-X
which	B-X
displayed	B-X
qualitatively	B-X
different	B-X
metastatic	B-X
phenotypes	B-X
following	B-X
subdermal	B-X
inoculation	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
We	B-X
found	B-X
a	B-X
ser122-pro	B-X
mutation	B-X
in	B-X
the	B-X
NME2	B-X
gene	B-X
of	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X
These	B-X
mutations	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
since	B-X
they	B-X
eliminate	B-X
potential	B-X
phosphorylation	B-X
sites	B-X
and	B-X
may	B-X
affect	B-X
the	B-X
tertiary	B-X
structure	B-X
of	B-X
mature	B-X
protein	B-X
complexes	B-X
.	B-X

These	O
mutations	O
may	O
have	O
functional	O
consequences	O
since	O
they	O
eliminate	O
potential	O
phosphorylation	O
sites	O
and	O
may	O
affect	O
the	O
tertiary	O
structure	O
of	O
mature	O
protein	O
complexes	O
.	O
<EOS>	B-X
Highly	B-X
metastatic	B-X
IV	B-X
Cl	B-X
1	B-X
cells	B-X
expressed	B-X
approximately	B-X
5	B-X
fold	B-X
lower	B-X
levels	B-X
of	B-X
protein	B-X
encoded	B-X
by	B-X
NME	B-X
genes	B-X
than	B-X
non-metastatic	B-X
IV	B-X
Cl	B-X
3	B-X
cells	B-X
.	B-X
Similar	B-X
differences	B-X
in	B-X
NME	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
tumors	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
lines	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
NME	B-X
mRNA	B-X
levels	B-X
between	B-X
these	B-X
two	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
post-transcriptional	B-X
level	B-X
.	B-X
A	B-X
similar	B-X
ser120-gly	B-X
mutation	B-X
in	B-X
NME1	B-X
has	B-X
been	B-X
found	B-X
in	B-X
human	B-X
neuroblastoma	B-X
,	B-X
suggesting	B-X
that	B-X
mutation	B-X
in	B-X
this	B-X
region	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
related	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X
These	B-X
mutations	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
since	B-X
they	B-X
eliminate	B-X
potential	B-X
phosphorylation	B-X
sites	B-X
and	B-X
may	B-X
affect	B-X
the	B-X
tertiary	B-X
structure	B-X
of	B-X
mature	B-X
protein	B-X
complexes	B-X
.	B-X

Cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
/	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
cooperates	O
with	O
myc	B-Gene_or_gene_product
genes	O
in	O
the	O
generation	O
of	O
B	O
-	O
cell	O
lymphoma	O
in	O
transgenic	O
mice	O
.	O
<EOS>	B-X
The	B-X
chromosomal	B-X
translocation	B-X
t	B-X
(	B-X
11:14	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
human	B-X
lymphoid	B-X
neoplasia	B-X
affecting	B-X
centrocytic	B-X
B-cells	B-X
of	B-X
intermediate	B-X
differentiation	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
the	B-X
cyclin	B-X
D1	B-X
(	B-X
bcl-1	B-X
)	B-X
gene	B-X
is	B-X
juxtaposed	B-X
to	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
enhancer	B-X
E	B-X
mu	B-X
.	B-X
To	B-X
show	B-X
that	B-X
transcriptional	B-X
activation	B-X
of	B-X
cyclin	B-X
D1	B-X
is	B-X
causally	B-X
involved	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
B-cell	B-X
neoplasia	B-X
we	B-X
have	B-X
generated	B-X
transgenic	B-X
mice	B-X
that	B-X
carry	B-X
a	B-X
cyclin	B-X
D1	B-X
gene	B-X
under	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
the	B-X
E	B-X
mu	B-X
element	B-X
.	B-X
E	B-X
mu	B-X
cyclin	B-X
D1	B-X
transgenic	B-X
mice	B-X
show	B-X
only	B-X
very	B-X
subtle	B-X
alterations	B-X
in	B-X
the	B-X
cycling	B-X
behaviour	B-X
of	B-X
B-cell	B-X
populations	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
compared	B-X
with	B-X
normal	B-X
mice	B-X
and	B-X
do	B-X
not	B-X
develop	B-X
lymphoid	B-X
tumours	B-X
.	B-X
However	B-X
,	B-X
E	B-X
mu-directed	B-X
coexpression	B-X
of	B-X
cyclin	B-X
D1	B-X
and	B-X
N-MYC	B-X
or	B-X
L-MYC	B-X
in	B-X
double	B-X
transgenic	B-X
mice	B-X
reveals	B-X
a	B-X
strong	B-X
cooperative	B-X
effect	B-X
between	B-X
MYC	B-X
and	B-X
cyclin	B-X
D1	B-X
provoking	B-X
the	B-X
rapid	B-X
development	B-X
of	B-X
clonal	B-X
pre-B	B-X
and	B-X
B-cell	B-X
lymphomas	B-X
.	B-X
Interestingly	B-X
,	B-X
crossing	B-X
of	B-X
cyclin	B-X
D1	B-X
transgenic	B-X
mice	B-X
with	B-X
E	B-X
mu	B-X
L-myc	B-X
transgenics	B-X
that	B-X
express	B-X
their	B-X
transgene	B-X
in	B-X
both	B-X
B-	B-X
and	B-X
T-cells	B-X
but	B-X
predominantly	B-X
develop	B-X
T-cell	B-X
tumours	B-X
leads	B-X
in	B-X
double	B-X
transgenics	B-X
exclusively	B-X
to	B-X
B-cell	B-X
neoplasia	B-X
.	B-X
The	B-X
data	B-X
presented	B-X
here	B-X
demonstrate	B-X
that	B-X
transcriptional	B-X
activation	B-X
of	B-X
cyclin	B-X
D1	B-X
can	B-X
oncogenically	B-X
transform	B-X
B-cells	B-X
in	B-X
concert	B-X
with	B-X
a	B-X
myc	B-X
gene	B-X
.	B-X
They	B-X
establish	B-X
cyclin	B-X
D1	B-X
as	B-X
a	B-X
proto-oncogene	B-X
whose	B-X
activity	B-X
appears	B-X
to	B-X
depend	B-X
on	B-X
a	B-X
specific	B-X
cell	B-X
type	B-X
as	B-X
well	B-X
as	B-X
on	B-X
a	B-X
specific	B-X
cooperating	B-X
partner	B-X
and	B-X
link	B-X
disturbances	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
to	B-X
the	B-X
development	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X

The	O
chromosomal	O
translocation	O
t	O
(	O
11	O
:	O
14	O
)	O
is	O
associated	O
with	O
human	O
lymphoid	O
neoplasia	O
affecting	O
centrocytic	O
B	O
-	O
cells	O
of	O
intermediate	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
chromosomal	B-X
translocation	B-X
t	B-X
(	B-X
11:14	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
human	B-X
lymphoid	B-X
neoplasia	B-X
affecting	B-X
centrocytic	B-X
B-cells	B-X
of	B-X
intermediate	B-X
differentiation	B-X
.	B-X
To	B-X
show	B-X
that	B-X
transcriptional	B-X
activation	B-X
of	B-X
cyclin	B-X
D1	B-X
is	B-X
causally	B-X
involved	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
B-cell	B-X
neoplasia	B-X
we	B-X
have	B-X
generated	B-X
transgenic	B-X
mice	B-X
that	B-X
carry	B-X
a	B-X
cyclin	B-X
D1	B-X
gene	B-X
under	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
the	B-X
E	B-X
mu	B-X
element	B-X
.	B-X
E	B-X
mu	B-X
cyclin	B-X
D1	B-X
transgenic	B-X
mice	B-X
show	B-X
only	B-X
very	B-X
subtle	B-X
alterations	B-X
in	B-X
the	B-X
cycling	B-X
behaviour	B-X
of	B-X
B-cell	B-X
populations	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
compared	B-X
with	B-X
normal	B-X
mice	B-X
and	B-X
do	B-X
not	B-X
develop	B-X
lymphoid	B-X
tumours	B-X
.	B-X
However	B-X
,	B-X
E	B-X
mu-directed	B-X
coexpression	B-X
of	B-X
cyclin	B-X
D1	B-X
and	B-X
N-MYC	B-X
or	B-X
L-MYC	B-X
in	B-X
double	B-X
transgenic	B-X
mice	B-X
reveals	B-X
a	B-X
strong	B-X
cooperative	B-X
effect	B-X
between	B-X
MYC	B-X
and	B-X
cyclin	B-X
D1	B-X
provoking	B-X
the	B-X
rapid	B-X
development	B-X
of	B-X
clonal	B-X
pre-B	B-X
and	B-X
B-cell	B-X
lymphomas	B-X
.	B-X
Interestingly	B-X
,	B-X
crossing	B-X
of	B-X
cyclin	B-X
D1	B-X
transgenic	B-X
mice	B-X
with	B-X
E	B-X
mu	B-X
L-myc	B-X
transgenics	B-X
that	B-X
express	B-X
their	B-X
transgene	B-X
in	B-X
both	B-X
B-	B-X
and	B-X
T-cells	B-X
but	B-X
predominantly	B-X
develop	B-X
T-cell	B-X
tumours	B-X
leads	B-X
in	B-X
double	B-X
transgenics	B-X
exclusively	B-X
to	B-X
B-cell	B-X
neoplasia	B-X
.	B-X
The	B-X
data	B-X
presented	B-X
here	B-X
demonstrate	B-X
that	B-X
transcriptional	B-X
activation	B-X
of	B-X
cyclin	B-X
D1	B-X
can	B-X
oncogenically	B-X
transform	B-X
B-cells	B-X
in	B-X
concert	B-X
with	B-X
a	B-X
myc	B-X
gene	B-X
.	B-X
They	B-X
establish	B-X
cyclin	B-X
D1	B-X
as	B-X
a	B-X
proto-oncogene	B-X
whose	B-X
activity	B-X
appears	B-X
to	B-X
depend	B-X
on	B-X
a	B-X
specific	B-X
cell	B-X
type	B-X
as	B-X
well	B-X
as	B-X
on	B-X
a	B-X
specific	B-X
cooperating	B-X
partner	B-X
and	B-X
link	B-X
disturbances	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
to	B-X
the	B-X
development	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X

As	O
a	O
consequence	O
the	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
(	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	O
gene	O
is	O
juxtaposed	O
to	O
the	O
immunoglobulin	B-Gene_or_gene_product
heavy	I-Gene_or_gene_product
chain	I-Gene_or_gene_product
enhancer	I-Gene_or_gene_product
E	I-Gene_or_gene_product
mu	I-Gene_or_gene_product
.	O

To	O
show	O
that	O
transcriptional	O
activation	O
of	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
is	O
causally	O
involved	O
in	O
the	O
generation	O
of	O
B	O
-	O
cell	O
neoplasia	O
we	O
have	O
generated	O
transgenic	O
mice	O
that	O
carry	O
a	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
the	O
E	B-Gene_or_gene_product
mu	I-Gene_or_gene_product
element	O
.	O

E	B-Gene_or_gene_product
mu	I-Gene_or_gene_product
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
transgenic	O
mice	O
show	O
only	O
very	O
subtle	O
alterations	O
in	O
the	O
cycling	O
behaviour	O
of	O
B	O
-	O
cell	O
populations	O
in	O
the	O
bone	O
marrow	O
compared	O
with	O
normal	O
mice	O
and	O
do	O
not	O
develop	O
lymphoid	O
tumours	O
.	O

However	O
,	O
E	B-Gene_or_gene_product
mu	I-Gene_or_gene_product
-	O
directed	O
coexpression	O
of	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
and	O
N	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MYC	I-Gene_or_gene_product
or	O
L	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MYC	I-Gene_or_gene_product
in	O
double	O
transgenic	O
mice	O
reveals	O
a	O
strong	O
cooperative	O
effect	O
between	O
MYC	B-Gene_or_gene_product
and	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
provoking	O
the	O
rapid	O
development	O
of	O
clonal	O
pre	O
-	O
B	O
and	O
B	O
-	O
cell	O
lymphomas	O
.	O

Interestingly	O
,	O
crossing	O
of	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
transgenic	O
mice	O
with	O
E	B-Gene_or_gene_product
mu	I-Gene_or_gene_product
L	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
transgenics	O
that	O
express	O
their	O
transgene	O
in	O
both	O
B	O
-	O
and	O
T	O
-	O
cells	O
but	O
predominantly	O
develop	O
T	O
-	O
cell	O
tumours	O
leads	O
in	O
double	O
transgenics	O
exclusively	O
to	O
B	O
-	O
cell	O
neoplasia	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
transcriptional	O
activation	O
of	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
can	O
oncogenically	O
transform	O
B	O
-	O
cells	O
in	O
concert	O
with	O
a	O
myc	B-Gene_or_gene_product
gene	O
.	O
<EOS>	B-X
The	B-X
chromosomal	B-X
translocation	B-X
t	B-X
(	B-X
11:14	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
human	B-X
lymphoid	B-X
neoplasia	B-X
affecting	B-X
centrocytic	B-X
B-cells	B-X
of	B-X
intermediate	B-X
differentiation	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
the	B-X
cyclin	B-X
D1	B-X
(	B-X
bcl-1	B-X
)	B-X
gene	B-X
is	B-X
juxtaposed	B-X
to	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
enhancer	B-X
E	B-X
mu	B-X
.	B-X
To	B-X
show	B-X
that	B-X
transcriptional	B-X
activation	B-X
of	B-X
cyclin	B-X
D1	B-X
is	B-X
causally	B-X
involved	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
B-cell	B-X
neoplasia	B-X
we	B-X
have	B-X
generated	B-X
transgenic	B-X
mice	B-X
that	B-X
carry	B-X
a	B-X
cyclin	B-X
D1	B-X
gene	B-X
under	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
the	B-X
E	B-X
mu	B-X
element	B-X
.	B-X
E	B-X
mu	B-X
cyclin	B-X
D1	B-X
transgenic	B-X
mice	B-X
show	B-X
only	B-X
very	B-X
subtle	B-X
alterations	B-X
in	B-X
the	B-X
cycling	B-X
behaviour	B-X
of	B-X
B-cell	B-X
populations	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
compared	B-X
with	B-X
normal	B-X
mice	B-X
and	B-X
do	B-X
not	B-X
develop	B-X
lymphoid	B-X
tumours	B-X
.	B-X
However	B-X
,	B-X
E	B-X
mu-directed	B-X
coexpression	B-X
of	B-X
cyclin	B-X
D1	B-X
and	B-X
N-MYC	B-X
or	B-X
L-MYC	B-X
in	B-X
double	B-X
transgenic	B-X
mice	B-X
reveals	B-X
a	B-X
strong	B-X
cooperative	B-X
effect	B-X
between	B-X
MYC	B-X
and	B-X
cyclin	B-X
D1	B-X
provoking	B-X
the	B-X
rapid	B-X
development	B-X
of	B-X
clonal	B-X
pre-B	B-X
and	B-X
B-cell	B-X
lymphomas	B-X
.	B-X
Interestingly	B-X
,	B-X
crossing	B-X
of	B-X
cyclin	B-X
D1	B-X
transgenic	B-X
mice	B-X
with	B-X
E	B-X
mu	B-X
L-myc	B-X
transgenics	B-X
that	B-X
express	B-X
their	B-X
transgene	B-X
in	B-X
both	B-X
B-	B-X
and	B-X
T-cells	B-X
but	B-X
predominantly	B-X
develop	B-X
T-cell	B-X
tumours	B-X
leads	B-X
in	B-X
double	B-X
transgenics	B-X
exclusively	B-X
to	B-X
B-cell	B-X
neoplasia	B-X
.	B-X
The	B-X
data	B-X
presented	B-X
here	B-X
demonstrate	B-X
that	B-X
transcriptional	B-X
activation	B-X
of	B-X
cyclin	B-X
D1	B-X
can	B-X
oncogenically	B-X
transform	B-X
B-cells	B-X
in	B-X
concert	B-X
with	B-X
a	B-X
myc	B-X
gene	B-X
.	B-X
They	B-X
establish	B-X
cyclin	B-X
D1	B-X
as	B-X
a	B-X
proto-oncogene	B-X
whose	B-X
activity	B-X
appears	B-X
to	B-X
depend	B-X
on	B-X
a	B-X
specific	B-X
cell	B-X
type	B-X
as	B-X
well	B-X
as	B-X
on	B-X
a	B-X
specific	B-X
cooperating	B-X
partner	B-X
and	B-X
link	B-X
disturbances	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
to	B-X
the	B-X
development	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X

They	O
establish	O
cyclin	B-Gene_or_gene_product
D1	I-Gene_or_gene_product
as	O
a	O
proto	O
-	O
oncogene	O
whose	O
activity	O
appears	O
to	O
depend	O
on	O
a	O
specific	O
cell	O
type	O
as	O
well	O
as	O
on	O
a	O
specific	O
cooperating	O
partner	O
and	O
link	O
disturbances	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
progression	O
to	O
the	O
development	O
of	O
human	O
malignancies	O
.	O

Elevated	O
expression	O
of	O
the	O
junB	B-Gene_or_gene_product
proto	O
-	O
oncogene	O
is	O
essential	O
for	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
induced	O
transformation	O
of	O
Rat	O
-	O
1	O
cells	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
non-tumorigenic	B-X
revertants	B-X
from	B-X
mutagenized	B-X
populations	B-X
of	B-X
v-fos-transformed	B-X
Rat-1	B-X
cells	B-X
(	B-X
Zarbl	B-X
et	B-X
al.	B-X
,	B-X
1987	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
resulted	B-X
from	B-X
mutations	B-X
that	B-X
altered	B-X
the	B-X
expression	B-X
or	B-X
activities	B-X
of	B-X
the	B-X
c-jun	B-X
or	B-X
junB	B-X
proto-oncogenes	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
levels	B-X
of	B-X
the	B-X
c-jun	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
unchanged	B-X
in	B-X
the	B-X
revertants	B-X
when	B-X
compared	B-X
to	B-X
the	B-X
transformed	B-X
parental	B-X
cells	B-X
,	B-X
and	B-X
ectopic	B-X
overexpression	B-X
of	B-X
c-jun	B-X
failed	B-X
to	B-X
retransform	B-X
the	B-X
revertants	B-X
.	B-X
Although	B-X
one	B-X
mutant	B-X
allele	B-X
was	B-X
detected	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
overexpression	B-X
of	B-X
this	B-X
mutant	B-X
allele	B-X
failed	B-X
to	B-X
inhibit	B-X
v-fos	B-X
induced	B-X
cell	B-X
transformation	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
did	B-X
not	B-X
result	B-X
from	B-X
altered	B-X
expression	B-X
or	B-X
mutations	B-X
in	B-X
the	B-X
c-jun	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
c-jun	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
junB	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
found	B-X
to	B-X
be	B-X
reduced	B-X
two-	B-X
or	B-X
threefold	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
.	B-X
Ectopic	B-X
overexpression	B-X
of	B-X
junB	B-X
induced	B-X
transformation	B-X
of	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
transform	B-X
Rat-1	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
about	B-X
10	B-X
%	B-X
of	B-X
v-fos	B-X
transformed	B-X
cells	B-X
transfected	B-X
with	B-X
vectors	B-X
that	B-X
express	B-X
antisense	B-X
junB	B-X
mRNA	B-X
acquired	B-X
a	B-X
non-transformed	B-X
phenotype	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
expression	B-X
of	B-X
junB	B-X
above	B-X
a	B-X
threshold	B-X
level	B-X
is	B-X
essential	B-X
for	B-X
v-fos-induced	B-X
transformation	B-X
of	B-X
Rat-1	B-X
fibroblasts	B-X
.	B-X

We	O
previously	O
described	O
the	O
isolation	O
of	O
non	O
-	O
tumorigenic	O
revertants	O
from	O
mutagenized	O
populations	O
of	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
-	O
transformed	O
Rat	O
-	O
1	O
cells	O
(	O
Zarbl	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
non-tumorigenic	B-X
revertants	B-X
from	B-X
mutagenized	B-X
populations	B-X
of	B-X
v-fos-transformed	B-X
Rat-1	B-X
cells	B-X
(	B-X
Zarbl	B-X
et	B-X
al.	B-X
,	B-X
1987	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
resulted	B-X
from	B-X
mutations	B-X
that	B-X
altered	B-X
the	B-X
expression	B-X
or	B-X
activities	B-X
of	B-X
the	B-X
c-jun	B-X
or	B-X
junB	B-X
proto-oncogenes	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
levels	B-X
of	B-X
the	B-X
c-jun	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
unchanged	B-X
in	B-X
the	B-X
revertants	B-X
when	B-X
compared	B-X
to	B-X
the	B-X
transformed	B-X
parental	B-X
cells	B-X
,	B-X
and	B-X
ectopic	B-X
overexpression	B-X
of	B-X
c-jun	B-X
failed	B-X
to	B-X
retransform	B-X
the	B-X
revertants	B-X
.	B-X
Although	B-X
one	B-X
mutant	B-X
allele	B-X
was	B-X
detected	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
overexpression	B-X
of	B-X
this	B-X
mutant	B-X
allele	B-X
failed	B-X
to	B-X
inhibit	B-X
v-fos	B-X
induced	B-X
cell	B-X
transformation	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
did	B-X
not	B-X
result	B-X
from	B-X
altered	B-X
expression	B-X
or	B-X
mutations	B-X
in	B-X
the	B-X
c-jun	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
c-jun	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
junB	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
found	B-X
to	B-X
be	B-X
reduced	B-X
two-	B-X
or	B-X
threefold	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
.	B-X
Ectopic	B-X
overexpression	B-X
of	B-X
junB	B-X
induced	B-X
transformation	B-X
of	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
transform	B-X
Rat-1	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
about	B-X
10	B-X
%	B-X
of	B-X
v-fos	B-X
transformed	B-X
cells	B-X
transfected	B-X
with	B-X
vectors	B-X
that	B-X
express	B-X
antisense	B-X
junB	B-X
mRNA	B-X
acquired	B-X
a	B-X
non-transformed	B-X
phenotype	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
expression	B-X
of	B-X
junB	B-X
above	B-X
a	B-X
threshold	B-X
level	B-X
is	B-X
essential	B-X
for	B-X
v-fos-induced	B-X
transformation	B-X
of	B-X
Rat-1	B-X
fibroblasts	B-X
.	B-X

In	O
the	O
present	O
study	O
we	O
examined	O
the	O
possibility	O
that	O
the	O
revertant	O
phenotype	O
resulted	O
from	O
mutations	O
that	O
altered	O
the	O
expression	O
or	O
activities	O
of	O
the	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
jun	I-Gene_or_gene_product
or	O
junB	B-Gene_or_gene_product
proto	O
-	O
oncogenes	O
.	O
<EOS>	B-X
Psilocybin	B-X
is	B-X
a	B-X
serotonergic	B-X
psychedelic	B-X
found	B-X
in	B-X
``	B-X
magic	B-X
mushrooms	B-X
''	B-X
with	B-X
a	B-X
putative	B-X
therapeutic	B-X
potential	B-X
for	B-X
treatment-resistant	B-X
depression	B-X
,	B-X
anxiety	B-X
,	B-X
obsessive-compulsive	B-X
disorder	B-X
,	B-X
and	B-X
addiction	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
psilocybin	B-X
acutely	B-X
induces	B-X
plasticity-related	B-X
immediate	B-X
early	B-X
genes	B-X
in	B-X
cortical	B-X
tissue	B-X
;	B-X
however	B-X
,	B-X
studies	B-X
into	B-X
the	B-X
effects	B-X
on	B-X
subcortical	B-X
regions	B-X
,	B-X
of	B-X
different	B-X
doses	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
translation	B-X
of	B-X
corresponding	B-X
proteins	B-X
are	B-X
lacking	B-X
.	B-X
Since	B-X
its	B-X
discovery	B-X
more	B-X
than	B-X
two	B-X
decades	B-X
ago	B-X
the	B-X
involvement	B-X
of	B-X
the	B-X
Activating	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
in	B-X
proliferation	B-X
,	B-X
inflammation	B-X
,	B-X
differentiation	B-X
,	B-X
apoptosis	B-X
,	B-X
cellular	B-X
migration	B-X
and	B-X
wound	B-X
healing	B-X
has	B-X
been	B-X
intensively	B-X
studied	B-X
.	B-X
A	B-X
model	B-X
based	B-X
on	B-X
the	B-X
early	B-X
studies	B-X
suggested	B-X
antagonistic	B-X
roles	B-X
for	B-X
the	B-X
Jun	B-X
proteins	B-X
in	B-X
proliferation	B-X
and	B-X
transformation	B-X
.	B-X
c-Jun	B-X
was	B-X
suggested	B-X
to	B-X
enhance	B-X
transformation	B-X
whereas	B-X
JunB	B-X
suggested	B-X
to	B-X
inhibit	B-X
it	B-X
in	B-X
an	B-X
antagonistic	B-X
manner	B-X
.	B-X
Surprisingly	B-X
,	B-X
despite	B-X
accumulation	B-X
of	B-X
data	B-X
obtained	B-X
from	B-X
animal	B-X
models	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
Jun	B-X
proteins	B-X
in	B-X
cancer	B-X
and	B-X
identification	B-X
of	B-X
oncogenic	B-X
pathways	B-X
regulating	B-X
them	B-X
,	B-X
their	B-X
involvement	B-X
in	B-X
human	B-X
cancer	B-X
was	B-X
not	B-X
demonstrated	B-X
until	B-X
recently	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
will	B-X
describe	B-X
the	B-X
current	B-X
knowledge	B-X
about	B-X
the	B-X
roles	B-X
of	B-X
Jun	B-X
proteins	B-X
in	B-X
human	B-X
neoplasia	B-X
.	B-X
We	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
pathological	B-X
examples	B-X
demonstrating	B-X
that	B-X
the	B-X
initial	B-X
dogma	B-X
has	B-X
to	B-X
be	B-X
reexamined	B-X
.	B-X
For	B-X
example	B-X
,	B-X
like	B-X
c-Jun	B-X
,	B-X
JunB	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
oncogenic	B-X
role	B-X
in	B-X
lymphomas	B-X
,	B-X
particularly	B-X
in	B-X
Hodgkin	B-X
's	B-X
lympomas	B-X
.	B-X
Furthermore	B-X
,	B-X
unlike	B-X
the	B-X
antagonistic	B-X
activities	B-X
of	B-X
c-Jun	B-X
and	B-X
JunB	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
genes	B-X
coding	B-X
for	B-X
major	B-X
cell	B-X
cycle	B-X
regulators	B-X
such	B-X
as	B-X
CyclinD	B-X
or	B-X
p16INK4A	B-X
,	B-X
the	B-X
transcription	B-X
of	B-X
other	B-X
cell	B-X
cycle	B-X
regulating	B-X
genes	B-X
is	B-X
modified	B-X
similarly	B-X
by	B-X
c-Jun	B-X
or	B-X
JunB	B-X
.	B-X
Interestingly	B-X
,	B-X
some	B-X
of	B-X
these	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
ones	B-X
coding	B-X
for	B-X
CyclinA	B-X
or	B-X
p19	B-X
(	B-X
ARF	B-X
)	B-X
are	B-X
important	B-X
players	B-X
in	B-X
either	B-X
positive	B-X
or	B-X
negative	B-X
regulation	B-X
of	B-X
cellular	B-X
proliferation	B-X
and	B-X
survival	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
will	B-X
also	B-X
discuss	B-X
results	B-X
posing	B-X
JNK	B-X
,	B-X
known	B-X
so	B-X
far	B-X
as	B-X
the	B-X
major	B-X
activator	B-X
of	B-X
c-Jun	B-X
,	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
c-Jun	B-X
level	B-X
and	B-X
activity	B-X
.	B-X
These	B-X
recent	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
role	B-X
of	B-X
each	B-X
Jun	B-X
protein	B-X
in	B-X
neoplasia	B-X
as	B-X
well	B-X
as	B-X
in	B-X
cellular	B-X
survival	B-X
should	B-X
be	B-X
examined	B-X
in	B-X
a	B-X
context-dependent	B-X
manner	B-X
.	B-X

The	O
results	O
demonstrated	O
that	O
levels	O
of	O
the	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
jun	I-Gene_or_gene_product
mRNA	O
and	O
protein	O
were	O
unchanged	O
in	O
the	O
revertants	O
when	O
compared	O
to	O
the	O
transformed	O
parental	O
cells	O
,	O
and	O
ectopic	O
overexpression	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
jun	I-Gene_or_gene_product
failed	O
to	O
retransform	O
the	O
revertants	O
.	O

Although	O
one	O
mutant	O
allele	O
was	O
detected	O
in	O
revertant	O
EMS	O
-	O
1	O
-	O
19	O
,	O
overexpression	O
of	O
this	O
mutant	O
allele	O
failed	O
to	O
inhibit	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
induced	O
cell	O
transformation	O
.	O

Together	O
these	O
results	O
indicated	O
that	O
the	O
revertant	O
phenotype	O
did	O
not	O
result	O
from	O
altered	O
expression	O
or	O
mutations	O
in	O
the	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
jun	I-Gene_or_gene_product
gene	O
.	O
<EOS>	B-X
Macrophages	B-X
represent	B-X
a	B-X
major	B-X
immune	B-X
cell	B-X
population	B-X
in	B-X
atherosclerotic	B-X
plaques	B-X
and	B-X
play	B-X
central	B-X
role	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
this	B-X
lipid-driven	B-X
chronic	B-X
inflammatory	B-X
disease	B-X
.	B-X
Targeting	B-X
immunometabolism	B-X
is	B-X
proposed	B-X
as	B-X
a	B-X
strategy	B-X
to	B-X
revert	B-X
aberrant	B-X
macrophage	B-X
activation	B-X
to	B-X
improve	B-X
disease	B-X
outcome	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
ATP	B-X
citrate	B-X
lyase	B-X
(	B-X
Acly	B-X
)	B-X
to	B-X
be	B-X
activated	B-X
in	B-X
inflammatory	B-X
macrophages	B-X
and	B-X
human	B-X
atherosclerotic	B-X
plaques	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
myeloid	B-X
Acly	B-X
deficiency	B-X
induces	B-X
a	B-X
stable	B-X
plaque	B-X
phenotype	B-X
characterized	B-X
by	B-X
increased	B-X
collagen	B-X
deposition	B-X
and	B-X
fibrous	B-X
cap	B-X
thickness	B-X
,	B-X
along	B-X
with	B-X
a	B-X
smaller	B-X
necrotic	B-X
core	B-X
.	B-X
In-depth	B-X
functional	B-X
,	B-X
lipidomic	B-X
,	B-X
and	B-X
transcriptional	B-X
characterization	B-X
indicate	B-X
deregulated	B-X
fatty	B-X
acid	B-X
and	B-X
cholesterol	B-X
biosynthesis	B-X
and	B-X
reduced	B-X
liver	B-X
X	B-X
receptor	B-X
activation	B-X
within	B-X
the	B-X
macrophages	B-X
in	B-X
vitro	B-X
.	B-X
This	B-X
results	B-X
in	B-X
macrophages	B-X
that	B-X
are	B-X
more	B-X
prone	B-X
to	B-X
undergo	B-X
apoptosis	B-X
,	B-X
whilst	B-X
maintaining	B-X
their	B-X
capacity	B-X
to	B-X
phagocytose	B-X
apoptotic	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
targeting	B-X
macrophage	B-X
metabolism	B-X
improves	B-X
atherosclerosis	B-X
outcome	B-X
and	B-X
we	B-X
reveal	B-X
Acly	B-X
as	B-X
a	B-X
promising	B-X
therapeutic	B-X
target	B-X
to	B-X
stabilize	B-X
atherosclerotic	B-X
plaques	B-X
.	B-X

In	O
contrast	O
to	O
the	O
results	O
obtained	O
with	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
jun	I-Gene_or_gene_product
,	O
the	O
levels	O
of	O
junB	B-Gene_or_gene_product
mRNA	O
and	O
protein	O
were	O
found	O
to	O
be	O
reduced	O
two	O
-	O
or	O
threefold	O
in	O
revertant	O
EMS	O
-	O
1	O
-	O
19	O
.	O

Ectopic	O
overexpression	O
of	O
junB	B-Gene_or_gene_product
induced	O
transformation	O
of	O
revertant	O
EMS	O
-	O
1	O
-	O
19	O
,	O
but	O
failed	O
to	O
transform	O
Rat	O
-	O
1	O
cells	O
.	O

Moreover	O
,	O
about	O
10	O
%	O
of	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
transformed	O
cells	O
transfected	O
with	O
vectors	O
that	O
express	O
antisense	O
junB	B-Gene_or_gene_product
mRNA	O
acquired	O
a	O
non	O
-	O
transformed	O
phenotype	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
non-tumorigenic	B-X
revertants	B-X
from	B-X
mutagenized	B-X
populations	B-X
of	B-X
v-fos-transformed	B-X
Rat-1	B-X
cells	B-X
(	B-X
Zarbl	B-X
et	B-X
al.	B-X
,	B-X
1987	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
resulted	B-X
from	B-X
mutations	B-X
that	B-X
altered	B-X
the	B-X
expression	B-X
or	B-X
activities	B-X
of	B-X
the	B-X
c-jun	B-X
or	B-X
junB	B-X
proto-oncogenes	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
levels	B-X
of	B-X
the	B-X
c-jun	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
unchanged	B-X
in	B-X
the	B-X
revertants	B-X
when	B-X
compared	B-X
to	B-X
the	B-X
transformed	B-X
parental	B-X
cells	B-X
,	B-X
and	B-X
ectopic	B-X
overexpression	B-X
of	B-X
c-jun	B-X
failed	B-X
to	B-X
retransform	B-X
the	B-X
revertants	B-X
.	B-X
Although	B-X
one	B-X
mutant	B-X
allele	B-X
was	B-X
detected	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
overexpression	B-X
of	B-X
this	B-X
mutant	B-X
allele	B-X
failed	B-X
to	B-X
inhibit	B-X
v-fos	B-X
induced	B-X
cell	B-X
transformation	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
did	B-X
not	B-X
result	B-X
from	B-X
altered	B-X
expression	B-X
or	B-X
mutations	B-X
in	B-X
the	B-X
c-jun	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
c-jun	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
junB	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
found	B-X
to	B-X
be	B-X
reduced	B-X
two-	B-X
or	B-X
threefold	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
.	B-X
Ectopic	B-X
overexpression	B-X
of	B-X
junB	B-X
induced	B-X
transformation	B-X
of	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
transform	B-X
Rat-1	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
about	B-X
10	B-X
%	B-X
of	B-X
v-fos	B-X
transformed	B-X
cells	B-X
transfected	B-X
with	B-X
vectors	B-X
that	B-X
express	B-X
antisense	B-X
junB	B-X
mRNA	B-X
acquired	B-X
a	B-X
non-transformed	B-X
phenotype	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
expression	B-X
of	B-X
junB	B-X
above	B-X
a	B-X
threshold	B-X
level	B-X
is	B-X
essential	B-X
for	B-X
v-fos-induced	B-X
transformation	B-X
of	B-X
Rat-1	B-X
fibroblasts	B-X
.	B-X

Together	O
these	O
results	O
indicate	O
that	O
expression	O
of	O
junB	B-Gene_or_gene_product
above	O
a	O
threshold	O
level	O
is	O
essential	O
for	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
fos	I-Gene_or_gene_product
-	O
induced	O
transformation	O
of	O
Rat	O
-	O
1	O
fibroblasts	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
described	B-X
the	B-X
isolation	B-X
of	B-X
non-tumorigenic	B-X
revertants	B-X
from	B-X
mutagenized	B-X
populations	B-X
of	B-X
v-fos-transformed	B-X
Rat-1	B-X
cells	B-X
(	B-X
Zarbl	B-X
et	B-X
al.	B-X
,	B-X
1987	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
resulted	B-X
from	B-X
mutations	B-X
that	B-X
altered	B-X
the	B-X
expression	B-X
or	B-X
activities	B-X
of	B-X
the	B-X
c-jun	B-X
or	B-X
junB	B-X
proto-oncogenes	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
levels	B-X
of	B-X
the	B-X
c-jun	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
unchanged	B-X
in	B-X
the	B-X
revertants	B-X
when	B-X
compared	B-X
to	B-X
the	B-X
transformed	B-X
parental	B-X
cells	B-X
,	B-X
and	B-X
ectopic	B-X
overexpression	B-X
of	B-X
c-jun	B-X
failed	B-X
to	B-X
retransform	B-X
the	B-X
revertants	B-X
.	B-X
Although	B-X
one	B-X
mutant	B-X
allele	B-X
was	B-X
detected	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
overexpression	B-X
of	B-X
this	B-X
mutant	B-X
allele	B-X
failed	B-X
to	B-X
inhibit	B-X
v-fos	B-X
induced	B-X
cell	B-X
transformation	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
revertant	B-X
phenotype	B-X
did	B-X
not	B-X
result	B-X
from	B-X
altered	B-X
expression	B-X
or	B-X
mutations	B-X
in	B-X
the	B-X
c-jun	B-X
gene	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
c-jun	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
junB	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
found	B-X
to	B-X
be	B-X
reduced	B-X
two-	B-X
or	B-X
threefold	B-X
in	B-X
revertant	B-X
EMS-1-19	B-X
.	B-X
Ectopic	B-X
overexpression	B-X
of	B-X
junB	B-X
induced	B-X
transformation	B-X
of	B-X
revertant	B-X
EMS-1-19	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
transform	B-X
Rat-1	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
about	B-X
10	B-X
%	B-X
of	B-X
v-fos	B-X
transformed	B-X
cells	B-X
transfected	B-X
with	B-X
vectors	B-X
that	B-X
express	B-X
antisense	B-X
junB	B-X
mRNA	B-X
acquired	B-X
a	B-X
non-transformed	B-X
phenotype	B-X
.	B-X
Together	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
expression	B-X
of	B-X
junB	B-X
above	B-X
a	B-X
threshold	B-X
level	B-X
is	B-X
essential	B-X
for	B-X
v-fos-induced	B-X
transformation	B-X
of	B-X
Rat-1	B-X
fibroblasts	B-X
.	B-X

[	O
Treatment	O
of	O
the	O
diabetic	O
foot	O
by	O
hyperbaric	O
oxygen	O
]	O
<EOS>	B-X
Diabetic	B-X
foot	B-X
ulcers	B-X
(	B-X
DFUs	B-X
)	B-X
are	B-X
a	B-X
serious	B-X
complication	B-X
of	B-X
diabetes	B-X
that	B-X
results	B-X
in	B-X
significant	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
These	B-X
practices	B-X
are	B-X
best	B-X
coordinated	B-X
by	B-X
a	B-X
multidisciplinary	B-X
diabetic	B-X
foot	B-X
wound	B-X
clinic	B-X
.	B-X
The	B-X
adjuvant	B-X
therapies	B-X
reviewed	B-X
include	B-X
the	B-X
following	B-X
categories	B-X
:	B-X
nonsurgical	B-X
debridement	B-X
agents	B-X
,	B-X
dressings	B-X
and	B-X
topical	B-X
agents	B-X
,	B-X
oxygen	B-X
therapies	B-X
,	B-X
negative	B-X
pressure	B-X
wound	B-X
therapy	B-X
,	B-X
acellular	B-X
bioproducts	B-X
,	B-X
human	B-X
growth	B-X
factors	B-X
,	B-X
energy-based	B-X
therapies	B-X
,	B-X
and	B-X
systemic	B-X
therapies	B-X
.	B-X
Chronic	B-X
and	B-X
non-healing	B-X
wounds	B-X
,	B-X
especially	B-X
diabetic	B-X
foot	B-X
ulcers	B-X
and	B-X
radiation	B-X
injuries	B-X
,	B-X
imply	B-X
remarkable	B-X
morbidity	B-X
with	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
a	B-X
high	B-X
sanitary	B-X
cost	B-X
.	B-X
These	B-X
wounds	B-X
are	B-X
characterized	B-X
by	B-X
poor	B-X
oxygen	B-X
supply	B-X
resulting	B-X
in	B-X
inadequate	B-X
oxygenation	B-X
of	B-X
the	B-X
affected	B-X
tissue	B-X
.	B-X
The	B-X
adjuvant	B-X
treatment	B-X
with	B-X
hyperbaric	B-X
oxygen	B-X
therapy	B-X
(	B-X
HBOT	B-X
)	B-X
may	B-X
increase	B-X
tissue	B-X
oxygenation	B-X
favoring	B-X
the	B-X
healing	B-X
of	B-X
wounds	B-X
which	B-X
do	B-X
not	B-X
respond	B-X
to	B-X
the	B-X
usual	B-X
clinical	B-X
care	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
the	B-X
partial	B-X
pressure	B-X
of	B-X
oxygen	B-X
contributes	B-X
to	B-X
cover	B-X
the	B-X
energy	B-X
demands	B-X
necessary	B-X
for	B-X
the	B-X
healing	B-X
process	B-X
and	B-X
reduces	B-X
the	B-X
incidence	B-X
of	B-X
infections	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
oxygen	B-X
leads	B-X
to	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
species	B-X
with	B-X
hormetic	B-X
activity	B-X
,	B-X
acting	B-X
on	B-X
signaling	B-X
pathways	B-X
that	B-X
modulate	B-X
the	B-X
synthesis	B-X
of	B-X
inflammation	B-X
mediators	B-X
,	B-X
antioxidants	B-X
and	B-X
growth	B-X
factors	B-X
which	B-X
can	B-X
contribute	B-X
to	B-X
the	B-X
healing	B-X
process	B-X
.	B-X

Diabetic	O
foot	O
wounds	O
are	O
consequences	O
of	O
the	O
neuropathy	O
and	O
the	O
small	O
and	O
large	O
vessel	O
disease	O
that	O
complicate	O
diabetes	O
.	O
<EOS>	B-X
Diabetic	B-X
foot	B-X
wounds	B-X
are	B-X
consequences	B-X
of	B-X
the	B-X
neuropathy	B-X
and	B-X
the	B-X
small	B-X
and	B-X
large	B-X
vessel	B-X
disease	B-X
that	B-X
complicate	B-X
diabetes	B-X
.	B-X
14	B-X
diabetics	B-X
with	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
which	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
treatment	B-X
for	B-X
at	B-X
least	B-X
3	B-X
months	B-X
were	B-X
treated	B-X
by	B-X
HBO	B-X
.	B-X
HBO	B-X
is	B-X
useful	B-X
in	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
and	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
with	B-X
impending	B-X
amputation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
safe	B-X
mode	B-X
of	B-X
therapy	B-X
,	B-X
but	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
establish	B-X
its	B-X
efficacy	B-X
and	B-X
to	B-X
ascertain	B-X
which	B-X
diabetic	B-X
patients	B-X
and	B-X
wounds	B-X
will	B-X
benefit	B-X
the	B-X
most	B-X
from	B-X
it	B-X
.	B-X

At	O
the	O
cellular	O
level	O
,	O
the	O
result	O
is	O
hypoxia	O
which	O
impairs	O
wound	O
healing	O
.	O
<EOS>	B-X
Endothelial	B-X
malfunction	B-X
is	B-X
responsible	B-X
for	B-X
impaired	B-X
angiogenesis	B-X
in	B-X
diabetic	B-X
patients	B-X
,	B-X
thereby	B-X
causing	B-X
the	B-X
delayed	B-X
healing	B-X
progress	B-X
of	B-X
diabetic	B-X
wounds	B-X
.	B-X
Exosomes	B-X
or	B-X
extracellular	B-X
vesicles	B-X
(	B-X
EVs	B-X
)	B-X
have	B-X
emerged	B-X
as	B-X
potential	B-X
therapeutic	B-X
vectors	B-X
carrying	B-X
drug	B-X
cargoes	B-X
to	B-X
diseased	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
EVs	B-X
were	B-X
reported	B-X
as	B-X
a	B-X
new	B-X
treatment	B-X
for	B-X
diabetic	B-X
wounds	B-X
by	B-X
delivering	B-X
VH298	B-X
into	B-X
endothelial	B-X
cells	B-X
.	B-X
VH-EVs	B-X
were	B-X
also	B-X
found	B-X
to	B-X
have	B-X
a	B-X
therapeutic	B-X
effect	B-X
on	B-X
wound	B-X
healing	B-X
and	B-X
angiogenesis	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
diabetic	B-X
mice	B-X
,	B-X
GelMA	B-X
hydrogel	B-X
containing	B-X
VH-EVs	B-X
(	B-X
Gel-VH-EVs	B-X
)	B-X
effectively	B-X
promoted	B-X
wound	B-X
healing	B-X
by	B-X
locally	B-X
enhancing	B-X
blood	B-X
supply	B-X
and	B-X
angiogenesis	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
a	B-X
promising	B-X
EV-based	B-X
strategy	B-X
for	B-X
the	B-X
VH298	B-X
delivery	B-X
to	B-X
endothelial	B-X
cells	B-X
and	B-X
provide	B-X
a	B-X
new	B-X
bioactive	B-X
dressing	B-X
for	B-X
diabetic	B-X
wound	B-X
treatment	B-X
.	B-X
STATEMENT	B-X
OF	B-X
SIGNIFICANCE	B-X
:	B-X
The	B-X
angiogenic	B-X
dysfunction	B-X
is	B-X
the	B-X
main	B-X
cause	B-X
of	B-X
diabetic	B-X
wound	B-X
unhealing	B-X
.	B-X
Extracellular	B-X
vesicles	B-X
(	B-X
EVs	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
helpful	B-X
but	B-X
their	B-X
efficacy	B-X
is	B-X
limited	B-X
for	B-X
angiogenesis	B-X
in	B-X
cutaneous	B-X
regeneration	B-X
.	B-X
VH298	B-X
holds	B-X
great	B-X
promise	B-X
to	B-X
improve	B-X
angiogenesis	B-X
by	B-X
stabilizing	B-X
HIF-1Î±	B-X
which	B-X
is	B-X
reported	B-X
at	B-X
low	B-X
level	B-X
in	B-X
diabetic	B-X
wounds	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
loaded	B-X
EVs	B-X
with	B-X
VH298	B-X
(	B-X
VH-EVs	B-X
)	B-X
to	B-X
exert	B-X
an	B-X
on-target	B-X
enhancement	B-X
of	B-X
proangiogenic	B-X
capacity	B-X
in	B-X
diabetic	B-X
wound	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
significant	B-X
therapeutic	B-X
effect	B-X
of	B-X
Gel-VH-EVs	B-X
on	B-X
skin	B-X
defect	B-X
repair	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
a	B-X
promising	B-X
EVs-based	B-X
drug	B-X
delivery	B-X
strategy	B-X
and	B-X
a	B-X
new	B-X
functional	B-X
wound	B-X
dressing	B-X
for	B-X
patients	B-X
.	B-X

Hyperbaric	O
oxygenation	O
(	O
HBO	O
)	O
may	O
be	O
a	O
useful	O
adjuvant	O
to	O
wound	O
care	O
.	O
<EOS>	B-X
Diabetic	B-X
foot	B-X
wounds	B-X
are	B-X
consequences	B-X
of	B-X
the	B-X
neuropathy	B-X
and	B-X
the	B-X
small	B-X
and	B-X
large	B-X
vessel	B-X
disease	B-X
that	B-X
complicate	B-X
diabetes	B-X
.	B-X
At	B-X
the	B-X
cellular	B-X
level	B-X
,	B-X
the	B-X
result	B-X
is	B-X
hypoxia	B-X
which	B-X
impairs	B-X
wound	B-X
healing	B-X
.	B-X
Hyperbaric	B-X
oxygenation	B-X
(	B-X
HBO	B-X
)	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
adjuvant	B-X
to	B-X
wound	B-X
care	B-X
.	B-X
It	B-X
leads	B-X
to	B-X
enhanced	B-X
oxygenation	B-X
of	B-X
the	B-X
affected	B-X
tissues	B-X
,	B-X
has	B-X
an	B-X
antiseptic	B-X
effect	B-X
,	B-X
reduces	B-X
edema	B-X
,	B-X
and	B-X
accelerates	B-X
collagen	B-X
production	B-X
and	B-X
angiogenesis	B-X
,	B-X
thus	B-X
enhancing	B-X
tissue	B-X
repair	B-X
.	B-X
14	B-X
diabetics	B-X
with	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
which	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
treatment	B-X
for	B-X
at	B-X
least	B-X
3	B-X
months	B-X
were	B-X
treated	B-X
by	B-X
HBO	B-X
.	B-X
They	B-X
were	B-X
treated	B-X
with	B-X
HBO	B-X
in	B-X
56	B-X
+/-	B-X
10	B-X
consecutive	B-X
HBO	B-X
sessions	B-X
.	B-X
In	B-X
11	B-X
there	B-X
was	B-X
complete	B-X
wound	B-X
healing	B-X
,	B-X
while	B-X
in	B-X
1	B-X
there	B-X
was	B-X
partial	B-X
response	B-X
,	B-X
in	B-X
1	B-X
minimal	B-X
response	B-X
,	B-X
and	B-X
in	B-X
1	B-X
a	B-X
transient	B-X
response	B-X
.	B-X
HBO	B-X
is	B-X
useful	B-X
in	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
and	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
with	B-X
impending	B-X
amputation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
safe	B-X
mode	B-X
of	B-X
therapy	B-X
,	B-X
but	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
establish	B-X
its	B-X
efficacy	B-X
and	B-X
to	B-X
ascertain	B-X
which	B-X
diabetic	B-X
patients	B-X
and	B-X
wounds	B-X
will	B-X
benefit	B-X
the	B-X
most	B-X
from	B-X
it	B-X
.	B-X

It	O
leads	O
to	O
enhanced	O
oxygenation	O
of	O
the	O
affected	O
tissues	O
,	O
has	O
an	O
antiseptic	O
effect	O
,	O
reduces	O
edema	O
,	O
and	O
accelerates	O
collagen	B-Gene_or_gene_product
production	O
and	O
angiogenesis	O
,	O
thus	O
enhancing	O
tissue	O
repair	O
.	O
<EOS>	B-X
Hyperbaric	B-X
oxygenation	B-X
(	B-X
HBO	B-X
)	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
adjuvant	B-X
to	B-X
wound	B-X
care	B-X
.	B-X
It	B-X
leads	B-X
to	B-X
enhanced	B-X
oxygenation	B-X
of	B-X
the	B-X
affected	B-X
tissues	B-X
,	B-X
has	B-X
an	B-X
antiseptic	B-X
effect	B-X
,	B-X
reduces	B-X
edema	B-X
,	B-X
and	B-X
accelerates	B-X
collagen	B-X
production	B-X
and	B-X
angiogenesis	B-X
,	B-X
thus	B-X
enhancing	B-X
tissue	B-X
repair	B-X
.	B-X
Transcutaneous	B-X
measurements	B-X
of	B-X
tissue	B-X
pO2	B-X
showed	B-X
elevation	B-X
from	B-X
20	B-X
+/-	B-X
10	B-X
mm	B-X
Hg	B-X
during	B-X
air	B-X
breathing	B-X
to	B-X
643	B-X
+/-	B-X
242	B-X
mm	B-X
Hg	B-X
while	B-X
breathing	B-X
pure	B-X
oxygen	B-X
at	B-X
2.5	B-X
ATA	B-X
.	B-X

14	O
diabetics	O
with	O
chronic	O
nonhealing	O
wounds	O
which	O
did	O
not	O
respond	O
to	O
treatment	O
for	O
at	O
least	O
3	O
months	O
were	O
treated	O
by	O
HBO	O
.	O
<EOS>	B-X
With	B-X
the	B-X
global	B-X
prevalence	B-X
of	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
steeply	B-X
rising	B-X
,	B-X
instances	B-X
of	B-X
chronic	B-X
,	B-X
hard-healing	B-X
,	B-X
or	B-X
non-healing	B-X
diabetic	B-X
wounds	B-X
and	B-X
ulcers	B-X
are	B-X
predicted	B-X
to	B-X
increase	B-X
.	B-X
Despite	B-X
this	B-X
,	B-X
the	B-X
management	B-X
and	B-X
successful	B-X
treatment	B-X
of	B-X
diabetic	B-X
wounds	B-X
represents	B-X
a	B-X
significant	B-X
therapeutic	B-X
challenge	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
key	B-X
differences	B-X
between	B-X
normal	B-X
and	B-X
chronic	B-X
non-healing	B-X
diabetic	B-X
wounds	B-X
,	B-X
and	B-X
elaborate	B-X
on	B-X
recent	B-X
advances	B-X
in	B-X
wound	B-X
healing	B-X
treatments	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
biological	B-X
dressings	B-X
and	B-X
their	B-X
effect	B-X
on	B-X
key	B-X
wound	B-X
healing	B-X
pathways	B-X
.	B-X
Non-healing	B-X
or	B-X
slow	B-X
healing	B-X
chronic	B-X
wounds	B-X
are	B-X
among	B-X
serious	B-X
complications	B-X
of	B-X
diabetes	B-X
that	B-X
eventually	B-X
result	B-X
in	B-X
amputation	B-X
of	B-X
limbs	B-X
and	B-X
increased	B-X
morbidities	B-X
and	B-X
mortalities	B-X
.	B-X
Chronic	B-X
diabetic	B-X
wounds	B-X
show	B-X
reduced	B-X
blood	B-X
vessel	B-X
formation	B-X
(	B-X
lack	B-X
of	B-X
angiogenesis	B-X
)	B-X
,	B-X
inadequate	B-X
cell	B-X
proliferation	B-X
and	B-X
poor	B-X
cell	B-X
migration	B-X
near	B-X
wounds	B-X
.	B-X

All	O
had	O
palpable	O
pedal	O
pulses	O
.	O
<EOS>	B-X
Pedal	B-X
pulses	B-X
were	B-X
palpable	B-X
.	B-X
Aneurysm	B-X
of	B-X
the	B-X
pedal	B-X
arteries	B-X
is	B-X
uncommon	B-X
.	B-X
Initial	B-X
history	B-X
was	B-X
suggestive	B-X
of	B-X
micro-embolic	B-X
disease	B-X
to	B-X
the	B-X
medial	B-X
toes	B-X
of	B-X
the	B-X
left	B-X
foot	B-X
and	B-X
on	B-X
examination	B-X
pulses	B-X
were	B-X
palpable	B-X
throughout	B-X
the	B-X
lower	B-X
limbs	B-X
with	B-X
a	B-X
strong	B-X
,	B-X
palpable	B-X
dorasalis	B-X
pedis	B-X
pulse	B-X
.	B-X
Eight	B-X
patients	B-X
with	B-X
severe	B-X
pedal	B-X
ischemia	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
palpable	B-X
foot	B-X
pulses	B-X
are	B-X
described	B-X
.	B-X
There	B-X
were	B-X
two	B-X
anatomic	B-X
patterns	B-X
of	B-X
disease	B-X
,	B-X
including	B-X
supramalleolar	B-X
obstruction	B-X
with	B-X
reconstitution	B-X
of	B-X
pulsatile	B-X
flow	B-X
in	B-X
three	B-X
patients	B-X
and	B-X
segmental	B-X
occlusion	B-X
of	B-X
the	B-X
pedal	B-X
vessels	B-X
in	B-X
five	B-X
.	B-X
Palpable	B-X
pedal	B-X
pulses	B-X
and	B-X
satisfactory	B-X
ankle/brachial	B-X
indexes	B-X
did	B-X
not	B-X
rule	B-X
out	B-X
the	B-X
presence	B-X
of	B-X
surgically	B-X
correctable	B-X
distal	B-X
arterial	B-X
occlusive	B-X
disease	B-X
.	B-X

Transcutaneous	O
measurements	O
of	O
tissue	O
pO2	O
showed	O
elevation	O
from	O
20	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
during	O
air	O
breathing	O
to	O
643	O
+	O
/	O
-	O
242	O
mm	O
Hg	O
while	O
breathing	O
pure	O
oxygen	O
at	O
2	O
.	O
5	O
ATA	O
.	O
<EOS>	B-X
At	B-X
the	B-X
cellular	B-X
level	B-X
,	B-X
the	B-X
result	B-X
is	B-X
hypoxia	B-X
which	B-X
impairs	B-X
wound	B-X
healing	B-X
.	B-X
Hyperbaric	B-X
oxygenation	B-X
(	B-X
HBO	B-X
)	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
adjuvant	B-X
to	B-X
wound	B-X
care	B-X
.	B-X
It	B-X
leads	B-X
to	B-X
enhanced	B-X
oxygenation	B-X
of	B-X
the	B-X
affected	B-X
tissues	B-X
,	B-X
has	B-X
an	B-X
antiseptic	B-X
effect	B-X
,	B-X
reduces	B-X
edema	B-X
,	B-X
and	B-X
accelerates	B-X
collagen	B-X
production	B-X
and	B-X
angiogenesis	B-X
,	B-X
thus	B-X
enhancing	B-X
tissue	B-X
repair	B-X
.	B-X
Transcutaneous	B-X
measurements	B-X
of	B-X
tissue	B-X
pO2	B-X
showed	B-X
elevation	B-X
from	B-X
20	B-X
+/-	B-X
10	B-X
mm	B-X
Hg	B-X
during	B-X
air	B-X
breathing	B-X
to	B-X
643	B-X
+/-	B-X
242	B-X
mm	B-X
Hg	B-X
while	B-X
breathing	B-X
pure	B-X
oxygen	B-X
at	B-X
2.5	B-X
ATA	B-X
.	B-X
They	B-X
were	B-X
treated	B-X
with	B-X
HBO	B-X
in	B-X
56	B-X
+/-	B-X
10	B-X
consecutive	B-X
HBO	B-X
sessions	B-X
.	B-X

They	O
were	O
treated	O
with	O
HBO	O
in	O
56	O
+	O
/	O
-	O
10	O
consecutive	O
HBO	O
sessions	O
.	O
<EOS>	B-X
Hyperbaric	B-X
oxygenation	B-X
(	B-X
HBO	B-X
)	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
adjuvant	B-X
to	B-X
wound	B-X
care	B-X
.	B-X
14	B-X
diabetics	B-X
with	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
which	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
treatment	B-X
for	B-X
at	B-X
least	B-X
3	B-X
months	B-X
were	B-X
treated	B-X
by	B-X
HBO	B-X
.	B-X
Transcutaneous	B-X
measurements	B-X
of	B-X
tissue	B-X
pO2	B-X
showed	B-X
elevation	B-X
from	B-X
20	B-X
+/-	B-X
10	B-X
mm	B-X
Hg	B-X
during	B-X
air	B-X
breathing	B-X
to	B-X
643	B-X
+/-	B-X
242	B-X
mm	B-X
Hg	B-X
while	B-X
breathing	B-X
pure	B-X
oxygen	B-X
at	B-X
2.5	B-X
ATA	B-X
.	B-X
They	B-X
were	B-X
treated	B-X
with	B-X
HBO	B-X
in	B-X
56	B-X
+/-	B-X
10	B-X
consecutive	B-X
HBO	B-X
sessions	B-X
.	B-X
HBO	B-X
is	B-X
useful	B-X
in	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
and	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
with	B-X
impending	B-X
amputation	B-X
.	B-X

In	O
11	O
there	O
was	O
complete	O
wound	O
healing	O
,	O
while	O
in	O
1	O
there	O
was	O
partial	O
response	O
,	O
in	O
1	O
minimal	O
response	O
,	O
and	O
in	O
1	O
a	O
transient	O
response	O
.	O
<EOS>	B-X
Diabetic	B-X
foot	B-X
wounds	B-X
are	B-X
consequences	B-X
of	B-X
the	B-X
neuropathy	B-X
and	B-X
the	B-X
small	B-X
and	B-X
large	B-X
vessel	B-X
disease	B-X
that	B-X
complicate	B-X
diabetes	B-X
.	B-X
At	B-X
the	B-X
cellular	B-X
level	B-X
,	B-X
the	B-X
result	B-X
is	B-X
hypoxia	B-X
which	B-X
impairs	B-X
wound	B-X
healing	B-X
.	B-X
Hyperbaric	B-X
oxygenation	B-X
(	B-X
HBO	B-X
)	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
adjuvant	B-X
to	B-X
wound	B-X
care	B-X
.	B-X
14	B-X
diabetics	B-X
with	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
which	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
treatment	B-X
for	B-X
at	B-X
least	B-X
3	B-X
months	B-X
were	B-X
treated	B-X
by	B-X
HBO	B-X
.	B-X
Transcutaneous	B-X
measurements	B-X
of	B-X
tissue	B-X
pO2	B-X
showed	B-X
elevation	B-X
from	B-X
20	B-X
+/-	B-X
10	B-X
mm	B-X
Hg	B-X
during	B-X
air	B-X
breathing	B-X
to	B-X
643	B-X
+/-	B-X
242	B-X
mm	B-X
Hg	B-X
while	B-X
breathing	B-X
pure	B-X
oxygen	B-X
at	B-X
2.5	B-X
ATA	B-X
.	B-X
They	B-X
were	B-X
treated	B-X
with	B-X
HBO	B-X
in	B-X
56	B-X
+/-	B-X
10	B-X
consecutive	B-X
HBO	B-X
sessions	B-X
.	B-X
In	B-X
11	B-X
there	B-X
was	B-X
complete	B-X
wound	B-X
healing	B-X
,	B-X
while	B-X
in	B-X
1	B-X
there	B-X
was	B-X
partial	B-X
response	B-X
,	B-X
in	B-X
1	B-X
minimal	B-X
response	B-X
,	B-X
and	B-X
in	B-X
1	B-X
a	B-X
transient	B-X
response	B-X
.	B-X
HBO	B-X
is	B-X
useful	B-X
in	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
and	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
with	B-X
impending	B-X
amputation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
safe	B-X
mode	B-X
of	B-X
therapy	B-X
,	B-X
but	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
establish	B-X
its	B-X
efficacy	B-X
and	B-X
to	B-X
ascertain	B-X
which	B-X
diabetic	B-X
patients	B-X
and	B-X
wounds	B-X
will	B-X
benefit	B-X
the	B-X
most	B-X
from	B-X
it	B-X
.	B-X

HBO	O
is	O
useful	O
in	O
chronic	O
nonhealing	O
wounds	O
of	O
the	O
diabetic	O
foot	O
and	O
of	O
the	O
diabetic	O
foot	O
with	O
impending	O
amputation	O
.	O
<EOS>	B-X
Diabetic	B-X
foot	B-X
wounds	B-X
are	B-X
consequences	B-X
of	B-X
the	B-X
neuropathy	B-X
and	B-X
the	B-X
small	B-X
and	B-X
large	B-X
vessel	B-X
disease	B-X
that	B-X
complicate	B-X
diabetes	B-X
.	B-X
Hyperbaric	B-X
oxygenation	B-X
(	B-X
HBO	B-X
)	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
adjuvant	B-X
to	B-X
wound	B-X
care	B-X
.	B-X
14	B-X
diabetics	B-X
with	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
which	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
treatment	B-X
for	B-X
at	B-X
least	B-X
3	B-X
months	B-X
were	B-X
treated	B-X
by	B-X
HBO	B-X
.	B-X
They	B-X
were	B-X
treated	B-X
with	B-X
HBO	B-X
in	B-X
56	B-X
+/-	B-X
10	B-X
consecutive	B-X
HBO	B-X
sessions	B-X
.	B-X
HBO	B-X
is	B-X
useful	B-X
in	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
and	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
with	B-X
impending	B-X
amputation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
safe	B-X
mode	B-X
of	B-X
therapy	B-X
,	B-X
but	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
establish	B-X
its	B-X
efficacy	B-X
and	B-X
to	B-X
ascertain	B-X
which	B-X
diabetic	B-X
patients	B-X
and	B-X
wounds	B-X
will	B-X
benefit	B-X
the	B-X
most	B-X
from	B-X
it	B-X
.	B-X

It	O
is	O
a	O
safe	O
mode	O
of	O
therapy	O
,	O
but	O
further	O
studies	O
are	O
required	O
to	O
establish	O
its	O
efficacy	O
and	O
to	O
ascertain	O
which	O
diabetic	O
patients	O
and	O
wounds	O
will	O
benefit	O
the	O
most	O
from	O
it	O
.	O
<EOS>	B-X
Diabetic	B-X
foot	B-X
wounds	B-X
are	B-X
consequences	B-X
of	B-X
the	B-X
neuropathy	B-X
and	B-X
the	B-X
small	B-X
and	B-X
large	B-X
vessel	B-X
disease	B-X
that	B-X
complicate	B-X
diabetes	B-X
.	B-X
14	B-X
diabetics	B-X
with	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
which	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
treatment	B-X
for	B-X
at	B-X
least	B-X
3	B-X
months	B-X
were	B-X
treated	B-X
by	B-X
HBO	B-X
.	B-X
HBO	B-X
is	B-X
useful	B-X
in	B-X
chronic	B-X
nonhealing	B-X
wounds	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
and	B-X
of	B-X
the	B-X
diabetic	B-X
foot	B-X
with	B-X
impending	B-X
amputation	B-X
.	B-X
It	B-X
is	B-X
a	B-X
safe	B-X
mode	B-X
of	B-X
therapy	B-X
,	B-X
but	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
establish	B-X
its	B-X
efficacy	B-X
and	B-X
to	B-X
ascertain	B-X
which	B-X
diabetic	B-X
patients	B-X
and	B-X
wounds	B-X
will	B-X
benefit	B-X
the	B-X
most	B-X
from	B-X
it	B-X
.	B-X

Appearance	O
of	O
tumorous	O
phenotypes	O
in	O
goldfish	O
erythrophores	O
transfected	O
with	O
ras	B-Gene_or_gene_product
,	O
src	B-Gene_or_gene_product
,	O
and	O
myc	B-Gene_or_gene_product
oncogenes	O
and	O
spontaneous	O
differentiation	O
of	O
the	O
transformants	O
in	O
vitro	O
.	O
<EOS>	B-X
When	B-X
goldfish	B-X
erythrophores	B-X
isolated	B-X
from	B-X
the	B-X
skin	B-X
by	B-X
tissue	B-X
digestion	B-X
and	B-X
centrifugation	B-X
in	B-X
a	B-X
Percoll	B-X
density	B-X
gradient	B-X
were	B-X
transfected	B-X
in	B-X
a	B-X
monolayer-culture	B-X
with	B-X
v-Ha-ras	B-X
or	B-X
v-src	B-X
oncogene	B-X
either	B-X
singly	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
v-myc	B-X
by	B-X
means	B-X
of	B-X
calcium	B-X
phosphate-DNA	B-X
co-precipitation	B-X
,	B-X
there	B-X
appeared	B-X
a	B-X
certain	B-X
number	B-X
of	B-X
transformants	B-X
manifesting	B-X
a	B-X
chromatoblast-like	B-X
profile	B-X
and	B-X
tumorous	B-X
phenotypes	B-X
as	B-X
seen	B-X
in	B-X
the	B-X
capability	B-X
for	B-X
unlimited	B-X
growth	B-X
,	B-X
and	B-X
piling-up	B-X
in	B-X
a	B-X
monolayer-culture	B-X
or	B-X
colony	B-X
formation	B-X
in	B-X
semi-solid	B-X
soft	B-X
agar	B-X
.	B-X
After	B-X
successive	B-X
growth	B-X
in	B-X
vitro	B-X
for	B-X
longer	B-X
than	B-X
one	B-X
month	B-X
which	B-X
was	B-X
scarcely	B-X
observed	B-X
with	B-X
the	B-X
erythrophores	B-X
,	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
such	B-X
transformants	B-X
began	B-X
to	B-X
differentiate	B-X
into	B-X
erythrophores	B-X
and	B-X
ceased	B-X
proliferation	B-X
spontaneously	B-X
.	B-X
The	B-X
onset	B-X
of	B-X
their	B-X
differentiation	B-X
was	B-X
ascertained	B-X
by	B-X
the	B-X
deposition	B-X
of	B-X
marker	B-X
pteridine	B-X
pigments	B-X
.	B-X
None	B-X
of	B-X
the	B-X
transformants	B-X
differentiated	B-X
into	B-X
melanophores	B-X
or	B-X
iridophores	B-X
or	B-X
other	B-X
neural	B-X
crest	B-X
derivatives	B-X
as	B-X
seen	B-X
in	B-X
goldfish	B-X
erythrophoroma	B-X
cells	B-X
.	B-X
Little	B-X
difference	B-X
was	B-X
observed	B-X
in	B-X
their	B-X
transforming	B-X
efficiency	B-X
(	B-X
0.2-0.3	B-X
transformants/micrograms	B-X
DNA	B-X
)	B-X
between	B-X
the	B-X
combinations	B-X
of	B-X
oncogenes	B-X
applied	B-X
but	B-X
a	B-X
tendency	B-X
was	B-X
noted	B-X
that	B-X
cells	B-X
transfected	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
in	B-X
combination	B-X
with	B-X
myc	B-X
developed	B-X
the	B-X
capacity	B-X
to	B-X
grow	B-X
for	B-X
a	B-X
longer	B-X
period	B-X
and	B-X
differentiated	B-X
at	B-X
a	B-X
later	B-X
stage	B-X
than	B-X
those	B-X
transfected	B-X
solely	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
.	B-X
One	B-X
cell	B-X
line	B-X
(	B-X
ESM-1	B-X
)	B-X
derived	B-X
from	B-X
the	B-X
erythrophores	B-X
transfected	B-X
with	B-X
src/myc	B-X
grew	B-X
successively	B-X
over	B-X
nine	B-X
months	B-X
,	B-X
indicating	B-X
its	B-X
acquisition	B-X
of	B-X
immortality	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
transfected	B-X
oncogenes	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
was	B-X
examined	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
erythrophoroma	B-X
cells	B-X
by	B-X
Western	B-X
and	B-X
Northern	B-X
blot	B-X
analyses	B-X
.	B-X

When	O
goldfish	O
erythrophores	O
isolated	O
from	O
the	O
skin	O
by	O
tissue	O
digestion	O
and	O
centrifugation	O
in	O
a	O
Percoll	O
density	O
gradient	O
were	O
transfected	O
in	O
a	O
monolayer	O
-	O
culture	O
with	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ha	I-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
or	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	I-Gene_or_gene_product
oncogene	O
either	O
singly	O
or	O
in	O
combination	O
with	O
v	B-Gene_or_gene_product
-	I-Gene_or_gene_product
myc	I-Gene_or_gene_product
by	O
means	O
of	O
calcium	O
phosphate	O
-	O
DNA	O
co	O
-	O
precipitation	O
,	O
there	O
appeared	O
a	O
certain	O
number	O
of	O
transformants	O
manifesting	O
a	O
chromatoblast	O
-	O
like	O
profile	O
and	O
tumorous	O
phenotypes	O
as	O
seen	O
in	O
the	O
capability	O
for	O
unlimited	O
growth	O
,	O
and	O
piling	O
-	O
up	O
in	O
a	O
monolayer	O
-	O
culture	O
or	O
colony	O
formation	O
in	O
semi	O
-	O
solid	O
soft	O
agar	O
.	O
<EOS>	B-X
Anchorage-independent	B-X
growth	B-X
is	B-X
the	B-X
ability	B-X
of	B-X
transformed	B-X
cells	B-X
to	B-X
grow	B-X
independently	B-X
of	B-X
a	B-X
solid	B-X
surface	B-X
,	B-X
and	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
carcinogenesis	B-X
.	B-X
The	B-X
soft	B-X
agar	B-X
colony	B-X
formation	B-X
assay	B-X
is	B-X
a	B-X
well-established	B-X
method	B-X
for	B-X
characterizing	B-X
this	B-X
capability	B-X
in	B-X
vitro	B-X
and	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
one	B-X
of	B-X
the	B-X
most	B-X
stringent	B-X
tests	B-X
for	B-X
malignant	B-X
transformation	B-X
in	B-X
cells	B-X
.	B-X
This	B-X
assay	B-X
also	B-X
allows	B-X
for	B-X
semi-quantitative	B-X
evaluation	B-X
of	B-X
this	B-X
capability	B-X
in	B-X
response	B-X
to	B-X
various	B-X
treatment	B-X
conditions	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
will	B-X
demonstrate	B-X
the	B-X
soft	B-X
agar	B-X
colony	B-X
formation	B-X
assay	B-X
using	B-X
a	B-X
murine	B-X
lung	B-X
carcinoma	B-X
cell	B-X
line	B-X
,	B-X
CMT167	B-X
,	B-X
to	B-X
demonstrate	B-X
the	B-X
tumor	B-X
suppressive	B-X
effects	B-X
of	B-X
two	B-X
members	B-X
of	B-X
the	B-X
Wnt	B-X
signaling	B-X
pathway	B-X
,	B-X
Wnt7A	B-X
and	B-X
Frizzled-9	B-X
(	B-X
Fzd-9	B-X
)	B-X
.	B-X
Concurrent	B-X
overexpression	B-X
of	B-X
Wnt7a	B-X
and	B-X
Fzd-9	B-X
caused	B-X
an	B-X
inhibition	B-X
of	B-X
colony	B-X
formation	B-X
in	B-X
CMT167	B-X
cells	B-X
.	B-X
This	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
Wnt7a	B-X
ligand	B-X
and	B-X
its	B-X
Frizzled-9	B-X
receptor	B-X
is	B-X
sufficient	B-X
to	B-X
suppress	B-X
tumor	B-X
growth	B-X
in	B-X
a	B-X
murine	B-X
lung	B-X
carcinoma	B-X
model	B-X
.	B-X

After	O
successive	O
growth	O
in	O
vitro	O
for	O
longer	O
than	O
one	O
month	O
which	O
was	O
scarcely	O
observed	O
with	O
the	O
erythrophores	O
,	O
the	O
vast	O
majority	O
of	O
such	O
transformants	O
began	O
to	O
differentiate	O
into	O
erythrophores	O
and	O
ceased	O
proliferation	O
spontaneously	O
.	O
<EOS>	B-X
When	B-X
goldfish	B-X
erythrophores	B-X
isolated	B-X
from	B-X
the	B-X
skin	B-X
by	B-X
tissue	B-X
digestion	B-X
and	B-X
centrifugation	B-X
in	B-X
a	B-X
Percoll	B-X
density	B-X
gradient	B-X
were	B-X
transfected	B-X
in	B-X
a	B-X
monolayer-culture	B-X
with	B-X
v-Ha-ras	B-X
or	B-X
v-src	B-X
oncogene	B-X
either	B-X
singly	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
v-myc	B-X
by	B-X
means	B-X
of	B-X
calcium	B-X
phosphate-DNA	B-X
co-precipitation	B-X
,	B-X
there	B-X
appeared	B-X
a	B-X
certain	B-X
number	B-X
of	B-X
transformants	B-X
manifesting	B-X
a	B-X
chromatoblast-like	B-X
profile	B-X
and	B-X
tumorous	B-X
phenotypes	B-X
as	B-X
seen	B-X
in	B-X
the	B-X
capability	B-X
for	B-X
unlimited	B-X
growth	B-X
,	B-X
and	B-X
piling-up	B-X
in	B-X
a	B-X
monolayer-culture	B-X
or	B-X
colony	B-X
formation	B-X
in	B-X
semi-solid	B-X
soft	B-X
agar	B-X
.	B-X
After	B-X
successive	B-X
growth	B-X
in	B-X
vitro	B-X
for	B-X
longer	B-X
than	B-X
one	B-X
month	B-X
which	B-X
was	B-X
scarcely	B-X
observed	B-X
with	B-X
the	B-X
erythrophores	B-X
,	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
such	B-X
transformants	B-X
began	B-X
to	B-X
differentiate	B-X
into	B-X
erythrophores	B-X
and	B-X
ceased	B-X
proliferation	B-X
spontaneously	B-X
.	B-X
None	B-X
of	B-X
the	B-X
transformants	B-X
differentiated	B-X
into	B-X
melanophores	B-X
or	B-X
iridophores	B-X
or	B-X
other	B-X
neural	B-X
crest	B-X
derivatives	B-X
as	B-X
seen	B-X
in	B-X
goldfish	B-X
erythrophoroma	B-X
cells	B-X
.	B-X
Little	B-X
difference	B-X
was	B-X
observed	B-X
in	B-X
their	B-X
transforming	B-X
efficiency	B-X
(	B-X
0.2-0.3	B-X
transformants/micrograms	B-X
DNA	B-X
)	B-X
between	B-X
the	B-X
combinations	B-X
of	B-X
oncogenes	B-X
applied	B-X
but	B-X
a	B-X
tendency	B-X
was	B-X
noted	B-X
that	B-X
cells	B-X
transfected	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
in	B-X
combination	B-X
with	B-X
myc	B-X
developed	B-X
the	B-X
capacity	B-X
to	B-X
grow	B-X
for	B-X
a	B-X
longer	B-X
period	B-X
and	B-X
differentiated	B-X
at	B-X
a	B-X
later	B-X
stage	B-X
than	B-X
those	B-X
transfected	B-X
solely	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
.	B-X
One	B-X
cell	B-X
line	B-X
(	B-X
ESM-1	B-X
)	B-X
derived	B-X
from	B-X
the	B-X
erythrophores	B-X
transfected	B-X
with	B-X
src/myc	B-X
grew	B-X
successively	B-X
over	B-X
nine	B-X
months	B-X
,	B-X
indicating	B-X
its	B-X
acquisition	B-X
of	B-X
immortality	B-X
.	B-X

The	O
onset	O
of	O
their	O
differentiation	O
was	O
ascertained	O
by	O
the	O
deposition	O
of	O
marker	O
pteridine	O
pigments	O
.	O
<EOS>	B-X
The	B-X
onset	B-X
of	B-X
their	B-X
differentiation	B-X
was	B-X
ascertained	B-X
by	B-X
the	B-X
deposition	B-X
of	B-X
marker	B-X
pteridine	B-X
pigments	B-X
.	B-X

None	O
of	O
the	O
transformants	O
differentiated	O
into	O
melanophores	O
or	O
iridophores	O
or	O
other	O
neural	O
crest	O
derivatives	O
as	O
seen	O
in	O
goldfish	O
erythrophoroma	O
cells	O
.	O
<EOS>	B-X
Colour	B-X
patterns	B-X
of	B-X
adult	B-X
fish	B-X
are	B-X
produced	B-X
by	B-X
several	B-X
types	B-X
of	B-X
pigment	B-X
cells	B-X
that	B-X
distribute	B-X
in	B-X
the	B-X
dermis	B-X
during	B-X
juvenile	B-X
development	B-X
.	B-X
The	B-X
zebrafish	B-X
,	B-X
Danio	B-X
rerio	B-X
,	B-X
displays	B-X
a	B-X
striking	B-X
pattern	B-X
of	B-X
dark	B-X
stripes	B-X
of	B-X
melanophores	B-X
interspersed	B-X
by	B-X
light	B-X
stripes	B-X
of	B-X
xanthophores	B-X
.	B-X
A	B-X
third	B-X
cell	B-X
type	B-X
,	B-X
silvery	B-X
iridophores	B-X
,	B-X
participates	B-X
to	B-X
render	B-X
a	B-X
shiny	B-X
appearance	B-X
to	B-X
the	B-X
pattern	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
stripe	B-X
formation	B-X
has	B-X
been	B-X
unclear	B-X
.	B-X
Mutations	B-X
in	B-X
rose	B-X
(	B-X
rse	B-X
)	B-X
or	B-X
shady	B-X
(	B-X
shd	B-X
)	B-X
cause	B-X
a	B-X
lack	B-X
or	B-X
strong	B-X
reduction	B-X
of	B-X
iridophores	B-X
in	B-X
adult	B-X
fish	B-X
;	B-X
in	B-X
addition	B-X
,	B-X
the	B-X
melanophore	B-X
number	B-X
is	B-X
drastically	B-X
reduced	B-X
and	B-X
stripes	B-X
are	B-X
broken	B-X
up	B-X
into	B-X
spots	B-X
.	B-X
We	B-X
show	B-X
that	B-X
rse	B-X
and	B-X
shd	B-X
are	B-X
autonomously	B-X
required	B-X
in	B-X
iridophores	B-X
,	B-X
as	B-X
mutant	B-X
melanophores	B-X
form	B-X
normal	B-X
sized	B-X
stripes	B-X
when	B-X
confronted	B-X
with	B-X
wild-type	B-X
iridophores	B-X
in	B-X
chimeric	B-X
animals	B-X
.	B-X
None	B-X
of	B-X
the	B-X
chromatophore	B-X
types	B-X
alone	B-X
is	B-X
able	B-X
to	B-X
create	B-X
a	B-X
pattern	B-X
but	B-X
residual	B-X
stripe	B-X
formation	B-X
occurs	B-X
with	B-X
two	B-X
cell	B-X
types	B-X
.	B-X
Our	B-X
analysis	B-X
shows	B-X
that	B-X
iridophores	B-X
promote	B-X
and	B-X
sustain	B-X
melanophores	B-X
.	B-X
Furthermore	B-X
,	B-X
iridophores	B-X
attract	B-X
xanthophores	B-X
,	B-X
whereas	B-X
xanthophores	B-X
repel	B-X
melanophores	B-X
.	B-X
Stripe	B-X
formation	B-X
is	B-X
initiated	B-X
by	B-X
iridophores	B-X
appearing	B-X
at	B-X
the	B-X
horizontal	B-X
myoseptum	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
a	B-X
morphological	B-X
landmark	B-X
for	B-X
stripe	B-X
orientation	B-X
,	B-X
but	B-X
is	B-X
subsequently	B-X
a	B-X
self-organising	B-X
process	B-X
.	B-X

Little	O
difference	O
was	O
observed	O
in	O
their	O
transforming	O
efficiency	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
3	O
transformants	O
/	O
micrograms	O
DNA	O
)	O
between	O
the	O
combinations	O
of	O
oncogenes	O
applied	O
but	O
a	O
tendency	O
was	O
noted	O
that	O
cells	O
transfected	O
with	O
ras	B-Gene_or_gene_product
or	O
src	B-Gene_or_gene_product
in	O
combination	O
with	O
myc	B-Gene_or_gene_product
developed	O
the	O
capacity	O
to	O
grow	O
for	O
a	O
longer	O
period	O
and	O
differentiated	O
at	O
a	O
later	O
stage	O
than	O
those	O
transfected	O
solely	O
with	O
ras	B-Gene_or_gene_product
or	O
src	B-Gene_or_gene_product
.	O
<EOS>	B-X
Src	B-X
and	B-X
Src-family	B-X
protein	B-X
kinases	B-X
are	B-X
proto-oncogenes	B-X
that	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
cell	B-X
morphology	B-X
,	B-X
motility	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
survival	B-X
.	B-X
v-Src	B-X
(	B-X
a	B-X
viral	B-X
protein	B-X
)	B-X
is	B-X
encoded	B-X
by	B-X
the	B-X
chicken	B-X
oncogene	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
and	B-X
Src	B-X
(	B-X
the	B-X
cellular	B-X
homologue	B-X
)	B-X
is	B-X
encoded	B-X
by	B-X
a	B-X
physiological	B-X
gene	B-X
,	B-X
the	B-X
first	B-X
of	B-X
the	B-X
proto-oncogenes	B-X
.	B-X
From	B-X
the	B-X
N-	B-X
to	B-X
C-terminus	B-X
,	B-X
Src	B-X
contains	B-X
an	B-X
N-terminal	B-X
14-carbon	B-X
myristoyl	B-X
group	B-X
,	B-X
a	B-X
unique	B-X
segment	B-X
,	B-X
an	B-X
SH3	B-X
domain	B-X
,	B-X
an	B-X
SH2	B-X
domain	B-X
,	B-X
a	B-X
protein-tyrosine	B-X
kinase	B-X
domain	B-X
,	B-X
and	B-X
a	B-X
C-terminal	B-X
regulatory	B-X
tail	B-X
.	B-X
The	B-X
chief	B-X
phosphorylation	B-X
sites	B-X
of	B-X
Src	B-X
include	B-X
tyrosine	B-X
416	B-X
that	B-X
results	B-X
in	B-X
activation	B-X
from	B-X
autophosphorylation	B-X
and	B-X
tyrosine	B-X
527	B-X
that	B-X
results	B-X
in	B-X
inhibition	B-X
from	B-X
phosphorylation	B-X
by	B-X
C-terminal	B-X
Src	B-X
kinase	B-X
.	B-X
In	B-X
the	B-X
restrained	B-X
state	B-X
,	B-X
the	B-X
SH2	B-X
domain	B-X
forms	B-X
a	B-X
salt	B-X
bridge	B-X
with	B-X
phosphotyrosine	B-X
527	B-X
,	B-X
and	B-X
the	B-X
SH3	B-X
domain	B-X
binds	B-X
to	B-X
the	B-X
kinase	B-X
domain	B-X
via	B-X
a	B-X
polyproline	B-X
type	B-X
II	B-X
left-handed	B-X
helix	B-X
.	B-X
The	B-X
SH2	B-X
and	B-X
SH3	B-X
domains	B-X
occur	B-X
on	B-X
the	B-X
backside	B-X
of	B-X
the	B-X
kinase	B-X
domain	B-X
away	B-X
from	B-X
the	B-X
active	B-X
site	B-X
where	B-X
they	B-X
stabilize	B-X
a	B-X
dormant	B-X
enzyme	B-X
conformation	B-X
.	B-X
Protein-tyrosine	B-X
phosphatases	B-X
such	B-X
as	B-X
PTPalpha	B-X
displace	B-X
phosphotyrosine	B-X
527	B-X
from	B-X
the	B-X
Src	B-X
SH2	B-X
domain	B-X
and	B-X
mediate	B-X
its	B-X
dephosphorylation	B-X
leading	B-X
to	B-X
Src	B-X
kinase	B-X
activation	B-X
.	B-X
C-terminal	B-X
Src	B-X
kinase	B-X
consists	B-X
of	B-X
an	B-X
SH3	B-X
,	B-X
SH2	B-X
,	B-X
and	B-X
kinase	B-X
domain	B-X
;	B-X
it	B-X
lacks	B-X
an	B-X
N-terminal	B-X
myristoyl	B-X
group	B-X
and	B-X
a	B-X
C-terminal	B-X
regulatory	B-X
tail	B-X
.	B-X
Its	B-X
X-ray	B-X
structure	B-X
has	B-X
been	B-X
determined	B-X
,	B-X
and	B-X
the	B-X
SH2	B-X
lobe	B-X
occupies	B-X
a	B-X
position	B-X
that	B-X
is	B-X
entirely	B-X
different	B-X
from	B-X
that	B-X
of	B-X
Src	B-X
.	B-X
Unlike	B-X
Src	B-X
,	B-X
the	B-X
C-terminal	B-X
Src	B-X
kinase	B-X
SH2	B-X
and	B-X
SH3	B-X
domains	B-X
stabilize	B-X
an	B-X
active	B-X
enzyme	B-X
conformation	B-X
.	B-X

One	O
cell	O
line	O
(	O
ESM	O
-	O
1	O
)	O
derived	O
from	O
the	O
erythrophores	O
transfected	O
with	O
src	B-Gene_or_gene_product
/	O
myc	B-Gene_or_gene_product
grew	O
successively	O
over	O
nine	O
months	O
,	O
indicating	O
its	O
acquisition	O
of	O
immortality	O
.	O
<EOS>	B-X
When	B-X
goldfish	B-X
erythrophores	B-X
isolated	B-X
from	B-X
the	B-X
skin	B-X
by	B-X
tissue	B-X
digestion	B-X
and	B-X
centrifugation	B-X
in	B-X
a	B-X
Percoll	B-X
density	B-X
gradient	B-X
were	B-X
transfected	B-X
in	B-X
a	B-X
monolayer-culture	B-X
with	B-X
v-Ha-ras	B-X
or	B-X
v-src	B-X
oncogene	B-X
either	B-X
singly	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
v-myc	B-X
by	B-X
means	B-X
of	B-X
calcium	B-X
phosphate-DNA	B-X
co-precipitation	B-X
,	B-X
there	B-X
appeared	B-X
a	B-X
certain	B-X
number	B-X
of	B-X
transformants	B-X
manifesting	B-X
a	B-X
chromatoblast-like	B-X
profile	B-X
and	B-X
tumorous	B-X
phenotypes	B-X
as	B-X
seen	B-X
in	B-X
the	B-X
capability	B-X
for	B-X
unlimited	B-X
growth	B-X
,	B-X
and	B-X
piling-up	B-X
in	B-X
a	B-X
monolayer-culture	B-X
or	B-X
colony	B-X
formation	B-X
in	B-X
semi-solid	B-X
soft	B-X
agar	B-X
.	B-X
After	B-X
successive	B-X
growth	B-X
in	B-X
vitro	B-X
for	B-X
longer	B-X
than	B-X
one	B-X
month	B-X
which	B-X
was	B-X
scarcely	B-X
observed	B-X
with	B-X
the	B-X
erythrophores	B-X
,	B-X
the	B-X
vast	B-X
majority	B-X
of	B-X
such	B-X
transformants	B-X
began	B-X
to	B-X
differentiate	B-X
into	B-X
erythrophores	B-X
and	B-X
ceased	B-X
proliferation	B-X
spontaneously	B-X
.	B-X
None	B-X
of	B-X
the	B-X
transformants	B-X
differentiated	B-X
into	B-X
melanophores	B-X
or	B-X
iridophores	B-X
or	B-X
other	B-X
neural	B-X
crest	B-X
derivatives	B-X
as	B-X
seen	B-X
in	B-X
goldfish	B-X
erythrophoroma	B-X
cells	B-X
.	B-X
Little	B-X
difference	B-X
was	B-X
observed	B-X
in	B-X
their	B-X
transforming	B-X
efficiency	B-X
(	B-X
0.2-0.3	B-X
transformants/micrograms	B-X
DNA	B-X
)	B-X
between	B-X
the	B-X
combinations	B-X
of	B-X
oncogenes	B-X
applied	B-X
but	B-X
a	B-X
tendency	B-X
was	B-X
noted	B-X
that	B-X
cells	B-X
transfected	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
in	B-X
combination	B-X
with	B-X
myc	B-X
developed	B-X
the	B-X
capacity	B-X
to	B-X
grow	B-X
for	B-X
a	B-X
longer	B-X
period	B-X
and	B-X
differentiated	B-X
at	B-X
a	B-X
later	B-X
stage	B-X
than	B-X
those	B-X
transfected	B-X
solely	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
.	B-X
One	B-X
cell	B-X
line	B-X
(	B-X
ESM-1	B-X
)	B-X
derived	B-X
from	B-X
the	B-X
erythrophores	B-X
transfected	B-X
with	B-X
src/myc	B-X
grew	B-X
successively	B-X
over	B-X
nine	B-X
months	B-X
,	B-X
indicating	B-X
its	B-X
acquisition	B-X
of	B-X
immortality	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
transfected	B-X
oncogenes	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
was	B-X
examined	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
erythrophoroma	B-X
cells	B-X
by	B-X
Western	B-X
and	B-X
Northern	B-X
blot	B-X
analyses	B-X
.	B-X

The	O
expression	O
of	O
the	O
transfected	O
oncogenes	O
in	O
this	O
cell	O
line	O
was	O
examined	O
in	O
comparison	O
with	O
the	O
erythrophoroma	O
cells	O
by	O
Western	O
and	O
Northern	O
blot	O
analyses	O
.	O
<EOS>	B-X
When	B-X
goldfish	B-X
erythrophores	B-X
isolated	B-X
from	B-X
the	B-X
skin	B-X
by	B-X
tissue	B-X
digestion	B-X
and	B-X
centrifugation	B-X
in	B-X
a	B-X
Percoll	B-X
density	B-X
gradient	B-X
were	B-X
transfected	B-X
in	B-X
a	B-X
monolayer-culture	B-X
with	B-X
v-Ha-ras	B-X
or	B-X
v-src	B-X
oncogene	B-X
either	B-X
singly	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
v-myc	B-X
by	B-X
means	B-X
of	B-X
calcium	B-X
phosphate-DNA	B-X
co-precipitation	B-X
,	B-X
there	B-X
appeared	B-X
a	B-X
certain	B-X
number	B-X
of	B-X
transformants	B-X
manifesting	B-X
a	B-X
chromatoblast-like	B-X
profile	B-X
and	B-X
tumorous	B-X
phenotypes	B-X
as	B-X
seen	B-X
in	B-X
the	B-X
capability	B-X
for	B-X
unlimited	B-X
growth	B-X
,	B-X
and	B-X
piling-up	B-X
in	B-X
a	B-X
monolayer-culture	B-X
or	B-X
colony	B-X
formation	B-X
in	B-X
semi-solid	B-X
soft	B-X
agar	B-X
.	B-X
None	B-X
of	B-X
the	B-X
transformants	B-X
differentiated	B-X
into	B-X
melanophores	B-X
or	B-X
iridophores	B-X
or	B-X
other	B-X
neural	B-X
crest	B-X
derivatives	B-X
as	B-X
seen	B-X
in	B-X
goldfish	B-X
erythrophoroma	B-X
cells	B-X
.	B-X
Little	B-X
difference	B-X
was	B-X
observed	B-X
in	B-X
their	B-X
transforming	B-X
efficiency	B-X
(	B-X
0.2-0.3	B-X
transformants/micrograms	B-X
DNA	B-X
)	B-X
between	B-X
the	B-X
combinations	B-X
of	B-X
oncogenes	B-X
applied	B-X
but	B-X
a	B-X
tendency	B-X
was	B-X
noted	B-X
that	B-X
cells	B-X
transfected	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
in	B-X
combination	B-X
with	B-X
myc	B-X
developed	B-X
the	B-X
capacity	B-X
to	B-X
grow	B-X
for	B-X
a	B-X
longer	B-X
period	B-X
and	B-X
differentiated	B-X
at	B-X
a	B-X
later	B-X
stage	B-X
than	B-X
those	B-X
transfected	B-X
solely	B-X
with	B-X
ras	B-X
or	B-X
src	B-X
.	B-X
One	B-X
cell	B-X
line	B-X
(	B-X
ESM-1	B-X
)	B-X
derived	B-X
from	B-X
the	B-X
erythrophores	B-X
transfected	B-X
with	B-X
src/myc	B-X
grew	B-X
successively	B-X
over	B-X
nine	B-X
months	B-X
,	B-X
indicating	B-X
its	B-X
acquisition	B-X
of	B-X
immortality	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
transfected	B-X
oncogenes	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
was	B-X
examined	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
erythrophoroma	B-X
cells	B-X
by	B-X
Western	B-X
and	B-X
Northern	B-X
blot	B-X
analyses	B-X
.	B-X

Immune	O
consequences	O
of	O
burn	O
injury	O
.	O
<EOS>	B-X
Thermal	B-X
injury	B-X
is	B-X
often	B-X
associated	B-X
with	B-X
a	B-X
proinflammatory	B-X
state	B-X
resulting	B-X
in	B-X
serious	B-X
complications	B-X
.	B-X
After	B-X
a	B-X
burn	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
is	B-X
activated	B-X
with	B-X
subsequent	B-X
immune	B-X
cell	B-X
infiltration	B-X
and	B-X
cytokine	B-X
production	B-X
.	B-X
Recent	B-X
studies	B-X
involving	B-X
animal	B-X
models	B-X
along	B-X
with	B-X
human	B-X
studies	B-X
have	B-X
drawn	B-X
great	B-X
attention	B-X
to	B-X
the	B-X
possible	B-X
pathological	B-X
role	B-X
of	B-X
DAMPs	B-X
as	B-X
an	B-X
immune	B-X
consequence	B-X
of	B-X
thermal	B-X
injury	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
outline	B-X
DAMPs	B-X
and	B-X
their	B-X
function	B-X
in	B-X
thermal	B-X
injury	B-X
,	B-X
shedding	B-X
light	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
sterile	B-X
inflammation	B-X
during	B-X
tissue	B-X
injury	B-X
and	B-X
identifying	B-X
new	B-X
immune	B-X
targets	B-X
for	B-X
treating	B-X
thermal	B-X
injury	B-X
.	B-X

The	O
purpose	O
of	O
the	O
immune	O
system	O
is	O
to	O
protect	O
cells	O
from	O
invasion	O
by	O
microorganisms	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
to	B-X
protect	B-X
the	B-X
body	B-X
from	B-X
invasion	B-X
from	B-X
microorganisms	B-X
.	B-X
If	B-X
microorganisms	B-X
penetrate	B-X
the	B-X
external	B-X
surfaces	B-X
and	B-X
enter	B-X
the	B-X
body	B-X
,	B-X
the	B-X
inflammatory	B-X
process	B-X
is	B-X
triggered	B-X
.	B-X
Following	B-X
an	B-X
appropriate	B-X
level	B-X
of	B-X
response	B-X
,	B-X
T8	B-X
cells	B-X
suppress	B-X
immune	B-X
system	B-X
response	B-X
to	B-X
the	B-X
antigen	B-X
,	B-X
but	B-X
not	B-X
before	B-X
memory	B-X
B	B-X
and	B-X
T	B-X
cells	B-X
have	B-X
formed	B-X
.	B-X
These	B-X
memory	B-X
cells	B-X
protect	B-X
the	B-X
body	B-X
against	B-X
future	B-X
exposure	B-X
to	B-X
the	B-X
antigen	B-X
,	B-X
thus	B-X
creating	B-X
immunity	B-X
.	B-X
As	B-X
concepts	B-X
of	B-X
immunology	B-X
are	B-X
identified	B-X
and	B-X
validated	B-X
by	B-X
future	B-X
research	B-X
,	B-X
the	B-X
knowledge	B-X
base	B-X
of	B-X
immune	B-X
system	B-X
function	B-X
and	B-X
dysfunction	B-X
will	B-X
continue	B-X
to	B-X
grow	B-X
.	B-X
Critical	B-X
care	B-X
nurses	B-X
must	B-X
incorporate	B-X
new	B-X
knowledge	B-X
related	B-X
to	B-X
immune	B-X
system	B-X
function	B-X
into	B-X
their	B-X
practice	B-X
,	B-X
as	B-X
patients	B-X
in	B-X
the	B-X
ICU	B-X
are	B-X
at	B-X
risk	B-X
for	B-X
immunocompromise	B-X
from	B-X
their	B-X
underlying	B-X
disease	B-X
state	B-X
and	B-X
the	B-X
therapeutic	B-X
interventions	B-X
used	B-X
in	B-X
their	B-X
treatment	B-X
.	B-X
Nurses	B-X
must	B-X
expand	B-X
their	B-X
physiologic	B-X
data	B-X
base	B-X
to	B-X
include	B-X
a	B-X
nursing	B-X
assessment	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
A	B-X
framework	B-X
for	B-X
organizing	B-X
the	B-X
data	B-X
collection	B-X
process	B-X
would	B-X
include	B-X
:	B-X
(	B-X
1	B-X
)	B-X
a	B-X
survey	B-X
of	B-X
factors	B-X
affecting	B-X
immune	B-X
system	B-X
function	B-X
in	B-X
each	B-X
patient	B-X
,	B-X
(	B-X
2	B-X
)	B-X
assessment	B-X
of	B-X
the	B-X
cells	B-X
and	B-X
structures	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
(	B-X
3	B-X
)	B-X
monitoring	B-X
of	B-X
the	B-X
status	B-X
of	B-X
first	B-X
line	B-X
defenses	B-X
,	B-X
(	B-X
4	B-X
)	B-X
observing	B-X
for	B-X
activity	B-X
of	B-X
nonspecific	B-X
defenses	B-X
,	B-X
and	B-X
(	B-X
5	B-X
)	B-X
evidence	B-X
of	B-X
specific	B-X
acquired	B-X
immune	B-X
responses	B-X
.	B-X
After	B-X
complete	B-X
immune	B-X
system	B-X
assessment	B-X
has	B-X
identified	B-X
areas	B-X
of	B-X
risk	B-X
for	B-X
compromise	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
immunocompromise	B-X
,	B-X
specific	B-X
individualized	B-X
nursing	B-X
care	B-X
plans	B-X
can	B-X
be	B-X
developed	B-X
to	B-X
provide	B-X
nursing	B-X
support	B-X
to	B-X
maintain	B-X
and	B-X
enhance	B-X
the	B-X
patient	B-X
's	B-X
defenses	B-X
.	B-X

The	O
body	O
has	O
three	O
equally	O
important	O
interactive	O
immune	O
defense	O
systems	O
,	O
all	O
of	O
which	O
are	O
profoundly	O
disrupted	O
with	O
major	O
burn	O
injury	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
to	B-X
protect	B-X
cells	B-X
from	B-X
invasion	B-X
by	B-X
microorganisms	B-X
.	B-X
The	B-X
body	B-X
has	B-X
three	B-X
equally	B-X
important	B-X
interactive	B-X
immune	B-X
defense	B-X
systems	B-X
,	B-X
all	B-X
of	B-X
which	B-X
are	B-X
profoundly	B-X
disrupted	B-X
with	B-X
major	B-X
burn	B-X
injury	B-X
.	B-X
The	B-X
immune	B-X
response	B-X
to	B-X
burn	B-X
injury	B-X
is	B-X
immediate	B-X
,	B-X
prolonged	B-X
,	B-X
and	B-X
severe	B-X
.	B-X
The	B-X
end	B-X
result	B-X
in	B-X
individuals	B-X
surviving	B-X
burn	B-X
shock	B-X
is	B-X
immunosuppression	B-X
,	B-X
with	B-X
increased	B-X
susceptibility	B-X
to	B-X
potentially	B-X
fatal	B-X
systemic	B-X
burn	B-X
wound	B-X
or	B-X
pulmonary	B-X
sepsis	B-X
.	B-X
Nursing	B-X
actions	B-X
to	B-X
support	B-X
the	B-X
humoral	B-X
and	B-X
cell-mediated	B-X
immune	B-X
system	B-X
of	B-X
the	B-X
burned	B-X
patient	B-X
include	B-X
providing	B-X
nutritional	B-X
support	B-X
to	B-X
maintain	B-X
serum	B-X
protein	B-X
levels	B-X
at	B-X
optimal	B-X
levels	B-X
;	B-X
measures	B-X
to	B-X
decrease	B-X
edema	B-X
and	B-X
promote	B-X
angiogenesis	B-X
in	B-X
areas	B-X
of	B-X
partial-thickness	B-X
injury	B-X
;	B-X
meticulous	B-X
treatment	B-X
of	B-X
the	B-X
wound	B-X
to	B-X
prevent	B-X
infection	B-X
and	B-X
promote	B-X
healing	B-X
;	B-X
monitoring	B-X
of	B-X
antibiotic	B-X
use	B-X
;	B-X
conservative	B-X
use	B-X
of	B-X
invasive	B-X
techniques	B-X
,	B-X
including	B-X
intubation	B-X
and	B-X
vascular	B-X
access	B-X
devices	B-X
;	B-X
maintenance	B-X
of	B-X
fluid	B-X
and	B-X
electrolyte	B-X
balance	B-X
and	B-X
body	B-X
temperature	B-X
;	B-X
and	B-X
energy	B-X
conservation	B-X
measures	B-X
.	B-X

The	O
immune	O
response	O
to	O
burn	O
injury	O
is	O
immediate	O
,	O
prolonged	O
,	O
and	O
severe	O
.	O
<EOS>	B-X
In	B-X
the	B-X
literature	B-X
,	B-X
burns	B-X
are	B-X
understood	B-X
as	B-X
traumatic	B-X
events	B-X
accompanied	B-X
by	B-X
increased	B-X
morbidity	B-X
and	B-X
mortality	B-X
among	B-X
affected	B-X
patients	B-X
.	B-X
Their	B-X
characteristic	B-X
feature	B-X
is	B-X
the	B-X
formation	B-X
of	B-X
swelling	B-X
and	B-X
redness	B-X
at	B-X
the	B-X
site	B-X
of	B-X
the	B-X
burn	B-X
,	B-X
which	B-X
indicates	B-X
the	B-X
development	B-X
of	B-X
inflammation	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
not	B-X
only	B-X
important	B-X
in	B-X
the	B-X
healing	B-X
process	B-X
of	B-X
wounds	B-X
but	B-X
is	B-X
also	B-X
responsible	B-X
for	B-X
stimulating	B-X
the	B-X
patient	B-X
's	B-X
innate	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
burns	B-X
is	B-X
not	B-X
only	B-X
immediate	B-X
,	B-X
but	B-X
also	B-X
severe	B-X
and	B-X
prolonged	B-X
,	B-X
and	B-X
some	B-X
people	B-X
with	B-X
burn	B-X
shock	B-X
may	B-X
also	B-X
experience	B-X
immunosuppression	B-X
accompanied	B-X
by	B-X
an	B-X
increased	B-X
susceptibility	B-X
to	B-X
fatal	B-X
infections	B-X
.	B-X
This	B-X
is	B-X
why	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
how	B-X
the	B-X
immune	B-X
system	B-X
works	B-X
in	B-X
people	B-X
with	B-X
burns	B-X
and	B-X
during	B-X
infections	B-X
of	B-X
wounds	B-X
by	B-X
microorganisms	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
the	B-X
molecular	B-X
pathways	B-X
of	B-X
cell	B-X
signaling	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
of	B-X
people	B-X
affected	B-X
by	B-X
burns	B-X
,	B-X
taking	B-X
into	B-X
account	B-X
the	B-X
role	B-X
of	B-X
microbial	B-X
infections	B-X
.	B-X

The	O
end	O
result	O
in	O
individuals	O
surviving	O
burn	O
shock	O
is	O
immunosuppression	O
,	O
with	O
increased	O
susceptibility	O
to	O
potentially	O
fatal	O
systemic	O
burn	O
wound	O
or	O
pulmonary	O
sepsis	O
.	O
<EOS>	B-X
The	B-X
current	B-X
review	B-X
describes	B-X
the	B-X
immunological	B-X
mechanisms	B-X
responsible	B-X
for	B-X
bacterial	B-X
pneumonia	B-X
and	B-X
sepsis-induced	B-X
ALI	B-X
.	B-X
It	B-X
highlights	B-X
the	B-X
immunological	B-X
differences	B-X
for	B-X
the	B-X
severity	B-X
of	B-X
bacterial	B-X
sepsis-induced	B-X
ALI	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
pneumonia-associated	B-X
ALI	B-X
.	B-X
The	B-X
role	B-X
of	B-X
pulmonary	B-X
epithelial	B-X
cells	B-X
(	B-X
PECs	B-X
)	B-X
,	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AMs	B-X
)	B-X
,	B-X
innate	B-X
lymphoid	B-X
cells	B-X
(	B-X
ILCs	B-X
)	B-X
,	B-X
and	B-X
different	B-X
pattern-recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
,	B-X
including	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
and	B-X
inflammasome	B-X
proteins	B-X
)	B-X
in	B-X
neutrophil	B-X
infiltration	B-X
and	B-X
ALI	B-X
induction	B-X
have	B-X
been	B-X
described	B-X
during	B-X
pneumonia	B-X
and	B-X
sepsis-induced	B-X
ALI	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
resolution	B-X
of	B-X
inflammation	B-X
is	B-X
frequently	B-X
observed	B-X
during	B-X
ALI	B-X
associated	B-X
with	B-X
pneumonia	B-X
,	B-X
whereas	B-X
sepsis-associated	B-X
ALI	B-X
lacks	B-X
it	B-X
.	B-X
Hence	B-X
,	B-X
the	B-X
review	B-X
mainly	B-X
describes	B-X
the	B-X
different	B-X
immune	B-X
mechanisms	B-X
responsible	B-X
for	B-X
pneumonia	B-X
and	B-X
sepsis-induced	B-X
ALI	B-X
.	B-X
The	B-X
differences	B-X
in	B-X
immune	B-X
response	B-X
depending	B-X
on	B-X
the	B-X
causal	B-X
pathogen	B-X
(	B-X
Gram-positive	B-X
or	B-X
Gram-negative	B-X
bacteria	B-X
)	B-X
associated	B-X
pneumonia	B-X
or	B-X
sepsis-induced	B-X
ALI	B-X
should	B-X
be	B-X
taken	B-X
in	B-X
mind	B-X
specific	B-X
immune-based	B-X
therapeutics	B-X
.	B-X

Nursing	O
actions	O
to	O
support	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
system	O
of	O
the	O
burned	O
patient	O
include	O
providing	O
nutritional	O
support	O
to	O
maintain	O
serum	O
protein	O
levels	O
at	O
optimal	O
levels	O
;	O
measures	O
to	O
decrease	O
edema	O
and	O
promote	O
angiogenesis	O
in	O
areas	O
of	O
partial	O
-	O
thickness	O
injury	O
;	O
meticulous	O
treatment	O
of	O
the	O
wound	O
to	O
prevent	O
infection	O
and	O
promote	O
healing	O
;	O
monitoring	O
of	O
antibiotic	O
use	O
;	O
conservative	O
use	O
of	O
invasive	O
techniques	O
,	O
including	O
intubation	O
and	O
vascular	O
access	O
devices	O
;	O
maintenance	O
of	O
fluid	O
and	O
electrolyte	O
balance	O
and	O
body	O
temperature	O
;	O
and	O
energy	O
conservation	O
measures	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
to	B-X
protect	B-X
cells	B-X
from	B-X
invasion	B-X
by	B-X
microorganisms	B-X
.	B-X
The	B-X
body	B-X
has	B-X
three	B-X
equally	B-X
important	B-X
interactive	B-X
immune	B-X
defense	B-X
systems	B-X
,	B-X
all	B-X
of	B-X
which	B-X
are	B-X
profoundly	B-X
disrupted	B-X
with	B-X
major	B-X
burn	B-X
injury	B-X
.	B-X
The	B-X
immune	B-X
response	B-X
to	B-X
burn	B-X
injury	B-X
is	B-X
immediate	B-X
,	B-X
prolonged	B-X
,	B-X
and	B-X
severe	B-X
.	B-X
The	B-X
end	B-X
result	B-X
in	B-X
individuals	B-X
surviving	B-X
burn	B-X
shock	B-X
is	B-X
immunosuppression	B-X
,	B-X
with	B-X
increased	B-X
susceptibility	B-X
to	B-X
potentially	B-X
fatal	B-X
systemic	B-X
burn	B-X
wound	B-X
or	B-X
pulmonary	B-X
sepsis	B-X
.	B-X
Nursing	B-X
actions	B-X
to	B-X
support	B-X
the	B-X
humoral	B-X
and	B-X
cell-mediated	B-X
immune	B-X
system	B-X
of	B-X
the	B-X
burned	B-X
patient	B-X
include	B-X
providing	B-X
nutritional	B-X
support	B-X
to	B-X
maintain	B-X
serum	B-X
protein	B-X
levels	B-X
at	B-X
optimal	B-X
levels	B-X
;	B-X
measures	B-X
to	B-X
decrease	B-X
edema	B-X
and	B-X
promote	B-X
angiogenesis	B-X
in	B-X
areas	B-X
of	B-X
partial-thickness	B-X
injury	B-X
;	B-X
meticulous	B-X
treatment	B-X
of	B-X
the	B-X
wound	B-X
to	B-X
prevent	B-X
infection	B-X
and	B-X
promote	B-X
healing	B-X
;	B-X
monitoring	B-X
of	B-X
antibiotic	B-X
use	B-X
;	B-X
conservative	B-X
use	B-X
of	B-X
invasive	B-X
techniques	B-X
,	B-X
including	B-X
intubation	B-X
and	B-X
vascular	B-X
access	B-X
devices	B-X
;	B-X
maintenance	B-X
of	B-X
fluid	B-X
and	B-X
electrolyte	B-X
balance	B-X
and	B-X
body	B-X
temperature	B-X
;	B-X
and	B-X
energy	B-X
conservation	B-X
measures	B-X
.	B-X

Autocrine	O
angiogenic	O
vascular	O
prosthesis	O
with	O
bone	O
marrow	O
transplantation	O
.	O
<EOS>	B-X
Synthetic	B-X
vascular	B-X
prostheses	B-X
are	B-X
foreign	B-X
bodies	B-X
,	B-X
so	B-X
that	B-X
blood	B-X
coagulation	B-X
can	B-X
occur	B-X
on	B-X
their	B-X
luminal	B-X
surfaces	B-X
,	B-X
causing	B-X
graft	B-X
occlusion	B-X
very	B-X
frequently	B-X
in	B-X
prostheses	B-X
of	B-X
small	B-X
diameter	B-X
.	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Bone	B-X
marrow	B-X
with	B-X
its	B-X
unique	B-X
native	B-X
properties	B-X
produced	B-X
autocrine	B-X
angiogenicity	B-X
in	B-X
the	B-X
graft	B-X
.	B-X

Synthetic	O
vascular	O
prostheses	O
are	O
foreign	O
bodies	O
,	O
so	O
that	O
blood	O
coagulation	O
can	O
occur	O
on	O
their	O
luminal	O
surfaces	O
,	O
causing	O
graft	O
occlusion	O
very	O
frequently	O
in	O
prostheses	O
of	O
small	O
diameter	O
.	O
<EOS>	B-X
Synthetic	B-X
vascular	B-X
prostheses	B-X
are	B-X
foreign	B-X
bodies	B-X
,	B-X
so	B-X
that	B-X
blood	B-X
coagulation	B-X
can	B-X
occur	B-X
on	B-X
their	B-X
luminal	B-X
surfaces	B-X
,	B-X
causing	B-X
graft	B-X
occlusion	B-X
very	B-X
frequently	B-X
in	B-X
prostheses	B-X
of	B-X
small	B-X
diameter	B-X
.	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
The	B-X
grafts	B-X
were	B-X
implanted	B-X
in	B-X
the	B-X
abdominal	B-X
aortic	B-X
position	B-X
of	B-X
24	B-X
dogs	B-X
autologously	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X
Bone	B-X
marrow	B-X
with	B-X
its	B-X
unique	B-X
native	B-X
properties	B-X
produced	B-X
autocrine	B-X
angiogenicity	B-X
in	B-X
the	B-X
graft	B-X
.	B-X

A	O
vascular	O
prosthesis	O
needs	O
angiogenesis	O
for	O
endothelialization	O
of	O
the	O
luminal	O
surface	O
,	O
as	O
endothelial	O
cells	O
have	O
natural	O
and	O
permanent	O
antithrombogenic	O
properties	O
.	O
<EOS>	B-X
Synthetic	B-X
vascular	B-X
prostheses	B-X
are	B-X
foreign	B-X
bodies	B-X
,	B-X
so	B-X
that	B-X
blood	B-X
coagulation	B-X
can	B-X
occur	B-X
on	B-X
their	B-X
luminal	B-X
surfaces	B-X
,	B-X
causing	B-X
graft	B-X
occlusion	B-X
very	B-X
frequently	B-X
in	B-X
prostheses	B-X
of	B-X
small	B-X
diameter	B-X
.	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
Marrow	B-X
cells	B-X
survived	B-X
and	B-X
continued	B-X
exogenous	B-X
hemopoiesis	B-X
for	B-X
up	B-X
to	B-X
six	B-X
months	B-X
and	B-X
were	B-X
immunohistochemically	B-X
reactive	B-X
to	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X
Bone	B-X
marrow	B-X
with	B-X
its	B-X
unique	B-X
native	B-X
properties	B-X
produced	B-X
autocrine	B-X
angiogenicity	B-X
in	B-X
the	B-X
graft	B-X
.	B-X

To	O
induce	O
capillary	O
growth	O
into	O
the	O
graft	O
,	O
we	O
developed	O
a	O
method	O
of	O
transplanting	O
bone	O
marrow	O
cells	O
,	O
which	O
are	O
primitive	O
,	O
strong	O
enough	O
to	O
survive	O
,	O
and	O
create	O
blood	O
cells	O
,	O
resulting	O
in	O
the	O
inducement	O
of	O
capillary	O
growth	O
.	O
<EOS>	B-X
Synthetic	B-X
vascular	B-X
prostheses	B-X
are	B-X
foreign	B-X
bodies	B-X
,	B-X
so	B-X
that	B-X
blood	B-X
coagulation	B-X
can	B-X
occur	B-X
on	B-X
their	B-X
luminal	B-X
surfaces	B-X
,	B-X
causing	B-X
graft	B-X
occlusion	B-X
very	B-X
frequently	B-X
in	B-X
prostheses	B-X
of	B-X
small	B-X
diameter	B-X
.	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
The	B-X
grafts	B-X
were	B-X
implanted	B-X
in	B-X
the	B-X
abdominal	B-X
aortic	B-X
position	B-X
of	B-X
24	B-X
dogs	B-X
autologously	B-X
.	B-X
Marrow	B-X
cells	B-X
survived	B-X
and	B-X
continued	B-X
exogenous	B-X
hemopoiesis	B-X
for	B-X
up	B-X
to	B-X
six	B-X
months	B-X
and	B-X
were	B-X
immunohistochemically	B-X
reactive	B-X
to	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X
Bone	B-X
marrow	B-X
with	B-X
its	B-X
unique	B-X
native	B-X
properties	B-X
produced	B-X
autocrine	B-X
angiogenicity	B-X
in	B-X
the	B-X
graft	B-X
.	B-X

In	O
an	O
animal	O
experiment	O
,	O
marrow	O
cells	O
were	O
infiltrated	O
into	O
the	O
walls	O
of	O
long	O
-	O
fibril	O
expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
.	O

The	O
grafts	O
were	O
implanted	O
in	O
the	O
abdominal	O
aortic	O
position	O
of	O
24	O
dogs	O
autologously	O
.	O
<EOS>	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
The	B-X
grafts	B-X
were	B-X
implanted	B-X
in	B-X
the	B-X
abdominal	B-X
aortic	B-X
position	B-X
of	B-X
24	B-X
dogs	B-X
autologously	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X

Marrow	O
cells	O
survived	O
and	O
continued	O
exogenous	O
hemopoiesis	O
for	O
up	O
to	O
six	O
months	O
and	O
were	O
immunohistochemically	O
reactive	O
to	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
bFGF	B-Gene_or_gene_product
)	O
.	O
<EOS>	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
Marrow	B-X
cells	B-X
survived	B-X
and	B-X
continued	B-X
exogenous	B-X
hemopoiesis	B-X
for	B-X
up	B-X
to	B-X
six	B-X
months	B-X
and	B-X
were	B-X
immunohistochemically	B-X
reactive	B-X
to	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X

All	O
the	O
grafts	O
older	O
than	O
three	O
weeks	O
had	O
complete	O
endothelialization	O
and	O
maintained	O
their	O
patency	O
.	O
<EOS>	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
The	B-X
grafts	B-X
were	B-X
implanted	B-X
in	B-X
the	B-X
abdominal	B-X
aortic	B-X
position	B-X
of	B-X
24	B-X
dogs	B-X
autologously	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X

Twenty	O
grafts	O
without	O
bone	O
marrow	O
were	O
implanted	O
as	O
controls	O
.	O
<EOS>	B-X
Cell-based	B-X
approaches	B-X
,	B-X
utilizing	B-X
adult	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
,	B-X
are	B-X
reported	B-X
to	B-X
overcome	B-X
the	B-X
limitations	B-X
of	B-X
conventional	B-X
bone	B-X
augmentation	B-X
procedures	B-X
.	B-X
Since	B-X
osteonecrosis	B-X
may	B-X
be	B-X
a	B-X
disease	B-X
of	B-X
mesenchymal	B-X
cells	B-X
or	B-X
bone	B-X
cells	B-X
,	B-X
the	B-X
possibility	B-X
has	B-X
been	B-X
raised	B-X
that	B-X
bone	B-X
marrow	B-X
containing	B-X
osteogenic	B-X
precursors	B-X
implanted	B-X
into	B-X
a	B-X
necrotic	B-X
lesion	B-X
of	B-X
the	B-X
femoral	B-X
head	B-X
may	B-X
be	B-X
of	B-X
benefit	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
this	B-X
condition	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
implantation	B-X
of	B-X
autologous	B-X
bone-marrow	B-X
mononuclear	B-X
cells	B-X
in	B-X
a	B-X
necrotic	B-X
lesion	B-X
of	B-X
the	B-X
femoral	B-X
head	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
on	B-X
the	B-X
clinical	B-X
symptoms	B-X
and	B-X
the	B-X
stage	B-X
and	B-X
volume	B-X
of	B-X
osteonecrosis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
bone	B-X
healing	B-X
observed	B-X
after	B-X
the	B-X
use	B-X
of	B-X
(	B-X
1	B-X
)	B-X
a	B-X
scaffold	B-X
enriched	B-X
with	B-X
fresh	B-X
bone	B-X
marrow	B-X
,	B-X
(	B-X
2	B-X
)	B-X
a	B-X
scaffold	B-X
enriched	B-X
with	B-X
bone	B-X
marrow	B-X
mononuclear	B-X
fraction	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
a	B-X
scaffold	B-X
alone	B-X
.	B-X

Endothelialization	O
was	O
present	O
at	O
anastomotic	O
sites	O
,	O
but	O
other	O
areas	O
were	O
covered	O
with	O
fresh	O
thrombi	O
.	O
<EOS>	B-X
Endothelialization	B-X
was	B-X
present	B-X
at	B-X
anastomotic	B-X
sites	B-X
,	B-X
but	B-X
other	B-X
areas	B-X
were	B-X
covered	B-X
with	B-X
fresh	B-X
thrombi	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X

Four	O
out	O
of	O
seven	O
control	O
grafts	O
were	O
patent	O
with	O
endothelial	O
cell	O
lining	O
at	O
six	O
months	O
,	O
but	O
three	O
were	O
occluded	O
and	O
one	O
of	O
the	O
four	O
grafts	O
was	O
still	O
covered	O
with	O
a	O
thrombus	O
layer	O
.	O
<EOS>	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
The	B-X
grafts	B-X
were	B-X
implanted	B-X
in	B-X
the	B-X
abdominal	B-X
aortic	B-X
position	B-X
of	B-X
24	B-X
dogs	B-X
autologously	B-X
.	B-X
Marrow	B-X
cells	B-X
survived	B-X
and	B-X
continued	B-X
exogenous	B-X
hemopoiesis	B-X
for	B-X
up	B-X
to	B-X
six	B-X
months	B-X
and	B-X
were	B-X
immunohistochemically	B-X
reactive	B-X
to	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Endothelialization	B-X
was	B-X
present	B-X
at	B-X
anastomotic	B-X
sites	B-X
,	B-X
but	B-X
other	B-X
areas	B-X
were	B-X
covered	B-X
with	B-X
fresh	B-X
thrombi	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X
Bone	B-X
marrow	B-X
with	B-X
its	B-X
unique	B-X
native	B-X
properties	B-X
produced	B-X
autocrine	B-X
angiogenicity	B-X
in	B-X
the	B-X
graft	B-X
.	B-X

Bone	O
marrow	O
with	O
its	O
unique	O
native	O
properties	O
produced	O
autocrine	O
angiogenicity	O
in	O
the	O
graft	O
.	O
<EOS>	B-X
Synthetic	B-X
vascular	B-X
prostheses	B-X
are	B-X
foreign	B-X
bodies	B-X
,	B-X
so	B-X
that	B-X
blood	B-X
coagulation	B-X
can	B-X
occur	B-X
on	B-X
their	B-X
luminal	B-X
surfaces	B-X
,	B-X
causing	B-X
graft	B-X
occlusion	B-X
very	B-X
frequently	B-X
in	B-X
prostheses	B-X
of	B-X
small	B-X
diameter	B-X
.	B-X
A	B-X
vascular	B-X
prosthesis	B-X
needs	B-X
angiogenesis	B-X
for	B-X
endothelialization	B-X
of	B-X
the	B-X
luminal	B-X
surface	B-X
,	B-X
as	B-X
endothelial	B-X
cells	B-X
have	B-X
natural	B-X
and	B-X
permanent	B-X
antithrombogenic	B-X
properties	B-X
.	B-X
To	B-X
induce	B-X
capillary	B-X
growth	B-X
into	B-X
the	B-X
graft	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
method	B-X
of	B-X
transplanting	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
primitive	B-X
,	B-X
strong	B-X
enough	B-X
to	B-X
survive	B-X
,	B-X
and	B-X
create	B-X
blood	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
inducement	B-X
of	B-X
capillary	B-X
growth	B-X
.	B-X
In	B-X
an	B-X
animal	B-X
experiment	B-X
,	B-X
marrow	B-X
cells	B-X
were	B-X
infiltrated	B-X
into	B-X
the	B-X
walls	B-X
of	B-X
long-fibril	B-X
expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
ePTFE	B-X
)	B-X
vascular	B-X
grafts	B-X
.	B-X
The	B-X
grafts	B-X
were	B-X
implanted	B-X
in	B-X
the	B-X
abdominal	B-X
aortic	B-X
position	B-X
of	B-X
24	B-X
dogs	B-X
autologously	B-X
.	B-X
All	B-X
the	B-X
grafts	B-X
older	B-X
than	B-X
three	B-X
weeks	B-X
had	B-X
complete	B-X
endothelialization	B-X
and	B-X
maintained	B-X
their	B-X
patency	B-X
.	B-X
Twenty	B-X
grafts	B-X
without	B-X
bone	B-X
marrow	B-X
were	B-X
implanted	B-X
as	B-X
controls	B-X
.	B-X
Four	B-X
out	B-X
of	B-X
seven	B-X
control	B-X
grafts	B-X
were	B-X
patent	B-X
with	B-X
endothelial	B-X
cell	B-X
lining	B-X
at	B-X
six	B-X
months	B-X
,	B-X
but	B-X
three	B-X
were	B-X
occluded	B-X
and	B-X
one	B-X
of	B-X
the	B-X
four	B-X
grafts	B-X
was	B-X
still	B-X
covered	B-X
with	B-X
a	B-X
thrombus	B-X
layer	B-X
.	B-X
Bone	B-X
marrow	B-X
with	B-X
its	B-X
unique	B-X
native	B-X
properties	B-X
produced	B-X
autocrine	B-X
angiogenicity	B-X
in	B-X
the	B-X
graft	B-X
.	B-X

Application	O
of	O
clonal	O
analysis	O
.	O
<EOS>	B-X
The	B-X
third	B-X
generation	B-X
of	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
droplet	B-X
digital	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
ddPCR	B-X
)	B-X
,	B-X
is	B-X
a	B-X
biotechnological	B-X
refinement	B-X
of	B-X
conventional	B-X
polymerase	B-X
chain	B-X
reaction	B-X
methods	B-X
that	B-X
can	B-X
be	B-X
used	B-X
to	B-X
directly	B-X
quantify	B-X
and	B-X
clonally	B-X
amplify	B-X
DNA	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
our	B-X
ability	B-X
to	B-X
detect	B-X
natural	B-X
or	B-X
synthetic	B-X
cellular	B-X
barcodes	B-X
,	B-X
paired	B-X
with	B-X
single-cell	B-X
readouts	B-X
of	B-X
cell	B-X
state	B-X
,	B-X
have	B-X
markedly	B-X
increased	B-X
our	B-X
knowledge	B-X
of	B-X
clonal	B-X
dynamics	B-X
and	B-X
genealogies	B-X
of	B-X
the	B-X
cells	B-X
that	B-X
compose	B-X
a	B-X
variety	B-X
of	B-X
tissues	B-X
and	B-X
organs	B-X
.	B-X
We	B-X
discuss	B-X
unanticipated	B-X
insights	B-X
gained	B-X
through	B-X
barcoding	B-X
in	B-X
studies	B-X
of	B-X
cancer	B-X
and	B-X
blood	B-X
cell	B-X
production	B-X
and	B-X
describe	B-X
how	B-X
barcoding	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
a	B-X
growing	B-X
array	B-X
of	B-X
medical	B-X
fields	B-X
,	B-X
particularly	B-X
with	B-X
the	B-X
increasing	B-X
recognition	B-X
of	B-X
clonal	B-X
contributions	B-X
in	B-X
human	B-X
diseases	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
broadly	B-X
review	B-X
the	B-X
application	B-X
of	B-X
cfDNA	B-X
analysis	B-X
to	B-X
the	B-X
diagnosis	B-X
and	B-X
management	B-X
of	B-X
lymphoma	B-X
.	B-X
These	B-X
include	B-X
cell-free	B-X
DNA	B-X
fragment	B-X
structure	B-X
analysis	B-X
or	B-X
'fragmentomics	B-X
'	B-X
,	B-X
epigenetic	B-X
modifications	B-X
,	B-X
and	B-X
novel	B-X
circulating	B-X
analytes	B-X
such	B-X
as	B-X
tumor-educated	B-X
platelets	B-X
and	B-X
extracellular	B-X
vesicular	B-X
DNA	B-X
.	B-X

Differential	O
diagnosis	O
for	O
synchronous	O
primary	O
ovarian	O
and	O
endometrial	O
cancers	O
and	O
metastatic	O
cancer	O
.	O
<EOS>	B-X
In	B-X
the	B-X
event	B-X
of	B-X
multiple	B-X
synchronous	B-X
gynecological	B-X
lesions	B-X
,	B-X
a	B-X
fundamental	B-X
piece	B-X
of	B-X
information	B-X
to	B-X
determine	B-X
patient	B-X
management	B-X
,	B-X
prognosis	B-X
,	B-X
and	B-X
therapeutic	B-X
regimen	B-X
choice	B-X
is	B-X
whether	B-X
the	B-X
simultaneous	B-X
malignancies	B-X
arise	B-X
independently	B-X
or	B-X
as	B-X
a	B-X
result	B-X
of	B-X
metastatic	B-X
dissemination	B-X
.	B-X
An	B-X
example	B-X
of	B-X
synchronous	B-X
primary	B-X
tumors	B-X
of	B-X
the	B-X
female	B-X
genital	B-X
tract	B-X
most	B-X
frequently	B-X
described	B-X
are	B-X
ovarian	B-X
and	B-X
endometrial	B-X
cancers	B-X
.	B-X
We	B-X
showed	B-X
mtDNA	B-X
sequencing	B-X
to	B-X
be	B-X
informative	B-X
in	B-X
synchronous	B-X
primary	B-X
ovarian	B-X
and	B-X
endometrial	B-X
cancer	B-X
,	B-X
detecting	B-X
tumor-specific	B-X
mutations	B-X
in	B-X
both	B-X
lesions	B-X
,	B-X
ruling	B-X
out	B-X
independence	B-X
of	B-X
the	B-X
two	B-X
neoplasms	B-X
,	B-X
and	B-X
indicating	B-X
clonality	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
tested	B-X
this	B-X
method	B-X
in	B-X
another	B-X
frequent	B-X
simultaneously	B-X
detected	B-X
gynecological	B-X
lesion	B-X
type	B-X
,	B-X
borderline	B-X
ovarian	B-X
cancer	B-X
and	B-X
their	B-X
peritoneal	B-X
implants	B-X
,	B-X
which	B-X
may	B-X
be	B-X
monoclonal	B-X
extra-ovarian	B-X
metastases	B-X
or	B-X
polyclonal	B-X
independent	B-X
masses	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
provide	B-X
an	B-X
update	B-X
on	B-X
the	B-X
potential	B-X
use	B-X
of	B-X
mtDNA	B-X
sequencing	B-X
in	B-X
distinguishing	B-X
independent	B-X
and	B-X
metastatic	B-X
lesions	B-X
in	B-X
gynecological	B-X
cancers	B-X
,	B-X
and	B-X
to	B-X
compare	B-X
the	B-X
efficiency	B-X
of	B-X
molecular	B-X
analyses	B-X
currently	B-X
in	B-X
use	B-X
with	B-X
this	B-X
novel	B-X
method	B-X
.	B-X

Simultaneous	O
involvement	O
of	O
the	O
endometrium	O
and	O
the	O
ovary	O
by	O
carcinoma	O
is	O
a	O
familiar	O
problem	O
in	O
the	O
routine	O
practice	O
of	O
surgical	O
pathology	O
.	O
<EOS>	B-X
Simultaneous	B-X
involvement	B-X
of	B-X
the	B-X
endometrium	B-X
and	B-X
the	B-X
ovary	B-X
by	B-X
carcinoma	B-X
is	B-X
a	B-X
familiar	B-X
problem	B-X
in	B-X
the	B-X
routine	B-X
practice	B-X
of	B-X
surgical	B-X
pathology	B-X
.	B-X
Such	B-X
cases	B-X
may	B-X
be	B-X
considered	B-X
either	B-X
examples	B-X
of	B-X
a	B-X
single	B-X
primary	B-X
carcinoma	B-X
with	B-X
metastasis	B-X
or	B-X
as	B-X
synchronous	B-X
primary	B-X
neoplasms	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
authors	B-X
used	B-X
molecular	B-X
techniques	B-X
to	B-X
analyze	B-X
the	B-X
clonal	B-X
composition	B-X
of	B-X
five	B-X
cases	B-X
of	B-X
concurrent	B-X
adenocarcinomas	B-X
of	B-X
the	B-X
endometrium	B-X
and	B-X
ovary	B-X
that	B-X
were	B-X
clinicopathologically	B-X
diagnosed	B-X
as	B-X
synchronous	B-X
primary	B-X
tumors	B-X
.	B-X
The	B-X
application	B-X
of	B-X
molecular	B-X
technology	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
for	B-X
the	B-X
differential	B-X
diagnosis	B-X
between	B-X
synchronous	B-X
primary	B-X
carcinomas	B-X
and	B-X
a	B-X
single	B-X
carcinoma	B-X
with	B-X
metastasis	B-X
.	B-X

Such	O
cases	O
may	O
be	O
considered	O
either	O
examples	O
of	O
a	O
single	O
primary	O
carcinoma	O
with	O
metastasis	O
or	O
as	O
synchronous	O
primary	O
neoplasms	O
.	O
<EOS>	B-X
The	B-X
risk	B-X
of	B-X
multiple	B-X
primary	B-X
cancers	B-X
is	B-X
also	B-X
increasing	B-X
due	B-X
to	B-X
increasing	B-X
numbers	B-X
of	B-X
cancer	B-X
survivors	B-X
,	B-X
long-term	B-X
side	B-X
effects	B-X
of	B-X
chemotherapy	B-X
and/or	B-X
radiation	B-X
therapy	B-X
,	B-X
increased	B-X
diagnostic	B-X
sensitivity	B-X
,	B-X
and	B-X
persisting	B-X
effects	B-X
of	B-X
genetic	B-X
and	B-X
behavioral	B-X
risk	B-X
factors	B-X
.	B-X
Multiple	B-X
primary	B-X
cancers	B-X
are	B-X
defined	B-X
as	B-X
more	B-X
than	B-X
one	B-X
synchronous	B-X
or	B-X
metachronous	B-X
cancer	B-X
in	B-X
the	B-X
same	B-X
individual	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
definition	B-X
,	B-X
overall	B-X
reported	B-X
frequency	B-X
of	B-X
multiple	B-X
primary	B-X
cancers	B-X
varies	B-X
between	B-X
2.4	B-X
%	B-X
and	B-X
17	B-X
%	B-X
.	B-X
Underlying	B-X
causes	B-X
for	B-X
multiple	B-X
primary	B-X
cancers	B-X
may	B-X
include	B-X
host	B-X
and	B-X
lifestyle-related	B-X
factors	B-X
,	B-X
environmental	B-X
and	B-X
genetic	B-X
factors	B-X
and	B-X
treatment	B-X
related	B-X
factors	B-X
.	B-X
Significant	B-X
temporal	B-X
changes	B-X
have	B-X
been	B-X
found	B-X
in	B-X
the	B-X
prevalence	B-X
of	B-X
cancer	B-X
risk	B-X
factors	B-X
(	B-X
ie	B-X
,	B-X
smoking	B-X
,	B-X
alcohol	B-X
consumption	B-X
,	B-X
obesity	B-X
)	B-X
as	B-X
well	B-X
as	B-X
advances	B-X
in	B-X
diagnostic	B-X
sensitivity	B-X
and	B-X
improved	B-X
screening	B-X
programs	B-X
that	B-X
may	B-X
affect	B-X
the	B-X
incidence	B-X
of	B-X
second	B-X
or	B-X
more	B-X
cancers	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
literature	B-X
on	B-X
multiple	B-X
primary	B-X
cancers	B-X
is	B-X
analyzed	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
clinical	B-X
situations	B-X
where	B-X
a	B-X
treating	B-X
physician	B-X
should	B-X
take	B-X
into	B-X
consideration	B-X
the	B-X
possibility	B-X
of	B-X
multiple	B-X
primaries	B-X
.	B-X

The	O
distinction	O
between	O
these	O
two	O
possibilities	O
is	O
made	O
based	O
on	O
clinicopathologic	O
observations	O
,	O
and	O
therefore	O
may	O
not	O
be	O
definitive	O
.	O
<EOS>	B-X
The	B-X
authors	B-X
studied	B-X
11	B-X
pediatric	B-X
intrathoracic	B-X
neoplasms	B-X
that	B-X
share	B-X
clinicopathologic	B-X
features	B-X
and	B-X
constitute	B-X
a	B-X
specific	B-X
tumor	B-X
in	B-X
children	B-X
.	B-X
These	B-X
neoplasms	B-X
were	B-X
intrapulmonary	B-X
,	B-X
mediastinal	B-X
,	B-X
or	B-X
pleural-based	B-X
masses	B-X
.	B-X
The	B-X
clinicopathologic	B-X
features	B-X
,	B-X
immunophenotypic	B-X
and	B-X
ultrastructural	B-X
characteristics	B-X
,	B-X
possible	B-X
histogenesis	B-X
,	B-X
and	B-X
differential	B-X
diagnosis	B-X
of	B-X
these	B-X
neoplasms	B-X
from	B-X
other	B-X
thoracopulmonary	B-X
tumors	B-X
in	B-X
children	B-X
serve	B-X
as	B-X
the	B-X
basis	B-X
for	B-X
this	B-X
report	B-X
.	B-X
Distinction	B-X
between	B-X
the	B-X
two	B-X
is	B-X
based	B-X
on	B-X
an	B-X
arbitrary	B-X
cutoff	B-X
of	B-X
25	B-X
%	B-X
bone	B-X
marrow	B-X
involvement	B-X
.	B-X
Findings	B-X
demonstrated	B-X
that	B-X
pediatric	B-X
B-ALL	B-X
and	B-X
B-LBL	B-X
exhibit	B-X
dissimilar	B-X
genomic	B-X
profiles	B-X
,	B-X
suggesting	B-X
possible	B-X
differences	B-X
in	B-X
pathogenesis	B-X
between	B-X
the	B-X
two	B-X
closely-related	B-X
neoplasms	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
used	O
molecular	O
techniques	O
to	O
analyze	O
the	O
clonal	O
composition	O
of	O
five	O
cases	O
of	O
concurrent	O
adenocarcinomas	O
of	O
the	O
endometrium	O
and	O
ovary	O
that	O
were	O
clinicopathologically	O
diagnosed	O
as	O
synchronous	O
primary	O
tumors	O
.	O

Patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
,	O
mutations	O
in	O
the	O
K	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ras	I-Gene_or_gene_product
gene	O
,	O
mutations	O
or	O
allelic	O
loss	O
of	O
the	O
p53	B-Gene_or_gene_product
gene	O
,	O
or	O
human	O
papillomavirus	O
detection	O
were	O
identical	O
in	O
both	O
endometrial	O
and	O
ovarian	O
lesions	O
in	O
three	O
of	O
the	O
cases	O
suggesting	O
that	O
those	O
three	O
cases	O
represented	O
single	O
primary	O
tumors	O
with	O
metastases	O
.	O
<EOS>	B-X
The	B-X
biomarkers	B-X
of	B-X
early	B-X
biological	B-X
effects	B-X
of	B-X
ingested	B-X
inorganic	B-X
arsenic	B-X
included	B-X
blood	B-X
levels	B-X
of	B-X
reactive	B-X
oxidants	B-X
and	B-X
anti-oxidant	B-X
capacity	B-X
,	B-X
genetic	B-X
expression	B-X
of	B-X
inflammatory	B-X
molecules	B-X
,	B-X
as	B-X
well	B-X
as	B-X
cytogenetic	B-X
changes	B-X
including	B-X
sister	B-X
chromatid	B-X
exchange	B-X
,	B-X
micronuclei	B-X
,	B-X
and	B-X
chromosome	B-X
aberrations	B-X
of	B-X
peripheral	B-X
lymphocytes	B-X
.	B-X
Both	B-X
mutation	B-X
type	B-X
and	B-X
hot	B-X
spots	B-X
of	B-X
p53	B-X
gene	B-X
were	B-X
significantly	B-X
different	B-X
in	B-X
arsenic-induced	B-X
and	B-X
non-arsenic-induced	B-X
TCCs	B-X
.	B-X
The	B-X
frequency	B-X
of	B-X
chromosomal	B-X
imbalances	B-X
analyzed	B-X
by	B-X
comparative	B-X
genomic	B-X
hybridization	B-X
and	B-X
the	B-X
frequency	B-X
of	B-X
loss	B-X
of	B-X
heterozygosity	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
arsenic-induced	B-X
TCC	B-X
than	B-X
non-arsenic-induced	B-X
TCC	B-X
at	B-X
specific	B-X
sites	B-X
.	B-X
Biomarkers	B-X
of	B-X
susceptibility	B-X
to	B-X
arsenic-induced	B-X
health	B-X
hazards	B-X
included	B-X
genetic	B-X
polymorphisms	B-X
of	B-X
enzymes	B-X
involved	B-X
in	B-X
xenobiotic	B-X
metabolism	B-X
,	B-X
DNA	B-X
repair	B-X
,	B-X
and	B-X
oxidative	B-X
stress	B-X
,	B-X
as	B-X
well	B-X
as	B-X
serum	B-X
level	B-X
of	B-X
carotenoids	B-X
.	B-X
Gene-gene	B-X
and	B-X
gene-environment	B-X
interactions	B-X
are	B-X
involved	B-X
in	B-X
arsenic-induced	B-X
health	B-X
hazards	B-X
through	B-X
toxicological	B-X
mechanisms	B-X
including	B-X
genomic	B-X
instability	B-X
and	B-X
oxidative	B-X
stress	B-X
.	B-X

In	O
both	O
of	O
the	O
other	O
two	O
cases	O
,	O
the	O
patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
clearly	O
demonstrated	O
the	O
presence	O
of	O
independent	O
primary	O
tumors	O
.	O
<EOS>	B-X
Such	B-X
cases	B-X
may	B-X
be	B-X
considered	B-X
either	B-X
examples	B-X
of	B-X
a	B-X
single	B-X
primary	B-X
carcinoma	B-X
with	B-X
metastasis	B-X
or	B-X
as	B-X
synchronous	B-X
primary	B-X
neoplasms	B-X
.	B-X
The	B-X
distinction	B-X
between	B-X
these	B-X
two	B-X
possibilities	B-X
is	B-X
made	B-X
based	B-X
on	B-X
clinicopathologic	B-X
observations	B-X
,	B-X
and	B-X
therefore	B-X
may	B-X
not	B-X
be	B-X
definitive	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
authors	B-X
used	B-X
molecular	B-X
techniques	B-X
to	B-X
analyze	B-X
the	B-X
clonal	B-X
composition	B-X
of	B-X
five	B-X
cases	B-X
of	B-X
concurrent	B-X
adenocarcinomas	B-X
of	B-X
the	B-X
endometrium	B-X
and	B-X
ovary	B-X
that	B-X
were	B-X
clinicopathologically	B-X
diagnosed	B-X
as	B-X
synchronous	B-X
primary	B-X
tumors	B-X
.	B-X
Patterns	B-X
of	B-X
X-chromosome	B-X
inactivation	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
K-ras	B-X
gene	B-X
,	B-X
mutations	B-X
or	B-X
allelic	B-X
loss	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
,	B-X
or	B-X
human	B-X
papillomavirus	B-X
detection	B-X
were	B-X
identical	B-X
in	B-X
both	B-X
endometrial	B-X
and	B-X
ovarian	B-X
lesions	B-X
in	B-X
three	B-X
of	B-X
the	B-X
cases	B-X
suggesting	B-X
that	B-X
those	B-X
three	B-X
cases	B-X
represented	B-X
single	B-X
primary	B-X
tumors	B-X
with	B-X
metastases	B-X
.	B-X
In	B-X
both	B-X
of	B-X
the	B-X
other	B-X
two	B-X
cases	B-X
,	B-X
the	B-X
patterns	B-X
of	B-X
X-chromosome	B-X
inactivation	B-X
clearly	B-X
demonstrated	B-X
the	B-X
presence	B-X
of	B-X
independent	B-X
primary	B-X
tumors	B-X
.	B-X
The	B-X
application	B-X
of	B-X
molecular	B-X
technology	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
for	B-X
the	B-X
differential	B-X
diagnosis	B-X
between	B-X
synchronous	B-X
primary	B-X
carcinomas	B-X
and	B-X
a	B-X
single	B-X
carcinoma	B-X
with	B-X
metastasis	B-X
.	B-X

The	O
application	O
of	O
molecular	O
technology	O
may	O
play	O
an	O
important	O
role	O
for	O
the	O
differential	O
diagnosis	O
between	O
synchronous	O
primary	O
carcinomas	O
and	O
a	O
single	O
carcinoma	O
with	O
metastasis	O
.	O

Molecular	O
biology	O
of	O
cervical	O
cancer	O
and	O
its	O
precursors	O
.	O
<EOS>	B-X
For	B-X
cancer	B-X
screening	B-X
to	B-X
be	B-X
successful	B-X
,	B-X
it	B-X
should	B-X
primarily	B-X
detect	B-X
cancers	B-X
with	B-X
lethal	B-X
potential	B-X
or	B-X
their	B-X
precursors	B-X
early	B-X
,	B-X
leading	B-X
to	B-X
therapy	B-X
that	B-X
reduces	B-X
mortality	B-X
and	B-X
morbidity	B-X
.	B-X
Screening	B-X
programmes	B-X
have	B-X
been	B-X
successful	B-X
for	B-X
colon	B-X
and	B-X
cervical	B-X
cancers	B-X
,	B-X
where	B-X
subsequent	B-X
surgical	B-X
removal	B-X
of	B-X
precursor	B-X
lesions	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
reduction	B-X
in	B-X
cancer	B-X
incidence	B-X
and	B-X
mortality	B-X
.	B-X
However	B-X
,	B-X
many	B-X
types	B-X
of	B-X
cancer	B-X
exhibit	B-X
a	B-X
range	B-X
of	B-X
heterogeneous	B-X
behaviours	B-X
and	B-X
variable	B-X
likelihoods	B-X
of	B-X
progression	B-X
and	B-X
death	B-X
.	B-X
Consequently	B-X
,	B-X
screening	B-X
for	B-X
some	B-X
cancers	B-X
may	B-X
have	B-X
minimal	B-X
impact	B-X
on	B-X
mortality	B-X
and	B-X
may	B-X
do	B-X
more	B-X
harm	B-X
than	B-X
good	B-X
.	B-X
Since	B-X
the	B-X
implementation	B-X
of	B-X
screening	B-X
tests	B-X
for	B-X
certain	B-X
cancers	B-X
(	B-X
for	B-X
example	B-X
,	B-X
breast	B-X
and	B-X
prostate	B-X
cancers	B-X
)	B-X
,	B-X
a	B-X
spike	B-X
in	B-X
incidence	B-X
of	B-X
in	B-X
situ	B-X
and	B-X
early-stage	B-X
cancers	B-X
has	B-X
been	B-X
observed	B-X
,	B-X
but	B-X
a	B-X
link	B-X
to	B-X
reduction	B-X
in	B-X
cancer-specific	B-X
mortality	B-X
has	B-X
not	B-X
been	B-X
as	B-X
clear	B-X
.	B-X
In	B-X
cancers	B-X
with	B-X
lower	B-X
incidence	B-X
but	B-X
high	B-X
mortality	B-X
(	B-X
for	B-X
example	B-X
,	B-X
pancreatic	B-X
cancer	B-X
)	B-X
,	B-X
screening	B-X
has	B-X
focused	B-X
on	B-X
high-risk	B-X
populations	B-X
,	B-X
but	B-X
challenges	B-X
similar	B-X
to	B-X
those	B-X
for	B-X
general	B-X
population	B-X
screening	B-X
remain	B-X
,	B-X
particularly	B-X
with	B-X
regard	B-X
to	B-X
finding	B-X
lesions	B-X
with	B-X
difficult-to-characterize	B-X
malignant	B-X
potential	B-X
(	B-X
for	B-X
example	B-X
,	B-X
intraductal	B-X
papillary	B-X
mucinous	B-X
neoplasms	B-X
)	B-X
.	B-X
More	B-X
sensitive	B-X
screening	B-X
methods	B-X
are	B-X
detecting	B-X
smaller	B-X
and	B-X
smaller	B-X
lesions	B-X
,	B-X
but	B-X
this	B-X
has	B-X
not	B-X
been	B-X
accompanied	B-X
by	B-X
a	B-X
comparable	B-X
reduction	B-X
in	B-X
the	B-X
incidence	B-X
of	B-X
invasive	B-X
cancers	B-X
.	B-X
In	B-X
this	B-X
Opinion	B-X
article	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
contribution	B-X
of	B-X
screening	B-X
in	B-X
general	B-X
and	B-X
high-risk	B-X
populations	B-X
to	B-X
overdiagnosis	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
overdiagnosis	B-X
on	B-X
patients	B-X
and	B-X
emerging	B-X
strategies	B-X
to	B-X
reduce	B-X
overdiagnosis	B-X
of	B-X
indolent	B-X
cancers	B-X
through	B-X
an	B-X
understanding	B-X
of	B-X
tumour	B-X
heterogeneity	B-X
,	B-X
the	B-X
biology	B-X
of	B-X
how	B-X
cancers	B-X
evolve	B-X
and	B-X
progress	B-X
,	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
features	B-X
of	B-X
early	B-X
neoplasia	B-X
and	B-X
the	B-X
dynamics	B-X
of	B-X
the	B-X
interactions	B-X
of	B-X
early	B-X
lesions	B-X
with	B-X
their	B-X
surrounding	B-X
tissue	B-X
microenvironment	B-X
.	B-X

Cervical	O
cancer	O
develops	O
from	O
well	O
-	O
defined	O
precursor	O
lesions	O
referred	O
to	O
as	O
either	O
cervical	O
intraepithelial	O
neoplasia	O
or	O
squamous	O
intraepithelial	O
lesions	O
.	O
<EOS>	B-X
The	B-X
incidence	B-X
of	B-X
anal	B-X
cancer	B-X
is	B-X
substantially	B-X
higher	B-X
among	B-X
persons	B-X
living	B-X
with	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
than	B-X
in	B-X
the	B-X
general	B-X
population	B-X
.	B-X
Similar	B-X
to	B-X
cervical	B-X
cancer	B-X
,	B-X
anal	B-X
cancer	B-X
is	B-X
preceded	B-X
by	B-X
high-grade	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
(	B-X
HSILs	B-X
)	B-X
.	B-X
Treatment	B-X
for	B-X
cervical	B-X
HSIL	B-X
reduces	B-X
progression	B-X
to	B-X
cervical	B-X
cancer	B-X
;	B-X
however	B-X
,	B-X
data	B-X
from	B-X
prospective	B-X
studies	B-X
of	B-X
treatment	B-X
for	B-X
anal	B-X
HSIL	B-X
to	B-X
prevent	B-X
anal	B-X
cancer	B-X
are	B-X
lacking	B-X
.	B-X
The	B-X
risk	B-X
of	B-X
vulvar	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
VSCC	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
high-grade	B-X
vulvar	B-X
intraepithelial	B-X
neoplasia	B-X
(	B-X
VIN	B-X
)	B-X
is	B-X
considered	B-X
lower	B-X
in	B-X
high-grade	B-X
squamous	B-X
intraepithelial	B-X
lesion	B-X
(	B-X
HSIL	B-X
)	B-X
compared	B-X
to	B-X
differentiated	B-X
VIN	B-X
(	B-X
dVIN	B-X
)	B-X
,	B-X
but	B-X
studies	B-X
are	B-X
limited	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
high	B-X
cancer	B-X
risk	B-X
in	B-X
patients	B-X
with	B-X
dVIN	B-X
,	B-X
better	B-X
identification	B-X
and	B-X
timely	B-X
recognition	B-X
are	B-X
urgently	B-X
needed	B-X
.	B-X

It	O
is	O
now	O
known	O
that	O
specific	O
types	O
of	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
are	O
the	O
principal	O
etiologic	O
agents	O
for	O
both	O
cervical	O
cancer	O
and	O
its	O
precursors	O
.	O
<EOS>	B-X
Cervical	B-X
cancer	B-X
develops	B-X
from	B-X
well-defined	B-X
precursor	B-X
lesions	B-X
referred	B-X
to	B-X
as	B-X
either	B-X
cervical	B-X
intraepithelial	B-X
neoplasia	B-X
or	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
.	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
virally	B-X
derived	B-X
and	B-X
endogenous	B-X
cellular	B-X
proteins	B-X
converges	B-X
in	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
One	B-X
additional	B-X
event	B-X
that	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
is	B-X
integration	B-X
of	B-X
HPV	B-X
DNA	B-X
into	B-X
the	B-X
host	B-X
genome	B-X
.	B-X
Integration	B-X
of	B-X
HPV	B-X
DNA	B-X
frequently	B-X
disrupts	B-X
the	B-X
E2	B-X
open	B-X
reading	B-X
frames	B-X
,	B-X
resulting	B-X
in	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
possibly	B-X
causing	B-X
genomic	B-X
instability	B-X
.	B-X
Additional	B-X
cofactors	B-X
and	B-X
mutational	B-X
events	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
invasive	B-X
cervical	B-X
cancers	B-X
and	B-X
may	B-X
include	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
,	B-X
and	B-X
proto-oncogene	B-X
activation	B-X
.	B-X

The	O
high	O
-	O
oncogenic	O
-	O
risk	O
HPV	O
types	O
associated	O
with	O
invasive	O
cervical	O
cancer	O
produce	O
two	O
oncoproteins	O
,	O
designated	O
E6	B-Gene_or_gene_product
and	O
E7	B-Gene_or_gene_product
,	O
which	O
interact	O
with	O
endogenous	O
cell	O
cycle	O
regulatory	O
proteins	O
,	O
including	O
p53	B-Gene_or_gene_product
and	O
Rb	B-Gene_or_gene_product
.	O
<EOS>	B-X
Cervical	B-X
cancer	B-X
develops	B-X
from	B-X
well-defined	B-X
precursor	B-X
lesions	B-X
referred	B-X
to	B-X
as	B-X
either	B-X
cervical	B-X
intraepithelial	B-X
neoplasia	B-X
or	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
.	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
virally	B-X
derived	B-X
and	B-X
endogenous	B-X
cellular	B-X
proteins	B-X
converges	B-X
in	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
One	B-X
additional	B-X
event	B-X
that	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
is	B-X
integration	B-X
of	B-X
HPV	B-X
DNA	B-X
into	B-X
the	B-X
host	B-X
genome	B-X
.	B-X
Integration	B-X
of	B-X
HPV	B-X
DNA	B-X
frequently	B-X
disrupts	B-X
the	B-X
E2	B-X
open	B-X
reading	B-X
frames	B-X
,	B-X
resulting	B-X
in	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
possibly	B-X
causing	B-X
genomic	B-X
instability	B-X
.	B-X
Additional	B-X
cofactors	B-X
and	B-X
mutational	B-X
events	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
invasive	B-X
cervical	B-X
cancers	B-X
and	B-X
may	B-X
include	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
,	B-X
and	B-X
proto-oncogene	B-X
activation	B-X
.	B-X

The	O
interaction	O
of	O
virally	O
derived	O
and	O
endogenous	O
cellular	O
proteins	O
converges	O
in	O
deregulation	O
of	O
cell	O
cycle	O
progression	O
and	O
appears	O
to	O
be	O
critical	O
for	O
the	O
development	O
of	O
cervical	O
cancers	O
.	O
<EOS>	B-X
Cervical	B-X
cancer	B-X
develops	B-X
from	B-X
well-defined	B-X
precursor	B-X
lesions	B-X
referred	B-X
to	B-X
as	B-X
either	B-X
cervical	B-X
intraepithelial	B-X
neoplasia	B-X
or	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
.	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
virally	B-X
derived	B-X
and	B-X
endogenous	B-X
cellular	B-X
proteins	B-X
converges	B-X
in	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
One	B-X
additional	B-X
event	B-X
that	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
is	B-X
integration	B-X
of	B-X
HPV	B-X
DNA	B-X
into	B-X
the	B-X
host	B-X
genome	B-X
.	B-X
Integration	B-X
of	B-X
HPV	B-X
DNA	B-X
frequently	B-X
disrupts	B-X
the	B-X
E2	B-X
open	B-X
reading	B-X
frames	B-X
,	B-X
resulting	B-X
in	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
possibly	B-X
causing	B-X
genomic	B-X
instability	B-X
.	B-X
Additional	B-X
cofactors	B-X
and	B-X
mutational	B-X
events	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
invasive	B-X
cervical	B-X
cancers	B-X
and	B-X
may	B-X
include	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
,	B-X
and	B-X
proto-oncogene	B-X
activation	B-X
.	B-X

However	O
,	O
the	O
development	O
of	O
cervical	O
cancer	O
is	O
a	O
multistep	O
process	O
that	O
cannot	O
be	O
explained	O
simply	O
by	O
infection	O
with	O
specific	O
types	O
of	O
HPV	O
.	O
<EOS>	B-X
Cervical	B-X
cancer	B-X
develops	B-X
from	B-X
well-defined	B-X
precursor	B-X
lesions	B-X
referred	B-X
to	B-X
as	B-X
either	B-X
cervical	B-X
intraepithelial	B-X
neoplasia	B-X
or	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
.	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
virally	B-X
derived	B-X
and	B-X
endogenous	B-X
cellular	B-X
proteins	B-X
converges	B-X
in	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
One	B-X
additional	B-X
event	B-X
that	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
is	B-X
integration	B-X
of	B-X
HPV	B-X
DNA	B-X
into	B-X
the	B-X
host	B-X
genome	B-X
.	B-X
Integration	B-X
of	B-X
HPV	B-X
DNA	B-X
frequently	B-X
disrupts	B-X
the	B-X
E2	B-X
open	B-X
reading	B-X
frames	B-X
,	B-X
resulting	B-X
in	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
possibly	B-X
causing	B-X
genomic	B-X
instability	B-X
.	B-X
Additional	B-X
cofactors	B-X
and	B-X
mutational	B-X
events	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
invasive	B-X
cervical	B-X
cancers	B-X
and	B-X
may	B-X
include	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
,	B-X
and	B-X
proto-oncogene	B-X
activation	B-X
.	B-X

One	O
additional	O
event	O
that	O
appears	O
to	O
play	O
a	O
role	O
in	O
tumor	O
progression	O
is	O
integration	O
of	O
HPV	O
DNA	O
into	O
the	O
host	O
genome	O
.	O
<EOS>	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
virally	B-X
derived	B-X
and	B-X
endogenous	B-X
cellular	B-X
proteins	B-X
converges	B-X
in	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
One	B-X
additional	B-X
event	B-X
that	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
is	B-X
integration	B-X
of	B-X
HPV	B-X
DNA	B-X
into	B-X
the	B-X
host	B-X
genome	B-X
.	B-X
Integration	B-X
of	B-X
HPV	B-X
DNA	B-X
frequently	B-X
disrupts	B-X
the	B-X
E2	B-X
open	B-X
reading	B-X
frames	B-X
,	B-X
resulting	B-X
in	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
possibly	B-X
causing	B-X
genomic	B-X
instability	B-X
.	B-X
Additional	B-X
cofactors	B-X
and	B-X
mutational	B-X
events	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
invasive	B-X
cervical	B-X
cancers	B-X
and	B-X
may	B-X
include	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
,	B-X
and	B-X
proto-oncogene	B-X
activation	B-X
.	B-X

Integration	O
of	O
HPV	O
DNA	O
frequently	O
disrupts	O
the	O
E2	B-Gene_or_gene_product
open	O
reading	O
frames	O
,	O
resulting	O
in	O
overexpression	O
of	O
the	O
E6	B-Gene_or_gene_product
and	O
E7	B-Gene_or_gene_product
oncoproteins	O
and	O
possibly	O
causing	O
genomic	O
instability	O
.	O
<EOS>	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
One	B-X
additional	B-X
event	B-X
that	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
tumor	B-X
progression	B-X
is	B-X
integration	B-X
of	B-X
HPV	B-X
DNA	B-X
into	B-X
the	B-X
host	B-X
genome	B-X
.	B-X
Integration	B-X
of	B-X
HPV	B-X
DNA	B-X
frequently	B-X
disrupts	B-X
the	B-X
E2	B-X
open	B-X
reading	B-X
frames	B-X
,	B-X
resulting	B-X
in	B-X
overexpression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
oncoproteins	B-X
and	B-X
possibly	B-X
causing	B-X
genomic	B-X
instability	B-X
.	B-X

Additional	O
cofactors	O
and	O
mutational	O
events	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
invasive	O
cervical	O
cancers	O
and	O
may	O
include	O
chromosomal	O
rearrangements	O
,	O
loss	O
of	O
constitutional	O
heterozygosity	O
,	O
and	O
proto	O
-	O
oncogene	O
activation	O
.	O
<EOS>	B-X
Cervical	B-X
cancer	B-X
develops	B-X
from	B-X
well-defined	B-X
precursor	B-X
lesions	B-X
referred	B-X
to	B-X
as	B-X
either	B-X
cervical	B-X
intraepithelial	B-X
neoplasia	B-X
or	B-X
squamous	B-X
intraepithelial	B-X
lesions	B-X
.	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
specific	B-X
types	B-X
of	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HPV	B-X
)	B-X
are	B-X
the	B-X
principal	B-X
etiologic	B-X
agents	B-X
for	B-X
both	B-X
cervical	B-X
cancer	B-X
and	B-X
its	B-X
precursors	B-X
.	B-X
The	B-X
high-oncogenic-risk	B-X
HPV	B-X
types	B-X
associated	B-X
with	B-X
invasive	B-X
cervical	B-X
cancer	B-X
produce	B-X
two	B-X
oncoproteins	B-X
,	B-X
designated	B-X
E6	B-X
and	B-X
E7	B-X
,	B-X
which	B-X
interact	B-X
with	B-X
endogenous	B-X
cell	B-X
cycle	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
p53	B-X
and	B-X
Rb	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
virally	B-X
derived	B-X
and	B-X
endogenous	B-X
cellular	B-X
proteins	B-X
converges	B-X
in	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
development	B-X
of	B-X
cervical	B-X
cancer	B-X
is	B-X
a	B-X
multistep	B-X
process	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
simply	B-X
by	B-X
infection	B-X
with	B-X
specific	B-X
types	B-X
of	B-X
HPV	B-X
.	B-X
Additional	B-X
cofactors	B-X
and	B-X
mutational	B-X
events	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
invasive	B-X
cervical	B-X
cancers	B-X
and	B-X
may	B-X
include	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
loss	B-X
of	B-X
constitutional	B-X
heterozygosity	B-X
,	B-X
and	B-X
proto-oncogene	B-X
activation	B-X
.	B-X

The	O
effects	O
of	O
radiation	O
on	O
neovascularization	O
in	O
a	O
rat	O
model	O
.	O

It	O
is	O
thought	O
that	O
radiation	O
treatment	O
inhibits	O
neovascularization	O
of	O
recipient	O
and	O
/	O
or	O
graft	O
tissues	O
,	O
and	O
this	O
may	O
account	O
in	O
part	O
for	O
abnormalities	O
in	O
wound	O
healing	O
associated	O
with	O
radiation	O
therapy	O
.	O
<EOS>	B-X
It	B-X
is	B-X
thought	B-X
that	B-X
radiation	B-X
treatment	B-X
inhibits	B-X
neovascularization	B-X
of	B-X
recipient	B-X
and/or	B-X
graft	B-X
tissues	B-X
,	B-X
and	B-X
this	B-X
may	B-X
account	B-X
in	B-X
part	B-X
for	B-X
abnormalities	B-X
in	B-X
wound	B-X
healing	B-X
associated	B-X
with	B-X
radiation	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
this	B-X
hypothesis	B-X
using	B-X
a	B-X
model	B-X
that	B-X
measures	B-X
the	B-X
neovascularization	B-X
of	B-X
an	B-X
implanted	B-X
foreign	B-X
material	B-X
.	B-X
Expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
PTFE	B-X
)	B-X
sheets	B-X
were	B-X
implanted	B-X
adjacent	B-X
to	B-X
both	B-X
superficial	B-X
epigastric	B-X
vascular	B-X
pedicles	B-X
of	B-X
63	B-X
rats	B-X
distributed	B-X
into	B-X
7	B-X
groups	B-X
(	B-X
n	B-X
=	B-X
7	B-X
)	B-X
that	B-X
differed	B-X
with	B-X
respect	B-X
to	B-X
dose	B-X
and	B-X
timing	B-X
of	B-X
irradiation	B-X
.	B-X
Zero	B-X
to	B-X
10	B-X
daily	B-X
fractions	B-X
of	B-X
electron-beam	B-X
radiation	B-X
(	B-X
300	B-X
cGy	B-X
each	B-X
)	B-X
were	B-X
delivered	B-X
to	B-X
the	B-X
implant	B-X
in	B-X
the	B-X
right	B-X
groin	B-X
,	B-X
while	B-X
the	B-X
implant	B-X
in	B-X
the	B-X
left	B-X
groin	B-X
served	B-X
as	B-X
a	B-X
nonirradiated	B-X
internal	B-X
control	B-X
.	B-X
Unirradiated	B-X
animals	B-X
showed	B-X
equal	B-X
neovascularization	B-X
of	B-X
both	B-X
implants	B-X
.	B-X
Rats	B-X
that	B-X
were	B-X
irradiated	B-X
twice	B-X
(	B-X
single	B-X
fractions	B-X
at	B-X
0	B-X
and	B-X
24	B-X
hours	B-X
after	B-X
implantation	B-X
)	B-X
did	B-X
not	B-X
show	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
neovascularization	B-X
of	B-X
the	B-X
irradiated	B-X
implant	B-X
compared	B-X
with	B-X
the	B-X
contralateral	B-X
control	B-X
implant	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
implants	B-X
that	B-X
were	B-X
irradiated	B-X
three	B-X
times	B-X
(	B-X
single	B-X
fractions	B-X
at	B-X
0	B-X
,	B-X
24	B-X
,	B-X
and	B-X
48	B-X
hours	B-X
after	B-X
implantation	B-X
)	B-X
demonstrated	B-X
significantly	B-X
diminished	B-X
(	B-X
>	B-X
25	B-X
percent	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
neovascularization	B-X
beyond	B-X
day	B-X
7	B-X
,	B-X
whereas	B-X
implants	B-X
irradiated	B-X
only	B-X
at	B-X
48	B-X
hours	B-X
after	B-X
implantation	B-X
did	B-X
not	B-X
.	B-X
Interestingly	B-X
,	B-X
neovascularization	B-X
of	B-X
the	B-X
implants	B-X
irradiated	B-X
with	B-X
10	B-X
fractions	B-X
(	B-X
3000	B-X
cGy	B-X
)	B-X
was	B-X
not	B-X
significantly	B-X
decreased	B-X
compared	B-X
with	B-X
irradiation	B-X
with	B-X
three	B-X
fractions	B-X
(	B-X
900	B-X
cGy	B-X
)	B-X
.	B-X
Irradiation	B-X
delivered	B-X
before	B-X
implantation	B-X
(	B-X
900	B-X
cGy	B-X
)	B-X
inhibited	B-X
neovascularization	B-X
significantly	B-X
less	B-X
than	B-X
the	B-X
same	B-X
dose	B-X
administered	B-X
after	B-X
implantation	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
a	B-X
subclinical	B-X
cumulative	B-X
dose	B-X
of	B-X
900	B-X
cGy	B-X
is	B-X
the	B-X
threshold	B-X
for	B-X
impaired	B-X
tissue	B-X
revascularization	B-X
provided	B-X
that	B-X
treatment	B-X
is	B-X
delivered	B-X
immediately	B-X
after	B-X
implantation	B-X
over	B-X
a	B-X
48-hour	B-X
interval	B-X
.	B-X

We	O
have	O
examined	O
this	O
hypothesis	O
using	O
a	O
model	O
that	O
measures	O
the	O
neovascularization	O
of	O
an	O
implanted	O
foreign	O
material	O
.	O

Expanded	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
sheets	O
were	O
implanted	O
adjacent	O
to	O
both	O
superficial	O
epigastric	O
vascular	O
pedicles	O
of	O
63	O
rats	O
distributed	O
into	O
7	O
groups	O
(	O
n	O
=	O
7	O
)	O
that	O
differed	O
with	O
respect	O
to	O
dose	O
and	O
timing	O
of	O
irradiation	O
.	O
<EOS>	B-X
It	B-X
is	B-X
thought	B-X
that	B-X
radiation	B-X
treatment	B-X
inhibits	B-X
neovascularization	B-X
of	B-X
recipient	B-X
and/or	B-X
graft	B-X
tissues	B-X
,	B-X
and	B-X
this	B-X
may	B-X
account	B-X
in	B-X
part	B-X
for	B-X
abnormalities	B-X
in	B-X
wound	B-X
healing	B-X
associated	B-X
with	B-X
radiation	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
this	B-X
hypothesis	B-X
using	B-X
a	B-X
model	B-X
that	B-X
measures	B-X
the	B-X
neovascularization	B-X
of	B-X
an	B-X
implanted	B-X
foreign	B-X
material	B-X
.	B-X
Expanded	B-X
polytetrafluoroethylene	B-X
(	B-X
PTFE	B-X
)	B-X
sheets	B-X
were	B-X
implanted	B-X
adjacent	B-X
to	B-X
both	B-X
superficial	B-X
epigastric	B-X
vascular	B-X
pedicles	B-X
of	B-X
63	B-X
rats	B-X
distributed	B-X
into	B-X
7	B-X
groups	B-X
(	B-X
n	B-X
=	B-X
7	B-X
)	B-X
that	B-X
differed	B-X
with	B-X
respect	B-X
to	B-X
dose	B-X
and	B-X
timing	B-X
of	B-X
irradiation	B-X
.	B-X
Zero	B-X
to	B-X
10	B-X
daily	B-X
fractions	B-X
of	B-X
electron-beam	B-X
radiation	B-X
(	B-X
300	B-X
cGy	B-X
each	B-X
)	B-X
were	B-X
delivered	B-X
to	B-X
the	B-X
implant	B-X
in	B-X
the	B-X
right	B-X
groin	B-X
,	B-X
while	B-X
the	B-X
implant	B-X
in	B-X
the	B-X
left	B-X
groin	B-X
served	B-X
as	B-X
a	B-X
nonirradiated	B-X
internal	B-X
control	B-X
.	B-X
Unirradiated	B-X
animals	B-X
showed	B-X
equal	B-X
neovascularization	B-X
of	B-X
both	B-X
implants	B-X
.	B-X
Rats	B-X
that	B-X
were	B-X
irradiated	B-X
twice	B-X
(	B-X
single	B-X
fractions	B-X
at	B-X
0	B-X
and	B-X
24	B-X
hours	B-X
after	B-X
implantation	B-X
)	B-X
did	B-X
not	B-X
show	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
neovascularization	B-X
of	B-X
the	B-X
irradiated	B-X
implant	B-X
compared	B-X
with	B-X
the	B-X
contralateral	B-X
control	B-X
implant	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
implants	B-X
that	B-X
were	B-X
irradiated	B-X
three	B-X
times	B-X
(	B-X
single	B-X
fractions	B-X
at	B-X
0	B-X
,	B-X
24	B-X
,	B-X
and	B-X
48	B-X
hours	B-X
after	B-X
implantation	B-X
)	B-X
demonstrated	B-X
significantly	B-X
diminished	B-X
(	B-X
>	B-X
25	B-X
percent	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
neovascularization	B-X
beyond	B-X
day	B-X
7	B-X
,	B-X
whereas	B-X
implants	B-X
irradiated	B-X
only	B-X
at	B-X
48	B-X
hours	B-X
after	B-X
implantation	B-X
did	B-X
not	B-X
.	B-X
Interestingly	B-X
,	B-X
neovascularization	B-X
of	B-X
the	B-X
implants	B-X
irradiated	B-X
with	B-X
10	B-X
fractions	B-X
(	B-X
3000	B-X
cGy	B-X
)	B-X
was	B-X
not	B-X
significantly	B-X
decreased	B-X
compared	B-X
with	B-X
irradiation	B-X
with	B-X
three	B-X
fractions	B-X
(	B-X
900	B-X
cGy	B-X
)	B-X
.	B-X
Irradiation	B-X
delivered	B-X
before	B-X
implantation	B-X
(	B-X
900	B-X
cGy	B-X
)	B-X
inhibited	B-X
neovascularization	B-X
significantly	B-X
less	B-X
than	B-X
the	B-X
same	B-X
dose	B-X
administered	B-X
after	B-X
implantation	B-X
.	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
a	B-X
subclinical	B-X
cumulative	B-X
dose	B-X
of	B-X
900	B-X
cGy	B-X
is	B-X
the	B-X
threshold	B-X
for	B-X
impaired	B-X
tissue	B-X
revascularization	B-X
provided	B-X
that	B-X
treatment	B-X
is	B-X
delivered	B-X
immediately	B-X
after	B-X
implantation	B-X
over	B-X
a	B-X
48-hour	B-X
interval	B-X
.	B-X

Zero	O
to	O
10	O
daily	O
fractions	O
of	O
electron	O
-	O
beam	O
radiation	O
(	O
300	O
cGy	O
each	O
)	O
were	O
delivered	O
to	O
the	O
implant	O
in	O
the	O
right	O
groin	O
,	O
while	O
the	O
implant	O
in	O
the	O
left	O
groin	O
served	O
as	O
a	O
nonirradiated	O
internal	O
control	O
.	O

Unirradiated	O
animals	O
showed	O
equal	O
neovascularization	O
of	O
both	O
implants	O
.	O
<EOS>	B-X
It	B-X
is	B-X
thought	B-X
that	B-X
radiation	B-X
treatment	B-X
inhibits	B-X
neovascularization	B-X
of	B-X
recipient	B-X
and/or	B-X
graft	B-X
tissues	B-X
,	B-X
and	B-X
this	B-X
may	B-X
account	B-X
in	B-X
part	B-X
for	B-X
abnormalities	B-X
in	B-X
wound	B-X
healing	B-X
associated	B-X
with	B-X
radiation	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
this	B-X
hypothesis	B-X
using	B-X
a	B-X
model	B-X
that	B-X
measures	B-X
the	B-X
neovascularization	B-X
of	B-X
an	B-X
implanted	B-X
foreign	B-X
material	B-X
.	B-X
Unirradiated	B-X
animals	B-X
showed	B-X
equal	B-X
neovascularization	B-X
of	B-X
both	B-X
implants	B-X
.	B-X
Rats	B-X
that	B-X
were	B-X
irradiated	B-X
twice	B-X
(	B-X
single	B-X
fractions	B-X
at	B-X
0	B-X
and	B-X
24	B-X
hours	B-X
after	B-X
implantation	B-X
)	B-X
did	B-X
not	B-X
show	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
neovascularization	B-X
of	B-X
the	B-X
irradiated	B-X
implant	B-X
compared	B-X
with	B-X
the	B-X
contralateral	B-X
control	B-X
implant	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
implants	B-X
that	B-X
were	B-X
irradiated	B-X
three	B-X
times	B-X
(	B-X
single	B-X
fractions	B-X
at	B-X
0	B-X
,	B-X
24	B-X
,	B-X
and	B-X
48	B-X
hours	B-X
after	B-X
implantation	B-X
)	B-X
demonstrated	B-X
significantly	B-X
diminished	B-X
(	B-X
>	B-X
25	B-X
percent	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
neovascularization	B-X
beyond	B-X
day	B-X
7	B-X
,	B-X
whereas	B-X
implants	B-X
irradiated	B-X
only	B-X
at	B-X
48	B-X
hours	B-X
after	B-X
implantation	B-X
did	B-X
not	B-X
.	B-X
Interestingly	B-X
,	B-X
neovascularization	B-X
of	B-X
the	B-X
implants	B-X
irradiated	B-X
with	B-X
10	B-X
fractions	B-X
(	B-X
3000	B-X
cGy	B-X
)	B-X
was	B-X
not	B-X
significantly	B-X
decreased	B-X
compared	B-X
with	B-X
irradiation	B-X
with	B-X
three	B-X
fractions	B-X
(	B-X
900	B-X
cGy	B-X
)	B-X
.	B-X
Irradiation	B-X
delivered	B-X
before	B-X
implantation	B-X
(	B-X
900	B-X
cGy	B-X
)	B-X
inhibited	B-X
neovascularization	B-X
significantly	B-X
less	B-X
than	B-X
the	B-X
same	B-X
dose	B-X
administered	B-X
after	B-X
implantation	B-X
.	B-X

Rats	O
that	O
were	O
irradiated	O
twice	O
(	O
single	O
fractions	O
at	O
0	O
and	O
24	O
hours	O
after	O
implantation	O
)	O
did	O
not	O
show	O
a	O
significant	O
decrease	O
in	O
the	O
neovascularization	O
of	O
the	O
irradiated	O
implant	O
compared	O
with	O
the	O
contralateral	O
control	O
implant	O
.	O

In	O
contrast	O
,	O
the	O
implants	O
that	O
were	O
irradiated	O
three	O
times	O
(	O
single	O
fractions	O
at	O
0	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
implantation	O
)	O
demonstrated	O
significantly	O
diminished	O
(	O
greater	O
than	O
25	O
percent	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
neovascularization	O
beyond	O
day	O
7	O
,	O
whereas	O
implants	O
irradiated	O
only	O
at	O
48	O
hours	O
after	O
implantation	O
did	O
not	O
.	O

Interestingly	O
,	O
neovascularization	O
of	O
the	O
implants	O
irradiated	O
with	O
10	O
fractions	O
(	O
3000	O
cGy	O
)	O
was	O
not	O
significantly	O
decreased	O
compared	O
with	O
irradiation	O
with	O
three	O
fractions	O
(	O
900	O
cGy	O
)	O
.	O

Irradiation	O
delivered	O
before	O
implantation	O
(	O
900	O
cGy	O
)	O
inhibited	O
neovascularization	O
significantly	O
less	O
than	O
the	O
same	O
dose	O
administered	O
after	O
implantation	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
a	O
subclinical	O
cumulative	O
dose	O
of	O
900	O
cGy	O
is	O
the	O
threshold	O
for	O
impaired	O
tissue	O
revascularization	O
provided	O
that	O
treatment	O
is	O
delivered	O
immediately	O
after	O
implantation	O
over	O
a	O
48	O
-	O
hour	O
interval	O
.	O

Prognostic	O
value	O
of	O
angiogenesis	O
in	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O
<EOS>	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
clinical	B-X
,	B-X
angiogenic	B-X
,	B-X
and	B-X
lymphangiogenic	B-X
significance	B-X
of	B-X
TAMs	B-X
in	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Tumor	B-X
cells	B-X
stimulate	B-X
local	B-X
angiogenesis	B-X
,	B-X
resulting	B-X
in	B-X
their	B-X
further	B-X
multiplication	B-X
and	B-X
spread	B-X
.	B-X
Angiopoietin-1	B-X
(	B-X
Ang-1	B-X
)	B-X
through	B-X
its	B-X
receptor	B-X
Tie2	B-X
stimulates	B-X
endothelial	B-X
cell	B-X
survival	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
the	B-X
endothelial	B-X
barrier	B-X
.	B-X
These	B-X
phenomena	B-X
can	B-X
support	B-X
tumour	B-X
growth	B-X
by	B-X
promoting	B-X
angiogenesis	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
overproduction	B-X
of	B-X
Ang-1	B-X
triggers	B-X
endothelium	B-X
stability	B-X
and	B-X
can	B-X
lead	B-X
to	B-X
angiogenesis	B-X
inhibition	B-X
.	B-X
In	B-X
a	B-X
group	B-X
of	B-X
47	B-X
patients	B-X
,	B-X
tumours	B-X
and	B-X
the	B-X
adjacent	B-X
non-cancerous	B-X
tissues	B-X
were	B-X
assessed	B-X
for	B-X
ANG-1	B-X
mRNA	B-X
expression	B-X
(	B-X
using	B-X
Q-RT-PCR	B-X
analysis	B-X
)	B-X
and	B-X
Ang-1	B-X
concentration	B-X
(	B-X
by	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
)	B-X
together	B-X
with	B-X
clinical	B-X
parameters	B-X
and	B-X
the	B-X
five-year	B-X
survival	B-X
rate	B-X
.	B-X

Tumour	O
angiogenesis	O
is	O
an	O
important	O
factor	O
for	O
tumour	O
growth	O
and	O
metastasis	O
.	O
<EOS>	B-X
Tumor	B-X
angiogenesis	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
continued	B-X
survival	B-X
and	B-X
development	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
their	B-X
growth	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
tumor	B-X
microenvironment-composed	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
surrounding	B-X
cells	B-X
,	B-X
and	B-X
secreted	B-X
cytokines-provides	B-X
a	B-X
conducive	B-X
environment	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
survival	B-X
of	B-X
tumors	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
have	B-X
discussed	B-X
the	B-X
regulatory	B-X
role	B-X
of	B-X
the	B-X
microenvironment	B-X
in	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
High	B-X
expression	B-X
of	B-X
angiogenic	B-X
factors	B-X
and	B-X
inflammatory	B-X
cytokines	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
as	B-X
well	B-X
as	B-X
hypoxia	B-X
,	B-X
are	B-X
presumed	B-X
to	B-X
be	B-X
the	B-X
reasons	B-X
for	B-X
poor	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
current	B-X
anti-angiogenic	B-X
drugs	B-X
.	B-X

Although	O
some	O
recent	O
reports	O
suggest	O
that	O
microvessel	O
counts	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
are	O
related	O
to	O
a	O
poor	O
disease	O
outcome	O
,	O
the	O
results	O
were	O
not	O
conclusive	O
and	O
were	O
not	O
compared	O
with	O
other	O
molecular	O
prognostic	O
markers	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
vascular	O
grade	O
was	O
assessed	O
in	O
107	O
(	O
T1	O
,	O
2	O
-	O
N0	O
,	O
1	O
)	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
carcinomas	O
,	O
using	O
the	O
JC70	B-Gene_or_gene_product
monoclonal	I-Gene_or_gene_product
antibody	I-Gene_or_gene_product
to	I-Gene_or_gene_product
CD31	I-Gene_or_gene_product
.	O

Three	O
vascular	O
grades	O
were	O
defined	O
with	O
appraisal	O
by	O
eye	O
and	O
by	O
Chalkley	O
counting	O
:	O
high	O
(	O
Chalkley	O
score	O
7	O
-	O
12	O
)	O
,	O
medium	O
(	O
5	O
-	O
6	O
)	O
,	O
and	O
low	O
(	O
2	O
-	O
4	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
eye	O
appraisal	O
and	O
Chalkley	O
counting	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

Vascular	O
grade	O
was	O
not	O
related	O
to	O
histology	O
,	O
grade	O
,	O
proliferation	O
index	O
(	O
Ki67	B-Gene_or_gene_product
)	O
,	O
or	O
EGFR	B-Gene_or_gene_product
or	O
p53	B-Gene_or_gene_product
expression	O
.	O
<EOS>	B-X
CD93	B-X
is	B-X
a	B-X
transmembrane	B-X
receptor	B-X
that	B-X
is	B-X
upregulated	B-X
in	B-X
tumor	B-X
vessels	B-X
in	B-X
many	B-X
cancers	B-X
,	B-X
including	B-X
high-grade	B-X
glioma	B-X
.	B-X
PD-L1	B-X
expression	B-X
on	B-X
glioblastoma	B-X
surface	B-X
promotes	B-X
PD-1	B-X
receptor	B-X
activation	B-X
in	B-X
microglia	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
T	B-X
cell	B-X
responses	B-X
.	B-X
Glioblastoma	B-X
multiforme	B-X
cells	B-X
induce	B-X
PD-L1	B-X
secretion	B-X
by	B-X
activation	B-X
of	B-X
various	B-X
receptors	B-X
such	B-X
as	B-X
toll	B-X
like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
,	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
,	B-X
interferon	B-X
alpha	B-X
receptor	B-X
(	B-X
IFNAR	B-X
)	B-X
,	B-X
interferon-gamma	B-X
receptor	B-X
(	B-X
IFNGR	B-X
)	B-X
.	B-X
Binding	B-X
of	B-X
the	B-X
PD-1	B-X
ligand	B-X
to	B-X
the	B-X
PD-1	B-X
receptor	B-X
activates	B-X
the	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
SHP-2	B-X
,	B-X
which	B-X
dephosphorylates	B-X
Zap	B-X
70	B-X
,	B-X
and	B-X
this	B-X
inhibits	B-X
T	B-X
cell	B-X
proliferation	B-X
and	B-X
downregulates	B-X
lymphocyte	B-X
cytotoxic	B-X
activity	B-X
.	B-X
Relevant	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
PD-L1	B-X
in	B-X
glioma	B-X
correlates	B-X
with	B-X
WHO	B-X
grading	B-X
and	B-X
could	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
biomarker	B-X
.	B-X

Tumours	O
from	O
younger	O
patients	O
had	O
a	O
higher	O
grade	O
of	O
angiogenesis	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Apart	O
from	O
the	O
vascular	O
grade	O
,	O
none	O
of	O
the	O
other	O
factors	O
examined	O
was	O
statistically	O
related	O
to	O
lymph	O
node	O
metastasis	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

A	O
univariate	O
analysis	O
of	O
survival	O
showed	O
that	O
vascular	O
grade	O
was	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
,	O
followed	O
by	O
N	O
-	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
N	O
-	O
stage	O
and	O
vascular	O
grade	O
were	O
not	O
found	O
to	O
be	O
independent	O
prognostic	O
factors	O
,	O
since	O
they	O
were	O
strongly	O
related	O
to	O
each	O
other	O
.	O

Excluding	O
N	O
-	O
stage	O
,	O
vascular	O
grade	O
was	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
showed	O
a	O
statistically	O
significant	O
worse	O
prognosis	O
for	O
patients	O
with	O
high	O
vascular	O
grade	O
,	O
but	O
no	O
difference	O
was	O
observed	O
between	O
low	O
and	O
medium	O
vascular	O
grade	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
vascular	B-X
grade	B-X
was	B-X
assessed	B-X
in	B-X
107	B-X
(	B-X
T1,2-N0,1	B-X
)	B-X
operable	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinomas	B-X
,	B-X
using	B-X
the	B-X
JC70	B-X
monoclonal	B-X
antibody	B-X
to	B-X
CD31	B-X
.	B-X
Three	B-X
vascular	B-X
grades	B-X
were	B-X
defined	B-X
with	B-X
appraisal	B-X
by	B-X
eye	B-X
and	B-X
by	B-X
Chalkley	B-X
counting	B-X
:	B-X
high	B-X
(	B-X
Chalkley	B-X
score	B-X
7-12	B-X
)	B-X
,	B-X
medium	B-X
(	B-X
5-6	B-X
)	B-X
,	B-X
and	B-X
low	B-X
(	B-X
2-4	B-X
)	B-X
.	B-X
There	B-X
was	B-X
a	B-X
significant	B-X
correlation	B-X
between	B-X
eye	B-X
appraisal	B-X
and	B-X
Chalkley	B-X
counting	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Vascular	B-X
grade	B-X
was	B-X
not	B-X
related	B-X
to	B-X
histology	B-X
,	B-X
grade	B-X
,	B-X
proliferation	B-X
index	B-X
(	B-X
Ki67	B-X
)	B-X
,	B-X
or	B-X
EGFR	B-X
or	B-X
p53	B-X
expression	B-X
.	B-X
Tumours	B-X
from	B-X
younger	B-X
patients	B-X
had	B-X
a	B-X
higher	B-X
grade	B-X
of	B-X
angiogenesis	B-X
(	B-X
P	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
Apart	B-X
from	B-X
the	B-X
vascular	B-X
grade	B-X
,	B-X
none	B-X
of	B-X
the	B-X
other	B-X
factors	B-X
examined	B-X
was	B-X
statistically	B-X
related	B-X
to	B-X
lymph	B-X
node	B-X
metastasis	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
A	B-X
univariate	B-X
analysis	B-X
of	B-X
survival	B-X
showed	B-X
that	B-X
vascular	B-X
grade	B-X
was	B-X
the	B-X
most	B-X
significant	B-X
prognostic	B-X
factor	B-X
(	B-X
P	B-X
=	B-X
0.0004	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
N-stage	B-X
(	B-X
P	B-X
=	B-X
0.001	B-X
)	B-X
.	B-X
In	B-X
a	B-X
multivariate	B-X
analysis	B-X
,	B-X
N-stage	B-X
and	B-X
vascular	B-X
grade	B-X
were	B-X
not	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
prognostic	B-X
factors	B-X
,	B-X
since	B-X
they	B-X
were	B-X
strongly	B-X
related	B-X
to	B-X
each	B-X
other	B-X
.	B-X
Excluding	B-X
N-stage	B-X
,	B-X
vascular	B-X
grade	B-X
was	B-X
the	B-X
only	B-X
independent	B-X
prognostic	B-X
factor	B-X
(	B-X
P	B-X
=	B-X
0.007	B-X
)	B-X
.	B-X
Kaplan-Meier	B-X
survival	B-X
curves	B-X
showed	B-X
a	B-X
statistically	B-X
significant	B-X
worse	B-X
prognosis	B-X
for	B-X
patients	B-X
with	B-X
high	B-X
vascular	B-X
grade	B-X
,	B-X
but	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
low	B-X
and	B-X
medium	B-X
vascular	B-X
grade	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
angiogenesis	B-X
in	B-X
operable	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
is	B-X
a	B-X
major	B-X
prognostic	B-X
factor	B-X
for	B-X
survival	B-X
and	B-X
,	B-X
among	B-X
the	B-X
parameters	B-X
tested	B-X
,	B-X
is	B-X
the	B-X
only	B-X
factor	B-X
related	B-X
to	B-X
cancer	B-X
cell	B-X
migration	B-X
to	B-X
lymph	B-X
nodes	B-X
.	B-X
The	B-X
integration	B-X
of	B-X
vascular	B-X
grading	B-X
in	B-X
clinical	B-X
trials	B-X
on	B-X
adjuvant	B-X
chemotherapy	B-X
and/or	B-X
radiotherapy	B-X
could	B-X
substantially	B-X
contribute	B-X
in	B-X
defining	B-X
groups	B-X
of	B-X
operable	B-X
patients	B-X
who	B-X
might	B-X
benefit	B-X
from	B-X
cytotoxic	B-X
treatment	B-X
.	B-X

These	O
data	O
suggest	O
that	O
angiogenesis	O
in	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
is	O
a	O
major	O
prognostic	O
factor	O
for	O
survival	O
and	O
,	O
among	O
the	O
parameters	O
tested	O
,	O
is	O
the	O
only	O
factor	O
related	O
to	O
cancer	O
cell	O
migration	O
to	O
lymph	O
nodes	O
.	O

The	O
integration	O
of	O
vascular	O
grading	O
in	O
clinical	O
trials	O
on	O
adjuvant	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
could	O
substantially	O
contribute	O
in	O
defining	O
groups	O
of	O
operable	O
patients	O
who	O
might	O
benefit	O
from	O
cytotoxic	O
treatment	O
.	O
<EOS>	B-X
Standard	B-X
first-line	B-X
treatment	B-X
of	B-X
advanced	B-X
HGS	B-X
carcinoma	B-X
includes	B-X
cytoreductive	B-X
surgery	B-X
plus	B-X
intravenous	B-X
paclitaxel/platinum-based	B-X
chemotherapy	B-X
.	B-X
Despite	B-X
excellent	B-X
responses	B-X
to	B-X
initial	B-X
treatment	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
develop	B-X
recurrent	B-X
disease	B-X
within	B-X
3	B-X
years	B-X
.	B-X
The	B-X
introduction	B-X
of	B-X
the	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
inhibitor	B-X
,	B-X
bevacizumab	B-X
,	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
inhibitors	B-X
into	B-X
first-line	B-X
management	B-X
has	B-X
changed	B-X
the	B-X
outlook	B-X
for	B-X
this	B-X
lethal	B-X
disease	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarise	B-X
the	B-X
most	B-X
recent	B-X
clinical	B-X
trials	B-X
that	B-X
determine	B-X
current	B-X
primary	B-X
therapy	B-X
of	B-X
advanced	B-X
HGS	B-X
carcinoma	B-X
and	B-X
the	B-X
ongoing	B-X
trials	B-X
that	B-X
aim	B-X
to	B-X
change	B-X
management	B-X
in	B-X
the	B-X
future	B-X
.	B-X

Vitamin	O
E	O
inhibits	O
experimental	O
carcinogenesis	O
and	O
tumour	O
angiogenesis	O
.	O
<EOS>	B-X
In	B-X
an	B-X
experiment	B-X
in	B-X
which	B-X
vitamin	B-X
E	B-X
inhibited	B-X
carcinogenesis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
tumour	B-X
angiogenesis	B-X
and	B-X
tumour	B-X
growth-factor	B-X
alpha	B-X
(	B-X
TGF	B-X
alpha	B-X
)	B-X
expression	B-X
were	B-X
also	B-X
inhibited	B-X
.	B-X
Groups	B-X
3	B-X
and	B-X
4	B-X
were	B-X
vitamin	B-X
E	B-X
and	B-X
untreated	B-X
controls	B-X
.	B-X
Mean	B-X
tumour	B-X
volume	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
compared	B-X
to	B-X
the	B-X
tumour	B-X
control	B-X
group	B-X
.	B-X
Angiogenesis	B-X
was	B-X
significantly	B-X
inhibited	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
and	B-X
TGF	B-X
alpha	B-X
expression	B-X
was	B-X
also	B-X
inhibited	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
inhibition	B-X
of	B-X
tumour	B-X
angiogenesis	B-X
by	B-X
vitamin	B-X
E	B-X
may	B-X
be	B-X
an	B-X
additional	B-X
mechanism	B-X
for	B-X
the	B-X
anticancer	B-X
action	B-X
of	B-X
vitamin	B-X
E	B-X
.	B-X

In	O
an	O
experiment	O
in	O
which	O
vitamin	O
E	O
inhibited	O
carcinogenesis	O
,	O
it	O
was	O
found	O
that	O
tumour	O
angiogenesis	O
and	O
tumour	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
-	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	I-Gene_or_gene_product
(	O
TGF	B-Gene_or_gene_product
alpha	I-Gene_or_gene_product
)	O
expression	O
were	O
also	O
inhibited	O
.	O

Forty	O
male	O
golden	O
hamsters	O
were	O
divided	O
into	O
four	O
equal	O
groups	O
.	O
<EOS>	B-X
Forty	B-X
male	B-X
and	B-X
female	B-X
Syrian	B-X
hamsters	B-X
(	B-X
Mesocricetus	B-X
auratus	B-X
)	B-X
were	B-X
divided	B-X
into	B-X
four	B-X
equal	B-X
groups	B-X
.	B-X
Two	B-X
animals	B-X
in	B-X
each	B-X
of	B-X
the	B-X
four	B-X
groups	B-X
were	B-X
killed	B-X
with	B-X
ether	B-X
at	B-X
8	B-X
,	B-X
10	B-X
,	B-X
12	B-X
,	B-X
13	B-X
,	B-X
and	B-X
14	B-X
weeks	B-X
after	B-X
the	B-X
start	B-X
of	B-X
the	B-X
experiment	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
effects	B-X
of	B-X
topical	B-X
administrations	B-X
of	B-X
the	B-X
essential	B-X
oil	B-X
extracted	B-X
from	B-X
hull	B-X
of	B-X
Pistacia	B-X
atlantica	B-X
fruit	B-X
(	B-X
bene	B-X
)	B-X
on	B-X
healing	B-X
of	B-X
oral	B-X
mucositis	B-X
in	B-X
golden	B-X
hamsters	B-X
.	B-X
Forty	B-X
male	B-X
Syrian	B-X
golden	B-X
hamsters	B-X
treated	B-X
with	B-X
DMBA	B-X
were	B-X
divided	B-X
into	B-X
two	B-X
equal	B-X
groups	B-X
--	B-X
one	B-X
with	B-X
surgical	B-X
excision	B-X
of	B-X
their	B-X
tumors	B-X
and	B-X
a	B-X
control	B-X
group	B-X
without	B-X
tumor	B-X
excision	B-X
.	B-X
Following	B-X
a	B-X
three-week	B-X
observation	B-X
period	B-X
,	B-X
the	B-X
tumors	B-X
in	B-X
the	B-X
pouch	B-X
were	B-X
excised	B-X
at	B-X
their	B-X
base	B-X
,	B-X
and	B-X
the	B-X
animals	B-X
were	B-X
killed	B-X
after	B-X
four	B-X
weeks	B-X
of	B-X
further	B-X
observation	B-X
.	B-X

Group	O
1	O
animals	O
had	O
the	O
left	O
buccal	O
pouches	O
painted	O
three	O
times	O
weekly	O
with	O
7	O
,	O
12	O
-	O
dimethylbenz	O
(	O
a	O
)	O
anthracene	O
(	O
DMBA	O
)	O
for	O
14	O
weeks	O
.	O

Group	O
2	O
animals	O
had	O
the	O
same	O
procedure	O
of	O
DMBA	O
applications	O
but	O
also	O
received	O
alpha	O
tocopherol	O
.	O
<EOS>	B-X
In	B-X
an	B-X
experiment	B-X
in	B-X
which	B-X
vitamin	B-X
E	B-X
inhibited	B-X
carcinogenesis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
tumour	B-X
angiogenesis	B-X
and	B-X
tumour	B-X
growth-factor	B-X
alpha	B-X
(	B-X
TGF	B-X
alpha	B-X
)	B-X
expression	B-X
were	B-X
also	B-X
inhibited	B-X
.	B-X
Group	B-X
1	B-X
animals	B-X
had	B-X
the	B-X
left	B-X
buccal	B-X
pouches	B-X
painted	B-X
three	B-X
times	B-X
weekly	B-X
with	B-X
7,12-dimethylbenz	B-X
(	B-X
a	B-X
)	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
for	B-X
14	B-X
weeks	B-X
.	B-X
Group	B-X
2	B-X
animals	B-X
had	B-X
the	B-X
same	B-X
procedure	B-X
of	B-X
DMBA	B-X
applications	B-X
but	B-X
also	B-X
received	B-X
alpha	B-X
tocopherol	B-X
.	B-X
Groups	B-X
3	B-X
and	B-X
4	B-X
were	B-X
vitamin	B-X
E	B-X
and	B-X
untreated	B-X
controls	B-X
.	B-X
TGF	B-X
alpha	B-X
was	B-X
studied	B-X
with	B-X
the	B-X
appropriate	B-X
antibody	B-X
.	B-X
Mean	B-X
tumour	B-X
volume	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
compared	B-X
to	B-X
the	B-X
tumour	B-X
control	B-X
group	B-X
.	B-X
Angiogenesis	B-X
was	B-X
significantly	B-X
inhibited	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
and	B-X
TGF	B-X
alpha	B-X
expression	B-X
was	B-X
also	B-X
inhibited	B-X
.	B-X

Groups	O
3	O
and	O
4	O
were	O
vitamin	O
E	O
and	O
untreated	O
controls	O
.	O
<EOS>	B-X
Vitamins	B-X
C	B-X
and	B-X
E	B-X
are	B-X
natural	B-X
antioxidants	B-X
and	B-X
anti-inflammatory	B-X
agents	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
vitamins	B-X
C	B-X
and	B-X
E	B-X
treatment	B-X
in	B-X
rats	B-X
with	B-X
sepsis-induced	B-X
lung	B-X
damage	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
zinc	B-X
(	B-X
Zn	B-X
)	B-X
and	B-X
vitamin	B-X
E	B-X
,	B-X
i.e	B-X
.	B-X
The	B-X
control	B-X
group	B-X
was	B-X
fed	B-X
an	B-X
untreated	B-X
diet	B-X
,	B-X
and	B-X
the	B-X
diets	B-X
of	B-X
two	B-X
other	B-X
groups	B-X
were	B-X
overdosed	B-X
with	B-X
Se	B-X
in	B-X
the	B-X
form	B-X
of	B-X
sodium	B-X
selenite	B-X
(	B-X
9	B-X
mg/kg	B-X
)	B-X
and	B-X
supplemented	B-X
with	B-X
Zn	B-X
(	B-X
13	B-X
mg/kg	B-X
)	B-X
.	B-X
Two	B-X
experimental	B-X
groups	B-X
were	B-X
fed	B-X
a	B-X
diet	B-X
supplemented	B-X
with	B-X
Zn	B-X
(	B-X
13	B-X
mg/kg	B-X
)	B-X
and	B-X
Se	B-X
at	B-X
an	B-X
adequate	B-X
level	B-X
(	B-X
0.009	B-X
mg/kg	B-X
)	B-X
;	B-X
a	B-X
half	B-X
of	B-X
the	B-X
animals	B-X
was	B-X
supplemented	B-X
with	B-X
vitamin	B-X
E.	B-X
The	B-X
results	B-X
showed	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
Se	B-X
contents	B-X
between	B-X
the	B-X
rat	B-X
strains	B-X
in	B-X
case	B-X
of	B-X
Se-overdosed	B-X
groups	B-X
,	B-X
where	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
kidney	B-X
tissue	B-X
Se	B-X
contents	B-X
of	B-X
SHR	B-X
rats	B-X
exceeded	B-X
3-	B-X
and	B-X
7-fold	B-X
the	B-X
normotensive	B-X
ones	B-X
.	B-X
The	B-X
Se	B-X
uptake	B-X
was	B-X
altered	B-X
by	B-X
the	B-X
vitamin	B-X
E	B-X
;	B-X
no	B-X
effect	B-X
of	B-X
Zn	B-X
was	B-X
observed	B-X
.	B-X

Angiogenesis	O
was	O
studied	O
with	O
factor	B-Gene_or_gene_product
8	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
(	O
F8	B-Gene_or_gene_product
-	I-Gene_or_gene_product
RA	I-Gene_or_gene_product
)	O
which	O
identifies	O
endothelial	O
cells	O
.	O
<EOS>	B-X
In	B-X
an	B-X
experiment	B-X
in	B-X
which	B-X
vitamin	B-X
E	B-X
inhibited	B-X
carcinogenesis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
tumour	B-X
angiogenesis	B-X
and	B-X
tumour	B-X
growth-factor	B-X
alpha	B-X
(	B-X
TGF	B-X
alpha	B-X
)	B-X
expression	B-X
were	B-X
also	B-X
inhibited	B-X
.	B-X
Angiogenesis	B-X
was	B-X
studied	B-X
with	B-X
factor	B-X
8-related	B-X
antigen	B-X
(	B-X
F8-RA	B-X
)	B-X
which	B-X
identifies	B-X
endothelial	B-X
cells	B-X
.	B-X
TGF	B-X
alpha	B-X
was	B-X
studied	B-X
with	B-X
the	B-X
appropriate	B-X
antibody	B-X
.	B-X
Angiogenesis	B-X
was	B-X
significantly	B-X
inhibited	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
and	B-X
TGF	B-X
alpha	B-X
expression	B-X
was	B-X
also	B-X
inhibited	B-X
.	B-X

TGF	B-Gene_or_gene_product
alpha	I-Gene_or_gene_product
was	O
studied	O
with	O
the	O
appropriate	O
antibody	O
.	O
<EOS>	B-X
inhibiting	B-X
TGF-Î²1	B-X
and	B-X
-Î²3	B-X
or	B-X
treating	B-X
with	B-X
Imatinib	B-X
,	B-X
which	B-X
results	B-X
in	B-X
scarcer	B-X
collagen	B-X
fibril	B-X
structure	B-X
in	B-X
xenografted	B-X
human	B-X
KAT-4/HT29	B-X
(	B-X
KAT-4	B-X
)	B-X
colon	B-X
adenocarcinoma	B-X
.	B-X
It	B-X
does	B-X
not	B-X
cause	B-X
marrow	B-X
suppression	B-X
and	B-X
has	B-X
stimulatory	B-X
effects	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
production	B-X
.	B-X
Because	B-X
IL-2	B-X
stimulation	B-X
of	B-X
cytotoxic	B-X
T-cells	B-X
will	B-X
depend	B-X
on	B-X
appropriate	B-X
antigen	B-X
presentation	B-X
,	B-X
human	B-X
lymphocyte	B-X
antigen	B-X
Class	B-X
I	B-X
expression	B-X
was	B-X
studied	B-X
,	B-X
as	B-X
was	B-X
the	B-X
peptide	B-X
transporter	B-X
system	B-X
RING4	B-X
(	B-X
TAP1	B-X
)	B-X
.	B-X
The	B-X
epithelial-to-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
is	B-X
known	B-X
to	B-X
have	B-X
a	B-X
role	B-X
in	B-X
appropriate	B-X
embryonic	B-X
development	B-X
,	B-X
the	B-X
physiological	B-X
response	B-X
to	B-X
injury	B-X
and	B-X
pathological	B-X
events	B-X
such	B-X
as	B-X
organ	B-X
fibrosis	B-X
and	B-X
cancer	B-X
progression	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
GC	B-X
on	B-X
preserving	B-X
peritoneal	B-X
membrane	B-X
function	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
dexamethasone	B-X
(	B-X
DEXA	B-X
)	B-X
,	B-X
a	B-X
synthetic	B-X
GC	B-X
,	B-X
on	B-X
the	B-X
transforming	B-X
growth	B-X
factor-Î²1	B-X
(	B-X
TGF-Î²1	B-X
)	B-X
-induced	B-X
EMT	B-X
in	B-X
HPMCs	B-X
.	B-X
As	B-X
assessed	B-X
by	B-X
changes	B-X
in	B-X
cell	B-X
morphology	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
epithelial	B-X
and	B-X
mesenchymal	B-X
cell	B-X
markers	B-X
(	B-X
such	B-X
as	B-X
E-cadherin	B-X
,	B-X
ZO-1	B-X
and	B-X
Î±-SMA	B-X
,	B-X
Î±-smooth	B-X
muscle	B-X
actin	B-X
)	B-X
and	B-X
cell	B-X
migration	B-X
,	B-X
DEXA	B-X
inhibited	B-X
the	B-X
TGF-Î²1-induced	B-X
EMT	B-X
.	B-X
RU486	B-X
,	B-X
a	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
antagonist	B-X
,	B-X
blocked	B-X
the	B-X
effect	B-X
of	B-X
DEXA	B-X
on	B-X
the	B-X
TGF-Î²1-induced	B-X
EMT	B-X
.	B-X
Importantly	B-X
,	B-X
DEXA	B-X
also	B-X
induced	B-X
the	B-X
mesenchymal-to-epithelial	B-X
transition	B-X
of	B-X
TGF-Î²1-stimulated	B-X
HPMCs	B-X
.	B-X
The	B-X
beneficial	B-X
effect	B-X
of	B-X
DEXA	B-X
on	B-X
the	B-X
TGF-Î²1-induced	B-X
EMT	B-X
was	B-X
mediated	B-X
through	B-X
the	B-X
amelioration	B-X
of	B-X
ERK	B-X
and	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
phosphorylation	B-X
;	B-X
however	B-X
,	B-X
this	B-X
effect	B-X
was	B-X
not	B-X
related	B-X
to	B-X
the	B-X
TGF-Î²1-induced	B-X
activation	B-X
of	B-X
Smad2/3	B-X
signaling	B-X
.	B-X
DEXA	B-X
inhibited	B-X
glycogen	B-X
synthase	B-X
kinase-3Î²	B-X
(	B-X
GSK-3Î²	B-X
)	B-X
phosphorylation	B-X
and	B-X
the	B-X
Snail	B-X
upregulation	B-X
induced	B-X
by	B-X
TGF-Î²1	B-X
,	B-X
which	B-X
were	B-X
also	B-X
ameliorated	B-X
by	B-X
inhibitors	B-X
of	B-X
MAPK	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
this	B-X
is	B-X
the	B-X
first	B-X
study	B-X
demonstrating	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
DEXA	B-X
on	B-X
the	B-X
EMT	B-X
in	B-X
TGF-Î²1-stimulated	B-X
HPMCs	B-X
by	B-X
inhibiting	B-X
MAPK	B-X
activation	B-X
,	B-X
GSK-3Î²	B-X
phosphorylation	B-X
and	B-X
Snail	B-X
upregulation	B-X
.	B-X

Staining	O
was	O
effected	O
by	O
the	O
standard	O
avidin	B-Gene_or_gene_product
-	O
biotin	O
horseradish	O
peroxidase	B-Gene_or_gene_product
system	O
.	O
<EOS>	B-X
Staining	B-X
was	B-X
effected	B-X
by	B-X
the	B-X
standard	B-X
avidin-biotin	B-X
horseradish	B-X
peroxidase	B-X
system	B-X
.	B-X

Mean	O
tumour	O
volume	O
was	O
significantly	O
lower	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
compared	O
to	O
the	O
tumour	O
control	O
group	O
.	O

Angiogenesis	O
was	O
significantly	O
inhibited	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
and	O
TGF	B-Gene_or_gene_product
alpha	I-Gene_or_gene_product
expression	O
was	O
also	O
inhibited	O
.	O
<EOS>	B-X
In	B-X
an	B-X
experiment	B-X
in	B-X
which	B-X
vitamin	B-X
E	B-X
inhibited	B-X
carcinogenesis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
tumour	B-X
angiogenesis	B-X
and	B-X
tumour	B-X
growth-factor	B-X
alpha	B-X
(	B-X
TGF	B-X
alpha	B-X
)	B-X
expression	B-X
were	B-X
also	B-X
inhibited	B-X
.	B-X
Forty	B-X
male	B-X
golden	B-X
hamsters	B-X
were	B-X
divided	B-X
into	B-X
four	B-X
equal	B-X
groups	B-X
.	B-X
Group	B-X
1	B-X
animals	B-X
had	B-X
the	B-X
left	B-X
buccal	B-X
pouches	B-X
painted	B-X
three	B-X
times	B-X
weekly	B-X
with	B-X
7,12-dimethylbenz	B-X
(	B-X
a	B-X
)	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
for	B-X
14	B-X
weeks	B-X
.	B-X
Group	B-X
2	B-X
animals	B-X
had	B-X
the	B-X
same	B-X
procedure	B-X
of	B-X
DMBA	B-X
applications	B-X
but	B-X
also	B-X
received	B-X
alpha	B-X
tocopherol	B-X
.	B-X
Groups	B-X
3	B-X
and	B-X
4	B-X
were	B-X
vitamin	B-X
E	B-X
and	B-X
untreated	B-X
controls	B-X
.	B-X
Angiogenesis	B-X
was	B-X
studied	B-X
with	B-X
factor	B-X
8-related	B-X
antigen	B-X
(	B-X
F8-RA	B-X
)	B-X
which	B-X
identifies	B-X
endothelial	B-X
cells	B-X
.	B-X
TGF	B-X
alpha	B-X
was	B-X
studied	B-X
with	B-X
the	B-X
appropriate	B-X
antibody	B-X
.	B-X
Mean	B-X
tumour	B-X
volume	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
compared	B-X
to	B-X
the	B-X
tumour	B-X
control	B-X
group	B-X
.	B-X
Angiogenesis	B-X
was	B-X
significantly	B-X
inhibited	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
and	B-X
TGF	B-X
alpha	B-X
expression	B-X
was	B-X
also	B-X
inhibited	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
inhibition	B-X
of	B-X
tumour	B-X
angiogenesis	B-X
by	B-X
vitamin	B-X
E	B-X
may	B-X
be	B-X
an	B-X
additional	B-X
mechanism	B-X
for	B-X
the	B-X
anticancer	B-X
action	B-X
of	B-X
vitamin	B-X
E	B-X
.	B-X

It	O
is	O
suggested	O
that	O
inhibition	O
of	O
tumour	O
angiogenesis	O
by	O
vitamin	O
E	O
may	O
be	O
an	O
additional	O
mechanism	O
for	O
the	O
anticancer	O
action	O
of	O
vitamin	O
E	O
.	O
<EOS>	B-X
In	B-X
an	B-X
experiment	B-X
in	B-X
which	B-X
vitamin	B-X
E	B-X
inhibited	B-X
carcinogenesis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
tumour	B-X
angiogenesis	B-X
and	B-X
tumour	B-X
growth-factor	B-X
alpha	B-X
(	B-X
TGF	B-X
alpha	B-X
)	B-X
expression	B-X
were	B-X
also	B-X
inhibited	B-X
.	B-X
Groups	B-X
3	B-X
and	B-X
4	B-X
were	B-X
vitamin	B-X
E	B-X
and	B-X
untreated	B-X
controls	B-X
.	B-X
Mean	B-X
tumour	B-X
volume	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
compared	B-X
to	B-X
the	B-X
tumour	B-X
control	B-X
group	B-X
.	B-X
Angiogenesis	B-X
was	B-X
significantly	B-X
inhibited	B-X
in	B-X
the	B-X
DMBA-vitamin	B-X
E	B-X
group	B-X
and	B-X
TGF	B-X
alpha	B-X
expression	B-X
was	B-X
also	B-X
inhibited	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
inhibition	B-X
of	B-X
tumour	B-X
angiogenesis	B-X
by	B-X
vitamin	B-X
E	B-X
may	B-X
be	B-X
an	B-X
additional	B-X
mechanism	B-X
for	B-X
the	B-X
anticancer	B-X
action	B-X
of	B-X
vitamin	B-X
E	B-X
.	B-X

Curcumin	O
induces	O
apoptosis	O
in	O
immortalized	O
NIH	O
3T3	O
and	O
malignant	O
cancer	O
cell	O
lines	O
.	O
<EOS>	B-X
Curcumin	B-X
,	B-X
which	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
dietary	B-X
pigment	B-X
and	B-X
spice	B-X
,	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
inhibitor	B-X
of	B-X
tumor	B-X
promotion	B-X
in	B-X
mouse	B-X
skin	B-X
carcinogenesis	B-X
.	B-X
We	B-X
report	B-X
that	B-X
curcumin	B-X
induces	B-X
cell	B-X
shrinkage	B-X
,	B-X
chromatin	B-X
condensation	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
,	B-X
characteristics	B-X
of	B-X
apoptosis	B-X
,	B-X
in	B-X
immortalized	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
NIH	B-X
3T3	B-X
erb	B-X
B2	B-X
oncogene-transformed	B-X
NIH	B-X
3T3	B-X
,	B-X
mouse	B-X
sarcoma	B-X
S180	B-X
,	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
HT-29	B-X
,	B-X
human	B-X
kidney	B-X
cancer	B-X
cell	B-X
293	B-X
,	B-X
and	B-X
human	B-X
hepatocellular	B-X
carcinoma	B-X
Hep	B-X
G2	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
primary	B-X
culture	B-X
of	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
C3H	B-X
10T1/2	B-X
,	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
,	B-X
and	B-X
human	B-X
foreskin	B-X
fibroblast	B-X
cells	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Many	B-X
cellular	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
curcumin	B-X
in	B-X
mouse	B-X
fibroblast	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activity	B-X
induced	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
treatment	B-X
,	B-X
inhibition	B-X
of	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
metabolism	B-X
.	B-X
Treatment	B-X
of	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
,	B-X
and	B-X
the	B-X
AA	B-X
metabolism	B-X
inhibitor	B-X
quinacrine	B-X
induces	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
some	B-X
immortalized	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
blocking	B-X
the	B-X
cellular	B-X
signal	B-X
transduction	B-X
might	B-X
trigger	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X

Curcumin	O
,	O
which	O
is	O
a	O
widely	O
used	O
dietary	O
pigment	O
and	O
spice	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
an	O
effective	O
inhibitor	O
of	O
tumor	O
promotion	O
in	O
mouse	O
skin	O
carcinogenesis	O
.	O
<EOS>	B-X
Curcumin	B-X
,	B-X
which	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
dietary	B-X
pigment	B-X
and	B-X
spice	B-X
,	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
inhibitor	B-X
of	B-X
tumor	B-X
promotion	B-X
in	B-X
mouse	B-X
skin	B-X
carcinogenesis	B-X
.	B-X
We	B-X
report	B-X
that	B-X
curcumin	B-X
induces	B-X
cell	B-X
shrinkage	B-X
,	B-X
chromatin	B-X
condensation	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
,	B-X
characteristics	B-X
of	B-X
apoptosis	B-X
,	B-X
in	B-X
immortalized	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
NIH	B-X
3T3	B-X
erb	B-X
B2	B-X
oncogene-transformed	B-X
NIH	B-X
3T3	B-X
,	B-X
mouse	B-X
sarcoma	B-X
S180	B-X
,	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
HT-29	B-X
,	B-X
human	B-X
kidney	B-X
cancer	B-X
cell	B-X
293	B-X
,	B-X
and	B-X
human	B-X
hepatocellular	B-X
carcinoma	B-X
Hep	B-X
G2	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
primary	B-X
culture	B-X
of	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
C3H	B-X
10T1/2	B-X
,	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
,	B-X
and	B-X
human	B-X
foreskin	B-X
fibroblast	B-X
cells	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Many	B-X
cellular	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
curcumin	B-X
in	B-X
mouse	B-X
fibroblast	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activity	B-X
induced	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
treatment	B-X
,	B-X
inhibition	B-X
of	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
metabolism	B-X
.	B-X
Treatment	B-X
of	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
,	B-X
and	B-X
the	B-X
AA	B-X
metabolism	B-X
inhibitor	B-X
quinacrine	B-X
induces	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X

We	O
report	O
that	O
curcumin	O
induces	O
cell	O
shrinkage	O
,	O
chromatin	O
condensation	O
,	O
and	O
DNA	O
fragmentation	O
,	O
characteristics	O
of	O
apoptosis	O
,	O
in	O
immortalized	O
mouse	O
embryo	O
fibroblast	O
NIH	O
3T3	O
erb	B-Gene_or_gene_product
B2	I-Gene_or_gene_product
oncogene	O
-	O
transformed	O
NIH	O
3T3	O
,	O
mouse	O
sarcoma	O
S180	O
,	O
human	O
colon	O
cancer	O
cell	O
HT	O
-	O
29	O
,	O
human	O
kidney	O
cancer	O
cell	O
293	O
,	O
and	O
human	O
hepatocellular	O
carcinoma	O
Hep	O
G2	O
cells	O
,	O
but	O
not	O
in	O
primary	O
culture	O
of	O
mouse	O
embryonic	O
fibroblast	O
C3H	O
10T1	O
/	O
2	O
,	O
rat	O
embryonic	O
fibroblast	O
,	O
and	O
human	O
foreskin	O
fibroblast	O
cells	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
<EOS>	B-X
Curcumin	B-X
,	B-X
which	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
dietary	B-X
pigment	B-X
and	B-X
spice	B-X
,	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
inhibitor	B-X
of	B-X
tumor	B-X
promotion	B-X
in	B-X
mouse	B-X
skin	B-X
carcinogenesis	B-X
.	B-X
We	B-X
report	B-X
that	B-X
curcumin	B-X
induces	B-X
cell	B-X
shrinkage	B-X
,	B-X
chromatin	B-X
condensation	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
,	B-X
characteristics	B-X
of	B-X
apoptosis	B-X
,	B-X
in	B-X
immortalized	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
NIH	B-X
3T3	B-X
erb	B-X
B2	B-X
oncogene-transformed	B-X
NIH	B-X
3T3	B-X
,	B-X
mouse	B-X
sarcoma	B-X
S180	B-X
,	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
HT-29	B-X
,	B-X
human	B-X
kidney	B-X
cancer	B-X
cell	B-X
293	B-X
,	B-X
and	B-X
human	B-X
hepatocellular	B-X
carcinoma	B-X
Hep	B-X
G2	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
primary	B-X
culture	B-X
of	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
C3H	B-X
10T1/2	B-X
,	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
,	B-X
and	B-X
human	B-X
foreskin	B-X
fibroblast	B-X
cells	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Many	B-X
cellular	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
curcumin	B-X
in	B-X
mouse	B-X
fibroblast	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activity	B-X
induced	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
treatment	B-X
,	B-X
inhibition	B-X
of	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
metabolism	B-X
.	B-X
Treatment	B-X
of	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
,	B-X
and	B-X
the	B-X
AA	B-X
metabolism	B-X
inhibitor	B-X
quinacrine	B-X
induces	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
some	B-X
immortalized	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
blocking	B-X
the	B-X
cellular	B-X
signal	B-X
transduction	B-X
might	B-X
trigger	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X

Many	O
cellular	O
and	O
biochemical	O
effects	O
of	O
curcumin	O
in	O
mouse	O
fibroblast	O
cells	O
have	O
been	O
reported	O
,	O
such	O
as	O
inhibition	O
of	O
protein	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
C	I-Gene_or_gene_product
(	O
PKC	B-Gene_or_gene_product
)	O
activity	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
treatment	O
,	O
inhibition	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
and	O
inhibition	O
of	O
arachidonic	O
acid	O
(	O
AA	O
)	O
metabolism	O
.	O
<EOS>	B-X
Curcumin	B-X
,	B-X
which	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
dietary	B-X
pigment	B-X
and	B-X
spice	B-X
,	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
inhibitor	B-X
of	B-X
tumor	B-X
promotion	B-X
in	B-X
mouse	B-X
skin	B-X
carcinogenesis	B-X
.	B-X
We	B-X
report	B-X
that	B-X
curcumin	B-X
induces	B-X
cell	B-X
shrinkage	B-X
,	B-X
chromatin	B-X
condensation	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
,	B-X
characteristics	B-X
of	B-X
apoptosis	B-X
,	B-X
in	B-X
immortalized	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
NIH	B-X
3T3	B-X
erb	B-X
B2	B-X
oncogene-transformed	B-X
NIH	B-X
3T3	B-X
,	B-X
mouse	B-X
sarcoma	B-X
S180	B-X
,	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
HT-29	B-X
,	B-X
human	B-X
kidney	B-X
cancer	B-X
cell	B-X
293	B-X
,	B-X
and	B-X
human	B-X
hepatocellular	B-X
carcinoma	B-X
Hep	B-X
G2	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
primary	B-X
culture	B-X
of	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
C3H	B-X
10T1/2	B-X
,	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
,	B-X
and	B-X
human	B-X
foreskin	B-X
fibroblast	B-X
cells	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Many	B-X
cellular	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
curcumin	B-X
in	B-X
mouse	B-X
fibroblast	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activity	B-X
induced	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
treatment	B-X
,	B-X
inhibition	B-X
of	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
metabolism	B-X
.	B-X
Treatment	B-X
of	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
,	B-X
and	B-X
the	B-X
AA	B-X
metabolism	B-X
inhibitor	B-X
quinacrine	B-X
induces	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
some	B-X
immortalized	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
blocking	B-X
the	B-X
cellular	B-X
signal	B-X
transduction	B-X
might	B-X
trigger	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X

Treatment	O
of	O
NIH	O
3T3	O
cells	O
with	O
the	O
PKC	B-Gene_or_gene_product
inhibitor	O
staurosporine	O
,	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
,	O
and	O
the	O
AA	O
metabolism	O
inhibitor	O
quinacrine	O
induces	O
apoptotic	O
cell	O
death	O
.	O
<EOS>	B-X
Curcumin	B-X
,	B-X
which	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
dietary	B-X
pigment	B-X
and	B-X
spice	B-X
,	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
inhibitor	B-X
of	B-X
tumor	B-X
promotion	B-X
in	B-X
mouse	B-X
skin	B-X
carcinogenesis	B-X
.	B-X
We	B-X
report	B-X
that	B-X
curcumin	B-X
induces	B-X
cell	B-X
shrinkage	B-X
,	B-X
chromatin	B-X
condensation	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
,	B-X
characteristics	B-X
of	B-X
apoptosis	B-X
,	B-X
in	B-X
immortalized	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
NIH	B-X
3T3	B-X
erb	B-X
B2	B-X
oncogene-transformed	B-X
NIH	B-X
3T3	B-X
,	B-X
mouse	B-X
sarcoma	B-X
S180	B-X
,	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
HT-29	B-X
,	B-X
human	B-X
kidney	B-X
cancer	B-X
cell	B-X
293	B-X
,	B-X
and	B-X
human	B-X
hepatocellular	B-X
carcinoma	B-X
Hep	B-X
G2	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
primary	B-X
culture	B-X
of	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
C3H	B-X
10T1/2	B-X
,	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
,	B-X
and	B-X
human	B-X
foreskin	B-X
fibroblast	B-X
cells	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Many	B-X
cellular	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
curcumin	B-X
in	B-X
mouse	B-X
fibroblast	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activity	B-X
induced	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
treatment	B-X
,	B-X
inhibition	B-X
of	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
metabolism	B-X
.	B-X
Treatment	B-X
of	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
,	B-X
and	B-X
the	B-X
AA	B-X
metabolism	B-X
inhibitor	B-X
quinacrine	B-X
induces	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
some	B-X
immortalized	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
blocking	B-X
the	B-X
cellular	B-X
signal	B-X
transduction	B-X
might	B-X
trigger	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X

These	O
results	O
suggest	O
that	O
,	O
in	O
some	O
immortalized	O
and	O
transformed	O
cells	O
,	O
blocking	O
the	O
cellular	O
signal	O
transduction	O
might	O
trigger	O
the	O
induction	O
of	O
apoptosis	O
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
curcumin	B-X
induces	B-X
cell	B-X
shrinkage	B-X
,	B-X
chromatin	B-X
condensation	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
,	B-X
characteristics	B-X
of	B-X
apoptosis	B-X
,	B-X
in	B-X
immortalized	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
NIH	B-X
3T3	B-X
erb	B-X
B2	B-X
oncogene-transformed	B-X
NIH	B-X
3T3	B-X
,	B-X
mouse	B-X
sarcoma	B-X
S180	B-X
,	B-X
human	B-X
colon	B-X
cancer	B-X
cell	B-X
HT-29	B-X
,	B-X
human	B-X
kidney	B-X
cancer	B-X
cell	B-X
293	B-X
,	B-X
and	B-X
human	B-X
hepatocellular	B-X
carcinoma	B-X
Hep	B-X
G2	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
primary	B-X
culture	B-X
of	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
C3H	B-X
10T1/2	B-X
,	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
,	B-X
and	B-X
human	B-X
foreskin	B-X
fibroblast	B-X
cells	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Many	B-X
cellular	B-X
and	B-X
biochemical	B-X
effects	B-X
of	B-X
curcumin	B-X
in	B-X
mouse	B-X
fibroblast	B-X
cells	B-X
have	B-X
been	B-X
reported	B-X
,	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activity	B-X
induced	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
treatment	B-X
,	B-X
inhibition	B-X
of	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
metabolism	B-X
.	B-X
Treatment	B-X
of	B-X
NIH	B-X
3T3	B-X
cells	B-X
with	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
,	B-X
and	B-X
the	B-X
AA	B-X
metabolism	B-X
inhibitor	B-X
quinacrine	B-X
induces	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
some	B-X
immortalized	B-X
and	B-X
transformed	B-X
cells	B-X
,	B-X
blocking	B-X
the	B-X
cellular	B-X
signal	B-X
transduction	B-X
might	B-X
trigger	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X

Fas	B-Gene_or_gene_product
-	O
signaling	O
and	O
effects	O
on	O
receptor	B-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
signal	O
transduction	O
in	O
human	O
breast	O
epithelial	O
cells	O
.	O
<EOS>	B-X
Fas-mediated	B-X
cell	B-X
death	B-X
was	B-X
examined	B-X
in	B-X
MCF-10AT	B-X
preneoplastic	B-X
human	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
apoptosis	B-X
with	B-X
cells	B-X
exhibiting	B-X
typical	B-X
apoptotic	B-X
features	B-X
including	B-X
loss	B-X
of	B-X
cell	B-X
contact	B-X
,	B-X
condensation	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
increased	B-X
staining	B-X
of	B-X
the	B-X
nuclear	B-X
membrane	B-X
.	B-X
DNA	B-X
fragmentation	B-X
occurred	B-X
in	B-X
response	B-X
to	B-X
anti-Fas	B-X
treatment	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
resulted	B-X
in	B-X
decreased	B-X
p53	B-X
protein	B-X
levels	B-X
,	B-X
while	B-X
bcl-2	B-X
and	B-X
bax	B-X
protein	B-X
levels	B-X
remained	B-X
unaffected	B-X
.	B-X
Cells	B-X
treated	B-X
with	B-X
anti-Fas	B-X
also	B-X
exhibited	B-X
increased	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
c-met	B-X
growth	B-X
factor	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
demonstrated	B-X
that	B-X
Fas	B-X
associated	B-X
with	B-X
c-erbB2	B-X
and	B-X
c-met	B-X
in	B-X
untreated	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
,	B-X
however	B-X
,	B-X
significantly	B-X
decreased	B-X
Fas-c-erbB2	B-X
and	B-X
Fas-c-met	B-X
association	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
of	B-X
these	B-X
cells	B-X
caused	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
p120-GAP	B-X
levels	B-X
,	B-X
ERK-1	B-X
levels	B-X
,	B-X
and	B-X
phosphorylation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Grb2-Sosl	B-X
and	B-X
MEK-1-ERK-1	B-X
association	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Fas-signaling	B-X
exerted	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
p53	B-X
levels	B-X
and	B-X
on	B-X
downstream	B-X
effectors	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
signal	B-X
transduction	B-X
,	B-X
thereby	B-X
ensuring	B-X
cell	B-X
death	B-X
.	B-X

Fas	B-Gene_or_gene_product
-	O
mediated	O
cell	O
death	O
was	O
examined	O
in	O
MCF	O
-	O
10AT	O
preneoplastic	O
human	O
breast	O
epithelial	O
cells	O
.	O
<EOS>	B-X
Proliferative	B-X
breast	B-X
disease	B-X
(	B-X
PBD	B-X
)	B-X
may	B-X
increase	B-X
a	B-X
woman	B-X
's	B-X
risk	B-X
of	B-X
developing	B-X
breast	B-X
cancer	B-X
,	B-X
perhaps	B-X
by	B-X
decreasing	B-X
cellular	B-X
sensitivity	B-X
to	B-X
apoptosis	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
resistance	B-X
to	B-X
apoptosis	B-X
develops	B-X
during	B-X
PBD	B-X
,	B-X
we	B-X
investigated	B-X
apoptosis	B-X
initiated	B-X
through	B-X
the	B-X
Fas	B-X
pathway	B-X
in	B-X
a	B-X
series	B-X
of	B-X
cell	B-X
lines	B-X
that	B-X
recapitulates	B-X
the	B-X
morphologic	B-X
changes	B-X
of	B-X
PBD	B-X
in	B-X
nude/beige	B-X
mice	B-X
.	B-X
Fas-mediated	B-X
cell	B-X
death	B-X
was	B-X
examined	B-X
in	B-X
MCF-10AT	B-X
preneoplastic	B-X
human	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
apoptosis	B-X
with	B-X
cells	B-X
exhibiting	B-X
typical	B-X
apoptotic	B-X
features	B-X
including	B-X
loss	B-X
of	B-X
cell	B-X
contact	B-X
,	B-X
condensation	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
increased	B-X
staining	B-X
of	B-X
the	B-X
nuclear	B-X
membrane	B-X
.	B-X
DNA	B-X
fragmentation	B-X
occurred	B-X
in	B-X
response	B-X
to	B-X
anti-Fas	B-X
treatment	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
resulted	B-X
in	B-X
decreased	B-X
p53	B-X
protein	B-X
levels	B-X
,	B-X
while	B-X
bcl-2	B-X
and	B-X
bax	B-X
protein	B-X
levels	B-X
remained	B-X
unaffected	B-X
.	B-X
Cells	B-X
treated	B-X
with	B-X
anti-Fas	B-X
also	B-X
exhibited	B-X
increased	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
c-met	B-X
growth	B-X
factor	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
demonstrated	B-X
that	B-X
Fas	B-X
associated	B-X
with	B-X
c-erbB2	B-X
and	B-X
c-met	B-X
in	B-X
untreated	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
,	B-X
however	B-X
,	B-X
significantly	B-X
decreased	B-X
Fas-c-erbB2	B-X
and	B-X
Fas-c-met	B-X
association	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
of	B-X
these	B-X
cells	B-X
caused	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
p120-GAP	B-X
levels	B-X
,	B-X
ERK-1	B-X
levels	B-X
,	B-X
and	B-X
phosphorylation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Grb2-Sosl	B-X
and	B-X
MEK-1-ERK-1	B-X
association	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Fas-signaling	B-X
exerted	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
p53	B-X
levels	B-X
and	B-X
on	B-X
downstream	B-X
effectors	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
signal	B-X
transduction	B-X
,	B-X
thereby	B-X
ensuring	B-X
cell	B-X
death	B-X
.	B-X

Treatment	O
with	O
anti	O
-	O
Fas	B-Gene_or_gene_product
for	O
48	O
h	O
induced	O
apoptosis	O
with	O
cells	O
exhibiting	O
typical	O
apoptotic	O
features	O
including	O
loss	O
of	O
cell	O
contact	O
,	O
condensation	O
of	O
chromatin	O
,	O
and	O
increased	O
staining	O
of	O
the	O
nuclear	O
membrane	O
.	O
<EOS>	B-X
Fas-mediated	B-X
cell	B-X
death	B-X
was	B-X
examined	B-X
in	B-X
MCF-10AT	B-X
preneoplastic	B-X
human	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
apoptosis	B-X
with	B-X
cells	B-X
exhibiting	B-X
typical	B-X
apoptotic	B-X
features	B-X
including	B-X
loss	B-X
of	B-X
cell	B-X
contact	B-X
,	B-X
condensation	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
increased	B-X
staining	B-X
of	B-X
the	B-X
nuclear	B-X
membrane	B-X
.	B-X
DNA	B-X
fragmentation	B-X
occurred	B-X
in	B-X
response	B-X
to	B-X
anti-Fas	B-X
treatment	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
resulted	B-X
in	B-X
decreased	B-X
p53	B-X
protein	B-X
levels	B-X
,	B-X
while	B-X
bcl-2	B-X
and	B-X
bax	B-X
protein	B-X
levels	B-X
remained	B-X
unaffected	B-X
.	B-X
Cells	B-X
treated	B-X
with	B-X
anti-Fas	B-X
also	B-X
exhibited	B-X
increased	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
c-met	B-X
growth	B-X
factor	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
demonstrated	B-X
that	B-X
Fas	B-X
associated	B-X
with	B-X
c-erbB2	B-X
and	B-X
c-met	B-X
in	B-X
untreated	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
,	B-X
however	B-X
,	B-X
significantly	B-X
decreased	B-X
Fas-c-erbB2	B-X
and	B-X
Fas-c-met	B-X
association	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
of	B-X
these	B-X
cells	B-X
caused	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
p120-GAP	B-X
levels	B-X
,	B-X
ERK-1	B-X
levels	B-X
,	B-X
and	B-X
phosphorylation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Grb2-Sosl	B-X
and	B-X
MEK-1-ERK-1	B-X
association	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Fas-signaling	B-X
exerted	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
p53	B-X
levels	B-X
and	B-X
on	B-X
downstream	B-X
effectors	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
signal	B-X
transduction	B-X
,	B-X
thereby	B-X
ensuring	B-X
cell	B-X
death	B-X
.	B-X

DNA	O
fragmentation	O
occurred	O
in	O
response	O
to	O
anti	O
-	O
Fas	B-Gene_or_gene_product
treatment	O
.	O
<EOS>	B-X
We	B-X
examined	B-X
mitochondrial	B-X
function	B-X
in	B-X
FA	B-X
cells	B-X
,	B-X
comparing	B-X
the	B-X
intrinsic	B-X
death	B-X
pathway	B-X
induced	B-X
by	B-X
MMC	B-X
with	B-X
the	B-X
extrinsic	B-X
pathway	B-X
via	B-X
Fas	B-X
antibody	B-X
,	B-X
which	B-X
can	B-X
bypass	B-X
the	B-X
mitochondria	B-X
.	B-X
Many	B-X
therapeutically	B-X
active	B-X
anticancer	B-X
treatments	B-X
exert	B-X
their	B-X
effect	B-X
by	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
and	B-X
necrosis	B-X
.	B-X
Serial	B-X
biopsies	B-X
in	B-X
breast	B-X
cancer	B-X
patients	B-X
have	B-X
suggested	B-X
that	B-X
response	B-X
to	B-X
therapy	B-X
correlates	B-X
with	B-X
early	B-X
posttreatment	B-X
increases	B-X
in	B-X
tumor	B-X
apoptotic	B-X
index	B-X
.	B-X
Radiolabeled	B-X
technetium	B-X
Tc	B-X
99m-recombinant	B-X
human	B-X
(	B-X
rh	B-X
)	B-X
annexin	B-X
V	B-X
provides	B-X
a	B-X
noninvasive	B-X
technique	B-X
for	B-X
imaging	B-X
treatment-induced	B-X
cell	B-X
death	B-X
.	B-X
Annexin	B-X
also	B-X
gains	B-X
access	B-X
to	B-X
PS	B-X
as	B-X
a	B-X
result	B-X
of	B-X
the	B-X
membrane	B-X
fragmentation	B-X
associated	B-X
with	B-X
necrosis	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
of	B-X
apoptosis	B-X
using	B-X
fluorescein	B-X
annexin	B-X
have	B-X
shown	B-X
good	B-X
correlation	B-X
with	B-X
assessments	B-X
of	B-X
apoptosis	B-X
documented	B-X
by	B-X
nuclear	B-X
DNA	B-X
degradation	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
In	B-X
vivo	B-X
localization	B-X
of	B-X
intravenously	B-X
administered	B-X
Tc	B-X
99m-annexin	B-X
V	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
numerous	B-X
preclinical	B-X
models	B-X
of	B-X
apoptosis	B-X
,	B-X
including	B-X
anti-Fas-mediated	B-X
hepatic	B-X
apoptosis	B-X
,	B-X
rejection	B-X
of	B-X
allogeneic	B-X
heterotopic	B-X
cardiac	B-X
allografts	B-X
,	B-X
cyclophosphamide	B-X
treatment	B-X
of	B-X
murine	B-X
lymphoma	B-X
,	B-X
cyclophosphamide-induced	B-X
apoptosis	B-X
in	B-X
bone	B-X
marrow	B-X
,	B-X
and	B-X
leukocyte	B-X
apoptosis	B-X
associated	B-X
with	B-X
abscess	B-X
formation	B-X
.	B-X
Scintigraphic	B-X
studies	B-X
in	B-X
humans	B-X
using	B-X
Tc	B-X
99m-rh	B-X
annexin	B-X
V	B-X
have	B-X
demonstrated	B-X
the	B-X
feasibility	B-X
of	B-X
imaging	B-X
cell	B-X
death	B-X
in	B-X
acute	B-X
myocardial	B-X
infarction	B-X
,	B-X
in	B-X
tumors	B-X
with	B-X
a	B-X
high	B-X
apoptotic	B-X
index	B-X
,	B-X
and	B-X
in	B-X
response	B-X
to	B-X
anti-tumor	B-X
chemotherapy	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
,	B-X
small-cell	B-X
lung	B-X
cancer	B-X
,	B-X
breast	B-X
cancer	B-X
,	B-X
lymphoma	B-X
,	B-X
and	B-X
sarcoma	B-X
.	B-X
To	B-X
date	B-X
,	B-X
most	B-X
subjects	B-X
showing	B-X
increased	B-X
Tc	B-X
99m-rh	B-X
annexin	B-X
V	B-X
uptake	B-X
after	B-X
the	B-X
first	B-X
course	B-X
of	B-X
chemotherapy	B-X
have	B-X
shown	B-X
objective	B-X
clinical	B-X
responses	B-X
.	B-X
A	B-X
single	B-X
site	B-X
study	B-X
in	B-X
15	B-X
subjects	B-X
with	B-X
1-year	B-X
follow-up	B-X
has	B-X
suggested	B-X
that	B-X
increased	B-X
posttreatment	B-X
Tc	B-X
99m-rh	B-X
annexin	B-X
uptake	B-X
is	B-X
associated	B-X
with	B-X
improved	B-X
time	B-X
to	B-X
progression	B-X
of	B-X
disease	B-X
and	B-X
survival	B-X
time	B-X
.	B-X
In	B-X
vivo	B-X
imaging	B-X
of	B-X
cell	B-X
death	B-X
may	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
improve	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
patients	B-X
by	B-X
allowing	B-X
rapid	B-X
,	B-X
objective	B-X
,	B-X
patient-by-patient	B-X
assessment	B-X
of	B-X
the	B-X
efficacy	B-X
of	B-X
tumor	B-X
cell	B-X
killing	B-X
.	B-X

Anti	O
-	O
Fas	B-Gene_or_gene_product
treatment	O
resulted	O
in	O
decreased	O
p53	B-Gene_or_gene_product
protein	O
levels	O
,	O
while	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
and	O
bax	B-Gene_or_gene_product
protein	O
levels	O
remained	O
unaffected	O
.	O
<EOS>	B-X
Fas-mediated	B-X
cell	B-X
death	B-X
was	B-X
examined	B-X
in	B-X
MCF-10AT	B-X
preneoplastic	B-X
human	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
apoptosis	B-X
with	B-X
cells	B-X
exhibiting	B-X
typical	B-X
apoptotic	B-X
features	B-X
including	B-X
loss	B-X
of	B-X
cell	B-X
contact	B-X
,	B-X
condensation	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
increased	B-X
staining	B-X
of	B-X
the	B-X
nuclear	B-X
membrane	B-X
.	B-X
DNA	B-X
fragmentation	B-X
occurred	B-X
in	B-X
response	B-X
to	B-X
anti-Fas	B-X
treatment	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
resulted	B-X
in	B-X
decreased	B-X
p53	B-X
protein	B-X
levels	B-X
,	B-X
while	B-X
bcl-2	B-X
and	B-X
bax	B-X
protein	B-X
levels	B-X
remained	B-X
unaffected	B-X
.	B-X
Cells	B-X
treated	B-X
with	B-X
anti-Fas	B-X
also	B-X
exhibited	B-X
increased	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
c-met	B-X
growth	B-X
factor	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
demonstrated	B-X
that	B-X
Fas	B-X
associated	B-X
with	B-X
c-erbB2	B-X
and	B-X
c-met	B-X
in	B-X
untreated	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
,	B-X
however	B-X
,	B-X
significantly	B-X
decreased	B-X
Fas-c-erbB2	B-X
and	B-X
Fas-c-met	B-X
association	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
of	B-X
these	B-X
cells	B-X
caused	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
p120-GAP	B-X
levels	B-X
,	B-X
ERK-1	B-X
levels	B-X
,	B-X
and	B-X
phosphorylation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Grb2-Sosl	B-X
and	B-X
MEK-1-ERK-1	B-X
association	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Fas-signaling	B-X
exerted	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
p53	B-X
levels	B-X
and	B-X
on	B-X
downstream	B-X
effectors	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
signal	B-X
transduction	B-X
,	B-X
thereby	B-X
ensuring	B-X
cell	B-X
death	B-X
.	B-X

Cells	O
treated	O
with	O
anti	O
-	O
Fas	B-Gene_or_gene_product
also	O
exhibited	O
increased	O
tyrosine	O
phosphorylation	O
of	O
the	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
met	I-Gene_or_gene_product
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
.	O

Immunoprecipitation	O
experiments	O
demonstrated	O
that	O
Fas	B-Gene_or_gene_product
associated	O
with	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
erbB2	I-Gene_or_gene_product
and	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
met	I-Gene_or_gene_product
in	O
untreated	O
cells	O
.	O

Treatment	O
with	O
anti	O
-	O
Fas	B-Gene_or_gene_product
,	O
however	O
,	O
significantly	O
decreased	O
Fas	B-Gene_or_gene_product
-	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
erbB2	I-Gene_or_gene_product
and	O
Fas	B-Gene_or_gene_product
-	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
met	I-Gene_or_gene_product
association	O
.	O

Anti	O
-	O
Fas	B-Gene_or_gene_product
treatment	O
of	O
these	O
cells	O
caused	O
a	O
significant	O
decrease	O
in	O
p120	B-Gene_or_gene_product
-	O
GAP	B-Gene_or_gene_product
levels	O
,	O
ERK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
levels	O
,	O
and	O
phosphorylation	O
,	O
as	O
well	O
as	O
Grb2	B-Gene_or_gene_product
-	O
Sosl	B-Gene_or_gene_product
and	O
MEK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
ERK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
association	O
.	O
<EOS>	B-X
Fas-mediated	B-X
cell	B-X
death	B-X
was	B-X
examined	B-X
in	B-X
MCF-10AT	B-X
preneoplastic	B-X
human	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
apoptosis	B-X
with	B-X
cells	B-X
exhibiting	B-X
typical	B-X
apoptotic	B-X
features	B-X
including	B-X
loss	B-X
of	B-X
cell	B-X
contact	B-X
,	B-X
condensation	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
increased	B-X
staining	B-X
of	B-X
the	B-X
nuclear	B-X
membrane	B-X
.	B-X
DNA	B-X
fragmentation	B-X
occurred	B-X
in	B-X
response	B-X
to	B-X
anti-Fas	B-X
treatment	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
resulted	B-X
in	B-X
decreased	B-X
p53	B-X
protein	B-X
levels	B-X
,	B-X
while	B-X
bcl-2	B-X
and	B-X
bax	B-X
protein	B-X
levels	B-X
remained	B-X
unaffected	B-X
.	B-X
Cells	B-X
treated	B-X
with	B-X
anti-Fas	B-X
also	B-X
exhibited	B-X
increased	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
c-met	B-X
growth	B-X
factor	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
demonstrated	B-X
that	B-X
Fas	B-X
associated	B-X
with	B-X
c-erbB2	B-X
and	B-X
c-met	B-X
in	B-X
untreated	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
,	B-X
however	B-X
,	B-X
significantly	B-X
decreased	B-X
Fas-c-erbB2	B-X
and	B-X
Fas-c-met	B-X
association	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
of	B-X
these	B-X
cells	B-X
caused	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
p120-GAP	B-X
levels	B-X
,	B-X
ERK-1	B-X
levels	B-X
,	B-X
and	B-X
phosphorylation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Grb2-Sosl	B-X
and	B-X
MEK-1-ERK-1	B-X
association	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Fas-signaling	B-X
exerted	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
p53	B-X
levels	B-X
and	B-X
on	B-X
downstream	B-X
effectors	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
signal	B-X
transduction	B-X
,	B-X
thereby	B-X
ensuring	B-X
cell	B-X
death	B-X
.	B-X

These	O
results	O
show	O
that	O
Fas	B-Gene_or_gene_product
-	O
signaling	O
exerted	O
a	O
suppressive	O
effect	O
on	O
p53	B-Gene_or_gene_product
levels	O
and	O
on	O
downstream	O
effectors	O
of	O
receptor	B-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
signal	O
transduction	O
,	O
thereby	O
ensuring	O
cell	O
death	O
.	O
<EOS>	B-X
Fas-mediated	B-X
cell	B-X
death	B-X
was	B-X
examined	B-X
in	B-X
MCF-10AT	B-X
preneoplastic	B-X
human	B-X
breast	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
for	B-X
48	B-X
h	B-X
induced	B-X
apoptosis	B-X
with	B-X
cells	B-X
exhibiting	B-X
typical	B-X
apoptotic	B-X
features	B-X
including	B-X
loss	B-X
of	B-X
cell	B-X
contact	B-X
,	B-X
condensation	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
increased	B-X
staining	B-X
of	B-X
the	B-X
nuclear	B-X
membrane	B-X
.	B-X
DNA	B-X
fragmentation	B-X
occurred	B-X
in	B-X
response	B-X
to	B-X
anti-Fas	B-X
treatment	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
resulted	B-X
in	B-X
decreased	B-X
p53	B-X
protein	B-X
levels	B-X
,	B-X
while	B-X
bcl-2	B-X
and	B-X
bax	B-X
protein	B-X
levels	B-X
remained	B-X
unaffected	B-X
.	B-X
Cells	B-X
treated	B-X
with	B-X
anti-Fas	B-X
also	B-X
exhibited	B-X
increased	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
c-met	B-X
growth	B-X
factor	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
.	B-X
Immunoprecipitation	B-X
experiments	B-X
demonstrated	B-X
that	B-X
Fas	B-X
associated	B-X
with	B-X
c-erbB2	B-X
and	B-X
c-met	B-X
in	B-X
untreated	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
anti-Fas	B-X
,	B-X
however	B-X
,	B-X
significantly	B-X
decreased	B-X
Fas-c-erbB2	B-X
and	B-X
Fas-c-met	B-X
association	B-X
.	B-X
Anti-Fas	B-X
treatment	B-X
of	B-X
these	B-X
cells	B-X
caused	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
p120-GAP	B-X
levels	B-X
,	B-X
ERK-1	B-X
levels	B-X
,	B-X
and	B-X
phosphorylation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Grb2-Sosl	B-X
and	B-X
MEK-1-ERK-1	B-X
association	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Fas-signaling	B-X
exerted	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
p53	B-X
levels	B-X
and	B-X
on	B-X
downstream	B-X
effectors	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
signal	B-X
transduction	B-X
,	B-X
thereby	B-X
ensuring	B-X
cell	B-X
death	B-X
.	B-X

Prevention	O
of	O
hepatic	O
tumor	O
metastases	O
in	O
rats	O
with	O
herpes	O
viral	O
vaccines	O
and	O
gamma	B-Gene_or_gene_product
-	I-Gene_or_gene_product
interferon	I-Gene_or_gene_product
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

Previous	O
studies	O
showed	O
that	O
gammaIFN	B-Gene_or_gene_product
decreases	O
metastatic	O
hepatic	O
tumor	O
growth	O
by	O
stimulating	O
Kupffer	O
cells	O
(	O
KC	O
)	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

The	O
present	O
studies	O
examine	O
whether	O
lymphocyte	O
stimulation	O
via	O
cells	O
engineered	O
to	O
secrete	O
GM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	I-Gene_or_gene_product
or	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
decreases	O
hepatic	O
tumor	O
growth	O
,	O
and	O
whether	O
stimulation	O
of	O
both	O
macrophages	O
and	O
lymphocytes	O
is	O
more	O
effective	O
than	O
either	O
individually	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Therapy	B-X
was	B-X
equally	B-X
effective	B-X
in	B-X
this	B-X
immunosuppressive	B-X
setting	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

Rats	O
were	O
immunized	O
with	O
irradiated	O
hepatoma	O
cells	O
transduced	O
by	O
herpes	O
viral	O
amplicon	O
vectors	O
containing	O
the	O
genes	O
for	O
GM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	I-Gene_or_gene_product
,	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
or	O
LacZ	B-Gene_or_gene_product
.	O
<EOS>	B-X
Endocardial	B-X
cells	B-X
are	B-X
thought	B-X
to	B-X
contribute	B-X
at	B-X
least	B-X
in	B-X
part	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
endocardial	B-X
cushion	B-X
mesenchyme	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
created	B-X
Tie2-Cre	B-X
transgenic	B-X
mice	B-X
,	B-X
in	B-X
which	B-X
expression	B-X
of	B-X
Cre	B-X
recombinase	B-X
is	B-X
driven	B-X
by	B-X
an	B-X
endothelial-specific	B-X
promoter/enhancer	B-X
.	B-X
To	B-X
analyze	B-X
the	B-X
lineage	B-X
of	B-X
Cre	B-X
expressing	B-X
cells	B-X
,	B-X
we	B-X
used	B-X
CAG-CAT-Z	B-X
transgenic	B-X
mice	B-X
,	B-X
in	B-X
which	B-X
expression	B-X
of	B-X
lacZ	B-X
is	B-X
activated	B-X
only	B-X
after	B-X
Cre-mediated	B-X
recombination	B-X
.	B-X
We	B-X
detected	B-X
pan-endothelial	B-X
expression	B-X
of	B-X
the	B-X
Cre	B-X
transgene	B-X
in	B-X
Tie2-Cre	B-X
;	B-X
CAG-CAT-Z	B-X
double-transgenic	B-X
mice	B-X
.	B-X
This	B-X
expression	B-X
pattern	B-X
is	B-X
almost	B-X
identical	B-X
to	B-X
Tie2-lacZ	B-X
transgenic	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
interestingly	B-X
,	B-X
we	B-X
observed	B-X
strong	B-X
and	B-X
uniform	B-X
lacZ	B-X
expression	B-X
in	B-X
mesenchymal	B-X
cells	B-X
of	B-X
the	B-X
atrioventricular	B-X
canal	B-X
of	B-X
Tie2-Cre	B-X
;	B-X
CAG-CAT-Z	B-X
double-transgenic	B-X
mice	B-X
.	B-X
We	B-X
also	B-X
detected	B-X
lacZ	B-X
expression	B-X
in	B-X
the	B-X
mesenchymal	B-X
cells	B-X
in	B-X
part	B-X
of	B-X
the	B-X
proximal	B-X
cardiac	B-X
outflow	B-X
tract	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
mesenchymal	B-X
cells	B-X
of	B-X
the	B-X
distal	B-X
outflow	B-X
tract	B-X
and	B-X
branchial	B-X
arch	B-X
arteries	B-X
.	B-X
LacZ	B-X
staining	B-X
in	B-X
Tie2-Cre	B-X
;	B-X
CAG-CAT-Z	B-X
embryos	B-X
is	B-X
consistent	B-X
with	B-X
endocardial-mesenchymal	B-X
transformation	B-X
in	B-X
the	B-X
atrioventricular	B-X
canal	B-X
and	B-X
outflow	B-X
tract	B-X
regions	B-X
.	B-X
Our	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
previously	B-X
reported	B-X
results	B-X
from	B-X
Cx43-lacZ	B-X
,	B-X
Wnt1-Cre	B-X
;	B-X
R26R	B-X
,	B-X
and	B-X
Pax3-Cre	B-X
;	B-X
R26R	B-X
transgenic	B-X
mice	B-X
,	B-X
in	B-X
which	B-X
lacZ	B-X
expression	B-X
in	B-X
the	B-X
cardiac	B-X
outflow	B-X
tract	B-X
identified	B-X
contributions	B-X
in	B-X
part	B-X
from	B-X
the	B-X
cardiac	B-X
neural	B-X
crest	B-X
.	B-X
Tie2-Cre	B-X
transgenic	B-X
mice	B-X
are	B-X
a	B-X
new	B-X
genetic	B-X
tool	B-X
for	B-X
the	B-X
analyses	B-X
of	B-X
endothelial	B-X
cell-lineage	B-X
and	B-X
endothelial	B-X
cell-specific	B-X
gene	B-X
targeting	B-X
.	B-X

On	O
day	O
18	O
,	O
half	O
of	O
each	O
group	O
was	O
treated	O
with	O
5	O
x	O
10	O
(	O
4	O
)	O
U	O
gammaIFN	B-Gene_or_gene_product
,	O
or	O
saline	O
intraperitoneally	O
for	O
3	O
d	O
.	O
<EOS>	B-X
For	B-X
mice	B-X
,	B-X
if	B-X
a	B-X
pure	B-X
,	B-X
soluble	B-X
protein	B-X
antigen	B-X
is	B-X
being	B-X
used	B-X
and	B-X
is	B-X
abundant	B-X
,	B-X
a	B-X
dose	B-X
of	B-X
50-100	B-X
Âµg	B-X
in	B-X
adjuvant	B-X
at	B-X
each	B-X
immunization	B-X
is	B-X
a	B-X
sensible	B-X
general	B-X
recommendation	B-X
;	B-X
for	B-X
rats	B-X
and	B-X
hamsters	B-X
,	B-X
a	B-X
dose	B-X
of	B-X
100-200	B-X
Âµg	B-X
is	B-X
sufficient	B-X
.	B-X
Adjuvants	B-X
(	B-X
Freund	B-X
's	B-X
,	B-X
Ribi	B-X
,	B-X
Hunter	B-X
's	B-X
TiterMax	B-X
,	B-X
ImmunEasy	B-X
,	B-X
or	B-X
Alum	B-X
)	B-X
should	B-X
be	B-X
mixed	B-X
with	B-X
the	B-X
immunizing	B-X
antigen	B-X
for	B-X
the	B-X
first	B-X
two	B-X
immunizations	B-X
only	B-X
;	B-X
Complete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
is	B-X
only	B-X
used	B-X
with	B-X
the	B-X
first	B-X
immunization	B-X
.	B-X
Subsequent	B-X
immunizations	B-X
are	B-X
performed	B-X
in	B-X
phosphate-buffered	B-X
saline	B-X
(	B-X
PBS	B-X
)	B-X
or	B-X
normal	B-X
saline	B-X
,	B-X
with	B-X
or	B-X
without	B-X
Incomplete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
.	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
the	B-X
6-wk	B-X
immunization	B-X
schedule	B-X
,	B-X
each	B-X
animal	B-X
usually	B-X
receives	B-X
a	B-X
total	B-X
of	B-X
six	B-X
injections	B-X
(	B-X
three	B-X
subcutaneous	B-X
and	B-X
three	B-X
intraperitoneal	B-X
)	B-X
.	B-X
Once	B-X
a	B-X
good	B-X
titer	B-X
has	B-X
developed	B-X
against	B-X
the	B-X
antigen	B-X
of	B-X
interest	B-X
,	B-X
regular	B-X
boosts	B-X
and	B-X
bleeds	B-X
are	B-X
performed	B-X
to	B-X
collect	B-X
the	B-X
maximum	B-X
amount	B-X
of	B-X
serum	B-X
.	B-X
For	B-X
rats	B-X
and	B-X
hamsters	B-X
,	B-X
boosts	B-X
should	B-X
be	B-X
spaced	B-X
every	B-X
2-3	B-X
wk	B-X
,	B-X
and	B-X
serum	B-X
samples	B-X
of	B-X
400-500	B-X
ÂµL	B-X
should	B-X
be	B-X
collected	B-X
10-12	B-X
d	B-X
after	B-X
each	B-X
boost	B-X
.	B-X
For	B-X
mice	B-X
,	B-X
boosts	B-X
should	B-X
be	B-X
spaced	B-X
every	B-X
2-3	B-X
wk	B-X
,	B-X
and	B-X
serum	B-X
samples	B-X
of	B-X
200-300	B-X
ÂµL	B-X
should	B-X
be	B-X
collected	B-X
10-12	B-X
d	B-X
after	B-X
each	B-X
boost	B-X
.	B-X

On	O
day	O
21	O
,	O
all	O
rats	O
received	O
5	O
x	O
10	O
(	O
5	O
)	O
hepatoma	O
cells	O
intrasplenically	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X

On	O
day	O
41	O
,	O
rats	O
were	O
killed	O
and	O
tumor	O
nodules	O
were	O
counted	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

Separate	O
rats	O
underwent	O
splenocyte	O
and	O
KC	O
harvest	O
for	O
assessment	O
of	O
lymphocyte	O
-	O
and	O
macrophage	O
-	O
mediated	O
tumor	O
cell	O
kill	O
in	O
vitro	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

GM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	I-Gene_or_gene_product
or	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
vaccines	O
or	O
gammaIFN	B-Gene_or_gene_product
decreased	O
tumor	O
nodules	O
significantly	O
(	O
GM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	I-Gene_or_gene_product
13	O
+	O
/	O
-	O
4	O
,	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
14	O
+	O
/	O
-	O
6	O
vs	O
.	O
control	O
75	O
+	O
/	O
-	O
24	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
was	B-X
initially	B-X
classified	B-X
as	B-X
a	B-X
hematopoietic	B-X
growth	B-X
factor	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
its	B-X
close	B-X
relatives	B-X
macrophage	B-X
CSF	B-X
(	B-X
M-CSF	B-X
)	B-X
and	B-X
granulocyte	B-X
CSF	B-X
(	B-X
G-CSF	B-X
)	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
myeloid	B-X
cells	B-X
do	B-X
not	B-X
require	B-X
GM-CSF	B-X
for	B-X
steady-state	B-X
myelopoiesis	B-X
.	B-X
Instead	B-X
,	B-X
in	B-X
inflammation	B-X
,	B-X
GM-CSF	B-X
serves	B-X
as	B-X
a	B-X
communication	B-X
conduit	B-X
between	B-X
tissue-invading	B-X
lymphocytes	B-X
and	B-X
myeloid	B-X
cells	B-X
.	B-X
Even	B-X
though	B-X
lymphocytes	B-X
are	B-X
in	B-X
all	B-X
likelihood	B-X
the	B-X
instigators	B-X
of	B-X
chronic	B-X
inflammatory	B-X
disease	B-X
,	B-X
GM-CSF-activated	B-X
phagocytes	B-X
are	B-X
well	B-X
equipped	B-X
to	B-X
cause	B-X
tissue	B-X
damage	B-X
.	B-X
The	B-X
pivotal	B-X
role	B-X
of	B-X
GM-CSF	B-X
at	B-X
the	B-X
T	B-X
cell	B-X
:	B-X
myeloid	B-X
cell	B-X
interface	B-X
might	B-X
shift	B-X
our	B-X
attention	B-X
toward	B-X
studying	B-X
the	B-X
function	B-X
of	B-X
the	B-X
myeloid	B-X
compartment	B-X
in	B-X
immunopathology	B-X
.	B-X
Targeting	B-X
specifically	B-X
the	B-X
crosstalk	B-X
between	B-X
T	B-X
cells	B-X
and	B-X
myeloid	B-X
cells	B-X
through	B-X
GM-CSF	B-X
holds	B-X
promise	B-X
for	B-X
the	B-X
development	B-X
of	B-X
therapeutics	B-X
to	B-X
combat	B-X
chronic	B-X
tissue	B-X
inflammation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
will	B-X
review	B-X
some	B-X
of	B-X
the	B-X
major	B-X
discoveries	B-X
of	B-X
the	B-X
recent	B-X
past	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
GM-CSF	B-X
is	B-X
so	B-X
much	B-X
more	B-X
than	B-X
its	B-X
name	B-X
suggests	B-X
.	B-X

Combination	O
therapy	O
was	O
more	O
effective	O
,	O
and	O
completely	O
eliminated	O
tumor	O
in	O
4	O
of	O
12	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
GM	I-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	I-Gene_or_gene_product
and	O
8	O
of	O
11	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IL	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
animals	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Therapy	B-X
was	B-X
equally	B-X
effective	B-X
in	B-X
this	B-X
immunosuppressive	B-X
setting	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

Additional	O
rats	O
underwent	O
partial	O
hepatectomy	O
,	O
an	O
immunosuppressive	O
procedure	O
known	O
to	O
accelerate	O
the	O
growth	O
of	O
hepatic	O
tumor	O
,	O
following	O
tumor	O
challenge	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Therapy	B-X
was	B-X
equally	B-X
effective	B-X
in	B-X
this	B-X
immunosuppressive	B-X
setting	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

Therapy	O
was	O
equally	O
effective	O
in	O
this	O
immunosuppressive	O
setting	O
.	O
<EOS>	B-X
In	B-X
clinical	B-X
settings	B-X
,	B-X
three	B-X
monoclonal	B-X
anti-TNF-Î±	B-X
full	B-X
IgG1	B-X
antibodies	B-X
infliximab	B-X
,	B-X
adalimumab	B-X
,	B-X
and	B-X
golimumab	B-X
,	B-X
PEGylated	B-X
Fab	B-X
'	B-X
fragment	B-X
of	B-X
anti-TNF-Î±	B-X
antibody	B-X
certolizumab	B-X
pegol	B-X
,	B-X
extracellular	B-X
domain	B-X
of	B-X
TNF	B-X
receptor	B-X
2/IgG1-Fc	B-X
fusion	B-X
protein	B-X
etanercept	B-X
,	B-X
are	B-X
almost	B-X
equally	B-X
effective	B-X
for	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Although	B-X
monoclonal	B-X
full	B-X
IgG1	B-X
antibodies	B-X
are	B-X
able	B-X
to	B-X
induce	B-X
clinical	B-X
and	B-X
endoscopic	B-X
remission	B-X
in	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
,	B-X
certolizumab	B-X
pegol	B-X
without	B-X
Fc	B-X
portion	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
less	B-X
effective	B-X
for	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
compared	B-X
to	B-X
full	B-X
IgG1	B-X
antibodies	B-X
.	B-X
Hypersensitivity	B-X
reactions	B-X
(	B-X
HSRs	B-X
)	B-X
to	B-X
chemotherapeutic	B-X
drugs	B-X
,	B-X
including	B-X
mAbs	B-X
,	B-X
often	B-X
require	B-X
that	B-X
the	B-X
provoking	B-X
medication	B-X
be	B-X
discontinued	B-X
,	B-X
thus	B-X
raising	B-X
a	B-X
dilemma	B-X
for	B-X
the	B-X
caregiver	B-X
:	B-X
further	B-X
use	B-X
could	B-X
precipitate	B-X
a	B-X
severe	B-X
,	B-X
even	B-X
fatal	B-X
,	B-X
allergic	B-X
reaction	B-X
on	B-X
re-exposure	B-X
,	B-X
but	B-X
alternative	B-X
drugs	B-X
might	B-X
be	B-X
poorly	B-X
tolerated	B-X
or	B-X
much	B-X
less	B-X
effective	B-X
compared	B-X
with	B-X
the	B-X
preferred	B-X
agent	B-X
.	B-X
However	B-X
,	B-X
not	B-X
all	B-X
patients	B-X
are	B-X
equally	B-X
responsive	B-X
;	B-X
therefore	B-X
,	B-X
differentiating	B-X
potential	B-X
respondents	B-X
from	B-X
nonrespondents	B-X
is	B-X
clinically	B-X
important	B-X
.	B-X

Vaccination	O
is	O
associated	O
with	O
enhancement	O
of	O
splenocyte	O
-	O
mediated	O
tumoricidal	O
activity	O
,	O
whereas	O
the	O
effect	O
of	O
gammaIFN	B-Gene_or_gene_product
is	O
mediated	O
by	O
KC	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Therapy	B-X
was	B-X
equally	B-X
effective	B-X
in	B-X
this	B-X
immunosuppressive	B-X
setting	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

GM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	I-Gene_or_gene_product
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
vaccine	O
therapy	O
and	O
pretreatment	O
with	O
gammaIFN	B-Gene_or_gene_product
represent	O
effective	O
strategies	O
in	O
reducing	O
hepatic	O
tumor	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
gammaIFN	B-X
decreases	B-X
metastatic	B-X
hepatic	B-X
tumor	B-X
growth	B-X
by	B-X
stimulating	B-X
Kupffer	B-X
cells	B-X
(	B-X
KC	B-X
)	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
examine	B-X
whether	B-X
lymphocyte	B-X
stimulation	B-X
via	B-X
cells	B-X
engineered	B-X
to	B-X
secrete	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
decreases	B-X
hepatic	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
whether	B-X
stimulation	B-X
of	B-X
both	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
is	B-X
more	B-X
effective	B-X
than	B-X
either	B-X
individually	B-X
.	B-X
Rats	B-X
were	B-X
immunized	B-X
with	B-X
irradiated	B-X
hepatoma	B-X
cells	B-X
transduced	B-X
by	B-X
herpes	B-X
viral	B-X
amplicon	B-X
vectors	B-X
containing	B-X
the	B-X
genes	B-X
for	B-X
GM-CSF	B-X
,	B-X
IL-2	B-X
or	B-X
LacZ	B-X
.	B-X
On	B-X
day	B-X
18	B-X
,	B-X
half	B-X
of	B-X
each	B-X
group	B-X
was	B-X
treated	B-X
with	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
U	B-X
gammaIFN	B-X
,	B-X
or	B-X
saline	B-X
intraperitoneally	B-X
for	B-X
3	B-X
d.	B-X
On	B-X
day	B-X
21	B-X
,	B-X
all	B-X
rats	B-X
received	B-X
5	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
hepatoma	B-X
cells	B-X
intrasplenically	B-X
.	B-X
On	B-X
day	B-X
41	B-X
,	B-X
rats	B-X
were	B-X
killed	B-X
and	B-X
tumor	B-X
nodules	B-X
were	B-X
counted	B-X
.	B-X
Separate	B-X
rats	B-X
underwent	B-X
splenocyte	B-X
and	B-X
KC	B-X
harvest	B-X
for	B-X
assessment	B-X
of	B-X
lymphocyte-	B-X
and	B-X
macrophage-mediated	B-X
tumor	B-X
cell	B-X
kill	B-X
in	B-X
vitro	B-X
.	B-X
GM-CSF	B-X
or	B-X
IL-2	B-X
vaccines	B-X
or	B-X
gammaIFN	B-X
decreased	B-X
tumor	B-X
nodules	B-X
significantly	B-X
(	B-X
GM-CSF	B-X
13+/-4	B-X
,	B-X
IL-2	B-X
14+/-6	B-X
vs.	B-X
control	B-X
75+/-24	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Combination	B-X
therapy	B-X
was	B-X
more	B-X
effective	B-X
,	B-X
and	B-X
completely	B-X
eliminated	B-X
tumor	B-X
in	B-X
4	B-X
of	B-X
12	B-X
IFN-GM-CSF	B-X
and	B-X
8	B-X
of	B-X
11	B-X
IFN-IL-2	B-X
animals	B-X
.	B-X
Additional	B-X
rats	B-X
underwent	B-X
partial	B-X
hepatectomy	B-X
,	B-X
an	B-X
immunosuppressive	B-X
procedure	B-X
known	B-X
to	B-X
accelerate	B-X
the	B-X
growth	B-X
of	B-X
hepatic	B-X
tumor	B-X
,	B-X
following	B-X
tumor	B-X
challenge	B-X
.	B-X
Therapy	B-X
was	B-X
equally	B-X
effective	B-X
in	B-X
this	B-X
immunosuppressive	B-X
setting	B-X
.	B-X
Vaccination	B-X
is	B-X
associated	B-X
with	B-X
enhancement	B-X
of	B-X
splenocyte-mediated	B-X
tumoricidal	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
effect	B-X
of	B-X
gammaIFN	B-X
is	B-X
mediated	B-X
by	B-X
KC	B-X
.	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
vaccine	B-X
therapy	B-X
and	B-X
pretreatment	B-X
with	B-X
gammaIFN	B-X
represent	B-X
effective	B-X
strategies	B-X
in	B-X
reducing	B-X
hepatic	B-X
tumor	B-X
.	B-X
Combination	B-X
therapy	B-X
targets	B-X
both	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
and	B-X
is	B-X
more	B-X
effective	B-X
in	B-X
reducing	B-X
tumor	B-X
than	B-X
either	B-X
therapy	B-X
alone	B-X
.	B-X

Combination	O
therapy	O
targets	O
both	O
lymphocytes	O
and	O
macrophages	O
,	O
and	O
is	O
more	O
effective	O
in	O
reducing	O
tumor	O
than	O
either	O
therapy	O
alone	O
.	O
<EOS>	B-X
High	B-X
ERÎ²/HER	B-X
oncogenic	B-X
signaling	B-X
defines	B-X
lung	B-X
tumors	B-X
with	B-X
an	B-X
aggressive	B-X
biology	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
combining	B-X
the	B-X
anti-estrogen	B-X
fulvestrant	B-X
with	B-X
the	B-X
pan-HER	B-X
inhibitor	B-X
dacomitinib	B-X
reduced	B-X
ER/HER	B-X
crosstalk	B-X
and	B-X
produced	B-X
synergistic	B-X
anti-tumor	B-X
effects	B-X
in	B-X
immunocompromised	B-X
lung	B-X
cancer	B-X
models	B-X
,	B-X
including	B-X
Our	B-X
earlier	B-X
work	B-X
revealed	B-X
that	B-X
PGE-mediated	B-X
inactivation	B-X
of	B-X
NK	B-X
cells	B-X
in	B-X
tumor-bearing	B-X
mice	B-X
by	B-X
host	B-X
macrophages	B-X
promoted	B-X
spontaneous	B-X
lung	B-X
metastasis	B-X
that	B-X
could	B-X
be	B-X
prevented	B-X
or	B-X
ameliorated	B-X
by	B-X
chronic	B-X
indomethacin	B-X
therapy	B-X
.	B-X
Since	B-X
PGE	B-X
was	B-X
found	B-X
to	B-X
suppress	B-X
the	B-X
in	B-X
vitro	B-X
development	B-X
and/or	B-X
activation	B-X
of	B-X
a	B-X
family	B-X
of	B-X
tumoricidal	B-X
lymphocytes	B-X
such	B-X
as	B-X
CTL	B-X
,	B-X
NK	B-X
,	B-X
and	B-X
LAK	B-X
cells	B-X
by	B-X
one	B-X
or	B-X
both	B-X
of	B-X
two	B-X
mechanisms	B-X
,	B-X
that	B-X
is	B-X
to	B-X
say	B-X
,	B-X
a	B-X
down	B-X
regulation	B-X
of	B-X
IL-2-R	B-X
and	B-X
an	B-X
inhibition	B-X
of	B-X
IL-2	B-X
production	B-X
,	B-X
the	B-X
present	B-X
study	B-X
tested	B-X
whether	B-X
a	B-X
combined	B-X
therapy	B-X
with	B-X
indomethacin	B-X
and	B-X
IL-2	B-X
was	B-X
more	B-X
effective	B-X
than	B-X
one	B-X
with	B-X
indomethacin	B-X
or	B-X
IL-2	B-X
alone	B-X
in	B-X
ameliorating	B-X
established	B-X
experimental	B-X
lung	B-X
metastasis	B-X
.	B-X
Chronic	B-X
indomethacin	B-X
therapy	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
(	B-X
14	B-X
micrograms/ml	B-X
in	B-X
drinking	B-X
water	B-X
)	B-X
starting	B-X
on	B-X
day	B-X
0	B-X
or	B-X
day	B-X
5	B-X
,	B-X
or	B-X
a	B-X
single	B-X
round	B-X
of	B-X
IL-2	B-X
therapy	B-X
(	B-X
25,000	B-X
U	B-X
rIL-2	B-X
,	B-X
every	B-X
8	B-X
h	B-X
for	B-X
5	B-X
d	B-X
on	B-X
days	B-X
10-14	B-X
)	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
metastatic	B-X
nodules	B-X
by	B-X
two-thirds	B-X
(	B-X
from	B-X
a	B-X
median	B-X
of	B-X
473	B-X
in	B-X
control	B-X
mice	B-X
receiving	B-X
vehicles	B-X
alone	B-X
)	B-X
by	B-X
day	B-X
21	B-X
.	B-X
A	B-X
single	B-X
round	B-X
of	B-X
IL-2	B-X
as	B-X
above	B-X
,	B-X
combined	B-X
with	B-X
either	B-X
protocol	B-X
of	B-X
indomethacin	B-X
therapy	B-X
,	B-X
completely	B-X
or	B-X
nearly	B-X
completely	B-X
irradicated	B-X
the	B-X
lung	B-X
metastases	B-X
,	B-X
corroborated	B-X
by	B-X
a	B-X
histological	B-X
examination	B-X
.	B-X
An	B-X
evaluation	B-X
of	B-X
splenic	B-X
killer	B-X
cell	B-X
activity	B-X
measured	B-X
with	B-X
a	B-X
4-h	B-X
51Cr-release	B-X
assay	B-X
against	B-X
NK-sensitive	B-X
YAC-1	B-X
lymphoma	B-X
and	B-X
B16F10	B-X
melanoma	B-X
or	B-X
NK-resistant	B-X
thymic	B-X
lymphoma	B-X
9705	B-X
targets	B-X
revealed	B-X
negligible	B-X
activity	B-X
in	B-X
control	B-X
tumor-bearing	B-X
mice	B-X
,	B-X
and	B-X
a	B-X
good	B-X
restoration	B-X
of	B-X
activity	B-X
against	B-X
NK-sensitive	B-X
targets	B-X
with	B-X
either	B-X
protocols	B-X
of	B-X
indomethacin	B-X
therapy	B-X
.	B-X
IL-2	B-X
alone	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
IL-2	B-X
and	B-X
indomethacin	B-X
given	B-X
by	B-X
either	B-X
protocol	B-X
generated	B-X
strong	B-X
killer	B-X
activity	B-X
against	B-X
all	B-X
these	B-X
targets	B-X
,	B-X
most	B-X
marked	B-X
with	B-X
the	B-X
combination	B-X
therapy	B-X
.	B-X
The	B-X
combination	B-X
therapy	B-X
resulted	B-X
in	B-X
the	B-X
strongest	B-X
mononuclear	B-X
cell	B-X
infiltration	B-X
in	B-X
the	B-X
lungs	B-X
,	B-X
with	B-X
areas	B-X
of	B-X
young	B-X
granulation	B-X
tissue	B-X
suggestive	B-X
of	B-X
repair	B-X
sites	B-X
of	B-X
original	B-X
metastases	B-X
.	B-X

Insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
I	I-Gene_or_gene_product
induces	O
tumor	O
hexokinase	B-Gene_or_gene_product
RNA	O
expression	O
in	O
cancer	O
cells	O
.	O
<EOS>	B-X
Increased	B-X
glycolysis	B-X
is	B-X
a	B-X
characteristic	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X
Though	B-X
less	B-X
efficient	B-X
in	B-X
energy	B-X
production	B-X
,	B-X
it	B-X
ensures	B-X
continuous	B-X
supply	B-X
of	B-X
energy	B-X
and	B-X
phosphometabolites	B-X
for	B-X
biosynthesis	B-X
enabling	B-X
metastatic	B-X
and	B-X
less	B-X
vascularized	B-X
cancer	B-X
cells	B-X
to	B-X
proliferate	B-X
even	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Since	B-X
hexokinase	B-X
is	B-X
the	B-X
first	B-X
rate	B-X
limiting	B-X
enzyme	B-X
in	B-X
the	B-X
glycolytic	B-X
pathway	B-X
,	B-X
elevated	B-X
levels	B-X
of	B-X
Type	B-X
II	B-X
like	B-X
hexokinase	B-X
in	B-X
tumors	B-X
are	B-X
of	B-X
great	B-X
significance	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Under	B-X
normal	B-X
conditions	B-X
insulin	B-X
regulates	B-X
expression	B-X
of	B-X
hexokinase	B-X
Type	B-X
II	B-X
isoenzyme	B-X
,	B-X
which	B-X
is	B-X
predominantly	B-X
expressed	B-X
in	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
cancer	B-X
cells	B-X
overexpress	B-X
insulin-like	B-X
growth	B-X
factors	B-X
and	B-X
their	B-X
receptors	B-X
which	B-X
mimic	B-X
many	B-X
activities	B-X
of	B-X
insulin	B-X
.	B-X
This	B-X
prompted	B-X
us	B-X
to	B-X
examine	B-X
a	B-X
hypothesis	B-X
that	B-X
insulin-like	B-X
growth	B-X
factors	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
overexpression	B-X
of	B-X
tumor	B-X
hexokinase	B-X
.	B-X
Our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor	B-X
I	B-X
indeed	B-X
induces	B-X
hexokinase	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
concentration	B-X
and	B-X
time	B-X
dependent	B-X
manner	B-X
in	B-X
two	B-X
cancer	B-X
cell	B-X
lines	B-X
we	B-X
studied	B-X
.	B-X

Increased	O
glycolysis	O
is	O
a	O
characteristic	O
of	O
cancer	O
cells	O
.	O
<EOS>	B-X
T	B-X
cell-output	B-X
decline	B-X
is	B-X
an	B-X
important	B-X
feature	B-X
of	B-X
immunosenescence	B-X
as	B-X
well	B-X
as	B-X
the	B-X
production	B-X
of	B-X
senescence-associated	B-X
secretory	B-X
phenotype	B-X
,	B-X
increased	B-X
glycolysis	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
Senescent	B-X
T	B-X
cells	B-X
exhibit	B-X
abnormal	B-X
phenotypes	B-X
,	B-X
including	B-X
downregulation	B-X
of	B-X
CD27	B-X
,	B-X
CD28	B-X
,	B-X
and	B-X
upregulation	B-X
of	B-X
CD57	B-X
,	B-X
killer	B-X
cell	B-X
lectin-like	B-X
receptor	B-X
subfamily	B-X
G	B-X
,	B-X
Tim-3	B-X
,	B-X
Tight	B-X
,	B-X
and	B-X
cytotoxic	B-X
T-lymphocyte-associated	B-X
protein	B-X
4	B-X
,	B-X
which	B-X
are	B-X
tightly	B-X
related	B-X
to	B-X
malignant	B-X
tumors	B-X
.	B-X
The	B-X
role	B-X
of	B-X
immunosenescence	B-X
in	B-X
tumors	B-X
is	B-X
sophisticated	B-X
:	B-X
the	B-X
many	B-X
factors	B-X
involved	B-X
include	B-X
cAMP	B-X
,	B-X
glucose	B-X
competition	B-X
,	B-X
and	B-X
oncogenic	B-X
stress	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
which	B-X
can	B-X
induce	B-X
the	B-X
senescence	B-X
of	B-X
T	B-X
cells	B-X
,	B-X
macrophages	B-X
,	B-X
natural	B-X
killer	B-X
cells	B-X
,	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
Accordingly	B-X
,	B-X
these	B-X
senescent	B-X
immune	B-X
cells	B-X
could	B-X
also	B-X
affect	B-X
tumor	B-X
progression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
immunosenescence	B-X
on	B-X
the	B-X
response	B-X
to	B-X
immune	B-X
checkpoint	B-X
blocking	B-X
antibody	B-X
therapy	B-X
so	B-X
far	B-X
is	B-X
ambiguous	B-X
due	B-X
to	B-X
the	B-X
low	B-X
participation	B-X
of	B-X
elderly	B-X
cancer	B-X
patients	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X

Though	O
less	O
efficient	O
in	O
energy	O
production	O
,	O
it	O
ensures	O
continuous	O
supply	O
of	O
energy	O
and	O
phosphometabolites	O
for	O
biosynthesis	O
enabling	O
metastatic	O
and	O
less	O
vascularized	O
cancer	O
cells	O
to	O
proliferate	O
even	O
under	O
hypoxic	O
conditions	O
.	O
<EOS>	B-X
Increased	B-X
glycolysis	B-X
is	B-X
a	B-X
characteristic	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X
Though	B-X
less	B-X
efficient	B-X
in	B-X
energy	B-X
production	B-X
,	B-X
it	B-X
ensures	B-X
continuous	B-X
supply	B-X
of	B-X
energy	B-X
and	B-X
phosphometabolites	B-X
for	B-X
biosynthesis	B-X
enabling	B-X
metastatic	B-X
and	B-X
less	B-X
vascularized	B-X
cancer	B-X
cells	B-X
to	B-X
proliferate	B-X
even	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Under	B-X
normal	B-X
conditions	B-X
insulin	B-X
regulates	B-X
expression	B-X
of	B-X
hexokinase	B-X
Type	B-X
II	B-X
isoenzyme	B-X
,	B-X
which	B-X
is	B-X
predominantly	B-X
expressed	B-X
in	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
cancer	B-X
cells	B-X
overexpress	B-X
insulin-like	B-X
growth	B-X
factors	B-X
and	B-X
their	B-X
receptors	B-X
which	B-X
mimic	B-X
many	B-X
activities	B-X
of	B-X
insulin	B-X
.	B-X
Our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor	B-X
I	B-X
indeed	B-X
induces	B-X
hexokinase	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
concentration	B-X
and	B-X
time	B-X
dependent	B-X
manner	B-X
in	B-X
two	B-X
cancer	B-X
cell	B-X
lines	B-X
we	B-X
studied	B-X
.	B-X

Since	O
hexokinase	B-Gene_or_gene_product
is	O
the	O
first	O
rate	O
limiting	O
enzyme	O
in	O
the	O
glycolytic	O
pathway	O
,	O
elevated	O
levels	O
of	O
Type	B-Gene_or_gene_product
II	I-Gene_or_gene_product
like	I-Gene_or_gene_product
hexokinase	I-Gene_or_gene_product
in	O
tumors	O
are	O
of	O
great	O
significance	O
in	O
this	O
context	O
.	O
<EOS>	B-X
Though	B-X
less	B-X
efficient	B-X
in	B-X
energy	B-X
production	B-X
,	B-X
it	B-X
ensures	B-X
continuous	B-X
supply	B-X
of	B-X
energy	B-X
and	B-X
phosphometabolites	B-X
for	B-X
biosynthesis	B-X
enabling	B-X
metastatic	B-X
and	B-X
less	B-X
vascularized	B-X
cancer	B-X
cells	B-X
to	B-X
proliferate	B-X
even	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Since	B-X
hexokinase	B-X
is	B-X
the	B-X
first	B-X
rate	B-X
limiting	B-X
enzyme	B-X
in	B-X
the	B-X
glycolytic	B-X
pathway	B-X
,	B-X
elevated	B-X
levels	B-X
of	B-X
Type	B-X
II	B-X
like	B-X
hexokinase	B-X
in	B-X
tumors	B-X
are	B-X
of	B-X
great	B-X
significance	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Under	B-X
normal	B-X
conditions	B-X
insulin	B-X
regulates	B-X
expression	B-X
of	B-X
hexokinase	B-X
Type	B-X
II	B-X
isoenzyme	B-X
,	B-X
which	B-X
is	B-X
predominantly	B-X
expressed	B-X
in	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
cancer	B-X
cells	B-X
overexpress	B-X
insulin-like	B-X
growth	B-X
factors	B-X
and	B-X
their	B-X
receptors	B-X
which	B-X
mimic	B-X
many	B-X
activities	B-X
of	B-X
insulin	B-X
.	B-X
This	B-X
prompted	B-X
us	B-X
to	B-X
examine	B-X
a	B-X
hypothesis	B-X
that	B-X
insulin-like	B-X
growth	B-X
factors	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
overexpression	B-X
of	B-X
tumor	B-X
hexokinase	B-X
.	B-X
Our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor	B-X
I	B-X
indeed	B-X
induces	B-X
hexokinase	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
concentration	B-X
and	B-X
time	B-X
dependent	B-X
manner	B-X
in	B-X
two	B-X
cancer	B-X
cell	B-X
lines	B-X
we	B-X
studied	B-X
.	B-X

Under	O
normal	O
conditions	O
insulin	B-Gene_or_gene_product
regulates	O
expression	O
of	O
hexokinase	B-Gene_or_gene_product
Type	I-Gene_or_gene_product
II	I-Gene_or_gene_product
isoenzyme	O
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
muscle	O
.	O
<EOS>	B-X
Though	B-X
less	B-X
efficient	B-X
in	B-X
energy	B-X
production	B-X
,	B-X
it	B-X
ensures	B-X
continuous	B-X
supply	B-X
of	B-X
energy	B-X
and	B-X
phosphometabolites	B-X
for	B-X
biosynthesis	B-X
enabling	B-X
metastatic	B-X
and	B-X
less	B-X
vascularized	B-X
cancer	B-X
cells	B-X
to	B-X
proliferate	B-X
even	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Since	B-X
hexokinase	B-X
is	B-X
the	B-X
first	B-X
rate	B-X
limiting	B-X
enzyme	B-X
in	B-X
the	B-X
glycolytic	B-X
pathway	B-X
,	B-X
elevated	B-X
levels	B-X
of	B-X
Type	B-X
II	B-X
like	B-X
hexokinase	B-X
in	B-X
tumors	B-X
are	B-X
of	B-X
great	B-X
significance	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Under	B-X
normal	B-X
conditions	B-X
insulin	B-X
regulates	B-X
expression	B-X
of	B-X
hexokinase	B-X
Type	B-X
II	B-X
isoenzyme	B-X
,	B-X
which	B-X
is	B-X
predominantly	B-X
expressed	B-X
in	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
cancer	B-X
cells	B-X
overexpress	B-X
insulin-like	B-X
growth	B-X
factors	B-X
and	B-X
their	B-X
receptors	B-X
which	B-X
mimic	B-X
many	B-X
activities	B-X
of	B-X
insulin	B-X
.	B-X
This	B-X
prompted	B-X
us	B-X
to	B-X
examine	B-X
a	B-X
hypothesis	B-X
that	B-X
insulin-like	B-X
growth	B-X
factors	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
overexpression	B-X
of	B-X
tumor	B-X
hexokinase	B-X
.	B-X
Our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor	B-X
I	B-X
indeed	B-X
induces	B-X
hexokinase	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
concentration	B-X
and	B-X
time	B-X
dependent	B-X
manner	B-X
in	B-X
two	B-X
cancer	B-X
cell	B-X
lines	B-X
we	B-X
studied	B-X
.	B-X

On	O
the	O
other	O
hand	O
cancer	O
cells	O
overexpress	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	I-Gene_or_gene_product
and	O
their	O
receptors	O
which	O
mimic	O
many	O
activities	O
of	O
insulin	B-Gene_or_gene_product
.	O
<EOS>	B-X
Increased	B-X
glycolysis	B-X
is	B-X
a	B-X
characteristic	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X
Though	B-X
less	B-X
efficient	B-X
in	B-X
energy	B-X
production	B-X
,	B-X
it	B-X
ensures	B-X
continuous	B-X
supply	B-X
of	B-X
energy	B-X
and	B-X
phosphometabolites	B-X
for	B-X
biosynthesis	B-X
enabling	B-X
metastatic	B-X
and	B-X
less	B-X
vascularized	B-X
cancer	B-X
cells	B-X
to	B-X
proliferate	B-X
even	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Since	B-X
hexokinase	B-X
is	B-X
the	B-X
first	B-X
rate	B-X
limiting	B-X
enzyme	B-X
in	B-X
the	B-X
glycolytic	B-X
pathway	B-X
,	B-X
elevated	B-X
levels	B-X
of	B-X
Type	B-X
II	B-X
like	B-X
hexokinase	B-X
in	B-X
tumors	B-X
are	B-X
of	B-X
great	B-X
significance	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Under	B-X
normal	B-X
conditions	B-X
insulin	B-X
regulates	B-X
expression	B-X
of	B-X
hexokinase	B-X
Type	B-X
II	B-X
isoenzyme	B-X
,	B-X
which	B-X
is	B-X
predominantly	B-X
expressed	B-X
in	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
cancer	B-X
cells	B-X
overexpress	B-X
insulin-like	B-X
growth	B-X
factors	B-X
and	B-X
their	B-X
receptors	B-X
which	B-X
mimic	B-X
many	B-X
activities	B-X
of	B-X
insulin	B-X
.	B-X
This	B-X
prompted	B-X
us	B-X
to	B-X
examine	B-X
a	B-X
hypothesis	B-X
that	B-X
insulin-like	B-X
growth	B-X
factors	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
overexpression	B-X
of	B-X
tumor	B-X
hexokinase	B-X
.	B-X
Our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor	B-X
I	B-X
indeed	B-X
induces	B-X
hexokinase	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
concentration	B-X
and	B-X
time	B-X
dependent	B-X
manner	B-X
in	B-X
two	B-X
cancer	B-X
cell	B-X
lines	B-X
we	B-X
studied	B-X
.	B-X

This	O
prompted	O
us	O
to	O
examine	O
a	O
hypothesis	O
that	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	I-Gene_or_gene_product
may	O
be	O
responsible	O
for	O
overexpression	O
of	O
tumor	O
hexokinase	B-Gene_or_gene_product
.	O
<EOS>	B-X
Though	B-X
less	B-X
efficient	B-X
in	B-X
energy	B-X
production	B-X
,	B-X
it	B-X
ensures	B-X
continuous	B-X
supply	B-X
of	B-X
energy	B-X
and	B-X
phosphometabolites	B-X
for	B-X
biosynthesis	B-X
enabling	B-X
metastatic	B-X
and	B-X
less	B-X
vascularized	B-X
cancer	B-X
cells	B-X
to	B-X
proliferate	B-X
even	B-X
under	B-X
hypoxic	B-X
conditions	B-X
.	B-X
Since	B-X
hexokinase	B-X
is	B-X
the	B-X
first	B-X
rate	B-X
limiting	B-X
enzyme	B-X
in	B-X
the	B-X
glycolytic	B-X
pathway	B-X
,	B-X
elevated	B-X
levels	B-X
of	B-X
Type	B-X
II	B-X
like	B-X
hexokinase	B-X
in	B-X
tumors	B-X
are	B-X
of	B-X
great	B-X
significance	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Under	B-X
normal	B-X
conditions	B-X
insulin	B-X
regulates	B-X
expression	B-X
of	B-X
hexokinase	B-X
Type	B-X
II	B-X
isoenzyme	B-X
,	B-X
which	B-X
is	B-X
predominantly	B-X
expressed	B-X
in	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
cancer	B-X
cells	B-X
overexpress	B-X
insulin-like	B-X
growth	B-X
factors	B-X
and	B-X
their	B-X
receptors	B-X
which	B-X
mimic	B-X
many	B-X
activities	B-X
of	B-X
insulin	B-X
.	B-X
This	B-X
prompted	B-X
us	B-X
to	B-X
examine	B-X
a	B-X
hypothesis	B-X
that	B-X
insulin-like	B-X
growth	B-X
factors	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
overexpression	B-X
of	B-X
tumor	B-X
hexokinase	B-X
.	B-X
Our	B-X
experiments	B-X
demonstrate	B-X
that	B-X
insulin-like	B-X
growth	B-X
factor	B-X
I	B-X
indeed	B-X
induces	B-X
hexokinase	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
concentration	B-X
and	B-X
time	B-X
dependent	B-X
manner	B-X
in	B-X
two	B-X
cancer	B-X
cell	B-X
lines	B-X
we	B-X
studied	B-X
.	B-X

Our	O
experiments	O
demonstrate	O
that	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
I	I-Gene_or_gene_product
indeed	O
induces	O
hexokinase	B-Gene_or_gene_product
gene	O
expression	O
in	O
a	O
concentration	O
and	O
time	O
dependent	O
manner	O
in	O
two	O
cancer	O
cell	O
lines	O
we	O
studied	O
.	O

Suppression	O
of	O
tumor	O
growth	O
by	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
mel	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
in	O
3Y1	O
cells	O
transformed	O
by	O
the	O
E6	B-Gene_or_gene_product
and	O
E7	B-Gene_or_gene_product
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
.	O
<EOS>	B-X
By	B-X
introducing	B-X
a	B-X
cDNA	B-X
library	B-X
derived	B-X
from	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
cells	B-X
,	B-X
we	B-X
isolated	B-X
several	B-X
morphologically	B-X
flat	B-X
revertants	B-X
of	B-X
rat	B-X
3Y1	B-X
cells	B-X
transformed	B-X
by	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
genes	B-X
of	B-X
human	B-X
papillomavirus	B-X
type	B-X
18	B-X
(	B-X
HPV18	B-X
)	B-X
.	B-X
From	B-X
one	B-X
of	B-X
the	B-X
revertants	B-X
,	B-X
we	B-X
recovered	B-X
a	B-X
0.2-kb	B-X
cDNA	B-X
,	B-X
N56	B-X
,	B-X
that	B-X
suppresses	B-X
the	B-X
tumor	B-X
growth	B-X
of	B-X
the	B-X
transformed	B-X
3Y1	B-X
cells	B-X
irrespective	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
genes	B-X
.	B-X
The	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
cDNA	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
3	B-X
'	B-X
untranslated	B-X
region	B-X
of	B-X
a	B-X
putative	B-X
mammalian	B-X
polycomb	B-X
group	B-X
gene	B-X
,	B-X
mel-18	B-X
.	B-X

By	O
introducing	O
a	O
cDNA	O
library	O
derived	O
from	O
rat	O
embryonic	O
fibroblast	O
cells	O
,	O
we	O
isolated	O
several	O
morphologically	O
flat	O
revertants	O
of	O
rat	O
3Y1	O
cells	O
transformed	O
by	O
the	O
E6	B-Gene_or_gene_product
and	O
E7	B-Gene_or_gene_product
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
(	O
HPV18	O
)	O
.	O
<EOS>	B-X
By	B-X
introducing	B-X
a	B-X
cDNA	B-X
library	B-X
derived	B-X
from	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
cells	B-X
,	B-X
we	B-X
isolated	B-X
several	B-X
morphologically	B-X
flat	B-X
revertants	B-X
of	B-X
rat	B-X
3Y1	B-X
cells	B-X
transformed	B-X
by	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
genes	B-X
of	B-X
human	B-X
papillomavirus	B-X
type	B-X
18	B-X
(	B-X
HPV18	B-X
)	B-X
.	B-X
From	B-X
one	B-X
of	B-X
the	B-X
revertants	B-X
,	B-X
we	B-X
recovered	B-X
a	B-X
0.2-kb	B-X
cDNA	B-X
,	B-X
N56	B-X
,	B-X
that	B-X
suppresses	B-X
the	B-X
tumor	B-X
growth	B-X
of	B-X
the	B-X
transformed	B-X
3Y1	B-X
cells	B-X
irrespective	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
genes	B-X
.	B-X
The	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
cDNA	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
3	B-X
'	B-X
untranslated	B-X
region	B-X
of	B-X
a	B-X
putative	B-X
mammalian	B-X
polycomb	B-X
group	B-X
gene	B-X
,	B-X
mel-18	B-X
.	B-X

From	O
one	O
of	O
the	O
revertants	O
,	O
we	O
recovered	O
a	O
0	O
.	O
2	O
-	O
kb	O
cDNA	O
,	O
N56	B-Gene_or_gene_product
,	O
that	O
suppresses	O
the	O
tumor	O
growth	O
of	O
the	O
transformed	O
3Y1	O
cells	O
irrespective	O
of	O
the	O
expression	O
of	O
the	O
E6	B-Gene_or_gene_product
and	O
E7	B-Gene_or_gene_product
genes	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
cDNA	O
was	O
shown	O
to	O
be	O
identical	O
to	O
that	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
a	O
putative	O
mammalian	O
polycomb	O
group	O
gene	O
,	O
mel	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	I-Gene_or_gene_product
.	O
<EOS>	B-X
By	B-X
introducing	B-X
a	B-X
cDNA	B-X
library	B-X
derived	B-X
from	B-X
rat	B-X
embryonic	B-X
fibroblast	B-X
cells	B-X
,	B-X
we	B-X
isolated	B-X
several	B-X
morphologically	B-X
flat	B-X
revertants	B-X
of	B-X
rat	B-X
3Y1	B-X
cells	B-X
transformed	B-X
by	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
genes	B-X
of	B-X
human	B-X
papillomavirus	B-X
type	B-X
18	B-X
(	B-X
HPV18	B-X
)	B-X
.	B-X
From	B-X
one	B-X
of	B-X
the	B-X
revertants	B-X
,	B-X
we	B-X
recovered	B-X
a	B-X
0.2-kb	B-X
cDNA	B-X
,	B-X
N56	B-X
,	B-X
that	B-X
suppresses	B-X
the	B-X
tumor	B-X
growth	B-X
of	B-X
the	B-X
transformed	B-X
3Y1	B-X
cells	B-X
irrespective	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
E6	B-X
and	B-X
E7	B-X
genes	B-X
.	B-X
The	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
cDNA	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
3	B-X
'	B-X
untranslated	B-X
region	B-X
of	B-X
a	B-X
putative	B-X
mammalian	B-X
polycomb	B-X
group	B-X
gene	B-X
,	B-X
mel-18	B-X
.	B-X

Calretinin	B-Gene_or_gene_product
.	O
<EOS>	B-X
Calretinin	B-X
(	B-X
CR	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
three	B-X
major	B-X
types	B-X
of	B-X
calcium-binding	B-X
proteins	B-X
present	B-X
in	B-X
inhibitory	B-X
GABAergic	B-X
neurons	B-X
.	B-X
Calretinin	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
calcium-binding	B-X
protein	B-X
EF-hand	B-X
family	B-X
first	B-X
identified	B-X
in	B-X
the	B-X
retina	B-X
.	B-X
Calretinin	B-X
cells	B-X
are	B-X
probably	B-X
the	B-X
best	B-X
morphologically	B-X
characterized	B-X
interneurons	B-X
among	B-X
PG	B-X
cells	B-X
in	B-X
OB	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
function	B-X
except	B-X
for	B-X
their	B-X
inhibitory	B-X
effect	B-X
on	B-X
noisy	B-X
random	B-X
excitatory	B-X
signals	B-X
arriving	B-X
at	B-X
the	B-X
main	B-X
neurons	B-X
.	B-X
Calretinin	B-X
staining	B-X
might	B-X
be	B-X
helpful	B-X
in	B-X
these	B-X
biopsies	B-X
.	B-X

A	O
selective	O
marker	O
of	O
normal	O
and	O
neoplastic	O
mesothelial	O
cells	O
in	O
serous	O
effusions	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X
Serous	B-X
effusions	B-X
are	B-X
frequently	B-X
a	B-X
clinical	B-X
manifestation	B-X
of	B-X
metastatic	B-X
disease	B-X
,	B-X
with	B-X
lung	B-X
,	B-X
breast	B-X
and	B-X
ovarian	B-X
carcinoma	B-X
and	B-X
mesothelioma	B-X
leading	B-X
the	B-X
list	B-X
.	B-X
The	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
a	B-X
dense	B-X
exudative	B-X
fluid	B-X
suggests	B-X
that	B-X
the	B-X
malignant	B-X
cells	B-X
are	B-X
capable	B-X
of	B-X
acquiring	B-X
nutrients	B-X
,	B-X
surviving	B-X
and	B-X
proliferating	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
a	B-X
solid-phase	B-X
scaffold	B-X
.	B-X
During	B-X
proliferation	B-X
,	B-X
neoplastic	B-X
cells	B-X
release	B-X
ligands	B-X
and	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
into	B-X
their	B-X
environment	B-X
,	B-X
which	B-X
dissolve	B-X
the	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
preliminary	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
,	B-X
by	B-X
immunocytochemistry	B-X
,	B-X
TIMP-2	B-X
expression	B-X
in	B-X
non-neoplastic	B-X
and	B-X
metastatic	B-X
adenocarcinoma	B-X
pleural	B-X
effusions	B-X
.	B-X
We	B-X
selected	B-X
16	B-X
cases	B-X
of	B-X
reactive	B-X
mesothelio	B-X
,	B-X
7	B-X
of	B-X
normal	B-X
mesothelio	B-X
,	B-X
14	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
,	B-X
9	B-X
from	B-X
the	B-X
ovary	B-X
,	B-X
4	B-X
from	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
and	B-X
3	B-X
from	B-X
the	B-X
breast	B-X
.	B-X
In	B-X
23/30	B-X
cases	B-X
(	B-X
76	B-X
%	B-X
)	B-X
,	B-X
we	B-X
detected	B-X
adenocarcinoma	B-X
cells	B-X
with	B-X
strong	B-X
TIMP-2	B-X
expression	B-X
.	B-X
Positive	B-X
TIMP-2	B-X
expression	B-X
was	B-X
found	B-X
in	B-X
2/7	B-X
cases	B-X
(	B-X
28	B-X
%	B-X
)	B-X
of	B-X
normal	B-X
and	B-X
2/16	B-X
(	B-X
12	B-X
%	B-X
)	B-X
of	B-X
reactive	B-X
mesothelio	B-X
.	B-X
A	B-X
statistical	B-X
association	B-X
was	B-X
detected	B-X
between	B-X
TIMP-2	B-X
expression	B-X
and	B-X
metastatic	B-X
adenocarcinoma	B-X
cells	B-X
compared	B-X
to	B-X
reactive	B-X
and	B-X
normal	B-X
mesothelial	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0.00003	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
immunocytochemical	B-X
detection	B-X
of	B-X
TIMP-2	B-X
could	B-X
be	B-X
considered	B-X
an	B-X
interesting	B-X
marker	B-X
in	B-X
metastatic	B-X
adenocarcinoma	B-X
pleural	B-X
effusions	B-X
,	B-X
and	B-X
could	B-X
possibly	B-X
be	B-X
used	B-X
as	B-X
a	B-X
component	B-X
of	B-X
an	B-X
antibody	B-X
panel	B-X
in	B-X
diagnostic	B-X
cytopathology	B-X
.	B-X

OBJECTIVE	O
:	O
To	O
document	O
that	O
a	O
polyclonal	O
antiserum	O
to	O
calretinin	B-Gene_or_gene_product
,	O
a	O
29	O
-	O
kd	O
calcium	O
-	O
binding	O
protein	O
,	O
consistently	O
decorates	O
normal	O
and	O
tumor	O
mesothelial	O
cells	O
in	O
cytologic	O
preparations	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

STUDY	O
DESIGN	O
:	O
Thirty	O
-	O
three	O
archival	O
cytologic	O
specimens	O
from	O
eight	O
patients	O
with	O
histologically	O
confirmed	O
malignant	O
mesothelioma	O
and	O
13	O
from	O
patients	O
with	O
metastatic	O
serous	O
effusions	O
were	O
destained	O
and	O
then	O
immunostained	O
with	O
anticalretinin	O
antiserum	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

For	O
investigation	O
of	O
cell	O
suspensions	O
,	O
four	O
pleural	O
fluids	O
were	O
incubated	O
with	O
anticalretinin	O
antiserum	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

After	O
cytocentrifugation	O
the	O
specimens	O
were	O
stained	O
in	O
accordance	O
with	O
the	O
alkaline	B-Gene_or_gene_product
phosphatase	I-Gene_or_gene_product
anti	O
-	O
alkaline	B-Gene_or_gene_product
phosphatase	I-Gene_or_gene_product
(	O
APAAP	O
)	O
method	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

For	O
electron	O
microscopic	O
examination	O
the	O
cell	O
suspensions	O
were	O
then	O
incubated	O
with	O
gold	O
-	O
labeled	O
antirabbit	O
antibody	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

RESULTS	O
:	O
The	O
diagnostic	O
sensitivity	O
of	O
this	O
new	O
immunocytochemical	O
approach	O
reached	O
100	O
%	O
for	O
the	O
eight	O
malignant	O
mesotheliomas	O
investigated	O
.	O

Only	O
3	O
of	O
the	O
13	O
adenocarcinomas	O
metastatic	O
to	O
the	O
serous	O
membranes	O
included	O
in	O
this	O
study	O
were	O
weakly	O
reactive	O
,	O
accounting	O
for	O
81	O
%	O
specificity	O
.	O

Binding	O
of	O
anticalretinin	O
antiserum	O
to	O
living	O
mesothelial	O
cells	O
was	O
consistently	O
documented	O
in	O
all	O
four	O
cases	O
investigated	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

CONCLUSION	O
:	O
Calretinin	B-Gene_or_gene_product
is	O
a	O
very	O
useful	O
marker	O
for	O
positive	O
identification	O
of	O
normal	O
and	O
tumor	O
mesothelial	O
cells	O
in	O
serous	O
effusions	O
.	O
<EOS>	B-X
To	B-X
document	B-X
that	B-X
a	B-X
polyclonal	B-X
antiserum	B-X
to	B-X
calretinin	B-X
,	B-X
a	B-X
29-kd	B-X
calcium-binding	B-X
protein	B-X
,	B-X
consistently	B-X
decorates	B-X
normal	B-X
and	B-X
tumor	B-X
mesothelial	B-X
cells	B-X
in	B-X
cytologic	B-X
preparations	B-X
.	B-X

Prognostic	O
value	O
of	O
HLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
DR	I-Gene_or_gene_product
expression	O
and	O
dendritic	O
cell	O
infiltration	O
in	O
gastric	O
cancer	O
.	O
<EOS>	B-X
We	B-X
attempted	B-X
to	B-X
correlate	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
leukocyte	B-X
antigen	B-X
DR	B-X
(	B-X
HLA-DR	B-X
)	B-X
and	B-X
tumor	B-X
infiltration	B-X
by	B-X
S-100-protein-positive	B-X
dendritic	B-X
cells	B-X
with	B-X
clinicopathologic	B-X
features	B-X
in	B-X
165	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
HLA-DR	B-X
was	B-X
correlated	B-X
with	B-X
the	B-X
histologic	B-X
type	B-X
.	B-X
Infiltration	B-X
of	B-X
dendritic	B-X
cells	B-X
correlated	B-X
negatively	B-X
with	B-X
distant	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
clinical	B-X
stage	B-X
,	B-X
and	B-X
peritoneal	B-X
invasion	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
HLA-DR	B-X
and	B-X
infiltration	B-X
by	B-X
dendritic	B-X
cells	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
resectable	B-X
gastric	B-X
cancer	B-X
,	B-X
the	B-X
grade	B-X
of	B-X
infiltrating	B-X
dendritic	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
suitable	B-X
predictor	B-X
of	B-X
prognosis	B-X
.	B-X

We	O
attempted	O
to	O
correlate	O
the	O
expression	O
of	O
human	B-Gene_or_gene_product
leukocyte	I-Gene_or_gene_product
antigen	I-Gene_or_gene_product
DR	I-Gene_or_gene_product
(	O
HLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
DR	I-Gene_or_gene_product
)	O
and	O
tumor	O
infiltration	O
by	O
S	B-Gene_or_gene_product
-	I-Gene_or_gene_product
100	I-Gene_or_gene_product
-	O
protein	O
-	O
positive	O
dendritic	O
cells	O
with	O
clinicopathologic	O
features	O
in	O
165	O
patients	O
with	O
gastric	O
cancer	O
.	O

The	O
expression	O
of	O
HLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
DR	I-Gene_or_gene_product
was	O
correlated	O
with	O
the	O
histologic	O
type	O
.	O
<EOS>	B-X
CD74	B-X
and	B-X
HLA-DRA	B-X
in	B-X
Cervical	B-X
Carcinogenesis	B-X
:	B-X
Potential	B-X
Targets	B-X
for	B-X
Antitumour	B-X
Therapy	B-X
.	B-X
We	B-X
attempted	B-X
to	B-X
correlate	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
leukocyte	B-X
antigen	B-X
DR	B-X
(	B-X
HLA-DR	B-X
)	B-X
and	B-X
tumor	B-X
infiltration	B-X
by	B-X
S-100-protein-positive	B-X
dendritic	B-X
cells	B-X
with	B-X
clinicopathologic	B-X
features	B-X
in	B-X
165	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
HLA-DR	B-X
was	B-X
correlated	B-X
with	B-X
the	B-X
histologic	B-X
type	B-X
.	B-X
Infiltration	B-X
of	B-X
dendritic	B-X
cells	B-X
correlated	B-X
negatively	B-X
with	B-X
distant	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
clinical	B-X
stage	B-X
,	B-X
and	B-X
peritoneal	B-X
invasion	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
HLA-DR	B-X
and	B-X
infiltration	B-X
by	B-X
dendritic	B-X
cells	B-X
.	B-X

Infiltration	O
of	O
dendritic	O
cells	O
correlated	O
negatively	O
with	O
distant	O
lymph	O
node	O
metastases	O
,	O
clinical	O
stage	O
,	O
and	O
peritoneal	O
invasion	O
.	O
<EOS>	B-X
We	B-X
attempted	B-X
to	B-X
correlate	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
leukocyte	B-X
antigen	B-X
DR	B-X
(	B-X
HLA-DR	B-X
)	B-X
and	B-X
tumor	B-X
infiltration	B-X
by	B-X
S-100-protein-positive	B-X
dendritic	B-X
cells	B-X
with	B-X
clinicopathologic	B-X
features	B-X
in	B-X
165	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
HLA-DR	B-X
was	B-X
correlated	B-X
with	B-X
the	B-X
histologic	B-X
type	B-X
.	B-X
Infiltration	B-X
of	B-X
dendritic	B-X
cells	B-X
correlated	B-X
negatively	B-X
with	B-X
distant	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
clinical	B-X
stage	B-X
,	B-X
and	B-X
peritoneal	B-X
invasion	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
HLA-DR	B-X
and	B-X
infiltration	B-X
by	B-X
dendritic	B-X
cells	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
resectable	B-X
gastric	B-X
cancer	B-X
,	B-X
the	B-X
grade	B-X
of	B-X
infiltrating	B-X
dendritic	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
suitable	B-X
predictor	B-X
of	B-X
prognosis	B-X
.	B-X

There	O
was	O
no	O
correlation	O
between	O
the	O
expression	O
of	O
HLA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
DR	I-Gene_or_gene_product
and	O
infiltration	O
by	O
dendritic	O
cells	O
.	O
<EOS>	B-X
Immunoperoxidase	B-X
staining	B-X
of	B-X
skin	B-X
sections	B-X
and	B-X
immunofluorescence	B-X
analysis	B-X
of	B-X
keratinocyte	B-X
suspensions	B-X
obtained	B-X
from	B-X
suction	B-X
blisters	B-X
of	B-X
psoriatic	B-X
plaques	B-X
were	B-X
performed	B-X
using	B-X
an	B-X
mAb	B-X
,	B-X
Josh	B-X
524.4.1	B-X
,	B-X
and	B-X
Fab	B-X
'	B-X
2	B-X
fragments	B-X
of	B-X
a	B-X
rabbit	B-X
antiserum	B-X
,	B-X
both	B-X
of	B-X
which	B-X
are	B-X
directed	B-X
against	B-X
nonpolymorphic	B-X
determinants	B-X
of	B-X
HLA-DR	B-X
molecules	B-X
.	B-X
HLA-DR+	B-X
keratinocytes	B-X
were	B-X
present	B-X
in	B-X
plaques	B-X
,	B-X
but	B-X
not	B-X
normal-appearing	B-X
skin	B-X
,	B-X
from	B-X
a	B-X
significant	B-X
portion	B-X
of	B-X
patients	B-X
with	B-X
active	B-X
psoriasis	B-X
.	B-X
Double-labelling	B-X
immunofluorescence	B-X
experiments	B-X
with	B-X
either	B-X
the	B-X
monoclonal	B-X
or	B-X
polyclonal	B-X
anti-HLA-DR	B-X
antibody	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
mAb	B-X
OKT6	B-X
,	B-X
which	B-X
identifies	B-X
DR+	B-X
Langerhans	B-X
cells	B-X
,	B-X
demonstrated	B-X
that	B-X
HLA-DR	B-X
molecules	B-X
were	B-X
present	B-X
on	B-X
OKT6-	B-X
keratinocytes	B-X
.	B-X
The	B-X
dermal	B-X
infiltrate	B-X
of	B-X
psoriatic	B-X
plaques	B-X
contained	B-X
T	B-X
cells	B-X
expressing	B-X
the	B-X
activation	B-X
antigens	B-X
,	B-X
IL-2	B-X
receptor	B-X
(	B-X
Tac	B-X
)	B-X
and	B-X
HLA-DR	B-X
,	B-X
as	B-X
well	B-X
as	B-X
macrophages	B-X
and	B-X
OKT6+	B-X
cells	B-X
.	B-X
There	B-X
was	B-X
little	B-X
difference	B-X
in	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
dermal	B-X
infiltrate	B-X
between	B-X
the	B-X
lesions	B-X
with	B-X
or	B-X
without	B-X
HLA-DR+	B-X
keratinocytes	B-X
.	B-X
OKT6+	B-X
presumptive	B-X
Langerhans	B-X
cells	B-X
were	B-X
also	B-X
found	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
patients	B-X
with	B-X
lichen	B-X
planus	B-X
,	B-X
contact	B-X
dermatitis	B-X
,	B-X
spongiotic	B-X
dermatitis	B-X
,	B-X
erythema	B-X
multiforme	B-X
,	B-X
basal	B-X
and	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
Studies	B-X
of	B-X
keratinocyte	B-X
suspensions	B-X
showed	B-X
that	B-X
7-84	B-X
%	B-X
of	B-X
keratinocytes	B-X
were	B-X
HLA-DR+	B-X
.	B-X
Flow	B-X
cytometry	B-X
experiments	B-X
showed	B-X
that	B-X
keratinocytes	B-X
at	B-X
all	B-X
stages	B-X
of	B-X
differentiation	B-X
were	B-X
HLA-DR+	B-X
.	B-X
However	B-X
,	B-X
the	B-X
stem	B-X
cell-enriched	B-X
population	B-X
contained	B-X
the	B-X
highest	B-X
proportion	B-X
of	B-X
HLA-DR+	B-X
cells	B-X
.	B-X
HLA-DR	B-X
expression	B-X
by	B-X
keratinocytes	B-X
correlated	B-X
with	B-X
disease	B-X
activity	B-X
.	B-X
The	B-X
expression	B-X
was	B-X
reversible	B-X
with	B-X
successful	B-X
medical	B-X
therapy	B-X
.	B-X
HLA-DR+	B-X
keratinocytes	B-X
may	B-X
activate	B-X
T	B-X
cells	B-X
directly	B-X
or	B-X
may	B-X
present	B-X
an	B-X
as	B-X
yet	B-X
unknown	B-X
antigen	B-X
to	B-X
T	B-X
cells	B-X
.	B-X

In	O
patients	O
with	O
resectable	O
gastric	O
cancer	O
,	O
the	O
grade	O
of	O
infiltrating	O
dendritic	O
cells	O
may	O
be	O
a	O
suitable	O
predictor	O
of	O
prognosis	O
.	O
<EOS>	B-X
We	B-X
attempted	B-X
to	B-X
correlate	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
leukocyte	B-X
antigen	B-X
DR	B-X
(	B-X
HLA-DR	B-X
)	B-X
and	B-X
tumor	B-X
infiltration	B-X
by	B-X
S-100-protein-positive	B-X
dendritic	B-X
cells	B-X
with	B-X
clinicopathologic	B-X
features	B-X
in	B-X
165	B-X
patients	B-X
with	B-X
gastric	B-X
cancer	B-X
.	B-X
Infiltration	B-X
of	B-X
dendritic	B-X
cells	B-X
correlated	B-X
negatively	B-X
with	B-X
distant	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
clinical	B-X
stage	B-X
,	B-X
and	B-X
peritoneal	B-X
invasion	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
HLA-DR	B-X
and	B-X
infiltration	B-X
by	B-X
dendritic	B-X
cells	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
resectable	B-X
gastric	B-X
cancer	B-X
,	B-X
the	B-X
grade	B-X
of	B-X
infiltrating	B-X
dendritic	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
suitable	B-X
predictor	B-X
of	B-X
prognosis	B-X
.	B-X

Integrin	B-Gene_or_gene_product
alphavbeta3	I-Gene_or_gene_product
requirement	O
for	O
sustained	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
activity	O
during	O
angiogenesis	O
.	O
<EOS>	B-X
Integrins	B-X
and	B-X
growth	B-X
factors	B-X
are	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
ras/MAP	B-X
kinase	B-X
pathway	B-X
in	B-X
vitro	B-X
,	B-X
yet	B-X
how	B-X
these	B-X
signals	B-X
influence	B-X
endothelial	B-X
cells	B-X
during	B-X
angiogenesis	B-X
is	B-X
unknown	B-X
.	B-X
Upon	B-X
initiation	B-X
of	B-X
angiogenesis	B-X
with	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
on	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
activity	B-X
was	B-X
detected	B-X
as	B-X
early	B-X
as	B-X
5	B-X
min	B-X
yet	B-X
was	B-X
sustained	B-X
for	B-X
at	B-X
least	B-X
20	B-X
h.	B-X
The	B-X
initial	B-X
wave	B-X
of	B-X
ERK	B-X
activity	B-X
(	B-X
5-120	B-X
min	B-X
)	B-X
was	B-X
refractory	B-X
to	B-X
integrin	B-X
antagonists	B-X
,	B-X
whereas	B-X
the	B-X
sustained	B-X
activity	B-X
(	B-X
4-20	B-X
h	B-X
)	B-X
depended	B-X
on	B-X
integrin	B-X
alphavbeta3	B-X
,	B-X
but	B-X
not	B-X
beta1	B-X
integrins	B-X
.	B-X
Inhibition	B-X
of	B-X
MAP	B-X
kinase	B-X
kinase	B-X
(	B-X
MEK	B-X
)	B-X
during	B-X
this	B-X
sustained	B-X
alphavbeta3-dependent	B-X
ERK	B-X
signal	B-X
blocked	B-X
the	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
while	B-X
not	B-X
influencing	B-X
preexisting	B-X
blood	B-X
vessels	B-X
on	B-X
the	B-X
CAM	B-X
.	B-X
Therefore	B-X
,	B-X
angiogenesis	B-X
depends	B-X
on	B-X
sustained	B-X
ERK	B-X
activity	B-X
regulated	B-X
by	B-X
the	B-X
ligation	B-X
state	B-X
of	B-X
both	B-X
a	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
integrin	B-X
alphavbeta3	B-X
.	B-X

Angiogenesis	O
depends	O
on	O
growth	O
factors	O
and	O
vascular	O
cell	O
adhesion	O
events	O
.	O
<EOS>	B-X
These	B-X
pregnancy-related	B-X
processes	B-X
require	B-X
marked	B-X
uteroplacental	B-X
and	B-X
vascular	B-X
remodeling	B-X
by	B-X
proteolytic	B-X
enzymes	B-X
and	B-X
metalloproteinases	B-X
.	B-X
In	B-X
NP	B-X
,	B-X
ADAMs	B-X
and	B-X
ADAMTS	B-X
regulate	B-X
sperm-egg	B-X
fusion	B-X
,	B-X
embryo	B-X
implantation	B-X
,	B-X
trophoblast	B-X
invasion	B-X
,	B-X
placental	B-X
angiogenesis	B-X
and	B-X
spiral	B-X
arteries	B-X
remodeling	B-X
through	B-X
their	B-X
ectodomain	B-X
proteolysis	B-X
of	B-X
cell	B-X
surface	B-X
cytokines	B-X
,	B-X
cadherins	B-X
and	B-X
growth	B-X
factors	B-X
as	B-X
well	B-X
as	B-X
their	B-X
adhesion	B-X
with	B-X
integrins	B-X
and	B-X
cell-cell	B-X
junction	B-X
proteins	B-X
.	B-X
Insufficient	B-X
trophoblast	B-X
invasion	B-X
of	B-X
the	B-X
uterine	B-X
wall	B-X
,	B-X
inadequate	B-X
expansive	B-X
remodeling	B-X
of	B-X
the	B-X
spiral	B-X
arteries	B-X
,	B-X
reduced	B-X
uteroplacental	B-X
perfusion	B-X
pressure	B-X
,	B-X
and	B-X
placental	B-X
ischemia/hypoxia	B-X
are	B-X
major	B-X
initiating	B-X
events	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
PE	B-X
.	B-X
In	B-X
PE	B-X
,	B-X
abnormal	B-X
expression/activity	B-X
of	B-X
specific	B-X
ADAMs	B-X
and	B-X
ADAMTS	B-X
that	B-X
function	B-X
as	B-X
proteolytic	B-X
sheddases	B-X
could	B-X
alter	B-X
proangiogenic	B-X
and	B-X
growth	B-X
factors	B-X
,	B-X
and	B-X
promote	B-X
the	B-X
release	B-X
of	B-X
antiangiogenic	B-X
factors	B-X
and	B-X
inflammatory	B-X
cytokines	B-X
into	B-X
the	B-X
placenta	B-X
and	B-X
maternal	B-X
circulation	B-X
leading	B-X
to	B-X
generalized	B-X
inflammation	B-X
,	B-X
endothelial	B-X
cell	B-X
injury	B-X
and	B-X
HTN-Preg	B-X
,	B-X
renal	B-X
injury	B-X
and	B-X
proteinuria	B-X
,	B-X
and	B-X
further	B-X
decreases	B-X
in	B-X
uteroplacental	B-X
blood	B-X
flow	B-X
,	B-X
exaggeration	B-X
of	B-X
placental	B-X
ischemia	B-X
,	B-X
and	B-X
consequently	B-X
fetal	B-X
growth	B-X
restriction	B-X
.	B-X
Identifying	B-X
the	B-X
role	B-X
of	B-X
ADAMs	B-X
and	B-X
ADAMTS	B-X
in	B-X
NP	B-X
and	B-X
PE	B-X
has	B-X
led	B-X
to	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
underlying	B-X
molecular	B-X
and	B-X
vascular	B-X
pathways	B-X
,	B-X
and	B-X
advanced	B-X
the	B-X
potential	B-X
for	B-X
novel	B-X
biomarkers	B-X
for	B-X
prediction	B-X
and	B-X
early	B-X
detection	B-X
,	B-X
and	B-X
new	B-X
approaches	B-X
for	B-X
the	B-X
management	B-X
of	B-X
PE	B-X
.	B-X

Integrins	B-Gene_or_gene_product
and	O
growth	O
factors	O
are	O
capable	O
of	O
activating	O
the	O
ras	B-Gene_or_gene_product
/	O
MAP	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
pathway	O
in	O
vitro	O
,	O
yet	O
how	O
these	O
signals	O
influence	O
endothelial	O
cells	O
during	O
angiogenesis	O
is	O
unknown	O
.	O
<EOS>	B-X
Angiogenesis	B-X
depends	B-X
on	B-X
growth	B-X
factors	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
events	B-X
.	B-X
Integrins	B-X
and	B-X
growth	B-X
factors	B-X
are	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
ras/MAP	B-X
kinase	B-X
pathway	B-X
in	B-X
vitro	B-X
,	B-X
yet	B-X
how	B-X
these	B-X
signals	B-X
influence	B-X
endothelial	B-X
cells	B-X
during	B-X
angiogenesis	B-X
is	B-X
unknown	B-X
.	B-X
Upon	B-X
initiation	B-X
of	B-X
angiogenesis	B-X
with	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
on	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
activity	B-X
was	B-X
detected	B-X
as	B-X
early	B-X
as	B-X
5	B-X
min	B-X
yet	B-X
was	B-X
sustained	B-X
for	B-X
at	B-X
least	B-X
20	B-X
h.	B-X
The	B-X
initial	B-X
wave	B-X
of	B-X
ERK	B-X
activity	B-X
(	B-X
5-120	B-X
min	B-X
)	B-X
was	B-X
refractory	B-X
to	B-X
integrin	B-X
antagonists	B-X
,	B-X
whereas	B-X
the	B-X
sustained	B-X
activity	B-X
(	B-X
4-20	B-X
h	B-X
)	B-X
depended	B-X
on	B-X
integrin	B-X
alphavbeta3	B-X
,	B-X
but	B-X
not	B-X
beta1	B-X
integrins	B-X
.	B-X
Inhibition	B-X
of	B-X
MAP	B-X
kinase	B-X
kinase	B-X
(	B-X
MEK	B-X
)	B-X
during	B-X
this	B-X
sustained	B-X
alphavbeta3-dependent	B-X
ERK	B-X
signal	B-X
blocked	B-X
the	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
while	B-X
not	B-X
influencing	B-X
preexisting	B-X
blood	B-X
vessels	B-X
on	B-X
the	B-X
CAM	B-X
.	B-X
Inhibition	B-X
of	B-X
MEK	B-X
also	B-X
blocked	B-X
growth	B-X
factor	B-X
induced	B-X
migration	B-X
but	B-X
not	B-X
adhesion	B-X
of	B-X
endothelial	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Therefore	B-X
,	B-X
angiogenesis	B-X
depends	B-X
on	B-X
sustained	B-X
ERK	B-X
activity	B-X
regulated	B-X
by	B-X
the	B-X
ligation	B-X
state	B-X
of	B-X
both	B-X
a	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
integrin	B-X
alphavbeta3	B-X
.	B-X

Upon	O
initiation	O
of	O
angiogenesis	O
with	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
bFGF	B-Gene_or_gene_product
)	O
on	O
the	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
,	O
endothelial	O
cell	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
(	I-Gene_or_gene_product
MAP	I-Gene_or_gene_product
)	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
ERK	B-Gene_or_gene_product
)	O
activity	O
was	O
detected	O
as	O
early	O
as	O
5	O
min	O
yet	O
was	O
sustained	O
for	O
at	O
least	O
20	O
h	O
.	O

The	O
initial	O
wave	O
of	O
ERK	B-Gene_or_gene_product
activity	O
(	O
5	O
-	O
120	O
min	O
)	O
was	O
refractory	O
to	O
integrin	O
antagonists	O
,	O
whereas	O
the	O
sustained	O
activity	O
(	O
4	O
-	O
20	O
h	O
)	O
depended	O
on	O
integrin	B-Gene_or_gene_product
alphavbeta3	I-Gene_or_gene_product
,	O
but	O
not	O
beta1	B-Gene_or_gene_product
integrins	I-Gene_or_gene_product
.	O

Inhibition	O
of	O
MAP	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	O
MEK	B-Gene_or_gene_product
)	O
during	O
this	O
sustained	O
alphavbeta3	B-Gene_or_gene_product
-	O
dependent	O
ERK	B-Gene_or_gene_product
signal	O
blocked	O
the	O
formation	O
of	O
new	O
blood	O
vessels	O
while	O
not	O
influencing	O
preexisting	O
blood	O
vessels	O
on	O
the	O
CAM	O
.	O

Inhibition	O
of	O
MEK	B-Gene_or_gene_product
also	O
blocked	O
growth	O
factor	O
induced	O
migration	O
but	O
not	O
adhesion	O
of	O
endothelial	O
cells	O
in	O
vitro	O
.	O
<EOS>	B-X
Cell	B-X
migration	B-X
is	B-X
a	B-X
necessary	B-X
part	B-X
of	B-X
malignant	B-X
invasiveness	B-X
.	B-X
Oral	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
(	B-X
OSCC	B-X
)	B-X
have	B-X
a	B-X
great	B-X
tendency	B-X
for	B-X
local	B-X
invasive	B-X
growth	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
signalling	B-X
pathways	B-X
involved	B-X
in	B-X
cell	B-X
migration	B-X
induced	B-X
by	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
and	B-X
hepatocyte	B-X
growth	B-X
factor	B-X
(	B-X
HGF	B-X
)	B-X
in	B-X
OSCC	B-X
cells	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
various	B-X
experimental	B-X
and	B-X
clinically	B-X
approved	B-X
anti-tumour	B-X
signal	B-X
inhibitors	B-X
on	B-X
the	B-X
migratory	B-X
activity	B-X
.	B-X
Platelet-derived	B-X
growth	B-X
factor	B-X
BB	B-X
(	B-X
PDGFBB	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
activate	B-X
the	B-X
migration	B-X
of	B-X
bone	B-X
marrow-derived	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
BM-MSCs	B-X
)	B-X
,	B-X
and	B-X
to	B-X
contribute	B-X
to	B-X
mediating	B-X
the	B-X
tropism	B-X
of	B-X
BM-MSCs	B-X
towards	B-X
gliomas	B-X
.	B-X
The	B-X
present	B-X
study	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule-1	B-X
(	B-X
VCAM-1	B-X
)	B-X
in	B-X
the	B-X
PDGFBB-induced	B-X
migration	B-X
of	B-X
BM-MSCs	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
PDGFBB	B-X
on	B-X
VCAM-1	B-X
expression	B-X
of	B-X
BM-MSCs	B-X
and	B-X
related	B-X
signaling	B-X
pathways	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
PDGFBB	B-X
in	B-X
the	B-X
conditioned	B-X
medium	B-X
of	B-X
C6	B-X
and	B-X
U87	B-X
cells	B-X
were	B-X
measured	B-X
using	B-X
the	B-X
ELISA	B-X
method	B-X
.	B-X
In	B-X
vitro	B-X
migration	B-X
assays	B-X
using	B-X
a	B-X
VCAM-1	B-X
blocking	B-X
antibody	B-X
were	B-X
performed	B-X
to	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
VCAM-1	B-X
in	B-X
PDGFBB-induced	B-X
migration	B-X
of	B-X
BM-MSCs	B-X
.	B-X
LY294002	B-X
,	B-X
SB203580	B-X
,	B-X
PD98059	B-X
,	B-X
SP600125	B-X
and	B-X
BAY11-7082	B-X
were	B-X
used	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
PI3K	B-X
,	B-X
p38	B-X
MAPK	B-X
,	B-X
MEK	B-X
,	B-X
JNK	B-X
and	B-X
NF-ÎºB	B-X
in	B-X
the	B-X
related	B-X
intracellular	B-X
signal	B-X
transduction	B-X
of	B-X
PDGFBB	B-X
stimulation	B-X
on	B-X
VCAM-1	B-X
expression	B-X
of	B-X
BM-MSCs	B-X
.	B-X
The	B-X
data	B-X
demonstrated	B-X
that	B-X
the	B-X
neutralization	B-X
of	B-X
VCAM-1	B-X
inhibited	B-X
the	B-X
migration	B-X
of	B-X
BM-MSCs	B-X
induced	B-X
by	B-X
PDGFBB	B-X
.	B-X
It	B-X
is	B-X
reasonable	B-X
to	B-X
conclude	B-X
that	B-X
PDGFBB	B-X
significantly	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
VCAM-1	B-X
in	B-X
BM-MSCs	B-X
,	B-X
which	B-X
facilitated	B-X
the	B-X
migration	B-X
of	B-X
BM-MSCs	B-X
towards	B-X
PDGFBB	B-X
.	B-X

Therefore	O
,	O
angiogenesis	O
depends	O
on	O
sustained	O
ERK	B-Gene_or_gene_product
activity	O
regulated	O
by	O
the	O
ligation	O
state	O
of	O
both	O
a	O
growth	O
factor	O
receptor	O
and	O
integrin	B-Gene_or_gene_product
alphavbeta3	I-Gene_or_gene_product
.	O
<EOS>	B-X
Angiogenesis	B-X
depends	B-X
on	B-X
growth	B-X
factors	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
events	B-X
.	B-X
Integrins	B-X
and	B-X
growth	B-X
factors	B-X
are	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
ras/MAP	B-X
kinase	B-X
pathway	B-X
in	B-X
vitro	B-X
,	B-X
yet	B-X
how	B-X
these	B-X
signals	B-X
influence	B-X
endothelial	B-X
cells	B-X
during	B-X
angiogenesis	B-X
is	B-X
unknown	B-X
.	B-X
Upon	B-X
initiation	B-X
of	B-X
angiogenesis	B-X
with	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
on	B-X
the	B-X
chick	B-X
chorioallantoic	B-X
membrane	B-X
(	B-X
CAM	B-X
)	B-X
,	B-X
endothelial	B-X
cell	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
activity	B-X
was	B-X
detected	B-X
as	B-X
early	B-X
as	B-X
5	B-X
min	B-X
yet	B-X
was	B-X
sustained	B-X
for	B-X
at	B-X
least	B-X
20	B-X
h.	B-X
The	B-X
initial	B-X
wave	B-X
of	B-X
ERK	B-X
activity	B-X
(	B-X
5-120	B-X
min	B-X
)	B-X
was	B-X
refractory	B-X
to	B-X
integrin	B-X
antagonists	B-X
,	B-X
whereas	B-X
the	B-X
sustained	B-X
activity	B-X
(	B-X
4-20	B-X
h	B-X
)	B-X
depended	B-X
on	B-X
integrin	B-X
alphavbeta3	B-X
,	B-X
but	B-X
not	B-X
beta1	B-X
integrins	B-X
.	B-X
Inhibition	B-X
of	B-X
MAP	B-X
kinase	B-X
kinase	B-X
(	B-X
MEK	B-X
)	B-X
during	B-X
this	B-X
sustained	B-X
alphavbeta3-dependent	B-X
ERK	B-X
signal	B-X
blocked	B-X
the	B-X
formation	B-X
of	B-X
new	B-X
blood	B-X
vessels	B-X
while	B-X
not	B-X
influencing	B-X
preexisting	B-X
blood	B-X
vessels	B-X
on	B-X
the	B-X
CAM	B-X
.	B-X
Inhibition	B-X
of	B-X
MEK	B-X
also	B-X
blocked	B-X
growth	B-X
factor	B-X
induced	B-X
migration	B-X
but	B-X
not	B-X
adhesion	B-X
of	B-X
endothelial	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Therefore	B-X
,	B-X
angiogenesis	B-X
depends	B-X
on	B-X
sustained	B-X
ERK	B-X
activity	B-X
regulated	B-X
by	B-X
the	B-X
ligation	B-X
state	B-X
of	B-X
both	B-X
a	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
integrin	B-X
alphavbeta3	B-X
.	B-X

Basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
:	O
a	O
missing	O
link	O
between	O
collagen	B-Gene_or_gene_product
VII	I-Gene_or_gene_product
,	O
increased	O
collagenase	B-Gene_or_gene_product
,	O
and	O
squamous	O
cell	O
carcinoma	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
recessive	B-X
dystrophic	B-X
epidermolysis	B-X
bullosa	B-X
(	B-X
RDEB	B-X
)	B-X
have	B-X
deficiencies	B-X
of	B-X
collagen	B-X
type	B-X
VII	B-X
and	B-X
have	B-X
elevated	B-X
levels	B-X
of	B-X
fibroblast	B-X
collagenase	B-X
,	B-X
and	B-X
a	B-X
greatly	B-X
increased	B-X
risk	B-X
of	B-X
cutaneous	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
Patients	B-X
with	B-X
other	B-X
genetic	B-X
blistering	B-X
disorders	B-X
do	B-X
not	B-X
have	B-X
elevated	B-X
collagenase	B-X
or	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
,	B-X
despite	B-X
chronic	B-X
wounding	B-X
.	B-X
The	B-X
connection	B-X
between	B-X
collagen	B-X
type	B-X
VII	B-X
deficiency	B-X
,	B-X
increased	B-X
collagenase	B-X
,	B-X
and	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
is	B-X
not	B-X
understood	B-X
.	B-X

BACKGROUND	O
:	O
Patients	O
with	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(	O
RDEB	O
)	O
have	O
deficiencies	O
of	O
collagen	B-Gene_or_gene_product
type	I-Gene_or_gene_product
VII	I-Gene_or_gene_product
and	O
have	O
elevated	O
levels	O
of	O
fibroblast	B-Gene_or_gene_product
collagenase	I-Gene_or_gene_product
,	O
and	O
a	O
greatly	O
increased	O
risk	O
of	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
.	O

Patients	O
with	O
other	O
genetic	O
blistering	O
disorders	O
do	O
not	O
have	O
elevated	O
collagenase	B-Gene_or_gene_product
or	O
an	O
increased	O
risk	O
of	O
squamous	O
cell	O
carcinoma	O
,	O
despite	O
chronic	O
wounding	O
.	O
<EOS>	B-X
Several	B-X
drugs	B-X
are	B-X
at	B-X
``	B-X
high	B-X
''	B-X
risk	B-X
of	B-X
inducing	B-X
TEN/SJS	B-X
including	B-X
:	B-X
Allopurinol	B-X
,	B-X
Trimethoprim-sulfamethoxazole	B-X
and	B-X
other	B-X
sulfonamide-antibiotics	B-X
,	B-X
aminopenicillins	B-X
,	B-X
cephalosporins	B-X
,	B-X
quinolones	B-X
,	B-X
carbamazepine	B-X
,	B-X
phenytoin	B-X
,	B-X
phenobarbital	B-X
and	B-X
NSAID	B-X
's	B-X
of	B-X
the	B-X
oxicam-type	B-X
.	B-X
Genetic	B-X
susceptibility	B-X
to	B-X
SJS	B-X
and	B-X
TEN	B-X
is	B-X
likely	B-X
as	B-X
exemplified	B-X
by	B-X
the	B-X
strong	B-X
association	B-X
observed	B-X
in	B-X
Han	B-X
Chinese	B-X
between	B-X
a	B-X
genetic	B-X
marker	B-X
,	B-X
the	B-X
human	B-X
leukocyte	B-X
antigen	B-X
HLA-B	B-X
*	B-X
1502	B-X
,	B-X
and	B-X
SJS	B-X
induced	B-X
by	B-X
carbamazepine	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
high	B-X
risk	B-X
of	B-X
mortality	B-X
,	B-X
management	B-X
of	B-X
patients	B-X
with	B-X
SJS/TEN	B-X
requires	B-X
rapid	B-X
diagnosis	B-X
,	B-X
evaluation	B-X
of	B-X
the	B-X
prognosis	B-X
using	B-X
SCORTEN	B-X
,	B-X
identification	B-X
and	B-X
interruption	B-X
of	B-X
the	B-X
culprit	B-X
drug	B-X
,	B-X
specialized	B-X
supportive	B-X
care	B-X
ideally	B-X
in	B-X
an	B-X
intensive	B-X
care	B-X
unit	B-X
,	B-X
and	B-X
consideration	B-X
of	B-X
immunomodulating	B-X
agents	B-X
such	B-X
as	B-X
high-dose	B-X
intravenous	B-X
immunoglobulin	B-X
therapy	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
clinical	B-X
features	B-X
of	B-X
PPP	B-X
and	B-X
GPP	B-X
,	B-X
and	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
genetics	B-X
and	B-X
immunopathology	B-X
of	B-X
these	B-X
conditions	B-X
;	B-X
it	B-X
also	B-X
provides	B-X
an	B-X
update	B-X
on	B-X
emerging	B-X
treatments	B-X
.	B-X

The	O
connection	O
between	O
collagen	B-Gene_or_gene_product
type	I-Gene_or_gene_product
VII	I-Gene_or_gene_product
deficiency	O
,	O
increased	O
collagenase	B-Gene_or_gene_product
,	O
and	O
squamous	O
cell	O
carcinoma	O
is	O
not	O
understood	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Urine	O
from	O
81	O
patients	O
with	O
RDEB	O
(	O
39	O
patients	O
)	O
,	O
junctional	O
epidermolysis	O
bullosa	O
(	O
JEB	O
;	O
12	O
patients	O
)	O
,	O
and	O
epidermolysis	O
bullosa	O
simplex	O
(	O
EBS	O
;	O
30	O
patients	O
)	O
,	O
as	O
well	O
as	O
unaffected	O
family	O
members	O
of	O
RDEB	O
patients	O
(	O
33	O
patients	O
)	O
,	O
was	O
tested	O
for	O
the	O
presence	O
of	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	O
bFGF	B-Gene_or_gene_product
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
recessive	B-X
dystrophic	B-X
epidermolysis	B-X
bullosa	B-X
(	B-X
RDEB	B-X
)	B-X
have	B-X
deficiencies	B-X
of	B-X
collagen	B-X
type	B-X
VII	B-X
and	B-X
have	B-X
elevated	B-X
levels	B-X
of	B-X
fibroblast	B-X
collagenase	B-X
,	B-X
and	B-X
a	B-X
greatly	B-X
increased	B-X
risk	B-X
of	B-X
cutaneous	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X

These	O
patients	O
included	O
many	O
who	O
were	O
enrolled	O
in	O
the	O
Epidermolysis	O
Bullosa	O
Registry	O
and	O
others	O
who	O
were	O
referred	O
by	O
their	O
physicians	O
.	O

RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
RDEB	O
had	O
elevated	O
levels	O
(	O
greater	O
than	O
5000	O
pg	O
/	O
g	O
)	O
of	O
urinary	O
bFGF	B-Gene_or_gene_product
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
patients	O
with	O
JEB	O
had	O
elevated	O
levels	O
of	O
bFGF	B-Gene_or_gene_product
.	O

Twenty	O
-	O
one	O
percent	O
of	O
clinically	O
unaffected	O
family	O
members	O
had	O
elevated	O
levels	O
of	O
bFGF	B-Gene_or_gene_product
,	O
and	O
13	O
%	O
of	O
patients	O
with	O
EBS	O
had	O
elevated	O
levels	O
of	O
bFGF	B-Gene_or_gene_product
.	O
<EOS>	B-X
Patients	B-X
with	B-X
recessive	B-X
dystrophic	B-X
epidermolysis	B-X
bullosa	B-X
(	B-X
RDEB	B-X
)	B-X
have	B-X
deficiencies	B-X
of	B-X
collagen	B-X
type	B-X
VII	B-X
and	B-X
have	B-X
elevated	B-X
levels	B-X
of	B-X
fibroblast	B-X
collagenase	B-X
,	B-X
and	B-X
a	B-X
greatly	B-X
increased	B-X
risk	B-X
of	B-X
cutaneous	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
Patients	B-X
with	B-X
other	B-X
genetic	B-X
blistering	B-X
disorders	B-X
do	B-X
not	B-X
have	B-X
elevated	B-X
collagenase	B-X
or	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
,	B-X
despite	B-X
chronic	B-X
wounding	B-X
.	B-X

The	O
frequency	O
of	O
elevated	O
bFGF	B-Gene_or_gene_product
values	O
among	O
all	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
the	O
levels	O
of	O
bFGF	B-Gene_or_gene_product
in	O
RDEB	O
patients	O
were	O
significantly	O
elevated	O
compared	O
with	O
those	O
of	O
other	O
groups	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
found	O
that	O
patients	O
with	O
RDEB	O
have	O
elevated	O
levels	O
of	O
bFGF	B-Gene_or_gene_product
,	O
which	O
may	O
contribute	O
to	O
increased	O
fibroblast	B-Gene_or_gene_product
collagenase	I-Gene_or_gene_product
and	O
the	O
development	O
of	O
squamous	O
cell	O
carcinoma	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
recessive	B-X
dystrophic	B-X
epidermolysis	B-X
bullosa	B-X
(	B-X
RDEB	B-X
)	B-X
have	B-X
deficiencies	B-X
of	B-X
collagen	B-X
type	B-X
VII	B-X
and	B-X
have	B-X
elevated	B-X
levels	B-X
of	B-X
fibroblast	B-X
collagenase	B-X
,	B-X
and	B-X
a	B-X
greatly	B-X
increased	B-X
risk	B-X
of	B-X
cutaneous	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
Patients	B-X
with	B-X
other	B-X
genetic	B-X
blistering	B-X
disorders	B-X
do	B-X
not	B-X
have	B-X
elevated	B-X
collagenase	B-X
or	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
,	B-X
despite	B-X
chronic	B-X
wounding	B-X
.	B-X
The	B-X
connection	B-X
between	B-X
collagen	B-X
type	B-X
VII	B-X
deficiency	B-X
,	B-X
increased	B-X
collagenase	B-X
,	B-X
and	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
is	B-X
not	B-X
understood	B-X
.	B-X

These	O
results	O
suggest	O
a	O
novel	O
treatment	O
for	O
RDEB	O
,	O
namely	O
,	O
angiogenesis	O
inhibitors	O
,	O
which	O
may	O
antagonize	O
the	O
effects	O
of	O
bFGF	B-Gene_or_gene_product
in	O
this	O
disorder	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
recessive	B-X
dystrophic	B-X
epidermolysis	B-X
bullosa	B-X
(	B-X
RDEB	B-X
)	B-X
have	B-X
deficiencies	B-X
of	B-X
collagen	B-X
type	B-X
VII	B-X
and	B-X
have	B-X
elevated	B-X
levels	B-X
of	B-X
fibroblast	B-X
collagenase	B-X
,	B-X
and	B-X
a	B-X
greatly	B-X
increased	B-X
risk	B-X
of	B-X
cutaneous	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
Patients	B-X
with	B-X
other	B-X
genetic	B-X
blistering	B-X
disorders	B-X
do	B-X
not	B-X
have	B-X
elevated	B-X
collagenase	B-X
or	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
,	B-X
despite	B-X
chronic	B-X
wounding	B-X
.	B-X

There	O
are	O
currently	O
no	O
other	O
means	O
of	O
treatment	O
for	O
this	O
disorder	O
,	O
which	O
has	O
a	O
high	O
morbidity	O
and	O
mortality	O
rate	O
.	O

The	O
myoadipose	O
flap	O
:	O
a	O
new	O
composite	O
.	O
<EOS>	B-X
A	B-X
prefabricated	B-X
composite	B-X
fat	B-X
flap	B-X
consisting	B-X
of	B-X
muscle	B-X
woven	B-X
into	B-X
an	B-X
anatomically	B-X
distinct	B-X
fat	B-X
pad	B-X
was	B-X
studied	B-X
in	B-X
a	B-X
rabbit	B-X
model	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prefabrication	B-X
of	B-X
a	B-X
fat	B-X
flap	B-X
is	B-X
possible	B-X
and	B-X
may	B-X
have	B-X
extensive	B-X
application	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
plastic	B-X
surgery	B-X
.	B-X

A	O
prefabricated	O
composite	O
fat	O
flap	O
consisting	O
of	O
muscle	O
woven	O
into	O
an	O
anatomically	O
distinct	O
fat	O
pad	O
was	O
studied	O
in	O
a	O
rabbit	O
model	O
.	O

In	O
17	O
rabbits	O
,	O
a	O
2	O
-	O
cm	O
strip	O
of	O
latissimus	O
dorsi	O
was	O
woven	O
into	O
the	O
parascapular	O
fat	O
pad	O
on	O
one	O
side	O
,	O
with	O
the	O
contralateral	O
fat	O
pad	O
serving	O
as	O
a	O
control	O
.	O

At	O
3	O
weeks	O
,	O
the	O
endogenous	O
blood	O
supply	O
of	O
both	O
the	O
control	O
and	O
the	O
experimental	O
fat	O
pads	O
was	O
isolated	O
and	O
ligated	O
,	O
and	O
the	O
composite	O
fat	O
/	O
muscle	O
flap	O
was	O
transferred	O
to	O
the	O
chest	O
wall	O
.	O

At	O
6	O
weeks	O
,	O
animals	O
were	O
killed	O
,	O
and	O
flaps	O
were	O
analyzed	O
for	O
length	O
,	O
width	O
,	O
and	O
weight	O
;	O
perfused	O
with	O
fluorescein	O
or	O
lead	O
oxide	O
;	O
and	O
examined	O
histologically	O
.	O
<EOS>	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X

Significant	O
differences	O
were	O
found	O
between	O
the	O
control	O
and	O
experimental	O
fat	O
pads	O
with	O
regard	O
to	O
weight	O
and	O
length	O
.	O
<EOS>	B-X
A	B-X
prefabricated	B-X
composite	B-X
fat	B-X
flap	B-X
consisting	B-X
of	B-X
muscle	B-X
woven	B-X
into	B-X
an	B-X
anatomically	B-X
distinct	B-X
fat	B-X
pad	B-X
was	B-X
studied	B-X
in	B-X
a	B-X
rabbit	B-X
model	B-X
.	B-X
In	B-X
17	B-X
rabbits	B-X
,	B-X
a	B-X
2-cm	B-X
strip	B-X
of	B-X
latissimus	B-X
dorsi	B-X
was	B-X
woven	B-X
into	B-X
the	B-X
parascapular	B-X
fat	B-X
pad	B-X
on	B-X
one	B-X
side	B-X
,	B-X
with	B-X
the	B-X
contralateral	B-X
fat	B-X
pad	B-X
serving	B-X
as	B-X
a	B-X
control	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
No	B-X
vessels	B-X
were	B-X
visualized	B-X
in	B-X
the	B-X
controls	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prefabrication	B-X
of	B-X
a	B-X
fat	B-X
flap	B-X
is	B-X
possible	B-X
and	B-X
may	B-X
have	B-X
extensive	B-X
application	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
plastic	B-X
surgery	B-X
.	B-X

Experimental	O
flaps	O
were	O
found	O
to	O
be	O
perfused	O
fully	O
with	O
fluorescein	O
and	O
lead	O
oxide	O
;	O
control	O
fat	O
pads	O
were	O
found	O
not	O
to	O
be	O
perfused	O
.	O
<EOS>	B-X
A	B-X
prefabricated	B-X
composite	B-X
fat	B-X
flap	B-X
consisting	B-X
of	B-X
muscle	B-X
woven	B-X
into	B-X
an	B-X
anatomically	B-X
distinct	B-X
fat	B-X
pad	B-X
was	B-X
studied	B-X
in	B-X
a	B-X
rabbit	B-X
model	B-X
.	B-X
In	B-X
17	B-X
rabbits	B-X
,	B-X
a	B-X
2-cm	B-X
strip	B-X
of	B-X
latissimus	B-X
dorsi	B-X
was	B-X
woven	B-X
into	B-X
the	B-X
parascapular	B-X
fat	B-X
pad	B-X
on	B-X
one	B-X
side	B-X
,	B-X
with	B-X
the	B-X
contralateral	B-X
fat	B-X
pad	B-X
serving	B-X
as	B-X
a	B-X
control	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
No	B-X
vessels	B-X
were	B-X
visualized	B-X
in	B-X
the	B-X
controls	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prefabrication	B-X
of	B-X
a	B-X
fat	B-X
flap	B-X
is	B-X
possible	B-X
and	B-X
may	B-X
have	B-X
extensive	B-X
application	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
plastic	B-X
surgery	B-X
.	B-X

The	O
lead	O
oxide	O
group	O
revealed	O
extensive	O
growth	O
of	O
blood	O
vessels	O
from	O
the	O
latissimus	O
graft	O
into	O
the	O
experimental	O
fat	O
pad	O
.	O
<EOS>	B-X
A	B-X
prefabricated	B-X
composite	B-X
fat	B-X
flap	B-X
consisting	B-X
of	B-X
muscle	B-X
woven	B-X
into	B-X
an	B-X
anatomically	B-X
distinct	B-X
fat	B-X
pad	B-X
was	B-X
studied	B-X
in	B-X
a	B-X
rabbit	B-X
model	B-X
.	B-X
In	B-X
17	B-X
rabbits	B-X
,	B-X
a	B-X
2-cm	B-X
strip	B-X
of	B-X
latissimus	B-X
dorsi	B-X
was	B-X
woven	B-X
into	B-X
the	B-X
parascapular	B-X
fat	B-X
pad	B-X
on	B-X
one	B-X
side	B-X
,	B-X
with	B-X
the	B-X
contralateral	B-X
fat	B-X
pad	B-X
serving	B-X
as	B-X
a	B-X
control	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
No	B-X
vessels	B-X
were	B-X
visualized	B-X
in	B-X
the	B-X
controls	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prefabrication	B-X
of	B-X
a	B-X
fat	B-X
flap	B-X
is	B-X
possible	B-X
and	B-X
may	B-X
have	B-X
extensive	B-X
application	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
plastic	B-X
surgery	B-X
.	B-X

No	O
vessels	O
were	O
visualized	O
in	O
the	O
controls	O
.	O
<EOS>	B-X
Under	B-X
physiologic	B-X
conditions	B-X
the	B-X
endothelium	B-X
is	B-X
impermeable	B-X
to	B-X
albumin	B-X
,	B-X
so	B-X
Evans	B-X
blue	B-X
bound	B-X
albumin	B-X
remains	B-X
restricted	B-X
within	B-X
blood	B-X
vessels	B-X
.	B-X
Results	B-X
indicate	B-X
that	B-X
the	B-X
vascular	B-X
volume	B-X
of	B-X
the	B-X
surgically	B-X
manipulated	B-X
limb	B-X
was	B-X
reconstituted	B-X
as	B-X
early	B-X
as	B-X
3	B-X
days	B-X
after	B-X
femoral	B-X
artery	B-X
excision	B-X
through	B-X
development	B-X
of	B-X
a	B-X
series	B-X
of	B-X
highly	B-X
connected	B-X
,	B-X
small	B-X
caliber	B-X
,	B-X
closely	B-X
spaced	B-X
,	B-X
and	B-X
isotropically	B-X
oriented	B-X
collateral	B-X
vessels	B-X
.	B-X
Ultrasound	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
diagnosis	B-X
of	B-X
rare	B-X
arterial	B-X
diseases	B-X
like	B-X
large	B-X
vessel	B-X
vasculitis	B-X
,	B-X
arterial	B-X
dissection	B-X
,	B-X
cystic	B-X
adventitial	B-X
degeneration	B-X
,	B-X
and	B-X
the	B-X
differentiation	B-X
of	B-X
vascular	B-X
malformation	B-X
especially	B-X
in	B-X
children	B-X
,	B-X
thus	B-X
,	B-X
permitting	B-X
ultrasound-guided	B-X
intervention	B-X
and	B-X
follow-up	B-X
controls	B-X
.	B-X
In	B-X
venous	B-X
thrombosis	B-X
,	B-X
sonography	B-X
is	B-X
the	B-X
primary	B-X
imaging	B-X
method	B-X
,	B-X
while	B-X
follow-up	B-X
controls	B-X
help	B-X
in	B-X
the	B-X
prediction	B-X
of	B-X
recurrent	B-X
venous	B-X
thrombosis	B-X
.	B-X

Finally	O
,	O
sections	O
of	O
the	O
control	O
and	O
experimental	O
flaps	O
were	O
analyzed	O
histologically	O
.	O
<EOS>	B-X
In	B-X
17	B-X
rabbits	B-X
,	B-X
a	B-X
2-cm	B-X
strip	B-X
of	B-X
latissimus	B-X
dorsi	B-X
was	B-X
woven	B-X
into	B-X
the	B-X
parascapular	B-X
fat	B-X
pad	B-X
on	B-X
one	B-X
side	B-X
,	B-X
with	B-X
the	B-X
contralateral	B-X
fat	B-X
pad	B-X
serving	B-X
as	B-X
a	B-X
control	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
No	B-X
vessels	B-X
were	B-X
visualized	B-X
in	B-X
the	B-X
controls	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X

A	O
preponderance	O
of	O
viable	O
fat	O
,	O
with	O
evidence	O
of	O
neovascularization	O
,	O
was	O
found	O
in	O
experimental	O
flaps	O
,	O
compared	O
with	O
the	O
necrotic	O
fat	O
that	O
characterized	O
the	O
controls	O
.	O
<EOS>	B-X
A	B-X
prefabricated	B-X
composite	B-X
fat	B-X
flap	B-X
consisting	B-X
of	B-X
muscle	B-X
woven	B-X
into	B-X
an	B-X
anatomically	B-X
distinct	B-X
fat	B-X
pad	B-X
was	B-X
studied	B-X
in	B-X
a	B-X
rabbit	B-X
model	B-X
.	B-X
In	B-X
17	B-X
rabbits	B-X
,	B-X
a	B-X
2-cm	B-X
strip	B-X
of	B-X
latissimus	B-X
dorsi	B-X
was	B-X
woven	B-X
into	B-X
the	B-X
parascapular	B-X
fat	B-X
pad	B-X
on	B-X
one	B-X
side	B-X
,	B-X
with	B-X
the	B-X
contralateral	B-X
fat	B-X
pad	B-X
serving	B-X
as	B-X
a	B-X
control	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
No	B-X
vessels	B-X
were	B-X
visualized	B-X
in	B-X
the	B-X
controls	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prefabrication	B-X
of	B-X
a	B-X
fat	B-X
flap	B-X
is	B-X
possible	B-X
and	B-X
may	B-X
have	B-X
extensive	B-X
application	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
plastic	B-X
surgery	B-X
.	B-X

We	O
conclude	O
that	O
prefabrication	O
of	O
a	O
fat	O
flap	O
is	O
possible	O
and	O
may	O
have	O
extensive	O
application	O
in	O
various	O
areas	O
of	O
plastic	O
surgery	O
.	O
<EOS>	B-X
A	B-X
prefabricated	B-X
composite	B-X
fat	B-X
flap	B-X
consisting	B-X
of	B-X
muscle	B-X
woven	B-X
into	B-X
an	B-X
anatomically	B-X
distinct	B-X
fat	B-X
pad	B-X
was	B-X
studied	B-X
in	B-X
a	B-X
rabbit	B-X
model	B-X
.	B-X
In	B-X
17	B-X
rabbits	B-X
,	B-X
a	B-X
2-cm	B-X
strip	B-X
of	B-X
latissimus	B-X
dorsi	B-X
was	B-X
woven	B-X
into	B-X
the	B-X
parascapular	B-X
fat	B-X
pad	B-X
on	B-X
one	B-X
side	B-X
,	B-X
with	B-X
the	B-X
contralateral	B-X
fat	B-X
pad	B-X
serving	B-X
as	B-X
a	B-X
control	B-X
.	B-X
At	B-X
3	B-X
weeks	B-X
,	B-X
the	B-X
endogenous	B-X
blood	B-X
supply	B-X
of	B-X
both	B-X
the	B-X
control	B-X
and	B-X
the	B-X
experimental	B-X
fat	B-X
pads	B-X
was	B-X
isolated	B-X
and	B-X
ligated	B-X
,	B-X
and	B-X
the	B-X
composite	B-X
fat/muscle	B-X
flap	B-X
was	B-X
transferred	B-X
to	B-X
the	B-X
chest	B-X
wall	B-X
.	B-X
At	B-X
6	B-X
weeks	B-X
,	B-X
animals	B-X
were	B-X
killed	B-X
,	B-X
and	B-X
flaps	B-X
were	B-X
analyzed	B-X
for	B-X
length	B-X
,	B-X
width	B-X
,	B-X
and	B-X
weight	B-X
;	B-X
perfused	B-X
with	B-X
fluorescein	B-X
or	B-X
lead	B-X
oxide	B-X
;	B-X
and	B-X
examined	B-X
histologically	B-X
.	B-X
Significant	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
fat	B-X
pads	B-X
with	B-X
regard	B-X
to	B-X
weight	B-X
and	B-X
length	B-X
.	B-X
Experimental	B-X
flaps	B-X
were	B-X
found	B-X
to	B-X
be	B-X
perfused	B-X
fully	B-X
with	B-X
fluorescein	B-X
and	B-X
lead	B-X
oxide	B-X
;	B-X
control	B-X
fat	B-X
pads	B-X
were	B-X
found	B-X
not	B-X
to	B-X
be	B-X
perfused	B-X
.	B-X
The	B-X
lead	B-X
oxide	B-X
group	B-X
revealed	B-X
extensive	B-X
growth	B-X
of	B-X
blood	B-X
vessels	B-X
from	B-X
the	B-X
latissimus	B-X
graft	B-X
into	B-X
the	B-X
experimental	B-X
fat	B-X
pad	B-X
.	B-X
Finally	B-X
,	B-X
sections	B-X
of	B-X
the	B-X
control	B-X
and	B-X
experimental	B-X
flaps	B-X
were	B-X
analyzed	B-X
histologically	B-X
.	B-X
A	B-X
preponderance	B-X
of	B-X
viable	B-X
fat	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
neovascularization	B-X
,	B-X
was	B-X
found	B-X
in	B-X
experimental	B-X
flaps	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
necrotic	B-X
fat	B-X
that	B-X
characterized	B-X
the	B-X
controls	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prefabrication	B-X
of	B-X
a	B-X
fat	B-X
flap	B-X
is	B-X
possible	B-X
and	B-X
may	B-X
have	B-X
extensive	B-X
application	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
plastic	B-X
surgery	B-X
.	B-X

Requirement	O
of	O
estrogen	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
expression	O
and	O
function	O
for	O
[	O
12Val	O
]	O
K	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ras	I-Gene_or_gene_product
-	O
mediated	O
NIH3T3	O
cell	O
transformation	O
.	O

We	O
investigated	O
the	O
biological	O
significance	O
of	O
estrogen	B-Gene_or_gene_product
receptors	I-Gene_or_gene_product
(	O
ERs	B-Gene_or_gene_product
)	O
in	O
NIH3T3	O
cell	O
transformation	O
by	O
the	O
[	O
12Val	O
]	O
K	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ras	I-Gene_or_gene_product
mutant	O
.	O

This	O
mutant	O
enhanced	O
the	O
steady	O
-	O
level	O
and	O
transcriptional	O
activity	O
of	O
ER	B-Gene_or_gene_product
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
estrogen	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
NIH3T3	B-X
cell	B-X
transformation	B-X
by	B-X
the	B-X
[	B-X
12Val	B-X
]	B-X
K-Ras	B-X
mutant	B-X
.	B-X
This	B-X
mutant	B-X
enhanced	B-X
the	B-X
steady	B-X
state	B-X
level	B-X
of	B-X
ER	B-X
.	B-X
Cells	B-X
expressing	B-X
mutant	B-X
K-Ras	B-X
(	B-X
K12V	B-X
cell	B-X
)	B-X
were	B-X
tumorigenic	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
ER	B-X
accumulation	B-X
in	B-X
Ras-transformed	B-X
cells	B-X
,	B-X
we	B-X
developed	B-X
cells	B-X
(	B-X
KwtER	B-X
cells	B-X
)	B-X
that	B-X
overexpressed	B-X
both	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
K-Ras	B-X
and	B-X
ER	B-X
,	B-X
and	B-X
found	B-X
these	B-X
cells	B-X
were	B-X
also	B-X
tumorigenic	B-X
.	B-X
E2	B-X
stimulated	B-X
the	B-X
transcriptional	B-X
activity	B-X
by	B-X
ER	B-X
dominantly	B-X
in	B-X
K12V	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
partial	B-X
activation	B-X
of	B-X
ER	B-X
by	B-X
E2	B-X
was	B-X
seen	B-X
in	B-X
KwtER	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
10	B-X
%	B-X
serum	B-X
in	B-X
media	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
ER	B-X
appeared	B-X
only	B-X
in	B-X
transformed	B-X
KtwER	B-X
and	B-X
K12V	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
two	B-X
independently	B-X
transmitted	B-X
signals	B-X
,	B-X
the	B-X
E2-ER	B-X
binding	B-X
and	B-X
the	B-X
ER-AF1	B-X
activation	B-X
,	B-X
are	B-X
necessary	B-X
for	B-X
ER	B-X
activation	B-X
and	B-X
that	B-X
the	B-X
dominant	B-X
activation	B-X
of	B-X
ER	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
Ras-mediated	B-X
cell	B-X
transformation	B-X
.	B-X
Co-expression	B-X
of	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
with	B-X
mutant	B-X
K-Ras	B-X
led	B-X
to	B-X
suppression	B-X
of	B-X
tumorigenicity	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
activation	B-X
of	B-X
ER	B-X
.	B-X
The	B-X
antisense	B-X
oligomers	B-X
complementary	B-X
to	B-X
the	B-X
ER	B-X
suppressed	B-X
proliferation	B-X
and	B-X
transformed	B-X
phenotypes	B-X
of	B-X
K12V	B-X
cells	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
the	B-X
importance	B-X
of	B-X
ER	B-X
in	B-X
Ras-mediated	B-X
cell	B-X
transformation	B-X
.	B-X

Coexpression	O
of	O
the	O
progesterone	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
with	O
mutant	O
K	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ras	I-Gene_or_gene_product
led	O
to	O
suppression	O
of	O
tumorigenicity	O
and	O
inhibition	O
of	O
the	O
activation	O
of	O
ER	B-Gene_or_gene_product
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
estrogen	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
NIH3T3	B-X
cell	B-X
transformation	B-X
by	B-X
the	B-X
[	B-X
12Val	B-X
]	B-X
K-Ras	B-X
mutant	B-X
.	B-X
This	B-X
mutant	B-X
enhanced	B-X
the	B-X
steady	B-X
state	B-X
level	B-X
of	B-X
ER	B-X
.	B-X
Cells	B-X
expressing	B-X
mutant	B-X
K-Ras	B-X
(	B-X
K12V	B-X
cell	B-X
)	B-X
were	B-X
tumorigenic	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
ER	B-X
accumulation	B-X
in	B-X
Ras-transformed	B-X
cells	B-X
,	B-X
we	B-X
developed	B-X
cells	B-X
(	B-X
KwtER	B-X
cells	B-X
)	B-X
that	B-X
overexpressed	B-X
both	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
K-Ras	B-X
and	B-X
ER	B-X
,	B-X
and	B-X
found	B-X
these	B-X
cells	B-X
were	B-X
also	B-X
tumorigenic	B-X
.	B-X
E2	B-X
stimulated	B-X
the	B-X
transcriptional	B-X
activity	B-X
by	B-X
ER	B-X
dominantly	B-X
in	B-X
K12V	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
partial	B-X
activation	B-X
of	B-X
ER	B-X
by	B-X
E2	B-X
was	B-X
seen	B-X
in	B-X
KwtER	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
10	B-X
%	B-X
serum	B-X
in	B-X
media	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
ER	B-X
appeared	B-X
only	B-X
in	B-X
transformed	B-X
KtwER	B-X
and	B-X
K12V	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
two	B-X
independently	B-X
transmitted	B-X
signals	B-X
,	B-X
the	B-X
E2-ER	B-X
binding	B-X
and	B-X
the	B-X
ER-AF1	B-X
activation	B-X
,	B-X
are	B-X
necessary	B-X
for	B-X
ER	B-X
activation	B-X
and	B-X
that	B-X
the	B-X
dominant	B-X
activation	B-X
of	B-X
ER	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
Ras-mediated	B-X
cell	B-X
transformation	B-X
.	B-X
Co-expression	B-X
of	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
with	B-X
mutant	B-X
K-Ras	B-X
led	B-X
to	B-X
suppression	B-X
of	B-X
tumorigenicity	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
activation	B-X
of	B-X
ER	B-X
.	B-X
The	B-X
antisense	B-X
oligomers	B-X
complementary	B-X
to	B-X
the	B-X
ER	B-X
suppressed	B-X
proliferation	B-X
and	B-X
transformed	B-X
phenotypes	B-X
of	B-X
K12V	B-X
cells	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
the	B-X
importance	B-X
of	B-X
ER	B-X
in	B-X
Ras-mediated	B-X
cell	B-X
transformation	B-X
.	B-X

The	O
antisense	O
oligomers	O
complementary	O
to	O
the	O
ER	B-Gene_or_gene_product
suppressed	O
proliferation	O
and	O
transformed	O
phenotypes	O
of	O
K12V	O
cells	O
.	O

These	O
observations	O
support	O
the	O
importance	O
of	O
ER	B-Gene_or_gene_product
in	O
Ras	B-Gene_or_gene_product
-	O
mediated	O
cell	O
transformation	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
estrogen	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
NIH3T3	B-X
cell	B-X
transformation	B-X
by	B-X
the	B-X
[	B-X
12Val	B-X
]	B-X
K-Ras	B-X
mutant	B-X
.	B-X
This	B-X
mutant	B-X
enhanced	B-X
the	B-X
steady	B-X
state	B-X
level	B-X
of	B-X
ER	B-X
.	B-X
Cells	B-X
expressing	B-X
mutant	B-X
K-Ras	B-X
(	B-X
K12V	B-X
cell	B-X
)	B-X
were	B-X
tumorigenic	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
ER	B-X
accumulation	B-X
in	B-X
Ras-transformed	B-X
cells	B-X
,	B-X
we	B-X
developed	B-X
cells	B-X
(	B-X
KwtER	B-X
cells	B-X
)	B-X
that	B-X
overexpressed	B-X
both	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
K-Ras	B-X
and	B-X
ER	B-X
,	B-X
and	B-X
found	B-X
these	B-X
cells	B-X
were	B-X
also	B-X
tumorigenic	B-X
.	B-X
E2	B-X
stimulated	B-X
the	B-X
transcriptional	B-X
activity	B-X
by	B-X
ER	B-X
dominantly	B-X
in	B-X
K12V	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
only	B-X
partial	B-X
activation	B-X
of	B-X
ER	B-X
by	B-X
E2	B-X
was	B-X
seen	B-X
in	B-X
KwtER	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
10	B-X
%	B-X
serum	B-X
in	B-X
media	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
ER	B-X
appeared	B-X
only	B-X
in	B-X
transformed	B-X
KtwER	B-X
and	B-X
K12V	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
two	B-X
independently	B-X
transmitted	B-X
signals	B-X
,	B-X
the	B-X
E2-ER	B-X
binding	B-X
and	B-X
the	B-X
ER-AF1	B-X
activation	B-X
,	B-X
are	B-X
necessary	B-X
for	B-X
ER	B-X
activation	B-X
and	B-X
that	B-X
the	B-X
dominant	B-X
activation	B-X
of	B-X
ER	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
Ras-mediated	B-X
cell	B-X
transformation	B-X
.	B-X
Co-expression	B-X
of	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
with	B-X
mutant	B-X
K-Ras	B-X
led	B-X
to	B-X
suppression	B-X
of	B-X
tumorigenicity	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
activation	B-X
of	B-X
ER	B-X
.	B-X
The	B-X
antisense	B-X
oligomers	B-X
complementary	B-X
to	B-X
the	B-X
ER	B-X
suppressed	B-X
proliferation	B-X
and	B-X
transformed	B-X
phenotypes	B-X
of	B-X
K12V	B-X
cells	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
the	B-X
importance	B-X
of	B-X
ER	B-X
in	B-X
Ras-mediated	B-X
cell	B-X
transformation	B-X
.	B-X

Gene	O
therapy	O
for	O
gliomas	O
:	O
p53	B-Gene_or_gene_product
and	O
E2F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
proteins	O
and	O
the	O
target	O
of	O
apoptosis	O
.	O
<EOS>	B-X
Current	B-X
therapy	B-X
for	B-X
glioma	B-X
is	B-X
suboptimal	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
apoptosis	B-X
genes	B-X
to	B-X
tumors	B-X
constitutes	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
strategies	B-X
for	B-X
cancer	B-X
gene	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
massive	B-X
apoptosis	B-X
occurs	B-X
when	B-X
wild-type	B-X
p53	B-X
or	B-X
E2F-1	B-X
expression	B-X
is	B-X
induced	B-X
in	B-X
glioma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
and	B-X
the	B-X
efficiency	B-X
in	B-X
inducing	B-X
apoptosis	B-X
of	B-X
these	B-X
two	B-X
proteins	B-X
are	B-X
not	B-X
similar	B-X
.	B-X
Adenovirus-mediated	B-X
p53	B-X
gene	B-X
transfer	B-X
is	B-X
ineffective	B-X
in	B-X
causing	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
that	B-X
retain	B-X
wild-type	B-X
p53	B-X
genotype	B-X
or	B-X
overexpress	B-X
the	B-X
p21	B-X
protein	B-X
.	B-X
The	B-X
p16/Rb/E2F	B-X
pathway	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
target	B-X
of	B-X
genetic	B-X
alterations	B-X
in	B-X
gliomas	B-X
,	B-X
and	B-X
therefore	B-X
constitutes	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
gene	B-X
therapy	B-X
strategies	B-X
.	B-X
However	B-X
,	B-X
the	B-X
transfer	B-X
of	B-X
either	B-X
the	B-X
p16	B-X
or	B-X
Rb	B-X
gene	B-X
to	B-X
glioma	B-X
cells	B-X
results	B-X
in	B-X
cytostatic	B-X
effect	B-X
.	B-X
The	B-X
E2F-1	B-X
protein	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
generalized	B-X
apoptosis	B-X
in	B-X
gliomas	B-X
independently	B-X
of	B-X
the	B-X
p53	B-X
,	B-X
p16	B-X
or	B-X
Rb	B-X
status	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
p21-	B-X
or	B-X
p16-mediated	B-X
growth	B-X
arrest	B-X
did	B-X
not	B-X
protect	B-X
glioma	B-X
cells	B-X
from	B-X
E2F-1-mediated	B-X
apoptosis	B-X
.	B-X
The	B-X
apoptotic	B-X
molecule	B-X
bax	B-X
is	B-X
induced	B-X
in	B-X
p53-mediated	B-X
apoptosis	B-X
,	B-X
but	B-X
bax	B-X
is	B-X
not	B-X
induced	B-X
in	B-X
E2F-1-mediated	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
Careful	B-X
selection	B-X
of	B-X
patients	B-X
may	B-X
be	B-X
necessary	B-X
before	B-X
designing	B-X
therapeutic	B-X
strategies	B-X
using	B-X
either	B-X
p53	B-X
or	B-X
E2F-1	B-X
as	B-X
a	B-X
therapeutic	B-X
tools	B-X
for	B-X
glioma	B-X
patients	B-X
.	B-X

Current	O
therapy	O
for	O
glioma	O
is	O
suboptimal	O
.	O
<EOS>	B-X
Brain	B-X
tumors	B-X
are	B-X
the	B-X
most	B-X
common	B-X
solid	B-X
tumors	B-X
in	B-X
children	B-X
,	B-X
and	B-X
,	B-X
unfortunately	B-X
,	B-X
many	B-X
subtypes	B-X
continue	B-X
to	B-X
have	B-X
a	B-X
suboptimal	B-X
long-term	B-X
outcome	B-X
.	B-X
Likewise	B-X
,	B-X
high-grade	B-X
glioma	B-X
,	B-X
which	B-X
for	B-X
decades	B-X
was	B-X
considered	B-X
a	B-X
single	B-X
high-risk	B-X
entity	B-X
,	B-X
is	B-X
now	B-X
known	B-X
to	B-X
comprise	B-X
multiple	B-X
subsets	B-X
of	B-X
tumors	B-X
that	B-X
differ	B-X
in	B-X
terms	B-X
of	B-X
patient	B-X
age	B-X
,	B-X
tumor	B-X
location	B-X
,	B-X
and	B-X
prognosis	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
present	B-X
era	B-X
is	B-X
one	B-X
in	B-X
which	B-X
treatment	B-X
is	B-X
evolving	B-X
from	B-X
the	B-X
historical	B-X
standard	B-X
of	B-X
radiation	B-X
and	B-X
conventional	B-X
chemotherapy	B-X
to	B-X
a	B-X
more	B-X
nuanced	B-X
approach	B-X
in	B-X
which	B-X
these	B-X
modalities	B-X
are	B-X
applied	B-X
in	B-X
a	B-X
risk-adapted	B-X
framework	B-X
and	B-X
molecularly	B-X
targeted	B-X
therapies	B-X
are	B-X
implemented	B-X
to	B-X
augment	B-X
or	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
replace	B-X
conventional	B-X
therapy	B-X
.	B-X
Glioblastoma	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
difficult	B-X
tumor	B-X
types	B-X
to	B-X
treat	B-X
with	B-X
conventional	B-X
therapy	B-X
options	B-X
like	B-X
tumor	B-X
debulking	B-X
and	B-X
chemo-	B-X
and	B-X
radiotherapy	B-X
.	B-X
Immunotherapeutic	B-X
agents	B-X
like	B-X
oncolytic	B-X
viruses	B-X
,	B-X
immune	B-X
checkpoint	B-X
inhibitors	B-X
,	B-X
and	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
T	B-X
cells	B-X
have	B-X
revolutionized	B-X
cancer	B-X
therapy	B-X
,	B-X
but	B-X
their	B-X
success	B-X
in	B-X
glioblastoma	B-X
remains	B-X
limited	B-X
and	B-X
further	B-X
optimization	B-X
of	B-X
immunotherapies	B-X
is	B-X
needed	B-X
.	B-X
Several	B-X
oncolytic	B-X
viruses	B-X
have	B-X
demonstrated	B-X
the	B-X
ability	B-X
to	B-X
infect	B-X
tumors	B-X
and	B-X
trigger	B-X
anti-tumor	B-X
immune	B-X
responses	B-X
in	B-X
malignant	B-X
glioma	B-X
patients	B-X
.	B-X
Leading	B-X
the	B-X
pack	B-X
,	B-X
oncolytic	B-X
herpesvirus	B-X
,	B-X
first	B-X
in	B-X
its	B-X
class	B-X
,	B-X
awaits	B-X
an	B-X
approval	B-X
for	B-X
treating	B-X
malignant	B-X
glioma	B-X
from	B-X
MHLW	B-X
,	B-X
the	B-X
federal	B-X
authority	B-X
of	B-X
Japan	B-X
.	B-X
Nevertheless	B-X
,	B-X
some	B-X
major	B-X
hurdles	B-X
like	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
the	B-X
immunosuppressive	B-X
tumor	B-X
microenvironment	B-X
,	B-X
and	B-X
tumor	B-X
heterogeneity	B-X
can	B-X
engender	B-X
suboptimal	B-X
efficacy	B-X
in	B-X
malignant	B-X
glioma	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
current	B-X
status	B-X
of	B-X
malignant	B-X
glioma	B-X
therapies	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
oncolytic	B-X
viruses	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
obstacles	B-X
faced	B-X
by	B-X
oncolytic	B-X
viruses	B-X
in	B-X
malignant	B-X
glioma	B-X
patients	B-X
and	B-X
strategies	B-X
that	B-X
are	B-X
being	B-X
used	B-X
to	B-X
overcome	B-X
these	B-X
limitations	B-X
to	B-X
(	B-X
1	B-X
)	B-X
optimize	B-X
delivery	B-X
of	B-X
oncolytic	B-X
viruses	B-X
beyond	B-X
the	B-X
blood-brain	B-X
barrier	B-X
;	B-X
(	B-X
2	B-X
)	B-X
trigger	B-X
inflammatory	B-X
immune	B-X
responses	B-X
in	B-X
and	B-X
around	B-X
tumors	B-X
;	B-X
and	B-X
(	B-X
3	B-X
)	B-X
use	B-X
multimodal	B-X
therapies	B-X
in	B-X
combination	B-X
to	B-X
tackle	B-X
tumor	B-X
heterogeneity	B-X
,	B-X
with	B-X
an	B-X
end	B-X
goal	B-X
of	B-X
optimizing	B-X
the	B-X
therapeutic	B-X
outcome	B-X
of	B-X
oncolytic	B-X
virotherapy	B-X
.	B-X

The	O
transfer	O
of	O
apoptosis	O
genes	O
to	O
tumors	O
constitutes	O
one	O
of	O
the	O
most	O
promising	O
strategies	O
for	O
cancer	O
gene	O
therapy	O
.	O
<EOS>	B-X
Current	B-X
therapy	B-X
for	B-X
glioma	B-X
is	B-X
suboptimal	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
apoptosis	B-X
genes	B-X
to	B-X
tumors	B-X
constitutes	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
strategies	B-X
for	B-X
cancer	B-X
gene	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
massive	B-X
apoptosis	B-X
occurs	B-X
when	B-X
wild-type	B-X
p53	B-X
or	B-X
E2F-1	B-X
expression	B-X
is	B-X
induced	B-X
in	B-X
glioma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
and	B-X
the	B-X
efficiency	B-X
in	B-X
inducing	B-X
apoptosis	B-X
of	B-X
these	B-X
two	B-X
proteins	B-X
are	B-X
not	B-X
similar	B-X
.	B-X
Adenovirus-mediated	B-X
p53	B-X
gene	B-X
transfer	B-X
is	B-X
ineffective	B-X
in	B-X
causing	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
that	B-X
retain	B-X
wild-type	B-X
p53	B-X
genotype	B-X
or	B-X
overexpress	B-X
the	B-X
p21	B-X
protein	B-X
.	B-X
The	B-X
p16/Rb/E2F	B-X
pathway	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
target	B-X
of	B-X
genetic	B-X
alterations	B-X
in	B-X
gliomas	B-X
,	B-X
and	B-X
therefore	B-X
constitutes	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
gene	B-X
therapy	B-X
strategies	B-X
.	B-X
However	B-X
,	B-X
the	B-X
transfer	B-X
of	B-X
either	B-X
the	B-X
p16	B-X
or	B-X
Rb	B-X
gene	B-X
to	B-X
glioma	B-X
cells	B-X
results	B-X
in	B-X
cytostatic	B-X
effect	B-X
.	B-X
The	B-X
E2F-1	B-X
protein	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
generalized	B-X
apoptosis	B-X
in	B-X
gliomas	B-X
independently	B-X
of	B-X
the	B-X
p53	B-X
,	B-X
p16	B-X
or	B-X
Rb	B-X
status	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
p21-	B-X
or	B-X
p16-mediated	B-X
growth	B-X
arrest	B-X
did	B-X
not	B-X
protect	B-X
glioma	B-X
cells	B-X
from	B-X
E2F-1-mediated	B-X
apoptosis	B-X
.	B-X
The	B-X
apoptotic	B-X
molecule	B-X
bax	B-X
is	B-X
induced	B-X
in	B-X
p53-mediated	B-X
apoptosis	B-X
,	B-X
but	B-X
bax	B-X
is	B-X
not	B-X
induced	B-X
in	B-X
E2F-1-mediated	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
Careful	B-X
selection	B-X
of	B-X
patients	B-X
may	B-X
be	B-X
necessary	B-X
before	B-X
designing	B-X
therapeutic	B-X
strategies	B-X
using	B-X
either	B-X
p53	B-X
or	B-X
E2F-1	B-X
as	B-X
a	B-X
therapeutic	B-X
tools	B-X
for	B-X
glioma	B-X
patients	B-X
.	B-X

We	O
have	O
previously	O
shown	O
that	O
massive	O
apoptosis	O
occurs	O
when	O
wild	O
-	O
type	O
p53	B-Gene_or_gene_product
or	O
E2F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
expression	O
is	O
induced	O
in	O
glioma	O
.	O
<EOS>	B-X
Acquired	B-X
drug	B-X
resistance	B-X
is	B-X
a	B-X
major	B-X
challenge	B-X
in	B-X
the	B-X
clinical	B-X
treatment	B-X
of	B-X
glioblastoma	B-X
(	B-X
GBM	B-X
)	B-X
,	B-X
and	B-X
lncRNAs	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
chemotherapy	B-X
resistance	B-X
.	B-X
Current	B-X
therapy	B-X
for	B-X
glioma	B-X
is	B-X
suboptimal	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
apoptosis	B-X
genes	B-X
to	B-X
tumors	B-X
constitutes	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
strategies	B-X
for	B-X
cancer	B-X
gene	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
massive	B-X
apoptosis	B-X
occurs	B-X
when	B-X
wild-type	B-X
p53	B-X
or	B-X
E2F-1	B-X
expression	B-X
is	B-X
induced	B-X
in	B-X
glioma	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
and	B-X
the	B-X
efficiency	B-X
in	B-X
inducing	B-X
apoptosis	B-X
of	B-X
these	B-X
two	B-X
proteins	B-X
are	B-X
not	B-X
similar	B-X
.	B-X
Adenovirus-mediated	B-X
p53	B-X
gene	B-X
transfer	B-X
is	B-X
ineffective	B-X
in	B-X
causing	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
that	B-X
retain	B-X
wild-type	B-X
p53	B-X
genotype	B-X
or	B-X
overexpress	B-X
the	B-X
p21	B-X
protein	B-X
.	B-X
The	B-X
p16/Rb/E2F	B-X
pathway	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
target	B-X
of	B-X
genetic	B-X
alterations	B-X
in	B-X
gliomas	B-X
,	B-X
and	B-X
therefore	B-X
constitutes	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
gene	B-X
therapy	B-X
strategies	B-X
.	B-X
However	B-X
,	B-X
the	B-X
transfer	B-X
of	B-X
either	B-X
the	B-X
p16	B-X
or	B-X
Rb	B-X
gene	B-X
to	B-X
glioma	B-X
cells	B-X
results	B-X
in	B-X
cytostatic	B-X
effect	B-X
.	B-X
The	B-X
E2F-1	B-X
protein	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
generalized	B-X
apoptosis	B-X
in	B-X
gliomas	B-X
independently	B-X
of	B-X
the	B-X
p53	B-X
,	B-X
p16	B-X
or	B-X
Rb	B-X
status	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
p21-	B-X
or	B-X
p16-mediated	B-X
growth	B-X
arrest	B-X
did	B-X
not	B-X
protect	B-X
glioma	B-X
cells	B-X
from	B-X
E2F-1-mediated	B-X
apoptosis	B-X
.	B-X
The	B-X
apoptotic	B-X
molecule	B-X
bax	B-X
is	B-X
induced	B-X
in	B-X
p53-mediated	B-X
apoptosis	B-X
,	B-X
but	B-X
bax	B-X
is	B-X
not	B-X
induced	B-X
in	B-X
E2F-1-mediated	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
Careful	B-X
selection	B-X
of	B-X
patients	B-X
may	B-X
be	B-X
necessary	B-X
before	B-X
designing	B-X
therapeutic	B-X
strategies	B-X
using	B-X
either	B-X
p53	B-X
or	B-X
E2F-1	B-X
as	B-X
a	B-X
therapeutic	B-X
tools	B-X
for	B-X
glioma	B-X
patients	B-X
.	B-X

However	O
,	O
the	O
mechanism	O
of	O
action	O
and	O
the	O
efficiency	O
in	O
inducing	O
apoptosis	O
of	O
these	O
two	O
proteins	O
are	O
not	O
similar	O
.	O
<EOS>	B-X
Val-boroPro	B-X
(	B-X
Talabostat	B-X
,	B-X
PT-100	B-X
)	B-X
,	B-X
a	B-X
nonselective	B-X
inhibitor	B-X
of	B-X
post-proline	B-X
cleaving	B-X
serine	B-X
proteases	B-X
,	B-X
stimulates	B-X
mammalian	B-X
immune	B-X
systems	B-X
through	B-X
an	B-X
unknown	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
two	B-X
serine	B-X
proteases	B-X
,	B-X
DPP8	B-X
and	B-X
DPP9	B-X
,	B-X
activates	B-X
the	B-X
pro-protein	B-X
form	B-X
of	B-X
caspase-1	B-X
independent	B-X
of	B-X
the	B-X
inflammasome	B-X
adaptor	B-X
ASC	B-X
.	B-X
Antiangiogenic	B-X
and	B-X
cytotoxic	B-X
effects	B-X
are	B-X
considered	B-X
the	B-X
principal	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
sorafenib	B-X
,	B-X
a	B-X
multitarget	B-X
kinase	B-X
inhibitor	B-X
approved	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
In	B-X
vivo	B-X
cell	B-X
depletion	B-X
experiments	B-X
in	B-X
two	B-X
orthotopic	B-X
HCC	B-X
mouse	B-X
models	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vitro	B-X
analysis	B-X
identified	B-X
macrophages	B-X
(	B-X
MÎ¦	B-X
)	B-X
as	B-X
the	B-X
key	B-X
mediators	B-X
of	B-X
the	B-X
antitumoral	B-X
effect	B-X
and	B-X
demonstrate	B-X
a	B-X
strong	B-X
interdependency	B-X
of	B-X
MÎ¦	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
for	B-X
efficient	B-X
tumor	B-X
cell	B-X
killing	B-X
.	B-X
Conclusion	B-X
:	B-X
We	B-X
report	B-X
an	B-X
immunomodulatory	B-X
mechanism	B-X
of	B-X
sorafenib	B-X
involving	B-X
MÎ¦	B-X
pyroptosis	B-X
and	B-X
unleashing	B-X
of	B-X
an	B-X
NK-cell	B-X
response	B-X
that	B-X
sets	B-X
it	B-X
apart	B-X
from	B-X
other	B-X
spectrum	B-X
kinase	B-X
inhibitors	B-X
as	B-X
a	B-X
promising	B-X
immunotherapy	B-X
combination	B-X
partner	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
HCC	B-X
.	B-X

Adenovirus	O
-	O
mediated	O
p53	B-Gene_or_gene_product
gene	O
transfer	O
is	O
ineffective	O
in	O
causing	O
apoptosis	O
in	O
glioma	O
cells	O
that	O
retain	O
wild	O
-	O
type	O
p53	B-Gene_or_gene_product
genotype	O
or	O
overexpress	O
the	O
p21	B-Gene_or_gene_product
protein	O
.	O
<EOS>	B-X
The	B-X
p21	B-X
Activated	B-X
Kinases	B-X
(	B-X
PAKs	B-X
)	B-X
are	B-X
a	B-X
family	B-X
of	B-X
serine	B-X
threonine	B-X
kinases	B-X
,	B-X
that	B-X
consist	B-X
of	B-X
6	B-X
members	B-X
,	B-X
PAKs	B-X
1-6	B-X
,	B-X
which	B-X
are	B-X
positioned	B-X
at	B-X
an	B-X
intersection	B-X
of	B-X
multiple	B-X
signaling	B-X
pathways	B-X
implicated	B-X
in	B-X
oncogenesis	B-X
.	B-X
The	B-X
PAKs	B-X
were	B-X
originally	B-X
identified	B-X
as	B-X
protein	B-X
kinases	B-X
that	B-X
function	B-X
downstream	B-X
of	B-X
the	B-X
Ras	B-X
related	B-X
Rho	B-X
GTPases	B-X
Cdc42	B-X
and	B-X
Rac	B-X
.	B-X
PAK1	B-X
and	B-X
PAK4	B-X
,	B-X
which	B-X
belong	B-X
to	B-X
Group	B-X
I	B-X
and	B-X
Group	B-X
II	B-X
PAKs	B-X
,	B-X
respectively	B-X
,	B-X
are	B-X
most	B-X
often	B-X
associated	B-X
with	B-X
tumorigenesis	B-X
.	B-X
Studies	B-X
to	B-X
delineate	B-X
PAK	B-X
regulated	B-X
signaling	B-X
pathways	B-X
as	B-X
well	B-X
as	B-X
the	B-X
long	B-X
term	B-X
effects	B-X
of	B-X
PAK	B-X
overexpression	B-X
on	B-X
gene	B-X
expression	B-X
are	B-X
beginning	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
PAK	B-X
proteins	B-X
may	B-X
lead	B-X
to	B-X
cancer	B-X
when	B-X
they	B-X
are	B-X
overexpressed	B-X
or	B-X
activated	B-X
.	B-X

The	O
p16	B-Gene_or_gene_product
/	O
Rb	B-Gene_or_gene_product
/	O
E2F	B-Gene_or_gene_product
pathway	O
is	O
the	O
most	O
frequent	O
target	O
of	O
genetic	O
alterations	O
in	O
gliomas	O
,	O
and	O
therefore	O
constitutes	O
a	O
suitable	O
target	O
for	O
gene	O
therapy	O
strategies	O
.	O
<EOS>	B-X
Current	B-X
therapy	B-X
for	B-X
glioma	B-X
is	B-X
suboptimal	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
apoptosis	B-X
genes	B-X
to	B-X
tumors	B-X
constitutes	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
strategies	B-X
for	B-X
cancer	B-X
gene	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
massive	B-X
apoptosis	B-X
occurs	B-X
when	B-X
wild-type	B-X
p53	B-X
or	B-X
E2F-1	B-X
expression	B-X
is	B-X
induced	B-X
in	B-X
glioma	B-X
.	B-X
Adenovirus-mediated	B-X
p53	B-X
gene	B-X
transfer	B-X
is	B-X
ineffective	B-X
in	B-X
causing	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
that	B-X
retain	B-X
wild-type	B-X
p53	B-X
genotype	B-X
or	B-X
overexpress	B-X
the	B-X
p21	B-X
protein	B-X
.	B-X
The	B-X
p16/Rb/E2F	B-X
pathway	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
target	B-X
of	B-X
genetic	B-X
alterations	B-X
in	B-X
gliomas	B-X
,	B-X
and	B-X
therefore	B-X
constitutes	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
gene	B-X
therapy	B-X
strategies	B-X
.	B-X
However	B-X
,	B-X
the	B-X
transfer	B-X
of	B-X
either	B-X
the	B-X
p16	B-X
or	B-X
Rb	B-X
gene	B-X
to	B-X
glioma	B-X
cells	B-X
results	B-X
in	B-X
cytostatic	B-X
effect	B-X
.	B-X
The	B-X
E2F-1	B-X
protein	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
generalized	B-X
apoptosis	B-X
in	B-X
gliomas	B-X
independently	B-X
of	B-X
the	B-X
p53	B-X
,	B-X
p16	B-X
or	B-X
Rb	B-X
status	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
p21-	B-X
or	B-X
p16-mediated	B-X
growth	B-X
arrest	B-X
did	B-X
not	B-X
protect	B-X
glioma	B-X
cells	B-X
from	B-X
E2F-1-mediated	B-X
apoptosis	B-X
.	B-X
The	B-X
apoptotic	B-X
molecule	B-X
bax	B-X
is	B-X
induced	B-X
in	B-X
p53-mediated	B-X
apoptosis	B-X
,	B-X
but	B-X
bax	B-X
is	B-X
not	B-X
induced	B-X
in	B-X
E2F-1-mediated	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
Careful	B-X
selection	B-X
of	B-X
patients	B-X
may	B-X
be	B-X
necessary	B-X
before	B-X
designing	B-X
therapeutic	B-X
strategies	B-X
using	B-X
either	B-X
p53	B-X
or	B-X
E2F-1	B-X
as	B-X
a	B-X
therapeutic	B-X
tools	B-X
for	B-X
glioma	B-X
patients	B-X
.	B-X

However	O
,	O
the	O
transfer	O
of	O
either	O
the	O
p16	B-Gene_or_gene_product
or	O
Rb	B-Gene_or_gene_product
gene	O
to	O
glioma	O
cells	O
results	O
in	O
cytostatic	O
effect	O
.	O
<EOS>	B-X
Aurora-A/SOX8/FOXK1	B-X
signaling	B-X
axis	B-X
promotes	B-X
chemoresistance	B-X
via	B-X
suppression	B-X
of	B-X
cell	B-X
senescence	B-X
and	B-X
induction	B-X
of	B-X
glucose	B-X
metabolism	B-X
in	B-X
ovarian	B-X
cancer	B-X
organoids	B-X
and	B-X
cells	B-X
.	B-X
The	B-X
``	B-X
isomorphic	B-X
subtype	B-X
of	B-X
diffuse	B-X
astrocytoma	B-X
''	B-X
was	B-X
identified	B-X
histologically	B-X
in	B-X
2004	B-X
as	B-X
a	B-X
supratentorial	B-X
,	B-X
highly	B-X
differentiated	B-X
glioma	B-X
with	B-X
low	B-X
cellularity	B-X
,	B-X
low	B-X
proliferation	B-X
and	B-X
focal	B-X
diffuse	B-X
brain	B-X
infiltration	B-X
.	B-X
To	B-X
define	B-X
the	B-X
position	B-X
of	B-X
these	B-X
lesions	B-X
among	B-X
brain	B-X
tumours	B-X
,	B-X
we	B-X
histologically	B-X
,	B-X
molecularly	B-X
and	B-X
clinically	B-X
analysed	B-X
26	B-X
histologically	B-X
prototypical	B-X
isomorphic	B-X
diffuse	B-X
gliomas	B-X
.	B-X
In	B-X
cluster	B-X
analyses	B-X
of	B-X
DNA	B-X
methylation	B-X
data	B-X
,	B-X
isomorphic	B-X
diffuse	B-X
gliomas	B-X
formed	B-X
a	B-X
group	B-X
clearly	B-X
distinct	B-X
from	B-X
other	B-X
glial/glio-neuronal	B-X
brain	B-X
tumours	B-X
and	B-X
normal	B-X
hemispheric	B-X
tissue	B-X
,	B-X
most	B-X
closely	B-X
related	B-X
to	B-X
paediatric	B-X
MYB/MYBL1-altered	B-X
diffuse	B-X
astrocytomas	B-X
and	B-X
angiocentric	B-X
gliomas	B-X
.	B-X
Half	B-X
of	B-X
the	B-X
isomorphic	B-X
diffuse	B-X
gliomas	B-X
had	B-X
copy	B-X
number	B-X
alterations	B-X
of	B-X
MYBL1	B-X
or	B-X
MYB	B-X
(	B-X
13/25	B-X
,	B-X
52	B-X
%	B-X
)	B-X
.	B-X
Gene	B-X
fusions	B-X
of	B-X
MYBL1	B-X
or	B-X
MYB	B-X
with	B-X
various	B-X
gene	B-X
partners	B-X
were	B-X
identified	B-X
in	B-X
11/22	B-X
(	B-X
50	B-X
%	B-X
)	B-X
and	B-X
were	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
RNA-expression	B-X
of	B-X
the	B-X
respective	B-X
MYB-family	B-X
gene	B-X
.	B-X
Integrating	B-X
copy	B-X
number	B-X
alterations	B-X
and	B-X
available	B-X
RNA	B-X
sequencing	B-X
data	B-X
,	B-X
20/26	B-X
(	B-X
77	B-X
%	B-X
)	B-X
of	B-X
isomorphic	B-X
diffuse	B-X
gliomas	B-X
demonstrated	B-X
MYBL1	B-X
(	B-X
54	B-X
%	B-X
)	B-X
or	B-X
MYB	B-X
(	B-X
23	B-X
%	B-X
)	B-X
alterations	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
here	B-X
define	B-X
a	B-X
distinct	B-X
benign	B-X
tumour	B-X
class	B-X
belonging	B-X
to	B-X
the	B-X
family	B-X
of	B-X
MYB/MYBL1-altered	B-X
gliomas	B-X
.	B-X
Isomorphic	B-X
diffuse	B-X
glioma	B-X
occurs	B-X
both	B-X
in	B-X
children	B-X
and	B-X
adults	B-X
,	B-X
has	B-X
a	B-X
concise	B-X
morphology	B-X
,	B-X
frequent	B-X
MYBL1	B-X
and	B-X
MYB	B-X
alterations	B-X
and	B-X
a	B-X
specific	B-X
DNA	B-X
methylation	B-X
profile	B-X
.	B-X
As	B-X
an	B-X
exclusively	B-X
histological	B-X
diagnosis	B-X
may	B-X
be	B-X
very	B-X
challenging	B-X
and	B-X
as	B-X
paediatric	B-X
MYB/MYBL1-altered	B-X
diffuse	B-X
astrocytomas	B-X
may	B-X
have	B-X
the	B-X
same	B-X
gene	B-X
fusions	B-X
,	B-X
we	B-X
consider	B-X
DNA	B-X
methylation	B-X
profiling	B-X
very	B-X
helpful	B-X
for	B-X
their	B-X
identification	B-X
.	B-X

The	O
E2F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
protein	O
is	O
able	O
to	O
induce	O
generalized	O
apoptosis	O
in	O
gliomas	O
independently	O
of	O
the	O
p53	B-Gene_or_gene_product
,	O
p16	B-Gene_or_gene_product
or	O
Rb	B-Gene_or_gene_product
status	O
.	O
<EOS>	B-X
RB1	B-X
mutations	B-X
and	B-X
loss	B-X
of	B-X
retinoblastoma	B-X
(	B-X
Rb	B-X
)	B-X
expression	B-X
represent	B-X
consistent	B-X
but	B-X
not	B-X
entirely	B-X
invariable	B-X
hallmarks	B-X
of	B-X
small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
SCLC	B-X
)	B-X
.	B-X
The	B-X
prevalence	B-X
and	B-X
characteristics	B-X
of	B-X
SCLC	B-X
retaining	B-X
wild-type	B-X
Rb	B-X
are	B-X
not	B-X
well-established	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
performance	B-X
of	B-X
targeted	B-X
next-generation	B-X
sequencing	B-X
(	B-X
NGS	B-X
)	B-X
versus	B-X
immunohistochemistry	B-X
for	B-X
Rb	B-X
assessment	B-X
is	B-X
not	B-X
well-defined	B-X
.	B-X
Integrated	B-X
genomic	B-X
and	B-X
IHC	B-X
profiling	B-X
of	B-X
Rb	B-X
status	B-X
in	B-X
SCLC	B-X
yields	B-X
new	B-X
diagnostic	B-X
insights	B-X
and	B-X
has	B-X
translational	B-X
implications	B-X
.	B-X

In	O
addition	O
,	O
p21	B-Gene_or_gene_product
-	O
or	O
p16	B-Gene_or_gene_product
-	O
mediated	O
growth	O
arrest	O
did	O
not	O
protect	O
glioma	O
cells	O
from	O
E2F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
Cellular	B-X
senescence	B-X
is	B-X
an	B-X
irreversible	B-X
arrest	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X
While	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
senescence	B-X
involves	B-X
p16	B-X
and	B-X
p53	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
telomere	B-X
shortening	B-X
,	B-X
this	B-X
review	B-X
is	B-X
focused	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
p16	B-X
control	B-X
.	B-X
The	B-X
p16-mediated	B-X
senescence	B-X
acts	B-X
through	B-X
the	B-X
retinoblastoma	B-X
(	B-X
Rb	B-X
)	B-X
pathway	B-X
inhibiting	B-X
the	B-X
action	B-X
of	B-X
the	B-X
cyclin	B-X
dependant	B-X
kinases	B-X
leading	B-X
to	B-X
G1	B-X
cell	B-X
cycle	B-X
arrest	B-X
.	B-X
Rb	B-X
is	B-X
maintained	B-X
in	B-X
a	B-X
hypophosphorylated	B-X
state	B-X
resulting	B-X
in	B-X
the	B-X
inhibition	B-X
of	B-X
transcription	B-X
factor	B-X
E2F1	B-X
.	B-X
Regulation	B-X
of	B-X
p16	B-X
expression	B-X
is	B-X
complex	B-X
and	B-X
involves	B-X
epigenetic	B-X
control	B-X
and	B-X
multiple	B-X
transcription	B-X
factors	B-X
.	B-X
PRC1	B-X
(	B-X
Pombe	B-X
repressor	B-X
complex	B-X
(	B-X
1	B-X
)	B-X
and	B-X
PRC2	B-X
(	B-X
Pombe	B-X
repressor	B-X
complex	B-X
(	B-X
2	B-X
)	B-X
proteins	B-X
and	B-X
histone	B-X
deacetylases	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
promoter	B-X
hypermethylation	B-X
for	B-X
suppressing	B-X
p16	B-X
expression	B-X
.	B-X
While	B-X
transcription	B-X
factors	B-X
YY1	B-X
and	B-X
Id1	B-X
suppress	B-X
p16	B-X
expression	B-X
,	B-X
transcription	B-X
factors	B-X
CTCF	B-X
,	B-X
Sp1	B-X
and	B-X
Ets	B-X
family	B-X
members	B-X
activate	B-X
p16	B-X
transcription	B-X
.	B-X
Senescence	B-X
occurs	B-X
with	B-X
the	B-X
inactivation	B-X
of	B-X
suppressor	B-X
elements	B-X
leading	B-X
to	B-X
the	B-X
enhanced	B-X
expression	B-X
of	B-X
p16	B-X
.	B-X

The	O
apoptotic	O
molecule	O
bax	B-Gene_or_gene_product
is	O
induced	O
in	O
p53	B-Gene_or_gene_product
-	O
mediated	O
apoptosis	O
,	O
but	O
bax	B-Gene_or_gene_product
is	O
not	O
induced	O
in	O
E2F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
-	O
mediated	O
apoptosis	O
in	O
glioma	O
cells	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
green	B-X
tea	B-X
extract	B-X
exerted	B-X
inhibitory	B-X
effects	B-X
on	B-X
a	B-X
variety	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X
As	B-X
a	B-X
pigment	B-X
active	B-X
substance	B-X
of	B-X
green	B-X
tea	B-X
,	B-X
theabrownin	B-X
(	B-X
TB	B-X
)	B-X
has	B-X
been	B-X
found	B-X
to	B-X
inhibit	B-X
many	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
pro-apoptotic	B-X
protein	B-X
Siva-1	B-X
functions	B-X
in	B-X
both	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
cell	B-X
death	B-X
signaling	B-X
;	B-X
however	B-X
,	B-X
the	B-X
exact	B-X
contribution	B-X
of	B-X
the	B-X
endogenous	B-X
Siva-1	B-X
to	B-X
DNA	B-X
damage-induced	B-X
apoptosis	B-X
is	B-X
unclear	B-X
.	B-X
Using	B-X
cisplatin	B-X
,	B-X
a	B-X
chemotherapeutic	B-X
drug	B-X
,	B-X
to	B-X
induce	B-X
DNA	B-X
damage	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
role	B-X
of	B-X
Siva-1	B-X
.	B-X

Careful	O
selection	O
of	O
patients	O
may	O
be	O
necessary	O
before	O
designing	O
therapeutic	O
strategies	O
using	O
either	O
p53	B-Gene_or_gene_product
or	O
E2F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
as	O
a	O
therapeutic	O
tools	O
for	O
glioma	O
patients	O
.	O
<EOS>	B-X
Current	B-X
therapy	B-X
for	B-X
glioma	B-X
is	B-X
suboptimal	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
apoptosis	B-X
genes	B-X
to	B-X
tumors	B-X
constitutes	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
strategies	B-X
for	B-X
cancer	B-X
gene	B-X
therapy	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
massive	B-X
apoptosis	B-X
occurs	B-X
when	B-X
wild-type	B-X
p53	B-X
or	B-X
E2F-1	B-X
expression	B-X
is	B-X
induced	B-X
in	B-X
glioma	B-X
.	B-X
Adenovirus-mediated	B-X
p53	B-X
gene	B-X
transfer	B-X
is	B-X
ineffective	B-X
in	B-X
causing	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
that	B-X
retain	B-X
wild-type	B-X
p53	B-X
genotype	B-X
or	B-X
overexpress	B-X
the	B-X
p21	B-X
protein	B-X
.	B-X
The	B-X
p16/Rb/E2F	B-X
pathway	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
target	B-X
of	B-X
genetic	B-X
alterations	B-X
in	B-X
gliomas	B-X
,	B-X
and	B-X
therefore	B-X
constitutes	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
gene	B-X
therapy	B-X
strategies	B-X
.	B-X
However	B-X
,	B-X
the	B-X
transfer	B-X
of	B-X
either	B-X
the	B-X
p16	B-X
or	B-X
Rb	B-X
gene	B-X
to	B-X
glioma	B-X
cells	B-X
results	B-X
in	B-X
cytostatic	B-X
effect	B-X
.	B-X
The	B-X
E2F-1	B-X
protein	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
generalized	B-X
apoptosis	B-X
in	B-X
gliomas	B-X
independently	B-X
of	B-X
the	B-X
p53	B-X
,	B-X
p16	B-X
or	B-X
Rb	B-X
status	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
p21-	B-X
or	B-X
p16-mediated	B-X
growth	B-X
arrest	B-X
did	B-X
not	B-X
protect	B-X
glioma	B-X
cells	B-X
from	B-X
E2F-1-mediated	B-X
apoptosis	B-X
.	B-X
The	B-X
apoptotic	B-X
molecule	B-X
bax	B-X
is	B-X
induced	B-X
in	B-X
p53-mediated	B-X
apoptosis	B-X
,	B-X
but	B-X
bax	B-X
is	B-X
not	B-X
induced	B-X
in	B-X
E2F-1-mediated	B-X
apoptosis	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
Careful	B-X
selection	B-X
of	B-X
patients	B-X
may	B-X
be	B-X
necessary	B-X
before	B-X
designing	B-X
therapeutic	B-X
strategies	B-X
using	B-X
either	B-X
p53	B-X
or	B-X
E2F-1	B-X
as	B-X
a	B-X
therapeutic	B-X
tools	B-X
for	B-X
glioma	B-X
patients	B-X
.	B-X

Protective	O
function	O
of	O
von	B-Gene_or_gene_product
Hippel	I-Gene_or_gene_product
-	I-Gene_or_gene_product
Lindau	I-Gene_or_gene_product
protein	O
against	O
impaired	O
protein	O
processing	O
in	O
renal	O
carcinoma	O
cells	O
.	O

The	O
absence	O
of	O
functional	O
von	B-Gene_or_gene_product
Hippel	I-Gene_or_gene_product
-	I-Gene_or_gene_product
Lindau	I-Gene_or_gene_product
(	O
VHL	B-Gene_or_gene_product
)	O
tumor	O
suppressor	O
gene	O
leads	O
to	O
the	O
development	O
of	O
neoplasias	O
characteristic	O
of	O
VHL	B-Gene_or_gene_product
disease	O
,	O
including	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
.	O

Here	O
,	O
we	O
compared	O
the	O
sensitivity	O
of	O
RCC	O
cells	O
lacking	O
VHL	B-Gene_or_gene_product
gene	O
function	O
with	O
that	O
of	O
RCC	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
VHL	B-Gene_or_gene_product
gene	O
(	O
wtVHL	B-Gene_or_gene_product
)	O
after	O
exposure	O
to	O
various	O
stresses	O
.	O
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
functional	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
leads	B-X
to	B-X
the	B-X
development	B-X
of	B-X
neoplasias	B-X
characteristic	B-X
of	B-X
VHL	B-X
disease	B-X
,	B-X
including	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
sensitivity	B-X
of	B-X
RCC	B-X
cells	B-X
lacking	B-X
VHL	B-X
gene	B-X
function	B-X
with	B-X
that	B-X
of	B-X
RCC	B-X
cells	B-X
expressing	B-X
the	B-X
wild-type	B-X
VHL	B-X
gene	B-X
(	B-X
wtVHL	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
various	B-X
stresses	B-X
.	B-X
While	B-X
the	B-X
response	B-X
to	B-X
most	B-X
treatments	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
VHL	B-X
gene	B-X
status	B-X
,	B-X
glucose	B-X
deprivation	B-X
was	B-X
found	B-X
to	B-X
be	B-X
much	B-X
more	B-X
cytotoxic	B-X
for	B-X
RCC	B-X
cells	B-X
lacking	B-X
VHL	B-X
gene	B-X
function	B-X
than	B-X
for	B-X
wtVHL-expressing	B-X
cells	B-X
.	B-X
The	B-X
heightened	B-X
sensitivity	B-X
of	B-X
VHL-deficient	B-X
cells	B-X
was	B-X
not	B-X
attributed	B-X
to	B-X
dissimilar	B-X
energy	B-X
requirements	B-X
or	B-X
to	B-X
differences	B-X
in	B-X
glucose	B-X
uptake	B-X
,	B-X
but	B-X
more	B-X
likely	B-X
reflects	B-X
a	B-X
lesser	B-X
ability	B-X
of	B-X
VHL-deficient	B-X
cells	B-X
to	B-X
handle	B-X
abnormally	B-X
processed	B-X
proteins	B-X
arising	B-X
from	B-X
impaired	B-X
glycosylation	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
hypothesis	B-X
,	B-X
other	B-X
treatments	B-X
which	B-X
act	B-X
through	B-X
different	B-X
mechanisms	B-X
to	B-X
interfere	B-X
with	B-X
protein	B-X
processing	B-X
(	B-X
i.e.	B-X
,	B-X
tunicamycin	B-X
,	B-X
brefeldin	B-X
A	B-X
,	B-X
and	B-X
azetidine	B-X
)	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
much	B-X
more	B-X
toxic	B-X
for	B-X
VHL-deficient	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
ubiquitination	B-X
of	B-X
cellular	B-X
proteins	B-X
was	B-X
elevated	B-X
in	B-X
VHL-deficient	B-X
cells	B-X
,	B-X
particularly	B-X
after	B-X
glucose	B-X
deprivation	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
VHL	B-X
gene	B-X
in	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
rate	B-X
of	B-X
elimination	B-X
of	B-X
abnormal	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
cells	B-X
lacking	B-X
a	B-X
functional	B-X
VHL	B-X
gene	B-X
than	B-X
in	B-X
wtVHL-expressing	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
pVHL	B-X
appears	B-X
to	B-X
participate	B-X
in	B-X
the	B-X
elimination	B-X
of	B-X
misprocessed	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
those	B-X
arising	B-X
in	B-X
the	B-X
cell	B-X
due	B-X
to	B-X
the	B-X
unavailability	B-X
of	B-X
glucose	B-X
or	B-X
to	B-X
other	B-X
stresses	B-X
.	B-X

While	O
the	O
response	O
to	O
most	O
treatments	O
was	O
not	O
affected	O
by	O
the	O
VHL	B-Gene_or_gene_product
gene	O
status	O
,	O
glucose	O
deprivation	O
was	O
found	O
to	O
be	O
much	O
more	O
cytotoxic	O
for	O
RCC	O
cells	O
lacking	O
VHL	B-Gene_or_gene_product
gene	O
function	O
than	O
for	O
wtVHL	B-Gene_or_gene_product
-	O
expressing	O
cells	O
.	O
<EOS>	B-X
Biomarkers	B-X
to	B-X
predict	B-X
response	B-X
to	B-X
neuromodulation	B-X
therapies	B-X
are	B-X
not	B-X
available	B-X
,	B-X
and	B-X
high-level	B-X
evidence	B-X
to	B-X
aid	B-X
decision	B-X
making	B-X
about	B-X
when	B-X
and	B-X
for	B-X
whom	B-X
these	B-X
therapies	B-X
should	B-X
be	B-X
preferred	B-X
over	B-X
other	B-X
antiepileptic	B-X
treatments	B-X
is	B-X
scant	B-X
.	B-X
In	B-X
order	B-X
to	B-X
replace	B-X
the	B-X
function	B-X
of	B-X
the	B-X
destroyed	B-X
pancreatic	B-X
beta	B-X
cells	B-X
in	B-X
diabetes	B-X
,	B-X
islet	B-X
transplantation	B-X
is	B-X
the	B-X
most	B-X
widely	B-X
practiced	B-X
treatment	B-X
.	B-X
As	B-X
an	B-X
alternative	B-X
approach	B-X
,	B-X
human	B-X
pluripotent	B-X
stem	B-X
cells	B-X
(	B-X
hPSCs	B-X
)	B-X
can	B-X
provide	B-X
an	B-X
unlimited	B-X
source	B-X
of	B-X
pancreatic	B-X
cells	B-X
that	B-X
have	B-X
the	B-X
ability	B-X
to	B-X
secrete	B-X
insulin	B-X
in	B-X
response	B-X
to	B-X
a	B-X
high	B-X
blood	B-X
glucose	B-X
level	B-X
.	B-X
While	B-X
hPSC-derived	B-X
beta	B-X
cells	B-X
are	B-X
perceived	B-X
as	B-X
the	B-X
ultimate	B-X
candidate	B-X
,	B-X
their	B-X
efficiency	B-X
needs	B-X
further	B-X
improvement	B-X
in	B-X
order	B-X
to	B-X
obtain	B-X
a	B-X
sufficient	B-X
number	B-X
of	B-X
glucose	B-X
responsive	B-X
beta	B-X
cells	B-X
for	B-X
transplantation	B-X
therapy	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
hPSC-derived	B-X
pancreatic	B-X
progenitors	B-X
can	B-X
be	B-X
efficiently	B-X
generated	B-X
in	B-X
vitro	B-X
and	B-X
can	B-X
further	B-X
mature	B-X
into	B-X
glucose	B-X
responsive	B-X
beta	B-X
cells	B-X
in	B-X
vivo	B-X
after	B-X
transplantation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
address	B-X
the	B-X
co-generation	B-X
of	B-X
functionally	B-X
relevant	B-X
islet	B-X
cell	B-X
subpopulations	B-X
and	B-X
structural	B-X
properties	B-X
contributing	B-X
to	B-X
the	B-X
glucose	B-X
responsiveness	B-X
of	B-X
beta	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
available	B-X
encapsulation	B-X
technology	B-X
for	B-X
these	B-X
cells	B-X
.	B-X

The	O
heightened	O
sensitivity	O
of	O
VHL	B-Gene_or_gene_product
-	O
deficient	O
cells	O
was	O
not	O
attributed	O
to	O
dissimilar	O
energy	O
requirements	O
or	O
to	O
differences	O
in	O
glucose	O
uptake	O
,	O
but	O
more	O
likely	O
reflects	O
a	O
lesser	O
ability	O
of	O
VHL	B-Gene_or_gene_product
-	O
deficient	O
cells	O
to	O
handle	O
abnormally	O
processed	O
proteins	O
arising	O
from	O
impaired	O
glycosylation	O
.	O
<EOS>	B-X
In	B-X
renal	B-X
cell	B-X
carcinomas	B-X
(	B-X
RCC	B-X
)	B-X
,	B-X
NF-kappaB	B-X
blockade	B-X
is	B-X
required	B-X
for	B-X
maximal	B-X
bortezomib-induced	B-X
apoptosis	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
protein	B-X
downregulates	B-X
NF-kappaB	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
expression	B-X
of	B-X
wild-type	B-X
(	B-X
wt	B-X
)	B-X
VHL	B-X
sensitizes	B-X
RCC	B-X
cells	B-X
to	B-X
bortezomib	B-X
by	B-X
reducing	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
.	B-X
Using	B-X
isogenic	B-X
paired	B-X
cell	B-X
lines	B-X
with	B-X
and	B-X
without	B-X
expression	B-X
of	B-X
wtVHL	B-X
,	B-X
we	B-X
have	B-X
confirmed	B-X
that	B-X
VHL	B-X
expression	B-X
reduces	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
VHL	B-X
expression	B-X
confers	B-X
markedly	B-X
heightened	B-X
sensitivity	B-X
to	B-X
the	B-X
growth	B-X
inhibitory	B-X
effects	B-X
of	B-X
bortezomib	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
bortezomib	B-X
IC50	B-X
values	B-X
were	B-X
greater	B-X
than	B-X
two	B-X
logs	B-X
lower	B-X
in	B-X
the	B-X
VHL-expressing	B-X
cell	B-X
lines	B-X
compared	B-X
to	B-X
the	B-X
VHL-deficient	B-X
counterparts	B-X
.	B-X
By	B-X
manipulating	B-X
the	B-X
level	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
an	B-X
isogenic	B-X
pair	B-X
of	B-X
RCC	B-X
cell	B-X
lines	B-X
independently	B-X
of	B-X
VHL	B-X
expression	B-X
,	B-X
we	B-X
were	B-X
able	B-X
to	B-X
demonstrate	B-X
that	B-X
the	B-X
VHL	B-X
sensitization	B-X
effect	B-X
is	B-X
due	B-X
to	B-X
downregulation	B-X
of	B-X
NF-kappaB	B-X
activity	B-X
.	B-X
These	B-X
findings	B-X
offer	B-X
the	B-X
enticing	B-X
possibility	B-X
of	B-X
using	B-X
VHL	B-X
status	B-X
as	B-X
a	B-X
molecular	B-X
marker	B-X
to	B-X
identify	B-X
RCC	B-X
patients	B-X
who	B-X
may	B-X
be	B-X
sensitive	B-X
to	B-X
bortezomib	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
RCC	B-X
patients	B-X
who	B-X
have	B-X
non-clear-cell	B-X
histologies	B-X
as	B-X
well	B-X
as	B-X
approximately	B-X
25	B-X
%	B-X
of	B-X
clear-cell	B-X
RCCs	B-X
manifest	B-X
expression	B-X
of	B-X
wtVHL	B-X
and	B-X
represent	B-X
a	B-X
subpopulation	B-X
of	B-X
patients	B-X
that	B-X
is	B-X
apt	B-X
to	B-X
respond	B-X
to	B-X
bortezomib	B-X
.	B-X

In	O
support	O
of	O
this	O
hypothesis	O
,	O
other	O
treatments	O
which	O
act	O
through	O
different	O
mechanisms	O
to	O
interfere	O
with	O
protein	O
processing	O
(	O
i	O
.	O
e	O
.	O
,	O
tunicamycin	O
,	O
brefeldin	O
A	O
,	O
and	O
azetidine	O
)	O
were	O
also	O
found	O
to	O
be	O
much	O
more	O
toxic	O
for	O
VHL	B-Gene_or_gene_product
-	O
deficient	O
cells	O
.	O

Furthermore	O
,	O
ubiquitination	O
of	O
cellular	O
proteins	O
was	O
elevated	O
in	O
VHL	B-Gene_or_gene_product
-	O
deficient	O
cells	O
,	O
particularly	O
after	O
glucose	O
deprivation	O
,	O
supporting	O
a	O
role	O
for	O
the	O
VHL	B-Gene_or_gene_product
gene	O
in	O
ubiquitin	B-Gene_or_gene_product
-	O
mediated	O
proteolysis	O
.	O
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
functional	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
leads	B-X
to	B-X
the	B-X
development	B-X
of	B-X
neoplasias	B-X
characteristic	B-X
of	B-X
VHL	B-X
disease	B-X
,	B-X
including	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
sensitivity	B-X
of	B-X
RCC	B-X
cells	B-X
lacking	B-X
VHL	B-X
gene	B-X
function	B-X
with	B-X
that	B-X
of	B-X
RCC	B-X
cells	B-X
expressing	B-X
the	B-X
wild-type	B-X
VHL	B-X
gene	B-X
(	B-X
wtVHL	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
various	B-X
stresses	B-X
.	B-X
While	B-X
the	B-X
response	B-X
to	B-X
most	B-X
treatments	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
VHL	B-X
gene	B-X
status	B-X
,	B-X
glucose	B-X
deprivation	B-X
was	B-X
found	B-X
to	B-X
be	B-X
much	B-X
more	B-X
cytotoxic	B-X
for	B-X
RCC	B-X
cells	B-X
lacking	B-X
VHL	B-X
gene	B-X
function	B-X
than	B-X
for	B-X
wtVHL-expressing	B-X
cells	B-X
.	B-X
The	B-X
heightened	B-X
sensitivity	B-X
of	B-X
VHL-deficient	B-X
cells	B-X
was	B-X
not	B-X
attributed	B-X
to	B-X
dissimilar	B-X
energy	B-X
requirements	B-X
or	B-X
to	B-X
differences	B-X
in	B-X
glucose	B-X
uptake	B-X
,	B-X
but	B-X
more	B-X
likely	B-X
reflects	B-X
a	B-X
lesser	B-X
ability	B-X
of	B-X
VHL-deficient	B-X
cells	B-X
to	B-X
handle	B-X
abnormally	B-X
processed	B-X
proteins	B-X
arising	B-X
from	B-X
impaired	B-X
glycosylation	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
hypothesis	B-X
,	B-X
other	B-X
treatments	B-X
which	B-X
act	B-X
through	B-X
different	B-X
mechanisms	B-X
to	B-X
interfere	B-X
with	B-X
protein	B-X
processing	B-X
(	B-X
i.e.	B-X
,	B-X
tunicamycin	B-X
,	B-X
brefeldin	B-X
A	B-X
,	B-X
and	B-X
azetidine	B-X
)	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
much	B-X
more	B-X
toxic	B-X
for	B-X
VHL-deficient	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
ubiquitination	B-X
of	B-X
cellular	B-X
proteins	B-X
was	B-X
elevated	B-X
in	B-X
VHL-deficient	B-X
cells	B-X
,	B-X
particularly	B-X
after	B-X
glucose	B-X
deprivation	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
VHL	B-X
gene	B-X
in	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
rate	B-X
of	B-X
elimination	B-X
of	B-X
abnormal	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
cells	B-X
lacking	B-X
a	B-X
functional	B-X
VHL	B-X
gene	B-X
than	B-X
in	B-X
wtVHL-expressing	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
pVHL	B-X
appears	B-X
to	B-X
participate	B-X
in	B-X
the	B-X
elimination	B-X
of	B-X
misprocessed	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
those	B-X
arising	B-X
in	B-X
the	B-X
cell	B-X
due	B-X
to	B-X
the	B-X
unavailability	B-X
of	B-X
glucose	B-X
or	B-X
to	B-X
other	B-X
stresses	B-X
.	B-X

Accordingly	O
,	O
the	O
rate	O
of	O
elimination	O
of	O
abnormal	O
proteins	O
was	O
lower	O
in	O
cells	O
lacking	O
a	O
functional	O
VHL	B-Gene_or_gene_product
gene	O
than	O
in	O
wtVHL	B-Gene_or_gene_product
-	O
expressing	O
cells	O
.	O
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
functional	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
leads	B-X
to	B-X
the	B-X
development	B-X
of	B-X
neoplasias	B-X
characteristic	B-X
of	B-X
VHL	B-X
disease	B-X
,	B-X
including	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
sensitivity	B-X
of	B-X
RCC	B-X
cells	B-X
lacking	B-X
VHL	B-X
gene	B-X
function	B-X
with	B-X
that	B-X
of	B-X
RCC	B-X
cells	B-X
expressing	B-X
the	B-X
wild-type	B-X
VHL	B-X
gene	B-X
(	B-X
wtVHL	B-X
)	B-X
after	B-X
exposure	B-X
to	B-X
various	B-X
stresses	B-X
.	B-X
While	B-X
the	B-X
response	B-X
to	B-X
most	B-X
treatments	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
VHL	B-X
gene	B-X
status	B-X
,	B-X
glucose	B-X
deprivation	B-X
was	B-X
found	B-X
to	B-X
be	B-X
much	B-X
more	B-X
cytotoxic	B-X
for	B-X
RCC	B-X
cells	B-X
lacking	B-X
VHL	B-X
gene	B-X
function	B-X
than	B-X
for	B-X
wtVHL-expressing	B-X
cells	B-X
.	B-X
The	B-X
heightened	B-X
sensitivity	B-X
of	B-X
VHL-deficient	B-X
cells	B-X
was	B-X
not	B-X
attributed	B-X
to	B-X
dissimilar	B-X
energy	B-X
requirements	B-X
or	B-X
to	B-X
differences	B-X
in	B-X
glucose	B-X
uptake	B-X
,	B-X
but	B-X
more	B-X
likely	B-X
reflects	B-X
a	B-X
lesser	B-X
ability	B-X
of	B-X
VHL-deficient	B-X
cells	B-X
to	B-X
handle	B-X
abnormally	B-X
processed	B-X
proteins	B-X
arising	B-X
from	B-X
impaired	B-X
glycosylation	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
hypothesis	B-X
,	B-X
other	B-X
treatments	B-X
which	B-X
act	B-X
through	B-X
different	B-X
mechanisms	B-X
to	B-X
interfere	B-X
with	B-X
protein	B-X
processing	B-X
(	B-X
i.e.	B-X
,	B-X
tunicamycin	B-X
,	B-X
brefeldin	B-X
A	B-X
,	B-X
and	B-X
azetidine	B-X
)	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
much	B-X
more	B-X
toxic	B-X
for	B-X
VHL-deficient	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
ubiquitination	B-X
of	B-X
cellular	B-X
proteins	B-X
was	B-X
elevated	B-X
in	B-X
VHL-deficient	B-X
cells	B-X
,	B-X
particularly	B-X
after	B-X
glucose	B-X
deprivation	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
VHL	B-X
gene	B-X
in	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
rate	B-X
of	B-X
elimination	B-X
of	B-X
abnormal	B-X
proteins	B-X
was	B-X
lower	B-X
in	B-X
cells	B-X
lacking	B-X
a	B-X
functional	B-X
VHL	B-X
gene	B-X
than	B-X
in	B-X
wtVHL-expressing	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
pVHL	B-X
appears	B-X
to	B-X
participate	B-X
in	B-X
the	B-X
elimination	B-X
of	B-X
misprocessed	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
those	B-X
arising	B-X
in	B-X
the	B-X
cell	B-X
due	B-X
to	B-X
the	B-X
unavailability	B-X
of	B-X
glucose	B-X
or	B-X
to	B-X
other	B-X
stresses	B-X
.	B-X

Thus	O
,	O
pVHL	B-Gene_or_gene_product
appears	O
to	O
participate	O
in	O
the	O
elimination	O
of	O
misprocessed	O
proteins	O
,	O
such	O
as	O
those	O
arising	O
in	O
the	O
cell	O
due	O
to	O
the	O
unavailability	O
of	O
glucose	O
or	O
to	O
other	O
stresses	O
.	O
<EOS>	B-X
Plants	B-X
are	B-X
challenged	B-X
with	B-X
numerous	B-X
abiotic	B-X
stresses	B-X
,	B-X
such	B-X
as	B-X
drought	B-X
,	B-X
cold	B-X
,	B-X
heat	B-X
,	B-X
and	B-X
salt	B-X
stress	B-X
.	B-X
These	B-X
environmental	B-X
stresses	B-X
are	B-X
major	B-X
causes	B-X
of	B-X
crop	B-X
failure	B-X
and	B-X
reduced	B-X
yields	B-X
worldwide	B-X
.	B-X
Plants	B-X
are	B-X
constantly	B-X
exposed	B-X
to	B-X
various	B-X
stresses	B-X
,	B-X
which	B-X
can	B-X
degrade	B-X
their	B-X
health	B-X
.	B-X
The	B-X
stresses	B-X
can	B-X
be	B-X
alleviated	B-X
by	B-X
the	B-X
application	B-X
of	B-X
methyl	B-X
jasmonate	B-X
(	B-X
MeJA	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
hormone	B-X
involved	B-X
in	B-X
plant	B-X
signalling	B-X
.	B-X
Thus	B-X
,	B-X
MeJA	B-X
may	B-X
be	B-X
used	B-X
against	B-X
pathogens	B-X
,	B-X
salt	B-X
stress	B-X
,	B-X
drought	B-X
stress	B-X
,	B-X
low	B-X
temperature	B-X
,	B-X
heavy	B-X
metal	B-X
stress	B-X
and	B-X
toxicities	B-X
of	B-X
other	B-X
elements	B-X
.	B-X
For	B-X
these	B-X
reasons	B-X
,	B-X
we	B-X
reviewed	B-X
the	B-X
use	B-X
of	B-X
exogenous	B-X
MeJA	B-X
in	B-X
alleviating	B-X
biotic	B-X
(	B-X
pathogens	B-X
and	B-X
insects	B-X
)	B-X
and	B-X
abiotic	B-X
stresses	B-X
in	B-X
plants	B-X
.	B-X

